group,indication,Score,side_effects,generic_name
sign_symptom,adverse reaction,0.789032," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
sign_symptom,pain,0.9997068," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
sign_symptom,adverse reactions,0.97730947," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
disease_disorder,rheuma,0.8858123," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
disease_disorder,arthritis,0.997771," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
sign_symptom,flare,0.99773717," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
sign_symptom,rash,0.999561," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
disease_disorder,diverticuli,0.959265," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
disease_disorder,diverticulitis,0.9997782," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
disease_disorder,appendiceal perforations,0.96571696," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
disease_disorder,bilia,0.91838396," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
disease_disorder,immune system,0.7614405," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
disease_disorder,cell carcinoma,0.9983458," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
disease_disorder,nervous system,0.9927107," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
disease_disorder,demyelinating disorders,0.92759717," the most common adverse reaction with adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). the most common adverse reactions leading to discontinuation of adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.  
 
 other adverse reactions of adalimumab includes- gastrointestinal disorders: diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis. 
 general disorders and administration site conditions: pyrexia. 
 hepato-biliary disorders: liver failure, hepatitis. 
 immune system disorders: sarcoidosis. 
 neoplasms benign, malignant and unspecified (including cysts and polyps): merkel cell carcinoma (neuroendocrine carcinoma of the skin). 
 nervous system disorders: demyelinating disorders (e.g., optic neuritis, guillain-barr syndrome). 
 cerebrovascular accident respiratory disorders: interstitial lung disease, including pulmonary fibrosis. 
 pulmonary embolism skin reactions: stevens johnson syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia. 
 vascular disorders: systemic vasculitis, deep vein thrombosis. 
  ",adalimumab
sign_symptom,adverse reactions,0.99967563," the following most common adverse reactions (&lt;1%) were local skin reactions like drying or flaking of the skin; burning or tingling, erythema; pigmentation changes, application site reactions including signs and symptoms of inflammation. ",acyclovir + hydrocortisone
sign_symptom,skin reactions,0.9321515," the following most common adverse reactions (&lt;1%) were local skin reactions like drying or flaking of the skin; burning or tingling, erythema; pigmentation changes, application site reactions including signs and symptoms of inflammation. ",acyclovir + hydrocortisone
sign_symptom,drying,0.98654336," the following most common adverse reactions (&lt;1%) were local skin reactions like drying or flaking of the skin; burning or tingling, erythema; pigmentation changes, application site reactions including signs and symptoms of inflammation. ",acyclovir + hydrocortisone
sign_symptom,adverse reactions,0.99296075," the most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging on skin; each adverse reaction occurred in less than 1% of patients receiving acyclovircream and placebo. three patients on acyclovircream and one patient on placebo discontinued treatment due to an adverse event. ",acyclovir (topical)
sign_symptom,dryness,0.75440824," the most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging on skin; each adverse reaction occurred in less than 1% of patients receiving acyclovircream and placebo. three patients on acyclovircream and one patient on placebo discontinued treatment due to an adverse event. ",acyclovir (topical)
sign_symptom,flakiness,0.90086156," the most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging on skin; each adverse reaction occurred in less than 1% of patients receiving acyclovircream and placebo. three patients on acyclovircream and one patient on placebo discontinued treatment due to an adverse event. ",acyclovir (topical)
sign_symptom,stinging,0.8798617," the most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging on skin; each adverse reaction occurred in less than 1% of patients receiving acyclovircream and placebo. three patients on acyclovircream and one patient on placebo discontinued treatment due to an adverse event. ",acyclovir (topical)
sign_symptom,adverse reaction,0.9996006," the most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging on skin; each adverse reaction occurred in less than 1% of patients receiving acyclovircream and placebo. three patients on acyclovircream and one patient on placebo discontinued treatment due to an adverse event. ",acyclovir (topical)
medication,place,0.9908783," the most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging on skin; each adverse reaction occurred in less than 1% of patients receiving acyclovircream and placebo. three patients on acyclovircream and one patient on placebo discontinued treatment due to an adverse event. ",acyclovir (topical)
medication,placebo,0.9996451," the most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging on skin; each adverse reaction occurred in less than 1% of patients receiving acyclovircream and placebo. three patients on acyclovircream and one patient on placebo discontinued treatment due to an adverse event. ",acyclovir (topical)
sign_symptom,stinging,0.9999304," very common: superficial punctate keratopathy. this did not necessitate an early termination of therapy and healed without apparent sequelae. common: transient mild stinging of the eye occurring immediately following application, conjunctivitis. rare: blepharitis. ",acyclovir (ophthalmic)
sign_symptom,adverse reactions,0.9973279," some infrequent adverse reactions are lethargy, obtundation, tremors, confusion, hallucinations, agitation, somnolence, psychosis, convulsions and coma, phlebitis, nausea, vomiting, reversible increases in liver-related enzymes, pruritus, urticaria, rashes, increases in blood urea and creatinine. local inflammatory reactions may occur if acyclovir iv infusion is inadvertently infused into extracellular tissues. ",acyclovir (injection)
sign_symptom,tremor,0.9972445," some infrequent adverse reactions are lethargy, obtundation, tremors, confusion, hallucinations, agitation, somnolence, psychosis, convulsions and coma, phlebitis, nausea, vomiting, reversible increases in liver-related enzymes, pruritus, urticaria, rashes, increases in blood urea and creatinine. local inflammatory reactions may occur if acyclovir iv infusion is inadvertently infused into extracellular tissues. ",acyclovir (injection)
sign_symptom,confusion,0.8368436," some infrequent adverse reactions are lethargy, obtundation, tremors, confusion, hallucinations, agitation, somnolence, psychosis, convulsions and coma, phlebitis, nausea, vomiting, reversible increases in liver-related enzymes, pruritus, urticaria, rashes, increases in blood urea and creatinine. local inflammatory reactions may occur if acyclovir iv infusion is inadvertently infused into extracellular tissues. ",acyclovir (injection)
sign_symptom,halluc,0.7153324," some infrequent adverse reactions are lethargy, obtundation, tremors, confusion, hallucinations, agitation, somnolence, psychosis, convulsions and coma, phlebitis, nausea, vomiting, reversible increases in liver-related enzymes, pruritus, urticaria, rashes, increases in blood urea and creatinine. local inflammatory reactions may occur if acyclovir iv infusion is inadvertently infused into extracellular tissues. ",acyclovir (injection)
sign_symptom,inflammatory reactions,0.99773204," some infrequent adverse reactions are lethargy, obtundation, tremors, confusion, hallucinations, agitation, somnolence, psychosis, convulsions and coma, phlebitis, nausea, vomiting, reversible increases in liver-related enzymes, pruritus, urticaria, rashes, increases in blood urea and creatinine. local inflammatory reactions may occur if acyclovir iv infusion is inadvertently infused into extracellular tissues. ",acyclovir (injection)
medication,acyclovir iv,0.9911206," some infrequent adverse reactions are lethargy, obtundation, tremors, confusion, hallucinations, agitation, somnolence, psychosis, convulsions and coma, phlebitis, nausea, vomiting, reversible increases in liver-related enzymes, pruritus, urticaria, rashes, increases in blood urea and creatinine. local inflammatory reactions may occur if acyclovir iv infusion is inadvertently infused into extracellular tissues. ",acyclovir (injection)
sign_symptom,adverse reactions,0.99976134," as most undesirable effects are based on post-marketing spontaneous reporting, precise frequency estimation is not possible. no adverse reactions to ultracarbon are known to occur if taken in the recommended dosage to treat the diarrhoea. after very high doses as those taken in intoxications, constipation and intestinal obstruction (mechanical ileus) may occur in individual cases; this can be prevented by administering saline laxatives (eg, sodium sulfate). as medicinal charcoal is excreted in unchanged form, the stools turn black (discoloured faeces) after intake of ultracarbon tablets. ",activated charcoal
medication,ultracarbon,0.9919897," as most undesirable effects are based on post-marketing spontaneous reporting, precise frequency estimation is not possible. no adverse reactions to ultracarbon are known to occur if taken in the recommended dosage to treat the diarrhoea. after very high doses as those taken in intoxications, constipation and intestinal obstruction (mechanical ileus) may occur in individual cases; this can be prevented by administering saline laxatives (eg, sodium sulfate). as medicinal charcoal is excreted in unchanged form, the stools turn black (discoloured faeces) after intake of ultracarbon tablets. ",activated charcoal
sign_symptom,consti,0.9958608," as most undesirable effects are based on post-marketing spontaneous reporting, precise frequency estimation is not possible. no adverse reactions to ultracarbon are known to occur if taken in the recommended dosage to treat the diarrhoea. after very high doses as those taken in intoxications, constipation and intestinal obstruction (mechanical ileus) may occur in individual cases; this can be prevented by administering saline laxatives (eg, sodium sulfate). as medicinal charcoal is excreted in unchanged form, the stools turn black (discoloured faeces) after intake of ultracarbon tablets. ",activated charcoal
sign_symptom,intestinal obstruction,0.93641156," as most undesirable effects are based on post-marketing spontaneous reporting, precise frequency estimation is not possible. no adverse reactions to ultracarbon are known to occur if taken in the recommended dosage to treat the diarrhoea. after very high doses as those taken in intoxications, constipation and intestinal obstruction (mechanical ileus) may occur in individual cases; this can be prevented by administering saline laxatives (eg, sodium sulfate). as medicinal charcoal is excreted in unchanged form, the stools turn black (discoloured faeces) after intake of ultracarbon tablets. ",activated charcoal
sign_symptom,adverse reactions,0.9991071, most common adverse reactions (incidence 3% and more common than with placebo) include: upper respiratory tract infection and headache. ,aclidinium bromide + formoterol fumarate
sign_symptom,infection,0.8158817, most common adverse reactions (incidence 3% and more common than with placebo) include: upper respiratory tract infection and headache. ,aclidinium bromide + formoterol fumarate
sign_symptom,adverse effects,0.96279234," adverse effects are seen in most patients receiving acitretin. most of the clinical side-effects of acitretin are dose-related and are usually well-tolerated at the recommended dosages. however, the toxic dose of acitretin is close to the therapeutic dose and most patients experience some side-effects during theinitial period whilst dosage is being adjusted. the skin and mucous membranes are most commonly affected. an initial worsening of psoriasis symptoms issometimes seen at the beginning of the treatment period. ",acitretin
medication,acitret,0.8778185," adverse effects are seen in most patients receiving acitretin. most of the clinical side-effects of acitretin are dose-related and are usually well-tolerated at the recommended dosages. however, the toxic dose of acitretin is close to the therapeutic dose and most patients experience some side-effects during theinitial period whilst dosage is being adjusted. the skin and mucous membranes are most commonly affected. an initial worsening of psoriasis symptoms issometimes seen at the beginning of the treatment period. ",acitretin
sign_symptom,side - effects,0.99886227," adverse effects are seen in most patients receiving acitretin. most of the clinical side-effects of acitretin are dose-related and are usually well-tolerated at the recommended dosages. however, the toxic dose of acitretin is close to the therapeutic dose and most patients experience some side-effects during theinitial period whilst dosage is being adjusted. the skin and mucous membranes are most commonly affected. an initial worsening of psoriasis symptoms issometimes seen at the beginning of the treatment period. ",acitretin
medication,acetylcysteine,0.96098167," like all medicines, acetylcysteine can cause side effects, although not everybody gets them. in very rare cases, severe immune reactions may occur such as anaphylactic shock and severe skin reaction. in rare cases the oral administration can be followed by shortness of breath, upset stomach and bronchospasm. the most frequent side effects are headache, increased heart rate, stomatitis, pruritus, urticaria, nausea, vomiting, abdominal pain, fever, decrease in the blood pressure, diarrhoea and noises in the ears. ",acetylcysteine
sign_symptom,immune reactions,0.99899364," like all medicines, acetylcysteine can cause side effects, although not everybody gets them. in very rare cases, severe immune reactions may occur such as anaphylactic shock and severe skin reaction. in rare cases the oral administration can be followed by shortness of breath, upset stomach and bronchospasm. the most frequent side effects are headache, increased heart rate, stomatitis, pruritus, urticaria, nausea, vomiting, abdominal pain, fever, decrease in the blood pressure, diarrhoea and noises in the ears. ",acetylcysteine
sign_symptom,shortness of breath,0.9714336," like all medicines, acetylcysteine can cause side effects, although not everybody gets them. in very rare cases, severe immune reactions may occur such as anaphylactic shock and severe skin reaction. in rare cases the oral administration can be followed by shortness of breath, upset stomach and bronchospasm. the most frequent side effects are headache, increased heart rate, stomatitis, pruritus, urticaria, nausea, vomiting, abdominal pain, fever, decrease in the blood pressure, diarrhoea and noises in the ears. ",acetylcysteine
sign_symptom,upset stomach,0.8013763," like all medicines, acetylcysteine can cause side effects, although not everybody gets them. in very rare cases, severe immune reactions may occur such as anaphylactic shock and severe skin reaction. in rare cases the oral administration can be followed by shortness of breath, upset stomach and bronchospasm. the most frequent side effects are headache, increased heart rate, stomatitis, pruritus, urticaria, nausea, vomiting, abdominal pain, fever, decrease in the blood pressure, diarrhoea and noises in the ears. ",acetylcysteine
sign_symptom,depressed,0.9707345," common side effects include anorexia, nausea, vomiting, diarrhoea and constipation, peptic ulceration, headache, dizziness &amp; vertigo. rarely confusion, depressed mood, oedema, chest pain, blood urea elevation are found. ",acemetacin
medication,aceclofenac,0.9441322,"  aceclofenac is a non-steroidal drug with anti-inflammatory and analgesic properties. it is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. after oral administration, it is rapidly and completely absorbed an unchanged drug.  ",aceclofenac
sign_symptom,side effect,0.7559587, no significant side effect has been observed in the therapeutic dosage. ,"bandish [oak galls, tannic acid]"
sign_symptom,side effect,0.7559587, no significant side effect has been observed in the therapeutic dosage. ,"mudir [aloe, saffron, ferrus sulphate]"
sign_symptom,side effect,0.7559587, no significant side effect has been observed in the therapeutic dosage. ,salep + coconut + poppy seeds +  almond
sign_symptom,side effect,0.7559587, no significant side effect has been observed in the therapeutic dosage. ,nux-vomica + black pepper + long pepper
sign_symptom,side effect,0.7559587, no significant side effect has been observed in the therapeutic dosage. ,belgiri [bael fruit + connessi bark]
sign_symptom,side effect,0.7559587, no significant side effect has been observed in the therapeutic dosage. ,almond + coconut + edible pine + salep
sign_symptom,side effect,0.7559587, no significant side effect has been observed in the therapeutic dosage. ,acacia + dates + asparagus + edible pine
medication,bacopa,0.9844163, there are no side effects associated with the use of bacopa in the above mentioned therapeutic doses. bacopa has been used safely as an ayurvedic medicine for hundreds of years. ,bacopa extract [natural memory enhancer]
sign_symptom,hazards,0.943784, no health hazards or side effects are known in conjunction with the proper administration of designated therapeutic dosages. ,aushokarist [saraca indica]
sign_symptom,effects,0.99212086, no health hazards or side effects are known in conjunction with the proper administration of designated therapeutic dosages. ,aushokarist [saraca indica]
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,antacid [unani]
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,ambergris + salep + galangal
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,ambar momiyaee
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,chebulic myrobalan + barberry
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,camphor + thymol + menthol + eucalyptus oil
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,buzuri
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,garlitab
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,espand
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,emblic myrobalan + chebulic + belleric
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,emblic myrobalan + aswagandha + grape
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,ejaz
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,"jadwar [denudatum, saffron, henbane]"
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,herbal gastric preparation
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,marwareedi
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,marham kharish
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,liquorice + cascara sagrada + belladona
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,pechish
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,"salajeet [mineral pitch, red sage]"
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,saffron + sand lizard + nutmeg fruit
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,"tila jadeed [madar, mace arillus, nutmeg nut]"
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,"suzark [chir pine, chickpea, pearl]"
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,suranjan
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,saffron + mace arillus + nutmeg fruit
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,rehmin
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,natural medicine for diabetes
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,licorice + yellow silk cotton + mastic tree
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,licorice + vasaka + basil + peppermint
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,lavendar [lavendula stoechas]
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,kusta qalyee [calcined stannum]
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,khakshi
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,herbal cough syrup [glycyrrhiza glabra]
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,dinar
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,devils cotton + ashoka bark + aswagandha
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,datura + rhubarb + ginger
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,date palm + betel nut + acacia
sign_symptom,side effect,0.99700356, no significant side effect has been observed in proper dosage. ,aloe + black pepper + henbane
sign_symptom,side effect,0.91499245, no significant side effect has been reported in therapeutic dosage. ,aniseed + indian dill + black cardamom + peppermint
sign_symptom,side effect,0.91499245, no significant side effect has been reported in therapeutic dosage. ,"fishar [snake root, potassium, magnesium]"
sign_symptom,side effect,0.91499245, no significant side effect has been reported in therapeutic dosage. ,tabkheer
sign_symptom,side effect,0.91499245, no significant side effect has been reported in therapeutic dosage. ,barsina
sign_symptom,vomiting,0.99986935," large oral doses may cause gastric discomfort, vomiting and loss of appetite. these side-effects appear to be due to the bitter taste of andrographolide. ",andrographis paniculata
sign_symptom,loss of appetite,0.9992735," large oral doses may cause gastric discomfort, vomiting and loss of appetite. these side-effects appear to be due to the bitter taste of andrographolide. ",andrographis paniculata
sign_symptom,allergic reaction,0.99968654, occasionally allergic reaction may occur. chronic use may cause loss of electrolytes (potassium) that will reverse upon discontinuation. ,aloe indica+ hyoscyamus niger + piper nigrum
sign_symptom,allergic reaction,0.99968654, occasionally allergic reaction may occur. chronic use may cause loss of electrolytes (potassium) that will reverse upon discontinuation. ,psyllium [ispaghula husk] + senna extract
sign_symptom,rash,0.9213555," rashes, gastro intestinal disorders, rearly malaise, headache,vertigo, drowsiness, visual and test disturbances, hypertension, alopecia,hepatotoxicity, neuropathy, gynaeconastia and blood disorders. ",allopurinol
sign_symptom,mala,0.99904436," rashes, gastro intestinal disorders, rearly malaise, headache,vertigo, drowsiness, visual and test disturbances, hypertension, alopecia,hepatotoxicity, neuropathy, gynaeconastia and blood disorders. ",allopurinol
sign_symptom,irritation,0.9996569," this gel is generally well tolerated even in long-term use. in rare cases, some local irritations are reported such as slight erythema and itching. these side effects do not require discontinuation of the treatment. ",allium cepa + heparin + allantoin
sign_symptom,sync,0.85476255," classification of expected frequencies: very common (&lt;1/10), common (&lt;1/100 to &lt;1/10), uncommon (&lt;1/1,000 to &lt;1/100), rare (&lt;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. nervous system disorders: common: faintness/dizziness, headache; uncommon: syncope, vertigo, malaise, drowsiness. eye disorders: uncommon: vision abnormal; not known: intraoperative floppy iris syndrome. cardiac disorders: uncommon: tachycardia, palpitations, hypotension (postural); very rare: new onset, aggravation or recurrence of angina pectoris in patients with pre-existing coronary artery disease; not known: atrial fibrillation. vascular disorders: uncommon: hypotension (postural), flushing. blood and lymphatic system disorders: not known: neutropenia, thrombocytopenia. respiratory, thoracic and mediastinal disorders: uncommon: rhinitis. gastro-intestinal disorders: common: nausea, abdominal pain; uncommon: diarrhoea, dry mouth, vomiting; not known: vomiting. hepatobiliary disorders: frequency unknown: hepatocellular injury, cholestatic liver disease. skin and subcutaneous tissue disorders: uncommon: rash, pruritus; very rare: urticaria, angioedema. reproductive system and breast disorders: frequency unknown: priapism. general disorders and administration site conditions: common: asthenia; uncommon: flushes, oedema, chest pain. ",alfuzosin hydrochloride
sign_symptom,vertigo,0.748189," classification of expected frequencies: very common (&lt;1/10), common (&lt;1/100 to &lt;1/10), uncommon (&lt;1/1,000 to &lt;1/100), rare (&lt;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. nervous system disorders: common: faintness/dizziness, headache; uncommon: syncope, vertigo, malaise, drowsiness. eye disorders: uncommon: vision abnormal; not known: intraoperative floppy iris syndrome. cardiac disorders: uncommon: tachycardia, palpitations, hypotension (postural); very rare: new onset, aggravation or recurrence of angina pectoris in patients with pre-existing coronary artery disease; not known: atrial fibrillation. vascular disorders: uncommon: hypotension (postural), flushing. blood and lymphatic system disorders: not known: neutropenia, thrombocytopenia. respiratory, thoracic and mediastinal disorders: uncommon: rhinitis. gastro-intestinal disorders: common: nausea, abdominal pain; uncommon: diarrhoea, dry mouth, vomiting; not known: vomiting. hepatobiliary disorders: frequency unknown: hepatocellular injury, cholestatic liver disease. skin and subcutaneous tissue disorders: uncommon: rash, pruritus; very rare: urticaria, angioedema. reproductive system and breast disorders: frequency unknown: priapism. general disorders and administration site conditions: common: asthenia; uncommon: flushes, oedema, chest pain. ",alfuzosin hydrochloride
sign_symptom,mala,0.999385," classification of expected frequencies: very common (&lt;1/10), common (&lt;1/100 to &lt;1/10), uncommon (&lt;1/1,000 to &lt;1/100), rare (&lt;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. nervous system disorders: common: faintness/dizziness, headache; uncommon: syncope, vertigo, malaise, drowsiness. eye disorders: uncommon: vision abnormal; not known: intraoperative floppy iris syndrome. cardiac disorders: uncommon: tachycardia, palpitations, hypotension (postural); very rare: new onset, aggravation or recurrence of angina pectoris in patients with pre-existing coronary artery disease; not known: atrial fibrillation. vascular disorders: uncommon: hypotension (postural), flushing. blood and lymphatic system disorders: not known: neutropenia, thrombocytopenia. respiratory, thoracic and mediastinal disorders: uncommon: rhinitis. gastro-intestinal disorders: common: nausea, abdominal pain; uncommon: diarrhoea, dry mouth, vomiting; not known: vomiting. hepatobiliary disorders: frequency unknown: hepatocellular injury, cholestatic liver disease. skin and subcutaneous tissue disorders: uncommon: rash, pruritus; very rare: urticaria, angioedema. reproductive system and breast disorders: frequency unknown: priapism. general disorders and administration site conditions: common: asthenia; uncommon: flushes, oedema, chest pain. ",alfuzosin hydrochloride
sign_symptom,floppy,0.9952068," classification of expected frequencies: very common (&lt;1/10), common (&lt;1/100 to &lt;1/10), uncommon (&lt;1/1,000 to &lt;1/100), rare (&lt;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. nervous system disorders: common: faintness/dizziness, headache; uncommon: syncope, vertigo, malaise, drowsiness. eye disorders: uncommon: vision abnormal; not known: intraoperative floppy iris syndrome. cardiac disorders: uncommon: tachycardia, palpitations, hypotension (postural); very rare: new onset, aggravation or recurrence of angina pectoris in patients with pre-existing coronary artery disease; not known: atrial fibrillation. vascular disorders: uncommon: hypotension (postural), flushing. blood and lymphatic system disorders: not known: neutropenia, thrombocytopenia. respiratory, thoracic and mediastinal disorders: uncommon: rhinitis. gastro-intestinal disorders: common: nausea, abdominal pain; uncommon: diarrhoea, dry mouth, vomiting; not known: vomiting. hepatobiliary disorders: frequency unknown: hepatocellular injury, cholestatic liver disease. skin and subcutaneous tissue disorders: uncommon: rash, pruritus; very rare: urticaria, angioedema. reproductive system and breast disorders: frequency unknown: priapism. general disorders and administration site conditions: common: asthenia; uncommon: flushes, oedema, chest pain. ",alfuzosin hydrochloride
sign_symptom,hypotension,0.8697201," classification of expected frequencies: very common (&lt;1/10), common (&lt;1/100 to &lt;1/10), uncommon (&lt;1/1,000 to &lt;1/100), rare (&lt;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. nervous system disorders: common: faintness/dizziness, headache; uncommon: syncope, vertigo, malaise, drowsiness. eye disorders: uncommon: vision abnormal; not known: intraoperative floppy iris syndrome. cardiac disorders: uncommon: tachycardia, palpitations, hypotension (postural); very rare: new onset, aggravation or recurrence of angina pectoris in patients with pre-existing coronary artery disease; not known: atrial fibrillation. vascular disorders: uncommon: hypotension (postural), flushing. blood and lymphatic system disorders: not known: neutropenia, thrombocytopenia. respiratory, thoracic and mediastinal disorders: uncommon: rhinitis. gastro-intestinal disorders: common: nausea, abdominal pain; uncommon: diarrhoea, dry mouth, vomiting; not known: vomiting. hepatobiliary disorders: frequency unknown: hepatocellular injury, cholestatic liver disease. skin and subcutaneous tissue disorders: uncommon: rash, pruritus; very rare: urticaria, angioedema. reproductive system and breast disorders: frequency unknown: priapism. general disorders and administration site conditions: common: asthenia; uncommon: flushes, oedema, chest pain. ",alfuzosin hydrochloride
disease_disorder,vascular,0.9974831," classification of expected frequencies: very common (&lt;1/10), common (&lt;1/100 to &lt;1/10), uncommon (&lt;1/1,000 to &lt;1/100), rare (&lt;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. nervous system disorders: common: faintness/dizziness, headache; uncommon: syncope, vertigo, malaise, drowsiness. eye disorders: uncommon: vision abnormal; not known: intraoperative floppy iris syndrome. cardiac disorders: uncommon: tachycardia, palpitations, hypotension (postural); very rare: new onset, aggravation or recurrence of angina pectoris in patients with pre-existing coronary artery disease; not known: atrial fibrillation. vascular disorders: uncommon: hypotension (postural), flushing. blood and lymphatic system disorders: not known: neutropenia, thrombocytopenia. respiratory, thoracic and mediastinal disorders: uncommon: rhinitis. gastro-intestinal disorders: common: nausea, abdominal pain; uncommon: diarrhoea, dry mouth, vomiting; not known: vomiting. hepatobiliary disorders: frequency unknown: hepatocellular injury, cholestatic liver disease. skin and subcutaneous tissue disorders: uncommon: rash, pruritus; very rare: urticaria, angioedema. reproductive system and breast disorders: frequency unknown: priapism. general disorders and administration site conditions: common: asthenia; uncommon: flushes, oedema, chest pain. ",alfuzosin hydrochloride
sign_symptom,poly,0.9438186," anorexia, nausea, vomiting, diarrhoea, lassitude, polyuria, sweating, headache, thirst, vertigo, pruritus, rash, urticaria. hypercalcaemia, hypercalciuria and ectopic calcification.  in case of renal impairment, hyperphosphataemia. in hypercalcaemic dialysis patients, possibility of calcium influx from the dialysate should be considered. ",alfacalcidol
sign_symptom,hyper,0.99793196," anorexia, nausea, vomiting, diarrhoea, lassitude, polyuria, sweating, headache, thirst, vertigo, pruritus, rash, urticaria. hypercalcaemia, hypercalciuria and ectopic calcification.  in case of renal impairment, hyperphosphataemia. in hypercalcaemic dialysis patients, possibility of calcium influx from the dialysate should be considered. ",alfacalcidol
sign_symptom,hyperph,0.8308392," anorexia, nausea, vomiting, diarrhoea, lassitude, polyuria, sweating, headache, thirst, vertigo, pruritus, rash, urticaria. hypercalcaemia, hypercalciuria and ectopic calcification.  in case of renal impairment, hyperphosphataemia. in hypercalcaemic dialysis patients, possibility of calcium influx from the dialysate should be considered. ",alfacalcidol
sign_symptom,pain,0.99991155," usually mild and generally do not require discontinuation of therapy. side effects include esophageal reactions, abdominal pain and distension, diarrhoea or constipation, flatulence, musculoskeletal pain, headache, rash, erythema and transient decreases in serum calcium and phosphate. ",alendronic acid + vitamin d3
sign_symptom,diarr,0.9029431," usually mild and generally do not require discontinuation of therapy. side effects include esophageal reactions, abdominal pain and distension, diarrhoea or constipation, flatulence, musculoskeletal pain, headache, rash, erythema and transient decreases in serum calcium and phosphate. ",alendronic acid + vitamin d3
sign_symptom,flat,0.9985417," usually mild and generally do not require discontinuation of therapy. side effects include esophageal reactions, abdominal pain and distension, diarrhoea or constipation, flatulence, musculoskeletal pain, headache, rash, erythema and transient decreases in serum calcium and phosphate. ",alendronic acid + vitamin d3
sign_symptom,flatule,0.9291485," the commonest symptomatic side effects are constipation, diarrhoea, oesophageal ulcer, flatulence, dysphagia, musculoskeletal pain, headache, rarely rash, erythema, transient decrease in serum calcium and phosphate, nausea, vomiting, peptic ulceration, hypersensitivity reactions including urticaria and angio-oedema. ",alendronic acid
sign_symptom,hypersensitivity reactions,0.9437793," the commonest symptomatic side effects are constipation, diarrhoea, oesophageal ulcer, flatulence, dysphagia, musculoskeletal pain, headache, rarely rash, erythema, transient decrease in serum calcium and phosphate, nausea, vomiting, peptic ulceration, hypersensitivity reactions including urticaria and angio-oedema. ",alendronic acid
sign_symptom,adverse,0.9949426," the most common adverse drug reactions were constipation, edema including peripheral, generalized, eyelid, periorbital; myalgia (31% including myalgia and musculoskeletal pain), nausea, increased bilirubin (21% including increased blood bilirubin, hyperbilirubinemia and increased bilirubin conjugated), anemia (20%, including anemia and hemoglobin decreased), and rash (20%, including rash, rash maculopapular, dermatitis acneiform, erythema, rash generalized, rash papular, rash pruritic and rash macular). ",alectinib
sign_symptom,consti,0.86798346," the most common adverse drug reactions were constipation, edema including peripheral, generalized, eyelid, periorbital; myalgia (31% including myalgia and musculoskeletal pain), nausea, increased bilirubin (21% including increased blood bilirubin, hyperbilirubinemia and increased bilirubin conjugated), anemia (20%, including anemia and hemoglobin decreased), and rash (20%, including rash, rash maculopapular, dermatitis acneiform, erythema, rash generalized, rash papular, rash pruritic and rash macular). ",alectinib
sign_symptom,myalgia,0.8903597," the most common adverse drug reactions were constipation, edema including peripheral, generalized, eyelid, periorbital; myalgia (31% including myalgia and musculoskeletal pain), nausea, increased bilirubin (21% including increased blood bilirubin, hyperbilirubinemia and increased bilirubin conjugated), anemia (20%, including anemia and hemoglobin decreased), and rash (20%, including rash, rash maculopapular, dermatitis acneiform, erythema, rash generalized, rash papular, rash pruritic and rash macular). ",alectinib
sign_symptom,myal,0.9746933," the most common adverse drug reactions were constipation, edema including peripheral, generalized, eyelid, periorbital; myalgia (31% including myalgia and musculoskeletal pain), nausea, increased bilirubin (21% including increased blood bilirubin, hyperbilirubinemia and increased bilirubin conjugated), anemia (20%, including anemia and hemoglobin decreased), and rash (20%, including rash, rash maculopapular, dermatitis acneiform, erythema, rash generalized, rash papular, rash pruritic and rash macular). ",alectinib
sign_symptom,nausea,0.9923023," the most common adverse drug reactions were constipation, edema including peripheral, generalized, eyelid, periorbital; myalgia (31% including myalgia and musculoskeletal pain), nausea, increased bilirubin (21% including increased blood bilirubin, hyperbilirubinemia and increased bilirubin conjugated), anemia (20%, including anemia and hemoglobin decreased), and rash (20%, including rash, rash maculopapular, dermatitis acneiform, erythema, rash generalized, rash papular, rash pruritic and rash macular). ",alectinib
sign_symptom,hyper,0.99929714," the most common adverse drug reactions were constipation, edema including peripheral, generalized, eyelid, periorbital; myalgia (31% including myalgia and musculoskeletal pain), nausea, increased bilirubin (21% including increased blood bilirubin, hyperbilirubinemia and increased bilirubin conjugated), anemia (20%, including anemia and hemoglobin decreased), and rash (20%, including rash, rash maculopapular, dermatitis acneiform, erythema, rash generalized, rash papular, rash pruritic and rash macular). ",alectinib
sign_symptom,rash,0.9999449," the most common adverse drug reactions were constipation, edema including peripheral, generalized, eyelid, periorbital; myalgia (31% including myalgia and musculoskeletal pain), nausea, increased bilirubin (21% including increased blood bilirubin, hyperbilirubinemia and increased bilirubin conjugated), anemia (20%, including anemia and hemoglobin decreased), and rash (20%, including rash, rash maculopapular, dermatitis acneiform, erythema, rash generalized, rash papular, rash pruritic and rash macular). ",alectinib
sign_symptom,nasopharyngitis,0.9955428," the most frequent ocular reactions are eye irritation, burning or/and stinging upon instillation, eye redness and eye pruritus, nasopharyngitis and headache. ",alcaftadine
sign_symptom,allergic,0.9973569," allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. should an adverse reaction occur, slow or stop the infusion for a period of time which may result in the disappearance of the symptoms. if administration has been stopped and the patient requires additional albumin (human), material from a different lot should be used. albumin (human), particularly if administered rapidly, may result in vascular overload with resultant pulmonary edema. ",albumin (human)
sign_symptom,fever,0.9999558," allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. should an adverse reaction occur, slow or stop the infusion for a period of time which may result in the disappearance of the symptoms. if administration has been stopped and the patient requires additional albumin (human), material from a different lot should be used. albumin (human), particularly if administered rapidly, may result in vascular overload with resultant pulmonary edema. ",albumin (human)
sign_symptom,chill,0.9605723," allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. should an adverse reaction occur, slow or stop the infusion for a period of time which may result in the disappearance of the symptoms. if administration has been stopped and the patient requires additional albumin (human), material from a different lot should be used. albumin (human), particularly if administered rapidly, may result in vascular overload with resultant pulmonary edema. ",albumin (human)
sign_symptom,rash,0.998621," allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. should an adverse reaction occur, slow or stop the infusion for a period of time which may result in the disappearance of the symptoms. if administration has been stopped and the patient requires additional albumin (human), material from a different lot should be used. albumin (human), particularly if administered rapidly, may result in vascular overload with resultant pulmonary edema. ",albumin (human)
sign_symptom,nausea,0.9998153," allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. should an adverse reaction occur, slow or stop the infusion for a period of time which may result in the disappearance of the symptoms. if administration has been stopped and the patient requires additional albumin (human), material from a different lot should be used. albumin (human), particularly if administered rapidly, may result in vascular overload with resultant pulmonary edema. ",albumin (human)
sign_symptom,vomiting,0.9998561," allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. should an adverse reaction occur, slow or stop the infusion for a period of time which may result in the disappearance of the symptoms. if administration has been stopped and the patient requires additional albumin (human), material from a different lot should be used. albumin (human), particularly if administered rapidly, may result in vascular overload with resultant pulmonary edema. ",albumin (human)
sign_symptom,adverse reaction,0.9920914," allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. should an adverse reaction occur, slow or stop the infusion for a period of time which may result in the disappearance of the symptoms. if administration has been stopped and the patient requires additional albumin (human), material from a different lot should be used. albumin (human), particularly if administered rapidly, may result in vascular overload with resultant pulmonary edema. ",albumin (human)
medication,album,0.99716383," allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. should an adverse reaction occur, slow or stop the infusion for a period of time which may result in the disappearance of the symptoms. if administration has been stopped and the patient requires additional albumin (human), material from a different lot should be used. albumin (human), particularly if administered rapidly, may result in vascular overload with resultant pulmonary edema. ",albumin (human)
sign_symptom,vascular overload,0.99480414," allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. should an adverse reaction occur, slow or stop the infusion for a period of time which may result in the disappearance of the symptoms. if administration has been stopped and the patient requires additional albumin (human), material from a different lot should be used. albumin (human), particularly if administered rapidly, may result in vascular overload with resultant pulmonary edema. ",albumin (human)
sign_symptom,changes,0.82037467," gastrointestinal disturbances, headache, dizziness, changes in liver enzymes, rarely reversible alopecia; rash, fever, blood disorders including leucopenia and pancytopenia reported; allergic shock if cyst leakage; convulsion and meningism in cerebral disease. ",albendazole
disease_disorder,disorders,0.93431467," gastrointestinal disturbances, headache, dizziness, changes in liver enzymes, rarely reversible alopecia; rash, fever, blood disorders including leucopenia and pancytopenia reported; allergic shock if cyst leakage; convulsion and meningism in cerebral disease. ",albendazole
disease_disorder,leucopenia,0.9815469," gastrointestinal disturbances, headache, dizziness, changes in liver enzymes, rarely reversible alopecia; rash, fever, blood disorders including leucopenia and pancytopenia reported; allergic shock if cyst leakage; convulsion and meningism in cerebral disease. ",albendazole
sign_symptom,allergic shock,0.9997207," gastrointestinal disturbances, headache, dizziness, changes in liver enzymes, rarely reversible alopecia; rash, fever, blood disorders including leucopenia and pancytopenia reported; allergic shock if cyst leakage; convulsion and meningism in cerebral disease. ",albendazole
sign_symptom,meningism,0.9413335," gastrointestinal disturbances, headache, dizziness, changes in liver enzymes, rarely reversible alopecia; rash, fever, blood disorders including leucopenia and pancytopenia reported; allergic shock if cyst leakage; convulsion and meningism in cerebral disease. ",albendazole
sign_symptom,nausea,0.99934226," the commonly reported adverse effects in the clinical trials of agomelatine are headache, nausea and diarrhea. ",agomelatine
sign_symptom,adverse reactions,0.9971304," most common adverse reactions (all grades, 20% incidence and at least 2% greater incidence for the aflibercept/folfiri regimen) were leukopenia, diarrhea, neutropenia, proteinuria, ast increased, stomatitis, fatigue, thrombocytopenia, alt increased, hypertension, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, and headache ",aflibercept
sign_symptom,pain,0.9999074," most common adverse reactions (all grades, 20% incidence and at least 2% greater incidence for the aflibercept/folfiri regimen) were leukopenia, diarrhea, neutropenia, proteinuria, ast increased, stomatitis, fatigue, thrombocytopenia, alt increased, hypertension, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, and headache ",aflibercept
sign_symptom,headache,0.99995804," most common adverse reactions (all grades, 20% incidence and at least 2% greater incidence for the aflibercept/folfiri regimen) were leukopenia, diarrhea, neutropenia, proteinuria, ast increased, stomatitis, fatigue, thrombocytopenia, alt increased, hypertension, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, and headache ",aflibercept
disease_disorder,stomati,0.8146133," most common adverse reactions (20%) were diarrhea, rash/acneiform dermatitis, stomatitis, paronychia, dry skin, decreased appetite, nausea, vomiting, pruritus. ",afatinib dimaleate
medication,vaccine,0.89908195," adsorbed tetanus vaccine is generally well tolerated. most recipients of tetanus vaccine experience some reactions upon vaccination. these are generally moderate and short in duration. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise and elevated temperature) are reported less commonly. ",adsorbed tetanus vaccine
sign_symptom,reactions,0.75140595," adsorbed tetanus vaccine is generally well tolerated. most recipients of tetanus vaccine experience some reactions upon vaccination. these are generally moderate and short in duration. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise and elevated temperature) are reported less commonly. ",adsorbed tetanus vaccine
sign_symptom,mala,0.999948," adsorbed tetanus vaccine is generally well tolerated. most recipients of tetanus vaccine experience some reactions upon vaccination. these are generally moderate and short in duration. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise and elevated temperature) are reported less commonly. ",adsorbed tetanus vaccine
sign_symptom,restless,0.83859295," common side effects are anxiety, restlessness, dizziness, headache, palpitations, rapid pulse, tremors, weakness and coldness of the extremities may be reported even with small doses and especially when given in conjunction with local anaesthetics. ",adrenaline
sign_symptom,tremor,0.99772555," common side effects are anxiety, restlessness, dizziness, headache, palpitations, rapid pulse, tremors, weakness and coldness of the extremities may be reported even with small doses and especially when given in conjunction with local anaesthetics. ",adrenaline
sign_symptom,weakness,0.9999199," common side effects are anxiety, restlessness, dizziness, headache, palpitations, rapid pulse, tremors, weakness and coldness of the extremities may be reported even with small doses and especially when given in conjunction with local anaesthetics. ",adrenaline
sign_symptom,coldness,0.90654373," common side effects are anxiety, restlessness, dizziness, headache, palpitations, rapid pulse, tremors, weakness and coldness of the extremities may be reported even with small doses and especially when given in conjunction with local anaesthetics. ",adrenaline
sign_symptom,adverse effect,0.9040396, no side effect or adverse effect if used at recommended dose. ,dasamularista
sign_symptom,adverse effect,0.9040396, no side effect or adverse effect if used at recommended dose. ,compound asparagus
sign_symptom,adverse effect,0.9040396, no side effect or adverse effect if used at recommended dose. ,brahmi rasayan
sign_symptom,adverse effect,0.9040396, no side effect or adverse effect if used at recommended dose. ,prasarani sandhan
sign_symptom,gastrointestinal disturbance,0.99362075, curcuminoids is well tolerated in recommended dose. occasionally gastrointestinal disturbance may occur with overdose. ,curcuminoids [curcuma longa]
sign_symptom,turmeric,0.788383," turmeric usually does not cause significant side effects; however, some people can experience stomach upset, nausea, dizziness, or diarrhea. ",curcuma longa [turmeric extract]
sign_symptom,diarr,0.99279374, well tolerated in recommended dose. occasionally diarrhea or mild gastrointestinal upset may occur at high dose. ,cranberry [vaccinium macrocarpon]
sign_symptom,gastro,0.99146587, well tolerated in recommended dose. occasionally diarrhea or mild gastrointestinal upset may occur at high dose. ,cranberry [vaccinium macrocarpon]
sign_symptom,loss of appetite,0.9935367," co-enzyme q10 is safe for most adults. it can cause some mild side effects including stomach upset, loss of appetite, nausea, vomiting, and diarrhea. it can cause allergic skin rashes in some people. ",coenzyme q10 [ubidecarenone]
sign_symptom,rash,0.9988771," co-enzyme q10 is safe for most adults. it can cause some mild side effects including stomach upset, loss of appetite, nausea, vomiting, and diarrhea. it can cause allergic skin rashes in some people. ",coenzyme q10 [ubidecarenone]
sign_symptom,side effects,0.9997035, no significant side effects have been observed in proper dosage. ,chirata [swertia chirata]
sign_symptom,discomfort,0.9999149," black cohosh is safe for most people. it might cause some mild side effects such as stomach upset, cramping, headache, rash, a feeling of heaviness, and weight gain. occasional gastrointestinal discomfort may occur. ",black cohosh [cimicifuga racemosa]
sign_symptom,hyper,0.9999136," hypercalcemia may develop. in this case it is recommended to decrease vitamin d intake. if hypercalcaemia persists, reduce the dosage of this tablet as well as other source of calcium. the serum calcium level should be monitored regularly. ensure sufficient calorie intake. no experience has been gained so far with the administration in paediatric patients. ",amino acid + calcium
sign_symptom,amino acid,0.8326755," due to the special composition of this preparation, use in indications other than those recommended may result in amino acid imbalances and severe metabolic disorders. ",amino acid
medication,amikacin,0.9945553," the adverse effects have been reported with the use of amikacin are tinnitus, vertigo, partial reversible or irreversible deafness, skin rash, drug fever, headache, paraesthesia, nausea and vomiting. ",amikacin
sign_symptom,stomach,0.8282708," gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. ",ambroxol hydrochloride
sign_symptom,overfill feeling,0.9688793," gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. ",ambroxol hydrochloride
sign_symptom,allergic responses,0.99990904," gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. ",ambroxol hydrochloride
sign_symptom,"eruption,",0.9965348," gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. ",ambroxol hydrochloride
sign_symptom,urticaria,0.98163486," gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported. ",ambroxol hydrochloride
medication,endothelin receptor antagonists,0.9254427, decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with ambrisentan ,ambrisentan
sign_symptom,lightheaded,0.8354187," the adverse effects of amantadine are generally mild and, when they occur, may diminish or cease after a week or more on the medication. the most commonly reported side effects include nausea, dizziness/ lightheadedness, and insomnia.  other side effects may include edema of ankles, livedo reticularis; anxiety, elevation of mood, headache, lethargy, hallucinations, ataxia, slurred speech, blurred vision, loss of concentration, nervousness, depression, myalgia, palpitations, orthostatic hypotension, dry mouth, anorexia, constipation and diaphoresis. ",amantadine hydrochloride
sign_symptom,loss of concentration,0.910832," the adverse effects of amantadine are generally mild and, when they occur, may diminish or cease after a week or more on the medication. the most commonly reported side effects include nausea, dizziness/ lightheadedness, and insomnia.  other side effects may include edema of ankles, livedo reticularis; anxiety, elevation of mood, headache, lethargy, hallucinations, ataxia, slurred speech, blurred vision, loss of concentration, nervousness, depression, myalgia, palpitations, orthostatic hypotension, dry mouth, anorexia, constipation and diaphoresis. ",amantadine hydrochloride
sign_symptom,effects,0.7509875," gastrointestinal side effects are uncommon. occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur. ",aluminium hydroxide + magnesium hydroxide + simethicone
sign_symptom,constipation,0.9832044," gastrointestinal side effects are uncommon. occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur. ",aluminium hydroxide + magnesium hydroxide + simethicone
medication,aluminium chloride hexahydrate,0.9747512," aluminium chloride hexahydrate is normally well tolerated and adverse effects are only mild and short-lasting. but sometimes irritation of the skin like- stinging, burning, redness, swelling, tingling or itching of treated skin areas may occur. these irritations may be alleviated by use of a weak corticosteroid cream. ",aluminium chloride hexahydrate
sign_symptom,adverse,0.7729778," aluminium chloride hexahydrate is normally well tolerated and adverse effects are only mild and short-lasting. but sometimes irritation of the skin like- stinging, burning, redness, swelling, tingling or itching of treated skin areas may occur. these irritations may be alleviated by use of a weak corticosteroid cream. ",aluminium chloride hexahydrate
sign_symptom,irritation,0.9999579," aluminium chloride hexahydrate is normally well tolerated and adverse effects are only mild and short-lasting. but sometimes irritation of the skin like- stinging, burning, redness, swelling, tingling or itching of treated skin areas may occur. these irritations may be alleviated by use of a weak corticosteroid cream. ",aluminium chloride hexahydrate
sign_symptom,tingling,0.71548253," aluminium chloride hexahydrate is normally well tolerated and adverse effects are only mild and short-lasting. but sometimes irritation of the skin like- stinging, burning, redness, swelling, tingling or itching of treated skin areas may occur. these irritations may be alleviated by use of a weak corticosteroid cream. ",aluminium chloride hexahydrate
disease_disorder,angioedema,0.9154097," the following adverse reactions are: 
 
 bleeding 
 orolingual angioedema 
 cholesterol embolization 
 reembolization of deep venous thrombi during treatment for acute massive pulmonary 
 embolism. 
  ",alteplase
sign_symptom,light - headed,0.9739947," side effects, if occur, are generally observed at the beginning of therapy and usually disappear upon continued medication. the most frequent side effects are drowsiness and light-headedness. the other side effects, that may occur include depression, headache, confusion, dry mouth, constipation, etc. ",alprazolam
sign_symptom,adverse events,0.99988663," the most frequent adverse events reported with alphanate in &gt;5% of patients are respiratory distress, pruritus, rash, urticaria, face edema, paresthesia, pain, fever, chills, joint pain and fatigue ",alphanate
medication,alphanate,0.9990847," the most frequent adverse events reported with alphanate in &gt;5% of patients are respiratory distress, pruritus, rash, urticaria, face edema, paresthesia, pain, fever, chills, joint pain and fatigue ",alphanate
sign_symptom,chill,0.99917847," the most frequent adverse events reported with alphanate in &gt;5% of patients are respiratory distress, pruritus, rash, urticaria, face edema, paresthesia, pain, fever, chills, joint pain and fatigue ",alphanate
sign_symptom,pain,0.99996245," the most frequent adverse events reported with alphanate in &gt;5% of patients are respiratory distress, pruritus, rash, urticaria, face edema, paresthesia, pain, fever, chills, joint pain and fatigue ",alphanate
sign_symptom,fatigue,0.99994445," the most frequent adverse events reported with alphanate in &gt;5% of patients are respiratory distress, pruritus, rash, urticaria, face edema, paresthesia, pain, fever, chills, joint pain and fatigue ",alphanate
sign_symptom,side effects,0.99442005," no side effects following proper administration of designated therapeutic dosages. in pooled clinical trials involving 10,000 patients, the incidence of side effects produced by ginkgo biloba extract was extremely small. there were few cases of headaches, dizziness, palpitation, gastrointestinal disturbances, bleeding disorders &amp; skin hypersensitivity reactions. in higher than recommended doses, diarrhea, nausea, vomiting, restlessness, and weakness may occur. ",ginkgo biloba
medication,ginkgo biloba,0.9709602," no side effects following proper administration of designated therapeutic dosages. in pooled clinical trials involving 10,000 patients, the incidence of side effects produced by ginkgo biloba extract was extremely small. there were few cases of headaches, dizziness, palpitation, gastrointestinal disturbances, bleeding disorders &amp; skin hypersensitivity reactions. in higher than recommended doses, diarrhea, nausea, vomiting, restlessness, and weakness may occur. ",ginkgo biloba
sign_symptom,headache,0.97545743," no side effects following proper administration of designated therapeutic dosages. in pooled clinical trials involving 10,000 patients, the incidence of side effects produced by ginkgo biloba extract was extremely small. there were few cases of headaches, dizziness, palpitation, gastrointestinal disturbances, bleeding disorders &amp; skin hypersensitivity reactions. in higher than recommended doses, diarrhea, nausea, vomiting, restlessness, and weakness may occur. ",ginkgo biloba
sign_symptom,hyper,0.94998413," no side effects following proper administration of designated therapeutic dosages. in pooled clinical trials involving 10,000 patients, the incidence of side effects produced by ginkgo biloba extract was extremely small. there were few cases of headaches, dizziness, palpitation, gastrointestinal disturbances, bleeding disorders &amp; skin hypersensitivity reactions. in higher than recommended doses, diarrhea, nausea, vomiting, restlessness, and weakness may occur. ",ginkgo biloba
sign_symptom,restless,0.9499543," no side effects following proper administration of designated therapeutic dosages. in pooled clinical trials involving 10,000 patients, the incidence of side effects produced by ginkgo biloba extract was extremely small. there were few cases of headaches, dizziness, palpitation, gastrointestinal disturbances, bleeding disorders &amp; skin hypersensitivity reactions. in higher than recommended doses, diarrhea, nausea, vomiting, restlessness, and weakness may occur. ",ginkgo biloba
sign_symptom,weakness,0.9997291," no side effects following proper administration of designated therapeutic dosages. in pooled clinical trials involving 10,000 patients, the incidence of side effects produced by ginkgo biloba extract was extremely small. there were few cases of headaches, dizziness, palpitation, gastrointestinal disturbances, bleeding disorders &amp; skin hypersensitivity reactions. in higher than recommended doses, diarrhea, nausea, vomiting, restlessness, and weakness may occur. ",ginkgo biloba
sign_symptom,changes,0.9999063," gastro-intestinal symptoms, changes to the flora of the intestine and allergic reactions are rare ",garlic oil
sign_symptom,allergic reactions,0.999853," gastro-intestinal symptoms, changes to the flora of the intestine and allergic reactions are rare ",garlic oil
sign_symptom,adverse effects,0.9990798, adverse effects are rare at recommended dosages. overdose may cause loose stool and abdominal pain ,flaxseed oil [linum usitatissimum]
sign_symptom,pain,0.99995387, adverse effects are rare at recommended dosages. overdose may cause loose stool and abdominal pain ,flaxseed oil [linum usitatissimum]
medication,fennel,0.9041537, there is no significant side effect associated with the use of fennel in the above mentioned therapeutic doses. ,"fennel [mouri, gohkshura, kasni]"
sign_symptom,effects,0.96120554, side effects are rare at recommended dosages. overdose may cause loose stool and abdominal pain. ,evening primrose oil
sign_symptom,side effect,0.9934629, no significant side effect has been observed in proper usage. ,emblic myrobalan + sesame
sign_symptom,side effect,0.9934629, no significant side effect has been observed in proper usage. ,herbal multivitamin
sign_symptom,side effect,0.9934629, no significant side effect has been observed in proper usage. ,sanoon babla
sign_symptom,effects,0.8168761,"  
 rare side-effects (occurring in less than 1 in 1000 people)- nail may become discolored broken or brittle. 
 very rare side-effects (occurring in less than 1 in 10000 people)- a burning sensation or allergic skin reaction (contact dermatitis) 
 unknown frequency of occurrence-skin redness, itching hives, blisters and allergic skin reaction (contact dermatitis). 
  ",amorolfine hydrochloride (nail lacquer)
sign_symptom,disco,0.9987876,"  
 rare side-effects (occurring in less than 1 in 1000 people)- nail may become discolored broken or brittle. 
 very rare side-effects (occurring in less than 1 in 10000 people)- a burning sensation or allergic skin reaction (contact dermatitis) 
 unknown frequency of occurrence-skin redness, itching hives, blisters and allergic skin reaction (contact dermatitis). 
  ",amorolfine hydrochloride (nail lacquer)
sign_symptom,broken,0.9373428,"  
 rare side-effects (occurring in less than 1 in 1000 people)- nail may become discolored broken or brittle. 
 very rare side-effects (occurring in less than 1 in 10000 people)- a burning sensation or allergic skin reaction (contact dermatitis) 
 unknown frequency of occurrence-skin redness, itching hives, blisters and allergic skin reaction (contact dermatitis). 
  ",amorolfine hydrochloride (nail lacquer)
sign_symptom,burning sensation,0.9997411,"  
 rare side-effects (occurring in less than 1 in 1000 people)- nail may become discolored broken or brittle. 
 very rare side-effects (occurring in less than 1 in 10000 people)- a burning sensation or allergic skin reaction (contact dermatitis) 
 unknown frequency of occurrence-skin redness, itching hives, blisters and allergic skin reaction (contact dermatitis). 
  ",amorolfine hydrochloride (nail lacquer)
sign_symptom,allergic,0.9997851,"  
 rare side-effects (occurring in less than 1 in 1000 people)- nail may become discolored broken or brittle. 
 very rare side-effects (occurring in less than 1 in 10000 people)- a burning sensation or allergic skin reaction (contact dermatitis) 
 unknown frequency of occurrence-skin redness, itching hives, blisters and allergic skin reaction (contact dermatitis). 
  ",amorolfine hydrochloride (nail lacquer)
sign_symptom,skin reaction,0.9858446,"  
 rare side-effects (occurring in less than 1 in 1000 people)- nail may become discolored broken or brittle. 
 very rare side-effects (occurring in less than 1 in 10000 people)- a burning sensation or allergic skin reaction (contact dermatitis) 
 unknown frequency of occurrence-skin redness, itching hives, blisters and allergic skin reaction (contact dermatitis). 
  ",amorolfine hydrochloride (nail lacquer)
sign_symptom,allergic skin reaction,0.8330102,"  
 rare side-effects (occurring in less than 1 in 1000 people)- nail may become discolored broken or brittle. 
 very rare side-effects (occurring in less than 1 in 10000 people)- a burning sensation or allergic skin reaction (contact dermatitis) 
 unknown frequency of occurrence-skin redness, itching hives, blisters and allergic skin reaction (contact dermatitis). 
  ",amorolfine hydrochloride (nail lacquer)
sign_symptom,hypersensitivity,0.9585047," side effects are skin irritation, erythema, pruritus, skin burning sensation, hypersensitivity (systemic allergic reaction). ",amorolfine hydrochloride (cream)
sign_symptom,sore,0.9998374," generally been mild and transient in nature. the most common side effects include peripheral edema, nasal congestion, sore throat and discomfort when swallowing, upper respiratory tract infection, dizziness etc. ",amlodipine besilate + valsartan
sign_symptom,discomfort,0.9999441," generally been mild and transient in nature. the most common side effects include peripheral edema, nasal congestion, sore throat and discomfort when swallowing, upper respiratory tract infection, dizziness etc. ",amlodipine besilate + valsartan
sign_symptom,hypotension,0.9988555," dizziness, peripheral edema, migraine, headache, paraesthesia, vertigo, bradycardia, palpitations, hypotension, cough, abdominal pain, diarrhea, nausea, pruritus, myalgia, spasm, erectile dysfunction,chest pain, fatigue, edema etc. ",amlodipine besilate + telmisartan
disease_disorder,erectile dysfunction,0.9964623," dizziness, peripheral edema, migraine, headache, paraesthesia, vertigo, bradycardia, palpitations, hypotension, cough, abdominal pain, diarrhea, nausea, pruritus, myalgia, spasm, erectile dysfunction,chest pain, fatigue, edema etc. ",amlodipine besilate + telmisartan
medication,amlodipine,0.98366535," benazepril/amlodipine has been evaluated for safety in patients with hypertension for at least 6 months and more than 1 year. the reported side effects were generally mild and transient, and there was no relationship between side effects and age, sex, race or duration of therapy. discontinuation of therapy due to side effects was required in approximately 4% of patients treated with benazepril/amlodipine and in 3% of patients treated with placebo. the most common reasons for discontinuation of therapy with benazepril/amlodipine in u.s. studies were cough and edema. the side effects considered possibly or probably related to study drug that occurred in u.s. placebo-controlled trials in more than 1% of patients treated with benazepril/amlodipine are cough, headache, dizziness and edema.  the incidence of edema was statistically greater in patients treated with amlodipine monotherapy than in patients treated with the combination. edema and certain other side effects are associated with amlodipine monotherapy in a dose-dependent manner, and appear to affect women more than men. the addition of benazepril resulted in lower incidences as shown in study; the protective effect of benazepril was independent of race and (within the range of doses tested) of dose.  other rare side effects are angioedema, asthenia, fatigue, insomnia, nervousness, anxiety, tremor, decreased libido, flushing, hot flashes, rash, skin nodule, dermatitis, dry mouth, nausea, abdominal pain, constipation, diarrhea, dyspepsia, esophagitis, hypokalemia, pharyngitis etc. ",amlodipine besilate + benazepril hydrochloride
sign_symptom,hypertension,0.99747086," benazepril/amlodipine has been evaluated for safety in patients with hypertension for at least 6 months and more than 1 year. the reported side effects were generally mild and transient, and there was no relationship between side effects and age, sex, race or duration of therapy. discontinuation of therapy due to side effects was required in approximately 4% of patients treated with benazepril/amlodipine and in 3% of patients treated with placebo. the most common reasons for discontinuation of therapy with benazepril/amlodipine in u.s. studies were cough and edema. the side effects considered possibly or probably related to study drug that occurred in u.s. placebo-controlled trials in more than 1% of patients treated with benazepril/amlodipine are cough, headache, dizziness and edema.  the incidence of edema was statistically greater in patients treated with amlodipine monotherapy than in patients treated with the combination. edema and certain other side effects are associated with amlodipine monotherapy in a dose-dependent manner, and appear to affect women more than men. the addition of benazepril resulted in lower incidences as shown in study; the protective effect of benazepril was independent of race and (within the range of doses tested) of dose.  other rare side effects are angioedema, asthenia, fatigue, insomnia, nervousness, anxiety, tremor, decreased libido, flushing, hot flashes, rash, skin nodule, dermatitis, dry mouth, nausea, abdominal pain, constipation, diarrhea, dyspepsia, esophagitis, hypokalemia, pharyngitis etc. ",amlodipine besilate + benazepril hydrochloride
sign_symptom,cough,0.9997435," benazepril/amlodipine has been evaluated for safety in patients with hypertension for at least 6 months and more than 1 year. the reported side effects were generally mild and transient, and there was no relationship between side effects and age, sex, race or duration of therapy. discontinuation of therapy due to side effects was required in approximately 4% of patients treated with benazepril/amlodipine and in 3% of patients treated with placebo. the most common reasons for discontinuation of therapy with benazepril/amlodipine in u.s. studies were cough and edema. the side effects considered possibly or probably related to study drug that occurred in u.s. placebo-controlled trials in more than 1% of patients treated with benazepril/amlodipine are cough, headache, dizziness and edema.  the incidence of edema was statistically greater in patients treated with amlodipine monotherapy than in patients treated with the combination. edema and certain other side effects are associated with amlodipine monotherapy in a dose-dependent manner, and appear to affect women more than men. the addition of benazepril resulted in lower incidences as shown in study; the protective effect of benazepril was independent of race and (within the range of doses tested) of dose.  other rare side effects are angioedema, asthenia, fatigue, insomnia, nervousness, anxiety, tremor, decreased libido, flushing, hot flashes, rash, skin nodule, dermatitis, dry mouth, nausea, abdominal pain, constipation, diarrhea, dyspepsia, esophagitis, hypokalemia, pharyngitis etc. ",amlodipine besilate + benazepril hydrochloride
sign_symptom,edema,0.9934894," benazepril/amlodipine has been evaluated for safety in patients with hypertension for at least 6 months and more than 1 year. the reported side effects were generally mild and transient, and there was no relationship between side effects and age, sex, race or duration of therapy. discontinuation of therapy due to side effects was required in approximately 4% of patients treated with benazepril/amlodipine and in 3% of patients treated with placebo. the most common reasons for discontinuation of therapy with benazepril/amlodipine in u.s. studies were cough and edema. the side effects considered possibly or probably related to study drug that occurred in u.s. placebo-controlled trials in more than 1% of patients treated with benazepril/amlodipine are cough, headache, dizziness and edema.  the incidence of edema was statistically greater in patients treated with amlodipine monotherapy than in patients treated with the combination. edema and certain other side effects are associated with amlodipine monotherapy in a dose-dependent manner, and appear to affect women more than men. the addition of benazepril resulted in lower incidences as shown in study; the protective effect of benazepril was independent of race and (within the range of doses tested) of dose.  other rare side effects are angioedema, asthenia, fatigue, insomnia, nervousness, anxiety, tremor, decreased libido, flushing, hot flashes, rash, skin nodule, dermatitis, dry mouth, nausea, abdominal pain, constipation, diarrhea, dyspepsia, esophagitis, hypokalemia, pharyngitis etc. ",amlodipine besilate + benazepril hydrochloride
medication,amlo,0.7905426," benazepril/amlodipine has been evaluated for safety in patients with hypertension for at least 6 months and more than 1 year. the reported side effects were generally mild and transient, and there was no relationship between side effects and age, sex, race or duration of therapy. discontinuation of therapy due to side effects was required in approximately 4% of patients treated with benazepril/amlodipine and in 3% of patients treated with placebo. the most common reasons for discontinuation of therapy with benazepril/amlodipine in u.s. studies were cough and edema. the side effects considered possibly or probably related to study drug that occurred in u.s. placebo-controlled trials in more than 1% of patients treated with benazepril/amlodipine are cough, headache, dizziness and edema.  the incidence of edema was statistically greater in patients treated with amlodipine monotherapy than in patients treated with the combination. edema and certain other side effects are associated with amlodipine monotherapy in a dose-dependent manner, and appear to affect women more than men. the addition of benazepril resulted in lower incidences as shown in study; the protective effect of benazepril was independent of race and (within the range of doses tested) of dose.  other rare side effects are angioedema, asthenia, fatigue, insomnia, nervousness, anxiety, tremor, decreased libido, flushing, hot flashes, rash, skin nodule, dermatitis, dry mouth, nausea, abdominal pain, constipation, diarrhea, dyspepsia, esophagitis, hypokalemia, pharyngitis etc. ",amlodipine besilate + benazepril hydrochloride
medication,amlodipine,0.89743805,"  amlodipine : general: since the vasodilatation induced by amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of amlodipine. nonetheless, caution should be exercised when administering amlodipine as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. use in patients with congestive heart failure: although hemodynamic studies and a controlled trial in class-ii-iii heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptoms. in general, all calcium channel blockers should be used with caution in patients with heart failure. beta-blocker rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class.    atorvastatin : atorvastatin may cause an elevation in serum creatine phosphokinase levels. this should be considered in the differential diagnosis of chest pain in patients on therapy with atorvastatin. uncomplicated myalgia has been reported in atorvastatin-treated patients. atorvastatin therapy should be discontinued if markedly elevated cpk levels occur or myopathy is diagnosed or suspected. side effects: atorvastatin is generally well tolerated. adverse effects reported commonly include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, asthenia and insomnia. ",amlodipine besilate + atorvastatin
medication,amlo,0.9807108,"  amlodipine : general: since the vasodilatation induced by amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of amlodipine. nonetheless, caution should be exercised when administering amlodipine as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. use in patients with congestive heart failure: although hemodynamic studies and a controlled trial in class-ii-iii heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptoms. in general, all calcium channel blockers should be used with caution in patients with heart failure. beta-blocker rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class.    atorvastatin : atorvastatin may cause an elevation in serum creatine phosphokinase levels. this should be considered in the differential diagnosis of chest pain in patients on therapy with atorvastatin. uncomplicated myalgia has been reported in atorvastatin-treated patients. atorvastatin therapy should be discontinued if markedly elevated cpk levels occur or myopathy is diagnosed or suspected. side effects: atorvastatin is generally well tolerated. adverse effects reported commonly include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, asthenia and insomnia. ",amlodipine besilate + atorvastatin
disease_disorder,heart,0.9750265,"  amlodipine : general: since the vasodilatation induced by amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of amlodipine. nonetheless, caution should be exercised when administering amlodipine as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. use in patients with congestive heart failure: although hemodynamic studies and a controlled trial in class-ii-iii heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptoms. in general, all calcium channel blockers should be used with caution in patients with heart failure. beta-blocker rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class.    atorvastatin : atorvastatin may cause an elevation in serum creatine phosphokinase levels. this should be considered in the differential diagnosis of chest pain in patients on therapy with atorvastatin. uncomplicated myalgia has been reported in atorvastatin-treated patients. atorvastatin therapy should be discontinued if markedly elevated cpk levels occur or myopathy is diagnosed or suspected. side effects: atorvastatin is generally well tolerated. adverse effects reported commonly include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, asthenia and insomnia. ",amlodipine besilate + atorvastatin
disease_disorder,heart failure,0.9992924,"  amlodipine : general: since the vasodilatation induced by amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of amlodipine. nonetheless, caution should be exercised when administering amlodipine as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. use in patients with congestive heart failure: although hemodynamic studies and a controlled trial in class-ii-iii heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptoms. in general, all calcium channel blockers should be used with caution in patients with heart failure. beta-blocker rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class.    atorvastatin : atorvastatin may cause an elevation in serum creatine phosphokinase levels. this should be considered in the differential diagnosis of chest pain in patients on therapy with atorvastatin. uncomplicated myalgia has been reported in atorvastatin-treated patients. atorvastatin therapy should be discontinued if markedly elevated cpk levels occur or myopathy is diagnosed or suspected. side effects: atorvastatin is generally well tolerated. adverse effects reported commonly include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, asthenia and insomnia. ",amlodipine besilate + atorvastatin
sign_symptom,deterioration,0.9929113,"  amlodipine : general: since the vasodilatation induced by amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of amlodipine. nonetheless, caution should be exercised when administering amlodipine as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. use in patients with congestive heart failure: although hemodynamic studies and a controlled trial in class-ii-iii heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptoms. in general, all calcium channel blockers should be used with caution in patients with heart failure. beta-blocker rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class.    atorvastatin : atorvastatin may cause an elevation in serum creatine phosphokinase levels. this should be considered in the differential diagnosis of chest pain in patients on therapy with atorvastatin. uncomplicated myalgia has been reported in atorvastatin-treated patients. atorvastatin therapy should be discontinued if markedly elevated cpk levels occur or myopathy is diagnosed or suspected. side effects: atorvastatin is generally well tolerated. adverse effects reported commonly include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, asthenia and insomnia. ",amlodipine besilate + atorvastatin
medication,calcium channel blockers,0.9533061,"  amlodipine : general: since the vasodilatation induced by amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of amlodipine. nonetheless, caution should be exercised when administering amlodipine as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. use in patients with congestive heart failure: although hemodynamic studies and a controlled trial in class-ii-iii heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptoms. in general, all calcium channel blockers should be used with caution in patients with heart failure. beta-blocker rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class.    atorvastatin : atorvastatin may cause an elevation in serum creatine phosphokinase levels. this should be considered in the differential diagnosis of chest pain in patients on therapy with atorvastatin. uncomplicated myalgia has been reported in atorvastatin-treated patients. atorvastatin therapy should be discontinued if markedly elevated cpk levels occur or myopathy is diagnosed or suspected. side effects: atorvastatin is generally well tolerated. adverse effects reported commonly include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, asthenia and insomnia. ",amlodipine besilate + atorvastatin
medication,beta - blocker,0.99817973,"  amlodipine : general: since the vasodilatation induced by amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of amlodipine. nonetheless, caution should be exercised when administering amlodipine as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. use in patients with congestive heart failure: although hemodynamic studies and a controlled trial in class-ii-iii heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptoms. in general, all calcium channel blockers should be used with caution in patients with heart failure. beta-blocker rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class.    atorvastatin : atorvastatin may cause an elevation in serum creatine phosphokinase levels. this should be considered in the differential diagnosis of chest pain in patients on therapy with atorvastatin. uncomplicated myalgia has been reported in atorvastatin-treated patients. atorvastatin therapy should be discontinued if markedly elevated cpk levels occur or myopathy is diagnosed or suspected. side effects: atorvastatin is generally well tolerated. adverse effects reported commonly include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, asthenia and insomnia. ",amlodipine besilate + atorvastatin
disease_disorder,renal failure,0.9985714,"  amlodipine : general: since the vasodilatation induced by amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of amlodipine. nonetheless, caution should be exercised when administering amlodipine as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. use in patients with congestive heart failure: although hemodynamic studies and a controlled trial in class-ii-iii heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptoms. in general, all calcium channel blockers should be used with caution in patients with heart failure. beta-blocker rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class.    atorvastatin : atorvastatin may cause an elevation in serum creatine phosphokinase levels. this should be considered in the differential diagnosis of chest pain in patients on therapy with atorvastatin. uncomplicated myalgia has been reported in atorvastatin-treated patients. atorvastatin therapy should be discontinued if markedly elevated cpk levels occur or myopathy is diagnosed or suspected. side effects: atorvastatin is generally well tolerated. adverse effects reported commonly include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, asthenia and insomnia. ",amlodipine besilate + atorvastatin
sign_symptom,pain,0.9999287,"  amlodipine : general: since the vasodilatation induced by amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of amlodipine. nonetheless, caution should be exercised when administering amlodipine as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. use in patients with congestive heart failure: although hemodynamic studies and a controlled trial in class-ii-iii heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptoms. in general, all calcium channel blockers should be used with caution in patients with heart failure. beta-blocker rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class.    atorvastatin : atorvastatin may cause an elevation in serum creatine phosphokinase levels. this should be considered in the differential diagnosis of chest pain in patients on therapy with atorvastatin. uncomplicated myalgia has been reported in atorvastatin-treated patients. atorvastatin therapy should be discontinued if markedly elevated cpk levels occur or myopathy is diagnosed or suspected. side effects: atorvastatin is generally well tolerated. adverse effects reported commonly include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, asthenia and insomnia. ",amlodipine besilate + atorvastatin
sign_symptom,myalgia,0.99882823,"  amlodipine : general: since the vasodilatation induced by amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of amlodipine. nonetheless, caution should be exercised when administering amlodipine as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. use in patients with congestive heart failure: although hemodynamic studies and a controlled trial in class-ii-iii heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptoms. in general, all calcium channel blockers should be used with caution in patients with heart failure. beta-blocker rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class.    atorvastatin : atorvastatin may cause an elevation in serum creatine phosphokinase levels. this should be considered in the differential diagnosis of chest pain in patients on therapy with atorvastatin. uncomplicated myalgia has been reported in atorvastatin-treated patients. atorvastatin therapy should be discontinued if markedly elevated cpk levels occur or myopathy is diagnosed or suspected. side effects: atorvastatin is generally well tolerated. adverse effects reported commonly include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, asthenia and insomnia. ",amlodipine besilate + atorvastatin
sign_symptom,flat,0.98235357,"  amlodipine : general: since the vasodilatation induced by amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration of amlodipine. nonetheless, caution should be exercised when administering amlodipine as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. use in patients with congestive heart failure: although hemodynamic studies and a controlled trial in class-ii-iii heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptoms. in general, all calcium channel blockers should be used with caution in patients with heart failure. beta-blocker rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported with other drugs in this class.    atorvastatin : atorvastatin may cause an elevation in serum creatine phosphokinase levels. this should be considered in the differential diagnosis of chest pain in patients on therapy with atorvastatin. uncomplicated myalgia has been reported in atorvastatin-treated patients. atorvastatin therapy should be discontinued if markedly elevated cpk levels occur or myopathy is diagnosed or suspected. side effects: atorvastatin is generally well tolerated. adverse effects reported commonly include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, asthenia and insomnia. ",amlodipine besilate + atorvastatin
medication,amlodipine,0.8911461," the most common adverse effects of amlodipine are associated with vasodilatory action, such as dizziness, flushing, headache, hypotension and peripheral edema. gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain and mental depression may also occur. a paradoxical increase in ischaemic chest pain may occur at the start of the treatment and in a few patients excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness. rashes, fever and abnormalities in liver function due to hypersensitivity reaction of amlodipine may occur. ",amlodipine besilate
sign_symptom,headache,0.8372395," the most common adverse effects of amlodipine are associated with vasodilatory action, such as dizziness, flushing, headache, hypotension and peripheral edema. gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain and mental depression may also occur. a paradoxical increase in ischaemic chest pain may occur at the start of the treatment and in a few patients excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness. rashes, fever and abnormalities in liver function due to hypersensitivity reaction of amlodipine may occur. ",amlodipine besilate
sign_symptom,lethargy,0.91966695," the most common adverse effects of amlodipine are associated with vasodilatory action, such as dizziness, flushing, headache, hypotension and peripheral edema. gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain and mental depression may also occur. a paradoxical increase in ischaemic chest pain may occur at the start of the treatment and in a few patients excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness. rashes, fever and abnormalities in liver function due to hypersensitivity reaction of amlodipine may occur. ",amlodipine besilate
sign_symptom,pain,0.9999176," the most common adverse effects of amlodipine are associated with vasodilatory action, such as dizziness, flushing, headache, hypotension and peripheral edema. gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain and mental depression may also occur. a paradoxical increase in ischaemic chest pain may occur at the start of the treatment and in a few patients excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness. rashes, fever and abnormalities in liver function due to hypersensitivity reaction of amlodipine may occur. ",amlodipine besilate
sign_symptom,mental depression,0.99580437," the most common adverse effects of amlodipine are associated with vasodilatory action, such as dizziness, flushing, headache, hypotension and peripheral edema. gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain and mental depression may also occur. a paradoxical increase in ischaemic chest pain may occur at the start of the treatment and in a few patients excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness. rashes, fever and abnormalities in liver function due to hypersensitivity reaction of amlodipine may occur. ",amlodipine besilate
sign_symptom,rash,0.99994826," the most common adverse effects of amlodipine are associated with vasodilatory action, such as dizziness, flushing, headache, hypotension and peripheral edema. gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain and mental depression may also occur. a paradoxical increase in ischaemic chest pain may occur at the start of the treatment and in a few patients excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness. rashes, fever and abnormalities in liver function due to hypersensitivity reaction of amlodipine may occur. ",amlodipine besilate
sign_symptom,fever,0.999961," the most common adverse effects of amlodipine are associated with vasodilatory action, such as dizziness, flushing, headache, hypotension and peripheral edema. gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain and mental depression may also occur. a paradoxical increase in ischaemic chest pain may occur at the start of the treatment and in a few patients excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness. rashes, fever and abnormalities in liver function due to hypersensitivity reaction of amlodipine may occur. ",amlodipine besilate
sign_symptom,abnormalities,0.9987764," the most common adverse effects of amlodipine are associated with vasodilatory action, such as dizziness, flushing, headache, hypotension and peripheral edema. gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain and mental depression may also occur. a paradoxical increase in ischaemic chest pain may occur at the start of the treatment and in a few patients excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness. rashes, fever and abnormalities in liver function due to hypersensitivity reaction of amlodipine may occur. ",amlodipine besilate
sign_symptom,hypersensitivity reaction,0.99899673," the most common adverse effects of amlodipine are associated with vasodilatory action, such as dizziness, flushing, headache, hypotension and peripheral edema. gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain and mental depression may also occur. a paradoxical increase in ischaemic chest pain may occur at the start of the treatment and in a few patients excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness. rashes, fever and abnormalities in liver function due to hypersensitivity reaction of amlodipine may occur. ",amlodipine besilate
medication,amlo,0.959941," the most common adverse effects of amlodipine are associated with vasodilatory action, such as dizziness, flushing, headache, hypotension and peripheral edema. gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain and mental depression may also occur. a paradoxical increase in ischaemic chest pain may occur at the start of the treatment and in a few patients excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness. rashes, fever and abnormalities in liver function due to hypersensitivity reaction of amlodipine may occur. ",amlodipine besilate
sign_symptom,adverse reactions,0.9997051," adverse reactions reported by 1-2% of patients were transient pain, stinging and/or burning at the site of application. infrequent (&lt;1%) adverse reactions in the clinical studies were contact mucositis, nausea, and diarrhea. ",amlexanox
sign_symptom,pain,0.9956721," adverse reactions reported by 1-2% of patients were transient pain, stinging and/or burning at the site of application. infrequent (&lt;1%) adverse reactions in the clinical studies were contact mucositis, nausea, and diarrhea. ",amlexanox
sign_symptom,burning,0.98608613," adverse reactions reported by 1-2% of patients were transient pain, stinging and/or burning at the site of application. infrequent (&lt;1%) adverse reactions in the clinical studies were contact mucositis, nausea, and diarrhea. ",amlexanox
sign_symptom,symptoms,0.8933122," side effects: many symptoms common to the depressive state, such as anorexia, fatigue, weakness, restlessness and lethargy, have been reported as side effects of treatment with this preparation.  adverse reactions: most frequently reported were drowsiness, dry mouth, constipation, blurred vision, dizziness and bloating. less commonly included vivid dreams, impotence, tremor, confusion and nasal congestion. ",amitriptyline hydrochloride + chlordiazepoxide
sign_symptom,restless,0.96165437," side effects: many symptoms common to the depressive state, such as anorexia, fatigue, weakness, restlessness and lethargy, have been reported as side effects of treatment with this preparation.  adverse reactions: most frequently reported were drowsiness, dry mouth, constipation, blurred vision, dizziness and bloating. less commonly included vivid dreams, impotence, tremor, confusion and nasal congestion. ",amitriptyline hydrochloride + chlordiazepoxide
sign_symptom,consti,0.94372106," side effects: many symptoms common to the depressive state, such as anorexia, fatigue, weakness, restlessness and lethargy, have been reported as side effects of treatment with this preparation.  adverse reactions: most frequently reported were drowsiness, dry mouth, constipation, blurred vision, dizziness and bloating. less commonly included vivid dreams, impotence, tremor, confusion and nasal congestion. ",amitriptyline hydrochloride + chlordiazepoxide
sign_symptom,blurred,0.80739796," side effects: many symptoms common to the depressive state, such as anorexia, fatigue, weakness, restlessness and lethargy, have been reported as side effects of treatment with this preparation.  adverse reactions: most frequently reported were drowsiness, dry mouth, constipation, blurred vision, dizziness and bloating. less commonly included vivid dreams, impotence, tremor, confusion and nasal congestion. ",amitriptyline hydrochloride + chlordiazepoxide
sign_symptom,blurred vision,0.86109936,"  
  anticholinergic : excessive perspiration, dry mouth, blurred vision, hyperpyrexia, urinary retention and urinary tract dilatation. 
  cardiovascular reactions : hypotension, syncope, postural hypotension, hypertension, tachycardia, palpitations, myocardial infarction, etc. 
  cns and neuromuscular : confusional states, disturbed concentration, disorientation, delusions, etc. 
  allergic : skin rash, urticaria, photosensitization, etc. 
  haematological : bone-marrow depression. 
  gastrointestinal : nausea, epigastric distress, vomiting, anorexia, stomatitis, unpleasant taste, weight loss, diarrhoea, constipation, etc. 
  endocrine : testicular swelling, gynaecomastia, breast enlargement, galactorrhoea, etc. 
  ",amitriptyline hydrochloride
sign_symptom,urina,0.7302509,"  
  anticholinergic : excessive perspiration, dry mouth, blurred vision, hyperpyrexia, urinary retention and urinary tract dilatation. 
  cardiovascular reactions : hypotension, syncope, postural hypotension, hypertension, tachycardia, palpitations, myocardial infarction, etc. 
  cns and neuromuscular : confusional states, disturbed concentration, disorientation, delusions, etc. 
  allergic : skin rash, urticaria, photosensitization, etc. 
  haematological : bone-marrow depression. 
  gastrointestinal : nausea, epigastric distress, vomiting, anorexia, stomatitis, unpleasant taste, weight loss, diarrhoea, constipation, etc. 
  endocrine : testicular swelling, gynaecomastia, breast enlargement, galactorrhoea, etc. 
  ",amitriptyline hydrochloride
sign_symptom,confusional,0.87456334,"  
  anticholinergic : excessive perspiration, dry mouth, blurred vision, hyperpyrexia, urinary retention and urinary tract dilatation. 
  cardiovascular reactions : hypotension, syncope, postural hypotension, hypertension, tachycardia, palpitations, myocardial infarction, etc. 
  cns and neuromuscular : confusional states, disturbed concentration, disorientation, delusions, etc. 
  allergic : skin rash, urticaria, photosensitization, etc. 
  haematological : bone-marrow depression. 
  gastrointestinal : nausea, epigastric distress, vomiting, anorexia, stomatitis, unpleasant taste, weight loss, diarrhoea, constipation, etc. 
  endocrine : testicular swelling, gynaecomastia, breast enlargement, galactorrhoea, etc. 
  ",amitriptyline hydrochloride
medication,amioda,0.7958003," the most severe side effects of amiodarone therapy are related to the lungs. these reactions can be fatal. patients should report any symptoms of cough, fever, or painful breathing. although quite rare, fatal liver toxicity may occur with amiodarone therapy. reversible corneal microdeposits (sometimes with night glare), rarely impaired vision due to optic neuritis; peripheral neuropathy and myopathy (usually reversible on withdrawal); bradycardia and conduction disturbances; phototoxicity and rarely persistent skin discolouration; hypothyroidism, hyperthyroidism; raised serum transaminases; jaundice, hepatitis and cirrhosis are reported. other rare complaints are nausea, vomiting, metallic taste, tremor, sweating, vertigo, headache, sleeplessness, fatigue, alopecia, benign raised intracranial pressure, ataxia, rashes, vasculitis, renal involvement, thrombocytopenia, haemolytic or aplastic anaemia. in some cases, dose of amiodarone may be reduced. in other cases, amiodarone therapy may need to be stopped. ",amiodarone hydrochloride
sign_symptom,toxicity,0.7774731," the most severe side effects of amiodarone therapy are related to the lungs. these reactions can be fatal. patients should report any symptoms of cough, fever, or painful breathing. although quite rare, fatal liver toxicity may occur with amiodarone therapy. reversible corneal microdeposits (sometimes with night glare), rarely impaired vision due to optic neuritis; peripheral neuropathy and myopathy (usually reversible on withdrawal); bradycardia and conduction disturbances; phototoxicity and rarely persistent skin discolouration; hypothyroidism, hyperthyroidism; raised serum transaminases; jaundice, hepatitis and cirrhosis are reported. other rare complaints are nausea, vomiting, metallic taste, tremor, sweating, vertigo, headache, sleeplessness, fatigue, alopecia, benign raised intracranial pressure, ataxia, rashes, vasculitis, renal involvement, thrombocytopenia, haemolytic or aplastic anaemia. in some cases, dose of amiodarone may be reduced. in other cases, amiodarone therapy may need to be stopped. ",amiodarone hydrochloride
sign_symptom,corneal micro,0.810177," the most severe side effects of amiodarone therapy are related to the lungs. these reactions can be fatal. patients should report any symptoms of cough, fever, or painful breathing. although quite rare, fatal liver toxicity may occur with amiodarone therapy. reversible corneal microdeposits (sometimes with night glare), rarely impaired vision due to optic neuritis; peripheral neuropathy and myopathy (usually reversible on withdrawal); bradycardia and conduction disturbances; phototoxicity and rarely persistent skin discolouration; hypothyroidism, hyperthyroidism; raised serum transaminases; jaundice, hepatitis and cirrhosis are reported. other rare complaints are nausea, vomiting, metallic taste, tremor, sweating, vertigo, headache, sleeplessness, fatigue, alopecia, benign raised intracranial pressure, ataxia, rashes, vasculitis, renal involvement, thrombocytopenia, haemolytic or aplastic anaemia. in some cases, dose of amiodarone may be reduced. in other cases, amiodarone therapy may need to be stopped. ",amiodarone hydrochloride
sign_symptom,impaired vision,0.99263954," the most severe side effects of amiodarone therapy are related to the lungs. these reactions can be fatal. patients should report any symptoms of cough, fever, or painful breathing. although quite rare, fatal liver toxicity may occur with amiodarone therapy. reversible corneal microdeposits (sometimes with night glare), rarely impaired vision due to optic neuritis; peripheral neuropathy and myopathy (usually reversible on withdrawal); bradycardia and conduction disturbances; phototoxicity and rarely persistent skin discolouration; hypothyroidism, hyperthyroidism; raised serum transaminases; jaundice, hepatitis and cirrhosis are reported. other rare complaints are nausea, vomiting, metallic taste, tremor, sweating, vertigo, headache, sleeplessness, fatigue, alopecia, benign raised intracranial pressure, ataxia, rashes, vasculitis, renal involvement, thrombocytopenia, haemolytic or aplastic anaemia. in some cases, dose of amiodarone may be reduced. in other cases, amiodarone therapy may need to be stopped. ",amiodarone hydrochloride
sign_symptom,neuropathy,0.93967056," the most severe side effects of amiodarone therapy are related to the lungs. these reactions can be fatal. patients should report any symptoms of cough, fever, or painful breathing. although quite rare, fatal liver toxicity may occur with amiodarone therapy. reversible corneal microdeposits (sometimes with night glare), rarely impaired vision due to optic neuritis; peripheral neuropathy and myopathy (usually reversible on withdrawal); bradycardia and conduction disturbances; phototoxicity and rarely persistent skin discolouration; hypothyroidism, hyperthyroidism; raised serum transaminases; jaundice, hepatitis and cirrhosis are reported. other rare complaints are nausea, vomiting, metallic taste, tremor, sweating, vertigo, headache, sleeplessness, fatigue, alopecia, benign raised intracranial pressure, ataxia, rashes, vasculitis, renal involvement, thrombocytopenia, haemolytic or aplastic anaemia. in some cases, dose of amiodarone may be reduced. in other cases, amiodarone therapy may need to be stopped. ",amiodarone hydrochloride
sign_symptom,myopathy,0.9613419," the most severe side effects of amiodarone therapy are related to the lungs. these reactions can be fatal. patients should report any symptoms of cough, fever, or painful breathing. although quite rare, fatal liver toxicity may occur with amiodarone therapy. reversible corneal microdeposits (sometimes with night glare), rarely impaired vision due to optic neuritis; peripheral neuropathy and myopathy (usually reversible on withdrawal); bradycardia and conduction disturbances; phototoxicity and rarely persistent skin discolouration; hypothyroidism, hyperthyroidism; raised serum transaminases; jaundice, hepatitis and cirrhosis are reported. other rare complaints are nausea, vomiting, metallic taste, tremor, sweating, vertigo, headache, sleeplessness, fatigue, alopecia, benign raised intracranial pressure, ataxia, rashes, vasculitis, renal involvement, thrombocytopenia, haemolytic or aplastic anaemia. in some cases, dose of amiodarone may be reduced. in other cases, amiodarone therapy may need to be stopped. ",amiodarone hydrochloride
sign_symptom,bradycardia,0.9996434," the most severe side effects of amiodarone therapy are related to the lungs. these reactions can be fatal. patients should report any symptoms of cough, fever, or painful breathing. although quite rare, fatal liver toxicity may occur with amiodarone therapy. reversible corneal microdeposits (sometimes with night glare), rarely impaired vision due to optic neuritis; peripheral neuropathy and myopathy (usually reversible on withdrawal); bradycardia and conduction disturbances; phototoxicity and rarely persistent skin discolouration; hypothyroidism, hyperthyroidism; raised serum transaminases; jaundice, hepatitis and cirrhosis are reported. other rare complaints are nausea, vomiting, metallic taste, tremor, sweating, vertigo, headache, sleeplessness, fatigue, alopecia, benign raised intracranial pressure, ataxia, rashes, vasculitis, renal involvement, thrombocytopenia, haemolytic or aplastic anaemia. in some cases, dose of amiodarone may be reduced. in other cases, amiodarone therapy may need to be stopped. ",amiodarone hydrochloride
sign_symptom,conduct,0.9997832," the most severe side effects of amiodarone therapy are related to the lungs. these reactions can be fatal. patients should report any symptoms of cough, fever, or painful breathing. although quite rare, fatal liver toxicity may occur with amiodarone therapy. reversible corneal microdeposits (sometimes with night glare), rarely impaired vision due to optic neuritis; peripheral neuropathy and myopathy (usually reversible on withdrawal); bradycardia and conduction disturbances; phototoxicity and rarely persistent skin discolouration; hypothyroidism, hyperthyroidism; raised serum transaminases; jaundice, hepatitis and cirrhosis are reported. other rare complaints are nausea, vomiting, metallic taste, tremor, sweating, vertigo, headache, sleeplessness, fatigue, alopecia, benign raised intracranial pressure, ataxia, rashes, vasculitis, renal involvement, thrombocytopenia, haemolytic or aplastic anaemia. in some cases, dose of amiodarone may be reduced. in other cases, amiodarone therapy may need to be stopped. ",amiodarone hydrochloride
sign_symptom,phototoxicity,0.999181," the most severe side effects of amiodarone therapy are related to the lungs. these reactions can be fatal. patients should report any symptoms of cough, fever, or painful breathing. although quite rare, fatal liver toxicity may occur with amiodarone therapy. reversible corneal microdeposits (sometimes with night glare), rarely impaired vision due to optic neuritis; peripheral neuropathy and myopathy (usually reversible on withdrawal); bradycardia and conduction disturbances; phototoxicity and rarely persistent skin discolouration; hypothyroidism, hyperthyroidism; raised serum transaminases; jaundice, hepatitis and cirrhosis are reported. other rare complaints are nausea, vomiting, metallic taste, tremor, sweating, vertigo, headache, sleeplessness, fatigue, alopecia, benign raised intracranial pressure, ataxia, rashes, vasculitis, renal involvement, thrombocytopenia, haemolytic or aplastic anaemia. in some cases, dose of amiodarone may be reduced. in other cases, amiodarone therapy may need to be stopped. ",amiodarone hydrochloride
sign_symptom,skin disco,0.98295486," the most severe side effects of amiodarone therapy are related to the lungs. these reactions can be fatal. patients should report any symptoms of cough, fever, or painful breathing. although quite rare, fatal liver toxicity may occur with amiodarone therapy. reversible corneal microdeposits (sometimes with night glare), rarely impaired vision due to optic neuritis; peripheral neuropathy and myopathy (usually reversible on withdrawal); bradycardia and conduction disturbances; phototoxicity and rarely persistent skin discolouration; hypothyroidism, hyperthyroidism; raised serum transaminases; jaundice, hepatitis and cirrhosis are reported. other rare complaints are nausea, vomiting, metallic taste, tremor, sweating, vertigo, headache, sleeplessness, fatigue, alopecia, benign raised intracranial pressure, ataxia, rashes, vasculitis, renal involvement, thrombocytopenia, haemolytic or aplastic anaemia. in some cases, dose of amiodarone may be reduced. in other cases, amiodarone therapy may need to be stopped. ",amiodarone hydrochloride
disease_disorder,cirrhosis,0.75188094," the most severe side effects of amiodarone therapy are related to the lungs. these reactions can be fatal. patients should report any symptoms of cough, fever, or painful breathing. although quite rare, fatal liver toxicity may occur with amiodarone therapy. reversible corneal microdeposits (sometimes with night glare), rarely impaired vision due to optic neuritis; peripheral neuropathy and myopathy (usually reversible on withdrawal); bradycardia and conduction disturbances; phototoxicity and rarely persistent skin discolouration; hypothyroidism, hyperthyroidism; raised serum transaminases; jaundice, hepatitis and cirrhosis are reported. other rare complaints are nausea, vomiting, metallic taste, tremor, sweating, vertigo, headache, sleeplessness, fatigue, alopecia, benign raised intracranial pressure, ataxia, rashes, vasculitis, renal involvement, thrombocytopenia, haemolytic or aplastic anaemia. in some cases, dose of amiodarone may be reduced. in other cases, amiodarone therapy may need to be stopped. ",amiodarone hydrochloride
sign_symptom,pain,0.8505794," the most common adverse effects are gastric irritation, nausea, vomiting, diarrhea, hematemesis, epigastric pain and tremor. these are usually early signs of toxicity; however, with high doses, ventricular arrhythmias or seizures may be the first signs to appear and reactivation of peptic ulcer, headache, irritability, restlessness, insomnia, twitching, convulsion and reflex hyperexcitability, palpitation, tachycardia, hypotension, circulatory failure, ventricular arrhythmias, and flushing, albuminuria, diuresis and hematuria. also inappropriate adh syndrome may occur. ",aminophylline
sign_symptom,seizures,0.99977547," the most common adverse effects are gastric irritation, nausea, vomiting, diarrhea, hematemesis, epigastric pain and tremor. these are usually early signs of toxicity; however, with high doses, ventricular arrhythmias or seizures may be the first signs to appear and reactivation of peptic ulcer, headache, irritability, restlessness, insomnia, twitching, convulsion and reflex hyperexcitability, palpitation, tachycardia, hypotension, circulatory failure, ventricular arrhythmias, and flushing, albuminuria, diuresis and hematuria. also inappropriate adh syndrome may occur. ",aminophylline
sign_symptom,convulsion,0.9228399," the most common adverse effects are gastric irritation, nausea, vomiting, diarrhea, hematemesis, epigastric pain and tremor. these are usually early signs of toxicity; however, with high doses, ventricular arrhythmias or seizures may be the first signs to appear and reactivation of peptic ulcer, headache, irritability, restlessness, insomnia, twitching, convulsion and reflex hyperexcitability, palpitation, tachycardia, hypotension, circulatory failure, ventricular arrhythmias, and flushing, albuminuria, diuresis and hematuria. also inappropriate adh syndrome may occur. ",aminophylline
sign_symptom,effect,0.96239376, no significant side effect has been observed in therapeutic dosage. ,kabid nawshadri
sign_symptom,effect,0.96239376, no significant side effect has been observed in therapeutic dosage. ,jinsin
sign_symptom,effect,0.96239376, no significant side effect has been observed in therapeutic dosage. ,mumshik
sign_symptom,effect,0.96239376, no significant side effect has been observed in therapeutic dosage. ,"qurs mulayin [scammony, lavender, fennel]"
sign_symptom,effect,0.96239376, no significant side effect has been observed in therapeutic dosage. ,penitab
sign_symptom,effect,0.96239376, no significant side effect has been observed in therapeutic dosage. ,sana + revand chini + neem + chirata + tulsi
sign_symptom,effect,0.96239376, no significant side effect has been observed in therapeutic dosage. ,white damar + acacia + bole rubra
sign_symptom,effect,0.96239376, no significant side effect has been observed in therapeutic dosage. ,rhubarb + ginger
sign_symptom,effect,0.96239376, no significant side effect has been observed in therapeutic dosage. ,guggul + barberry + chebulic myrobalan
sign_symptom,side effects,0.9997831," no severe side effects have been observed with jogaraj guggulu during the clinical practice for the last twenty-five years; however, systematic phase 1 study with this drug is carried out and general tolerability of jogaraj guggulu is found good.maximum tolerable dose is about 9 gm per day. in rare case very high dose than prescribed may lead to stomach irritation,diarrhea,stomatitis &amp; urticaria. ",jogaraj guggulu
disease_disorder,stoma,0.8053795," no severe side effects have been observed with jogaraj guggulu during the clinical practice for the last twenty-five years; however, systematic phase 1 study with this drug is carried out and general tolerability of jogaraj guggulu is found good.maximum tolerable dose is about 9 gm per day. in rare case very high dose than prescribed may lead to stomach irritation,diarrhea,stomatitis &amp; urticaria. ",jogaraj guggulu
sign_symptom,side effect,0.8654026, there is no known significant side effect ,jeerakaddarishta carminative
sign_symptom,irritation,0.99975544," in few cases it may occurs flatulence, stomach irritation &amp; intestinal obstruction. ",ispaghula husk + sonapata
medication,ispaghula,0.90347946," ispaghula husk and mebeverine hydrochloride are generally safe. but, some people may experience mild abdominal distension or flatulence for the first few days after starting this medicine. these effects should lessen as you continue the treatment. ",ispaghula husk + mebeverine hydrochloride
sign_symptom,flatulence,0.9987635," ispaghula husk and mebeverine hydrochloride are generally safe. but, some people may experience mild abdominal distension or flatulence for the first few days after starting this medicine. these effects should lessen as you continue the treatment. ",ispaghula husk + mebeverine hydrochloride
sign_symptom,side effects,0.95779425," ayurvedic medicine is clinically proven as safe &amp; well tolerated. in the recommended doses, side effects are rare. ",herbal cough syrup [vasakarista]
sign_symptom,gl disturbance,0.9466861," mild gl disturbance, dizziness, tinnitus, reduction in reticulocyte and leucocyte counts, nausea, vomiting, abdominal pain, bradycardia, first degree heart block, transient increase in serum transaminases. ",artemether
disease_disorder,stevens - johnson syndrome,0.7120228," the most common side effects of armodafinil are serious rash, including stevens-johnson syndrome, angioedema and anaphylaxis reactions, multi-organ hypersensitivity reactions, persistent sleepiness, psychiatric symptoms and some cardiovascular events. ",armodafinil
sign_symptom,anaphylaxis,0.9903973," the most common side effects of armodafinil are serious rash, including stevens-johnson syndrome, angioedema and anaphylaxis reactions, multi-organ hypersensitivity reactions, persistent sleepiness, psychiatric symptoms and some cardiovascular events. ",armodafinil
sign_symptom,hypersensitivity,0.7972182," the most common side effects of armodafinil are serious rash, including stevens-johnson syndrome, angioedema and anaphylaxis reactions, multi-organ hypersensitivity reactions, persistent sleepiness, psychiatric symptoms and some cardiovascular events. ",armodafinil
sign_symptom,psychiatric symptoms,0.99930894," the most common side effects of armodafinil are serious rash, including stevens-johnson syndrome, angioedema and anaphylaxis reactions, multi-organ hypersensitivity reactions, persistent sleepiness, psychiatric symptoms and some cardiovascular events. ",armodafinil
sign_symptom,dysp,0.7248089," most common adverse reactions are pain, chest pain, back pain, diarrhea, sinusitis, leg cramps, dyspnea, rash, flu syndrome, peripheral edema and lung disorder. arformoterol can cause serious side effects, including: people with asthma, who take laba medicines, have an increased risk of death from asthma problems. patient should get emergency medical care if: 
 
 breathing problems worsen quickly 
 after the use of rescue inhaler medicine, it does not relieve breathing problems. 
  ",arformoterol tartrate
sign_symptom,breathing problems,0.9988425," most common adverse reactions are pain, chest pain, back pain, diarrhea, sinusitis, leg cramps, dyspnea, rash, flu syndrome, peripheral edema and lung disorder. arformoterol can cause serious side effects, including: people with asthma, who take laba medicines, have an increased risk of death from asthma problems. patient should get emergency medical care if: 
 
 breathing problems worsen quickly 
 after the use of rescue inhaler medicine, it does not relieve breathing problems. 
  ",arformoterol tartrate
medication,arabinoxylan compound,0.986958," arabinoxylan compound is a natural product that has no adverse or toxic side-effects, confirmed by blood tests and examinations of liver and kidney function of people who have taken high amounts of the compound over several months. the only obvious contraindication is that, as an immunomodulator, able to boost weak immune systems, it should not be taken in conjunction with any medication specifically for suppressing the immune system.  and, although mushroom enzymes are used in arabinoxylan manufacture, there is no mushroom content in the final product, which means that nearly all those with mushroom intolerances have been able to take it without an allergic reaction. this compound has also been authorized by the japan health food and nutrition food association, and has passed strict evaluation standards set under the guidance of the ministry of health and welfare. ",arabinoxylan
medication,product,0.81474316," arabinoxylan compound is a natural product that has no adverse or toxic side-effects, confirmed by blood tests and examinations of liver and kidney function of people who have taken high amounts of the compound over several months. the only obvious contraindication is that, as an immunomodulator, able to boost weak immune systems, it should not be taken in conjunction with any medication specifically for suppressing the immune system.  and, although mushroom enzymes are used in arabinoxylan manufacture, there is no mushroom content in the final product, which means that nearly all those with mushroom intolerances have been able to take it without an allergic reaction. this compound has also been authorized by the japan health food and nutrition food association, and has passed strict evaluation standards set under the guidance of the ministry of health and welfare. ",arabinoxylan
medication,medication,0.8783241," arabinoxylan compound is a natural product that has no adverse or toxic side-effects, confirmed by blood tests and examinations of liver and kidney function of people who have taken high amounts of the compound over several months. the only obvious contraindication is that, as an immunomodulator, able to boost weak immune systems, it should not be taken in conjunction with any medication specifically for suppressing the immune system.  and, although mushroom enzymes are used in arabinoxylan manufacture, there is no mushroom content in the final product, which means that nearly all those with mushroom intolerances have been able to take it without an allergic reaction. this compound has also been authorized by the japan health food and nutrition food association, and has passed strict evaluation standards set under the guidance of the ministry of health and welfare. ",arabinoxylan
sign_symptom,mushroom enzymes,0.7690797," arabinoxylan compound is a natural product that has no adverse or toxic side-effects, confirmed by blood tests and examinations of liver and kidney function of people who have taken high amounts of the compound over several months. the only obvious contraindication is that, as an immunomodulator, able to boost weak immune systems, it should not be taken in conjunction with any medication specifically for suppressing the immune system.  and, although mushroom enzymes are used in arabinoxylan manufacture, there is no mushroom content in the final product, which means that nearly all those with mushroom intolerances have been able to take it without an allergic reaction. this compound has also been authorized by the japan health food and nutrition food association, and has passed strict evaluation standards set under the guidance of the ministry of health and welfare. ",arabinoxylan
medication,arabinoxylan,0.87407255," arabinoxylan compound is a natural product that has no adverse or toxic side-effects, confirmed by blood tests and examinations of liver and kidney function of people who have taken high amounts of the compound over several months. the only obvious contraindication is that, as an immunomodulator, able to boost weak immune systems, it should not be taken in conjunction with any medication specifically for suppressing the immune system.  and, although mushroom enzymes are used in arabinoxylan manufacture, there is no mushroom content in the final product, which means that nearly all those with mushroom intolerances have been able to take it without an allergic reaction. this compound has also been authorized by the japan health food and nutrition food association, and has passed strict evaluation standards set under the guidance of the ministry of health and welfare. ",arabinoxylan
sign_symptom,mushroom,0.99974924," arabinoxylan compound is a natural product that has no adverse or toxic side-effects, confirmed by blood tests and examinations of liver and kidney function of people who have taken high amounts of the compound over several months. the only obvious contraindication is that, as an immunomodulator, able to boost weak immune systems, it should not be taken in conjunction with any medication specifically for suppressing the immune system.  and, although mushroom enzymes are used in arabinoxylan manufacture, there is no mushroom content in the final product, which means that nearly all those with mushroom intolerances have been able to take it without an allergic reaction. this compound has also been authorized by the japan health food and nutrition food association, and has passed strict evaluation standards set under the guidance of the ministry of health and welfare. ",arabinoxylan
sign_symptom,mushroom intolerances,0.9980798," arabinoxylan compound is a natural product that has no adverse or toxic side-effects, confirmed by blood tests and examinations of liver and kidney function of people who have taken high amounts of the compound over several months. the only obvious contraindication is that, as an immunomodulator, able to boost weak immune systems, it should not be taken in conjunction with any medication specifically for suppressing the immune system.  and, although mushroom enzymes are used in arabinoxylan manufacture, there is no mushroom content in the final product, which means that nearly all those with mushroom intolerances have been able to take it without an allergic reaction. this compound has also been authorized by the japan health food and nutrition food association, and has passed strict evaluation standards set under the guidance of the ministry of health and welfare. ",arabinoxylan
medication,apixaban,0.9929454, apixaban can cause a skin rash or severe allergic reaction. ,apixaban
sign_symptom,rash,0.9992816, apixaban can cause a skin rash or severe allergic reaction. ,apixaban
sign_symptom,allergic reactions,0.99633265," allergic reactions e.g. chills, chest tightness, fever, headache, hyperfibrinogenaemia, jittery feeling, lethargy, nausea, vomiting, somnolence, stinging at infusion site, stomach discomfort, tingling, urticaria, vasomotor reactions with rapid infusion. ",antihemophilic factor [factor viii]
sign_symptom,tight,0.9943733," allergic reactions e.g. chills, chest tightness, fever, headache, hyperfibrinogenaemia, jittery feeling, lethargy, nausea, vomiting, somnolence, stinging at infusion site, stomach discomfort, tingling, urticaria, vasomotor reactions with rapid infusion. ",antihemophilic factor [factor viii]
sign_symptom,hyperfibrinogenaemia,0.87439376," allergic reactions e.g. chills, chest tightness, fever, headache, hyperfibrinogenaemia, jittery feeling, lethargy, nausea, vomiting, somnolence, stinging at infusion site, stomach discomfort, tingling, urticaria, vasomotor reactions with rapid infusion. ",antihemophilic factor [factor viii]
sign_symptom,adverse reactions,0.99980026," the most common adverse reactions and laboratory abnormalities (incidence&gt;5% higher than comparator) are urinary tract infection, abdominal pain, hypertension, nausea, shortness of breath, fever, headache, anxiety, chills, increased potassium levels in the blood, low counts of platelets and white blood cells ",anti-thymocyte globulin
sign_symptom,abnormalities,0.74224585," the most common adverse reactions and laboratory abnormalities (incidence&gt;5% higher than comparator) are urinary tract infection, abdominal pain, hypertension, nausea, shortness of breath, fever, headache, anxiety, chills, increased potassium levels in the blood, low counts of platelets and white blood cells ",anti-thymocyte globulin
sign_symptom,pain,0.8883151," the most common adverse reactions and laboratory abnormalities (incidence&gt;5% higher than comparator) are urinary tract infection, abdominal pain, hypertension, nausea, shortness of breath, fever, headache, anxiety, chills, increased potassium levels in the blood, low counts of platelets and white blood cells ",anti-thymocyte globulin
sign_symptom,shortness of breath,0.9997231," the most common adverse reactions and laboratory abnormalities (incidence&gt;5% higher than comparator) are urinary tract infection, abdominal pain, hypertension, nausea, shortness of breath, fever, headache, anxiety, chills, increased potassium levels in the blood, low counts of platelets and white blood cells ",anti-thymocyte globulin
disease_disorder,candidemia,0.91646427," adults- 
 
 candidemia and other forms of candida infections: most common adverse reactions (15%) are hypokalemia, nausea, diarrhea, vomiting, pyrexia, insomnia, hypotension. 
 esophageal candidiasis: most common adverse reactions (5%) are diarrhea, pyrexia, anemia, headache, vomiting, nausea, dyspepsia, oral candidiasis, and hypokalemia. 
 
pediatric patients (1 month and older): candidemia and other forms of candida infections: most common adverse reactions ( 5%): diarrhea, vomiting, pyrexia, abdominal pain, anemia, thrombocytopenia, alanine aminotransferase (alt) and aspartate aminotransferase (ast) increased, hypoglycemia, epistaxis, and rash. ",anidulafungin
disease_disorder,candida infections,0.9612675," adults- 
 
 candidemia and other forms of candida infections: most common adverse reactions (15%) are hypokalemia, nausea, diarrhea, vomiting, pyrexia, insomnia, hypotension. 
 esophageal candidiasis: most common adverse reactions (5%) are diarrhea, pyrexia, anemia, headache, vomiting, nausea, dyspepsia, oral candidiasis, and hypokalemia. 
 
pediatric patients (1 month and older): candidemia and other forms of candida infections: most common adverse reactions ( 5%): diarrhea, vomiting, pyrexia, abdominal pain, anemia, thrombocytopenia, alanine aminotransferase (alt) and aspartate aminotransferase (ast) increased, hypoglycemia, epistaxis, and rash. ",anidulafungin
sign_symptom,candi,0.8540202," adults- 
 
 candidemia and other forms of candida infections: most common adverse reactions (15%) are hypokalemia, nausea, diarrhea, vomiting, pyrexia, insomnia, hypotension. 
 esophageal candidiasis: most common adverse reactions (5%) are diarrhea, pyrexia, anemia, headache, vomiting, nausea, dyspepsia, oral candidiasis, and hypokalemia. 
 
pediatric patients (1 month and older): candidemia and other forms of candida infections: most common adverse reactions ( 5%): diarrhea, vomiting, pyrexia, abdominal pain, anemia, thrombocytopenia, alanine aminotransferase (alt) and aspartate aminotransferase (ast) increased, hypoglycemia, epistaxis, and rash. ",anidulafungin
sign_symptom,vomiting,0.8700604," adults- 
 
 candidemia and other forms of candida infections: most common adverse reactions (15%) are hypokalemia, nausea, diarrhea, vomiting, pyrexia, insomnia, hypotension. 
 esophageal candidiasis: most common adverse reactions (5%) are diarrhea, pyrexia, anemia, headache, vomiting, nausea, dyspepsia, oral candidiasis, and hypokalemia. 
 
pediatric patients (1 month and older): candidemia and other forms of candida infections: most common adverse reactions ( 5%): diarrhea, vomiting, pyrexia, abdominal pain, anemia, thrombocytopenia, alanine aminotransferase (alt) and aspartate aminotransferase (ast) increased, hypoglycemia, epistaxis, and rash. ",anidulafungin
medication,nabay,0.7490349, nabayas louha capsules are not known to have any side effects if taken as per prescribed dosage. ,nabayas louha herbal haematinic
medication,louha,0.8393364, nabayas louha capsules are not known to have any side effects if taken as per prescribed dosage. ,nabayas louha herbal haematinic
sign_symptom,effects,0.93546474, nabayas louha capsules are not known to have any side effects if taken as per prescribed dosage. ,nabayas louha herbal haematinic
sign_symptom,side effects,0.99724627, this capsule is generally well tolerated. no significant side effects have been observed in therapeutic dosage. ,marine collagen
sign_symptom,pain,0.9997651," there are no side effects associated with the use of drakkha in the above-mentioned therapeutic doses. drakkha has been used safely as an ayurvedic medicine for hundreds of years. but in very rare case stomach pain, headache and an allergic reaction have been reported. ",mahadrakkharist [grape extract]
sign_symptom,headache,0.9999604," there are no side effects associated with the use of drakkha in the above-mentioned therapeutic doses. drakkha has been used safely as an ayurvedic medicine for hundreds of years. but in very rare case stomach pain, headache and an allergic reaction have been reported. ",mahadrakkharist [grape extract]
sign_symptom,allergic reaction,0.9999322," there are no side effects associated with the use of drakkha in the above-mentioned therapeutic doses. drakkha has been used safely as an ayurvedic medicine for hundreds of years. but in very rare case stomach pain, headache and an allergic reaction have been reported. ",mahadrakkharist [grape extract]
sign_symptom,adverse side effects,0.99991816, no adverse side effects have been reported. ames testing has demonstrated an absence of any mutagenic effects for purified lutein and zeaxanthin. ,lutein + zeaxanthin
sign_symptom,effects,0.74674636, no adverse side effects have been reported. ames testing has demonstrated an absence of any mutagenic effects for purified lutein and zeaxanthin. ,lutein + zeaxanthin
sign_symptom,irritation,0.9998945," local skin irritation (e.g. erythema, scaling, itching or burning) occurs in occasional cases, usually at the start of treatment. however, in the majority of cases the irritation is mild and regresses as treatment continues. ",azelaic acid
disease_disorder,infections,0.9997004," opportunistic infections especially in transplant patients receiving concomitant other immunosuppressants. bone marrow depression, leucopenia, thrombocytopenia, nausea. uncommonly, anaemia, hypersensitivity reactions, cholestasis, pancreatitis. ",azathioprine
sign_symptom,adverse reactions,0.9993998," selected adverse reactions (all grades) that were reported in &lt; 10% of patients treated with axitinibincluded dizziness (9%), upper abdominal pain (8%),myalgia(7%), dehydration (6%),epistaxis(6%),anemia(4%),hemorrhoids(4%),hematuria(3%),tinnitus(3%), lipase increased (3%), glossodynia (3%),pulmonary embolism(2%), rectal hemorrhage (2%),hemoptysis(2%),deep vein thrombosis(1%), retinal-veinocclusion/thrombosis(1%),polycythemia(1%), andtransient ischemic attack(1%). ",axitinib
sign_symptom,pain,0.99994373," selected adverse reactions (all grades) that were reported in &lt; 10% of patients treated with axitinibincluded dizziness (9%), upper abdominal pain (8%),myalgia(7%), dehydration (6%),epistaxis(6%),anemia(4%),hemorrhoids(4%),hematuria(3%),tinnitus(3%), lipase increased (3%), glossodynia (3%),pulmonary embolism(2%), rectal hemorrhage (2%),hemoptysis(2%),deep vein thrombosis(1%), retinal-veinocclusion/thrombosis(1%),polycythemia(1%), andtransient ischemic attack(1%). ",axitinib
sign_symptom,hematuria,0.98264474," selected adverse reactions (all grades) that were reported in &lt; 10% of patients treated with axitinibincluded dizziness (9%), upper abdominal pain (8%),myalgia(7%), dehydration (6%),epistaxis(6%),anemia(4%),hemorrhoids(4%),hematuria(3%),tinnitus(3%), lipase increased (3%), glossodynia (3%),pulmonary embolism(2%), rectal hemorrhage (2%),hemoptysis(2%),deep vein thrombosis(1%), retinal-veinocclusion/thrombosis(1%),polycythemia(1%), andtransient ischemic attack(1%). ",axitinib
sign_symptom,tinnitus,0.83359176," selected adverse reactions (all grades) that were reported in &lt; 10% of patients treated with axitinibincluded dizziness (9%), upper abdominal pain (8%),myalgia(7%), dehydration (6%),epistaxis(6%),anemia(4%),hemorrhoids(4%),hematuria(3%),tinnitus(3%), lipase increased (3%), glossodynia (3%),pulmonary embolism(2%), rectal hemorrhage (2%),hemoptysis(2%),deep vein thrombosis(1%), retinal-veinocclusion/thrombosis(1%),polycythemia(1%), andtransient ischemic attack(1%). ",axitinib
disease_disorder,glossodynia,0.9862168," selected adverse reactions (all grades) that were reported in &lt; 10% of patients treated with axitinibincluded dizziness (9%), upper abdominal pain (8%),myalgia(7%), dehydration (6%),epistaxis(6%),anemia(4%),hemorrhoids(4%),hematuria(3%),tinnitus(3%), lipase increased (3%), glossodynia (3%),pulmonary embolism(2%), rectal hemorrhage (2%),hemoptysis(2%),deep vein thrombosis(1%), retinal-veinocclusion/thrombosis(1%),polycythemia(1%), andtransient ischemic attack(1%). ",axitinib
disease_disorder,embolism,0.7913559," selected adverse reactions (all grades) that were reported in &lt; 10% of patients treated with axitinibincluded dizziness (9%), upper abdominal pain (8%),myalgia(7%), dehydration (6%),epistaxis(6%),anemia(4%),hemorrhoids(4%),hematuria(3%),tinnitus(3%), lipase increased (3%), glossodynia (3%),pulmonary embolism(2%), rectal hemorrhage (2%),hemoptysis(2%),deep vein thrombosis(1%), retinal-veinocclusion/thrombosis(1%),polycythemia(1%), andtransient ischemic attack(1%). ",axitinib
disease_disorder,hemoptysis,0.94745743," selected adverse reactions (all grades) that were reported in &lt; 10% of patients treated with axitinibincluded dizziness (9%), upper abdominal pain (8%),myalgia(7%), dehydration (6%),epistaxis(6%),anemia(4%),hemorrhoids(4%),hematuria(3%),tinnitus(3%), lipase increased (3%), glossodynia (3%),pulmonary embolism(2%), rectal hemorrhage (2%),hemoptysis(2%),deep vein thrombosis(1%), retinal-veinocclusion/thrombosis(1%),polycythemia(1%), andtransient ischemic attack(1%). ",axitinib
disease_disorder,deep vein thrombosis,0.99873286," selected adverse reactions (all grades) that were reported in &lt; 10% of patients treated with axitinibincluded dizziness (9%), upper abdominal pain (8%),myalgia(7%), dehydration (6%),epistaxis(6%),anemia(4%),hemorrhoids(4%),hematuria(3%),tinnitus(3%), lipase increased (3%), glossodynia (3%),pulmonary embolism(2%), rectal hemorrhage (2%),hemoptysis(2%),deep vein thrombosis(1%), retinal-veinocclusion/thrombosis(1%),polycythemia(1%), andtransient ischemic attack(1%). ",axitinib
sign_symptom,retinal,0.73404235," selected adverse reactions (all grades) that were reported in &lt; 10% of patients treated with axitinibincluded dizziness (9%), upper abdominal pain (8%),myalgia(7%), dehydration (6%),epistaxis(6%),anemia(4%),hemorrhoids(4%),hematuria(3%),tinnitus(3%), lipase increased (3%), glossodynia (3%),pulmonary embolism(2%), rectal hemorrhage (2%),hemoptysis(2%),deep vein thrombosis(1%), retinal-veinocclusion/thrombosis(1%),polycythemia(1%), andtransient ischemic attack(1%). ",axitinib
sign_symptom,ischemic attack,0.7274151," selected adverse reactions (all grades) that were reported in &lt; 10% of patients treated with axitinibincluded dizziness (9%), upper abdominal pain (8%),myalgia(7%), dehydration (6%),epistaxis(6%),anemia(4%),hemorrhoids(4%),hematuria(3%),tinnitus(3%), lipase increased (3%), glossodynia (3%),pulmonary embolism(2%), rectal hemorrhage (2%),hemoptysis(2%),deep vein thrombosis(1%), retinal-veinocclusion/thrombosis(1%),polycythemia(1%), andtransient ischemic attack(1%). ",axitinib
sign_symptom,adverse reactions,0.7680256," most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain ",avanafil
sign_symptom,pain,0.9999703," most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain ",avanafil
sign_symptom,flushing,0.9998528,"  injection : dry mouth, dysphagia, constipation, flushing and dryness of skin, tachycardia, palpitations, arrhythmias, mydriasis, photophobia, cycloplegia, raised intraocular pressure. toxic doses cause tachycardia, hyperpyrexia, restlessness, confusion, excitement, hallucinations, delirium and may progress to circulatory failure and resp depression.    eye drops or ointment : systemic toxicity esp in children, on prolonged use may lead to irritation, hyperaemia, oedema and conjunctivitis. increased intraocular pressure. ",atropine sulfate
sign_symptom,restless,0.76989126,"  injection : dry mouth, dysphagia, constipation, flushing and dryness of skin, tachycardia, palpitations, arrhythmias, mydriasis, photophobia, cycloplegia, raised intraocular pressure. toxic doses cause tachycardia, hyperpyrexia, restlessness, confusion, excitement, hallucinations, delirium and may progress to circulatory failure and resp depression.    eye drops or ointment : systemic toxicity esp in children, on prolonged use may lead to irritation, hyperaemia, oedema and conjunctivitis. increased intraocular pressure. ",atropine sulfate
sign_symptom,delirium,0.9591751,"  injection : dry mouth, dysphagia, constipation, flushing and dryness of skin, tachycardia, palpitations, arrhythmias, mydriasis, photophobia, cycloplegia, raised intraocular pressure. toxic doses cause tachycardia, hyperpyrexia, restlessness, confusion, excitement, hallucinations, delirium and may progress to circulatory failure and resp depression.    eye drops or ointment : systemic toxicity esp in children, on prolonged use may lead to irritation, hyperaemia, oedema and conjunctivitis. increased intraocular pressure. ",atropine sulfate
sign_symptom,toxicity,0.81871134,"  injection : dry mouth, dysphagia, constipation, flushing and dryness of skin, tachycardia, palpitations, arrhythmias, mydriasis, photophobia, cycloplegia, raised intraocular pressure. toxic doses cause tachycardia, hyperpyrexia, restlessness, confusion, excitement, hallucinations, delirium and may progress to circulatory failure and resp depression.    eye drops or ointment : systemic toxicity esp in children, on prolonged use may lead to irritation, hyperaemia, oedema and conjunctivitis. increased intraocular pressure. ",atropine sulfate
sign_symptom,sick,0.9994186," very common (affects more than 1 in 10 people): feeling sick (nausea).  common (affects less than 1 in 10 people): headache, feeling dizzy, hot flushes, being sick (vomiting), fast heartbeat, low blood pressure. signs may include feeling dizzy or light-headed, a reaction at the site where the injection was given, high blood sugar.  uncommon (affects less than 1 in 100 people): high temperature (fever), difficulty sleeping (insomnia), itching, rash. ",atosiban acetate
sign_symptom,dizzy,0.9830421," very common (affects more than 1 in 10 people): feeling sick (nausea).  common (affects less than 1 in 10 people): headache, feeling dizzy, hot flushes, being sick (vomiting), fast heartbeat, low blood pressure. signs may include feeling dizzy or light-headed, a reaction at the site where the injection was given, high blood sugar.  uncommon (affects less than 1 in 100 people): high temperature (fever), difficulty sleeping (insomnia), itching, rash. ",atosiban acetate
sign_symptom,difficulty,0.8794208," very common (affects more than 1 in 10 people): feeling sick (nausea).  common (affects less than 1 in 10 people): headache, feeling dizzy, hot flushes, being sick (vomiting), fast heartbeat, low blood pressure. signs may include feeling dizzy or light-headed, a reaction at the site where the injection was given, high blood sugar.  uncommon (affects less than 1 in 100 people): high temperature (fever), difficulty sleeping (insomnia), itching, rash. ",atosiban acetate
sign_symptom,flat,0.9188825," atorvastatin is generally well-tolerated. the most frequent side effects related to atorvastatin are constipation, flatulence, dyspepsia, abdominal pain. other side effects includes infection, headache, back pain, rash, asthenia, arthralgia, myalgia. ",atorvastatin calcium
sign_symptom,dyspe,0.90272063," atorvastatin is generally well-tolerated. the most frequent side effects related to atorvastatin are constipation, flatulence, dyspepsia, abdominal pain. other side effects includes infection, headache, back pain, rash, asthenia, arthralgia, myalgia. ",atorvastatin calcium
sign_symptom,headache,0.9996699, decreased appetite; headache; nausea; increased bp &amp; heart rate; insomnia; dry mouth in adults; somnolence; abdominal pain; vomiting in children. ,atomoxetine hydrochloride
sign_symptom,nausea,0.9930512, decreased appetite; headache; nausea; increased bp &amp; heart rate; insomnia; dry mouth in adults; somnolence; abdominal pain; vomiting in children. ,atomoxetine hydrochloride
sign_symptom,dry mouth,0.999485, decreased appetite; headache; nausea; increased bp &amp; heart rate; insomnia; dry mouth in adults; somnolence; abdominal pain; vomiting in children. ,atomoxetine hydrochloride
sign_symptom,pain,0.9970661, decreased appetite; headache; nausea; increased bp &amp; heart rate; insomnia; dry mouth in adults; somnolence; abdominal pain; vomiting in children. ,atomoxetine hydrochloride
sign_symptom,vomiting,0.99995375, decreased appetite; headache; nausea; increased bp &amp; heart rate; insomnia; dry mouth in adults; somnolence; abdominal pain; vomiting in children. ,atomoxetine hydrochloride
sign_symptom,cold,0.9937622," the adverse effects observed for this combination are essentially the same as those seen with the individual components. atenolol: bradycardia, cold extremities, postural hypotension, leg pain, dizziness, vertigo, light headedness, tiredness, fatigue, lethargy, drowsiness, depression, dreaming, diarrhea, nausea, wheeziness, dyspnea, chlorthalidone orthostatic hypotension, anorexia, gastric irritation, vomiting, cramping, constipation, vertigo, purpura, photosensitivity, rash, urticaria, hyperglycemia, glycosuria, hyperuricemia, muscle spasm, weakness, restlessness. ",atenolol + chlorthalidone
sign_symptom,light headed,0.96928585," the adverse effects observed for this combination are essentially the same as those seen with the individual components. atenolol: bradycardia, cold extremities, postural hypotension, leg pain, dizziness, vertigo, light headedness, tiredness, fatigue, lethargy, drowsiness, depression, dreaming, diarrhea, nausea, wheeziness, dyspnea, chlorthalidone orthostatic hypotension, anorexia, gastric irritation, vomiting, cramping, constipation, vertigo, purpura, photosensitivity, rash, urticaria, hyperglycemia, glycosuria, hyperuricemia, muscle spasm, weakness, restlessness. ",atenolol + chlorthalidone
sign_symptom,tired,0.85910904," the adverse effects observed for this combination are essentially the same as those seen with the individual components. atenolol: bradycardia, cold extremities, postural hypotension, leg pain, dizziness, vertigo, light headedness, tiredness, fatigue, lethargy, drowsiness, depression, dreaming, diarrhea, nausea, wheeziness, dyspnea, chlorthalidone orthostatic hypotension, anorexia, gastric irritation, vomiting, cramping, constipation, vertigo, purpura, photosensitivity, rash, urticaria, hyperglycemia, glycosuria, hyperuricemia, muscle spasm, weakness, restlessness. ",atenolol + chlorthalidone
sign_symptom,brady,0.9999571," in a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. in addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of atenolol. 
 
  hematologic : agranulocytosis. 
  allergic : fever, combined with aching and sore throat, laryngospasm, and respiratory distress. 
  central nervous system : reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics. 
  gastrointestinal : mesenteric arterial thrombosis, ischemic colitis. 
  miscellaneous : there have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. discontinuance of the drug should be considered if any such reaction is not otherwise explicable. patients should be closely monitored following cessation of therapy. 
  other : erythematous rash 
  ",atenolol
medication,beta block,0.89656544," in a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. in addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of atenolol. 
 
  hematologic : agranulocytosis. 
  allergic : fever, combined with aching and sore throat, laryngospasm, and respiratory distress. 
  central nervous system : reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics. 
  gastrointestinal : mesenteric arterial thrombosis, ischemic colitis. 
  miscellaneous : there have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. discontinuance of the drug should be considered if any such reaction is not otherwise explicable. patients should be closely monitored following cessation of therapy. 
  other : erythematous rash 
  ",atenolol
sign_symptom,adverse efects,0.9171206," in a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. in addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of atenolol. 
 
  hematologic : agranulocytosis. 
  allergic : fever, combined with aching and sore throat, laryngospasm, and respiratory distress. 
  central nervous system : reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics. 
  gastrointestinal : mesenteric arterial thrombosis, ischemic colitis. 
  miscellaneous : there have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. discontinuance of the drug should be considered if any such reaction is not otherwise explicable. patients should be closely monitored following cessation of therapy. 
  other : erythematous rash 
  ",atenolol
sign_symptom,aching,0.99944013," in a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. in addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of atenolol. 
 
  hematologic : agranulocytosis. 
  allergic : fever, combined with aching and sore throat, laryngospasm, and respiratory distress. 
  central nervous system : reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics. 
  gastrointestinal : mesenteric arterial thrombosis, ischemic colitis. 
  miscellaneous : there have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. discontinuance of the drug should be considered if any such reaction is not otherwise explicable. patients should be closely monitored following cessation of therapy. 
  other : erythematous rash 
  ",atenolol
sign_symptom,sore,0.9996984," in a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. in addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of atenolol. 
 
  hematologic : agranulocytosis. 
  allergic : fever, combined with aching and sore throat, laryngospasm, and respiratory distress. 
  central nervous system : reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics. 
  gastrointestinal : mesenteric arterial thrombosis, ischemic colitis. 
  miscellaneous : there have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. discontinuance of the drug should be considered if any such reaction is not otherwise explicable. patients should be closely monitored following cessation of therapy. 
  other : erythematous rash 
  ",atenolol
sign_symptom,mental depression,0.77859086," in a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. in addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of atenolol. 
 
  hematologic : agranulocytosis. 
  allergic : fever, combined with aching and sore throat, laryngospasm, and respiratory distress. 
  central nervous system : reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics. 
  gastrointestinal : mesenteric arterial thrombosis, ischemic colitis. 
  miscellaneous : there have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. discontinuance of the drug should be considered if any such reaction is not otherwise explicable. patients should be closely monitored following cessation of therapy. 
  other : erythematous rash 
  ",atenolol
disease_disorder,syndrome,0.7306862," in a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. in addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of atenolol. 
 
  hematologic : agranulocytosis. 
  allergic : fever, combined with aching and sore throat, laryngospasm, and respiratory distress. 
  central nervous system : reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics. 
  gastrointestinal : mesenteric arterial thrombosis, ischemic colitis. 
  miscellaneous : there have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. discontinuance of the drug should be considered if any such reaction is not otherwise explicable. patients should be closely monitored following cessation of therapy. 
  other : erythematous rash 
  ",atenolol
sign_symptom,emotional,0.9394779," in a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. in addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of atenolol. 
 
  hematologic : agranulocytosis. 
  allergic : fever, combined with aching and sore throat, laryngospasm, and respiratory distress. 
  central nervous system : reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics. 
  gastrointestinal : mesenteric arterial thrombosis, ischemic colitis. 
  miscellaneous : there have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. discontinuance of the drug should be considered if any such reaction is not otherwise explicable. patients should be closely monitored following cessation of therapy. 
  other : erythematous rash 
  ",atenolol
sign_symptom,rash,0.9999362," in a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. in addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of atenolol. 
 
  hematologic : agranulocytosis. 
  allergic : fever, combined with aching and sore throat, laryngospasm, and respiratory distress. 
  central nervous system : reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics. 
  gastrointestinal : mesenteric arterial thrombosis, ischemic colitis. 
  miscellaneous : there have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. discontinuance of the drug should be considered if any such reaction is not otherwise explicable. patients should be closely monitored following cessation of therapy. 
  other : erythematous rash 
  ",atenolol
sign_symptom,dry eyes,0.99750006," in a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. in addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of atenolol. 
 
  hematologic : agranulocytosis. 
  allergic : fever, combined with aching and sore throat, laryngospasm, and respiratory distress. 
  central nervous system : reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics. 
  gastrointestinal : mesenteric arterial thrombosis, ischemic colitis. 
  miscellaneous : there have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. discontinuance of the drug should be considered if any such reaction is not otherwise explicable. patients should be closely monitored following cessation of therapy. 
  other : erythematous rash 
  ",atenolol
medication,beta,0.7707805," in a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. in addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of atenolol. 
 
  hematologic : agranulocytosis. 
  allergic : fever, combined with aching and sore throat, laryngospasm, and respiratory distress. 
  central nervous system : reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics. 
  gastrointestinal : mesenteric arterial thrombosis, ischemic colitis. 
  miscellaneous : there have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. discontinuance of the drug should be considered if any such reaction is not otherwise explicable. patients should be closely monitored following cessation of therapy. 
  other : erythematous rash 
  ",atenolol
sign_symptom,side effects,0.99983656, no severe side effects have been reported yet. ,astaxanthin
sign_symptom,adverse reactions,0.99988276, no adverse reactions are known at the recommended dosage. animal data showed that excessive may reduce fertility ,red clover isoflavones
sign_symptom,side effects,0.8608453, pumpkin is likely safe in food amounts. it is possibly safe to take pumpkin seed or pumpkin seed oil in medicinal amounts. side effects from pumpkin products are rare. ,pumpkin [cucurbita pepo]
sign_symptom,adverse reactions,0.9999122, no clinically significant adverse reactions have been observed in therapeutic dosage. probiotics are likely safe for most people. ,probiotic combination [2.3 billion]
medication,probiotic,0.99861157, no clinically significant adverse reactions have been observed in therapeutic dosage. probiotics are likely safe for most people. ,probiotic combination [2.3 billion]
sign_symptom,adverse reactions,0.9998776, no clinically signif icant adverse reactions have been observed in therapeutic dosage. probiotics are likely safe for most people. ,probiotic combination [2 billion]
medication,probiotic,0.9991616, no clinically signif icant adverse reactions have been observed in therapeutic dosage. probiotics are likely safe for most people. ,probiotic combination [2 billion]
sign_symptom,side effects,0.99650264," no serious side effects have been reported. to avoid gastric upset, diarrhea &amp; constipation, proanthocyanidins should be taken with meals. minor adverse effects including headache and dizziness may occur. ",proanthocyanidins
medication,proanthocyanidins,0.9896587," no serious side effects have been reported. to avoid gastric upset, diarrhea &amp; constipation, proanthocyanidins should be taken with meals. minor adverse effects including headache and dizziness may occur. ",proanthocyanidins
sign_symptom,adverse effects,0.9081937," no serious side effects have been reported. to avoid gastric upset, diarrhea &amp; constipation, proanthocyanidins should be taken with meals. minor adverse effects including headache and dizziness may occur. ",proanthocyanidins
sign_symptom,headache,0.99994063," no serious side effects have been reported. to avoid gastric upset, diarrhea &amp; constipation, proanthocyanidins should be taken with meals. minor adverse effects including headache and dizziness may occur. ",proanthocyanidins
medication,ginsen,0.74622154," over ginseng's many years of use, no serious side effects or drug interactions have been reported. ",panax ginseng
sign_symptom,side effects,0.97985184," over ginseng's many years of use, no serious side effects or drug interactions have been reported. ",panax ginseng
sign_symptom,interactions,0.87209195," over ginseng's many years of use, no serious side effects or drug interactions have been reported. ",panax ginseng
sign_symptom,irritation,0.9997907," the following is a list of possible side effects that may occur from all constituting ingredients of chloramphenicol beclomethasone &amp; clotrimazole ear drops. this is not a comprehensive list. these side effects are possible but do not always occur. some of the side effects may be rare but serious. consult your doctor if you observe any of the following side effects, especially if they do not go away. 
 
 inflammation of the skin 
 irritation 
 itchy rash 
 blisters 
 peeling or flaking of the skin 
 discomfort. 
  ",beclomethasone dipropionate + chloramphenicol + clotrimazole + lidocaine
sign_symptom,rash,0.9997371," the following is a list of possible side effects that may occur from all constituting ingredients of chloramphenicol beclomethasone &amp; clotrimazole ear drops. this is not a comprehensive list. these side effects are possible but do not always occur. some of the side effects may be rare but serious. consult your doctor if you observe any of the following side effects, especially if they do not go away. 
 
 inflammation of the skin 
 irritation 
 itchy rash 
 blisters 
 peeling or flaking of the skin 
 discomfort. 
  ",beclomethasone dipropionate + chloramphenicol + clotrimazole + lidocaine
disease_disorder,nasal septum,0.99932903," rare instances of nasal septum perforation have been reported following intranasal administration. as with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste &amp; smell and epistaxis have been reported rarely. rare instances of wheezing, cataracts, glaucoma and increased intra-ocular pressure have been reported following the intranasal use of beclomethasone. ",beclomethasone dipropionate (nasal spray)
disease_disorder,perforation,0.99897367," rare instances of nasal septum perforation have been reported following intranasal administration. as with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste &amp; smell and epistaxis have been reported rarely. rare instances of wheezing, cataracts, glaucoma and increased intra-ocular pressure have been reported following the intranasal use of beclomethasone. ",beclomethasone dipropionate (nasal spray)
sign_symptom,dryness,0.99855447," rare instances of nasal septum perforation have been reported following intranasal administration. as with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste &amp; smell and epistaxis have been reported rarely. rare instances of wheezing, cataracts, glaucoma and increased intra-ocular pressure have been reported following the intranasal use of beclomethasone. ",beclomethasone dipropionate (nasal spray)
sign_symptom,irritation,0.9999435," rare instances of nasal septum perforation have been reported following intranasal administration. as with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste &amp; smell and epistaxis have been reported rarely. rare instances of wheezing, cataracts, glaucoma and increased intra-ocular pressure have been reported following the intranasal use of beclomethasone. ",beclomethasone dipropionate (nasal spray)
sign_symptom,unpleasant taste,0.941643," rare instances of nasal septum perforation have been reported following intranasal administration. as with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste &amp; smell and epistaxis have been reported rarely. rare instances of wheezing, cataracts, glaucoma and increased intra-ocular pressure have been reported following the intranasal use of beclomethasone. ",beclomethasone dipropionate (nasal spray)
sign_symptom,smell,0.9997547," rare instances of nasal septum perforation have been reported following intranasal administration. as with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste &amp; smell and epistaxis have been reported rarely. rare instances of wheezing, cataracts, glaucoma and increased intra-ocular pressure have been reported following the intranasal use of beclomethasone. ",beclomethasone dipropionate (nasal spray)
sign_symptom,catara,0.98076534," rare instances of nasal septum perforation have been reported following intranasal administration. as with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste &amp; smell and epistaxis have been reported rarely. rare instances of wheezing, cataracts, glaucoma and increased intra-ocular pressure have been reported following the intranasal use of beclomethasone. ",beclomethasone dipropionate (nasal spray)
sign_symptom,glaucoma,0.98118305," rare instances of nasal septum perforation have been reported following intranasal administration. as with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste &amp; smell and epistaxis have been reported rarely. rare instances of wheezing, cataracts, glaucoma and increased intra-ocular pressure have been reported following the intranasal use of beclomethasone. ",beclomethasone dipropionate (nasal spray)
medication,corti,0.9633782," systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. possible systemic effects include cushing's syndrome, cushingoid features, and adrenal suppression, growth retardation in children andadolescents, decrease in bone mineral density, cataract, and glaucoma. ",beclomethasone dipropionate (inhaler)
sign_symptom,growth retardation,0.97827744," systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. possible systemic effects include cushing's syndrome, cushingoid features, and adrenal suppression, growth retardation in children andadolescents, decrease in bone mineral density, cataract, and glaucoma. ",beclomethasone dipropionate (inhaler)
medication,beclometasone,0.8232695," as the drug contains beclometasone dipropionate and formoterol fumarate dihydrate, the type and severity of adverse reactions associated with each of the compounds may be expected. common side effects are pharyngitis, oral candidiasis, headache, dysphonia. ",beclometasone dipropionate + formoterol fumarate
medication,dipropionate,0.9743905," as the drug contains beclometasone dipropionate and formoterol fumarate dihydrate, the type and severity of adverse reactions associated with each of the compounds may be expected. common side effects are pharyngitis, oral candidiasis, headache, dysphonia. ",beclometasone dipropionate + formoterol fumarate
medication,formoterol fumarate,0.99690133," as the drug contains beclometasone dipropionate and formoterol fumarate dihydrate, the type and severity of adverse reactions associated with each of the compounds may be expected. common side effects are pharyngitis, oral candidiasis, headache, dysphonia. ",beclometasone dipropionate + formoterol fumarate
sign_symptom,pain,0.999918," serious side effect such as: 
 
 pain or burning when you urinate 
 easy bruising or bleeding, unusual weakness 
 tremors, shaking 
 fever, chills, body aches, flu symptoms, vomiting, diarrhea 
 trouble breathing 
 pale skin, feeling light-headed or short of breath, rapid heart rate, trouble 
  ",basiliximab
sign_symptom,body ache,0.887553," serious side effect such as: 
 
 pain or burning when you urinate 
 easy bruising or bleeding, unusual weakness 
 tremors, shaking 
 fever, chills, body aches, flu symptoms, vomiting, diarrhea 
 trouble breathing 
 pale skin, feeling light-headed or short of breath, rapid heart rate, trouble 
  ",basiliximab
sign_symptom,diarrhea,0.999412," serious side effect such as: 
 
 pain or burning when you urinate 
 easy bruising or bleeding, unusual weakness 
 tremors, shaking 
 fever, chills, body aches, flu symptoms, vomiting, diarrhea 
 trouble breathing 
 pale skin, feeling light-headed or short of breath, rapid heart rate, trouble 
  ",basiliximab
sign_symptom,trouble,0.9994229," serious side effect such as: 
 
 pain or burning when you urinate 
 easy bruising or bleeding, unusual weakness 
 tremors, shaking 
 fever, chills, body aches, flu symptoms, vomiting, diarrhea 
 trouble breathing 
 pale skin, feeling light-headed or short of breath, rapid heart rate, trouble 
  ",basiliximab
sign_symptom,light - headed,0.9723267," serious side effect such as: 
 
 pain or burning when you urinate 
 easy bruising or bleeding, unusual weakness 
 tremors, shaking 
 fever, chills, body aches, flu symptoms, vomiting, diarrhea 
 trouble breathing 
 pale skin, feeling light-headed or short of breath, rapid heart rate, trouble 
  ",basiliximab
sign_symptom,short of breath,0.99670076," serious side effect such as: 
 
 pain or burning when you urinate 
 easy bruising or bleeding, unusual weakness 
 tremors, shaking 
 fever, chills, body aches, flu symptoms, vomiting, diarrhea 
 trouble breathing 
 pale skin, feeling light-headed or short of breath, rapid heart rate, trouble 
  ",basiliximab
sign_symptom,pale,0.8930071," common side effects are:severe stomach pain, severe cramping, diarrhea, or constipation, sweating, ringing in your ears, confusion, fast heart rate, pale skin, weakness ",barium sulfate
sign_symptom,weakness,0.9994185," common side effects are:severe stomach pain, severe cramping, diarrhea, or constipation, sweating, ringing in your ears, confusion, fast heart rate, pale skin, weakness ",barium sulfate
medication,baricitini,0.89347893," it is not known if baricitinib will harm an unborn baby. because of the potential for serious adverse reactions in nursing infants, advice an baricitinib treated woman not to breastfeed. ",baricitinib
sign_symptom,adverse reactions,0.99979645," it is not known if baricitinib will harm an unborn baby. because of the potential for serious adverse reactions in nursing infants, advice an baricitinib treated woman not to breastfeed. ",baricitinib
sign_symptom,adverse events,0.99987566," adverse events reported in at least 1% of adult and adolescent influenza subjects treated with baloxavir marboxil included diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%). ",baloxavir marboxil
sign_symptom,diarrhea,0.9917508," adverse events reported in at least 1% of adult and adolescent influenza subjects treated with baloxavir marboxil included diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%). ",baloxavir marboxil
disease_disorder,bronch,0.9468756," adverse events reported in at least 1% of adult and adolescent influenza subjects treated with baloxavir marboxil included diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%). ",baloxavir marboxil
sign_symptom,nausea,0.9999461," adverse events reported in at least 1% of adult and adolescent influenza subjects treated with baloxavir marboxil included diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%). ",baloxavir marboxil
sign_symptom,sinusitis,0.9993296," adverse events reported in at least 1% of adult and adolescent influenza subjects treated with baloxavir marboxil included diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%). ",baloxavir marboxil
sign_symptom,headache,0.99991536," adverse events reported in at least 1% of adult and adolescent influenza subjects treated with baloxavir marboxil included diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%). ",baloxavir marboxil
sign_symptom,inflammatory reactions,0.99990636," when the corneal endothelium is abnormal, irrigation or any other trauma may result in bullous keratopathy. postoperative inflammatory reactions as well as incidents of corneal edema and corneal decompensation have been reported. their relationship to the use of balanced salt solution has not been established. ",balanced salt solution
sign_symptom,edema,0.979903," when the corneal endothelium is abnormal, irrigation or any other trauma may result in bullous keratopathy. postoperative inflammatory reactions as well as incidents of corneal edema and corneal decompensation have been reported. their relationship to the use of balanced salt solution has not been established. ",balanced salt solution
sign_symptom,decompensation,0.9841412," when the corneal endothelium is abnormal, irrigation or any other trauma may result in bullous keratopathy. postoperative inflammatory reactions as well as incidents of corneal edema and corneal decompensation have been reported. their relationship to the use of balanced salt solution has not been established. ",balanced salt solution
medication,balanced salt solution,0.973062," when the corneal endothelium is abnormal, irrigation or any other trauma may result in bullous keratopathy. postoperative inflammatory reactions as well as incidents of corneal edema and corneal decompensation have been reported. their relationship to the use of balanced salt solution has not been established. ",balanced salt solution
sign_symptom,adverse reactions,0.9196148," the most common adverse reactions associated with baclofen are transient drowsiness, daytime sedation, dizziness, weakness and fatigue. 
 
  central nervous system : headache (&lt;10%), insomnia (&lt;10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression. 
  cardiovascular:  hypotension (&lt;10%), rare instances of dyspnoea, palpitation, chest pain, syncope. 
  gastrointestinal : nausea (approximately 10%), constipation (&lt;10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool. 
  genitourinary : urinary frequency (&lt;10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria. 
  other : instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. for this purpose, the daytime dosage may be reduced and the evening dosage increased. 
  ",baclofen
sign_symptom,weakness,0.99889106," the most common adverse reactions associated with baclofen are transient drowsiness, daytime sedation, dizziness, weakness and fatigue. 
 
  central nervous system : headache (&lt;10%), insomnia (&lt;10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression. 
  cardiovascular:  hypotension (&lt;10%), rare instances of dyspnoea, palpitation, chest pain, syncope. 
  gastrointestinal : nausea (approximately 10%), constipation (&lt;10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool. 
  genitourinary : urinary frequency (&lt;10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria. 
  other : instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. for this purpose, the daytime dosage may be reduced and the evening dosage increased. 
  ",baclofen
sign_symptom,headache,0.9999317," the most common adverse reactions associated with baclofen are transient drowsiness, daytime sedation, dizziness, weakness and fatigue. 
 
  central nervous system : headache (&lt;10%), insomnia (&lt;10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression. 
  cardiovascular:  hypotension (&lt;10%), rare instances of dyspnoea, palpitation, chest pain, syncope. 
  gastrointestinal : nausea (approximately 10%), constipation (&lt;10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool. 
  genitourinary : urinary frequency (&lt;10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria. 
  other : instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. for this purpose, the daytime dosage may be reduced and the evening dosage increased. 
  ",baclofen
sign_symptom,blurred vision,0.7038733," the most common adverse reactions associated with baclofen are transient drowsiness, daytime sedation, dizziness, weakness and fatigue. 
 
  central nervous system : headache (&lt;10%), insomnia (&lt;10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression. 
  cardiovascular:  hypotension (&lt;10%), rare instances of dyspnoea, palpitation, chest pain, syncope. 
  gastrointestinal : nausea (approximately 10%), constipation (&lt;10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool. 
  genitourinary : urinary frequency (&lt;10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria. 
  other : instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. for this purpose, the daytime dosage may be reduced and the evening dosage increased. 
  ",baclofen
sign_symptom,sync,0.70631474," the most common adverse reactions associated with baclofen are transient drowsiness, daytime sedation, dizziness, weakness and fatigue. 
 
  central nervous system : headache (&lt;10%), insomnia (&lt;10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression. 
  cardiovascular:  hypotension (&lt;10%), rare instances of dyspnoea, palpitation, chest pain, syncope. 
  gastrointestinal : nausea (approximately 10%), constipation (&lt;10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool. 
  genitourinary : urinary frequency (&lt;10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria. 
  other : instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. for this purpose, the daytime dosage may be reduced and the evening dosage increased. 
  ",baclofen
sign_symptom,nausea,0.9999516," the most common adverse reactions associated with baclofen are transient drowsiness, daytime sedation, dizziness, weakness and fatigue. 
 
  central nervous system : headache (&lt;10%), insomnia (&lt;10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression. 
  cardiovascular:  hypotension (&lt;10%), rare instances of dyspnoea, palpitation, chest pain, syncope. 
  gastrointestinal : nausea (approximately 10%), constipation (&lt;10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool. 
  genitourinary : urinary frequency (&lt;10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria. 
  other : instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. for this purpose, the daytime dosage may be reduced and the evening dosage increased. 
  ",baclofen
sign_symptom,consti,0.9993346," the most common adverse reactions associated with baclofen are transient drowsiness, daytime sedation, dizziness, weakness and fatigue. 
 
  central nervous system : headache (&lt;10%), insomnia (&lt;10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression. 
  cardiovascular:  hypotension (&lt;10%), rare instances of dyspnoea, palpitation, chest pain, syncope. 
  gastrointestinal : nausea (approximately 10%), constipation (&lt;10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool. 
  genitourinary : urinary frequency (&lt;10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria. 
  other : instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. for this purpose, the daytime dosage may be reduced and the evening dosage increased. 
  ",baclofen
sign_symptom,diarr,0.9962648," the most common adverse reactions associated with baclofen are transient drowsiness, daytime sedation, dizziness, weakness and fatigue. 
 
  central nervous system : headache (&lt;10%), insomnia (&lt;10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression. 
  cardiovascular:  hypotension (&lt;10%), rare instances of dyspnoea, palpitation, chest pain, syncope. 
  gastrointestinal : nausea (approximately 10%), constipation (&lt;10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool. 
  genitourinary : urinary frequency (&lt;10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria. 
  other : instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. for this purpose, the daytime dosage may be reduced and the evening dosage increased. 
  ",baclofen
sign_symptom,inability to ejaculate,0.9966548," the most common adverse reactions associated with baclofen are transient drowsiness, daytime sedation, dizziness, weakness and fatigue. 
 
  central nervous system : headache (&lt;10%), insomnia (&lt;10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression. 
  cardiovascular:  hypotension (&lt;10%), rare instances of dyspnoea, palpitation, chest pain, syncope. 
  gastrointestinal : nausea (approximately 10%), constipation (&lt;10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool. 
  genitourinary : urinary frequency (&lt;10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria. 
  other : instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. for this purpose, the daytime dosage may be reduced and the evening dosage increased. 
  ",baclofen
sign_symptom,swelling,0.83330166," sometimes this ointmentmay be absorbed in the blood, but shows no blood related toxicity. moreover allergic reaction, eye irritation, eye redness, itching, swelling may occur. ",bacitracin zinc + polymyxin b sulfate
sign_symptom,side effects,0.9994196," no side effects have been reported with the use of enterogermina. however, it is important to communicate any undesirable effects. ",bacillus clausii spores
medication,enter,0.9514874," no side effects have been reported with the use of enterogermina. however, it is important to communicate any undesirable effects. ",bacillus clausii spores
sign_symptom,discomfort,0.99990606," local reactions such as phlebitis/thrombophlebitis following iv administration and discomfort/swelling at the injection site following im administration may occur. systemic reactions like diarrhea, nausea and/or vomiting, and rash may occur. other side effects include anaphylaxis, angioedema, bronchospasm, pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis, abdominal cramps, dermatitis, urticaria, pruritus, hypotension, flushing, seizure, weakness, headache, fever, malaise may occur. ",aztreonam
sign_symptom,swelling,0.9999112," local reactions such as phlebitis/thrombophlebitis following iv administration and discomfort/swelling at the injection site following im administration may occur. systemic reactions like diarrhea, nausea and/or vomiting, and rash may occur. other side effects include anaphylaxis, angioedema, bronchospasm, pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis, abdominal cramps, dermatitis, urticaria, pruritus, hypotension, flushing, seizure, weakness, headache, fever, malaise may occur. ",aztreonam
sign_symptom,nausea,0.9998708," local reactions such as phlebitis/thrombophlebitis following iv administration and discomfort/swelling at the injection site following im administration may occur. systemic reactions like diarrhea, nausea and/or vomiting, and rash may occur. other side effects include anaphylaxis, angioedema, bronchospasm, pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis, abdominal cramps, dermatitis, urticaria, pruritus, hypotension, flushing, seizure, weakness, headache, fever, malaise may occur. ",aztreonam
sign_symptom,vomiting,0.86268437," local reactions such as phlebitis/thrombophlebitis following iv administration and discomfort/swelling at the injection site following im administration may occur. systemic reactions like diarrhea, nausea and/or vomiting, and rash may occur. other side effects include anaphylaxis, angioedema, bronchospasm, pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis, abdominal cramps, dermatitis, urticaria, pruritus, hypotension, flushing, seizure, weakness, headache, fever, malaise may occur. ",aztreonam
sign_symptom,rash,0.9996654," local reactions such as phlebitis/thrombophlebitis following iv administration and discomfort/swelling at the injection site following im administration may occur. systemic reactions like diarrhea, nausea and/or vomiting, and rash may occur. other side effects include anaphylaxis, angioedema, bronchospasm, pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis, abdominal cramps, dermatitis, urticaria, pruritus, hypotension, flushing, seizure, weakness, headache, fever, malaise may occur. ",aztreonam
sign_symptom,mala,0.99565744," local reactions such as phlebitis/thrombophlebitis following iv administration and discomfort/swelling at the injection site following im administration may occur. systemic reactions like diarrhea, nausea and/or vomiting, and rash may occur. other side effects include anaphylaxis, angioedema, bronchospasm, pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis, abdominal cramps, dermatitis, urticaria, pruritus, hypotension, flushing, seizure, weakness, headache, fever, malaise may occur. ",aztreonam
sign_symptom,side effects,0.96599144, no known side effects are found. ,stevia rebaudiana
sign_symptom,nausea,0.9999068," spirulina is generally well tolerated. occasional diarrhea, gastrointestinal discomfort, such as nausea have been reported. also there are few reports of allergic reactions to spirulina containing supplements. ",spirulina
sign_symptom,allergic reactions,0.99985826," spirulina is generally well tolerated. occasional diarrhea, gastrointestinal discomfort, such as nausea have been reported. also there are few reports of allergic reactions to spirulina containing supplements. ",spirulina
medication,spirulin,0.8612631," spirulina is generally well tolerated. occasional diarrhea, gastrointestinal discomfort, such as nausea have been reported. also there are few reports of allergic reactions to spirulina containing supplements. ",spirulina
sign_symptom,side effects,0.99828935, no significant side effects have been observed in therapeutic dosage. ,sharbat amla
sign_symptom,gi disturbance,0.9994135, rare case of gi disturbance has been reported. ingestion on an empty stomach may cause nausea. hypertension was reported in 3.1% taking saw palmetto extract. ,saw palmetto (160 mg)
sign_symptom,hyper,0.9999622, rare case of gi disturbance has been reported. ingestion on an empty stomach may cause nausea. hypertension was reported in 3.1% taking saw palmetto extract. ,saw palmetto (160 mg)
sign_symptom,adverse reactions,0.71403956, the most common adverse reactions are folliculitis and burning sensation of skin. ,betamethasone + calcipotriol
sign_symptom,burning,0.8578579, the most common adverse reactions are folliculitis and burning sensation of skin. ,betamethasone + calcipotriol
sign_symptom,moods,0.7800908," feeling depressed, including thinking about suicide; feeling high (mania) or moods that go up and down; feeling anxious, having problems sleeping, difficulty in thinking or being confused and losing your memory; feeling, seeing or hearing things which do not exist. having strange and frightening thoughts, changing how you act or having feelings of being alone. ",betamethasone
sign_symptom,difficulty in thinking,0.9981027," feeling depressed, including thinking about suicide; feeling high (mania) or moods that go up and down; feeling anxious, having problems sleeping, difficulty in thinking or being confused and losing your memory; feeling, seeing or hearing things which do not exist. having strange and frightening thoughts, changing how you act or having feelings of being alone. ",betamethasone
sign_symptom,confused,0.9754583," feeling depressed, including thinking about suicide; feeling high (mania) or moods that go up and down; feeling anxious, having problems sleeping, difficulty in thinking or being confused and losing your memory; feeling, seeing or hearing things which do not exist. having strange and frightening thoughts, changing how you act or having feelings of being alone. ",betamethasone
sign_symptom,nausea,0.99994016," digestive: nausea or vomiting may rarely occur. hypersensitivity: hypersensitivity reactions, such as skin rash, may rarely occur. ",betahistine mesylate
sign_symptom,vomiting,0.99992514," digestive: nausea or vomiting may rarely occur. hypersensitivity: hypersensitivity reactions, such as skin rash, may rarely occur. ",betahistine mesylate
sign_symptom,hypersensitivity,0.9938663," digestive: nausea or vomiting may rarely occur. hypersensitivity: hypersensitivity reactions, such as skin rash, may rarely occur. ",betahistine mesylate
sign_symptom,hypersensitivity reactions,0.93520945," digestive: nausea or vomiting may rarely occur. hypersensitivity: hypersensitivity reactions, such as skin rash, may rarely occur. ",betahistine mesylate
medication,betahistine,0.9948794," betahistine is generally well tolerated and there is no known serious adverse effects. in some circumstances gastrointestinal disturbances, headache, rashes and pruritus have been reported. ",betahistine dihydrochloride
sign_symptom,headache,0.99969256," betahistine is generally well tolerated and there is no known serious adverse effects. in some circumstances gastrointestinal disturbances, headache, rashes and pruritus have been reported. ",betahistine dihydrochloride
sign_symptom,rashes,0.94251096," betahistine is generally well tolerated and there is no known serious adverse effects. in some circumstances gastrointestinal disturbances, headache, rashes and pruritus have been reported. ",betahistine dihydrochloride
sign_symptom,pruritus,0.840091," betahistine is generally well tolerated and there is no known serious adverse effects. in some circumstances gastrointestinal disturbances, headache, rashes and pruritus have been reported. ",betahistine dihydrochloride
medication,carotene,0.99000335,"   carotene  is comparatively safe even at high and prolonged exposure. individuals who routinely ingest large amounts of carotenoids can develop hypercarotenosis, which is characterised by a yellowish colouration of the skin and a very high concentration of carotenoids in the plasma. this benign condition, although resembling jaundice, gradually disappears upon correcting the excessive intake of carotenoids.   vitamin c  is generally a safe drug for human use in normal doses. larger doses may lead to gastrointestinal tract upset and renal stone formation.   vitamin e  is considered safe even in large doses. doses over 800 mg may cause diarrhoea, abdominal pain or cramps, fatigue and reduced resistance to bacterial infection and transiently raised blood pressure. ",betacarotene + vitamin c + vitamin e
medication,carotenoids,0.9913095,"   carotene  is comparatively safe even at high and prolonged exposure. individuals who routinely ingest large amounts of carotenoids can develop hypercarotenosis, which is characterised by a yellowish colouration of the skin and a very high concentration of carotenoids in the plasma. this benign condition, although resembling jaundice, gradually disappears upon correcting the excessive intake of carotenoids.   vitamin c  is generally a safe drug for human use in normal doses. larger doses may lead to gastrointestinal tract upset and renal stone formation.   vitamin e  is considered safe even in large doses. doses over 800 mg may cause diarrhoea, abdominal pain or cramps, fatigue and reduced resistance to bacterial infection and transiently raised blood pressure. ",betacarotene + vitamin c + vitamin e
sign_symptom,hyper,0.96972924,"   carotene  is comparatively safe even at high and prolonged exposure. individuals who routinely ingest large amounts of carotenoids can develop hypercarotenosis, which is characterised by a yellowish colouration of the skin and a very high concentration of carotenoids in the plasma. this benign condition, although resembling jaundice, gradually disappears upon correcting the excessive intake of carotenoids.   vitamin c  is generally a safe drug for human use in normal doses. larger doses may lead to gastrointestinal tract upset and renal stone formation.   vitamin e  is considered safe even in large doses. doses over 800 mg may cause diarrhoea, abdominal pain or cramps, fatigue and reduced resistance to bacterial infection and transiently raised blood pressure. ",betacarotene + vitamin c + vitamin e
sign_symptom,colouration,0.9391371,"   carotene  is comparatively safe even at high and prolonged exposure. individuals who routinely ingest large amounts of carotenoids can develop hypercarotenosis, which is characterised by a yellowish colouration of the skin and a very high concentration of carotenoids in the plasma. this benign condition, although resembling jaundice, gradually disappears upon correcting the excessive intake of carotenoids.   vitamin c  is generally a safe drug for human use in normal doses. larger doses may lead to gastrointestinal tract upset and renal stone formation.   vitamin e  is considered safe even in large doses. doses over 800 mg may cause diarrhoea, abdominal pain or cramps, fatigue and reduced resistance to bacterial infection and transiently raised blood pressure. ",betacarotene + vitamin c + vitamin e
medication,vitamin c,0.9860823,"   carotene  is comparatively safe even at high and prolonged exposure. individuals who routinely ingest large amounts of carotenoids can develop hypercarotenosis, which is characterised by a yellowish colouration of the skin and a very high concentration of carotenoids in the plasma. this benign condition, although resembling jaundice, gradually disappears upon correcting the excessive intake of carotenoids.   vitamin c  is generally a safe drug for human use in normal doses. larger doses may lead to gastrointestinal tract upset and renal stone formation.   vitamin e  is considered safe even in large doses. doses over 800 mg may cause diarrhoea, abdominal pain or cramps, fatigue and reduced resistance to bacterial infection and transiently raised blood pressure. ",betacarotene + vitamin c + vitamin e
sign_symptom,upset,0.999864,"   carotene  is comparatively safe even at high and prolonged exposure. individuals who routinely ingest large amounts of carotenoids can develop hypercarotenosis, which is characterised by a yellowish colouration of the skin and a very high concentration of carotenoids in the plasma. this benign condition, although resembling jaundice, gradually disappears upon correcting the excessive intake of carotenoids.   vitamin c  is generally a safe drug for human use in normal doses. larger doses may lead to gastrointestinal tract upset and renal stone formation.   vitamin e  is considered safe even in large doses. doses over 800 mg may cause diarrhoea, abdominal pain or cramps, fatigue and reduced resistance to bacterial infection and transiently raised blood pressure. ",betacarotene + vitamin c + vitamin e
medication,vitamin e,0.99724996,"   carotene  is comparatively safe even at high and prolonged exposure. individuals who routinely ingest large amounts of carotenoids can develop hypercarotenosis, which is characterised by a yellowish colouration of the skin and a very high concentration of carotenoids in the plasma. this benign condition, although resembling jaundice, gradually disappears upon correcting the excessive intake of carotenoids.   vitamin c  is generally a safe drug for human use in normal doses. larger doses may lead to gastrointestinal tract upset and renal stone formation.   vitamin e  is considered safe even in large doses. doses over 800 mg may cause diarrhoea, abdominal pain or cramps, fatigue and reduced resistance to bacterial infection and transiently raised blood pressure. ",betacarotene + vitamin c + vitamin e
sign_symptom,pain,0.99993455,"   carotene  is comparatively safe even at high and prolonged exposure. individuals who routinely ingest large amounts of carotenoids can develop hypercarotenosis, which is characterised by a yellowish colouration of the skin and a very high concentration of carotenoids in the plasma. this benign condition, although resembling jaundice, gradually disappears upon correcting the excessive intake of carotenoids.   vitamin c  is generally a safe drug for human use in normal doses. larger doses may lead to gastrointestinal tract upset and renal stone formation.   vitamin e  is considered safe even in large doses. doses over 800 mg may cause diarrhoea, abdominal pain or cramps, fatigue and reduced resistance to bacterial infection and transiently raised blood pressure. ",betacarotene + vitamin c + vitamin e
sign_symptom,fatigue,0.9998857,"   carotene  is comparatively safe even at high and prolonged exposure. individuals who routinely ingest large amounts of carotenoids can develop hypercarotenosis, which is characterised by a yellowish colouration of the skin and a very high concentration of carotenoids in the plasma. this benign condition, although resembling jaundice, gradually disappears upon correcting the excessive intake of carotenoids.   vitamin c  is generally a safe drug for human use in normal doses. larger doses may lead to gastrointestinal tract upset and renal stone formation.   vitamin e  is considered safe even in large doses. doses over 800 mg may cause diarrhoea, abdominal pain or cramps, fatigue and reduced resistance to bacterial infection and transiently raised blood pressure. ",betacarotene + vitamin c + vitamin e
disease_disorder,bacterial infection,0.8496597,"   carotene  is comparatively safe even at high and prolonged exposure. individuals who routinely ingest large amounts of carotenoids can develop hypercarotenosis, which is characterised by a yellowish colouration of the skin and a very high concentration of carotenoids in the plasma. this benign condition, although resembling jaundice, gradually disappears upon correcting the excessive intake of carotenoids.   vitamin c  is generally a safe drug for human use in normal doses. larger doses may lead to gastrointestinal tract upset and renal stone formation.   vitamin e  is considered safe even in large doses. doses over 800 mg may cause diarrhoea, abdominal pain or cramps, fatigue and reduced resistance to bacterial infection and transiently raised blood pressure. ",betacarotene + vitamin c + vitamin e
sign_symptom,adverse,0.9993585," the most frequently reported ocular adverse event was conjunctival redness, reported in approximately 2% of patients. other adverse events reported in patients receiving besifloxacin occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache. ",besifloxacin
sign_symptom,adverse events,0.99659365," the most frequently reported ocular adverse event was conjunctival redness, reported in approximately 2% of patients. other adverse events reported in patients receiving besifloxacin occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache. ",besifloxacin
sign_symptom,blurred vision,0.9481981," the most frequently reported ocular adverse event was conjunctival redness, reported in approximately 2% of patients. other adverse events reported in patients receiving besifloxacin occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache. ",besifloxacin
sign_symptom,interstitial nephritis,0.9401227," nausea, vomiting, stomatitis, black or hairy tongue, rash, fever, serum-like sickness, convulsions, interstitial nephritis, haemolytic anaemia, granulocytopenia, agranulocytosis, leucopenia, thrombocytopenia ",benzyl penicillin
sign_symptom,gran,0.8157364," nausea, vomiting, stomatitis, black or hairy tongue, rash, fever, serum-like sickness, convulsions, interstitial nephritis, haemolytic anaemia, granulocytopenia, agranulocytosis, leucopenia, thrombocytopenia ",benzyl penicillin
disease_disorder,agranulocy,0.9862421," nausea, vomiting, stomatitis, black or hairy tongue, rash, fever, serum-like sickness, convulsions, interstitial nephritis, haemolytic anaemia, granulocytopenia, agranulocytosis, leucopenia, thrombocytopenia ",benzyl penicillin
sign_symptom,drying effects,0.8845433," irritant to eyes and mucous membranes, allergic dermatitis reactions, drying effects in the elderly. ",benzyl benzoate
sign_symptom,allergic reactions,0.9999004," generally well tolerated. however, a few allergic reactions may be seen. irritation, itching, redness, tingling, or numbness at the application site may occur. however, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. ",benzyl alcohol
sign_symptom,numbness,0.99175334," generally well tolerated. however, a few allergic reactions may be seen. irritation, itching, redness, tingling, or numbness at the application site may occur. however, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. ",benzyl alcohol
sign_symptom,swelling,0.998818," generally well tolerated. however, a few allergic reactions may be seen. irritation, itching, redness, tingling, or numbness at the application site may occur. however, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. ",benzyl alcohol
medication,benzydamine,0.99954957," benzydamine hydrochloride mouthwash can cause side effects, although not everybody gets them. side effects are generally minor.  
 
 severe allergic reaction which may include a red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) and feeling faint. if the swelling affects throat and makes breathing difficult and swallowing difficult, patients should be hospitalized 
 itchy rash, sometimes with pale, raised areas of skin with red edges (urticaria). 
 a feeling of numbness in mouth. 
 a stinging feeling in mouth- the mouthwash may be diluted with water if you experience stinging. this should help to reduce the stinging effect. 
  ",benzydamine hydrochloride
medication,hydrochloride,0.7520472," benzydamine hydrochloride mouthwash can cause side effects, although not everybody gets them. side effects are generally minor.  
 
 severe allergic reaction which may include a red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) and feeling faint. if the swelling affects throat and makes breathing difficult and swallowing difficult, patients should be hospitalized 
 itchy rash, sometimes with pale, raised areas of skin with red edges (urticaria). 
 a feeling of numbness in mouth. 
 a stinging feeling in mouth- the mouthwash may be diluted with water if you experience stinging. this should help to reduce the stinging effect. 
  ",benzydamine hydrochloride
sign_symptom,allergic reaction,0.99902856," benzydamine hydrochloride mouthwash can cause side effects, although not everybody gets them. side effects are generally minor.  
 
 severe allergic reaction which may include a red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) and feeling faint. if the swelling affects throat and makes breathing difficult and swallowing difficult, patients should be hospitalized 
 itchy rash, sometimes with pale, raised areas of skin with red edges (urticaria). 
 a feeling of numbness in mouth. 
 a stinging feeling in mouth- the mouthwash may be diluted with water if you experience stinging. this should help to reduce the stinging effect. 
  ",benzydamine hydrochloride
sign_symptom,difficulty breathing,0.9929558," benzydamine hydrochloride mouthwash can cause side effects, although not everybody gets them. side effects are generally minor.  
 
 severe allergic reaction which may include a red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) and feeling faint. if the swelling affects throat and makes breathing difficult and swallowing difficult, patients should be hospitalized 
 itchy rash, sometimes with pale, raised areas of skin with red edges (urticaria). 
 a feeling of numbness in mouth. 
 a stinging feeling in mouth- the mouthwash may be diluted with water if you experience stinging. this should help to reduce the stinging effect. 
  ",benzydamine hydrochloride
sign_symptom,swelling,0.9999474," benzydamine hydrochloride mouthwash can cause side effects, although not everybody gets them. side effects are generally minor.  
 
 severe allergic reaction which may include a red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) and feeling faint. if the swelling affects throat and makes breathing difficult and swallowing difficult, patients should be hospitalized 
 itchy rash, sometimes with pale, raised areas of skin with red edges (urticaria). 
 a feeling of numbness in mouth. 
 a stinging feeling in mouth- the mouthwash may be diluted with water if you experience stinging. this should help to reduce the stinging effect. 
  ",benzydamine hydrochloride
sign_symptom,high temperature,0.9144677," benzydamine hydrochloride mouthwash can cause side effects, although not everybody gets them. side effects are generally minor.  
 
 severe allergic reaction which may include a red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) and feeling faint. if the swelling affects throat and makes breathing difficult and swallowing difficult, patients should be hospitalized 
 itchy rash, sometimes with pale, raised areas of skin with red edges (urticaria). 
 a feeling of numbness in mouth. 
 a stinging feeling in mouth- the mouthwash may be diluted with water if you experience stinging. this should help to reduce the stinging effect. 
  ",benzydamine hydrochloride
sign_symptom,numbness,0.99610436," benzydamine hydrochloride mouthwash can cause side effects, although not everybody gets them. side effects are generally minor.  
 
 severe allergic reaction which may include a red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) and feeling faint. if the swelling affects throat and makes breathing difficult and swallowing difficult, patients should be hospitalized 
 itchy rash, sometimes with pale, raised areas of skin with red edges (urticaria). 
 a feeling of numbness in mouth. 
 a stinging feeling in mouth- the mouthwash may be diluted with water if you experience stinging. this should help to reduce the stinging effect. 
  ",benzydamine hydrochloride
sign_symptom,stinging,0.9997582," benzydamine hydrochloride mouthwash can cause side effects, although not everybody gets them. side effects are generally minor.  
 
 severe allergic reaction which may include a red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) and feeling faint. if the swelling affects throat and makes breathing difficult and swallowing difficult, patients should be hospitalized 
 itchy rash, sometimes with pale, raised areas of skin with red edges (urticaria). 
 a feeling of numbness in mouth. 
 a stinging feeling in mouth- the mouthwash may be diluted with water if you experience stinging. this should help to reduce the stinging effect. 
  ",benzydamine hydrochloride
sign_symptom,feeling,0.9991335," benzydamine hydrochloride mouthwash can cause side effects, although not everybody gets them. side effects are generally minor.  
 
 severe allergic reaction which may include a red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) and feeling faint. if the swelling affects throat and makes breathing difficult and swallowing difficult, patients should be hospitalized 
 itchy rash, sometimes with pale, raised areas of skin with red edges (urticaria). 
 a feeling of numbness in mouth. 
 a stinging feeling in mouth- the mouthwash may be diluted with water if you experience stinging. this should help to reduce the stinging effect. 
  ",benzydamine hydrochloride
medication,benzoyl peroxide,0.9666869," the major adverse reaction reported to date with benzoyl peroxide cutaneous therapy is irritation of the skin including erythema, burning, peeling, dryness, itching, stinging, feeling of skin tension locally at the site of application. this is reversible when treatment is reduced in frequency or discontinued. allergic contact dermatitis, including face oedema, may occur. ",benzoyl peroxide
sign_symptom,irritation,0.9999304," the major adverse reaction reported to date with benzoyl peroxide cutaneous therapy is irritation of the skin including erythema, burning, peeling, dryness, itching, stinging, feeling of skin tension locally at the site of application. this is reversible when treatment is reduced in frequency or discontinued. allergic contact dermatitis, including face oedema, may occur. ",benzoyl peroxide
sign_symptom,tension,0.9978859," the major adverse reaction reported to date with benzoyl peroxide cutaneous therapy is irritation of the skin including erythema, burning, peeling, dryness, itching, stinging, feeling of skin tension locally at the site of application. this is reversible when treatment is reduced in frequency or discontinued. allergic contact dermatitis, including face oedema, may occur. ",benzoyl peroxide
medication,benzocaine,0.9984997," benzocaine are more likely to cause contact sensitization. slight burning, tingling, or stinging may occur. ",benzocaine + camphor + methanol + phenol
sign_symptom,hyper,0.99796766," hypersensitivity reactions: unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. the most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. this occurs most commonly in patients following prolonged self-medication, which is contraindicated. if rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. to minimize the possibility of a serious allergic reaction, this topical gel preparations should not be applied for prolonged periods except under continual supervision. dehydration of the epithelium or an escharotic effect may also result from prolonged contact. ",benzocaine + butamben + tetracaine hydrochloride
sign_symptom,adverse reactions,0.9992887," hypersensitivity reactions: unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. the most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. this occurs most commonly in patients following prolonged self-medication, which is contraindicated. if rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. to minimize the possibility of a serious allergic reaction, this topical gel preparations should not be applied for prolonged periods except under continual supervision. dehydration of the epithelium or an escharotic effect may also result from prolonged contact. ",benzocaine + butamben + tetracaine hydrochloride
sign_symptom,allergic reactions,0.9992025," hypersensitivity reactions: unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. the most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. this occurs most commonly in patients following prolonged self-medication, which is contraindicated. if rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. to minimize the possibility of a serious allergic reaction, this topical gel preparations should not be applied for prolonged periods except under continual supervision. dehydration of the epithelium or an escharotic effect may also result from prolonged contact. ",benzocaine + butamben + tetracaine hydrochloride
medication,aminobenzoate,0.99189067," hypersensitivity reactions: unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. the most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. this occurs most commonly in patients following prolonged self-medication, which is contraindicated. if rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. to minimize the possibility of a serious allergic reaction, this topical gel preparations should not be applied for prolonged periods except under continual supervision. dehydration of the epithelium or an escharotic effect may also result from prolonged contact. ",benzocaine + butamben + tetracaine hydrochloride
sign_symptom,adverse reaction,0.92118156," hypersensitivity reactions: unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. the most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. this occurs most commonly in patients following prolonged self-medication, which is contraindicated. if rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. to minimize the possibility of a serious allergic reaction, this topical gel preparations should not be applied for prolonged periods except under continual supervision. dehydration of the epithelium or an escharotic effect may also result from prolonged contact. ",benzocaine + butamben + tetracaine hydrochloride
sign_symptom,erythema,0.98110825," hypersensitivity reactions: unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. the most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. this occurs most commonly in patients following prolonged self-medication, which is contraindicated. if rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. to minimize the possibility of a serious allergic reaction, this topical gel preparations should not be applied for prolonged periods except under continual supervision. dehydration of the epithelium or an escharotic effect may also result from prolonged contact. ",benzocaine + butamben + tetracaine hydrochloride
sign_symptom,pruritus,0.9982485," hypersensitivity reactions: unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. the most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. this occurs most commonly in patients following prolonged self-medication, which is contraindicated. if rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. to minimize the possibility of a serious allergic reaction, this topical gel preparations should not be applied for prolonged periods except under continual supervision. dehydration of the epithelium or an escharotic effect may also result from prolonged contact. ",benzocaine + butamben + tetracaine hydrochloride
sign_symptom,allergy,0.8518423," hypersensitivity reactions: unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. the most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. this occurs most commonly in patients following prolonged self-medication, which is contraindicated. if rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. to minimize the possibility of a serious allergic reaction, this topical gel preparations should not be applied for prolonged periods except under continual supervision. dehydration of the epithelium or an escharotic effect may also result from prolonged contact. ",benzocaine + butamben + tetracaine hydrochloride
sign_symptom,side effects to,0.99905586, no side effects to the product have been reported so far except for rare allergic reactions to sesame oil. ,-sitosterol
sign_symptom,allergic reactions,0.9973857, no side effects to the product have been reported so far except for rare allergic reactions to sesame oil. ,-sitosterol
sign_symptom,anxiety,0.88567454," anxiety states, elevated blood pressure, exanthema, nausea, insomnia, tachycardia, tremor, mania and vomiting. ",yohimbine hydrochloride
sign_symptom,mania,0.97066206," anxiety states, elevated blood pressure, exanthema, nausea, insomnia, tachycardia, tremor, mania and vomiting. ",yohimbine hydrochloride
sign_symptom,over,0.8122721," overdosage (&gt;1 gm) have been associated with minor side effects, including hypertension, fatigue, diarrhea and myopathy. ",vitamin e [alpha tocopherol acetate]
sign_symptom,discomfort,0.9996203, generally well-tolerated in the recommended dose. occasionally may cause gastrointestinal discomfort ,tart cherry
sign_symptom,swelling,0.9999192," side effects are less common. the side effects include allergies, swelling in the mouth or throatetc. ",benzocaine
sign_symptom,allergic,0.9793418," the toxicity of penicillins is generally low, but in a small number of patients penicillin can cause sensitization and allergic reactions. acute, lifethreatening anaphylactic reactions are rare, but they do occur.   intramuscular injection of benzathine penicillin can cause moderate burning discomfort, local pain, and deep muscle soreness and tenderness at the site of injection, lasting for one to three days in about 10% of patients. some patients had low-grade fever (102f) associated with local pain and tenderness. this febrile reaction disappeared within 24 to 48 hours. ",benzathine penicillin
sign_symptom,anaphylactic reactions,0.99762," the toxicity of penicillins is generally low, but in a small number of patients penicillin can cause sensitization and allergic reactions. acute, lifethreatening anaphylactic reactions are rare, but they do occur.   intramuscular injection of benzathine penicillin can cause moderate burning discomfort, local pain, and deep muscle soreness and tenderness at the site of injection, lasting for one to three days in about 10% of patients. some patients had low-grade fever (102f) associated with local pain and tenderness. this febrile reaction disappeared within 24 to 48 hours. ",benzathine penicillin
sign_symptom,sore,0.99991965," the toxicity of penicillins is generally low, but in a small number of patients penicillin can cause sensitization and allergic reactions. acute, lifethreatening anaphylactic reactions are rare, but they do occur.   intramuscular injection of benzathine penicillin can cause moderate burning discomfort, local pain, and deep muscle soreness and tenderness at the site of injection, lasting for one to three days in about 10% of patients. some patients had low-grade fever (102f) associated with local pain and tenderness. this febrile reaction disappeared within 24 to 48 hours. ",benzathine penicillin
sign_symptom,tenderness,0.99991536," the toxicity of penicillins is generally low, but in a small number of patients penicillin can cause sensitization and allergic reactions. acute, lifethreatening anaphylactic reactions are rare, but they do occur.   intramuscular injection of benzathine penicillin can cause moderate burning discomfort, local pain, and deep muscle soreness and tenderness at the site of injection, lasting for one to three days in about 10% of patients. some patients had low-grade fever (102f) associated with local pain and tenderness. this febrile reaction disappeared within 24 to 48 hours. ",benzathine penicillin
sign_symptom,fever,0.99992204," the toxicity of penicillins is generally low, but in a small number of patients penicillin can cause sensitization and allergic reactions. acute, lifethreatening anaphylactic reactions are rare, but they do occur.   intramuscular injection of benzathine penicillin can cause moderate burning discomfort, local pain, and deep muscle soreness and tenderness at the site of injection, lasting for one to three days in about 10% of patients. some patients had low-grade fever (102f) associated with local pain and tenderness. this febrile reaction disappeared within 24 to 48 hours. ",benzathine penicillin
sign_symptom,pain,0.99992704," the toxicity of penicillins is generally low, but in a small number of patients penicillin can cause sensitization and allergic reactions. acute, lifethreatening anaphylactic reactions are rare, but they do occur.   intramuscular injection of benzathine penicillin can cause moderate burning discomfort, local pain, and deep muscle soreness and tenderness at the site of injection, lasting for one to three days in about 10% of patients. some patients had low-grade fever (102f) associated with local pain and tenderness. this febrile reaction disappeared within 24 to 48 hours. ",benzathine penicillin
sign_symptom,reaction,0.76254165," the toxicity of penicillins is generally low, but in a small number of patients penicillin can cause sensitization and allergic reactions. acute, lifethreatening anaphylactic reactions are rare, but they do occur.   intramuscular injection of benzathine penicillin can cause moderate burning discomfort, local pain, and deep muscle soreness and tenderness at the site of injection, lasting for one to three days in about 10% of patients. some patients had low-grade fever (102f) associated with local pain and tenderness. this febrile reaction disappeared within 24 to 48 hours. ",benzathine penicillin
medication,bisacodyl,0.8986622, bisacodyl is free of side effects if taken in the recommended doses. overuse of bisacodyl may result in diarrhea and malabsorption. bisacodyl overuse might be expected to deplete potassium. ,bisacodyl
medication,bisacody,0.9753387, bisacodyl is free of side effects if taken in the recommended doses. overuse of bisacodyl may result in diarrhea and malabsorption. bisacodyl overuse might be expected to deplete potassium. ,bisacodyl
sign_symptom,diarrhea,0.9744577, bisacodyl is free of side effects if taken in the recommended doses. overuse of bisacodyl may result in diarrhea and malabsorption. bisacodyl overuse might be expected to deplete potassium. ,bisacodyl
medication,insulin,0.9892329," side effects of insulin aspart are hypoglycemia, lipodystrophy, weight gain, peripheral edema. ",biphasic insulin aspart [rdna]
sign_symptom,hyper,0.99867886," in clinical trials, ocular hyperemia was reported in approximately 26% of patients. 5 to 10 % in these clinical studies included decreased visual acuity, eye discomfort, foreign body sensation, pain and pruritis. ",bimatoprost + timolol
sign_symptom,foreign body,0.96054447," in clinical trials, ocular hyperemia was reported in approximately 26% of patients. 5 to 10 % in these clinical studies included decreased visual acuity, eye discomfort, foreign body sensation, pain and pruritis. ",bimatoprost + timolol
sign_symptom,pain,0.8697144," in clinical trials, ocular hyperemia was reported in approximately 26% of patients. 5 to 10 % in these clinical studies included decreased visual acuity, eye discomfort, foreign body sensation, pain and pruritis. ",bimatoprost + timolol
sign_symptom,stinging,0.74849194," common side effects are: burning/stinging/irritation/ redness/discomfort of the eye, feeling as if something is in your eye, dry eyes, watering eyes, temporary unstable vision, increased sensitivity to light, dizziness. ",bimatoprost
sign_symptom,irritation,0.9998636," common side effects are: burning/stinging/irritation/ redness/discomfort of the eye, feeling as if something is in your eye, dry eyes, watering eyes, temporary unstable vision, increased sensitivity to light, dizziness. ",bimatoprost
sign_symptom,discomfort,0.99987006," common side effects are: burning/stinging/irritation/ redness/discomfort of the eye, feeling as if something is in your eye, dry eyes, watering eyes, temporary unstable vision, increased sensitivity to light, dizziness. ",bimatoprost
sign_symptom,feeling,0.8320982," common side effects are: burning/stinging/irritation/ redness/discomfort of the eye, feeling as if something is in your eye, dry eyes, watering eyes, temporary unstable vision, increased sensitivity to light, dizziness. ",bimatoprost
sign_symptom,adverse,0.99631625," the most commonly reported side effects in clinical trial are headache, dizziness, somnolence and fatigue. these adverse events occurred with a comparable frequency in patients receiving placebo. ",bilastine
sign_symptom,loss of appetite,0.9962673," dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection. ",bevacizumab
sign_symptom,consti,0.92501175," dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection. ",bevacizumab
sign_symptom,cold,0.98182344," dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection. ",bevacizumab
sign_symptom,watery,0.87075573," dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection. ",bevacizumab
sign_symptom,flaky,0.7784159," dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection. ",bevacizumab
sign_symptom,pain,0.9999194," dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection. ",bevacizumab
sign_symptom,swelling,0.9876794," dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection. ",bevacizumab
sign_symptom,discomfort,0.99994576,"  ocular : discomfort of short duration, occasional tearing has been reported. rare instances of decreased corneal sensitivity, erythema, itching sensation, corneal punctuate staining, keratitis, edema and photophobia have been reported.   systemic : systemic reactions following administration of betaxolol hydrochloride ophthalmic solution 0.5% have been rarely reported. these include: 
 
 cardiovascular: bradycardia, heart block, congestive heart failure. 
 respiratory: bronchospasm, respiratory failure. 
 others: hives, toxic epidermal necrolysis, hair loss and glossitis. 
  ",betaxolol hydrochloride
sign_symptom,tearing,0.999941,"  ocular : discomfort of short duration, occasional tearing has been reported. rare instances of decreased corneal sensitivity, erythema, itching sensation, corneal punctuate staining, keratitis, edema and photophobia have been reported.   systemic : systemic reactions following administration of betaxolol hydrochloride ophthalmic solution 0.5% have been rarely reported. these include: 
 
 cardiovascular: bradycardia, heart block, congestive heart failure. 
 respiratory: bronchospasm, respiratory failure. 
 others: hives, toxic epidermal necrolysis, hair loss and glossitis. 
  ",betaxolol hydrochloride
sign_symptom,photophobia,0.9986253,"  ocular : discomfort of short duration, occasional tearing has been reported. rare instances of decreased corneal sensitivity, erythema, itching sensation, corneal punctuate staining, keratitis, edema and photophobia have been reported.   systemic : systemic reactions following administration of betaxolol hydrochloride ophthalmic solution 0.5% have been rarely reported. these include: 
 
 cardiovascular: bradycardia, heart block, congestive heart failure. 
 respiratory: bronchospasm, respiratory failure. 
 others: hives, toxic epidermal necrolysis, hair loss and glossitis. 
  ",betaxolol hydrochloride
sign_symptom,reactions,0.9930754,"  ocular : discomfort of short duration, occasional tearing has been reported. rare instances of decreased corneal sensitivity, erythema, itching sensation, corneal punctuate staining, keratitis, edema and photophobia have been reported.   systemic : systemic reactions following administration of betaxolol hydrochloride ophthalmic solution 0.5% have been rarely reported. these include: 
 
 cardiovascular: bradycardia, heart block, congestive heart failure. 
 respiratory: bronchospasm, respiratory failure. 
 others: hives, toxic epidermal necrolysis, hair loss and glossitis. 
  ",betaxolol hydrochloride
medication,betaxolol hydrochloride,0.9807888,"  ocular : discomfort of short duration, occasional tearing has been reported. rare instances of decreased corneal sensitivity, erythema, itching sensation, corneal punctuate staining, keratitis, edema and photophobia have been reported.   systemic : systemic reactions following administration of betaxolol hydrochloride ophthalmic solution 0.5% have been rarely reported. these include: 
 
 cardiovascular: bradycardia, heart block, congestive heart failure. 
 respiratory: bronchospasm, respiratory failure. 
 others: hives, toxic epidermal necrolysis, hair loss and glossitis. 
  ",betaxolol hydrochloride
medication,ophthalmic solution,0.99879277,"  ocular : discomfort of short duration, occasional tearing has been reported. rare instances of decreased corneal sensitivity, erythema, itching sensation, corneal punctuate staining, keratitis, edema and photophobia have been reported.   systemic : systemic reactions following administration of betaxolol hydrochloride ophthalmic solution 0.5% have been rarely reported. these include: 
 
 cardiovascular: bradycardia, heart block, congestive heart failure. 
 respiratory: bronchospasm, respiratory failure. 
 others: hives, toxic epidermal necrolysis, hair loss and glossitis. 
  ",betaxolol hydrochloride
sign_symptom,adverse reactions,0.9986731," the following local adverse reactions are more common with the use of high doses, long term use and with the use of occlusive dressings of cream/ointment: dryness, itching, burning, skin thinning, local irritation, features of hypercorticolism, telagiectasia, striaea, skin atrophy. hypertrichosis, change in pigmentation, secondary infection, perioral dermatiis, allergic contact dermatitis, maceration of the skin, acneform eruption, exacerbation of symptoms. ",betamethasone valerate
sign_symptom,mace,0.99517375," the following local adverse reactions are more common with the use of high doses, long term use and with the use of occlusive dressings of cream/ointment: dryness, itching, burning, skin thinning, local irritation, features of hypercorticolism, telagiectasia, striaea, skin atrophy. hypertrichosis, change in pigmentation, secondary infection, perioral dermatiis, allergic contact dermatitis, maceration of the skin, acneform eruption, exacerbation of symptoms. ",betamethasone valerate
sign_symptom,hyper,0.99976534," hypersensitivity reactions may occur leading to irritation, burning, stinging, itching and dermatitis. topical corticosteroid use may result in corneal ulceration, increased intraocular pressure leading to optic nerve damage, reduced visual acuity. intensive or prolonged use of topical corticosteroids may lead to formation of posterior subcapsular cataracts. in those diseases causing thinning of the cornea or sclera, corticosteroid therapy may result in thinning of the globe leading to perforation. mydriasis, ptosis and epithelial punctate keratitis have also been reported following ophthalmic use of corticosteroids. ",betamethasone sodium phosphate
medication,corticosteroid,0.98929864," hypersensitivity reactions may occur leading to irritation, burning, stinging, itching and dermatitis. topical corticosteroid use may result in corneal ulceration, increased intraocular pressure leading to optic nerve damage, reduced visual acuity. intensive or prolonged use of topical corticosteroids may lead to formation of posterior subcapsular cataracts. in those diseases causing thinning of the cornea or sclera, corticosteroid therapy may result in thinning of the globe leading to perforation. mydriasis, ptosis and epithelial punctate keratitis have also been reported following ophthalmic use of corticosteroids. ",betamethasone sodium phosphate
medication,corticosteroids,0.98449975," hypersensitivity reactions may occur leading to irritation, burning, stinging, itching and dermatitis. topical corticosteroid use may result in corneal ulceration, increased intraocular pressure leading to optic nerve damage, reduced visual acuity. intensive or prolonged use of topical corticosteroids may lead to formation of posterior subcapsular cataracts. in those diseases causing thinning of the cornea or sclera, corticosteroid therapy may result in thinning of the globe leading to perforation. mydriasis, ptosis and epithelial punctate keratitis have also been reported following ophthalmic use of corticosteroids. ",betamethasone sodium phosphate
sign_symptom,thin,0.9999198," hypersensitivity reactions may occur leading to irritation, burning, stinging, itching and dermatitis. topical corticosteroid use may result in corneal ulceration, increased intraocular pressure leading to optic nerve damage, reduced visual acuity. intensive or prolonged use of topical corticosteroids may lead to formation of posterior subcapsular cataracts. in those diseases causing thinning of the cornea or sclera, corticosteroid therapy may result in thinning of the globe leading to perforation. mydriasis, ptosis and epithelial punctate keratitis have also been reported following ophthalmic use of corticosteroids. ",betamethasone sodium phosphate
sign_symptom,thinning,0.99181825," hypersensitivity reactions may occur leading to irritation, burning, stinging, itching and dermatitis. topical corticosteroid use may result in corneal ulceration, increased intraocular pressure leading to optic nerve damage, reduced visual acuity. intensive or prolonged use of topical corticosteroids may lead to formation of posterior subcapsular cataracts. in those diseases causing thinning of the cornea or sclera, corticosteroid therapy may result in thinning of the globe leading to perforation. mydriasis, ptosis and epithelial punctate keratitis have also been reported following ophthalmic use of corticosteroids. ",betamethasone sodium phosphate
disease_disorder,ptosis,0.8430137," hypersensitivity reactions may occur leading to irritation, burning, stinging, itching and dermatitis. topical corticosteroid use may result in corneal ulceration, increased intraocular pressure leading to optic nerve damage, reduced visual acuity. intensive or prolonged use of topical corticosteroids may lead to formation of posterior subcapsular cataracts. in those diseases causing thinning of the cornea or sclera, corticosteroid therapy may result in thinning of the globe leading to perforation. mydriasis, ptosis and epithelial punctate keratitis have also been reported following ophthalmic use of corticosteroids. ",betamethasone sodium phosphate
medication,beta,0.9993388," the most frequent side effects reported with betamethasone dipropionate are mild to moderate transient burning/stinging, dry skin, pruritus, irritation and folliculitis. rarely reported adverse effects include tingling, prickly skin/tightening or cracking of skin, warm feeling,laminar scaling and perilesional scaling,follicular rash, skin atrophy, erythema, urticaria, vesiculation, telangiectasia, acneiform papules and hyperaesthesia.  adverse reactions reported with the use of the betamethasone dipropionate ointment pulse dose regimen were mild intermittent hypertension and paraesthesia. other local adverse reactions that have been reported with the use of topical corticosteroids include: itching, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria and exacerbation of untreated infections ",betamethasone dipropionate
sign_symptom,irritation,0.9999298," the most frequent side effects reported with betamethasone dipropionate are mild to moderate transient burning/stinging, dry skin, pruritus, irritation and folliculitis. rarely reported adverse effects include tingling, prickly skin/tightening or cracking of skin, warm feeling,laminar scaling and perilesional scaling,follicular rash, skin atrophy, erythema, urticaria, vesiculation, telangiectasia, acneiform papules and hyperaesthesia.  adverse reactions reported with the use of the betamethasone dipropionate ointment pulse dose regimen were mild intermittent hypertension and paraesthesia. other local adverse reactions that have been reported with the use of topical corticosteroids include: itching, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria and exacerbation of untreated infections ",betamethasone dipropionate
sign_symptom,cracking,0.9997441," the most frequent side effects reported with betamethasone dipropionate are mild to moderate transient burning/stinging, dry skin, pruritus, irritation and folliculitis. rarely reported adverse effects include tingling, prickly skin/tightening or cracking of skin, warm feeling,laminar scaling and perilesional scaling,follicular rash, skin atrophy, erythema, urticaria, vesiculation, telangiectasia, acneiform papules and hyperaesthesia.  adverse reactions reported with the use of the betamethasone dipropionate ointment pulse dose regimen were mild intermittent hypertension and paraesthesia. other local adverse reactions that have been reported with the use of topical corticosteroids include: itching, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria and exacerbation of untreated infections ",betamethasone dipropionate
sign_symptom,hyper,0.99005985," the most frequent side effects reported with betamethasone dipropionate are mild to moderate transient burning/stinging, dry skin, pruritus, irritation and folliculitis. rarely reported adverse effects include tingling, prickly skin/tightening or cracking of skin, warm feeling,laminar scaling and perilesional scaling,follicular rash, skin atrophy, erythema, urticaria, vesiculation, telangiectasia, acneiform papules and hyperaesthesia.  adverse reactions reported with the use of the betamethasone dipropionate ointment pulse dose regimen were mild intermittent hypertension and paraesthesia. other local adverse reactions that have been reported with the use of topical corticosteroids include: itching, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria and exacerbation of untreated infections ",betamethasone dipropionate
sign_symptom,adverse reactions,0.9730403," the most frequent side effects reported with betamethasone dipropionate are mild to moderate transient burning/stinging, dry skin, pruritus, irritation and folliculitis. rarely reported adverse effects include tingling, prickly skin/tightening or cracking of skin, warm feeling,laminar scaling and perilesional scaling,follicular rash, skin atrophy, erythema, urticaria, vesiculation, telangiectasia, acneiform papules and hyperaesthesia.  adverse reactions reported with the use of the betamethasone dipropionate ointment pulse dose regimen were mild intermittent hypertension and paraesthesia. other local adverse reactions that have been reported with the use of topical corticosteroids include: itching, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria and exacerbation of untreated infections ",betamethasone dipropionate
medication,dipropionate,0.99540526," the most frequent side effects reported with betamethasone dipropionate are mild to moderate transient burning/stinging, dry skin, pruritus, irritation and folliculitis. rarely reported adverse effects include tingling, prickly skin/tightening or cracking of skin, warm feeling,laminar scaling and perilesional scaling,follicular rash, skin atrophy, erythema, urticaria, vesiculation, telangiectasia, acneiform papules and hyperaesthesia.  adverse reactions reported with the use of the betamethasone dipropionate ointment pulse dose regimen were mild intermittent hypertension and paraesthesia. other local adverse reactions that have been reported with the use of topical corticosteroids include: itching, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria and exacerbation of untreated infections ",betamethasone dipropionate
sign_symptom,adverse,0.89032835," the most frequent side effects reported with betamethasone dipropionate are mild to moderate transient burning/stinging, dry skin, pruritus, irritation and folliculitis. rarely reported adverse effects include tingling, prickly skin/tightening or cracking of skin, warm feeling,laminar scaling and perilesional scaling,follicular rash, skin atrophy, erythema, urticaria, vesiculation, telangiectasia, acneiform papules and hyperaesthesia.  adverse reactions reported with the use of the betamethasone dipropionate ointment pulse dose regimen were mild intermittent hypertension and paraesthesia. other local adverse reactions that have been reported with the use of topical corticosteroids include: itching, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria and exacerbation of untreated infections ",betamethasone dipropionate
medication,corticosteroids,0.9359643," the most frequent side effects reported with betamethasone dipropionate are mild to moderate transient burning/stinging, dry skin, pruritus, irritation and folliculitis. rarely reported adverse effects include tingling, prickly skin/tightening or cracking of skin, warm feeling,laminar scaling and perilesional scaling,follicular rash, skin atrophy, erythema, urticaria, vesiculation, telangiectasia, acneiform papules and hyperaesthesia.  adverse reactions reported with the use of the betamethasone dipropionate ointment pulse dose regimen were mild intermittent hypertension and paraesthesia. other local adverse reactions that have been reported with the use of topical corticosteroids include: itching, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria and exacerbation of untreated infections ",betamethasone dipropionate
sign_symptom,mace,0.84786296," the most frequent side effects reported with betamethasone dipropionate are mild to moderate transient burning/stinging, dry skin, pruritus, irritation and folliculitis. rarely reported adverse effects include tingling, prickly skin/tightening or cracking of skin, warm feeling,laminar scaling and perilesional scaling,follicular rash, skin atrophy, erythema, urticaria, vesiculation, telangiectasia, acneiform papules and hyperaesthesia.  adverse reactions reported with the use of the betamethasone dipropionate ointment pulse dose regimen were mild intermittent hypertension and paraesthesia. other local adverse reactions that have been reported with the use of topical corticosteroids include: itching, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria and exacerbation of untreated infections ",betamethasone dipropionate
disease_disorder,infections,0.98014235," the most frequent side effects reported with betamethasone dipropionate are mild to moderate transient burning/stinging, dry skin, pruritus, irritation and folliculitis. rarely reported adverse effects include tingling, prickly skin/tightening or cracking of skin, warm feeling,laminar scaling and perilesional scaling,follicular rash, skin atrophy, erythema, urticaria, vesiculation, telangiectasia, acneiform papules and hyperaesthesia.  adverse reactions reported with the use of the betamethasone dipropionate ointment pulse dose regimen were mild intermittent hypertension and paraesthesia. other local adverse reactions that have been reported with the use of topical corticosteroids include: itching, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria and exacerbation of untreated infections ",betamethasone dipropionate
sign_symptom,thin,0.9831693," this preparation is well tolerated. but prolonged and high doses may cause cushing's syndrome, acne, thinning and dilatation of blood vessels, particularly when occlusive dressings are used. ",betamethasone + neomycin sulphate (topical)
sign_symptom,pigmentation changes,0.99950963," as with all topical corticosteroids, its use for prolonged periods, may cause systemic absorption, specially in children. prolonged and intensive treatment with active corticosteroid preparations may also cause local atrophic changes in the skin. there are reports of pigmentation changes and hypertrichosis with topical steroids, and in this situation it should be discontinued. some patients may experience burning upon application, specially if the mucous membrane is not intact. ",betamethasone + phenylephrine + lignocaine
sign_symptom,hyper,0.9996611," as with all topical corticosteroids, its use for prolonged periods, may cause systemic absorption, specially in children. prolonged and intensive treatment with active corticosteroid preparations may also cause local atrophic changes in the skin. there are reports of pigmentation changes and hypertrichosis with topical steroids, and in this situation it should be discontinued. some patients may experience burning upon application, specially if the mucous membrane is not intact. ",betamethasone + phenylephrine + lignocaine
sign_symptom,thin,0.99993825," acute sensitization to neomycin is a rare event but can occur after topical application to the eye. eye drops containing corticosteroids cause a serious rise in intra-ocular pressure in a small percentage of the population, including most of those with a family history of glaucoma. a milder rise may be experienced by a larger proportion of subjects if treatment is continued for longer than a few weeks. thinning of the cornea leading to perforation has occurred with use of topical corticosteroids. cataract is reported to have occurred after unduly prolonged treatment of eye conditions with topical corticosteroids. ",betamethasone + neomycin sulphate (e/e)
medication,corticoster,0.75729597," acute sensitization to neomycin is a rare event but can occur after topical application to the eye. eye drops containing corticosteroids cause a serious rise in intra-ocular pressure in a small percentage of the population, including most of those with a family history of glaucoma. a milder rise may be experienced by a larger proportion of subjects if treatment is continued for longer than a few weeks. thinning of the cornea leading to perforation has occurred with use of topical corticosteroids. cataract is reported to have occurred after unduly prolonged treatment of eye conditions with topical corticosteroids. ",betamethasone + neomycin sulphate (e/e)
sign_symptom,adverse,0.99993026," the following local adverse skin reactions have been reported with the use of topical steroids: dryness, itching, burning, local irritation, striae, skin atrophy, hypertrichosis, change in pigmentation and secondary infection. adrenal suppression has also been reported following topical corticosteroid therapy. posterior subcapsular cataracts have been reported following systemic use of corticosteroids.. ",betamethasone + gentamicin
sign_symptom,skin reactions,0.9779817," the following local adverse skin reactions have been reported with the use of topical steroids: dryness, itching, burning, local irritation, striae, skin atrophy, hypertrichosis, change in pigmentation and secondary infection. adrenal suppression has also been reported following topical corticosteroid therapy. posterior subcapsular cataracts have been reported following systemic use of corticosteroids.. ",betamethasone + gentamicin
sign_symptom,change in pigmentation,0.99296933," the following local adverse skin reactions have been reported with the use of topical steroids: dryness, itching, burning, local irritation, striae, skin atrophy, hypertrichosis, change in pigmentation and secondary infection. adrenal suppression has also been reported following topical corticosteroid therapy. posterior subcapsular cataracts have been reported following systemic use of corticosteroids.. ",betamethasone + gentamicin
sign_symptom,adren,0.86648095," the following local adverse skin reactions have been reported with the use of topical steroids: dryness, itching, burning, local irritation, striae, skin atrophy, hypertrichosis, change in pigmentation and secondary infection. adrenal suppression has also been reported following topical corticosteroid therapy. posterior subcapsular cataracts have been reported following systemic use of corticosteroids.. ",betamethasone + gentamicin
medication,corti,0.9236667," the following local adverse skin reactions have been reported with the use of topical steroids: dryness, itching, burning, local irritation, striae, skin atrophy, hypertrichosis, change in pigmentation and secondary infection. adrenal suppression has also been reported following topical corticosteroid therapy. posterior subcapsular cataracts have been reported following systemic use of corticosteroids.. ",betamethasone + gentamicin
sign_symptom,subcapsul,0.89127606," the following local adverse skin reactions have been reported with the use of topical steroids: dryness, itching, burning, local irritation, striae, skin atrophy, hypertrichosis, change in pigmentation and secondary infection. adrenal suppression has also been reported following topical corticosteroid therapy. posterior subcapsular cataracts have been reported following systemic use of corticosteroids.. ",betamethasone + gentamicin
sign_symptom,cataracts,0.9950575," the following local adverse skin reactions have been reported with the use of topical steroids: dryness, itching, burning, local irritation, striae, skin atrophy, hypertrichosis, change in pigmentation and secondary infection. adrenal suppression has also been reported following topical corticosteroid therapy. posterior subcapsular cataracts have been reported following systemic use of corticosteroids.. ",betamethasone + gentamicin
sign_symptom,adverse reactions,0.9997522," adverse reactions reported for the preparation in clinical trials were paresthesia in 1.9% of patients, rash, edema and secondary infection, each in less than 1% of patients. other adverse reactions reported with the preparation were burning and dry skin in 1.6% of patients and stinging in less than 1% of patients ",betamethasone + clotrimazole
sign_symptom,burning,0.97557515," adverse reactions reported for the preparation in clinical trials were paresthesia in 1.9% of patients, rash, edema and secondary infection, each in less than 1% of patients. other adverse reactions reported with the preparation were burning and dry skin in 1.6% of patients and stinging in less than 1% of patients ",betamethasone + clotrimazole
sign_symptom,stinging,0.99975365," adverse reactions reported for the preparation in clinical trials were paresthesia in 1.9% of patients, rash, edema and secondary infection, each in less than 1% of patients. other adverse reactions reported with the preparation were burning and dry skin in 1.6% of patients and stinging in less than 1% of patients ",betamethasone + clotrimazole
sign_symptom,adverse reactions,0.9998684," adverse reactions have been reported very rarely and include hypochromia, burning, erythema, exudation etc. ",betamethasone + clotrimazole + gentamicin
sign_symptom,hypersen,0.7454581, repeated application may cause hypersensitivity reactions. may cause nausea and vomiting if ingested. ,benzalkonium chloride
sign_symptom,nausea,0.9999013, repeated application may cause hypersensitivity reactions. may cause nausea and vomiting if ingested. ,benzalkonium chloride
sign_symptom,vomiting,0.9999082, repeated application may cause hypersensitivity reactions. may cause nausea and vomiting if ingested. ,benzalkonium chloride
disease_disorder,infection,0.996451,"  
 upper respiratory tract infection 
 muscle spasms 
 hyperuricemia 
 back pain 
 abdominal pain or discomfort 
 bronchitis 
 pain in extremity 
 anemia 
 elevated liver enzymes 
  ",bempedoic acid
disease_disorder,hyperuricemia,0.8917241,"  
 upper respiratory tract infection 
 muscle spasms 
 hyperuricemia 
 back pain 
 abdominal pain or discomfort 
 bronchitis 
 pain in extremity 
 anemia 
 elevated liver enzymes 
  ",bempedoic acid
sign_symptom,pain,0.9999416,"  
 upper respiratory tract infection 
 muscle spasms 
 hyperuricemia 
 back pain 
 abdominal pain or discomfort 
 bronchitis 
 pain in extremity 
 anemia 
 elevated liver enzymes 
  ",bempedoic acid
sign_symptom,discomfort,0.99993074,"  
 upper respiratory tract infection 
 muscle spasms 
 hyperuricemia 
 back pain 
 abdominal pain or discomfort 
 bronchitis 
 pain in extremity 
 anemia 
 elevated liver enzymes 
  ",bempedoic acid
medication,azithromycin,0.99832594," azithromycin is well tolerated with a low incidence of side effects. the side effects include nausea, vomiting, abdominal discomfort (pain/cramps), flatulence, diarrhoea, headache, dizziness, and skin rashes and are reversible upon discontinuation of therapy. ",azithromycin dihydrate
sign_symptom,discomfort,0.999887," azithromycin is well tolerated with a low incidence of side effects. the side effects include nausea, vomiting, abdominal discomfort (pain/cramps), flatulence, diarrhoea, headache, dizziness, and skin rashes and are reversible upon discontinuation of therapy. ",azithromycin dihydrate
sign_symptom,flat,0.99821705," azithromycin is well tolerated with a low incidence of side effects. the side effects include nausea, vomiting, abdominal discomfort (pain/cramps), flatulence, diarrhoea, headache, dizziness, and skin rashes and are reversible upon discontinuation of therapy. ",azithromycin dihydrate
sign_symptom,rash,0.99979347," azithromycin is well tolerated with a low incidence of side effects. the side effects include nausea, vomiting, abdominal discomfort (pain/cramps), flatulence, diarrhoea, headache, dizziness, and skin rashes and are reversible upon discontinuation of therapy. ",azithromycin dihydrate
sign_symptom,adverse reactions,0.9991522," the following potential adverse reactions are- 
 
 fetal toxicity 
 hypotension in volume- or salt-depleted patients 
 impaired renal function 
 hypokalemia hyperuricemia 
  ",azilsartan medoxomil + chlorthalidone
sign_symptom,toxicity,0.8941524," the following potential adverse reactions are- 
 
 fetal toxicity 
 hypotension in volume- or salt-depleted patients 
 impaired renal function 
 hypokalemia hyperuricemia 
  ",azilsartan medoxomil + chlorthalidone
sign_symptom,impaired,0.7018246," the following potential adverse reactions are- 
 
 fetal toxicity 
 hypotension in volume- or salt-depleted patients 
 impaired renal function 
 hypokalemia hyperuricemia 
  ",azilsartan medoxomil + chlorthalidone
sign_symptom,hypokalemia,0.95567816," the following potential adverse reactions are- 
 
 fetal toxicity 
 hypotension in volume- or salt-depleted patients 
 impaired renal function 
 hypokalemia hyperuricemia 
  ",azilsartan medoxomil + chlorthalidone
sign_symptom,hyperuricemia,0.9962137," the following potential adverse reactions are- 
 
 fetal toxicity 
 hypotension in volume- or salt-depleted patients 
 impaired renal function 
 hypokalemia hyperuricemia 
  ",azilsartan medoxomil + chlorthalidone
sign_symptom,side effects,0.9207846," gastrointestinal side effects may occur occasionally. a transient rise in serum aminotransferase values has been reported. other reported side effects include-headache, vertigo (dizziness) and allergic reactions. ",bromhexine hydrochloride
sign_symptom,vertigo,0.99890494," gastrointestinal side effects may occur occasionally. a transient rise in serum aminotransferase values has been reported. other reported side effects include-headache, vertigo (dizziness) and allergic reactions. ",bromhexine hydrochloride
sign_symptom,adverse reactions,0.99956715," the most commonly reported adverse reactions following use of bromfenac after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache and iritis. these events were reported in 2-7% of patients ",bromfenac sodium
sign_symptom,irritation,0.99990284," the most commonly reported adverse reactions following use of bromfenac after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache and iritis. these events were reported in 2-7% of patients ",bromfenac sodium
sign_symptom,pain,0.87099224," the most commonly reported adverse reactions following use of bromfenac after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache and iritis. these events were reported in 2-7% of patients ",bromfenac sodium
sign_symptom,headache,0.99990845," the most commonly reported adverse reactions following use of bromfenac after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache and iritis. these events were reported in 2-7% of patients ",bromfenac sodium
medication,tryps,0.959989, trypsin seems to be safe when used by healthcare professionals for wound cleaning and healing. it can cause side effects such as pain and burning. not enough is known about the safety of trypsin for its other uses. ,bromelain + trypsin
medication,trypsin,0.8485535, trypsin seems to be safe when used by healthcare professionals for wound cleaning and healing. it can cause side effects such as pain and burning. not enough is known about the safety of trypsin for its other uses. ,bromelain + trypsin
sign_symptom,fatigue,0.80619645," common side-effects include fatigue, drowsiness, muscle weakness, numbed muscle, reduced alertness, confusion, headache, ataxia etc. these phenomena occur predominantly at the start of therapy and usually disappear with prolonged administration. anterograde amnesia may occur using therapeutic doses. ",bromazepam
sign_symptom,numbed,0.93801105," common side-effects include fatigue, drowsiness, muscle weakness, numbed muscle, reduced alertness, confusion, headache, ataxia etc. these phenomena occur predominantly at the start of therapy and usually disappear with prolonged administration. anterograde amnesia may occur using therapeutic doses. ",bromazepam
sign_symptom,reduced alertness,0.99588156," common side-effects include fatigue, drowsiness, muscle weakness, numbed muscle, reduced alertness, confusion, headache, ataxia etc. these phenomena occur predominantly at the start of therapy and usually disappear with prolonged administration. anterograde amnesia may occur using therapeutic doses. ",bromazepam
sign_symptom,confusion,0.9894944," common side-effects include fatigue, drowsiness, muscle weakness, numbed muscle, reduced alertness, confusion, headache, ataxia etc. these phenomena occur predominantly at the start of therapy and usually disappear with prolonged administration. anterograde amnesia may occur using therapeutic doses. ",bromazepam
sign_symptom,headache,0.965252," common side-effects include fatigue, drowsiness, muscle weakness, numbed muscle, reduced alertness, confusion, headache, ataxia etc. these phenomena occur predominantly at the start of therapy and usually disappear with prolonged administration. anterograde amnesia may occur using therapeutic doses. ",bromazepam
sign_symptom,adverse reactions,0.9969138," most common adverse reactions (at least 5% for brivaracetam and at least 2% more frequently than placebo) are somnolence/sedation, dizziness, fatigue, and nausea or vomiting. ",brivaracetam
sign_symptom,nausea,0.99804085," most common adverse reactions (at least 5% for brivaracetam and at least 2% more frequently than placebo) are somnolence/sedation, dizziness, fatigue, and nausea or vomiting. ",brivaracetam
sign_symptom,bad taste,0.99064064," the most commonly reported side effects include blurred vision, eye irritation, bad taste and dry mouth. ",brinzolamide + brimonidine tartrate
sign_symptom,blurred,0.94147563," dysgeusia, blurred vision, eye pain &amp; irritation, foreign body sensation. ",brinzolamide + timolol
sign_symptom,pain,0.99992335," dysgeusia, blurred vision, eye pain &amp; irritation, foreign body sensation. ",brinzolamide + timolol
sign_symptom,blurred vision,0.9388226," reported side effects are blurred vision and bitter, sour or unusual taste. other side effects are blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus and rhinitis. ",brinzolamide
sign_symptom,adverse events,0.9504551," adverse events occurring in approximately 10-30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus. events occurring in approximately 3-9% of the subjects, in descending order included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision and muscular pain. the following adverse reactions were reported in less than 3% of the patients: lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression, hypertension, anxiety, palpitations/arrhythmias, nasal dryness and syncope. ",brimonidine tartrate
sign_symptom,fatigue,0.99801034," adverse events occurring in approximately 10-30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus. events occurring in approximately 3-9% of the subjects, in descending order included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision and muscular pain. the following adverse reactions were reported in less than 3% of the patients: lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression, hypertension, anxiety, palpitations/arrhythmias, nasal dryness and syncope. ",brimonidine tartrate
sign_symptom,ache,0.98836666," adverse events occurring in approximately 10-30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus. events occurring in approximately 3-9% of the subjects, in descending order included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision and muscular pain. the following adverse reactions were reported in less than 3% of the patients: lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression, hypertension, anxiety, palpitations/arrhythmias, nasal dryness and syncope. ",brimonidine tartrate
sign_symptom,abnormal vision,0.9610405," adverse events occurring in approximately 10-30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus. events occurring in approximately 3-9% of the subjects, in descending order included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision and muscular pain. the following adverse reactions were reported in less than 3% of the patients: lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression, hypertension, anxiety, palpitations/arrhythmias, nasal dryness and syncope. ",brimonidine tartrate
sign_symptom,adverse reactions,0.9801549," adverse events occurring in approximately 10-30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus. events occurring in approximately 3-9% of the subjects, in descending order included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision and muscular pain. the following adverse reactions were reported in less than 3% of the patients: lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression, hypertension, anxiety, palpitations/arrhythmias, nasal dryness and syncope. ",brimonidine tartrate
disease_disorder,interstitial lung disease,0.999063,"  
 interstitial lung disease (ild)/pneumonitis 
 hypertension 
 bradycardia 
 visual disturbance 
 creatine phosphokinase (cpk) elevation 
 pancreatic enzyme elevation 
 hyperglycemia 
  ",brigatinib
disease_disorder,pneumonitis,0.97659796,"  
 interstitial lung disease (ild)/pneumonitis 
 hypertension 
 bradycardia 
 visual disturbance 
 creatine phosphokinase (cpk) elevation 
 pancreatic enzyme elevation 
 hyperglycemia 
  ",brigatinib
disease_disorder,hypertension,0.9994917,"  
 interstitial lung disease (ild)/pneumonitis 
 hypertension 
 bradycardia 
 visual disturbance 
 creatine phosphokinase (cpk) elevation 
 pancreatic enzyme elevation 
 hyperglycemia 
  ",brigatinib
disease_disorder,bradycardia,0.8297022,"  
 interstitial lung disease (ild)/pneumonitis 
 hypertension 
 bradycardia 
 visual disturbance 
 creatine phosphokinase (cpk) elevation 
 pancreatic enzyme elevation 
 hyperglycemia 
  ",brigatinib
sign_symptom,visual disturbance,0.9117316,"  
 interstitial lung disease (ild)/pneumonitis 
 hypertension 
 bradycardia 
 visual disturbance 
 creatine phosphokinase (cpk) elevation 
 pancreatic enzyme elevation 
 hyperglycemia 
  ",brigatinib
disease_disorder,elevation,0.95960516,"  
 interstitial lung disease (ild)/pneumonitis 
 hypertension 
 bradycardia 
 visual disturbance 
 creatine phosphokinase (cpk) elevation 
 pancreatic enzyme elevation 
 hyperglycemia 
  ",brigatinib
disease_disorder,hyperglycemia,0.9630127,"  
 interstitial lung disease (ild)/pneumonitis 
 hypertension 
 bradycardia 
 visual disturbance 
 creatine phosphokinase (cpk) elevation 
 pancreatic enzyme elevation 
 hyperglycemia 
  ",brigatinib
sign_symptom,adverse reactions,0.9954289," most commonly reported adverse reactions (incidence 30%) in clinical studies include asthenic conditions, diarrhea, nausea, constipation, peripheral neuropathy, vomiting, pyrexia, thrombocytopenia, psychiatric disorders, anorexia and decreased appetite, neutropenia, neuralgia, leukopenia and anemia. other adverse reactions, including serious adverse reactions, have been reported ",bortezomib
sign_symptom,adverse,0.9942899," most commonly reported adverse reactions (incidence 30%) in clinical studies include asthenic conditions, diarrhea, nausea, constipation, peripheral neuropathy, vomiting, pyrexia, thrombocytopenia, psychiatric disorders, anorexia and decreased appetite, neutropenia, neuralgia, leukopenia and anemia. other adverse reactions, including serious adverse reactions, have been reported ",bortezomib
disease_disorder,liver failure,0.8263956," treatment with bosentan has been associated with dose dependent elevations in liver aminotransferases and decreases in haemoglobin concentration. other side effects include anaemia, haemoglobin decrease, thrombocytopenia, neutropenia, leucopenia, hypersensitivity reactions, headache, syncope, palpitations, flushing, hypotension, gastroesophageal reflux disease, aminotransferase elevations associated with hepatitis and/or jaundice, liver cirrhosis, liver failure (rarely), erythema, diarrhoea, oedema, fluid retention. ",bosentan monohydrate
sign_symptom,loss of appetite,0.99445873," common side effects of bleomycin sulfate include injection site reactions (pain, redness, warmth, itching, or swelling), fever, chills, vomiting, loss of appetite, weight loss, darkening or discoloration of the skin, changes in fingernails or toenails, itching, or pain near your tumor. ",bleomycin sulfate
sign_symptom,darkening,0.9973731," common side effects of bleomycin sulfate include injection site reactions (pain, redness, warmth, itching, or swelling), fever, chills, vomiting, loss of appetite, weight loss, darkening or discoloration of the skin, changes in fingernails or toenails, itching, or pain near your tumor. ",bleomycin sulfate
sign_symptom,discoloration,0.98361653," common side effects of bleomycin sulfate include injection site reactions (pain, redness, warmth, itching, or swelling), fever, chills, vomiting, loss of appetite, weight loss, darkening or discoloration of the skin, changes in fingernails or toenails, itching, or pain near your tumor. ",bleomycin sulfate
sign_symptom,changes,0.9530409," common side effects of bleomycin sulfate include injection site reactions (pain, redness, warmth, itching, or swelling), fever, chills, vomiting, loss of appetite, weight loss, darkening or discoloration of the skin, changes in fingernails or toenails, itching, or pain near your tumor. ",bleomycin sulfate
sign_symptom,pain,0.9998987," common side effects of bleomycin sulfate include injection site reactions (pain, redness, warmth, itching, or swelling), fever, chills, vomiting, loss of appetite, weight loss, darkening or discoloration of the skin, changes in fingernails or toenails, itching, or pain near your tumor. ",bleomycin sulfate
medication,bisop,0.8422382," bisoprolol, like any medication, may have some side effects. it is important that you keep your doctor informed of all side effects especially if you experience one of the following for several days. the most common side effects, whether or not caused by bisoprolol, are: headache, fatigue, urinary tract infection, rhinitis or sinusitis (inflammation in the nose), diarrhea, dizziness, peripheral edema (swelling of the ankles), joint pain, cough, insomnia (trouble sleeping), nausea (feeling like vomiting), and sore throat. you must seek medical attention immediately if you experience an allergic reaction with symptoms of rash, itching, swelling, dizziness or trouble breathing.   medicines affect different people in different ways. just because side effects have occurred in other patients does not mean you will get them. discuss how you feel on bisoprolol with your doctor or pharmacist. do not stop or restart bisoprolol on your own. ",bisoprolol hemifumarate
sign_symptom,inflammation,0.9849749," bisoprolol, like any medication, may have some side effects. it is important that you keep your doctor informed of all side effects especially if you experience one of the following for several days. the most common side effects, whether or not caused by bisoprolol, are: headache, fatigue, urinary tract infection, rhinitis or sinusitis (inflammation in the nose), diarrhea, dizziness, peripheral edema (swelling of the ankles), joint pain, cough, insomnia (trouble sleeping), nausea (feeling like vomiting), and sore throat. you must seek medical attention immediately if you experience an allergic reaction with symptoms of rash, itching, swelling, dizziness or trouble breathing.   medicines affect different people in different ways. just because side effects have occurred in other patients does not mean you will get them. discuss how you feel on bisoprolol with your doctor or pharmacist. do not stop or restart bisoprolol on your own. ",bisoprolol hemifumarate
sign_symptom,edema,0.735955," bisoprolol, like any medication, may have some side effects. it is important that you keep your doctor informed of all side effects especially if you experience one of the following for several days. the most common side effects, whether or not caused by bisoprolol, are: headache, fatigue, urinary tract infection, rhinitis or sinusitis (inflammation in the nose), diarrhea, dizziness, peripheral edema (swelling of the ankles), joint pain, cough, insomnia (trouble sleeping), nausea (feeling like vomiting), and sore throat. you must seek medical attention immediately if you experience an allergic reaction with symptoms of rash, itching, swelling, dizziness or trouble breathing.   medicines affect different people in different ways. just because side effects have occurred in other patients does not mean you will get them. discuss how you feel on bisoprolol with your doctor or pharmacist. do not stop or restart bisoprolol on your own. ",bisoprolol hemifumarate
sign_symptom,swelling,0.99776816," bisoprolol, like any medication, may have some side effects. it is important that you keep your doctor informed of all side effects especially if you experience one of the following for several days. the most common side effects, whether or not caused by bisoprolol, are: headache, fatigue, urinary tract infection, rhinitis or sinusitis (inflammation in the nose), diarrhea, dizziness, peripheral edema (swelling of the ankles), joint pain, cough, insomnia (trouble sleeping), nausea (feeling like vomiting), and sore throat. you must seek medical attention immediately if you experience an allergic reaction with symptoms of rash, itching, swelling, dizziness or trouble breathing.   medicines affect different people in different ways. just because side effects have occurred in other patients does not mean you will get them. discuss how you feel on bisoprolol with your doctor or pharmacist. do not stop or restart bisoprolol on your own. ",bisoprolol hemifumarate
sign_symptom,nausea,0.99969614," bisoprolol, like any medication, may have some side effects. it is important that you keep your doctor informed of all side effects especially if you experience one of the following for several days. the most common side effects, whether or not caused by bisoprolol, are: headache, fatigue, urinary tract infection, rhinitis or sinusitis (inflammation in the nose), diarrhea, dizziness, peripheral edema (swelling of the ankles), joint pain, cough, insomnia (trouble sleeping), nausea (feeling like vomiting), and sore throat. you must seek medical attention immediately if you experience an allergic reaction with symptoms of rash, itching, swelling, dizziness or trouble breathing.   medicines affect different people in different ways. just because side effects have occurred in other patients does not mean you will get them. discuss how you feel on bisoprolol with your doctor or pharmacist. do not stop or restart bisoprolol on your own. ",bisoprolol hemifumarate
sign_symptom,sore,0.9931138," bisoprolol, like any medication, may have some side effects. it is important that you keep your doctor informed of all side effects especially if you experience one of the following for several days. the most common side effects, whether or not caused by bisoprolol, are: headache, fatigue, urinary tract infection, rhinitis or sinusitis (inflammation in the nose), diarrhea, dizziness, peripheral edema (swelling of the ankles), joint pain, cough, insomnia (trouble sleeping), nausea (feeling like vomiting), and sore throat. you must seek medical attention immediately if you experience an allergic reaction with symptoms of rash, itching, swelling, dizziness or trouble breathing.   medicines affect different people in different ways. just because side effects have occurred in other patients does not mean you will get them. discuss how you feel on bisoprolol with your doctor or pharmacist. do not stop or restart bisoprolol on your own. ",bisoprolol hemifumarate
sign_symptom,allergic reaction,0.9948552," bisoprolol, like any medication, may have some side effects. it is important that you keep your doctor informed of all side effects especially if you experience one of the following for several days. the most common side effects, whether or not caused by bisoprolol, are: headache, fatigue, urinary tract infection, rhinitis or sinusitis (inflammation in the nose), diarrhea, dizziness, peripheral edema (swelling of the ankles), joint pain, cough, insomnia (trouble sleeping), nausea (feeling like vomiting), and sore throat. you must seek medical attention immediately if you experience an allergic reaction with symptoms of rash, itching, swelling, dizziness or trouble breathing.   medicines affect different people in different ways. just because side effects have occurred in other patients does not mean you will get them. discuss how you feel on bisoprolol with your doctor or pharmacist. do not stop or restart bisoprolol on your own. ",bisoprolol hemifumarate
medication,medicines,0.7906972," bisoprolol, like any medication, may have some side effects. it is important that you keep your doctor informed of all side effects especially if you experience one of the following for several days. the most common side effects, whether or not caused by bisoprolol, are: headache, fatigue, urinary tract infection, rhinitis or sinusitis (inflammation in the nose), diarrhea, dizziness, peripheral edema (swelling of the ankles), joint pain, cough, insomnia (trouble sleeping), nausea (feeling like vomiting), and sore throat. you must seek medical attention immediately if you experience an allergic reaction with symptoms of rash, itching, swelling, dizziness or trouble breathing.   medicines affect different people in different ways. just because side effects have occurred in other patients does not mean you will get them. discuss how you feel on bisoprolol with your doctor or pharmacist. do not stop or restart bisoprolol on your own. ",bisoprolol hemifumarate
sign_symptom,effects,0.9672235," bisoprolol, like any medication, may have some side effects. it is important that you keep your doctor informed of all side effects especially if you experience one of the following for several days. the most common side effects, whether or not caused by bisoprolol, are: headache, fatigue, urinary tract infection, rhinitis or sinusitis (inflammation in the nose), diarrhea, dizziness, peripheral edema (swelling of the ankles), joint pain, cough, insomnia (trouble sleeping), nausea (feeling like vomiting), and sore throat. you must seek medical attention immediately if you experience an allergic reaction with symptoms of rash, itching, swelling, dizziness or trouble breathing.   medicines affect different people in different ways. just because side effects have occurred in other patients does not mean you will get them. discuss how you feel on bisoprolol with your doctor or pharmacist. do not stop or restart bisoprolol on your own. ",bisoprolol hemifumarate
medication,bisoprolol,0.8228508," bisoprolol, like any medication, may have some side effects. it is important that you keep your doctor informed of all side effects especially if you experience one of the following for several days. the most common side effects, whether or not caused by bisoprolol, are: headache, fatigue, urinary tract infection, rhinitis or sinusitis (inflammation in the nose), diarrhea, dizziness, peripheral edema (swelling of the ankles), joint pain, cough, insomnia (trouble sleeping), nausea (feeling like vomiting), and sore throat. you must seek medical attention immediately if you experience an allergic reaction with symptoms of rash, itching, swelling, dizziness or trouble breathing.   medicines affect different people in different ways. just because side effects have occurred in other patients does not mean you will get them. discuss how you feel on bisoprolol with your doctor or pharmacist. do not stop or restart bisoprolol on your own. ",bisoprolol hemifumarate
sign_symptom,cold,0.99914753," generally well tolerated. most side effects have been mild and transient. side effects which may occur: fatigue, dizziness, headache, bradycardia, arrhythmia, peripheral ischemia, chest pain, palpitations, rhythm disturbances, cold extremities, claudication, orthostatic hypotension, diarrhoea, constipation, nausea, dyspepsia, rhinitis, pharyngitis etc. ",bisoprolol fumarate + hydrochlorothiazide
disease_disorder,pharyngitis,0.9954643," generally well tolerated. most side effects have been mild and transient. side effects which may occur: fatigue, dizziness, headache, bradycardia, arrhythmia, peripheral ischemia, chest pain, palpitations, rhythm disturbances, cold extremities, claudication, orthostatic hypotension, diarrhoea, constipation, nausea, dyspepsia, rhinitis, pharyngitis etc. ",bisoprolol fumarate + hydrochlorothiazide
sign_symptom,coldness,0.9948342,"  common : dizziness, headache, somnolence, palpitations, flushing, feeling of coldness or numbness in the extremities, gastrointestinal complaints such as nausea, vomiting, diarrhea, constipation, abdominal pain; edema (e.g. ankle edema), fatigue.    uncommon : insomnia, mood changes (incl. anxiety), depression, sleep disorders, hypaesthesia, paresthesia, dysgeusia, tremor, visual disturbances (incl. diplopia), tinnitus, av conduction disturbances, worsening of pre existing heart failure, bradycardia, hypotension, syncope, dyspnea, bronchospasm in patients with bronchial asthma or a history of obstructive airway disease, rhinitis, dyspepsia, dry mouth, alopecia, purpura, skin discoloration, pruritus, exanthema, arthralgia, myalgia, muscular weakness, muscle cramps, back pain, micturition disorder, nocturia, pollakisuria, potency disorders, gynecomastia, asthenia, chest pain, pain, malaise, weight increase, weight decrease.    rare : allergic reactions mainly affecting the skin, nightmares, hallucinations, confusion, decreased tear secretion, hearing disorders, allergic rhinitis, hepatitis, increased triglycerides, increased liver enzymes (alat, asat). ",bisoprolol fumarate + amlodipine besilate
sign_symptom,numbness,0.95326054,"  common : dizziness, headache, somnolence, palpitations, flushing, feeling of coldness or numbness in the extremities, gastrointestinal complaints such as nausea, vomiting, diarrhea, constipation, abdominal pain; edema (e.g. ankle edema), fatigue.    uncommon : insomnia, mood changes (incl. anxiety), depression, sleep disorders, hypaesthesia, paresthesia, dysgeusia, tremor, visual disturbances (incl. diplopia), tinnitus, av conduction disturbances, worsening of pre existing heart failure, bradycardia, hypotension, syncope, dyspnea, bronchospasm in patients with bronchial asthma or a history of obstructive airway disease, rhinitis, dyspepsia, dry mouth, alopecia, purpura, skin discoloration, pruritus, exanthema, arthralgia, myalgia, muscular weakness, muscle cramps, back pain, micturition disorder, nocturia, pollakisuria, potency disorders, gynecomastia, asthenia, chest pain, pain, malaise, weight increase, weight decrease.    rare : allergic reactions mainly affecting the skin, nightmares, hallucinations, confusion, decreased tear secretion, hearing disorders, allergic rhinitis, hepatitis, increased triglycerides, increased liver enzymes (alat, asat). ",bisoprolol fumarate + amlodipine besilate
sign_symptom,mood changes,0.9980682,"  common : dizziness, headache, somnolence, palpitations, flushing, feeling of coldness or numbness in the extremities, gastrointestinal complaints such as nausea, vomiting, diarrhea, constipation, abdominal pain; edema (e.g. ankle edema), fatigue.    uncommon : insomnia, mood changes (incl. anxiety), depression, sleep disorders, hypaesthesia, paresthesia, dysgeusia, tremor, visual disturbances (incl. diplopia), tinnitus, av conduction disturbances, worsening of pre existing heart failure, bradycardia, hypotension, syncope, dyspnea, bronchospasm in patients with bronchial asthma or a history of obstructive airway disease, rhinitis, dyspepsia, dry mouth, alopecia, purpura, skin discoloration, pruritus, exanthema, arthralgia, myalgia, muscular weakness, muscle cramps, back pain, micturition disorder, nocturia, pollakisuria, potency disorders, gynecomastia, asthenia, chest pain, pain, malaise, weight increase, weight decrease.    rare : allergic reactions mainly affecting the skin, nightmares, hallucinations, confusion, decreased tear secretion, hearing disorders, allergic rhinitis, hepatitis, increased triglycerides, increased liver enzymes (alat, asat). ",bisoprolol fumarate + amlodipine besilate
sign_symptom,visual disturbances,0.8930099,"  common : dizziness, headache, somnolence, palpitations, flushing, feeling of coldness or numbness in the extremities, gastrointestinal complaints such as nausea, vomiting, diarrhea, constipation, abdominal pain; edema (e.g. ankle edema), fatigue.    uncommon : insomnia, mood changes (incl. anxiety), depression, sleep disorders, hypaesthesia, paresthesia, dysgeusia, tremor, visual disturbances (incl. diplopia), tinnitus, av conduction disturbances, worsening of pre existing heart failure, bradycardia, hypotension, syncope, dyspnea, bronchospasm in patients with bronchial asthma or a history of obstructive airway disease, rhinitis, dyspepsia, dry mouth, alopecia, purpura, skin discoloration, pruritus, exanthema, arthralgia, myalgia, muscular weakness, muscle cramps, back pain, micturition disorder, nocturia, pollakisuria, potency disorders, gynecomastia, asthenia, chest pain, pain, malaise, weight increase, weight decrease.    rare : allergic reactions mainly affecting the skin, nightmares, hallucinations, confusion, decreased tear secretion, hearing disorders, allergic rhinitis, hepatitis, increased triglycerides, increased liver enzymes (alat, asat). ",bisoprolol fumarate + amlodipine besilate
sign_symptom,sync,0.9963917,"  common : dizziness, headache, somnolence, palpitations, flushing, feeling of coldness or numbness in the extremities, gastrointestinal complaints such as nausea, vomiting, diarrhea, constipation, abdominal pain; edema (e.g. ankle edema), fatigue.    uncommon : insomnia, mood changes (incl. anxiety), depression, sleep disorders, hypaesthesia, paresthesia, dysgeusia, tremor, visual disturbances (incl. diplopia), tinnitus, av conduction disturbances, worsening of pre existing heart failure, bradycardia, hypotension, syncope, dyspnea, bronchospasm in patients with bronchial asthma or a history of obstructive airway disease, rhinitis, dyspepsia, dry mouth, alopecia, purpura, skin discoloration, pruritus, exanthema, arthralgia, myalgia, muscular weakness, muscle cramps, back pain, micturition disorder, nocturia, pollakisuria, potency disorders, gynecomastia, asthenia, chest pain, pain, malaise, weight increase, weight decrease.    rare : allergic reactions mainly affecting the skin, nightmares, hallucinations, confusion, decreased tear secretion, hearing disorders, allergic rhinitis, hepatitis, increased triglycerides, increased liver enzymes (alat, asat). ",bisoprolol fumarate + amlodipine besilate
sign_symptom,dysp,0.8315318,"  common : dizziness, headache, somnolence, palpitations, flushing, feeling of coldness or numbness in the extremities, gastrointestinal complaints such as nausea, vomiting, diarrhea, constipation, abdominal pain; edema (e.g. ankle edema), fatigue.    uncommon : insomnia, mood changes (incl. anxiety), depression, sleep disorders, hypaesthesia, paresthesia, dysgeusia, tremor, visual disturbances (incl. diplopia), tinnitus, av conduction disturbances, worsening of pre existing heart failure, bradycardia, hypotension, syncope, dyspnea, bronchospasm in patients with bronchial asthma or a history of obstructive airway disease, rhinitis, dyspepsia, dry mouth, alopecia, purpura, skin discoloration, pruritus, exanthema, arthralgia, myalgia, muscular weakness, muscle cramps, back pain, micturition disorder, nocturia, pollakisuria, potency disorders, gynecomastia, asthenia, chest pain, pain, malaise, weight increase, weight decrease.    rare : allergic reactions mainly affecting the skin, nightmares, hallucinations, confusion, decreased tear secretion, hearing disorders, allergic rhinitis, hepatitis, increased triglycerides, increased liver enzymes (alat, asat). ",bisoprolol fumarate + amlodipine besilate
sign_symptom,bronchospasm,0.9373382,"  common : dizziness, headache, somnolence, palpitations, flushing, feeling of coldness or numbness in the extremities, gastrointestinal complaints such as nausea, vomiting, diarrhea, constipation, abdominal pain; edema (e.g. ankle edema), fatigue.    uncommon : insomnia, mood changes (incl. anxiety), depression, sleep disorders, hypaesthesia, paresthesia, dysgeusia, tremor, visual disturbances (incl. diplopia), tinnitus, av conduction disturbances, worsening of pre existing heart failure, bradycardia, hypotension, syncope, dyspnea, bronchospasm in patients with bronchial asthma or a history of obstructive airway disease, rhinitis, dyspepsia, dry mouth, alopecia, purpura, skin discoloration, pruritus, exanthema, arthralgia, myalgia, muscular weakness, muscle cramps, back pain, micturition disorder, nocturia, pollakisuria, potency disorders, gynecomastia, asthenia, chest pain, pain, malaise, weight increase, weight decrease.    rare : allergic reactions mainly affecting the skin, nightmares, hallucinations, confusion, decreased tear secretion, hearing disorders, allergic rhinitis, hepatitis, increased triglycerides, increased liver enzymes (alat, asat). ",bisoprolol fumarate + amlodipine besilate
sign_symptom,allergic reactions,0.9973641,"  common : dizziness, headache, somnolence, palpitations, flushing, feeling of coldness or numbness in the extremities, gastrointestinal complaints such as nausea, vomiting, diarrhea, constipation, abdominal pain; edema (e.g. ankle edema), fatigue.    uncommon : insomnia, mood changes (incl. anxiety), depression, sleep disorders, hypaesthesia, paresthesia, dysgeusia, tremor, visual disturbances (incl. diplopia), tinnitus, av conduction disturbances, worsening of pre existing heart failure, bradycardia, hypotension, syncope, dyspnea, bronchospasm in patients with bronchial asthma or a history of obstructive airway disease, rhinitis, dyspepsia, dry mouth, alopecia, purpura, skin discoloration, pruritus, exanthema, arthralgia, myalgia, muscular weakness, muscle cramps, back pain, micturition disorder, nocturia, pollakisuria, potency disorders, gynecomastia, asthenia, chest pain, pain, malaise, weight increase, weight decrease.    rare : allergic reactions mainly affecting the skin, nightmares, hallucinations, confusion, decreased tear secretion, hearing disorders, allergic rhinitis, hepatitis, increased triglycerides, increased liver enzymes (alat, asat). ",bisoprolol fumarate + amlodipine besilate
sign_symptom,tear,0.83586663,"  common : dizziness, headache, somnolence, palpitations, flushing, feeling of coldness or numbness in the extremities, gastrointestinal complaints such as nausea, vomiting, diarrhea, constipation, abdominal pain; edema (e.g. ankle edema), fatigue.    uncommon : insomnia, mood changes (incl. anxiety), depression, sleep disorders, hypaesthesia, paresthesia, dysgeusia, tremor, visual disturbances (incl. diplopia), tinnitus, av conduction disturbances, worsening of pre existing heart failure, bradycardia, hypotension, syncope, dyspnea, bronchospasm in patients with bronchial asthma or a history of obstructive airway disease, rhinitis, dyspepsia, dry mouth, alopecia, purpura, skin discoloration, pruritus, exanthema, arthralgia, myalgia, muscular weakness, muscle cramps, back pain, micturition disorder, nocturia, pollakisuria, potency disorders, gynecomastia, asthenia, chest pain, pain, malaise, weight increase, weight decrease.    rare : allergic reactions mainly affecting the skin, nightmares, hallucinations, confusion, decreased tear secretion, hearing disorders, allergic rhinitis, hepatitis, increased triglycerides, increased liver enzymes (alat, asat). ",bisoprolol fumarate + amlodipine besilate
sign_symptom,black stool,0.99909174," black stool and black tongue is common with use of bismuth subsalicylate. bismuth subsalicylate should not be used if symptoms are severe or persist for more than 2 days. do not exceed the recommended dose, shake the bottle before use. for oral use only. ",bismuth subsalicylate
sign_symptom,black tongue,0.9994344," black stool and black tongue is common with use of bismuth subsalicylate. bismuth subsalicylate should not be used if symptoms are severe or persist for more than 2 days. do not exceed the recommended dose, shake the bottle before use. for oral use only. ",bismuth subsalicylate
medication,bismuth,0.9940057," black stool and black tongue is common with use of bismuth subsalicylate. bismuth subsalicylate should not be used if symptoms are severe or persist for more than 2 days. do not exceed the recommended dose, shake the bottle before use. for oral use only. ",bismuth subsalicylate
sign_symptom,symptoms,0.99980766," black stool and black tongue is common with use of bismuth subsalicylate. bismuth subsalicylate should not be used if symptoms are severe or persist for more than 2 days. do not exceed the recommended dose, shake the bottle before use. for oral use only. ",bismuth subsalicylate
sign_symptom,adverse reaction,0.95638585," the most common adverse reaction in adults is diarrhea. the other side effects are nausea, asthenia, fatigue, muscle spasm, dizziness and cough. ",azilsartan medoxomil
sign_symptom,adverse reactions,0.99577594," the most common adverse reactions (&gt;2% incidence) are: dysgeusia, epistaxis, and headache. ",azelastine hydrochloride + fluticasone propionate
sign_symptom,epista,0.9580749," the most common adverse reactions (&gt;2% incidence) are: dysgeusia, epistaxis, and headache. ",azelastine hydrochloride + fluticasone propionate
sign_symptom,stinging,0.9968515," headache, dizziness, sneezing, nosebleed, nausea, stinging or itching in nose, dry mouth, sore throat, bitter taste etc. ",azelastine hydrochloride (nasal spray)
sign_symptom,sore,0.9855641," headache, dizziness, sneezing, nosebleed, nausea, stinging or itching in nose, dry mouth, sore throat, bitter taste etc. ",azelastine hydrochloride (nasal spray)
medication,neem,0.9987695, there is no significant side effect associated with the use of neem in the above mentioned therapeutic doses. ,neem
sign_symptom,adverse reactions,0.9990033," the most frequently reported adverse reactions are headache, dyspepsia, abdominal pain, nausea and diarrhea. ",aspirin + dipyridamole
sign_symptom,dyspepsia,0.9562458," the most frequently reported adverse reactions are headache, dyspepsia, abdominal pain, nausea and diarrhea. ",aspirin + dipyridamole
sign_symptom,nausea,0.9995871," the most frequently reported adverse reactions are headache, dyspepsia, abdominal pain, nausea and diarrhea. ",aspirin + dipyridamole
sign_symptom,nausea,0.9998104," side effects for the usual dosage of aspirin are mild including nausea, dyspepsia, gastrointestinal ulceration and bronchospasm etc. ",aspirin
sign_symptom,dyspepsia,0.9492118," side effects for the usual dosage of aspirin are mild including nausea, dyspepsia, gastrointestinal ulceration and bronchospasm etc. ",aspirin
sign_symptom,ulceration,0.86612654," side effects for the usual dosage of aspirin are mild including nausea, dyspepsia, gastrointestinal ulceration and bronchospasm etc. ",aspirin
disease_disorder,contact dermatitis,0.9680153," photosensitivity reactions, skin discolouration, bullous eruption, skin exfoliation, contact dermatitis and allergic reactions have been reported with topical calcipotriol therapy. ",calcipotriol monohydrate
sign_symptom,allergic reactions,0.999893," photosensitivity reactions, skin discolouration, bullous eruption, skin exfoliation, contact dermatitis and allergic reactions have been reported with topical calcipotriol therapy. ",calcipotriol monohydrate
medication,calcipotriol,0.90518236," photosensitivity reactions, skin discolouration, bullous eruption, skin exfoliation, contact dermatitis and allergic reactions have been reported with topical calcipotriol therapy. ",calcipotriol monohydrate
sign_symptom,allergic reaction,0.9998628," a very serious allergic reaction to this drug is rare. however, seek immediate medical attention if you notice any symptoms of a serious allergic reaction including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. ",calamine + zinc oxide + glycerine
sign_symptom,swelling,0.9988047," a very serious allergic reaction to this drug is rare. however, seek immediate medical attention if you notice any symptoms of a serious allergic reaction including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. ",calamine + zinc oxide + glycerine
disease_disorder,kidney failure,0.9982775," few cases of sepsis, hemorrhage, necrotizing enterocolitis, gastritis, gastrointestinal hemorrhage, acidosis, cerebral hemorrhage, dyspnea, lung edema, dry skin, rash, skin breakdown, kidney failure were reported. ",caffeine citrate
sign_symptom,hemorrhage,0.9962503,"  
 hemorrhage 
 perforations and fistulas 
 thrombotic events 
 hypertension and hypertensive crisis 
 diarrhea 
 palmar-plantar erythrodysesthesia 
 proteinuria 
 osteonecrosis of the jaw 
 wound complications 
 reversible posterior leukoencephalopathy syndrome 
  ",cabozantinib
sign_symptom,perforations,0.975671,"  
 hemorrhage 
 perforations and fistulas 
 thrombotic events 
 hypertension and hypertensive crisis 
 diarrhea 
 palmar-plantar erythrodysesthesia 
 proteinuria 
 osteonecrosis of the jaw 
 wound complications 
 reversible posterior leukoencephalopathy syndrome 
  ",cabozantinib
sign_symptom,fistulas,0.99521905,"  
 hemorrhage 
 perforations and fistulas 
 thrombotic events 
 hypertension and hypertensive crisis 
 diarrhea 
 palmar-plantar erythrodysesthesia 
 proteinuria 
 osteonecrosis of the jaw 
 wound complications 
 reversible posterior leukoencephalopathy syndrome 
  ",cabozantinib
sign_symptom,thrombotic events,0.99834764,"  
 hemorrhage 
 perforations and fistulas 
 thrombotic events 
 hypertension and hypertensive crisis 
 diarrhea 
 palmar-plantar erythrodysesthesia 
 proteinuria 
 osteonecrosis of the jaw 
 wound complications 
 reversible posterior leukoencephalopathy syndrome 
  ",cabozantinib
sign_symptom,hypertension,0.99985826,"  
 hemorrhage 
 perforations and fistulas 
 thrombotic events 
 hypertension and hypertensive crisis 
 diarrhea 
 palmar-plantar erythrodysesthesia 
 proteinuria 
 osteonecrosis of the jaw 
 wound complications 
 reversible posterior leukoencephalopathy syndrome 
  ",cabozantinib
sign_symptom,hypertensive crisis,0.9995148,"  
 hemorrhage 
 perforations and fistulas 
 thrombotic events 
 hypertension and hypertensive crisis 
 diarrhea 
 palmar-plantar erythrodysesthesia 
 proteinuria 
 osteonecrosis of the jaw 
 wound complications 
 reversible posterior leukoencephalopathy syndrome 
  ",cabozantinib
sign_symptom,diarrhea,0.9984657,"  
 hemorrhage 
 perforations and fistulas 
 thrombotic events 
 hypertension and hypertensive crisis 
 diarrhea 
 palmar-plantar erythrodysesthesia 
 proteinuria 
 osteonecrosis of the jaw 
 wound complications 
 reversible posterior leukoencephalopathy syndrome 
  ",cabozantinib
sign_symptom,erythrodysesthes,0.80448616,"  
 hemorrhage 
 perforations and fistulas 
 thrombotic events 
 hypertension and hypertensive crisis 
 diarrhea 
 palmar-plantar erythrodysesthesia 
 proteinuria 
 osteonecrosis of the jaw 
 wound complications 
 reversible posterior leukoencephalopathy syndrome 
  ",cabozantinib
sign_symptom,protein,0.9993843,"  
 hemorrhage 
 perforations and fistulas 
 thrombotic events 
 hypertension and hypertensive crisis 
 diarrhea 
 palmar-plantar erythrodysesthesia 
 proteinuria 
 osteonecrosis of the jaw 
 wound complications 
 reversible posterior leukoencephalopathy syndrome 
  ",cabozantinib
disease_disorder,osteonecrosis,0.99961025,"  
 hemorrhage 
 perforations and fistulas 
 thrombotic events 
 hypertension and hypertensive crisis 
 diarrhea 
 palmar-plantar erythrodysesthesia 
 proteinuria 
 osteonecrosis of the jaw 
 wound complications 
 reversible posterior leukoencephalopathy syndrome 
  ",cabozantinib
disease_disorder,posterior leukoencephalopathy syndrome,0.9996766,"  
 hemorrhage 
 perforations and fistulas 
 thrombotic events 
 hypertension and hypertensive crisis 
 diarrhea 
 palmar-plantar erythrodysesthesia 
 proteinuria 
 osteonecrosis of the jaw 
 wound complications 
 reversible posterior leukoencephalopathy syndrome 
  ",cabozantinib
sign_symptom,hyper,0.99984646," pathological gambling, increased libido, and hypersexuality have been reported in patients treated with dopamine agonists including cabergoline. this has been generally reversible upon reduction of the dose or treatment discontinuation. ",cabergoline
medication,dopamine agonist,0.99667346," pathological gambling, increased libido, and hypersexuality have been reported in patients treated with dopamine agonists including cabergoline. this has been generally reversible upon reduction of the dose or treatment discontinuation. ",cabergoline
sign_symptom,complaints,0.9983967," of the 314 patients treated with butoconazole for 1 day in controlled clinical trials, 18 patients (5.7%) reported complaints such as vulvar/vaginal burning, itching, soreness and swelling, pelvic or abdominal pain or cramping, or a combination of two or more of these symptoms. in 3 patients (1%) these complaints were considered treatment-related. five of the 18 patients reporting adverse events discontinued the study because of them. ",butoconazole nitrate
sign_symptom,soreness,0.97501266," of the 314 patients treated with butoconazole for 1 day in controlled clinical trials, 18 patients (5.7%) reported complaints such as vulvar/vaginal burning, itching, soreness and swelling, pelvic or abdominal pain or cramping, or a combination of two or more of these symptoms. in 3 patients (1%) these complaints were considered treatment-related. five of the 18 patients reporting adverse events discontinued the study because of them. ",butoconazole nitrate
sign_symptom,pain,0.9999429," of the 314 patients treated with butoconazole for 1 day in controlled clinical trials, 18 patients (5.7%) reported complaints such as vulvar/vaginal burning, itching, soreness and swelling, pelvic or abdominal pain or cramping, or a combination of two or more of these symptoms. in 3 patients (1%) these complaints were considered treatment-related. five of the 18 patients reporting adverse events discontinued the study because of them. ",butoconazole nitrate
sign_symptom,adverse events,0.9997355," of the 314 patients treated with butoconazole for 1 day in controlled clinical trials, 18 patients (5.7%) reported complaints such as vulvar/vaginal burning, itching, soreness and swelling, pelvic or abdominal pain or cramping, or a combination of two or more of these symptoms. in 3 patients (1%) these complaints were considered treatment-related. five of the 18 patients reporting adverse events discontinued the study because of them. ",butoconazole nitrate
sign_symptom,burning,0.99981946, rarely local mild burning or irritation may be experienced. hypersensitivity reactions may occur. ,butenafine hydrochloride
sign_symptom,burning,0.99981946, rarely local mild burning or irritation may be experienced. hypersensitivity reactions may occur. ,clotrimazole + hydrocortisone
sign_symptom,irritation,0.9998832, rarely local mild burning or irritation may be experienced. hypersensitivity reactions may occur. ,butenafine hydrochloride
sign_symptom,irritation,0.9998832, rarely local mild burning or irritation may be experienced. hypersensitivity reactions may occur. ,clotrimazole + hydrocortisone
sign_symptom,hypersensitivity reactions,0.9995886, rarely local mild burning or irritation may be experienced. hypersensitivity reactions may occur. ,butenafine hydrochloride
sign_symptom,hypersensitivity reactions,0.9995886, rarely local mild burning or irritation may be experienced. hypersensitivity reactions may occur. ,clotrimazole + hydrocortisone
sign_symptom,adverse reactions,0.99987954," tolerance of butamirate citrate is good.adverse reactions such as rash,nausea,diarrhoea and vertigo have been observed in a few rare cases,resolving after dose reduction or treatment withdrawal. ",butamirate citrate
sign_symptom,rash,0.99960846," tolerance of butamirate citrate is good.adverse reactions such as rash,nausea,diarrhoea and vertigo have been observed in a few rare cases,resolving after dose reduction or treatment withdrawal. ",butamirate citrate
sign_symptom,nausea,0.9996946," tolerance of butamirate citrate is good.adverse reactions such as rash,nausea,diarrhoea and vertigo have been observed in a few rare cases,resolving after dose reduction or treatment withdrawal. ",butamirate citrate
sign_symptom,diarr,0.997698," tolerance of butamirate citrate is good.adverse reactions such as rash,nausea,diarrhoea and vertigo have been observed in a few rare cases,resolving after dose reduction or treatment withdrawal. ",butamirate citrate
sign_symptom,vertigo,0.99994874," tolerance of butamirate citrate is good.adverse reactions such as rash,nausea,diarrhoea and vertigo have been observed in a few rare cases,resolving after dose reduction or treatment withdrawal. ",butamirate citrate
sign_symptom,hyper,0.72198397," bone marrow depression, manifested as leucopenia, thrombocytopenia and anaemia; hyperpigmentation, gi disturbances, impaired fertility and gonadal function. rarely, dry skin, gynaecomastia, cataract formation, at high doses, cns effects including convulsions. ",busulfan
sign_symptom,fertility,0.8430538," bone marrow depression, manifested as leucopenia, thrombocytopenia and anaemia; hyperpigmentation, gi disturbances, impaired fertility and gonadal function. rarely, dry skin, gynaecomastia, cataract formation, at high doses, cns effects including convulsions. ",busulfan
sign_symptom,agitation,0.9890505," agitation, anxiety, and insomnia often occur during the initial stages of bupropion therapy. other relatively common side effects reported with bupropion include fever, dry mouth, headache or migraine, dizziness, nausea and vomiting, constipation, tremor, sweating, and skin rashes. hypersensitivity reactions, ranging from pruritus and urticaria, less commonly, angio-oedema, dyspnoea, and anaphylactoid reactions have been reported. ",bupropion hydrochloride
sign_symptom,anxiety,0.99856746," agitation, anxiety, and insomnia often occur during the initial stages of bupropion therapy. other relatively common side effects reported with bupropion include fever, dry mouth, headache or migraine, dizziness, nausea and vomiting, constipation, tremor, sweating, and skin rashes. hypersensitivity reactions, ranging from pruritus and urticaria, less commonly, angio-oedema, dyspnoea, and anaphylactoid reactions have been reported. ",bupropion hydrochloride
sign_symptom,headache,0.70771086," agitation, anxiety, and insomnia often occur during the initial stages of bupropion therapy. other relatively common side effects reported with bupropion include fever, dry mouth, headache or migraine, dizziness, nausea and vomiting, constipation, tremor, sweating, and skin rashes. hypersensitivity reactions, ranging from pruritus and urticaria, less commonly, angio-oedema, dyspnoea, and anaphylactoid reactions have been reported. ",bupropion hydrochloride
sign_symptom,nausea,0.9763051," agitation, anxiety, and insomnia often occur during the initial stages of bupropion therapy. other relatively common side effects reported with bupropion include fever, dry mouth, headache or migraine, dizziness, nausea and vomiting, constipation, tremor, sweating, and skin rashes. hypersensitivity reactions, ranging from pruritus and urticaria, less commonly, angio-oedema, dyspnoea, and anaphylactoid reactions have been reported. ",bupropion hydrochloride
sign_symptom,hyper,0.99991524," agitation, anxiety, and insomnia often occur during the initial stages of bupropion therapy. other relatively common side effects reported with bupropion include fever, dry mouth, headache or migraine, dizziness, nausea and vomiting, constipation, tremor, sweating, and skin rashes. hypersensitivity reactions, ranging from pruritus and urticaria, less commonly, angio-oedema, dyspnoea, and anaphylactoid reactions have been reported. ",bupropion hydrochloride
medication,local anesthetics,0.9963994," the adverse reaction profile for bupivacaine is similar to those for other long acting local anesthetics administered intrathecally. adverse reactions caused by the drug are difficult to distinguish from the physiological effects of the nerve block (e.g. decrease in blood pressure, bradycardia, temporary urinary retention), events caused directly (e.g. nerve trauma) or indirectly (e.g. epidural abscess) by the needle puncture or events associated to cerebrospinal leakage (eg. postdural puncture headache). ",bupivacaine hydrochloride + dextrose
sign_symptom,adverse reactions,0.9996667," the adverse reaction profile for bupivacaine is similar to those for other long acting local anesthetics administered intrathecally. adverse reactions caused by the drug are difficult to distinguish from the physiological effects of the nerve block (e.g. decrease in blood pressure, bradycardia, temporary urinary retention), events caused directly (e.g. nerve trauma) or indirectly (e.g. epidural abscess) by the needle puncture or events associated to cerebrospinal leakage (eg. postdural puncture headache). ",bupivacaine hydrochloride + dextrose
sign_symptom,events,0.9856096," the adverse reaction profile for bupivacaine is similar to those for other long acting local anesthetics administered intrathecally. adverse reactions caused by the drug are difficult to distinguish from the physiological effects of the nerve block (e.g. decrease in blood pressure, bradycardia, temporary urinary retention), events caused directly (e.g. nerve trauma) or indirectly (e.g. epidural abscess) by the needle puncture or events associated to cerebrospinal leakage (eg. postdural puncture headache). ",bupivacaine hydrochloride + dextrose
disease_disorder,cerebrospinal leakage,0.9633646," the adverse reaction profile for bupivacaine is similar to those for other long acting local anesthetics administered intrathecally. adverse reactions caused by the drug are difficult to distinguish from the physiological effects of the nerve block (e.g. decrease in blood pressure, bradycardia, temporary urinary retention), events caused directly (e.g. nerve trauma) or indirectly (e.g. epidural abscess) by the needle puncture or events associated to cerebrospinal leakage (eg. postdural puncture headache). ",bupivacaine hydrochloride + dextrose
sign_symptom,restless,0.9854903,"  central nervous system and neurological : restlessness, excitement, nervousness, dizziness, tinnitus, blurred vision, miosis, nausea, vomiting, numbness of the tongue and perioral region, chills, tremors, muscle twitching, convulsions.    cardiovascular system reactions : myocardial depression and peripheral vasodilatation resulting hypotension and bradycardia, ventricular arrhythmia, cardiac arrest.    hypersensitivity : urticaria, pruritus, erythema, angioneurotic edema ,tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid reactions. ",bupivacaine hydrochloride
sign_symptom,blurred vision,0.8047422,"  central nervous system and neurological : restlessness, excitement, nervousness, dizziness, tinnitus, blurred vision, miosis, nausea, vomiting, numbness of the tongue and perioral region, chills, tremors, muscle twitching, convulsions.    cardiovascular system reactions : myocardial depression and peripheral vasodilatation resulting hypotension and bradycardia, ventricular arrhythmia, cardiac arrest.    hypersensitivity : urticaria, pruritus, erythema, angioneurotic edema ,tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid reactions. ",bupivacaine hydrochloride
sign_symptom,numb,0.999204,"  central nervous system and neurological : restlessness, excitement, nervousness, dizziness, tinnitus, blurred vision, miosis, nausea, vomiting, numbness of the tongue and perioral region, chills, tremors, muscle twitching, convulsions.    cardiovascular system reactions : myocardial depression and peripheral vasodilatation resulting hypotension and bradycardia, ventricular arrhythmia, cardiac arrest.    hypersensitivity : urticaria, pruritus, erythema, angioneurotic edema ,tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid reactions. ",bupivacaine hydrochloride
sign_symptom,depression,0.9398717,"  central nervous system and neurological : restlessness, excitement, nervousness, dizziness, tinnitus, blurred vision, miosis, nausea, vomiting, numbness of the tongue and perioral region, chills, tremors, muscle twitching, convulsions.    cardiovascular system reactions : myocardial depression and peripheral vasodilatation resulting hypotension and bradycardia, ventricular arrhythmia, cardiac arrest.    hypersensitivity : urticaria, pruritus, erythema, angioneurotic edema ,tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid reactions. ",bupivacaine hydrochloride
sign_symptom,vasodilatation,0.99652326,"  central nervous system and neurological : restlessness, excitement, nervousness, dizziness, tinnitus, blurred vision, miosis, nausea, vomiting, numbness of the tongue and perioral region, chills, tremors, muscle twitching, convulsions.    cardiovascular system reactions : myocardial depression and peripheral vasodilatation resulting hypotension and bradycardia, ventricular arrhythmia, cardiac arrest.    hypersensitivity : urticaria, pruritus, erythema, angioneurotic edema ,tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid reactions. ",bupivacaine hydrochloride
sign_symptom,hyper,0.99161845,"  central nervous system and neurological : restlessness, excitement, nervousness, dizziness, tinnitus, blurred vision, miosis, nausea, vomiting, numbness of the tongue and perioral region, chills, tremors, muscle twitching, convulsions.    cardiovascular system reactions : myocardial depression and peripheral vasodilatation resulting hypotension and bradycardia, ventricular arrhythmia, cardiac arrest.    hypersensitivity : urticaria, pruritus, erythema, angioneurotic edema ,tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid reactions. ",bupivacaine hydrochloride
sign_symptom,sync,0.9313487,"  central nervous system and neurological : restlessness, excitement, nervousness, dizziness, tinnitus, blurred vision, miosis, nausea, vomiting, numbness of the tongue and perioral region, chills, tremors, muscle twitching, convulsions.    cardiovascular system reactions : myocardial depression and peripheral vasodilatation resulting hypotension and bradycardia, ventricular arrhythmia, cardiac arrest.    hypersensitivity : urticaria, pruritus, erythema, angioneurotic edema ,tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid reactions. ",bupivacaine hydrochloride
medication,bumetanide,0.8915894," the side effects of bumetanide include: headache, dizziness, fatigue, postural hypotension and gastrointestinal symptoms. various skin reactions, photosensitivity reactions and metabolic disturbances, including reduced glucose tolerance are less frequent. electrolyte disturbances can occur especially during long term treatment. ",bumetanide
sign_symptom,hypotension,0.95937526," the side effects of bumetanide include: headache, dizziness, fatigue, postural hypotension and gastrointestinal symptoms. various skin reactions, photosensitivity reactions and metabolic disturbances, including reduced glucose tolerance are less frequent. electrolyte disturbances can occur especially during long term treatment. ",bumetanide
sign_symptom,photosensitivity reactions,0.96412116," the side effects of bumetanide include: headache, dizziness, fatigue, postural hypotension and gastrointestinal symptoms. various skin reactions, photosensitivity reactions and metabolic disturbances, including reduced glucose tolerance are less frequent. electrolyte disturbances can occur especially during long term treatment. ",bumetanide
sign_symptom,metabolic,0.97161883," the side effects of bumetanide include: headache, dizziness, fatigue, postural hypotension and gastrointestinal symptoms. various skin reactions, photosensitivity reactions and metabolic disturbances, including reduced glucose tolerance are less frequent. electrolyte disturbances can occur especially during long term treatment. ",bumetanide
sign_symptom,electro,0.9939606," the side effects of bumetanide include: headache, dizziness, fatigue, postural hypotension and gastrointestinal symptoms. various skin reactions, photosensitivity reactions and metabolic disturbances, including reduced glucose tolerance are less frequent. electrolyte disturbances can occur especially during long term treatment. ",bumetanide
sign_symptom,disturbances,0.77299607," the side effects of bumetanide include: headache, dizziness, fatigue, postural hypotension and gastrointestinal symptoms. various skin reactions, photosensitivity reactions and metabolic disturbances, including reduced glucose tolerance are less frequent. electrolyte disturbances can occur especially during long term treatment. ",bumetanide
sign_symptom,budesonide,0.84741974," budesonide: hoarseness, and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported.  formoterol fumarate dihydrate: tremor, palpitations, and headache have been reported. cardiac arrhythmias, muscle cramps, and hypersensitivity reactions, including rash, oedema, and angio-oedema, may occur in some patients. ",budesonide + formoterol fumarate
sign_symptom,hoarse,0.9998858," budesonide: hoarseness, and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported.  formoterol fumarate dihydrate: tremor, palpitations, and headache have been reported. cardiac arrhythmias, muscle cramps, and hypersensitivity reactions, including rash, oedema, and angio-oedema, may occur in some patients. ",budesonide + formoterol fumarate
sign_symptom,candidiasis,0.9995207," budesonide: hoarseness, and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported.  formoterol fumarate dihydrate: tremor, palpitations, and headache have been reported. cardiac arrhythmias, muscle cramps, and hypersensitivity reactions, including rash, oedema, and angio-oedema, may occur in some patients. ",budesonide + formoterol fumarate
sign_symptom,thrush,0.9717202," budesonide: hoarseness, and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported.  formoterol fumarate dihydrate: tremor, palpitations, and headache have been reported. cardiac arrhythmias, muscle cramps, and hypersensitivity reactions, including rash, oedema, and angio-oedema, may occur in some patients. ",budesonide + formoterol fumarate
sign_symptom,hypersensitivity reactions,0.9988903," budesonide: hoarseness, and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported.  formoterol fumarate dihydrate: tremor, palpitations, and headache have been reported. cardiac arrhythmias, muscle cramps, and hypersensitivity reactions, including rash, oedema, and angio-oedema, may occur in some patients. ",budesonide + formoterol fumarate
medication,formoterol,0.9739061," budesonide: hoarseness, and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported.  formoterol fumarate dihydrate: tremor, palpitations, and headache have been reported. cardiac arrhythmias, muscle cramps, and hypersensitivity reactions, including rash, oedema, and angio-oedema, may occur in some patients. ",budesonide + formoterol fumarate
sign_symptom,tremor,0.95206535," budesonide: hoarseness, and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported.  formoterol fumarate dihydrate: tremor, palpitations, and headache have been reported. cardiac arrhythmias, muscle cramps, and hypersensitivity reactions, including rash, oedema, and angio-oedema, may occur in some patients. ",budesonide + formoterol fumarate
sign_symptom,palpit,0.98089886," budesonide: hoarseness, and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported.  formoterol fumarate dihydrate: tremor, palpitations, and headache have been reported. cardiac arrhythmias, muscle cramps, and hypersensitivity reactions, including rash, oedema, and angio-oedema, may occur in some patients. ",budesonide + formoterol fumarate
sign_symptom,headache,0.9999167," budesonide: hoarseness, and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported.  formoterol fumarate dihydrate: tremor, palpitations, and headache have been reported. cardiac arrhythmias, muscle cramps, and hypersensitivity reactions, including rash, oedema, and angio-oedema, may occur in some patients. ",budesonide + formoterol fumarate
sign_symptom,hyper,0.999534," budesonide: hoarseness, and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported.  formoterol fumarate dihydrate: tremor, palpitations, and headache have been reported. cardiac arrhythmias, muscle cramps, and hypersensitivity reactions, including rash, oedema, and angio-oedema, may occur in some patients. ",budesonide + formoterol fumarate
sign_symptom,sore throat,0.90340066," sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects ",budesonide (nebuliser suspension)
sign_symptom,dry mouth,0.9881259," sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects ",budesonide (nebuliser suspension)
sign_symptom,nausea,0.9998958," sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects ",budesonide (nebuliser suspension)
sign_symptom,adverse,0.98200905," adverse local reactions following budesonide use are mild and usually transient. systemic side effects have not been reported during clinical studies of budesonide nasal preparations. sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects. ",budesonide (nasal spray)
sign_symptom,reactions,0.9971993," adverse local reactions following budesonide use are mild and usually transient. systemic side effects have not been reported during clinical studies of budesonide nasal preparations. sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects. ",budesonide (nasal spray)
medication,budeson,0.8134237," adverse local reactions following budesonide use are mild and usually transient. systemic side effects have not been reported during clinical studies of budesonide nasal preparations. sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects. ",budesonide (nasal spray)
sign_symptom,sore,0.99301493," adverse local reactions following budesonide use are mild and usually transient. systemic side effects have not been reported during clinical studies of budesonide nasal preparations. sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects. ",budesonide (nasal spray)
sign_symptom,nausea,0.99971133," adverse local reactions following budesonide use are mild and usually transient. systemic side effects have not been reported during clinical studies of budesonide nasal preparations. sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects. ",budesonide (nasal spray)
sign_symptom,adverse reactions,0.9998789," the following adverse reactions were reported in patients treated with budesonide inhaler. 
 
 general: headache, flu-like syndrome, pain, back pain, fever, neck pain, asthenia. 
 respiratory system: respiratory tract infections, pharyngitis, sinusitis, rhinitis, voice alteration, cough aggravation. 
 digestive system: oral candidiasis, dyspepsia, gastroenteritis, nausea, abdominal pain, dry mouth, vomiting. 
 metabolic and nutritional: weight gain. 
 musculoskeletal: fracture, myalgia, arthralgia. 
 nervous system: syncope, hypertonia, migraine. 
 skin: ecchymosis. 
 psychiatric: insomnia. 
 resistance mechanisms: infection. 
 special senses: taste perversion. 
  ",budesonide (inhaler)
medication,budesonide,0.87214327," the following adverse reactions were reported in patients treated with budesonide inhaler. 
 
 general: headache, flu-like syndrome, pain, back pain, fever, neck pain, asthenia. 
 respiratory system: respiratory tract infections, pharyngitis, sinusitis, rhinitis, voice alteration, cough aggravation. 
 digestive system: oral candidiasis, dyspepsia, gastroenteritis, nausea, abdominal pain, dry mouth, vomiting. 
 metabolic and nutritional: weight gain. 
 musculoskeletal: fracture, myalgia, arthralgia. 
 nervous system: syncope, hypertonia, migraine. 
 skin: ecchymosis. 
 psychiatric: insomnia. 
 resistance mechanisms: infection. 
 special senses: taste perversion. 
  ",budesonide (inhaler)
sign_symptom,arthral,0.7630454," the following adverse reactions were reported in patients treated with budesonide inhaler. 
 
 general: headache, flu-like syndrome, pain, back pain, fever, neck pain, asthenia. 
 respiratory system: respiratory tract infections, pharyngitis, sinusitis, rhinitis, voice alteration, cough aggravation. 
 digestive system: oral candidiasis, dyspepsia, gastroenteritis, nausea, abdominal pain, dry mouth, vomiting. 
 metabolic and nutritional: weight gain. 
 musculoskeletal: fracture, myalgia, arthralgia. 
 nervous system: syncope, hypertonia, migraine. 
 skin: ecchymosis. 
 psychiatric: insomnia. 
 resistance mechanisms: infection. 
 special senses: taste perversion. 
  ",budesonide (inhaler)
sign_symptom,fatigue,0.82531416," side effects in decreasing order of frequency are: nausea, headache, dizziness, fatigue, lightheadedness, vomiting, abdominal cramps, nasal congestion constipation, diarrhea and drowsiness. a slight hypotensive effect may accompany treatment. the occurrence of adverse reactions may be lessened by temporarily reducing dosage to 0.5 mg. abnormalities in laboratory tests may include elevations in blood urea nitrogen, sgot, sgpt, ggpt, cpk, alkaline phosphatase and uric acid,which are usually transient and not of clinical significance ",bromocriptine mesylate
sign_symptom,lightheadedness,0.89987725," side effects in decreasing order of frequency are: nausea, headache, dizziness, fatigue, lightheadedness, vomiting, abdominal cramps, nasal congestion constipation, diarrhea and drowsiness. a slight hypotensive effect may accompany treatment. the occurrence of adverse reactions may be lessened by temporarily reducing dosage to 0.5 mg. abnormalities in laboratory tests may include elevations in blood urea nitrogen, sgot, sgpt, ggpt, cpk, alkaline phosphatase and uric acid,which are usually transient and not of clinical significance ",bromocriptine mesylate
sign_symptom,vomiting,0.97204596," side effects in decreasing order of frequency are: nausea, headache, dizziness, fatigue, lightheadedness, vomiting, abdominal cramps, nasal congestion constipation, diarrhea and drowsiness. a slight hypotensive effect may accompany treatment. the occurrence of adverse reactions may be lessened by temporarily reducing dosage to 0.5 mg. abnormalities in laboratory tests may include elevations in blood urea nitrogen, sgot, sgpt, ggpt, cpk, alkaline phosphatase and uric acid,which are usually transient and not of clinical significance ",bromocriptine mesylate
sign_symptom,nasal congestion,0.79152775," side effects in decreasing order of frequency are: nausea, headache, dizziness, fatigue, lightheadedness, vomiting, abdominal cramps, nasal congestion constipation, diarrhea and drowsiness. a slight hypotensive effect may accompany treatment. the occurrence of adverse reactions may be lessened by temporarily reducing dosage to 0.5 mg. abnormalities in laboratory tests may include elevations in blood urea nitrogen, sgot, sgpt, ggpt, cpk, alkaline phosphatase and uric acid,which are usually transient and not of clinical significance ",bromocriptine mesylate
sign_symptom,diarrhea,0.912669," side effects in decreasing order of frequency are: nausea, headache, dizziness, fatigue, lightheadedness, vomiting, abdominal cramps, nasal congestion constipation, diarrhea and drowsiness. a slight hypotensive effect may accompany treatment. the occurrence of adverse reactions may be lessened by temporarily reducing dosage to 0.5 mg. abnormalities in laboratory tests may include elevations in blood urea nitrogen, sgot, sgpt, ggpt, cpk, alkaline phosphatase and uric acid,which are usually transient and not of clinical significance ",bromocriptine mesylate
sign_symptom,adverse reactions,0.9956987," side effects in decreasing order of frequency are: nausea, headache, dizziness, fatigue, lightheadedness, vomiting, abdominal cramps, nasal congestion constipation, diarrhea and drowsiness. a slight hypotensive effect may accompany treatment. the occurrence of adverse reactions may be lessened by temporarily reducing dosage to 0.5 mg. abnormalities in laboratory tests may include elevations in blood urea nitrogen, sgot, sgpt, ggpt, cpk, alkaline phosphatase and uric acid,which are usually transient and not of clinical significance ",bromocriptine mesylate
sign_symptom,discomfort,0.9999645," constipation; faecal impaction; haemorrhoids; abdominal discomfort or pain; heartburn; flatulence; nausea; vomiting; diarrhoea; increased bleeding tendency (chronic use); osteoporosis; steatorrhoea (high doses); skin rashes; pruritus of the tongue, skin and perianal region; hyperchloraemic acidosis. ",aspartame
sign_symptom,flat,0.9995993," constipation; faecal impaction; haemorrhoids; abdominal discomfort or pain; heartburn; flatulence; nausea; vomiting; diarrhoea; increased bleeding tendency (chronic use); osteoporosis; steatorrhoea (high doses); skin rashes; pruritus of the tongue, skin and perianal region; hyperchloraemic acidosis. ",aspartame
sign_symptom,bleeding tendency,0.9994329," constipation; faecal impaction; haemorrhoids; abdominal discomfort or pain; heartburn; flatulence; nausea; vomiting; diarrhoea; increased bleeding tendency (chronic use); osteoporosis; steatorrhoea (high doses); skin rashes; pruritus of the tongue, skin and perianal region; hyperchloraemic acidosis. ",aspartame
sign_symptom,steator,0.7689918," constipation; faecal impaction; haemorrhoids; abdominal discomfort or pain; heartburn; flatulence; nausea; vomiting; diarrhoea; increased bleeding tendency (chronic use); osteoporosis; steatorrhoea (high doses); skin rashes; pruritus of the tongue, skin and perianal region; hyperchloraemic acidosis. ",aspartame
sign_symptom,rash,0.99993336," constipation; faecal impaction; haemorrhoids; abdominal discomfort or pain; heartburn; flatulence; nausea; vomiting; diarrhoea; increased bleeding tendency (chronic use); osteoporosis; steatorrhoea (high doses); skin rashes; pruritus of the tongue, skin and perianal region; hyperchloraemic acidosis. ",aspartame
sign_symptom,hyper,0.9983317," constipation; faecal impaction; haemorrhoids; abdominal discomfort or pain; heartburn; flatulence; nausea; vomiting; diarrhoea; increased bleeding tendency (chronic use); osteoporosis; steatorrhoea (high doses); skin rashes; pruritus of the tongue, skin and perianal region; hyperchloraemic acidosis. ",aspartame
sign_symptom,nausea,0.9998901," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,vomiting,0.9949319," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,effects,0.7541484," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,arthral,0.8725652," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,side effects,0.8669126," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,sleepiness,0.7554006," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,malaise,0.9415255," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,asthenia,0.9798276," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,numb,0.7050773," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,palpitation,0.991458," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,hemorrhage,0.90679514," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,"migraine, syncope",0.9625107," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,tachycardia,0.8735409," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,sinus pain,0.9709595," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
sign_symptom,sinus congestion,0.9833173," common side effects include pain, headache, facial edema, gingivitis, paresthesia, infection. other side effects include pain, headache, positive blood aspiration into syringe, swelling, face edema, infection, neck pain, abdominal pain, ear pain, taste perversion, and accidental injury have been reported   gastrointestinal side effects  including nausea and emesis, gingivitis, constipation, diarrhea, dyspepsia, glossitis, gum hemorrhage, mouth ulceration, nausea, stomatitis, tongue edema, tooth disorder, and vomiting have been reported.   musculoskeletal side effects  including trismus, arthralgia, myalgia, back pain, and osteomyelitis have been reported.   general side effects  including sleepiness, malaise, and asthenia have been reported.   nervous system side effects  including paresthesia, numbness and tingling, dizziness, dry mouth, facial paralysis, hyperesthesia, increased salivation, nervousness, neuropathy, paresthesia, somnolence, and exacerbation of kearns-sayre syndrome have been reported.   cardiovascular side effects  including palpitation, hemorrhage, migraine, syncope, tachycardia, and elevated blood pressure have been reported.   respiratory side effects  including pharyngitis, rhinitis, sinus pain, and sinus congestion have been reported. ",articaine hydrochloride + epinephrine
medication,artesun,0.7802788, artesunate tablet is well tolerated. no adverse effects have been reported from the treatment of artesunate at recommended dose. ,artesunate
sign_symptom,adverse effects,0.99985695, artesunate tablet is well tolerated. no adverse effects have been reported from the treatment of artesunate at recommended dose. ,artesunate
medication,artesunate,0.97568536, artesunate tablet is well tolerated. no adverse effects have been reported from the treatment of artesunate at recommended dose. ,artesunate
sign_symptom,rash,0.992144," very common side effects: hot flushes, asthenia, joint stiffness, arthritis, headache, nausea, rash etc. common side effects: hair thinning, allergic reactions, diarrhea, vomiting, somnolence etc. ",anastrozole
sign_symptom,rash,0.9971886," nausea, vomiting, diarrhoea, erythematous maculo-papular rashes, sore mouth, black/hairy tongue, rash, erythema multiforme, stevens-johnson syndrome, toxic epidermal necrolysis, angioedema, fever, joint pains, serum sickness-like symptoms, haemolytic anaemia, thrombocytopenia, leucopenia, neutropenia, coagulation disorders, prolonged bleeding time and prothrombin time, cns toxicity (e.g. convulsions); paraesthesia, nephropathy, interstitial nephritis, hepatitis, cholestatic jaundice, moderate and transient increase in transaminases, anaphylaxis, clostridium difficile-associated diarrhoea (cdad). ",ampicillin sodium
sign_symptom,sore,0.99650264," nausea, vomiting, diarrhoea, erythematous maculo-papular rashes, sore mouth, black/hairy tongue, rash, erythema multiforme, stevens-johnson syndrome, toxic epidermal necrolysis, angioedema, fever, joint pains, serum sickness-like symptoms, haemolytic anaemia, thrombocytopenia, leucopenia, neutropenia, coagulation disorders, prolonged bleeding time and prothrombin time, cns toxicity (e.g. convulsions); paraesthesia, nephropathy, interstitial nephritis, hepatitis, cholestatic jaundice, moderate and transient increase in transaminases, anaphylaxis, clostridium difficile-associated diarrhoea (cdad). ",ampicillin sodium
sign_symptom,bleeding,0.98802805," nausea, vomiting, diarrhoea, erythematous maculo-papular rashes, sore mouth, black/hairy tongue, rash, erythema multiforme, stevens-johnson syndrome, toxic epidermal necrolysis, angioedema, fever, joint pains, serum sickness-like symptoms, haemolytic anaemia, thrombocytopenia, leucopenia, neutropenia, coagulation disorders, prolonged bleeding time and prothrombin time, cns toxicity (e.g. convulsions); paraesthesia, nephropathy, interstitial nephritis, hepatitis, cholestatic jaundice, moderate and transient increase in transaminases, anaphylaxis, clostridium difficile-associated diarrhoea (cdad). ",ampicillin sodium
sign_symptom,toxicity,0.9408275," nausea, vomiting, diarrhoea, erythematous maculo-papular rashes, sore mouth, black/hairy tongue, rash, erythema multiforme, stevens-johnson syndrome, toxic epidermal necrolysis, angioedema, fever, joint pains, serum sickness-like symptoms, haemolytic anaemia, thrombocytopenia, leucopenia, neutropenia, coagulation disorders, prolonged bleeding time and prothrombin time, cns toxicity (e.g. convulsions); paraesthesia, nephropathy, interstitial nephritis, hepatitis, cholestatic jaundice, moderate and transient increase in transaminases, anaphylaxis, clostridium difficile-associated diarrhoea (cdad). ",ampicillin sodium
sign_symptom,mala,0.99539965," common side effects are fever, chills, convulsions, malaise; nausea, vomiting, diarrhoea, anorexia; tinnitus, vertigo, hearing loss; hypotension, hypertension, cardiac arrhythmias; peripheral neuropathy; phloebitis, pain at inj site, disturbances in renal function and renal toxicity. ",amphotericin b
sign_symptom,pain,0.99983656," common side effects are fever, chills, convulsions, malaise; nausea, vomiting, diarrhoea, anorexia; tinnitus, vertigo, hearing loss; hypotension, hypertension, cardiac arrhythmias; peripheral neuropathy; phloebitis, pain at inj site, disturbances in renal function and renal toxicity. ",amphotericin b
sign_symptom,swelling,0.99995744," bloating and swelling in the abdomen are common side effects of calcium orotate. loss of appetite, upset stomach, constipation, nausea, vomiting, unusual weight loss, increased thirst/urination, weakness, unusual tiredness, formation of kidney stones may occur infrequently. ",calcium orotate
sign_symptom,loss of appetite,0.9121755," bloating and swelling in the abdomen are common side effects of calcium orotate. loss of appetite, upset stomach, constipation, nausea, vomiting, unusual weight loss, increased thirst/urination, weakness, unusual tiredness, formation of kidney stones may occur infrequently. ",calcium orotate
sign_symptom,upset,0.82342076," bloating and swelling in the abdomen are common side effects of calcium orotate. loss of appetite, upset stomach, constipation, nausea, vomiting, unusual weight loss, increased thirst/urination, weakness, unusual tiredness, formation of kidney stones may occur infrequently. ",calcium orotate
sign_symptom,weight,0.7687568," bloating and swelling in the abdomen are common side effects of calcium orotate. loss of appetite, upset stomach, constipation, nausea, vomiting, unusual weight loss, increased thirst/urination, weakness, unusual tiredness, formation of kidney stones may occur infrequently. ",calcium orotate
sign_symptom,thirst,0.90888166," bloating and swelling in the abdomen are common side effects of calcium orotate. loss of appetite, upset stomach, constipation, nausea, vomiting, unusual weight loss, increased thirst/urination, weakness, unusual tiredness, formation of kidney stones may occur infrequently. ",calcium orotate
medication,calcium carbonate,0.99815774," orally administered calcium carbonate may be irritating to the gi tract. it may also cause constipation. hypercalcemia is rarely produced by administration of calcium alone, but may occur when large doses are given to patients with chronic renal failure. also there may be allergic reactions, irregular heartbeats, nausea, vomiting, decreased appetite dry mouth and drowsiness, skin rash. ",calcium lactate gluconate + calcium carbonate + vitamin d3
sign_symptom,hyper,0.99974245," orally administered calcium carbonate may be irritating to the gi tract. it may also cause constipation. hypercalcemia is rarely produced by administration of calcium alone, but may occur when large doses are given to patients with chronic renal failure. also there may be allergic reactions, irregular heartbeats, nausea, vomiting, decreased appetite dry mouth and drowsiness, skin rash. ",calcium lactate gluconate + calcium carbonate + vitamin d3
medication,calcium,0.9960685," orally administered calcium carbonate may be irritating to the gi tract. it may also cause constipation. hypercalcemia is rarely produced by administration of calcium alone, but may occur when large doses are given to patients with chronic renal failure. also there may be allergic reactions, irregular heartbeats, nausea, vomiting, decreased appetite dry mouth and drowsiness, skin rash. ",calcium lactate gluconate + calcium carbonate + vitamin d3
sign_symptom,allergic,0.99877626," orally administered calcium carbonate may be irritating to the gi tract. it may also cause constipation. hypercalcemia is rarely produced by administration of calcium alone, but may occur when large doses are given to patients with chronic renal failure. also there may be allergic reactions, irregular heartbeats, nausea, vomiting, decreased appetite dry mouth and drowsiness, skin rash. ",calcium lactate gluconate + calcium carbonate + vitamin d3
sign_symptom,irregular heartbeat,0.9979367," orally administered calcium carbonate may be irritating to the gi tract. it may also cause constipation. hypercalcemia is rarely produced by administration of calcium alone, but may occur when large doses are given to patients with chronic renal failure. also there may be allergic reactions, irregular heartbeats, nausea, vomiting, decreased appetite dry mouth and drowsiness, skin rash. ",calcium lactate gluconate + calcium carbonate + vitamin d3
sign_symptom,decreased appetite,0.9978584," orally administered calcium carbonate may be irritating to the gi tract. it may also cause constipation. hypercalcemia is rarely produced by administration of calcium alone, but may occur when large doses are given to patients with chronic renal failure. also there may be allergic reactions, irregular heartbeats, nausea, vomiting, decreased appetite dry mouth and drowsiness, skin rash. ",calcium lactate gluconate + calcium carbonate + vitamin d3
sign_symptom,dry mouth,0.99896944," orally administered calcium carbonate may be irritating to the gi tract. it may also cause constipation. hypercalcemia is rarely produced by administration of calcium alone, but may occur when large doses are given to patients with chronic renal failure. also there may be allergic reactions, irregular heartbeats, nausea, vomiting, decreased appetite dry mouth and drowsiness, skin rash. ",calcium lactate gluconate + calcium carbonate + vitamin d3
medication,calcium supplements,0.99921525," the use of calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. following administration of vitamin-d supplements occasional skin rash has been reported. hypercalciuria, and in rare cases hypercalcaemia have been seen in long-term treatment with vitamin-d at high doses. ",calcium lactate gluconate + calcium carbonate + vitamin c + vitamin d3
sign_symptom,consti,0.831687," the use of calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. following administration of vitamin-d supplements occasional skin rash has been reported. hypercalciuria, and in rare cases hypercalcaemia have been seen in long-term treatment with vitamin-d at high doses. ",calcium lactate gluconate + calcium carbonate + vitamin c + vitamin d3
sign_symptom,flatulence,0.99668497," the use of calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. following administration of vitamin-d supplements occasional skin rash has been reported. hypercalciuria, and in rare cases hypercalcaemia have been seen in long-term treatment with vitamin-d at high doses. ",calcium lactate gluconate + calcium carbonate + vitamin c + vitamin d3
sign_symptom,nausea,0.9997682," the use of calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. following administration of vitamin-d supplements occasional skin rash has been reported. hypercalciuria, and in rare cases hypercalcaemia have been seen in long-term treatment with vitamin-d at high doses. ",calcium lactate gluconate + calcium carbonate + vitamin c + vitamin d3
sign_symptom,pain,0.9999099," the use of calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. following administration of vitamin-d supplements occasional skin rash has been reported. hypercalciuria, and in rare cases hypercalcaemia have been seen in long-term treatment with vitamin-d at high doses. ",calcium lactate gluconate + calcium carbonate + vitamin c + vitamin d3
sign_symptom,diarr,0.9684291," the use of calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. following administration of vitamin-d supplements occasional skin rash has been reported. hypercalciuria, and in rare cases hypercalcaemia have been seen in long-term treatment with vitamin-d at high doses. ",calcium lactate gluconate + calcium carbonate + vitamin c + vitamin d3
medication,vitamin - d supplements,0.9986563," the use of calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. following administration of vitamin-d supplements occasional skin rash has been reported. hypercalciuria, and in rare cases hypercalcaemia have been seen in long-term treatment with vitamin-d at high doses. ",calcium lactate gluconate + calcium carbonate + vitamin c + vitamin d3
sign_symptom,rash,0.9999231," the use of calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. following administration of vitamin-d supplements occasional skin rash has been reported. hypercalciuria, and in rare cases hypercalcaemia have been seen in long-term treatment with vitamin-d at high doses. ",calcium lactate gluconate + calcium carbonate + vitamin c + vitamin d3
sign_symptom,hyper,0.99995553," the use of calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. following administration of vitamin-d supplements occasional skin rash has been reported. hypercalciuria, and in rare cases hypercalcaemia have been seen in long-term treatment with vitamin-d at high doses. ",calcium lactate gluconate + calcium carbonate + vitamin c + vitamin d3
medication,vitamin - d,0.9996753," the use of calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. following administration of vitamin-d supplements occasional skin rash has been reported. hypercalciuria, and in rare cases hypercalcaemia have been seen in long-term treatment with vitamin-d at high doses. ",calcium lactate gluconate + calcium carbonate + vitamin c + vitamin d3
sign_symptom,gastrointestinal disturbances,0.99755895," in rare cases, mild gastrointestinal disturbances (bloating, diarrhoea) can occur. in predisposed patients prolonged treatment with high doses may promote the formation of calculi in the urinary tract. ",calcium lactate gluconate + calcium carbonate + vitamin c
sign_symptom,calculi,0.99881315," in rare cases, mild gastrointestinal disturbances (bloating, diarrhoea) can occur. in predisposed patients prolonged treatment with high doses may promote the formation of calculi in the urinary tract. ",calcium lactate gluconate + calcium carbonate + vitamin c
sign_symptom,discomfort,0.99993277," gl discomfort e.g. nausea, vomiting, constipation; bradycardia, arrhythmias. dry mouth, increased thirst or increased urination. mental confusion, milk-alkali syndrome. ",calcium lactate
sign_symptom,thirst,0.99920386," gl discomfort e.g. nausea, vomiting, constipation; bradycardia, arrhythmias. dry mouth, increased thirst or increased urination. mental confusion, milk-alkali syndrome. ",calcium lactate
sign_symptom,hyper,0.9688665," gi irritation; soft-tissue calcification, skin sloughing or necrosis after im/sc inj. hypercalcaemia characterised by anorexia, nausea, vomiting, constipation, abdominal pain, muscle weakness, mental disturbances, polydipsia, polyuria, nephrocalcinosis, renal calculi; chalky taste, hot flushes and peripheral vasodilation. ",calcium gluconate
sign_symptom,rash,0.999925,"  
 allergic reaction: one may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing). 
 fits and fainting. 
  ",calcium folinate [folinic acid]
sign_symptom,swelling,0.99995434,"  
 allergic reaction: one may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing). 
 fits and fainting. 
  ",calcium folinate [folinic acid]
sign_symptom,burning,0.9895989," very rare cases have been reported: modifications of the intestinal transit, temporary burning sensation and local pain. hypersensitivity reactions together with skin reactions and/or fever can occur. these reactions can be of allergic origin and in this case, the treatment must be discontinued. ",calcium dobesilate + lidocaine + dexamethasone
sign_symptom,hypersensitivity reactions,0.99494016," very rare cases have been reported: modifications of the intestinal transit, temporary burning sensation and local pain. hypersensitivity reactions together with skin reactions and/or fever can occur. these reactions can be of allergic origin and in this case, the treatment must be discontinued. ",calcium dobesilate + lidocaine + dexamethasone
sign_symptom,skin reactions,0.9996806," very rare cases have been reported: modifications of the intestinal transit, temporary burning sensation and local pain. hypersensitivity reactions together with skin reactions and/or fever can occur. these reactions can be of allergic origin and in this case, the treatment must be discontinued. ",calcium dobesilate + lidocaine + dexamethasone
sign_symptom,fever,0.99993336," very rare cases have been reported: modifications of the intestinal transit, temporary burning sensation and local pain. hypersensitivity reactions together with skin reactions and/or fever can occur. these reactions can be of allergic origin and in this case, the treatment must be discontinued. ",calcium dobesilate + lidocaine + dexamethasone
disease_disorder,gastrointestinal disorders,0.99833953," rarely gastrointestinal disorders including nausea and diarrhea, skin reactions, fever, articular pain and in very rare cases agranulocytosis have been reported. these reactions are generally spontaneously reversible after treatment withdrawal. ",calcium dobesilate
sign_symptom,nausea,0.9807674," rarely gastrointestinal disorders including nausea and diarrhea, skin reactions, fever, articular pain and in very rare cases agranulocytosis have been reported. these reactions are generally spontaneously reversible after treatment withdrawal. ",calcium dobesilate
sign_symptom,skin,0.76129127," rarely gastrointestinal disorders including nausea and diarrhea, skin reactions, fever, articular pain and in very rare cases agranulocytosis have been reported. these reactions are generally spontaneously reversible after treatment withdrawal. ",calcium dobesilate
sign_symptom,fever,0.9127783," rarely gastrointestinal disorders including nausea and diarrhea, skin reactions, fever, articular pain and in very rare cases agranulocytosis have been reported. these reactions are generally spontaneously reversible after treatment withdrawal. ",calcium dobesilate
sign_symptom,pain,0.9997197," rarely gastrointestinal disorders including nausea and diarrhea, skin reactions, fever, articular pain and in very rare cases agranulocytosis have been reported. these reactions are generally spontaneously reversible after treatment withdrawal. ",calcium dobesilate
disease_disorder,agranulocytosis,0.9954034," rarely gastrointestinal disorders including nausea and diarrhea, skin reactions, fever, articular pain and in very rare cases agranulocytosis have been reported. these reactions are generally spontaneously reversible after treatment withdrawal. ",calcium dobesilate
sign_symptom,urination,0.99896806," it is generally well tolerated. if there is experience like nausea, vomiting, stomach cramps, dry mouth, increased thirst, increased urination while taking, noticed to physicians. side effects from micronutrient are rare. ",calcium carbonate + vitamin d3 + multimineral
sign_symptom,side effects,0.9770621," it is generally well tolerated. if there is experience like nausea, vomiting, stomach cramps, dry mouth, increased thirst, increased urination while taking, noticed to physicians. side effects from micronutrient are rare. ",calcium carbonate + vitamin d3 + multimineral
sign_symptom,micronutrient,0.72205144," it is generally well tolerated. if there is experience like nausea, vomiting, stomach cramps, dry mouth, increased thirst, increased urination while taking, noticed to physicians. side effects from micronutrient are rare. ",calcium carbonate + vitamin d3 + multimineral
sign_symptom,urination,0.9997188," it is generally well tolerated. if there is experience like nausea, vomiting, stomach cramps, dry mouth, increased thirst, increased urination while taking, noticed to physicians. constipation may occur. ",calcium carbonate [elemental source] + vitamin d3
medication,calcium carbonate,0.9594258," common side effects: generally orally administered calcium carbonate may be irritating to the gl tract and it may also cause constipation but eggshell calcium is safe for long-term use without causing any gl discomfort or constipation. rare side effects: kidney stone, hypercalcemia, alkalosis, loss of appetite. ",calcium carbonate [eggshell source] + vitamin d3
sign_symptom,consti,0.9937734," common side effects: generally orally administered calcium carbonate may be irritating to the gl tract and it may also cause constipation but eggshell calcium is safe for long-term use without causing any gl discomfort or constipation. rare side effects: kidney stone, hypercalcemia, alkalosis, loss of appetite. ",calcium carbonate [eggshell source] + vitamin d3
sign_symptom,discomfort,0.9997259," common side effects: generally orally administered calcium carbonate may be irritating to the gl tract and it may also cause constipation but eggshell calcium is safe for long-term use without causing any gl discomfort or constipation. rare side effects: kidney stone, hypercalcemia, alkalosis, loss of appetite. ",calcium carbonate [eggshell source] + vitamin d3
sign_symptom,hyper,0.8113778," common side effects: generally orally administered calcium carbonate may be irritating to the gl tract and it may also cause constipation but eggshell calcium is safe for long-term use without causing any gl discomfort or constipation. rare side effects: kidney stone, hypercalcemia, alkalosis, loss of appetite. ",calcium carbonate [eggshell source] + vitamin d3
sign_symptom,flatule,0.9956278," flatulence, diarrhoea, constipation, upper gi discomfort etc. are rare manifestation. hypercalcaemia due to prolong use has rarely been reported. ",calcium carbonate [coral source] + vitamin d3
sign_symptom,diarr,0.9243103," flatulence, diarrhoea, constipation, upper gi discomfort etc. are rare manifestation. hypercalcaemia due to prolong use has rarely been reported. ",calcium carbonate [coral source] + vitamin d3
sign_symptom,consti,0.9876529," flatulence, diarrhoea, constipation, upper gi discomfort etc. are rare manifestation. hypercalcaemia due to prolong use has rarely been reported. ",calcium carbonate [coral source] + vitamin d3
sign_symptom,discomfort,0.9999155," flatulence, diarrhoea, constipation, upper gi discomfort etc. are rare manifestation. hypercalcaemia due to prolong use has rarely been reported. ",calcium carbonate [coral source] + vitamin d3
sign_symptom,hyper,0.99996185," flatulence, diarrhoea, constipation, upper gi discomfort etc. are rare manifestation. hypercalcaemia due to prolong use has rarely been reported. ",calcium carbonate [coral source] + vitamin d3
sign_symptom,pain,0.99982065," common side effects of calcium and vitamin d3 may include an irregular heartbeat, nausea, dry mouth, weakness, headache, a metallic taste in mouth, muscle or bone pain and drowsiness. rare side effects are high amount of calcium in blood, constipation, diarrhoea, loss of appetite. ",calcium carbonate [algae source] + vitamin d3
medication,calcium carbonate,0.99685585," orally administered calcium carbonate may be irritating to the gi tract. it may also cause constipation. hypercalcaemia is rarely produced by administration of calcium alone, but may occur when large doses are given to patients with chronic renal failure. ",calcium carbonate
sign_symptom,hyper,0.99994504," orally administered calcium carbonate may be irritating to the gi tract. it may also cause constipation. hypercalcaemia is rarely produced by administration of calcium alone, but may occur when large doses are given to patients with chronic renal failure. ",calcium carbonate
medication,calcium,0.99521756," orally administered calcium carbonate may be irritating to the gi tract. it may also cause constipation. hypercalcaemia is rarely produced by administration of calcium alone, but may occur when large doses are given to patients with chronic renal failure. ",calcium carbonate
sign_symptom,nausea,0.9999417," patients may occasionally experience nausea during calcium acetate therapy. hypercalcemia may occur during treatment with calcium acetate. mild hypercalcemia (ca &gt;10.5 mg/dl) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. more severe hypercalcemia (ca &gt;12 mg/dl) is associated with confusion, delirium, stupor and coma. mild hypercalcemia is easily controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy. decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate induced hypercalcemia. the long-term effect of calcium acetate on the progression of vascular or soft-tissue calcification has not been determined. isolated cases of pruritus have been reported which may represent allergic reactions. ",calcium acetate
medication,calcium acetate,0.992722," patients may occasionally experience nausea during calcium acetate therapy. hypercalcemia may occur during treatment with calcium acetate. mild hypercalcemia (ca &gt;10.5 mg/dl) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. more severe hypercalcemia (ca &gt;12 mg/dl) is associated with confusion, delirium, stupor and coma. mild hypercalcemia is easily controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy. decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate induced hypercalcemia. the long-term effect of calcium acetate on the progression of vascular or soft-tissue calcification has not been determined. isolated cases of pruritus have been reported which may represent allergic reactions. ",calcium acetate
sign_symptom,hyper,0.9999434," patients may occasionally experience nausea during calcium acetate therapy. hypercalcemia may occur during treatment with calcium acetate. mild hypercalcemia (ca &gt;10.5 mg/dl) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. more severe hypercalcemia (ca &gt;12 mg/dl) is associated with confusion, delirium, stupor and coma. mild hypercalcemia is easily controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy. decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate induced hypercalcemia. the long-term effect of calcium acetate on the progression of vascular or soft-tissue calcification has not been determined. isolated cases of pruritus have been reported which may represent allergic reactions. ",calcium acetate
medication,calcium ace,0.7994288," patients may occasionally experience nausea during calcium acetate therapy. hypercalcemia may occur during treatment with calcium acetate. mild hypercalcemia (ca &gt;10.5 mg/dl) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. more severe hypercalcemia (ca &gt;12 mg/dl) is associated with confusion, delirium, stupor and coma. mild hypercalcemia is easily controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy. decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate induced hypercalcemia. the long-term effect of calcium acetate on the progression of vascular or soft-tissue calcification has not been determined. isolated cases of pruritus have been reported which may represent allergic reactions. ",calcium acetate
sign_symptom,hypercalcemia,0.880932," patients may occasionally experience nausea during calcium acetate therapy. hypercalcemia may occur during treatment with calcium acetate. mild hypercalcemia (ca &gt;10.5 mg/dl) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. more severe hypercalcemia (ca &gt;12 mg/dl) is associated with confusion, delirium, stupor and coma. mild hypercalcemia is easily controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy. decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate induced hypercalcemia. the long-term effect of calcium acetate on the progression of vascular or soft-tissue calcification has not been determined. isolated cases of pruritus have been reported which may represent allergic reactions. ",calcium acetate
sign_symptom,consti,0.98080456," patients may occasionally experience nausea during calcium acetate therapy. hypercalcemia may occur during treatment with calcium acetate. mild hypercalcemia (ca &gt;10.5 mg/dl) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. more severe hypercalcemia (ca &gt;12 mg/dl) is associated with confusion, delirium, stupor and coma. mild hypercalcemia is easily controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy. decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate induced hypercalcemia. the long-term effect of calcium acetate on the progression of vascular or soft-tissue calcification has not been determined. isolated cases of pruritus have been reported which may represent allergic reactions. ",calcium acetate
sign_symptom,pruritus,0.97707844," patients may occasionally experience nausea during calcium acetate therapy. hypercalcemia may occur during treatment with calcium acetate. mild hypercalcemia (ca &gt;10.5 mg/dl) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. more severe hypercalcemia (ca &gt;12 mg/dl) is associated with confusion, delirium, stupor and coma. mild hypercalcemia is easily controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy. decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate induced hypercalcemia. the long-term effect of calcium acetate on the progression of vascular or soft-tissue calcification has not been determined. isolated cases of pruritus have been reported which may represent allergic reactions. ",calcium acetate
medication,calcium salts,0.97042465," calcium salts may cause mild gastrointestinal side effects such as constipation, flatulence, nausea, abdominal pain &amp; bloating. hypercalcaemia &amp; in rare cases hypercalciuria have been seen with long term intake of calcium at high doses. side effects from micronutrients are rare. ",calcium + vitamin d3 + vitamin c + vitamin e + multimineral
sign_symptom,consti,0.7582483," calcium salts may cause mild gastrointestinal side effects such as constipation, flatulence, nausea, abdominal pain &amp; bloating. hypercalcaemia &amp; in rare cases hypercalciuria have been seen with long term intake of calcium at high doses. side effects from micronutrients are rare. ",calcium + vitamin d3 + vitamin c + vitamin e + multimineral
sign_symptom,flatulence,0.883029," calcium salts may cause mild gastrointestinal side effects such as constipation, flatulence, nausea, abdominal pain &amp; bloating. hypercalcaemia &amp; in rare cases hypercalciuria have been seen with long term intake of calcium at high doses. side effects from micronutrients are rare. ",calcium + vitamin d3 + vitamin c + vitamin e + multimineral
sign_symptom,nausea,0.9989612," calcium salts may cause mild gastrointestinal side effects such as constipation, flatulence, nausea, abdominal pain &amp; bloating. hypercalcaemia &amp; in rare cases hypercalciuria have been seen with long term intake of calcium at high doses. side effects from micronutrients are rare. ",calcium + vitamin d3 + vitamin c + vitamin e + multimineral
sign_symptom,pain,0.9998981," calcium salts may cause mild gastrointestinal side effects such as constipation, flatulence, nausea, abdominal pain &amp; bloating. hypercalcaemia &amp; in rare cases hypercalciuria have been seen with long term intake of calcium at high doses. side effects from micronutrients are rare. ",calcium + vitamin d3 + vitamin c + vitamin e + multimineral
sign_symptom,hyper,0.99995744," calcium salts may cause mild gastrointestinal side effects such as constipation, flatulence, nausea, abdominal pain &amp; bloating. hypercalcaemia &amp; in rare cases hypercalciuria have been seen with long term intake of calcium at high doses. side effects from micronutrients are rare. ",calcium + vitamin d3 + vitamin c + vitamin e + multimineral
medication,calcium,0.98728454," calcium salts may cause mild gastrointestinal side effects such as constipation, flatulence, nausea, abdominal pain &amp; bloating. hypercalcaemia &amp; in rare cases hypercalciuria have been seen with long term intake of calcium at high doses. side effects from micronutrients are rare. ",calcium + vitamin d3 + vitamin c + vitamin e + multimineral
sign_symptom,side effects,0.99500364," calcium salts may cause mild gastrointestinal side effects such as constipation, flatulence, nausea, abdominal pain &amp; bloating. hypercalcaemia &amp; in rare cases hypercalciuria have been seen with long term intake of calcium at high doses. side effects from micronutrients are rare. ",calcium + vitamin d3 + vitamin c + vitamin e + multimineral
sign_symptom,pain,0.99834967, weakness; headache; somnolence; nausea; vomiting; dry mouth; constipation; muscle pain; bone pain; metallic taste; polyuria; polydipsia; anorexia; irritability; weight loss; nocturia; mild acidosis; reversible azotemia; generalized vascular calcification; nephrocalcinosis; conjunctivitis (calcific); pancreatitis; photophobia; rhinorrhoea; pruritus; hyperthermia; decreased libido; elevated bun; albuminuria; hypercholesterolaemia; elevated ast and alt; ectopic calcification; hypertension; cardiac arrhythmias. ,calcitriol + calcium citrate
sign_symptom,metallic,0.97345465, weakness; headache; somnolence; nausea; vomiting; dry mouth; constipation; muscle pain; bone pain; metallic taste; polyuria; polydipsia; anorexia; irritability; weight loss; nocturia; mild acidosis; reversible azotemia; generalized vascular calcification; nephrocalcinosis; conjunctivitis (calcific); pancreatitis; photophobia; rhinorrhoea; pruritus; hyperthermia; decreased libido; elevated bun; albuminuria; hypercholesterolaemia; elevated ast and alt; ectopic calcification; hypertension; cardiac arrhythmias. ,calcitriol + calcium citrate
sign_symptom,polyuria,0.82555485, weakness; headache; somnolence; nausea; vomiting; dry mouth; constipation; muscle pain; bone pain; metallic taste; polyuria; polydipsia; anorexia; irritability; weight loss; nocturia; mild acidosis; reversible azotemia; generalized vascular calcification; nephrocalcinosis; conjunctivitis (calcific); pancreatitis; photophobia; rhinorrhoea; pruritus; hyperthermia; decreased libido; elevated bun; albuminuria; hypercholesterolaemia; elevated ast and alt; ectopic calcification; hypertension; cardiac arrhythmias. ,calcitriol + calcium citrate
sign_symptom,polydips,0.99593145, weakness; headache; somnolence; nausea; vomiting; dry mouth; constipation; muscle pain; bone pain; metallic taste; polyuria; polydipsia; anorexia; irritability; weight loss; nocturia; mild acidosis; reversible azotemia; generalized vascular calcification; nephrocalcinosis; conjunctivitis (calcific); pancreatitis; photophobia; rhinorrhoea; pruritus; hyperthermia; decreased libido; elevated bun; albuminuria; hypercholesterolaemia; elevated ast and alt; ectopic calcification; hypertension; cardiac arrhythmias. ,calcitriol + calcium citrate
sign_symptom,weight,0.99854326, weakness; headache; somnolence; nausea; vomiting; dry mouth; constipation; muscle pain; bone pain; metallic taste; polyuria; polydipsia; anorexia; irritability; weight loss; nocturia; mild acidosis; reversible azotemia; generalized vascular calcification; nephrocalcinosis; conjunctivitis (calcific); pancreatitis; photophobia; rhinorrhoea; pruritus; hyperthermia; decreased libido; elevated bun; albuminuria; hypercholesterolaemia; elevated ast and alt; ectopic calcification; hypertension; cardiac arrhythmias. ,calcitriol + calcium citrate
sign_symptom,azotemia,0.97799677, weakness; headache; somnolence; nausea; vomiting; dry mouth; constipation; muscle pain; bone pain; metallic taste; polyuria; polydipsia; anorexia; irritability; weight loss; nocturia; mild acidosis; reversible azotemia; generalized vascular calcification; nephrocalcinosis; conjunctivitis (calcific); pancreatitis; photophobia; rhinorrhoea; pruritus; hyperthermia; decreased libido; elevated bun; albuminuria; hypercholesterolaemia; elevated ast and alt; ectopic calcification; hypertension; cardiac arrhythmias. ,calcitriol + calcium citrate
sign_symptom,photo,0.9104747, weakness; headache; somnolence; nausea; vomiting; dry mouth; constipation; muscle pain; bone pain; metallic taste; polyuria; polydipsia; anorexia; irritability; weight loss; nocturia; mild acidosis; reversible azotemia; generalized vascular calcification; nephrocalcinosis; conjunctivitis (calcific); pancreatitis; photophobia; rhinorrhoea; pruritus; hyperthermia; decreased libido; elevated bun; albuminuria; hypercholesterolaemia; elevated ast and alt; ectopic calcification; hypertension; cardiac arrhythmias. ,calcitriol + calcium citrate
sign_symptom,rhinorr,0.77332675, weakness; headache; somnolence; nausea; vomiting; dry mouth; constipation; muscle pain; bone pain; metallic taste; polyuria; polydipsia; anorexia; irritability; weight loss; nocturia; mild acidosis; reversible azotemia; generalized vascular calcification; nephrocalcinosis; conjunctivitis (calcific); pancreatitis; photophobia; rhinorrhoea; pruritus; hyperthermia; decreased libido; elevated bun; albuminuria; hypercholesterolaemia; elevated ast and alt; ectopic calcification; hypertension; cardiac arrhythmias. ,calcitriol + calcium citrate
sign_symptom,hyper,0.99991584, weakness; headache; somnolence; nausea; vomiting; dry mouth; constipation; muscle pain; bone pain; metallic taste; polyuria; polydipsia; anorexia; irritability; weight loss; nocturia; mild acidosis; reversible azotemia; generalized vascular calcification; nephrocalcinosis; conjunctivitis (calcific); pancreatitis; photophobia; rhinorrhoea; pruritus; hyperthermia; decreased libido; elevated bun; albuminuria; hypercholesterolaemia; elevated ast and alt; ectopic calcification; hypertension; cardiac arrhythmias. ,calcitriol + calcium citrate
sign_symptom,album,0.9547881, weakness; headache; somnolence; nausea; vomiting; dry mouth; constipation; muscle pain; bone pain; metallic taste; polyuria; polydipsia; anorexia; irritability; weight loss; nocturia; mild acidosis; reversible azotemia; generalized vascular calcification; nephrocalcinosis; conjunctivitis (calcific); pancreatitis; photophobia; rhinorrhoea; pruritus; hyperthermia; decreased libido; elevated bun; albuminuria; hypercholesterolaemia; elevated ast and alt; ectopic calcification; hypertension; cardiac arrhythmias. ,calcitriol + calcium citrate
sign_symptom,vomiting,0.97685003," occasional symptoms include anorexia, headache, vomiting and constipation. chronic effects may include dystrophy, fever, polyuria, dehydration, apathy and urinary tract infection. ",calcitriol
sign_symptom,indigestion,0.9979667," side effects are mild and transient in nature. this may include diarrhoea, indigestion or occasionally rash. pseudo-membranous colitis has been reported rarely. ",amoxicillin trihydrate
sign_symptom,indigestion,0.99140793," side effects, as with amoxicillin, are uncommon and mainly of a mild and transitory nature. diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking co-amoxiclav at the start of meals. hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. urticarial and erythematous rashes sometimes occur. rarely erythema multiforme, stevens-johnson syndrome and exfoliative dermatitis have been reported. in common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported. ",amoxicillin + clavulanic acid
sign_symptom,nausea,0.9977081," side effects, as with amoxicillin, are uncommon and mainly of a mild and transitory nature. diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking co-amoxiclav at the start of meals. hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. urticarial and erythematous rashes sometimes occur. rarely erythema multiforme, stevens-johnson syndrome and exfoliative dermatitis have been reported. in common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported. ",amoxicillin + clavulanic acid
sign_symptom,vomiting,0.9996481," side effects, as with amoxicillin, are uncommon and mainly of a mild and transitory nature. diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking co-amoxiclav at the start of meals. hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. urticarial and erythematous rashes sometimes occur. rarely erythema multiforme, stevens-johnson syndrome and exfoliative dermatitis have been reported. in common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported. ",amoxicillin + clavulanic acid
sign_symptom,candidiasis,0.90122366," side effects, as with amoxicillin, are uncommon and mainly of a mild and transitory nature. diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking co-amoxiclav at the start of meals. hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. urticarial and erythematous rashes sometimes occur. rarely erythema multiforme, stevens-johnson syndrome and exfoliative dermatitis have been reported. in common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported. ",amoxicillin + clavulanic acid
medication,amoxiclav,0.95299566," side effects, as with amoxicillin, are uncommon and mainly of a mild and transitory nature. diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking co-amoxiclav at the start of meals. hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. urticarial and erythematous rashes sometimes occur. rarely erythema multiforme, stevens-johnson syndrome and exfoliative dermatitis have been reported. in common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported. ",amoxicillin + clavulanic acid
disease_disorder,hepatitis,0.8306411," side effects, as with amoxicillin, are uncommon and mainly of a mild and transitory nature. diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking co-amoxiclav at the start of meals. hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. urticarial and erythematous rashes sometimes occur. rarely erythema multiforme, stevens-johnson syndrome and exfoliative dermatitis have been reported. in common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported. ",amoxicillin + clavulanic acid
sign_symptom,rash,0.9998814," side effects, as with amoxicillin, are uncommon and mainly of a mild and transitory nature. diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking co-amoxiclav at the start of meals. hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. urticarial and erythematous rashes sometimes occur. rarely erythema multiforme, stevens-johnson syndrome and exfoliative dermatitis have been reported. in common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported. ",amoxicillin + clavulanic acid
disease_disorder,stevens - johnson syndrome,0.9997691," side effects, as with amoxicillin, are uncommon and mainly of a mild and transitory nature. diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking co-amoxiclav at the start of meals. hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. urticarial and erythematous rashes sometimes occur. rarely erythema multiforme, stevens-johnson syndrome and exfoliative dermatitis have been reported. in common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported. ",amoxicillin + clavulanic acid
medication,beta,0.998027," side effects, as with amoxicillin, are uncommon and mainly of a mild and transitory nature. diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking co-amoxiclav at the start of meals. hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. urticarial and erythematous rashes sometimes occur. rarely erythema multiforme, stevens-johnson syndrome and exfoliative dermatitis have been reported. in common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported. ",amoxicillin + clavulanic acid
medication,lactam,0.93152684," side effects, as with amoxicillin, are uncommon and mainly of a mild and transitory nature. diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking co-amoxiclav at the start of meals. hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. urticarial and erythematous rashes sometimes occur. rarely erythema multiforme, stevens-johnson syndrome and exfoliative dermatitis have been reported. in common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported. ",amoxicillin + clavulanic acid
disease_disorder,angio,0.78841925," side effects, as with amoxicillin, are uncommon and mainly of a mild and transitory nature. diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported, if gastrointestinal side effects occur with oral therapy, that may be reduced by taking co-amoxiclav at the start of meals. hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. urticarial and erythematous rashes sometimes occur. rarely erythema multiforme, stevens-johnson syndrome and exfoliative dermatitis have been reported. in common with other beta-lactam antibiotics, angioedema and anaphylaxis have been reported. ",amoxicillin + clavulanic acid
sign_symptom,vomiting,0.9998677," this syrup is proven as safe. it is well tolerated. in high dose diarrhea, vomiting may occur. ",herbal cough syrup [adhatoda vasica]
sign_symptom,side effect,0.9983833, no significant side effect has been observed in proper dosages. ,hazmina
sign_symptom,pain,0.9999155," mild muscle pain or weakness; headache, tired feeling; nausea, vomiting, stomach pain, diarrhea; (in men) decreased amount of semen when having an orgasm; stuffy nose, watery eyes; vision problems, ringing in your ears; or mild skin rash. ",aminocaproic acid
sign_symptom,tired,0.9921334," mild muscle pain or weakness; headache, tired feeling; nausea, vomiting, stomach pain, diarrhea; (in men) decreased amount of semen when having an orgasm; stuffy nose, watery eyes; vision problems, ringing in your ears; or mild skin rash. ",aminocaproic acid
sign_symptom,stuff,0.9998723," mild muscle pain or weakness; headache, tired feeling; nausea, vomiting, stomach pain, diarrhea; (in men) decreased amount of semen when having an orgasm; stuffy nose, watery eyes; vision problems, ringing in your ears; or mild skin rash. ",aminocaproic acid
sign_symptom,watery,0.8923335," mild muscle pain or weakness; headache, tired feeling; nausea, vomiting, stomach pain, diarrhea; (in men) decreased amount of semen when having an orgasm; stuffy nose, watery eyes; vision problems, ringing in your ears; or mild skin rash. ",aminocaproic acid
sign_symptom,ringing,0.9972905," mild muscle pain or weakness; headache, tired feeling; nausea, vomiting, stomach pain, diarrhea; (in men) decreased amount of semen when having an orgasm; stuffy nose, watery eyes; vision problems, ringing in your ears; or mild skin rash. ",aminocaproic acid
sign_symptom,hyper,0.9999467," hypercalcaemia (very rare), if hypercalcaemia occurs, the intake of vitamin d should be reduced. in case of persisting hypercalcaemia, the dose of amino acid keto analogues as well as the intake of any other calcium sources has to be reduced. ",amino acid keto analogues
medication,vitamin d,0.96690995," hypercalcaemia (very rare), if hypercalcaemia occurs, the intake of vitamin d should be reduced. in case of persisting hypercalcaemia, the dose of amino acid keto analogues as well as the intake of any other calcium sources has to be reduced. ",amino acid keto analogues
medication,amino acid keto analogue,0.9909937," hypercalcaemia (very rare), if hypercalcaemia occurs, the intake of vitamin d should be reduced. in case of persisting hypercalcaemia, the dose of amino acid keto analogues as well as the intake of any other calcium sources has to be reduced. ",amino acid keto analogues
medication,calcium,0.7940195," hypercalcaemia (very rare), if hypercalcaemia occurs, the intake of vitamin d should be reduced. in case of persisting hypercalcaemia, the dose of amino acid keto analogues as well as the intake of any other calcium sources has to be reduced. ",amino acid keto analogues
sign_symptom,nausea,0.99992967," this preparation is usually well tolerated. nausea occurs rarely. vomiting, flushing and sweating have been observed during infusion of the solution at rates exceeding the recommended maximal rate. transient increases in liver test during intravenous nutrition have been reported. the reasons are at present unclear. the underlying disease and the components and their amount in the intravenous feeding regimens have been suggested. hypersensitivity reactions have been reported. as with all hypertonic infusion solution, thrombophlebitis may occur when peripheral veins are used. the incidence may be reduced by the simultaneous infusion of 10% fat emulsion. ",amino acid + glucose + electrolytes
sign_symptom,flushing,0.9999579," this preparation is usually well tolerated. nausea occurs rarely. vomiting, flushing and sweating have been observed during infusion of the solution at rates exceeding the recommended maximal rate. transient increases in liver test during intravenous nutrition have been reported. the reasons are at present unclear. the underlying disease and the components and their amount in the intravenous feeding regimens have been suggested. hypersensitivity reactions have been reported. as with all hypertonic infusion solution, thrombophlebitis may occur when peripheral veins are used. the incidence may be reduced by the simultaneous infusion of 10% fat emulsion. ",amino acid + glucose + electrolytes
sign_symptom,sweating,0.9999329," this preparation is usually well tolerated. nausea occurs rarely. vomiting, flushing and sweating have been observed during infusion of the solution at rates exceeding the recommended maximal rate. transient increases in liver test during intravenous nutrition have been reported. the reasons are at present unclear. the underlying disease and the components and their amount in the intravenous feeding regimens have been suggested. hypersensitivity reactions have been reported. as with all hypertonic infusion solution, thrombophlebitis may occur when peripheral veins are used. the incidence may be reduced by the simultaneous infusion of 10% fat emulsion. ",amino acid + glucose + electrolytes
sign_symptom,hypersensitivity reactions,0.9990077," this preparation is usually well tolerated. nausea occurs rarely. vomiting, flushing and sweating have been observed during infusion of the solution at rates exceeding the recommended maximal rate. transient increases in liver test during intravenous nutrition have been reported. the reasons are at present unclear. the underlying disease and the components and their amount in the intravenous feeding regimens have been suggested. hypersensitivity reactions have been reported. as with all hypertonic infusion solution, thrombophlebitis may occur when peripheral veins are used. the incidence may be reduced by the simultaneous infusion of 10% fat emulsion. ",amino acid + glucose + electrolytes
sign_symptom,nausea,0.9999403," nausea occurs rarely. transient increases in liver tests during iv nutrition have been reported. hypersensitivity reactions have been reported with amino acid solutions. as with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used. hyperphenylalaninemia may occur in severely ill, premature infants. ",amino acid + dextrose + eloctrolytes
sign_symptom,hypersensitivity reactions,0.9998952," nausea occurs rarely. transient increases in liver tests during iv nutrition have been reported. hypersensitivity reactions have been reported with amino acid solutions. as with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used. hyperphenylalaninemia may occur in severely ill, premature infants. ",amino acid + dextrose + eloctrolytes
medication,amino acid,0.7567029," nausea occurs rarely. transient increases in liver tests during iv nutrition have been reported. hypersensitivity reactions have been reported with amino acid solutions. as with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used. hyperphenylalaninemia may occur in severely ill, premature infants. ",amino acid + dextrose + eloctrolytes
sign_symptom,hyper,0.99972457," nausea occurs rarely. transient increases in liver tests during iv nutrition have been reported. hypersensitivity reactions have been reported with amino acid solutions. as with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used. hyperphenylalaninemia may occur in severely ill, premature infants. ",amino acid + dextrose + eloctrolytes
sign_symptom,irritation,0.999912," burning, eye irritation or pruritus, visual disturbance, ocular discharge were reported with this eye drop. ",carboxymethylcellulose sodium
sign_symptom,adverse reactions,0.9998083," the most frequent adverse reactions observed are related to its contractile effect on smooth muscle, especially gastrointestinal effects like vomiting, nausea, diarrhea and pyrexia. endometritis, retained placental fragments, and excessive uterine bleeding occurred as the most common complications after abortion with carboprost. ",carboprost tromethamine
sign_symptom,diarrhea,0.86118263," the most frequent adverse reactions observed are related to its contractile effect on smooth muscle, especially gastrointestinal effects like vomiting, nausea, diarrhea and pyrexia. endometritis, retained placental fragments, and excessive uterine bleeding occurred as the most common complications after abortion with carboprost. ",carboprost tromethamine
sign_symptom,bleeding,0.99978346," the most frequent adverse reactions observed are related to its contractile effect on smooth muscle, especially gastrointestinal effects like vomiting, nausea, diarrhea and pyrexia. endometritis, retained placental fragments, and excessive uterine bleeding occurred as the most common complications after abortion with carboprost. ",carboprost tromethamine
sign_symptom,allergic sensitization,0.9999068," allergic sensitization has been reported following oral administration of folic acid. oral iron preparation may cause constipation, particularly in older patients. ",carbonyl iron + folic acid + zinc sulfate + vitamin b complex + vitamin c
sign_symptom,irritation,0.9996263," gastrointestinal irritations such as nausea, anorexia, vomiting, discomfort, constipation and diarrhoea may occur. patients may complain of dark stool. carbonyl iron pellets incorporated into the capsules to reduce the possibility of gastrointestinal irritations. rarely there may be allergic reactions. ",carbonyl iron + folic acid + zinc sulfate
sign_symptom,vomiting,0.9275983," gastrointestinal irritations such as nausea, anorexia, vomiting, discomfort, constipation and diarrhoea may occur. patients may complain of dark stool. carbonyl iron pellets incorporated into the capsules to reduce the possibility of gastrointestinal irritations. rarely there may be allergic reactions. ",carbonyl iron + folic acid + zinc sulfate
sign_symptom,discomfort,0.9891361," gastrointestinal irritations such as nausea, anorexia, vomiting, discomfort, constipation and diarrhoea may occur. patients may complain of dark stool. carbonyl iron pellets incorporated into the capsules to reduce the possibility of gastrointestinal irritations. rarely there may be allergic reactions. ",carbonyl iron + folic acid + zinc sulfate
sign_symptom,constipation,0.899935," gastrointestinal irritations such as nausea, anorexia, vomiting, discomfort, constipation and diarrhoea may occur. patients may complain of dark stool. carbonyl iron pellets incorporated into the capsules to reduce the possibility of gastrointestinal irritations. rarely there may be allergic reactions. ",carbonyl iron + folic acid + zinc sulfate
sign_symptom,diarr,0.96195734," gastrointestinal irritations such as nausea, anorexia, vomiting, discomfort, constipation and diarrhoea may occur. patients may complain of dark stool. carbonyl iron pellets incorporated into the capsules to reduce the possibility of gastrointestinal irritations. rarely there may be allergic reactions. ",carbonyl iron + folic acid + zinc sulfate
sign_symptom,- effects,0.98939025," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,effects,0.8998173," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,side - effects,0.9171977," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,consti,0.9972886," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,diarrhea,0.98039824," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,cramps,0.98241127," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,upset,0.9998118," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,allergic reactions,0.99987656," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,nausea,0.9999324," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,flatulence,0.9990144," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,bitter,0.99791855," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,bad taste,0.9971742," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,altered sleep patterns,0.9615688," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,irritability,0.98653334," the following is a list of possible side-effects that may occur from all constituting ingredients of this capsule. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 constipation 
 diarrhea 
 stomach cramps 
 upset stomach 
 allergic reactions 
 anorexia 
 nausea 
 abdominal distention 
 flatulence 
 bitter or bad taste 
 altered sleep patterns 
 difficulty in concentrating 
 irritability 
  ",carbonyl iron + folic acid
sign_symptom,rash,0.9580473," gastrointestinal discomfort, nausea, diarrhoea, gastrointestinal bleeding, palpitation, dizziness, headache, heartburn and skin rash may occur. ",carbocisteine
sign_symptom,arthral,0.9866173," nausea, headache, arthralgia, fever, jaundice, malaise, mild gastric distress, skin rashes, pruritus, taste disturbance; bone marrow depression including neutropenia, eosinophilia, leucopenia. rarely, pancytopenia/aplastic anaemia and isolated thrombocytopenia, haemolytic anaemia. ",carbimazole
sign_symptom,mala,0.9996183," nausea, headache, arthralgia, fever, jaundice, malaise, mild gastric distress, skin rashes, pruritus, taste disturbance; bone marrow depression including neutropenia, eosinophilia, leucopenia. rarely, pancytopenia/aplastic anaemia and isolated thrombocytopenia, haemolytic anaemia. ",carbimazole
sign_symptom,rash,0.9298116," nausea, headache, arthralgia, fever, jaundice, malaise, mild gastric distress, skin rashes, pruritus, taste disturbance; bone marrow depression including neutropenia, eosinophilia, leucopenia. rarely, pancytopenia/aplastic anaemia and isolated thrombocytopenia, haemolytic anaemia. ",carbimazole
sign_symptom,taste,0.80725694," nausea, headache, arthralgia, fever, jaundice, malaise, mild gastric distress, skin rashes, pruritus, taste disturbance; bone marrow depression including neutropenia, eosinophilia, leucopenia. rarely, pancytopenia/aplastic anaemia and isolated thrombocytopenia, haemolytic anaemia. ",carbimazole
sign_symptom,depression,0.92278767," nausea, headache, arthralgia, fever, jaundice, malaise, mild gastric distress, skin rashes, pruritus, taste disturbance; bone marrow depression including neutropenia, eosinophilia, leucopenia. rarely, pancytopenia/aplastic anaemia and isolated thrombocytopenia, haemolytic anaemia. ",carbimazole
sign_symptom,trembling,0.9248062," 10-40% of patients experienced nausea, vomiting, abdominal pain, itching skin, increased body temperature, trembling and weakness. infrequent adverse events (1-5% of patients) included back pain, dizziness, metallic taste, anaemia, sweating, chest pain, dyspnoea, chills, tachycardia and anxiety. ",carbetocin
sign_symptom,adverse events,0.99927276," 10-40% of patients experienced nausea, vomiting, abdominal pain, itching skin, increased body temperature, trembling and weakness. infrequent adverse events (1-5% of patients) included back pain, dizziness, metallic taste, anaemia, sweating, chest pain, dyspnoea, chills, tachycardia and anxiety. ",carbetocin
sign_symptom,pain,0.9211598," 10-40% of patients experienced nausea, vomiting, abdominal pain, itching skin, increased body temperature, trembling and weakness. infrequent adverse events (1-5% of patients) included back pain, dizziness, metallic taste, anaemia, sweating, chest pain, dyspnoea, chills, tachycardia and anxiety. ",carbetocin
sign_symptom,taste,0.83132017," 10-40% of patients experienced nausea, vomiting, abdominal pain, itching skin, increased body temperature, trembling and weakness. infrequent adverse events (1-5% of patients) included back pain, dizziness, metallic taste, anaemia, sweating, chest pain, dyspnoea, chills, tachycardia and anxiety. ",carbetocin
sign_symptom,adverse reactions,0.9963669," the common side effects are dizziness, drowsiness, ataxia, dry mouth, abdominal pain, nausea, vomiting, anorexia, leucopenia, proteinuria, bradycardia, heart failure and hypotension. erythematous skin rash, aplastic anemia may also be observed.   the most severe adverse reactions have been observed in the hemopoietic system, the skin and the cardiovascular system.the most frequently observed adverse reactions, particularly during the initial phases of therapy, are dizziness, drowsiness, unsteadiness, nausea, and vomiting. this medicine may cause increased sensitivity to the sun. exposure to the sun, sunlamps, or tanning booths should be avoided if the increased sensitivity is seen. a sunscreen or protective clothing may be helpful at outside for a prolonged period. ",carbamazepine
sign_symptom,adverse,0.9984263," the common side effects are dizziness, drowsiness, ataxia, dry mouth, abdominal pain, nausea, vomiting, anorexia, leucopenia, proteinuria, bradycardia, heart failure and hypotension. erythematous skin rash, aplastic anemia may also be observed.   the most severe adverse reactions have been observed in the hemopoietic system, the skin and the cardiovascular system.the most frequently observed adverse reactions, particularly during the initial phases of therapy, are dizziness, drowsiness, unsteadiness, nausea, and vomiting. this medicine may cause increased sensitivity to the sun. exposure to the sun, sunlamps, or tanning booths should be avoided if the increased sensitivity is seen. a sunscreen or protective clothing may be helpful at outside for a prolonged period. ",carbamazepine
sign_symptom,anaemia,0.938199," neutropenia, anaemia and thrombocytopenia; proteinuria, elevated blood urea and creatinine, elevated serum potassium and acidosis;hypotension, tachycardia;rashes usually pruritic, may occur;reversible and usually self limiting taste impairment has been reported. stomatitis resembling aphthous ulcers has also been reported. ",captopril
sign_symptom,proteinuria,0.7224103," neutropenia, anaemia and thrombocytopenia; proteinuria, elevated blood urea and creatinine, elevated serum potassium and acidosis;hypotension, tachycardia;rashes usually pruritic, may occur;reversible and usually self limiting taste impairment has been reported. stomatitis resembling aphthous ulcers has also been reported. ",captopril
sign_symptom,rash,0.99995196," neutropenia, anaemia and thrombocytopenia; proteinuria, elevated blood urea and creatinine, elevated serum potassium and acidosis;hypotension, tachycardia;rashes usually pruritic, may occur;reversible and usually self limiting taste impairment has been reported. stomatitis resembling aphthous ulcers has also been reported. ",captopril
sign_symptom,taste impairment,0.96930546," neutropenia, anaemia and thrombocytopenia; proteinuria, elevated blood urea and creatinine, elevated serum potassium and acidosis;hypotension, tachycardia;rashes usually pruritic, may occur;reversible and usually self limiting taste impairment has been reported. stomatitis resembling aphthous ulcers has also been reported. ",captopril
disease_disorder,ulcers,0.7114691," neutropenia, anaemia and thrombocytopenia; proteinuria, elevated blood urea and creatinine, elevated serum potassium and acidosis;hypotension, tachycardia;rashes usually pruritic, may occur;reversible and usually self limiting taste impairment has been reported. stomatitis resembling aphthous ulcers has also been reported. ",captopril
sign_symptom,burning,0.7834601, capsaicin may cause transient burning on application. this burning is observed more frequently when the application schedules are more than 3-4 times daily. the burning can be enhanced if too much cream is used and if it is applied just before or after a bath or shower. ,capsaicin
sign_symptom,tired,0.99987686," abdominal pain, rash, dry or itchy skin, tiredness, loss of appetite (anorexia), diarrhea, vomiting, nausea, stomatitis, hand-and-foot skin-reaction, fever, infection, chest pain, steven-johnson syndrome ",capecitabine
sign_symptom,loss of appetite,0.99990416," abdominal pain, rash, dry or itchy skin, tiredness, loss of appetite (anorexia), diarrhea, vomiting, nausea, stomatitis, hand-and-foot skin-reaction, fever, infection, chest pain, steven-johnson syndrome ",capecitabine
disease_disorder,- johnson syndrome,0.79655915," abdominal pain, rash, dry or itchy skin, tiredness, loss of appetite (anorexia), diarrhea, vomiting, nausea, stomatitis, hand-and-foot skin-reaction, fever, infection, chest pain, steven-johnson syndrome ",capecitabine
sign_symptom,adverse events,0.99985623," mild and transient in nature. the overall incidence of adverse events is comparable to placebo. side effects are headache, upper respiratory tract infection, back pain, influenza-like symptoms. ",candesartan cilexetil + hydrochlorothiazide
disease_disorder,intravas,0.72074896," side-effects are usually mild. symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion (e.g. those taking high dose diuretics). hyperkalemia occurs occassionally; angioedema has also been reported with some angiotension ii receptor antagonist. also vertigo, headache; rarely hepatitis, blood disorders, hyponatraemia, back pain, arthralgia, myalgia, rash, urticaria, pruritous. ",candesartan cilexetil
disease_disorder,volume depletion,0.9805452," side-effects are usually mild. symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion (e.g. those taking high dose diuretics). hyperkalemia occurs occassionally; angioedema has also been reported with some angiotension ii receptor antagonist. also vertigo, headache; rarely hepatitis, blood disorders, hyponatraemia, back pain, arthralgia, myalgia, rash, urticaria, pruritous. ",candesartan cilexetil
sign_symptom,hyper,0.9999707," side-effects are usually mild. symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion (e.g. those taking high dose diuretics). hyperkalemia occurs occassionally; angioedema has also been reported with some angiotension ii receptor antagonist. also vertigo, headache; rarely hepatitis, blood disorders, hyponatraemia, back pain, arthralgia, myalgia, rash, urticaria, pruritous. ",candesartan cilexetil
sign_symptom,angio,0.90140975," side-effects are usually mild. symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion (e.g. those taking high dose diuretics). hyperkalemia occurs occassionally; angioedema has also been reported with some angiotension ii receptor antagonist. also vertigo, headache; rarely hepatitis, blood disorders, hyponatraemia, back pain, arthralgia, myalgia, rash, urticaria, pruritous. ",candesartan cilexetil
medication,angiot,0.7574523," side-effects are usually mild. symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion (e.g. those taking high dose diuretics). hyperkalemia occurs occassionally; angioedema has also been reported with some angiotension ii receptor antagonist. also vertigo, headache; rarely hepatitis, blood disorders, hyponatraemia, back pain, arthralgia, myalgia, rash, urticaria, pruritous. ",candesartan cilexetil
sign_symptom,irritation,0.99985933," redness, irritation, rash or pruritis may occur with sensitive skin. ",camphor + menthol + oil clove + oil eucalyptus + oil turpentine
sign_symptom,rash,0.99989915," redness, irritation, rash or pruritis may occur with sensitive skin. ",camphor + menthol + oil clove + oil eucalyptus + oil turpentine
sign_symptom,constipation,0.9500106," nausea, vomiting, gastric irritation, anorexia, constipation and occasionally diarrhea, fecal impaction, gastrointestinal stenosis and intestinal obstruction, gastrointestinal ischemia, ischemic colitis, rectal haemorrhage, gastrointestinal tract ulceration or necrosis, hypomagnesemia, hypercalcemia etc. some cases of acute bronchitis and bronchopneumonia have been reported. ",calcium polystyrene sulfonate
disease_disorder,ischemic,0.9901666," nausea, vomiting, gastric irritation, anorexia, constipation and occasionally diarrhea, fecal impaction, gastrointestinal stenosis and intestinal obstruction, gastrointestinal ischemia, ischemic colitis, rectal haemorrhage, gastrointestinal tract ulceration or necrosis, hypomagnesemia, hypercalcemia etc. some cases of acute bronchitis and bronchopneumonia have been reported. ",calcium polystyrene sulfonate
disease_disorder,colitis,0.74486494," nausea, vomiting, gastric irritation, anorexia, constipation and occasionally diarrhea, fecal impaction, gastrointestinal stenosis and intestinal obstruction, gastrointestinal ischemia, ischemic colitis, rectal haemorrhage, gastrointestinal tract ulceration or necrosis, hypomagnesemia, hypercalcemia etc. some cases of acute bronchitis and bronchopneumonia have been reported. ",calcium polystyrene sulfonate
sign_symptom,hyper,0.9999434," nausea, vomiting, gastric irritation, anorexia, constipation and occasionally diarrhea, fecal impaction, gastrointestinal stenosis and intestinal obstruction, gastrointestinal ischemia, ischemic colitis, rectal haemorrhage, gastrointestinal tract ulceration or necrosis, hypomagnesemia, hypercalcemia etc. some cases of acute bronchitis and bronchopneumonia have been reported. ",calcium polystyrene sulfonate
disease_disorder,bronchopneumonia,0.92420405," nausea, vomiting, gastric irritation, anorexia, constipation and occasionally diarrhea, fecal impaction, gastrointestinal stenosis and intestinal obstruction, gastrointestinal ischemia, ischemic colitis, rectal haemorrhage, gastrointestinal tract ulceration or necrosis, hypomagnesemia, hypercalcemia etc. some cases of acute bronchitis and bronchopneumonia have been reported. ",calcium polystyrene sulfonate
sign_symptom,bradicardia,0.9128414," mild gastrointestinal disturbances, bradicardia, arrythmia and irritation after iv injection ",calcium pantothenate
sign_symptom,arrythmia,0.9923123," mild gastrointestinal disturbances, bradicardia, arrythmia and irritation after iv injection ",calcium pantothenate
sign_symptom,irritation,0.9999461," mild gastrointestinal disturbances, bradicardia, arrythmia and irritation after iv injection ",calcium pantothenate
sign_symptom,nausea,0.9999292," this preparation is usually well tolerated. nausea occurs rarely. vomiting, flushing and sweating have been observed during infusion of amino acid at rates exceeding the recommended maximal rate. transient increases liver test during intravenous nutrition have been reported. the reasons are at present unclear. hypersensitivity reactions have been reported. as with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used. the incidence may be reduced by the simultaneous infusion of 10% fat emulsion. if given to severely ill, premature infants, hyperphenylalaninemia may occur. ",amino acid + d-sorbitol + electrolytes
sign_symptom,flushing,0.99994886," this preparation is usually well tolerated. nausea occurs rarely. vomiting, flushing and sweating have been observed during infusion of amino acid at rates exceeding the recommended maximal rate. transient increases liver test during intravenous nutrition have been reported. the reasons are at present unclear. hypersensitivity reactions have been reported. as with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used. the incidence may be reduced by the simultaneous infusion of 10% fat emulsion. if given to severely ill, premature infants, hyperphenylalaninemia may occur. ",amino acid + d-sorbitol + electrolytes
sign_symptom,sweating,0.9999236," this preparation is usually well tolerated. nausea occurs rarely. vomiting, flushing and sweating have been observed during infusion of amino acid at rates exceeding the recommended maximal rate. transient increases liver test during intravenous nutrition have been reported. the reasons are at present unclear. hypersensitivity reactions have been reported. as with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used. the incidence may be reduced by the simultaneous infusion of 10% fat emulsion. if given to severely ill, premature infants, hyperphenylalaninemia may occur. ",amino acid + d-sorbitol + electrolytes
medication,amino acid,0.9941323," this preparation is usually well tolerated. nausea occurs rarely. vomiting, flushing and sweating have been observed during infusion of amino acid at rates exceeding the recommended maximal rate. transient increases liver test during intravenous nutrition have been reported. the reasons are at present unclear. hypersensitivity reactions have been reported. as with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used. the incidence may be reduced by the simultaneous infusion of 10% fat emulsion. if given to severely ill, premature infants, hyperphenylalaninemia may occur. ",amino acid + d-sorbitol + electrolytes
sign_symptom,hypersensitivity reactions,0.98114175," this preparation is usually well tolerated. nausea occurs rarely. vomiting, flushing and sweating have been observed during infusion of amino acid at rates exceeding the recommended maximal rate. transient increases liver test during intravenous nutrition have been reported. the reasons are at present unclear. hypersensitivity reactions have been reported. as with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used. the incidence may be reduced by the simultaneous infusion of 10% fat emulsion. if given to severely ill, premature infants, hyperphenylalaninemia may occur. ",amino acid + d-sorbitol + electrolytes
disease_disorder,hyper,0.9981652," this preparation is usually well tolerated. nausea occurs rarely. vomiting, flushing and sweating have been observed during infusion of amino acid at rates exceeding the recommended maximal rate. transient increases liver test during intravenous nutrition have been reported. the reasons are at present unclear. hypersensitivity reactions have been reported. as with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used. the incidence may be reduced by the simultaneous infusion of 10% fat emulsion. if given to severely ill, premature infants, hyperphenylalaninemia may occur. ",amino acid + d-sorbitol + electrolytes
sign_symptom,of appetite,0.7591765," devil's claw is possibly safe for most adults when taken by mouth in appropriate doses for up to a year. the most common side effect is diarrhea. about 8% of the people participating in one research study developed diarrhea. other possible side effects include nausea, vomiting, abdominal pain, headaches, ringing in the ears, loss of appetite, and loss of taste. it can also cause allergic skin reactions, menstrual problems, and changes in blood pressure. however, not enough is known about the safety of using devil's claw long-term or applying it to the skin. ",devil's claw
sign_symptom,headache,0.9859262," common side effects are nasopharyngitis, headache and upper respiratory tract infection. ",alogliptin benzoate
medication,malate,0.88505816," serious cardiac reactions, including myocardial infarction, have occurred following the use of almotriptan malate tablets. these reactions are extremely rare and most have been reported in patients with risk factors predictive of cad (coronary artery disease). ",almotriptan
sign_symptom,burning,0.9749619," weight loss, nausea, sensations of heaviness or burning in the stomach, gastrointestinal disorders, diarrhoea or constipation, insomnia, drowsiness, agitation, anxiety, dizziness, palpitations. ",almitrine bismesylate + raubasine
sign_symptom,diarrhoea,0.9762877," weight loss, nausea, sensations of heaviness or burning in the stomach, gastrointestinal disorders, diarrhoea or constipation, insomnia, drowsiness, agitation, anxiety, dizziness, palpitations. ",almitrine bismesylate + raubasine
medication,allyles,0.9477023," treatment with allylestrenol (especially a long term treatment) is known to cause some gastrointestinal complaints such as vomiting, nausea, and sometimes epigastric discomfort. ",allylestrenol
sign_symptom,adverse reactions,0.7418786," the adverse reactions to cefprozil are similar to those observed with other orally administered cephalosporins. cefprozil was usually well tolerated in controlled clinical trials. the most common adverse effects of cefprozil are diarrhea, nausea, vomiting, abdominal pain, rash, urticaria, dizziness, hyperactivity, insomnia, confusion etc. ",cefprozil
sign_symptom,hyper,0.8423271," the adverse reactions to cefprozil are similar to those observed with other orally administered cephalosporins. cefprozil was usually well tolerated in controlled clinical trials. the most common adverse effects of cefprozil are diarrhea, nausea, vomiting, abdominal pain, rash, urticaria, dizziness, hyperactivity, insomnia, confusion etc. ",cefprozil
sign_symptom,confusion,0.99851114," the adverse reactions to cefprozil are similar to those observed with other orally administered cephalosporins. cefprozil was usually well tolerated in controlled clinical trials. the most common adverse effects of cefprozil are diarrhea, nausea, vomiting, abdominal pain, rash, urticaria, dizziness, hyperactivity, insomnia, confusion etc. ",cefprozil
medication,cefpodoxime,0.9145338," cefpodoxime is well tolerated. most common gastrointestinal adverse effects are diarrhea, vomiting and abdominal pain. ",cefpodoxime proxetil + clavulanic acid
sign_symptom,vomiting,0.99841666," cefpodoxime is well tolerated. most common gastrointestinal adverse effects are diarrhea, vomiting and abdominal pain. ",cefpodoxime proxetil + clavulanic acid
sign_symptom,adverse,0.86362386," cefpirome is generally well tolerated. there are no predictable life threatening effects of cefpirome. adverse gastrointestinal reactions include diarrhea, nausea, vomiting, pseudomembraneous colitis, abdominal pain and have been noted 3.86% of the patients. superficial phlebitis, thrombophlebitis and infection site reaction have been reported in 2.31% of patients receiving intravenous cefpirome. ",cefpirome sulphate
sign_symptom,pain,0.99995434," cefpirome is generally well tolerated. there are no predictable life threatening effects of cefpirome. adverse gastrointestinal reactions include diarrhea, nausea, vomiting, pseudomembraneous colitis, abdominal pain and have been noted 3.86% of the patients. superficial phlebitis, thrombophlebitis and infection site reaction have been reported in 2.31% of patients receiving intravenous cefpirome. ",cefpirome sulphate
sign_symptom,infection,0.996062," cefpirome is generally well tolerated. there are no predictable life threatening effects of cefpirome. adverse gastrointestinal reactions include diarrhea, nausea, vomiting, pseudomembraneous colitis, abdominal pain and have been noted 3.86% of the patients. superficial phlebitis, thrombophlebitis and infection site reaction have been reported in 2.31% of patients receiving intravenous cefpirome. ",cefpirome sulphate
sign_symptom,reaction,0.93740547," cefpirome is generally well tolerated. there are no predictable life threatening effects of cefpirome. adverse gastrointestinal reactions include diarrhea, nausea, vomiting, pseudomembraneous colitis, abdominal pain and have been noted 3.86% of the patients. superficial phlebitis, thrombophlebitis and infection site reaction have been reported in 2.31% of patients receiving intravenous cefpirome. ",cefpirome sulphate
sign_symptom,hyper,0.9999521," hypersensitivity reactions (e.g. maculopapular or erythematous rash, exfoliative dermatitis, pruritus, urticaria, eosinophilia, fever, angioedema); elevated serum creatinine and/or bun concentrations, anaemia; transient increase in serum ast (sgot), alt (sgpt), ldh and alkaline phosphatase levels; jaundice; thrombophlebitis. rarely, oliguria, renal toxicity, neutropenia, transient leucopenia, granulocytopenia, thrombocytopenia, bone marrow depression; gi effects (e.g. nausea, vomiting, diarrhoea). ",cefoxitin
sign_symptom,adverse reactions,0.8729937," adverse reactions to cefotaxime have occurred relatively infrequently and have generally been mild and transient. effects reported include candidiasis, rashes, fever, transient rises in liver transaminase and/or alkaline phosphatase and diarrhoea. as with all cephalosporins, pseudomembranous colitis may rarely occur during treatment. if this occurs the drug should be stopped and specific treatment instituted.as with other cephalosporins, changes in renal function have been rarely observed with high doses of cefotaxime. administration of high doses of cephalosporins particularly in patients with renal insufficiency may result in encephalopathy. hypersensitivity reactions have been reported, these include skin rashes, drug fever and very rarely anaphylaxis. ",cefotaxime
medication,cefotaxime,0.79746026," adverse reactions to cefotaxime have occurred relatively infrequently and have generally been mild and transient. effects reported include candidiasis, rashes, fever, transient rises in liver transaminase and/or alkaline phosphatase and diarrhoea. as with all cephalosporins, pseudomembranous colitis may rarely occur during treatment. if this occurs the drug should be stopped and specific treatment instituted.as with other cephalosporins, changes in renal function have been rarely observed with high doses of cefotaxime. administration of high doses of cephalosporins particularly in patients with renal insufficiency may result in encephalopathy. hypersensitivity reactions have been reported, these include skin rashes, drug fever and very rarely anaphylaxis. ",cefotaxime
sign_symptom,candidia,0.9830462," adverse reactions to cefotaxime have occurred relatively infrequently and have generally been mild and transient. effects reported include candidiasis, rashes, fever, transient rises in liver transaminase and/or alkaline phosphatase and diarrhoea. as with all cephalosporins, pseudomembranous colitis may rarely occur during treatment. if this occurs the drug should be stopped and specific treatment instituted.as with other cephalosporins, changes in renal function have been rarely observed with high doses of cefotaxime. administration of high doses of cephalosporins particularly in patients with renal insufficiency may result in encephalopathy. hypersensitivity reactions have been reported, these include skin rashes, drug fever and very rarely anaphylaxis. ",cefotaxime
sign_symptom,rash,0.99123424," adverse reactions to cefotaxime have occurred relatively infrequently and have generally been mild and transient. effects reported include candidiasis, rashes, fever, transient rises in liver transaminase and/or alkaline phosphatase and diarrhoea. as with all cephalosporins, pseudomembranous colitis may rarely occur during treatment. if this occurs the drug should be stopped and specific treatment instituted.as with other cephalosporins, changes in renal function have been rarely observed with high doses of cefotaxime. administration of high doses of cephalosporins particularly in patients with renal insufficiency may result in encephalopathy. hypersensitivity reactions have been reported, these include skin rashes, drug fever and very rarely anaphylaxis. ",cefotaxime
disease_disorder,pseudo,0.9652596," adverse reactions to cefotaxime have occurred relatively infrequently and have generally been mild and transient. effects reported include candidiasis, rashes, fever, transient rises in liver transaminase and/or alkaline phosphatase and diarrhoea. as with all cephalosporins, pseudomembranous colitis may rarely occur during treatment. if this occurs the drug should be stopped and specific treatment instituted.as with other cephalosporins, changes in renal function have been rarely observed with high doses of cefotaxime. administration of high doses of cephalosporins particularly in patients with renal insufficiency may result in encephalopathy. hypersensitivity reactions have been reported, these include skin rashes, drug fever and very rarely anaphylaxis. ",cefotaxime
disease_disorder,colitis,0.729969," adverse reactions to cefotaxime have occurred relatively infrequently and have generally been mild and transient. effects reported include candidiasis, rashes, fever, transient rises in liver transaminase and/or alkaline phosphatase and diarrhoea. as with all cephalosporins, pseudomembranous colitis may rarely occur during treatment. if this occurs the drug should be stopped and specific treatment instituted.as with other cephalosporins, changes in renal function have been rarely observed with high doses of cefotaxime. administration of high doses of cephalosporins particularly in patients with renal insufficiency may result in encephalopathy. hypersensitivity reactions have been reported, these include skin rashes, drug fever and very rarely anaphylaxis. ",cefotaxime
medication,cefo,0.8194647," adverse reactions to cefotaxime have occurred relatively infrequently and have generally been mild and transient. effects reported include candidiasis, rashes, fever, transient rises in liver transaminase and/or alkaline phosphatase and diarrhoea. as with all cephalosporins, pseudomembranous colitis may rarely occur during treatment. if this occurs the drug should be stopped and specific treatment instituted.as with other cephalosporins, changes in renal function have been rarely observed with high doses of cefotaxime. administration of high doses of cephalosporins particularly in patients with renal insufficiency may result in encephalopathy. hypersensitivity reactions have been reported, these include skin rashes, drug fever and very rarely anaphylaxis. ",cefotaxime
disease_disorder,renal,0.993167," adverse reactions to cefotaxime have occurred relatively infrequently and have generally been mild and transient. effects reported include candidiasis, rashes, fever, transient rises in liver transaminase and/or alkaline phosphatase and diarrhoea. as with all cephalosporins, pseudomembranous colitis may rarely occur during treatment. if this occurs the drug should be stopped and specific treatment instituted.as with other cephalosporins, changes in renal function have been rarely observed with high doses of cefotaxime. administration of high doses of cephalosporins particularly in patients with renal insufficiency may result in encephalopathy. hypersensitivity reactions have been reported, these include skin rashes, drug fever and very rarely anaphylaxis. ",cefotaxime
sign_symptom,hypersensitivity reactions,0.99818325," adverse reactions to cefotaxime have occurred relatively infrequently and have generally been mild and transient. effects reported include candidiasis, rashes, fever, transient rises in liver transaminase and/or alkaline phosphatase and diarrhoea. as with all cephalosporins, pseudomembranous colitis may rarely occur during treatment. if this occurs the drug should be stopped and specific treatment instituted.as with other cephalosporins, changes in renal function have been rarely observed with high doses of cefotaxime. administration of high doses of cephalosporins particularly in patients with renal insufficiency may result in encephalopathy. hypersensitivity reactions have been reported, these include skin rashes, drug fever and very rarely anaphylaxis. ",cefotaxime
sign_symptom,hyper,0.99644715," hypersensitivity: as with all cephalosporins, hypersensitivity manifested by skin reactions (1 patient in 45), drug fever (1 in 260), or a change in coombs test (1 in 60) has been reported. these reactions are more likely to occur in patients with a history of allergies, particularly to penicillin. ",cefoperazone sodium
sign_symptom,hypersensitivity,0.99892944," hypersensitivity: as with all cephalosporins, hypersensitivity manifested by skin reactions (1 patient in 45), drug fever (1 in 260), or a change in coombs test (1 in 60) has been reported. these reactions are more likely to occur in patients with a history of allergies, particularly to penicillin. ",cefoperazone sodium
sign_symptom,skin reactions,0.9961889," hypersensitivity: as with all cephalosporins, hypersensitivity manifested by skin reactions (1 patient in 45), drug fever (1 in 260), or a change in coombs test (1 in 60) has been reported. these reactions are more likely to occur in patients with a history of allergies, particularly to penicillin. ",cefoperazone sodium
sign_symptom,dyspeps,0.95940673," the drug is generally well tolerated. the most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. these reactions usually subsided upon dicontinuation of therapy. ",cefixime trihydrate
sign_symptom,vomiting,0.7826607," the drug is generally well tolerated. the most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. these reactions usually subsided upon dicontinuation of therapy. ",cefixime trihydrate
sign_symptom,flat,0.9977574," the drug is generally well tolerated. the most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. these reactions usually subsided upon dicontinuation of therapy. ",cefixime trihydrate
sign_symptom,headache,0.9973808," the drug is generally well tolerated. the most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. these reactions usually subsided upon dicontinuation of therapy. ",cefixime trihydrate
sign_symptom,allergies,0.9865764," the drug is generally well tolerated. the most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. these reactions usually subsided upon dicontinuation of therapy. ",cefixime trihydrate
sign_symptom,fever,0.96652037," the drug is generally well tolerated. the most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. these reactions usually subsided upon dicontinuation of therapy. ",cefixime trihydrate
sign_symptom,arthralgia,0.996812," the drug is generally well tolerated. the most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. these reactions usually subsided upon dicontinuation of therapy. ",cefixime trihydrate
medication,cefepi,0.8885959," cefepime is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibiotics, penicillin, or other betalactum antibiotics. ",cefepime hydrochloride
sign_symptom,hypersensitivity reactions,0.99412596," cefepime is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibiotics, penicillin, or other betalactum antibiotics. ",cefepime hydrochloride
medication,cephalosporin,0.90854186," cefepime is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibiotics, penicillin, or other betalactum antibiotics. ",cefepime hydrochloride
sign_symptom,dyspeps,0.9634293," the most common side effects of cefditoren are diarrhea, nausea, headache, abdominal pain, vaginal moniliasis, dyspepsia, vomiting, abnormal dreams, allergic reaction, anorexia, constipation, dizziness, dry mouth and fever. ",cefditoren
sign_symptom,nausea,0.9999553," common side effects are diarrhea, vaginal moniliasis, nausea &amp; vomiting, headache, rash etc. ",cefdinir
sign_symptom,vomiting,0.96829045," common side effects are diarrhea, vaginal moniliasis, nausea &amp; vomiting, headache, rash etc. ",cefdinir
sign_symptom,headache,0.98945296," common side effects are diarrhea, vaginal moniliasis, nausea &amp; vomiting, headache, rash etc. ",cefdinir
sign_symptom,rash,0.9997893," common side effects are diarrhea, vaginal moniliasis, nausea &amp; vomiting, headache, rash etc. ",cefdinir
sign_symptom,of appetite,0.9210665," common side effects include:injection site reactions (pain, swelling, skin rash, or a hard lump), diarrhea, stomach pain, stomach cramps, nausea, vomiting, loss of appetite, skin rash or itching, hives, white patches or sores inside the mouth or on the lips, vaginal itching or discharge,heartburn, gas,rectal itching,confusion, weakness, hypotension, drowsiness, headache and allergic reactions. ",cefazolin sodium
sign_symptom,rash,0.7907056," common side effects include:injection site reactions (pain, swelling, skin rash, or a hard lump), diarrhea, stomach pain, stomach cramps, nausea, vomiting, loss of appetite, skin rash or itching, hives, white patches or sores inside the mouth or on the lips, vaginal itching or discharge,heartburn, gas,rectal itching,confusion, weakness, hypotension, drowsiness, headache and allergic reactions. ",cefazolin sodium
sign_symptom,sore,0.9931283," common side effects include:injection site reactions (pain, swelling, skin rash, or a hard lump), diarrhea, stomach pain, stomach cramps, nausea, vomiting, loss of appetite, skin rash or itching, hives, white patches or sores inside the mouth or on the lips, vaginal itching or discharge,heartburn, gas,rectal itching,confusion, weakness, hypotension, drowsiness, headache and allergic reactions. ",cefazolin sodium
sign_symptom,gastrointestinal disturbances,0.9972097," generally cefadroxil is well tolerated. however, the most commonly reported side effects are gastrointestinal disturbances and hypersensitivity phenomena. ",cefadroxil monohydrate
sign_symptom,hypersensitivity,0.99985623," generally cefadroxil is well tolerated. however, the most commonly reported side effects are gastrointestinal disturbances and hypersensitivity phenomena. ",cefadroxil monohydrate
sign_symptom,nausea,0.9999367,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,vomiting,0.9999305,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,hyper,0.9995327,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,allergic reactions,0.99992174,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,"eruptions,",0.9988655,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,pruritis,0.98625135,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,urticaria,0.9975465,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,reactions,0.9847979,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,serum sickness,0.8236793,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,leuc,0.991889,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,hepatitis,0.89641094,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,interstitial nephritis,0.9920602,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,nervousness,0.7639811,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,confusion,0.97223413,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,hypertonia,0.99034554,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,"dizziness,",0.9475425,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,hallucinations,0.8990011,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,somnolence,0.98838854,"  gastro-intestinal : diarrhoea, nausea and vomiting have been reported. hypersensitivity: allergic reactions such as eruptions, pruritis and urticaria have been observed. these reactions usually subside upon discontinuation of therapy. serum sickness like reactions have been reported.    haematological : eosinophilia, thrombocytopenia, transient lymphocytosis and leucopenia may occur rarely. hepatic: transient hepatitis and cholestatic jaundice, slight elevation in ast, alt or alkaline phosphate values have been reported rarely.    renal : reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.   central nervous system : reversible hyperactivity, nervousness, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely. ",cefaclor monohydrate
sign_symptom,oedema,0.82890826," postural hypotension, dizziness, headache, fatigue, gastro-intestinal disturbances, bradycardia; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms, rarely angina, av block, exacerbation of intermittent claudication or raynaud's phenomenon, allergic skin reactions, exacerbation of psoriasis, nasal stuffiness, wheezing, depressed mood, sleep disturbances, paresthesia, heart failure, changes in liver enzymes, thrombocytopenia, leukopenia are also reported. ",carvedilol
sign_symptom,painful ex,0.75236267," postural hypotension, dizziness, headache, fatigue, gastro-intestinal disturbances, bradycardia; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms, rarely angina, av block, exacerbation of intermittent claudication or raynaud's phenomenon, allergic skin reactions, exacerbation of psoriasis, nasal stuffiness, wheezing, depressed mood, sleep disturbances, paresthesia, heart failure, changes in liver enzymes, thrombocytopenia, leukopenia are also reported. ",carvedilol
sign_symptom,dry eyes,0.9198377," postural hypotension, dizziness, headache, fatigue, gastro-intestinal disturbances, bradycardia; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms, rarely angina, av block, exacerbation of intermittent claudication or raynaud's phenomenon, allergic skin reactions, exacerbation of psoriasis, nasal stuffiness, wheezing, depressed mood, sleep disturbances, paresthesia, heart failure, changes in liver enzymes, thrombocytopenia, leukopenia are also reported. ",carvedilol
sign_symptom,irritation,0.9960056," postural hypotension, dizziness, headache, fatigue, gastro-intestinal disturbances, bradycardia; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms, rarely angina, av block, exacerbation of intermittent claudication or raynaud's phenomenon, allergic skin reactions, exacerbation of psoriasis, nasal stuffiness, wheezing, depressed mood, sleep disturbances, paresthesia, heart failure, changes in liver enzymes, thrombocytopenia, leukopenia are also reported. ",carvedilol
sign_symptom,impote,0.9060258," postural hypotension, dizziness, headache, fatigue, gastro-intestinal disturbances, bradycardia; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms, rarely angina, av block, exacerbation of intermittent claudication or raynaud's phenomenon, allergic skin reactions, exacerbation of psoriasis, nasal stuffiness, wheezing, depressed mood, sleep disturbances, paresthesia, heart failure, changes in liver enzymes, thrombocytopenia, leukopenia are also reported. ",carvedilol
sign_symptom,claudication,0.78884476," postural hypotension, dizziness, headache, fatigue, gastro-intestinal disturbances, bradycardia; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms, rarely angina, av block, exacerbation of intermittent claudication or raynaud's phenomenon, allergic skin reactions, exacerbation of psoriasis, nasal stuffiness, wheezing, depressed mood, sleep disturbances, paresthesia, heart failure, changes in liver enzymes, thrombocytopenia, leukopenia are also reported. ",carvedilol
sign_symptom,allergic,0.7911663," postural hypotension, dizziness, headache, fatigue, gastro-intestinal disturbances, bradycardia; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms, rarely angina, av block, exacerbation of intermittent claudication or raynaud's phenomenon, allergic skin reactions, exacerbation of psoriasis, nasal stuffiness, wheezing, depressed mood, sleep disturbances, paresthesia, heart failure, changes in liver enzymes, thrombocytopenia, leukopenia are also reported. ",carvedilol
sign_symptom,depressed,0.99982065," postural hypotension, dizziness, headache, fatigue, gastro-intestinal disturbances, bradycardia; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms, rarely angina, av block, exacerbation of intermittent claudication or raynaud's phenomenon, allergic skin reactions, exacerbation of psoriasis, nasal stuffiness, wheezing, depressed mood, sleep disturbances, paresthesia, heart failure, changes in liver enzymes, thrombocytopenia, leukopenia are also reported. ",carvedilol
sign_symptom,changes in liver,0.8166661," postural hypotension, dizziness, headache, fatigue, gastro-intestinal disturbances, bradycardia; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms, rarely angina, av block, exacerbation of intermittent claudication or raynaud's phenomenon, allergic skin reactions, exacerbation of psoriasis, nasal stuffiness, wheezing, depressed mood, sleep disturbances, paresthesia, heart failure, changes in liver enzymes, thrombocytopenia, leukopenia are also reported. ",carvedilol
sign_symptom,irritation,0.95152724," common side effects are eye irritation (including burning and discomfort), eye pain, itchy eyes, visual disturbance. ",carmellose sodium
sign_symptom,matting,0.7037604," common side effects are blurred vision, matting or stickiness of eyelashes. ",carboxymethylcellulose sodium + hypromellose
sign_symptom,stickiness,0.94483495," common side effects are blurred vision, matting or stickiness of eyelashes. ",carboxymethylcellulose sodium + hypromellose
sign_symptom,burning,0.75584215," vision may be temporarily blurred when this product is first used. also, minor burning/ stinging/ irritation may temporarily occur. ",carboxymethylcellulose sodium + glycerin
sign_symptom,stinging,0.9990509," vision may be temporarily blurred when this product is first used. also, minor burning/ stinging/ irritation may temporarily occur. ",carboxymethylcellulose sodium + glycerin
sign_symptom,irritation,0.99990547," vision may be temporarily blurred when this product is first used. also, minor burning/ stinging/ irritation may temporarily occur. ",carboxymethylcellulose sodium + glycerin
sign_symptom,side effect,0.9061742, a balanced formulation of bitter melon is well tolerated. no significant side effect has been observed in proper dosage. ,bitter melon [korola]
sign_symptom,toxicity,0.9201238, well tolerated in the recommended dose. no biotin toxicity has been reported in individuals supplemented with as much as 200 mg orally or 20mg intravenously per day. ,biotin
sign_symptom,shortness of breath,0.9992766,"  cardiovascular : facial flushing, headache, sweating, palpitations, chest pain, hypotension. respiratory: shortness of breath/dyspnea, chest pressure, hyperventilation, head pressure.    central nervous system : lightheadedness, dizziness, tingling in arms, numbness, apprehension, blurred vision, burning sensation, heaviness in arms, neck and back pain.    gastrointestinal : nausea, metallic taste, tightness in throat, pressure in groin. in post-market clinical experience with adenosine, cases of prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood pressure, bradycardia, hypotension, atrial fibrillation and bronchospasm, in association with adenosine use, have been reported. ",adenosine
sign_symptom,dysp,0.9047368,"  cardiovascular : facial flushing, headache, sweating, palpitations, chest pain, hypotension. respiratory: shortness of breath/dyspnea, chest pressure, hyperventilation, head pressure.    central nervous system : lightheadedness, dizziness, tingling in arms, numbness, apprehension, blurred vision, burning sensation, heaviness in arms, neck and back pain.    gastrointestinal : nausea, metallic taste, tightness in throat, pressure in groin. in post-market clinical experience with adenosine, cases of prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood pressure, bradycardia, hypotension, atrial fibrillation and bronchospasm, in association with adenosine use, have been reported. ",adenosine
sign_symptom,light,0.9980075,"  cardiovascular : facial flushing, headache, sweating, palpitations, chest pain, hypotension. respiratory: shortness of breath/dyspnea, chest pressure, hyperventilation, head pressure.    central nervous system : lightheadedness, dizziness, tingling in arms, numbness, apprehension, blurred vision, burning sensation, heaviness in arms, neck and back pain.    gastrointestinal : nausea, metallic taste, tightness in throat, pressure in groin. in post-market clinical experience with adenosine, cases of prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood pressure, bradycardia, hypotension, atrial fibrillation and bronchospasm, in association with adenosine use, have been reported. ",adenosine
sign_symptom,tingling,0.9995371,"  cardiovascular : facial flushing, headache, sweating, palpitations, chest pain, hypotension. respiratory: shortness of breath/dyspnea, chest pressure, hyperventilation, head pressure.    central nervous system : lightheadedness, dizziness, tingling in arms, numbness, apprehension, blurred vision, burning sensation, heaviness in arms, neck and back pain.    gastrointestinal : nausea, metallic taste, tightness in throat, pressure in groin. in post-market clinical experience with adenosine, cases of prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood pressure, bradycardia, hypotension, atrial fibrillation and bronchospasm, in association with adenosine use, have been reported. ",adenosine
sign_symptom,tightness,0.9760046,"  cardiovascular : facial flushing, headache, sweating, palpitations, chest pain, hypotension. respiratory: shortness of breath/dyspnea, chest pressure, hyperventilation, head pressure.    central nervous system : lightheadedness, dizziness, tingling in arms, numbness, apprehension, blurred vision, burning sensation, heaviness in arms, neck and back pain.    gastrointestinal : nausea, metallic taste, tightness in throat, pressure in groin. in post-market clinical experience with adenosine, cases of prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood pressure, bradycardia, hypotension, atrial fibrillation and bronchospasm, in association with adenosine use, have been reported. ",adenosine
sign_symptom,pressure,0.99982315,"  cardiovascular : facial flushing, headache, sweating, palpitations, chest pain, hypotension. respiratory: shortness of breath/dyspnea, chest pressure, hyperventilation, head pressure.    central nervous system : lightheadedness, dizziness, tingling in arms, numbness, apprehension, blurred vision, burning sensation, heaviness in arms, neck and back pain.    gastrointestinal : nausea, metallic taste, tightness in throat, pressure in groin. in post-market clinical experience with adenosine, cases of prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood pressure, bradycardia, hypotension, atrial fibrillation and bronchospasm, in association with adenosine use, have been reported. ",adenosine
medication,dipivoxil,0.94227034," the most common side effects of adefovir dipivoxil are weakness, headache, stomach pain and nausea. severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-hepatitis b therapy, including therapy with adefovir dipivoxil. in patients at risk of or having underlying renal dysfunction, chronic administration of adefovir dipivoxil may result in nephrotoxicity. lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals. ",adefovir dipivoxil
sign_symptom,headache,0.8389061," the most common side effects of adefovir dipivoxil are weakness, headache, stomach pain and nausea. severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-hepatitis b therapy, including therapy with adefovir dipivoxil. in patients at risk of or having underlying renal dysfunction, chronic administration of adefovir dipivoxil may result in nephrotoxicity. lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals. ",adefovir dipivoxil
sign_symptom,pain,0.9999057," the most common side effects of adefovir dipivoxil are weakness, headache, stomach pain and nausea. severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-hepatitis b therapy, including therapy with adefovir dipivoxil. in patients at risk of or having underlying renal dysfunction, chronic administration of adefovir dipivoxil may result in nephrotoxicity. lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals. ",adefovir dipivoxil
disease_disorder,hepatitis,0.99274546," the most common side effects of adefovir dipivoxil are weakness, headache, stomach pain and nausea. severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-hepatitis b therapy, including therapy with adefovir dipivoxil. in patients at risk of or having underlying renal dysfunction, chronic administration of adefovir dipivoxil may result in nephrotoxicity. lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals. ",adefovir dipivoxil
sign_symptom,lactic acidosis,0.7462379," the most common side effects of adefovir dipivoxil are weakness, headache, stomach pain and nausea. severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-hepatitis b therapy, including therapy with adefovir dipivoxil. in patients at risk of or having underlying renal dysfunction, chronic administration of adefovir dipivoxil may result in nephrotoxicity. lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals. ",adefovir dipivoxil
medication,nucleoside analog,0.99496543," the most common side effects of adefovir dipivoxil are weakness, headache, stomach pain and nausea. severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-hepatitis b therapy, including therapy with adefovir dipivoxil. in patients at risk of or having underlying renal dysfunction, chronic administration of adefovir dipivoxil may result in nephrotoxicity. lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals. ",adefovir dipivoxil
sign_symptom,adverse reaction,0.99904025," the systemic adverse reaction has not been observed within short-term topical use of chloramphenicol. the most frequently reported adverse reactions have been burning, stinging, conjunctival hyperemia, blood dyscrasia, allergic or inflammatory reactions, vesicular and maculopapular dermatitis. ",chloramphenicol (ophthalmic)
sign_symptom,adverse reactions,0.9992949," the systemic adverse reaction has not been observed within short-term topical use of chloramphenicol. the most frequently reported adverse reactions have been burning, stinging, conjunctival hyperemia, blood dyscrasia, allergic or inflammatory reactions, vesicular and maculopapular dermatitis. ",chloramphenicol (ophthalmic)
sign_symptom,seizures,0.99985564," bone marrow suppression, seizures in childn with nephrotic syndrome, nausea, vomiting, diarrhoea, oral ulceration. rarely, irreversible bone marrow failure, allergic reactions, stevens-johnson syndrome, toxic epidermal necrolysis, seizures, movement disorders, interstitial pulmonary fibrosis, interstitial pneumonia, hepatotoxicity, jaundice, sterile cystitis, drug fever ",chlorambucil
sign_symptom,reactions,0.99939895," mild and transient reactions at inj site, nausea, headache, ovarian hyperstimulation syndrome, systemic hypersensitivity reactions. ",cetrorelix acetate
sign_symptom,hyper,0.9962508," mild and transient reactions at inj site, nausea, headache, ovarian hyperstimulation syndrome, systemic hypersensitivity reactions. ",cetrorelix acetate
sign_symptom,pain,0.9998528," the most common adverse reactions are ocular hyperemia, instillation site pain and visual acuity reduction. ",cetirizine hydrochloride (ophthalmic)
sign_symptom,asthma attacks,0.9598528, salicylates may produce bronchospasm and induce asthma attacks in susceptible patients. ,cetalkonium chloride + choline salicylate
sign_symptom,adverse reactions,0.8799077,"  
 gastrointestinal adverse reactions 
 hepatotoxicity 
 interstitial lung disease/pneumonitis 
 qt interval prolongation 
 hyperglycemia 
 bradycardia 
 pancreatitis 
  ",ceritinib
disease_disorder,hepatotoxicity,0.99648905,"  
 gastrointestinal adverse reactions 
 hepatotoxicity 
 interstitial lung disease/pneumonitis 
 qt interval prolongation 
 hyperglycemia 
 bradycardia 
 pancreatitis 
  ",ceritinib
disease_disorder,interstitial lung disease,0.98746365,"  
 gastrointestinal adverse reactions 
 hepatotoxicity 
 interstitial lung disease/pneumonitis 
 qt interval prolongation 
 hyperglycemia 
 bradycardia 
 pancreatitis 
  ",ceritinib
disease_disorder,hyperglycemia,0.9982071,"  
 gastrointestinal adverse reactions 
 hepatotoxicity 
 interstitial lung disease/pneumonitis 
 qt interval prolongation 
 hyperglycemia 
 bradycardia 
 pancreatitis 
  ",ceritinib
disease_disorder,bradycardia pancreatitis,0.99981225,"  
 gastrointestinal adverse reactions 
 hepatotoxicity 
 interstitial lung disease/pneumonitis 
 qt interval prolongation 
 hyperglycemia 
 bradycardia 
 pancreatitis 
  ",ceritinib
medication,candida,0.845343," side effects include nausea, vomiting, diarrhoea and abdominal discomfort. symptoms of pseudomembranous colitis may appear either during or after antibiotic treatment. skin rash, angio oedema, rise in serum aminotransferases, eosinophilia, neutropenia have been reported very rarely. superinfection with resistant micro organisms, particularly candida may follow the treatment. ",cephalexin
sign_symptom,gastro - intestinal disturbances,0.9993437," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,hypersensitivity,0.99974334," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,skin reactions,0.9997405," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,tightness,0.98159397," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,hyper,0.9999052," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,rash,0.9992957," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
disease_disorder,blood,0.9624971," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
disease_disorder,agranulocy,0.86604816," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,fever,0.84981215," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,serum sickness,0.9598406," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,anaphylaxis,0.9964088," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,sleep disturbances,0.99896973," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,nervous system,0.7083365," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,headache,0.998478," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,jaundice,0.9989142," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,urinary disorders,0.73354924," limited essentially to gastro-intestinal disturbances and on occasions to hypersensitivity phenomena. the latter are more likely to occur in individuals, who have previously demonstrated hypersensitivity and thos with a history of allergy, asthma, hay fever or urticaria. skin reactions have occasionally been reported. rare- glossitis, heartburn, dizziness, tightness in the chest, nausea, vomiting, diarrhoea, abdominal pain, vaginitis, candida overgrowth. skin and hypersensitivity reactions include urticaria, skin rashes, joint pains, oedema. 
 
 blood and lymphatic system disorders- unknown: blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia) 
 immune system disorders- unknown: fever, serum sickness like reactions, anaphylaxis 
 psychiatric disorders- unknown: confusion, sleep disturbances 
 nervous system disorders- unknown: hyperactivity, hypertonia, dizziness, nervousness; rarely: headache 
 hepatobiliary disorders- frequency unknown: liver, enzyme disturbances, transient hepatitis, cholestatic jaundice 
 renal and urinary disorders- unknown: reversible interstitial nephritis 
 investigations- unknown: elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. 
  ",cephradine
sign_symptom,reaction,0.73243326,"  serious side effects : allergic reaction: a rash, swallowing or breathing problems, swelling of your face, lips, throat or tongue. you get flu like symptoms, swollen or painful joints, increased sensitivity to sunlight, hair loss, abdominal pain, anaemia. this may mean you have a condition called systemic lupus erythematosus (sle). these symptoms will usually go away after celiprolol hydrochloride has been stopped. these are very serious side effects. if you have them you may have had a serious allergic reaction to celiprolol hydrochloride. you may need urgent medical attention or hospitalization.   common side effects  (may affect up to 1 in 10 people): dizziness or light headedness, weakness, or fainting especially when standing up from a lying position. these could be signs of low blood pressure.skin rashes, excessive itching ",celiprolol hydrochloride
sign_symptom,swelling,0.99994063,"  serious side effects : allergic reaction: a rash, swallowing or breathing problems, swelling of your face, lips, throat or tongue. you get flu like symptoms, swollen or painful joints, increased sensitivity to sunlight, hair loss, abdominal pain, anaemia. this may mean you have a condition called systemic lupus erythematosus (sle). these symptoms will usually go away after celiprolol hydrochloride has been stopped. these are very serious side effects. if you have them you may have had a serious allergic reaction to celiprolol hydrochloride. you may need urgent medical attention or hospitalization.   common side effects  (may affect up to 1 in 10 people): dizziness or light headedness, weakness, or fainting especially when standing up from a lying position. these could be signs of low blood pressure.skin rashes, excessive itching ",celiprolol hydrochloride
medication,celiprolol hydrochloride,0.99691784,"  serious side effects : allergic reaction: a rash, swallowing or breathing problems, swelling of your face, lips, throat or tongue. you get flu like symptoms, swollen or painful joints, increased sensitivity to sunlight, hair loss, abdominal pain, anaemia. this may mean you have a condition called systemic lupus erythematosus (sle). these symptoms will usually go away after celiprolol hydrochloride has been stopped. these are very serious side effects. if you have them you may have had a serious allergic reaction to celiprolol hydrochloride. you may need urgent medical attention or hospitalization.   common side effects  (may affect up to 1 in 10 people): dizziness or light headedness, weakness, or fainting especially when standing up from a lying position. these could be signs of low blood pressure.skin rashes, excessive itching ",celiprolol hydrochloride
medication,celiprolol hydroch,0.98164296,"  serious side effects : allergic reaction: a rash, swallowing or breathing problems, swelling of your face, lips, throat or tongue. you get flu like symptoms, swollen or painful joints, increased sensitivity to sunlight, hair loss, abdominal pain, anaemia. this may mean you have a condition called systemic lupus erythematosus (sle). these symptoms will usually go away after celiprolol hydrochloride has been stopped. these are very serious side effects. if you have them you may have had a serious allergic reaction to celiprolol hydrochloride. you may need urgent medical attention or hospitalization.   common side effects  (may affect up to 1 in 10 people): dizziness or light headedness, weakness, or fainting especially when standing up from a lying position. these could be signs of low blood pressure.skin rashes, excessive itching ",celiprolol hydrochloride
sign_symptom,light headed,0.9910687,"  serious side effects : allergic reaction: a rash, swallowing or breathing problems, swelling of your face, lips, throat or tongue. you get flu like symptoms, swollen or painful joints, increased sensitivity to sunlight, hair loss, abdominal pain, anaemia. this may mean you have a condition called systemic lupus erythematosus (sle). these symptoms will usually go away after celiprolol hydrochloride has been stopped. these are very serious side effects. if you have them you may have had a serious allergic reaction to celiprolol hydrochloride. you may need urgent medical attention or hospitalization.   common side effects  (may affect up to 1 in 10 people): dizziness or light headedness, weakness, or fainting especially when standing up from a lying position. these could be signs of low blood pressure.skin rashes, excessive itching ",celiprolol hydrochloride
sign_symptom,fainting,0.99977946,"  serious side effects : allergic reaction: a rash, swallowing or breathing problems, swelling of your face, lips, throat or tongue. you get flu like symptoms, swollen or painful joints, increased sensitivity to sunlight, hair loss, abdominal pain, anaemia. this may mean you have a condition called systemic lupus erythematosus (sle). these symptoms will usually go away after celiprolol hydrochloride has been stopped. these are very serious side effects. if you have them you may have had a serious allergic reaction to celiprolol hydrochloride. you may need urgent medical attention or hospitalization.   common side effects  (may affect up to 1 in 10 people): dizziness or light headedness, weakness, or fainting especially when standing up from a lying position. these could be signs of low blood pressure.skin rashes, excessive itching ",celiprolol hydrochloride
sign_symptom,rash,0.9998734,"  serious side effects : allergic reaction: a rash, swallowing or breathing problems, swelling of your face, lips, throat or tongue. you get flu like symptoms, swollen or painful joints, increased sensitivity to sunlight, hair loss, abdominal pain, anaemia. this may mean you have a condition called systemic lupus erythematosus (sle). these symptoms will usually go away after celiprolol hydrochloride has been stopped. these are very serious side effects. if you have them you may have had a serious allergic reaction to celiprolol hydrochloride. you may need urgent medical attention or hospitalization.   common side effects  (may affect up to 1 in 10 people): dizziness or light headedness, weakness, or fainting especially when standing up from a lying position. these could be signs of low blood pressure.skin rashes, excessive itching ",celiprolol hydrochloride
sign_symptom,adverse events,0.9997611," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,pain,0.9999467," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,diarr,0.99572635," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,dyspepsia,0.99986684," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,flatulence,0.999893," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,nausea,0.99993455," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,peripheral oedema,0.85159975," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,injury,0.87821007," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,headache,0.9999163," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,pharyngitis,0.917318," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,rhinitis,0.91856384," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,sinusitis,0.9596755," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,infections,0.9952631," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
sign_symptom,rash,0.99988174," adverse events occurring in 2% of patients at recommended doses - abdominal pain 4.1%, diarrhoea 5.6%, dyspepsia 8.8%, flatulence 2.2%, nausea 3.5%, back pain 2.8%, peripheral oedema 2.1%, accidental injury 2.9%, dizziness 2.0%, headache 15.8%, insomnia 2.3%, pharyngitis 2.3%, rhinitis 2.0%, sinusitis 5.0%, upper respiratory tract infections 8.1%, rash 2.2%. the following adverse events occurred in 0.1-1.9% of patients- 
 
  general : allergy aggravated, allergic reaction, asthenia, chest pain, oedema generalised, face oedema, fatigue, fever, hot flushes, influenza like symptoms, pain, peripheral pain. 
  gastrointestinal : constipation, diverticulitis, dysphagia, oesophagitis, gastritis, gastroenteritis, gastro-oesophageal reflux disease, haemorrhoids, hiatal hernia, melaena, dry mouth, stomatitis, tenesmus, tooth disorder, vomiting. 
  cardiovascular : aggravated hypertension, angina pectoris, coronary artery disease, myocardial infarction. 
  nervous system : leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, vertigo. female reproductive system : breast fibroadenosis, breast neoplasm, breast pain, dysmenorrhoea, menstrual disorder, menorrhagia, vaginitis. 
  male reproductive system : prostatic disorder. 
  resistance mechanism disorders : herpes simplex, herpes zoster, bacterial infection, fungal infection, infection of soft tissue, viral infection, moniliasis, moniliasis genital, otitis media. 
  hearing and vestibular : deafness, ear abnormality, earache, tinnitus. 
  heart rate and rhythm : palpitation, tachycardia. 
  respiratory : bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnoea, laryngitis, pneumonia. 
  liver and biliary system : peptic function abnormal, increased ast and alt. 
  musculoskeletal : arthralgia, arthrosis, accidental fracture, myalgia, neck stiffness, synovitis, tendinitis. 
  urinary system : albuminuria, cystitis, dysuria, haematuria, micturition frequency, renal calculus, urinary incontinence, urinary tract infection. 
  metabolic and nutritiona l: blood urea nitrogen (bun), cpk, creatinine, alkaline phosphatase, are increased. hypercholesterolaemia, hyperglycaemia, hypokalaemia. bodyweight is also increased. 
  psychiatric : anorexia, anxiety, increased appetite, depression, nervousness, somnolence. 
  haemic : anaemia, ecchymosis, epistaxis, thrombocythaemia. 
  skin and appendages : alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, dry skin, increased sweating, urticaria. 
  application site disorders : cellulitis, contact dermatitis, skin nodule. 
  special sense s: taste perversion. 
  vision : blurred vision, cataract, conjunctivitis, eye pain, glaucoma. 
  ",celecoxib
medication,cefur,0.8295938," generally cefuroxime-clavulanic acid is well tolerated. however, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. as with other broad-spectrum antibiotics, prolonged administration of cefuroxime and clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. rarely (&lt;0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear. ",cefuroxime axetil + clavulanic acid
medication,clavulanic acid,0.9403359," generally cefuroxime-clavulanic acid is well tolerated. however, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. as with other broad-spectrum antibiotics, prolonged administration of cefuroxime and clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. rarely (&lt;0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear. ",cefuroxime axetil + clavulanic acid
sign_symptom,side effects,0.97451085," generally cefuroxime-clavulanic acid is well tolerated. however, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. as with other broad-spectrum antibiotics, prolonged administration of cefuroxime and clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. rarely (&lt;0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear. ",cefuroxime axetil + clavulanic acid
sign_symptom,nausea,0.98777896," generally cefuroxime-clavulanic acid is well tolerated. however, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. as with other broad-spectrum antibiotics, prolonged administration of cefuroxime and clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. rarely (&lt;0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear. ",cefuroxime axetil + clavulanic acid
sign_symptom,vomiting,0.98905015," generally cefuroxime-clavulanic acid is well tolerated. however, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. as with other broad-spectrum antibiotics, prolonged administration of cefuroxime and clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. rarely (&lt;0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear. ",cefuroxime axetil + clavulanic acid
sign_symptom,discomfort,0.99993443," generally cefuroxime-clavulanic acid is well tolerated. however, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. as with other broad-spectrum antibiotics, prolonged administration of cefuroxime and clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. rarely (&lt;0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear. ",cefuroxime axetil + clavulanic acid
sign_symptom,pain,0.9999536," generally cefuroxime-clavulanic acid is well tolerated. however, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. as with other broad-spectrum antibiotics, prolonged administration of cefuroxime and clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. rarely (&lt;0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear. ",cefuroxime axetil + clavulanic acid
sign_symptom,rash,0.99991715," generally cefuroxime-clavulanic acid is well tolerated. however, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. as with other broad-spectrum antibiotics, prolonged administration of cefuroxime and clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. rarely (&lt;0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear. ",cefuroxime axetil + clavulanic acid
disease_disorder,serum,0.83282083," generally cefuroxime-clavulanic acid is well tolerated. however, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. as with other broad-spectrum antibiotics, prolonged administration of cefuroxime and clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. rarely (&lt;0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear. ",cefuroxime axetil + clavulanic acid
sign_symptom,sickness,0.9469187," generally cefuroxime-clavulanic acid is well tolerated. however, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. as with other broad-spectrum antibiotics, prolonged administration of cefuroxime and clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. rarely (&lt;0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear. ",cefuroxime axetil + clavulanic acid
sign_symptom,rash,0.9998857," adverse effects to cefuroxime have occurred infrequently and have been generally mild and transient in nature. effects reported include rashes and gastrointestinal disturbances. as with other antibiotics, prolonged use may result in the overgrowth of non susceptible organisms e.g. candida. ",cefuroxime axetil
sign_symptom,over,0.799202," adverse effects to cefuroxime have occurred infrequently and have been generally mild and transient in nature. effects reported include rashes and gastrointestinal disturbances. as with other antibiotics, prolonged use may result in the overgrowth of non susceptible organisms e.g. candida. ",cefuroxime axetil
sign_symptom,side effects,0.8660877," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,nausea,0.99975365," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
disease_disorder,gloss,0.7609197," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,cutaneous reactions,0.99892884," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,rash,0.99849975," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,urticaria,0.943036," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,edema,0.9980593," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,erythema,0.9957633," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,hemato,0.83527946," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,reactions,0.9310246," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,leucopen,0.98799163," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,anemia,0.82494116," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,nervous,0.9996946," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,confusion,0.9979564," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,sleep,0.9528596," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,hyperactivity,0.9833774," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,hypertonia,0.83862036," ceftriaxone is generally well tolerated. a few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of sgot or sgpt, bilirubinemia; cns reactions including nervousness, confusion, sleep disturbances, headache, hyperactivity, convulsion, hypertonia and dizziness were reported. local phlebitis occurs rarely following intravenous administration but can be minimized by slow injections over 2-4 minutes. ",ceftriaxone sodium
sign_symptom,dyspeps,0.9994054," nausea, headache, diarrhea, dyspepsia, dizziness, abdominal pain, vomiting. ",ceftibuten dihydrate
sign_symptom,reactions,0.7664159," the most common side-effects are local reactions following iv injection and allergic and gastrointestinal reactions. hypersensitivity reactions are pruritus, rash, and fever. angioedema and anaphylaxis have been reported very rarely. gastrointestinal symptoms are diarrhea, nausea, vomiting, and abdominal pain. central nervous system reactions included headache, dizziness, and paresthesia. ",ceftazidime pentahydrate
sign_symptom,hypersensitivity reactions,0.96638566," the most common side-effects are local reactions following iv injection and allergic and gastrointestinal reactions. hypersensitivity reactions are pruritus, rash, and fever. angioedema and anaphylaxis have been reported very rarely. gastrointestinal symptoms are diarrhea, nausea, vomiting, and abdominal pain. central nervous system reactions included headache, dizziness, and paresthesia. ",ceftazidime pentahydrate
sign_symptom,angioedema,0.9993677," the most common side-effects are local reactions following iv injection and allergic and gastrointestinal reactions. hypersensitivity reactions are pruritus, rash, and fever. angioedema and anaphylaxis have been reported very rarely. gastrointestinal symptoms are diarrhea, nausea, vomiting, and abdominal pain. central nervous system reactions included headache, dizziness, and paresthesia. ",ceftazidime pentahydrate
sign_symptom,anaphylaxis,0.97031194," the most common side-effects are local reactions following iv injection and allergic and gastrointestinal reactions. hypersensitivity reactions are pruritus, rash, and fever. angioedema and anaphylaxis have been reported very rarely. gastrointestinal symptoms are diarrhea, nausea, vomiting, and abdominal pain. central nervous system reactions included headache, dizziness, and paresthesia. ",ceftazidime pentahydrate
sign_symptom,allergic reactions,0.90979254," severe allergic reactions: signs include sudden swelling of your lips, face, throat or tongue, a severe rash or other severe skin reactions, difficulty swallowing or breathing. this reaction may be life-threatening. diarrhoea that keeps getting worse or does not go away, or stools that contains blood or mucus-this may happen during or after treatment is stopped with this combination. if this happens do not take medicines that stop or slow bowel movement. ",ceftazidime + avibactam
sign_symptom,swelling,0.9999658," severe allergic reactions: signs include sudden swelling of your lips, face, throat or tongue, a severe rash or other severe skin reactions, difficulty swallowing or breathing. this reaction may be life-threatening. diarrhoea that keeps getting worse or does not go away, or stools that contains blood or mucus-this may happen during or after treatment is stopped with this combination. if this happens do not take medicines that stop or slow bowel movement. ",ceftazidime + avibactam
sign_symptom,rash,0.999808," severe allergic reactions: signs include sudden swelling of your lips, face, throat or tongue, a severe rash or other severe skin reactions, difficulty swallowing or breathing. this reaction may be life-threatening. diarrhoea that keeps getting worse or does not go away, or stools that contains blood or mucus-this may happen during or after treatment is stopped with this combination. if this happens do not take medicines that stop or slow bowel movement. ",ceftazidime + avibactam
sign_symptom,diarrhoea,0.9992553," severe allergic reactions: signs include sudden swelling of your lips, face, throat or tongue, a severe rash or other severe skin reactions, difficulty swallowing or breathing. this reaction may be life-threatening. diarrhoea that keeps getting worse or does not go away, or stools that contains blood or mucus-this may happen during or after treatment is stopped with this combination. if this happens do not take medicines that stop or slow bowel movement. ",ceftazidime + avibactam
sign_symptom,stools,0.95371044," severe allergic reactions: signs include sudden swelling of your lips, face, throat or tongue, a severe rash or other severe skin reactions, difficulty swallowing or breathing. this reaction may be life-threatening. diarrhoea that keeps getting worse or does not go away, or stools that contains blood or mucus-this may happen during or after treatment is stopped with this combination. if this happens do not take medicines that stop or slow bowel movement. ",ceftazidime + avibactam
medication,medicines,0.92790496," severe allergic reactions: signs include sudden swelling of your lips, face, throat or tongue, a severe rash or other severe skin reactions, difficulty swallowing or breathing. this reaction may be life-threatening. diarrhoea that keeps getting worse or does not go away, or stools that contains blood or mucus-this may happen during or after treatment is stopped with this combination. if this happens do not take medicines that stop or slow bowel movement. ",ceftazidime + avibactam
sign_symptom,pain,0.99992144," diarrhea, gas, upset stomach, constipation, or stomach pain may occur in the first few weeks of treatment as your body adjusts to this medication but usually improve with time. follow your prescribed diet to help lessen these side effects. if any of these effects persist or worsen, tell your doctor or pharmacist promptly. ",acarbose
sign_symptom,adverse reactions,0.9897709," most common adverse reactions (incidence 30%) were: anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, headache, diarrhea, and musculoskeletal pain. ",acalabrutinib
sign_symptom,reactions,0.78677106," the most common adverse reactions are fatigue, arthralgia, hypertension, nausea, edema, hypokalemia, hot flush, diarrhea, vomiting, upper respiratory infection, cough, and headache. ",abiraterone acetate
sign_symptom,adverse reactions,0.9963207," most common adverse reactions (incidence 20%) were diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, and thrombocytopenia. ",abemaciclib
sign_symptom,adverse reactions,0.9998932," the most commonly reported adverse reactions (incidence at least 10%) in clinical trials were nausea, headache, malaise and fatigue, and nausea and vomiting. ",abacavir + lamivudine + zidovudine
sign_symptom,mala,0.999905," the most commonly reported adverse reactions (incidence at least 10%) in clinical trials were nausea, headache, malaise and fatigue, and nausea and vomiting. ",abacavir + lamivudine + zidovudine
sign_symptom,nausea,0.9997267," the most commonly reported adverse reactions (incidence at least 10%) in clinical trials were nausea, headache, malaise and fatigue, and nausea and vomiting. ",abacavir + lamivudine + zidovudine
sign_symptom,redness,0.9988073, commonly redness/burning of treated skin or changes in shape/color of the nail may occur. very serious allergic reaction to ciclopirox is rare. ,ciclopirox olamine (nail lacquer)
sign_symptom,burning,0.9997613, commonly redness/burning of treated skin or changes in shape/color of the nail may occur. very serious allergic reaction to ciclopirox is rare. ,ciclopirox olamine (nail lacquer)
sign_symptom,changes in shape / color,0.99588597, commonly redness/burning of treated skin or changes in shape/color of the nail may occur. very serious allergic reaction to ciclopirox is rare. ,ciclopirox olamine (nail lacquer)
sign_symptom,allergic reaction,0.99958175, commonly redness/burning of treated skin or changes in shape/color of the nail may occur. very serious allergic reaction to ciclopirox is rare. ,ciclopirox olamine (nail lacquer)
medication,ciclopirox,0.93154955, commonly redness/burning of treated skin or changes in shape/color of the nail may occur. very serious allergic reaction to ciclopirox is rare. ,ciclopirox olamine (nail lacquer)
sign_symptom,adverse reactions,0.9999239, ciclopirox olamine cream is well tolerated with a low incidence of adverse reactions reported in clinical trials. ,ciclopirox olamine (cream)
medication,ciclesonide,0.96882," ciclesonide nasal spray is absorbed less into rest of the body; therefore fewer side effects are seen. however, few side-effects like headache, dizziness, nosebleed, stuffy nose, earache may occur. ",ciclesonide (nasal spray)
medication,spray,0.85727733," ciclesonide nasal spray is absorbed less into rest of the body; therefore fewer side effects are seen. however, few side-effects like headache, dizziness, nosebleed, stuffy nose, earache may occur. ",ciclesonide (nasal spray)
sign_symptom,side,0.7103351," ciclesonide nasal spray is absorbed less into rest of the body; therefore fewer side effects are seen. however, few side-effects like headache, dizziness, nosebleed, stuffy nose, earache may occur. ",ciclesonide (nasal spray)
sign_symptom,stuffy,0.8719039," ciclesonide nasal spray is absorbed less into rest of the body; therefore fewer side effects are seen. however, few side-effects like headache, dizziness, nosebleed, stuffy nose, earache may occur. ",ciclesonide (nasal spray)
sign_symptom,cough,0.99084723," common (1-10%): paradoxical bronchospasm; uncommon (0.1-1%): bad taste, application site reactions, application site dryness, hoarseness, cough after inhalation, rash and eczema.  systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. these effects are much less likely to occur than with oral corticosteroids. possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. patients with severe hepatic impairment should be monitored for potential systemic effects. ",ciclesonide (inhalation aerosol)
sign_symptom,rash,0.99308527," common (1-10%): paradoxical bronchospasm; uncommon (0.1-1%): bad taste, application site reactions, application site dryness, hoarseness, cough after inhalation, rash and eczema.  systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. these effects are much less likely to occur than with oral corticosteroids. possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. patients with severe hepatic impairment should be monitored for potential systemic effects. ",ciclesonide (inhalation aerosol)
medication,corti,0.7437628," common (1-10%): paradoxical bronchospasm; uncommon (0.1-1%): bad taste, application site reactions, application site dryness, hoarseness, cough after inhalation, rash and eczema.  systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. these effects are much less likely to occur than with oral corticosteroids. possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. patients with severe hepatic impairment should be monitored for potential systemic effects. ",ciclesonide (inhalation aerosol)
sign_symptom,growth retardation,0.9783565," common (1-10%): paradoxical bronchospasm; uncommon (0.1-1%): bad taste, application site reactions, application site dryness, hoarseness, cough after inhalation, rash and eczema.  systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. these effects are much less likely to occur than with oral corticosteroids. possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. patients with severe hepatic impairment should be monitored for potential systemic effects. ",ciclesonide (inhalation aerosol)
sign_symptom,emotionallab,0.8055873," injection site inflammation and reaction,flatulence, diarrhea, hiccup,ectopic pregnancy,breast pain, intermenstrual bleeding, vaginal hemorrhage, cervicallesion, leukorrhea, ovarian hyperstimulation, uterine disorders,vaginitis, vaginal discomfort, body pain,back pain, fever, dizziness, headache, hot flashes,malaise, paraesthesias, rash, emotionallability, insomnia, upper respiratory tract infection, cough, dysuria, urinary tract infection,urinary incontinence, albuminuria, cardiac arrhythmia, genital moniliasis, genital herpes,leukocytosis,heart murmurand cervical carcinoma. ",choriogonadotropin alpha
sign_symptom,swelling,0.9998541,"  
 severe burning, pain, or swelling around the iv needle; 
 warmth, redness, oozing, or bleeding where the iv was placed; 
 fever, ongoing cough. 
  ",cholera saline
sign_symptom,electroly,0.8276532,"  electrolytes and metabolic disorders : frequent: mainly at higher doses, hypokalemia, hyperuricemia and rise in blood lipids. occasional: hyponatremia, hypomagnesemia and hyperglycemia. rare: hypercalcemia, glycosuria, worsening of diabetic metabolic state and gout.   isolated cases : hypochloremic alkalosis.   dermatology : occasional: urticaria and other forms of skin rash. rare: photosensitization.   liver : rare: intrahepatic cholestasis or jaundice.   cardiovascular : occasional: postural hypotension, which may be aggravated by alcohol, anesthetics or sedatives. rare: cardiac arrhythmias.   cns : occasional: dizziness, slow mentation and decreased reaction time. ",chlorthalidone
sign_symptom,hyperuricemia,0.9972844,"  electrolytes and metabolic disorders : frequent: mainly at higher doses, hypokalemia, hyperuricemia and rise in blood lipids. occasional: hyponatremia, hypomagnesemia and hyperglycemia. rare: hypercalcemia, glycosuria, worsening of diabetic metabolic state and gout.   isolated cases : hypochloremic alkalosis.   dermatology : occasional: urticaria and other forms of skin rash. rare: photosensitization.   liver : rare: intrahepatic cholestasis or jaundice.   cardiovascular : occasional: postural hypotension, which may be aggravated by alcohol, anesthetics or sedatives. rare: cardiac arrhythmias.   cns : occasional: dizziness, slow mentation and decreased reaction time. ",chlorthalidone
sign_symptom,hyperglyce,0.9917256,"  electrolytes and metabolic disorders : frequent: mainly at higher doses, hypokalemia, hyperuricemia and rise in blood lipids. occasional: hyponatremia, hypomagnesemia and hyperglycemia. rare: hypercalcemia, glycosuria, worsening of diabetic metabolic state and gout.   isolated cases : hypochloremic alkalosis.   dermatology : occasional: urticaria and other forms of skin rash. rare: photosensitization.   liver : rare: intrahepatic cholestasis or jaundice.   cardiovascular : occasional: postural hypotension, which may be aggravated by alcohol, anesthetics or sedatives. rare: cardiac arrhythmias.   cns : occasional: dizziness, slow mentation and decreased reaction time. ",chlorthalidone
sign_symptom,hyper,0.99961424,"  electrolytes and metabolic disorders : frequent: mainly at higher doses, hypokalemia, hyperuricemia and rise in blood lipids. occasional: hyponatremia, hypomagnesemia and hyperglycemia. rare: hypercalcemia, glycosuria, worsening of diabetic metabolic state and gout.   isolated cases : hypochloremic alkalosis.   dermatology : occasional: urticaria and other forms of skin rash. rare: photosensitization.   liver : rare: intrahepatic cholestasis or jaundice.   cardiovascular : occasional: postural hypotension, which may be aggravated by alcohol, anesthetics or sedatives. rare: cardiac arrhythmias.   cns : occasional: dizziness, slow mentation and decreased reaction time. ",chlorthalidone
sign_symptom,metabolic state,0.9864611,"  electrolytes and metabolic disorders : frequent: mainly at higher doses, hypokalemia, hyperuricemia and rise in blood lipids. occasional: hyponatremia, hypomagnesemia and hyperglycemia. rare: hypercalcemia, glycosuria, worsening of diabetic metabolic state and gout.   isolated cases : hypochloremic alkalosis.   dermatology : occasional: urticaria and other forms of skin rash. rare: photosensitization.   liver : rare: intrahepatic cholestasis or jaundice.   cardiovascular : occasional: postural hypotension, which may be aggravated by alcohol, anesthetics or sedatives. rare: cardiac arrhythmias.   cns : occasional: dizziness, slow mentation and decreased reaction time. ",chlorthalidone
sign_symptom,rash,0.9997738,"  electrolytes and metabolic disorders : frequent: mainly at higher doses, hypokalemia, hyperuricemia and rise in blood lipids. occasional: hyponatremia, hypomagnesemia and hyperglycemia. rare: hypercalcemia, glycosuria, worsening of diabetic metabolic state and gout.   isolated cases : hypochloremic alkalosis.   dermatology : occasional: urticaria and other forms of skin rash. rare: photosensitization.   liver : rare: intrahepatic cholestasis or jaundice.   cardiovascular : occasional: postural hypotension, which may be aggravated by alcohol, anesthetics or sedatives. rare: cardiac arrhythmias.   cns : occasional: dizziness, slow mentation and decreased reaction time. ",chlorthalidone
sign_symptom,choles,0.82737374,"  electrolytes and metabolic disorders : frequent: mainly at higher doses, hypokalemia, hyperuricemia and rise in blood lipids. occasional: hyponatremia, hypomagnesemia and hyperglycemia. rare: hypercalcemia, glycosuria, worsening of diabetic metabolic state and gout.   isolated cases : hypochloremic alkalosis.   dermatology : occasional: urticaria and other forms of skin rash. rare: photosensitization.   liver : rare: intrahepatic cholestasis or jaundice.   cardiovascular : occasional: postural hypotension, which may be aggravated by alcohol, anesthetics or sedatives. rare: cardiac arrhythmias.   cns : occasional: dizziness, slow mentation and decreased reaction time. ",chlorthalidone
sign_symptom,hyper,0.74123615," the following adverse effects have been reported for chlorpromazine or phenothiazines in general. 
 
 cardiovascular: postural hypotension, ecg changes. 
 dermatological 
 contact dermatitis, photosensitivity, urticarial, maculopapular, petechial or oedematous reactions. 
 endocrine: elevated prolactin levels, impaired thermoregulation, hyperglycaemia, other hypothalamic effects. 
 gastrointestinal: dry mouth, constipation. 
 immunological: raised ana titre, positive sle cells. 
 genitourinary: urinary retention. 
 haematological: leucopenia, agranulocytosis, eosinophilia, hemolytic anaemia, aplastic anaemia, thrombocytopenic purpura and pancytopenia have been reported. 
  ",chlorpromazine hydrochloride
disease_disorder,agra,0.7364215," the following adverse effects have been reported for chlorpromazine or phenothiazines in general. 
 
 cardiovascular: postural hypotension, ecg changes. 
 dermatological 
 contact dermatitis, photosensitivity, urticarial, maculopapular, petechial or oedematous reactions. 
 endocrine: elevated prolactin levels, impaired thermoregulation, hyperglycaemia, other hypothalamic effects. 
 gastrointestinal: dry mouth, constipation. 
 immunological: raised ana titre, positive sle cells. 
 genitourinary: urinary retention. 
 haematological: leucopenia, agranulocytosis, eosinophilia, hemolytic anaemia, aplastic anaemia, thrombocytopenic purpura and pancytopenia have been reported. 
  ",chlorpromazine hydrochloride
sign_symptom,upset,0.99923563," chlorpheniramine is well-tolerated, but sometimes drowsiness, dizziness, muscular weakness, and gastrointestinal upset may occur. ",chlorpheniramine maleate
sign_symptom,irritation,0.99995315," skin sensitivity; irritation of conjunctiva, mucosal irritation; reversible brown staining of the teeth; tongue discoloration and burning sensation; transient taste disturbance; parotid gland swelling. ",chloroxylenol + triclosan
sign_symptom,irritation,0.99995315," skin sensitivity; irritation of conjunctiva, mucosal irritation; reversible brown staining of the teeth; tongue discoloration and burning sensation; transient taste disturbance; parotid gland swelling. ",chloroxylenol
sign_symptom,discoloration,0.96793467," skin sensitivity; irritation of conjunctiva, mucosal irritation; reversible brown staining of the teeth; tongue discoloration and burning sensation; transient taste disturbance; parotid gland swelling. ",chloroxylenol + triclosan
sign_symptom,discoloration,0.96793467," skin sensitivity; irritation of conjunctiva, mucosal irritation; reversible brown staining of the teeth; tongue discoloration and burning sensation; transient taste disturbance; parotid gland swelling. ",chloroxylenol
sign_symptom,taste,0.99835986," skin sensitivity; irritation of conjunctiva, mucosal irritation; reversible brown staining of the teeth; tongue discoloration and burning sensation; transient taste disturbance; parotid gland swelling. ",chloroxylenol + triclosan
sign_symptom,taste,0.99835986," skin sensitivity; irritation of conjunctiva, mucosal irritation; reversible brown staining of the teeth; tongue discoloration and burning sensation; transient taste disturbance; parotid gland swelling. ",chloroxylenol
medication,choroquine,0.98973393," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
sign_symptom,effects,0.99388427," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
sign_symptom,headache,0.99991846," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
sign_symptom,gastro,0.92393327," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
sign_symptom,side effects,0.9991697," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
sign_symptom,skin eruptions,0.9954759," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
sign_symptom,depigmentation,0.920813," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
sign_symptom,blur,0.9975963," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
sign_symptom,corneal opacities,0.975222," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
medication,choro,0.82869494," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
sign_symptom,defects,0.7322352," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
sign_symptom,accommodation,0.9427271," choroquine is well tolerated at the standard dosage regimens, side effects such as headache and gastrointestinal disturbances which may occur are not of a serious nature. where prolonged high dose is required side effects can be of greater severity and patients may develop skin eruptions, occasional depigmentation or loss of hair, difficulty in accommodation, blurring of vision. corneal opacities disappear completely when the drug is stopped. rarely thrombocytopenia, agranulocytosis and aplastic anemia have been reported.  the most serious toxic hazard of prolonged therapy with doses is the occasional development of irreversible retinal damage. for this reason considerable caution is needed in the use of choroquine for long-term high dosage therapy and such use should only be considered when no other drug is available. defects in visual accommodation may occur on first taking choloquine and patients should be warned regarding driving or operating machinery. ",chloroquine phosphate
sign_symptom,rash,0.9920156," common side effects: allergic skin reactions such as dermatitis, pruritus, erythema, eczema, rash and skin irritation. rare side effects: severe allergic reactions, leading to a drop in blood pressure and even to unconsciousness. ",chlorhexidine hydrochloride + nystatin
sign_symptom,skin reactions,0.8731916, irritative skin reactions can occasionally occur. generalised allergic reactions have also been reported but are extremely rare ,chlorhexidine gluconate + isopropyl alcohol
sign_symptom,allergic reactions,0.9999106, irritative skin reactions can occasionally occur. generalised allergic reactions have also been reported but are extremely rare ,chlorhexidine gluconate + isopropyl alcohol
sign_symptom,skin reactions,0.9021677," irritative skin reactions and hypersensitivity reactions to chlorhexidine have been reported. in the event that these reactions occur, discontinue use. cetrimide may have a prolonging effect on the wound healing process. ",chlorhexidine gluconate + cetrimide
sign_symptom,hypersensitivity reactions,0.9994798," irritative skin reactions and hypersensitivity reactions to chlorhexidine have been reported. in the event that these reactions occur, discontinue use. cetrimide may have a prolonging effect on the wound healing process. ",chlorhexidine gluconate + cetrimide
medication,cetrimide,0.78969294," irritative skin reactions and hypersensitivity reactions to chlorhexidine have been reported. in the event that these reactions occur, discontinue use. cetrimide may have a prolonging effect on the wound healing process. ",chlorhexidine gluconate + cetrimide
sign_symptom,allergic reactions,0.99933875," allergic reactions like sudden wheeziness, difficulty in breathing, swelling of the eyelids, face or lips, rash or itching (specially affecting the whole body) may occur. ",chlorhexidine gluconate [1%]
sign_symptom,difficulty,0.9879248," allergic reactions like sudden wheeziness, difficulty in breathing, swelling of the eyelids, face or lips, rash or itching (specially affecting the whole body) may occur. ",chlorhexidine gluconate [1%]
sign_symptom,swelling,0.99995625," allergic reactions like sudden wheeziness, difficulty in breathing, swelling of the eyelids, face or lips, rash or itching (specially affecting the whole body) may occur. ",chlorhexidine gluconate [1%]
sign_symptom,rash,0.9999274," allergic reactions like sudden wheeziness, difficulty in breathing, swelling of the eyelids, face or lips, rash or itching (specially affecting the whole body) may occur. ",chlorhexidine gluconate [1%]
sign_symptom,disco,0.9997727, skin sensitivity; mucosal irritation; reversible brown staining of the teeth; tongue discoloration and burning sensation; transient taste disturbance; parotid gland swelling. ,chlorhexidine gluconate [0.2%]
sign_symptom,adverse reaction,0.96138096," because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.  in two identical multicenter, randomized, double-blind, vehicle-controlled trials, 1421 subjects 12 years and older with facial acne vulgaris applied clascoterone cream or vehicle twice daily for 12 weeks. overall, 62% of the subjects were female, and 38% were male, 91% of the patients were caucasian, and the mean age was 19.7 years.  local skin reactions (edema, erythema/redness, pruritus, scaling/dryness, skin atrophy, stinging/burning, striae rubrea, telangiectasia) were observed during the 12-week treatment and occurred in a similar percentage of subjects treated with vehicle. ",clascoterone
disease_disorder,acne vulgaris,0.9861734," because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.  in two identical multicenter, randomized, double-blind, vehicle-controlled trials, 1421 subjects 12 years and older with facial acne vulgaris applied clascoterone cream or vehicle twice daily for 12 weeks. overall, 62% of the subjects were female, and 38% were male, 91% of the patients were caucasian, and the mean age was 19.7 years.  local skin reactions (edema, erythema/redness, pruritus, scaling/dryness, skin atrophy, stinging/burning, striae rubrea, telangiectasia) were observed during the 12-week treatment and occurred in a similar percentage of subjects treated with vehicle. ",clascoterone
disease_disorder,glossitis,0.9990627," clarithromycin is generally well tolerated. side effects include nausea, vomiting, diarrhoea and abdominal pain. stomatitis and glossitis have also been reported. other side effects include headache, allergic reactions ranging from urticaria and mild skin reactions to anaphylaxis. taste perversion may occur. there have been reports of transient central nervous system side effects including anxiety, dizziness, insomnia and hallucination. ",clarithromycin
sign_symptom,allergic reactions,0.99944496," clarithromycin is generally well tolerated. side effects include nausea, vomiting, diarrhoea and abdominal pain. stomatitis and glossitis have also been reported. other side effects include headache, allergic reactions ranging from urticaria and mild skin reactions to anaphylaxis. taste perversion may occur. there have been reports of transient central nervous system side effects including anxiety, dizziness, insomnia and hallucination. ",clarithromycin
sign_symptom,skin reactions,0.9690091," clarithromycin is generally well tolerated. side effects include nausea, vomiting, diarrhoea and abdominal pain. stomatitis and glossitis have also been reported. other side effects include headache, allergic reactions ranging from urticaria and mild skin reactions to anaphylaxis. taste perversion may occur. there have been reports of transient central nervous system side effects including anxiety, dizziness, insomnia and hallucination. ",clarithromycin
sign_symptom,taste perversion,0.99208015," clarithromycin is generally well tolerated. side effects include nausea, vomiting, diarrhoea and abdominal pain. stomatitis and glossitis have also been reported. other side effects include headache, allergic reactions ranging from urticaria and mild skin reactions to anaphylaxis. taste perversion may occur. there have been reports of transient central nervous system side effects including anxiety, dizziness, insomnia and hallucination. ",clarithromycin
sign_symptom,effects,0.86366165," there are no known side effects from using this medicine when used as directed. if taken excessively above the stated dose, glycerol present in the medicine may cause headache, stomach upset and diarrhea. ",citric acid monohydrate
medication,ssris,0.9178193," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. however, side-effects may be seen, includes gastro-intestinal effects (nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss, palpitations, tachycardia, postural hypotension, cough, confusion, impaired concentration, amnesia, urinary retention, sweating, movement disorders, urticaria, anaphylaxis, arthralgia, myalgia and photosensitivity. ",citalopram hydrobromide
sign_symptom,cardiotoxic,0.7883624," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. however, side-effects may be seen, includes gastro-intestinal effects (nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss, palpitations, tachycardia, postural hypotension, cough, confusion, impaired concentration, amnesia, urinary retention, sweating, movement disorders, urticaria, anaphylaxis, arthralgia, myalgia and photosensitivity. ",citalopram hydrobromide
medication,antidepress,0.8105407," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. however, side-effects may be seen, includes gastro-intestinal effects (nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss, palpitations, tachycardia, postural hypotension, cough, confusion, impaired concentration, amnesia, urinary retention, sweating, movement disorders, urticaria, anaphylaxis, arthralgia, myalgia and photosensitivity. ",citalopram hydrobromide
sign_symptom,myalgia,0.7015943," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. however, side-effects may be seen, includes gastro-intestinal effects (nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss, palpitations, tachycardia, postural hypotension, cough, confusion, impaired concentration, amnesia, urinary retention, sweating, movement disorders, urticaria, anaphylaxis, arthralgia, myalgia and photosensitivity. ",citalopram hydrobromide
sign_symptom,nausea,0.99983275," severe nausea and vomiting. serious toxic effects on the kidneys, bone marrows and ears. hypomagnesaemia, hypocalcaemia, hyperuricaemia. peripheral neuropathies, papilloedema, optic neuritis, seizures. ototoxicity (children) manifested as tinnitus, loss of hearing, deafness or vestibular toxicity. ",cisplatin
sign_symptom,toxic,0.9930426," severe nausea and vomiting. serious toxic effects on the kidneys, bone marrows and ears. hypomagnesaemia, hypocalcaemia, hyperuricaemia. peripheral neuropathies, papilloedema, optic neuritis, seizures. ototoxicity (children) manifested as tinnitus, loss of hearing, deafness or vestibular toxicity. ",cisplatin
sign_symptom,hyperurica,0.9231886," severe nausea and vomiting. serious toxic effects on the kidneys, bone marrows and ears. hypomagnesaemia, hypocalcaemia, hyperuricaemia. peripheral neuropathies, papilloedema, optic neuritis, seizures. ototoxicity (children) manifested as tinnitus, loss of hearing, deafness or vestibular toxicity. ",cisplatin
sign_symptom,loss of hearing,0.9989582," severe nausea and vomiting. serious toxic effects on the kidneys, bone marrows and ears. hypomagnesaemia, hypocalcaemia, hyperuricaemia. peripheral neuropathies, papilloedema, optic neuritis, seizures. ototoxicity (children) manifested as tinnitus, loss of hearing, deafness or vestibular toxicity. ",cisplatin
sign_symptom,deaf,0.9672773," severe nausea and vomiting. serious toxic effects on the kidneys, bone marrows and ears. hypomagnesaemia, hypocalcaemia, hyperuricaemia. peripheral neuropathies, papilloedema, optic neuritis, seizures. ototoxicity (children) manifested as tinnitus, loss of hearing, deafness or vestibular toxicity. ",cisplatin
sign_symptom,adverse reactions,0.9989424," the most frequently reported drug-related adverse reactions seen with ciprofloxacin are transient ocular burning or discomfort. other reported reactions include stinging, redness, itching, periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness and eye pain. rare reports of dizziness have been received.  the reactions due to the steroid component are elevation of intraocular pressure (iop) with possible development of glaucoma and infrequent optic nerve damage, posterior sub-capsular cataract formation and delayed wound healing. ",ciprofloxacin + hydrocortisone acetate
sign_symptom,foreign,0.82373935," the most frequently reported drug-related adverse reactions seen with ciprofloxacin are transient ocular burning or discomfort. other reported reactions include stinging, redness, itching, periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness and eye pain. rare reports of dizziness have been received.  the reactions due to the steroid component are elevation of intraocular pressure (iop) with possible development of glaucoma and infrequent optic nerve damage, posterior sub-capsular cataract formation and delayed wound healing. ",ciprofloxacin + hydrocortisone acetate
medication,steroid,0.76531017," the most frequently reported drug-related adverse reactions seen with ciprofloxacin are transient ocular burning or discomfort. other reported reactions include stinging, redness, itching, periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness and eye pain. rare reports of dizziness have been received.  the reactions due to the steroid component are elevation of intraocular pressure (iop) with possible development of glaucoma and infrequent optic nerve damage, posterior sub-capsular cataract formation and delayed wound healing. ",ciprofloxacin + hydrocortisone acetate
sign_symptom,adverse reactions,0.99945337," frequently reported adverse reactions are transient ocular burning or discomfort. other reported reactions include stinging, redness, itching, photophobia, conjunctivitis/ keratitis, periocular/ facial edema, foreign body sensation, blurred vision, tearing, dryness, and eye pain. elevation of iop with development of glaucoma, and delayed wound healing may rarely occur. ",ciprofloxacin + dexamethasone
disease_disorder,conjunctivitis,0.8021838," frequently reported adverse reactions are transient ocular burning or discomfort. other reported reactions include stinging, redness, itching, photophobia, conjunctivitis/ keratitis, periocular/ facial edema, foreign body sensation, blurred vision, tearing, dryness, and eye pain. elevation of iop with development of glaucoma, and delayed wound healing may rarely occur. ",ciprofloxacin + dexamethasone
sign_symptom,foreign body,0.89505607," frequently reported adverse reactions are transient ocular burning or discomfort. other reported reactions include stinging, redness, itching, photophobia, conjunctivitis/ keratitis, periocular/ facial edema, foreign body sensation, blurred vision, tearing, dryness, and eye pain. elevation of iop with development of glaucoma, and delayed wound healing may rarely occur. ",ciprofloxacin + dexamethasone
sign_symptom,burning,0.98203343," local burning or discomfort, itching, foreign body sensation, crystalline precipitates, lid margin crusting, conjunctival hyperemia and a bad taste following administration. photophobia and nausea may be reported. ",ciprofloxacin (ophthalmic)
sign_symptom,foreign,0.8540459," local burning or discomfort, itching, foreign body sensation, crystalline precipitates, lid margin crusting, conjunctival hyperemia and a bad taste following administration. photophobia and nausea may be reported. ",ciprofloxacin (ophthalmic)
sign_symptom,crystalline,0.95848095," local burning or discomfort, itching, foreign body sensation, crystalline precipitates, lid margin crusting, conjunctival hyperemia and a bad taste following administration. photophobia and nausea may be reported. ",ciprofloxacin (ophthalmic)
sign_symptom,hyper,0.99996424," local burning or discomfort, itching, foreign body sensation, crystalline precipitates, lid margin crusting, conjunctival hyperemia and a bad taste following administration. photophobia and nausea may be reported. ",ciprofloxacin (ophthalmic)
sign_symptom,photophobia,0.9998498," local burning or discomfort, itching, foreign body sensation, crystalline precipitates, lid margin crusting, conjunctival hyperemia and a bad taste following administration. photophobia and nausea may be reported. ",ciprofloxacin (ophthalmic)
sign_symptom,nausea,0.9999498," local burning or discomfort, itching, foreign body sensation, crystalline precipitates, lid margin crusting, conjunctival hyperemia and a bad taste following administration. photophobia and nausea may be reported. ",ciprofloxacin (ophthalmic)
sign_symptom,nausea,0.999923," side effects include- nausea and other gastrointestinal disturbances, headache, dizziness, joint pain and skin rashes. ",ciprofloxacin
sign_symptom,pain,0.99991095," side effects include- nausea and other gastrointestinal disturbances, headache, dizziness, joint pain and skin rashes. ",ciprofloxacin
sign_symptom,rash,0.8579131," side effects include- nausea and other gastrointestinal disturbances, headache, dizziness, joint pain and skin rashes. ",ciprofloxacin
sign_symptom,dyspepsia,0.88936913," headache, dizziness, somnolence, vertigo, nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, rash, alopecia, myalgia, fatigue. ",ciprofibrate
sign_symptom,drows,0.74023247," drowsiness, dry mouth, headache, and stomach pain may occur. rare side effects are impaired vision, allergic reactions, light sensitivity, and difficulty in urinating. other possible reactions which may occur: weight gain, constipation, tightness of the chest, jaundice, worsening of angle-closure glaucoma, uncontrollable movements, unusual excitement and restlessness, severe skin reactions. ",cinnarizine + dimenhydrinate
sign_symptom,pain,0.99975234," drowsiness, dry mouth, headache, and stomach pain may occur. rare side effects are impaired vision, allergic reactions, light sensitivity, and difficulty in urinating. other possible reactions which may occur: weight gain, constipation, tightness of the chest, jaundice, worsening of angle-closure glaucoma, uncontrollable movements, unusual excitement and restlessness, severe skin reactions. ",cinnarizine + dimenhydrinate
sign_symptom,tight,0.9997918," drowsiness, dry mouth, headache, and stomach pain may occur. rare side effects are impaired vision, allergic reactions, light sensitivity, and difficulty in urinating. other possible reactions which may occur: weight gain, constipation, tightness of the chest, jaundice, worsening of angle-closure glaucoma, uncontrollable movements, unusual excitement and restlessness, severe skin reactions. ",cinnarizine + dimenhydrinate
sign_symptom,- closure,0.7330169," drowsiness, dry mouth, headache, and stomach pain may occur. rare side effects are impaired vision, allergic reactions, light sensitivity, and difficulty in urinating. other possible reactions which may occur: weight gain, constipation, tightness of the chest, jaundice, worsening of angle-closure glaucoma, uncontrollable movements, unusual excitement and restlessness, severe skin reactions. ",cinnarizine + dimenhydrinate
sign_symptom,side effects,0.9998442, side effects such as somnolence and gastrointestinal disturbances are extremely rare. they are transient and may be readily prevented by achieving the optimal dosage gradually. allergic skin reactions and fatigue have been reported on rare occasions. an aggravation or appearance of extrapyramidal symptoms has been reported extremely rarely in elderly people during prolonged therapy. the treatment should be reduced or stopped in such cases. ,cinnarizine
sign_symptom,gastrointestinal disturbances,0.99938774, side effects such as somnolence and gastrointestinal disturbances are extremely rare. they are transient and may be readily prevented by achieving the optimal dosage gradually. allergic skin reactions and fatigue have been reported on rare occasions. an aggravation or appearance of extrapyramidal symptoms has been reported extremely rarely in elderly people during prolonged therapy. the treatment should be reduced or stopped in such cases. ,cinnarizine
sign_symptom,allergic,0.9999471, side effects such as somnolence and gastrointestinal disturbances are extremely rare. they are transient and may be readily prevented by achieving the optimal dosage gradually. allergic skin reactions and fatigue have been reported on rare occasions. an aggravation or appearance of extrapyramidal symptoms has been reported extremely rarely in elderly people during prolonged therapy. the treatment should be reduced or stopped in such cases. ,cinnarizine
sign_symptom,skin reactions,0.99973667, side effects such as somnolence and gastrointestinal disturbances are extremely rare. they are transient and may be readily prevented by achieving the optimal dosage gradually. allergic skin reactions and fatigue have been reported on rare occasions. an aggravation or appearance of extrapyramidal symptoms has been reported extremely rarely in elderly people during prolonged therapy. the treatment should be reduced or stopped in such cases. ,cinnarizine
sign_symptom,fatigue,0.9999397, side effects such as somnolence and gastrointestinal disturbances are extremely rare. they are transient and may be readily prevented by achieving the optimal dosage gradually. allergic skin reactions and fatigue have been reported on rare occasions. an aggravation or appearance of extrapyramidal symptoms has been reported extremely rarely in elderly people during prolonged therapy. the treatment should be reduced or stopped in such cases. ,cinnarizine
sign_symptom,extrapyramidal symptoms,0.99973345, side effects such as somnolence and gastrointestinal disturbances are extremely rare. they are transient and may be readily prevented by achieving the optimal dosage gradually. allergic skin reactions and fatigue have been reported on rare occasions. an aggravation or appearance of extrapyramidal symptoms has been reported extremely rarely in elderly people during prolonged therapy. the treatment should be reduced or stopped in such cases. ,cinnarizine
sign_symptom,restless,0.99543756, restlessness; excitement; nervousness; paraesthesias; dizziness; tinnitus; blurred vision; nausea; vomiting; muscle twitching; tremors; convulsions; hypotension; bradycardia; arrhythmias; cardiac arrest. ,cinchocaine hydrochloride
sign_symptom,blurred,0.9132305, restlessness; excitement; nervousness; paraesthesias; dizziness; tinnitus; blurred vision; nausea; vomiting; muscle twitching; tremors; convulsions; hypotension; bradycardia; arrhythmias; cardiac arrest. ,cinchocaine hydrochloride
sign_symptom,vomiting,0.92119944, restlessness; excitement; nervousness; paraesthesias; dizziness; tinnitus; blurred vision; nausea; vomiting; muscle twitching; tremors; convulsions; hypotension; bradycardia; arrhythmias; cardiac arrest. ,cinchocaine hydrochloride
sign_symptom,tremor,0.99395233, restlessness; excitement; nervousness; paraesthesias; dizziness; tinnitus; blurred vision; nausea; vomiting; muscle twitching; tremors; convulsions; hypotension; bradycardia; arrhythmias; cardiac arrest. ,cinchocaine hydrochloride
sign_symptom,side effects,0.93994015, side effects which have been reported for individual constituents may occur and appropriate precautions should be taken when using this preparation. ,cinchocaine + hydrocortisone + neomycin + esculin
medication,corticosteroids,0.98986214," long-term continuous treatment with topical corticosteroids should be avoided as far as possible as this may cause atrophic changes in the skin leading to thinning, loss of elasticity, dilatation of superficial blood vessels, telangiectasia and ecchymoses. these changes are particularly likely to occur when occlusive dressings are used. systemic absorption of topically applied corticosteroids may occur, particularly under the following conditions: when large quantities are used or when application is made to wide areas of the body, or to damaged skin; when potent topical corticosteroids are used, and when the occlusive dressing technique is applied. depression of the hypothalamic-pituitary-adrenal axis with consequent suppression of the adrenal gland may occur. these effects are most likely to be severe in children. growth may be retarded and a cushingoid state may be produced. benign intracranial hypertension has been rarely reported. ",cinchocaine + hydrocortisone + framycetin + esculin
sign_symptom,depression,0.9999316," long-term continuous treatment with topical corticosteroids should be avoided as far as possible as this may cause atrophic changes in the skin leading to thinning, loss of elasticity, dilatation of superficial blood vessels, telangiectasia and ecchymoses. these changes are particularly likely to occur when occlusive dressings are used. systemic absorption of topically applied corticosteroids may occur, particularly under the following conditions: when large quantities are used or when application is made to wide areas of the body, or to damaged skin; when potent topical corticosteroids are used, and when the occlusive dressing technique is applied. depression of the hypothalamic-pituitary-adrenal axis with consequent suppression of the adrenal gland may occur. these effects are most likely to be severe in children. growth may be retarded and a cushingoid state may be produced. benign intracranial hypertension has been rarely reported. ",cinchocaine + hydrocortisone + framycetin + esculin
sign_symptom,suppression,0.89757943," long-term continuous treatment with topical corticosteroids should be avoided as far as possible as this may cause atrophic changes in the skin leading to thinning, loss of elasticity, dilatation of superficial blood vessels, telangiectasia and ecchymoses. these changes are particularly likely to occur when occlusive dressings are used. systemic absorption of topically applied corticosteroids may occur, particularly under the following conditions: when large quantities are used or when application is made to wide areas of the body, or to damaged skin; when potent topical corticosteroids are used, and when the occlusive dressing technique is applied. depression of the hypothalamic-pituitary-adrenal axis with consequent suppression of the adrenal gland may occur. these effects are most likely to be severe in children. growth may be retarded and a cushingoid state may be produced. benign intracranial hypertension has been rarely reported. ",cinchocaine + hydrocortisone + framycetin + esculin
sign_symptom,growth,0.9998492," long-term continuous treatment with topical corticosteroids should be avoided as far as possible as this may cause atrophic changes in the skin leading to thinning, loss of elasticity, dilatation of superficial blood vessels, telangiectasia and ecchymoses. these changes are particularly likely to occur when occlusive dressings are used. systemic absorption of topically applied corticosteroids may occur, particularly under the following conditions: when large quantities are used or when application is made to wide areas of the body, or to damaged skin; when potent topical corticosteroids are used, and when the occlusive dressing technique is applied. depression of the hypothalamic-pituitary-adrenal axis with consequent suppression of the adrenal gland may occur. these effects are most likely to be severe in children. growth may be retarded and a cushingoid state may be produced. benign intracranial hypertension has been rarely reported. ",cinchocaine + hydrocortisone + framycetin + esculin
sign_symptom,cushingoid state,0.9915283," long-term continuous treatment with topical corticosteroids should be avoided as far as possible as this may cause atrophic changes in the skin leading to thinning, loss of elasticity, dilatation of superficial blood vessels, telangiectasia and ecchymoses. these changes are particularly likely to occur when occlusive dressings are used. systemic absorption of topically applied corticosteroids may occur, particularly under the following conditions: when large quantities are used or when application is made to wide areas of the body, or to damaged skin; when potent topical corticosteroids are used, and when the occlusive dressing technique is applied. depression of the hypothalamic-pituitary-adrenal axis with consequent suppression of the adrenal gland may occur. these effects are most likely to be severe in children. growth may be retarded and a cushingoid state may be produced. benign intracranial hypertension has been rarely reported. ",cinchocaine + hydrocortisone + framycetin + esculin
sign_symptom,hyper,0.9996977," long-term continuous treatment with topical corticosteroids should be avoided as far as possible as this may cause atrophic changes in the skin leading to thinning, loss of elasticity, dilatation of superficial blood vessels, telangiectasia and ecchymoses. these changes are particularly likely to occur when occlusive dressings are used. systemic absorption of topically applied corticosteroids may occur, particularly under the following conditions: when large quantities are used or when application is made to wide areas of the body, or to damaged skin; when potent topical corticosteroids are used, and when the occlusive dressing technique is applied. depression of the hypothalamic-pituitary-adrenal axis with consequent suppression of the adrenal gland may occur. these effects are most likely to be severe in children. growth may be retarded and a cushingoid state may be produced. benign intracranial hypertension has been rarely reported. ",cinchocaine + hydrocortisone + framycetin + esculin
medication,testosterone,0.72235507," the common side effects of cinacalcet are nausea, vomiting, anorexia; dizziness, paraesthesia, asthenia; reduced testosterone concentrations; myalgia; rash; less commonly dyspepsia, diarrhoea, and seizures; hypotension and heart failure also reported. ",cinacalcet
sign_symptom,dyspeps,0.77854866," the common side effects of cinacalcet are nausea, vomiting, anorexia; dizziness, paraesthesia, asthenia; reduced testosterone concentrations; myalgia; rash; less commonly dyspepsia, diarrhoea, and seizures; hypotension and heart failure also reported. ",cinacalcet
disease_disorder,heart failure,0.9995696," the common side effects of cinacalcet are nausea, vomiting, anorexia; dizziness, paraesthesia, asthenia; reduced testosterone concentrations; myalgia; rash; less commonly dyspepsia, diarrhoea, and seizures; hypotension and heart failure also reported. ",cinacalcet
sign_symptom,rash,0.9148412," the most common side effects are headache, diarrhoea, vomiting, leg cramps, rash etc. the less frequent side effects are anorexia and edema. ",cilostazol
sign_symptom,mictur,0.7073347, the most common side effects of cilnidipine are: dizziness; flushing; headache; hypotension; peripheral oedema; palpitations; gi disturbances; increased micturition frequency; lethargy; eye pain; depression. ,cilnidipine
medication,ciclopirox olamine shampoo,0.8919822, ciclopirox olamine shampoo is well tolerated with a low incidence of adverse reactions reported in clinical trials. ,ciclopirox olamine (shampoo)
sign_symptom,adverse reactions,0.9999219, ciclopirox olamine shampoo is well tolerated with a low incidence of adverse reactions reported in clinical trials. ,ciclopirox olamine (shampoo)
sign_symptom,adverse reactions,0.99977624," serious adverse reactions were not observed in clinical trials. the most common adverse reaction was skin rash. other reactions such as chills, muscle cramps, back pain, fever, nausea, vomiting, and wheezing were the most frequent adverse reactions observed during the clinical trials of similarly-prepared human igiv products. ",clostridium botulinum toxin type a neurotoxin
sign_symptom,adverse reaction,0.9952338," serious adverse reactions were not observed in clinical trials. the most common adverse reaction was skin rash. other reactions such as chills, muscle cramps, back pain, fever, nausea, vomiting, and wheezing were the most frequent adverse reactions observed during the clinical trials of similarly-prepared human igiv products. ",clostridium botulinum toxin type a neurotoxin
sign_symptom,rash,0.8591898," serious adverse reactions were not observed in clinical trials. the most common adverse reaction was skin rash. other reactions such as chills, muscle cramps, back pain, fever, nausea, vomiting, and wheezing were the most frequent adverse reactions observed during the clinical trials of similarly-prepared human igiv products. ",clostridium botulinum toxin type a neurotoxin
sign_symptom,chill,0.9968838," serious adverse reactions were not observed in clinical trials. the most common adverse reaction was skin rash. other reactions such as chills, muscle cramps, back pain, fever, nausea, vomiting, and wheezing were the most frequent adverse reactions observed during the clinical trials of similarly-prepared human igiv products. ",clostridium botulinum toxin type a neurotoxin
medication,clopidogrel,0.870554," clopidogrel is generally well tolerated drug.  
 
  common side effects : bleeding, diarrhoea, gastrointestinal discomfort, haemorrhage, skin reactions. 
  rare side effects : acquired haemophilia, anaemia, angioedema, arthralgia, arthritis, bone marrow disorders. 
  ",clopidogrel bisulphate
sign_symptom,impotence,0.77533984," headache, dizziness, drowsiness, dry mouth, constipation, depression, anxiety, nausea, fatigue, anorexia, parotid pain, paraesthesia, delusional perception, sleep disturbances, vivid dreams, impotence and loss of libido, urinary retention or incontinence, orthostatic hypotension, itching or burning sensations in the eye, accommodation disorder, decreased lacrimation, fluid retention, pruritus and rashes (transdermal), bradycardia, other ecg disturbances, heart failure, hallucinations, cramp, raynaud's syndrome, gynaecomastia, transient abnormalities in lfts. ",clonidine hydrochloride
sign_symptom,loss of libido,0.99947584," headache, dizziness, drowsiness, dry mouth, constipation, depression, anxiety, nausea, fatigue, anorexia, parotid pain, paraesthesia, delusional perception, sleep disturbances, vivid dreams, impotence and loss of libido, urinary retention or incontinence, orthostatic hypotension, itching or burning sensations in the eye, accommodation disorder, decreased lacrimation, fluid retention, pruritus and rashes (transdermal), bradycardia, other ecg disturbances, heart failure, hallucinations, cramp, raynaud's syndrome, gynaecomastia, transient abnormalities in lfts. ",clonidine hydrochloride
sign_symptom,urina,0.9838872," headache, dizziness, drowsiness, dry mouth, constipation, depression, anxiety, nausea, fatigue, anorexia, parotid pain, paraesthesia, delusional perception, sleep disturbances, vivid dreams, impotence and loss of libido, urinary retention or incontinence, orthostatic hypotension, itching or burning sensations in the eye, accommodation disorder, decreased lacrimation, fluid retention, pruritus and rashes (transdermal), bradycardia, other ecg disturbances, heart failure, hallucinations, cramp, raynaud's syndrome, gynaecomastia, transient abnormalities in lfts. ",clonidine hydrochloride
sign_symptom,fluid,0.99524814," headache, dizziness, drowsiness, dry mouth, constipation, depression, anxiety, nausea, fatigue, anorexia, parotid pain, paraesthesia, delusional perception, sleep disturbances, vivid dreams, impotence and loss of libido, urinary retention or incontinence, orthostatic hypotension, itching or burning sensations in the eye, accommodation disorder, decreased lacrimation, fluid retention, pruritus and rashes (transdermal), bradycardia, other ecg disturbances, heart failure, hallucinations, cramp, raynaud's syndrome, gynaecomastia, transient abnormalities in lfts. ",clonidine hydrochloride
sign_symptom,rash,0.9994979," headache, dizziness, drowsiness, dry mouth, constipation, depression, anxiety, nausea, fatigue, anorexia, parotid pain, paraesthesia, delusional perception, sleep disturbances, vivid dreams, impotence and loss of libido, urinary retention or incontinence, orthostatic hypotension, itching or burning sensations in the eye, accommodation disorder, decreased lacrimation, fluid retention, pruritus and rashes (transdermal), bradycardia, other ecg disturbances, heart failure, hallucinations, cramp, raynaud's syndrome, gynaecomastia, transient abnormalities in lfts. ",clonidine hydrochloride
sign_symptom,seizures,0.99993896," the most frequently occurring side effects of clonazepam are referable to cns depression. experience in treatment of seizures has shown that drowsiness has occurred in approximately 50% of patients and ataxia in approximately 30%. in some cases, these may diminish with time; behavior problems have been noted in approximately 25% of patients. abnormal eye movements, aphonia, coma, tremor, vertigo, confusion, depression, amnesia, hallucinations, hysteria, increased libido, insomnia, psychosis &amp; palpitations may also occur. ",clonazepam
sign_symptom,behavior problems,0.9502748," the most frequently occurring side effects of clonazepam are referable to cns depression. experience in treatment of seizures has shown that drowsiness has occurred in approximately 50% of patients and ataxia in approximately 30%. in some cases, these may diminish with time; behavior problems have been noted in approximately 25% of patients. abnormal eye movements, aphonia, coma, tremor, vertigo, confusion, depression, amnesia, hallucinations, hysteria, increased libido, insomnia, psychosis &amp; palpitations may also occur. ",clonazepam
sign_symptom,tired,0.99642664," very common side effects are increase in appetite and weight gain, headaches, dizziness, nausea, constipation, dry mouth, increased sweating, shaking hands, tremor, difficulty in passing urine, problems with their eyes, feeling tired or sleepy, sexual disturbances, restlessness. ",clomipramine hydrochloride
medication,clomiphene citrate,0.99014294," clomiphene citrate is well tolerated. however a few side effects like dizziness, headache, nausea, vomiting, depression, fatigue, insomnia, vasomotor flushing, and allergic reaction may occur. rarely ovarian enlargement and cyst formation may occur. all these effects disappear promptly after the treatment is discontinued. ",clomiphene citrate
sign_symptom,side effects,0.98248816," clomiphene citrate is well tolerated. however a few side effects like dizziness, headache, nausea, vomiting, depression, fatigue, insomnia, vasomotor flushing, and allergic reaction may occur. rarely ovarian enlargement and cyst formation may occur. all these effects disappear promptly after the treatment is discontinued. ",clomiphene citrate
sign_symptom,allergic reaction,0.99017537," clomiphene citrate is well tolerated. however a few side effects like dizziness, headache, nausea, vomiting, depression, fatigue, insomnia, vasomotor flushing, and allergic reaction may occur. rarely ovarian enlargement and cyst formation may occur. all these effects disappear promptly after the treatment is discontinued. ",clomiphene citrate
sign_symptom,enlargement,0.87236476," clomiphene citrate is well tolerated. however a few side effects like dizziness, headache, nausea, vomiting, depression, fatigue, insomnia, vasomotor flushing, and allergic reaction may occur. rarely ovarian enlargement and cyst formation may occur. all these effects disappear promptly after the treatment is discontinued. ",clomiphene citrate
sign_symptom,cyst formation,0.99727315," clomiphene citrate is well tolerated. however a few side effects like dizziness, headache, nausea, vomiting, depression, fatigue, insomnia, vasomotor flushing, and allergic reaction may occur. rarely ovarian enlargement and cyst formation may occur. all these effects disappear promptly after the treatment is discontinued. ",clomiphene citrate
disease_disorder,infections,0.9877237," local atrophic changes; pigmentation changes &amp; hypertrichosis. increased liability to infection. infections may be masked. acute adrenal insufficiency. growth retardation in child. cushingoid symptoms. amenorrhoea, hyperhidrosis, skin thinning ",clobetasone butyrate
sign_symptom,growth retardation,0.99669665," local atrophic changes; pigmentation changes &amp; hypertrichosis. increased liability to infection. infections may be masked. acute adrenal insufficiency. growth retardation in child. cushingoid symptoms. amenorrhoea, hyperhidrosis, skin thinning ",clobetasone butyrate
sign_symptom,hyper,0.978211," local atrophic changes; pigmentation changes &amp; hypertrichosis. increased liability to infection. infections may be masked. acute adrenal insufficiency. growth retardation in child. cushingoid symptoms. amenorrhoea, hyperhidrosis, skin thinning ",clobetasone butyrate
sign_symptom,skin,0.9593615," local atrophic changes; pigmentation changes &amp; hypertrichosis. increased liability to infection. infections may be masked. acute adrenal insufficiency. growth retardation in child. cushingoid symptoms. amenorrhoea, hyperhidrosis, skin thinning ",clobetasone butyrate
medication,clobetasol propionate,0.95419085," as with other topical corticosteroids, prolonged use of large amounts of clobetasol propionate or treatment of extensive areas can result in sufficient systemic absorption to produce the features of hypercortisolism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. local atrophy may occur after prolonged treatment. in rare instances, treatment of psoriasis with corticosteroids (or its withdrawal) is thought to have provoked the pustular form of the diseases. clobetasol propionate is usually well tolerated, but if signs of hypersensitivity appear, application should be stopped immediately. possible sensitivity reactions, drying and irritation when using salicylic acid. ",clobetasol propionate + salicylic acid
sign_symptom,irritation,0.9980484," as with other topical corticosteroids, prolonged use of large amounts of clobetasol propionate or treatment of extensive areas can result in sufficient systemic absorption to produce the features of hypercortisolism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. local atrophy may occur after prolonged treatment. in rare instances, treatment of psoriasis with corticosteroids (or its withdrawal) is thought to have provoked the pustular form of the diseases. clobetasol propionate is usually well tolerated, but if signs of hypersensitivity appear, application should be stopped immediately. possible sensitivity reactions, drying and irritation when using salicylic acid. ",clobetasol propionate + salicylic acid
sign_symptom,changes,0.85512286," as with other topical corticosteroids, prolonged use of large amount or treatment of extensive areas can result in sufficient systemic absorption to produce the features of hypercortisolism. the effect is more likely to occur in infants and children and if occlusive dressings are used. prolonged and intensive treatment with highly active corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, and dilatation of the superficial blood vessels, particularly when occlusive dressings are used, or when skin folds are involved. there are reports of pigmentation changes and hypertrichosis with topical steroids. ",clobetasol propionate + neomycin sulphate + nystatin
sign_symptom,thin,0.9977563," as with other topical corticosteroids, prolonged use of large amount or treatment of extensive areas can result in sufficient systemic absorption to produce the features of hypercortisolism. the effect is more likely to occur in infants and children and if occlusive dressings are used. prolonged and intensive treatment with highly active corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, and dilatation of the superficial blood vessels, particularly when occlusive dressings are used, or when skin folds are involved. there are reports of pigmentation changes and hypertrichosis with topical steroids. ",clobetasol propionate + neomycin sulphate + nystatin
sign_symptom,pigmentation changes,0.98291665," as with other topical corticosteroids, prolonged use of large amount or treatment of extensive areas can result in sufficient systemic absorption to produce the features of hypercortisolism. the effect is more likely to occur in infants and children and if occlusive dressings are used. prolonged and intensive treatment with highly active corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, and dilatation of the superficial blood vessels, particularly when occlusive dressings are used, or when skin folds are involved. there are reports of pigmentation changes and hypertrichosis with topical steroids. ",clobetasol propionate + neomycin sulphate + nystatin
sign_symptom,hypertrichosis,0.83970785," as with other topical corticosteroids, prolonged use of large amount or treatment of extensive areas can result in sufficient systemic absorption to produce the features of hypercortisolism. the effect is more likely to occur in infants and children and if occlusive dressings are used. prolonged and intensive treatment with highly active corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, and dilatation of the superficial blood vessels, particularly when occlusive dressings are used, or when skin folds are involved. there are reports of pigmentation changes and hypertrichosis with topical steroids. ",clobetasol propionate + neomycin sulphate + nystatin
sign_symptom,adverse reactions,0.98806155," the most reported side effects are burning and stinging sensation. less frequent adverse reactions are itching, skin atrophy, cracking and fissuring of the skin. cushing syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations. ",clobetasol propionate (topical preparation)
sign_symptom,cracking,0.998242," the most reported side effects are burning and stinging sensation. less frequent adverse reactions are itching, skin atrophy, cracking and fissuring of the skin. cushing syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations. ",clobetasol propionate (topical preparation)
medication,clobetasol propionate,0.9885906," the most reported side effects are burning and stinging sensation. less frequent adverse reactions are itching, skin atrophy, cracking and fissuring of the skin. cushing syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations. ",clobetasol propionate (topical preparation)
medication,corti,0.7977725," as with other corticosteroids, prolonged use of large amounts or treatment of extensive areas, can result in sufficient systemic absorption to produce the features of hypercortisolism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. local atrophy may occur after prolonged treatment. in rare instances, treatment of psoriasis with corticosteroids (or its withdrawal) is thought to have provoked the pustular form of the disease. if signs of hypersensitivity appear with the use of clobetasol propionate scalp solution then application should be stopped immediately. ",clobetasol propionate (scalp preparation)
sign_symptom,hyper,0.9994849," as with other corticosteroids, prolonged use of large amounts or treatment of extensive areas, can result in sufficient systemic absorption to produce the features of hypercortisolism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. local atrophy may occur after prolonged treatment. in rare instances, treatment of psoriasis with corticosteroids (or its withdrawal) is thought to have provoked the pustular form of the disease. if signs of hypersensitivity appear with the use of clobetasol propionate scalp solution then application should be stopped immediately. ",clobetasol propionate (scalp preparation)
sign_symptom,decreased appetite,0.91890144,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
disease_disorder,psychiatric,0.93801814,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
sign_symptom,aggression,0.9276854,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
sign_symptom,restlessness,0.99421,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
disease_disorder,nervous system disorders,0.8707072,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
sign_symptom,disturbance,0.99903274,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
sign_symptom,speech /,0.8064784,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
disease_disorder,speech disorder,0.99656105,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
disease_disorder,mediasti,0.8279637,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
disease_disorder,disorders,0.9874594,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
disease_disorder,respiratory depression,0.99957407,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
disease_disorder,respiratory failure,0.999823,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
sign_symptom,dry mouth,0.8088751,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
sign_symptom,constipation skin,0.8664061,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
sign_symptom,photosensitivity reaction,0.81676465,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
disease_disorder,connective tissue disorders,0.98994756,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
disease_disorder,muscle,0.9107328,"  metabolism and nutrition disorders : common: decreased appetite   psychiatric disorders : common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.   nervous system disorders : very common: somnolence, especially at the beginning of treatment and when higher doses are used; common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.   eye disorders : uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)   respiratory, thoracic and mediastinal disorders : not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)   gastrointestinal disorders : common: dry mouth, nausea, constipation   skin and subcutaneous disorders : uncommon: rash; not known: photosensitivity reaction urticaria; steven johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);   musculoskeleteal and connective tissue disorders : not known: muscle spasms, muscle weakness   general disorders and administration site conditions : very common: fatigue, especially at the beginning of treatment and when higher doses are used. not known: slow response to stimuli, hypothermia   investigations : uncommon: weight increased (particularly with high doses or in long-term treatment). ",clobazam
sign_symptom,rash,0.99952376," occasionally burning sensation, itching or skin rash may occur. treatment should be discontinued if severe irritation or sensitization develops. ",clioquinol + flumetasone pivalate
sign_symptom,irritation,0.9998996," occasionally burning sensation, itching or skin rash may occur. treatment should be discontinued if severe irritation or sensitization develops. ",clioquinol + flumetasone pivalate
sign_symptom,nasopharyn,0.98746455," erythema, scaling, nasopharyngitis, dry skin, cough, sinusitis and diarrhea are the common side effects. ",clindamycin + tretinoin
sign_symptom,cough,0.9990404," erythema, scaling, nasopharyngitis, dry skin, cough, sinusitis and diarrhea are the common side effects. ",clindamycin + tretinoin
sign_symptom,sinusitis,0.9976432," erythema, scaling, nasopharyngitis, dry skin, cough, sinusitis and diarrhea are the common side effects. ",clindamycin + tretinoin
medication,clindamycin,0.9741239," clindamycin may results the following side effects. genital tract: vaginitis, vulvo-vaginal irritation central nervous system: dizziness, headache, vertigo.gastro-intestinal: heartburn, nausea, vomiting, diarrhea, constipation, abdominal pain. dermatological: rash, exanthema. hypersensitivity: urticaria. ",clindamycin (vaginal cream)
sign_symptom,irritation,0.9998312," clindamycin may results the following side effects. genital tract: vaginitis, vulvo-vaginal irritation central nervous system: dizziness, headache, vertigo.gastro-intestinal: heartburn, nausea, vomiting, diarrhea, constipation, abdominal pain. dermatological: rash, exanthema. hypersensitivity: urticaria. ",clindamycin (vaginal cream)
sign_symptom,in skin,0.84141636," side effects are usually rare. possible side-effects may includes skin rash, itching, oily skin, dryness, erythema, burning, change in skin color, diarrhea, colitis, gi disturbance etc. ",clindamycin (lotion)
disease_disorder,colitis,0.79557073," side effects are usually rare. possible side-effects may includes skin rash, itching, oily skin, dryness, erythema, burning, change in skin color, diarrhea, colitis, gi disturbance etc. ",clindamycin (lotion)
sign_symptom,oesophagitis,0.99957013," the adverse effects have been reported with the use of clindamycin are- abdominal pain, oesophagitis and oesophagial ulcer, nausea, vomiting and diarrhoea, pruritus, skin rashes, urticaria. ",clindamycin
sign_symptom,oesophagial,0.9978443," the adverse effects have been reported with the use of clindamycin are- abdominal pain, oesophagitis and oesophagial ulcer, nausea, vomiting and diarrhoea, pruritus, skin rashes, urticaria. ",clindamycin
sign_symptom,vomiting,0.9995122," the adverse effects have been reported with the use of clindamycin are- abdominal pain, oesophagitis and oesophagial ulcer, nausea, vomiting and diarrhoea, pruritus, skin rashes, urticaria. ",clindamycin
sign_symptom,diarrhoe,0.7721265," the adverse effects have been reported with the use of clindamycin are- abdominal pain, oesophagitis and oesophagial ulcer, nausea, vomiting and diarrhoea, pruritus, skin rashes, urticaria. ",clindamycin
sign_symptom,rash,0.86404693," the adverse effects have been reported with the use of clindamycin are- abdominal pain, oesophagitis and oesophagial ulcer, nausea, vomiting and diarrhoea, pruritus, skin rashes, urticaria. ",clindamycin
sign_symptom,dyspeps,0.9943843," in four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain. ",conjugated estrogen + bazedoxifene
sign_symptom,pain,0.9999305," in four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain. ",conjugated estrogen + bazedoxifene
sign_symptom,tenderness,0.9999293," breast pain, tenderness or enlargement, headache/migraine, gut disturbances, such as nausea, abdominal pain, bloating, flatulence, indigestion, legcramps, fatigue, weightchanges, vaginalthrush, depression, anxiety, dizziness, changes in sex drive, rise in blood pressure, gall bladder disease, swelling of the ankles due to to fluid retention (peripheral oedema), skin reactions such as rash and itch, steepening of corneal curvature which may make contact lenses uncomfortable, premenstrual-like symptoms, disturbance in liver function, irregular brown patches on the skin, usually of the face (chloasma), blood clots in the blood vessels. ",conjugated estrogen (tablet)
sign_symptom,headache,0.99975234," breast pain, tenderness or enlargement, headache/migraine, gut disturbances, such as nausea, abdominal pain, bloating, flatulence, indigestion, legcramps, fatigue, weightchanges, vaginalthrush, depression, anxiety, dizziness, changes in sex drive, rise in blood pressure, gall bladder disease, swelling of the ankles due to to fluid retention (peripheral oedema), skin reactions such as rash and itch, steepening of corneal curvature which may make contact lenses uncomfortable, premenstrual-like symptoms, disturbance in liver function, irregular brown patches on the skin, usually of the face (chloasma), blood clots in the blood vessels. ",conjugated estrogen (tablet)
sign_symptom,swelling,0.9999081," breast pain, tenderness or enlargement, headache/migraine, gut disturbances, such as nausea, abdominal pain, bloating, flatulence, indigestion, legcramps, fatigue, weightchanges, vaginalthrush, depression, anxiety, dizziness, changes in sex drive, rise in blood pressure, gall bladder disease, swelling of the ankles due to to fluid retention (peripheral oedema), skin reactions such as rash and itch, steepening of corneal curvature which may make contact lenses uncomfortable, premenstrual-like symptoms, disturbance in liver function, irregular brown patches on the skin, usually of the face (chloasma), blood clots in the blood vessels. ",conjugated estrogen (tablet)
sign_symptom,skin,0.8456023," breast pain, tenderness or enlargement, headache/migraine, gut disturbances, such as nausea, abdominal pain, bloating, flatulence, indigestion, legcramps, fatigue, weightchanges, vaginalthrush, depression, anxiety, dizziness, changes in sex drive, rise in blood pressure, gall bladder disease, swelling of the ankles due to to fluid retention (peripheral oedema), skin reactions such as rash and itch, steepening of corneal curvature which may make contact lenses uncomfortable, premenstrual-like symptoms, disturbance in liver function, irregular brown patches on the skin, usually of the face (chloasma), blood clots in the blood vessels. ",conjugated estrogen (tablet)
sign_symptom,rash,0.9998448," breast pain, tenderness or enlargement, headache/migraine, gut disturbances, such as nausea, abdominal pain, bloating, flatulence, indigestion, legcramps, fatigue, weightchanges, vaginalthrush, depression, anxiety, dizziness, changes in sex drive, rise in blood pressure, gall bladder disease, swelling of the ankles due to to fluid retention (peripheral oedema), skin reactions such as rash and itch, steepening of corneal curvature which may make contact lenses uncomfortable, premenstrual-like symptoms, disturbance in liver function, irregular brown patches on the skin, usually of the face (chloasma), blood clots in the blood vessels. ",conjugated estrogen (tablet)
sign_symptom,corneal curvature,0.9948101," breast pain, tenderness or enlargement, headache/migraine, gut disturbances, such as nausea, abdominal pain, bloating, flatulence, indigestion, legcramps, fatigue, weightchanges, vaginalthrush, depression, anxiety, dizziness, changes in sex drive, rise in blood pressure, gall bladder disease, swelling of the ankles due to to fluid retention (peripheral oedema), skin reactions such as rash and itch, steepening of corneal curvature which may make contact lenses uncomfortable, premenstrual-like symptoms, disturbance in liver function, irregular brown patches on the skin, usually of the face (chloasma), blood clots in the blood vessels. ",conjugated estrogen (tablet)
sign_symptom,disturbance,0.9400078," breast pain, tenderness or enlargement, headache/migraine, gut disturbances, such as nausea, abdominal pain, bloating, flatulence, indigestion, legcramps, fatigue, weightchanges, vaginalthrush, depression, anxiety, dizziness, changes in sex drive, rise in blood pressure, gall bladder disease, swelling of the ankles due to to fluid retention (peripheral oedema), skin reactions such as rash and itch, steepening of corneal curvature which may make contact lenses uncomfortable, premenstrual-like symptoms, disturbance in liver function, irregular brown patches on the skin, usually of the face (chloasma), blood clots in the blood vessels. ",conjugated estrogen (tablet)
sign_symptom,clots,0.9727733," breast pain, tenderness or enlargement, headache/migraine, gut disturbances, such as nausea, abdominal pain, bloating, flatulence, indigestion, legcramps, fatigue, weightchanges, vaginalthrush, depression, anxiety, dizziness, changes in sex drive, rise in blood pressure, gall bladder disease, swelling of the ankles due to to fluid retention (peripheral oedema), skin reactions such as rash and itch, steepening of corneal curvature which may make contact lenses uncomfortable, premenstrual-like symptoms, disturbance in liver function, irregular brown patches on the skin, usually of the face (chloasma), blood clots in the blood vessels. ",conjugated estrogen (tablet)
sign_symptom,adverse reactions,0.99972326," the most serious adverse reactions associated with the use of estrogen are indicated under warnings and precautions. the following additional adverse reactions have been reported with estrogenic therapy. 
 
 genitourinary system: breakthrough bleeding, spotting, change in menstrual flow, amenorrhea. 
 breasts: tenderness, enlargement, secretion. 
 gastrointestinal: nausea, vomiting, abdominal cramps, bloating, cholestatic jaundice. 
 skin: chloasma or melasma which may persist when drug is discontinued, alopecia, rash. 
 eyes: steepening of the corneal curvature; intolerance to contact lenses. 
 central nervous system: headache, migraine, dizziness; chorea. 
 miscellaneous: increase or decrease in weight; edema; changes in libido, aggravation of porphyria. 
 
common side effects include headache, breast pain, irregular vaginal bleeding or spotting, stomach or abdominal cramps, bloating, nausea and vomiting, hair loss, fluid retention, vaginal yeast infection, reactions from inserting conjugated estrogen vaginal cream, such as vaginal burning, irritation and itching.  uncommon side effects heart attack, stroke, blood clots, dementia, breast cancer, cancer of the lining of the uterus (womb), cancer of the ovary, high blood pressure, high blood sugar, gallbladder disease, enlargement of benign tumors of the uterus (fibroids), severe allergic reaction. ",conjugated estrogen (cream)
sign_symptom,chlo,0.86051714," the most serious adverse reactions associated with the use of estrogen are indicated under warnings and precautions. the following additional adverse reactions have been reported with estrogenic therapy. 
 
 genitourinary system: breakthrough bleeding, spotting, change in menstrual flow, amenorrhea. 
 breasts: tenderness, enlargement, secretion. 
 gastrointestinal: nausea, vomiting, abdominal cramps, bloating, cholestatic jaundice. 
 skin: chloasma or melasma which may persist when drug is discontinued, alopecia, rash. 
 eyes: steepening of the corneal curvature; intolerance to contact lenses. 
 central nervous system: headache, migraine, dizziness; chorea. 
 miscellaneous: increase or decrease in weight; edema; changes in libido, aggravation of porphyria. 
 
common side effects include headache, breast pain, irregular vaginal bleeding or spotting, stomach or abdominal cramps, bloating, nausea and vomiting, hair loss, fluid retention, vaginal yeast infection, reactions from inserting conjugated estrogen vaginal cream, such as vaginal burning, irritation and itching.  uncommon side effects heart attack, stroke, blood clots, dementia, breast cancer, cancer of the lining of the uterus (womb), cancer of the ovary, high blood pressure, high blood sugar, gallbladder disease, enlargement of benign tumors of the uterus (fibroids), severe allergic reaction. ",conjugated estrogen (cream)
sign_symptom,tumors,0.990884," the most serious adverse reactions associated with the use of estrogen are indicated under warnings and precautions. the following additional adverse reactions have been reported with estrogenic therapy. 
 
 genitourinary system: breakthrough bleeding, spotting, change in menstrual flow, amenorrhea. 
 breasts: tenderness, enlargement, secretion. 
 gastrointestinal: nausea, vomiting, abdominal cramps, bloating, cholestatic jaundice. 
 skin: chloasma or melasma which may persist when drug is discontinued, alopecia, rash. 
 eyes: steepening of the corneal curvature; intolerance to contact lenses. 
 central nervous system: headache, migraine, dizziness; chorea. 
 miscellaneous: increase or decrease in weight; edema; changes in libido, aggravation of porphyria. 
 
common side effects include headache, breast pain, irregular vaginal bleeding or spotting, stomach or abdominal cramps, bloating, nausea and vomiting, hair loss, fluid retention, vaginal yeast infection, reactions from inserting conjugated estrogen vaginal cream, such as vaginal burning, irritation and itching.  uncommon side effects heart attack, stroke, blood clots, dementia, breast cancer, cancer of the lining of the uterus (womb), cancer of the ovary, high blood pressure, high blood sugar, gallbladder disease, enlargement of benign tumors of the uterus (fibroids), severe allergic reaction. ",conjugated estrogen (cream)
sign_symptom,adverse reactions,0.99942917," the following adverse reactions have been reported: gastrointestinal upset, tingling of extremities and tongue, slurred speech, dizziness, vertigo and paresthesia, generalized itching, urticaria and rash, fever, increased blood urea nitrogen (bun), elevated creatinine and decreased creatinine clearance, respiratory distress and apnea, nephrotoxicity and decreased urine output. ",colistimethate sodium
sign_symptom,tingling,0.9999459," the following adverse reactions have been reported: gastrointestinal upset, tingling of extremities and tongue, slurred speech, dizziness, vertigo and paresthesia, generalized itching, urticaria and rash, fever, increased blood urea nitrogen (bun), elevated creatinine and decreased creatinine clearance, respiratory distress and apnea, nephrotoxicity and decreased urine output. ",colistimethate sodium
sign_symptom,vertigo,0.99567765," the following adverse reactions have been reported: gastrointestinal upset, tingling of extremities and tongue, slurred speech, dizziness, vertigo and paresthesia, generalized itching, urticaria and rash, fever, increased blood urea nitrogen (bun), elevated creatinine and decreased creatinine clearance, respiratory distress and apnea, nephrotoxicity and decreased urine output. ",colistimethate sodium
sign_symptom,urticaria,0.99359673," the following adverse reactions have been reported: gastrointestinal upset, tingling of extremities and tongue, slurred speech, dizziness, vertigo and paresthesia, generalized itching, urticaria and rash, fever, increased blood urea nitrogen (bun), elevated creatinine and decreased creatinine clearance, respiratory distress and apnea, nephrotoxicity and decreased urine output. ",colistimethate sodium
sign_symptom,respiratory,0.9997348," the following adverse reactions have been reported: gastrointestinal upset, tingling of extremities and tongue, slurred speech, dizziness, vertigo and paresthesia, generalized itching, urticaria and rash, fever, increased blood urea nitrogen (bun), elevated creatinine and decreased creatinine clearance, respiratory distress and apnea, nephrotoxicity and decreased urine output. ",colistimethate sodium
sign_symptom,distress,0.9746953," the following adverse reactions have been reported: gastrointestinal upset, tingling of extremities and tongue, slurred speech, dizziness, vertigo and paresthesia, generalized itching, urticaria and rash, fever, increased blood urea nitrogen (bun), elevated creatinine and decreased creatinine clearance, respiratory distress and apnea, nephrotoxicity and decreased urine output. ",colistimethate sodium
sign_symptom,neph,0.9908935," the following adverse reactions have been reported: gastrointestinal upset, tingling of extremities and tongue, slurred speech, dizziness, vertigo and paresthesia, generalized itching, urticaria and rash, fever, increased blood urea nitrogen (bun), elevated creatinine and decreased creatinine clearance, respiratory distress and apnea, nephrotoxicity and decreased urine output. ",colistimethate sodium
sign_symptom,dyscrasia,0.8805951," blood dyscrasias: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported. diarrhea and pharyngolaryngeal pain may occur. ",colchicine
sign_symptom,anemia,0.83751583," blood dyscrasias: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported. diarrhea and pharyngolaryngeal pain may occur. ",colchicine
sign_symptom,diarr,0.9967489," blood dyscrasias: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported. diarrhea and pharyngolaryngeal pain may occur. ",colchicine
sign_symptom,pain,0.99968684," blood dyscrasias: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported. diarrhea and pharyngolaryngeal pain may occur. ",colchicine
sign_symptom,hypervitamin,0.882171," prolonged usage of large amounts can lead to hypervitaminosis symptoms of which include dry mouth, rough skin, painful joints swelling, fatigue, anorexia, loss of weight, vomiting and other gastrointestinal disturbances. these may disappear on discontinuation of supplementation. ",cod liver oil
sign_symptom,dry mouth,0.9055332," prolonged usage of large amounts can lead to hypervitaminosis symptoms of which include dry mouth, rough skin, painful joints swelling, fatigue, anorexia, loss of weight, vomiting and other gastrointestinal disturbances. these may disappear on discontinuation of supplementation. ",cod liver oil
sign_symptom,painful,0.9952779," prolonged usage of large amounts can lead to hypervitaminosis symptoms of which include dry mouth, rough skin, painful joints swelling, fatigue, anorexia, loss of weight, vomiting and other gastrointestinal disturbances. these may disappear on discontinuation of supplementation. ",cod liver oil
sign_symptom,fatigue,0.99020785," prolonged usage of large amounts can lead to hypervitaminosis symptoms of which include dry mouth, rough skin, painful joints swelling, fatigue, anorexia, loss of weight, vomiting and other gastrointestinal disturbances. these may disappear on discontinuation of supplementation. ",cod liver oil
sign_symptom,anorexia,0.99008054," prolonged usage of large amounts can lead to hypervitaminosis symptoms of which include dry mouth, rough skin, painful joints swelling, fatigue, anorexia, loss of weight, vomiting and other gastrointestinal disturbances. these may disappear on discontinuation of supplementation. ",cod liver oil
sign_symptom,loss of weight,0.99976516," prolonged usage of large amounts can lead to hypervitaminosis symptoms of which include dry mouth, rough skin, painful joints swelling, fatigue, anorexia, loss of weight, vomiting and other gastrointestinal disturbances. these may disappear on discontinuation of supplementation. ",cod liver oil
sign_symptom,vomiting,0.99988043," prolonged usage of large amounts can lead to hypervitaminosis symptoms of which include dry mouth, rough skin, painful joints swelling, fatigue, anorexia, loss of weight, vomiting and other gastrointestinal disturbances. these may disappear on discontinuation of supplementation. ",cod liver oil
sign_symptom,allergies,0.8251669," in rare cases, polytar scalp shampoo is associated with skin reactions due to allergies (rashes, swelling, difficulty breathing). other possible rare side effects include eye irritation, hair loss, itchy and redskin, change of hair colour or texture, and burning sensations on the skin.  if you are taking other medications, speak to your doctor before using this shampoo, as certain antibiotics and tranquilizers increase sensitivity to sunlight. ",coal tar solution
sign_symptom,rash,0.9976502," in rare cases, polytar scalp shampoo is associated with skin reactions due to allergies (rashes, swelling, difficulty breathing). other possible rare side effects include eye irritation, hair loss, itchy and redskin, change of hair colour or texture, and burning sensations on the skin.  if you are taking other medications, speak to your doctor before using this shampoo, as certain antibiotics and tranquilizers increase sensitivity to sunlight. ",coal tar solution
sign_symptom,of hair colour,0.8795487," in rare cases, polytar scalp shampoo is associated with skin reactions due to allergies (rashes, swelling, difficulty breathing). other possible rare side effects include eye irritation, hair loss, itchy and redskin, change of hair colour or texture, and burning sensations on the skin.  if you are taking other medications, speak to your doctor before using this shampoo, as certain antibiotics and tranquilizers increase sensitivity to sunlight. ",coal tar solution
medication,antibiotics,0.9994055," in rare cases, polytar scalp shampoo is associated with skin reactions due to allergies (rashes, swelling, difficulty breathing). other possible rare side effects include eye irritation, hair loss, itchy and redskin, change of hair colour or texture, and burning sensations on the skin.  if you are taking other medications, speak to your doctor before using this shampoo, as certain antibiotics and tranquilizers increase sensitivity to sunlight. ",coal tar solution
medication,tranquilizers,0.8917892," in rare cases, polytar scalp shampoo is associated with skin reactions due to allergies (rashes, swelling, difficulty breathing). other possible rare side effects include eye irritation, hair loss, itchy and redskin, change of hair colour or texture, and burning sensations on the skin.  if you are taking other medications, speak to your doctor before using this shampoo, as certain antibiotics and tranquilizers increase sensitivity to sunlight. ",coal tar solution
sign_symptom,irritation,0.9999331," coal ta ointment may occasionally cause irritation of the skin, inflammation of the hair follicles and rarely photosensitivity of the skin. ",coal tar + precipitated sulphur + salicylic acid
sign_symptom,inflammation,0.9995197," coal ta ointment may occasionally cause irritation of the skin, inflammation of the hair follicles and rarely photosensitivity of the skin. ",coal tar + precipitated sulphur + salicylic acid
sign_symptom,photosens,0.75466084," coal ta ointment may occasionally cause irritation of the skin, inflammation of the hair follicles and rarely photosensitivity of the skin. ",coal tar + precipitated sulphur + salicylic acid
sign_symptom,photosens,0.76462996," skin and subcutaneous tissue disorders: skin irritation, photosensitivity of the skin, coal tar cream may cause acne-like eruptions of the skin. there is an increased risk of skin cancer in psoriatic patients treated with a combination of coal tar cream and uvb radiation has been reported. however epidemiological studies of patients treated with coal tar cream on its own are inconclusive. the risk of toxicity should be taken into account when considering the prescribing this product for the patient. ",coal tar
sign_symptom,eruptions,0.9997222," skin and subcutaneous tissue disorders: skin irritation, photosensitivity of the skin, coal tar cream may cause acne-like eruptions of the skin. there is an increased risk of skin cancer in psoriatic patients treated with a combination of coal tar cream and uvb radiation has been reported. however epidemiological studies of patients treated with coal tar cream on its own are inconclusive. the risk of toxicity should be taken into account when considering the prescribing this product for the patient. ",coal tar
sign_symptom,cancer,0.9565187," skin and subcutaneous tissue disorders: skin irritation, photosensitivity of the skin, coal tar cream may cause acne-like eruptions of the skin. there is an increased risk of skin cancer in psoriatic patients treated with a combination of coal tar cream and uvb radiation has been reported. however epidemiological studies of patients treated with coal tar cream on its own are inconclusive. the risk of toxicity should be taken into account when considering the prescribing this product for the patient. ",coal tar
sign_symptom,toxicity,0.9296994," skin and subcutaneous tissue disorders: skin irritation, photosensitivity of the skin, coal tar cream may cause acne-like eruptions of the skin. there is an increased risk of skin cancer in psoriatic patients treated with a combination of coal tar cream and uvb radiation has been reported. however epidemiological studies of patients treated with coal tar cream on its own are inconclusive. the risk of toxicity should be taken into account when considering the prescribing this product for the patient. ",coal tar
sign_symptom,vomiting,0.98277676," nausea, vomiting, skin reactions, fever, headache and changes in bp. rarely, anaphylaxis. ",coagulation factor viia [eptacog alfa]
sign_symptom,headache,0.9997658," nausea, vomiting, skin reactions, fever, headache and changes in bp. rarely, anaphylaxis. ",coagulation factor viia [eptacog alfa]
sign_symptom,lightheadedness,0.99955165," common side effects are constipation, dizziness or lightheadedness (mild), drowsiness, headache (mild), increased watering of mouth, nausea or vomiting, unusual weight gain. less common side effects include abdominal discomfort or heartburn, dryness of mouth. ",clozapine
sign_symptom,headache,0.99987125," common side effects are constipation, dizziness or lightheadedness (mild), drowsiness, headache (mild), increased watering of mouth, nausea or vomiting, unusual weight gain. less common side effects include abdominal discomfort or heartburn, dryness of mouth. ",clozapine
sign_symptom,watering,0.9608171," common side effects are constipation, dizziness or lightheadedness (mild), drowsiness, headache (mild), increased watering of mouth, nausea or vomiting, unusual weight gain. less common side effects include abdominal discomfort or heartburn, dryness of mouth. ",clozapine
sign_symptom,nausea,0.9898226," common side effects are constipation, dizziness or lightheadedness (mild), drowsiness, headache (mild), increased watering of mouth, nausea or vomiting, unusual weight gain. less common side effects include abdominal discomfort or heartburn, dryness of mouth. ",clozapine
sign_symptom,discomfort,0.9995925," common side effects are constipation, dizziness or lightheadedness (mild), drowsiness, headache (mild), increased watering of mouth, nausea or vomiting, unusual weight gain. less common side effects include abdominal discomfort or heartburn, dryness of mouth. ",clozapine
sign_symptom,irritation,0.9999366," since there is practically no clotrimazole absorption through the vaginal skin, no systemic effect is expected. the local tolerance of clotrimazole vaginal tablet is generally good. local irritation or burning sensation may occur in a very few cases but these symptoms are not considered harmful. ",clotrimazole (vaginal tablet)
sign_symptom,burning sensation,0.99908704," since there is practically no clotrimazole absorption through the vaginal skin, no systemic effect is expected. the local tolerance of clotrimazole vaginal tablet is generally good. local irritation or burning sensation may occur in a very few cases but these symptoms are not considered harmful. ",clotrimazole (vaginal tablet)
sign_symptom,irritation,0.9999089, occasional skin irritation or burning sensation may occur in a very few cases which are not considered harmful. ,clotrimazole (vaginal suppository)
sign_symptom,burning sensation,0.9979687, occasional skin irritation or burning sensation may occur in a very few cases which are not considered harmful. ,clotrimazole (vaginal suppository)
sign_symptom,irritation,0.99993205," when applied topically, clotrimazole is well tolerated.with external application, systemic effects are not observed. local irritation or burning sensation may occur in a very few cases but these symptoms are not considered harmful. ",clotrimazole (topical)
sign_symptom,burning sensation,0.99963915," when applied topically, clotrimazole is well tolerated.with external application, systemic effects are not observed. local irritation or burning sensation may occur in a very few cases but these symptoms are not considered harmful. ",clotrimazole (topical)
sign_symptom,burning,0.9986528, rarely patients may experience burning or irritation immediately after applying the ointment. ,clotrimazole (eye ointment)
sign_symptom,irritation,0.99990094, rarely patients may experience burning or irritation immediately after applying the ointment. ,clotrimazole (eye ointment)
sign_symptom,adverse reactions,0.8427874," most common adverse reactions (incidence &gt;20%) are diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, and pruritus. ",dacomitinib
disease_disorder,stomati,0.70918196," most common adverse reactions (incidence &gt;20%) are diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, and pruritus. ",dacomitinib
sign_symptom,decreased,0.9582009," most common adverse reactions (incidence &gt;20%) are diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, and pruritus. ",dacomitinib
sign_symptom,adverse reactions,0.9999082," the following serious adverse reactions are described below and elsewhere in the labeling: serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone. one can get any of the following symptoms: fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, memory problems. ",daclatasvir
sign_symptom,bradycardia,0.9879181," the following serious adverse reactions are described below and elsewhere in the labeling: serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone. one can get any of the following symptoms: fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, memory problems. ",daclatasvir
medication,amioda,0.77778506," the following serious adverse reactions are described below and elsewhere in the labeling: serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone. one can get any of the following symptoms: fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, memory problems. ",daclatasvir
sign_symptom,fainting,0.92332333," the following serious adverse reactions are described below and elsewhere in the labeling: serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone. one can get any of the following symptoms: fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, memory problems. ",daclatasvir
sign_symptom,faint,0.8982864," the following serious adverse reactions are described below and elsewhere in the labeling: serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone. one can get any of the following symptoms: fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, memory problems. ",daclatasvir
sign_symptom,lightheaded,0.7847479," the following serious adverse reactions are described below and elsewhere in the labeling: serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone. one can get any of the following symptoms: fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, memory problems. ",daclatasvir
sign_symptom,not feeling well,0.98625684," the following serious adverse reactions are described below and elsewhere in the labeling: serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone. one can get any of the following symptoms: fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, memory problems. ",daclatasvir
sign_symptom,shortness of breath,0.99976724," the following serious adverse reactions are described below and elsewhere in the labeling: serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone. one can get any of the following symptoms: fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, memory problems. ",daclatasvir
sign_symptom,nausea,0.9999453," symptoms of anorexia, nausea and vomiting are the most frequently noted of all toxic reactions. over 90% of patients are affected with the initial few doses. the vomiting lasts 1 to 12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine. rarely, intractable nausea and vomiting have necessitated discontinuance of therapy with dacarbazine for injection. rarely, dacarbazine for injection has caused diarrhea. some helpful suggestions include restricting the patients oral intake of food for 4 to 6 hours prior to treatment. the rapid toleration of these symptoms suggests that a central nervous system mechanism may be involved, and usually these symptoms subside after the first 1 or 2 days. ",dacarbazine
sign_symptom,vomiting,0.9998841," symptoms of anorexia, nausea and vomiting are the most frequently noted of all toxic reactions. over 90% of patients are affected with the initial few doses. the vomiting lasts 1 to 12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine. rarely, intractable nausea and vomiting have necessitated discontinuance of therapy with dacarbazine for injection. rarely, dacarbazine for injection has caused diarrhea. some helpful suggestions include restricting the patients oral intake of food for 4 to 6 hours prior to treatment. the rapid toleration of these symptoms suggests that a central nervous system mechanism may be involved, and usually these symptoms subside after the first 1 or 2 days. ",dacarbazine
medication,pheno,0.93643975," symptoms of anorexia, nausea and vomiting are the most frequently noted of all toxic reactions. over 90% of patients are affected with the initial few doses. the vomiting lasts 1 to 12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine. rarely, intractable nausea and vomiting have necessitated discontinuance of therapy with dacarbazine for injection. rarely, dacarbazine for injection has caused diarrhea. some helpful suggestions include restricting the patients oral intake of food for 4 to 6 hours prior to treatment. the rapid toleration of these symptoms suggests that a central nervous system mechanism may be involved, and usually these symptoms subside after the first 1 or 2 days. ",dacarbazine
medication,dacarbazine,0.96998936," symptoms of anorexia, nausea and vomiting are the most frequently noted of all toxic reactions. over 90% of patients are affected with the initial few doses. the vomiting lasts 1 to 12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine. rarely, intractable nausea and vomiting have necessitated discontinuance of therapy with dacarbazine for injection. rarely, dacarbazine for injection has caused diarrhea. some helpful suggestions include restricting the patients oral intake of food for 4 to 6 hours prior to treatment. the rapid toleration of these symptoms suggests that a central nervous system mechanism may be involved, and usually these symptoms subside after the first 1 or 2 days. ",dacarbazine
sign_symptom,adverse reactions,0.99988174," the following clinically significant adverse reactions are described elsewhere in the labeling: 
 
 increased risk of thrombotic events after premature discontinuation 
 risk of bleeding 
 spinal/epidural anesthesia or puncture 
 thromboembolic and bleeding events in patients with prosthetic heart valves 
 increased risk of thrombosis in patients with triple-positive antiphospholipid syndrome 
  ",dabigatran etexilate mesylate
sign_symptom,bleeding,0.9998259," the following clinically significant adverse reactions are described elsewhere in the labeling: 
 
 increased risk of thrombotic events after premature discontinuation 
 risk of bleeding 
 spinal/epidural anesthesia or puncture 
 thromboembolic and bleeding events in patients with prosthetic heart valves 
 increased risk of thrombosis in patients with triple-positive antiphospholipid syndrome 
  ",dabigatran etexilate mesylate
disease_disorder,antiphospholipid syndrome,0.97140205," the following clinically significant adverse reactions are described elsewhere in the labeling: 
 
 increased risk of thrombotic events after premature discontinuation 
 risk of bleeding 
 spinal/epidural anesthesia or puncture 
 thromboembolic and bleeding events in patients with prosthetic heart valves 
 increased risk of thrombosis in patients with triple-positive antiphospholipid syndrome 
  ",dabigatran etexilate mesylate
disease_disorder,inflammation,0.9877132," nausea, vomiting, fever, rash, diarrhoea, anorexia, oral and anal inflammation or ulceration, hepatic dysfunction, headache, weakness, confusion, thrombocytopenia, fatigue. ",cytarabine
sign_symptom,adverse,0.8758743," the most common adverse event was ocular burning. other events reported included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring). ",cyclosporine (ophthalmic)
sign_symptom,foreign,0.9962997," the most common adverse event was ocular burning. other events reported included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring). ",cyclosporine (ophthalmic)
sign_symptom,visual disturbance,0.79124093," the most common adverse event was ocular burning. other events reported included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring). ",cyclosporine (ophthalmic)
sign_symptom,hyperlipidae,0.77543133," renal dysfunction; hypertension;tremor, headache, paraesthesia;anorexia, nausea, vomiting, abdominal pain, diarrhoea, gingival hyperplasia and hepatic dysfunction; hyperlipidaemia, hyperuricaemia, hyperkalaemia, hypomagnesaemia;muscle cramps, myalgia and rarely muscle weakness, myopathy;usually uncommon but anaemia, thrombocytopenia can occur;hypertrichosis and allergic rashes. ",cyclosporine
sign_symptom,hyper,0.9817417," renal dysfunction; hypertension;tremor, headache, paraesthesia;anorexia, nausea, vomiting, abdominal pain, diarrhoea, gingival hyperplasia and hepatic dysfunction; hyperlipidaemia, hyperuricaemia, hyperkalaemia, hypomagnesaemia;muscle cramps, myalgia and rarely muscle weakness, myopathy;usually uncommon but anaemia, thrombocytopenia can occur;hypertrichosis and allergic rashes. ",cyclosporine
sign_symptom,myalgia,0.9950929," renal dysfunction; hypertension;tremor, headache, paraesthesia;anorexia, nausea, vomiting, abdominal pain, diarrhoea, gingival hyperplasia and hepatic dysfunction; hyperlipidaemia, hyperuricaemia, hyperkalaemia, hypomagnesaemia;muscle cramps, myalgia and rarely muscle weakness, myopathy;usually uncommon but anaemia, thrombocytopenia can occur;hypertrichosis and allergic rashes. ",cyclosporine
sign_symptom,hypertrichosis,0.7938755," renal dysfunction; hypertension;tremor, headache, paraesthesia;anorexia, nausea, vomiting, abdominal pain, diarrhoea, gingival hyperplasia and hepatic dysfunction; hyperlipidaemia, hyperuricaemia, hyperkalaemia, hypomagnesaemia;muscle cramps, myalgia and rarely muscle weakness, myopathy;usually uncommon but anaemia, thrombocytopenia can occur;hypertrichosis and allergic rashes. ",cyclosporine
disease_disorder,alopecia,0.76369685," alopecia, skin and nails hyperpigmentation, nausea and vomiting, mucositis, inappropriate antidiuretic hormone secretion, carbohydrate metabolism disturbances, gonadal suppression, interstitial pulmonary fibrosis. ",cyclophosphamide
sign_symptom,hyper,0.98892397," alopecia, skin and nails hyperpigmentation, nausea and vomiting, mucositis, inappropriate antidiuretic hormone secretion, carbohydrate metabolism disturbances, gonadal suppression, interstitial pulmonary fibrosis. ",cyclophosphamide
sign_symptom,nausea,0.99990714," alopecia, skin and nails hyperpigmentation, nausea and vomiting, mucositis, inappropriate antidiuretic hormone secretion, carbohydrate metabolism disturbances, gonadal suppression, interstitial pulmonary fibrosis. ",cyclophosphamide
sign_symptom,glau,0.89363384," blinding acute angle-closure glaucoma and raised intraocular pressure may occur during cyclopentolate therapy. the mydriasis may be reduced by the intraocular application of pilocarpine, physostigmine or isoflurophate. transient burning sensation of the eye is more likely with the 0.5% solution. systemic effects, resulting from excessive absorption from mucosal surfaces or from ingestion of the drug, may include xerostomia, flushing, tachycardia and urinary retention. more severe systemic effects are tachypnea, scarlatiniform rash, delirium, psychosis, fever, stupor, coma, respiratory failure and death. ",cyclopentolate hydrochloride
sign_symptom,mydrias,0.83937407," blinding acute angle-closure glaucoma and raised intraocular pressure may occur during cyclopentolate therapy. the mydriasis may be reduced by the intraocular application of pilocarpine, physostigmine or isoflurophate. transient burning sensation of the eye is more likely with the 0.5% solution. systemic effects, resulting from excessive absorption from mucosal surfaces or from ingestion of the drug, may include xerostomia, flushing, tachycardia and urinary retention. more severe systemic effects are tachypnea, scarlatiniform rash, delirium, psychosis, fever, stupor, coma, respiratory failure and death. ",cyclopentolate hydrochloride
sign_symptom,burning sensation,0.95885146," blinding acute angle-closure glaucoma and raised intraocular pressure may occur during cyclopentolate therapy. the mydriasis may be reduced by the intraocular application of pilocarpine, physostigmine or isoflurophate. transient burning sensation of the eye is more likely with the 0.5% solution. systemic effects, resulting from excessive absorption from mucosal surfaces or from ingestion of the drug, may include xerostomia, flushing, tachycardia and urinary retention. more severe systemic effects are tachypnea, scarlatiniform rash, delirium, psychosis, fever, stupor, coma, respiratory failure and death. ",cyclopentolate hydrochloride
sign_symptom,adverse reactions,0.99886763," the adverse reactions reported most frequently with cyclobenzaprine hydrochloride are drowsiness, dry mouth and dizziness. the incidence of these common adverse reactions is lower in the surveillance program than in the controlled clinical studies. ",cyclobenzaprine hydrochloride
medication,cyclobenzaprine hydrochloride,0.991319," the adverse reactions reported most frequently with cyclobenzaprine hydrochloride are drowsiness, dry mouth and dizziness. the incidence of these common adverse reactions is lower in the surveillance program than in the controlled clinical studies. ",cyclobenzaprine hydrochloride
sign_symptom,dry mouth,0.9993519," the adverse reactions reported most frequently with cyclobenzaprine hydrochloride are drowsiness, dry mouth and dizziness. the incidence of these common adverse reactions is lower in the surveillance program than in the controlled clinical studies. ",cyclobenzaprine hydrochloride
sign_symptom,effects,0.8148677," the following side effects are reported with a not known frequency (frequency cannot be estimated from the available data): skin rashes or itching, drowsiness, lack of coordination, headache, a dry mouth, nose or throat, blurred vision, involuntary rolling of the eyes, fast heartbeat, irregular heartbeat, difficulty in passing water, constipation, heartburn (reflux), feeling sick, being sick, diarrhea, stomach pain, loss of appetite, restlessness, nervousness, euphoria. ",cyclizine hydrochloride
sign_symptom,rash,0.99987185," the following side effects are reported with a not known frequency (frequency cannot be estimated from the available data): skin rashes or itching, drowsiness, lack of coordination, headache, a dry mouth, nose or throat, blurred vision, involuntary rolling of the eyes, fast heartbeat, irregular heartbeat, difficulty in passing water, constipation, heartburn (reflux), feeling sick, being sick, diarrhea, stomach pain, loss of appetite, restlessness, nervousness, euphoria. ",cyclizine hydrochloride
sign_symptom,lack of coordination,0.89609337," the following side effects are reported with a not known frequency (frequency cannot be estimated from the available data): skin rashes or itching, drowsiness, lack of coordination, headache, a dry mouth, nose or throat, blurred vision, involuntary rolling of the eyes, fast heartbeat, irregular heartbeat, difficulty in passing water, constipation, heartburn (reflux), feeling sick, being sick, diarrhea, stomach pain, loss of appetite, restlessness, nervousness, euphoria. ",cyclizine hydrochloride
sign_symptom,rolling of the eyes,0.7960588," the following side effects are reported with a not known frequency (frequency cannot be estimated from the available data): skin rashes or itching, drowsiness, lack of coordination, headache, a dry mouth, nose or throat, blurred vision, involuntary rolling of the eyes, fast heartbeat, irregular heartbeat, difficulty in passing water, constipation, heartburn (reflux), feeling sick, being sick, diarrhea, stomach pain, loss of appetite, restlessness, nervousness, euphoria. ",cyclizine hydrochloride
sign_symptom,arthralgia,0.99983865," arthralgia (12%), dizziness (12%), headache (12%), nasopharyngitis (12%), anaphylaxis, angioedema, congestive heart failure, peripheral vascular disease,pulmonary edema, diarrhea, dyspepsia, polycythemia vera, sore throat, nervousness, rhinitis, glossitis, hypoesthesia ",cyanocobalamin
sign_symptom,headache,0.999892," arthralgia (12%), dizziness (12%), headache (12%), nasopharyngitis (12%), anaphylaxis, angioedema, congestive heart failure, peripheral vascular disease,pulmonary edema, diarrhea, dyspepsia, polycythemia vera, sore throat, nervousness, rhinitis, glossitis, hypoesthesia ",cyanocobalamin
sign_symptom,nasopharyngitis,0.9996287," arthralgia (12%), dizziness (12%), headache (12%), nasopharyngitis (12%), anaphylaxis, angioedema, congestive heart failure, peripheral vascular disease,pulmonary edema, diarrhea, dyspepsia, polycythemia vera, sore throat, nervousness, rhinitis, glossitis, hypoesthesia ",cyanocobalamin
disease_disorder,poly,0.7682092," arthralgia (12%), dizziness (12%), headache (12%), nasopharyngitis (12%), anaphylaxis, angioedema, congestive heart failure, peripheral vascular disease,pulmonary edema, diarrhea, dyspepsia, polycythemia vera, sore throat, nervousness, rhinitis, glossitis, hypoesthesia ",cyanocobalamin
sign_symptom,nervous,0.9863079," arthralgia (12%), dizziness (12%), headache (12%), nasopharyngitis (12%), anaphylaxis, angioedema, congestive heart failure, peripheral vascular disease,pulmonary edema, diarrhea, dyspepsia, polycythemia vera, sore throat, nervousness, rhinitis, glossitis, hypoesthesia ",cyanocobalamin
sign_symptom,gloss,0.9898885," arthralgia (12%), dizziness (12%), headache (12%), nasopharyngitis (12%), anaphylaxis, angioedema, congestive heart failure, peripheral vascular disease,pulmonary edema, diarrhea, dyspepsia, polycythemia vera, sore throat, nervousness, rhinitis, glossitis, hypoesthesia ",cyanocobalamin
sign_symptom,irritation,0.99991417, occasionally irritation of the skin or contact allergy may occur. in such cases the preparation should be discontinued. ,crotamiton
sign_symptom,allergy,0.92443997, occasionally irritation of the skin or contact allergy may occur. in such cases the preparation should be discontinued. ,crotamiton
sign_symptom,adverse reactions,0.99912727," the most common adverse reactions (25%) are vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy. ",crizotinib
sign_symptom,allergic reactions,0.99969137," allergic reactions- crisaborole may cause allergic reactions at or near the application site. these can be serious and may include hives, itching, swelling, and redness. the most common side effect of crisaboroleis application site pain, such as burning or stinging. ",crisaborole
sign_symptom,dyspepsia,0.9947913," less common side effects may include headache, nausea, fatigue, dizziness, pharyngitis, dyspepsia and myalgia. ",desloratadine
disease_disorder,yeast infection,0.79390943," sometimes the symptoms of vaginal infections (such as itching, burning and discharge) can get worse at the beginning of the treatment, before they start to get better. you should continue with the treatment, but if the complaints persist see your doctor for advice as soon as possible. common side effects are vaginal discharge; vaginal itching or vaginal burning; vaginal yeast infection (thrush). ",dequalinium chloride
sign_symptom,adverse reactions,0.99768865," most common adverse reactions (incidence 2%) are nausea, diarrhea, headache, transaminase elevations, and vomiting. ",delafloxacin
disease_disorder,insuf,0.78650004," studies in adrenal insufficiency suggest dhea is generally well tolerated. however, data from long-term studies are lacking. observed adverse effects include mania and hypomania, acne, hirsutism, gynecomastia, testicular changes, increased blood pressure, and decreased high-density lipoprotein (hdl) levels.  use caution in individuals with psychiatric disorders; agitation, confusion, anxiety, paranoia, and suicidal thoughts have been reported. use of hormones like dhea may cause erythrocytosis. use caution in individuals with diabetes, as dhea may increase insulin resistance or sensitivity. use caution in individuals with liver dysfunction, as dhea may exacerbate this condition. use caution in individuals with polycystic ovarian syndrome, as dhea may worsen this condition. ",dehydroepiandrosterone
sign_symptom,mania,0.98996514," studies in adrenal insufficiency suggest dhea is generally well tolerated. however, data from long-term studies are lacking. observed adverse effects include mania and hypomania, acne, hirsutism, gynecomastia, testicular changes, increased blood pressure, and decreased high-density lipoprotein (hdl) levels.  use caution in individuals with psychiatric disorders; agitation, confusion, anxiety, paranoia, and suicidal thoughts have been reported. use of hormones like dhea may cause erythrocytosis. use caution in individuals with diabetes, as dhea may increase insulin resistance or sensitivity. use caution in individuals with liver dysfunction, as dhea may exacerbate this condition. use caution in individuals with polycystic ovarian syndrome, as dhea may worsen this condition. ",dehydroepiandrosterone
sign_symptom,suicidal thoughts,0.9878552," studies in adrenal insufficiency suggest dhea is generally well tolerated. however, data from long-term studies are lacking. observed adverse effects include mania and hypomania, acne, hirsutism, gynecomastia, testicular changes, increased blood pressure, and decreased high-density lipoprotein (hdl) levels.  use caution in individuals with psychiatric disorders; agitation, confusion, anxiety, paranoia, and suicidal thoughts have been reported. use of hormones like dhea may cause erythrocytosis. use caution in individuals with diabetes, as dhea may increase insulin resistance or sensitivity. use caution in individuals with liver dysfunction, as dhea may exacerbate this condition. use caution in individuals with polycystic ovarian syndrome, as dhea may worsen this condition. ",dehydroepiandrosterone
medication,dhea,0.8651395," studies in adrenal insufficiency suggest dhea is generally well tolerated. however, data from long-term studies are lacking. observed adverse effects include mania and hypomania, acne, hirsutism, gynecomastia, testicular changes, increased blood pressure, and decreased high-density lipoprotein (hdl) levels.  use caution in individuals with psychiatric disorders; agitation, confusion, anxiety, paranoia, and suicidal thoughts have been reported. use of hormones like dhea may cause erythrocytosis. use caution in individuals with diabetes, as dhea may increase insulin resistance or sensitivity. use caution in individuals with liver dysfunction, as dhea may exacerbate this condition. use caution in individuals with polycystic ovarian syndrome, as dhea may worsen this condition. ",dehydroepiandrosterone
sign_symptom,adverse reactions,0.97006845," the most commonly observed adverse reactions during degarelix therapy in the confirmatory phase iii study (n=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).  the injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). these events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and &lt;1 for erythema, swelling, nodule and induration. the reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (&lt;1%). serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. ",degarelix acetate
sign_symptom,hot flush,0.8328048," the most commonly observed adverse reactions during degarelix therapy in the confirmatory phase iii study (n=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).  the injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). these events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and &lt;1 for erythema, swelling, nodule and induration. the reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (&lt;1%). serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. ",degarelix acetate
sign_symptom,weight increase,0.9880103," the most commonly observed adverse reactions during degarelix therapy in the confirmatory phase iii study (n=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).  the injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). these events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and &lt;1 for erythema, swelling, nodule and induration. the reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (&lt;1%). serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. ",degarelix acetate
sign_symptom,adverse,0.80166185," the most commonly observed adverse reactions during degarelix therapy in the confirmatory phase iii study (n=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).  the injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). these events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and &lt;1 for erythema, swelling, nodule and induration. the reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (&lt;1%). serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. ",degarelix acetate
sign_symptom,chill,0.99215186," the most commonly observed adverse reactions during degarelix therapy in the confirmatory phase iii study (n=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).  the injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). these events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and &lt;1 for erythema, swelling, nodule and induration. the reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (&lt;1%). serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. ",degarelix acetate
sign_symptom,fever,0.99993193," the most commonly observed adverse reactions during degarelix therapy in the confirmatory phase iii study (n=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).  the injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). these events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and &lt;1 for erythema, swelling, nodule and induration. the reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (&lt;1%). serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. ",degarelix acetate
sign_symptom,influenza like illness,0.95193624," the most commonly observed adverse reactions during degarelix therapy in the confirmatory phase iii study (n=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).  the injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). these events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and &lt;1 for erythema, swelling, nodule and induration. the reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (&lt;1%). serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. ",degarelix acetate
sign_symptom,pain,0.99995923," the most commonly observed adverse reactions during degarelix therapy in the confirmatory phase iii study (n=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).  the injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). these events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and &lt;1 for erythema, swelling, nodule and induration. the reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (&lt;1%). serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. ",degarelix acetate
sign_symptom,swelling,0.99995494," the most commonly observed adverse reactions during degarelix therapy in the confirmatory phase iii study (n=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).  the injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). these events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and &lt;1 for erythema, swelling, nodule and induration. the reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (&lt;1%). serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. ",degarelix acetate
sign_symptom,induration,0.98466945," the most commonly observed adverse reactions during degarelix therapy in the confirmatory phase iii study (n=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).  the injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). these events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and &lt;1 for erythema, swelling, nodule and induration. the reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (&lt;1%). serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. ",degarelix acetate
sign_symptom,nodule,0.97455573," the most commonly observed adverse reactions during degarelix therapy in the confirmatory phase iii study (n=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).  the injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). these events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and &lt;1 for erythema, swelling, nodule and induration. the reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (&lt;1%). serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage. ",degarelix acetate
disease_disorder,gastrointestinal disorders,0.9958979," gastrointestinal disorders such as diarrhoea, nausea, vomiting and abdominal pain are common during deferiprone treatment and may require temporary reduction in dose. a reddish brown discoloration of the urine is also common. other adverse effects that have been reported include arthralgia and increased liver enzymes. ",deferiprone
sign_symptom,nausea,0.99948895," gastrointestinal disorders such as diarrhoea, nausea, vomiting and abdominal pain are common during deferiprone treatment and may require temporary reduction in dose. a reddish brown discoloration of the urine is also common. other adverse effects that have been reported include arthralgia and increased liver enzymes. ",deferiprone
sign_symptom,vomiting,0.99983263," gastrointestinal disorders such as diarrhoea, nausea, vomiting and abdominal pain are common during deferiprone treatment and may require temporary reduction in dose. a reddish brown discoloration of the urine is also common. other adverse effects that have been reported include arthralgia and increased liver enzymes. ",deferiprone
sign_symptom,pain,0.9999106," gastrointestinal disorders such as diarrhoea, nausea, vomiting and abdominal pain are common during deferiprone treatment and may require temporary reduction in dose. a reddish brown discoloration of the urine is also common. other adverse effects that have been reported include arthralgia and increased liver enzymes. ",deferiprone
sign_symptom,discoloration,0.98928505," gastrointestinal disorders such as diarrhoea, nausea, vomiting and abdominal pain are common during deferiprone treatment and may require temporary reduction in dose. a reddish brown discoloration of the urine is also common. other adverse effects that have been reported include arthralgia and increased liver enzymes. ",deferiprone
sign_symptom,arthralgia,0.99927545," gastrointestinal disorders such as diarrhoea, nausea, vomiting and abdominal pain are common during deferiprone treatment and may require temporary reduction in dose. a reddish brown discoloration of the urine is also common. other adverse effects that have been reported include arthralgia and increased liver enzymes. ",deferiprone
sign_symptom,nasopharyn,0.97550416," serum creatinine increase, abdominal pain, nausea, vomiting, diarrhea, proteinuria, pyrexia, headache, cough , nasopharyngitis, pharyngolaryngeal pain, influenza, rash, respiratory tract infection, bronchitis, alt increased, arthralgia, back pain, acute tonsillitis, rhinitis, fatigue, ear infection, transaminitis, urticaria, anaphylaxis, angioedema, cytopenias, including agranulocytosis, neutropenia and thrombocytopenia; leukocytoclastic vasculitis ",deferasirox
disease_disorder,vasculitis,0.8598435," serum creatinine increase, abdominal pain, nausea, vomiting, diarrhea, proteinuria, pyrexia, headache, cough , nasopharyngitis, pharyngolaryngeal pain, influenza, rash, respiratory tract infection, bronchitis, alt increased, arthralgia, back pain, acute tonsillitis, rhinitis, fatigue, ear infection, transaminitis, urticaria, anaphylaxis, angioedema, cytopenias, including agranulocytosis, neutropenia and thrombocytopenia; leukocytoclastic vasculitis ",deferasirox
sign_symptom,myelo,0.8906425," dose-limiting toxicity includes myelosuppression and cardiotoxicity. other reactions include: 
 
  cutaneous : reversible alopecia occurs in most patients. rash, contact dermatitis and urticaria have occurred rarely. 
  gastrointestinal : acute nausea and vomiting occur but are usually mild. antiemetic therapy may be of some help. mucositis may occur 3 to 7 days after administration. diarrhea and abdominal pain have occasionally been reported. 
  local : if extravasation occurs during administration, severe local tissue necrosis, severe cellulitis, thrombophlebitis or painful induration can result. 
  acute reactions : rarely, anaphylactoid reaction, fever, and chills can occur. hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored. 
  ",daunorubicin
disease_disorder,alopecia,0.9954419," dose-limiting toxicity includes myelosuppression and cardiotoxicity. other reactions include: 
 
  cutaneous : reversible alopecia occurs in most patients. rash, contact dermatitis and urticaria have occurred rarely. 
  gastrointestinal : acute nausea and vomiting occur but are usually mild. antiemetic therapy may be of some help. mucositis may occur 3 to 7 days after administration. diarrhea and abdominal pain have occasionally been reported. 
  local : if extravasation occurs during administration, severe local tissue necrosis, severe cellulitis, thrombophlebitis or painful induration can result. 
  acute reactions : rarely, anaphylactoid reaction, fever, and chills can occur. hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored. 
  ",daunorubicin
disease_disorder,contact dermatitis,0.9933657," dose-limiting toxicity includes myelosuppression and cardiotoxicity. other reactions include: 
 
  cutaneous : reversible alopecia occurs in most patients. rash, contact dermatitis and urticaria have occurred rarely. 
  gastrointestinal : acute nausea and vomiting occur but are usually mild. antiemetic therapy may be of some help. mucositis may occur 3 to 7 days after administration. diarrhea and abdominal pain have occasionally been reported. 
  local : if extravasation occurs during administration, severe local tissue necrosis, severe cellulitis, thrombophlebitis or painful induration can result. 
  acute reactions : rarely, anaphylactoid reaction, fever, and chills can occur. hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored. 
  ",daunorubicin
sign_symptom,nausea,0.9999516," dose-limiting toxicity includes myelosuppression and cardiotoxicity. other reactions include: 
 
  cutaneous : reversible alopecia occurs in most patients. rash, contact dermatitis and urticaria have occurred rarely. 
  gastrointestinal : acute nausea and vomiting occur but are usually mild. antiemetic therapy may be of some help. mucositis may occur 3 to 7 days after administration. diarrhea and abdominal pain have occasionally been reported. 
  local : if extravasation occurs during administration, severe local tissue necrosis, severe cellulitis, thrombophlebitis or painful induration can result. 
  acute reactions : rarely, anaphylactoid reaction, fever, and chills can occur. hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored. 
  ",daunorubicin
sign_symptom,vomiting,0.9999496," dose-limiting toxicity includes myelosuppression and cardiotoxicity. other reactions include: 
 
  cutaneous : reversible alopecia occurs in most patients. rash, contact dermatitis and urticaria have occurred rarely. 
  gastrointestinal : acute nausea and vomiting occur but are usually mild. antiemetic therapy may be of some help. mucositis may occur 3 to 7 days after administration. diarrhea and abdominal pain have occasionally been reported. 
  local : if extravasation occurs during administration, severe local tissue necrosis, severe cellulitis, thrombophlebitis or painful induration can result. 
  acute reactions : rarely, anaphylactoid reaction, fever, and chills can occur. hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored. 
  ",daunorubicin
sign_symptom,pain,0.9999473," dose-limiting toxicity includes myelosuppression and cardiotoxicity. other reactions include: 
 
  cutaneous : reversible alopecia occurs in most patients. rash, contact dermatitis and urticaria have occurred rarely. 
  gastrointestinal : acute nausea and vomiting occur but are usually mild. antiemetic therapy may be of some help. mucositis may occur 3 to 7 days after administration. diarrhea and abdominal pain have occasionally been reported. 
  local : if extravasation occurs during administration, severe local tissue necrosis, severe cellulitis, thrombophlebitis or painful induration can result. 
  acute reactions : rarely, anaphylactoid reaction, fever, and chills can occur. hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored. 
  ",daunorubicin
sign_symptom,extra,0.9999621," dose-limiting toxicity includes myelosuppression and cardiotoxicity. other reactions include: 
 
  cutaneous : reversible alopecia occurs in most patients. rash, contact dermatitis and urticaria have occurred rarely. 
  gastrointestinal : acute nausea and vomiting occur but are usually mild. antiemetic therapy may be of some help. mucositis may occur 3 to 7 days after administration. diarrhea and abdominal pain have occasionally been reported. 
  local : if extravasation occurs during administration, severe local tissue necrosis, severe cellulitis, thrombophlebitis or painful induration can result. 
  acute reactions : rarely, anaphylactoid reaction, fever, and chills can occur. hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored. 
  ",daunorubicin
disease_disorder,cell,0.9629353," dose-limiting toxicity includes myelosuppression and cardiotoxicity. other reactions include: 
 
  cutaneous : reversible alopecia occurs in most patients. rash, contact dermatitis and urticaria have occurred rarely. 
  gastrointestinal : acute nausea and vomiting occur but are usually mild. antiemetic therapy may be of some help. mucositis may occur 3 to 7 days after administration. diarrhea and abdominal pain have occasionally been reported. 
  local : if extravasation occurs during administration, severe local tissue necrosis, severe cellulitis, thrombophlebitis or painful induration can result. 
  acute reactions : rarely, anaphylactoid reaction, fever, and chills can occur. hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored. 
  ",daunorubicin
sign_symptom,painful,0.99808455," dose-limiting toxicity includes myelosuppression and cardiotoxicity. other reactions include: 
 
  cutaneous : reversible alopecia occurs in most patients. rash, contact dermatitis and urticaria have occurred rarely. 
  gastrointestinal : acute nausea and vomiting occur but are usually mild. antiemetic therapy may be of some help. mucositis may occur 3 to 7 days after administration. diarrhea and abdominal pain have occasionally been reported. 
  local : if extravasation occurs during administration, severe local tissue necrosis, severe cellulitis, thrombophlebitis or painful induration can result. 
  acute reactions : rarely, anaphylactoid reaction, fever, and chills can occur. hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored. 
  ",daunorubicin
sign_symptom,chills,0.9828384," dose-limiting toxicity includes myelosuppression and cardiotoxicity. other reactions include: 
 
  cutaneous : reversible alopecia occurs in most patients. rash, contact dermatitis and urticaria have occurred rarely. 
  gastrointestinal : acute nausea and vomiting occur but are usually mild. antiemetic therapy may be of some help. mucositis may occur 3 to 7 days after administration. diarrhea and abdominal pain have occasionally been reported. 
  local : if extravasation occurs during administration, severe local tissue necrosis, severe cellulitis, thrombophlebitis or painful induration can result. 
  acute reactions : rarely, anaphylactoid reaction, fever, and chills can occur. hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored. 
  ",daunorubicin
disease_disorder,hyper,0.9746694," dose-limiting toxicity includes myelosuppression and cardiotoxicity. other reactions include: 
 
  cutaneous : reversible alopecia occurs in most patients. rash, contact dermatitis and urticaria have occurred rarely. 
  gastrointestinal : acute nausea and vomiting occur but are usually mild. antiemetic therapy may be of some help. mucositis may occur 3 to 7 days after administration. diarrhea and abdominal pain have occasionally been reported. 
  local : if extravasation occurs during administration, severe local tissue necrosis, severe cellulitis, thrombophlebitis or painful induration can result. 
  acute reactions : rarely, anaphylactoid reaction, fever, and chills can occur. hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored. 
  ",daunorubicin
sign_symptom,appetite,0.91662717," reversible myelosuppression, neutropenia, anaemia, thrombocytopenia, fluid retention, pulmonary arterial htn, qt prolongation, cardiac failure, arrhythmias, htn, musculoskeletal pain, gi disturbances, headache, chills, fatigue, asthenia, myalgia, chest pain, arthralgia, pyrexia, mucositis, flushing, colitis, electrolyte disturbances, appetite and wt disturbances, rash, dermatitis, hyperhidrosis, pruritus, acne. ",dasatinib
sign_symptom,abnormal,0.8764524," the most common side effects are dry mouth &amp; constipation. other less commonly reported side effects include- abnormal vision, back pain, dry skin, hypertension, vomiting, peripheral edema, weight gain, arthralgia, bronchitis, pharyngitis, rhinitis, sinusitis, rash, pruritus, urinary tract disorder and vaginitis. ",darifenacin
sign_symptom,tumor progression,0.9978689," increased mortality,myocardial infarction,stroke, andthromboembolism; increased mortality and/or increased risk of tumor progression or recurrence in patients with cancer; hypertension; seizures; serious allergic reaction; severecutaneousreactions ",darbepoetin alfa
sign_symptom,recurrence,0.9927299," increased mortality,myocardial infarction,stroke, andthromboembolism; increased mortality and/or increased risk of tumor progression or recurrence in patients with cancer; hypertension; seizures; serious allergic reaction; severecutaneousreactions ",darbepoetin alfa
sign_symptom,seizures,0.842551," increased mortality,myocardial infarction,stroke, andthromboembolism; increased mortality and/or increased risk of tumor progression or recurrence in patients with cancer; hypertension; seizures; serious allergic reaction; severecutaneousreactions ",darbepoetin alfa
sign_symptom,allergic reaction,0.99974525," increased mortality,myocardial infarction,stroke, andthromboembolism; increased mortality and/or increased risk of tumor progression or recurrence in patients with cancer; hypertension; seizures; serious allergic reaction; severecutaneousreactions ",darbepoetin alfa
sign_symptom,volume,0.9159507," renal impairment, female genital mycotic infections, urinary tract infection, increased urination, male genital mycotic infections, dyslipidemia, constipation, discomfort with urination, extremity pain, volume depletion, hypersensitivity ",dapagliflozin propanediol
sign_symptom,hypersensitivity,0.9998831," renal impairment, female genital mycotic infections, urinary tract infection, increased urination, male genital mycotic infections, dyslipidemia, constipation, discomfort with urination, extremity pain, volume depletion, hypersensitivity ",dapagliflozin propanediol
sign_symptom,malaise,0.85758114," the most frequently occurring side effects of dantrolene have been drowsiness, dizziness, weakness, general malaise, fatigue, and diarrhea. these are generally transient, occurring early in treatment, and can often be obviated by beginning with a low dose and increasing dosage gradually until an optimal regimen is established. diarrhea may be severe and may necessitate temporary withdrawal of dantrolene therapy. if diarrhea recurs upon readministration of dantrolene, therapy should probably be withdrawn permanently ",dantrolene sodium
sign_symptom,diarrhea,0.9921748," the most frequently occurring side effects of dantrolene have been drowsiness, dizziness, weakness, general malaise, fatigue, and diarrhea. these are generally transient, occurring early in treatment, and can often be obviated by beginning with a low dose and increasing dosage gradually until an optimal regimen is established. diarrhea may be severe and may necessitate temporary withdrawal of dantrolene therapy. if diarrhea recurs upon readministration of dantrolene, therapy should probably be withdrawn permanently ",dantrolene sodium
sign_symptom,allergic reactions,0.9999178," elevated serum transaminase levels (ast and alt), allergic reactions (e.g. pruritus, rash, fever, inj site reaction, bullous eruption), pain on inj site.epidural or spinal haematomas that may result in permanent paralysis, severe haemorrhage, thrombocytopenia. ",dalteparin sodium
sign_symptom,rash,0.98484725," elevated serum transaminase levels (ast and alt), allergic reactions (e.g. pruritus, rash, fever, inj site reaction, bullous eruption), pain on inj site.epidural or spinal haematomas that may result in permanent paralysis, severe haemorrhage, thrombocytopenia. ",dalteparin sodium
sign_symptom,pain,0.99996257," elevated serum transaminase levels (ast and alt), allergic reactions (e.g. pruritus, rash, fever, inj site reaction, bullous eruption), pain on inj site.epidural or spinal haematomas that may result in permanent paralysis, severe haemorrhage, thrombocytopenia. ",dalteparin sodium
sign_symptom,physical dependence,0.9496035, it may cause drowsiness and constipation. other side effects that may occur include git discomfort. no apparent evidence of physical dependence of the morphine type. ,dextromethorphan + pseudoephedrine + triprolidine
sign_symptom,dependence,0.8329993," it may cause drowsiness, dottiness and constipation. other side effects that may occur include git discomfort. no apparent evidence of physical dependence of the morphine type. other less common side effects may include transient hypertension, dry mouth, restlessness, palpitations, allergic reactions such as rashes, tightness of chest, thickening of bronchial secretions, toxic psychosis and blood dyscrasia. ",dextromethorphan + phenylephrine + triprolidine
sign_symptom,allergic reactions,0.840045," it may cause drowsiness, dottiness and constipation. other side effects that may occur include git discomfort. no apparent evidence of physical dependence of the morphine type. other less common side effects may include transient hypertension, dry mouth, restlessness, palpitations, allergic reactions such as rashes, tightness of chest, thickening of bronchial secretions, toxic psychosis and blood dyscrasia. ",dextromethorphan + phenylephrine + triprolidine
sign_symptom,tight,0.9989808," it may cause drowsiness, dottiness and constipation. other side effects that may occur include git discomfort. no apparent evidence of physical dependence of the morphine type. other less common side effects may include transient hypertension, dry mouth, restlessness, palpitations, allergic reactions such as rashes, tightness of chest, thickening of bronchial secretions, toxic psychosis and blood dyscrasia. ",dextromethorphan + phenylephrine + triprolidine
sign_symptom,thick,0.99789256," it may cause drowsiness, dottiness and constipation. other side effects that may occur include git discomfort. no apparent evidence of physical dependence of the morphine type. other less common side effects may include transient hypertension, dry mouth, restlessness, palpitations, allergic reactions such as rashes, tightness of chest, thickening of bronchial secretions, toxic psychosis and blood dyscrasia. ",dextromethorphan + phenylephrine + triprolidine
sign_symptom,bronchial secretions,0.99872476," it may cause drowsiness, dottiness and constipation. other side effects that may occur include git discomfort. no apparent evidence of physical dependence of the morphine type. other less common side effects may include transient hypertension, dry mouth, restlessness, palpitations, allergic reactions such as rashes, tightness of chest, thickening of bronchial secretions, toxic psychosis and blood dyscrasia. ",dextromethorphan + phenylephrine + triprolidine
sign_symptom,headache,0.7407816," gi disturbances; headache, dizziness; allergic reactions; raised liver enzyme values; alopecia; bone marrow suppression. ",dextran + sodium chloride
sign_symptom,effects,0.9777974," there are no known side effects with the use of it, however, if the patient experiences any reaction in eye or other part of the body after using this medication then consult with doctor ",dextran + hypromellose
sign_symptom,reaction,0.99986327," there are no known side effects with the use of it, however, if the patient experiences any reaction in eye or other part of the body after using this medication then consult with doctor ",dextran + hypromellose
medication,medication,0.9625295," there are no known side effects with the use of it, however, if the patient experiences any reaction in eye or other part of the body after using this medication then consult with doctor ",dextran + hypromellose
sign_symptom,tight,0.9998123," congestive heart failure, mild hypotension, tightness of chest, thrombocytopenia, anaphylaxis, injection site infection/phlebitis, acute renal failure, acidosis (if naci soln used), pulmonary edema, wheezing ",dextran + dextrose
sign_symptom,anaphylaxi,0.81796926," congestive heart failure, mild hypotension, tightness of chest, thrombocytopenia, anaphylaxis, injection site infection/phlebitis, acute renal failure, acidosis (if naci soln used), pulmonary edema, wheezing ",dextran + dextrose
disease_disorder,infection,0.8779446," congestive heart failure, mild hypotension, tightness of chest, thrombocytopenia, anaphylaxis, injection site infection/phlebitis, acute renal failure, acidosis (if naci soln used), pulmonary edema, wheezing ",dextran + dextrose
sign_symptom,acidosis,0.9960671," congestive heart failure, mild hypotension, tightness of chest, thrombocytopenia, anaphylaxis, injection site infection/phlebitis, acute renal failure, acidosis (if naci soln used), pulmonary edema, wheezing ",dextran + dextrose
sign_symptom,allergic reaction,0.99984336," as with any medicine, use of dexpanthenol may cause side effects in some users. do not be alarmed by the list of side effects. you may not suffer from any of them. discontinue use and refer to a doctor immediately in the event of: allergic reaction and/or allergic skin reaction such as: atopic dermatitis, allergic dermatitis, pruritus, redness, rash, eczema, urticaria, local irritation or blistering. if a side effect occurs, worsens, or if you suffer from a side effect not mentioned in this leaflet, consult with the doctor. ",dexpanthenol
sign_symptom,allergic,0.99683714," as with any medicine, use of dexpanthenol may cause side effects in some users. do not be alarmed by the list of side effects. you may not suffer from any of them. discontinue use and refer to a doctor immediately in the event of: allergic reaction and/or allergic skin reaction such as: atopic dermatitis, allergic dermatitis, pruritus, redness, rash, eczema, urticaria, local irritation or blistering. if a side effect occurs, worsens, or if you suffer from a side effect not mentioned in this leaflet, consult with the doctor. ",dexpanthenol
sign_symptom,reaction,0.99951303," as with any medicine, use of dexpanthenol may cause side effects in some users. do not be alarmed by the list of side effects. you may not suffer from any of them. discontinue use and refer to a doctor immediately in the event of: allergic reaction and/or allergic skin reaction such as: atopic dermatitis, allergic dermatitis, pruritus, redness, rash, eczema, urticaria, local irritation or blistering. if a side effect occurs, worsens, or if you suffer from a side effect not mentioned in this leaflet, consult with the doctor. ",dexpanthenol
sign_symptom,irritation,0.9658956," as with any medicine, use of dexpanthenol may cause side effects in some users. do not be alarmed by the list of side effects. you may not suffer from any of them. discontinue use and refer to a doctor immediately in the event of: allergic reaction and/or allergic skin reaction such as: atopic dermatitis, allergic dermatitis, pruritus, redness, rash, eczema, urticaria, local irritation or blistering. if a side effect occurs, worsens, or if you suffer from a side effect not mentioned in this leaflet, consult with the doctor. ",dexpanthenol
sign_symptom,adverse reactions,0.9979619," the most common adverse reactions (incidence greater than 10%) were hypotension, respiratory depression, and bradycardia. ",dexmedetomidine hydrochloride
sign_symptom,vomiting,0.9994215," common side effects: diarrhea, abdominal pain, nausea, vomiting &amp; flatulence. ",dexlansoprazole
medication,dexketoprofen,0.99008334," as with all medicines, dexketoprofen 25 mg tablets may cause some unwanted effects in some patients. these are described below and are characteristic of non-steroidal antiinflammatory drugs:  
 
 common (1-10%): nausea, vomiting, diarrhoea, stomach pain or heartburn. 
 uncommon (0.1-1%): sleep disorders, nervousness, headache, dizziness, vertigo, palpitations, constipation, dry mouth, flatulence, skin rash, fatigue, hot flushes, shivering, general malaise. 
 rare (0.01 0.1%): stomach ulceration, gastric haemorrhage or perforation; pins and needles, high blood pressure, water retention, slowed breathing rate, hepatic enzymes increased, increased sweating. 
 very rare/isolated cases (&lt;0.01%): blurred vision, ringing in the ear, low blood pressure, haematological reactions, hepatic or renal damage, dermatological and photosensitivity reactions, bronchospasm or anaphylaxis. 
 in patients with systemic lupus erythematosus or mixed connective tissue disease, antiinflammatory medicines may rarely cause isolated cases of fever, headache and rigidity of the nape (back of the neck). 
  ",dexketoprofen
sign_symptom,effects,0.82997674," as with all medicines, dexketoprofen 25 mg tablets may cause some unwanted effects in some patients. these are described below and are characteristic of non-steroidal antiinflammatory drugs:  
 
 common (1-10%): nausea, vomiting, diarrhoea, stomach pain or heartburn. 
 uncommon (0.1-1%): sleep disorders, nervousness, headache, dizziness, vertigo, palpitations, constipation, dry mouth, flatulence, skin rash, fatigue, hot flushes, shivering, general malaise. 
 rare (0.01 0.1%): stomach ulceration, gastric haemorrhage or perforation; pins and needles, high blood pressure, water retention, slowed breathing rate, hepatic enzymes increased, increased sweating. 
 very rare/isolated cases (&lt;0.01%): blurred vision, ringing in the ear, low blood pressure, haematological reactions, hepatic or renal damage, dermatological and photosensitivity reactions, bronchospasm or anaphylaxis. 
 in patients with systemic lupus erythematosus or mixed connective tissue disease, antiinflammatory medicines may rarely cause isolated cases of fever, headache and rigidity of the nape (back of the neck). 
  ",dexketoprofen
sign_symptom,pain,0.99938834," as with all medicines, dexketoprofen 25 mg tablets may cause some unwanted effects in some patients. these are described below and are characteristic of non-steroidal antiinflammatory drugs:  
 
 common (1-10%): nausea, vomiting, diarrhoea, stomach pain or heartburn. 
 uncommon (0.1-1%): sleep disorders, nervousness, headache, dizziness, vertigo, palpitations, constipation, dry mouth, flatulence, skin rash, fatigue, hot flushes, shivering, general malaise. 
 rare (0.01 0.1%): stomach ulceration, gastric haemorrhage or perforation; pins and needles, high blood pressure, water retention, slowed breathing rate, hepatic enzymes increased, increased sweating. 
 very rare/isolated cases (&lt;0.01%): blurred vision, ringing in the ear, low blood pressure, haematological reactions, hepatic or renal damage, dermatological and photosensitivity reactions, bronchospasm or anaphylaxis. 
 in patients with systemic lupus erythematosus or mixed connective tissue disease, antiinflammatory medicines may rarely cause isolated cases of fever, headache and rigidity of the nape (back of the neck). 
  ",dexketoprofen
sign_symptom,dry mouth,0.9078552," as with all medicines, dexketoprofen 25 mg tablets may cause some unwanted effects in some patients. these are described below and are characteristic of non-steroidal antiinflammatory drugs:  
 
 common (1-10%): nausea, vomiting, diarrhoea, stomach pain or heartburn. 
 uncommon (0.1-1%): sleep disorders, nervousness, headache, dizziness, vertigo, palpitations, constipation, dry mouth, flatulence, skin rash, fatigue, hot flushes, shivering, general malaise. 
 rare (0.01 0.1%): stomach ulceration, gastric haemorrhage or perforation; pins and needles, high blood pressure, water retention, slowed breathing rate, hepatic enzymes increased, increased sweating. 
 very rare/isolated cases (&lt;0.01%): blurred vision, ringing in the ear, low blood pressure, haematological reactions, hepatic or renal damage, dermatological and photosensitivity reactions, bronchospasm or anaphylaxis. 
 in patients with systemic lupus erythematosus or mixed connective tissue disease, antiinflammatory medicines may rarely cause isolated cases of fever, headache and rigidity of the nape (back of the neck). 
  ",dexketoprofen
sign_symptom,flat,0.999887," as with all medicines, dexketoprofen 25 mg tablets may cause some unwanted effects in some patients. these are described below and are characteristic of non-steroidal antiinflammatory drugs:  
 
 common (1-10%): nausea, vomiting, diarrhoea, stomach pain or heartburn. 
 uncommon (0.1-1%): sleep disorders, nervousness, headache, dizziness, vertigo, palpitations, constipation, dry mouth, flatulence, skin rash, fatigue, hot flushes, shivering, general malaise. 
 rare (0.01 0.1%): stomach ulceration, gastric haemorrhage or perforation; pins and needles, high blood pressure, water retention, slowed breathing rate, hepatic enzymes increased, increased sweating. 
 very rare/isolated cases (&lt;0.01%): blurred vision, ringing in the ear, low blood pressure, haematological reactions, hepatic or renal damage, dermatological and photosensitivity reactions, bronchospasm or anaphylaxis. 
 in patients with systemic lupus erythematosus or mixed connective tissue disease, antiinflammatory medicines may rarely cause isolated cases of fever, headache and rigidity of the nape (back of the neck). 
  ",dexketoprofen
sign_symptom,fever,0.99980515," as with all medicines, dexketoprofen 25 mg tablets may cause some unwanted effects in some patients. these are described below and are characteristic of non-steroidal antiinflammatory drugs:  
 
 common (1-10%): nausea, vomiting, diarrhoea, stomach pain or heartburn. 
 uncommon (0.1-1%): sleep disorders, nervousness, headache, dizziness, vertigo, palpitations, constipation, dry mouth, flatulence, skin rash, fatigue, hot flushes, shivering, general malaise. 
 rare (0.01 0.1%): stomach ulceration, gastric haemorrhage or perforation; pins and needles, high blood pressure, water retention, slowed breathing rate, hepatic enzymes increased, increased sweating. 
 very rare/isolated cases (&lt;0.01%): blurred vision, ringing in the ear, low blood pressure, haematological reactions, hepatic or renal damage, dermatological and photosensitivity reactions, bronchospasm or anaphylaxis. 
 in patients with systemic lupus erythematosus or mixed connective tissue disease, antiinflammatory medicines may rarely cause isolated cases of fever, headache and rigidity of the nape (back of the neck). 
  ",dexketoprofen
sign_symptom,headache,0.9999236," as with all medicines, dexketoprofen 25 mg tablets may cause some unwanted effects in some patients. these are described below and are characteristic of non-steroidal antiinflammatory drugs:  
 
 common (1-10%): nausea, vomiting, diarrhoea, stomach pain or heartburn. 
 uncommon (0.1-1%): sleep disorders, nervousness, headache, dizziness, vertigo, palpitations, constipation, dry mouth, flatulence, skin rash, fatigue, hot flushes, shivering, general malaise. 
 rare (0.01 0.1%): stomach ulceration, gastric haemorrhage or perforation; pins and needles, high blood pressure, water retention, slowed breathing rate, hepatic enzymes increased, increased sweating. 
 very rare/isolated cases (&lt;0.01%): blurred vision, ringing in the ear, low blood pressure, haematological reactions, hepatic or renal damage, dermatological and photosensitivity reactions, bronchospasm or anaphylaxis. 
 in patients with systemic lupus erythematosus or mixed connective tissue disease, antiinflammatory medicines may rarely cause isolated cases of fever, headache and rigidity of the nape (back of the neck). 
  ",dexketoprofen
sign_symptom,rigidity of the nape,0.99936706," as with all medicines, dexketoprofen 25 mg tablets may cause some unwanted effects in some patients. these are described below and are characteristic of non-steroidal antiinflammatory drugs:  
 
 common (1-10%): nausea, vomiting, diarrhoea, stomach pain or heartburn. 
 uncommon (0.1-1%): sleep disorders, nervousness, headache, dizziness, vertigo, palpitations, constipation, dry mouth, flatulence, skin rash, fatigue, hot flushes, shivering, general malaise. 
 rare (0.01 0.1%): stomach ulceration, gastric haemorrhage or perforation; pins and needles, high blood pressure, water retention, slowed breathing rate, hepatic enzymes increased, increased sweating. 
 very rare/isolated cases (&lt;0.01%): blurred vision, ringing in the ear, low blood pressure, haematological reactions, hepatic or renal damage, dermatological and photosensitivity reactions, bronchospasm or anaphylaxis. 
 in patients with systemic lupus erythematosus or mixed connective tissue disease, antiinflammatory medicines may rarely cause isolated cases of fever, headache and rigidity of the nape (back of the neck). 
  ",dexketoprofen
medication,dexib,0.9665381," clinical experience has shown that adverse effects of dexibuprofen are similar to those of racemic ibuprofen. common side-effects are dyspepsia, diarrhea, fatigue, and headache, nausea, vomiting, abdominal pain, hypersensitivity reactions - bleeding, ulcer. ",dexibuprofen
sign_symptom,dyspeps,0.9985044," clinical experience has shown that adverse effects of dexibuprofen are similar to those of racemic ibuprofen. common side-effects are dyspepsia, diarrhea, fatigue, and headache, nausea, vomiting, abdominal pain, hypersensitivity reactions - bleeding, ulcer. ",dexibuprofen
sign_symptom,lid itching,0.99779624," the most frequent side effects to topical ocular tobramycin are localized ocular toxicity and hypersensitivity, including lid itching and swelling and conjuntival erythema. the reactions due to the steroid component are elevation of intraocular pressure (iop) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsule cataract formation. ",dexamethasone + tobramycin
sign_symptom,swelling,0.99995387," the most frequent side effects to topical ocular tobramycin are localized ocular toxicity and hypersensitivity, including lid itching and swelling and conjuntival erythema. the reactions due to the steroid component are elevation of intraocular pressure (iop) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsule cataract formation. ",dexamethasone + tobramycin
medication,steroid,0.76356745," the most frequent side effects to topical ocular tobramycin are localized ocular toxicity and hypersensitivity, including lid itching and swelling and conjuntival erythema. the reactions due to the steroid component are elevation of intraocular pressure (iop) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsule cataract formation. ",dexamethasone + tobramycin
medication,steroid,0.94314027," adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. exact incidence figures are not available since no denominator of treated patients is available. reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations. the reactions due to the steroid component in decreasing order of frequency are: elevation of intraocular pressure (iop) with possible development of glaucoma, and infrequent optic nerve damage, posterior sub-capsular cataract formation and delayed wound healing. ",dexamethasone + neomycin sulphate + polymyxin b sulphate
sign_symptom,burning,0.8096289," adverse reactions seen with chloramphenicol are transient ocular burning or discomfort and other reported reactions include stinging, redness, itching, conjunctivitis, foreign body sensation, photophobia, blurred vision, dryness and eye pain. allergic sensitization may occur with the local use of chloramphenicol. elevation of intraocular pressure with possible development of glaucoma, infrequent optic nerve damage and posterior subcapsular cataract formation. ",dexamethasone + chloramphenicol
sign_symptom,discomfort,0.9999536," adverse reactions seen with chloramphenicol are transient ocular burning or discomfort and other reported reactions include stinging, redness, itching, conjunctivitis, foreign body sensation, photophobia, blurred vision, dryness and eye pain. allergic sensitization may occur with the local use of chloramphenicol. elevation of intraocular pressure with possible development of glaucoma, infrequent optic nerve damage and posterior subcapsular cataract formation. ",dexamethasone + chloramphenicol
sign_symptom,foreign,0.8804735," adverse reactions seen with chloramphenicol are transient ocular burning or discomfort and other reported reactions include stinging, redness, itching, conjunctivitis, foreign body sensation, photophobia, blurred vision, dryness and eye pain. allergic sensitization may occur with the local use of chloramphenicol. elevation of intraocular pressure with possible development of glaucoma, infrequent optic nerve damage and posterior subcapsular cataract formation. ",dexamethasone + chloramphenicol
sign_symptom,allergic sensitization,0.95819634," adverse reactions seen with chloramphenicol are transient ocular burning or discomfort and other reported reactions include stinging, redness, itching, conjunctivitis, foreign body sensation, photophobia, blurred vision, dryness and eye pain. allergic sensitization may occur with the local use of chloramphenicol. elevation of intraocular pressure with possible development of glaucoma, infrequent optic nerve damage and posterior subcapsular cataract formation. ",dexamethasone + chloramphenicol
disease_disorder,optic nerve damage,0.98302174," adverse reactions seen with chloramphenicol are transient ocular burning or discomfort and other reported reactions include stinging, redness, itching, conjunctivitis, foreign body sensation, photophobia, blurred vision, dryness and eye pain. allergic sensitization may occur with the local use of chloramphenicol. elevation of intraocular pressure with possible development of glaucoma, infrequent optic nerve damage and posterior subcapsular cataract formation. ",dexamethasone + chloramphenicol
disease_disorder,glaucoma,0.9938594," glaucoma with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, perforation of the globe. rarely, stinging and burning may occur. ",dexamethasone (ophthalmic)
disease_disorder,optic nerve,0.8015022," glaucoma with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, perforation of the globe. rarely, stinging and burning may occur. ",dexamethasone (ophthalmic)
disease_disorder,infection,0.78262955," glaucoma with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, perforation of the globe. rarely, stinging and burning may occur. ",dexamethasone (ophthalmic)
sign_symptom,adverse reactions,0.9968984," the following adverse reactions have been associated with prolonged systemic glucocorticoid therapy.   endocrine and metabolic disturbances : cushing-like syndrome, hirsutism, menstrual irregularities, premature epiphyseal closure, secondary adrenocortical and pituitary unresponsiveness, decreased glucose tolerance, negative nitrogen and calcium balance.   fluid and electrolyte disturbances : sodium and fluid retention, hypertension, potassium loss, hypokalaemic alkalosis.   musculo-skeletal effects : myopathy, abdominal distension, osteoporosis, aseptic necrosis of femoral and humeral heads.   gastro-intestinal effects : gastric and duodenal ulceration, perforation and haemorrhage.   dermatological effects : impaired wound healing, skin atrophy, striae, petechiae and ecchymoses, bruising, facial erythema, increased sweating, acne.   central nervous system effects : psychic disturbances ranging from euphoria to frank psychotic manifestations,convulsions,in children pseudotumor cerebri (benign intracranial hypertension) with vomiting and papilloedema.   ophthalmic effects : glaucoma, increased intraocular pressure, posterior subcapsular cataracts.   immunosuppressive effects : increased susceptibility to infections, decreased responsiveness to vaccination and skin tests. ",dexamethasone
sign_symptom,metabolic,0.9001314," the following adverse reactions have been associated with prolonged systemic glucocorticoid therapy.   endocrine and metabolic disturbances : cushing-like syndrome, hirsutism, menstrual irregularities, premature epiphyseal closure, secondary adrenocortical and pituitary unresponsiveness, decreased glucose tolerance, negative nitrogen and calcium balance.   fluid and electrolyte disturbances : sodium and fluid retention, hypertension, potassium loss, hypokalaemic alkalosis.   musculo-skeletal effects : myopathy, abdominal distension, osteoporosis, aseptic necrosis of femoral and humeral heads.   gastro-intestinal effects : gastric and duodenal ulceration, perforation and haemorrhage.   dermatological effects : impaired wound healing, skin atrophy, striae, petechiae and ecchymoses, bruising, facial erythema, increased sweating, acne.   central nervous system effects : psychic disturbances ranging from euphoria to frank psychotic manifestations,convulsions,in children pseudotumor cerebri (benign intracranial hypertension) with vomiting and papilloedema.   ophthalmic effects : glaucoma, increased intraocular pressure, posterior subcapsular cataracts.   immunosuppressive effects : increased susceptibility to infections, decreased responsiveness to vaccination and skin tests. ",dexamethasone
sign_symptom,psychic disturbances,0.99648035," the following adverse reactions have been associated with prolonged systemic glucocorticoid therapy.   endocrine and metabolic disturbances : cushing-like syndrome, hirsutism, menstrual irregularities, premature epiphyseal closure, secondary adrenocortical and pituitary unresponsiveness, decreased glucose tolerance, negative nitrogen and calcium balance.   fluid and electrolyte disturbances : sodium and fluid retention, hypertension, potassium loss, hypokalaemic alkalosis.   musculo-skeletal effects : myopathy, abdominal distension, osteoporosis, aseptic necrosis of femoral and humeral heads.   gastro-intestinal effects : gastric and duodenal ulceration, perforation and haemorrhage.   dermatological effects : impaired wound healing, skin atrophy, striae, petechiae and ecchymoses, bruising, facial erythema, increased sweating, acne.   central nervous system effects : psychic disturbances ranging from euphoria to frank psychotic manifestations,convulsions,in children pseudotumor cerebri (benign intracranial hypertension) with vomiting and papilloedema.   ophthalmic effects : glaucoma, increased intraocular pressure, posterior subcapsular cataracts.   immunosuppressive effects : increased susceptibility to infections, decreased responsiveness to vaccination and skin tests. ",dexamethasone
sign_symptom,vomiting,0.9997172," the following adverse reactions have been associated with prolonged systemic glucocorticoid therapy.   endocrine and metabolic disturbances : cushing-like syndrome, hirsutism, menstrual irregularities, premature epiphyseal closure, secondary adrenocortical and pituitary unresponsiveness, decreased glucose tolerance, negative nitrogen and calcium balance.   fluid and electrolyte disturbances : sodium and fluid retention, hypertension, potassium loss, hypokalaemic alkalosis.   musculo-skeletal effects : myopathy, abdominal distension, osteoporosis, aseptic necrosis of femoral and humeral heads.   gastro-intestinal effects : gastric and duodenal ulceration, perforation and haemorrhage.   dermatological effects : impaired wound healing, skin atrophy, striae, petechiae and ecchymoses, bruising, facial erythema, increased sweating, acne.   central nervous system effects : psychic disturbances ranging from euphoria to frank psychotic manifestations,convulsions,in children pseudotumor cerebri (benign intracranial hypertension) with vomiting and papilloedema.   ophthalmic effects : glaucoma, increased intraocular pressure, posterior subcapsular cataracts.   immunosuppressive effects : increased susceptibility to infections, decreased responsiveness to vaccination and skin tests. ",dexamethasone
disease_disorder,erect,0.7075709," suicidal thinking/ behaviour, htn, mydriasis, seizure, hyponatraemia, interstitial lung disease and eosinophilic pneumonia; nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, sexual function disorders in males (e.g. anorgasmia, decreased libido, abnormal orgasm, delayed ejaculation, erectile dysfunction, ejaculation disorder, ejaculation failure, sexual dysfunction). ",desvenlafaxine
sign_symptom,rash,0.99991095," the most common local side effects are burning, rash and pruritus at the application site. the following additional local side effects have been reported infrequently with topical corticosteroids. they may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria. ",desonide
sign_symptom,pain,0.99992657," side-effects include headache, stomach pain and nausea. isolated cases of allergic skin reactions and more severe general allergic reactions have been reported. very rare cases of emotional disorders including aggression in children have been reported. treatment with desmopressin without concomitant reduction of fluid intake may lead to water retention/hyponatraemia with accompanying symptoms of headache, nausea, vomiting, weight gain, decreased serum sodium and in serious cases, convulsions. ",desmopressin acetate
sign_symptom,allergic skin reactions,0.94535303," side-effects include headache, stomach pain and nausea. isolated cases of allergic skin reactions and more severe general allergic reactions have been reported. very rare cases of emotional disorders including aggression in children have been reported. treatment with desmopressin without concomitant reduction of fluid intake may lead to water retention/hyponatraemia with accompanying symptoms of headache, nausea, vomiting, weight gain, decreased serum sodium and in serious cases, convulsions. ",desmopressin acetate
sign_symptom,allergic reactions,0.99988824," side-effects include headache, stomach pain and nausea. isolated cases of allergic skin reactions and more severe general allergic reactions have been reported. very rare cases of emotional disorders including aggression in children have been reported. treatment with desmopressin without concomitant reduction of fluid intake may lead to water retention/hyponatraemia with accompanying symptoms of headache, nausea, vomiting, weight gain, decreased serum sodium and in serious cases, convulsions. ",desmopressin acetate
disease_disorder,emotional,0.8712579," side-effects include headache, stomach pain and nausea. isolated cases of allergic skin reactions and more severe general allergic reactions have been reported. very rare cases of emotional disorders including aggression in children have been reported. treatment with desmopressin without concomitant reduction of fluid intake may lead to water retention/hyponatraemia with accompanying symptoms of headache, nausea, vomiting, weight gain, decreased serum sodium and in serious cases, convulsions. ",desmopressin acetate
sign_symptom,aggression,0.8864656," side-effects include headache, stomach pain and nausea. isolated cases of allergic skin reactions and more severe general allergic reactions have been reported. very rare cases of emotional disorders including aggression in children have been reported. treatment with desmopressin without concomitant reduction of fluid intake may lead to water retention/hyponatraemia with accompanying symptoms of headache, nausea, vomiting, weight gain, decreased serum sodium and in serious cases, convulsions. ",desmopressin acetate
sign_symptom,water retention,0.999833," side-effects include headache, stomach pain and nausea. isolated cases of allergic skin reactions and more severe general allergic reactions have been reported. very rare cases of emotional disorders including aggression in children have been reported. treatment with desmopressin without concomitant reduction of fluid intake may lead to water retention/hyponatraemia with accompanying symptoms of headache, nausea, vomiting, weight gain, decreased serum sodium and in serious cases, convulsions. ",desmopressin acetate
sign_symptom,weight,0.9892281," side-effects include headache, stomach pain and nausea. isolated cases of allergic skin reactions and more severe general allergic reactions have been reported. very rare cases of emotional disorders including aggression in children have been reported. treatment with desmopressin without concomitant reduction of fluid intake may lead to water retention/hyponatraemia with accompanying symptoms of headache, nausea, vomiting, weight gain, decreased serum sodium and in serious cases, convulsions. ",desmopressin acetate
sign_symptom,thin,0.99991477," adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects; posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera. ocular adverse reactions occurring with difluprednate included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis for patient with ocular surgery. ",difluprednate
sign_symptom,adverse,0.8705763," adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects; posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera. ocular adverse reactions occurring with difluprednate included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis for patient with ocular surgery. ",difluprednate
sign_symptom,hyper,0.999946," fever, headache, vomiting, dizziness, drowsiness, nausea, chills.  potentially fatal: severe hypersensitivity reactions may occur especially in the treatment of onchocerciasis where rare mazzotti reaction characterised by rash, itching, headache, muscle and joint pains, tachycardia, postural hypotension may start within 2 hr of drug administration. encephalitis and retinal haemorrhage. ",diethylcarbamazine citrate
disease_disorder,oncho,0.7825135," fever, headache, vomiting, dizziness, drowsiness, nausea, chills.  potentially fatal: severe hypersensitivity reactions may occur especially in the treatment of onchocerciasis where rare mazzotti reaction characterised by rash, itching, headache, muscle and joint pains, tachycardia, postural hypotension may start within 2 hr of drug administration. encephalitis and retinal haemorrhage. ",diethylcarbamazine citrate
sign_symptom,reaction,0.983933," fever, headache, vomiting, dizziness, drowsiness, nausea, chills.  potentially fatal: severe hypersensitivity reactions may occur especially in the treatment of onchocerciasis where rare mazzotti reaction characterised by rash, itching, headache, muscle and joint pains, tachycardia, postural hypotension may start within 2 hr of drug administration. encephalitis and retinal haemorrhage. ",diethylcarbamazine citrate
sign_symptom,adverse reactions,0.9998635," the most common adverse reactions (2%) in clinical trials for natazia are headache (including migraines) 13%, breast pain 7%, menstrual disorders 7%, nausea or vomiting 6%, acne 4%, mood changes (3%) and increased weight 3%. ",dienogest + estradiol valerate
sign_symptom,headache,0.9999373," the most common adverse reactions (2%) in clinical trials for natazia are headache (including migraines) 13%, breast pain 7%, menstrual disorders 7%, nausea or vomiting 6%, acne 4%, mood changes (3%) and increased weight 3%. ",dienogest + estradiol valerate
sign_symptom,pain,0.9999436," the most common adverse reactions (2%) in clinical trials for natazia are headache (including migraines) 13%, breast pain 7%, menstrual disorders 7%, nausea or vomiting 6%, acne 4%, mood changes (3%) and increased weight 3%. ",dienogest + estradiol valerate
sign_symptom,nausea,0.9999372," the most common adverse reactions (2%) in clinical trials for natazia are headache (including migraines) 13%, breast pain 7%, menstrual disorders 7%, nausea or vomiting 6%, acne 4%, mood changes (3%) and increased weight 3%. ",dienogest + estradiol valerate
sign_symptom,vomiting,0.9999188," the most common adverse reactions (2%) in clinical trials for natazia are headache (including migraines) 13%, breast pain 7%, menstrual disorders 7%, nausea or vomiting 6%, acne 4%, mood changes (3%) and increased weight 3%. ",dienogest + estradiol valerate
sign_symptom,mood changes,0.999747," the most common adverse reactions (2%) in clinical trials for natazia are headache (including migraines) 13%, breast pain 7%, menstrual disorders 7%, nausea or vomiting 6%, acne 4%, mood changes (3%) and increased weight 3%. ",dienogest + estradiol valerate
sign_symptom,undesirable effects,0.98019916," undesirable effects are more common during the 1st months after start of intake of dienogest, and subside with duration of treatment. the following undesirable effects have been reported in users of dienogest. the most frequently reported undesirable effects during treatment that were considered at least possibly related to dienogest were headache (9%), breast discomfort (5.4%), depressed mood (5.1%) and acne (5.1%). 
 
 nervous system disorders: headache, migraine. 
 cardiac disorders: uncommon: unspecified circulatory system disorder, palpitations. 
 vascular disorders: uncommon: hypotension. 
 gastrointestinal disorders: common: nausea, abdominal pain, flatulence. 
 metabolism and nutrition disorders: weight increase (3.6%) 
 psychiatric disorders: depressed mood, irritability, nervousness, altered mood. 
  ",dienogest
sign_symptom,effects,0.77200633," undesirable effects are more common during the 1st months after start of intake of dienogest, and subside with duration of treatment. the following undesirable effects have been reported in users of dienogest. the most frequently reported undesirable effects during treatment that were considered at least possibly related to dienogest were headache (9%), breast discomfort (5.4%), depressed mood (5.1%) and acne (5.1%). 
 
 nervous system disorders: headache, migraine. 
 cardiac disorders: uncommon: unspecified circulatory system disorder, palpitations. 
 vascular disorders: uncommon: hypotension. 
 gastrointestinal disorders: common: nausea, abdominal pain, flatulence. 
 metabolism and nutrition disorders: weight increase (3.6%) 
 psychiatric disorders: depressed mood, irritability, nervousness, altered mood. 
  ",dienogest
sign_symptom,headache,0.99994636," undesirable effects are more common during the 1st months after start of intake of dienogest, and subside with duration of treatment. the following undesirable effects have been reported in users of dienogest. the most frequently reported undesirable effects during treatment that were considered at least possibly related to dienogest were headache (9%), breast discomfort (5.4%), depressed mood (5.1%) and acne (5.1%). 
 
 nervous system disorders: headache, migraine. 
 cardiac disorders: uncommon: unspecified circulatory system disorder, palpitations. 
 vascular disorders: uncommon: hypotension. 
 gastrointestinal disorders: common: nausea, abdominal pain, flatulence. 
 metabolism and nutrition disorders: weight increase (3.6%) 
 psychiatric disorders: depressed mood, irritability, nervousness, altered mood. 
  ",dienogest
sign_symptom,discomfort,0.9999379," undesirable effects are more common during the 1st months after start of intake of dienogest, and subside with duration of treatment. the following undesirable effects have been reported in users of dienogest. the most frequently reported undesirable effects during treatment that were considered at least possibly related to dienogest were headache (9%), breast discomfort (5.4%), depressed mood (5.1%) and acne (5.1%). 
 
 nervous system disorders: headache, migraine. 
 cardiac disorders: uncommon: unspecified circulatory system disorder, palpitations. 
 vascular disorders: uncommon: hypotension. 
 gastrointestinal disorders: common: nausea, abdominal pain, flatulence. 
 metabolism and nutrition disorders: weight increase (3.6%) 
 psychiatric disorders: depressed mood, irritability, nervousness, altered mood. 
  ",dienogest
sign_symptom,depressed mood,0.9988968," undesirable effects are more common during the 1st months after start of intake of dienogest, and subside with duration of treatment. the following undesirable effects have been reported in users of dienogest. the most frequently reported undesirable effects during treatment that were considered at least possibly related to dienogest were headache (9%), breast discomfort (5.4%), depressed mood (5.1%) and acne (5.1%). 
 
 nervous system disorders: headache, migraine. 
 cardiac disorders: uncommon: unspecified circulatory system disorder, palpitations. 
 vascular disorders: uncommon: hypotension. 
 gastrointestinal disorders: common: nausea, abdominal pain, flatulence. 
 metabolism and nutrition disorders: weight increase (3.6%) 
 psychiatric disorders: depressed mood, irritability, nervousness, altered mood. 
  ",dienogest
sign_symptom,flat,0.99874556," undesirable effects are more common during the 1st months after start of intake of dienogest, and subside with duration of treatment. the following undesirable effects have been reported in users of dienogest. the most frequently reported undesirable effects during treatment that were considered at least possibly related to dienogest were headache (9%), breast discomfort (5.4%), depressed mood (5.1%) and acne (5.1%). 
 
 nervous system disorders: headache, migraine. 
 cardiac disorders: uncommon: unspecified circulatory system disorder, palpitations. 
 vascular disorders: uncommon: hypotension. 
 gastrointestinal disorders: common: nausea, abdominal pain, flatulence. 
 metabolism and nutrition disorders: weight increase (3.6%) 
 psychiatric disorders: depressed mood, irritability, nervousness, altered mood. 
  ",dienogest
sign_symptom,depressed,0.99071103," undesirable effects are more common during the 1st months after start of intake of dienogest, and subside with duration of treatment. the following undesirable effects have been reported in users of dienogest. the most frequently reported undesirable effects during treatment that were considered at least possibly related to dienogest were headache (9%), breast discomfort (5.4%), depressed mood (5.1%) and acne (5.1%). 
 
 nervous system disorders: headache, migraine. 
 cardiac disorders: uncommon: unspecified circulatory system disorder, palpitations. 
 vascular disorders: uncommon: hypotension. 
 gastrointestinal disorders: common: nausea, abdominal pain, flatulence. 
 metabolism and nutrition disorders: weight increase (3.6%) 
 psychiatric disorders: depressed mood, irritability, nervousness, altered mood. 
  ",dienogest
sign_symptom,pain,0.9999604," the most common reported side effects are abdominal pain, diarrhea and other gi symptoms. diarrhea and abdominal pain developed early in the course of therapy and were usually self-limited (resolved after 2 to 7 days). rare instances of profound diarrhea leading to severe dehydration have been reported in patients receiving misoprostol. ",diclofenac sodium + misoprostol
sign_symptom,dehy,0.99953866," the most common reported side effects are abdominal pain, diarrhea and other gi symptoms. diarrhea and abdominal pain developed early in the course of therapy and were usually self-limited (resolved after 2 to 7 days). rare instances of profound diarrhea leading to severe dehydration have been reported in patients receiving misoprostol. ",diclofenac sodium + misoprostol
sign_symptom,hypersensitivity,0.95099926, usually well tolerated. extremely low frequency of hypersensitivity reactions. ,diclofenac sodium + methyl salicylate + linseed oil + menthol
sign_symptom,side effects,0.8500455," side effects to diclofenac sodium and lidocaine injection are usually mild and transient. however if serious side effects occur the injection should be discontinued. gastrointestinal discomfort, nausea, diarrhea and occasionally bleeding may occur. in very rare instances, injection site disorder may occur. in isolated cases, abscesses and local necrosis may occur. the adverse effects due to lidocaine mainly involve the cns, are usually of short duration, and are dose related. the cns reactions may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadedness etc. ",diclofenac sodium + lidocaine hydrochloride
medication,sodium,0.9800378," side effects to diclofenac sodium and lidocaine injection are usually mild and transient. however if serious side effects occur the injection should be discontinued. gastrointestinal discomfort, nausea, diarrhea and occasionally bleeding may occur. in very rare instances, injection site disorder may occur. in isolated cases, abscesses and local necrosis may occur. the adverse effects due to lidocaine mainly involve the cns, are usually of short duration, and are dose related. the cns reactions may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadedness etc. ",diclofenac sodium + lidocaine hydrochloride
medication,lidocaine,0.8739538," side effects to diclofenac sodium and lidocaine injection are usually mild and transient. however if serious side effects occur the injection should be discontinued. gastrointestinal discomfort, nausea, diarrhea and occasionally bleeding may occur. in very rare instances, injection site disorder may occur. in isolated cases, abscesses and local necrosis may occur. the adverse effects due to lidocaine mainly involve the cns, are usually of short duration, and are dose related. the cns reactions may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadedness etc. ",diclofenac sodium + lidocaine hydrochloride
sign_symptom,diarrhea,0.98488444," side effects to diclofenac sodium and lidocaine injection are usually mild and transient. however if serious side effects occur the injection should be discontinued. gastrointestinal discomfort, nausea, diarrhea and occasionally bleeding may occur. in very rare instances, injection site disorder may occur. in isolated cases, abscesses and local necrosis may occur. the adverse effects due to lidocaine mainly involve the cns, are usually of short duration, and are dose related. the cns reactions may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadedness etc. ",diclofenac sodium + lidocaine hydrochloride
sign_symptom,bleeding,0.9997489," side effects to diclofenac sodium and lidocaine injection are usually mild and transient. however if serious side effects occur the injection should be discontinued. gastrointestinal discomfort, nausea, diarrhea and occasionally bleeding may occur. in very rare instances, injection site disorder may occur. in isolated cases, abscesses and local necrosis may occur. the adverse effects due to lidocaine mainly involve the cns, are usually of short duration, and are dose related. the cns reactions may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadedness etc. ",diclofenac sodium + lidocaine hydrochloride
sign_symptom,confusion,0.9865209," side effects to diclofenac sodium and lidocaine injection are usually mild and transient. however if serious side effects occur the injection should be discontinued. gastrointestinal discomfort, nausea, diarrhea and occasionally bleeding may occur. in very rare instances, injection site disorder may occur. in isolated cases, abscesses and local necrosis may occur. the adverse effects due to lidocaine mainly involve the cns, are usually of short duration, and are dose related. the cns reactions may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadedness etc. ",diclofenac sodium + lidocaine hydrochloride
sign_symptom,lightheadedness,0.97633183," side effects to diclofenac sodium and lidocaine injection are usually mild and transient. however if serious side effects occur the injection should be discontinued. gastrointestinal discomfort, nausea, diarrhea and occasionally bleeding may occur. in very rare instances, injection site disorder may occur. in isolated cases, abscesses and local necrosis may occur. the adverse effects due to lidocaine mainly involve the cns, are usually of short duration, and are dose related. the cns reactions may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadedness etc. ",diclofenac sodium + lidocaine hydrochloride
sign_symptom,burning sensation,0.9996845," mild to moderate burning sensation in 5-15% patients which is transient in nature and almost never necessitated discontinuation of treatment. other less common side-effects are sensitivity to light, bad taste, feeling of pressure, allergic reactions etc. ",diclofenac sodium (ophthalmic)
sign_symptom,bad taste,0.8249588," mild to moderate burning sensation in 5-15% patients which is transient in nature and almost never necessitated discontinuation of treatment. other less common side-effects are sensitivity to light, bad taste, feeling of pressure, allergic reactions etc. ",diclofenac sodium (ophthalmic)
sign_symptom,feeling of pressure,0.8731306," mild to moderate burning sensation in 5-15% patients which is transient in nature and almost never necessitated discontinuation of treatment. other less common side-effects are sensitivity to light, bad taste, feeling of pressure, allergic reactions etc. ",diclofenac sodium (ophthalmic)
sign_symptom,allergic reactions,0.99988264," mild to moderate burning sensation in 5-15% patients which is transient in nature and almost never necessitated discontinuation of treatment. other less common side-effects are sensitivity to light, bad taste, feeling of pressure, allergic reactions etc. ",diclofenac sodium (ophthalmic)
medication,diclofenac sodium,0.9043124," diclofenac sodium is generally well tolerated. adverse effects are mild, rare and transient. at the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. these effects are usually mild in nature. peripheral edema and skin reactions, such as rash and eczema have also been encountered. diclofenac sodium gel may cause local irritation and reddening of the skin and skin rash. ",diclofenac sodium
sign_symptom,adverse effects,0.94001985," diclofenac sodium is generally well tolerated. adverse effects are mild, rare and transient. at the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. these effects are usually mild in nature. peripheral edema and skin reactions, such as rash and eczema have also been encountered. diclofenac sodium gel may cause local irritation and reddening of the skin and skin rash. ",diclofenac sodium
sign_symptom,nausea,0.9998957," diclofenac sodium is generally well tolerated. adverse effects are mild, rare and transient. at the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. these effects are usually mild in nature. peripheral edema and skin reactions, such as rash and eczema have also been encountered. diclofenac sodium gel may cause local irritation and reddening of the skin and skin rash. ",diclofenac sodium
sign_symptom,diarrhea,0.97673875," diclofenac sodium is generally well tolerated. adverse effects are mild, rare and transient. at the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. these effects are usually mild in nature. peripheral edema and skin reactions, such as rash and eczema have also been encountered. diclofenac sodium gel may cause local irritation and reddening of the skin and skin rash. ",diclofenac sodium
sign_symptom,rash,0.99993074," diclofenac sodium is generally well tolerated. adverse effects are mild, rare and transient. at the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. these effects are usually mild in nature. peripheral edema and skin reactions, such as rash and eczema have also been encountered. diclofenac sodium gel may cause local irritation and reddening of the skin and skin rash. ",diclofenac sodium
sign_symptom,eczema,0.9951191," diclofenac sodium is generally well tolerated. adverse effects are mild, rare and transient. at the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. these effects are usually mild in nature. peripheral edema and skin reactions, such as rash and eczema have also been encountered. diclofenac sodium gel may cause local irritation and reddening of the skin and skin rash. ",diclofenac sodium
medication,diclofenac sodium gel,0.85337687," diclofenac sodium is generally well tolerated. adverse effects are mild, rare and transient. at the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. these effects are usually mild in nature. peripheral edema and skin reactions, such as rash and eczema have also been encountered. diclofenac sodium gel may cause local irritation and reddening of the skin and skin rash. ",diclofenac sodium
sign_symptom,irritation,0.9999181," diclofenac sodium is generally well tolerated. adverse effects are mild, rare and transient. at the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. these effects are usually mild in nature. peripheral edema and skin reactions, such as rash and eczema have also been encountered. diclofenac sodium gel may cause local irritation and reddening of the skin and skin rash. ",diclofenac sodium
sign_symptom,reddening,0.99856657," diclofenac sodium is generally well tolerated. adverse effects are mild, rare and transient. at the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. these effects are usually mild in nature. peripheral edema and skin reactions, such as rash and eczema have also been encountered. diclofenac sodium gel may cause local irritation and reddening of the skin and skin rash. ",diclofenac sodium
medication,diclofenac,0.8818262," side-effects of diclofenac are usually mild and transient. however, if serious side-effects occur. diclofenac should be discontinued. occasional: epigastric pain, other gastro-intestinal disorders (e.g., nausea, vomiting, diarrhoea, abdominal cramps, dyspepsia,flatulence,anorexia). rare: gastro-intestinal bleeding, peptic ulcer (with or without bleeding or perforation), bloody diarrhoea. ",diclofenac potassium
disease_disorder,peptic ul,0.77786463," side-effects of diclofenac are usually mild and transient. however, if serious side-effects occur. diclofenac should be discontinued. occasional: epigastric pain, other gastro-intestinal disorders (e.g., nausea, vomiting, diarrhoea, abdominal cramps, dyspepsia,flatulence,anorexia). rare: gastro-intestinal bleeding, peptic ulcer (with or without bleeding or perforation), bloody diarrhoea. ",diclofenac potassium
disease_disorder,diarrhea,0.8239281," the adverse reactions are thrombocytopenia, pancreatitis, hypotension, diarrhea, heart failure etc. ",diazoxide
disease_disorder,heart failure,0.99959815," the adverse reactions are thrombocytopenia, pancreatitis, hypotension, diarrhea, heart failure etc. ",diazoxide
medication,diazepam,0.99910337," diazepam is generally well tolerated. higher doses may cause somnolence, dizziness, light headedness, confusion and ataxia. ",diazepam
sign_symptom,light headed,0.9955874," diazepam is generally well tolerated. higher doses may cause somnolence, dizziness, light headedness, confusion and ataxia. ",diazepam
sign_symptom,adverse events,0.9982225," phosphate enema is well tolerated when used as indicated. however, adverse events possibly associated with the use of phosphate enema have been infrequently reported. in some cases, adverse events may occur, especially if the enema is misused. ",diabasic sodium phosphate + monobasic sodium phosphate
sign_symptom,enema,0.9683238," phosphate enema is well tolerated when used as indicated. however, adverse events possibly associated with the use of phosphate enema have been infrequently reported. in some cases, adverse events may occur, especially if the enema is misused. ",diabasic sodium phosphate + monobasic sodium phosphate
sign_symptom,allergic reactions,0.99991244," allergic reactions or anaphylactoid symptoms such as localized or generalized urticaria and pruritus; periorbital, facial, and/or laryngeal edema, coughing, sneezing, and/or difficulty with breathing have been reported during administration. the reporting frequency of these signs and symptoms is higher in women during pregnancy. ",dextrose & hartmann's solution
sign_symptom,difficulty with breathing,0.89899844," allergic reactions or anaphylactoid symptoms such as localized or generalized urticaria and pruritus; periorbital, facial, and/or laryngeal edema, coughing, sneezing, and/or difficulty with breathing have been reported during administration. the reporting frequency of these signs and symptoms is higher in women during pregnancy. ",dextrose & hartmann's solution
sign_symptom,swelling,0.9998053,"  
 severe burning, pain, or swelling around the iv needle; 
 warmth, redness, oozing, or bleeding where the iv was placed; 
 fever, ongoing cough; 
 high blood sugar, headache, trouble concentrating, memory problems, weakness, feeling unsteady, hallucinations, fainting, seizure, shallow breathing or breathing that stops; 
 low potassium or anxiety, sweating, pale skin, severe shortness of breath, wheezing, pain, fast or uneven heart rate. 
  ",dextrose
sign_symptom,shortness,0.9848093,"  
 severe burning, pain, or swelling around the iv needle; 
 warmth, redness, oozing, or bleeding where the iv was placed; 
 fever, ongoing cough; 
 high blood sugar, headache, trouble concentrating, memory problems, weakness, feeling unsteady, hallucinations, fainting, seizure, shallow breathing or breathing that stops; 
 low potassium or anxiety, sweating, pale skin, severe shortness of breath, wheezing, pain, fast or uneven heart rate. 
  ",dextrose
sign_symptom,nausea,0.9997036," common side effects are hypersensitivity, rash, nausea &amp; vomiting. ",dextromethorphan hydrobromide + guaifenesin
sign_symptom,adverse effects,0.9980096," adverse effects with dextromethorphan are rare, but nausea and dizziness sometimes occur. the drug produces no analgesia or addiction and little or no cns depression. excitation, confusion and respiratory depression may occur after overdosage. ",dextromethorphan hydrobromide
medication,dextromethorphan,0.93483144," adverse effects with dextromethorphan are rare, but nausea and dizziness sometimes occur. the drug produces no analgesia or addiction and little or no cns depression. excitation, confusion and respiratory depression may occur after overdosage. ",dextromethorphan hydrobromide
sign_symptom,nausea,0.99992156," adverse effects with dextromethorphan are rare, but nausea and dizziness sometimes occur. the drug produces no analgesia or addiction and little or no cns depression. excitation, confusion and respiratory depression may occur after overdosage. ",dextromethorphan hydrobromide
sign_symptom,analgesia,0.8904269," adverse effects with dextromethorphan are rare, but nausea and dizziness sometimes occur. the drug produces no analgesia or addiction and little or no cns depression. excitation, confusion and respiratory depression may occur after overdosage. ",dextromethorphan hydrobromide
sign_symptom,addiction,0.9955474," adverse effects with dextromethorphan are rare, but nausea and dizziness sometimes occur. the drug produces no analgesia or addiction and little or no cns depression. excitation, confusion and respiratory depression may occur after overdosage. ",dextromethorphan hydrobromide
sign_symptom,confusion,0.9998776," adverse effects with dextromethorphan are rare, but nausea and dizziness sometimes occur. the drug produces no analgesia or addiction and little or no cns depression. excitation, confusion and respiratory depression may occur after overdosage. ",dextromethorphan hydrobromide
sign_symptom,respiratory depression,0.94691205," adverse effects with dextromethorphan are rare, but nausea and dizziness sometimes occur. the drug produces no analgesia or addiction and little or no cns depression. excitation, confusion and respiratory depression may occur after overdosage. ",dextromethorphan hydrobromide
sign_symptom,vomiting,0.9998603," generally well tolerated but some patients may experience nausea, vomiting &amp; diarrhoea. these adverse events are of mild intensity and transient, resolving during continued treatment without the need for dose modification. less frequent side effects are insomnia, fatigue, anorexia, muscle cramps, generalized seizure etc. ",donepezil hydrochloride
sign_symptom,adverse,0.98905855," generally well tolerated but some patients may experience nausea, vomiting &amp; diarrhoea. these adverse events are of mild intensity and transient, resolving during continued treatment without the need for dose modification. less frequent side effects are insomnia, fatigue, anorexia, muscle cramps, generalized seizure etc. ",donepezil hydrochloride
sign_symptom,seizure,0.9999461," generally well tolerated but some patients may experience nausea, vomiting &amp; diarrhoea. these adverse events are of mild intensity and transient, resolving during continued treatment without the need for dose modification. less frequent side effects are insomnia, fatigue, anorexia, muscle cramps, generalized seizure etc. ",donepezil hydrochloride
sign_symptom,hyper,0.9999566," domperidone may produce hyperprolactinemia (1.3%).this may result in galactorrhea, breast enlargement, and soreness and reduced libido. dry mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with domperidone. extra-pyramidal reactions are seen in 0.05% of patients in clinical studies. ",domperidone maleate
sign_symptom,soreness,0.97378457," domperidone may produce hyperprolactinemia (1.3%).this may result in galactorrhea, breast enlargement, and soreness and reduced libido. dry mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with domperidone. extra-pyramidal reactions are seen in 0.05% of patients in clinical studies. ",domperidone maleate
sign_symptom,dry mouth,0.9856603," domperidone may produce hyperprolactinemia (1.3%).this may result in galactorrhea, breast enlargement, and soreness and reduced libido. dry mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with domperidone. extra-pyramidal reactions are seen in 0.05% of patients in clinical studies. ",domperidone maleate
sign_symptom,thirst,0.99967074," domperidone may produce hyperprolactinemia (1.3%).this may result in galactorrhea, breast enlargement, and soreness and reduced libido. dry mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with domperidone. extra-pyramidal reactions are seen in 0.05% of patients in clinical studies. ",domperidone maleate
sign_symptom,headache,0.99990094," domperidone may produce hyperprolactinemia (1.3%).this may result in galactorrhea, breast enlargement, and soreness and reduced libido. dry mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with domperidone. extra-pyramidal reactions are seen in 0.05% of patients in clinical studies. ",domperidone maleate
sign_symptom,nervous,0.70291686," domperidone may produce hyperprolactinemia (1.3%).this may result in galactorrhea, breast enlargement, and soreness and reduced libido. dry mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with domperidone. extra-pyramidal reactions are seen in 0.05% of patients in clinical studies. ",domperidone maleate
sign_symptom,diarrhea,0.9873763," domperidone may produce hyperprolactinemia (1.3%).this may result in galactorrhea, breast enlargement, and soreness and reduced libido. dry mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with domperidone. extra-pyramidal reactions are seen in 0.05% of patients in clinical studies. ",domperidone maleate
sign_symptom,rash,0.9998846," domperidone may produce hyperprolactinemia (1.3%).this may result in galactorrhea, breast enlargement, and soreness and reduced libido. dry mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with domperidone. extra-pyramidal reactions are seen in 0.05% of patients in clinical studies. ",domperidone maleate
sign_symptom,extra - pyramidal reactions,0.99990606," domperidone may produce hyperprolactinemia (1.3%).this may result in galactorrhea, breast enlargement, and soreness and reduced libido. dry mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with domperidone. extra-pyramidal reactions are seen in 0.05% of patients in clinical studies. ",domperidone maleate
medication,sodium soft,0.93081695," rarely, docusate sodium softgel capsules can cause diarrhea, nausea, abdominal cramps or skin rash. ",docusate sodium (oral)
disease_disorder,immune system,0.8692837, immune system disorders: hypersensitivity/allergic reactions; skin disorders: contact dermatitis and allergic skin reactions; general disorders: application site reactions rarely including transient stinging or irritation may occur. ,docusate sodium (ear drop)
sign_symptom,hyper,0.97697574, immune system disorders: hypersensitivity/allergic reactions; skin disorders: contact dermatitis and allergic skin reactions; general disorders: application site reactions rarely including transient stinging or irritation may occur. ,docusate sodium (ear drop)
disease_disorder,skin,0.7508631, immune system disorders: hypersensitivity/allergic reactions; skin disorders: contact dermatitis and allergic skin reactions; general disorders: application site reactions rarely including transient stinging or irritation may occur. ,docusate sodium (ear drop)
disease_disorder,contact,0.9828992, immune system disorders: hypersensitivity/allergic reactions; skin disorders: contact dermatitis and allergic skin reactions; general disorders: application site reactions rarely including transient stinging or irritation may occur. ,docusate sodium (ear drop)
disease_disorder,general,0.86042947, immune system disorders: hypersensitivity/allergic reactions; skin disorders: contact dermatitis and allergic skin reactions; general disorders: application site reactions rarely including transient stinging or irritation may occur. ,docusate sodium (ear drop)
sign_symptom,stinging,0.9995308, immune system disorders: hypersensitivity/allergic reactions; skin disorders: contact dermatitis and allergic skin reactions; general disorders: application site reactions rarely including transient stinging or irritation may occur. ,docusate sodium (ear drop)
sign_symptom,irritation,0.9998368, immune system disorders: hypersensitivity/allergic reactions; skin disorders: contact dermatitis and allergic skin reactions; general disorders: application site reactions rarely including transient stinging or irritation may occur. ,docusate sodium (ear drop)
sign_symptom,adverse reactions,0.9928061," the most common adverse reactions across all docetaxel indications are infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, and myalgia. incidence varies depending on the indication. adverse reactions are described according to indication. because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. ",docetaxel trihydrate
sign_symptom,adverse reaction,0.96992886," the most common adverse reactions across all docetaxel indications are infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, and myalgia. incidence varies depending on the indication. adverse reactions are described according to indication. because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. ",docetaxel trihydrate
sign_symptom,inflammatory changes,0.9993479,"  increased heart rate, blood pressure, and ventricular ectopic activity : a 10- to 20-mm increase insystolicblood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (seewarningsregarding exaggerated chronotropic and pressor effects). approximately 5% of patients have had increased prematureventricularbeats during infusions. these effects are dose related.   hypotension : precipitous decreases in blood pressure have occasionally been described in association withdobutaminetherapy. decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. in rare cases, however, intervention may be required and reversibility may not be immediate.   reactions at sites of intravenous infusion : phlebitishas occasionally been reported. local inflammatory changes have been described following inadvertent infiltration. isolated cases of cutaneous necrosis(destruction of skin tissue) have been reported.   miscellaneous uncommon effects : the following adverse effects have been reported in 1% to 3% of patients: nausea, headache, anginal pain, nonspecific chest pain,palpitations, and shortness of breath. isolated cases ofthrombocytopeniahave been reported.  administration of dobutamine, like other catecholamines, can produce a mild reduction in serumpotassiumconcentration, rarely to hypokalemic levels.   longer-term safety : infusions of up to 72 hours have revealed no adverse effects other than those seen with shorter infusions. ",dobutamine
sign_symptom,destruction,0.9994004,"  increased heart rate, blood pressure, and ventricular ectopic activity : a 10- to 20-mm increase insystolicblood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (seewarningsregarding exaggerated chronotropic and pressor effects). approximately 5% of patients have had increased prematureventricularbeats during infusions. these effects are dose related.   hypotension : precipitous decreases in blood pressure have occasionally been described in association withdobutaminetherapy. decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. in rare cases, however, intervention may be required and reversibility may not be immediate.   reactions at sites of intravenous infusion : phlebitishas occasionally been reported. local inflammatory changes have been described following inadvertent infiltration. isolated cases of cutaneous necrosis(destruction of skin tissue) have been reported.   miscellaneous uncommon effects : the following adverse effects have been reported in 1% to 3% of patients: nausea, headache, anginal pain, nonspecific chest pain,palpitations, and shortness of breath. isolated cases ofthrombocytopeniahave been reported.  administration of dobutamine, like other catecholamines, can produce a mild reduction in serumpotassiumconcentration, rarely to hypokalemic levels.   longer-term safety : infusions of up to 72 hours have revealed no adverse effects other than those seen with shorter infusions. ",dobutamine
sign_symptom,adverse effects,0.9952501,"  increased heart rate, blood pressure, and ventricular ectopic activity : a 10- to 20-mm increase insystolicblood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (seewarningsregarding exaggerated chronotropic and pressor effects). approximately 5% of patients have had increased prematureventricularbeats during infusions. these effects are dose related.   hypotension : precipitous decreases in blood pressure have occasionally been described in association withdobutaminetherapy. decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. in rare cases, however, intervention may be required and reversibility may not be immediate.   reactions at sites of intravenous infusion : phlebitishas occasionally been reported. local inflammatory changes have been described following inadvertent infiltration. isolated cases of cutaneous necrosis(destruction of skin tissue) have been reported.   miscellaneous uncommon effects : the following adverse effects have been reported in 1% to 3% of patients: nausea, headache, anginal pain, nonspecific chest pain,palpitations, and shortness of breath. isolated cases ofthrombocytopeniahave been reported.  administration of dobutamine, like other catecholamines, can produce a mild reduction in serumpotassiumconcentration, rarely to hypokalemic levels.   longer-term safety : infusions of up to 72 hours have revealed no adverse effects other than those seen with shorter infusions. ",dobutamine
sign_symptom,shortness,0.93150616,"  increased heart rate, blood pressure, and ventricular ectopic activity : a 10- to 20-mm increase insystolicblood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (seewarningsregarding exaggerated chronotropic and pressor effects). approximately 5% of patients have had increased prematureventricularbeats during infusions. these effects are dose related.   hypotension : precipitous decreases in blood pressure have occasionally been described in association withdobutaminetherapy. decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. in rare cases, however, intervention may be required and reversibility may not be immediate.   reactions at sites of intravenous infusion : phlebitishas occasionally been reported. local inflammatory changes have been described following inadvertent infiltration. isolated cases of cutaneous necrosis(destruction of skin tissue) have been reported.   miscellaneous uncommon effects : the following adverse effects have been reported in 1% to 3% of patients: nausea, headache, anginal pain, nonspecific chest pain,palpitations, and shortness of breath. isolated cases ofthrombocytopeniahave been reported.  administration of dobutamine, like other catecholamines, can produce a mild reduction in serumpotassiumconcentration, rarely to hypokalemic levels.   longer-term safety : infusions of up to 72 hours have revealed no adverse effects other than those seen with shorter infusions. ",dobutamine
medication,dobutam,0.8492432,"  increased heart rate, blood pressure, and ventricular ectopic activity : a 10- to 20-mm increase insystolicblood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (seewarningsregarding exaggerated chronotropic and pressor effects). approximately 5% of patients have had increased prematureventricularbeats during infusions. these effects are dose related.   hypotension : precipitous decreases in blood pressure have occasionally been described in association withdobutaminetherapy. decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. in rare cases, however, intervention may be required and reversibility may not be immediate.   reactions at sites of intravenous infusion : phlebitishas occasionally been reported. local inflammatory changes have been described following inadvertent infiltration. isolated cases of cutaneous necrosis(destruction of skin tissue) have been reported.   miscellaneous uncommon effects : the following adverse effects have been reported in 1% to 3% of patients: nausea, headache, anginal pain, nonspecific chest pain,palpitations, and shortness of breath. isolated cases ofthrombocytopeniahave been reported.  administration of dobutamine, like other catecholamines, can produce a mild reduction in serumpotassiumconcentration, rarely to hypokalemic levels.   longer-term safety : infusions of up to 72 hours have revealed no adverse effects other than those seen with shorter infusions. ",dobutamine
sign_symptom,- effects,0.973997," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,effects,0.94056153," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,allergic reactions,0.99970645," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,irritation,0.99995327," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,lesions,0.99991894," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,soreness,0.99915254," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,disco,0.99996185," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,cold,0.99972075," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,burning sensation,0.9814132," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,allergic reaction,0.99981534," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,cardiovascular defects,0.9940448," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,skeletal variations,0.9995899," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,infertility,0.9984661," the following is a list of possible side-effects that may occur from all constituting ingredients of this ointment. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 contact allergic reactions 
 irritation in skin areas surrounding treated lesions 
 soreness 
 temporary discoloration of hair and fingernails 
 mild cold or burning sensation at the site of application 
 severe allergic reaction 
 cardiovascular defects 
 skeletal variations 
 mild kidney lesions 
 infertility 
  ",dithranol + boric acid + salicylic acid
sign_symptom,loss of appetite,0.9956252," the safety profile is described below according to the clinical data generated in france, south korea, chile and thailand. in clinical studies in children who received tetraxim as a primary series, stand alone or combined with the act- hib vaccine, the most frequently reported reactions are local injection-site reactions, abnormal crying, loss of appetite and irritability. these signs and symptoms usually occur within 48 hours following the vaccination and may continue for 48-72 hours. they resolve spontaneously without requiring specific treatment. the frequency of injection-site reactions tends to increase at booster vaccination compared with the frequency observed for primary series. the safety profile of tetraxim does not differ significantly according to age groups. however certain reactions (myalgia, malaise, headache) are specific to children aged 2 years or more. ","diphtheria, tetanus, pertussis, poliomyelitis vaccine"
sign_symptom,allergic reactions,0.9998095," serious allergic reactions (anaphylactic reaction): difficulty in breathing, blueness of tongue/lips, a rash, swelling of face/throat, sudden and dizziness, loss of consciousness, accelerated heart rate with respiratory disorders. serious allergic reactions are a rare possibility (may up to 1 in 1,000 people) after receiving this vaccine. other side effects: 
 
 very common: anorexia, crying, somnolence, vomiting, pain redness and swelling at injection site, irritability, fever 
 common side effects: prolonged crying, diarrhoea, induration 
 uncommon side effects: allergicreaction, lump at injection site, high fever. 
  ","diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, influenzae vaccine"
sign_symptom,blue,0.9998523," serious allergic reactions (anaphylactic reaction): difficulty in breathing, blueness of tongue/lips, a rash, swelling of face/throat, sudden and dizziness, loss of consciousness, accelerated heart rate with respiratory disorders. serious allergic reactions are a rare possibility (may up to 1 in 1,000 people) after receiving this vaccine. other side effects: 
 
 very common: anorexia, crying, somnolence, vomiting, pain redness and swelling at injection site, irritability, fever 
 common side effects: prolonged crying, diarrhoea, induration 
 uncommon side effects: allergicreaction, lump at injection site, high fever. 
  ","diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, influenzae vaccine"
sign_symptom,rash,0.9497349," serious allergic reactions (anaphylactic reaction): difficulty in breathing, blueness of tongue/lips, a rash, swelling of face/throat, sudden and dizziness, loss of consciousness, accelerated heart rate with respiratory disorders. serious allergic reactions are a rare possibility (may up to 1 in 1,000 people) after receiving this vaccine. other side effects: 
 
 very common: anorexia, crying, somnolence, vomiting, pain redness and swelling at injection site, irritability, fever 
 common side effects: prolonged crying, diarrhoea, induration 
 uncommon side effects: allergicreaction, lump at injection site, high fever. 
  ","diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, influenzae vaccine"
sign_symptom,swelling,0.9999654," serious allergic reactions (anaphylactic reaction): difficulty in breathing, blueness of tongue/lips, a rash, swelling of face/throat, sudden and dizziness, loss of consciousness, accelerated heart rate with respiratory disorders. serious allergic reactions are a rare possibility (may up to 1 in 1,000 people) after receiving this vaccine. other side effects: 
 
 very common: anorexia, crying, somnolence, vomiting, pain redness and swelling at injection site, irritability, fever 
 common side effects: prolonged crying, diarrhoea, induration 
 uncommon side effects: allergicreaction, lump at injection site, high fever. 
  ","diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, influenzae vaccine"
sign_symptom,loss of consciousness,0.8982826," serious allergic reactions (anaphylactic reaction): difficulty in breathing, blueness of tongue/lips, a rash, swelling of face/throat, sudden and dizziness, loss of consciousness, accelerated heart rate with respiratory disorders. serious allergic reactions are a rare possibility (may up to 1 in 1,000 people) after receiving this vaccine. other side effects: 
 
 very common: anorexia, crying, somnolence, vomiting, pain redness and swelling at injection site, irritability, fever 
 common side effects: prolonged crying, diarrhoea, induration 
 uncommon side effects: allergicreaction, lump at injection site, high fever. 
  ","diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, influenzae vaccine"
sign_symptom,pain,0.99993753," serious allergic reactions (anaphylactic reaction): difficulty in breathing, blueness of tongue/lips, a rash, swelling of face/throat, sudden and dizziness, loss of consciousness, accelerated heart rate with respiratory disorders. serious allergic reactions are a rare possibility (may up to 1 in 1,000 people) after receiving this vaccine. other side effects: 
 
 very common: anorexia, crying, somnolence, vomiting, pain redness and swelling at injection site, irritability, fever 
 common side effects: prolonged crying, diarrhoea, induration 
 uncommon side effects: allergicreaction, lump at injection site, high fever. 
  ","diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, influenzae vaccine"
sign_symptom,fever,0.99993503," serious allergic reactions (anaphylactic reaction): difficulty in breathing, blueness of tongue/lips, a rash, swelling of face/throat, sudden and dizziness, loss of consciousness, accelerated heart rate with respiratory disorders. serious allergic reactions are a rare possibility (may up to 1 in 1,000 people) after receiving this vaccine. other side effects: 
 
 very common: anorexia, crying, somnolence, vomiting, pain redness and swelling at injection site, irritability, fever 
 common side effects: prolonged crying, diarrhoea, induration 
 uncommon side effects: allergicreaction, lump at injection site, high fever. 
  ","diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, influenzae vaccine"
sign_symptom,induration,0.99844503," serious allergic reactions (anaphylactic reaction): difficulty in breathing, blueness of tongue/lips, a rash, swelling of face/throat, sudden and dizziness, loss of consciousness, accelerated heart rate with respiratory disorders. serious allergic reactions are a rare possibility (may up to 1 in 1,000 people) after receiving this vaccine. other side effects: 
 
 very common: anorexia, crying, somnolence, vomiting, pain redness and swelling at injection site, irritability, fever 
 common side effects: prolonged crying, diarrhoea, induration 
 uncommon side effects: allergicreaction, lump at injection site, high fever. 
  ","diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, influenzae vaccine"
sign_symptom,allergic,0.8425762," serious allergic reactions (anaphylactic reaction): difficulty in breathing, blueness of tongue/lips, a rash, swelling of face/throat, sudden and dizziness, loss of consciousness, accelerated heart rate with respiratory disorders. serious allergic reactions are a rare possibility (may up to 1 in 1,000 people) after receiving this vaccine. other side effects: 
 
 very common: anorexia, crying, somnolence, vomiting, pain redness and swelling at injection site, irritability, fever 
 common side effects: prolonged crying, diarrhoea, induration 
 uncommon side effects: allergicreaction, lump at injection site, high fever. 
  ","diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, influenzae vaccine"
sign_symptom,lump,0.9999534," serious allergic reactions (anaphylactic reaction): difficulty in breathing, blueness of tongue/lips, a rash, swelling of face/throat, sudden and dizziness, loss of consciousness, accelerated heart rate with respiratory disorders. serious allergic reactions are a rare possibility (may up to 1 in 1,000 people) after receiving this vaccine. other side effects: 
 
 very common: anorexia, crying, somnolence, vomiting, pain redness and swelling at injection site, irritability, fever 
 common side effects: prolonged crying, diarrhoea, induration 
 uncommon side effects: allergicreaction, lump at injection site, high fever. 
  ","diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, influenzae vaccine"
sign_symptom,pain,0.9999635," the most common solicited injection site reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: pain (77.8%), swelling (20.9%), erythema (20.8%). 
 for adults 18-64 years of age: pain (65.7%), swelling (21.0%), erythema (24.7%). 
 
the most common solicited systemic reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: headache (43.7%), body ache or muscle weakness (30.4%), tiredness (15.1%). 
 for adults 18-64 years of age: headache (33.9%), body ache or muscle weakness (21.9%). 
  ",diphtheria + pertussis + tetanus [dpt]
sign_symptom,swelling,0.99996877," the most common solicited injection site reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: pain (77.8%), swelling (20.9%), erythema (20.8%). 
 for adults 18-64 years of age: pain (65.7%), swelling (21.0%), erythema (24.7%). 
 
the most common solicited systemic reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: headache (43.7%), body ache or muscle weakness (30.4%), tiredness (15.1%). 
 for adults 18-64 years of age: headache (33.9%), body ache or muscle weakness (21.9%). 
  ",diphtheria + pertussis + tetanus [dpt]
sign_symptom,headache,0.9999547," the most common solicited injection site reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: pain (77.8%), swelling (20.9%), erythema (20.8%). 
 for adults 18-64 years of age: pain (65.7%), swelling (21.0%), erythema (24.7%). 
 
the most common solicited systemic reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: headache (43.7%), body ache or muscle weakness (30.4%), tiredness (15.1%). 
 for adults 18-64 years of age: headache (33.9%), body ache or muscle weakness (21.9%). 
  ",diphtheria + pertussis + tetanus [dpt]
sign_symptom,body ache,0.9603748," the most common solicited injection site reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: pain (77.8%), swelling (20.9%), erythema (20.8%). 
 for adults 18-64 years of age: pain (65.7%), swelling (21.0%), erythema (24.7%). 
 
the most common solicited systemic reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: headache (43.7%), body ache or muscle weakness (30.4%), tiredness (15.1%). 
 for adults 18-64 years of age: headache (33.9%), body ache or muscle weakness (21.9%). 
  ",diphtheria + pertussis + tetanus [dpt]
sign_symptom,muscle weakness,0.9993386," the most common solicited injection site reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: pain (77.8%), swelling (20.9%), erythema (20.8%). 
 for adults 18-64 years of age: pain (65.7%), swelling (21.0%), erythema (24.7%). 
 
the most common solicited systemic reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: headache (43.7%), body ache or muscle weakness (30.4%), tiredness (15.1%). 
 for adults 18-64 years of age: headache (33.9%), body ache or muscle weakness (21.9%). 
  ",diphtheria + pertussis + tetanus [dpt]
sign_symptom,tiredness,0.99938536," the most common solicited injection site reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: pain (77.8%), swelling (20.9%), erythema (20.8%). 
 for adults 18-64 years of age: pain (65.7%), swelling (21.0%), erythema (24.7%). 
 
the most common solicited systemic reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: headache (43.7%), body ache or muscle weakness (30.4%), tiredness (15.1%). 
 for adults 18-64 years of age: headache (33.9%), body ache or muscle weakness (21.9%). 
  ",diphtheria + pertussis + tetanus [dpt]
sign_symptom,body,0.98604196," the most common solicited injection site reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: pain (77.8%), swelling (20.9%), erythema (20.8%). 
 for adults 18-64 years of age: pain (65.7%), swelling (21.0%), erythema (24.7%). 
 
the most common solicited systemic reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: headache (43.7%), body ache or muscle weakness (30.4%), tiredness (15.1%). 
 for adults 18-64 years of age: headache (33.9%), body ache or muscle weakness (21.9%). 
  ",diphtheria + pertussis + tetanus [dpt]
sign_symptom,ache,0.9783497," the most common solicited injection site reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: pain (77.8%), swelling (20.9%), erythema (20.8%). 
 for adults 18-64 years of age: pain (65.7%), swelling (21.0%), erythema (24.7%). 
 
the most common solicited systemic reactions occurring within 0-14 days following vaccination with this were: 
 
 for adolescents 11-17 years of age: headache (43.7%), body ache or muscle weakness (30.4%), tiredness (15.1%). 
 for adults 18-64 years of age: headache (33.9%), body ache or muscle weakness (21.9%). 
  ",diphtheria + pertussis + tetanus [dpt]
disease_disorder,dermatitis,0.9949047, contact dermatitis with mild erythematous vesicular lesions and papules has occasionally been reported. ,diphenhydramine hydrochloride + zinc acetate
sign_symptom,lesions,0.999943, contact dermatitis with mild erythematous vesicular lesions and papules has occasionally been reported. ,diphenhydramine hydrochloride + zinc acetate
sign_symptom,dry mouth,0.9919609," diphenhydramine may cause drowsiness, dizziness, gastrointestinal disturbance, dry mouth/nose/throat, difficulty in urination or blurred vision ",diphenhydramine + levomenthol
sign_symptom,difficulty in urination,0.9962745," diphenhydramine may cause drowsiness, dizziness, gastrointestinal disturbance, dry mouth/nose/throat, difficulty in urination or blurred vision ",diphenhydramine + levomenthol
sign_symptom,blurred vision,0.99988365," diphenhydramine may cause drowsiness, dizziness, gastrointestinal disturbance, dry mouth/nose/throat, difficulty in urination or blurred vision ",diphenhydramine + levomenthol
sign_symptom,mala,0.9861006," bradycardia, sino-atrial block, atrioventricular block, hypertension, malaise, headache, hot flushes, git disturbances, oedema, hepatitis and depression reported. ",diltiazem hydrochloride (sr tablet)
disease_disorder,hepatitis,0.70624816," bradycardia, sino-atrial block, atrioventricular block, hypertension, malaise, headache, hot flushes, git disturbances, oedema, hepatitis and depression reported. ",diltiazem hydrochloride (sr tablet)
sign_symptom,depression,0.99603134," bradycardia, sino-atrial block, atrioventricular block, hypertension, malaise, headache, hot flushes, git disturbances, oedema, hepatitis and depression reported. ",diltiazem hydrochloride (sr tablet)
sign_symptom,hyper,0.9934487," with diltiazem headache, ankle oedema, hypertension, dizziness, flushing, rashes (toxic erythema), nausea and gl disturbances may occur. transient elevation in liver enzyme values and occasionally hepatitis have been reported. diltiazem may depress cardiac conduction and has occasionally led to av block, bradycardia and rarely asystoleor sinus arrest. ",diltiazem hydrochloride (fc tablet)
sign_symptom,rash,0.99990153," with diltiazem headache, ankle oedema, hypertension, dizziness, flushing, rashes (toxic erythema), nausea and gl disturbances may occur. transient elevation in liver enzyme values and occasionally hepatitis have been reported. diltiazem may depress cardiac conduction and has occasionally led to av block, bradycardia and rarely asystoleor sinus arrest. ",diltiazem hydrochloride (fc tablet)
sign_symptom,nausea,0.99994445," with diltiazem headache, ankle oedema, hypertension, dizziness, flushing, rashes (toxic erythema), nausea and gl disturbances may occur. transient elevation in liver enzyme values and occasionally hepatitis have been reported. diltiazem may depress cardiac conduction and has occasionally led to av block, bradycardia and rarely asystoleor sinus arrest. ",diltiazem hydrochloride (fc tablet)
sign_symptom,gl disturbances,0.9998999," with diltiazem headache, ankle oedema, hypertension, dizziness, flushing, rashes (toxic erythema), nausea and gl disturbances may occur. transient elevation in liver enzyme values and occasionally hepatitis have been reported. diltiazem may depress cardiac conduction and has occasionally led to av block, bradycardia and rarely asystoleor sinus arrest. ",diltiazem hydrochloride (fc tablet)
medication,diltiaze,0.76917416," with diltiazem headache, ankle oedema, hypertension, dizziness, flushing, rashes (toxic erythema), nausea and gl disturbances may occur. transient elevation in liver enzyme values and occasionally hepatitis have been reported. diltiazem may depress cardiac conduction and has occasionally led to av block, bradycardia and rarely asystoleor sinus arrest. ",diltiazem hydrochloride (fc tablet)
sign_symptom,bradycardia,0.9093816," with diltiazem headache, ankle oedema, hypertension, dizziness, flushing, rashes (toxic erythema), nausea and gl disturbances may occur. transient elevation in liver enzyme values and occasionally hepatitis have been reported. diltiazem may depress cardiac conduction and has occasionally led to av block, bradycardia and rarely asystoleor sinus arrest. ",diltiazem hydrochloride (fc tablet)
sign_symptom,vomiting,0.9999254," the frequency of these side-effects is unknown flatulence, itching, urticaria, vomiting ",diloxanide furoate
medication,digoxin,0.8992768," usually associated with excessive dosage include anorexia, nausea, vomiting, diarrhoea, abdominal pain, visual disturbance, headache, fatigue, drowsiness, confusion, delirium, hallucination, depression, arrhythmia, heart block, intestinal ischaemia, gynaecomastia on long term use, thrombocytopenia reported. digoxin can be safely used in pregnancy ",digoxin
sign_symptom,adverse events,0.99695635," adverse events were primarily mild in intensity and generally resolved without medical treatment or discontinuation of eflornithine. side effects can include acne, barbae, pseudofolliculitis, stinging skin, headache, burning skin, dry skin, erythema (redness), pruritus (itching), tingling skin, dyspepsia, skin irritation, rash, alopecia, dizziness, folliculitis, hair ingrown, facial edema, anorexia, nausea, asthenia, vertigo ",eflornithine hydrochloride
sign_symptom,vertigo,0.92568463," adverse events were primarily mild in intensity and generally resolved without medical treatment or discontinuation of eflornithine. side effects can include acne, barbae, pseudofolliculitis, stinging skin, headache, burning skin, dry skin, erythema (redness), pruritus (itching), tingling skin, dyspepsia, skin irritation, rash, alopecia, dizziness, folliculitis, hair ingrown, facial edema, anorexia, nausea, asthenia, vertigo ",eflornithine hydrochloride
sign_symptom,impaired,0.8618814," rashes, psychiatric or cns disturbances, amnesia, agitation, confusion, dizziness, vertigo, headache, euphoria, insomnia or somnolence, impaired concentration, abnormal thinking or dreaming, depersonalisation, convulsions, hallucinations, nausea, vomiting, diarrhoea, pancreatitis, fatigue, hepatic failure, photoallergic dermatitis; autoimmune disorders (e.g. graves disease, polymyositis, guillain-barre syndrome), osteonecrosis. accumulation or redistribution of body fat (lipodystrophy) including central obesity, peripheral and facial wasting, buffalo hump, breast enlargement, cushingoid appearance. metabolic abnormalities e.g. hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, hyperlactataemia, insulin resistance. ",efavirenz
sign_symptom,abnormal thinking,0.9861903," rashes, psychiatric or cns disturbances, amnesia, agitation, confusion, dizziness, vertigo, headache, euphoria, insomnia or somnolence, impaired concentration, abnormal thinking or dreaming, depersonalisation, convulsions, hallucinations, nausea, vomiting, diarrhoea, pancreatitis, fatigue, hepatic failure, photoallergic dermatitis; autoimmune disorders (e.g. graves disease, polymyositis, guillain-barre syndrome), osteonecrosis. accumulation or redistribution of body fat (lipodystrophy) including central obesity, peripheral and facial wasting, buffalo hump, breast enlargement, cushingoid appearance. metabolic abnormalities e.g. hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, hyperlactataemia, insulin resistance. ",efavirenz
disease_disorder,autoimmune disorders,0.97305834," rashes, psychiatric or cns disturbances, amnesia, agitation, confusion, dizziness, vertigo, headache, euphoria, insomnia or somnolence, impaired concentration, abnormal thinking or dreaming, depersonalisation, convulsions, hallucinations, nausea, vomiting, diarrhoea, pancreatitis, fatigue, hepatic failure, photoallergic dermatitis; autoimmune disorders (e.g. graves disease, polymyositis, guillain-barre syndrome), osteonecrosis. accumulation or redistribution of body fat (lipodystrophy) including central obesity, peripheral and facial wasting, buffalo hump, breast enlargement, cushingoid appearance. metabolic abnormalities e.g. hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, hyperlactataemia, insulin resistance. ",efavirenz
disease_disorder,polymyosi,0.89108324," rashes, psychiatric or cns disturbances, amnesia, agitation, confusion, dizziness, vertigo, headache, euphoria, insomnia or somnolence, impaired concentration, abnormal thinking or dreaming, depersonalisation, convulsions, hallucinations, nausea, vomiting, diarrhoea, pancreatitis, fatigue, hepatic failure, photoallergic dermatitis; autoimmune disorders (e.g. graves disease, polymyositis, guillain-barre syndrome), osteonecrosis. accumulation or redistribution of body fat (lipodystrophy) including central obesity, peripheral and facial wasting, buffalo hump, breast enlargement, cushingoid appearance. metabolic abnormalities e.g. hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, hyperlactataemia, insulin resistance. ",efavirenz
disease_disorder,osteonecrosis,0.85308886," rashes, psychiatric or cns disturbances, amnesia, agitation, confusion, dizziness, vertigo, headache, euphoria, insomnia or somnolence, impaired concentration, abnormal thinking or dreaming, depersonalisation, convulsions, hallucinations, nausea, vomiting, diarrhoea, pancreatitis, fatigue, hepatic failure, photoallergic dermatitis; autoimmune disorders (e.g. graves disease, polymyositis, guillain-barre syndrome), osteonecrosis. accumulation or redistribution of body fat (lipodystrophy) including central obesity, peripheral and facial wasting, buffalo hump, breast enlargement, cushingoid appearance. metabolic abnormalities e.g. hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, hyperlactataemia, insulin resistance. ",efavirenz
sign_symptom,redistribution,0.8947573," rashes, psychiatric or cns disturbances, amnesia, agitation, confusion, dizziness, vertigo, headache, euphoria, insomnia or somnolence, impaired concentration, abnormal thinking or dreaming, depersonalisation, convulsions, hallucinations, nausea, vomiting, diarrhoea, pancreatitis, fatigue, hepatic failure, photoallergic dermatitis; autoimmune disorders (e.g. graves disease, polymyositis, guillain-barre syndrome), osteonecrosis. accumulation or redistribution of body fat (lipodystrophy) including central obesity, peripheral and facial wasting, buffalo hump, breast enlargement, cushingoid appearance. metabolic abnormalities e.g. hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, hyperlactataemia, insulin resistance. ",efavirenz
sign_symptom,redness,0.74478054," rarely, transient local mild irritation, itching &amp; redness may occur immediately after application. econazole has the minimal allergenic effect and is well tolerated, even by delicate skin. adrenal suppression on long term continuous topical steroid therapy may occur, particularly in infants or children, or when occlusive dressings are applied. it should be noted that an infant's napkin may act as an occlusive dressing. ",econazole nitrate + triamcinolone acetonide
medication,cream,0.9646274," during clinical trials, approximately 3% of patients treated with econazole nitrate 1% cream reported side effects thought possibly to be due to the drug, consisting mainly of burning, itching, stinging, and erythema. one case of a pruritic rash has also been reported. ",econazole nitrate
sign_symptom,rash,0.99991035," during clinical trials, approximately 3% of patients treated with econazole nitrate 1% cream reported side effects thought possibly to be due to the drug, consisting mainly of burning, itching, stinging, and erythema. one case of a pruritic rash has also been reported. ",econazole nitrate
sign_symptom,dry mouth,0.9863486," the most common side-effects are headache, dry mouth and drowsiness. less commonly reported side effects include abdominal pain, dyspepsia, nausea and insomnia. ",ebastine
sign_symptom,dyspeps,0.99503756," the most common side-effects are headache, dry mouth and drowsiness. less commonly reported side effects include abdominal pain, dyspepsia, nausea and insomnia. ",ebastine
sign_symptom,nausea,0.96889347," the most common side-effects are headache, dry mouth and drowsiness. less commonly reported side effects include abdominal pain, dyspepsia, nausea and insomnia. ",ebastine
sign_symptom,adverse drug reactions,0.99605113," the most commonly reported adverse drug reactions of patients treated with dydrogesterone in clinical trials of indications without oestrogen treatment are migraines/headache, nausea, menstrual disorders and breast pain/tenderness. ",dydrogesterone
medication,oestrogen treatment,0.99342024," the most commonly reported adverse drug reactions of patients treated with dydrogesterone in clinical trials of indications without oestrogen treatment are migraines/headache, nausea, menstrual disorders and breast pain/tenderness. ",dydrogesterone
sign_symptom,migraines,0.83172053," the most commonly reported adverse drug reactions of patients treated with dydrogesterone in clinical trials of indications without oestrogen treatment are migraines/headache, nausea, menstrual disorders and breast pain/tenderness. ",dydrogesterone
disease_disorder,menst,0.95400745," the most commonly reported adverse drug reactions of patients treated with dydrogesterone in clinical trials of indications without oestrogen treatment are migraines/headache, nausea, menstrual disorders and breast pain/tenderness. ",dydrogesterone
sign_symptom,pain,0.90552735," the most commonly reported adverse drug reactions of patients treated with dydrogesterone in clinical trials of indications without oestrogen treatment are migraines/headache, nausea, menstrual disorders and breast pain/tenderness. ",dydrogesterone
sign_symptom,sexual problems,0.9907708,"  
 sexual problems (such as decreased sexual interest/ ability, decrease in the amount of semen/ sperm released during sex) 
 impotence (trouble getting or keeping an erection) 
 testicle pain or swelling 
 increased breast size 
 breast tenderness. 
  ",dutasteride
sign_symptom,trouble,0.97071236,"  
 sexual problems (such as decreased sexual interest/ ability, decrease in the amount of semen/ sperm released during sex) 
 impotence (trouble getting or keeping an erection) 
 testicle pain or swelling 
 increased breast size 
 breast tenderness. 
  ",dutasteride
sign_symptom,pain,0.9995914,"  
 sexual problems (such as decreased sexual interest/ ability, decrease in the amount of semen/ sperm released during sex) 
 impotence (trouble getting or keeping an erection) 
 testicle pain or swelling 
 increased breast size 
 breast tenderness. 
  ",dutasteride
sign_symptom,swelling,0.9981061,"  
 sexual problems (such as decreased sexual interest/ ability, decrease in the amount of semen/ sperm released during sex) 
 impotence (trouble getting or keeping an erection) 
 testicle pain or swelling 
 increased breast size 
 breast tenderness. 
  ",dutasteride
sign_symptom,adverse,0.99563015," the most commonly observed adverse events in duloxetine hydrochloride treated patients were nausea, dizziness, dry mouth, constipation, decreased appetite, fatigue, somnolence, increased sweating, hyperhidrosis and asthenia. it may slightly increase blood pressure. no clinically significant differences were observed for qt, pr, and qrs intervals between duloxetine-treated and placebo-treated patients. ",duloxetine hydrochloride
medication,hydrochloride,0.80010414," the most commonly observed adverse events in duloxetine hydrochloride treated patients were nausea, dizziness, dry mouth, constipation, decreased appetite, fatigue, somnolence, increased sweating, hyperhidrosis and asthenia. it may slightly increase blood pressure. no clinically significant differences were observed for qt, pr, and qrs intervals between duloxetine-treated and placebo-treated patients. ",duloxetine hydrochloride
medication,dulaglutide,0.981223," the most common adverse reactions, reported in 5% of patients treated with dulaglutide are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite ",dulaglutide
sign_symptom,vomiting,0.80315423," the most common adverse reactions, reported in 5% of patients treated with dulaglutide are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite ",dulaglutide
sign_symptom,decreased appetite,0.8984662," the most common adverse reactions, reported in 5% of patients treated with dulaglutide are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite ",dulaglutide
sign_symptom,effects,0.9578034," the following clinically significant side effects are described elsewhere in other sections of the labeling: 
 
 hyperkalemia 
 bleeding irregularities and amenorrhea 
 because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. 
  ",drospirenone
sign_symptom,hyper,0.9999635," the following clinically significant side effects are described elsewhere in other sections of the labeling: 
 
 hyperkalemia 
 bleeding irregularities and amenorrhea 
 because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. 
  ",drospirenone
sign_symptom,bleeding irregularities,0.99991107," the following clinically significant side effects are described elsewhere in other sections of the labeling: 
 
 hyperkalemia 
 bleeding irregularities and amenorrhea 
 because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. 
  ",drospirenone
sign_symptom,ameno,0.966882," the following clinically significant side effects are described elsewhere in other sections of the labeling: 
 
 hyperkalemia 
 bleeding irregularities and amenorrhea 
 because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. 
  ",drospirenone
sign_symptom,adverse reaction rates,0.993741," the following clinically significant side effects are described elsewhere in other sections of the labeling: 
 
 hyperkalemia 
 bleeding irregularities and amenorrhea 
 because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. 
  ",drospirenone
sign_symptom,dystonic reactions,0.93899393," acute dystonic reactions and long-lasting impaired consciousness in child. cns depression including slight drowsiness to deep sleep, lassitude, dizziness, incoordination. headache, psychomotor impairment and antimuscarinic effects. rarely rashes and hypersensitivity reactions, blood disorders, convulsions, sweating, myalgia, extrapyramidal effects, tremor, confusion, tinnitus, hypotension, hair loss. ",doxylamine succinate
sign_symptom,impaired,0.99915445," acute dystonic reactions and long-lasting impaired consciousness in child. cns depression including slight drowsiness to deep sleep, lassitude, dizziness, incoordination. headache, psychomotor impairment and antimuscarinic effects. rarely rashes and hypersensitivity reactions, blood disorders, convulsions, sweating, myalgia, extrapyramidal effects, tremor, confusion, tinnitus, hypotension, hair loss. ",doxylamine succinate
sign_symptom,consciousness,0.9572089," acute dystonic reactions and long-lasting impaired consciousness in child. cns depression including slight drowsiness to deep sleep, lassitude, dizziness, incoordination. headache, psychomotor impairment and antimuscarinic effects. rarely rashes and hypersensitivity reactions, blood disorders, convulsions, sweating, myalgia, extrapyramidal effects, tremor, confusion, tinnitus, hypotension, hair loss. ",doxylamine succinate
sign_symptom,depression,0.9998599," acute dystonic reactions and long-lasting impaired consciousness in child. cns depression including slight drowsiness to deep sleep, lassitude, dizziness, incoordination. headache, psychomotor impairment and antimuscarinic effects. rarely rashes and hypersensitivity reactions, blood disorders, convulsions, sweating, myalgia, extrapyramidal effects, tremor, confusion, tinnitus, hypotension, hair loss. ",doxylamine succinate
sign_symptom,rash,0.99994636," acute dystonic reactions and long-lasting impaired consciousness in child. cns depression including slight drowsiness to deep sleep, lassitude, dizziness, incoordination. headache, psychomotor impairment and antimuscarinic effects. rarely rashes and hypersensitivity reactions, blood disorders, convulsions, sweating, myalgia, extrapyramidal effects, tremor, confusion, tinnitus, hypotension, hair loss. ",doxylamine succinate
sign_symptom,hypersensitivity,0.9987672," acute dystonic reactions and long-lasting impaired consciousness in child. cns depression including slight drowsiness to deep sleep, lassitude, dizziness, incoordination. headache, psychomotor impairment and antimuscarinic effects. rarely rashes and hypersensitivity reactions, blood disorders, convulsions, sweating, myalgia, extrapyramidal effects, tremor, confusion, tinnitus, hypotension, hair loss. ",doxylamine succinate
sign_symptom,vomiting,0.9875179," nausea, vomiting, diarrhoea, skin rashes, hemolytic anaemia, eosinophilia may be reported. ",doxycycline hydrochloride
sign_symptom,diarr,0.9572071," nausea, vomiting, diarrhoea, skin rashes, hemolytic anaemia, eosinophilia may be reported. ",doxycycline hydrochloride
sign_symptom,rash,0.99968445," nausea, vomiting, diarrhoea, skin rashes, hemolytic anaemia, eosinophilia may be reported. ",doxycycline hydrochloride
sign_symptom,eosinophilia,0.992665," nausea, vomiting, diarrhoea, skin rashes, hemolytic anaemia, eosinophilia may be reported. ",doxycycline hydrochloride
medication,doxophylline,0.98456013," doxophylline rarely causes serious side effects, however possible side effects are similar for taking excess amount of caffeine. these include: nausea, vomiting, headache, upset stomach and heartburn. ",doxophylline
sign_symptom,upset,0.9781246," doxophylline rarely causes serious side effects, however possible side effects are similar for taking excess amount of caffeine. these include: nausea, vomiting, headache, upset stomach and heartburn. ",doxophylline
sign_symptom,gastro - intestinal disturbances,0.9638178," drowsiness, local burning, stinging, irritation, tingling, rash; systemic side-effects such as antimuscarinic effects, headache, fever, dizziness, gastro-intestinal disturbances has been reported. ",doxepin (topical)
sign_symptom,adverse reactions,0.9998226," the following serious adverse reactions are as follows: 
 
 abnormal thinking and behavioral changes 
 suicide risk and worsening of depression 
 cns depressant effects 
  ",doxepin (oral)
sign_symptom,abnormal thinking,0.9995669," the following serious adverse reactions are as follows: 
 
 abnormal thinking and behavioral changes 
 suicide risk and worsening of depression 
 cns depressant effects 
  ",doxepin (oral)
sign_symptom,behavioral changes,0.9958637," the following serious adverse reactions are as follows: 
 
 abnormal thinking and behavioral changes 
 suicide risk and worsening of depression 
 cns depressant effects 
  ",doxepin (oral)
disease_disorder,suicide,0.8326667," the following serious adverse reactions are as follows: 
 
 abnormal thinking and behavioral changes 
 suicide risk and worsening of depression 
 cns depressant effects 
  ",doxepin (oral)
sign_symptom,depression,0.999708," the following serious adverse reactions are as follows: 
 
 abnormal thinking and behavioral changes 
 suicide risk and worsening of depression 
 cns depressant effects 
  ",doxepin (oral)
sign_symptom,depressant effects,0.9739244," the following serious adverse reactions are as follows: 
 
 abnormal thinking and behavioral changes 
 suicide risk and worsening of depression 
 cns depressant effects 
  ",doxepin (oral)
sign_symptom,hyper,0.99788564," mild burning, ocular hyperemia, blurred vision may occur. ",dorzolamide + timolol
sign_symptom,blurred vision,0.9998852," mild burning, ocular hyperemia, blurred vision may occur. ",dorzolamide + timolol
sign_symptom,adverse reactions,0.9964452," the most frequent reported adverse reactions are ectopic beats, nausea, vomiting, tachycardia, anginal pain, palpitations, dyspnoea, headache, hypotension, hypertension and vasoconstriction. other less frequent adverse reactions are aberrant ventricular conduction, bradycardia, piloerection, mydriasis, widened qrs complex, azotaemia and elevated blood pressure. peripheral ischemic gangrene in patients with pre-existing vascular disease. fatal ventricular arrhythmias have been reported on rare occasions. ",dopamine hydrochloride
sign_symptom,vomiting,0.70762104," the most frequent reported adverse reactions are ectopic beats, nausea, vomiting, tachycardia, anginal pain, palpitations, dyspnoea, headache, hypotension, hypertension and vasoconstriction. other less frequent adverse reactions are aberrant ventricular conduction, bradycardia, piloerection, mydriasis, widened qrs complex, azotaemia and elevated blood pressure. peripheral ischemic gangrene in patients with pre-existing vascular disease. fatal ventricular arrhythmias have been reported on rare occasions. ",dopamine hydrochloride
sign_symptom,palpitations,0.9950123," the most frequent reported adverse reactions are ectopic beats, nausea, vomiting, tachycardia, anginal pain, palpitations, dyspnoea, headache, hypotension, hypertension and vasoconstriction. other less frequent adverse reactions are aberrant ventricular conduction, bradycardia, piloerection, mydriasis, widened qrs complex, azotaemia and elevated blood pressure. peripheral ischemic gangrene in patients with pre-existing vascular disease. fatal ventricular arrhythmias have been reported on rare occasions. ",dopamine hydrochloride
sign_symptom,dyspnoea,0.9963168," the most frequent reported adverse reactions are ectopic beats, nausea, vomiting, tachycardia, anginal pain, palpitations, dyspnoea, headache, hypotension, hypertension and vasoconstriction. other less frequent adverse reactions are aberrant ventricular conduction, bradycardia, piloerection, mydriasis, widened qrs complex, azotaemia and elevated blood pressure. peripheral ischemic gangrene in patients with pre-existing vascular disease. fatal ventricular arrhythmias have been reported on rare occasions. ",dopamine hydrochloride
sign_symptom,hypertension,0.9711282," the most frequent reported adverse reactions are ectopic beats, nausea, vomiting, tachycardia, anginal pain, palpitations, dyspnoea, headache, hypotension, hypertension and vasoconstriction. other less frequent adverse reactions are aberrant ventricular conduction, bradycardia, piloerection, mydriasis, widened qrs complex, azotaemia and elevated blood pressure. peripheral ischemic gangrene in patients with pre-existing vascular disease. fatal ventricular arrhythmias have been reported on rare occasions. ",dopamine hydrochloride
sign_symptom,gangrene,0.99983245," the most frequent reported adverse reactions are ectopic beats, nausea, vomiting, tachycardia, anginal pain, palpitations, dyspnoea, headache, hypotension, hypertension and vasoconstriction. other less frequent adverse reactions are aberrant ventricular conduction, bradycardia, piloerection, mydriasis, widened qrs complex, azotaemia and elevated blood pressure. peripheral ischemic gangrene in patients with pre-existing vascular disease. fatal ventricular arrhythmias have been reported on rare occasions. ",dopamine hydrochloride
sign_symptom,allergic reactions,0.85888946," bleeding is the most common adverse effect. adverse reactions include intracranial hemorrhage &amp; stroke, thrombocytopenia, allergic reactions and hypotension. ",eptifibatide
sign_symptom,skin reactions,0.9996929," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,rash,0.99984777," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,pruritus,0.994644," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,urticaria,0.99961406," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,reactions,0.99944943," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,anaphylactoid reactions,0.99947244," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,hypersensitivity reactions,0.93798465," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,flu -,0.92378235," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,symptoms,0.8093328," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,fever,0.9985543," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,chill,0.99349535," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,headache,0.9991742," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,pain,0.99996436," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,mala,0.9999659," rarely (1/10,000 to 1/1,000), skin reactions such as rash, pruritus, urticaria or injection site reactions may occur. in very rare cases (1/10,000) anaphylactoid reactions have been reported. however, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. in very rare cases (1/10,000), particularly when starting treatment, flu-like symptoms such as fever, chills, headaches, pain in the limbs, malaise and/or bone pain have been reported. these reactions were mild or moderate in nature and subsided after a couple of hours or days. ",epoetin beta
sign_symptom,cough,0.98438567," headache, dizziness, diarrhea, stomach pain, nausea, cough or flu-like symptoms may occur. symptoms of a serious allergic reaction like: rash, itching, swelling, severe dizziness, trouble breathing can occur. ",eplerenone
sign_symptom,allergic reaction,0.99952906," headache, dizziness, diarrhea, stomach pain, nausea, cough or flu-like symptoms may occur. symptoms of a serious allergic reaction like: rash, itching, swelling, severe dizziness, trouble breathing can occur. ",eplerenone
sign_symptom,trouble breathing,0.99843585," headache, dizziness, diarrhea, stomach pain, nausea, cough or flu-like symptoms may occur. symptoms of a serious allergic reaction like: rash, itching, swelling, severe dizziness, trouble breathing can occur. ",eplerenone
sign_symptom,adverse events,0.99960184," in early breast cancer, acute adverse events occurring in 10% of patients are leucopenia, neutropenia, anemia, thrombocytopenia, amenhorrhea, lethargy, nausea/vomiting, mucositis, diarrhea, infection, conjunctivitis/keratitis, alopecia, local toxicity and rash/itch.  long term adverse events occurring at a frequency of 1-2% are asymptomatic drops in lvef and chf and secondary leukemia. ",epirubicin hydrochloride
sign_symptom,nausea,0.9995455," in early breast cancer, acute adverse events occurring in 10% of patients are leucopenia, neutropenia, anemia, thrombocytopenia, amenhorrhea, lethargy, nausea/vomiting, mucositis, diarrhea, infection, conjunctivitis/keratitis, alopecia, local toxicity and rash/itch.  long term adverse events occurring at a frequency of 1-2% are asymptomatic drops in lvef and chf and secondary leukemia. ",epirubicin hydrochloride
sign_symptom,toxicity,0.9881479," in early breast cancer, acute adverse events occurring in 10% of patients are leucopenia, neutropenia, anemia, thrombocytopenia, amenhorrhea, lethargy, nausea/vomiting, mucositis, diarrhea, infection, conjunctivitis/keratitis, alopecia, local toxicity and rash/itch.  long term adverse events occurring at a frequency of 1-2% are asymptomatic drops in lvef and chf and secondary leukemia. ",epirubicin hydrochloride
sign_symptom,rash,0.99980074," in early breast cancer, acute adverse events occurring in 10% of patients are leucopenia, neutropenia, anemia, thrombocytopenia, amenhorrhea, lethargy, nausea/vomiting, mucositis, diarrhea, infection, conjunctivitis/keratitis, alopecia, local toxicity and rash/itch.  long term adverse events occurring at a frequency of 1-2% are asymptomatic drops in lvef and chf and secondary leukemia. ",epirubicin hydrochloride
sign_symptom,drowsiness,0.87985545," the side effects of eperisone are very rare, only a few cases have been observed. these are excessive relaxation, stomachache, nausea, vertigo, anorexia, drowsiness, skin rashes, diarrhea, vomiting, indigestion, gi disturbances, insomnia, headache, constipation, etc. ",eperisone hydrochloride
sign_symptom,rash,0.9902164," the side effects of eperisone are very rare, only a few cases have been observed. these are excessive relaxation, stomachache, nausea, vertigo, anorexia, drowsiness, skin rashes, diarrhea, vomiting, indigestion, gi disturbances, insomnia, headache, constipation, etc. ",eperisone hydrochloride
sign_symptom,consti,0.7665734," the side effects of eperisone are very rare, only a few cases have been observed. these are excessive relaxation, stomachache, nausea, vertigo, anorexia, drowsiness, skin rashes, diarrhea, vomiting, indigestion, gi disturbances, insomnia, headache, constipation, etc. ",eperisone hydrochloride
sign_symptom,adverse reactions,0.8622526," the most commonly reported adverse reactions include abdominal pain, nausea, rash, itch, erythema and blister. ",epalrestat
sign_symptom,marks,0.77621305," haemorrhage (bleeding), thrombocytopenia, elevations of serum aminotransferase. pain, bluish marks at injection sites to skin rash at injection sites. cases of neuraxial hematomas with the concurrent use of enoxaparin and spinal/epidural anesthesia or spinal puncture have resulted in varying degrees of neurologic injuries. ",enoxaparin sodium
sign_symptom,rash,0.99993634," haemorrhage (bleeding), thrombocytopenia, elevations of serum aminotransferase. pain, bluish marks at injection sites to skin rash at injection sites. cases of neuraxial hematomas with the concurrent use of enoxaparin and spinal/epidural anesthesia or spinal puncture have resulted in varying degrees of neurologic injuries. ",enoxaparin sodium
sign_symptom,hemato,0.84375775," haemorrhage (bleeding), thrombocytopenia, elevations of serum aminotransferase. pain, bluish marks at injection sites to skin rash at injection sites. cases of neuraxial hematomas with the concurrent use of enoxaparin and spinal/epidural anesthesia or spinal puncture have resulted in varying degrees of neurologic injuries. ",enoxaparin sodium
sign_symptom,tired,0.9998745,"  very common : headache, muscle pain, injection site pain, injection site tenderness, tiredness.   common : nausea, influenza like illness, fever, other injection site reactions (e.g. redness, hardening, swelling, itching).   uncommon : vomiting, skin rash, changes in the lymph-nodes, migraine (throbbing headache, often accompanied by nausea and vomiting and sensitivity to light), dizziness, vertigo (spinning sensation), diarrhoea, belly pain, excessive sweating, itching, chills, general condition of feeling unwell, musculoskeletal stiffness, joint pain, weakness, abnormal laboratory liver test results (hepatic enzymes increased). ",encephalitis vaccine
sign_symptom,changes,0.99966764,"  very common : headache, muscle pain, injection site pain, injection site tenderness, tiredness.   common : nausea, influenza like illness, fever, other injection site reactions (e.g. redness, hardening, swelling, itching).   uncommon : vomiting, skin rash, changes in the lymph-nodes, migraine (throbbing headache, often accompanied by nausea and vomiting and sensitivity to light), dizziness, vertigo (spinning sensation), diarrhoea, belly pain, excessive sweating, itching, chills, general condition of feeling unwell, musculoskeletal stiffness, joint pain, weakness, abnormal laboratory liver test results (hepatic enzymes increased). ",encephalitis vaccine
sign_symptom,migraine,0.87407583,"  very common : headache, muscle pain, injection site pain, injection site tenderness, tiredness.   common : nausea, influenza like illness, fever, other injection site reactions (e.g. redness, hardening, swelling, itching).   uncommon : vomiting, skin rash, changes in the lymph-nodes, migraine (throbbing headache, often accompanied by nausea and vomiting and sensitivity to light), dizziness, vertigo (spinning sensation), diarrhoea, belly pain, excessive sweating, itching, chills, general condition of feeling unwell, musculoskeletal stiffness, joint pain, weakness, abnormal laboratory liver test results (hepatic enzymes increased). ",encephalitis vaccine
sign_symptom,nausea,0.99992657,"  very common : headache, muscle pain, injection site pain, injection site tenderness, tiredness.   common : nausea, influenza like illness, fever, other injection site reactions (e.g. redness, hardening, swelling, itching).   uncommon : vomiting, skin rash, changes in the lymph-nodes, migraine (throbbing headache, often accompanied by nausea and vomiting and sensitivity to light), dizziness, vertigo (spinning sensation), diarrhoea, belly pain, excessive sweating, itching, chills, general condition of feeling unwell, musculoskeletal stiffness, joint pain, weakness, abnormal laboratory liver test results (hepatic enzymes increased). ",encephalitis vaccine
sign_symptom,vomiting,0.9998673,"  very common : headache, muscle pain, injection site pain, injection site tenderness, tiredness.   common : nausea, influenza like illness, fever, other injection site reactions (e.g. redness, hardening, swelling, itching).   uncommon : vomiting, skin rash, changes in the lymph-nodes, migraine (throbbing headache, often accompanied by nausea and vomiting and sensitivity to light), dizziness, vertigo (spinning sensation), diarrhoea, belly pain, excessive sweating, itching, chills, general condition of feeling unwell, musculoskeletal stiffness, joint pain, weakness, abnormal laboratory liver test results (hepatic enzymes increased). ",encephalitis vaccine
sign_symptom,vertigo,0.99994004,"  very common : headache, muscle pain, injection site pain, injection site tenderness, tiredness.   common : nausea, influenza like illness, fever, other injection site reactions (e.g. redness, hardening, swelling, itching).   uncommon : vomiting, skin rash, changes in the lymph-nodes, migraine (throbbing headache, often accompanied by nausea and vomiting and sensitivity to light), dizziness, vertigo (spinning sensation), diarrhoea, belly pain, excessive sweating, itching, chills, general condition of feeling unwell, musculoskeletal stiffness, joint pain, weakness, abnormal laboratory liver test results (hepatic enzymes increased). ",encephalitis vaccine
sign_symptom,diarr,0.81985116,"  very common : headache, muscle pain, injection site pain, injection site tenderness, tiredness.   common : nausea, influenza like illness, fever, other injection site reactions (e.g. redness, hardening, swelling, itching).   uncommon : vomiting, skin rash, changes in the lymph-nodes, migraine (throbbing headache, often accompanied by nausea and vomiting and sensitivity to light), dizziness, vertigo (spinning sensation), diarrhoea, belly pain, excessive sweating, itching, chills, general condition of feeling unwell, musculoskeletal stiffness, joint pain, weakness, abnormal laboratory liver test results (hepatic enzymes increased). ",encephalitis vaccine
sign_symptom,chill,0.96852,"  very common : headache, muscle pain, injection site pain, injection site tenderness, tiredness.   common : nausea, influenza like illness, fever, other injection site reactions (e.g. redness, hardening, swelling, itching).   uncommon : vomiting, skin rash, changes in the lymph-nodes, migraine (throbbing headache, often accompanied by nausea and vomiting and sensitivity to light), dizziness, vertigo (spinning sensation), diarrhoea, belly pain, excessive sweating, itching, chills, general condition of feeling unwell, musculoskeletal stiffness, joint pain, weakness, abnormal laboratory liver test results (hepatic enzymes increased). ",encephalitis vaccine
sign_symptom,stiff,0.99981314,"  very common : headache, muscle pain, injection site pain, injection site tenderness, tiredness.   common : nausea, influenza like illness, fever, other injection site reactions (e.g. redness, hardening, swelling, itching).   uncommon : vomiting, skin rash, changes in the lymph-nodes, migraine (throbbing headache, often accompanied by nausea and vomiting and sensitivity to light), dizziness, vertigo (spinning sensation), diarrhoea, belly pain, excessive sweating, itching, chills, general condition of feeling unwell, musculoskeletal stiffness, joint pain, weakness, abnormal laboratory liver test results (hepatic enzymes increased). ",encephalitis vaccine
sign_symptom,headache,0.99992776," dizziness and headache are more commonly reported side effects. fatigue and asthenia were reported in 2-3% of patients. other side effects occurredin less than 2% of patients and included hypotension, orthostatic hypotension, syncope, nausea, diarrhoea, muscle cramps, rash and cough.  less frequently renal dysfunction, renal failure and oliguria have been reported. angioedema, hyperkalemia and hyponatremia have also been reported rarely ",enalapril maleate
sign_symptom,fatigue,0.9999343," dizziness and headache are more commonly reported side effects. fatigue and asthenia were reported in 2-3% of patients. other side effects occurredin less than 2% of patients and included hypotension, orthostatic hypotension, syncope, nausea, diarrhoea, muscle cramps, rash and cough.  less frequently renal dysfunction, renal failure and oliguria have been reported. angioedema, hyperkalemia and hyponatremia have also been reported rarely ",enalapril maleate
sign_symptom,hypotens,0.96829665," dizziness and headache are more commonly reported side effects. fatigue and asthenia were reported in 2-3% of patients. other side effects occurredin less than 2% of patients and included hypotension, orthostatic hypotension, syncope, nausea, diarrhoea, muscle cramps, rash and cough.  less frequently renal dysfunction, renal failure and oliguria have been reported. angioedema, hyperkalemia and hyponatremia have also been reported rarely ",enalapril maleate
sign_symptom,syncope,0.99470204," dizziness and headache are more commonly reported side effects. fatigue and asthenia were reported in 2-3% of patients. other side effects occurredin less than 2% of patients and included hypotension, orthostatic hypotension, syncope, nausea, diarrhoea, muscle cramps, rash and cough.  less frequently renal dysfunction, renal failure and oliguria have been reported. angioedema, hyperkalemia and hyponatremia have also been reported rarely ",enalapril maleate
sign_symptom,rash,0.99976975," dizziness and headache are more commonly reported side effects. fatigue and asthenia were reported in 2-3% of patients. other side effects occurredin less than 2% of patients and included hypotension, orthostatic hypotension, syncope, nausea, diarrhoea, muscle cramps, rash and cough.  less frequently renal dysfunction, renal failure and oliguria have been reported. angioedema, hyperkalemia and hyponatremia have also been reported rarely ",enalapril maleate
disease_disorder,renal failure,0.99867356," dizziness and headache are more commonly reported side effects. fatigue and asthenia were reported in 2-3% of patients. other side effects occurredin less than 2% of patients and included hypotension, orthostatic hypotension, syncope, nausea, diarrhoea, muscle cramps, rash and cough.  less frequently renal dysfunction, renal failure and oliguria have been reported. angioedema, hyperkalemia and hyponatremia have also been reported rarely ",enalapril maleate
disease_disorder,angioede,0.908804," dizziness and headache are more commonly reported side effects. fatigue and asthenia were reported in 2-3% of patients. other side effects occurredin less than 2% of patients and included hypotension, orthostatic hypotension, syncope, nausea, diarrhoea, muscle cramps, rash and cough.  less frequently renal dysfunction, renal failure and oliguria have been reported. angioedema, hyperkalemia and hyponatremia have also been reported rarely ",enalapril maleate
sign_symptom,hyperkalemia,0.83082414," dizziness and headache are more commonly reported side effects. fatigue and asthenia were reported in 2-3% of patients. other side effects occurredin less than 2% of patients and included hypotension, orthostatic hypotension, syncope, nausea, diarrhoea, muscle cramps, rash and cough.  less frequently renal dysfunction, renal failure and oliguria have been reported. angioedema, hyperkalemia and hyponatremia have also been reported rarely ",enalapril maleate
sign_symptom,adverse reactions,0.982581," most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. most common adverse reactions associated with metformin (&gt;5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache. the following important adverse reactions are given below: 
 
  very common : hypoglycemia (when used with sulphonylurea or insulin), gastrointestinal symptoms 
  common : vaginal moniliasis, vulvovaginitis, balanitis and other genital infection. urinary tract infection (including pyelonephritis and urosepsis), thirst, taste disturbance, pruritus (generalised), rash, increased urination, serum lipids increased 
  uncommon : volume depletion, urticaria, dysuria, blood creatinine increased/glomerular filtration rate decreased, haematocrit increased 
  rare : diabetic ketoacidosis. 
  ",empagliflozin + metformin hydrochloride
medication,metformin,0.9851952," most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. most common adverse reactions associated with metformin (&gt;5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache. the following important adverse reactions are given below: 
 
  very common : hypoglycemia (when used with sulphonylurea or insulin), gastrointestinal symptoms 
  common : vaginal moniliasis, vulvovaginitis, balanitis and other genital infection. urinary tract infection (including pyelonephritis and urosepsis), thirst, taste disturbance, pruritus (generalised), rash, increased urination, serum lipids increased 
  uncommon : volume depletion, urticaria, dysuria, blood creatinine increased/glomerular filtration rate decreased, haematocrit increased 
  rare : diabetic ketoacidosis. 
  ",empagliflozin + metformin hydrochloride
sign_symptom,nausea,0.99809486," most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. most common adverse reactions associated with metformin (&gt;5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache. the following important adverse reactions are given below: 
 
  very common : hypoglycemia (when used with sulphonylurea or insulin), gastrointestinal symptoms 
  common : vaginal moniliasis, vulvovaginitis, balanitis and other genital infection. urinary tract infection (including pyelonephritis and urosepsis), thirst, taste disturbance, pruritus (generalised), rash, increased urination, serum lipids increased 
  uncommon : volume depletion, urticaria, dysuria, blood creatinine increased/glomerular filtration rate decreased, haematocrit increased 
  rare : diabetic ketoacidosis. 
  ",empagliflozin + metformin hydrochloride
sign_symptom,flat,0.8744333," most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. most common adverse reactions associated with metformin (&gt;5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache. the following important adverse reactions are given below: 
 
  very common : hypoglycemia (when used with sulphonylurea or insulin), gastrointestinal symptoms 
  common : vaginal moniliasis, vulvovaginitis, balanitis and other genital infection. urinary tract infection (including pyelonephritis and urosepsis), thirst, taste disturbance, pruritus (generalised), rash, increased urination, serum lipids increased 
  uncommon : volume depletion, urticaria, dysuria, blood creatinine increased/glomerular filtration rate decreased, haematocrit increased 
  rare : diabetic ketoacidosis. 
  ",empagliflozin + metformin hydrochloride
medication,sulphonylurea,0.9633381," most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. most common adverse reactions associated with metformin (&gt;5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache. the following important adverse reactions are given below: 
 
  very common : hypoglycemia (when used with sulphonylurea or insulin), gastrointestinal symptoms 
  common : vaginal moniliasis, vulvovaginitis, balanitis and other genital infection. urinary tract infection (including pyelonephritis and urosepsis), thirst, taste disturbance, pruritus (generalised), rash, increased urination, serum lipids increased 
  uncommon : volume depletion, urticaria, dysuria, blood creatinine increased/glomerular filtration rate decreased, haematocrit increased 
  rare : diabetic ketoacidosis. 
  ",empagliflozin + metformin hydrochloride
medication,insulin,0.99926263," most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. most common adverse reactions associated with metformin (&gt;5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache. the following important adverse reactions are given below: 
 
  very common : hypoglycemia (when used with sulphonylurea or insulin), gastrointestinal symptoms 
  common : vaginal moniliasis, vulvovaginitis, balanitis and other genital infection. urinary tract infection (including pyelonephritis and urosepsis), thirst, taste disturbance, pruritus (generalised), rash, increased urination, serum lipids increased 
  uncommon : volume depletion, urticaria, dysuria, blood creatinine increased/glomerular filtration rate decreased, haematocrit increased 
  rare : diabetic ketoacidosis. 
  ",empagliflozin + metformin hydrochloride
disease_disorder,vulvovaginitis,0.90941834," most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. most common adverse reactions associated with metformin (&gt;5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache. the following important adverse reactions are given below: 
 
  very common : hypoglycemia (when used with sulphonylurea or insulin), gastrointestinal symptoms 
  common : vaginal moniliasis, vulvovaginitis, balanitis and other genital infection. urinary tract infection (including pyelonephritis and urosepsis), thirst, taste disturbance, pruritus (generalised), rash, increased urination, serum lipids increased 
  uncommon : volume depletion, urticaria, dysuria, blood creatinine increased/glomerular filtration rate decreased, haematocrit increased 
  rare : diabetic ketoacidosis. 
  ",empagliflozin + metformin hydrochloride
disease_disorder,balanitis,0.9990973," most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. most common adverse reactions associated with metformin (&gt;5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache. the following important adverse reactions are given below: 
 
  very common : hypoglycemia (when used with sulphonylurea or insulin), gastrointestinal symptoms 
  common : vaginal moniliasis, vulvovaginitis, balanitis and other genital infection. urinary tract infection (including pyelonephritis and urosepsis), thirst, taste disturbance, pruritus (generalised), rash, increased urination, serum lipids increased 
  uncommon : volume depletion, urticaria, dysuria, blood creatinine increased/glomerular filtration rate decreased, haematocrit increased 
  rare : diabetic ketoacidosis. 
  ",empagliflozin + metformin hydrochloride
sign_symptom,rash,0.824952," most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. most common adverse reactions associated with metformin (&gt;5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache. the following important adverse reactions are given below: 
 
  very common : hypoglycemia (when used with sulphonylurea or insulin), gastrointestinal symptoms 
  common : vaginal moniliasis, vulvovaginitis, balanitis and other genital infection. urinary tract infection (including pyelonephritis and urosepsis), thirst, taste disturbance, pruritus (generalised), rash, increased urination, serum lipids increased 
  uncommon : volume depletion, urticaria, dysuria, blood creatinine increased/glomerular filtration rate decreased, haematocrit increased 
  rare : diabetic ketoacidosis. 
  ",empagliflozin + metformin hydrochloride
disease_disorder,infection,0.9996978," the most common side effects are: 
 
 urinary tract infection 
 stuffy or runny nose and sore throat 
 upper respiratory tract infection 
  ",empagliflozin + linagliptin
sign_symptom,sore,0.9994779," the most common side effects are: 
 
 urinary tract infection 
 stuffy or runny nose and sore throat 
 upper respiratory tract infection 
  ",empagliflozin + linagliptin
sign_symptom,irritation,0.9994511, skin irritation in people hypersensitive to any of the ingredients. ,emollient [cepalin+allantoin]
sign_symptom,hyper,0.95465827, skin irritation in people hypersensitive to any of the ingredients. ,emollient [cepalin+allantoin]
sign_symptom,adverse reactions,0.99056375," most common adverse reactions are constipation, nausea and abdominal pain. ",eluxadoline
sign_symptom,nausea,0.9997651," most common adverse reactions are constipation, nausea and abdominal pain. ",eluxadoline
sign_symptom,adverse reactions,0.9991788," the most common side effects of eltrombopag in adults when used to treat chronic itp are: in adult patients with itp, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased alt, myalgia and urinary tract infection. in pediatric patients age 1 year and older with itp, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection and nasopharyngitis.  in patients with chronic hepatitis c-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia and peripheral edema. in patients with severe aplastic anemia, the most common adverse reactions (greater than or equal to 20%) were: nausea, fatigue, cough, diarrhea and headache. ",eltrombopag olamine
sign_symptom,nausea,0.99030006," the most common side effects of eltrombopag in adults when used to treat chronic itp are: in adult patients with itp, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased alt, myalgia and urinary tract infection. in pediatric patients age 1 year and older with itp, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection and nasopharyngitis.  in patients with chronic hepatitis c-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia and peripheral edema. in patients with severe aplastic anemia, the most common adverse reactions (greater than or equal to 20%) were: nausea, fatigue, cough, diarrhea and headache. ",eltrombopag olamine
sign_symptom,myalgia,0.9054814," the most common side effects of eltrombopag in adults when used to treat chronic itp are: in adult patients with itp, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased alt, myalgia and urinary tract infection. in pediatric patients age 1 year and older with itp, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection and nasopharyngitis.  in patients with chronic hepatitis c-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia and peripheral edema. in patients with severe aplastic anemia, the most common adverse reactions (greater than or equal to 20%) were: nausea, fatigue, cough, diarrhea and headache. ",eltrombopag olamine
disease_disorder,hepatitis c,0.9883609," the most common side effects of eltrombopag in adults when used to treat chronic itp are: in adult patients with itp, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased alt, myalgia and urinary tract infection. in pediatric patients age 1 year and older with itp, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection and nasopharyngitis.  in patients with chronic hepatitis c-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia and peripheral edema. in patients with severe aplastic anemia, the most common adverse reactions (greater than or equal to 20%) were: nausea, fatigue, cough, diarrhea and headache. ",eltrombopag olamine
sign_symptom,adverse reactions,0.9979161," most common adverse reactions (&gt;5%) in clinical trials included hot flushes and night sweats, headache, nausea, insomnia, amenorrhea, anxiety, arthralgia, depression-related adverse reactions and mood changes. ",elagolix
sign_symptom,tension,0.99871886," breast tension or pain, nausea, spotting, fluid retention and cervical hypersecretion may occasionally occur and be indicative of too high dosage. headache, hypertension, leg cramps and vision disturbances are seldom observed. in general, most of these adverse reactions disappear after the 1 st week of treatment.  breast enlargement, vaginal candidiasis, change in vaginal bleeding pattern, vomiting, stomach cramps, cholestatic jaundice, chloasma or melasma, erythema multiforme, erythema nodosum, hemorrhagic eruption, mental depression, chorea, increasing or decreasing body weight, edema, changes in libido. ",estriol (oral)
sign_symptom,fluid retention,0.9994313," breast tension or pain, nausea, spotting, fluid retention and cervical hypersecretion may occasionally occur and be indicative of too high dosage. headache, hypertension, leg cramps and vision disturbances are seldom observed. in general, most of these adverse reactions disappear after the 1 st week of treatment.  breast enlargement, vaginal candidiasis, change in vaginal bleeding pattern, vomiting, stomach cramps, cholestatic jaundice, chloasma or melasma, erythema multiforme, erythema nodosum, hemorrhagic eruption, mental depression, chorea, increasing or decreasing body weight, edema, changes in libido. ",estriol (oral)
sign_symptom,hyper,0.9999478," breast tension or pain, nausea, spotting, fluid retention and cervical hypersecretion may occasionally occur and be indicative of too high dosage. headache, hypertension, leg cramps and vision disturbances are seldom observed. in general, most of these adverse reactions disappear after the 1 st week of treatment.  breast enlargement, vaginal candidiasis, change in vaginal bleeding pattern, vomiting, stomach cramps, cholestatic jaundice, chloasma or melasma, erythema multiforme, erythema nodosum, hemorrhagic eruption, mental depression, chorea, increasing or decreasing body weight, edema, changes in libido. ",estriol (oral)
sign_symptom,headache,0.8788255," breast tension or pain, nausea, spotting, fluid retention and cervical hypersecretion may occasionally occur and be indicative of too high dosage. headache, hypertension, leg cramps and vision disturbances are seldom observed. in general, most of these adverse reactions disappear after the 1 st week of treatment.  breast enlargement, vaginal candidiasis, change in vaginal bleeding pattern, vomiting, stomach cramps, cholestatic jaundice, chloasma or melasma, erythema multiforme, erythema nodosum, hemorrhagic eruption, mental depression, chorea, increasing or decreasing body weight, edema, changes in libido. ",estriol (oral)
sign_symptom,vision disturbances,0.99981534," breast tension or pain, nausea, spotting, fluid retention and cervical hypersecretion may occasionally occur and be indicative of too high dosage. headache, hypertension, leg cramps and vision disturbances are seldom observed. in general, most of these adverse reactions disappear after the 1 st week of treatment.  breast enlargement, vaginal candidiasis, change in vaginal bleeding pattern, vomiting, stomach cramps, cholestatic jaundice, chloasma or melasma, erythema multiforme, erythema nodosum, hemorrhagic eruption, mental depression, chorea, increasing or decreasing body weight, edema, changes in libido. ",estriol (oral)
sign_symptom,adverse reactions,0.99920475," breast tension or pain, nausea, spotting, fluid retention and cervical hypersecretion may occasionally occur and be indicative of too high dosage. headache, hypertension, leg cramps and vision disturbances are seldom observed. in general, most of these adverse reactions disappear after the 1 st week of treatment.  breast enlargement, vaginal candidiasis, change in vaginal bleeding pattern, vomiting, stomach cramps, cholestatic jaundice, chloasma or melasma, erythema multiforme, erythema nodosum, hemorrhagic eruption, mental depression, chorea, increasing or decreasing body weight, edema, changes in libido. ",estriol (oral)
disease_disorder,cancer,0.8838704," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,growth,0.7750356," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,cancer,0.99757713," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,blood clots,0.8007016," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,memory loss,0.99950194," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
medication,oral hormone replacement thera,0.91852534," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,bleeding,0.999871," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,thick,0.9999163," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,tenderness,0.9999399," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,rash,0.95728064," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
disease_disorder,skin,0.8007761," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,problems,0.9822598," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,fatigue,0.99987507," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,inflammation of,0.8992865," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,swelling,0.9999479," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,appetite,0.98602515," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,leg pains,0.78241146," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,visual disturbances,0.996155," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
sign_symptom,allergic,0.93414956," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
disease_disorder,rare,0.8713155," the following diseases are reported more often in women using hrt compared to women not using hrt: 
 
 breast cancer 
 abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer) 
 ovarian cancer 
 blood clots in the veins of the legs or lungs (venous thromboembolism) 
 heart disease 
 stroke 
 probable memory loss if hrt is started over the age of 65 other side effects that have been linked to the use of estradiol valerate and other oral hormone replacement therapies 
 during the first few months of treatment you may experience some vaginal bleeding at unexpected times (breakthrough bleeding and spotting). these symptoms normally lessen with continued treatment. if they dont, contact your doctor (see section 2 hrt and cancer/excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) for more information) 
 breast pain, tenderness or enlargement, breast discharge 
 painful periods, changes in vaginal secretions, pre-menstrual symptoms, increased size of fibroids in the womb, thrush, changes to the neck of the womb 
 indigestion, a feeling of being bloated, passing wind, feeling or being sick, abdominal pain, gall bladder disease 
 skin rashes or discolouration, itching, eczema, acne, unusual hair loss or hair growth, increased skin pigment especially on the face (chloasma other conditions for more information), some rare skin problems 
 headache, migraine, dizziness, anxiety or depressive symptoms, fatigue 
 fast or irregular heartbeat (palpitations), high blood pressure, inflammation of veins usually in the legs 
 fluid retention leading to swelling of parts of the body 
 changes in body weight and sex drive, increased appetite 
 muscle cramps, leg pains 
 nose bleeds, visual disturbances (such as blurred vision), discomfort with contact lenses, allergic-type reactions, a worsening of glucose tolerance, bladder inflammation, rare disorders (porphyria, chorea). 
  ",estradiol valerate
medication,h. pylori eradication therapy,0.8620011, h. pylori eradication therapy is generally well tolerated. adverse events reported during clinical trials were not unexpected given the component substances. common adverse reactions included diarrhoea and nausea. ,esomeprazole + amoxicillin + clarithromycin
sign_symptom,adverse events,0.9988088, h. pylori eradication therapy is generally well tolerated. adverse events reported during clinical trials were not unexpected given the component substances. common adverse reactions included diarrhoea and nausea. ,esomeprazole + amoxicillin + clarithromycin
sign_symptom,adverse reactions,0.9814794, h. pylori eradication therapy is generally well tolerated. adverse events reported during clinical trials were not unexpected given the component substances. common adverse reactions included diarrhoea and nausea. ,esomeprazole + amoxicillin + clarithromycin
sign_symptom,adverse events,0.9944097," the most frequently occurring adverse events reported with esomeprazole include headache, diarrhoea, nausea, flatulence, abdominal pain, constipation and dry mouth. there are no difference in types of related adverse events seen during maintenance treatment upto 12 months compared to short term treatment. ",esomeprazole (mups tablet)
sign_symptom,adverse events,0.9944097," the most frequently occurring adverse events reported with esomeprazole include headache, diarrhoea, nausea, flatulence, abdominal pain, constipation and dry mouth. there are no difference in types of related adverse events seen during maintenance treatment upto 12 months compared to short term treatment. ",esomeprazole
sign_symptom,flatulence,0.8298569," the most frequently occurring adverse events reported with esomeprazole include headache, diarrhoea, nausea, flatulence, abdominal pain, constipation and dry mouth. there are no difference in types of related adverse events seen during maintenance treatment upto 12 months compared to short term treatment. ",esomeprazole (mups tablet)
sign_symptom,flatulence,0.8298569," the most frequently occurring adverse events reported with esomeprazole include headache, diarrhoea, nausea, flatulence, abdominal pain, constipation and dry mouth. there are no difference in types of related adverse events seen during maintenance treatment upto 12 months compared to short term treatment. ",esomeprazole
sign_symptom,consti,0.9018359," the most frequently occurring adverse events reported with esomeprazole include headache, diarrhoea, nausea, flatulence, abdominal pain, constipation and dry mouth. there are no difference in types of related adverse events seen during maintenance treatment upto 12 months compared to short term treatment. ",esomeprazole (mups tablet)
sign_symptom,consti,0.9018359," the most frequently occurring adverse events reported with esomeprazole include headache, diarrhoea, nausea, flatulence, abdominal pain, constipation and dry mouth. there are no difference in types of related adverse events seen during maintenance treatment upto 12 months compared to short term treatment. ",esomeprazole
sign_symptom,adverse reactions,0.7387202," most common adverse reactions (incidence&gt; 10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension. ",esmolol hydrochloride
sign_symptom,hypote,0.7860926," most common adverse reactions (incidence&gt; 10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension. ",esmolol hydrochloride
medication,acetate,0.99189067," the use of eslicarbazepine acetate is associated with increase in the pr interval. adverse reactions associated with pr interval prolongation (e.g. av block, syncope, bradycardia) may occur. ",eslicarbazepine acetate
sign_symptom,adverse reactions,0.7510146," the use of eslicarbazepine acetate is associated with increase in the pr interval. adverse reactions associated with pr interval prolongation (e.g. av block, syncope, bradycardia) may occur. ",eslicarbazepine acetate
sign_symptom,card,0.91628605," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. side-effects of the ssris include gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances. ",escitalopram oxalate
sign_symptom,gastroint,0.9776148," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. side-effects of the ssris include gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances. ",escitalopram oxalate
sign_symptom,effects,0.9972192," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. side-effects of the ssris include gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances. ",escitalopram oxalate
sign_symptom,dyspe,0.7293984," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. side-effects of the ssris include gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances. ",escitalopram oxalate
sign_symptom,weight loss,0.9997411," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. side-effects of the ssris include gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances. ",escitalopram oxalate
sign_symptom,appetite,0.99025565," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. side-effects of the ssris include gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances. ",escitalopram oxalate
sign_symptom,weight gain,0.99876857," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. side-effects of the ssris include gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances. ",escitalopram oxalate
sign_symptom,hypersensitivity reactions,0.98562354," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. side-effects of the ssris include gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances. ",escitalopram oxalate
sign_symptom,anaphylaxi,0.71055865," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. side-effects of the ssris include gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances. ",escitalopram oxalate
sign_symptom,arthral,0.90727264," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. side-effects of the ssris include gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances. ",escitalopram oxalate
sign_symptom,disorders,0.814052," ssris are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. side-effects of the ssris include gastrointestinal effects (dose-related and fairly common include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances. ",escitalopram oxalate
sign_symptom,adverse reactions,0.765345," adverse reactions in 5% of erythropoietin alfa treated patients in clinical studies were: 
 
 patients with ckd: hypertension, arthralgia, muscle spasm, pyrexia, dizziness, medical device malfunction, vascular occlusion, and upper respiratory tract infection. 
 zidovudine-treated hiv-infected patients: pyrexia, cough, rash, and injection site irritation. 
 cancer patients on chemotherapy: nausea, vomiting, myalgia, arthralgia, stomatitis, cough, weight decrease, leukopenia, bone pain, rash, hyperglycemia, headache, depression, dysphagia, hypokalemia, and thrombosis. 
 surgery patients: nausea, vomiting, pruritus, headache, injection site pain, chills, deep vein thrombosis, cough, and hypertension. 
 premature infants: a fall in serum ferritin values is very common (&gt;10%) 
  ",erythropoietin alfa
medication,alfa,0.99266535," adverse reactions in 5% of erythropoietin alfa treated patients in clinical studies were: 
 
 patients with ckd: hypertension, arthralgia, muscle spasm, pyrexia, dizziness, medical device malfunction, vascular occlusion, and upper respiratory tract infection. 
 zidovudine-treated hiv-infected patients: pyrexia, cough, rash, and injection site irritation. 
 cancer patients on chemotherapy: nausea, vomiting, myalgia, arthralgia, stomatitis, cough, weight decrease, leukopenia, bone pain, rash, hyperglycemia, headache, depression, dysphagia, hypokalemia, and thrombosis. 
 surgery patients: nausea, vomiting, pruritus, headache, injection site pain, chills, deep vein thrombosis, cough, and hypertension. 
 premature infants: a fall in serum ferritin values is very common (&gt;10%) 
  ",erythropoietin alfa
sign_symptom,mala,0.9998784," general: headache, dizziness, fever, malaise, arthralgia and occasionally hyperkalemia. cardiovascular: hypertension is the most common side effect, palpitations. gastrointestinal: nausea, vomiting, anorexia and diarrhea may occur occasionally. allergic reactions. ",erythropoietin
sign_symptom,arthralgia,0.9998278," general: headache, dizziness, fever, malaise, arthralgia and occasionally hyperkalemia. cardiovascular: hypertension is the most common side effect, palpitations. gastrointestinal: nausea, vomiting, anorexia and diarrhea may occur occasionally. allergic reactions. ",erythropoietin
sign_symptom,hyper,0.9975816," general: headache, dizziness, fever, malaise, arthralgia and occasionally hyperkalemia. cardiovascular: hypertension is the most common side effect, palpitations. gastrointestinal: nausea, vomiting, anorexia and diarrhea may occur occasionally. allergic reactions. ",erythropoietin
sign_symptom,vomiting,0.7144167," general: headache, dizziness, fever, malaise, arthralgia and occasionally hyperkalemia. cardiovascular: hypertension is the most common side effect, palpitations. gastrointestinal: nausea, vomiting, anorexia and diarrhea may occur occasionally. allergic reactions. ",erythropoietin
sign_symptom,diarrhea,0.8396897," general: headache, dizziness, fever, malaise, arthralgia and occasionally hyperkalemia. cardiovascular: hypertension is the most common side effect, palpitations. gastrointestinal: nausea, vomiting, anorexia and diarrhea may occur occasionally. allergic reactions. ",erythropoietin
sign_symptom,oily,0.78970563," erythema, desquamation, burning sensation, eye irritation, tenderness, dryness, oily skin etc. ",erythromycin (lotion)
sign_symptom,allergic reactions,0.99901175," allergic reactions are rare and mild although anaphylaxis has occurred. occasionally there is abdominal discomfort after oral administration, sometimes with nausea and vomiting. this discomfort usually subsides after a few days without it being necessary to reduce the dosage. ",erythromycin (oral)
sign_symptom,discomfort,0.9999434," allergic reactions are rare and mild although anaphylaxis has occurred. occasionally there is abdominal discomfort after oral administration, sometimes with nausea and vomiting. this discomfort usually subsides after a few days without it being necessary to reduce the dosage. ",erythromycin (oral)
sign_symptom,nausea,0.9999037," allergic reactions are rare and mild although anaphylaxis has occurred. occasionally there is abdominal discomfort after oral administration, sometimes with nausea and vomiting. this discomfort usually subsides after a few days without it being necessary to reduce the dosage. ",erythromycin (oral)
sign_symptom,adverse reactions,0.9995016," the following important adverse reactions are described elsewhere in the labeling: 
 
 ketoacidosis 
 lower limb amputation 
 volume depletion 
 urosepsis and pyelonephritis 
 hypoglycemia with concomitant use with insulin and insulin secretagogues 
 necrotizing fasciitis of the perineum (fourniers gangrene) 
 genital mycotic infections 
  ",ertugliflozin
disease_disorder,ketoacidosis,0.9997339," the following important adverse reactions are described elsewhere in the labeling: 
 
 ketoacidosis 
 lower limb amputation 
 volume depletion 
 urosepsis and pyelonephritis 
 hypoglycemia with concomitant use with insulin and insulin secretagogues 
 necrotizing fasciitis of the perineum (fourniers gangrene) 
 genital mycotic infections 
  ",ertugliflozin
disease_disorder,lower limb amputation,0.9600531," the following important adverse reactions are described elsewhere in the labeling: 
 
 ketoacidosis 
 lower limb amputation 
 volume depletion 
 urosepsis and pyelonephritis 
 hypoglycemia with concomitant use with insulin and insulin secretagogues 
 necrotizing fasciitis of the perineum (fourniers gangrene) 
 genital mycotic infections 
  ",ertugliflozin
disease_disorder,volume depletion,0.9929282," the following important adverse reactions are described elsewhere in the labeling: 
 
 ketoacidosis 
 lower limb amputation 
 volume depletion 
 urosepsis and pyelonephritis 
 hypoglycemia with concomitant use with insulin and insulin secretagogues 
 necrotizing fasciitis of the perineum (fourniers gangrene) 
 genital mycotic infections 
  ",ertugliflozin
disease_disorder,urosepsis,0.99832344," the following important adverse reactions are described elsewhere in the labeling: 
 
 ketoacidosis 
 lower limb amputation 
 volume depletion 
 urosepsis and pyelonephritis 
 hypoglycemia with concomitant use with insulin and insulin secretagogues 
 necrotizing fasciitis of the perineum (fourniers gangrene) 
 genital mycotic infections 
  ",ertugliflozin
medication,insulin,0.99973494," the following important adverse reactions are described elsewhere in the labeling: 
 
 ketoacidosis 
 lower limb amputation 
 volume depletion 
 urosepsis and pyelonephritis 
 hypoglycemia with concomitant use with insulin and insulin secretagogues 
 necrotizing fasciitis of the perineum (fourniers gangrene) 
 genital mycotic infections 
  ",ertugliflozin
disease_disorder,secretagogues,0.9823539," the following important adverse reactions are described elsewhere in the labeling: 
 
 ketoacidosis 
 lower limb amputation 
 volume depletion 
 urosepsis and pyelonephritis 
 hypoglycemia with concomitant use with insulin and insulin secretagogues 
 necrotizing fasciitis of the perineum (fourniers gangrene) 
 genital mycotic infections 
  ",ertugliflozin
disease_disorder,fasciitis,0.99903804," the following important adverse reactions are described elsewhere in the labeling: 
 
 ketoacidosis 
 lower limb amputation 
 volume depletion 
 urosepsis and pyelonephritis 
 hypoglycemia with concomitant use with insulin and insulin secretagogues 
 necrotizing fasciitis of the perineum (fourniers gangrene) 
 genital mycotic infections 
  ",ertugliflozin
disease_disorder,infections,0.99965," the following important adverse reactions are described elsewhere in the labeling: 
 
 ketoacidosis 
 lower limb amputation 
 volume depletion 
 urosepsis and pyelonephritis 
 hypoglycemia with concomitant use with insulin and insulin secretagogues 
 necrotizing fasciitis of the perineum (fourniers gangrene) 
 genital mycotic infections 
  ",ertugliflozin
sign_symptom,adverse reactions,0.99988294,"  adults : the most common adverse reactions (5%) in patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, nausea, headache and infused vein complication. in the prophylaxis indication, the overall adverse experience profile was generally comparable to that observed for ertapenem in other clinical trials.   pediatrics : adverse reactions in this population were comparable to adults. the most common adverse reactions (5%) in pediatric patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, vomiting and infusion site pain. ",ertapenem
sign_symptom,headache,0.99989676,"  adults : the most common adverse reactions (5%) in patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, nausea, headache and infused vein complication. in the prophylaxis indication, the overall adverse experience profile was generally comparable to that observed for ertapenem in other clinical trials.   pediatrics : adverse reactions in this population were comparable to adults. the most common adverse reactions (5%) in pediatric patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, vomiting and infusion site pain. ",ertapenem
sign_symptom,adverse experience,0.99980897,"  adults : the most common adverse reactions (5%) in patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, nausea, headache and infused vein complication. in the prophylaxis indication, the overall adverse experience profile was generally comparable to that observed for ertapenem in other clinical trials.   pediatrics : adverse reactions in this population were comparable to adults. the most common adverse reactions (5%) in pediatric patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, vomiting and infusion site pain. ",ertapenem
medication,ertapen,0.9516377,"  adults : the most common adverse reactions (5%) in patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, nausea, headache and infused vein complication. in the prophylaxis indication, the overall adverse experience profile was generally comparable to that observed for ertapenem in other clinical trials.   pediatrics : adverse reactions in this population were comparable to adults. the most common adverse reactions (5%) in pediatric patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, vomiting and infusion site pain. ",ertapenem
medication,erta,0.9274837,"  adults : the most common adverse reactions (5%) in patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, nausea, headache and infused vein complication. in the prophylaxis indication, the overall adverse experience profile was generally comparable to that observed for ertapenem in other clinical trials.   pediatrics : adverse reactions in this population were comparable to adults. the most common adverse reactions (5%) in pediatric patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, vomiting and infusion site pain. ",ertapenem
sign_symptom,vomiting,0.9999527,"  adults : the most common adverse reactions (5%) in patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, nausea, headache and infused vein complication. in the prophylaxis indication, the overall adverse experience profile was generally comparable to that observed for ertapenem in other clinical trials.   pediatrics : adverse reactions in this population were comparable to adults. the most common adverse reactions (5%) in pediatric patients treated with ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, vomiting and infusion site pain. ",ertapenem
sign_symptom,adverse reactions,0.9954692," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
sign_symptom,dysp,0.96053225," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
sign_symptom,adverse,0.84273547," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
disease_disorder,inter,0.999658," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
disease_disorder,renal failure,0.99979454," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
disease_disorder,hepatotoxicity,0.9411218," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
disease_disorder,gastrointestinal,0.9990536," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
disease_disorder,perforation,0.87856036," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
disease_disorder,skin disorders,0.99972713," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
disease_disorder,myocardial infarction,0.98582506," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
disease_disorder,ischemia,0.9780049," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
disease_disorder,cerebrovascular accident,0.9972186," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
sign_symptom,anemia,0.99059033," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
medication,warfarin,0.99869865," the most common adverse reactions (20%) with erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. the following serious adverse reactions, which may include fatalities. 
 
 interstitial lung disease (ild) 
 renal failure 
 hepatotoxicity with or without hepatic impairment 
 gastrointestinal perforation 
 bullous and exfoliative skin disorders 
 myocardial infarction/ischemia 
 cerebrovascular accident 
 microangiopathic hemolytic anemia with thrombocytopenia 
 ocular disorders 
 hemorrhage in patients taking warfarin 
  ",erlotinib
sign_symptom,adverse reactions,0.9955915," the most common adverse reactions (incidence 25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. ",eribulin mesylate
sign_symptom,asthenia,0.9270876," the most common adverse reactions (incidence 25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. ",eribulin mesylate
sign_symptom,blurred vision,0.9280064," increased bp, hypotension, rapid and weak pulse, palpitations, arrhythmias, precordial pain, coronary infarction, fibrotic thickening of the heart valves. cerebral ischaemia and thrombosis, blurred vision, sleep disturbances, urinary retention, muscle cramps and joint pains.   gi symptoms such as nausea, vomiting, constipation, abdominal pain. dysaesthesia, paraesthesia, formication, tremor, convulsions, headache, extrapyramidal effects. anxiety, depression, confusion, hallucinations, psychomotor impairment. ",ergotamine tartrate + caffeine
sign_symptom,vomiting,0.9299526," increased bp, hypotension, rapid and weak pulse, palpitations, arrhythmias, precordial pain, coronary infarction, fibrotic thickening of the heart valves. cerebral ischaemia and thrombosis, blurred vision, sleep disturbances, urinary retention, muscle cramps and joint pains.   gi symptoms such as nausea, vomiting, constipation, abdominal pain. dysaesthesia, paraesthesia, formication, tremor, convulsions, headache, extrapyramidal effects. anxiety, depression, confusion, hallucinations, psychomotor impairment. ",ergotamine tartrate + caffeine
sign_symptom,form,0.78161305," increased bp, hypotension, rapid and weak pulse, palpitations, arrhythmias, precordial pain, coronary infarction, fibrotic thickening of the heart valves. cerebral ischaemia and thrombosis, blurred vision, sleep disturbances, urinary retention, muscle cramps and joint pains.   gi symptoms such as nausea, vomiting, constipation, abdominal pain. dysaesthesia, paraesthesia, formication, tremor, convulsions, headache, extrapyramidal effects. anxiety, depression, confusion, hallucinations, psychomotor impairment. ",ergotamine tartrate + caffeine
sign_symptom,hyper,0.9996513," nausea, vomiting, abdominal pain, diarrhoea; headache, dizziness; tinnitus; chest pain, palpitation, bradycardia, transient hypertension and other cardiac arrhythmias; dyspnoea, sometimes rashes, shock ",ergometrine maleate
sign_symptom,rash,0.9998518," nausea, vomiting, abdominal pain, diarrhoea; headache, dizziness; tinnitus; chest pain, palpitation, bradycardia, transient hypertension and other cardiac arrhythmias; dyspnoea, sometimes rashes, shock ",ergometrine maleate
sign_symptom,shock,0.9999068," nausea, vomiting, abdominal pain, diarrhoea; headache, dizziness; tinnitus; chest pain, palpitation, bradycardia, transient hypertension and other cardiac arrhythmias; dyspnoea, sometimes rashes, shock ",ergometrine maleate
sign_symptom,constipation,0.8031175," the common side effects of etodolac involve the gastrointestinal system. it can cause abdominal pain, constipation, diarrhea, dyspepsia, flatulence, heartburn, nausea, gl ulcers, vomiting. other events including abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritis, rashes, tinnitus etc. ",etodolac
sign_symptom,diarrhea,0.8112877," the common side effects of etodolac involve the gastrointestinal system. it can cause abdominal pain, constipation, diarrhea, dyspepsia, flatulence, heartburn, nausea, gl ulcers, vomiting. other events including abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritis, rashes, tinnitus etc. ",etodolac
sign_symptom,dyspepsia,0.9935085," the common side effects of etodolac involve the gastrointestinal system. it can cause abdominal pain, constipation, diarrhea, dyspepsia, flatulence, heartburn, nausea, gl ulcers, vomiting. other events including abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritis, rashes, tinnitus etc. ",etodolac
sign_symptom,flatule,0.794873," the common side effects of etodolac involve the gastrointestinal system. it can cause abdominal pain, constipation, diarrhea, dyspepsia, flatulence, heartburn, nausea, gl ulcers, vomiting. other events including abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritis, rashes, tinnitus etc. ",etodolac
sign_symptom,rash,0.9936144," the common side effects of etodolac involve the gastrointestinal system. it can cause abdominal pain, constipation, diarrhea, dyspepsia, flatulence, heartburn, nausea, gl ulcers, vomiting. other events including abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritis, rashes, tinnitus etc. ",etodolac
sign_symptom,toxic,0.8661874," blood toxicities and disorders; headache, fatigue, lethargy, drowsiness, dizziness, ataxia, hiccup and mild euphoria; more rarely, psychotic states, rashes, hepatic and renal changes, and haematological disorders. sle, erythema multiforme. gum hypertrophy, swelling of tongue, irritability, hyperactivity, sleep disturbances, night terrors, inability to concentrate, aggressiveness, increased libido, myopia, vag bleeding. ",ethosuximide
sign_symptom,hiccup,0.98327285," blood toxicities and disorders; headache, fatigue, lethargy, drowsiness, dizziness, ataxia, hiccup and mild euphoria; more rarely, psychotic states, rashes, hepatic and renal changes, and haematological disorders. sle, erythema multiforme. gum hypertrophy, swelling of tongue, irritability, hyperactivity, sleep disturbances, night terrors, inability to concentrate, aggressiveness, increased libido, myopia, vag bleeding. ",ethosuximide
sign_symptom,rash,0.8273353," blood toxicities and disorders; headache, fatigue, lethargy, drowsiness, dizziness, ataxia, hiccup and mild euphoria; more rarely, psychotic states, rashes, hepatic and renal changes, and haematological disorders. sle, erythema multiforme. gum hypertrophy, swelling of tongue, irritability, hyperactivity, sleep disturbances, night terrors, inability to concentrate, aggressiveness, increased libido, myopia, vag bleeding. ",ethosuximide
sign_symptom,swelling,0.99993634," blood toxicities and disorders; headache, fatigue, lethargy, drowsiness, dizziness, ataxia, hiccup and mild euphoria; more rarely, psychotic states, rashes, hepatic and renal changes, and haematological disorders. sle, erythema multiforme. gum hypertrophy, swelling of tongue, irritability, hyperactivity, sleep disturbances, night terrors, inability to concentrate, aggressiveness, increased libido, myopia, vag bleeding. ",ethosuximide
sign_symptom,hyper,0.8219658," blood toxicities and disorders; headache, fatigue, lethargy, drowsiness, dizziness, ataxia, hiccup and mild euphoria; more rarely, psychotic states, rashes, hepatic and renal changes, and haematological disorders. sle, erythema multiforme. gum hypertrophy, swelling of tongue, irritability, hyperactivity, sleep disturbances, night terrors, inability to concentrate, aggressiveness, increased libido, myopia, vag bleeding. ",ethosuximide
sign_symptom,night terror,0.72172225," blood toxicities and disorders; headache, fatigue, lethargy, drowsiness, dizziness, ataxia, hiccup and mild euphoria; more rarely, psychotic states, rashes, hepatic and renal changes, and haematological disorders. sle, erythema multiforme. gum hypertrophy, swelling of tongue, irritability, hyperactivity, sleep disturbances, night terrors, inability to concentrate, aggressiveness, increased libido, myopia, vag bleeding. ",ethosuximide
sign_symptom,inability to concentrate,0.8707598," blood toxicities and disorders; headache, fatigue, lethargy, drowsiness, dizziness, ataxia, hiccup and mild euphoria; more rarely, psychotic states, rashes, hepatic and renal changes, and haematological disorders. sle, erythema multiforme. gum hypertrophy, swelling of tongue, irritability, hyperactivity, sleep disturbances, night terrors, inability to concentrate, aggressiveness, increased libido, myopia, vag bleeding. ",ethosuximide
sign_symptom,mood changes,0.9834795," common: headache, nausea, mood changes including depression, vaginal infections, irregular vaginal bleeding, pain and discomfort. rare: liver tumors, jaundice, high blood pressure &amp; gallbladder problem. ",ethinyl estradiol + levonorgestrel + ferrous fumarate
sign_symptom,pain,0.9970509," common: headache, nausea, mood changes including depression, vaginal infections, irregular vaginal bleeding, pain and discomfort. rare: liver tumors, jaundice, high blood pressure &amp; gallbladder problem. ",ethinyl estradiol + levonorgestrel + ferrous fumarate
sign_symptom,high,0.99160016," common: headache, nausea, mood changes including depression, vaginal infections, irregular vaginal bleeding, pain and discomfort. rare: liver tumors, jaundice, high blood pressure &amp; gallbladder problem. ",ethinyl estradiol + levonorgestrel + ferrous fumarate
sign_symptom,side,0.9747967," at the initial stage some women may experience side-effects like dizziness, headache, nausea, diarrhea, abdominal pain, weight gain, fluid retension, depression, mood changes, breast pain, breast tenderness, rash, vaginal discharge, erythema etc. if taken regularly, such types of side-effects normally lessen with time. if she continues to have the side effects beyond 2-3 months, she could consult with a doctor. ",ethinyl estradiol + gestodene
sign_symptom,adverse reactions,0.99965763," the most frequent adverse reactions ( 2%) in contraception, acne and folate clinical trials are headache/migraine (5.9%), menstrual irregularities (4.1%), nausea/vomiting (3.5%) and breast pain/tenderness (3.2%). the most frequent adverse reactions ( 2%) in pmdd clinical trials are menstrual irregularities (24.9%), nausea (15.8%), headache (13.0%), breast tenderness (10.5%), fatigue (4.2%), irritability (2.8%), decreased libido (2.8%), increased weight (2.5%), and affect lability (2.1%) ",ethinyl estradiol + drospirenone + levomefolate
sign_symptom,headache,0.99995136," the most frequent adverse reactions ( 2%) in contraception, acne and folate clinical trials are headache/migraine (5.9%), menstrual irregularities (4.1%), nausea/vomiting (3.5%) and breast pain/tenderness (3.2%). the most frequent adverse reactions ( 2%) in pmdd clinical trials are menstrual irregularities (24.9%), nausea (15.8%), headache (13.0%), breast tenderness (10.5%), fatigue (4.2%), irritability (2.8%), decreased libido (2.8%), increased weight (2.5%), and affect lability (2.1%) ",ethinyl estradiol + drospirenone + levomefolate
sign_symptom,menstrual irregularities,0.9472002," the most frequent adverse reactions ( 2%) in contraception, acne and folate clinical trials are headache/migraine (5.9%), menstrual irregularities (4.1%), nausea/vomiting (3.5%) and breast pain/tenderness (3.2%). the most frequent adverse reactions ( 2%) in pmdd clinical trials are menstrual irregularities (24.9%), nausea (15.8%), headache (13.0%), breast tenderness (10.5%), fatigue (4.2%), irritability (2.8%), decreased libido (2.8%), increased weight (2.5%), and affect lability (2.1%) ",ethinyl estradiol + drospirenone + levomefolate
sign_symptom,nausea /,0.9969828," the most frequent adverse reactions ( 2%) in contraception, acne and folate clinical trials are headache/migraine (5.9%), menstrual irregularities (4.1%), nausea/vomiting (3.5%) and breast pain/tenderness (3.2%). the most frequent adverse reactions ( 2%) in pmdd clinical trials are menstrual irregularities (24.9%), nausea (15.8%), headache (13.0%), breast tenderness (10.5%), fatigue (4.2%), irritability (2.8%), decreased libido (2.8%), increased weight (2.5%), and affect lability (2.1%) ",ethinyl estradiol + drospirenone + levomefolate
sign_symptom,vomiting,0.99988234," the most frequent adverse reactions ( 2%) in contraception, acne and folate clinical trials are headache/migraine (5.9%), menstrual irregularities (4.1%), nausea/vomiting (3.5%) and breast pain/tenderness (3.2%). the most frequent adverse reactions ( 2%) in pmdd clinical trials are menstrual irregularities (24.9%), nausea (15.8%), headache (13.0%), breast tenderness (10.5%), fatigue (4.2%), irritability (2.8%), decreased libido (2.8%), increased weight (2.5%), and affect lability (2.1%) ",ethinyl estradiol + drospirenone + levomefolate
sign_symptom,pain,0.99996495," the most frequent adverse reactions ( 2%) in contraception, acne and folate clinical trials are headache/migraine (5.9%), menstrual irregularities (4.1%), nausea/vomiting (3.5%) and breast pain/tenderness (3.2%). the most frequent adverse reactions ( 2%) in pmdd clinical trials are menstrual irregularities (24.9%), nausea (15.8%), headache (13.0%), breast tenderness (10.5%), fatigue (4.2%), irritability (2.8%), decreased libido (2.8%), increased weight (2.5%), and affect lability (2.1%) ",ethinyl estradiol + drospirenone + levomefolate
sign_symptom,tenderness,0.99994385," the most frequent adverse reactions ( 2%) in contraception, acne and folate clinical trials are headache/migraine (5.9%), menstrual irregularities (4.1%), nausea/vomiting (3.5%) and breast pain/tenderness (3.2%). the most frequent adverse reactions ( 2%) in pmdd clinical trials are menstrual irregularities (24.9%), nausea (15.8%), headache (13.0%), breast tenderness (10.5%), fatigue (4.2%), irritability (2.8%), decreased libido (2.8%), increased weight (2.5%), and affect lability (2.1%) ",ethinyl estradiol + drospirenone + levomefolate
sign_symptom,nausea,0.9999491," the most frequent adverse reactions ( 2%) in contraception, acne and folate clinical trials are headache/migraine (5.9%), menstrual irregularities (4.1%), nausea/vomiting (3.5%) and breast pain/tenderness (3.2%). the most frequent adverse reactions ( 2%) in pmdd clinical trials are menstrual irregularities (24.9%), nausea (15.8%), headache (13.0%), breast tenderness (10.5%), fatigue (4.2%), irritability (2.8%), decreased libido (2.8%), increased weight (2.5%), and affect lability (2.1%) ",ethinyl estradiol + drospirenone + levomefolate
sign_symptom,fatigue,0.99994564," the most frequent adverse reactions ( 2%) in contraception, acne and folate clinical trials are headache/migraine (5.9%), menstrual irregularities (4.1%), nausea/vomiting (3.5%) and breast pain/tenderness (3.2%). the most frequent adverse reactions ( 2%) in pmdd clinical trials are menstrual irregularities (24.9%), nausea (15.8%), headache (13.0%), breast tenderness (10.5%), fatigue (4.2%), irritability (2.8%), decreased libido (2.8%), increased weight (2.5%), and affect lability (2.1%) ",ethinyl estradiol + drospirenone + levomefolate
sign_symptom,adverse drug reactions,0.9944919," the most commonly reported adverse drug reactions (adrs) with ethinylestradiol &amp; drospirenone are breast pain, female genital tract bleeding and gastrointestinal and abdominal pains. they occur in &gt;6% of users. bleeding irregularities usually subside during continued treatment. the frequency of bleeding decreases with the duration of treatment. serious adverse reactions are arterial and venous thromboembolic events as well as breast cancer ",ethinyl estradiol + drospirenone (hrt)
medication,amp ; drospirenone,0.84681785," the most commonly reported adverse drug reactions (adrs) with ethinylestradiol &amp; drospirenone are breast pain, female genital tract bleeding and gastrointestinal and abdominal pains. they occur in &gt;6% of users. bleeding irregularities usually subside during continued treatment. the frequency of bleeding decreases with the duration of treatment. serious adverse reactions are arterial and venous thromboembolic events as well as breast cancer ",ethinyl estradiol + drospirenone (hrt)
sign_symptom,bleeding,0.9990553," the most commonly reported adverse drug reactions (adrs) with ethinylestradiol &amp; drospirenone are breast pain, female genital tract bleeding and gastrointestinal and abdominal pains. they occur in &gt;6% of users. bleeding irregularities usually subside during continued treatment. the frequency of bleeding decreases with the duration of treatment. serious adverse reactions are arterial and venous thromboembolic events as well as breast cancer ",ethinyl estradiol + drospirenone (hrt)
sign_symptom,adverse reactions,0.9985404," the most commonly reported adverse drug reactions (adrs) with ethinylestradiol &amp; drospirenone are breast pain, female genital tract bleeding and gastrointestinal and abdominal pains. they occur in &gt;6% of users. bleeding irregularities usually subside during continued treatment. the frequency of bleeding decreases with the duration of treatment. serious adverse reactions are arterial and venous thromboembolic events as well as breast cancer ",ethinyl estradiol + drospirenone (hrt)
disease_disorder,cancer,0.8703424," the most commonly reported adverse drug reactions (adrs) with ethinylestradiol &amp; drospirenone are breast pain, female genital tract bleeding and gastrointestinal and abdominal pains. they occur in &gt;6% of users. bleeding irregularities usually subside during continued treatment. the frequency of bleeding decreases with the duration of treatment. serious adverse reactions are arterial and venous thromboembolic events as well as breast cancer ",ethinyl estradiol + drospirenone (hrt)
medication,tablet,0.852986," different types of tablet suit to different types of woman. at the initial stage some women may experience side-effects like dizziness, headache, breast pain, nausea or unscheduled uterine bleeding. these symptoms may occur in &gt;3% of users. after starting one brand of oral contraceptive tablets, if you feel any inconvenience such as migraine, changes in eyesight or speech, unusual pain or swelling in your legs, sharp chest pains or shortness of breath, rash, yellow skin or a rise in blood pressure take immediate advice from your doctor. ",ethinyl estradiol + drospirenone (24 tablet)
sign_symptom,headache,0.9979328," different types of tablet suit to different types of woman. at the initial stage some women may experience side-effects like dizziness, headache, breast pain, nausea or unscheduled uterine bleeding. these symptoms may occur in &gt;3% of users. after starting one brand of oral contraceptive tablets, if you feel any inconvenience such as migraine, changes in eyesight or speech, unusual pain or swelling in your legs, sharp chest pains or shortness of breath, rash, yellow skin or a rise in blood pressure take immediate advice from your doctor. ",ethinyl estradiol + drospirenone (24 tablet)
sign_symptom,pain,0.981204," different types of tablet suit to different types of woman. at the initial stage some women may experience side-effects like dizziness, headache, breast pain, nausea or unscheduled uterine bleeding. these symptoms may occur in &gt;3% of users. after starting one brand of oral contraceptive tablets, if you feel any inconvenience such as migraine, changes in eyesight or speech, unusual pain or swelling in your legs, sharp chest pains or shortness of breath, rash, yellow skin or a rise in blood pressure take immediate advice from your doctor. ",ethinyl estradiol + drospirenone (24 tablet)
sign_symptom,nausea,0.9998584," different types of tablet suit to different types of woman. at the initial stage some women may experience side-effects like dizziness, headache, breast pain, nausea or unscheduled uterine bleeding. these symptoms may occur in &gt;3% of users. after starting one brand of oral contraceptive tablets, if you feel any inconvenience such as migraine, changes in eyesight or speech, unusual pain or swelling in your legs, sharp chest pains or shortness of breath, rash, yellow skin or a rise in blood pressure take immediate advice from your doctor. ",ethinyl estradiol + drospirenone (24 tablet)
medication,contra,0.94302785," different types of tablet suit to different types of woman. at the initial stage some women may experience side-effects like dizziness, headache, breast pain, nausea or unscheduled uterine bleeding. these symptoms may occur in &gt;3% of users. after starting one brand of oral contraceptive tablets, if you feel any inconvenience such as migraine, changes in eyesight or speech, unusual pain or swelling in your legs, sharp chest pains or shortness of breath, rash, yellow skin or a rise in blood pressure take immediate advice from your doctor. ",ethinyl estradiol + drospirenone (24 tablet)
sign_symptom,changes,0.9882535," different types of tablet suit to different types of woman. at the initial stage some women may experience side-effects like dizziness, headache, breast pain, nausea or unscheduled uterine bleeding. these symptoms may occur in &gt;3% of users. after starting one brand of oral contraceptive tablets, if you feel any inconvenience such as migraine, changes in eyesight or speech, unusual pain or swelling in your legs, sharp chest pains or shortness of breath, rash, yellow skin or a rise in blood pressure take immediate advice from your doctor. ",ethinyl estradiol + drospirenone (24 tablet)
sign_symptom,eyesight,0.95011485," different types of tablet suit to different types of woman. at the initial stage some women may experience side-effects like dizziness, headache, breast pain, nausea or unscheduled uterine bleeding. these symptoms may occur in &gt;3% of users. after starting one brand of oral contraceptive tablets, if you feel any inconvenience such as migraine, changes in eyesight or speech, unusual pain or swelling in your legs, sharp chest pains or shortness of breath, rash, yellow skin or a rise in blood pressure take immediate advice from your doctor. ",ethinyl estradiol + drospirenone (24 tablet)
sign_symptom,swelling,0.9999447," different types of tablet suit to different types of woman. at the initial stage some women may experience side-effects like dizziness, headache, breast pain, nausea or unscheduled uterine bleeding. these symptoms may occur in &gt;3% of users. after starting one brand of oral contraceptive tablets, if you feel any inconvenience such as migraine, changes in eyesight or speech, unusual pain or swelling in your legs, sharp chest pains or shortness of breath, rash, yellow skin or a rise in blood pressure take immediate advice from your doctor. ",ethinyl estradiol + drospirenone (24 tablet)
sign_symptom,pains,0.9999503," different types of tablet suit to different types of woman. at the initial stage some women may experience side-effects like dizziness, headache, breast pain, nausea or unscheduled uterine bleeding. these symptoms may occur in &gt;3% of users. after starting one brand of oral contraceptive tablets, if you feel any inconvenience such as migraine, changes in eyesight or speech, unusual pain or swelling in your legs, sharp chest pains or shortness of breath, rash, yellow skin or a rise in blood pressure take immediate advice from your doctor. ",ethinyl estradiol + drospirenone (24 tablet)
sign_symptom,shortness of breath,0.9885743," different types of tablet suit to different types of woman. at the initial stage some women may experience side-effects like dizziness, headache, breast pain, nausea or unscheduled uterine bleeding. these symptoms may occur in &gt;3% of users. after starting one brand of oral contraceptive tablets, if you feel any inconvenience such as migraine, changes in eyesight or speech, unusual pain or swelling in your legs, sharp chest pains or shortness of breath, rash, yellow skin or a rise in blood pressure take immediate advice from your doctor. ",ethinyl estradiol + drospirenone (24 tablet)
medication,contraceptives,0.99860805," like other contraceptives some undesirable effects may have seen with this tablet, these include venous and arterial thromboembolic disorders. the following undesirable effects have been reported in users of cocs and whether this association is causal has not been confirmed: nausea, abdominal pain, vomiting, diarrhoea, weight increased, fluid retention, headache, migraine, depressed mood, mood altered, breast pain, breast tenderness, libido decreased, breast hypertrophy, rash, urticaria. in women with hereditary angioedema exogenous estrogens may induce or exacerbate symptoms of angioedema. ",ethinyl estradiol + drospirenone (21 tablet)
disease_disorder,angioedema,0.99831384," like other contraceptives some undesirable effects may have seen with this tablet, these include venous and arterial thromboembolic disorders. the following undesirable effects have been reported in users of cocs and whether this association is causal has not been confirmed: nausea, abdominal pain, vomiting, diarrhoea, weight increased, fluid retention, headache, migraine, depressed mood, mood altered, breast pain, breast tenderness, libido decreased, breast hypertrophy, rash, urticaria. in women with hereditary angioedema exogenous estrogens may induce or exacerbate symptoms of angioedema. ",ethinyl estradiol + drospirenone (21 tablet)
medication,estrogens,0.9591411," like other contraceptives some undesirable effects may have seen with this tablet, these include venous and arterial thromboembolic disorders. the following undesirable effects have been reported in users of cocs and whether this association is causal has not been confirmed: nausea, abdominal pain, vomiting, diarrhoea, weight increased, fluid retention, headache, migraine, depressed mood, mood altered, breast pain, breast tenderness, libido decreased, breast hypertrophy, rash, urticaria. in women with hereditary angioedema exogenous estrogens may induce or exacerbate symptoms of angioedema. ",ethinyl estradiol + drospirenone (21 tablet)
sign_symptom,pain,0.9997002,"  possible side effects : the following side effects have been reported by users of the pill, although they need not be caused by the pill. these side effects may occur in the first few months that you are using the pill and usually lessen with time. 
 
 breast tenderness, pain and secretion; 
 headache; 
 changes in sexual drive; depressive moods; 
 contact lens intolerance; 
 nausea, vomiting and feeling sick; 
 changes in vaginal secretion; 
 various skin reactions; 
 fluid retention; 
 changes in body weight; 
 hypersensitivity reactions. 
  ",ethinyl estradiol + desogestrel (0.03 mg)
sign_symptom,vomiting,0.9993894,"  possible side effects : the following side effects have been reported by users of the pill, although they need not be caused by the pill. these side effects may occur in the first few months that you are using the pill and usually lessen with time. 
 
 breast tenderness, pain and secretion; 
 headache; 
 changes in sexual drive; depressive moods; 
 contact lens intolerance; 
 nausea, vomiting and feeling sick; 
 changes in vaginal secretion; 
 various skin reactions; 
 fluid retention; 
 changes in body weight; 
 hypersensitivity reactions. 
  ",ethinyl estradiol + desogestrel (0.03 mg)
sign_symptom,hypersen,0.74688125,"  possible side effects : the following side effects have been reported by users of the pill, although they need not be caused by the pill. these side effects may occur in the first few months that you are using the pill and usually lessen with time. 
 
 breast tenderness, pain and secretion; 
 headache; 
 changes in sexual drive; depressive moods; 
 contact lens intolerance; 
 nausea, vomiting and feeling sick; 
 changes in vaginal secretion; 
 various skin reactions; 
 fluid retention; 
 changes in body weight; 
 hypersensitivity reactions. 
  ",ethinyl estradiol + desogestrel (0.03 mg)
sign_symptom,migraine,0.9986724,"  
 migraine or headache (see a doctor as soon as possible if this is your first migraine or its worse than usual, or if the headache is severe, unusual or long lasting) 
 putting on weight or losing weight 
 breast problems, such as painful or tender breasts; producing a milky fluid from the nipples 
 depression or mood changes 
 changes in sexual desire 
 heart or circulation problems, such as increased blood pressure, swollen hands, ankles or feet (a sign of fluid retention) 
 changes in vaginal secretions (irregular vaginal bleeding) 
 skin problems; such as, rash, bruise-like swelling to the shins (erythema nodosom) 
 stomach problems; such as, nausea, vomiting 
 discomfort of the eyes who wears contact lenses 
  ",ethinyl estradiol + desogestrel (0.02 mg)
sign_symptom,headache,0.9999238,"  
 migraine or headache (see a doctor as soon as possible if this is your first migraine or its worse than usual, or if the headache is severe, unusual or long lasting) 
 putting on weight or losing weight 
 breast problems, such as painful or tender breasts; producing a milky fluid from the nipples 
 depression or mood changes 
 changes in sexual desire 
 heart or circulation problems, such as increased blood pressure, swollen hands, ankles or feet (a sign of fluid retention) 
 changes in vaginal secretions (irregular vaginal bleeding) 
 skin problems; such as, rash, bruise-like swelling to the shins (erythema nodosom) 
 stomach problems; such as, nausea, vomiting 
 discomfort of the eyes who wears contact lenses 
  ",ethinyl estradiol + desogestrel (0.02 mg)
sign_symptom,weight,0.98662937,"  
 migraine or headache (see a doctor as soon as possible if this is your first migraine or its worse than usual, or if the headache is severe, unusual or long lasting) 
 putting on weight or losing weight 
 breast problems, such as painful or tender breasts; producing a milky fluid from the nipples 
 depression or mood changes 
 changes in sexual desire 
 heart or circulation problems, such as increased blood pressure, swollen hands, ankles or feet (a sign of fluid retention) 
 changes in vaginal secretions (irregular vaginal bleeding) 
 skin problems; such as, rash, bruise-like swelling to the shins (erythema nodosom) 
 stomach problems; such as, nausea, vomiting 
 discomfort of the eyes who wears contact lenses 
  ",ethinyl estradiol + desogestrel (0.02 mg)
sign_symptom,milky fluid,0.8441411,"  
 migraine or headache (see a doctor as soon as possible if this is your first migraine or its worse than usual, or if the headache is severe, unusual or long lasting) 
 putting on weight or losing weight 
 breast problems, such as painful or tender breasts; producing a milky fluid from the nipples 
 depression or mood changes 
 changes in sexual desire 
 heart or circulation problems, such as increased blood pressure, swollen hands, ankles or feet (a sign of fluid retention) 
 changes in vaginal secretions (irregular vaginal bleeding) 
 skin problems; such as, rash, bruise-like swelling to the shins (erythema nodosom) 
 stomach problems; such as, nausea, vomiting 
 discomfort of the eyes who wears contact lenses 
  ",ethinyl estradiol + desogestrel (0.02 mg)
sign_symptom,depression,0.9998634,"  
 migraine or headache (see a doctor as soon as possible if this is your first migraine or its worse than usual, or if the headache is severe, unusual or long lasting) 
 putting on weight or losing weight 
 breast problems, such as painful or tender breasts; producing a milky fluid from the nipples 
 depression or mood changes 
 changes in sexual desire 
 heart or circulation problems, such as increased blood pressure, swollen hands, ankles or feet (a sign of fluid retention) 
 changes in vaginal secretions (irregular vaginal bleeding) 
 skin problems; such as, rash, bruise-like swelling to the shins (erythema nodosom) 
 stomach problems; such as, nausea, vomiting 
 discomfort of the eyes who wears contact lenses 
  ",ethinyl estradiol + desogestrel (0.02 mg)
sign_symptom,mood changes,0.99921286,"  
 migraine or headache (see a doctor as soon as possible if this is your first migraine or its worse than usual, or if the headache is severe, unusual or long lasting) 
 putting on weight or losing weight 
 breast problems, such as painful or tender breasts; producing a milky fluid from the nipples 
 depression or mood changes 
 changes in sexual desire 
 heart or circulation problems, such as increased blood pressure, swollen hands, ankles or feet (a sign of fluid retention) 
 changes in vaginal secretions (irregular vaginal bleeding) 
 skin problems; such as, rash, bruise-like swelling to the shins (erythema nodosom) 
 stomach problems; such as, nausea, vomiting 
 discomfort of the eyes who wears contact lenses 
  ",ethinyl estradiol + desogestrel (0.02 mg)
sign_symptom,sexual desire,0.9645425,"  
 migraine or headache (see a doctor as soon as possible if this is your first migraine or its worse than usual, or if the headache is severe, unusual or long lasting) 
 putting on weight or losing weight 
 breast problems, such as painful or tender breasts; producing a milky fluid from the nipples 
 depression or mood changes 
 changes in sexual desire 
 heart or circulation problems, such as increased blood pressure, swollen hands, ankles or feet (a sign of fluid retention) 
 changes in vaginal secretions (irregular vaginal bleeding) 
 skin problems; such as, rash, bruise-like swelling to the shins (erythema nodosom) 
 stomach problems; such as, nausea, vomiting 
 discomfort of the eyes who wears contact lenses 
  ",ethinyl estradiol + desogestrel (0.02 mg)
sign_symptom,swollen,0.99993145,"  
 migraine or headache (see a doctor as soon as possible if this is your first migraine or its worse than usual, or if the headache is severe, unusual or long lasting) 
 putting on weight or losing weight 
 breast problems, such as painful or tender breasts; producing a milky fluid from the nipples 
 depression or mood changes 
 changes in sexual desire 
 heart or circulation problems, such as increased blood pressure, swollen hands, ankles or feet (a sign of fluid retention) 
 changes in vaginal secretions (irregular vaginal bleeding) 
 skin problems; such as, rash, bruise-like swelling to the shins (erythema nodosom) 
 stomach problems; such as, nausea, vomiting 
 discomfort of the eyes who wears contact lenses 
  ",ethinyl estradiol + desogestrel (0.02 mg)
sign_symptom,swelling,0.9999714,"  
 migraine or headache (see a doctor as soon as possible if this is your first migraine or its worse than usual, or if the headache is severe, unusual or long lasting) 
 putting on weight or losing weight 
 breast problems, such as painful or tender breasts; producing a milky fluid from the nipples 
 depression or mood changes 
 changes in sexual desire 
 heart or circulation problems, such as increased blood pressure, swollen hands, ankles or feet (a sign of fluid retention) 
 changes in vaginal secretions (irregular vaginal bleeding) 
 skin problems; such as, rash, bruise-like swelling to the shins (erythema nodosom) 
 stomach problems; such as, nausea, vomiting 
 discomfort of the eyes who wears contact lenses 
  ",ethinyl estradiol + desogestrel (0.02 mg)
sign_symptom,vomiting,0.999856,"  
 migraine or headache (see a doctor as soon as possible if this is your first migraine or its worse than usual, or if the headache is severe, unusual or long lasting) 
 putting on weight or losing weight 
 breast problems, such as painful or tender breasts; producing a milky fluid from the nipples 
 depression or mood changes 
 changes in sexual desire 
 heart or circulation problems, such as increased blood pressure, swollen hands, ankles or feet (a sign of fluid retention) 
 changes in vaginal secretions (irregular vaginal bleeding) 
 skin problems; such as, rash, bruise-like swelling to the shins (erythema nodosom) 
 stomach problems; such as, nausea, vomiting 
 discomfort of the eyes who wears contact lenses 
  ",ethinyl estradiol + desogestrel (0.02 mg)
sign_symptom,discomfort,0.9999566,"  
 migraine or headache (see a doctor as soon as possible if this is your first migraine or its worse than usual, or if the headache is severe, unusual or long lasting) 
 putting on weight or losing weight 
 breast problems, such as painful or tender breasts; producing a milky fluid from the nipples 
 depression or mood changes 
 changes in sexual desire 
 heart or circulation problems, such as increased blood pressure, swollen hands, ankles or feet (a sign of fluid retention) 
 changes in vaginal secretions (irregular vaginal bleeding) 
 skin problems; such as, rash, bruise-like swelling to the shins (erythema nodosom) 
 stomach problems; such as, nausea, vomiting 
 discomfort of the eyes who wears contact lenses 
  ",ethinyl estradiol + desogestrel (0.02 mg)
disease_disorder,retrobulbar neuritis,0.99431217," retrobulbar neuritis with reduction in visual acuity, constriction of visual field, central or peripheral scotoma and green-red colour blindness of 1 or both eyes. reduced renal clearance of urate and may precipitate acute gout. confusion, disorientation, hallucinations, headache, dizziness, malaise, jaundice or transient liver dysfunction, peripheral neuropathy, thrombocytopenia, pulmonary infiltrates, eosinophilia and gi disturbances (e.g. nausea, vomiting, anorexia, abdominal pain). rarely, retinal haemorrhage, hypersensitivity reactions including rashes, pruritus, leucopenia, fever, and joint pains. ",ethambutol
sign_symptom,const,0.99986625," retrobulbar neuritis with reduction in visual acuity, constriction of visual field, central or peripheral scotoma and green-red colour blindness of 1 or both eyes. reduced renal clearance of urate and may precipitate acute gout. confusion, disorientation, hallucinations, headache, dizziness, malaise, jaundice or transient liver dysfunction, peripheral neuropathy, thrombocytopenia, pulmonary infiltrates, eosinophilia and gi disturbances (e.g. nausea, vomiting, anorexia, abdominal pain). rarely, retinal haemorrhage, hypersensitivity reactions including rashes, pruritus, leucopenia, fever, and joint pains. ",ethambutol
sign_symptom,blindness,0.93612075," retrobulbar neuritis with reduction in visual acuity, constriction of visual field, central or peripheral scotoma and green-red colour blindness of 1 or both eyes. reduced renal clearance of urate and may precipitate acute gout. confusion, disorientation, hallucinations, headache, dizziness, malaise, jaundice or transient liver dysfunction, peripheral neuropathy, thrombocytopenia, pulmonary infiltrates, eosinophilia and gi disturbances (e.g. nausea, vomiting, anorexia, abdominal pain). rarely, retinal haemorrhage, hypersensitivity reactions including rashes, pruritus, leucopenia, fever, and joint pains. ",ethambutol
sign_symptom,halluc,0.9829579," retrobulbar neuritis with reduction in visual acuity, constriction of visual field, central or peripheral scotoma and green-red colour blindness of 1 or both eyes. reduced renal clearance of urate and may precipitate acute gout. confusion, disorientation, hallucinations, headache, dizziness, malaise, jaundice or transient liver dysfunction, peripheral neuropathy, thrombocytopenia, pulmonary infiltrates, eosinophilia and gi disturbances (e.g. nausea, vomiting, anorexia, abdominal pain). rarely, retinal haemorrhage, hypersensitivity reactions including rashes, pruritus, leucopenia, fever, and joint pains. ",ethambutol
sign_symptom,mala,0.99903333," retrobulbar neuritis with reduction in visual acuity, constriction of visual field, central or peripheral scotoma and green-red colour blindness of 1 or both eyes. reduced renal clearance of urate and may precipitate acute gout. confusion, disorientation, hallucinations, headache, dizziness, malaise, jaundice or transient liver dysfunction, peripheral neuropathy, thrombocytopenia, pulmonary infiltrates, eosinophilia and gi disturbances (e.g. nausea, vomiting, anorexia, abdominal pain). rarely, retinal haemorrhage, hypersensitivity reactions including rashes, pruritus, leucopenia, fever, and joint pains. ",ethambutol
sign_symptom,pulmonary,0.91656375," retrobulbar neuritis with reduction in visual acuity, constriction of visual field, central or peripheral scotoma and green-red colour blindness of 1 or both eyes. reduced renal clearance of urate and may precipitate acute gout. confusion, disorientation, hallucinations, headache, dizziness, malaise, jaundice or transient liver dysfunction, peripheral neuropathy, thrombocytopenia, pulmonary infiltrates, eosinophilia and gi disturbances (e.g. nausea, vomiting, anorexia, abdominal pain). rarely, retinal haemorrhage, hypersensitivity reactions including rashes, pruritus, leucopenia, fever, and joint pains. ",ethambutol
sign_symptom,eosinophilia,0.91439974," retrobulbar neuritis with reduction in visual acuity, constriction of visual field, central or peripheral scotoma and green-red colour blindness of 1 or both eyes. reduced renal clearance of urate and may precipitate acute gout. confusion, disorientation, hallucinations, headache, dizziness, malaise, jaundice or transient liver dysfunction, peripheral neuropathy, thrombocytopenia, pulmonary infiltrates, eosinophilia and gi disturbances (e.g. nausea, vomiting, anorexia, abdominal pain). rarely, retinal haemorrhage, hypersensitivity reactions including rashes, pruritus, leucopenia, fever, and joint pains. ",ethambutol
sign_symptom,gi disturbances,0.9774909," retrobulbar neuritis with reduction in visual acuity, constriction of visual field, central or peripheral scotoma and green-red colour blindness of 1 or both eyes. reduced renal clearance of urate and may precipitate acute gout. confusion, disorientation, hallucinations, headache, dizziness, malaise, jaundice or transient liver dysfunction, peripheral neuropathy, thrombocytopenia, pulmonary infiltrates, eosinophilia and gi disturbances (e.g. nausea, vomiting, anorexia, abdominal pain). rarely, retinal haemorrhage, hypersensitivity reactions including rashes, pruritus, leucopenia, fever, and joint pains. ",ethambutol
sign_symptom,hypersensitivity reactions,0.97065294," retrobulbar neuritis with reduction in visual acuity, constriction of visual field, central or peripheral scotoma and green-red colour blindness of 1 or both eyes. reduced renal clearance of urate and may precipitate acute gout. confusion, disorientation, hallucinations, headache, dizziness, malaise, jaundice or transient liver dysfunction, peripheral neuropathy, thrombocytopenia, pulmonary infiltrates, eosinophilia and gi disturbances (e.g. nausea, vomiting, anorexia, abdominal pain). rarely, retinal haemorrhage, hypersensitivity reactions including rashes, pruritus, leucopenia, fever, and joint pains. ",ethambutol
sign_symptom,rash,0.999795," retrobulbar neuritis with reduction in visual acuity, constriction of visual field, central or peripheral scotoma and green-red colour blindness of 1 or both eyes. reduced renal clearance of urate and may precipitate acute gout. confusion, disorientation, hallucinations, headache, dizziness, malaise, jaundice or transient liver dysfunction, peripheral neuropathy, thrombocytopenia, pulmonary infiltrates, eosinophilia and gi disturbances (e.g. nausea, vomiting, anorexia, abdominal pain). rarely, retinal haemorrhage, hypersensitivity reactions including rashes, pruritus, leucopenia, fever, and joint pains. ",ethambutol
disease_disorder,infections,0.9246026,"  very common : infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling). reactions at the injection site (these do not occur as often after the first month of treatment. some patients have developed a reaction at an injection site that was used before.   common : allergic reactions; fever; itching; antibodies directed against normal tissue (autoantibody formation).   uncommon : serious infections (including pneumonia, deep skin infections, joint infections, blood infection, and infections at various sites); low blood platelet count; skin cancer (excluding melanoma); localized swelling of the skin (angio edema); hives (elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or worsening); rash; inflammation or scarring of the lungs; inflammation of the blood vessels affecting multiple organs. ",etanercept
sign_symptom,reactions,0.9891657,"  very common : infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling). reactions at the injection site (these do not occur as often after the first month of treatment. some patients have developed a reaction at an injection site that was used before.   common : allergic reactions; fever; itching; antibodies directed against normal tissue (autoantibody formation).   uncommon : serious infections (including pneumonia, deep skin infections, joint infections, blood infection, and infections at various sites); low blood platelet count; skin cancer (excluding melanoma); localized swelling of the skin (angio edema); hives (elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or worsening); rash; inflammation or scarring of the lungs; inflammation of the blood vessels affecting multiple organs. ",etanercept
sign_symptom,reaction,0.9987949,"  very common : infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling). reactions at the injection site (these do not occur as often after the first month of treatment. some patients have developed a reaction at an injection site that was used before.   common : allergic reactions; fever; itching; antibodies directed against normal tissue (autoantibody formation).   uncommon : serious infections (including pneumonia, deep skin infections, joint infections, blood infection, and infections at various sites); low blood platelet count; skin cancer (excluding melanoma); localized swelling of the skin (angio edema); hives (elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or worsening); rash; inflammation or scarring of the lungs; inflammation of the blood vessels affecting multiple organs. ",etanercept
sign_symptom,allergic,0.99737275,"  very common : infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling). reactions at the injection site (these do not occur as often after the first month of treatment. some patients have developed a reaction at an injection site that was used before.   common : allergic reactions; fever; itching; antibodies directed against normal tissue (autoantibody formation).   uncommon : serious infections (including pneumonia, deep skin infections, joint infections, blood infection, and infections at various sites); low blood platelet count; skin cancer (excluding melanoma); localized swelling of the skin (angio edema); hives (elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or worsening); rash; inflammation or scarring of the lungs; inflammation of the blood vessels affecting multiple organs. ",etanercept
sign_symptom,swelling,0.99992585,"  very common : infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling). reactions at the injection site (these do not occur as often after the first month of treatment. some patients have developed a reaction at an injection site that was used before.   common : allergic reactions; fever; itching; antibodies directed against normal tissue (autoantibody formation).   uncommon : serious infections (including pneumonia, deep skin infections, joint infections, blood infection, and infections at various sites); low blood platelet count; skin cancer (excluding melanoma); localized swelling of the skin (angio edema); hives (elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or worsening); rash; inflammation or scarring of the lungs; inflammation of the blood vessels affecting multiple organs. ",etanercept
sign_symptom,hives,0.99885774,"  very common : infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling). reactions at the injection site (these do not occur as often after the first month of treatment. some patients have developed a reaction at an injection site that was used before.   common : allergic reactions; fever; itching; antibodies directed against normal tissue (autoantibody formation).   uncommon : serious infections (including pneumonia, deep skin infections, joint infections, blood infection, and infections at various sites); low blood platelet count; skin cancer (excluding melanoma); localized swelling of the skin (angio edema); hives (elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or worsening); rash; inflammation or scarring of the lungs; inflammation of the blood vessels affecting multiple organs. ",etanercept
sign_symptom,inflammation,0.9913634,"  very common : infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling). reactions at the injection site (these do not occur as often after the first month of treatment. some patients have developed a reaction at an injection site that was used before.   common : allergic reactions; fever; itching; antibodies directed against normal tissue (autoantibody formation).   uncommon : serious infections (including pneumonia, deep skin infections, joint infections, blood infection, and infections at various sites); low blood platelet count; skin cancer (excluding melanoma); localized swelling of the skin (angio edema); hives (elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or worsening); rash; inflammation or scarring of the lungs; inflammation of the blood vessels affecting multiple organs. ",etanercept
sign_symptom,scar,0.9991048,"  very common : infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling). reactions at the injection site (these do not occur as often after the first month of treatment. some patients have developed a reaction at an injection site that was used before.   common : allergic reactions; fever; itching; antibodies directed against normal tissue (autoantibody formation).   uncommon : serious infections (including pneumonia, deep skin infections, joint infections, blood infection, and infections at various sites); low blood platelet count; skin cancer (excluding melanoma); localized swelling of the skin (angio edema); hives (elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or worsening); rash; inflammation or scarring of the lungs; inflammation of the blood vessels affecting multiple organs. ",etanercept
sign_symptom,unpleasant taste,0.97143996," eszopiclone is generally well tolerated. however few side effects like fatigue, anorexia, nausea, unpleasant taste in the mouth, mood problems, abdominal pain, dyspepsia, asthenia, nervousness, dizziness and confusion have been reported. ",eszopiclone
sign_symptom,mood,0.81669605," eszopiclone is generally well tolerated. however few side effects like fatigue, anorexia, nausea, unpleasant taste in the mouth, mood problems, abdominal pain, dyspepsia, asthenia, nervousness, dizziness and confusion have been reported. ",eszopiclone
sign_symptom,dyspeps,0.9897652," eszopiclone is generally well tolerated. however few side effects like fatigue, anorexia, nausea, unpleasant taste in the mouth, mood problems, abdominal pain, dyspepsia, asthenia, nervousness, dizziness and confusion have been reported. ",eszopiclone
sign_symptom,confusion,0.99986017," eszopiclone is generally well tolerated. however few side effects like fatigue, anorexia, nausea, unpleasant taste in the mouth, mood problems, abdominal pain, dyspepsia, asthenia, nervousness, dizziness and confusion have been reported. ",eszopiclone
sign_symptom,irritation,0.99992204,"  
 local irritation or itching of vagina, swelling and increased tenderness of the breasts, increased vaginal discharge, nausea, fluid retention in the tissues, usually marked by swollen ankles or feet. 
 in most patients these side effects will disappear after the first weeks of treatment. tell your doctor if vaginal bleeding occurs or if any side effect becomes troublesome or persists. 
 other side effects which may occur with hrt are benign and malignant hormone-dependent tumors such as endometrial cancer, heart attack and stroke, gall bladder disease, skin problems such as rashes, discoloration or red patches on the skin, various skin diseases with blisters and nodules or bleeding into the skin, venous thromboembolism or deep leg or pelvic venous thrombosis and pulmonary embolism (see before you use estriol cream). using hrt for several years slightly increases the risk of breast cancer. 
  ",estriol (vaginal)
sign_symptom,swelling,0.99980634,"  
 local irritation or itching of vagina, swelling and increased tenderness of the breasts, increased vaginal discharge, nausea, fluid retention in the tissues, usually marked by swollen ankles or feet. 
 in most patients these side effects will disappear after the first weeks of treatment. tell your doctor if vaginal bleeding occurs or if any side effect becomes troublesome or persists. 
 other side effects which may occur with hrt are benign and malignant hormone-dependent tumors such as endometrial cancer, heart attack and stroke, gall bladder disease, skin problems such as rashes, discoloration or red patches on the skin, various skin diseases with blisters and nodules or bleeding into the skin, venous thromboembolism or deep leg or pelvic venous thrombosis and pulmonary embolism (see before you use estriol cream). using hrt for several years slightly increases the risk of breast cancer. 
  ",estriol (vaginal)
sign_symptom,tenderness,0.9998235,"  
 local irritation or itching of vagina, swelling and increased tenderness of the breasts, increased vaginal discharge, nausea, fluid retention in the tissues, usually marked by swollen ankles or feet. 
 in most patients these side effects will disappear after the first weeks of treatment. tell your doctor if vaginal bleeding occurs or if any side effect becomes troublesome or persists. 
 other side effects which may occur with hrt are benign and malignant hormone-dependent tumors such as endometrial cancer, heart attack and stroke, gall bladder disease, skin problems such as rashes, discoloration or red patches on the skin, various skin diseases with blisters and nodules or bleeding into the skin, venous thromboembolism or deep leg or pelvic venous thrombosis and pulmonary embolism (see before you use estriol cream). using hrt for several years slightly increases the risk of breast cancer. 
  ",estriol (vaginal)
sign_symptom,swollen,0.9998405,"  
 local irritation or itching of vagina, swelling and increased tenderness of the breasts, increased vaginal discharge, nausea, fluid retention in the tissues, usually marked by swollen ankles or feet. 
 in most patients these side effects will disappear after the first weeks of treatment. tell your doctor if vaginal bleeding occurs or if any side effect becomes troublesome or persists. 
 other side effects which may occur with hrt are benign and malignant hormone-dependent tumors such as endometrial cancer, heart attack and stroke, gall bladder disease, skin problems such as rashes, discoloration or red patches on the skin, various skin diseases with blisters and nodules or bleeding into the skin, venous thromboembolism or deep leg or pelvic venous thrombosis and pulmonary embolism (see before you use estriol cream). using hrt for several years slightly increases the risk of breast cancer. 
  ",estriol (vaginal)
sign_symptom,bleeding,0.99945337,"  
 local irritation or itching of vagina, swelling and increased tenderness of the breasts, increased vaginal discharge, nausea, fluid retention in the tissues, usually marked by swollen ankles or feet. 
 in most patients these side effects will disappear after the first weeks of treatment. tell your doctor if vaginal bleeding occurs or if any side effect becomes troublesome or persists. 
 other side effects which may occur with hrt are benign and malignant hormone-dependent tumors such as endometrial cancer, heart attack and stroke, gall bladder disease, skin problems such as rashes, discoloration or red patches on the skin, various skin diseases with blisters and nodules or bleeding into the skin, venous thromboembolism or deep leg or pelvic venous thrombosis and pulmonary embolism (see before you use estriol cream). using hrt for several years slightly increases the risk of breast cancer. 
  ",estriol (vaginal)
disease_disorder,gall,0.8830809,"  
 local irritation or itching of vagina, swelling and increased tenderness of the breasts, increased vaginal discharge, nausea, fluid retention in the tissues, usually marked by swollen ankles or feet. 
 in most patients these side effects will disappear after the first weeks of treatment. tell your doctor if vaginal bleeding occurs or if any side effect becomes troublesome or persists. 
 other side effects which may occur with hrt are benign and malignant hormone-dependent tumors such as endometrial cancer, heart attack and stroke, gall bladder disease, skin problems such as rashes, discoloration or red patches on the skin, various skin diseases with blisters and nodules or bleeding into the skin, venous thromboembolism or deep leg or pelvic venous thrombosis and pulmonary embolism (see before you use estriol cream). using hrt for several years slightly increases the risk of breast cancer. 
  ",estriol (vaginal)
sign_symptom,rash,0.9868745,"  
 local irritation or itching of vagina, swelling and increased tenderness of the breasts, increased vaginal discharge, nausea, fluid retention in the tissues, usually marked by swollen ankles or feet. 
 in most patients these side effects will disappear after the first weeks of treatment. tell your doctor if vaginal bleeding occurs or if any side effect becomes troublesome or persists. 
 other side effects which may occur with hrt are benign and malignant hormone-dependent tumors such as endometrial cancer, heart attack and stroke, gall bladder disease, skin problems such as rashes, discoloration or red patches on the skin, various skin diseases with blisters and nodules or bleeding into the skin, venous thromboembolism or deep leg or pelvic venous thrombosis and pulmonary embolism (see before you use estriol cream). using hrt for several years slightly increases the risk of breast cancer. 
  ",estriol (vaginal)
sign_symptom,discoloration,0.933945,"  
 local irritation or itching of vagina, swelling and increased tenderness of the breasts, increased vaginal discharge, nausea, fluid retention in the tissues, usually marked by swollen ankles or feet. 
 in most patients these side effects will disappear after the first weeks of treatment. tell your doctor if vaginal bleeding occurs or if any side effect becomes troublesome or persists. 
 other side effects which may occur with hrt are benign and malignant hormone-dependent tumors such as endometrial cancer, heart attack and stroke, gall bladder disease, skin problems such as rashes, discoloration or red patches on the skin, various skin diseases with blisters and nodules or bleeding into the skin, venous thromboembolism or deep leg or pelvic venous thrombosis and pulmonary embolism (see before you use estriol cream). using hrt for several years slightly increases the risk of breast cancer. 
  ",estriol (vaginal)
disease_disorder,skin diseases,0.8489676,"  
 local irritation or itching of vagina, swelling and increased tenderness of the breasts, increased vaginal discharge, nausea, fluid retention in the tissues, usually marked by swollen ankles or feet. 
 in most patients these side effects will disappear after the first weeks of treatment. tell your doctor if vaginal bleeding occurs or if any side effect becomes troublesome or persists. 
 other side effects which may occur with hrt are benign and malignant hormone-dependent tumors such as endometrial cancer, heart attack and stroke, gall bladder disease, skin problems such as rashes, discoloration or red patches on the skin, various skin diseases with blisters and nodules or bleeding into the skin, venous thromboembolism or deep leg or pelvic venous thrombosis and pulmonary embolism (see before you use estriol cream). using hrt for several years slightly increases the risk of breast cancer. 
  ",estriol (vaginal)
sign_symptom,pain,0.903009," side effects of iron, folic acid and zinc supplementation are mild and transient. these include epigastric pain, nausea, constipation, vomiting, diarrhoea, heart burn, etc. allergic sensitization has been reported following both oral and parenteral administration of folic acid. ",ferrous ascorbate + folic acid + zinc sulfate
sign_symptom,constipation,0.8635943," side effects of iron, folic acid and zinc supplementation are mild and transient. these include epigastric pain, nausea, constipation, vomiting, diarrhoea, heart burn, etc. allergic sensitization has been reported following both oral and parenteral administration of folic acid. ",ferrous ascorbate + folic acid + zinc sulfate
sign_symptom,diarr,0.8035854," side effects of iron, folic acid and zinc supplementation are mild and transient. these include epigastric pain, nausea, constipation, vomiting, diarrhoea, heart burn, etc. allergic sensitization has been reported following both oral and parenteral administration of folic acid. ",ferrous ascorbate + folic acid + zinc sulfate
sign_symptom,allergic sensitization,0.9997425," side effects of iron, folic acid and zinc supplementation are mild and transient. these include epigastric pain, nausea, constipation, vomiting, diarrhoea, heart burn, etc. allergic sensitization has been reported following both oral and parenteral administration of folic acid. ",ferrous ascorbate + folic acid + zinc sulfate
sign_symptom,nausea,0.99996054," the treatment of a neurotic patient was interrupted because of nausea and regurgitation. in pregnant women, the incidence of pyrosis and chronic constipation is slightly increased. ",ferrous ascorbate
sign_symptom,pyrosis,0.9898861," the treatment of a neurotic patient was interrupted because of nausea and regurgitation. in pregnant women, the incidence of pyrosis and chronic constipation is slightly increased. ",ferrous ascorbate
sign_symptom,pain,0.99288565," the most common side effects are headache, peripheral edema, asthenia, av fistula thrombosis, urinary tract infection, av fistula site hemorrhage, pyrexia, fatigue, hypotension, muscle spasms, pain in extremity, back pain, and dyspnea. ",ferric pyrophosphate citrate
sign_symptom,adverse reactions,0.9999047, most commonly reported adverse reactions (incidence 1%) are rash and nausea. ,ferric derisomaltose
sign_symptom,rash,0.99992144, most commonly reported adverse reactions (incidence 1%) are rash and nausea. ,ferric derisomaltose
sign_symptom,adverse reactions,0.9976513," most common adverse reactions (incidence 5%) are discolored feces, diarrhea, constipation, nausea, vomiting, cough, abdominal pain, and hyperkalemia. ",ferric citrate
sign_symptom,hyper,0.9923098," nausea, hypertension, flushing, decreased blood phosphorus, dizziness, vomiting, pruritus, rash, urticaria, wheezing, injection site discoloration, headache, increased alanine aminotransferase), dysgeusia, hypotension, constipation, serious anaphylactic/anaphylactoid reactions ",ferric carboxymaltose
sign_symptom,vomiting,0.90929586," nausea, hypertension, flushing, decreased blood phosphorus, dizziness, vomiting, pruritus, rash, urticaria, wheezing, injection site discoloration, headache, increased alanine aminotransferase), dysgeusia, hypotension, constipation, serious anaphylactic/anaphylactoid reactions ",ferric carboxymaltose
sign_symptom,anaphylactoid reactions,0.9892149," nausea, hypertension, flushing, decreased blood phosphorus, dizziness, vomiting, pruritus, rash, urticaria, wheezing, injection site discoloration, headache, increased alanine aminotransferase), dysgeusia, hypotension, constipation, serious anaphylactic/anaphylactoid reactions ",ferric carboxymaltose
sign_symptom,burning,0.9997342," after intravaginal administration slight transient burning (which usually disappears rapidly) may occasionally happen. prolonged topical application may cause sensitisation reactions. fenticonazole is generally well tolerated by the mucous membranes; only exceptionally mild and transient erythematous reactions have been reported. after topical application or intravaginal administration, a slight burning sensation may occur, usually subsiding soon. should more persistent irritation occur or resistant micro-organism develop, suspend the treatment and seek the doctor's advice. due to poor absorption of fenticonazole, no systemic effects should occur, provided the above instructions are carefully observed. ",fenticonazole nitrate [vaginal tablet]
sign_symptom,reactions,0.79365844," after intravaginal administration slight transient burning (which usually disappears rapidly) may occasionally happen. prolonged topical application may cause sensitisation reactions. fenticonazole is generally well tolerated by the mucous membranes; only exceptionally mild and transient erythematous reactions have been reported. after topical application or intravaginal administration, a slight burning sensation may occur, usually subsiding soon. should more persistent irritation occur or resistant micro-organism develop, suspend the treatment and seek the doctor's advice. due to poor absorption of fenticonazole, no systemic effects should occur, provided the above instructions are carefully observed. ",fenticonazole nitrate [vaginal tablet]
sign_symptom,burning sensation,0.95794535," after intravaginal administration slight transient burning (which usually disappears rapidly) may occasionally happen. prolonged topical application may cause sensitisation reactions. fenticonazole is generally well tolerated by the mucous membranes; only exceptionally mild and transient erythematous reactions have been reported. after topical application or intravaginal administration, a slight burning sensation may occur, usually subsiding soon. should more persistent irritation occur or resistant micro-organism develop, suspend the treatment and seek the doctor's advice. due to poor absorption of fenticonazole, no systemic effects should occur, provided the above instructions are carefully observed. ",fenticonazole nitrate [vaginal tablet]
sign_symptom,irritation,0.9999211," after intravaginal administration slight transient burning (which usually disappears rapidly) may occasionally happen. prolonged topical application may cause sensitisation reactions. fenticonazole is generally well tolerated by the mucous membranes; only exceptionally mild and transient erythematous reactions have been reported. after topical application or intravaginal administration, a slight burning sensation may occur, usually subsiding soon. should more persistent irritation occur or resistant micro-organism develop, suspend the treatment and seek the doctor's advice. due to poor absorption of fenticonazole, no systemic effects should occur, provided the above instructions are carefully observed. ",fenticonazole nitrate [vaginal tablet]
sign_symptom,burning,0.99971086," after intravaginal administration, slight transient burning may occasionally occur, which usually disappears rapidly. ",fenticonazole nitrate [vaginal cream]
sign_symptom,adverse reactions,0.99931395," as with other narcotic analgesics, the most common serious adverse reactions reported to occur with fentanyl are respiratory depression, apnoea, muscular rigidity, myoclonic movements, and bradycardia. respiratory depression is more likely to occur with intravenous administration if a dose is given too rapidly and it rarely occurs with intramuscular administration. ",fentanyl citrate
sign_symptom,respiratory depression,0.9445971," as with other narcotic analgesics, the most common serious adverse reactions reported to occur with fentanyl are respiratory depression, apnoea, muscular rigidity, myoclonic movements, and bradycardia. respiratory depression is more likely to occur with intravenous administration if a dose is given too rapidly and it rarely occurs with intramuscular administration. ",fentanyl citrate
sign_symptom,adverse events,0.8032006," the most common adverse events associated with the use of febuxostat may include liver function abnormalities, nausea, arthralgia, and rash. ",febuxostat
sign_symptom,high,0.9985447," eruption, constipation, diarrhoea, dry mouth, nausea, vomiting, tachycardia, high blood pressure, headache, drowsiness or insomnia may rarely occur. ",famotidine
sign_symptom,drowsiness,0.9504256," eruption, constipation, diarrhoea, dry mouth, nausea, vomiting, tachycardia, high blood pressure, headache, drowsiness or insomnia may rarely occur. ",famotidine
sign_symptom,flat,0.99826765," headache, nausea, diarrhoea, fatigue, dizziness, fever, paraesthesia, somnolence, vomiting, constipation, anorexia, abdominal pain, flatulence, dyspepsia; increased serum levels of alt, alkaline phosphatase, total bilirubin and albumin; pruritus, pharyngitis, sinusitis, injury, generalised pain, rigors, back pain, arthralgia; increased serum phosphate, na and k levels; abnormal leukocyte counts, purpura, angioedema. ",famciclovir
sign_symptom,dyspepsia,0.95920265," headache, nausea, diarrhoea, fatigue, dizziness, fever, paraesthesia, somnolence, vomiting, constipation, anorexia, abdominal pain, flatulence, dyspepsia; increased serum levels of alt, alkaline phosphatase, total bilirubin and albumin; pruritus, pharyngitis, sinusitis, injury, generalised pain, rigors, back pain, arthralgia; increased serum phosphate, na and k levels; abnormal leukocyte counts, purpura, angioedema. ",famciclovir
sign_symptom,adverse events,0.9998425," clinical studies of ezetimibe (administered alone or with an hmg-coa reductase inhibitor) demonstrated that ezetimibe was generally well tolerated. the overall incidence of adverse events reported with ezetimibe was similar to that reported with placebo, and the discontinuation rate due to adverse events was also similar for ezetimibe and placebo. ",ezetimibe
sign_symptom,hyper,0.9322592," stomatitis, constipation, infections, asthenia, fatigue, cough, diarrhea, rash, anemia, nausea, anorexia, edema, peripheral, dyspnea, pyrexia, vomiting, headache, epistaxis, decreased lymphocytes, grade 3, increased glucose, grade 3, pneumonitis, pruritus, dry skin, decreased hgb, grade 3, menstrual irregularities, dysgeusia, hypertension, hemorrhage, tachycardia, chf ",everolimus
sign_symptom,irritation,0.99995303," local irritation of mouth, nausea &amp; vomiting. ",eucalyptol + menthol + methyl salicylate + thymol + sodium fluoride
sign_symptom,nausea,0.99995935," local irritation of mouth, nausea &amp; vomiting. ",eucalyptol + menthol + methyl salicylate + thymol + sodium fluoride
sign_symptom,myalgia,0.9969528," side-effects may include palpitation, fatigue, influenza-like symptoms, ecchymosis; less commonly dry mouth, taste disturbance, mouth ulcer, appetite and weight change, atrial fibrillation, transient ischaemic attack, chest pain, flushing, cough, dyspnoea, epistaxis, anxiety, mental acuity impaired, paraesthesia, electrolyte disturbance, myalgia and arthralgia; very rarely confusion and hallucinations. ",etoricoxib
sign_symptom,arthral,0.9996447," side-effects may include palpitation, fatigue, influenza-like symptoms, ecchymosis; less commonly dry mouth, taste disturbance, mouth ulcer, appetite and weight change, atrial fibrillation, transient ischaemic attack, chest pain, flushing, cough, dyspnoea, epistaxis, anxiety, mental acuity impaired, paraesthesia, electrolyte disturbance, myalgia and arthralgia; very rarely confusion and hallucinations. ",etoricoxib
sign_symptom,confusion,0.99967957," side-effects may include palpitation, fatigue, influenza-like symptoms, ecchymosis; less commonly dry mouth, taste disturbance, mouth ulcer, appetite and weight change, atrial fibrillation, transient ischaemic attack, chest pain, flushing, cough, dyspnoea, epistaxis, anxiety, mental acuity impaired, paraesthesia, electrolyte disturbance, myalgia and arthralgia; very rarely confusion and hallucinations. ",etoricoxib
sign_symptom,hall,0.9992229," side-effects may include palpitation, fatigue, influenza-like symptoms, ecchymosis; less commonly dry mouth, taste disturbance, mouth ulcer, appetite and weight change, atrial fibrillation, transient ischaemic attack, chest pain, flushing, cough, dyspnoea, epistaxis, anxiety, mental acuity impaired, paraesthesia, electrolyte disturbance, myalgia and arthralgia; very rarely confusion and hallucinations. ",etoricoxib
sign_symptom,nausea,0.99769044," leukopenia, nausea and vomiting, thrombocytopenia, alopecia, anorexia, diarrhea, leukopenia, anemia, pancytopenia, stomatitis, hepatic toxicity, type 1 hypersensitivity, orthostatic hypotension, peripheral neuropathy  malaise,shivering,asthenia,fever,mucous membrane inflammation, hyperuricemia, local soft tissue toxicity has been reported following extravasation; ",etoposide
sign_symptom,hyper,0.99937785," leukopenia, nausea and vomiting, thrombocytopenia, alopecia, anorexia, diarrhea, leukopenia, anemia, pancytopenia, stomatitis, hepatic toxicity, type 1 hypersensitivity, orthostatic hypotension, peripheral neuropathy  malaise,shivering,asthenia,fever,mucous membrane inflammation, hyperuricemia, local soft tissue toxicity has been reported following extravasation; ",etoposide
sign_symptom,effects,0.99508154," side-effects are extremely rare, but as with all topical corticosteroids, patient may show hypersensitivity reaction. ",fluocinolone acetonide
sign_symptom,effects,0.99508154," side-effects are extremely rare, but as with all topical corticosteroids, patient may show hypersensitivity reaction. ",fluocinolone acetonide + neomycin sulfate
sign_symptom,hypersen,0.86973447," side-effects are extremely rare, but as with all topical corticosteroids, patient may show hypersensitivity reaction. ",fluocinolone acetonide
sign_symptom,hypersen,0.86973447," side-effects are extremely rare, but as with all topical corticosteroids, patient may show hypersensitivity reaction. ",fluocinolone acetonide + neomycin sulfate
sign_symptom,weight gain,0.99987406," drowsiness and/or fatigue, as well as weight gain and/or increased appetite may occur. the following adverse experiences have been reported during chronic treatment with flunarizine: depression, of which female patients with a history of depressive illness may be particularly at risk; extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, orofacial dyskinesia, tremor), of which elderly patients seem particularly at risk. infrequently reported adverse reaction are: heartburn; nausea; gastralgia; insomnia; anxiety; galactorrhoea; dry mouth; muscle ache; skin rash. ",flunarizine
sign_symptom,increased,0.9997365," drowsiness and/or fatigue, as well as weight gain and/or increased appetite may occur. the following adverse experiences have been reported during chronic treatment with flunarizine: depression, of which female patients with a history of depressive illness may be particularly at risk; extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, orofacial dyskinesia, tremor), of which elderly patients seem particularly at risk. infrequently reported adverse reaction are: heartburn; nausea; gastralgia; insomnia; anxiety; galactorrhoea; dry mouth; muscle ache; skin rash. ",flunarizine
sign_symptom,appetite,0.7471546," drowsiness and/or fatigue, as well as weight gain and/or increased appetite may occur. the following adverse experiences have been reported during chronic treatment with flunarizine: depression, of which female patients with a history of depressive illness may be particularly at risk; extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, orofacial dyskinesia, tremor), of which elderly patients seem particularly at risk. infrequently reported adverse reaction are: heartburn; nausea; gastralgia; insomnia; anxiety; galactorrhoea; dry mouth; muscle ache; skin rash. ",flunarizine
sign_symptom,adverse,0.9960478," drowsiness and/or fatigue, as well as weight gain and/or increased appetite may occur. the following adverse experiences have been reported during chronic treatment with flunarizine: depression, of which female patients with a history of depressive illness may be particularly at risk; extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, orofacial dyskinesia, tremor), of which elderly patients seem particularly at risk. infrequently reported adverse reaction are: heartburn; nausea; gastralgia; insomnia; anxiety; galactorrhoea; dry mouth; muscle ache; skin rash. ",flunarizine
disease_disorder,depressive illness,0.91376644," drowsiness and/or fatigue, as well as weight gain and/or increased appetite may occur. the following adverse experiences have been reported during chronic treatment with flunarizine: depression, of which female patients with a history of depressive illness may be particularly at risk; extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, orofacial dyskinesia, tremor), of which elderly patients seem particularly at risk. infrequently reported adverse reaction are: heartburn; nausea; gastralgia; insomnia; anxiety; galactorrhoea; dry mouth; muscle ache; skin rash. ",flunarizine
sign_symptom,extrapyramidal symptoms,0.9131912," drowsiness and/or fatigue, as well as weight gain and/or increased appetite may occur. the following adverse experiences have been reported during chronic treatment with flunarizine: depression, of which female patients with a history of depressive illness may be particularly at risk; extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, orofacial dyskinesia, tremor), of which elderly patients seem particularly at risk. infrequently reported adverse reaction are: heartburn; nausea; gastralgia; insomnia; anxiety; galactorrhoea; dry mouth; muscle ache; skin rash. ",flunarizine
sign_symptom,adverse reaction,0.9975294," drowsiness and/or fatigue, as well as weight gain and/or increased appetite may occur. the following adverse experiences have been reported during chronic treatment with flunarizine: depression, of which female patients with a history of depressive illness may be particularly at risk; extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, orofacial dyskinesia, tremor), of which elderly patients seem particularly at risk. infrequently reported adverse reaction are: heartburn; nausea; gastralgia; insomnia; anxiety; galactorrhoea; dry mouth; muscle ache; skin rash. ",flunarizine
sign_symptom,nausea,0.96325433," drowsiness and/or fatigue, as well as weight gain and/or increased appetite may occur. the following adverse experiences have been reported during chronic treatment with flunarizine: depression, of which female patients with a history of depressive illness may be particularly at risk; extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, orofacial dyskinesia, tremor), of which elderly patients seem particularly at risk. infrequently reported adverse reaction are: heartburn; nausea; gastralgia; insomnia; anxiety; galactorrhoea; dry mouth; muscle ache; skin rash. ",flunarizine
sign_symptom,galactorrhoea,0.8208521," drowsiness and/or fatigue, as well as weight gain and/or increased appetite may occur. the following adverse experiences have been reported during chronic treatment with flunarizine: depression, of which female patients with a history of depressive illness may be particularly at risk; extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, orofacial dyskinesia, tremor), of which elderly patients seem particularly at risk. infrequently reported adverse reaction are: heartburn; nausea; gastralgia; insomnia; anxiety; galactorrhoea; dry mouth; muscle ache; skin rash. ",flunarizine
sign_symptom,dry mouth,0.9944632," drowsiness and/or fatigue, as well as weight gain and/or increased appetite may occur. the following adverse experiences have been reported during chronic treatment with flunarizine: depression, of which female patients with a history of depressive illness may be particularly at risk; extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, orofacial dyskinesia, tremor), of which elderly patients seem particularly at risk. infrequently reported adverse reaction are: heartburn; nausea; gastralgia; insomnia; anxiety; galactorrhoea; dry mouth; muscle ache; skin rash. ",flunarizine
sign_symptom,ache,0.74566776," drowsiness and/or fatigue, as well as weight gain and/or increased appetite may occur. the following adverse experiences have been reported during chronic treatment with flunarizine: depression, of which female patients with a history of depressive illness may be particularly at risk; extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, orofacial dyskinesia, tremor), of which elderly patients seem particularly at risk. infrequently reported adverse reaction are: heartburn; nausea; gastralgia; insomnia; anxiety; galactorrhoea; dry mouth; muscle ache; skin rash. ",flunarizine
sign_symptom,adverse reactions,0.8416432," most adverse reactions are caused by the drugs mineralocorticoid activity (retention of sodium andwater) include erythema, purpura, vertigo, pancreatitis, increased intraocular pressure, muscular weakness, hypertension, edema, cardiac enlargement, congestive heart failure, steroid myopathy, peptic ulcer, osteoporosis, convulsions, menstrual irregularities, potassium loss, hypokalemic alkalosis, allergic and anaphylactic reaction etc. when fludrocortisones is used in the small dosages recommended, side effects are not usually a problem; however the above mentioned unwanted effects should be kept in mind, particularly when fludrocortisones is used over a prolonged period of time or in conjunction with cortisone or a similar glucocorticoid. ",fludrocortisone acetate
sign_symptom,allergic and,0.9161706," most adverse reactions are caused by the drugs mineralocorticoid activity (retention of sodium andwater) include erythema, purpura, vertigo, pancreatitis, increased intraocular pressure, muscular weakness, hypertension, edema, cardiac enlargement, congestive heart failure, steroid myopathy, peptic ulcer, osteoporosis, convulsions, menstrual irregularities, potassium loss, hypokalemic alkalosis, allergic and anaphylactic reaction etc. when fludrocortisones is used in the small dosages recommended, side effects are not usually a problem; however the above mentioned unwanted effects should be kept in mind, particularly when fludrocortisones is used over a prolonged period of time or in conjunction with cortisone or a similar glucocorticoid. ",fludrocortisone acetate
sign_symptom,anaphylactic reaction,0.8492967," most adverse reactions are caused by the drugs mineralocorticoid activity (retention of sodium andwater) include erythema, purpura, vertigo, pancreatitis, increased intraocular pressure, muscular weakness, hypertension, edema, cardiac enlargement, congestive heart failure, steroid myopathy, peptic ulcer, osteoporosis, convulsions, menstrual irregularities, potassium loss, hypokalemic alkalosis, allergic and anaphylactic reaction etc. when fludrocortisones is used in the small dosages recommended, side effects are not usually a problem; however the above mentioned unwanted effects should be kept in mind, particularly when fludrocortisones is used over a prolonged period of time or in conjunction with cortisone or a similar glucocorticoid. ",fludrocortisone acetate
medication,fludrocortisones,0.83375263," most adverse reactions are caused by the drugs mineralocorticoid activity (retention of sodium andwater) include erythema, purpura, vertigo, pancreatitis, increased intraocular pressure, muscular weakness, hypertension, edema, cardiac enlargement, congestive heart failure, steroid myopathy, peptic ulcer, osteoporosis, convulsions, menstrual irregularities, potassium loss, hypokalemic alkalosis, allergic and anaphylactic reaction etc. when fludrocortisones is used in the small dosages recommended, side effects are not usually a problem; however the above mentioned unwanted effects should be kept in mind, particularly when fludrocortisones is used over a prolonged period of time or in conjunction with cortisone or a similar glucocorticoid. ",fludrocortisone acetate
sign_symptom,chill,0.9989256," fever, chills, cough, dyspnoea, pneumonia; gi disturbances, stomatitis; oedema; tumour lysis syndrome; skin rashes; haemolytic anaemia, haemorrhagic cystitis; neurological disturbances including peripheral neuropathy, agitation, confusion, visual disturbances and coma. progressive encephalopathy and blindness (high doses). ",fludarabine phosphate
sign_symptom,rash,0.9999236," fever, chills, cough, dyspnoea, pneumonia; gi disturbances, stomatitis; oedema; tumour lysis syndrome; skin rashes; haemolytic anaemia, haemorrhagic cystitis; neurological disturbances including peripheral neuropathy, agitation, confusion, visual disturbances and coma. progressive encephalopathy and blindness (high doses). ",fludarabine phosphate
sign_symptom,neurological disturbances,0.9459987," fever, chills, cough, dyspnoea, pneumonia; gi disturbances, stomatitis; oedema; tumour lysis syndrome; skin rashes; haemolytic anaemia, haemorrhagic cystitis; neurological disturbances including peripheral neuropathy, agitation, confusion, visual disturbances and coma. progressive encephalopathy and blindness (high doses). ",fludarabine phosphate
sign_symptom,visual disturbances,0.94604576," fever, chills, cough, dyspnoea, pneumonia; gi disturbances, stomatitis; oedema; tumour lysis syndrome; skin rashes; haemolytic anaemia, haemorrhagic cystitis; neurological disturbances including peripheral neuropathy, agitation, confusion, visual disturbances and coma. progressive encephalopathy and blindness (high doses). ",fludarabine phosphate
disease_disorder,blindness,0.9997038," fever, chills, cough, dyspnoea, pneumonia; gi disturbances, stomatitis; oedema; tumour lysis syndrome; skin rashes; haemolytic anaemia, haemorrhagic cystitis; neurological disturbances including peripheral neuropathy, agitation, confusion, visual disturbances and coma. progressive encephalopathy and blindness (high doses). ",fludarabine phosphate
disease_disorder,eosinophillia,0.9235433, this drug is generally well tolerated. eosinophillia has been reported in some patients. ,fluconazole (ophthalmic)
medication,flucona,0.74979293," fluconazole is well tolerated. most common side effects of using fluconazole includes nausea, vomiting, abdominal pain, diarrhoea, headache and skin rash. ",fluconazole
sign_symptom,headache,0.9990766," fluconazole is well tolerated. most common side effects of using fluconazole includes nausea, vomiting, abdominal pain, diarrhoea, headache and skin rash. ",fluconazole
sign_symptom,nausea,0.9994236," there have been some common side effects of gastrointestinal tract such as nausea, vomiting, diarrhoea, dyspepsia and other minor gastrointestinal disturbances. besides these rashes, urticaria, purpura, fever, interstitial nephritis, hepatitis and cholestatic jaundice have been reported. ",flucloxacillin sodium
sign_symptom,vomiting,0.9985183," there have been some common side effects of gastrointestinal tract such as nausea, vomiting, diarrhoea, dyspepsia and other minor gastrointestinal disturbances. besides these rashes, urticaria, purpura, fever, interstitial nephritis, hepatitis and cholestatic jaundice have been reported. ",flucloxacillin sodium
sign_symptom,dyspepsia,0.9998535," there have been some common side effects of gastrointestinal tract such as nausea, vomiting, diarrhoea, dyspepsia and other minor gastrointestinal disturbances. besides these rashes, urticaria, purpura, fever, interstitial nephritis, hepatitis and cholestatic jaundice have been reported. ",flucloxacillin sodium
sign_symptom,rash,0.9999219," there have been some common side effects of gastrointestinal tract such as nausea, vomiting, diarrhoea, dyspepsia and other minor gastrointestinal disturbances. besides these rashes, urticaria, purpura, fever, interstitial nephritis, hepatitis and cholestatic jaundice have been reported. ",flucloxacillin sodium
sign_symptom,purpura,0.9963436," there have been some common side effects of gastrointestinal tract such as nausea, vomiting, diarrhoea, dyspepsia and other minor gastrointestinal disturbances. besides these rashes, urticaria, purpura, fever, interstitial nephritis, hepatitis and cholestatic jaundice have been reported. ",flucloxacillin sodium
sign_symptom,fever,0.9993197," there have been some common side effects of gastrointestinal tract such as nausea, vomiting, diarrhoea, dyspepsia and other minor gastrointestinal disturbances. besides these rashes, urticaria, purpura, fever, interstitial nephritis, hepatitis and cholestatic jaundice have been reported. ",flucloxacillin sodium
sign_symptom,interstitial nephritis,0.98547715," there have been some common side effects of gastrointestinal tract such as nausea, vomiting, diarrhoea, dyspepsia and other minor gastrointestinal disturbances. besides these rashes, urticaria, purpura, fever, interstitial nephritis, hepatitis and cholestatic jaundice have been reported. ",flucloxacillin sodium
disease_disorder,hepatitis,0.99606436," there have been some common side effects of gastrointestinal tract such as nausea, vomiting, diarrhoea, dyspepsia and other minor gastrointestinal disturbances. besides these rashes, urticaria, purpura, fever, interstitial nephritis, hepatitis and cholestatic jaundice have been reported. ",flucloxacillin sodium
sign_symptom,palpit,0.94562674,"  gastrointestinal:  nausea, vomiting, dry mouth.   cns:  vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.   hematologic:  leukopenia (which is reversible upon discontinuation of the drug).   cardiovascular:  tachycardia and palpitation.   allergic:  urticaria and other dermatoses, eosinophilia and hyperpyrexia.   ophthalmic:  increased ocular tension, blurred vision, disturbance in eye accommodation. ",flavoxate hydrochloride
disease_disorder,urticaria,0.7882181,"  gastrointestinal:  nausea, vomiting, dry mouth.   cns:  vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.   hematologic:  leukopenia (which is reversible upon discontinuation of the drug).   cardiovascular:  tachycardia and palpitation.   allergic:  urticaria and other dermatoses, eosinophilia and hyperpyrexia.   ophthalmic:  increased ocular tension, blurred vision, disturbance in eye accommodation. ",flavoxate hydrochloride
sign_symptom,hyperpy,0.73161155,"  gastrointestinal:  nausea, vomiting, dry mouth.   cns:  vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.   hematologic:  leukopenia (which is reversible upon discontinuation of the drug).   cardiovascular:  tachycardia and palpitation.   allergic:  urticaria and other dermatoses, eosinophilia and hyperpyrexia.   ophthalmic:  increased ocular tension, blurred vision, disturbance in eye accommodation. ",flavoxate hydrochloride
sign_symptom,tension,0.75085986,"  gastrointestinal:  nausea, vomiting, dry mouth.   cns:  vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.   hematologic:  leukopenia (which is reversible upon discontinuation of the drug).   cardiovascular:  tachycardia and palpitation.   allergic:  urticaria and other dermatoses, eosinophilia and hyperpyrexia.   ophthalmic:  increased ocular tension, blurred vision, disturbance in eye accommodation. ",flavoxate hydrochloride
sign_symptom,blurred,0.99886453,"  gastrointestinal:  nausea, vomiting, dry mouth.   cns:  vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.   hematologic:  leukopenia (which is reversible upon discontinuation of the drug).   cardiovascular:  tachycardia and palpitation.   allergic:  urticaria and other dermatoses, eosinophilia and hyperpyrexia.   ophthalmic:  increased ocular tension, blurred vision, disturbance in eye accommodation. ",flavoxate hydrochloride
sign_symptom,disturbance,0.99993956,"  gastrointestinal:  nausea, vomiting, dry mouth.   cns:  vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.   hematologic:  leukopenia (which is reversible upon discontinuation of the drug).   cardiovascular:  tachycardia and palpitation.   allergic:  urticaria and other dermatoses, eosinophilia and hyperpyrexia.   ophthalmic:  increased ocular tension, blurred vision, disturbance in eye accommodation. ",flavoxate hydrochloride
sign_symptom,adverse reactions,0.9999186, the following serious adverse reactions are discussed elsewhere in the labeling: hyperkalemia. ,finerenone
medication,finasteride,0.9946905," finasteride is well tolerated. in clinical studies, the following adverse experiences have been reported as possibly drug related in 1% of patients treated for 12 months with 5 mg finasteride daily: impotence (3.7%), decreased libido (3.3%), and decreased volume of ejaculate (2.8%). ",finasteride [for b.p.h.]
sign_symptom,adverse,0.99018806," finasteride is well tolerated. in clinical studies, the following adverse experiences have been reported as possibly drug related in 1% of patients treated for 12 months with 5 mg finasteride daily: impotence (3.7%), decreased libido (3.3%), and decreased volume of ejaculate (2.8%). ",finasteride [for b.p.h.]
sign_symptom,ejaculate,0.98462856," finasteride is well tolerated. in clinical studies, the following adverse experiences have been reported as possibly drug related in 1% of patients treated for 12 months with 5 mg finasteride daily: impotence (3.7%), decreased libido (3.3%), and decreased volume of ejaculate (2.8%). ",finasteride [for b.p.h.]
medication,finasteride,0.996618," finasteride is well tolerated. in clinical studies, the following adverse reactions were reported as possibly drug related in &gt;1% of patients treated for 12 months with finasteride 1 mg daily : decreased libido (1.8%), erectile dysfunction (1.3%), ejaculation disorder (1.2%) and decreased volume of ejaculate (0.8%). ",finasteride [for androgenic alopecia]
sign_symptom,adverse reactions,0.9995774," finasteride is well tolerated. in clinical studies, the following adverse reactions were reported as possibly drug related in &gt;1% of patients treated for 12 months with finasteride 1 mg daily : decreased libido (1.8%), erectile dysfunction (1.3%), ejaculation disorder (1.2%) and decreased volume of ejaculate (0.8%). ",finasteride [for androgenic alopecia]
medication,finaster,0.9989521," finasteride is well tolerated. in clinical studies, the following adverse reactions were reported as possibly drug related in &gt;1% of patients treated for 12 months with finasteride 1 mg daily : decreased libido (1.8%), erectile dysfunction (1.3%), ejaculation disorder (1.2%) and decreased volume of ejaculate (0.8%). ",finasteride [for androgenic alopecia]
disease_disorder,erectile dysfunction,0.9993054," finasteride is well tolerated. in clinical studies, the following adverse reactions were reported as possibly drug related in &gt;1% of patients treated for 12 months with finasteride 1 mg daily : decreased libido (1.8%), erectile dysfunction (1.3%), ejaculation disorder (1.2%) and decreased volume of ejaculate (0.8%). ",finasteride [for androgenic alopecia]
sign_symptom,hyper,0.9902277," musculoskeletal pain, bone pain, hypersensitivity reactions, splenic enlargement, hepatomegaly, thrombocytopaenia, anaemia, epistaxis, headache, nausea, vomiting, diarrhoea, urinary abnormalities (dysuria, proteinuria, haematuria), osteoporosis, exacerbation of rheumatoid arthritis, transient decrease in blood glucose, raised uric acid, cutaneous vasculitis, transient hypotension. ",filgrastim
sign_symptom,epista,0.86504865," musculoskeletal pain, bone pain, hypersensitivity reactions, splenic enlargement, hepatomegaly, thrombocytopaenia, anaemia, epistaxis, headache, nausea, vomiting, diarrhoea, urinary abnormalities (dysuria, proteinuria, haematuria), osteoporosis, exacerbation of rheumatoid arthritis, transient decrease in blood glucose, raised uric acid, cutaneous vasculitis, transient hypotension. ",filgrastim
sign_symptom,urinary,0.87964326," musculoskeletal pain, bone pain, hypersensitivity reactions, splenic enlargement, hepatomegaly, thrombocytopaenia, anaemia, epistaxis, headache, nausea, vomiting, diarrhoea, urinary abnormalities (dysuria, proteinuria, haematuria), osteoporosis, exacerbation of rheumatoid arthritis, transient decrease in blood glucose, raised uric acid, cutaneous vasculitis, transient hypotension. ",filgrastim
sign_symptom,abnormalities,0.88569915," musculoskeletal pain, bone pain, hypersensitivity reactions, splenic enlargement, hepatomegaly, thrombocytopaenia, anaemia, epistaxis, headache, nausea, vomiting, diarrhoea, urinary abnormalities (dysuria, proteinuria, haematuria), osteoporosis, exacerbation of rheumatoid arthritis, transient decrease in blood glucose, raised uric acid, cutaneous vasculitis, transient hypotension. ",filgrastim
sign_symptom,dry mouth,0.9619596," common side effects are headache, fatigue, drowsiness, nausea, dry mouth and gastrointestinal disturbances. ",fexofenadine hydrochloride
sign_symptom,nausea,0.99993265," dark stools are usual during iron therapy and nausea and other symptoms of gastrointestinal irritation such as anorexia, vomiting, discomfort, constipation and diarrhoea are sometimes encountered. zinc may also produce a gastrointestinal upset. these timed-release capsules are designed to reduce the possibility of gastrointestinal irritation. there have been rare reports of allergic reactions ",ferrous sulfate + folic acid + zinc sulfate
sign_symptom,irritation,0.9996581," dark stools are usual during iron therapy and nausea and other symptoms of gastrointestinal irritation such as anorexia, vomiting, discomfort, constipation and diarrhoea are sometimes encountered. zinc may also produce a gastrointestinal upset. these timed-release capsules are designed to reduce the possibility of gastrointestinal irritation. there have been rare reports of allergic reactions ",ferrous sulfate + folic acid + zinc sulfate
sign_symptom,vomiting,0.99922764," dark stools are usual during iron therapy and nausea and other symptoms of gastrointestinal irritation such as anorexia, vomiting, discomfort, constipation and diarrhoea are sometimes encountered. zinc may also produce a gastrointestinal upset. these timed-release capsules are designed to reduce the possibility of gastrointestinal irritation. there have been rare reports of allergic reactions ",ferrous sulfate + folic acid + zinc sulfate
sign_symptom,discomfort,0.9991326," dark stools are usual during iron therapy and nausea and other symptoms of gastrointestinal irritation such as anorexia, vomiting, discomfort, constipation and diarrhoea are sometimes encountered. zinc may also produce a gastrointestinal upset. these timed-release capsules are designed to reduce the possibility of gastrointestinal irritation. there have been rare reports of allergic reactions ",ferrous sulfate + folic acid + zinc sulfate
sign_symptom,constipation,0.9963536," dark stools are usual during iron therapy and nausea and other symptoms of gastrointestinal irritation such as anorexia, vomiting, discomfort, constipation and diarrhoea are sometimes encountered. zinc may also produce a gastrointestinal upset. these timed-release capsules are designed to reduce the possibility of gastrointestinal irritation. there have been rare reports of allergic reactions ",ferrous sulfate + folic acid + zinc sulfate
sign_symptom,diarr,0.9960865," dark stools are usual during iron therapy and nausea and other symptoms of gastrointestinal irritation such as anorexia, vomiting, discomfort, constipation and diarrhoea are sometimes encountered. zinc may also produce a gastrointestinal upset. these timed-release capsules are designed to reduce the possibility of gastrointestinal irritation. there have been rare reports of allergic reactions ",ferrous sulfate + folic acid + zinc sulfate
sign_symptom,allergic reactions,0.99992347," dark stools are usual during iron therapy and nausea and other symptoms of gastrointestinal irritation such as anorexia, vomiting, discomfort, constipation and diarrhoea are sometimes encountered. zinc may also produce a gastrointestinal upset. these timed-release capsules are designed to reduce the possibility of gastrointestinal irritation. there have been rare reports of allergic reactions ",ferrous sulfate + folic acid + zinc sulfate
medication,iron salts,0.98842436," because iron salts are astringent, gastrointestinal irritation may occur. nausea and epigastric pain are dose related. ",ferrous sulfate + folic acid
sign_symptom,irritation,0.99993193," because iron salts are astringent, gastrointestinal irritation may occur. nausea and epigastric pain are dose related. ",ferrous sulfate + folic acid
sign_symptom,nausea,0.9999596," because iron salts are astringent, gastrointestinal irritation may occur. nausea and epigastric pain are dose related. ",ferrous sulfate + folic acid
sign_symptom,pain,0.99992836," because iron salts are astringent, gastrointestinal irritation may occur. nausea and epigastric pain are dose related. ",ferrous sulfate + folic acid
medication,iron,0.8047464," therapeutic doses of iron may cause gastrointestinal symptoms like diarrhoea, nausea and vomiting. although iron is better absorbed between meals, side effects can be reduced by taking it with or immediately after food. continuous administration may sometimes cause constipation. iron containing liquid medication may cause temporary staining of teeth (this is less likely when diluted). ",ferrous sulfate
sign_symptom,symptoms,0.8000945," therapeutic doses of iron may cause gastrointestinal symptoms like diarrhoea, nausea and vomiting. although iron is better absorbed between meals, side effects can be reduced by taking it with or immediately after food. continuous administration may sometimes cause constipation. iron containing liquid medication may cause temporary staining of teeth (this is less likely when diluted). ",ferrous sulfate
sign_symptom,diarrhoea,0.9087368," therapeutic doses of iron may cause gastrointestinal symptoms like diarrhoea, nausea and vomiting. although iron is better absorbed between meals, side effects can be reduced by taking it with or immediately after food. continuous administration may sometimes cause constipation. iron containing liquid medication may cause temporary staining of teeth (this is less likely when diluted). ",ferrous sulfate
sign_symptom,nausea,0.9995395," therapeutic doses of iron may cause gastrointestinal symptoms like diarrhoea, nausea and vomiting. although iron is better absorbed between meals, side effects can be reduced by taking it with or immediately after food. continuous administration may sometimes cause constipation. iron containing liquid medication may cause temporary staining of teeth (this is less likely when diluted). ",ferrous sulfate
sign_symptom,staining,0.99906397," therapeutic doses of iron may cause gastrointestinal symptoms like diarrhoea, nausea and vomiting. although iron is better absorbed between meals, side effects can be reduced by taking it with or immediately after food. continuous administration may sometimes cause constipation. iron containing liquid medication may cause temporary staining of teeth (this is less likely when diluted). ",ferrous sulfate
sign_symptom,heartburn,0.859635," like all medicines, ferrous fumarate tablets can sometimes cause side effects, although not everybody gets them. they might be: 
 
 heartburn 
 feeling sick or being sick 
 diarrhoea or constipation. 
 
also, you might find your stools are darker in color after you have taken this medicine. this is quite commonly seen with all iron preparations and is normal. ",ferrous fumarate
sign_symptom,sick,0.99969506," like all medicines, ferrous fumarate tablets can sometimes cause side effects, although not everybody gets them. they might be: 
 
 heartburn 
 feeling sick or being sick 
 diarrhoea or constipation. 
 
also, you might find your stools are darker in color after you have taken this medicine. this is quite commonly seen with all iron preparations and is normal. ",ferrous fumarate
sign_symptom,diarrhoea,0.9273102," like all medicines, ferrous fumarate tablets can sometimes cause side effects, although not everybody gets them. they might be: 
 
 heartburn 
 feeling sick or being sick 
 diarrhoea or constipation. 
 
also, you might find your stools are darker in color after you have taken this medicine. this is quite commonly seen with all iron preparations and is normal. ",ferrous fumarate
medication,propionate,0.9902205," fluticasone propionate nasal spray is absorbed less into the rest of the body, therefore fewer side effects are seen. with the nasal spray, drying of the nose and throat, unpleasant taste and smell and an increase in the incidence of nosebleeds may occur. ",fluticasone propionate (nasal spray)
medication,spray,0.7834042," fluticasone propionate nasal spray is absorbed less into the rest of the body, therefore fewer side effects are seen. with the nasal spray, drying of the nose and throat, unpleasant taste and smell and an increase in the incidence of nosebleeds may occur. ",fluticasone propionate (nasal spray)
sign_symptom,drying,0.9997842," fluticasone propionate nasal spray is absorbed less into the rest of the body, therefore fewer side effects are seen. with the nasal spray, drying of the nose and throat, unpleasant taste and smell and an increase in the incidence of nosebleeds may occur. ",fluticasone propionate (nasal spray)
sign_symptom,unpleasant taste and smell,0.95609677," fluticasone propionate nasal spray is absorbed less into the rest of the body, therefore fewer side effects are seen. with the nasal spray, drying of the nose and throat, unpleasant taste and smell and an increase in the incidence of nosebleeds may occur. ",fluticasone propionate (nasal spray)
sign_symptom,nosebleeds,0.9973791," fluticasone propionate nasal spray is absorbed less into the rest of the body, therefore fewer side effects are seen. with the nasal spray, drying of the nose and throat, unpleasant taste and smell and an increase in the incidence of nosebleeds may occur. ",fluticasone propionate (nasal spray)
sign_symptom,adverse reactions,0.94708484," most common adverse reactions (incidence &gt;3%) are upper respiratory tract infection or inflammation, throat irritation, sinusitis, dysphonia, candidiasis, cough, bronchitis, and headache. ",fluticasone propionate (inhaler)
sign_symptom,dysphonia,0.92623836," most common adverse reactions (incidence &gt;3%) are upper respiratory tract infection or inflammation, throat irritation, sinusitis, dysphonia, candidiasis, cough, bronchitis, and headache. ",fluticasone propionate (inhaler)
medication,furoate,0.89872736," fluticasone furoate nasal spray is absorbed less into the rest of the body, therefore fewer side effects are seen. with the nasal spray, drying of the nose and an increase in the incidence of nosebleeds may occur.  most common adverse reactions of fluticasone furoate inhalation capsule reported in 5% of adult and adolescent subjects are nasopharyngitis, bronchitis, upper respiratory tract infection, and headache. most common adverse reactions reported in 3% of pediatric subjects aged 5 to 11 years are pharyngitis, bronchitis, and viral infection. ",fluticasone furoate
sign_symptom,drying,0.99972373," fluticasone furoate nasal spray is absorbed less into the rest of the body, therefore fewer side effects are seen. with the nasal spray, drying of the nose and an increase in the incidence of nosebleeds may occur.  most common adverse reactions of fluticasone furoate inhalation capsule reported in 5% of adult and adolescent subjects are nasopharyngitis, bronchitis, upper respiratory tract infection, and headache. most common adverse reactions reported in 3% of pediatric subjects aged 5 to 11 years are pharyngitis, bronchitis, and viral infection. ",fluticasone furoate
sign_symptom,adverse reactions,0.9944757," fluticasone furoate nasal spray is absorbed less into the rest of the body, therefore fewer side effects are seen. with the nasal spray, drying of the nose and an increase in the incidence of nosebleeds may occur.  most common adverse reactions of fluticasone furoate inhalation capsule reported in 5% of adult and adolescent subjects are nasopharyngitis, bronchitis, upper respiratory tract infection, and headache. most common adverse reactions reported in 3% of pediatric subjects aged 5 to 11 years are pharyngitis, bronchitis, and viral infection. ",fluticasone furoate
medication,furoat,0.9832423," fluticasone furoate nasal spray is absorbed less into the rest of the body, therefore fewer side effects are seen. with the nasal spray, drying of the nose and an increase in the incidence of nosebleeds may occur.  most common adverse reactions of fluticasone furoate inhalation capsule reported in 5% of adult and adolescent subjects are nasopharyngitis, bronchitis, upper respiratory tract infection, and headache. most common adverse reactions reported in 3% of pediatric subjects aged 5 to 11 years are pharyngitis, bronchitis, and viral infection. ",fluticasone furoate
sign_symptom,loss,0.9880641," hot flushes, loss of libido, impotence, gynaecomastia, nausea, vomiting, diarrhoea, increased appetite, sleep disturbances, skin reactions, anaemias, headache, dizziness, malaise, anxiety, hypertension, gastric and chest pain, oedema, blurred vision, hepatitis, jaundice, rash, thirst, pruritus, sle-like syndrome, drowsiness, confusion, depression, nervousness. ",flutamide
sign_symptom,libid,0.97943616," hot flushes, loss of libido, impotence, gynaecomastia, nausea, vomiting, diarrhoea, increased appetite, sleep disturbances, skin reactions, anaemias, headache, dizziness, malaise, anxiety, hypertension, gastric and chest pain, oedema, blurred vision, hepatitis, jaundice, rash, thirst, pruritus, sle-like syndrome, drowsiness, confusion, depression, nervousness. ",flutamide
sign_symptom,diarr,0.8976657," hot flushes, loss of libido, impotence, gynaecomastia, nausea, vomiting, diarrhoea, increased appetite, sleep disturbances, skin reactions, anaemias, headache, dizziness, malaise, anxiety, hypertension, gastric and chest pain, oedema, blurred vision, hepatitis, jaundice, rash, thirst, pruritus, sle-like syndrome, drowsiness, confusion, depression, nervousness. ",flutamide
sign_symptom,dyspepsia,0.9991533," oedema, abdominal pain, constipation, diarrhoea, dyspepsia/heartburn, liver enzyme elevations, flatulence, nausea, vomiting, wt change, headache, nervousness, cns stimulation (e.g. anxiety), cns inhibition (e.g. somnolence), rhinitis, vision changes, dizziness/vertigo, tinnitus, signs and symptoms of uti, rash. ocular hyperaemia, eye irritation, fibrosis, miosis, mydriasis. ",flurbiprofen
sign_symptom,flat,0.97036195," oedema, abdominal pain, constipation, diarrhoea, dyspepsia/heartburn, liver enzyme elevations, flatulence, nausea, vomiting, wt change, headache, nervousness, cns stimulation (e.g. anxiety), cns inhibition (e.g. somnolence), rhinitis, vision changes, dizziness/vertigo, tinnitus, signs and symptoms of uti, rash. ocular hyperaemia, eye irritation, fibrosis, miosis, mydriasis. ",flurbiprofen
sign_symptom,inhibition,0.99234456," oedema, abdominal pain, constipation, diarrhoea, dyspepsia/heartburn, liver enzyme elevations, flatulence, nausea, vomiting, wt change, headache, nervousness, cns stimulation (e.g. anxiety), cns inhibition (e.g. somnolence), rhinitis, vision changes, dizziness/vertigo, tinnitus, signs and symptoms of uti, rash. ocular hyperaemia, eye irritation, fibrosis, miosis, mydriasis. ",flurbiprofen
sign_symptom,hyper,0.94829124," oedema, abdominal pain, constipation, diarrhoea, dyspepsia/heartburn, liver enzyme elevations, flatulence, nausea, vomiting, wt change, headache, nervousness, cns stimulation (e.g. anxiety), cns inhibition (e.g. somnolence), rhinitis, vision changes, dizziness/vertigo, tinnitus, signs and symptoms of uti, rash. ocular hyperaemia, eye irritation, fibrosis, miosis, mydriasis. ",flurbiprofen
sign_symptom,light - headed,0.9944921," dizziness, drowsiness, light-headedness, staggering, ataxia have occurred, particularly in elderly or debilitated persons. severe sedation, lethargy, disorientation and coma have been reported. ",flurazepam
sign_symptom,coma,0.9999107," dizziness, drowsiness, light-headedness, staggering, ataxia have occurred, particularly in elderly or debilitated persons. severe sedation, lethargy, disorientation and coma have been reported. ",flurazepam
sign_symptom,hyper,0.99909914," the side effects include tardive dyskinesia, sedation, mental confusion; hypotension; hyperprolactinaemia leading to galactorrhoea and amenorrhoea in women; loss of libido, impotence and sterility in males. also include allergic reactions, cholestatic jaundice, corneal and lens deposists, skin pigmentation. other potential adverse reactions are agranulocytosis; neuroleptic syndrome. ",fluphenazine decanoate
sign_symptom,galactorrhoea,0.99171954," the side effects include tardive dyskinesia, sedation, mental confusion; hypotension; hyperprolactinaemia leading to galactorrhoea and amenorrhoea in women; loss of libido, impotence and sterility in males. also include allergic reactions, cholestatic jaundice, corneal and lens deposists, skin pigmentation. other potential adverse reactions are agranulocytosis; neuroleptic syndrome. ",fluphenazine decanoate
sign_symptom,amenorrhoea,0.9991864," the side effects include tardive dyskinesia, sedation, mental confusion; hypotension; hyperprolactinaemia leading to galactorrhoea and amenorrhoea in women; loss of libido, impotence and sterility in males. also include allergic reactions, cholestatic jaundice, corneal and lens deposists, skin pigmentation. other potential adverse reactions are agranulocytosis; neuroleptic syndrome. ",fluphenazine decanoate
sign_symptom,loss,0.93125683," the side effects include tardive dyskinesia, sedation, mental confusion; hypotension; hyperprolactinaemia leading to galactorrhoea and amenorrhoea in women; loss of libido, impotence and sterility in males. also include allergic reactions, cholestatic jaundice, corneal and lens deposists, skin pigmentation. other potential adverse reactions are agranulocytosis; neuroleptic syndrome. ",fluphenazine decanoate
sign_symptom,libid,0.9064268," the side effects include tardive dyskinesia, sedation, mental confusion; hypotension; hyperprolactinaemia leading to galactorrhoea and amenorrhoea in women; loss of libido, impotence and sterility in males. also include allergic reactions, cholestatic jaundice, corneal and lens deposists, skin pigmentation. other potential adverse reactions are agranulocytosis; neuroleptic syndrome. ",fluphenazine decanoate
sign_symptom,impotence,0.8597317," the side effects include tardive dyskinesia, sedation, mental confusion; hypotension; hyperprolactinaemia leading to galactorrhoea and amenorrhoea in women; loss of libido, impotence and sterility in males. also include allergic reactions, cholestatic jaundice, corneal and lens deposists, skin pigmentation. other potential adverse reactions are agranulocytosis; neuroleptic syndrome. ",fluphenazine decanoate
sign_symptom,jaund,0.8892764," the side effects include tardive dyskinesia, sedation, mental confusion; hypotension; hyperprolactinaemia leading to galactorrhoea and amenorrhoea in women; loss of libido, impotence and sterility in males. also include allergic reactions, cholestatic jaundice, corneal and lens deposists, skin pigmentation. other potential adverse reactions are agranulocytosis; neuroleptic syndrome. ",fluphenazine decanoate
disease_disorder,agra,0.9389136," the side effects include tardive dyskinesia, sedation, mental confusion; hypotension; hyperprolactinaemia leading to galactorrhoea and amenorrhoea in women; loss of libido, impotence and sterility in males. also include allergic reactions, cholestatic jaundice, corneal and lens deposists, skin pigmentation. other potential adverse reactions are agranulocytosis; neuroleptic syndrome. ",fluphenazine decanoate
sign_symptom,dyskinesias,0.98933375," tardive dyskinesias have been reported in phenothiazine therapy; usually after prolonged courses given at doses adequately to control psychotic illness. blood dyscrasia, malignant neuroleptic syndrome and sudden death have been reported rarely. agranulocytosis is a rare but potentially fatal adverse effect of nortriptyline hydrochloride. ",fluphenazine + nortriptyline
disease_disorder,blood d,0.8015832," tardive dyskinesias have been reported in phenothiazine therapy; usually after prolonged courses given at doses adequately to control psychotic illness. blood dyscrasia, malignant neuroleptic syndrome and sudden death have been reported rarely. agranulocytosis is a rare but potentially fatal adverse effect of nortriptyline hydrochloride. ",fluphenazine + nortriptyline
disease_disorder,malignant neuroleptic syndrome,0.9994517," tardive dyskinesias have been reported in phenothiazine therapy; usually after prolonged courses given at doses adequately to control psychotic illness. blood dyscrasia, malignant neuroleptic syndrome and sudden death have been reported rarely. agranulocytosis is a rare but potentially fatal adverse effect of nortriptyline hydrochloride. ",fluphenazine + nortriptyline
disease_disorder,sudden death,0.79214174," tardive dyskinesias have been reported in phenothiazine therapy; usually after prolonged courses given at doses adequately to control psychotic illness. blood dyscrasia, malignant neuroleptic syndrome and sudden death have been reported rarely. agranulocytosis is a rare but potentially fatal adverse effect of nortriptyline hydrochloride. ",fluphenazine + nortriptyline
disease_disorder,agranu,0.99896204," tardive dyskinesias have been reported in phenothiazine therapy; usually after prolonged courses given at doses adequately to control psychotic illness. blood dyscrasia, malignant neuroleptic syndrome and sudden death have been reported rarely. agranulocytosis is a rare but potentially fatal adverse effect of nortriptyline hydrochloride. ",fluphenazine + nortriptyline
sign_symptom,side effects,0.9967924, in the recommended doses side effects are rare. these could be transient restlessness and insomnia. ,flupentixol + melitracen
sign_symptom,restless,0.8705634, in the recommended doses side effects are rare. these could be transient restlessness and insomnia. ,flupentixol + melitracen
sign_symptom,tremor,0.99403363," rigidity, tremors, restlessness, tardive dyskinesia, insomnia, dryness of mouth, wt gain, sexual dysfunction, galactorrhoea and menstrual disturbances.   potentially fatal:  neuroleptic malignant syndrome (hyperthermia, hypertonicity of skeletal muscles, unconsciousness and autonomic nervous system instability). ",flupentixol
sign_symptom,restless,0.8292035," rigidity, tremors, restlessness, tardive dyskinesia, insomnia, dryness of mouth, wt gain, sexual dysfunction, galactorrhoea and menstrual disturbances.   potentially fatal:  neuroleptic malignant syndrome (hyperthermia, hypertonicity of skeletal muscles, unconsciousness and autonomic nervous system instability). ",flupentixol
disease_disorder,malignant syndrome,0.99798673," rigidity, tremors, restlessness, tardive dyskinesia, insomnia, dryness of mouth, wt gain, sexual dysfunction, galactorrhoea and menstrual disturbances.   potentially fatal:  neuroleptic malignant syndrome (hyperthermia, hypertonicity of skeletal muscles, unconsciousness and autonomic nervous system instability). ",flupentixol
sign_symptom,hyper,0.9996835," rigidity, tremors, restlessness, tardive dyskinesia, insomnia, dryness of mouth, wt gain, sexual dysfunction, galactorrhoea and menstrual disturbances.   potentially fatal:  neuroleptic malignant syndrome (hyperthermia, hypertonicity of skeletal muscles, unconsciousness and autonomic nervous system instability). ",flupentixol
sign_symptom,unconscious,0.9950368," rigidity, tremors, restlessness, tardive dyskinesia, insomnia, dryness of mouth, wt gain, sexual dysfunction, galactorrhoea and menstrual disturbances.   potentially fatal:  neuroleptic malignant syndrome (hyperthermia, hypertonicity of skeletal muscles, unconsciousness and autonomic nervous system instability). ",flupentixol
sign_symptom,dyspeps,0.9717046,"  gastrointestinal:  nausea, vomiting, dyspepsia, dry mouth, and diarrhoea.   neurological:  anxiety, nervousness, insomnia/ drowsiness and fatigue.   others : excessive sweating, pruritus, skin rashes associated with liver, kidney and lung involvement. it has therefore been advised that fluoxetine therapy should be discontinued in any patient who develops a skin rash. ",fluoxetine hydrochloride
sign_symptom,dry mouth,0.81021,"  gastrointestinal:  nausea, vomiting, dyspepsia, dry mouth, and diarrhoea.   neurological:  anxiety, nervousness, insomnia/ drowsiness and fatigue.   others : excessive sweating, pruritus, skin rashes associated with liver, kidney and lung involvement. it has therefore been advised that fluoxetine therapy should be discontinued in any patient who develops a skin rash. ",fluoxetine hydrochloride
sign_symptom,insomnia,0.97531486,"  gastrointestinal:  nausea, vomiting, dyspepsia, dry mouth, and diarrhoea.   neurological:  anxiety, nervousness, insomnia/ drowsiness and fatigue.   others : excessive sweating, pruritus, skin rashes associated with liver, kidney and lung involvement. it has therefore been advised that fluoxetine therapy should be discontinued in any patient who develops a skin rash. ",fluoxetine hydrochloride
sign_symptom,drowsiness,0.9542591,"  gastrointestinal:  nausea, vomiting, dyspepsia, dry mouth, and diarrhoea.   neurological:  anxiety, nervousness, insomnia/ drowsiness and fatigue.   others : excessive sweating, pruritus, skin rashes associated with liver, kidney and lung involvement. it has therefore been advised that fluoxetine therapy should be discontinued in any patient who develops a skin rash. ",fluoxetine hydrochloride
sign_symptom,rash,0.9998853,"  gastrointestinal:  nausea, vomiting, dyspepsia, dry mouth, and diarrhoea.   neurological:  anxiety, nervousness, insomnia/ drowsiness and fatigue.   others : excessive sweating, pruritus, skin rashes associated with liver, kidney and lung involvement. it has therefore been advised that fluoxetine therapy should be discontinued in any patient who develops a skin rash. ",fluoxetine hydrochloride
medication,fluorouracil,0.9759165,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
medication,5 - fluorouracil therapy,0.9457637,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
disease_disorder,cardiotoxicity,0.96723443,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,toxicity,0.84029543,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
medication,cytotoxic drugs,0.99885267,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,effects,0.98843956,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
disease_disorder,cerebellar syndrome,0.9589695,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
disease_disorder,myelopathy,0.9379862,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
disease_disorder,neurological syndrome,0.94994676,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,allergic,0.9066071,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,swelling,0.99332714,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
disease_disorder,hand,0.9768769,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,tenderness,0.88373995,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,sore,0.99966466,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,pain,0.9998851,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,vomiting,0.99711585,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,loss,0.74138355,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,balance,0.8950235,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,rash,0.7003862,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,duct,0.83486223,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,stenosis,0.8985535,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,painful,0.8262999,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
sign_symptom,tender,0.9996207,"  potentially life-threatening effects : severe effects from 5-fluorouracil are related to the dosage and duration of therapy.   cardiac effects : occasional case reports associating 5-fluorouracil therapy with 'ischemic cardiac events' evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.   hematological effects : potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolves within 3 weeks. at the recommended dose and schedule it is rather uncommon for hematological toxicity to be severe. any ontribute to severe effects from 5-fluorouracil on the blood-forming cells. thus extensive prior irradiation or the concomitant use of cytotoxic drugs tend to exacerbate the severity of the hematological side effects of 5-fluorouracil.   neurological effects : effects on the central nervous system have been occasionally reported and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer. other effects allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. conjunctivitis, both acute and chronic can proceed to tear duct stenosis and ectropion following prolonged administration. very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities. ",fluorouracil
disease_disorder,glaucoma,0.9906013," glaucoma with optic nerve damage, visual acuity or field defects, cataract formation, secondary ocular infection following suppression of host immunity, perforation of the globe. ",fluorometholone acetate
sign_symptom,burning sensation,0.99880785," a transient burning sensation may occur after instillation. rare: hypersensitivity reactions including eczema of the eyelid and puncture keratitis. prolonged use of topical steroids may delay wound healing, increase of iop, develop cataract and cause thinning of cornea &amp; sclera. ",fluorometholone + gentamicin
sign_symptom,hypersensitivity reactions,0.926921," a transient burning sensation may occur after instillation. rare: hypersensitivity reactions including eczema of the eyelid and puncture keratitis. prolonged use of topical steroids may delay wound healing, increase of iop, develop cataract and cause thinning of cornea &amp; sclera. ",fluorometholone + gentamicin
sign_symptom,eczema,0.9657085," a transient burning sensation may occur after instillation. rare: hypersensitivity reactions including eczema of the eyelid and puncture keratitis. prolonged use of topical steroids may delay wound healing, increase of iop, develop cataract and cause thinning of cornea &amp; sclera. ",fluorometholone + gentamicin
medication,steroids,0.9968344," a transient burning sensation may occur after instillation. rare: hypersensitivity reactions including eczema of the eyelid and puncture keratitis. prolonged use of topical steroids may delay wound healing, increase of iop, develop cataract and cause thinning of cornea &amp; sclera. ",fluorometholone + gentamicin
sign_symptom,cataract,0.7792781," a transient burning sensation may occur after instillation. rare: hypersensitivity reactions including eczema of the eyelid and puncture keratitis. prolonged use of topical steroids may delay wound healing, increase of iop, develop cataract and cause thinning of cornea &amp; sclera. ",fluorometholone + gentamicin
sign_symptom,thin,0.9986211," a transient burning sensation may occur after instillation. rare: hypersensitivity reactions including eczema of the eyelid and puncture keratitis. prolonged use of topical steroids may delay wound healing, increase of iop, develop cataract and cause thinning of cornea &amp; sclera. ",fluorometholone + gentamicin
sign_symptom,loss of part,0.97177225," the following side effects may occur: increased eye pressure (glaucoma), loss of part of the usual field of vision, blurred vision, cataracts (cloudy lens), eye irritation, red eye, eye pain, foreign body sensation, eyelid or eye swelling, itchy or watery eye, ulcers on the surface of the eye, secondary eye infections from fungi or viruses, skin rash, allergic reactions, change in your sense of taste. ",fluormetholone + neomycin sulphate
sign_symptom,infections,0.8140412," the following side effects may occur: increased eye pressure (glaucoma), loss of part of the usual field of vision, blurred vision, cataracts (cloudy lens), eye irritation, red eye, eye pain, foreign body sensation, eyelid or eye swelling, itchy or watery eye, ulcers on the surface of the eye, secondary eye infections from fungi or viruses, skin rash, allergic reactions, change in your sense of taste. ",fluormetholone + neomycin sulphate
sign_symptom,nausea,0.99996054," nausea and vomiting (iv); extravasation is painful; hypersensitivity reactions; transient yellow coloration of skin and urine; staining of the skin, clothing and soft contact lenses. ",fluorescein sodium
sign_symptom,vomiting,0.99995124," nausea and vomiting (iv); extravasation is painful; hypersensitivity reactions; transient yellow coloration of skin and urine; staining of the skin, clothing and soft contact lenses. ",fluorescein sodium
sign_symptom,extra,0.9999453," nausea and vomiting (iv); extravasation is painful; hypersensitivity reactions; transient yellow coloration of skin and urine; staining of the skin, clothing and soft contact lenses. ",fluorescein sodium
sign_symptom,hypersensitivity,0.9997049," nausea and vomiting (iv); extravasation is painful; hypersensitivity reactions; transient yellow coloration of skin and urine; staining of the skin, clothing and soft contact lenses. ",fluorescein sodium
sign_symptom,stain,0.9994374," nausea and vomiting (iv); extravasation is painful; hypersensitivity reactions; transient yellow coloration of skin and urine; staining of the skin, clothing and soft contact lenses. ",fluorescein sodium
sign_symptom,allergic reactions,0.9993887," a very few patients may get severe allergic reactions from this cream. they may have trouble breathing or severe asthma attacks. while patients use this cream, skin may develop mild to moderate redness, peeling, burning, dryness or itching. ",fluocinolone acetonide + hydroquinone + tretinoin
sign_symptom,trouble breathing,0.8660822," a very few patients may get severe allergic reactions from this cream. they may have trouble breathing or severe asthma attacks. while patients use this cream, skin may develop mild to moderate redness, peeling, burning, dryness or itching. ",fluocinolone acetonide + hydroquinone + tretinoin
medication,medicines,0.9987042," medicines and their possible side effects can affect individual people in different ways. just because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect. the following side effects are known to be associated with this medicine. 
 
 skin irritation at site of application, such as burning, itching and redness. 
 allergic inflammation of the skin (contact dermatitis). 
 thinning of the skin. 
 changes in skin pigmentation. 
 stretch marks (striae). 
 groupings of fine blood vessels becoming prominent under the skin (telangiectasia). 
  ",fluocinolone acetonide + clioquinol
sign_symptom,irritation,0.99994576," medicines and their possible side effects can affect individual people in different ways. just because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect. the following side effects are known to be associated with this medicine. 
 
 skin irritation at site of application, such as burning, itching and redness. 
 allergic inflammation of the skin (contact dermatitis). 
 thinning of the skin. 
 changes in skin pigmentation. 
 stretch marks (striae). 
 groupings of fine blood vessels becoming prominent under the skin (telangiectasia). 
  ",fluocinolone acetonide + clioquinol
sign_symptom,inflammation,0.9999113," medicines and their possible side effects can affect individual people in different ways. just because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect. the following side effects are known to be associated with this medicine. 
 
 skin irritation at site of application, such as burning, itching and redness. 
 allergic inflammation of the skin (contact dermatitis). 
 thinning of the skin. 
 changes in skin pigmentation. 
 stretch marks (striae). 
 groupings of fine blood vessels becoming prominent under the skin (telangiectasia). 
  ",fluocinolone acetonide + clioquinol
sign_symptom,thin,0.999943," medicines and their possible side effects can affect individual people in different ways. just because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect. the following side effects are known to be associated with this medicine. 
 
 skin irritation at site of application, such as burning, itching and redness. 
 allergic inflammation of the skin (contact dermatitis). 
 thinning of the skin. 
 changes in skin pigmentation. 
 stretch marks (striae). 
 groupings of fine blood vessels becoming prominent under the skin (telangiectasia). 
  ",fluocinolone acetonide + clioquinol
sign_symptom,stretch marks,0.9835217," medicines and their possible side effects can affect individual people in different ways. just because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect. the following side effects are known to be associated with this medicine. 
 
 skin irritation at site of application, such as burning, itching and redness. 
 allergic inflammation of the skin (contact dermatitis). 
 thinning of the skin. 
 changes in skin pigmentation. 
 stretch marks (striae). 
 groupings of fine blood vessels becoming prominent under the skin (telangiectasia). 
  ",fluocinolone acetonide + clioquinol
medication,fusidic acid,0.90724814, fusidic acid is generally associated with very few adverse effects. the most frequently reported treatment-related side-effect is slight stinging or irritation. ,fusidic acid (ophthalmic)
sign_symptom,headache,0.99985623," spironolactone may give rise to headache and drowsiness and gastrointestinal distress, including cramp and diarrhoea. ataxia, mental confusion, and skin rashes have been reported as side effect. gynaecomastia is not uncommon and in rare cases breast enlargement may persist. other endocrine disorders including hirsutism, deepening of the voice, menstrual irregularities and impotence. transient increase in blood-urea-nitrogen concentrations may occur and mild acidosis has been reported. spironolactone may cause hyponatremia and hyperkalemia. excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse with the possibility of vascular thrombosis and embolism particularly in elderly patients. serious depletion of potassium and magnesium may lead to cardiac arrhythmias. ",furosemide + spironolactone
sign_symptom,diarr,0.8774043," spironolactone may give rise to headache and drowsiness and gastrointestinal distress, including cramp and diarrhoea. ataxia, mental confusion, and skin rashes have been reported as side effect. gynaecomastia is not uncommon and in rare cases breast enlargement may persist. other endocrine disorders including hirsutism, deepening of the voice, menstrual irregularities and impotence. transient increase in blood-urea-nitrogen concentrations may occur and mild acidosis has been reported. spironolactone may cause hyponatremia and hyperkalemia. excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse with the possibility of vascular thrombosis and embolism particularly in elderly patients. serious depletion of potassium and magnesium may lead to cardiac arrhythmias. ",furosemide + spironolactone
sign_symptom,confusion,0.8520573," spironolactone may give rise to headache and drowsiness and gastrointestinal distress, including cramp and diarrhoea. ataxia, mental confusion, and skin rashes have been reported as side effect. gynaecomastia is not uncommon and in rare cases breast enlargement may persist. other endocrine disorders including hirsutism, deepening of the voice, menstrual irregularities and impotence. transient increase in blood-urea-nitrogen concentrations may occur and mild acidosis has been reported. spironolactone may cause hyponatremia and hyperkalemia. excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse with the possibility of vascular thrombosis and embolism particularly in elderly patients. serious depletion of potassium and magnesium may lead to cardiac arrhythmias. ",furosemide + spironolactone
sign_symptom,rash,0.99983644," spironolactone may give rise to headache and drowsiness and gastrointestinal distress, including cramp and diarrhoea. ataxia, mental confusion, and skin rashes have been reported as side effect. gynaecomastia is not uncommon and in rare cases breast enlargement may persist. other endocrine disorders including hirsutism, deepening of the voice, menstrual irregularities and impotence. transient increase in blood-urea-nitrogen concentrations may occur and mild acidosis has been reported. spironolactone may cause hyponatremia and hyperkalemia. excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse with the possibility of vascular thrombosis and embolism particularly in elderly patients. serious depletion of potassium and magnesium may lead to cardiac arrhythmias. ",furosemide + spironolactone
sign_symptom,menstrual irregularities,0.7060202," spironolactone may give rise to headache and drowsiness and gastrointestinal distress, including cramp and diarrhoea. ataxia, mental confusion, and skin rashes have been reported as side effect. gynaecomastia is not uncommon and in rare cases breast enlargement may persist. other endocrine disorders including hirsutism, deepening of the voice, menstrual irregularities and impotence. transient increase in blood-urea-nitrogen concentrations may occur and mild acidosis has been reported. spironolactone may cause hyponatremia and hyperkalemia. excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse with the possibility of vascular thrombosis and embolism particularly in elderly patients. serious depletion of potassium and magnesium may lead to cardiac arrhythmias. ",furosemide + spironolactone
sign_symptom,acidosis,0.7804577," spironolactone may give rise to headache and drowsiness and gastrointestinal distress, including cramp and diarrhoea. ataxia, mental confusion, and skin rashes have been reported as side effect. gynaecomastia is not uncommon and in rare cases breast enlargement may persist. other endocrine disorders including hirsutism, deepening of the voice, menstrual irregularities and impotence. transient increase in blood-urea-nitrogen concentrations may occur and mild acidosis has been reported. spironolactone may cause hyponatremia and hyperkalemia. excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse with the possibility of vascular thrombosis and embolism particularly in elderly patients. serious depletion of potassium and magnesium may lead to cardiac arrhythmias. ",furosemide + spironolactone
medication,spironolactone,0.899111," spironolactone may give rise to headache and drowsiness and gastrointestinal distress, including cramp and diarrhoea. ataxia, mental confusion, and skin rashes have been reported as side effect. gynaecomastia is not uncommon and in rare cases breast enlargement may persist. other endocrine disorders including hirsutism, deepening of the voice, menstrual irregularities and impotence. transient increase in blood-urea-nitrogen concentrations may occur and mild acidosis has been reported. spironolactone may cause hyponatremia and hyperkalemia. excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse with the possibility of vascular thrombosis and embolism particularly in elderly patients. serious depletion of potassium and magnesium may lead to cardiac arrhythmias. ",furosemide + spironolactone
sign_symptom,hyper,0.9998254," spironolactone may give rise to headache and drowsiness and gastrointestinal distress, including cramp and diarrhoea. ataxia, mental confusion, and skin rashes have been reported as side effect. gynaecomastia is not uncommon and in rare cases breast enlargement may persist. other endocrine disorders including hirsutism, deepening of the voice, menstrual irregularities and impotence. transient increase in blood-urea-nitrogen concentrations may occur and mild acidosis has been reported. spironolactone may cause hyponatremia and hyperkalemia. excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse with the possibility of vascular thrombosis and embolism particularly in elderly patients. serious depletion of potassium and magnesium may lead to cardiac arrhythmias. ",furosemide + spironolactone
disease_disorder,vascular thrombosis,0.99233496," spironolactone may give rise to headache and drowsiness and gastrointestinal distress, including cramp and diarrhoea. ataxia, mental confusion, and skin rashes have been reported as side effect. gynaecomastia is not uncommon and in rare cases breast enlargement may persist. other endocrine disorders including hirsutism, deepening of the voice, menstrual irregularities and impotence. transient increase in blood-urea-nitrogen concentrations may occur and mild acidosis has been reported. spironolactone may cause hyponatremia and hyperkalemia. excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse with the possibility of vascular thrombosis and embolism particularly in elderly patients. serious depletion of potassium and magnesium may lead to cardiac arrhythmias. ",furosemide + spironolactone
sign_symptom,uric acid,0.8269914," as with other diuretics, electrolytes and water balance may be disturbed as a result of diuresis of prolonged therapy. prolonged use can produce alkalosis. it may also cause uric acid retention and may rarely produce acute gout. furosemide may provoke hyperglycemia and glycosuria. ",furosemide
medication,furosemide,0.9742821," as with other diuretics, electrolytes and water balance may be disturbed as a result of diuresis of prolonged therapy. prolonged use can produce alkalosis. it may also cause uric acid retention and may rarely produce acute gout. furosemide may provoke hyperglycemia and glycosuria. ",furosemide
sign_symptom,hyper,0.9858662," as with other diuretics, electrolytes and water balance may be disturbed as a result of diuresis of prolonged therapy. prolonged use can produce alkalosis. it may also cause uric acid retention and may rarely produce acute gout. furosemide may provoke hyperglycemia and glycosuria. ",furosemide
sign_symptom,pain,0.99994636," hypersensitivity, contact dermatitis, eczema (aggravated condition), skin burning sensation, pruritus, dry skin, application site pain or irritation. rarely, erythema, urticaria (including rash erythematous and generalised rash), application site swelling or vesicles. ",fucidic acid + betamethasone
sign_symptom,rash,0.99993134," hypersensitivity, contact dermatitis, eczema (aggravated condition), skin burning sensation, pruritus, dry skin, application site pain or irritation. rarely, erythema, urticaria (including rash erythematous and generalised rash), application site swelling or vesicles. ",fucidic acid + betamethasone
sign_symptom,swelling,0.99992883," hypersensitivity, contact dermatitis, eczema (aggravated condition), skin burning sensation, pruritus, dry skin, application site pain or irritation. rarely, erythema, urticaria (including rash erythematous and generalised rash), application site swelling or vesicles. ",fucidic acid + betamethasone
disease_disorder,lactic acidosis,0.9001076," intravenous administration of fructose may cause lactic acidosis and hyperuricemia.the rapid infusion of fructose results in facial flushing, abdominal pain and sweating. ",fructose
sign_symptom,hyper,0.97059715," intravenous administration of fructose may cause lactic acidosis and hyperuricemia.the rapid infusion of fructose results in facial flushing, abdominal pain and sweating. ",fructose
sign_symptom,pain,0.99967587," intravenous administration of fructose may cause lactic acidosis and hyperuricemia.the rapid infusion of fructose results in facial flushing, abdominal pain and sweating. ",fructose
sign_symptom,adverse events,0.9996023," in clinical trials, the most frequently reported adverse events occurring in &gt;1% of the study population regardless of drug relationship were: diarrhea 10.4%, headache 10.3%, vaginitis 7.6%, nausea 5.2%, rhinitis 4.5%, back pain 3.0%, dysmenorrhea 2.6%, pharyngitis 2.5%, dizziness 2.3%, abdominal pain 2.2%, pain 2.2%, dyspepsia 1.8%, asthenia 1.7%, and rash 1.4%.the following adverse events occurred in clinical trials at a rate of less than 1%, regardless of drug relationship: abnormal stools, anorexia, constipation, dry mouth, dysuria, ear disorder, fever, flatulence, flu syndrome, hematuria, infection, insomnia, lymphadenopathy, menstrual disorder, migraine, myalgia, nervousness, paresthesia, pruritus, sgpt increased, skin disorder, somnolence, and vomiting. ",fosfomycin trometamol
sign_symptom,diarrhea,0.9909298," in clinical trials, the most frequently reported adverse events occurring in &gt;1% of the study population regardless of drug relationship were: diarrhea 10.4%, headache 10.3%, vaginitis 7.6%, nausea 5.2%, rhinitis 4.5%, back pain 3.0%, dysmenorrhea 2.6%, pharyngitis 2.5%, dizziness 2.3%, abdominal pain 2.2%, pain 2.2%, dyspepsia 1.8%, asthenia 1.7%, and rash 1.4%.the following adverse events occurred in clinical trials at a rate of less than 1%, regardless of drug relationship: abnormal stools, anorexia, constipation, dry mouth, dysuria, ear disorder, fever, flatulence, flu syndrome, hematuria, infection, insomnia, lymphadenopathy, menstrual disorder, migraine, myalgia, nervousness, paresthesia, pruritus, sgpt increased, skin disorder, somnolence, and vomiting. ",fosfomycin trometamol
sign_symptom,headache,0.9998462," in clinical trials, the most frequently reported adverse events occurring in &gt;1% of the study population regardless of drug relationship were: diarrhea 10.4%, headache 10.3%, vaginitis 7.6%, nausea 5.2%, rhinitis 4.5%, back pain 3.0%, dysmenorrhea 2.6%, pharyngitis 2.5%, dizziness 2.3%, abdominal pain 2.2%, pain 2.2%, dyspepsia 1.8%, asthenia 1.7%, and rash 1.4%.the following adverse events occurred in clinical trials at a rate of less than 1%, regardless of drug relationship: abnormal stools, anorexia, constipation, dry mouth, dysuria, ear disorder, fever, flatulence, flu syndrome, hematuria, infection, insomnia, lymphadenopathy, menstrual disorder, migraine, myalgia, nervousness, paresthesia, pruritus, sgpt increased, skin disorder, somnolence, and vomiting. ",fosfomycin trometamol
sign_symptom,vaginitis,0.98272544," in clinical trials, the most frequently reported adverse events occurring in &gt;1% of the study population regardless of drug relationship were: diarrhea 10.4%, headache 10.3%, vaginitis 7.6%, nausea 5.2%, rhinitis 4.5%, back pain 3.0%, dysmenorrhea 2.6%, pharyngitis 2.5%, dizziness 2.3%, abdominal pain 2.2%, pain 2.2%, dyspepsia 1.8%, asthenia 1.7%, and rash 1.4%.the following adverse events occurred in clinical trials at a rate of less than 1%, regardless of drug relationship: abnormal stools, anorexia, constipation, dry mouth, dysuria, ear disorder, fever, flatulence, flu syndrome, hematuria, infection, insomnia, lymphadenopathy, menstrual disorder, migraine, myalgia, nervousness, paresthesia, pruritus, sgpt increased, skin disorder, somnolence, and vomiting. ",fosfomycin trometamol
sign_symptom,nausea,0.9999305," in clinical trials, the most frequently reported adverse events occurring in &gt;1% of the study population regardless of drug relationship were: diarrhea 10.4%, headache 10.3%, vaginitis 7.6%, nausea 5.2%, rhinitis 4.5%, back pain 3.0%, dysmenorrhea 2.6%, pharyngitis 2.5%, dizziness 2.3%, abdominal pain 2.2%, pain 2.2%, dyspepsia 1.8%, asthenia 1.7%, and rash 1.4%.the following adverse events occurred in clinical trials at a rate of less than 1%, regardless of drug relationship: abnormal stools, anorexia, constipation, dry mouth, dysuria, ear disorder, fever, flatulence, flu syndrome, hematuria, infection, insomnia, lymphadenopathy, menstrual disorder, migraine, myalgia, nervousness, paresthesia, pruritus, sgpt increased, skin disorder, somnolence, and vomiting. ",fosfomycin trometamol
sign_symptom,pain,0.9999318," in clinical trials, the most frequently reported adverse events occurring in &gt;1% of the study population regardless of drug relationship were: diarrhea 10.4%, headache 10.3%, vaginitis 7.6%, nausea 5.2%, rhinitis 4.5%, back pain 3.0%, dysmenorrhea 2.6%, pharyngitis 2.5%, dizziness 2.3%, abdominal pain 2.2%, pain 2.2%, dyspepsia 1.8%, asthenia 1.7%, and rash 1.4%.the following adverse events occurred in clinical trials at a rate of less than 1%, regardless of drug relationship: abnormal stools, anorexia, constipation, dry mouth, dysuria, ear disorder, fever, flatulence, flu syndrome, hematuria, infection, insomnia, lymphadenopathy, menstrual disorder, migraine, myalgia, nervousness, paresthesia, pruritus, sgpt increased, skin disorder, somnolence, and vomiting. ",fosfomycin trometamol
sign_symptom,pharyngitis,0.9699611," in clinical trials, the most frequently reported adverse events occurring in &gt;1% of the study population regardless of drug relationship were: diarrhea 10.4%, headache 10.3%, vaginitis 7.6%, nausea 5.2%, rhinitis 4.5%, back pain 3.0%, dysmenorrhea 2.6%, pharyngitis 2.5%, dizziness 2.3%, abdominal pain 2.2%, pain 2.2%, dyspepsia 1.8%, asthenia 1.7%, and rash 1.4%.the following adverse events occurred in clinical trials at a rate of less than 1%, regardless of drug relationship: abnormal stools, anorexia, constipation, dry mouth, dysuria, ear disorder, fever, flatulence, flu syndrome, hematuria, infection, insomnia, lymphadenopathy, menstrual disorder, migraine, myalgia, nervousness, paresthesia, pruritus, sgpt increased, skin disorder, somnolence, and vomiting. ",fosfomycin trometamol
sign_symptom,asthenia,0.990072," in clinical trials, the most frequently reported adverse events occurring in &gt;1% of the study population regardless of drug relationship were: diarrhea 10.4%, headache 10.3%, vaginitis 7.6%, nausea 5.2%, rhinitis 4.5%, back pain 3.0%, dysmenorrhea 2.6%, pharyngitis 2.5%, dizziness 2.3%, abdominal pain 2.2%, pain 2.2%, dyspepsia 1.8%, asthenia 1.7%, and rash 1.4%.the following adverse events occurred in clinical trials at a rate of less than 1%, regardless of drug relationship: abnormal stools, anorexia, constipation, dry mouth, dysuria, ear disorder, fever, flatulence, flu syndrome, hematuria, infection, insomnia, lymphadenopathy, menstrual disorder, migraine, myalgia, nervousness, paresthesia, pruritus, sgpt increased, skin disorder, somnolence, and vomiting. ",fosfomycin trometamol
sign_symptom,rash,0.9999161," in clinical trials, the most frequently reported adverse events occurring in &gt;1% of the study population regardless of drug relationship were: diarrhea 10.4%, headache 10.3%, vaginitis 7.6%, nausea 5.2%, rhinitis 4.5%, back pain 3.0%, dysmenorrhea 2.6%, pharyngitis 2.5%, dizziness 2.3%, abdominal pain 2.2%, pain 2.2%, dyspepsia 1.8%, asthenia 1.7%, and rash 1.4%.the following adverse events occurred in clinical trials at a rate of less than 1%, regardless of drug relationship: abnormal stools, anorexia, constipation, dry mouth, dysuria, ear disorder, fever, flatulence, flu syndrome, hematuria, infection, insomnia, lymphadenopathy, menstrual disorder, migraine, myalgia, nervousness, paresthesia, pruritus, sgpt increased, skin disorder, somnolence, and vomiting. ",fosfomycin trometamol
sign_symptom,hypersensitivity reactions,0.9766083," serious asthma-related events-hospitalizations, intubations, death, candida albicans infection, increased risk of pneumonia, immunosuppression and risk of infections, hypercorticism and adrenal suppression, paradoxical bronchospasm, hypersensitivity reactions including anaphylaxis, cardiovascular effects, reduction in bone mineral density, worsening of narrow-angle glaucoma and cataracts, worsening of urinary retention ",formoterol fumarate + glycopyrrolate + budesonide
disease_disorder,glau,0.7454933," serious asthma-related events-hospitalizations, intubations, death, candida albicans infection, increased risk of pneumonia, immunosuppression and risk of infections, hypercorticism and adrenal suppression, paradoxical bronchospasm, hypersensitivity reactions including anaphylaxis, cardiovascular effects, reduction in bone mineral density, worsening of narrow-angle glaucoma and cataracts, worsening of urinary retention ",formoterol fumarate + glycopyrrolate + budesonide
sign_symptom,urinary retention,0.96960753," serious asthma-related events-hospitalizations, intubations, death, candida albicans infection, increased risk of pneumonia, immunosuppression and risk of infections, hypercorticism and adrenal suppression, paradoxical bronchospasm, hypersensitivity reactions including anaphylaxis, cardiovascular effects, reduction in bone mineral density, worsening of narrow-angle glaucoma and cataracts, worsening of urinary retention ",formoterol fumarate + glycopyrrolate + budesonide
disease_disorder,hyper,0.9977233," ovarian cysts, mild to severe inj site reactions, headache, mild to moderate ovarian hyperstimulation syndrome (ohss), abdominal pain, gi disturbances. rarely, severe ohss, ovarian torsion, thromboembolism, mild systemic allergic reactions. ",follitropin alfa
sign_symptom,pain,0.9999194," fsh sometimes excites the ovaries too much. this may cause pelvic pain or breathing problems. it may also make you urinate less. in rare cases, patients with this problem have had serious lung problems, including fluid in the lungs, troublebreathing, and worsening of asthma blood clots and strokes, severe pelvic pain, chest pain, or abdominal pain, nausea, vomiting, sudden weight gain, bloating, trouble, breathing. fsh may cause twins or multiple births. the most common side effects with fsh are headache, vaginal bleeding, nausea, and hot flashes. sometimes there is a reaction at the spot where you give yourself the injection. this can include bruising, pain, or redness. ",follicle stimulating hormone [urofollitropin]
sign_symptom,reaction,0.98756266," fsh sometimes excites the ovaries too much. this may cause pelvic pain or breathing problems. it may also make you urinate less. in rare cases, patients with this problem have had serious lung problems, including fluid in the lungs, troublebreathing, and worsening of asthma blood clots and strokes, severe pelvic pain, chest pain, or abdominal pain, nausea, vomiting, sudden weight gain, bloating, trouble, breathing. fsh may cause twins or multiple births. the most common side effects with fsh are headache, vaginal bleeding, nausea, and hot flashes. sometimes there is a reaction at the spot where you give yourself the injection. this can include bruising, pain, or redness. ",follicle stimulating hormone [urofollitropin]
medication,folic acid,0.7983839," folic acid &amp; zinc is well tolerated in the recommended dose. occasionally gastrointestinal disturbances like abdominal pain, dyspepsia, nausea, vomiting, fever and respiratory distress may occur. ",folic acid + zinc sulfate monohydrate
sign_symptom,gastro,0.9981871," folic acid &amp; zinc is well tolerated in the recommended dose. occasionally gastrointestinal disturbances like abdominal pain, dyspepsia, nausea, vomiting, fever and respiratory distress may occur. ",folic acid + zinc sulfate monohydrate
sign_symptom,pain,0.9902284," folic acid &amp; zinc is well tolerated in the recommended dose. occasionally gastrointestinal disturbances like abdominal pain, dyspepsia, nausea, vomiting, fever and respiratory distress may occur. ",folic acid + zinc sulfate monohydrate
sign_symptom,dyspepsia,0.9997736," folic acid &amp; zinc is well tolerated in the recommended dose. occasionally gastrointestinal disturbances like abdominal pain, dyspepsia, nausea, vomiting, fever and respiratory distress may occur. ",folic acid + zinc sulfate monohydrate
sign_symptom,nausea,0.99740136," folic acid &amp; zinc is well tolerated in the recommended dose. occasionally gastrointestinal disturbances like abdominal pain, dyspepsia, nausea, vomiting, fever and respiratory distress may occur. ",folic acid + zinc sulfate monohydrate
sign_symptom,vomiting,0.9992685," folic acid &amp; zinc is well tolerated in the recommended dose. occasionally gastrointestinal disturbances like abdominal pain, dyspepsia, nausea, vomiting, fever and respiratory distress may occur. ",folic acid + zinc sulfate monohydrate
sign_symptom,fever,0.99982965," folic acid &amp; zinc is well tolerated in the recommended dose. occasionally gastrointestinal disturbances like abdominal pain, dyspepsia, nausea, vomiting, fever and respiratory distress may occur. ",folic acid + zinc sulfate monohydrate
sign_symptom,respiratory distress,0.9996868," folic acid &amp; zinc is well tolerated in the recommended dose. occasionally gastrointestinal disturbances like abdominal pain, dyspepsia, nausea, vomiting, fever and respiratory distress may occur. ",folic acid + zinc sulfate monohydrate
medication,folic,0.7400998, folic acid is generally well tolerated. gastro-intestinal disturbances may occur. hypersensitivity reactions have been reported rarely. ,folic acid
sign_symptom,gastro - intestinal disturbances,0.9969542, folic acid is generally well tolerated. gastro-intestinal disturbances may occur. hypersensitivity reactions have been reported rarely. ,folic acid
sign_symptom,hypersensitivity reactions,0.9999277, folic acid is generally well tolerated. gastro-intestinal disturbances may occur. hypersensitivity reactions have been reported rarely. ,folic acid
sign_symptom,reactions,0.81663716," most common reactions in controlled trials with adult ocd and depression patients (incidence 5% and at least twice that for placebo) were nausea, somnolence, insomnia, asthenia, nervousness, dyspepsia, abnormal ejaculation, sweating, anorexia, tremor, and vomiting. using the above rule, the following events were also identified: anorgasmia, decreased libido, dry mouth, rhinitis, taste perversion, and urinary frequency in patients with ocd; and agitation, depression, dysmenorrhea, flatulence, hyperkinesia, and rash in pediatric patients with ocd. ",fluvoxamine maleate
sign_symptom,taste,0.7519193," most common reactions in controlled trials with adult ocd and depression patients (incidence 5% and at least twice that for placebo) were nausea, somnolence, insomnia, asthenia, nervousness, dyspepsia, abnormal ejaculation, sweating, anorexia, tremor, and vomiting. using the above rule, the following events were also identified: anorgasmia, decreased libido, dry mouth, rhinitis, taste perversion, and urinary frequency in patients with ocd; and agitation, depression, dysmenorrhea, flatulence, hyperkinesia, and rash in pediatric patients with ocd. ",fluvoxamine maleate
sign_symptom,flat,0.9924036," most common reactions in controlled trials with adult ocd and depression patients (incidence 5% and at least twice that for placebo) were nausea, somnolence, insomnia, asthenia, nervousness, dyspepsia, abnormal ejaculation, sweating, anorexia, tremor, and vomiting. using the above rule, the following events were also identified: anorgasmia, decreased libido, dry mouth, rhinitis, taste perversion, and urinary frequency in patients with ocd; and agitation, depression, dysmenorrhea, flatulence, hyperkinesia, and rash in pediatric patients with ocd. ",fluvoxamine maleate
sign_symptom,rash,0.99981505," most common reactions in controlled trials with adult ocd and depression patients (incidence 5% and at least twice that for placebo) were nausea, somnolence, insomnia, asthenia, nervousness, dyspepsia, abnormal ejaculation, sweating, anorexia, tremor, and vomiting. using the above rule, the following events were also identified: anorgasmia, decreased libido, dry mouth, rhinitis, taste perversion, and urinary frequency in patients with ocd; and agitation, depression, dysmenorrhea, flatulence, hyperkinesia, and rash in pediatric patients with ocd. ",fluvoxamine maleate
sign_symptom,diarr,0.8341694," headache, nausea, abdominal pain, dyspepsia, diarrhoea, bronchitis, sinusitis, insomnia, fatigue, myopathy, myalgia and uti. increased blood creatinine phosphokinase and transaminase. ",fluvastatin
sign_symptom,myalgia,0.81216043," headache, nausea, abdominal pain, dyspepsia, diarrhoea, bronchitis, sinusitis, insomnia, fatigue, myopathy, myalgia and uti. increased blood creatinine phosphokinase and transaminase. ",fluvastatin
sign_symptom,undesirable effects,0.9058425," undesirable effects which have been associated with this inhaler during clinical development are given in the table below, listed by system organ class. the following frequency categories form the basis for classification of the undesirable effects as: very common (1/10), common (1/100 and &lt;1/10), uncommon (1/1,000 and &lt;1/100), rare (1/10,000 &lt; 1/1,000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data). within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. ",fluticasone propionate + formoterol fumarate
medication,fluticasone,0.9645161," the fluticasone propionate preparations are usually well tolerated; local burning and pruritus have been reported. if signs of hypersensitivity appear, application should be stopped immediately. prolonged and intensive treatment with potent corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, dilatation of the superficial blood vessels, hypertrichosis and hypopigmentation.   secondary infection, particularly when occlusive dressings are used or when skin folds are involved and allergic contact dermatitis have also been reported with corticosteroid use. exacerbation of the signs and symptoms of the dermatoses have been reported with corticosteroid use.   prolonged use of large amounts of corticosteroids, or treatment of extensive areas, can result in sufficient systemic absorption to produce the features of hypercorticism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. in infants, the napkin may act as an occlusive dressing. ",fluticasone propionate (topical)
medication,propionate,0.9369066," the fluticasone propionate preparations are usually well tolerated; local burning and pruritus have been reported. if signs of hypersensitivity appear, application should be stopped immediately. prolonged and intensive treatment with potent corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, dilatation of the superficial blood vessels, hypertrichosis and hypopigmentation.   secondary infection, particularly when occlusive dressings are used or when skin folds are involved and allergic contact dermatitis have also been reported with corticosteroid use. exacerbation of the signs and symptoms of the dermatoses have been reported with corticosteroid use.   prolonged use of large amounts of corticosteroids, or treatment of extensive areas, can result in sufficient systemic absorption to produce the features of hypercorticism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. in infants, the napkin may act as an occlusive dressing. ",fluticasone propionate (topical)
medication,corti,0.8287651," the fluticasone propionate preparations are usually well tolerated; local burning and pruritus have been reported. if signs of hypersensitivity appear, application should be stopped immediately. prolonged and intensive treatment with potent corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, dilatation of the superficial blood vessels, hypertrichosis and hypopigmentation.   secondary infection, particularly when occlusive dressings are used or when skin folds are involved and allergic contact dermatitis have also been reported with corticosteroid use. exacerbation of the signs and symptoms of the dermatoses have been reported with corticosteroid use.   prolonged use of large amounts of corticosteroids, or treatment of extensive areas, can result in sufficient systemic absorption to produce the features of hypercorticism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. in infants, the napkin may act as an occlusive dressing. ",fluticasone propionate (topical)
disease_disorder,skin,0.7955498," the fluticasone propionate preparations are usually well tolerated; local burning and pruritus have been reported. if signs of hypersensitivity appear, application should be stopped immediately. prolonged and intensive treatment with potent corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, dilatation of the superficial blood vessels, hypertrichosis and hypopigmentation.   secondary infection, particularly when occlusive dressings are used or when skin folds are involved and allergic contact dermatitis have also been reported with corticosteroid use. exacerbation of the signs and symptoms of the dermatoses have been reported with corticosteroid use.   prolonged use of large amounts of corticosteroids, or treatment of extensive areas, can result in sufficient systemic absorption to produce the features of hypercorticism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. in infants, the napkin may act as an occlusive dressing. ",fluticasone propionate (topical)
disease_disorder,allergic contact dermatitis,0.9613098," the fluticasone propionate preparations are usually well tolerated; local burning and pruritus have been reported. if signs of hypersensitivity appear, application should be stopped immediately. prolonged and intensive treatment with potent corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, dilatation of the superficial blood vessels, hypertrichosis and hypopigmentation.   secondary infection, particularly when occlusive dressings are used or when skin folds are involved and allergic contact dermatitis have also been reported with corticosteroid use. exacerbation of the signs and symptoms of the dermatoses have been reported with corticosteroid use.   prolonged use of large amounts of corticosteroids, or treatment of extensive areas, can result in sufficient systemic absorption to produce the features of hypercorticism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. in infants, the napkin may act as an occlusive dressing. ",fluticasone propionate (topical)
medication,corticosteroid,0.97878903," the fluticasone propionate preparations are usually well tolerated; local burning and pruritus have been reported. if signs of hypersensitivity appear, application should be stopped immediately. prolonged and intensive treatment with potent corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, dilatation of the superficial blood vessels, hypertrichosis and hypopigmentation.   secondary infection, particularly when occlusive dressings are used or when skin folds are involved and allergic contact dermatitis have also been reported with corticosteroid use. exacerbation of the signs and symptoms of the dermatoses have been reported with corticosteroid use.   prolonged use of large amounts of corticosteroids, or treatment of extensive areas, can result in sufficient systemic absorption to produce the features of hypercorticism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. in infants, the napkin may act as an occlusive dressing. ",fluticasone propionate (topical)
disease_disorder,dermatoses,0.9052058," the fluticasone propionate preparations are usually well tolerated; local burning and pruritus have been reported. if signs of hypersensitivity appear, application should be stopped immediately. prolonged and intensive treatment with potent corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, dilatation of the superficial blood vessels, hypertrichosis and hypopigmentation.   secondary infection, particularly when occlusive dressings are used or when skin folds are involved and allergic contact dermatitis have also been reported with corticosteroid use. exacerbation of the signs and symptoms of the dermatoses have been reported with corticosteroid use.   prolonged use of large amounts of corticosteroids, or treatment of extensive areas, can result in sufficient systemic absorption to produce the features of hypercorticism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. in infants, the napkin may act as an occlusive dressing. ",fluticasone propionate (topical)
medication,corticoster,0.7894918," the fluticasone propionate preparations are usually well tolerated; local burning and pruritus have been reported. if signs of hypersensitivity appear, application should be stopped immediately. prolonged and intensive treatment with potent corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae, dilatation of the superficial blood vessels, hypertrichosis and hypopigmentation.   secondary infection, particularly when occlusive dressings are used or when skin folds are involved and allergic contact dermatitis have also been reported with corticosteroid use. exacerbation of the signs and symptoms of the dermatoses have been reported with corticosteroid use.   prolonged use of large amounts of corticosteroids, or treatment of extensive areas, can result in sufficient systemic absorption to produce the features of hypercorticism. this effect is more likely to occur in infants and children, and if occlusive dressings are used. in infants, the napkin may act as an occlusive dressing. ",fluticasone propionate (topical)
sign_symptom,candidiasis,0.96152323," candidiasis of the mouth and throat and/or hoarseness is commonly reported. patients may find it helpful to rinse out their mouth with water after inhalation. as with other inhalation therapy, paradoxical bronchospasm may occur rarely, with an immediate increase in wheezing after dosing. there have also been rare reports of hypersensitivity reactions manifesting as angioedema, bronchospasm and very rarely, anaphylactic reactions. other adverse events that may occur rarely include depression of plasma cortisol in adult patients on higher doses, bone density reduction, growth retardation, cataract, glaucoma. ",fluticasone propionate (nebuliser suspension)
sign_symptom,hoarseness,0.9958133," candidiasis of the mouth and throat and/or hoarseness is commonly reported. patients may find it helpful to rinse out their mouth with water after inhalation. as with other inhalation therapy, paradoxical bronchospasm may occur rarely, with an immediate increase in wheezing after dosing. there have also been rare reports of hypersensitivity reactions manifesting as angioedema, bronchospasm and very rarely, anaphylactic reactions. other adverse events that may occur rarely include depression of plasma cortisol in adult patients on higher doses, bone density reduction, growth retardation, cataract, glaucoma. ",fluticasone propionate (nebuliser suspension)
sign_symptom,paradoxical,0.957155," candidiasis of the mouth and throat and/or hoarseness is commonly reported. patients may find it helpful to rinse out their mouth with water after inhalation. as with other inhalation therapy, paradoxical bronchospasm may occur rarely, with an immediate increase in wheezing after dosing. there have also been rare reports of hypersensitivity reactions manifesting as angioedema, bronchospasm and very rarely, anaphylactic reactions. other adverse events that may occur rarely include depression of plasma cortisol in adult patients on higher doses, bone density reduction, growth retardation, cataract, glaucoma. ",fluticasone propionate (nebuliser suspension)
sign_symptom,hypersensitivity reactions,0.9996902," candidiasis of the mouth and throat and/or hoarseness is commonly reported. patients may find it helpful to rinse out their mouth with water after inhalation. as with other inhalation therapy, paradoxical bronchospasm may occur rarely, with an immediate increase in wheezing after dosing. there have also been rare reports of hypersensitivity reactions manifesting as angioedema, bronchospasm and very rarely, anaphylactic reactions. other adverse events that may occur rarely include depression of plasma cortisol in adult patients on higher doses, bone density reduction, growth retardation, cataract, glaucoma. ",fluticasone propionate (nebuliser suspension)
sign_symptom,adverse,0.9975259," candidiasis of the mouth and throat and/or hoarseness is commonly reported. patients may find it helpful to rinse out their mouth with water after inhalation. as with other inhalation therapy, paradoxical bronchospasm may occur rarely, with an immediate increase in wheezing after dosing. there have also been rare reports of hypersensitivity reactions manifesting as angioedema, bronchospasm and very rarely, anaphylactic reactions. other adverse events that may occur rarely include depression of plasma cortisol in adult patients on higher doses, bone density reduction, growth retardation, cataract, glaucoma. ",fluticasone propionate (nebuliser suspension)
medication,glibenclamide,0.95757324," glibenclamide is well tolerated. few side effects that may arise include nausea, vomiting, epigastric pain, dizziness, weakness, paraesthesia and headache. allergic skin reactions and haemopoietic reactions (leukopenia, thrombocytopenia, etc.) are occasionally observed. ",glibenclamide
sign_symptom,allergic,0.9992933," glibenclamide is well tolerated. few side effects that may arise include nausea, vomiting, epigastric pain, dizziness, weakness, paraesthesia and headache. allergic skin reactions and haemopoietic reactions (leukopenia, thrombocytopenia, etc.) are occasionally observed. ",glibenclamide
sign_symptom,skin reactions,0.9949511," glibenclamide is well tolerated. few side effects that may arise include nausea, vomiting, epigastric pain, dizziness, weakness, paraesthesia and headache. allergic skin reactions and haemopoietic reactions (leukopenia, thrombocytopenia, etc.) are occasionally observed. ",glibenclamide
sign_symptom,haemopoietic reactions,0.99908847," glibenclamide is well tolerated. few side effects that may arise include nausea, vomiting, epigastric pain, dizziness, weakness, paraesthesia and headache. allergic skin reactions and haemopoietic reactions (leukopenia, thrombocytopenia, etc.) are occasionally observed. ",glibenclamide
sign_symptom,adverse reactions,0.99990994," in subjects receiving this preparation, the most commonly reported adverse reactions (greater than 10%) are headache and fatigue. ",glecaprevir + pibrentasvir
sign_symptom,headache,0.9999062," in subjects receiving this preparation, the most commonly reported adverse reactions (greater than 10%) are headache and fatigue. ",glecaprevir + pibrentasvir
sign_symptom,fatigue,0.8357225," in subjects receiving this preparation, the most commonly reported adverse reactions (greater than 10%) are headache and fatigue. ",glecaprevir + pibrentasvir
sign_symptom,swelling,0.9997254," redness, irritation, swelling or pain persists or increases of if infection occurs. ",gentian violet
sign_symptom,pain,0.999721," redness, irritation, swelling or pain persists or increases of if infection occurs. ",gentian violet
disease_disorder,infection,0.9988111," redness, irritation, swelling or pain persists or increases of if infection occurs. ",gentian violet
sign_symptom,swelling,0.9999515," itching, redness, swelling or other signs of irritation. ",gentamicin sulfate (topical)
disease_disorder,dermatoses,0.8717206," in patients with dermatoses treated with gentamicin, irritation (erythema and pruritus) had been reported in small number of cases. itching, redness, swelling or other signs of irritation may develop. with the eye/ear drop bacterial and corneal ulcer have developed during treatment with gentamicin. most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non specific conjunctivitis, conjunctival epithelial defects, and conjunctival hyperemia. ",gentamicin sulfate (ophthalmic)
sign_symptom,irritation,0.9998888," in patients with dermatoses treated with gentamicin, irritation (erythema and pruritus) had been reported in small number of cases. itching, redness, swelling or other signs of irritation may develop. with the eye/ear drop bacterial and corneal ulcer have developed during treatment with gentamicin. most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non specific conjunctivitis, conjunctival epithelial defects, and conjunctival hyperemia. ",gentamicin sulfate (ophthalmic)
sign_symptom,swelling,0.99984396," in patients with dermatoses treated with gentamicin, irritation (erythema and pruritus) had been reported in small number of cases. itching, redness, swelling or other signs of irritation may develop. with the eye/ear drop bacterial and corneal ulcer have developed during treatment with gentamicin. most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non specific conjunctivitis, conjunctival epithelial defects, and conjunctival hyperemia. ",gentamicin sulfate (ophthalmic)
sign_symptom,ulcer,0.9993222," in patients with dermatoses treated with gentamicin, irritation (erythema and pruritus) had been reported in small number of cases. itching, redness, swelling or other signs of irritation may develop. with the eye/ear drop bacterial and corneal ulcer have developed during treatment with gentamicin. most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non specific conjunctivitis, conjunctival epithelial defects, and conjunctival hyperemia. ",gentamicin sulfate (ophthalmic)
sign_symptom,adverse reactions,0.9889399," in patients with dermatoses treated with gentamicin, irritation (erythema and pruritus) had been reported in small number of cases. itching, redness, swelling or other signs of irritation may develop. with the eye/ear drop bacterial and corneal ulcer have developed during treatment with gentamicin. most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non specific conjunctivitis, conjunctival epithelial defects, and conjunctival hyperemia. ",gentamicin sulfate (ophthalmic)
sign_symptom,ototoxicity,0.9925541," vestibular damage, reversible nephrotoxicity, auditory ototoxicity may occur. symptoms are dizziness, vertigo, tinnitus, roaring in the ears, rarely hearing loss. adverse renal effects may be also caused, more frequently in patients with a history of renal impairment treated with larger doses than recommended. ",gentamicin sulfate (injection)
disease_disorder,renal,0.85909146," vestibular damage, reversible nephrotoxicity, auditory ototoxicity may occur. symptoms are dizziness, vertigo, tinnitus, roaring in the ears, rarely hearing loss. adverse renal effects may be also caused, more frequently in patients with a history of renal impairment treated with larger doses than recommended. ",gentamicin sulfate (injection)
sign_symptom,effects,0.8557522," vestibular damage, reversible nephrotoxicity, auditory ototoxicity may occur. symptoms are dizziness, vertigo, tinnitus, roaring in the ears, rarely hearing loss. adverse renal effects may be also caused, more frequently in patients with a history of renal impairment treated with larger doses than recommended. ",gentamicin sulfate (injection)
disease_disorder,renal impairment,0.9982746," vestibular damage, reversible nephrotoxicity, auditory ototoxicity may occur. symptoms are dizziness, vertigo, tinnitus, roaring in the ears, rarely hearing loss. adverse renal effects may be also caused, more frequently in patients with a history of renal impairment treated with larger doses than recommended. ",gentamicin sulfate (injection)
sign_symptom,lacrimation,0.97393656," allergic contact dermatitis, transient irritation, burning, stinging, increased redness, lacrimation ",gentamicin + hydrocortisone acetate
sign_symptom,rash,0.988086," the general adverse events include abdominal pain, diarrhea, headache, nausea, rash and vomiting. some side effects have been infrequently reported such as fungal overgrowth in body, dizziness and insomnia, urticaria, pruritis and a maculopapular erythmatous skin rash. ",gemifloxacin
sign_symptom,fungal overgrowth,0.93793195," the general adverse events include abdominal pain, diarrhea, headache, nausea, rash and vomiting. some side effects have been infrequently reported such as fungal overgrowth in body, dizziness and insomnia, urticaria, pruritis and a maculopapular erythmatous skin rash. ",gemifloxacin
sign_symptom,pain,0.9999312," the most frequent adverse effect involves the g. i. tract. abdominal pain and epigastric pain or dyspepsia is common adverse g. i. effects. other adverse reaction includes pruritus, rash, headache, dizziness, blurred vision, painful extremities and rarely myalgia. ",gemfibrozil
sign_symptom,headache,0.748626," the most frequent adverse effect involves the g. i. tract. abdominal pain and epigastric pain or dyspepsia is common adverse g. i. effects. other adverse reaction includes pruritus, rash, headache, dizziness, blurred vision, painful extremities and rarely myalgia. ",gemfibrozil
sign_symptom,blurred,0.9703729," the most frequent adverse effect involves the g. i. tract. abdominal pain and epigastric pain or dyspepsia is common adverse g. i. effects. other adverse reaction includes pruritus, rash, headache, dizziness, blurred vision, painful extremities and rarely myalgia. ",gemfibrozil
sign_symptom,painful,0.99872726," the most frequent adverse effect involves the g. i. tract. abdominal pain and epigastric pain or dyspepsia is common adverse g. i. effects. other adverse reaction includes pruritus, rash, headache, dizziness, blurred vision, painful extremities and rarely myalgia. ",gemfibrozil
sign_symptom,bone marrow suppression,0.99583626," bone marrow suppression as manifested by leukopenia, thrombocytopenia, anaemia and myelosuppression. mild gi effects; rashes; renal impairment, pulmonary toxicity, influenza-like symptoms; interstitial pneumonia, pulmonary oedema. proteinuria, haematuria and haemolytic uraemic syndrome. elevation of serum transaminase. ",gemcitabine
sign_symptom,rash,0.9956735," bone marrow suppression as manifested by leukopenia, thrombocytopenia, anaemia and myelosuppression. mild gi effects; rashes; renal impairment, pulmonary toxicity, influenza-like symptoms; interstitial pneumonia, pulmonary oedema. proteinuria, haematuria and haemolytic uraemic syndrome. elevation of serum transaminase. ",gemcitabine
sign_symptom,haematuria,0.80113834," bone marrow suppression as manifested by leukopenia, thrombocytopenia, anaemia and myelosuppression. mild gi effects; rashes; renal impairment, pulmonary toxicity, influenza-like symptoms; interstitial pneumonia, pulmonary oedema. proteinuria, haematuria and haemolytic uraemic syndrome. elevation of serum transaminase. ",gemcitabine
disease_disorder,uraemic,0.95394087," bone marrow suppression as manifested by leukopenia, thrombocytopenia, anaemia and myelosuppression. mild gi effects; rashes; renal impairment, pulmonary toxicity, influenza-like symptoms; interstitial pneumonia, pulmonary oedema. proteinuria, haematuria and haemolytic uraemic syndrome. elevation of serum transaminase. ",gemcitabine
sign_symptom,protein,0.9814953," common side effects are pruritus, rash, angioedema, urticaria, epistaxis, haematuria, alopecia, dry mouth and skin, nausea, vomiting, anorexia, stomatitis, diarrhoea, nail disorders, asthenia, pyrexia, proteinuria, eye pain, corneal erosion or ulcer, aberrant eyelash growth and elevations in blood creatinine. rarely, pancreatitis, erythema multiforme, toxic epidermal necrolysis, corneal membrane sloughing, ocular ischemia, or ocular haemorrhage. ",gefitinib
sign_symptom,corn,0.9127817," common side effects are pruritus, rash, angioedema, urticaria, epistaxis, haematuria, alopecia, dry mouth and skin, nausea, vomiting, anorexia, stomatitis, diarrhoea, nail disorders, asthenia, pyrexia, proteinuria, eye pain, corneal erosion or ulcer, aberrant eyelash growth and elevations in blood creatinine. rarely, pancreatitis, erythema multiforme, toxic epidermal necrolysis, corneal membrane sloughing, ocular ischemia, or ocular haemorrhage. ",gefitinib
sign_symptom,erosion,0.8667908," common side effects are pruritus, rash, angioedema, urticaria, epistaxis, haematuria, alopecia, dry mouth and skin, nausea, vomiting, anorexia, stomatitis, diarrhoea, nail disorders, asthenia, pyrexia, proteinuria, eye pain, corneal erosion or ulcer, aberrant eyelash growth and elevations in blood creatinine. rarely, pancreatitis, erythema multiforme, toxic epidermal necrolysis, corneal membrane sloughing, ocular ischemia, or ocular haemorrhage. ",gefitinib
sign_symptom,redness,0.87524396," mild burning, chemosis, redness may occur. ",gatifloxacin + dexamethasone
medication,gati,0.9570676," gatifloxacin is generally well tolerated. the most common side effects that can occur while taking this drug are usually mild and include nausea, vomiting, stomach pain, diarrhea, dizziness,and headache . ",gatifloxacin (oral)
sign_symptom,adverse events,0.99960876," the most frequently reported adverse events in the overall study population were conjunctival irritation, increased lacrimation etc. ",gatifloxacin (ophthalmic)
sign_symptom,irritation,0.9995053," the most frequently reported adverse events in the overall study population were conjunctival irritation, increased lacrimation etc. ",gatifloxacin (ophthalmic)
sign_symptom,lacrimation,0.99988335," the most frequently reported adverse events in the overall study population were conjunctival irritation, increased lacrimation etc. ",gatifloxacin (ophthalmic)
sign_symptom,adverse reactions,0.99952704," most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%). ",ganciclovir (ophthalmic)
sign_symptom,blurred vision,0.99989694," most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%). ",ganciclovir (ophthalmic)
sign_symptom,irritation,0.9999087," most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%). ",ganciclovir (ophthalmic)
sign_symptom,hyperemia,0.79220116," most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%). ",ganciclovir (ophthalmic)
sign_symptom,adverse reactions,0.96268195," most common adverse reactions (incidence &gt;2%) are: headache, vasodilatation, taste perversion, dizziness, nausea and paresthesia. ",gadoversetamide
sign_symptom,nausea,0.99915993," most common adverse reactions (incidence &gt;2%) are: headache, vasodilatation, taste perversion, dizziness, nausea and paresthesia. ",gadoversetamide
sign_symptom,hypersensitivity reactions,0.9990508," nephrogenic systemic fibrosis, hypersensitivity reactions ",gadodiamide
sign_symptom,dry mouth,0.9952936," fatigue, dizziness, ataxia, weight gain, peripheral edema, dry mouth and somnolence may occur. ",gabapentin
medication,fusidic acid,0.9845743," fusidic acid has been reported to cause mild irritation at the application site, but did not usually require discontinuation of therapy. reports of hypersensitivity reactions have been rare. adverse effects are generally local and include: dryness, itching, burning, local irritation, striae, skin atrophy, atrophy of subcutaneous tissues, telangiectasia, hypertrichosis, change in pigmentation and secondary infection. if applied to the face, acne rosacea or perioral dermatitis can occur. ",fusidic acid + hydrocortisone
sign_symptom,irritation,0.99994814," fusidic acid has been reported to cause mild irritation at the application site, but did not usually require discontinuation of therapy. reports of hypersensitivity reactions have been rare. adverse effects are generally local and include: dryness, itching, burning, local irritation, striae, skin atrophy, atrophy of subcutaneous tissues, telangiectasia, hypertrichosis, change in pigmentation and secondary infection. if applied to the face, acne rosacea or perioral dermatitis can occur. ",fusidic acid + hydrocortisone
sign_symptom,hypersensitivity reactions,0.9996502," fusidic acid has been reported to cause mild irritation at the application site, but did not usually require discontinuation of therapy. reports of hypersensitivity reactions have been rare. adverse effects are generally local and include: dryness, itching, burning, local irritation, striae, skin atrophy, atrophy of subcutaneous tissues, telangiectasia, hypertrichosis, change in pigmentation and secondary infection. if applied to the face, acne rosacea or perioral dermatitis can occur. ",fusidic acid + hydrocortisone
sign_symptom,atrop,0.7526677," fusidic acid has been reported to cause mild irritation at the application site, but did not usually require discontinuation of therapy. reports of hypersensitivity reactions have been rare. adverse effects are generally local and include: dryness, itching, burning, local irritation, striae, skin atrophy, atrophy of subcutaneous tissues, telangiectasia, hypertrichosis, change in pigmentation and secondary infection. if applied to the face, acne rosacea or perioral dermatitis can occur. ",fusidic acid + hydrocortisone
sign_symptom,in pigmentation,0.79121804," fusidic acid has been reported to cause mild irritation at the application site, but did not usually require discontinuation of therapy. reports of hypersensitivity reactions have been rare. adverse effects are generally local and include: dryness, itching, burning, local irritation, striae, skin atrophy, atrophy of subcutaneous tissues, telangiectasia, hypertrichosis, change in pigmentation and secondary infection. if applied to the face, acne rosacea or perioral dermatitis can occur. ",fusidic acid + hydrocortisone
sign_symptom,redness,0.843678," possible side effects are allergic reactions, headache, skin rash, redness or itching, unusual tiredness or weakness, yellow eyes or skin. ",fusidic acid + betamethasone
sign_symptom,tired,0.9030251," possible side effects are allergic reactions, headache, skin rash, redness or itching, unusual tiredness or weakness, yellow eyes or skin. ",fusidic acid + betamethasone
sign_symptom,flat,0.857664,"  
 gastrointestinal: abdominal distention, abdominal pain, stomach discomfort, chapped lips, flatulence, retching, dry tongue 
 general disorders: irritability, pain 
 infections: pneumonia, sinusitis, tracheostomy infection, upper respiratory tract infection, urinary tract infection 
 investigations: heart rate increase 
 metabolism and nutrition: dehydration 
 nervous system: headache, convulsion, dysgeusia, nystagmus 
 psychiatric: agitation, restlessness, abnormal behavior, aggression, crying, impulse control disorder, moaning, mood altered 
 respiratory: increased viscosity of bronchial secretion, nasal congestion, nasal dryness 
 skin: dry skin, pruritus, rash 
 vascular: pallor 
  ",glycopyrronium bromide (oral solution)
sign_symptom,dry tongue,0.86972034,"  
 gastrointestinal: abdominal distention, abdominal pain, stomach discomfort, chapped lips, flatulence, retching, dry tongue 
 general disorders: irritability, pain 
 infections: pneumonia, sinusitis, tracheostomy infection, upper respiratory tract infection, urinary tract infection 
 investigations: heart rate increase 
 metabolism and nutrition: dehydration 
 nervous system: headache, convulsion, dysgeusia, nystagmus 
 psychiatric: agitation, restlessness, abnormal behavior, aggression, crying, impulse control disorder, moaning, mood altered 
 respiratory: increased viscosity of bronchial secretion, nasal congestion, nasal dryness 
 skin: dry skin, pruritus, rash 
 vascular: pallor 
  ",glycopyrronium bromide (oral solution)
sign_symptom,pain,0.72652745,"  
 gastrointestinal: abdominal distention, abdominal pain, stomach discomfort, chapped lips, flatulence, retching, dry tongue 
 general disorders: irritability, pain 
 infections: pneumonia, sinusitis, tracheostomy infection, upper respiratory tract infection, urinary tract infection 
 investigations: heart rate increase 
 metabolism and nutrition: dehydration 
 nervous system: headache, convulsion, dysgeusia, nystagmus 
 psychiatric: agitation, restlessness, abnormal behavior, aggression, crying, impulse control disorder, moaning, mood altered 
 respiratory: increased viscosity of bronchial secretion, nasal congestion, nasal dryness 
 skin: dry skin, pruritus, rash 
 vascular: pallor 
  ",glycopyrronium bromide (oral solution)
sign_symptom,restless,0.9653229,"  
 gastrointestinal: abdominal distention, abdominal pain, stomach discomfort, chapped lips, flatulence, retching, dry tongue 
 general disorders: irritability, pain 
 infections: pneumonia, sinusitis, tracheostomy infection, upper respiratory tract infection, urinary tract infection 
 investigations: heart rate increase 
 metabolism and nutrition: dehydration 
 nervous system: headache, convulsion, dysgeusia, nystagmus 
 psychiatric: agitation, restlessness, abnormal behavior, aggression, crying, impulse control disorder, moaning, mood altered 
 respiratory: increased viscosity of bronchial secretion, nasal congestion, nasal dryness 
 skin: dry skin, pruritus, rash 
 vascular: pallor 
  ",glycopyrronium bromide (oral solution)
sign_symptom,abnormal behavior,0.9007317,"  
 gastrointestinal: abdominal distention, abdominal pain, stomach discomfort, chapped lips, flatulence, retching, dry tongue 
 general disorders: irritability, pain 
 infections: pneumonia, sinusitis, tracheostomy infection, upper respiratory tract infection, urinary tract infection 
 investigations: heart rate increase 
 metabolism and nutrition: dehydration 
 nervous system: headache, convulsion, dysgeusia, nystagmus 
 psychiatric: agitation, restlessness, abnormal behavior, aggression, crying, impulse control disorder, moaning, mood altered 
 respiratory: increased viscosity of bronchial secretion, nasal congestion, nasal dryness 
 skin: dry skin, pruritus, rash 
 vascular: pallor 
  ",glycopyrronium bromide (oral solution)
medication,antimuscarinics,0.9922892," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,bradycardia,0.94665956," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,urgency,0.7428167," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,photo,0.71285695," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,flushing,0.9984849," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,confusion,0.9998834," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,vomiting,0.99890935," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,adverse reactions,0.96711785," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,allergic reactions,0.9983721," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,drug idiosyncrasies,0.96640503," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,loss,0.932334," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,taste,0.97154766," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,blurred vision,0.9767537," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,hyper,0.9982293," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
sign_symptom,pain,0.9994735," side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. these include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. the following reported adverse reactions are extensions of glycopyrronium bromides fundamental pharmacological actions: 
 
 cardiovascular: tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged qtc interval. 
 dermatological: flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. 
 gastrointestinal: nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. 
 genitourinary: urinary hesitancy and retention, impotence. 
 ocular: blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. 
 nervous system: inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. 
 pregnancy and perinatal: suppression of lactation. 
 respiratory system: respiratory arrest. 
 general: hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. injection site reactions including pruritus, oedema, erythema, pain have been reported rarely. 
  ",glycopyrronium bromide (injection)
medication,glycine,0.9674511," large intravenous doses of glycine are known to cause nausea and salivation. other consequences of systemic absorption of glycine include electrolyte loss, diuresis, edaema, thirst, dehydration, cardiovascular and pulmonary disorders. ",glycine
sign_symptom,nausea,0.99987817," large intravenous doses of glycine are known to cause nausea and salivation. other consequences of systemic absorption of glycine include electrolyte loss, diuresis, edaema, thirst, dehydration, cardiovascular and pulmonary disorders. ",glycine
sign_symptom,saliva,0.99941945," large intravenous doses of glycine are known to cause nausea and salivation. other consequences of systemic absorption of glycine include electrolyte loss, diuresis, edaema, thirst, dehydration, cardiovascular and pulmonary disorders. ",glycine
sign_symptom,sticky sensation,0.9673959," occasionally mild, transient burning or sticky sensation and very rarely irritation or hypersensitivity reactions reported. blurred vision after application may occur. ",glycerol + hypromellose + polyethylene glycol 400
sign_symptom,irritation,0.9999316," occasionally mild, transient burning or sticky sensation and very rarely irritation or hypersensitivity reactions reported. blurred vision after application may occur. ",glycerol + hypromellose + polyethylene glycol 400
sign_symptom,hypersensitivity reactions,0.9998884," occasionally mild, transient burning or sticky sensation and very rarely irritation or hypersensitivity reactions reported. blurred vision after application may occur. ",glycerol + hypromellose + polyethylene glycol 400
sign_symptom,blurred vision,0.99992007," occasionally mild, transient burning or sticky sensation and very rarely irritation or hypersensitivity reactions reported. blurred vision after application may occur. ",glycerol + hypromellose + polyethylene glycol 400
sign_symptom,side effects,0.95508873," no common side effects have been reported with this preparation. few allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); new or worsening skin irritation may occur. ",glycerol
sign_symptom,allergic reactions,0.9999135," no common side effects have been reported with this preparation. few allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); new or worsening skin irritation may occur. ",glycerol
sign_symptom,rash,0.99242944," no common side effects have been reported with this preparation. few allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); new or worsening skin irritation may occur. ",glycerol
sign_symptom,difficulty breathing,0.9138957," no common side effects have been reported with this preparation. few allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); new or worsening skin irritation may occur. ",glycerol
sign_symptom,tightness,0.9943099," no common side effects have been reported with this preparation. few allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); new or worsening skin irritation may occur. ",glycerol
sign_symptom,swelling,0.9977196," no common side effects have been reported with this preparation. few allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); new or worsening skin irritation may occur. ",glycerol
sign_symptom,irritation,0.9997671," no common side effects have been reported with this preparation. few allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); new or worsening skin irritation may occur. ",glycerol
sign_symptom,watering of the eye,0.952828," possible side effects include: temporary stinging or burning; redness, itching and watering of the eye ",glycerin + hypromellose + polyethylene glycol + tetrahydrozoline + zinc sulfate
sign_symptom,discomfort,0.9985506, when glycerin used rectally may cause rectal discomfort or a burning sensation. ,glycerin
sign_symptom,shivering,0.99704945," intralipid may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). transient increases in liver enzymes during intravenous nutrition have also been reported. as with all hypertonic solutions for infusion, thrombophlebitis may occur if peripheral veins are used. reports of other undesirable effects in conjunction with intralipid infusions are extremely rare; less than one adverse event per million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haemolysis, reticulocytosis, abdominal pain, headache, tiredness and priapism have been reported.  fat overload syndrome: an impaired capacity to eliminate intralipid (the fat component in this parenteral nutrition) may lead to the fat overload syndrome as a result of over-dosage, but also at recommended rates of infusion in association with a sudden change in the patients clinical condition, such as renal function impairment or infection. the fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly, splenomegaly, anaemia, leucopenia, thrombocytopenia, blood coagulation disorders and coma. all symptoms are usually reversible if the infusion is discontinued. ",glucose 19% + vamin 18 novum + intralipid 20%
sign_symptom,chills,0.99883544," intralipid may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). transient increases in liver enzymes during intravenous nutrition have also been reported. as with all hypertonic solutions for infusion, thrombophlebitis may occur if peripheral veins are used. reports of other undesirable effects in conjunction with intralipid infusions are extremely rare; less than one adverse event per million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haemolysis, reticulocytosis, abdominal pain, headache, tiredness and priapism have been reported.  fat overload syndrome: an impaired capacity to eliminate intralipid (the fat component in this parenteral nutrition) may lead to the fat overload syndrome as a result of over-dosage, but also at recommended rates of infusion in association with a sudden change in the patients clinical condition, such as renal function impairment or infection. the fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly, splenomegaly, anaemia, leucopenia, thrombocytopenia, blood coagulation disorders and coma. all symptoms are usually reversible if the infusion is discontinued. ",glucose 19% + vamin 18 novum + intralipid 20%
sign_symptom,nausea / vomiting,0.8904214," intralipid may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). transient increases in liver enzymes during intravenous nutrition have also been reported. as with all hypertonic solutions for infusion, thrombophlebitis may occur if peripheral veins are used. reports of other undesirable effects in conjunction with intralipid infusions are extremely rare; less than one adverse event per million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haemolysis, reticulocytosis, abdominal pain, headache, tiredness and priapism have been reported.  fat overload syndrome: an impaired capacity to eliminate intralipid (the fat component in this parenteral nutrition) may lead to the fat overload syndrome as a result of over-dosage, but also at recommended rates of infusion in association with a sudden change in the patients clinical condition, such as renal function impairment or infection. the fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly, splenomegaly, anaemia, leucopenia, thrombocytopenia, blood coagulation disorders and coma. all symptoms are usually reversible if the infusion is discontinued. ",glucose 19% + vamin 18 novum + intralipid 20%
sign_symptom,hyper,0.99987483," intralipid may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). transient increases in liver enzymes during intravenous nutrition have also been reported. as with all hypertonic solutions for infusion, thrombophlebitis may occur if peripheral veins are used. reports of other undesirable effects in conjunction with intralipid infusions are extremely rare; less than one adverse event per million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haemolysis, reticulocytosis, abdominal pain, headache, tiredness and priapism have been reported.  fat overload syndrome: an impaired capacity to eliminate intralipid (the fat component in this parenteral nutrition) may lead to the fat overload syndrome as a result of over-dosage, but also at recommended rates of infusion in association with a sudden change in the patients clinical condition, such as renal function impairment or infection. the fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly, splenomegaly, anaemia, leucopenia, thrombocytopenia, blood coagulation disorders and coma. all symptoms are usually reversible if the infusion is discontinued. ",glucose 19% + vamin 18 novum + intralipid 20%
sign_symptom,respiratory symptoms,0.99962866," intralipid may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). transient increases in liver enzymes during intravenous nutrition have also been reported. as with all hypertonic solutions for infusion, thrombophlebitis may occur if peripheral veins are used. reports of other undesirable effects in conjunction with intralipid infusions are extremely rare; less than one adverse event per million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haemolysis, reticulocytosis, abdominal pain, headache, tiredness and priapism have been reported.  fat overload syndrome: an impaired capacity to eliminate intralipid (the fat component in this parenteral nutrition) may lead to the fat overload syndrome as a result of over-dosage, but also at recommended rates of infusion in association with a sudden change in the patients clinical condition, such as renal function impairment or infection. the fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly, splenomegaly, anaemia, leucopenia, thrombocytopenia, blood coagulation disorders and coma. all symptoms are usually reversible if the infusion is discontinued. ",glucose 19% + vamin 18 novum + intralipid 20%
sign_symptom,pain,0.836787," intralipid may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). transient increases in liver enzymes during intravenous nutrition have also been reported. as with all hypertonic solutions for infusion, thrombophlebitis may occur if peripheral veins are used. reports of other undesirable effects in conjunction with intralipid infusions are extremely rare; less than one adverse event per million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haemolysis, reticulocytosis, abdominal pain, headache, tiredness and priapism have been reported.  fat overload syndrome: an impaired capacity to eliminate intralipid (the fat component in this parenteral nutrition) may lead to the fat overload syndrome as a result of over-dosage, but also at recommended rates of infusion in association with a sudden change in the patients clinical condition, such as renal function impairment or infection. the fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly, splenomegaly, anaemia, leucopenia, thrombocytopenia, blood coagulation disorders and coma. all symptoms are usually reversible if the infusion is discontinued. ",glucose 19% + vamin 18 novum + intralipid 20%
sign_symptom,headache,0.99360293," intralipid may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). transient increases in liver enzymes during intravenous nutrition have also been reported. as with all hypertonic solutions for infusion, thrombophlebitis may occur if peripheral veins are used. reports of other undesirable effects in conjunction with intralipid infusions are extremely rare; less than one adverse event per million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haemolysis, reticulocytosis, abdominal pain, headache, tiredness and priapism have been reported.  fat overload syndrome: an impaired capacity to eliminate intralipid (the fat component in this parenteral nutrition) may lead to the fat overload syndrome as a result of over-dosage, but also at recommended rates of infusion in association with a sudden change in the patients clinical condition, such as renal function impairment or infection. the fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly, splenomegaly, anaemia, leucopenia, thrombocytopenia, blood coagulation disorders and coma. all symptoms are usually reversible if the infusion is discontinued. ",glucose 19% + vamin 18 novum + intralipid 20%
sign_symptom,tiredness,0.9997701," intralipid may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). transient increases in liver enzymes during intravenous nutrition have also been reported. as with all hypertonic solutions for infusion, thrombophlebitis may occur if peripheral veins are used. reports of other undesirable effects in conjunction with intralipid infusions are extremely rare; less than one adverse event per million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haemolysis, reticulocytosis, abdominal pain, headache, tiredness and priapism have been reported.  fat overload syndrome: an impaired capacity to eliminate intralipid (the fat component in this parenteral nutrition) may lead to the fat overload syndrome as a result of over-dosage, but also at recommended rates of infusion in association with a sudden change in the patients clinical condition, such as renal function impairment or infection. the fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly, splenomegaly, anaemia, leucopenia, thrombocytopenia, blood coagulation disorders and coma. all symptoms are usually reversible if the infusion is discontinued. ",glucose 19% + vamin 18 novum + intralipid 20%
sign_symptom,priapism,0.9994162," intralipid may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). transient increases in liver enzymes during intravenous nutrition have also been reported. as with all hypertonic solutions for infusion, thrombophlebitis may occur if peripheral veins are used. reports of other undesirable effects in conjunction with intralipid infusions are extremely rare; less than one adverse event per million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haemolysis, reticulocytosis, abdominal pain, headache, tiredness and priapism have been reported.  fat overload syndrome: an impaired capacity to eliminate intralipid (the fat component in this parenteral nutrition) may lead to the fat overload syndrome as a result of over-dosage, but also at recommended rates of infusion in association with a sudden change in the patients clinical condition, such as renal function impairment or infection. the fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly, splenomegaly, anaemia, leucopenia, thrombocytopenia, blood coagulation disorders and coma. all symptoms are usually reversible if the infusion is discontinued. ",glucose 19% + vamin 18 novum + intralipid 20%
sign_symptom,shivering,0.9964992," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,chills,0.9994811," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,nausea /,0.9203385," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,vomiting,0.9971244," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,hypersensitivity reactions,0.9996151," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,respiratory symptoms,0.99507266," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,hyper,0.999964," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,/ hypotension,0.9401477," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,pain,0.9998902," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,headache,0.9981962," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,nausea,0.8814692," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,tiredness,0.99949825," the infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence&lt;1 %). transient increases in liver enzymes during intravenous nutrition have also been reported. reports of other undesirable effects in conjunction with the included components are extremely rare. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (e.g. tachypnoea) and hyper/hypotension have been described. haernolvsis. reticulocytosis, abdominal pain, headache, nausea, vomiting, tiredness and priapism have been reported. ",glucose 11% + vamin 18 novum + intralipid 20%
sign_symptom,adverse effect,0.99989396," no serious adverse effect has been reported. nausea, vomiting, diarrhea, epigastria pain, headache, skin rashes &amp; intense yellow coloring of urine may be occurred. ",glucosamine sulfate + diacerein
sign_symptom,epigastria,0.82203007," no serious adverse effect has been reported. nausea, vomiting, diarrhea, epigastria pain, headache, skin rashes &amp; intense yellow coloring of urine may be occurred. ",glucosamine sulfate + diacerein
sign_symptom,rash,0.99991286," no serious adverse effect has been reported. nausea, vomiting, diarrhea, epigastria pain, headache, skin rashes &amp; intense yellow coloring of urine may be occurred. ",glucosamine sulfate + diacerein
sign_symptom,coloring of,0.9709095," no serious adverse effect has been reported. nausea, vomiting, diarrhea, epigastria pain, headache, skin rashes &amp; intense yellow coloring of urine may be occurred. ",glucosamine sulfate + diacerein
medication,camphor,0.9956746, there are no known systemic side effects unless people have an allergy or skin sensitivity to camphor or one of the inactive ingredients. ,glucosamine sulfate + chondroitin + camphor + peppermint oil
medication,sulfate,0.9488851," safety studies with glucosamine sulfate &amp; chondroitin sulfate show no demonstrable side effects. rarely occurring side effects (such as, mild &amp; reversible intestinal flatulence) are almost like placebo. ",glucosamine sulfate + chondroitin
sign_symptom,flatulence,0.8491511, safety studies with glucosamine show no demonstrable toxicity. rarely occurring side effects like mild &amp; reversible intestinal flatulence are almost like placebo. ,glucosamine hydrochloride
sign_symptom,diarrhea,0.9962091," the most common side effects of glipizide &amp; metformin are hypoglycemia, diarrhea, nausea/vomiting, abdominal pain, headache, musculoskeletal pain etc. ",glipizide + metformin hydrochloride
sign_symptom,nausea,0.9999342," the most common side effects of glipizide &amp; metformin are hypoglycemia, diarrhea, nausea/vomiting, abdominal pain, headache, musculoskeletal pain etc. ",glipizide + metformin hydrochloride
sign_symptom,vomiting,0.99871933," the most common side effects of glipizide &amp; metformin are hypoglycemia, diarrhea, nausea/vomiting, abdominal pain, headache, musculoskeletal pain etc. ",glipizide + metformin hydrochloride
sign_symptom,pain,0.9998417," the most common side effects of glipizide &amp; metformin are hypoglycemia, diarrhea, nausea/vomiting, abdominal pain, headache, musculoskeletal pain etc. ",glipizide + metformin hydrochloride
sign_symptom,headache,0.9995053," the most common side effects of glipizide &amp; metformin are hypoglycemia, diarrhea, nausea/vomiting, abdominal pain, headache, musculoskeletal pain etc. ",glipizide + metformin hydrochloride
sign_symptom,side effects,0.9665803," the majority of side effects have been dose related, transient, and responded to dose reduction or withdrawal of the medication.   gastrointestinal : gastrointestinal complaints were reported with the following approximate incidences like nausea, diarrhoea, constipation and gastralgia. they appear to be dose related and usually disappear on division or reduction of dosage. cholestatic jaundice may occur rarely with these kind of drugs and glipizide should be discontinued if this occurs.   dermatological : allergic skin reactions including erythema, morbilliform or maculopapular eruption, urticaria, pruritus and eczema have been reported. they frequently disappear with continued therapy. however, if they persist, the drug should be discontinued.   haematologic : leucopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas.   metabolic : hepatic porphyria and disulphiram like reactions have been reported with sulphonylurea.   endocrine reactions : cases of hyponatraemia and the syndrome of inappropriate antidiuretic hormone (siadh) secretion have been reported with this and other sulphonylureas.   miscellaneous : dizziness, drowsiness and headache have been reported in patients treated with glipizide. they are usually transient and seldom require discontinuation of therapy. ",glipizide
sign_symptom,complaints,0.9966061," the majority of side effects have been dose related, transient, and responded to dose reduction or withdrawal of the medication.   gastrointestinal : gastrointestinal complaints were reported with the following approximate incidences like nausea, diarrhoea, constipation and gastralgia. they appear to be dose related and usually disappear on division or reduction of dosage. cholestatic jaundice may occur rarely with these kind of drugs and glipizide should be discontinued if this occurs.   dermatological : allergic skin reactions including erythema, morbilliform or maculopapular eruption, urticaria, pruritus and eczema have been reported. they frequently disappear with continued therapy. however, if they persist, the drug should be discontinued.   haematologic : leucopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas.   metabolic : hepatic porphyria and disulphiram like reactions have been reported with sulphonylurea.   endocrine reactions : cases of hyponatraemia and the syndrome of inappropriate antidiuretic hormone (siadh) secretion have been reported with this and other sulphonylureas.   miscellaneous : dizziness, drowsiness and headache have been reported in patients treated with glipizide. they are usually transient and seldom require discontinuation of therapy. ",glipizide
sign_symptom,consti,0.9977038," the majority of side effects have been dose related, transient, and responded to dose reduction or withdrawal of the medication.   gastrointestinal : gastrointestinal complaints were reported with the following approximate incidences like nausea, diarrhoea, constipation and gastralgia. they appear to be dose related and usually disappear on division or reduction of dosage. cholestatic jaundice may occur rarely with these kind of drugs and glipizide should be discontinued if this occurs.   dermatological : allergic skin reactions including erythema, morbilliform or maculopapular eruption, urticaria, pruritus and eczema have been reported. they frequently disappear with continued therapy. however, if they persist, the drug should be discontinued.   haematologic : leucopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas.   metabolic : hepatic porphyria and disulphiram like reactions have been reported with sulphonylurea.   endocrine reactions : cases of hyponatraemia and the syndrome of inappropriate antidiuretic hormone (siadh) secretion have been reported with this and other sulphonylureas.   miscellaneous : dizziness, drowsiness and headache have been reported in patients treated with glipizide. they are usually transient and seldom require discontinuation of therapy. ",glipizide
sign_symptom,allergic,0.9999106," the majority of side effects have been dose related, transient, and responded to dose reduction or withdrawal of the medication.   gastrointestinal : gastrointestinal complaints were reported with the following approximate incidences like nausea, diarrhoea, constipation and gastralgia. they appear to be dose related and usually disappear on division or reduction of dosage. cholestatic jaundice may occur rarely with these kind of drugs and glipizide should be discontinued if this occurs.   dermatological : allergic skin reactions including erythema, morbilliform or maculopapular eruption, urticaria, pruritus and eczema have been reported. they frequently disappear with continued therapy. however, if they persist, the drug should be discontinued.   haematologic : leucopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas.   metabolic : hepatic porphyria and disulphiram like reactions have been reported with sulphonylurea.   endocrine reactions : cases of hyponatraemia and the syndrome of inappropriate antidiuretic hormone (siadh) secretion have been reported with this and other sulphonylureas.   miscellaneous : dizziness, drowsiness and headache have been reported in patients treated with glipizide. they are usually transient and seldom require discontinuation of therapy. ",glipizide
sign_symptom,skin reactions,0.9984906," the majority of side effects have been dose related, transient, and responded to dose reduction or withdrawal of the medication.   gastrointestinal : gastrointestinal complaints were reported with the following approximate incidences like nausea, diarrhoea, constipation and gastralgia. they appear to be dose related and usually disappear on division or reduction of dosage. cholestatic jaundice may occur rarely with these kind of drugs and glipizide should be discontinued if this occurs.   dermatological : allergic skin reactions including erythema, morbilliform or maculopapular eruption, urticaria, pruritus and eczema have been reported. they frequently disappear with continued therapy. however, if they persist, the drug should be discontinued.   haematologic : leucopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas.   metabolic : hepatic porphyria and disulphiram like reactions have been reported with sulphonylurea.   endocrine reactions : cases of hyponatraemia and the syndrome of inappropriate antidiuretic hormone (siadh) secretion have been reported with this and other sulphonylureas.   miscellaneous : dizziness, drowsiness and headache have been reported in patients treated with glipizide. they are usually transient and seldom require discontinuation of therapy. ",glipizide
sign_symptom,morbill,0.7152809," the majority of side effects have been dose related, transient, and responded to dose reduction or withdrawal of the medication.   gastrointestinal : gastrointestinal complaints were reported with the following approximate incidences like nausea, diarrhoea, constipation and gastralgia. they appear to be dose related and usually disappear on division or reduction of dosage. cholestatic jaundice may occur rarely with these kind of drugs and glipizide should be discontinued if this occurs.   dermatological : allergic skin reactions including erythema, morbilliform or maculopapular eruption, urticaria, pruritus and eczema have been reported. they frequently disappear with continued therapy. however, if they persist, the drug should be discontinued.   haematologic : leucopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas.   metabolic : hepatic porphyria and disulphiram like reactions have been reported with sulphonylurea.   endocrine reactions : cases of hyponatraemia and the syndrome of inappropriate antidiuretic hormone (siadh) secretion have been reported with this and other sulphonylureas.   miscellaneous : dizziness, drowsiness and headache have been reported in patients treated with glipizide. they are usually transient and seldom require discontinuation of therapy. ",glipizide
sign_symptom,urticaria,0.82306415," the majority of side effects have been dose related, transient, and responded to dose reduction or withdrawal of the medication.   gastrointestinal : gastrointestinal complaints were reported with the following approximate incidences like nausea, diarrhoea, constipation and gastralgia. they appear to be dose related and usually disappear on division or reduction of dosage. cholestatic jaundice may occur rarely with these kind of drugs and glipizide should be discontinued if this occurs.   dermatological : allergic skin reactions including erythema, morbilliform or maculopapular eruption, urticaria, pruritus and eczema have been reported. they frequently disappear with continued therapy. however, if they persist, the drug should be discontinued.   haematologic : leucopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas.   metabolic : hepatic porphyria and disulphiram like reactions have been reported with sulphonylurea.   endocrine reactions : cases of hyponatraemia and the syndrome of inappropriate antidiuretic hormone (siadh) secretion have been reported with this and other sulphonylureas.   miscellaneous : dizziness, drowsiness and headache have been reported in patients treated with glipizide. they are usually transient and seldom require discontinuation of therapy. ",glipizide
sign_symptom,pruritus and,0.8823425," the majority of side effects have been dose related, transient, and responded to dose reduction or withdrawal of the medication.   gastrointestinal : gastrointestinal complaints were reported with the following approximate incidences like nausea, diarrhoea, constipation and gastralgia. they appear to be dose related and usually disappear on division or reduction of dosage. cholestatic jaundice may occur rarely with these kind of drugs and glipizide should be discontinued if this occurs.   dermatological : allergic skin reactions including erythema, morbilliform or maculopapular eruption, urticaria, pruritus and eczema have been reported. they frequently disappear with continued therapy. however, if they persist, the drug should be discontinued.   haematologic : leucopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas.   metabolic : hepatic porphyria and disulphiram like reactions have been reported with sulphonylurea.   endocrine reactions : cases of hyponatraemia and the syndrome of inappropriate antidiuretic hormone (siadh) secretion have been reported with this and other sulphonylureas.   miscellaneous : dizziness, drowsiness and headache have been reported in patients treated with glipizide. they are usually transient and seldom require discontinuation of therapy. ",glipizide
sign_symptom,eczema,0.9949154," the majority of side effects have been dose related, transient, and responded to dose reduction or withdrawal of the medication.   gastrointestinal : gastrointestinal complaints were reported with the following approximate incidences like nausea, diarrhoea, constipation and gastralgia. they appear to be dose related and usually disappear on division or reduction of dosage. cholestatic jaundice may occur rarely with these kind of drugs and glipizide should be discontinued if this occurs.   dermatological : allergic skin reactions including erythema, morbilliform or maculopapular eruption, urticaria, pruritus and eczema have been reported. they frequently disappear with continued therapy. however, if they persist, the drug should be discontinued.   haematologic : leucopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas.   metabolic : hepatic porphyria and disulphiram like reactions have been reported with sulphonylurea.   endocrine reactions : cases of hyponatraemia and the syndrome of inappropriate antidiuretic hormone (siadh) secretion have been reported with this and other sulphonylureas.   miscellaneous : dizziness, drowsiness and headache have been reported in patients treated with glipizide. they are usually transient and seldom require discontinuation of therapy. ",glipizide
sign_symptom,anaemia,0.9834057," the majority of side effects have been dose related, transient, and responded to dose reduction or withdrawal of the medication.   gastrointestinal : gastrointestinal complaints were reported with the following approximate incidences like nausea, diarrhoea, constipation and gastralgia. they appear to be dose related and usually disappear on division or reduction of dosage. cholestatic jaundice may occur rarely with these kind of drugs and glipizide should be discontinued if this occurs.   dermatological : allergic skin reactions including erythema, morbilliform or maculopapular eruption, urticaria, pruritus and eczema have been reported. they frequently disappear with continued therapy. however, if they persist, the drug should be discontinued.   haematologic : leucopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas.   metabolic : hepatic porphyria and disulphiram like reactions have been reported with sulphonylurea.   endocrine reactions : cases of hyponatraemia and the syndrome of inappropriate antidiuretic hormone (siadh) secretion have been reported with this and other sulphonylureas.   miscellaneous : dizziness, drowsiness and headache have been reported in patients treated with glipizide. they are usually transient and seldom require discontinuation of therapy. ",glipizide
sign_symptom,headache,0.9999242," the majority of side effects have been dose related, transient, and responded to dose reduction or withdrawal of the medication.   gastrointestinal : gastrointestinal complaints were reported with the following approximate incidences like nausea, diarrhoea, constipation and gastralgia. they appear to be dose related and usually disappear on division or reduction of dosage. cholestatic jaundice may occur rarely with these kind of drugs and glipizide should be discontinued if this occurs.   dermatological : allergic skin reactions including erythema, morbilliform or maculopapular eruption, urticaria, pruritus and eczema have been reported. they frequently disappear with continued therapy. however, if they persist, the drug should be discontinued.   haematologic : leucopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia have been reported with sulphonylureas.   metabolic : hepatic porphyria and disulphiram like reactions have been reported with sulphonylurea.   endocrine reactions : cases of hyponatraemia and the syndrome of inappropriate antidiuretic hormone (siadh) secretion have been reported with this and other sulphonylureas.   miscellaneous : dizziness, drowsiness and headache have been reported in patients treated with glipizide. they are usually transient and seldom require discontinuation of therapy. ",glipizide
sign_symptom,visual impairment,0.9017801,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,disorders,0.95942205,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,symptoms,0.90367967,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,nausea,0.9904316,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,vomiting,0.99803287,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,sensations of pressure,0.99969226,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,fulness,0.8213075,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,pain,0.9998982,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,diarr,0.75194144,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,choles,0.9695878,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
disease_disorder,agranu,0.7718483,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,allergic,0.9587789,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,allergic reactions,0.95354205,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,rash,0.9998791,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,reactions,0.9294137,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,vasculitis,0.9229065,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,hypersensitivity,0.99543667,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,weight gain,0.9992221,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,loss of appetite,0.99985003,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
sign_symptom,metallic taste,0.9837619,"  for glimepiride : metabolism and nutrition disorders- 
 
 as a result of the blood-glucose-lowering action of glimepiride, hypoglycaemia which may also be prolonged. 
 the clinical picture of a severe hypoglycaemic attack may resemble that of a stroke. 
 
eye disorders: especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels. the cause is a temporary alteration in the turgidity and hence the refractive index of the lens, this being dependent on blood glucose level.  gastrointestinal disorders- 
 
 occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the epigastrium, abdominal pain and diarrhea may occur. 
 in isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice, which may progress to life-threatening liver failure. 
 dysgeusia (frequency not known) 
 
blood and lymphatic system disorders- 
 
 changes in the blood picture may occur: rarely, thrombocytopenia and, in isolated cases, leucopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. cases of severe thrombocytopenia with platelet count less than 10,000/l and thrombocytopenic purpura have been reported in post-marketing experience (frequency not known). 
 
skin and subcutaneous tissue disorders: alopecia (frequency not known)  general disorders- 
 
 occasionally, allergic or pseudo allergic reactions may occur, e.g. in the form of itching, urticaria or rashes. such mild reactions may develop into serious reactions with dyspnoea and a fall in blood pressure, sometimes progressing to shock. 
 in isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the skin to light may occur. 
 
investigations: glimepiride, like all sulfonylureas, can cause weight gain (frequency not known)   for metformin : 
 
 gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (&gt;10%) are very common. these occur most frequently during initiation of therapy and resolve spontaneously in most cases. 
 metallic taste (3%) is common 
 decrease of vitamin b12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical signifcance (&lt;0.01%). however, cases of peripheral neuropathy in patients with vitamin b12 defciency have been reported in post-marketing experience (frequency not known). (frequency unknown) 
 lactic acidosis (0.03 cases/1000 patient-years) is very rare 
 hemolytic anemia (frequency unknown) 
 reduction of thyrotropin level in patients with hypothyroidism (frequency unknown) 
 hypomagnesemia in the context of diarrhea (frequency unknown) 
 encephalopathy (frequency unknown) 
 photosensitivity (frequency unknown) 
 hepatobiliary disorders: reports of liver function tests abnormalities and hepatitis resolving upon metformin discontinuation 
  ",glimepiride + metformin
medication,gliclazi,0.8111976," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,loss of consciousness,0.9974716," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,skin reactions,0.95049393," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,swelling,0.9992804," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,rash,0.9997472," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,hypersensitivity reactions,0.9914935," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,like symptoms,0.7943591," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,pale,0.96302825," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,sore,0.96312946," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,fever,0.999683," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,symptoms,0.7762563," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
medication,gliclazide,0.84043455," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,inflammation,0.98359054," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
sign_symptom,impairment,0.97979033," like all medicines, gliclazide can cause side effects, although not everybody gets them. the most commonly observed side effect is low blood sugar (hypoglycaemia). if left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. if an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.   liver disorders : there have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. if you get this, see your doctor immediately. the symptoms generally disappear if the medicine is stopped. your doctor will decide whether to stop your treatment.   skin disorders : skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. rash may progress to widespread blistering or peeling of the skin. if you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.   blood disorders : decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. these symptoms usually vanish when the treatment is discontinued.   digestive disorders : abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. these effects are reduced when gliclazide is taken with a meal as recommended.   eye disorders : your vision may be affected for a short time especially at the start of treatment. this effect is due to changes in blood sugar levels.    as for another sulfonylurea, the following adverse events have been observed : cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.   reporting of side effects : if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. by reporting side effects, you can help provide more information on the safety of this medicine. ",gliclazide
disease_disorder,hepatitis b vaccine,0.7430989," hepatitis b vaccine is generally well tolerated. most recipients of hepatitis b vaccine experience some reactions upon vaccination. these are generally moderate and short. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. in very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed. ",hepatitis b vaccine [rdna]
sign_symptom,reactions,0.98479885," hepatitis b vaccine is generally well tolerated. most recipients of hepatitis b vaccine experience some reactions upon vaccination. these are generally moderate and short. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. in very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed. ",hepatitis b vaccine [rdna]
sign_symptom,mala,0.99950874," hepatitis b vaccine is generally well tolerated. most recipients of hepatitis b vaccine experience some reactions upon vaccination. these are generally moderate and short. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. in very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed. ",hepatitis b vaccine [rdna]
sign_symptom,myalgia,0.8700471," hepatitis b vaccine is generally well tolerated. most recipients of hepatitis b vaccine experience some reactions upon vaccination. these are generally moderate and short. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. in very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed. ",hepatitis b vaccine [rdna]
sign_symptom,allergic type reactions,0.99674433," hepatitis b vaccine is generally well tolerated. most recipients of hepatitis b vaccine experience some reactions upon vaccination. these are generally moderate and short. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. in very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed. ",hepatitis b vaccine [rdna]
sign_symptom,anaphyla,0.7407573," hypersensitivity, anaphylactic shock, headache, tachycardia, hypotension, vomiting, erythema, itching, malaise ",hepatitis b immune globulin
sign_symptom,vomiting,0.9870029," hypersensitivity, anaphylactic shock, headache, tachycardia, hypotension, vomiting, erythema, itching, malaise ",hepatitis b immune globulin
sign_symptom,malaise,0.9992837," hypersensitivity, anaphylactic shock, headache, tachycardia, hypotension, vomiting, erythema, itching, malaise ",hepatitis b immune globulin
sign_symptom,mala,0.9981432," transient soreness, erythema, induration at inj site. fever, malaise, ",hepatitis a vaccine
sign_symptom,hyper,0.99996924," hypersensitivity reactions (e.g. chills, fever, urticaria, asthma, rhinitis); painful, ischaemic and cyanosed limbs; osteoporosis (in long-term admin), suppression of aldosterone synthesis leading to hyperkalaemia, cutaneous necrosis, delayed transient alopecia, priapism, rebound hyperlipaemia; increased serum concentrations of ast and alt, prolonged prothrombin time; local irritation, erythema, mild pain, haematoma or ulceration on inj site. ",heparin sodium
sign_symptom,suppression,0.7307881," hypersensitivity reactions (e.g. chills, fever, urticaria, asthma, rhinitis); painful, ischaemic and cyanosed limbs; osteoporosis (in long-term admin), suppression of aldosterone synthesis leading to hyperkalaemia, cutaneous necrosis, delayed transient alopecia, priapism, rebound hyperlipaemia; increased serum concentrations of ast and alt, prolonged prothrombin time; local irritation, erythema, mild pain, haematoma or ulceration on inj site. ",heparin sodium
sign_symptom,pain,0.99810106," hypersensitivity reactions (e.g. chills, fever, urticaria, asthma, rhinitis); painful, ischaemic and cyanosed limbs; osteoporosis (in long-term admin), suppression of aldosterone synthesis leading to hyperkalaemia, cutaneous necrosis, delayed transient alopecia, priapism, rebound hyperlipaemia; increased serum concentrations of ast and alt, prolonged prothrombin time; local irritation, erythema, mild pain, haematoma or ulceration on inj site. ",heparin sodium
sign_symptom,haematoma,0.9993369," hypersensitivity reactions (e.g. chills, fever, urticaria, asthma, rhinitis); painful, ischaemic and cyanosed limbs; osteoporosis (in long-term admin), suppression of aldosterone synthesis leading to hyperkalaemia, cutaneous necrosis, delayed transient alopecia, priapism, rebound hyperlipaemia; increased serum concentrations of ast and alt, prolonged prothrombin time; local irritation, erythema, mild pain, haematoma or ulceration on inj site. ",heparin sodium
sign_symptom,swollen,0.9999378," hands, ankles and feet may become mildly swollen from fluid retention. rarely, the lungs can also be affected, which may cause breathing difficulty. other possible symptoms include nausea, vomiting, headache, dizziness, drowsiness, confusion, and inflammation or swelling of the veins around the site of the injection. ",hartmann's solution
sign_symptom,drows,0.9288417," hands, ankles and feet may become mildly swollen from fluid retention. rarely, the lungs can also be affected, which may cause breathing difficulty. other possible symptoms include nausea, vomiting, headache, dizziness, drowsiness, confusion, and inflammation or swelling of the veins around the site of the injection. ",hartmann's solution
sign_symptom,swelling,0.99988115," hands, ankles and feet may become mildly swollen from fluid retention. rarely, the lungs can also be affected, which may cause breathing difficulty. other possible symptoms include nausea, vomiting, headache, dizziness, drowsiness, confusion, and inflammation or swelling of the veins around the site of the injection. ",hartmann's solution
medication,haloperidol,0.9862825," haloperidol is a safe neuroleptic. headache, vertigo, insomnia are the more common side effects encountered. drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported. ",haloperidol
sign_symptom,stupor,0.9103081," haloperidol is a safe neuroleptic. headache, vertigo, insomnia are the more common side effects encountered. drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported. ",haloperidol
sign_symptom,confusion,0.8052523," haloperidol is a safe neuroleptic. headache, vertigo, insomnia are the more common side effects encountered. drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported. ",haloperidol
sign_symptom,restlessness,0.9200882," haloperidol is a safe neuroleptic. headache, vertigo, insomnia are the more common side effects encountered. drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported. ",haloperidol
sign_symptom,euph,0.79962635," haloperidol is a safe neuroleptic. headache, vertigo, insomnia are the more common side effects encountered. drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported. ",haloperidol
sign_symptom,symptoms,0.9949904," haloperidol is a safe neuroleptic. headache, vertigo, insomnia are the more common side effects encountered. drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported. ",haloperidol
sign_symptom,hallucinations,0.938394," haloperidol is a safe neuroleptic. headache, vertigo, insomnia are the more common side effects encountered. drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported. ",haloperidol
sign_symptom,nausea,0.9352273," haloperidol is a safe neuroleptic. headache, vertigo, insomnia are the more common side effects encountered. drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported. ",haloperidol
sign_symptom,vomiting,0.99028313," haloperidol is a safe neuroleptic. headache, vertigo, insomnia are the more common side effects encountered. drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported. ",haloperidol
sign_symptom,diarrhea,0.93725014," haloperidol is a safe neuroleptic. headache, vertigo, insomnia are the more common side effects encountered. drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported. ",haloperidol
sign_symptom,hypersalivation,0.9771803," haloperidol is a safe neuroleptic. headache, vertigo, insomnia are the more common side effects encountered. drowsiness, lethargy, stupor, confusion, restlessness, agitation, anxiety, euphoria and exacerbation of psychotic symptoms including hallucinations also may occur. dry mouth, blurred vision, urinary retention, heartburn, nausea, vomiting, anorexia, diarrhea and hypersalivation have also been reported. ",haloperidol
sign_symptom,thinning,0.9986935," the most common side effects are redness, itching, swelling, burning, stinging, application site pain, inflamed hair follicles (folliculitis), thinning of the skin (atrophy), peeling and rash. ",halobetasol propionate + tazarotene
sign_symptom,skin,0.9668969," the most common side effects are redness, itching, swelling, burning, stinging, application site pain, inflamed hair follicles (folliculitis), thinning of the skin (atrophy), peeling and rash. ",halobetasol propionate + tazarotene
sign_symptom,broken,0.9866931," prolonged application causes epidermal thinning, contact dermatitis, perioral dermatitis, papular disorder, mild depigmentation; telangiectasia, striae (especially face and flexures). application on eyelids and surrounding skin can raise intraocular pressure, cataracts, glaucoma, corneal ulcers and raised intracranial pressure. systemic absorption with adrenal suppression may be seen when applied to large areas, when skin is broken or under occlusive dressing. ",halcinonide
sign_symptom,adverse reactions,0.85499334," very common adverse reactions are tenderness, erythema, induration, unusual crying, irritability, vomiting, diarrhoea, change in eating habits, sleepiness, fever. ",haemophilus influenzae type b vaccine [conjugated]
sign_symptom,nausea,0.8761039," this syrup may cause drowsiness, dizziness, nausea and vomiting, gastro-intestinal disturbance, dry mouth, nose and throat difficulty in urination or blurred vision. ",guaifenesin + levomenthol + diphenhydramine
sign_symptom,urination,0.9153352," this syrup may cause drowsiness, dizziness, nausea and vomiting, gastro-intestinal disturbance, dry mouth, nose and throat difficulty in urination or blurred vision. ",guaifenesin + levomenthol + diphenhydramine
sign_symptom,gastrointestinal disturbance,0.9956158," common side effects may include: 
 
 dizziness, drowsiness; 
 gastrointestinal disturbance 
 feeling nervous, restless, anxious, or irritable 
 
do not use for children less than 12 years of age. ",guaifenesin + dextromethorphan + menthol
sign_symptom,adverse reactions,0.86990666," when adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes,urticariaand rarely, angioneuroticedemaorerythemamultiforme-like drug reaction, and may necessitate withdrawal oftherapyand appropriate countermeasures. paresthesias of the hands and feet have been reported rarely after extended therapy. other side effects reported occasionally are oralthrush,nausea, vomiting, epigastric distress,diarrhea, headache,fatigue, dizziness,insomnia, mental confusion and impairment of performance of routine activities.  proteinuriaandleukopeniahave been reported rarely. administration of the drug should be discontinued ifgranulocytopeniaoccurs. when rare, serious reactions occur with griseofulvin, they are usually associated with high dosages, long periods of therapy, or both. ",griseofulvin [microsize]
sign_symptom,paresthesia,0.9537398," when adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes,urticariaand rarely, angioneuroticedemaorerythemamultiforme-like drug reaction, and may necessitate withdrawal oftherapyand appropriate countermeasures. paresthesias of the hands and feet have been reported rarely after extended therapy. other side effects reported occasionally are oralthrush,nausea, vomiting, epigastric distress,diarrhea, headache,fatigue, dizziness,insomnia, mental confusion and impairment of performance of routine activities.  proteinuriaandleukopeniahave been reported rarely. administration of the drug should be discontinued ifgranulocytopeniaoccurs. when rare, serious reactions occur with griseofulvin, they are usually associated with high dosages, long periods of therapy, or both. ",griseofulvin [microsize]
sign_symptom,confusion,0.97684926," when adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes,urticariaand rarely, angioneuroticedemaorerythemamultiforme-like drug reaction, and may necessitate withdrawal oftherapyand appropriate countermeasures. paresthesias of the hands and feet have been reported rarely after extended therapy. other side effects reported occasionally are oralthrush,nausea, vomiting, epigastric distress,diarrhea, headache,fatigue, dizziness,insomnia, mental confusion and impairment of performance of routine activities.  proteinuriaandleukopeniahave been reported rarely. administration of the drug should be discontinued ifgranulocytopeniaoccurs. when rare, serious reactions occur with griseofulvin, they are usually associated with high dosages, long periods of therapy, or both. ",griseofulvin [microsize]
sign_symptom,impairment,0.95721203," when adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes,urticariaand rarely, angioneuroticedemaorerythemamultiforme-like drug reaction, and may necessitate withdrawal oftherapyand appropriate countermeasures. paresthesias of the hands and feet have been reported rarely after extended therapy. other side effects reported occasionally are oralthrush,nausea, vomiting, epigastric distress,diarrhea, headache,fatigue, dizziness,insomnia, mental confusion and impairment of performance of routine activities.  proteinuriaandleukopeniahave been reported rarely. administration of the drug should be discontinued ifgranulocytopeniaoccurs. when rare, serious reactions occur with griseofulvin, they are usually associated with high dosages, long periods of therapy, or both. ",griseofulvin [microsize]
sign_symptom,adverse reactions,0.99825704," adverse reactions have occurred with the anti-infective components of this product. the exact incidence is not known. reactions occurring most often are allergic reactions including itching, swelling, and conjunctival erythema . more serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. local irritation on instillation has also been reported. ",gramacidin + neomycin + polymixin b
sign_symptom,reactions,0.97123444," adverse reactions have occurred with the anti-infective components of this product. the exact incidence is not known. reactions occurring most often are allergic reactions including itching, swelling, and conjunctival erythema . more serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. local irritation on instillation has also been reported. ",gramacidin + neomycin + polymixin b
sign_symptom,allergic reactions,0.995826," adverse reactions have occurred with the anti-infective components of this product. the exact incidence is not known. reactions occurring most often are allergic reactions including itching, swelling, and conjunctival erythema . more serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. local irritation on instillation has also been reported. ",gramacidin + neomycin + polymixin b
sign_symptom,hyper,0.9998772," adverse reactions have occurred with the anti-infective components of this product. the exact incidence is not known. reactions occurring most often are allergic reactions including itching, swelling, and conjunctival erythema . more serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. local irritation on instillation has also been reported. ",gramacidin + neomycin + polymixin b
sign_symptom,anaphylaxis,0.83439034," adverse reactions have occurred with the anti-infective components of this product. the exact incidence is not known. reactions occurring most often are allergic reactions including itching, swelling, and conjunctival erythema . more serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. local irritation on instillation has also been reported. ",gramacidin + neomycin + polymixin b
sign_symptom,irritation,0.9999461," adverse reactions have occurred with the anti-infective components of this product. the exact incidence is not known. reactions occurring most often are allergic reactions including itching, swelling, and conjunctival erythema . more serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. local irritation on instillation has also been reported. ",gramacidin + neomycin + polymixin b
sign_symptom,adverse reactions,0.99864376," most common adverse reactions (incidence &gt; 5%) are upper respiratory tract infection, nasopharyngitis, injection site reactions ",golimumab
disease_disorder,nasopharyngitis,0.87333566," most common adverse reactions (incidence &gt; 5%) are upper respiratory tract infection, nasopharyngitis, injection site reactions ",golimumab
sign_symptom,cough,0.9998202," the most common adverse reactions include cough and urinary tract infection. possible side efects are sudden breathing problems, headache, tremor, nervousness, rash, swelling of the face, mouth and tongue, hives, increase blood pressure, chest pain, irregular heartbeat, muscle spasm, muscle weakness, eye pain or discomfort and urinary retention. ",glycopyrronium bromide + formoterol fumarate
sign_symptom,swelling,0.99481285," the most common adverse reactions include cough and urinary tract infection. possible side efects are sudden breathing problems, headache, tremor, nervousness, rash, swelling of the face, mouth and tongue, hives, increase blood pressure, chest pain, irregular heartbeat, muscle spasm, muscle weakness, eye pain or discomfort and urinary retention. ",glycopyrronium bromide + formoterol fumarate
sign_symptom,pain,0.9997632," the most common adverse reactions include cough and urinary tract infection. possible side efects are sudden breathing problems, headache, tremor, nervousness, rash, swelling of the face, mouth and tongue, hives, increase blood pressure, chest pain, irregular heartbeat, muscle spasm, muscle weakness, eye pain or discomfort and urinary retention. ",glycopyrronium bromide + formoterol fumarate
sign_symptom,discomfort,0.9996902," the most common adverse reactions include cough and urinary tract infection. possible side efects are sudden breathing problems, headache, tremor, nervousness, rash, swelling of the face, mouth and tongue, hives, increase blood pressure, chest pain, irregular heartbeat, muscle spasm, muscle weakness, eye pain or discomfort and urinary retention. ",glycopyrronium bromide + formoterol fumarate
sign_symptom,adverse reactions,0.98669595," the following adverse reactions are found: 
 
 shortness of breath, 
 urinary tract infection, 
 wheezing, 
 upper respiratory tract infection, 
 runny nose, 
 fatigue. 
  ",glycopyrronium bromide (respirator solution)
sign_symptom,shortness of breath,0.9724106," the following adverse reactions are found: 
 
 shortness of breath, 
 urinary tract infection, 
 wheezing, 
 upper respiratory tract infection, 
 runny nose, 
 fatigue. 
  ",glycopyrronium bromide (respirator solution)
sign_symptom,burns,0.9998221," irritating burns on the skin and mucous membranes (strong solutions); reversible hypertrophy of the papillae of the tongue with continued use as mouthwash; gas embolism, rupture of the colon, proctitis, ulcerative colitis and gangrene of the intestines have occurred following colonic lavage with hydrogen peroxide solution. ",hydrogen peroxide
sign_symptom,hyper,0.9999213," irritating burns on the skin and mucous membranes (strong solutions); reversible hypertrophy of the papillae of the tongue with continued use as mouthwash; gas embolism, rupture of the colon, proctitis, ulcerative colitis and gangrene of the intestines have occurred following colonic lavage with hydrogen peroxide solution. ",hydrogen peroxide
disease_disorder,ulcerative colitis,0.99715316," irritating burns on the skin and mucous membranes (strong solutions); reversible hypertrophy of the papillae of the tongue with continued use as mouthwash; gas embolism, rupture of the colon, proctitis, ulcerative colitis and gangrene of the intestines have occurred following colonic lavage with hydrogen peroxide solution. ",hydrogen peroxide
sign_symptom,gangrene,0.9972427," irritating burns on the skin and mucous membranes (strong solutions); reversible hypertrophy of the papillae of the tongue with continued use as mouthwash; gas embolism, rupture of the colon, proctitis, ulcerative colitis and gangrene of the intestines have occurred following colonic lavage with hydrogen peroxide solution. ",hydrogen peroxide
medication,hydrogen peroxide,0.7724162," irritating burns on the skin and mucous membranes (strong solutions); reversible hypertrophy of the papillae of the tongue with continued use as mouthwash; gas embolism, rupture of the colon, proctitis, ulcerative colitis and gangrene of the intestines have occurred following colonic lavage with hydrogen peroxide solution. ",hydrogen peroxide
sign_symptom,sensitivity reactions,0.9996953," prolonged or excessive use may produce systemic corticosteroid effects, and use for periods longer than seven days is not recommended. rarely, there are sensitivity reactions and patients may occasionally experience transient burning on application especially if the anoderm is not intact. ",hydrocortisone acetate + benzyl benzoate + bismuth subgallate + bismuth oxide + balsam peru + zinc oxide
sign_symptom,burning,0.99807286," prolonged or excessive use may produce systemic corticosteroid effects, and use for periods longer than seven days is not recommended. rarely, there are sensitivity reactions and patients may occasionally experience transient burning on application especially if the anoderm is not intact. ",hydrocortisone acetate + benzyl benzoate + bismuth subgallate + bismuth oxide + balsam peru + zinc oxide
medication,hydrocortisone,0.9533777," hydrocortisone acetate 1% cream is usually well-tolerated, but if signs of hypersensitivity appear, application should be stopped. ",hydrocortisone acetate
sign_symptom,hyper,0.9974305," hydrocortisone acetate 1% cream is usually well-tolerated, but if signs of hypersensitivity appear, application should be stopped. ",hydrocortisone acetate
sign_symptom,swelling,0.9978822," side effects like rectal bleeding, swelling of the skin, adrenal suppression, anaphylaxis, angioedema, cushing syndrome, hirsutism, acne, cutaneous and subcutaneous atrophy, dry scaly skin, urticaria. ",hydrocortisone + lidocaine
medication,hydrocortisone,0.9933884," hydrocortisone is generally well tolerated except in prolonged high doses. it may cause cardiac arrhythmia, esophageal candidiasis, menstrual irregularity, decreased carbohydrate &amp; glucose tolerance, fluid retention, increased appetite, weight gain, euphoria, mood swings, depression, insomnia, acne etc. ",hydrocortisone
sign_symptom,vomiting,0.9092939,"  gastro-intestinal system : anorexia, gastric irritation, nausea, vomiting, cramps, diarrhoea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis, salivary gland inflammation.    central nervous system : dizziness, vertigo, paraesthesiae, headache, yellow vision.   heamatological : leucopenia, agranulocytosis, thrombocytopenia, aplastic anaemia,haemolytic anaemia.   cardiovascular : hypotension, including orthostatic hypotension.   hypersensitivity : purpura, photosensitivity, rash, urticaria, necrotising angiitis (vasculitis, cutaneous vasculitis), fever, respiratiory distress including pneumonitis and pulmonary oedema, anaphylactic reactions, toxic epidermal necrolysis.   metabolic : hyperglycaemia, glycosuria, hyperuricaema, electrolyte imbalance including hyponatraemia and hypokalaemia.   renal : renal dysfunction, interstitial nephritis, renal failure.   other : muscle spasm, weakness, restlessness, transient blurred vision, impotence. whenever side-effects are moderate to severe, thiazide dosage should be reduced or therapy was withdrawn. ",hydrochlorothiazide
sign_symptom,constipation,0.9935146,"  gastro-intestinal system : anorexia, gastric irritation, nausea, vomiting, cramps, diarrhoea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis, salivary gland inflammation.    central nervous system : dizziness, vertigo, paraesthesiae, headache, yellow vision.   heamatological : leucopenia, agranulocytosis, thrombocytopenia, aplastic anaemia,haemolytic anaemia.   cardiovascular : hypotension, including orthostatic hypotension.   hypersensitivity : purpura, photosensitivity, rash, urticaria, necrotising angiitis (vasculitis, cutaneous vasculitis), fever, respiratiory distress including pneumonitis and pulmonary oedema, anaphylactic reactions, toxic epidermal necrolysis.   metabolic : hyperglycaemia, glycosuria, hyperuricaema, electrolyte imbalance including hyponatraemia and hypokalaemia.   renal : renal dysfunction, interstitial nephritis, renal failure.   other : muscle spasm, weakness, restlessness, transient blurred vision, impotence. whenever side-effects are moderate to severe, thiazide dosage should be reduced or therapy was withdrawn. ",hydrochlorothiazide
disease_disorder,angiitis,0.9259947,"  gastro-intestinal system : anorexia, gastric irritation, nausea, vomiting, cramps, diarrhoea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis, salivary gland inflammation.    central nervous system : dizziness, vertigo, paraesthesiae, headache, yellow vision.   heamatological : leucopenia, agranulocytosis, thrombocytopenia, aplastic anaemia,haemolytic anaemia.   cardiovascular : hypotension, including orthostatic hypotension.   hypersensitivity : purpura, photosensitivity, rash, urticaria, necrotising angiitis (vasculitis, cutaneous vasculitis), fever, respiratiory distress including pneumonitis and pulmonary oedema, anaphylactic reactions, toxic epidermal necrolysis.   metabolic : hyperglycaemia, glycosuria, hyperuricaema, electrolyte imbalance including hyponatraemia and hypokalaemia.   renal : renal dysfunction, interstitial nephritis, renal failure.   other : muscle spasm, weakness, restlessness, transient blurred vision, impotence. whenever side-effects are moderate to severe, thiazide dosage should be reduced or therapy was withdrawn. ",hydrochlorothiazide
sign_symptom,hyper,0.8761176,"  gastro-intestinal system : anorexia, gastric irritation, nausea, vomiting, cramps, diarrhoea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis, salivary gland inflammation.    central nervous system : dizziness, vertigo, paraesthesiae, headache, yellow vision.   heamatological : leucopenia, agranulocytosis, thrombocytopenia, aplastic anaemia,haemolytic anaemia.   cardiovascular : hypotension, including orthostatic hypotension.   hypersensitivity : purpura, photosensitivity, rash, urticaria, necrotising angiitis (vasculitis, cutaneous vasculitis), fever, respiratiory distress including pneumonitis and pulmonary oedema, anaphylactic reactions, toxic epidermal necrolysis.   metabolic : hyperglycaemia, glycosuria, hyperuricaema, electrolyte imbalance including hyponatraemia and hypokalaemia.   renal : renal dysfunction, interstitial nephritis, renal failure.   other : muscle spasm, weakness, restlessness, transient blurred vision, impotence. whenever side-effects are moderate to severe, thiazide dosage should be reduced or therapy was withdrawn. ",hydrochlorothiazide
sign_symptom,hyperurica,0.91686934,"  gastro-intestinal system : anorexia, gastric irritation, nausea, vomiting, cramps, diarrhoea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis, salivary gland inflammation.    central nervous system : dizziness, vertigo, paraesthesiae, headache, yellow vision.   heamatological : leucopenia, agranulocytosis, thrombocytopenia, aplastic anaemia,haemolytic anaemia.   cardiovascular : hypotension, including orthostatic hypotension.   hypersensitivity : purpura, photosensitivity, rash, urticaria, necrotising angiitis (vasculitis, cutaneous vasculitis), fever, respiratiory distress including pneumonitis and pulmonary oedema, anaphylactic reactions, toxic epidermal necrolysis.   metabolic : hyperglycaemia, glycosuria, hyperuricaema, electrolyte imbalance including hyponatraemia and hypokalaemia.   renal : renal dysfunction, interstitial nephritis, renal failure.   other : muscle spasm, weakness, restlessness, transient blurred vision, impotence. whenever side-effects are moderate to severe, thiazide dosage should be reduced or therapy was withdrawn. ",hydrochlorothiazide
sign_symptom,electrolyte imbalance,0.94582015,"  gastro-intestinal system : anorexia, gastric irritation, nausea, vomiting, cramps, diarrhoea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis, salivary gland inflammation.    central nervous system : dizziness, vertigo, paraesthesiae, headache, yellow vision.   heamatological : leucopenia, agranulocytosis, thrombocytopenia, aplastic anaemia,haemolytic anaemia.   cardiovascular : hypotension, including orthostatic hypotension.   hypersensitivity : purpura, photosensitivity, rash, urticaria, necrotising angiitis (vasculitis, cutaneous vasculitis), fever, respiratiory distress including pneumonitis and pulmonary oedema, anaphylactic reactions, toxic epidermal necrolysis.   metabolic : hyperglycaemia, glycosuria, hyperuricaema, electrolyte imbalance including hyponatraemia and hypokalaemia.   renal : renal dysfunction, interstitial nephritis, renal failure.   other : muscle spasm, weakness, restlessness, transient blurred vision, impotence. whenever side-effects are moderate to severe, thiazide dosage should be reduced or therapy was withdrawn. ",hydrochlorothiazide
sign_symptom,side effects,0.984244," there have been no known side effects reported so far. but if you have any specific allergies, we recommend you to consult with your doctor before taking this supplement. ",hyaluronic acid
sign_symptom,adverse reaction,0.9996822," adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely. 
 
  local reactions at the injection site : local pain, tenderness or swelling. 
 
in rare cases the following adverse reactions may occur: 
 
  immune system disorders : allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins. 
  generalized reactions : chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain. 
  heart and vascular disorders : cardiovascular reactions particularly if the product is inadvertently injected intravascularly. 
  ",human tetanus immunoglobulin
medication,human tetanus immunoglobulin,0.9757191," adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely. 
 
  local reactions at the injection site : local pain, tenderness or swelling. 
 
in rare cases the following adverse reactions may occur: 
 
  immune system disorders : allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins. 
  generalized reactions : chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain. 
  heart and vascular disorders : cardiovascular reactions particularly if the product is inadvertently injected intravascularly. 
  ",human tetanus immunoglobulin
sign_symptom,reactions,0.9947395," adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely. 
 
  local reactions at the injection site : local pain, tenderness or swelling. 
 
in rare cases the following adverse reactions may occur: 
 
  immune system disorders : allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins. 
  generalized reactions : chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain. 
  heart and vascular disorders : cardiovascular reactions particularly if the product is inadvertently injected intravascularly. 
  ",human tetanus immunoglobulin
sign_symptom,tenderness,0.99992085," adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely. 
 
  local reactions at the injection site : local pain, tenderness or swelling. 
 
in rare cases the following adverse reactions may occur: 
 
  immune system disorders : allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins. 
  generalized reactions : chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain. 
  heart and vascular disorders : cardiovascular reactions particularly if the product is inadvertently injected intravascularly. 
  ",human tetanus immunoglobulin
sign_symptom,adverse reactions,0.9994722," adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely. 
 
  local reactions at the injection site : local pain, tenderness or swelling. 
 
in rare cases the following adverse reactions may occur: 
 
  immune system disorders : allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins. 
  generalized reactions : chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain. 
  heart and vascular disorders : cardiovascular reactions particularly if the product is inadvertently injected intravascularly. 
  ",human tetanus immunoglobulin
disease_disorder,immune,0.99913436," adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely. 
 
  local reactions at the injection site : local pain, tenderness or swelling. 
 
in rare cases the following adverse reactions may occur: 
 
  immune system disorders : allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins. 
  generalized reactions : chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain. 
  heart and vascular disorders : cardiovascular reactions particularly if the product is inadvertently injected intravascularly. 
  ",human tetanus immunoglobulin
sign_symptom,allergic reactions,0.9992015," adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely. 
 
  local reactions at the injection site : local pain, tenderness or swelling. 
 
in rare cases the following adverse reactions may occur: 
 
  immune system disorders : allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins. 
  generalized reactions : chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain. 
  heart and vascular disorders : cardiovascular reactions particularly if the product is inadvertently injected intravascularly. 
  ",human tetanus immunoglobulin
sign_symptom,mala,0.999721," adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely. 
 
  local reactions at the injection site : local pain, tenderness or swelling. 
 
in rare cases the following adverse reactions may occur: 
 
  immune system disorders : allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins. 
  generalized reactions : chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain. 
  heart and vascular disorders : cardiovascular reactions particularly if the product is inadvertently injected intravascularly. 
  ",human tetanus immunoglobulin
sign_symptom,vomiting,0.9950039," adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely. 
 
  local reactions at the injection site : local pain, tenderness or swelling. 
 
in rare cases the following adverse reactions may occur: 
 
  immune system disorders : allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins. 
  generalized reactions : chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain. 
  heart and vascular disorders : cardiovascular reactions particularly if the product is inadvertently injected intravascularly. 
  ",human tetanus immunoglobulin
sign_symptom,arthralgia,0.9785663," adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely. 
 
  local reactions at the injection site : local pain, tenderness or swelling. 
 
in rare cases the following adverse reactions may occur: 
 
  immune system disorders : allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins. 
  generalized reactions : chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain. 
  heart and vascular disorders : cardiovascular reactions particularly if the product is inadvertently injected intravascularly. 
  ",human tetanus immunoglobulin
sign_symptom,cardiovascular reactions,0.99166006," adverse reaction following administration of human tetanus immunoglobulin is infrequent and mild, but severe local and systemic reactions have occurred rarely. 
 
  local reactions at the injection site : local pain, tenderness or swelling. 
 
in rare cases the following adverse reactions may occur: 
 
  immune system disorders : allergic reactions including fall in blood pressure, dyspnoea, cutaneous reactions, in isolated cases reaching as far as anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration of immunoglobulins. 
  generalized reactions : chills, fever, headache, malaise, nausea, vomiting, arthralgia and moderate back pain. 
  heart and vascular disorders : cardiovascular reactions particularly if the product is inadvertently injected intravascularly. 
  ",human tetanus immunoglobulin
sign_symptom,adverse reaction,0.97539145," the most common adverse reaction was headache. common adverse reactions (frequency of at least 1.0% and greater than aahs control or saline placebo) are fever, nausea, dizziness; and injection-site pain, swelling, erythema, pruritus, and bruising. ","human papillomavirus quadrivalent (types 6, 11, 16, and 18)"
sign_symptom,adverse reactions,0.999511," the most common adverse reaction was headache. common adverse reactions (frequency of at least 1.0% and greater than aahs control or saline placebo) are fever, nausea, dizziness; and injection-site pain, swelling, erythema, pruritus, and bruising. ","human papillomavirus quadrivalent (types 6, 11, 16, and 18)"
sign_symptom,arthralgia,0.9997096," injection site pain, erythema, and inflammation fatigue, headache, myalgia, gi symptoms, arthralgia ",human papillomavirus bivalent (types 16 & 18)
sign_symptom,shock,0.999925,"  
 symptoms of shock may occur. if dyspnea, wheeze, chest pain, hypotension or weak pulse are watched, administration should be discontinued and 0.1-0.5 ml epinephrine (1:1000) or the administration of cortisone should be considered. 
 rapid administration can cause hypotension. 
 liver function disorders or jaundice accompanying and increase in alt or ast may occur. caution should be taken and proper treatment should be followed if needed. 
 renal failure may occur with the use of human normal immunoglobulin. if dehydration, hypouresis, increase of creatinine or increase of bun etc is observed, administration should be discontinued and proper treatment should be taken. 
 aseptic meningitis from a large volume of ivig administration may occur. 
 decrease in platelets may occur. other possible undesirable effects include drowsiness, chill, chest pain, abdominal pain, gluteal pain and anxiety etc. 
  ",human immunoglobulin-g [igg]
sign_symptom,pain,0.99485284,"  
 symptoms of shock may occur. if dyspnea, wheeze, chest pain, hypotension or weak pulse are watched, administration should be discontinued and 0.1-0.5 ml epinephrine (1:1000) or the administration of cortisone should be considered. 
 rapid administration can cause hypotension. 
 liver function disorders or jaundice accompanying and increase in alt or ast may occur. caution should be taken and proper treatment should be followed if needed. 
 renal failure may occur with the use of human normal immunoglobulin. if dehydration, hypouresis, increase of creatinine or increase of bun etc is observed, administration should be discontinued and proper treatment should be taken. 
 aseptic meningitis from a large volume of ivig administration may occur. 
 decrease in platelets may occur. other possible undesirable effects include drowsiness, chill, chest pain, abdominal pain, gluteal pain and anxiety etc. 
  ",human immunoglobulin-g [igg]
sign_symptom,weak pulse,0.99971706,"  
 symptoms of shock may occur. if dyspnea, wheeze, chest pain, hypotension or weak pulse are watched, administration should be discontinued and 0.1-0.5 ml epinephrine (1:1000) or the administration of cortisone should be considered. 
 rapid administration can cause hypotension. 
 liver function disorders or jaundice accompanying and increase in alt or ast may occur. caution should be taken and proper treatment should be followed if needed. 
 renal failure may occur with the use of human normal immunoglobulin. if dehydration, hypouresis, increase of creatinine or increase of bun etc is observed, administration should be discontinued and proper treatment should be taken. 
 aseptic meningitis from a large volume of ivig administration may occur. 
 decrease in platelets may occur. other possible undesirable effects include drowsiness, chill, chest pain, abdominal pain, gluteal pain and anxiety etc. 
  ",human immunoglobulin-g [igg]
medication,cortisone,0.9871391,"  
 symptoms of shock may occur. if dyspnea, wheeze, chest pain, hypotension or weak pulse are watched, administration should be discontinued and 0.1-0.5 ml epinephrine (1:1000) or the administration of cortisone should be considered. 
 rapid administration can cause hypotension. 
 liver function disorders or jaundice accompanying and increase in alt or ast may occur. caution should be taken and proper treatment should be followed if needed. 
 renal failure may occur with the use of human normal immunoglobulin. if dehydration, hypouresis, increase of creatinine or increase of bun etc is observed, administration should be discontinued and proper treatment should be taken. 
 aseptic meningitis from a large volume of ivig administration may occur. 
 decrease in platelets may occur. other possible undesirable effects include drowsiness, chill, chest pain, abdominal pain, gluteal pain and anxiety etc. 
  ",human immunoglobulin-g [igg]
disease_disorder,renal failure,0.99964803,"  
 symptoms of shock may occur. if dyspnea, wheeze, chest pain, hypotension or weak pulse are watched, administration should be discontinued and 0.1-0.5 ml epinephrine (1:1000) or the administration of cortisone should be considered. 
 rapid administration can cause hypotension. 
 liver function disorders or jaundice accompanying and increase in alt or ast may occur. caution should be taken and proper treatment should be followed if needed. 
 renal failure may occur with the use of human normal immunoglobulin. if dehydration, hypouresis, increase of creatinine or increase of bun etc is observed, administration should be discontinued and proper treatment should be taken. 
 aseptic meningitis from a large volume of ivig administration may occur. 
 decrease in platelets may occur. other possible undesirable effects include drowsiness, chill, chest pain, abdominal pain, gluteal pain and anxiety etc. 
  ",human immunoglobulin-g [igg]
disease_disorder,meningitis,0.99606705,"  
 symptoms of shock may occur. if dyspnea, wheeze, chest pain, hypotension or weak pulse are watched, administration should be discontinued and 0.1-0.5 ml epinephrine (1:1000) or the administration of cortisone should be considered. 
 rapid administration can cause hypotension. 
 liver function disorders or jaundice accompanying and increase in alt or ast may occur. caution should be taken and proper treatment should be followed if needed. 
 renal failure may occur with the use of human normal immunoglobulin. if dehydration, hypouresis, increase of creatinine or increase of bun etc is observed, administration should be discontinued and proper treatment should be taken. 
 aseptic meningitis from a large volume of ivig administration may occur. 
 decrease in platelets may occur. other possible undesirable effects include drowsiness, chill, chest pain, abdominal pain, gluteal pain and anxiety etc. 
  ",human immunoglobulin-g [igg]
medication,ivig,0.842275,"  
 symptoms of shock may occur. if dyspnea, wheeze, chest pain, hypotension or weak pulse are watched, administration should be discontinued and 0.1-0.5 ml epinephrine (1:1000) or the administration of cortisone should be considered. 
 rapid administration can cause hypotension. 
 liver function disorders or jaundice accompanying and increase in alt or ast may occur. caution should be taken and proper treatment should be followed if needed. 
 renal failure may occur with the use of human normal immunoglobulin. if dehydration, hypouresis, increase of creatinine or increase of bun etc is observed, administration should be discontinued and proper treatment should be taken. 
 aseptic meningitis from a large volume of ivig administration may occur. 
 decrease in platelets may occur. other possible undesirable effects include drowsiness, chill, chest pain, abdominal pain, gluteal pain and anxiety etc. 
  ",human immunoglobulin-g [igg]
sign_symptom,drows,0.8947737,"  
 symptoms of shock may occur. if dyspnea, wheeze, chest pain, hypotension or weak pulse are watched, administration should be discontinued and 0.1-0.5 ml epinephrine (1:1000) or the administration of cortisone should be considered. 
 rapid administration can cause hypotension. 
 liver function disorders or jaundice accompanying and increase in alt or ast may occur. caution should be taken and proper treatment should be followed if needed. 
 renal failure may occur with the use of human normal immunoglobulin. if dehydration, hypouresis, increase of creatinine or increase of bun etc is observed, administration should be discontinued and proper treatment should be taken. 
 aseptic meningitis from a large volume of ivig administration may occur. 
 decrease in platelets may occur. other possible undesirable effects include drowsiness, chill, chest pain, abdominal pain, gluteal pain and anxiety etc. 
  ",human immunoglobulin-g [igg]
sign_symptom,anxiety,0.99994004,"  
 symptoms of shock may occur. if dyspnea, wheeze, chest pain, hypotension or weak pulse are watched, administration should be discontinued and 0.1-0.5 ml epinephrine (1:1000) or the administration of cortisone should be considered. 
 rapid administration can cause hypotension. 
 liver function disorders or jaundice accompanying and increase in alt or ast may occur. caution should be taken and proper treatment should be followed if needed. 
 renal failure may occur with the use of human normal immunoglobulin. if dehydration, hypouresis, increase of creatinine or increase of bun etc is observed, administration should be discontinued and proper treatment should be taken. 
 aseptic meningitis from a large volume of ivig administration may occur. 
 decrease in platelets may occur. other possible undesirable effects include drowsiness, chill, chest pain, abdominal pain, gluteal pain and anxiety etc. 
  ",human immunoglobulin-g [igg]
sign_symptom,allergic reactions,0.9999027," allergic reactions have occasionally been reported with the use of urinary gonadotrophin preparations. these mostly involve local reactions such as pain and rash at the injection site, and generalized reactions such as rash and fever.   in the female : unwanted ovarian hyperstimulation syndrome. which is characteristic symptoms of unwanted ovarian hyperstimulation and the ovarian hyperstimulation syndrome are included under 'special warnings and special precautions for use'.   in the male : water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. treatment with human chorionic gonadotrophin leads to increased androgen production.   therefore : patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production. human chorionic gonadotrophinshould be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. skeletal maturation should be monitored regularly. ",human chorionic gonadotrophin
medication,gonad,0.8522667," allergic reactions have occasionally been reported with the use of urinary gonadotrophin preparations. these mostly involve local reactions such as pain and rash at the injection site, and generalized reactions such as rash and fever.   in the female : unwanted ovarian hyperstimulation syndrome. which is characteristic symptoms of unwanted ovarian hyperstimulation and the ovarian hyperstimulation syndrome are included under 'special warnings and special precautions for use'.   in the male : water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. treatment with human chorionic gonadotrophin leads to increased androgen production.   therefore : patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production. human chorionic gonadotrophinshould be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. skeletal maturation should be monitored regularly. ",human chorionic gonadotrophin
sign_symptom,pain,0.9999571," allergic reactions have occasionally been reported with the use of urinary gonadotrophin preparations. these mostly involve local reactions such as pain and rash at the injection site, and generalized reactions such as rash and fever.   in the female : unwanted ovarian hyperstimulation syndrome. which is characteristic symptoms of unwanted ovarian hyperstimulation and the ovarian hyperstimulation syndrome are included under 'special warnings and special precautions for use'.   in the male : water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. treatment with human chorionic gonadotrophin leads to increased androgen production.   therefore : patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production. human chorionic gonadotrophinshould be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. skeletal maturation should be monitored regularly. ",human chorionic gonadotrophin
sign_symptom,rash,0.99994314," allergic reactions have occasionally been reported with the use of urinary gonadotrophin preparations. these mostly involve local reactions such as pain and rash at the injection site, and generalized reactions such as rash and fever.   in the female : unwanted ovarian hyperstimulation syndrome. which is characteristic symptoms of unwanted ovarian hyperstimulation and the ovarian hyperstimulation syndrome are included under 'special warnings and special precautions for use'.   in the male : water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. treatment with human chorionic gonadotrophin leads to increased androgen production.   therefore : patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production. human chorionic gonadotrophinshould be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. skeletal maturation should be monitored regularly. ",human chorionic gonadotrophin
sign_symptom,hyper,0.9918006," allergic reactions have occasionally been reported with the use of urinary gonadotrophin preparations. these mostly involve local reactions such as pain and rash at the injection site, and generalized reactions such as rash and fever.   in the female : unwanted ovarian hyperstimulation syndrome. which is characteristic symptoms of unwanted ovarian hyperstimulation and the ovarian hyperstimulation syndrome are included under 'special warnings and special precautions for use'.   in the male : water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. treatment with human chorionic gonadotrophin leads to increased androgen production.   therefore : patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production. human chorionic gonadotrophinshould be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. skeletal maturation should be monitored regularly. ",human chorionic gonadotrophin
sign_symptom,hypersti,0.8234344," allergic reactions have occasionally been reported with the use of urinary gonadotrophin preparations. these mostly involve local reactions such as pain and rash at the injection site, and generalized reactions such as rash and fever.   in the female : unwanted ovarian hyperstimulation syndrome. which is characteristic symptoms of unwanted ovarian hyperstimulation and the ovarian hyperstimulation syndrome are included under 'special warnings and special precautions for use'.   in the male : water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. treatment with human chorionic gonadotrophin leads to increased androgen production.   therefore : patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production. human chorionic gonadotrophinshould be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. skeletal maturation should be monitored regularly. ",human chorionic gonadotrophin
disease_disorder,hyperstimulation syndrome,0.85792017," allergic reactions have occasionally been reported with the use of urinary gonadotrophin preparations. these mostly involve local reactions such as pain and rash at the injection site, and generalized reactions such as rash and fever.   in the female : unwanted ovarian hyperstimulation syndrome. which is characteristic symptoms of unwanted ovarian hyperstimulation and the ovarian hyperstimulation syndrome are included under 'special warnings and special precautions for use'.   in the male : water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. treatment with human chorionic gonadotrophin leads to increased androgen production.   therefore : patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production. human chorionic gonadotrophinshould be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. skeletal maturation should be monitored regularly. ",human chorionic gonadotrophin
disease_disorder,renal,0.755036," allergic reactions have occasionally been reported with the use of urinary gonadotrophin preparations. these mostly involve local reactions such as pain and rash at the injection site, and generalized reactions such as rash and fever.   in the female : unwanted ovarian hyperstimulation syndrome. which is characteristic symptoms of unwanted ovarian hyperstimulation and the ovarian hyperstimulation syndrome are included under 'special warnings and special precautions for use'.   in the male : water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. treatment with human chorionic gonadotrophin leads to increased androgen production.   therefore : patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production. human chorionic gonadotrophinshould be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. skeletal maturation should be monitored regularly. ",human chorionic gonadotrophin
sign_symptom,aggravation,0.9775999," allergic reactions have occasionally been reported with the use of urinary gonadotrophin preparations. these mostly involve local reactions such as pain and rash at the injection site, and generalized reactions such as rash and fever.   in the female : unwanted ovarian hyperstimulation syndrome. which is characteristic symptoms of unwanted ovarian hyperstimulation and the ovarian hyperstimulation syndrome are included under 'special warnings and special precautions for use'.   in the male : water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. treatment with human chorionic gonadotrophin leads to increased androgen production.   therefore : patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production. human chorionic gonadotrophinshould be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. skeletal maturation should be monitored regularly. ",human chorionic gonadotrophin
sign_symptom,recurrence,0.95850897," allergic reactions have occasionally been reported with the use of urinary gonadotrophin preparations. these mostly involve local reactions such as pain and rash at the injection site, and generalized reactions such as rash and fever.   in the female : unwanted ovarian hyperstimulation syndrome. which is characteristic symptoms of unwanted ovarian hyperstimulation and the ovarian hyperstimulation syndrome are included under 'special warnings and special precautions for use'.   in the male : water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. treatment with human chorionic gonadotrophin leads to increased androgen production.   therefore : patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production. human chorionic gonadotrophinshould be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. skeletal maturation should be monitored regularly. ",human chorionic gonadotrophin
sign_symptom,hypersensitivity reactions,0.9988081," hypersensitivity reactions such as hives, wheezing, urticaria, pain and tenderness at inj site. fever, chills, nausea, facial flushing, headache. ",human anti-d immunoglobulins
sign_symptom,hive,0.9975305," hypersensitivity reactions such as hives, wheezing, urticaria, pain and tenderness at inj site. fever, chills, nausea, facial flushing, headache. ",human anti-d immunoglobulins
sign_symptom,pain,0.99992275," hypersensitivity reactions such as hives, wheezing, urticaria, pain and tenderness at inj site. fever, chills, nausea, facial flushing, headache. ",human anti-d immunoglobulins
sign_symptom,tenderness,0.9998989," hypersensitivity reactions such as hives, wheezing, urticaria, pain and tenderness at inj site. fever, chills, nausea, facial flushing, headache. ",human anti-d immunoglobulins
sign_symptom,hypersensitivity,0.97303605, hypersensitivity may occur as conjunctivitis. ,homatropine hydrobromide
sign_symptom,upset,0.9995028," upset stomach, vomiting, heartburn, nausea may occur. ",ibuprofen
sign_symptom,nausea,0.9999099," upset stomach, vomiting, heartburn, nausea may occur. ",ibuprofen
sign_symptom,adverse reactions,0.97086215," the following adverse reactions are discussed in more detail in other sections of the labeling: hemorrhage, infections, cytopenias, atrial fibrillation, hypertension, second primary malignancies and tumor lysis syndrome. additional important adverse reactions: diarrhea, visual disturbance. ",ibrutinib
sign_symptom,flatule,0.86210907," ibandronic acid: common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bronchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium &amp; vitamin d3: most common side effects are flatulence, diarrhea, constipation, upper gi discomfort etc. hypercalciuria and hypercalcemia due to prolong use has rarely been reported. ",ibandronic acid + calcium carbonate + vitamin d3
sign_symptom,diarr,0.90165424," ibandronic acid: common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bronchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium &amp; vitamin d3: most common side effects are flatulence, diarrhea, constipation, upper gi discomfort etc. hypercalciuria and hypercalcemia due to prolong use has rarely been reported. ",ibandronic acid + calcium carbonate + vitamin d3
sign_symptom,consti,0.9997512," ibandronic acid: common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bronchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium &amp; vitamin d3: most common side effects are flatulence, diarrhea, constipation, upper gi discomfort etc. hypercalciuria and hypercalcemia due to prolong use has rarely been reported. ",ibandronic acid + calcium carbonate + vitamin d3
sign_symptom,discomfort,0.9999373," ibandronic acid: common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bronchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium &amp; vitamin d3: most common side effects are flatulence, diarrhea, constipation, upper gi discomfort etc. hypercalciuria and hypercalcemia due to prolong use has rarely been reported. ",ibandronic acid + calcium carbonate + vitamin d3
sign_symptom,hyper,0.9999629," ibandronic acid: common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bronchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium &amp; vitamin d3: most common side effects are flatulence, diarrhea, constipation, upper gi discomfort etc. hypercalciuria and hypercalcemia due to prolong use has rarely been reported. ",ibandronic acid + calcium carbonate + vitamin d3
sign_symptom,hypercalcemia,0.87685025," ibandronic acid: common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bronchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium &amp; vitamin d3: most common side effects are flatulence, diarrhea, constipation, upper gi discomfort etc. hypercalciuria and hypercalcemia due to prolong use has rarely been reported. ",ibandronic acid + calcium carbonate + vitamin d3
sign_symptom,swelling,0.9999485,"  ibandronic acid : common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bonchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium orotate : bloating and swelling in the abdomen are common side effects of calcium orotate, loss of appetite, upset stomach, constipation, nausea, vomiting, unusual weight loss, mood changes, bone/muscle pain, headache, increased thirst/urination, weakness, unusual tiredness, formation of kidney stones may occur infrequently. ",ibandronic acid & calcium orotate
medication,calcium,0.7892316,"  ibandronic acid : common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bonchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium orotate : bloating and swelling in the abdomen are common side effects of calcium orotate, loss of appetite, upset stomach, constipation, nausea, vomiting, unusual weight loss, mood changes, bone/muscle pain, headache, increased thirst/urination, weakness, unusual tiredness, formation of kidney stones may occur infrequently. ",ibandronic acid & calcium orotate
sign_symptom,loss of appetite,0.9824264,"  ibandronic acid : common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bonchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium orotate : bloating and swelling in the abdomen are common side effects of calcium orotate, loss of appetite, upset stomach, constipation, nausea, vomiting, unusual weight loss, mood changes, bone/muscle pain, headache, increased thirst/urination, weakness, unusual tiredness, formation of kidney stones may occur infrequently. ",ibandronic acid & calcium orotate
sign_symptom,upset,0.9989785,"  ibandronic acid : common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bonchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium orotate : bloating and swelling in the abdomen are common side effects of calcium orotate, loss of appetite, upset stomach, constipation, nausea, vomiting, unusual weight loss, mood changes, bone/muscle pain, headache, increased thirst/urination, weakness, unusual tiredness, formation of kidney stones may occur infrequently. ",ibandronic acid & calcium orotate
sign_symptom,thirst,0.9623856,"  ibandronic acid : common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bonchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium orotate : bloating and swelling in the abdomen are common side effects of calcium orotate, loss of appetite, upset stomach, constipation, nausea, vomiting, unusual weight loss, mood changes, bone/muscle pain, headache, increased thirst/urination, weakness, unusual tiredness, formation of kidney stones may occur infrequently. ",ibandronic acid & calcium orotate
sign_symptom,kidney stones,0.9495119,"  ibandronic acid : common side effects include hypertension, dyspepsia, nausea, diarrhea, abdominal pain, arthralgia, back pain, localized osteoarthritis, myalgia, muscle cramp, influenza, nasopharyngitis, bonchitis, urinary tract infection, upper respiratory tract infection, headache, dizziness, skin rash, insomnia etc.   calcium orotate : bloating and swelling in the abdomen are common side effects of calcium orotate, loss of appetite, upset stomach, constipation, nausea, vomiting, unusual weight loss, mood changes, bone/muscle pain, headache, increased thirst/urination, weakness, unusual tiredness, formation of kidney stones may occur infrequently. ",ibandronic acid & calcium orotate
medication,ibandronic acid,0.9533267," the main side effects of ibandronic acid are dyspepsia, nausea, diarrhea, abdominal pain, muscle aches, headaches, dizziness. ",ibandronic acid
sign_symptom,allergic reactions,0.9995892," this gel is very well tolerated by users. however, some cases of burning, stinging, allergic reactions or red eyes after instillation have been reported. transient blurring of vision after administration has also been reported. ",hypromellose + carbomer
sign_symptom,red eyes,0.9911746," this gel is very well tolerated by users. however, some cases of burning, stinging, allergic reactions or red eyes after instillation have been reported. transient blurring of vision after administration has also been reported. ",hypromellose + carbomer
sign_symptom,blur,0.9998925," this gel is very well tolerated by users. however, some cases of burning, stinging, allergic reactions or red eyes after instillation have been reported. transient blurring of vision after administration has also been reported. ",hypromellose + carbomer
sign_symptom,blurred vision,0.9999116," common side effects are brief blurred vision or a slight stinging sensation on instilling hypromellose. hypromellose enriched with carbomer 980 is very well tolerated by users. however, some cases of burning, stinging, allergic reactions or red eyes after instillation have been reported. transient blurring of vision after administration has also been reported. ",hypromellose
sign_symptom,stinging sensation,0.9985922," common side effects are brief blurred vision or a slight stinging sensation on instilling hypromellose. hypromellose enriched with carbomer 980 is very well tolerated by users. however, some cases of burning, stinging, allergic reactions or red eyes after instillation have been reported. transient blurring of vision after administration has also been reported. ",hypromellose
sign_symptom,allergic reactions,0.99917805," common side effects are brief blurred vision or a slight stinging sensation on instilling hypromellose. hypromellose enriched with carbomer 980 is very well tolerated by users. however, some cases of burning, stinging, allergic reactions or red eyes after instillation have been reported. transient blurring of vision after administration has also been reported. ",hypromellose
sign_symptom,red eyes,0.999184," common side effects are brief blurred vision or a slight stinging sensation on instilling hypromellose. hypromellose enriched with carbomer 980 is very well tolerated by users. however, some cases of burning, stinging, allergic reactions or red eyes after instillation have been reported. transient blurring of vision after administration has also been reported. ",hypromellose
sign_symptom,blurring of vision,0.9695129," common side effects are brief blurred vision or a slight stinging sensation on instilling hypromellose. hypromellose enriched with carbomer 980 is very well tolerated by users. however, some cases of burning, stinging, allergic reactions or red eyes after instillation have been reported. transient blurring of vision after administration has also been reported. ",hypromellose
sign_symptom,adverse events,0.99963444," the most commonly reported adverse events associated with hylan g-f 20 are the following: pain in the injected knee, swelling in the injected knee, joint effusion ",hylan g-f 20
sign_symptom,pain,0.9999691," the most commonly reported adverse events associated with hylan g-f 20 are the following: pain in the injected knee, swelling in the injected knee, joint effusion ",hylan g-f 20
sign_symptom,swelling,0.99995947," the most commonly reported adverse events associated with hylan g-f 20 are the following: pain in the injected knee, swelling in the injected knee, joint effusion ",hylan g-f 20
disease_disorder,joint effusion,0.92615384," the most commonly reported adverse events associated with hylan g-f 20 are the following: pain in the injected knee, swelling in the injected knee, joint effusion ",hylan g-f 20
medication,hydroxyzine,0.8939655," side effects reported with the administration of hydroxyzine hhydrochloride are usually mild and transitory in nature. more common side effects include drowsiness, headache, psychomotor impairment, and antimuscarinic effects such as urinary retention, dry mouth, blurred vision, and gastrointestinal disturbances. other rare side-effects of antihistamines include hypotension, palpitation, arrhythmias, extrapyramidal effects, dizziness, confusion, depression, sleep disturbances, tremor, convulsions, hypersensitivity reactions (including bronchospasm, angioedema, and anaphylaxis, rashes, and photosensitivity reactions), blood disorders, liver dysfunction, and angle-closure glaucoma. ",hydroxyzine  hydrochloride
medication,hhydrochloride,0.9954629," side effects reported with the administration of hydroxyzine hhydrochloride are usually mild and transitory in nature. more common side effects include drowsiness, headache, psychomotor impairment, and antimuscarinic effects such as urinary retention, dry mouth, blurred vision, and gastrointestinal disturbances. other rare side-effects of antihistamines include hypotension, palpitation, arrhythmias, extrapyramidal effects, dizziness, confusion, depression, sleep disturbances, tremor, convulsions, hypersensitivity reactions (including bronchospasm, angioedema, and anaphylaxis, rashes, and photosensitivity reactions), blood disorders, liver dysfunction, and angle-closure glaucoma. ",hydroxyzine  hydrochloride
sign_symptom,hypersensitivity reactions,0.89178," side effects reported with the administration of hydroxyzine hhydrochloride are usually mild and transitory in nature. more common side effects include drowsiness, headache, psychomotor impairment, and antimuscarinic effects such as urinary retention, dry mouth, blurred vision, and gastrointestinal disturbances. other rare side-effects of antihistamines include hypotension, palpitation, arrhythmias, extrapyramidal effects, dizziness, confusion, depression, sleep disturbances, tremor, convulsions, hypersensitivity reactions (including bronchospasm, angioedema, and anaphylaxis, rashes, and photosensitivity reactions), blood disorders, liver dysfunction, and angle-closure glaucoma. ",hydroxyzine  hydrochloride
sign_symptom,hyper,0.8388259," gl disturbances, nausea, vomiting, constipation, diarrhea, hyperuricemia, renal failure, rash, hyperpigmentation. pulmonary oedema, dermatological reactions, headache, dizziness. disorientation, drowsiness, hallucinations, convulsions, alopecia. ",hydroxyurea
sign_symptom,halluc,0.9809497," gl disturbances, nausea, vomiting, constipation, diarrhea, hyperuricemia, renal failure, rash, hyperpigmentation. pulmonary oedema, dermatological reactions, headache, dizziness. disorientation, drowsiness, hallucinations, convulsions, alopecia. ",hydroxyurea
medication,hydroxypropyl methylcellulose,0.9956315," hydroxypropyl methylcellulose has been extremely well tolerated after injection into the human eye. a transient rise in intraocular pressure postoperatively has been reported in some cases. rarely, postoperative inflammatory reactions (iritis, hypopyon), as well as incidents of corneal edema and corneal decompensation, have been reported with viscoelastic agents. ",hydroxypropyl methylcellulose
sign_symptom,inflammatory reactions,0.8645488," hydroxypropyl methylcellulose has been extremely well tolerated after injection into the human eye. a transient rise in intraocular pressure postoperatively has been reported in some cases. rarely, postoperative inflammatory reactions (iritis, hypopyon), as well as incidents of corneal edema and corneal decompensation, have been reported with viscoelastic agents. ",hydroxypropyl methylcellulose
sign_symptom,edema,0.710186," hydroxypropyl methylcellulose has been extremely well tolerated after injection into the human eye. a transient rise in intraocular pressure postoperatively has been reported in some cases. rarely, postoperative inflammatory reactions (iritis, hypopyon), as well as incidents of corneal edema and corneal decompensation, have been reported with viscoelastic agents. ",hydroxypropyl methylcellulose
sign_symptom,hive,0.99959785," most common: injection site reactions (pain, swelling, pruritus, nodule), hives, itching, nausea, and diarrhea. call your doctor if you get any of the symptoms below: 
 
  blood clots symptoms : leg swelling, redness in your leg, a spot on your leg that is warm to touch, leg pain that worsens when you bend your foot. 
  allergic reactions : hives, itching, swelling of the face. 
  ",hydroxyprogesterone caproate
sign_symptom,blood clots,0.99972254," most common: injection site reactions (pain, swelling, pruritus, nodule), hives, itching, nausea, and diarrhea. call your doctor if you get any of the symptoms below: 
 
  blood clots symptoms : leg swelling, redness in your leg, a spot on your leg that is warm to touch, leg pain that worsens when you bend your foot. 
  allergic reactions : hives, itching, swelling of the face. 
  ",hydroxyprogesterone caproate
sign_symptom,redness,0.79692876," most common: injection site reactions (pain, swelling, pruritus, nodule), hives, itching, nausea, and diarrhea. call your doctor if you get any of the symptoms below: 
 
  blood clots symptoms : leg swelling, redness in your leg, a spot on your leg that is warm to touch, leg pain that worsens when you bend your foot. 
  allergic reactions : hives, itching, swelling of the face. 
  ",hydroxyprogesterone caproate
sign_symptom,spot,0.99554753," most common: injection site reactions (pain, swelling, pruritus, nodule), hives, itching, nausea, and diarrhea. call your doctor if you get any of the symptoms below: 
 
  blood clots symptoms : leg swelling, redness in your leg, a spot on your leg that is warm to touch, leg pain that worsens when you bend your foot. 
  allergic reactions : hives, itching, swelling of the face. 
  ",hydroxyprogesterone caproate
sign_symptom,pain,0.9999645," most common: injection site reactions (pain, swelling, pruritus, nodule), hives, itching, nausea, and diarrhea. call your doctor if you get any of the symptoms below: 
 
  blood clots symptoms : leg swelling, redness in your leg, a spot on your leg that is warm to touch, leg pain that worsens when you bend your foot. 
  allergic reactions : hives, itching, swelling of the face. 
  ",hydroxyprogesterone caproate
sign_symptom,swelling,0.9999255," most common: injection site reactions (pain, swelling, pruritus, nodule), hives, itching, nausea, and diarrhea. call your doctor if you get any of the symptoms below: 
 
  blood clots symptoms : leg swelling, redness in your leg, a spot on your leg that is warm to touch, leg pain that worsens when you bend your foot. 
  allergic reactions : hives, itching, swelling of the face. 
  ",hydroxyprogesterone caproate
medication,hydro,0.95580596," common (may affect up to 1 in 10 people): 
 
 itching is a known side effect of hydroxyethyl starches when used over long periods of time and at high doses. 
 other effects are associated with the dilution of the blood, which occurs at high dosages, such as prolonged blood clotting time. 
 the level of the enzyme serum amylase can arise during the administration of hydroxyethyl starch and can interfere with the diagnosis of inflammation of the pancreas (pancreatitis). however, this solution does not cause pancreatitis. 
  ",hydroxyethyl starch + sodium chloride
medication,starch,0.84047496," common (may affect up to 1 in 10 people): 
 
 itching is a known side effect of hydroxyethyl starches when used over long periods of time and at high doses. 
 other effects are associated with the dilution of the blood, which occurs at high dosages, such as prolonged blood clotting time. 
 the level of the enzyme serum amylase can arise during the administration of hydroxyethyl starch and can interfere with the diagnosis of inflammation of the pancreas (pancreatitis). however, this solution does not cause pancreatitis. 
  ",hydroxyethyl starch + sodium chloride
disease_disorder,inflammation,0.99883765," common (may affect up to 1 in 10 people): 
 
 itching is a known side effect of hydroxyethyl starches when used over long periods of time and at high doses. 
 other effects are associated with the dilution of the blood, which occurs at high dosages, such as prolonged blood clotting time. 
 the level of the enzyme serum amylase can arise during the administration of hydroxyethyl starch and can interfere with the diagnosis of inflammation of the pancreas (pancreatitis). however, this solution does not cause pancreatitis. 
  ",hydroxyethyl starch + sodium chloride
medication,hydro,0.99958163," generally hydroxychloroquine sulphate is well tolerated. however, few side effects like nausea, vomiting, stomach upset, loss of appetite, diarrhea, tiredness, weakness or headache and visual problem may occur the first several days. ",hydroxychloroquine sulphate
sign_symptom,loss of appetite,0.9996426," generally hydroxychloroquine sulphate is well tolerated. however, few side effects like nausea, vomiting, stomach upset, loss of appetite, diarrhea, tiredness, weakness or headache and visual problem may occur the first several days. ",hydroxychloroquine sulphate
sign_symptom,tired,0.99964845," generally hydroxychloroquine sulphate is well tolerated. however, few side effects like nausea, vomiting, stomach upset, loss of appetite, diarrhea, tiredness, weakness or headache and visual problem may occur the first several days. ",hydroxychloroquine sulphate
sign_symptom,weakness,0.9998053," generally hydroxychloroquine sulphate is well tolerated. however, few side effects like nausea, vomiting, stomach upset, loss of appetite, diarrhea, tiredness, weakness or headache and visual problem may occur the first several days. ",hydroxychloroquine sulphate
sign_symptom,headache,0.9997899," generally hydroxychloroquine sulphate is well tolerated. however, few side effects like nausea, vomiting, stomach upset, loss of appetite, diarrhea, tiredness, weakness or headache and visual problem may occur the first several days. ",hydroxychloroquine sulphate
disease_disorder,visual problem,0.968595," generally hydroxychloroquine sulphate is well tolerated. however, few side effects like nausea, vomiting, stomach upset, loss of appetite, diarrhea, tiredness, weakness or headache and visual problem may occur the first several days. ",hydroxychloroquine sulphate
sign_symptom,swelling,0.9999397," mild transient diarrhea, itching, transitory exanthema, feeling of swelling of entire body, and anaphylaxis. a few patients may experience pain after injection of hydroxocobalamin. ",hydroxocobalamin
sign_symptom,pain,0.9999417," mild transient diarrhea, itching, transitory exanthema, feeling of swelling of entire body, and anaphylaxis. a few patients may experience pain after injection of hydroxocobalamin. ",hydroxocobalamin
medication,hydro,0.9991767," mild transient diarrhea, itching, transitory exanthema, feeling of swelling of entire body, and anaphylaxis. a few patients may experience pain after injection of hydroxocobalamin. ",hydroxocobalamin
sign_symptom,burning,0.99708766," transient erythema, mild burning sensations; hyperpigmentation. staining and corneal opacities. tremors and convulsions after systemic absorption. occasionally, hypersensitivity. ",hydroquinone + octyldimethyl + dioxybenzone + oxybenzone
sign_symptom,hyper,0.9999498," transient erythema, mild burning sensations; hyperpigmentation. staining and corneal opacities. tremors and convulsions after systemic absorption. occasionally, hypersensitivity. ",hydroquinone + octyldimethyl + dioxybenzone + oxybenzone
sign_symptom,opac,0.89666784," transient erythema, mild burning sensations; hyperpigmentation. staining and corneal opacities. tremors and convulsions after systemic absorption. occasionally, hypersensitivity. ",hydroquinone + octyldimethyl + dioxybenzone + oxybenzone
sign_symptom,tremors,0.99336755," transient erythema, mild burning sensations; hyperpigmentation. staining and corneal opacities. tremors and convulsions after systemic absorption. occasionally, hypersensitivity. ",hydroquinone + octyldimethyl + dioxybenzone + oxybenzone
sign_symptom,adverse reactions,0.99993396, no systemic adverse reactions have been reported. occasional hypersensitivity (localized contact dermatitis) may occur in which case the medication should be discontinued. ,hydroquinone
sign_symptom,hyper,0.99996054, no systemic adverse reactions have been reported. occasional hypersensitivity (localized contact dermatitis) may occur in which case the medication should be discontinued. ,hydroquinone
medication,medication,0.87142795, no systemic adverse reactions have been reported. occasional hypersensitivity (localized contact dermatitis) may occur in which case the medication should be discontinued. ,hydroquinone
sign_symptom,nausea,0.9995845," the most common side effects are headache, rash, paraesthesia, dizziness, nausea and vomiting, flushing, excessive fluid retention in the body tissues, postural hypotension, fainting ",inositol nicotinate
sign_symptom,fluid retention,0.9839549," the most common side effects are headache, rash, paraesthesia, dizziness, nausea and vomiting, flushing, excessive fluid retention in the body tissues, postural hypotension, fainting ",inositol nicotinate
sign_symptom,fainting,0.9910017," the most common side effects are headache, rash, paraesthesia, dizziness, nausea and vomiting, flushing, excessive fluid retention in the body tissues, postural hypotension, fainting ",inositol nicotinate
sign_symptom,adverse reactions,0.9994502," most common adverse reactions (&gt;10%)- infections (e.g. upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain. ",infliximab
disease_disorder,infections,0.86795956," most common adverse reactions (&gt;10%)- infections (e.g. upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain. ",infliximab
sign_symptom,headache,0.87264895," headache, usually in the morning and mild vertigo may occur during the early weeks of therapy. these symptoms are transient and usually disappear with continued use or by reduction of the dose. gastrointestinal reactions such as nausea, vomiting, diarrhea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced. ",indomethacin (rectal)
sign_symptom,vertigo,0.99990237," headache, usually in the morning and mild vertigo may occur during the early weeks of therapy. these symptoms are transient and usually disappear with continued use or by reduction of the dose. gastrointestinal reactions such as nausea, vomiting, diarrhea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced. ",indomethacin (rectal)
sign_symptom,symptoms,0.9998191," headache, usually in the morning and mild vertigo may occur during the early weeks of therapy. these symptoms are transient and usually disappear with continued use or by reduction of the dose. gastrointestinal reactions such as nausea, vomiting, diarrhea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced. ",indomethacin (rectal)
sign_symptom,gastro,0.7942492," headache, usually in the morning and mild vertigo may occur during the early weeks of therapy. these symptoms are transient and usually disappear with continued use or by reduction of the dose. gastrointestinal reactions such as nausea, vomiting, diarrhea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced. ",indomethacin (rectal)
sign_symptom,pain,0.9999486," headache, usually in the morning and mild vertigo may occur during the early weeks of therapy. these symptoms are transient and usually disappear with continued use or by reduction of the dose. gastrointestinal reactions such as nausea, vomiting, diarrhea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced. ",indomethacin (rectal)
sign_symptom,headache,0.9984994," headaches, usually in the morning and kild vertigo may occur during the early weeks of therapy. these symptoms are transient and usually disappear with continued use or by reduction of the dose. rare case of mild psychic disturbances was also reported which subsided after few days of treatment, gastrointestinal reactions such as nausea, vomiting, diarrhoea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced. administration of the capsule immediately after meals with an antacid it necessary, minimize the frequency and the severity of these untoward effects. ",indomethacin (oral)
sign_symptom,vertigo,0.9990752," headaches, usually in the morning and kild vertigo may occur during the early weeks of therapy. these symptoms are transient and usually disappear with continued use or by reduction of the dose. rare case of mild psychic disturbances was also reported which subsided after few days of treatment, gastrointestinal reactions such as nausea, vomiting, diarrhoea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced. administration of the capsule immediately after meals with an antacid it necessary, minimize the frequency and the severity of these untoward effects. ",indomethacin (oral)
sign_symptom,symptoms,0.9998919," headaches, usually in the morning and kild vertigo may occur during the early weeks of therapy. these symptoms are transient and usually disappear with continued use or by reduction of the dose. rare case of mild psychic disturbances was also reported which subsided after few days of treatment, gastrointestinal reactions such as nausea, vomiting, diarrhoea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced. administration of the capsule immediately after meals with an antacid it necessary, minimize the frequency and the severity of these untoward effects. ",indomethacin (oral)
sign_symptom,psychic disturbances,0.99985397," headaches, usually in the morning and kild vertigo may occur during the early weeks of therapy. these symptoms are transient and usually disappear with continued use or by reduction of the dose. rare case of mild psychic disturbances was also reported which subsided after few days of treatment, gastrointestinal reactions such as nausea, vomiting, diarrhoea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced. administration of the capsule immediately after meals with an antacid it necessary, minimize the frequency and the severity of these untoward effects. ",indomethacin (oral)
sign_symptom,gastrointestinal reactions,0.9889084," headaches, usually in the morning and kild vertigo may occur during the early weeks of therapy. these symptoms are transient and usually disappear with continued use or by reduction of the dose. rare case of mild psychic disturbances was also reported which subsided after few days of treatment, gastrointestinal reactions such as nausea, vomiting, diarrhoea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced. administration of the capsule immediately after meals with an antacid it necessary, minimize the frequency and the severity of these untoward effects. ",indomethacin (oral)
sign_symptom,pain,0.99996233," headaches, usually in the morning and kild vertigo may occur during the early weeks of therapy. these symptoms are transient and usually disappear with continued use or by reduction of the dose. rare case of mild psychic disturbances was also reported which subsided after few days of treatment, gastrointestinal reactions such as nausea, vomiting, diarrhoea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced. administration of the capsule immediately after meals with an antacid it necessary, minimize the frequency and the severity of these untoward effects. ",indomethacin (oral)
sign_symptom,headache,0.8834033," asthenia, dizziness, headache, mood swings and/or sleep disturbances, cramps, hypotension, allergic reactions, skin rashes, gastrointestinal disorders, dry cough, dry mouth, risk of dehydration in the elderly and in patients suffering from heart failure; changes in blood test results may occur. ",indapamide + perindopril arginine
sign_symptom,mood swings,0.99958754," asthenia, dizziness, headache, mood swings and/or sleep disturbances, cramps, hypotension, allergic reactions, skin rashes, gastrointestinal disorders, dry cough, dry mouth, risk of dehydration in the elderly and in patients suffering from heart failure; changes in blood test results may occur. ",indapamide + perindopril arginine
sign_symptom,sleep,0.960234," asthenia, dizziness, headache, mood swings and/or sleep disturbances, cramps, hypotension, allergic reactions, skin rashes, gastrointestinal disorders, dry cough, dry mouth, risk of dehydration in the elderly and in patients suffering from heart failure; changes in blood test results may occur. ",indapamide + perindopril arginine
sign_symptom,allergic reactions,0.97679055," asthenia, dizziness, headache, mood swings and/or sleep disturbances, cramps, hypotension, allergic reactions, skin rashes, gastrointestinal disorders, dry cough, dry mouth, risk of dehydration in the elderly and in patients suffering from heart failure; changes in blood test results may occur. ",indapamide + perindopril arginine
sign_symptom,rash,0.84648687," asthenia, dizziness, headache, mood swings and/or sleep disturbances, cramps, hypotension, allergic reactions, skin rashes, gastrointestinal disorders, dry cough, dry mouth, risk of dehydration in the elderly and in patients suffering from heart failure; changes in blood test results may occur. ",indapamide + perindopril arginine
sign_symptom,dehydration,0.96184534," asthenia, dizziness, headache, mood swings and/or sleep disturbances, cramps, hypotension, allergic reactions, skin rashes, gastrointestinal disorders, dry cough, dry mouth, risk of dehydration in the elderly and in patients suffering from heart failure; changes in blood test results may occur. ",indapamide + perindopril arginine
disease_disorder,heart,0.98397845," asthenia, dizziness, headache, mood swings and/or sleep disturbances, cramps, hypotension, allergic reactions, skin rashes, gastrointestinal disorders, dry cough, dry mouth, risk of dehydration in the elderly and in patients suffering from heart failure; changes in blood test results may occur. ",indapamide + perindopril arginine
sign_symptom,adverse reactions,0.9798484," the most commonly reported adverse reactions with indapamide and amlodipine given separately are somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, oedema and fatigue. ",indapamide + amlodipine
medication,amlodipine,0.9666586," the most commonly reported adverse reactions with indapamide and amlodipine given separately are somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, oedema and fatigue. ",indapamide + amlodipine
sign_symptom,nausea,0.8626501," side effects of indapamide include headache, anorexia, gastric irritation,nausea, vomiting, constipation, diarrhoea etc. ",indapamide
sign_symptom,vomiting,0.98399734," side effects of indapamide include headache, anorexia, gastric irritation,nausea, vomiting, constipation, diarrhoea etc. ",indapamide
sign_symptom,consti,0.97793764," side effects of indapamide include headache, anorexia, gastric irritation,nausea, vomiting, constipation, diarrhoea etc. ",indapamide
sign_symptom,diarr,0.99801517," side effects of indapamide include headache, anorexia, gastric irritation,nausea, vomiting, constipation, diarrhoea etc. ",indapamide
sign_symptom,nasopharyn,0.9086228," the most commonly reported adverse effects were cough, nasopharyngitis, headache, nausea, oropharyngeal pain. some other also reported of hypersensitivity reactions, paradoxical bronchospasm, tachycardia, pruritis and dizziness. ",indacaterol maleate
sign_symptom,hypersensitivity,0.99977106," the most commonly reported adverse effects were cough, nasopharyngitis, headache, nausea, oropharyngeal pain. some other also reported of hypersensitivity reactions, paradoxical bronchospasm, tachycardia, pruritis and dizziness. ",indacaterol maleate
medication,vaccine,0.90919876," following vaccine administration, a mild erythematous reaction and induration has been observed at the site of injection, in rare cases. in a few instances, the erythema may be accompanied by moderate fever. ",inactivated polio vaccine
sign_symptom,induration,0.9993682," following vaccine administration, a mild erythematous reaction and induration has been observed at the site of injection, in rare cases. in a few instances, the erythema may be accompanied by moderate fever. ",inactivated polio vaccine
sign_symptom,reactions,0.9999058," reactions at the site of injection are common but can be recovered within 72 hours without any treatment. some of the mild and temporary adverse reactions are: pain and redness at the site of injection, fever after vaccination. ",inactivated hepatitis a vaccine
sign_symptom,adverse reactions,0.9997295," reactions at the site of injection are common but can be recovered within 72 hours without any treatment. some of the mild and temporary adverse reactions are: pain and redness at the site of injection, fever after vaccination. ",inactivated hepatitis a vaccine
sign_symptom,pain,0.99996126," reactions at the site of injection are common but can be recovered within 72 hours without any treatment. some of the mild and temporary adverse reactions are: pain and redness at the site of injection, fever after vaccination. ",inactivated hepatitis a vaccine
sign_symptom,redness,0.9928747," reactions at the site of injection are common but can be recovered within 72 hours without any treatment. some of the mild and temporary adverse reactions are: pain and redness at the site of injection, fever after vaccination. ",inactivated hepatitis a vaccine
sign_symptom,fever,0.9999137," reactions at the site of injection are common but can be recovered within 72 hours without any treatment. some of the mild and temporary adverse reactions are: pain and redness at the site of injection, fever after vaccination. ",inactivated hepatitis a vaccine
sign_symptom,pain,0.998401," reported side effects are pustules, genital candidiasis, vaginitis, bacterial infection, fungal infection, upper respiratory tract infection, vulvitis, rhinitis, influenza, lymphadenopathy, anorexia, insomnia, depression, irritability, headache, paraesthesia, dizziness, migraine, somnolence, conjunctival irritation, eyelid oedema, tinnitus, flushing, pharyngitis, nasal congestion, pharyngo laryngeal pain, nausea, abdominal pain, diarrhoea, vomitting, rectal disorder, rectal tenesmus, dry mouth, pruritus, folliculitis, rash erythematous, eczema, rash, increased sweating, urticaria, erythema, face oedema, skin ulcer, myalgia, arthralgia, back pain, pain in extremity, dysuria, genital pain in male, penile disorder, dyspareunia, erectile dysfunction, uterovaginal prolapse, vaginal pain, vaginitis atrophic, vulval disorder, and general disorders and administration site disorders such as pruritus, pain, burning, irritation, erythema, reaction, bleeding, papules, rash, inflammation asthenia, malaise, rigors, lethargy, discomfort, fatigue, discharge, oedema, scar, ulcer, vesicle, warmth, pyrexia etc. reports have been received of localised hypopigmentation and hyperpigmentation following imiquimod cream use. clinical studies investigating the use of imiquimod for the treatment of actinic keratosis have detected a 0.4% frequency of alopecia at the treatment site or surrounding area. reductions in haemoglobin, white blood cell count, absolute neutrophils and platelets have been observed in clinical trials. ",imiquimod
sign_symptom,hyper,0.99598676," reported side effects are pustules, genital candidiasis, vaginitis, bacterial infection, fungal infection, upper respiratory tract infection, vulvitis, rhinitis, influenza, lymphadenopathy, anorexia, insomnia, depression, irritability, headache, paraesthesia, dizziness, migraine, somnolence, conjunctival irritation, eyelid oedema, tinnitus, flushing, pharyngitis, nasal congestion, pharyngo laryngeal pain, nausea, abdominal pain, diarrhoea, vomitting, rectal disorder, rectal tenesmus, dry mouth, pruritus, folliculitis, rash erythematous, eczema, rash, increased sweating, urticaria, erythema, face oedema, skin ulcer, myalgia, arthralgia, back pain, pain in extremity, dysuria, genital pain in male, penile disorder, dyspareunia, erectile dysfunction, uterovaginal prolapse, vaginal pain, vaginitis atrophic, vulval disorder, and general disorders and administration site disorders such as pruritus, pain, burning, irritation, erythema, reaction, bleeding, papules, rash, inflammation asthenia, malaise, rigors, lethargy, discomfort, fatigue, discharge, oedema, scar, ulcer, vesicle, warmth, pyrexia etc. reports have been received of localised hypopigmentation and hyperpigmentation following imiquimod cream use. clinical studies investigating the use of imiquimod for the treatment of actinic keratosis have detected a 0.4% frequency of alopecia at the treatment site or surrounding area. reductions in haemoglobin, white blood cell count, absolute neutrophils and platelets have been observed in clinical trials. ",imiquimod
medication,imip,0.8220979," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
sign_symptom,strokes,0.9991872," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
sign_symptom,confusion,0.9342982," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
sign_symptom,"delusions,",0.8903435," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
sign_symptom,insomnia,0.99382955," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
sign_symptom,anxiety,0.9687015," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
sign_symptom,problems,0.9977914," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
sign_symptom,loss of sensation,0.8367308," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
sign_symptom,numb,0.76897514," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
sign_symptom,ringing in the ears,0.99798733," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
sign_symptom,loss of appetite,0.99526674," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
medication,imipram,0.75071317," the most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. heart attacks, congestive heart failure, and strokes have been reported. confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people. ",imipramine hydrochloride
sign_symptom,nausea,0.9987608," most common side effects with imipenem are nausea and vomiting. other side effects reported with this drug are diarrhea, rash, thrombophlebitis, thrombocytosis, neutro-penia, eosinophilia and derangements of liver and renal functions. use of imipenem is not recommended for patient with history of anaphylactic reaction with penicillin. ",imipenem + cilastatin
sign_symptom,adverse reactions,0.99984396," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
sign_symptom,fluid retention,0.9999109," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
sign_symptom,edema,0.99930596," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
sign_symptom,hematologic toxicity,0.99966013," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
disease_disorder,heart failure,0.99985075," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
disease_disorder,left ventricular dysfunction,0.9939965," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
disease_disorder,hepatotoxicity,0.9990812," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
disease_disorder,hemorrhage,0.7545281," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
disease_disorder,gastrointestinal disorders,0.99318236," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
disease_disorder,cardiac,0.99214935," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
sign_symptom,toxicity,0.7172223," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
sign_symptom,dermatologic,0.9901476," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
sign_symptom,toxicities,0.99569464," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
sign_symptom,growth retardation,0.8063454," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
sign_symptom,tumor,0.97377354," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
sign_symptom,impairment,0.91331804," the following serious adverse reactions are described elsewhere in the labeling: 
 
 fluid retention and edema 
 hematologic toxicity 
 congestive heart failure and left ventricular dysfunction 
 hepatotoxicity 
 hemorrhage 
 gastrointestinal disorders 
 hypereosinophilic cardiac toxicity 
 dermatologic toxicities 
 hypothyroidism 
 growth retardation in children and adolescents 
 tumor lysis syndrome 
 impairments related to driving and using machinery 
 renal toxicity 
  ",imatinib mesylate
sign_symptom,dry mouth,0.99929845," dizziness (20%), dry mouth (15%), nausea (10%), somnolence (10%), tachycardia, diarrhea, ejaculation failure, myalgia, nasal congestion, orthostatic hypotension, palpitations, urinary incontinence, weight gain ",iloperidone
sign_symptom,nausea,0.9999393," dizziness (20%), dry mouth (15%), nausea (10%), somnolence (10%), tachycardia, diarrhea, ejaculation failure, myalgia, nasal congestion, orthostatic hypotension, palpitations, urinary incontinence, weight gain ",iloperidone
sign_symptom,ejaculation,0.9827707," dizziness (20%), dry mouth (15%), nausea (10%), somnolence (10%), tachycardia, diarrhea, ejaculation failure, myalgia, nasal congestion, orthostatic hypotension, palpitations, urinary incontinence, weight gain ",iloperidone
sign_symptom,urina,0.9496154," dizziness (20%), dry mouth (15%), nausea (10%), somnolence (10%), tachycardia, diarrhea, ejaculation failure, myalgia, nasal congestion, orthostatic hypotension, palpitations, urinary incontinence, weight gain ",iloperidone
sign_symptom,weight gain,0.9999057," dizziness (20%), dry mouth (15%), nausea (10%), somnolence (10%), tachycardia, diarrhea, ejaculation failure, myalgia, nasal congestion, orthostatic hypotension, palpitations, urinary incontinence, weight gain ",iloperidone
sign_symptom,irritation,0.96461827," common side effects are eye irritation or pain, redness, itching, swelling of the eye, increased sensitivity to light and glare ",idoxuridine
sign_symptom,swelling,0.9992631," common side effects are eye irritation or pain, redness, itching, swelling of the eye, increased sensitivity to light and glare ",idoxuridine
sign_symptom,glare,0.9827959," common side effects are eye irritation or pain, redness, itching, swelling of the eye, increased sensitivity to light and glare ",idoxuridine
sign_symptom,hypotension,0.896016," diarrhoea, fatigue, dyspepsia or heartburn, dizziness, orthostatic hypotension, nausea, vomiting, musculoskeletal pain, thrombocytopaenia, hyperkalaemia, elevated serum creatinine. ",irbesartan
sign_symptom,allergic - type reactions,0.99949086," allergic-type reactions such as skin rash, angio-oedema of the tongue, lips and face, urticaria (including giant urticaria), laryngospasm and anaphylactic reactions have been reported, with positive rechallenge in some cases. ",ipratropium bromide (nebuliser solution)
sign_symptom,angio - oedema,0.9989383," allergic-type reactions such as skin rash, angio-oedema of the tongue, lips and face, urticaria (including giant urticaria), laryngospasm and anaphylactic reactions have been reported, with positive rechallenge in some cases. ",ipratropium bromide (nebuliser solution)
sign_symptom,anaphyla,0.99955034," allergic-type reactions such as skin rash, angio-oedema of the tongue, lips and face, urticaria (including giant urticaria), laryngospasm and anaphylactic reactions have been reported, with positive rechallenge in some cases. ",ipratropium bromide (nebuliser solution)
medication,lpratropium,0.9590065," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
medication,bromide,0.9434486," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,adverse effects,0.99984443," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,inhibition,0.9998853," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,receptors,0.7431985," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,gang,0.9813891," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,blockade,0.977518," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
medication,ipratropium,0.7604202," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,dry mouth,0.9995548," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,adverse reactions,0.9990501," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,dryness,0.9952391," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,cough,0.8838431," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,imitation,0.9446088," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
medication,aerosol,0.80082214," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,headache,0.9999471," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,blurred vision,0.99954677," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,nervous,0.97815096," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,precipitation,0.9961415," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,pain,0.99931204," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,allergic - type reactions,0.9994406," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,skin,0.9339847," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,anaphyla,0.99828523," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,adverse,0.8438141," idiosyncratic reactions to lpratropium bromide are rare. severe adverse effects due to inhibition of muscarinic receptors and ganglion blockade are theoretically possible but unlikely with the metered-dose aerosol. regular use of ipratropium can lead to a dry mouth through inhibition of salivary flow.  other most common adverse reactions reported are - dryness of the oropharynx (5%); cough, exacerbation of symptoms, &amp; imitation from aerosol (3%); headache (2%); nausea, dizziness, blurred vision/difficulty in accommodation &amp; drying of secretions (1%).  less frequently reported adverse reactions include tachycardia, nervousness, paresthesias, drowsiness, co-ordination difficulty, itching, flushing, alopecia, constipation, tremor &amp; mucosal ulceration. case of precipitation or worsening of narrow-angle glaucoma, acute eye pain &amp; hypotension also have been reported. allergic-type reactions such as skin rash, angio-oedema of tongue, lips &amp; face, urticaria (including giant urticaria), laryngospasm and anaphylactic reaction have been also reported; with positive rechallenge in some cases.  ipratropium bromide dose not produce adverse effects on mucociliary clearance, in contrast to atropine and other muscarinic antagonists. there is no evidence that in the therapeutic does range ipratropium bromide has any adverse effect on bronchial secretion. ",ipratropium bromide (inhaler)
sign_symptom,tight,0.98349947," common side effects are arrhythmias, arterial spasm, flushing, vasodilatation, angina, cardiopulmonary arrest; dizziness, confusion, paraesthesia, visual disturbances, seizure, paralysis, coma, temporary amnesia; inj site pain, pallor, periorbital and facial oedema; coughing, sneezing, rhinitis, asthma, apnoea, laryngeal oedema, chest tightness; watery itchy eyes, lachrymation, conjunctivitis; muscle spasm, involuntary leg movement; tremors, malaise; severe retching and choking, abdominal pain; urogenital pain, haematuria. ",iopamidol
sign_symptom,mala,0.99958664," common side effects are arrhythmias, arterial spasm, flushing, vasodilatation, angina, cardiopulmonary arrest; dizziness, confusion, paraesthesia, visual disturbances, seizure, paralysis, coma, temporary amnesia; inj site pain, pallor, periorbital and facial oedema; coughing, sneezing, rhinitis, asthma, apnoea, laryngeal oedema, chest tightness; watery itchy eyes, lachrymation, conjunctivitis; muscle spasm, involuntary leg movement; tremors, malaise; severe retching and choking, abdominal pain; urogenital pain, haematuria. ",iopamidol
sign_symptom,adverse reactions,0.999827," most common adverse reactions (incidence greater than 0.5%) in adult patients after iodixanolinjection: discomfort, warmth, pain   cardiovascular : angina. gastrointestinal: diarrhea, nausea, vomiting.   nervous system : agitation, anxiety, insomnia, nervousness, dizziness, headache, migraine, unusual skin sensations, sensory disturbance, fainting, sensation of spinning.    skin : itchy rash, severe itching, hives.   special senses : smell, taste, and vision alteration. pediatric patients experienced similar adverse reactions. ",iodixanol
medication,iodixano,0.9205029," most common adverse reactions (incidence greater than 0.5%) in adult patients after iodixanolinjection: discomfort, warmth, pain   cardiovascular : angina. gastrointestinal: diarrhea, nausea, vomiting.   nervous system : agitation, anxiety, insomnia, nervousness, dizziness, headache, migraine, unusual skin sensations, sensory disturbance, fainting, sensation of spinning.    skin : itchy rash, severe itching, hives.   special senses : smell, taste, and vision alteration. pediatric patients experienced similar adverse reactions. ",iodixanol
sign_symptom,pain,0.9996853," most common adverse reactions (incidence greater than 0.5%) in adult patients after iodixanolinjection: discomfort, warmth, pain   cardiovascular : angina. gastrointestinal: diarrhea, nausea, vomiting.   nervous system : agitation, anxiety, insomnia, nervousness, dizziness, headache, migraine, unusual skin sensations, sensory disturbance, fainting, sensation of spinning.    skin : itchy rash, severe itching, hives.   special senses : smell, taste, and vision alteration. pediatric patients experienced similar adverse reactions. ",iodixanol
sign_symptom,hive,0.9804935," most common adverse reactions (incidence greater than 0.5%) in adult patients after iodixanolinjection: discomfort, warmth, pain   cardiovascular : angina. gastrointestinal: diarrhea, nausea, vomiting.   nervous system : agitation, anxiety, insomnia, nervousness, dizziness, headache, migraine, unusual skin sensations, sensory disturbance, fainting, sensation of spinning.    skin : itchy rash, severe itching, hives.   special senses : smell, taste, and vision alteration. pediatric patients experienced similar adverse reactions. ",iodixanol
sign_symptom,shivering,0.7459114," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,chills,0.9997292," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,nausea,0.9999491," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,vomiting,0.99909735," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,adverse events,0.99912834," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,hypersensitivity reactions,0.9966253," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,respiratory symptoms,0.99974203," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,tired,0.99985063," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,priapism,0.9996155," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,neurological,0.91363186," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,adverse reactions,0.9999228," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,headache,0.99987936," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,dyspno,0.9690473," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,slight,0.99905664," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,pressure over the,0.8000726," thisiv infusion may cause a rise in body temperature (incidence &lt;3%) and, less frequently, shivering, chills and nausea/vomiting (incidence &lt;1%). reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. thrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported. ",intravenous fat emulsion
sign_symptom,para,0.8874974," depressive illness, suicidal behaviour, irritability, insomnia, anxiety. flu-like symptoms. headache, dizziness, paraesthesia, confusion, impaired concentration, alteration in taste or smell. gl disturbances. dryness of oropharynx, epistaxis, rhinitis, arrhythmia, sinusitis. inj site reaction, alopecia, rash, dry skin or pruritus. conjunctivitis, menstrual irregularity, visual disturbances. coughing, dyspnoea. myalgia, joint or bone pain, arthritis or polyarthritis. bone marrow depression. ",interferon alfa-2a [recombinant]
sign_symptom,confusion,0.9443789," depressive illness, suicidal behaviour, irritability, insomnia, anxiety. flu-like symptoms. headache, dizziness, paraesthesia, confusion, impaired concentration, alteration in taste or smell. gl disturbances. dryness of oropharynx, epistaxis, rhinitis, arrhythmia, sinusitis. inj site reaction, alopecia, rash, dry skin or pruritus. conjunctivitis, menstrual irregularity, visual disturbances. coughing, dyspnoea. myalgia, joint or bone pain, arthritis or polyarthritis. bone marrow depression. ",interferon alfa-2a [recombinant]
sign_symptom,impaired concentration,0.9954878," depressive illness, suicidal behaviour, irritability, insomnia, anxiety. flu-like symptoms. headache, dizziness, paraesthesia, confusion, impaired concentration, alteration in taste or smell. gl disturbances. dryness of oropharynx, epistaxis, rhinitis, arrhythmia, sinusitis. inj site reaction, alopecia, rash, dry skin or pruritus. conjunctivitis, menstrual irregularity, visual disturbances. coughing, dyspnoea. myalgia, joint or bone pain, arthritis or polyarthritis. bone marrow depression. ",interferon alfa-2a [recombinant]
sign_symptom,alteration in taste,0.9996686," depressive illness, suicidal behaviour, irritability, insomnia, anxiety. flu-like symptoms. headache, dizziness, paraesthesia, confusion, impaired concentration, alteration in taste or smell. gl disturbances. dryness of oropharynx, epistaxis, rhinitis, arrhythmia, sinusitis. inj site reaction, alopecia, rash, dry skin or pruritus. conjunctivitis, menstrual irregularity, visual disturbances. coughing, dyspnoea. myalgia, joint or bone pain, arthritis or polyarthritis. bone marrow depression. ",interferon alfa-2a [recombinant]
sign_symptom,epistaxi,0.90711904," depressive illness, suicidal behaviour, irritability, insomnia, anxiety. flu-like symptoms. headache, dizziness, paraesthesia, confusion, impaired concentration, alteration in taste or smell. gl disturbances. dryness of oropharynx, epistaxis, rhinitis, arrhythmia, sinusitis. inj site reaction, alopecia, rash, dry skin or pruritus. conjunctivitis, menstrual irregularity, visual disturbances. coughing, dyspnoea. myalgia, joint or bone pain, arthritis or polyarthritis. bone marrow depression. ",interferon alfa-2a [recombinant]
sign_symptom,dry skin,0.9535545," depressive illness, suicidal behaviour, irritability, insomnia, anxiety. flu-like symptoms. headache, dizziness, paraesthesia, confusion, impaired concentration, alteration in taste or smell. gl disturbances. dryness of oropharynx, epistaxis, rhinitis, arrhythmia, sinusitis. inj site reaction, alopecia, rash, dry skin or pruritus. conjunctivitis, menstrual irregularity, visual disturbances. coughing, dyspnoea. myalgia, joint or bone pain, arthritis or polyarthritis. bone marrow depression. ",interferon alfa-2a [recombinant]
sign_symptom,hypersen,0.83413136," hypoglycaemia; hypokalemia, oedema; pruritus; pulpitation, nausea, rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with sc inj. ",insulin lispro protamine + insulin lispro
sign_symptom,lipohypertrophy,0.99748087," hypoglycaemia; hypokalemia, oedema; pruritus; pulpitation, nausea, rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with sc inj. ",insulin lispro protamine + insulin lispro
medication,insulin,0.99930394," clinical studies comparing insulin lispro with regular human insulin did not demonstrate a difference in frequency of adverse events between the two treatments. adverse events commonly associated with human insulin therapy include the following: body as a whole: allergic reactions. skin and appendages: injection site reaction, lipodystrophy, pruritus, rash. other: hypoglycemia. ",insulin lispro
sign_symptom,adverse events,0.9908707," clinical studies comparing insulin lispro with regular human insulin did not demonstrate a difference in frequency of adverse events between the two treatments. adverse events commonly associated with human insulin therapy include the following: body as a whole: allergic reactions. skin and appendages: injection site reaction, lipodystrophy, pruritus, rash. other: hypoglycemia. ",insulin lispro
sign_symptom,allergic,0.9997701," clinical studies comparing insulin lispro with regular human insulin did not demonstrate a difference in frequency of adverse events between the two treatments. adverse events commonly associated with human insulin therapy include the following: body as a whole: allergic reactions. skin and appendages: injection site reaction, lipodystrophy, pruritus, rash. other: hypoglycemia. ",insulin lispro
medication,insulin,0.94766456," hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. few cases of the allergic reaction such as red and swollen or itching are reported. it usually disappears in a few days. in some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. ",insulin human [rdna] + isophane insulin human
medication,insulin,0.94766456," hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. few cases of the allergic reaction such as red and swollen or itching are reported. it usually disappears in a few days. in some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. ",insulin human [long-acting]
disease_disorder,hypoglycemia,0.92507315," hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. few cases of the allergic reaction such as red and swollen or itching are reported. it usually disappears in a few days. in some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. ",insulin human [rdna] + isophane insulin human
disease_disorder,hypoglycemia,0.92507315," hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. few cases of the allergic reaction such as red and swollen or itching are reported. it usually disappears in a few days. in some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. ",insulin human [long-acting]
sign_symptom,allergic reaction,0.9992206," hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. few cases of the allergic reaction such as red and swollen or itching are reported. it usually disappears in a few days. in some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. ",insulin human [rdna] + isophane insulin human
sign_symptom,allergic reaction,0.9992206," hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. few cases of the allergic reaction such as red and swollen or itching are reported. it usually disappears in a few days. in some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. ",insulin human [long-acting]
sign_symptom,swollen,0.9992366," hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. few cases of the allergic reaction such as red and swollen or itching are reported. it usually disappears in a few days. in some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. ",insulin human [rdna] + isophane insulin human
sign_symptom,swollen,0.9992366," hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. few cases of the allergic reaction such as red and swollen or itching are reported. it usually disappears in a few days. in some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. ",insulin human [long-acting]
sign_symptom,cold,0.7978493, low blood sugar (hypoglycaemia) is a very common side effect. it may affect more than 1 in 10 people.  signs of low blood sugar: cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating. ,insulin human [fast-acting]
sign_symptom,sick,0.9429897, low blood sugar (hypoglycaemia) is a very common side effect. it may affect more than 1 in 10 people.  signs of low blood sugar: cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating. ,insulin human [fast-acting]
sign_symptom,hungry,0.7521552, low blood sugar (hypoglycaemia) is a very common side effect. it may affect more than 1 in 10 people.  signs of low blood sugar: cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating. ,insulin human [fast-acting]
sign_symptom,changes,0.973937, low blood sugar (hypoglycaemia) is a very common side effect. it may affect more than 1 in 10 people.  signs of low blood sugar: cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating. ,insulin human [fast-acting]
sign_symptom,drows,0.78994375, low blood sugar (hypoglycaemia) is a very common side effect. it may affect more than 1 in 10 people.  signs of low blood sugar: cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating. ,insulin human [fast-acting]
sign_symptom,tiredness,0.9903555, low blood sugar (hypoglycaemia) is a very common side effect. it may affect more than 1 in 10 people.  signs of low blood sugar: cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating. ,insulin human [fast-acting]
sign_symptom,nervousness,0.9975816, low blood sugar (hypoglycaemia) is a very common side effect. it may affect more than 1 in 10 people.  signs of low blood sugar: cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating. ,insulin human [fast-acting]
sign_symptom,allergic reactions,0.9998268," some times severe, life-threatening allergic reactions can happen with insulin. if you think you are having a severe allergic reaction, get medical help right away. signs of insulin allergy include: 
 
 rash all over your body 
 shortness of breath 
 wheezing (trouble breathing) 
 fast pulse 
 sweating 
 low blood pressure 
  ",insulin glulisine
medication,insulin,0.9930059," some times severe, life-threatening allergic reactions can happen with insulin. if you think you are having a severe allergic reaction, get medical help right away. signs of insulin allergy include: 
 
 rash all over your body 
 shortness of breath 
 wheezing (trouble breathing) 
 fast pulse 
 sweating 
 low blood pressure 
  ",insulin glulisine
sign_symptom,rash,0.9999474," some times severe, life-threatening allergic reactions can happen with insulin. if you think you are having a severe allergic reaction, get medical help right away. signs of insulin allergy include: 
 
 rash all over your body 
 shortness of breath 
 wheezing (trouble breathing) 
 fast pulse 
 sweating 
 low blood pressure 
  ",insulin glulisine
sign_symptom,body,0.8178071," some times severe, life-threatening allergic reactions can happen with insulin. if you think you are having a severe allergic reaction, get medical help right away. signs of insulin allergy include: 
 
 rash all over your body 
 shortness of breath 
 wheezing (trouble breathing) 
 fast pulse 
 sweating 
 low blood pressure 
  ",insulin glulisine
sign_symptom,shortness of breath,0.9998926," some times severe, life-threatening allergic reactions can happen with insulin. if you think you are having a severe allergic reaction, get medical help right away. signs of insulin allergy include: 
 
 rash all over your body 
 shortness of breath 
 wheezing (trouble breathing) 
 fast pulse 
 sweating 
 low blood pressure 
  ",insulin glulisine
sign_symptom,wheezing,0.7796583," some times severe, life-threatening allergic reactions can happen with insulin. if you think you are having a severe allergic reaction, get medical help right away. signs of insulin allergy include: 
 
 rash all over your body 
 shortness of breath 
 wheezing (trouble breathing) 
 fast pulse 
 sweating 
 low blood pressure 
  ",insulin glulisine
sign_symptom,trouble breathing,0.9947077," some times severe, life-threatening allergic reactions can happen with insulin. if you think you are having a severe allergic reaction, get medical help right away. signs of insulin allergy include: 
 
 rash all over your body 
 shortness of breath 
 wheezing (trouble breathing) 
 fast pulse 
 sweating 
 low blood pressure 
  ",insulin glulisine
sign_symptom,sweating,0.9976776," some times severe, life-threatening allergic reactions can happen with insulin. if you think you are having a severe allergic reaction, get medical help right away. signs of insulin allergy include: 
 
 rash all over your body 
 shortness of breath 
 wheezing (trouble breathing) 
 fast pulse 
 sweating 
 low blood pressure 
  ",insulin glulisine
sign_symptom,pressure,0.7730362," some times severe, life-threatening allergic reactions can happen with insulin. if you think you are having a severe allergic reaction, get medical help right away. signs of insulin allergy include: 
 
 rash all over your body 
 shortness of breath 
 wheezing (trouble breathing) 
 fast pulse 
 sweating 
 low blood pressure 
  ",insulin glulisine
medication,insulin,0.99953604," side effects of insulin glargine are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, and rash. ",insulin glargine [rdna]
sign_symptom,allergic,0.74300444," side effects of insulin glargine are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, and rash. ",insulin glargine [rdna]
sign_symptom,swelling,0.90275425," hypoglycaemia, lipodystrophy, pruritus, rash, wt gain, sodium retention and oedema. inj site reactions e.g. pain, itching, hives, swelling and inflammation. influenza-like symptoms, pallor, palpitation, tachycardia, mental confusion, weakness, blurred vision, itching, hunger, nausea. ",insulin detemir
sign_symptom,rash,0.73838323," hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain ",insulin degludec + insulin aspart premixed
sign_symptom,edema,0.9981327," hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain ",insulin degludec + insulin aspart premixed
sign_symptom,weight gain,0.99992836," hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain ",insulin degludec + insulin aspart premixed
sign_symptom,peripheral edema,0.9363062," nasopharyngitis, severe hypoglycemic episode, upper respiratory tract infection, headache, diarrhea, sinusitis, gastroenteritis, injection site reactions, peripheral edema ",insulin degludec
sign_symptom,hypersensitivity,0.9970685," most common side effects are hypoglycemia, hypersensitivity and allergic reactions, hypokalemia, injection site reaction, lipodystrophy, pruritus and rash. ",insulin aspart + insulin aspart protamine
medication,insulin,0.99855465," side effects of insulin aspart are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus and rash. ",insulin aspart
medication,insulin,0.99855465," side effects of insulin aspart are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus and rash. ",protamine crystallised insulin aspart
sign_symptom,irritation,0.99982125," in normal use, isotretinoin may cause stinging, burning or irritation; erythema andpeeling at the site of application may occur. if undue irritation occurs, treatment should beinterrupted temporarily and resumed once the reaction subsides. if irritation persists, treatmentshould be discontinued. reactions will normally resolve on discontinuation of therapy. ",isotretinoin (topical)
sign_symptom,reactions,0.95176756," in normal use, isotretinoin may cause stinging, burning or irritation; erythema andpeeling at the site of application may occur. if undue irritation occurs, treatment should beinterrupted temporarily and resumed once the reaction subsides. if irritation persists, treatmentshould be discontinued. reactions will normally resolve on discontinuation of therapy. ",isotretinoin (topical)
sign_symptom,side,0.87737876," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
sign_symptom,dryness,0.7682184," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
sign_symptom,mucosae,0.8500759," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
disease_disorder,infections,0.9878676," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
disease_disorder,system,0.86469084," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
sign_symptom,allergic,0.8407317," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
disease_disorder,hyper,0.98248625," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
disease_disorder,depression,0.8394896," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
disease_disorder,suicide,0.8969423," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
sign_symptom,blurred,0.9706162," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
disease_disorder,labyrinth disorders,0.83545864," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
disease_disorder,vascu,0.9151381," some of the side effects associated with the use of isotretinoin are dose-related. the side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. the following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).  the incidence of the adverse events was calculated from pooled clinical trial data involving 824 patients and from post-marketing data. frequency categories are defined as very common (1/10), common (1/100 to &lt;1/10), uncommon (1/1,000 to &lt;1/100), rare (1/10,000 to &lt;1/1,000), very rare (1/10,000 to &lt;1/1,000) and not known (cannot be estimated from the available data. infections: very rare: gram positive (mucocutaneous) bacterial infection blood and lymphatic system disorders: very common: anaemia, red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis; common: neutropenia; very rare: lymphadenopathy immune system disorders: rare: allergic skin reaction, anaphylactic reactions, hypersensitivity metabolism and nutrition disorders: very rare: diabetes mellitus, hyperuricaemia psychiatric disorders: rare: depression, depression aggravated, aggressive tendencies, anxiety, mood alterations. very rare: abnormal behaviour, psychotic disorder, suicidal ideation suicide attempt, suicide nervous system disorders: common: headache; very rare: benign intracranial hypertension, convulsions, drowsiness, dizziness eye disorders: very common: blepharitis, conjunctivitis, dry eye, eye irritation; very rare: blurred vision, cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, papilloedema (as sign of benign intracranial hypertension), photophobia, visual disturbances. ear and labyrinth disorders: very rare: hearing impaired vascular disorders: very rare: vasculitis (for example wegener's granulomatosis, allergic vasculitis) respiratory, thoracic and mediastinal disorders: common: epistaxis, nasal dryness, nasopharyngitis, very rare: bronchospasm (particularly in patients with asthma), hoarseness gastrointestinal disorders: very rare: colitis, ileitis, dry throat, gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, nausea, pancreatitis hepatobiliary disorders: very common: transaminase increased; very rare: hepatitis skin and subcutaneous tissues disorders: very common: pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma), rare: alopecia, very rare: acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased. musculo-skeletal and connective tissue disorders: very common: arthralgia, myalgia, back pain (particularly in children and adolescent patients), very rare: arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis. renal and urinary disorders: very rare: glomerulonephritis. general disorders and administration site conditions: very rare: granulation tissue (increased formation of), malaise. overdose isotretinoin is a derivative of vitamin a. although the acute toxicity of isotretinoin is low, signs of hypervitaminosis a could appear in cases of accidental overdose. manifestations of acute vitamin a toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. these symptoms would be expected to be reversible and to subside without the need for treatment. pharmaceutical precautions store in a cool and dry place protected from light. ",isotretinoin (oral)
medication,isopropyl alcohol,0.83938104," inhaling large amounts of isopropyl alcohol can cause nausea, vomiting, irritation of the nose and mucous membranes, throat irritations, and even difficulty with breathing as coughing can occur making it difficult for you to catch your breath. isopropyl alcohol may cause burning, stinging, or a cold feeling where the medicine is applied. ",isopropyl alcohol + hydrogen peroxide + glycerol
sign_symptom,irritation,0.9999155," inhaling large amounts of isopropyl alcohol can cause nausea, vomiting, irritation of the nose and mucous membranes, throat irritations, and even difficulty with breathing as coughing can occur making it difficult for you to catch your breath. isopropyl alcohol may cause burning, stinging, or a cold feeling where the medicine is applied. ",isopropyl alcohol + hydrogen peroxide + glycerol
sign_symptom,difficulty with breathing,0.9993579," inhaling large amounts of isopropyl alcohol can cause nausea, vomiting, irritation of the nose and mucous membranes, throat irritations, and even difficulty with breathing as coughing can occur making it difficult for you to catch your breath. isopropyl alcohol may cause burning, stinging, or a cold feeling where the medicine is applied. ",isopropyl alcohol + hydrogen peroxide + glycerol
sign_symptom,coughing,0.9971507," inhaling large amounts of isopropyl alcohol can cause nausea, vomiting, irritation of the nose and mucous membranes, throat irritations, and even difficulty with breathing as coughing can occur making it difficult for you to catch your breath. isopropyl alcohol may cause burning, stinging, or a cold feeling where the medicine is applied. ",isopropyl alcohol + hydrogen peroxide + glycerol
medication,alcohol,0.90005845," inhaling large amounts of isopropyl alcohol can cause nausea, vomiting, irritation of the nose and mucous membranes, throat irritations, and even difficulty with breathing as coughing can occur making it difficult for you to catch your breath. isopropyl alcohol may cause burning, stinging, or a cold feeling where the medicine is applied. ",isopropyl alcohol + hydrogen peroxide + glycerol
sign_symptom,cold feeling,0.80300605," inhaling large amounts of isopropyl alcohol can cause nausea, vomiting, irritation of the nose and mucous membranes, throat irritations, and even difficulty with breathing as coughing can occur making it difficult for you to catch your breath. isopropyl alcohol may cause burning, stinging, or a cold feeling where the medicine is applied. ",isopropyl alcohol + hydrogen peroxide + glycerol
sign_symptom,blurred vision,0.80237305," the usual anticholinergic side effects are dry mouth, blurred vision, urinary hesitancy and retention, and constipationhave been encountered with this tablet. ",isopropamide + trifluoperazine
sign_symptom,urinary hesitancy,0.72229177," the usual anticholinergic side effects are dry mouth, blurred vision, urinary hesitancy and retention, and constipationhave been encountered with this tablet. ",isopropamide + trifluoperazine
sign_symptom,consti,0.9987246," the usual anticholinergic side effects are dry mouth, blurred vision, urinary hesitancy and retention, and constipationhave been encountered with this tablet. ",isopropamide + trifluoperazine
disease_disorder,peripheral neuropathy,0.9996736," peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d), loss of appetite, nausea, vomiting, stomach pain, weakness 1-10%, dizziness, slurred speech, lethargy, progressive liver damage (increases with age; 2.3% in pts &gt; 50 yo), hyperreflexia, agranulocytosis, anemia, megaloblastic anemia, thrombocytopenia, systemic lupus erythematosus, seizure ",isoniazid
sign_symptom,loss of appetite,0.9979722," peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d), loss of appetite, nausea, vomiting, stomach pain, weakness 1-10%, dizziness, slurred speech, lethargy, progressive liver damage (increases with age; 2.3% in pts &gt; 50 yo), hyperreflexia, agranulocytosis, anemia, megaloblastic anemia, thrombocytopenia, systemic lupus erythematosus, seizure ",isoniazid
sign_symptom,vomiting,0.9798814," peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d), loss of appetite, nausea, vomiting, stomach pain, weakness 1-10%, dizziness, slurred speech, lethargy, progressive liver damage (increases with age; 2.3% in pts &gt; 50 yo), hyperreflexia, agranulocytosis, anemia, megaloblastic anemia, thrombocytopenia, systemic lupus erythematosus, seizure ",isoniazid
sign_symptom,weakness,0.9998909," peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d), loss of appetite, nausea, vomiting, stomach pain, weakness 1-10%, dizziness, slurred speech, lethargy, progressive liver damage (increases with age; 2.3% in pts &gt; 50 yo), hyperreflexia, agranulocytosis, anemia, megaloblastic anemia, thrombocytopenia, systemic lupus erythematosus, seizure ",isoniazid
sign_symptom,liver damage,0.85132396," peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d), loss of appetite, nausea, vomiting, stomach pain, weakness 1-10%, dizziness, slurred speech, lethargy, progressive liver damage (increases with age; 2.3% in pts &gt; 50 yo), hyperreflexia, agranulocytosis, anemia, megaloblastic anemia, thrombocytopenia, systemic lupus erythematosus, seizure ",isoniazid
sign_symptom,hyper,0.99874383," peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d), loss of appetite, nausea, vomiting, stomach pain, weakness 1-10%, dizziness, slurred speech, lethargy, progressive liver damage (increases with age; 2.3% in pts &gt; 50 yo), hyperreflexia, agranulocytosis, anemia, megaloblastic anemia, thrombocytopenia, systemic lupus erythematosus, seizure ",isoniazid
sign_symptom,agra,0.96733207," peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d), loss of appetite, nausea, vomiting, stomach pain, weakness 1-10%, dizziness, slurred speech, lethargy, progressive liver damage (increases with age; 2.3% in pts &gt; 50 yo), hyperreflexia, agranulocytosis, anemia, megaloblastic anemia, thrombocytopenia, systemic lupus erythematosus, seizure ",isoniazid
disease_disorder,lupus,0.97531307," peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d), loss of appetite, nausea, vomiting, stomach pain, weakness 1-10%, dizziness, slurred speech, lethargy, progressive liver damage (increases with age; 2.3% in pts &gt; 50 yo), hyperreflexia, agranulocytosis, anemia, megaloblastic anemia, thrombocytopenia, systemic lupus erythematosus, seizure ",isoniazid
sign_symptom,seizure,0.9989182," peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d), loss of appetite, nausea, vomiting, stomach pain, weakness 1-10%, dizziness, slurred speech, lethargy, progressive liver damage (increases with age; 2.3% in pts &gt; 50 yo), hyperreflexia, agranulocytosis, anemia, megaloblastic anemia, thrombocytopenia, systemic lupus erythematosus, seizure ",isoniazid
disease_disorder,malignant hyperthermia,0.9989607," nausea, vomiting, shivering, dose-dependent hypotension, arrhythmias, malignant hyperthermia (rare), elevations in white blood count, may decrease creatinine and increase bun, ileus, severe (fatal), hepatic dysfunction (postoperative period),respiratory depression may occur ",isoflurane
sign_symptom,respiratory depression,0.9891982," nausea, vomiting, shivering, dose-dependent hypotension, arrhythmias, malignant hyperthermia (rare), elevations in white blood count, may decrease creatinine and increase bun, ileus, severe (fatal), hepatic dysfunction (postoperative period),respiratory depression may occur ",isoflurane
medication,iron su,0.975716,"  
 adverse reactions, whether or not related to iron sucrose injection are as follows: hypotension, cramps/leg cramps, nausea, headache, vomiting, and diarrhea. some of these symptoms may be seen in patients with chronic renal failure or on hemodialysis not receiving intravenous iron. 
 body as a whole: headache, fever, pain, asthenia, unwell, malaise, accidental injury. cardiovascular disorders 
 general: hypotension, chest pain, hypertension, hypervolemia. 
 gastrointestinal disorders: nausea, vomiting, abdominal pain, elevated liver enzymes. 
 central and peripheral nervous system: dizziness. 
 musculoskeletal system: cramps/leg cramps, musculoskeletal pain. 
 respiratory system: dyspnea pneumonia, cough. 
 skin and appendages: pruritus, application site reaction. 
 hypersensitivity reactions: in safety studies, several patients experienced mild or moderate hypersensitivity reactions presenting with wheezing, dyspnea, hypotension, rashes, or pruritus. anaphylactoid reactions including patients who experienced serious or life-threatening reactions (anaphylactic shock, loss of consciousness or collapse, bronchospasm with dyspnea, or convulsion) associated with iron sucrose administration can occur. so, patients should be given a small test dose initially. 
  ",iron sucrose injection [elemental iron]
disease_disorder,renal failure,0.9994534,"  
 adverse reactions, whether or not related to iron sucrose injection are as follows: hypotension, cramps/leg cramps, nausea, headache, vomiting, and diarrhea. some of these symptoms may be seen in patients with chronic renal failure or on hemodialysis not receiving intravenous iron. 
 body as a whole: headache, fever, pain, asthenia, unwell, malaise, accidental injury. cardiovascular disorders 
 general: hypotension, chest pain, hypertension, hypervolemia. 
 gastrointestinal disorders: nausea, vomiting, abdominal pain, elevated liver enzymes. 
 central and peripheral nervous system: dizziness. 
 musculoskeletal system: cramps/leg cramps, musculoskeletal pain. 
 respiratory system: dyspnea pneumonia, cough. 
 skin and appendages: pruritus, application site reaction. 
 hypersensitivity reactions: in safety studies, several patients experienced mild or moderate hypersensitivity reactions presenting with wheezing, dyspnea, hypotension, rashes, or pruritus. anaphylactoid reactions including patients who experienced serious or life-threatening reactions (anaphylactic shock, loss of consciousness or collapse, bronchospasm with dyspnea, or convulsion) associated with iron sucrose administration can occur. so, patients should be given a small test dose initially. 
  ",iron sucrose injection [elemental iron]
sign_symptom,hypersensitivity reactions,0.9113906,"  
 adverse reactions, whether or not related to iron sucrose injection are as follows: hypotension, cramps/leg cramps, nausea, headache, vomiting, and diarrhea. some of these symptoms may be seen in patients with chronic renal failure or on hemodialysis not receiving intravenous iron. 
 body as a whole: headache, fever, pain, asthenia, unwell, malaise, accidental injury. cardiovascular disorders 
 general: hypotension, chest pain, hypertension, hypervolemia. 
 gastrointestinal disorders: nausea, vomiting, abdominal pain, elevated liver enzymes. 
 central and peripheral nervous system: dizziness. 
 musculoskeletal system: cramps/leg cramps, musculoskeletal pain. 
 respiratory system: dyspnea pneumonia, cough. 
 skin and appendages: pruritus, application site reaction. 
 hypersensitivity reactions: in safety studies, several patients experienced mild or moderate hypersensitivity reactions presenting with wheezing, dyspnea, hypotension, rashes, or pruritus. anaphylactoid reactions including patients who experienced serious or life-threatening reactions (anaphylactic shock, loss of consciousness or collapse, bronchospasm with dyspnea, or convulsion) associated with iron sucrose administration can occur. so, patients should be given a small test dose initially. 
  ",iron sucrose injection [elemental iron]
sign_symptom,threatening reactions,0.9679115,"  
 adverse reactions, whether or not related to iron sucrose injection are as follows: hypotension, cramps/leg cramps, nausea, headache, vomiting, and diarrhea. some of these symptoms may be seen in patients with chronic renal failure or on hemodialysis not receiving intravenous iron. 
 body as a whole: headache, fever, pain, asthenia, unwell, malaise, accidental injury. cardiovascular disorders 
 general: hypotension, chest pain, hypertension, hypervolemia. 
 gastrointestinal disorders: nausea, vomiting, abdominal pain, elevated liver enzymes. 
 central and peripheral nervous system: dizziness. 
 musculoskeletal system: cramps/leg cramps, musculoskeletal pain. 
 respiratory system: dyspnea pneumonia, cough. 
 skin and appendages: pruritus, application site reaction. 
 hypersensitivity reactions: in safety studies, several patients experienced mild or moderate hypersensitivity reactions presenting with wheezing, dyspnea, hypotension, rashes, or pruritus. anaphylactoid reactions including patients who experienced serious or life-threatening reactions (anaphylactic shock, loss of consciousness or collapse, bronchospasm with dyspnea, or convulsion) associated with iron sucrose administration can occur. so, patients should be given a small test dose initially. 
  ",iron sucrose injection [elemental iron]
sign_symptom,loss of consciousness,0.9686162,"  
 adverse reactions, whether or not related to iron sucrose injection are as follows: hypotension, cramps/leg cramps, nausea, headache, vomiting, and diarrhea. some of these symptoms may be seen in patients with chronic renal failure or on hemodialysis not receiving intravenous iron. 
 body as a whole: headache, fever, pain, asthenia, unwell, malaise, accidental injury. cardiovascular disorders 
 general: hypotension, chest pain, hypertension, hypervolemia. 
 gastrointestinal disorders: nausea, vomiting, abdominal pain, elevated liver enzymes. 
 central and peripheral nervous system: dizziness. 
 musculoskeletal system: cramps/leg cramps, musculoskeletal pain. 
 respiratory system: dyspnea pneumonia, cough. 
 skin and appendages: pruritus, application site reaction. 
 hypersensitivity reactions: in safety studies, several patients experienced mild or moderate hypersensitivity reactions presenting with wheezing, dyspnea, hypotension, rashes, or pruritus. anaphylactoid reactions including patients who experienced serious or life-threatening reactions (anaphylactic shock, loss of consciousness or collapse, bronchospasm with dyspnea, or convulsion) associated with iron sucrose administration can occur. so, patients should be given a small test dose initially. 
  ",iron sucrose injection [elemental iron]
medication,iron,0.99534154," this syrup is generally well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur. ",iron polymaltose complex + vitamin b complex + zinc
sign_symptom,consti,0.8398092," this syrup is generally well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur. ",iron polymaltose complex + vitamin b complex + zinc
sign_symptom,diarr,0.9107479," this syrup is generally well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur. ",iron polymaltose complex + vitamin b complex + zinc
medication,iron,0.990754," this tablet is generally well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur rarely. ",iron polymaltose complex + folic acid + zinc sulfate
sign_symptom,nausea,0.95141006," this tablet is generally well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur rarely. ",iron polymaltose complex + folic acid + zinc sulfate
sign_symptom,vomiting,0.9990526," this tablet is generally well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur rarely. ",iron polymaltose complex + folic acid + zinc sulfate
sign_symptom,consti,0.95698917," this tablet is generally well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur rarely. ",iron polymaltose complex + folic acid + zinc sulfate
sign_symptom,diarr,0.99252355," this tablet is generally well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur rarely. ",iron polymaltose complex + folic acid + zinc sulfate
sign_symptom,allergic reactions,0.9999189," generally well tolerated. however, a few allergic reactions may be seen. ",iron polymaltose complex + folic acid + zinc + vitamin b-complex
sign_symptom,allergic reactions,0.9999189," generally well tolerated. however, a few allergic reactions may be seen. ",iron + folic acid + vitamin b complex + vitamine c + zinc sulfate
sign_symptom,allergic reactions,0.9999189," generally well tolerated. however, a few allergic reactions may be seen. ",iron + folic acid + vitamin b complex + vitamin c
sign_symptom,allergic reactions,0.9999189," generally well tolerated. however, a few allergic reactions may be seen. ",multivitamin & cod liver oil
medication,iron,0.9956682," this preparation is well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur. ",iron polymaltose complex
sign_symptom,nausea,0.9778857," this preparation is well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur. ",iron polymaltose complex
sign_symptom,vomiting,0.9985291," this preparation is well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur. ",iron polymaltose complex
sign_symptom,diarr,0.9573388," this preparation is well tolerated. however, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur. ",iron polymaltose complex
sign_symptom,hyper,0.9999666,"  irbesartan: hyperkalemia (19%), chest pain (2%), tachycardia (1%), abnormal urination (2%), musculoskeletal pain (6%), flu-like syndrome (3%), edema (3%), tachycardia (1%), chest pain (2%), creatinine increased (1%), increased bun (2%), dizziness (10%), uri (9%), orthostatic hypotension (5%), fatigue (4%), diarrhea (3%), dyspepsia (2%)   hydrochlorothiazide: anorexia, epigastric distress, hypotension, orthostatic hypotension, photosensitivity, anaphylaxis, anemia, confusion, erythema multiforme, stevens-johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, dizziness, hypokalemia and/or hypomagnesemia, hyperuricemia, headache ",irbesartan + hydrochlorothiazide
sign_symptom,pain,0.9999559,"  irbesartan: hyperkalemia (19%), chest pain (2%), tachycardia (1%), abnormal urination (2%), musculoskeletal pain (6%), flu-like syndrome (3%), edema (3%), tachycardia (1%), chest pain (2%), creatinine increased (1%), increased bun (2%), dizziness (10%), uri (9%), orthostatic hypotension (5%), fatigue (4%), diarrhea (3%), dyspepsia (2%)   hydrochlorothiazide: anorexia, epigastric distress, hypotension, orthostatic hypotension, photosensitivity, anaphylaxis, anemia, confusion, erythema multiforme, stevens-johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, dizziness, hypokalemia and/or hypomagnesemia, hyperuricemia, headache ",irbesartan + hydrochlorothiazide
sign_symptom,abnormal,0.9993019,"  irbesartan: hyperkalemia (19%), chest pain (2%), tachycardia (1%), abnormal urination (2%), musculoskeletal pain (6%), flu-like syndrome (3%), edema (3%), tachycardia (1%), chest pain (2%), creatinine increased (1%), increased bun (2%), dizziness (10%), uri (9%), orthostatic hypotension (5%), fatigue (4%), diarrhea (3%), dyspepsia (2%)   hydrochlorothiazide: anorexia, epigastric distress, hypotension, orthostatic hypotension, photosensitivity, anaphylaxis, anemia, confusion, erythema multiforme, stevens-johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, dizziness, hypokalemia and/or hypomagnesemia, hyperuricemia, headache ",irbesartan + hydrochlorothiazide
sign_symptom,urination,0.8201461,"  irbesartan: hyperkalemia (19%), chest pain (2%), tachycardia (1%), abnormal urination (2%), musculoskeletal pain (6%), flu-like syndrome (3%), edema (3%), tachycardia (1%), chest pain (2%), creatinine increased (1%), increased bun (2%), dizziness (10%), uri (9%), orthostatic hypotension (5%), fatigue (4%), diarrhea (3%), dyspepsia (2%)   hydrochlorothiazide: anorexia, epigastric distress, hypotension, orthostatic hypotension, photosensitivity, anaphylaxis, anemia, confusion, erythema multiforme, stevens-johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, dizziness, hypokalemia and/or hypomagnesemia, hyperuricemia, headache ",irbesartan + hydrochlorothiazide
sign_symptom,flu - like syndrome,0.9333008,"  irbesartan: hyperkalemia (19%), chest pain (2%), tachycardia (1%), abnormal urination (2%), musculoskeletal pain (6%), flu-like syndrome (3%), edema (3%), tachycardia (1%), chest pain (2%), creatinine increased (1%), increased bun (2%), dizziness (10%), uri (9%), orthostatic hypotension (5%), fatigue (4%), diarrhea (3%), dyspepsia (2%)   hydrochlorothiazide: anorexia, epigastric distress, hypotension, orthostatic hypotension, photosensitivity, anaphylaxis, anemia, confusion, erythema multiforme, stevens-johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, dizziness, hypokalemia and/or hypomagnesemia, hyperuricemia, headache ",irbesartan + hydrochlorothiazide
sign_symptom,edema,0.99968016,"  irbesartan: hyperkalemia (19%), chest pain (2%), tachycardia (1%), abnormal urination (2%), musculoskeletal pain (6%), flu-like syndrome (3%), edema (3%), tachycardia (1%), chest pain (2%), creatinine increased (1%), increased bun (2%), dizziness (10%), uri (9%), orthostatic hypotension (5%), fatigue (4%), diarrhea (3%), dyspepsia (2%)   hydrochlorothiazide: anorexia, epigastric distress, hypotension, orthostatic hypotension, photosensitivity, anaphylaxis, anemia, confusion, erythema multiforme, stevens-johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, dizziness, hypokalemia and/or hypomagnesemia, hyperuricemia, headache ",irbesartan + hydrochlorothiazide
sign_symptom,fatigue,0.9999448,"  irbesartan: hyperkalemia (19%), chest pain (2%), tachycardia (1%), abnormal urination (2%), musculoskeletal pain (6%), flu-like syndrome (3%), edema (3%), tachycardia (1%), chest pain (2%), creatinine increased (1%), increased bun (2%), dizziness (10%), uri (9%), orthostatic hypotension (5%), fatigue (4%), diarrhea (3%), dyspepsia (2%)   hydrochlorothiazide: anorexia, epigastric distress, hypotension, orthostatic hypotension, photosensitivity, anaphylaxis, anemia, confusion, erythema multiforme, stevens-johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, dizziness, hypokalemia and/or hypomagnesemia, hyperuricemia, headache ",irbesartan + hydrochlorothiazide
sign_symptom,dyspepsia,0.9997743,"  irbesartan: hyperkalemia (19%), chest pain (2%), tachycardia (1%), abnormal urination (2%), musculoskeletal pain (6%), flu-like syndrome (3%), edema (3%), tachycardia (1%), chest pain (2%), creatinine increased (1%), increased bun (2%), dizziness (10%), uri (9%), orthostatic hypotension (5%), fatigue (4%), diarrhea (3%), dyspepsia (2%)   hydrochlorothiazide: anorexia, epigastric distress, hypotension, orthostatic hypotension, photosensitivity, anaphylaxis, anemia, confusion, erythema multiforme, stevens-johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, dizziness, hypokalemia and/or hypomagnesemia, hyperuricemia, headache ",irbesartan + hydrochlorothiazide
medication,hydro,0.998295,"  irbesartan: hyperkalemia (19%), chest pain (2%), tachycardia (1%), abnormal urination (2%), musculoskeletal pain (6%), flu-like syndrome (3%), edema (3%), tachycardia (1%), chest pain (2%), creatinine increased (1%), increased bun (2%), dizziness (10%), uri (9%), orthostatic hypotension (5%), fatigue (4%), diarrhea (3%), dyspepsia (2%)   hydrochlorothiazide: anorexia, epigastric distress, hypotension, orthostatic hypotension, photosensitivity, anaphylaxis, anemia, confusion, erythema multiforme, stevens-johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, dizziness, hypokalemia and/or hypomagnesemia, hyperuricemia, headache ",irbesartan + hydrochlorothiazide
sign_symptom,headache,0.99992776,"  irbesartan: hyperkalemia (19%), chest pain (2%), tachycardia (1%), abnormal urination (2%), musculoskeletal pain (6%), flu-like syndrome (3%), edema (3%), tachycardia (1%), chest pain (2%), creatinine increased (1%), increased bun (2%), dizziness (10%), uri (9%), orthostatic hypotension (5%), fatigue (4%), diarrhea (3%), dyspepsia (2%)   hydrochlorothiazide: anorexia, epigastric distress, hypotension, orthostatic hypotension, photosensitivity, anaphylaxis, anemia, confusion, erythema multiforme, stevens-johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, dizziness, hypokalemia and/or hypomagnesemia, hyperuricemia, headache ",irbesartan + hydrochlorothiazide
sign_symptom,dry mouth,0.9996449," drowsiness and in isolated cases, dry mouth and slight dizziness may occur at the beginning of treatment but usually disappear spontaneously after a few days. ",ketotifen fumarate (oral)
sign_symptom,blurring of vision,0.98627484," common side effects are burning, stinging, punctate corneal epithelial erosion, blurring of vision upon drug instillation, dry eyes, eyelid disorder, conjunctivitis, eye pain, photophobia, subconjunctival haemorrhage. ",ketotifen fumarate (ophthalmic)
sign_symptom,headache,0.9987993," transient stinging and burning on instillation, allergic reactions, corneal edema, iritis, ocular inflammation, ocular irritation, superficial keratitis and superficial ocular infections. corneal infiltrates, corneal ulcer, eye dryness, headaches, and visual disturbance (blurry vision) ",ketorolac tromethamine (ophthalmic)
sign_symptom,visual disturbance,0.99936223," transient stinging and burning on instillation, allergic reactions, corneal edema, iritis, ocular inflammation, ocular irritation, superficial keratitis and superficial ocular infections. corneal infiltrates, corneal ulcer, eye dryness, headaches, and visual disturbance (blurry vision) ",ketorolac tromethamine (ophthalmic)
disease_disorder,immune system disorders,0.9976124," immune system disorders- not known: anaphylactic shock, angioedema, hypersensitivity reactions.  gastrointestinal disorders- although plasma levels after administration of ketoprofengel are much lower than those reached after oral administration, systemic gastrointestinal side effects (such as nausea, abdominal pain, vomiting, and flatulence) are possible under rare circumstances depending on the amount of gel applied and the application of the gel to a large area of skin. uncommon: nausea. not known: abdominal pain, vomiting, flatulence.  skin and subcutaneous tissue disorders- uncommon: erythema, pruritus, eczema. rare: photosensitivity reactions, dermatitis bullous, urticaria. localised skin reactions have been reported which may spread outside the application site. not known: burning sensations, stevens-johnson syndrome.  renal and urinary disorders- very rare: worsening renal insufficiency. ",ketoprofen (topical)
disease_disorder,gastrointestinal disorders,0.99467564," immune system disorders- not known: anaphylactic shock, angioedema, hypersensitivity reactions.  gastrointestinal disorders- although plasma levels after administration of ketoprofengel are much lower than those reached after oral administration, systemic gastrointestinal side effects (such as nausea, abdominal pain, vomiting, and flatulence) are possible under rare circumstances depending on the amount of gel applied and the application of the gel to a large area of skin. uncommon: nausea. not known: abdominal pain, vomiting, flatulence.  skin and subcutaneous tissue disorders- uncommon: erythema, pruritus, eczema. rare: photosensitivity reactions, dermatitis bullous, urticaria. localised skin reactions have been reported which may spread outside the application site. not known: burning sensations, stevens-johnson syndrome.  renal and urinary disorders- very rare: worsening renal insufficiency. ",ketoprofen (topical)
sign_symptom,flat,0.8451355," immune system disorders- not known: anaphylactic shock, angioedema, hypersensitivity reactions.  gastrointestinal disorders- although plasma levels after administration of ketoprofengel are much lower than those reached after oral administration, systemic gastrointestinal side effects (such as nausea, abdominal pain, vomiting, and flatulence) are possible under rare circumstances depending on the amount of gel applied and the application of the gel to a large area of skin. uncommon: nausea. not known: abdominal pain, vomiting, flatulence.  skin and subcutaneous tissue disorders- uncommon: erythema, pruritus, eczema. rare: photosensitivity reactions, dermatitis bullous, urticaria. localised skin reactions have been reported which may spread outside the application site. not known: burning sensations, stevens-johnson syndrome.  renal and urinary disorders- very rare: worsening renal insufficiency. ",ketoprofen (topical)
sign_symptom,skin reactions,0.99915326," immune system disorders- not known: anaphylactic shock, angioedema, hypersensitivity reactions.  gastrointestinal disorders- although plasma levels after administration of ketoprofengel are much lower than those reached after oral administration, systemic gastrointestinal side effects (such as nausea, abdominal pain, vomiting, and flatulence) are possible under rare circumstances depending on the amount of gel applied and the application of the gel to a large area of skin. uncommon: nausea. not known: abdominal pain, vomiting, flatulence.  skin and subcutaneous tissue disorders- uncommon: erythema, pruritus, eczema. rare: photosensitivity reactions, dermatitis bullous, urticaria. localised skin reactions have been reported which may spread outside the application site. not known: burning sensations, stevens-johnson syndrome.  renal and urinary disorders- very rare: worsening renal insufficiency. ",ketoprofen (topical)
disease_disorder,renal,0.9876038," immune system disorders- not known: anaphylactic shock, angioedema, hypersensitivity reactions.  gastrointestinal disorders- although plasma levels after administration of ketoprofengel are much lower than those reached after oral administration, systemic gastrointestinal side effects (such as nausea, abdominal pain, vomiting, and flatulence) are possible under rare circumstances depending on the amount of gel applied and the application of the gel to a large area of skin. uncommon: nausea. not known: abdominal pain, vomiting, flatulence.  skin and subcutaneous tissue disorders- uncommon: erythema, pruritus, eczema. rare: photosensitivity reactions, dermatitis bullous, urticaria. localised skin reactions have been reported which may spread outside the application site. not known: burning sensations, stevens-johnson syndrome.  renal and urinary disorders- very rare: worsening renal insufficiency. ",ketoprofen (topical)
disease_disorder,urinary disorders,0.9729539," immune system disorders- not known: anaphylactic shock, angioedema, hypersensitivity reactions.  gastrointestinal disorders- although plasma levels after administration of ketoprofengel are much lower than those reached after oral administration, systemic gastrointestinal side effects (such as nausea, abdominal pain, vomiting, and flatulence) are possible under rare circumstances depending on the amount of gel applied and the application of the gel to a large area of skin. uncommon: nausea. not known: abdominal pain, vomiting, flatulence.  skin and subcutaneous tissue disorders- uncommon: erythema, pruritus, eczema. rare: photosensitivity reactions, dermatitis bullous, urticaria. localised skin reactions have been reported which may spread outside the application site. not known: burning sensations, stevens-johnson syndrome.  renal and urinary disorders- very rare: worsening renal insufficiency. ",ketoprofen (topical)
disease_disorder,blood and lymphatic system,0.7582244,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,agranulocy,0.9028633,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,leucopenia,0.7859448,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,system,0.749884,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,anaphyla,0.954546,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,nervous system,0.86397904,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,mening,0.9741701,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,convulsions,0.8651233,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,dysge,0.9328933,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,vertigo,0.9786962,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,disorders,0.75209975,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,vision,0.9983814,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,blurred ear,0.9980477,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,labyrinth disorders,0.9907427,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,tinnitus cardiac disorders,0.7971722,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,atrial fibrillation,0.96079415,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,disorders,0.8059055,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,media,0.93830585,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,vomiting,0.90744543,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,transaminases,0.993841,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,bull,0.70771563,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,eruption,0.9796117,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,exanthematou,0.86610436,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,renal,0.97686243,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,renal failure,0.9982005,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
disease_disorder,general disorders,0.8480595,"  
 blood and lymphatic system disorders- rare: haemorrhagic anaemia; unknown: agranulocytosis, thrombocytopenia, bone marrow failure, hemolytic anemia, leucopenia 
 immune system disorders- unknown: anaphylactic reactions (including shock) psychiatric disorders; unknown: depression, hallucinations, confusion, mood altered 
 nervous system disorders- uncommon: headache, dizziness, somnolence, rare: paraesthesia; unknown: aseptic meningitis, convulsions, dysgeusia, vertigo 
 eye disorders- rare: vision blurred 
 ear and labyrinth disorders- rare: tinnitus 
 cardiac disorders- unknown: exacerbation of heart failure, atrial fibrillation 
 vascular disorders- unknown: hypertension, vasodilatation, vasculitis (including leukocytoclastic vasculitis) 
 respiratory, thoracic and mediastinal disorders- rare: asthma; unknown: bronchospasm (particularly in patients with known hypersensitivity to asa and other nsaids) 
 gastrointestinal disorders- common: dyspepsia, nausea, abdominal pain, vomiting; uncommon: constipation, diarrhoea, flatulence, gastritis; rare: stomatitis, peptic ulcer; unknown: exacerbation of colitis and crohns disease, gastrointestinal haemorrhage and perforation, pancreatitis 
 hepatobiliary disorders- rare: hepatitis, transaminases increased 
 skin and subcutaneous disorders- uncommon: rash, pruritis; unknown: photosensitivity reaction, alopecia, urticaria, angioedema, bullous eruption including stevens-johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis renal and urinary disorders- unknown: renal failure acute, tubulointerstitial nephritis, nephritic syndrome, renal function tests abnormal 
 general disorders and administration site conditions- uncommon: oedema metabolism and nutritional disorders; unknown: hyponatremia, hyperkalemia investigations; rare: weight increased. 
  ",ketoprofen (oral & injection)
sign_symptom,nausea,0.99995613," ketoconazole is very well tolerated. nausea and itching may occasionally occur. in some patients, an idosyncratic liver reaction may occur (incidence 1:10000). ",ketoconazole (tablet)
sign_symptom,reaction,0.78773993," ketoconazole is very well tolerated. nausea and itching may occasionally occur. in some patients, an idosyncratic liver reaction may occur (incidence 1:10000). ",ketoconazole (tablet)
sign_symptom,irritation,0.8658386," topical treatment with ketoconazole shampoo 2% is generally well tolerated. as with other shampoos, a local burning sensation, itching or contact dermatitis (due to irritation or allergy) may occur on exposed areas. oily and dry hair have been reported rarely with the use of ketoconazole shampoo 2%. ",ketoconazole (shampoo)
sign_symptom,dry hair,0.958929," topical treatment with ketoconazole shampoo 2% is generally well tolerated. as with other shampoos, a local burning sensation, itching or contact dermatitis (due to irritation or allergy) may occur on exposed areas. oily and dry hair have been reported rarely with the use of ketoconazole shampoo 2%. ",ketoconazole (shampoo)
sign_symptom,adverse reactions,0.9974655," commonly observed adverse reactions to ketoconazole cream in clinical trials wereskin application site burning sensation, erythema and pruritus. uncommon adverse reactions areapplication site bleeding, discomfort, dryness, inflammation, irritation, paraesthesia andreaction; bullous eruption, dermatitis contact, rash, skin exfoliation and sticky skin. ",ketoconazole (cream)
medication,cream,0.9887311," commonly observed adverse reactions to ketoconazole cream in clinical trials wereskin application site burning sensation, erythema and pruritus. uncommon adverse reactions areapplication site bleeding, discomfort, dryness, inflammation, irritation, paraesthesia andreaction; bullous eruption, dermatitis contact, rash, skin exfoliation and sticky skin. ",ketoconazole (cream)
sign_symptom,sticky,0.95592684," commonly observed adverse reactions to ketoconazole cream in clinical trials wereskin application site burning sensation, erythema and pruritus. uncommon adverse reactions areapplication site bleeding, discomfort, dryness, inflammation, irritation, paraesthesia andreaction; bullous eruption, dermatitis contact, rash, skin exfoliation and sticky skin. ",ketoconazole (cream)
sign_symptom,emergence reactions,0.9955882," emergence reactions (e.g. vivid dreams, hallucinations, confusion, irrational behaviour); increased muscle tone sometimes resembling seizures; temporary htn and tachycardia, hypotension, bradycardia, arrhythmias, apnoea, laryngospasm, resp depression, diplopia, nystagmus, nausea, vomiting, lacrimation, hypersalivation, raised intraocular and csf pressure, transient rash and pain at inj site, cystitis. ",ketamine
sign_symptom,seizures,0.9985191," emergence reactions (e.g. vivid dreams, hallucinations, confusion, irrational behaviour); increased muscle tone sometimes resembling seizures; temporary htn and tachycardia, hypotension, bradycardia, arrhythmias, apnoea, laryngospasm, resp depression, diplopia, nystagmus, nausea, vomiting, lacrimation, hypersalivation, raised intraocular and csf pressure, transient rash and pain at inj site, cystitis. ",ketamine
sign_symptom,rash,0.99996114," emergence reactions (e.g. vivid dreams, hallucinations, confusion, irrational behaviour); increased muscle tone sometimes resembling seizures; temporary htn and tachycardia, hypotension, bradycardia, arrhythmias, apnoea, laryngospasm, resp depression, diplopia, nystagmus, nausea, vomiting, lacrimation, hypersalivation, raised intraocular and csf pressure, transient rash and pain at inj site, cystitis. ",ketamine
sign_symptom,pain,0.99996233," emergence reactions (e.g. vivid dreams, hallucinations, confusion, irrational behaviour); increased muscle tone sometimes resembling seizures; temporary htn and tachycardia, hypotension, bradycardia, arrhythmias, apnoea, laryngospasm, resp depression, diplopia, nystagmus, nausea, vomiting, lacrimation, hypersalivation, raised intraocular and csf pressure, transient rash and pain at inj site, cystitis. ",ketamine
disease_disorder,conjunctivitis,0.9979884," common side effects are- 
 
 conjunctivitis 
 ocular hyperemia 
 eye irritation 
 dandruff 
 dry skin 
 skin burning sensation etc. 
  ",ivermectin (topical)
sign_symptom,hyper,0.99990284," common side effects are- 
 
 conjunctivitis 
 ocular hyperemia 
 eye irritation 
 dandruff 
 dry skin 
 skin burning sensation etc. 
  ",ivermectin (topical)
sign_symptom,irritation,0.9999571," common side effects are- 
 
 conjunctivitis 
 ocular hyperemia 
 eye irritation 
 dandruff 
 dry skin 
 skin burning sensation etc. 
  ",ivermectin (topical)
sign_symptom,burning,0.72016543," common side effects are- 
 
 conjunctivitis 
 ocular hyperemia 
 eye irritation 
 dandruff 
 dry skin 
 skin burning sensation etc. 
  ",ivermectin (topical)
sign_symptom,strong,0.99913234,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,adverse reactions,0.9997177,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,fatigue,0.99995863,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,pain,0.9999627,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,consti,0.9993491,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,diarrhea,0.99926543,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,nausea,0.9999418,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,vomiting,0.9999491,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,somnolence,0.96396995,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,vertigo,0.9998821,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,tremor,0.9999106,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,rash,0.99994516,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,urticaria,0.99899584,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,onchocercia,0.9313698,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,arthralgia,0.9996972,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,synovitis,0.99162936,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,tenderness,0.99995506,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,skin,0.80428284,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,involvement,0.88481,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,fever,0.99996316,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,abnormal sensation,0.99961126,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,loss of vision,0.9999161,"  strongyloidiasis : in four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin. 
 
  body as a whole : asthenia/fatigue (0.9%), abdominal pain (0.9%) 
  gastrointestinal : anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%) nervous system/psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%) 
  skin : pruritus (2.8%), rash (0.9%), and urticaria (0.9%). 
 
 onchocerciasis : arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. these have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. the following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and stevens-johnson syndrome. ",ivermectin (tablet)
sign_symptom,blurred,0.82365507," visual symptoms, blurred vision, bradycardia, 1st degree av block, ventricular extrasystoles, headaches, and dizziness. ",ivabradine
sign_symptom,bradycard,0.8197559," visual symptoms, blurred vision, bradycardia, 1st degree av block, ventricular extrasystoles, headaches, and dizziness. ",ivabradine
sign_symptom,headache,0.9965487," visual symptoms, blurred vision, bradycardia, 1st degree av block, ventricular extrasystoles, headaches, and dizziness. ",ivabradine
sign_symptom,dyspeps,0.98727983," nausea, abdominal pain, dyspepsia, constipation, headache, dizziness, raised liver enzymes, hepatitis, cholestatic jaundice, peripheral neuropathy have been reported. ",itraconazole
sign_symptom,consti,0.78568906," nausea, abdominal pain, dyspepsia, constipation, headache, dizziness, raised liver enzymes, hepatitis, cholestatic jaundice, peripheral neuropathy have been reported. ",itraconazole
sign_symptom,headache,0.9224376," nausea, abdominal pain, dyspepsia, constipation, headache, dizziness, raised liver enzymes, hepatitis, cholestatic jaundice, peripheral neuropathy have been reported. ",itraconazole
disease_disorder,choles,0.74200726," nausea, abdominal pain, dyspepsia, constipation, headache, dizziness, raised liver enzymes, hepatitis, cholestatic jaundice, peripheral neuropathy have been reported. ",itraconazole
disease_disorder,peripheral neuropathy,0.9973575," nausea, abdominal pain, dyspepsia, constipation, headache, dizziness, raised liver enzymes, hepatitis, cholestatic jaundice, peripheral neuropathy have been reported. ",itraconazole
sign_symptom,adverse reactions,0.96885955," the most common adverse reactions for lanthanum carbonate were gastrointestinal events, such as nausea, vomiting, and abdominal pain and they generally abated over time with continued dosing. the following adverse reactions have been identified during post-approval use of lanthanum carbonate constipation, dyspepsia, allergic skin reactions, and tooth injury while chewing the tablet. ",lanthanum carbonate
sign_symptom,pain,0.9999608," the most common adverse reactions for lanthanum carbonate were gastrointestinal events, such as nausea, vomiting, and abdominal pain and they generally abated over time with continued dosing. the following adverse reactions have been identified during post-approval use of lanthanum carbonate constipation, dyspepsia, allergic skin reactions, and tooth injury while chewing the tablet. ",lanthanum carbonate
medication,carbonate,0.9841011," the most common adverse reactions for lanthanum carbonate were gastrointestinal events, such as nausea, vomiting, and abdominal pain and they generally abated over time with continued dosing. the following adverse reactions have been identified during post-approval use of lanthanum carbonate constipation, dyspepsia, allergic skin reactions, and tooth injury while chewing the tablet. ",lanthanum carbonate
disease_disorder,tooth injury,0.9214289," the most common adverse reactions for lanthanum carbonate were gastrointestinal events, such as nausea, vomiting, and abdominal pain and they generally abated over time with continued dosing. the following adverse reactions have been identified during post-approval use of lanthanum carbonate constipation, dyspepsia, allergic skin reactions, and tooth injury while chewing the tablet. ",lanthanum carbonate
sign_symptom,adverse reactions,0.99992955," adverse reactions which were reported as possibly or probably related to treatment (&gt;3%) in clinical trials when all three components of this therapy were given concomitantly are listed below and divided by body systems. digestive system: nausea, vomiting, diarrhea, dark stools, dry mouth, glossitis, oral moniliasis, stomatitis, tongue discoloration. musculoskeletal system: myalgia. nervous system: confusion, headache, dizziness; skin: skin reactions. urogenital system: vaginitis,vaginal moniliasis. ",lansoprazole + amoxicillin + clarithromycin
disease_disorder,carcinoid tumors,0.9958973,"  severe or irreversible adverse effects : the possible induction of carcinoid tumors by profound acid suppression, and a rise in serum gastrin may occur. there is a rise in serum gastrin levels in the first 3 months of treatment, which are then maintained though at a lower level than those found in pernicious anaemia. long term treatment with a proton pump inhibitor in patients with helicobacter pylori infection may accelerate the development of atrophic gastritis.   symptomatic adverse effect : dose dependent diarrhoea occurs with an incidence of about 4% at 30 mg per day, rising to 8% at 60 mg per day. headache occurs in 2-3% of treated patients ",lansoprazole
disease_disorder,helicobacter pylori infection,0.9985022,"  severe or irreversible adverse effects : the possible induction of carcinoid tumors by profound acid suppression, and a rise in serum gastrin may occur. there is a rise in serum gastrin levels in the first 3 months of treatment, which are then maintained though at a lower level than those found in pernicious anaemia. long term treatment with a proton pump inhibitor in patients with helicobacter pylori infection may accelerate the development of atrophic gastritis.   symptomatic adverse effect : dose dependent diarrhoea occurs with an incidence of about 4% at 30 mg per day, rising to 8% at 60 mg per day. headache occurs in 2-3% of treated patients ",lansoprazole
sign_symptom,headache,0.99984455,"  severe or irreversible adverse effects : the possible induction of carcinoid tumors by profound acid suppression, and a rise in serum gastrin may occur. there is a rise in serum gastrin levels in the first 3 months of treatment, which are then maintained though at a lower level than those found in pernicious anaemia. long term treatment with a proton pump inhibitor in patients with helicobacter pylori infection may accelerate the development of atrophic gastritis.   symptomatic adverse effect : dose dependent diarrhoea occurs with an incidence of about 4% at 30 mg per day, rising to 8% at 60 mg per day. headache occurs in 2-3% of treated patients ",lansoprazole
sign_symptom,of coordination,0.9967166,"  common side effects of lamotrigine include-dizziness, tremor, headache, rash, blurred vision, fever, lack of coordination, abdominal pain, infections, sleepiness, back pain, vomiting, diarrhea, tiredness, insomnia, dry mouth, stuffy nose, sore throat.  ",lamotrigine
sign_symptom,stuff,0.90833527,"  common side effects of lamotrigine include-dizziness, tremor, headache, rash, blurred vision, fever, lack of coordination, abdominal pain, infections, sleepiness, back pain, vomiting, diarrhea, tiredness, insomnia, dry mouth, stuffy nose, sore throat.  ",lamotrigine
sign_symptom,headache,0.9999335,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
medication,zidovudine,0.9490094,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,malaise,0.8025937,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,fever,0.99700826,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,nausea,0.99922895,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,diaph,0.90067565,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,rash,0.99967086,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,taste perversion,0.99087286,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,skin,0.8673139,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,myalgia,0.9909334,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,anaemia,0.72703433,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
disease_disorder,immunodefi,0.861475,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
disease_disorder,syndrome,0.81901324,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,gran,0.9999584,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
medication,zido,0.78856516,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,lactic acidosis,0.89225435,"  lamivudine : pancreatitis, paresthesia, peripheral neuropathy, cough, dizziness, fatigue, gastrointestinal problems, headache, insomnia, anaemia, neutropenia, drug induced skin rash, hair loss.   zidovudine : headache (which may be severe, has been reported in up to 63% of patients receiving zidovudine and asthenia has been reported in 9-69%), malaise and fatigue, fever or chills, nausea (61% cases), diaphoresis, dyspnoea, rash and taste perversion have been reported. skin rashes and myalgia has been reported in patients receiving zidovudine. myopathy and myositis with pathologic changes similar to that produced by hiv infection, have been associated with prolonged use of zidovudine. the major adverse effect is bone marrow toxicity resulting in severe anaemia and/or neutropenia. patients with low serum folate or vitamin b12 concentrations may be at increased risk for developing bone marrow toxicity during zidovudine therapy. there also are limited data suggesting that bone marrow of patients with fulminant acquired immunodeficiency syndrome (aids) may be more sensitive to zidovudine induced toxicity than that of patients with less advanced disease (eg, aids related complex). anaemia and granulocytopenia usually resolve when zidovudine is discontinued or when dosage is decreased. lactic acidosis (in the absence of hypoxaemia) and severe hepatomegaly with steatosis, including some fatalities, have been reported in patients receiving zidovudine.   nevirapine : more frequent incidences are skin rash, diarrhoea, gastrointestinal problems, headache, nausea and stomach pain. incidence of less frequents are aphthous stomatitis, fever, hepatitis and stevens johnson syndrome. ",lamivudine + zidovudine + nevirapine
sign_symptom,sore,0.9984818," side effects of this medicine- 
 
  more common : chills, fever, pale skin; sore throat; unusual tiredness or weakness, headache 
  less common : abdominal pain, burning, tingling, numbness, or pain in the hands, arms, feet, or legs, muscle tenderness and weakness, nausea, skin rash, vomiting, yellow eyes or skin. coughing, decreased appetite, diarrhea, dizziness and trouble in sleeping may occurs 
  ",lamivudine + zidovudine
sign_symptom,tiredness,0.9982834," side effects of this medicine- 
 
  more common : chills, fever, pale skin; sore throat; unusual tiredness or weakness, headache 
  less common : abdominal pain, burning, tingling, numbness, or pain in the hands, arms, feet, or legs, muscle tenderness and weakness, nausea, skin rash, vomiting, yellow eyes or skin. coughing, decreased appetite, diarrhea, dizziness and trouble in sleeping may occurs 
  ",lamivudine + zidovudine
sign_symptom,headache,0.99988604," side effects of this medicine- 
 
  more common : chills, fever, pale skin; sore throat; unusual tiredness or weakness, headache 
  less common : abdominal pain, burning, tingling, numbness, or pain in the hands, arms, feet, or legs, muscle tenderness and weakness, nausea, skin rash, vomiting, yellow eyes or skin. coughing, decreased appetite, diarrhea, dizziness and trouble in sleeping may occurs 
  ",lamivudine + zidovudine
sign_symptom,pain,0.99990714," side effects of this medicine- 
 
  more common : chills, fever, pale skin; sore throat; unusual tiredness or weakness, headache 
  less common : abdominal pain, burning, tingling, numbness, or pain in the hands, arms, feet, or legs, muscle tenderness and weakness, nausea, skin rash, vomiting, yellow eyes or skin. coughing, decreased appetite, diarrhea, dizziness and trouble in sleeping may occurs 
  ",lamivudine + zidovudine
sign_symptom,tenderness,0.9998118," side effects of this medicine- 
 
  more common : chills, fever, pale skin; sore throat; unusual tiredness or weakness, headache 
  less common : abdominal pain, burning, tingling, numbness, or pain in the hands, arms, feet, or legs, muscle tenderness and weakness, nausea, skin rash, vomiting, yellow eyes or skin. coughing, decreased appetite, diarrhea, dizziness and trouble in sleeping may occurs 
  ",lamivudine + zidovudine
sign_symptom,decreased,0.9554179," side effects of this medicine- 
 
  more common : chills, fever, pale skin; sore throat; unusual tiredness or weakness, headache 
  less common : abdominal pain, burning, tingling, numbness, or pain in the hands, arms, feet, or legs, muscle tenderness and weakness, nausea, skin rash, vomiting, yellow eyes or skin. coughing, decreased appetite, diarrhea, dizziness and trouble in sleeping may occurs 
  ",lamivudine + zidovudine
sign_symptom,trouble,0.9998939," side effects of this medicine- 
 
  more common : chills, fever, pale skin; sore throat; unusual tiredness or weakness, headache 
  less common : abdominal pain, burning, tingling, numbness, or pain in the hands, arms, feet, or legs, muscle tenderness and weakness, nausea, skin rash, vomiting, yellow eyes or skin. coughing, decreased appetite, diarrhea, dizziness and trouble in sleeping may occurs 
  ",lamivudine + zidovudine
sign_symptom,adverse events,0.99964404," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
sign_symptom,neut,0.8036737," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
sign_symptom,anaemia,0.99944615," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
sign_symptom,cell,0.97420484," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,aplasia,0.97784996," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,nervous system,0.95213753," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,peripheral neuropathy,0.9990047," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,mediastinal disorders,0.98244584," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
sign_symptom,nasal symptoms,0.9994222," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
sign_symptom,nausea,0.93966264," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
sign_symptom,vomiting,0.9995012," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
sign_symptom,pain,0.99995255," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
sign_symptom,diarrhea,0.8908257," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,pancreatitis,0.9994383," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,hepatobiliary disorders,0.9985258," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,hepatitis,0.9998838," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,skin,0.9980667," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,subcut,0.86126846," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,tissue disorders,0.9913379," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
sign_symptom,rash,0.99878985," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,alopecia,0.99199444," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,connect,0.9965591," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,arthra,0.76080704," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,muscle disorders,0.997911," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,lipodystrophy,0.94388276," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
disease_disorder,general disorders,0.98036826," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
sign_symptom,mala,0.9942807," the following adverse events have been reported during therapy for hiv disease with lamivudine.  blood and lymphatic systems disorders- 
 
  uncommon : neutropenia, anaemia and thrombocytopenia 
  very rare : pure red cell aplasia 
 
nervous system disorders- 
 
  common : headache, insomnia 
  very rare : cases of peripheral neuropathy (or paraesthesia). 
 
respiratory, thoracic and mediastinal disorders 
 
  common : cough, nasal symptoms- 
 
gastrointestinal disorders- 
 
  common : nausea, vomiting, abdominal pain or cramps, diarrhea 
  rare : rises in serum amylase. cases of pancreatitis have been reported. 
 
hepatobiliary disorders- 
 
  uncommon : transient rises in liver enzymes (ast, alt). 
  rare : hepatitis 
 
skin and subcutaneous tissue disorders- 
 
  common : rash, alopecia 
 
musculoskeletal and connective tissue disorders- 
 
  common : arthralgia, muscle disorders 
  rare : rhabdomyolysis, lipodystrophy 
 
general disorders and administration site conditions- 
 
  common : fatigue, malaise, fever. 
 
cases of lactic acidosis, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues. ",lamivudine [for hiv infection]
sign_symptom,adverse events,0.99979687," several serious adverse events reported with lamivudine (lactic acidosis and severe hepatomegaly with steatosis, post treatment exacerbations of hepatitis b, pancreatitis, and emergence of viral mutants associated with reduced drug susceptibility and diminished treatment response). malaise, fatigue, fever, ent infections, sore throat, nausea, vomiting, abdominal discomfort, pain, diarrhea, myalgia, arthralgia, headache, skin rashes may occur. lactic acidosis and severe hepatomegaly with steatosis, have been reported. ",lamivudine [for chronic hepatitis b]
sign_symptom,lactic acidosis,0.9401394," several serious adverse events reported with lamivudine (lactic acidosis and severe hepatomegaly with steatosis, post treatment exacerbations of hepatitis b, pancreatitis, and emergence of viral mutants associated with reduced drug susceptibility and diminished treatment response). malaise, fatigue, fever, ent infections, sore throat, nausea, vomiting, abdominal discomfort, pain, diarrhea, myalgia, arthralgia, headache, skin rashes may occur. lactic acidosis and severe hepatomegaly with steatosis, have been reported. ",lamivudine [for chronic hepatitis b]
sign_symptom,hepa,0.8872858," several serious adverse events reported with lamivudine (lactic acidosis and severe hepatomegaly with steatosis, post treatment exacerbations of hepatitis b, pancreatitis, and emergence of viral mutants associated with reduced drug susceptibility and diminished treatment response). malaise, fatigue, fever, ent infections, sore throat, nausea, vomiting, abdominal discomfort, pain, diarrhea, myalgia, arthralgia, headache, skin rashes may occur. lactic acidosis and severe hepatomegaly with steatosis, have been reported. ",lamivudine [for chronic hepatitis b]
sign_symptom,mala,0.9397617," several serious adverse events reported with lamivudine (lactic acidosis and severe hepatomegaly with steatosis, post treatment exacerbations of hepatitis b, pancreatitis, and emergence of viral mutants associated with reduced drug susceptibility and diminished treatment response). malaise, fatigue, fever, ent infections, sore throat, nausea, vomiting, abdominal discomfort, pain, diarrhea, myalgia, arthralgia, headache, skin rashes may occur. lactic acidosis and severe hepatomegaly with steatosis, have been reported. ",lamivudine [for chronic hepatitis b]
sign_symptom,myal,0.9932784," several serious adverse events reported with lamivudine (lactic acidosis and severe hepatomegaly with steatosis, post treatment exacerbations of hepatitis b, pancreatitis, and emergence of viral mutants associated with reduced drug susceptibility and diminished treatment response). malaise, fatigue, fever, ent infections, sore throat, nausea, vomiting, abdominal discomfort, pain, diarrhea, myalgia, arthralgia, headache, skin rashes may occur. lactic acidosis and severe hepatomegaly with steatosis, have been reported. ",lamivudine [for chronic hepatitis b]
sign_symptom,arthral,0.97287256," several serious adverse events reported with lamivudine (lactic acidosis and severe hepatomegaly with steatosis, post treatment exacerbations of hepatitis b, pancreatitis, and emergence of viral mutants associated with reduced drug susceptibility and diminished treatment response). malaise, fatigue, fever, ent infections, sore throat, nausea, vomiting, abdominal discomfort, pain, diarrhea, myalgia, arthralgia, headache, skin rashes may occur. lactic acidosis and severe hepatomegaly with steatosis, have been reported. ",lamivudine [for chronic hepatitis b]
sign_symptom,rash,0.99992144," several serious adverse events reported with lamivudine (lactic acidosis and severe hepatomegaly with steatosis, post treatment exacerbations of hepatitis b, pancreatitis, and emergence of viral mutants associated with reduced drug susceptibility and diminished treatment response). malaise, fatigue, fever, ent infections, sore throat, nausea, vomiting, abdominal discomfort, pain, diarrhea, myalgia, arthralgia, headache, skin rashes may occur. lactic acidosis and severe hepatomegaly with steatosis, have been reported. ",lamivudine [for chronic hepatitis b]
sign_symptom,discomfort,0.99993134," occasionally flatulence, cramp and abdominal discomfort can occur at the beginning of treatment; this is rapidly eliminated by reducing the dose. overdose can result in diarrhoea. in abuse, loss of electrolytes (primarily potassium). ",lactulose
medication,potassium,0.93087417," occasionally flatulence, cramp and abdominal discomfort can occur at the beginning of treatment; this is rapidly eliminated by reducing the dose. overdose can result in diarrhoea. in abuse, loss of electrolytes (primarily potassium). ",lactulose
sign_symptom,allergic reaction,0.99914104," an increase in stomach gas or bloating may occur. if this effect persists or worsens, notify your doctor or pharmacist promptly. a very serious allergic reaction to this product is rare. however, seek immediate medical attention if you notice any of the following symptoms of a serious allergic reaction: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. ",lactobacillus rhamnosus gg
sign_symptom,swelling,0.9991979," an increase in stomach gas or bloating may occur. if this effect persists or worsens, notify your doctor or pharmacist promptly. a very serious allergic reaction to this product is rare. however, seek immediate medical attention if you notice any of the following symptoms of a serious allergic reaction: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. ",lactobacillus rhamnosus gg
sign_symptom,discomfort,0.9999275," at the start of the treatment with lactitol may produce abdominal discomforts such as flatulence, pain, cramps or sensation of fullness. such effects tend to diminish or disappear after a few days of regular intake of lactitol. occasionally, nausea or anal pruritus has been reported in some cases. ",lactitol monohydrate
sign_symptom,flat,0.99977773," at the start of the treatment with lactitol may produce abdominal discomforts such as flatulence, pain, cramps or sensation of fullness. such effects tend to diminish or disappear after a few days of regular intake of lactitol. occasionally, nausea or anal pruritus has been reported in some cases. ",lactitol monohydrate
sign_symptom,pain,0.99953735," at the start of the treatment with lactitol may produce abdominal discomforts such as flatulence, pain, cramps or sensation of fullness. such effects tend to diminish or disappear after a few days of regular intake of lactitol. occasionally, nausea or anal pruritus has been reported in some cases. ",lactitol monohydrate
medication,lacti,0.9307996," at the start of the treatment with lactitol may produce abdominal discomforts such as flatulence, pain, cramps or sensation of fullness. such effects tend to diminish or disappear after a few days of regular intake of lactitol. occasionally, nausea or anal pruritus has been reported in some cases. ",lactitol monohydrate
sign_symptom,nausea,0.999956," at the start of the treatment with lactitol may produce abdominal discomforts such as flatulence, pain, cramps or sensation of fullness. such effects tend to diminish or disappear after a few days of regular intake of lactitol. occasionally, nausea or anal pruritus has been reported in some cases. ",lactitol monohydrate
sign_symptom,anal pruritus,0.988988," at the start of the treatment with lactitol may produce abdominal discomforts such as flatulence, pain, cramps or sensation of fullness. such effects tend to diminish or disappear after a few days of regular intake of lactitol. occasionally, nausea or anal pruritus has been reported in some cases. ",lactitol monohydrate
sign_symptom,irritation,0.99843806," most emollients can be used safely and effectively with no side effects. however, burning, stinging, redness, or irritation may occur. if any of these effects persist or worsen, tell your doctor orpharmacistpromptly. ",lactic acid + sodium pca
sign_symptom,adverse reactions,0.8149596," most common adverse reactions (2%) were vulvovaginal burning sensation, vulvovaginal pruritus, vulvovaginal mycotic infection, urinary tract infection, vulvovaginal discomfort, bacterial vaginosis, vaginal discharge, genital discomfort, dysuria, and vulvovaginal pain. ",lactic acid + citric acid + potassium bitartrate
sign_symptom,difficulty in breathing,0.9997476," there are no major side effects reported. the very few side effects may include rash, difficulty in breathing, tightness in chest etc. ",lactase
sign_symptom,tightness,0.9994123," there are no major side effects reported. the very few side effects may include rash, difficulty in breathing, tightness in chest etc. ",lactase
sign_symptom,adverse reactions,0.9999222,"  adjunctive therapy : most common adverse reactions in adults (10% and greater than placebo) are diplopia, headache, dizziness, nausea   monotherapy : most common adverse reactions are similar to those seen in adjunctive therapy studies   pediatric patients : adverse reactions are similar to those seen in adult patients ",lacosamide
sign_symptom,headache,0.8171328,"  adjunctive therapy : most common adverse reactions in adults (10% and greater than placebo) are diplopia, headache, dizziness, nausea   monotherapy : most common adverse reactions are similar to those seen in adjunctive therapy studies   pediatric patients : adverse reactions are similar to those seen in adult patients ",lacosamide
sign_symptom,nausea,0.998725,"  adjunctive therapy : most common adverse reactions in adults (10% and greater than placebo) are diplopia, headache, dizziness, nausea   monotherapy : most common adverse reactions are similar to those seen in adjunctive therapy studies   pediatric patients : adverse reactions are similar to those seen in adult patients ",lacosamide
medication,lacidipine,0.999494," lacidipine is generally well tolerated. some individuals may experience minor side effects like flushing, palpitation, edema, headache, dizziness, rarely gastro-intestinal disturbances, gum hyperplasia, mood disturbances, asthenia, polyuria, muscle cramps, skin rash etc. ",lacidipine
sign_symptom,mood,0.9960445," lacidipine is generally well tolerated. some individuals may experience minor side effects like flushing, palpitation, edema, headache, dizziness, rarely gastro-intestinal disturbances, gum hyperplasia, mood disturbances, asthenia, polyuria, muscle cramps, skin rash etc. ",lacidipine
sign_symptom,poly,0.8975592," lacidipine is generally well tolerated. some individuals may experience minor side effects like flushing, palpitation, edema, headache, dizziness, rarely gastro-intestinal disturbances, gum hyperplasia, mood disturbances, asthenia, polyuria, muscle cramps, skin rash etc. ",lacidipine
sign_symptom,rash,0.90750927," lacidipine is generally well tolerated. some individuals may experience minor side effects like flushing, palpitation, edema, headache, dizziness, rarely gastro-intestinal disturbances, gum hyperplasia, mood disturbances, asthenia, polyuria, muscle cramps, skin rash etc. ",lacidipine
sign_symptom,tired,0.99937004," adverse effects reported are postural hypotension (avoid upright position during and for 3 hours after intravenous administration), tiredness, weakness, headache, rashes, scalp tingling, difficulty in micturition, epigastric pain, nausea, vomiting; liver damage. ",labetalol hydrochloride (injection)
sign_symptom,rash,0.9906108," adverse effects reported are postural hypotension (avoid upright position during and for 3 hours after intravenous administration), tiredness, weakness, headache, rashes, scalp tingling, difficulty in micturition, epigastric pain, nausea, vomiting; liver damage. ",labetalol hydrochloride (injection)
sign_symptom,difficulty,0.9977227," adverse effects reported are postural hypotension (avoid upright position during and for 3 hours after intravenous administration), tiredness, weakness, headache, rashes, scalp tingling, difficulty in micturition, epigastric pain, nausea, vomiting; liver damage. ",labetalol hydrochloride (injection)
sign_symptom,- effects,0.9845655," the following is a list of possible side-effects that may occur in medicines that contain l-ornithine-l-aspartate / pancreatin. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 nausea 
 vomiting 
 abdominal 
 stomach pain 
 bloating 
 diarrhea 
  ",l-ornithine l-aspartate + pancreatin
medication,l - ornithine -,0.72614956," the following is a list of possible side-effects that may occur in medicines that contain l-ornithine-l-aspartate / pancreatin. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 nausea 
 vomiting 
 abdominal 
 stomach pain 
 bloating 
 diarrhea 
  ",l-ornithine l-aspartate + pancreatin
medication,aspartate,0.8197643," the following is a list of possible side-effects that may occur in medicines that contain l-ornithine-l-aspartate / pancreatin. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 nausea 
 vomiting 
 abdominal 
 stomach pain 
 bloating 
 diarrhea 
  ",l-ornithine l-aspartate + pancreatin
sign_symptom,effects,0.82433987," the following is a list of possible side-effects that may occur in medicines that contain l-ornithine-l-aspartate / pancreatin. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 nausea 
 vomiting 
 abdominal 
 stomach pain 
 bloating 
 diarrhea 
  ",l-ornithine l-aspartate + pancreatin
sign_symptom,side - effects,0.7246051," the following is a list of possible side-effects that may occur in medicines that contain l-ornithine-l-aspartate / pancreatin. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 nausea 
 vomiting 
 abdominal 
 stomach pain 
 bloating 
 diarrhea 
  ",l-ornithine l-aspartate + pancreatin
sign_symptom,nausea,0.99994504," the following is a list of possible side-effects that may occur in medicines that contain l-ornithine-l-aspartate / pancreatin. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 nausea 
 vomiting 
 abdominal 
 stomach pain 
 bloating 
 diarrhea 
  ",l-ornithine l-aspartate + pancreatin
sign_symptom,vomiting,0.99992037," the following is a list of possible side-effects that may occur in medicines that contain l-ornithine-l-aspartate / pancreatin. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 nausea 
 vomiting 
 abdominal 
 stomach pain 
 bloating 
 diarrhea 
  ",l-ornithine l-aspartate + pancreatin
sign_symptom,pain,0.9999578," the following is a list of possible side-effects that may occur in medicines that contain l-ornithine-l-aspartate / pancreatin. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 nausea 
 vomiting 
 abdominal 
 stomach pain 
 bloating 
 diarrhea 
  ",l-ornithine l-aspartate + pancreatin
sign_symptom,side effects,0.99786115, very rarely side effects like nausea and vomiting occur. these side effects are usually transient and do not necessitate the withdrawal of the drug. ,l-ornithine l-aspartate
sign_symptom,nausea,0.9999324, very rarely side effects like nausea and vomiting occur. these side effects are usually transient and do not necessitate the withdrawal of the drug. ,l-ornithine l-aspartate
sign_symptom,vomiting,0.99991, very rarely side effects like nausea and vomiting occur. these side effects are usually transient and do not necessitate the withdrawal of the drug. ,l-ornithine l-aspartate
sign_symptom,effects,0.9770503, very rarely side effects like nausea and vomiting occur. these side effects are usually transient and do not necessitate the withdrawal of the drug. ,l-ornithine l-aspartate
sign_symptom,side effects,0.9701433," generally, levocetirizine is well tolerated. however, a few side effects like headache, dry mouth, fatigue and skin rash have been reported rarely. ",levocetirizine dihydrochloride
sign_symptom,fatigue,0.99991655," generally, levocetirizine is well tolerated. however, a few side effects like headache, dry mouth, fatigue and skin rash have been reported rarely. ",levocetirizine dihydrochloride
sign_symptom,rash,0.99987423," generally, levocetirizine is well tolerated. however, a few side effects like headache, dry mouth, fatigue and skin rash have been reported rarely. ",levocetirizine dihydrochloride
medication,levocarnitine,0.88593304," generally, levocarnitine is well tolerated. however, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur. ",levocarnitine
sign_symptom,side effects,0.99682593," generally, levocarnitine is well tolerated. however, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur. ",levocarnitine
sign_symptom,nausea,0.99992," generally, levocarnitine is well tolerated. however, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur. ",levocarnitine
sign_symptom,diarr,0.86740476," generally, levocarnitine is well tolerated. however, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur. ",levocarnitine
sign_symptom,restless,0.9249135," cns effects such as restlessness, anxiety, dizziness, confusion, respiratory depression and convulsions. neuromuscular and skeletal weakness, blurred vision, pupillary constriction, tinnitus. hypotension, bradycardia and cv collapse which may lead to cardiac arrest. rarely, hypersensitivity reactions. ",levobupivacaine hydrochloride
sign_symptom,brady,0.99680954," cns effects such as restlessness, anxiety, dizziness, confusion, respiratory depression and convulsions. neuromuscular and skeletal weakness, blurred vision, pupillary constriction, tinnitus. hypotension, bradycardia and cv collapse which may lead to cardiac arrest. rarely, hypersensitivity reactions. ",levobupivacaine hydrochloride
disease_disorder,cv collapse,0.9940851," cns effects such as restlessness, anxiety, dizziness, confusion, respiratory depression and convulsions. neuromuscular and skeletal weakness, blurred vision, pupillary constriction, tinnitus. hypotension, bradycardia and cv collapse which may lead to cardiac arrest. rarely, hypersensitivity reactions. ",levobupivacaine hydrochloride
sign_symptom,hyper,0.9999254," cns effects such as restlessness, anxiety, dizziness, confusion, respiratory depression and convulsions. neuromuscular and skeletal weakness, blurred vision, pupillary constriction, tinnitus. hypotension, bradycardia and cv collapse which may lead to cardiac arrest. rarely, hypersensitivity reactions. ",levobupivacaine hydrochloride
sign_symptom,adverse reactions,0.99974024," most common adverse reactions (incidence  5% more than placebo) include: 
 
 adult patients: somnolence, asthenia, infection and dizziness 
 pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability 
  ",levetiracetam
sign_symptom,infection,0.94926196," most common adverse reactions (incidence  5% more than placebo) include: 
 
 adult patients: somnolence, asthenia, infection and dizziness 
 pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability 
  ",levetiracetam
sign_symptom,fatigue,0.97852707," most common adverse reactions (incidence  5% more than placebo) include: 
 
 adult patients: somnolence, asthenia, infection and dizziness 
 pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability 
  ",levetiracetam
sign_symptom,decreased,0.9980831," most common adverse reactions (incidence  5% more than placebo) include: 
 
 adult patients: somnolence, asthenia, infection and dizziness 
 pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability 
  ",levetiracetam
sign_symptom,side,0.99845564," side-effects are infrequent. they are usually mild and transient and include nausea, vomiting, abdominal pain, giddiness(dizziness) and headache. an encephalopathylike syndrome has been reported to have occurred in a few patients two or three weeks after treatment. ",levamisole
sign_symptom,effects,0.99284536," side-effects are infrequent. they are usually mild and transient and include nausea, vomiting, abdominal pain, giddiness(dizziness) and headache. an encephalopathylike syndrome has been reported to have occurred in a few patients two or three weeks after treatment. ",levamisole
sign_symptom,nausea,0.97457176," side-effects are infrequent. they are usually mild and transient and include nausea, vomiting, abdominal pain, giddiness(dizziness) and headache. an encephalopathylike syndrome has been reported to have occurred in a few patients two or three weeks after treatment. ",levamisole
sign_symptom,vomiting,0.73184973," side-effects are infrequent. they are usually mild and transient and include nausea, vomiting, abdominal pain, giddiness(dizziness) and headache. an encephalopathylike syndrome has been reported to have occurred in a few patients two or three weeks after treatment. ",levamisole
sign_symptom,giddiness,0.9887517," side-effects are infrequent. they are usually mild and transient and include nausea, vomiting, abdominal pain, giddiness(dizziness) and headache. an encephalopathylike syndrome has been reported to have occurred in a few patients two or three weeks after treatment. ",levamisole
sign_symptom,worse,0.8581534,"  treatment of precocious puberty : general pain, headache, acne, rash, seborrhoea, emotional lability, vaginitis, vaginal bleeding vaginal discharge   treatment of prostate cancer : transient worsening of signs and symptoms (usually increase in bone pain), ecg changes, high blood pressure, peripheral oedema, anorexia, constipation, nausea, vomiting, anaemia, myalgia, dizziness, general pain, headache, insomnia or sleep disorder, sinus congestion, urinary frequency/urgency, haematuria, uti, asthaenia, physiological effects of decreased testosterone (e.g. gynaecomastia, breast tenderness, decreased testicular size, hot flashes, impotence).   treatment of endometriosis and uterine fibroids treatment : general pain, headache, asthaenia, nausea, vomiting, oedema, weight changes, acne, hirsutism, dizziness, insomnia, sleep disturbance, paraesthesias, skin reactions, effects of hypoestrogenism such as hot flashes, joint disorder, myalgia, decreased libido, depression, emotional lability, nervousness, breast tenderness, vaginitis. ",leuprorelin acetate
sign_symptom,of signs and symptoms,0.9257717,"  treatment of precocious puberty : general pain, headache, acne, rash, seborrhoea, emotional lability, vaginitis, vaginal bleeding vaginal discharge   treatment of prostate cancer : transient worsening of signs and symptoms (usually increase in bone pain), ecg changes, high blood pressure, peripheral oedema, anorexia, constipation, nausea, vomiting, anaemia, myalgia, dizziness, general pain, headache, insomnia or sleep disorder, sinus congestion, urinary frequency/urgency, haematuria, uti, asthaenia, physiological effects of decreased testosterone (e.g. gynaecomastia, breast tenderness, decreased testicular size, hot flashes, impotence).   treatment of endometriosis and uterine fibroids treatment : general pain, headache, asthaenia, nausea, vomiting, oedema, weight changes, acne, hirsutism, dizziness, insomnia, sleep disturbance, paraesthesias, skin reactions, effects of hypoestrogenism such as hot flashes, joint disorder, myalgia, decreased libido, depression, emotional lability, nervousness, breast tenderness, vaginitis. ",leuprorelin acetate
sign_symptom,adverse events,0.99485016," adverse events associated with letrozole are generally mild to moderate and rarely severe enough to require discontinuation. many can be attributed to either the underlying disease or the normal pharmacological consequence of oestrogen deprivation (hot flushes, hair thinning). the most frequently reported adverse events are musculoskeletal pain, arthralgia, headache, fatigue, nausea, dyspnoea, peripheral oedema, coughing, constipation, vomiting, chest pain, viral infection, diarrhoea, rash, abdominal pain, dyspepsia and anorexia. dizziness, weight increase and pruritus are less commonly seen. ",letrozole
sign_symptom,weight increase,0.9507621," adverse events associated with letrozole are generally mild to moderate and rarely severe enough to require discontinuation. many can be attributed to either the underlying disease or the normal pharmacological consequence of oestrogen deprivation (hot flushes, hair thinning). the most frequently reported adverse events are musculoskeletal pain, arthralgia, headache, fatigue, nausea, dyspnoea, peripheral oedema, coughing, constipation, vomiting, chest pain, viral infection, diarrhoea, rash, abdominal pain, dyspepsia and anorexia. dizziness, weight increase and pruritus are less commonly seen. ",letrozole
sign_symptom,dyspepsia,0.8868529," treatment with lercanidipine is generally well tolerated. the most common side effects are related to the vasodilatory properties of lercanidipine such as flushing, peripheral edema, headache, dizziness and asthenia. other side effects, which occurred in less than 1% of patients include fatigue; gl disturbances such as dyspepsia, nausea, vomiting, epigastric pain and diarrhea, polyurea, rash, somnolence and myalgia. ",lercanidipine hydrochloride
sign_symptom,pain,0.99571383," treatment with lercanidipine is generally well tolerated. the most common side effects are related to the vasodilatory properties of lercanidipine such as flushing, peripheral edema, headache, dizziness and asthenia. other side effects, which occurred in less than 1% of patients include fatigue; gl disturbances such as dyspepsia, nausea, vomiting, epigastric pain and diarrhea, polyurea, rash, somnolence and myalgia. ",lercanidipine hydrochloride
sign_symptom,poly,0.75082874," treatment with lercanidipine is generally well tolerated. the most common side effects are related to the vasodilatory properties of lercanidipine such as flushing, peripheral edema, headache, dizziness and asthenia. other side effects, which occurred in less than 1% of patients include fatigue; gl disturbances such as dyspepsia, nausea, vomiting, epigastric pain and diarrhea, polyurea, rash, somnolence and myalgia. ",lercanidipine hydrochloride
disease_disorder,renal failure,0.8028259," hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, renal failure and impairment, proteinuria, diarrhea, fistula formation and gastrointestinal perforation, qt interval prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, hemorrhagic events, impairment of thyroid stimulating hormone suppression/thyroid dysfunction, wound healing complications. ",lenvatinib mesylate
sign_symptom,fistula,0.7492809," hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, renal failure and impairment, proteinuria, diarrhea, fistula formation and gastrointestinal perforation, qt interval prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, hemorrhagic events, impairment of thyroid stimulating hormone suppression/thyroid dysfunction, wound healing complications. ",lenvatinib mesylate
disease_disorder,leukoencephalopathy,0.8942645," hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, renal failure and impairment, proteinuria, diarrhea, fistula formation and gastrointestinal perforation, qt interval prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, hemorrhagic events, impairment of thyroid stimulating hormone suppression/thyroid dysfunction, wound healing complications. ",lenvatinib mesylate
disease_disorder,thyroid,0.8205293," hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, renal failure and impairment, proteinuria, diarrhea, fistula formation and gastrointestinal perforation, qt interval prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, hemorrhagic events, impairment of thyroid stimulating hormone suppression/thyroid dysfunction, wound healing complications. ",lenvatinib mesylate
sign_symptom,epista,0.9831144," musculoskeletal pain, bone pain, splenic enlargement, nausea, fever, thrombocytopenia, anaemia, epistaxis, headache, diarrhoea, dysuria, osteoporosis, cutaneous vasculitis, anorexia, sweet's syndrome, toxic epidermal necrolysis. ",lenograstim
sign_symptom,reaction,0.81840295," embryo-fetal toxicity, hematologic toxicity, venous and arterial thromboembolism, increased mortality in patients with cll, second primary malignancies, hepatotoxicity, severe cutaneous reaction tumor lysis syndrome, tumor flare reactions, impaired stem cell mobilization, thyroid disorders. early mortality in patients with mcl, hypersensitivity. severe hypersensitivity reactions: lenalidomide is contraindicated in patients who have demonstrated hypersensitivity (e.g., angioedema, stevens-johnson syndrome, toxic epidermal necrolysis) to lenalidomide. ",lenalidomide
sign_symptom,tumor,0.97968984," embryo-fetal toxicity, hematologic toxicity, venous and arterial thromboembolism, increased mortality in patients with cll, second primary malignancies, hepatotoxicity, severe cutaneous reaction tumor lysis syndrome, tumor flare reactions, impaired stem cell mobilization, thyroid disorders. early mortality in patients with mcl, hypersensitivity. severe hypersensitivity reactions: lenalidomide is contraindicated in patients who have demonstrated hypersensitivity (e.g., angioedema, stevens-johnson syndrome, toxic epidermal necrolysis) to lenalidomide. ",lenalidomide
sign_symptom,hyper,0.99958175," embryo-fetal toxicity, hematologic toxicity, venous and arterial thromboembolism, increased mortality in patients with cll, second primary malignancies, hepatotoxicity, severe cutaneous reaction tumor lysis syndrome, tumor flare reactions, impaired stem cell mobilization, thyroid disorders. early mortality in patients with mcl, hypersensitivity. severe hypersensitivity reactions: lenalidomide is contraindicated in patients who have demonstrated hypersensitivity (e.g., angioedema, stevens-johnson syndrome, toxic epidermal necrolysis) to lenalidomide. ",lenalidomide
medication,lenalidomide,0.913326," embryo-fetal toxicity, hematologic toxicity, venous and arterial thromboembolism, increased mortality in patients with cll, second primary malignancies, hepatotoxicity, severe cutaneous reaction tumor lysis syndrome, tumor flare reactions, impaired stem cell mobilization, thyroid disorders. early mortality in patients with mcl, hypersensitivity. severe hypersensitivity reactions: lenalidomide is contraindicated in patients who have demonstrated hypersensitivity (e.g., angioedema, stevens-johnson syndrome, toxic epidermal necrolysis) to lenalidomide. ",lenalidomide
sign_symptom,hypersensitivity,0.99978983," embryo-fetal toxicity, hematologic toxicity, venous and arterial thromboembolism, increased mortality in patients with cll, second primary malignancies, hepatotoxicity, severe cutaneous reaction tumor lysis syndrome, tumor flare reactions, impaired stem cell mobilization, thyroid disorders. early mortality in patients with mcl, hypersensitivity. severe hypersensitivity reactions: lenalidomide is contraindicated in patients who have demonstrated hypersensitivity (e.g., angioedema, stevens-johnson syndrome, toxic epidermal necrolysis) to lenalidomide. ",lenalidomide
medication,lena,0.99535286," embryo-fetal toxicity, hematologic toxicity, venous and arterial thromboembolism, increased mortality in patients with cll, second primary malignancies, hepatotoxicity, severe cutaneous reaction tumor lysis syndrome, tumor flare reactions, impaired stem cell mobilization, thyroid disorders. early mortality in patients with mcl, hypersensitivity. severe hypersensitivity reactions: lenalidomide is contraindicated in patients who have demonstrated hypersensitivity (e.g., angioedema, stevens-johnson syndrome, toxic epidermal necrolysis) to lenalidomide. ",lenalidomide
sign_symptom,adverse reactions,0.80730665," the most common adverse reactions with treatment with ledipasvir and sofosbuvir combination for 8, 12, or 24 weeks are fatigue and headache. ",ledipasvir + sofosbuvir
sign_symptom,fatigue,0.99992526," the most common adverse reactions with treatment with ledipasvir and sofosbuvir combination for 8, 12, or 24 weeks are fatigue and headache. ",ledipasvir + sofosbuvir
sign_symptom,lengthening,0.8372121," this combination is generally well tolerated. the most frequent findings of increased iris pigmentation were in patients with green-brown, yellow-brown and blue/grey/brown irides. in patients with homogeneously blue, grey, green or brown eyes, the change was only rarely seen. darkening, thickening and lengthening of the eye lashes have been reported. the most frequently reported undesirable effects in clinical trials were irritation of the eye, including stinging, burning and ,itching, eye hyperaemia, corneal disorders, coniunctivitis blepharitis, eye pain, headache and skin rash. ",latanoprost + timolol
sign_symptom,irritation,0.999913," this combination is generally well tolerated. the most frequent findings of increased iris pigmentation were in patients with green-brown, yellow-brown and blue/grey/brown irides. in patients with homogeneously blue, grey, green or brown eyes, the change was only rarely seen. darkening, thickening and lengthening of the eye lashes have been reported. the most frequently reported undesirable effects in clinical trials were irritation of the eye, including stinging, burning and ,itching, eye hyperaemia, corneal disorders, coniunctivitis blepharitis, eye pain, headache and skin rash. ",latanoprost + timolol
disease_disorder,coniunctivitis,0.96351326," this combination is generally well tolerated. the most frequent findings of increased iris pigmentation were in patients with green-brown, yellow-brown and blue/grey/brown irides. in patients with homogeneously blue, grey, green or brown eyes, the change was only rarely seen. darkening, thickening and lengthening of the eye lashes have been reported. the most frequently reported undesirable effects in clinical trials were irritation of the eye, including stinging, burning and ,itching, eye hyperaemia, corneal disorders, coniunctivitis blepharitis, eye pain, headache and skin rash. ",latanoprost + timolol
sign_symptom,headache,0.9716375," this combination is generally well tolerated. the most frequent findings of increased iris pigmentation were in patients with green-brown, yellow-brown and blue/grey/brown irides. in patients with homogeneously blue, grey, green or brown eyes, the change was only rarely seen. darkening, thickening and lengthening of the eye lashes have been reported. the most frequently reported undesirable effects in clinical trials were irritation of the eye, including stinging, burning and ,itching, eye hyperaemia, corneal disorders, coniunctivitis blepharitis, eye pain, headache and skin rash. ",latanoprost + timolol
disease_disorder,inflammation,0.9747157," eyelash changes (increased length, thickness, pigmentation, and number of lashes); eyelid skin darkening; intraocular inflammation (iritis/uveitis); iris pigmentation changes; and macular edema, including cystoid macular edema. the ocular adverse events and ocular signs and symptoms reported in 5- 15% of the patients on latanoprost in the 6 month, multicenter, double-masked, active-controlled trials were blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, and punctate epithelial keratopathy. local conjunctiva hyperemia was observed; however, less than 1% of the latanoprost treated patients required discontinuation of therapy because of intolerance to conjunctival hyperemia. ",latanoprost
sign_symptom,adverse events,0.9996189," eyelash changes (increased length, thickness, pigmentation, and number of lashes); eyelid skin darkening; intraocular inflammation (iritis/uveitis); iris pigmentation changes; and macular edema, including cystoid macular edema. the ocular adverse events and ocular signs and symptoms reported in 5- 15% of the patients on latanoprost in the 6 month, multicenter, double-masked, active-controlled trials were blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, and punctate epithelial keratopathy. local conjunctiva hyperemia was observed; however, less than 1% of the latanoprost treated patients required discontinuation of therapy because of intolerance to conjunctival hyperemia. ",latanoprost
sign_symptom,foreign body,0.9268396," eyelash changes (increased length, thickness, pigmentation, and number of lashes); eyelid skin darkening; intraocular inflammation (iritis/uveitis); iris pigmentation changes; and macular edema, including cystoid macular edema. the ocular adverse events and ocular signs and symptoms reported in 5- 15% of the patients on latanoprost in the 6 month, multicenter, double-masked, active-controlled trials were blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, and punctate epithelial keratopathy. local conjunctiva hyperemia was observed; however, less than 1% of the latanoprost treated patients required discontinuation of therapy because of intolerance to conjunctival hyperemia. ",latanoprost
sign_symptom,pain,0.99996376," gi disturbances, dermatological reactions (e.g. palmar-plantar erythrodysesthesia, rash), fatigue, decreases in lvef, qt interval prolongation, stomatitis, mucosal inflammation, pain in extremities, back pain, dyspnoea, insomnia, epistaxis, alopecia, nail disorders (e.g. paronychia), interstitial lung disease, pneumonitis and hypersensitivity reactions including anaphylaxis. ",lapatinib
sign_symptom,epista,0.88490206," gi disturbances, dermatological reactions (e.g. palmar-plantar erythrodysesthesia, rash), fatigue, decreases in lvef, qt interval prolongation, stomatitis, mucosal inflammation, pain in extremities, back pain, dyspnoea, insomnia, epistaxis, alopecia, nail disorders (e.g. paronychia), interstitial lung disease, pneumonitis and hypersensitivity reactions including anaphylaxis. ",lapatinib
disease_disorder,nail disorders,0.9890368," gi disturbances, dermatological reactions (e.g. palmar-plantar erythrodysesthesia, rash), fatigue, decreases in lvef, qt interval prolongation, stomatitis, mucosal inflammation, pain in extremities, back pain, dyspnoea, insomnia, epistaxis, alopecia, nail disorders (e.g. paronychia), interstitial lung disease, pneumonitis and hypersensitivity reactions including anaphylaxis. ",lapatinib
disease_disorder,inter,0.7757574," gi disturbances, dermatological reactions (e.g. palmar-plantar erythrodysesthesia, rash), fatigue, decreases in lvef, qt interval prolongation, stomatitis, mucosal inflammation, pain in extremities, back pain, dyspnoea, insomnia, epistaxis, alopecia, nail disorders (e.g. paronychia), interstitial lung disease, pneumonitis and hypersensitivity reactions including anaphylaxis. ",lapatinib
disease_disorder,pneumonitis,0.9539226," gi disturbances, dermatological reactions (e.g. palmar-plantar erythrodysesthesia, rash), fatigue, decreases in lvef, qt interval prolongation, stomatitis, mucosal inflammation, pain in extremities, back pain, dyspnoea, insomnia, epistaxis, alopecia, nail disorders (e.g. paronychia), interstitial lung disease, pneumonitis and hypersensitivity reactions including anaphylaxis. ",lapatinib
sign_symptom,hypersensitivity reactions,0.9967438," gi disturbances, dermatological reactions (e.g. palmar-plantar erythrodysesthesia, rash), fatigue, decreases in lvef, qt interval prolongation, stomatitis, mucosal inflammation, pain in extremities, back pain, dyspnoea, insomnia, epistaxis, alopecia, nail disorders (e.g. paronychia), interstitial lung disease, pneumonitis and hypersensitivity reactions including anaphylaxis. ",lapatinib
sign_symptom,nasopharyngit,0.9804118," there may be hypoglycaemia, nasopharyngitis, cough and pancreatitis in combination with metformin and sulfonylurea. ",linagliptin
sign_symptom,cough,0.99972385," there may be hypoglycaemia, nasopharyngitis, cough and pancreatitis in combination with metformin and sulfonylurea. ",linagliptin
sign_symptom,adverse effects,0.9999106, no remarkable adverse effects have been reported. ,light liquid paraffin + white soft paraffin + glycerine
sign_symptom,dysgeusia,0.9352479," the common adverse effects are instillation site irritation, dysgeusia and reduced visual acuity. less common are blurred vision, conjunctival hyperemia, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis. ",lifitegrast
sign_symptom,rash,0.9999218," skin rash or irritation, drowsiness, wheezing or difficulty breathing, chest pain, severe rash or itching, increased sweating, numbness. ",lidocaine hydrochloride (spray)
sign_symptom,wheezing,0.8903363," skin rash or irritation, drowsiness, wheezing or difficulty breathing, chest pain, severe rash or itching, increased sweating, numbness. ",lidocaine hydrochloride (spray)
sign_symptom,difficulty breathing,0.9678738," skin rash or irritation, drowsiness, wheezing or difficulty breathing, chest pain, severe rash or itching, increased sweating, numbness. ",lidocaine hydrochloride (spray)
sign_symptom,blurred vision,0.9925432," nervousness, dizziness, blurred vision, tremors, drowsiness, convulsions, unconsciousness, respiratory arrest, hypotension, myocardial depression, bradycardia, cardiac arrest and anaphylactic reactions (cutaneous lesion, urticaria, oedema). ",lidocaine hydrochloride (jelly)
sign_symptom,tremor,0.8009332," nervousness, dizziness, blurred vision, tremors, drowsiness, convulsions, unconsciousness, respiratory arrest, hypotension, myocardial depression, bradycardia, cardiac arrest and anaphylactic reactions (cutaneous lesion, urticaria, oedema). ",lidocaine hydrochloride (jelly)
sign_symptom,drowsiness,0.98580104," nervousness, dizziness, blurred vision, tremors, drowsiness, convulsions, unconsciousness, respiratory arrest, hypotension, myocardial depression, bradycardia, cardiac arrest and anaphylactic reactions (cutaneous lesion, urticaria, oedema). ",lidocaine hydrochloride (jelly)
sign_symptom,reactions,0.9949065," nervousness, dizziness, blurred vision, tremors, drowsiness, convulsions, unconsciousness, respiratory arrest, hypotension, myocardial depression, bradycardia, cardiac arrest and anaphylactic reactions (cutaneous lesion, urticaria, oedema). ",lidocaine hydrochloride (jelly)
sign_symptom,adverse reactions,0.99786156," in common with other local anaesthetics, adverse reactions to lidocaine are rare and are usually the result of excessively high blood concentrations due to inadvertent intravascular injection, excessive dosage, rapid absorption or occasionally to hypersensitivity, idiosyncracy or diminished tolerance on the part of the patient. in such circumstances systemic effects occur involving the central nervous system and/or the cardiovascular system. cns reactions are excitatory and/or depressant and may be characterized by nervousness, dizziness, blurred vision and tremors, followed by drowsiness, convulsions, unconsciousness and possibly respiratory arrest. cardiovascular reactions are hypotension, myocardial depression, bradycardia and possibly cardiac arrest. allergic reactions are extremely rare. they may be characterized by cutaneous lesions, urticaria, oedema or anaphylactoid reactions. ",lidocaine hydrochloride (injection)
medication,lidocaine,0.9709215," in common with other local anaesthetics, adverse reactions to lidocaine are rare and are usually the result of excessively high blood concentrations due to inadvertent intravascular injection, excessive dosage, rapid absorption or occasionally to hypersensitivity, idiosyncracy or diminished tolerance on the part of the patient. in such circumstances systemic effects occur involving the central nervous system and/or the cardiovascular system. cns reactions are excitatory and/or depressant and may be characterized by nervousness, dizziness, blurred vision and tremors, followed by drowsiness, convulsions, unconsciousness and possibly respiratory arrest. cardiovascular reactions are hypotension, myocardial depression, bradycardia and possibly cardiac arrest. allergic reactions are extremely rare. they may be characterized by cutaneous lesions, urticaria, oedema or anaphylactoid reactions. ",lidocaine hydrochloride (injection)
sign_symptom,idiosyncracy,0.8219306," in common with other local anaesthetics, adverse reactions to lidocaine are rare and are usually the result of excessively high blood concentrations due to inadvertent intravascular injection, excessive dosage, rapid absorption or occasionally to hypersensitivity, idiosyncracy or diminished tolerance on the part of the patient. in such circumstances systemic effects occur involving the central nervous system and/or the cardiovascular system. cns reactions are excitatory and/or depressant and may be characterized by nervousness, dizziness, blurred vision and tremors, followed by drowsiness, convulsions, unconsciousness and possibly respiratory arrest. cardiovascular reactions are hypotension, myocardial depression, bradycardia and possibly cardiac arrest. allergic reactions are extremely rare. they may be characterized by cutaneous lesions, urticaria, oedema or anaphylactoid reactions. ",lidocaine hydrochloride (injection)
sign_symptom,diminished tolerance,0.97229266," in common with other local anaesthetics, adverse reactions to lidocaine are rare and are usually the result of excessively high blood concentrations due to inadvertent intravascular injection, excessive dosage, rapid absorption or occasionally to hypersensitivity, idiosyncracy or diminished tolerance on the part of the patient. in such circumstances systemic effects occur involving the central nervous system and/or the cardiovascular system. cns reactions are excitatory and/or depressant and may be characterized by nervousness, dizziness, blurred vision and tremors, followed by drowsiness, convulsions, unconsciousness and possibly respiratory arrest. cardiovascular reactions are hypotension, myocardial depression, bradycardia and possibly cardiac arrest. allergic reactions are extremely rare. they may be characterized by cutaneous lesions, urticaria, oedema or anaphylactoid reactions. ",lidocaine hydrochloride (injection)
sign_symptom,blurred vision,0.9342922," in common with other local anaesthetics, adverse reactions to lidocaine are rare and are usually the result of excessively high blood concentrations due to inadvertent intravascular injection, excessive dosage, rapid absorption or occasionally to hypersensitivity, idiosyncracy or diminished tolerance on the part of the patient. in such circumstances systemic effects occur involving the central nervous system and/or the cardiovascular system. cns reactions are excitatory and/or depressant and may be characterized by nervousness, dizziness, blurred vision and tremors, followed by drowsiness, convulsions, unconsciousness and possibly respiratory arrest. cardiovascular reactions are hypotension, myocardial depression, bradycardia and possibly cardiac arrest. allergic reactions are extremely rare. they may be characterized by cutaneous lesions, urticaria, oedema or anaphylactoid reactions. ",lidocaine hydrochloride (injection)
sign_symptom,allergic reactions,0.9970307," in common with other local anaesthetics, adverse reactions to lidocaine are rare and are usually the result of excessively high blood concentrations due to inadvertent intravascular injection, excessive dosage, rapid absorption or occasionally to hypersensitivity, idiosyncracy or diminished tolerance on the part of the patient. in such circumstances systemic effects occur involving the central nervous system and/or the cardiovascular system. cns reactions are excitatory and/or depressant and may be characterized by nervousness, dizziness, blurred vision and tremors, followed by drowsiness, convulsions, unconsciousness and possibly respiratory arrest. cardiovascular reactions are hypotension, myocardial depression, bradycardia and possibly cardiac arrest. allergic reactions are extremely rare. they may be characterized by cutaneous lesions, urticaria, oedema or anaphylactoid reactions. ",lidocaine hydrochloride (injection)
sign_symptom,blurred vision,0.9899991," nervousness, dizziness, blurred vision, tremors, drowsiness, convulsions,unconsciousness, respiratory arrest, hypotension, myocardial depression, bradycardia, cardiacarrest and anaphylactoid reactions (cutaneous lesion, urticaria, oedema). ",lidocaine + prilocaine
sign_symptom,tremor,0.72672254," nervousness, dizziness, blurred vision, tremors, drowsiness, convulsions,unconsciousness, respiratory arrest, hypotension, myocardial depression, bradycardia, cardiacarrest and anaphylactoid reactions (cutaneous lesion, urticaria, oedema). ",lidocaine + prilocaine
sign_symptom,drowsiness,0.96742034," nervousness, dizziness, blurred vision, tremors, drowsiness, convulsions,unconsciousness, respiratory arrest, hypotension, myocardial depression, bradycardia, cardiacarrest and anaphylactoid reactions (cutaneous lesion, urticaria, oedema). ",lidocaine + prilocaine
sign_symptom,cardiac,0.91703403," nervousness, dizziness, blurred vision, tremors, drowsiness, convulsions,unconsciousness, respiratory arrest, hypotension, myocardial depression, bradycardia, cardiacarrest and anaphylactoid reactions (cutaneous lesion, urticaria, oedema). ",lidocaine + prilocaine
sign_symptom,reactions,0.997635," nervousness, dizziness, blurred vision, tremors, drowsiness, convulsions,unconsciousness, respiratory arrest, hypotension, myocardial depression, bradycardia, cardiacarrest and anaphylactoid reactions (cutaneous lesion, urticaria, oedema). ",lidocaine + prilocaine
sign_symptom,numb,0.9997286,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,allergic reactions,0.9994291,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,difficulty breathing,0.98101664,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,tightness,0.99698865,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,swelling,0.99994826,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,faint,0.95524496,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,loss,0.9970571,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,consciousness,0.95429933,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,pale,0.9202334,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,ringing in,0.8622502,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,heat,0.87357056,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,shortness of breath,0.9964683,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,blist,0.7341342,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,tremors,0.99331284,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,vision,0.9628451,"  more common side effects :minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.   severe side effects :severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting. ",lidocaine + adrenaline
sign_symptom,adverse reactions,0.99492335," adverse reactions associated with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdose. they include the following: 
 
 general: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating; 
 central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia. 
 musculoskeletal: tremors, muscle weakness. 
 cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure 
 respiratory: dyspnea. 
 gastrointestinal: diarrhea, vomiting, abdominal cramps. 
 dermatologic: hair loss, flushing. 
  ",levothyroxine sodium
medication,levothyrox,0.80746335," adverse reactions associated with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdose. they include the following: 
 
 general: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating; 
 central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia. 
 musculoskeletal: tremors, muscle weakness. 
 cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure 
 respiratory: dyspnea. 
 gastrointestinal: diarrhea, vomiting, abdominal cramps. 
 dermatologic: hair loss, flushing. 
  ",levothyroxine sodium
sign_symptom,hyper,0.9214779," adverse reactions associated with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdose. they include the following: 
 
 general: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating; 
 central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia. 
 musculoskeletal: tremors, muscle weakness. 
 cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure 
 respiratory: dyspnea. 
 gastrointestinal: diarrhea, vomiting, abdominal cramps. 
 dermatologic: hair loss, flushing. 
  ",levothyroxine sodium
sign_symptom,tremor,0.964523," hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. the other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. ",levosalbutamol (oral)
sign_symptom,pain,0.9858453," hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. the other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. ",levosalbutamol (oral)
medication,beta 2 -,0.9795764," potentially serious hypokalaemia may result from beta 2 - agonist therapy. this effect may be potentiated by hypoxia. other side effects such as palpitation, fine tremors of the skeletal muscle (particularly the hand) and muscle cramps may occur. in few cases nervousness, headache, dizziness, fatigue and sleeplessness have also been reported. ",levosalbutamol
sign_symptom,fine tremors,0.8803522," potentially serious hypokalaemia may result from beta 2 - agonist therapy. this effect may be potentiated by hypoxia. other side effects such as palpitation, fine tremors of the skeletal muscle (particularly the hand) and muscle cramps may occur. in few cases nervousness, headache, dizziness, fatigue and sleeplessness have also been reported. ",levosalbutamol
sign_symptom,nervousness,0.93130714," potentially serious hypokalaemia may result from beta 2 - agonist therapy. this effect may be potentiated by hypoxia. other side effects such as palpitation, fine tremors of the skeletal muscle (particularly the hand) and muscle cramps may occur. in few cases nervousness, headache, dizziness, fatigue and sleeplessness have also been reported. ",levosalbutamol
sign_symptom,headache,0.9993198," potentially serious hypokalaemia may result from beta 2 - agonist therapy. this effect may be potentiated by hypoxia. other side effects such as palpitation, fine tremors of the skeletal muscle (particularly the hand) and muscle cramps may occur. in few cases nervousness, headache, dizziness, fatigue and sleeplessness have also been reported. ",levosalbutamol
sign_symptom,fatigue,0.9998266," potentially serious hypokalaemia may result from beta 2 - agonist therapy. this effect may be potentiated by hypoxia. other side effects such as palpitation, fine tremors of the skeletal muscle (particularly the hand) and muscle cramps may occur. in few cases nervousness, headache, dizziness, fatigue and sleeplessness have also been reported. ",levosalbutamol
sign_symptom,sleeplessness,0.98685664," potentially serious hypokalaemia may result from beta 2 - agonist therapy. this effect may be potentiated by hypoxia. other side effects such as palpitation, fine tremors of the skeletal muscle (particularly the hand) and muscle cramps may occur. in few cases nervousness, headache, dizziness, fatigue and sleeplessness have also been reported. ",levosalbutamol
sign_symptom,nausea,0.9999304," undesirable effects which have been observed are: 
 
 nausea and vomiting 
 dizziness, fatigue, headache 
 abdominal pain 
 a feeling of breast tenderness 
 bleeding can occur after taking this medicine 
 
inform the doctor of any unwanted effect which is not mentioned here. ",levonorgestrel
sign_symptom,vomiting,0.9998965," undesirable effects which have been observed are: 
 
 nausea and vomiting 
 dizziness, fatigue, headache 
 abdominal pain 
 a feeling of breast tenderness 
 bleeding can occur after taking this medicine 
 
inform the doctor of any unwanted effect which is not mentioned here. ",levonorgestrel
sign_symptom,headache,0.9998965," undesirable effects which have been observed are: 
 
 nausea and vomiting 
 dizziness, fatigue, headache 
 abdominal pain 
 a feeling of breast tenderness 
 bleeding can occur after taking this medicine 
 
inform the doctor of any unwanted effect which is not mentioned here. ",levonorgestrel
sign_symptom,pain,0.9999541," undesirable effects which have been observed are: 
 
 nausea and vomiting 
 dizziness, fatigue, headache 
 abdominal pain 
 a feeling of breast tenderness 
 bleeding can occur after taking this medicine 
 
inform the doctor of any unwanted effect which is not mentioned here. ",levonorgestrel
sign_symptom,tenderness,0.99992466," undesirable effects which have been observed are: 
 
 nausea and vomiting 
 dizziness, fatigue, headache 
 abdominal pain 
 a feeling of breast tenderness 
 bleeding can occur after taking this medicine 
 
inform the doctor of any unwanted effect which is not mentioned here. ",levonorgestrel
sign_symptom,bleeding,0.9999329," undesirable effects which have been observed are: 
 
 nausea and vomiting 
 dizziness, fatigue, headache 
 abdominal pain 
 a feeling of breast tenderness 
 bleeding can occur after taking this medicine 
 
inform the doctor of any unwanted effect which is not mentioned here. ",levonorgestrel
sign_symptom,hyper,0.9999428,"  
 hypersensitivity 
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 elevated blood pressure 
 elevated heart rate 
 increased risk of bleeding 
 angle closure glaucoma 
 urinary hesitation or retention 
 activation of mania/hypomania 
 seizure 
 discontinuation syndrome 
 hyponatremia 
  ",levomilnacipran hydrochloride
sign_symptom,suicidal thoughts,0.9996708,"  
 hypersensitivity 
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 elevated blood pressure 
 elevated heart rate 
 increased risk of bleeding 
 angle closure glaucoma 
 urinary hesitation or retention 
 activation of mania/hypomania 
 seizure 
 discontinuation syndrome 
 hyponatremia 
  ",levomilnacipran hydrochloride
sign_symptom,behaviors,0.99960107,"  
 hypersensitivity 
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 elevated blood pressure 
 elevated heart rate 
 increased risk of bleeding 
 angle closure glaucoma 
 urinary hesitation or retention 
 activation of mania/hypomania 
 seizure 
 discontinuation syndrome 
 hyponatremia 
  ",levomilnacipran hydrochloride
disease_disorder,serotonin syndrome,0.8930158,"  
 hypersensitivity 
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 elevated blood pressure 
 elevated heart rate 
 increased risk of bleeding 
 angle closure glaucoma 
 urinary hesitation or retention 
 activation of mania/hypomania 
 seizure 
 discontinuation syndrome 
 hyponatremia 
  ",levomilnacipran hydrochloride
sign_symptom,bleeding angle closure,0.95679325,"  
 hypersensitivity 
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 elevated blood pressure 
 elevated heart rate 
 increased risk of bleeding 
 angle closure glaucoma 
 urinary hesitation or retention 
 activation of mania/hypomania 
 seizure 
 discontinuation syndrome 
 hyponatremia 
  ",levomilnacipran hydrochloride
sign_symptom,glaucoma,0.9752432,"  
 hypersensitivity 
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 elevated blood pressure 
 elevated heart rate 
 increased risk of bleeding 
 angle closure glaucoma 
 urinary hesitation or retention 
 activation of mania/hypomania 
 seizure 
 discontinuation syndrome 
 hyponatremia 
  ",levomilnacipran hydrochloride
sign_symptom,mania,0.9944207,"  
 hypersensitivity 
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 elevated blood pressure 
 elevated heart rate 
 increased risk of bleeding 
 angle closure glaucoma 
 urinary hesitation or retention 
 activation of mania/hypomania 
 seizure 
 discontinuation syndrome 
 hyponatremia 
  ",levomilnacipran hydrochloride
disease_disorder,hypomania seizure,0.8884943,"  
 hypersensitivity 
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 elevated blood pressure 
 elevated heart rate 
 increased risk of bleeding 
 angle closure glaucoma 
 urinary hesitation or retention 
 activation of mania/hypomania 
 seizure 
 discontinuation syndrome 
 hyponatremia 
  ",levomilnacipran hydrochloride
disease_disorder,hyponatremia,0.9992644,"  
 hypersensitivity 
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 elevated blood pressure 
 elevated heart rate 
 increased risk of bleeding 
 angle closure glaucoma 
 urinary hesitation or retention 
 activation of mania/hypomania 
 seizure 
 discontinuation syndrome 
 hyponatremia 
  ",levomilnacipran hydrochloride
medication,levofloxacin,0.98707896," levofloxacin is generally well tolerated. however, a few side-effects can usually be seen. there is a risk of retinal detachment. other side-effects include: nausea, vomiting, diarrhea, abdominal pain, flatulence and rare occurrence of phototoxicity (0.1%). side-effects that may be seen very rarely include tremors, depression, anxiety, confusion etc. ",levofloxacin hemihydrate
sign_symptom,flatulence,0.9998315," levofloxacin is generally well tolerated. however, a few side-effects can usually be seen. there is a risk of retinal detachment. other side-effects include: nausea, vomiting, diarrhea, abdominal pain, flatulence and rare occurrence of phototoxicity (0.1%). side-effects that may be seen very rarely include tremors, depression, anxiety, confusion etc. ",levofloxacin hemihydrate
disease_disorder,phototoxicity,0.90781534," levofloxacin is generally well tolerated. however, a few side-effects can usually be seen. there is a risk of retinal detachment. other side-effects include: nausea, vomiting, diarrhea, abdominal pain, flatulence and rare occurrence of phototoxicity (0.1%). side-effects that may be seen very rarely include tremors, depression, anxiety, confusion etc. ",levofloxacin hemihydrate
sign_symptom,tremors,0.88535243," levofloxacin is generally well tolerated. however, a few side-effects can usually be seen. there is a risk of retinal detachment. other side-effects include: nausea, vomiting, diarrhea, abdominal pain, flatulence and rare occurrence of phototoxicity (0.1%). side-effects that may be seen very rarely include tremors, depression, anxiety, confusion etc. ",levofloxacin hemihydrate
sign_symptom,depression,0.9985056," levofloxacin is generally well tolerated. however, a few side-effects can usually be seen. there is a risk of retinal detachment. other side-effects include: nausea, vomiting, diarrhea, abdominal pain, flatulence and rare occurrence of phototoxicity (0.1%). side-effects that may be seen very rarely include tremors, depression, anxiety, confusion etc. ",levofloxacin hemihydrate
sign_symptom,anxiety,0.9992373," levofloxacin is generally well tolerated. however, a few side-effects can usually be seen. there is a risk of retinal detachment. other side-effects include: nausea, vomiting, diarrhea, abdominal pain, flatulence and rare occurrence of phototoxicity (0.1%). side-effects that may be seen very rarely include tremors, depression, anxiety, confusion etc. ",levofloxacin hemihydrate
sign_symptom,confusion,0.9998826," levofloxacin is generally well tolerated. however, a few side-effects can usually be seen. there is a risk of retinal detachment. other side-effects include: nausea, vomiting, diarrhea, abdominal pain, flatulence and rare occurrence of phototoxicity (0.1%). side-effects that may be seen very rarely include tremors, depression, anxiety, confusion etc. ",levofloxacin hemihydrate
sign_symptom,effects,0.82307595," side effects occurred only approximately 1-3% of patients that may include transient blurred vision, fever, foreign body sensation, headache, transient ocular burning, ocular pain or discomfort, pharyngitis and photophobia. in less than 1% of patients included allergic reactions, lid edema, ocular dryness and ocular itching. ",levofloxacin (ophthalmic)
sign_symptom,allergic,0.85706335," side effects occurred only approximately 1-3% of patients that may include transient blurred vision, fever, foreign body sensation, headache, transient ocular burning, ocular pain or discomfort, pharyngitis and photophobia. in less than 1% of patients included allergic reactions, lid edema, ocular dryness and ocular itching. ",levofloxacin (ophthalmic)
sign_symptom,hyper,0.8343269," common side effects include dyskinesia, nausea, hyperkinesia, change in urine color, diarrhea and stomach pain. other side effects may include diarrhea, sometimes severe; colitis; hallucinations; other mental disturbances; orthostatic hypotension; rhabdomyolysis; and symptoms resembling neuroleptic malignant syndrome (a condition characterized by high fever, muscle stiffness, and confusion); fibrosis; skin cancer, etc. ",levodopa + carbidopa + entacapone
sign_symptom,change in urine,0.9910908," common side effects include dyskinesia, nausea, hyperkinesia, change in urine color, diarrhea and stomach pain. other side effects may include diarrhea, sometimes severe; colitis; hallucinations; other mental disturbances; orthostatic hypotension; rhabdomyolysis; and symptoms resembling neuroleptic malignant syndrome (a condition characterized by high fever, muscle stiffness, and confusion); fibrosis; skin cancer, etc. ",levodopa + carbidopa + entacapone
sign_symptom,coli,0.9983889," common side effects include dyskinesia, nausea, hyperkinesia, change in urine color, diarrhea and stomach pain. other side effects may include diarrhea, sometimes severe; colitis; hallucinations; other mental disturbances; orthostatic hypotension; rhabdomyolysis; and symptoms resembling neuroleptic malignant syndrome (a condition characterized by high fever, muscle stiffness, and confusion); fibrosis; skin cancer, etc. ",levodopa + carbidopa + entacapone
sign_symptom,halluc,0.9637755," common side effects include dyskinesia, nausea, hyperkinesia, change in urine color, diarrhea and stomach pain. other side effects may include diarrhea, sometimes severe; colitis; hallucinations; other mental disturbances; orthostatic hypotension; rhabdomyolysis; and symptoms resembling neuroleptic malignant syndrome (a condition characterized by high fever, muscle stiffness, and confusion); fibrosis; skin cancer, etc. ",levodopa + carbidopa + entacapone
disease_disorder,malignant syndrome,0.98706263," common side effects include dyskinesia, nausea, hyperkinesia, change in urine color, diarrhea and stomach pain. other side effects may include diarrhea, sometimes severe; colitis; hallucinations; other mental disturbances; orthostatic hypotension; rhabdomyolysis; and symptoms resembling neuroleptic malignant syndrome (a condition characterized by high fever, muscle stiffness, and confusion); fibrosis; skin cancer, etc. ",levodopa + carbidopa + entacapone
sign_symptom,adverse effects,0.95101535," adverse effects that occur frequently in patients receiving carbidopa-levodopa are those due to the central neuropharmacologic activity of dopamine. these reactions usually can be diminished by dosage reduction. the most common adverse effects are dyskinesias including choreiform, dystonic, and other involuntary movements and nausea. 
 
  body as a whole : syncope, chest pain, anorexia. 
  cardiovascular : palpitation, orthostatic effects including hypotensive episodes, hypertension, phlebitis. 
  gastrointestinal : vomiting, gastrointestinal bleeding, development of duodenal ulcer, diarrhoea, dark saliva. 
  haemotologic : leukopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis. 
  hypersensitivity : angioedema, urticaria, pruritus, henoch-schonlein purpura. 
  nervous system : dizziness, somnolence, paresthesia, delusions, hallucinations and paranoid ideation, depression with or without development of suicidal tendencies, dementia, dream abnormalities, agitation, confusion, increased libido. 
  respiratory : dyspnea. 
  skin : alopecia, rash, dark sweat. 
  urogenital : dark urine. 
  ",levodopa + carbidopa (fc tablet)
medication,dopamine,0.8325507," adverse effects that occur frequently in patients receiving carbidopa-levodopa are those due to the central neuropharmacologic activity of dopamine. these reactions usually can be diminished by dosage reduction. the most common adverse effects are dyskinesias including choreiform, dystonic, and other involuntary movements and nausea. 
 
  body as a whole : syncope, chest pain, anorexia. 
  cardiovascular : palpitation, orthostatic effects including hypotensive episodes, hypertension, phlebitis. 
  gastrointestinal : vomiting, gastrointestinal bleeding, development of duodenal ulcer, diarrhoea, dark saliva. 
  haemotologic : leukopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis. 
  hypersensitivity : angioedema, urticaria, pruritus, henoch-schonlein purpura. 
  nervous system : dizziness, somnolence, paresthesia, delusions, hallucinations and paranoid ideation, depression with or without development of suicidal tendencies, dementia, dream abnormalities, agitation, confusion, increased libido. 
  respiratory : dyspnea. 
  skin : alopecia, rash, dark sweat. 
  urogenital : dark urine. 
  ",levodopa + carbidopa (fc tablet)
sign_symptom,dyskinesias,0.953714," adverse effects that occur frequently in patients receiving carbidopa-levodopa are those due to the central neuropharmacologic activity of dopamine. these reactions usually can be diminished by dosage reduction. the most common adverse effects are dyskinesias including choreiform, dystonic, and other involuntary movements and nausea. 
 
  body as a whole : syncope, chest pain, anorexia. 
  cardiovascular : palpitation, orthostatic effects including hypotensive episodes, hypertension, phlebitis. 
  gastrointestinal : vomiting, gastrointestinal bleeding, development of duodenal ulcer, diarrhoea, dark saliva. 
  haemotologic : leukopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis. 
  hypersensitivity : angioedema, urticaria, pruritus, henoch-schonlein purpura. 
  nervous system : dizziness, somnolence, paresthesia, delusions, hallucinations and paranoid ideation, depression with or without development of suicidal tendencies, dementia, dream abnormalities, agitation, confusion, increased libido. 
  respiratory : dyspnea. 
  skin : alopecia, rash, dark sweat. 
  urogenital : dark urine. 
  ",levodopa + carbidopa (fc tablet)
sign_symptom,movements,0.98837644," adverse effects that occur frequently in patients receiving carbidopa-levodopa are those due to the central neuropharmacologic activity of dopamine. these reactions usually can be diminished by dosage reduction. the most common adverse effects are dyskinesias including choreiform, dystonic, and other involuntary movements and nausea. 
 
  body as a whole : syncope, chest pain, anorexia. 
  cardiovascular : palpitation, orthostatic effects including hypotensive episodes, hypertension, phlebitis. 
  gastrointestinal : vomiting, gastrointestinal bleeding, development of duodenal ulcer, diarrhoea, dark saliva. 
  haemotologic : leukopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis. 
  hypersensitivity : angioedema, urticaria, pruritus, henoch-schonlein purpura. 
  nervous system : dizziness, somnolence, paresthesia, delusions, hallucinations and paranoid ideation, depression with or without development of suicidal tendencies, dementia, dream abnormalities, agitation, confusion, increased libido. 
  respiratory : dyspnea. 
  skin : alopecia, rash, dark sweat. 
  urogenital : dark urine. 
  ",levodopa + carbidopa (fc tablet)
sign_symptom,depression,0.9903409," adverse effects that occur frequently in patients receiving carbidopa-levodopa are those due to the central neuropharmacologic activity of dopamine. these reactions usually can be diminished by dosage reduction. the most common adverse effects are dyskinesias including choreiform, dystonic, and other involuntary movements and nausea. 
 
  body as a whole : syncope, chest pain, anorexia. 
  cardiovascular : palpitation, orthostatic effects including hypotensive episodes, hypertension, phlebitis. 
  gastrointestinal : vomiting, gastrointestinal bleeding, development of duodenal ulcer, diarrhoea, dark saliva. 
  haemotologic : leukopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis. 
  hypersensitivity : angioedema, urticaria, pruritus, henoch-schonlein purpura. 
  nervous system : dizziness, somnolence, paresthesia, delusions, hallucinations and paranoid ideation, depression with or without development of suicidal tendencies, dementia, dream abnormalities, agitation, confusion, increased libido. 
  respiratory : dyspnea. 
  skin : alopecia, rash, dark sweat. 
  urogenital : dark urine. 
  ",levodopa + carbidopa (fc tablet)
medication,carbidopa,0.7742912," the side-effect reported most frequently was dyskinesia (a form of abnormal involuntary movements). a greater incidence of dyskinesias was seen with levodopa-carbidopa prolonged-release tablet than with levodopa-carbidopa tablet. other side-effects: nausea, hallucinations, confusion, dizziness, chorea, dry mouth, dream abnormalities, dystonia, insomnia, depression, asthenia, vomiting, anorexia, chest pain, palpitation, constipation, diarrhoea, dyspepsia, gastro-intestinal pain, dark saliva, angioedema, urticaria, pruritus, weight loss, neuroleptic malignant syndrome, agitation, anxiety, decreased mental acuity, paraesthesia, disorientation, fatigue, headache, extrapyramidal and movement disorders, falling, gait abnormalities, muscle cramps, on-off phenomenon, increased libido, psychotic episodes, dyspnoea, flushing, alopecia, rash, dark sweat, blurred vision, dark urine, cardiac irregularities, hypertension, phlebitis, bitter taste, sialorrhoea, dysphagia, bruxism, hiccups, gastro-intestinal bleeding, flatulence, burning sensation of tongue, development of duodenal ulcer, leucopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis. ",levodopa + carbidopa (cr tablet)
sign_symptom,adverse events,0.9830853," increased intraocular pressure, burning and stinging upon instillation, vision disorders, discharge, itching, lacrimation disorder, photophobia, corneal deposits, ocular discomfort, eyelid disorder, and other unspecified eye disorders may occur. the incidence of non-ocular adverse events (headache) also reported. ",loteprednol etabonate + tobramycin
sign_symptom,headache,0.9996197," increased intraocular pressure, burning and stinging upon instillation, vision disorders, discharge, itching, lacrimation disorder, photophobia, corneal deposits, ocular discomfort, eyelid disorder, and other unspecified eye disorders may occur. the incidence of non-ocular adverse events (headache) also reported. ",loteprednol etabonate + tobramycin
medication,steroid,0.86666274," adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component or the anti-infective component, or the combination. reactions associated with ophthalmic steroids include elevated iop, which may be associated with infrequent optic nerve damage, visual acuity and field detects, posterior sub capsular cataract formation, delayed wound healing, and secondary ocular infections from pathogens including herpes simplex, and perforation of the globe where there is thinning of cornea or sclera. the most frequently reported adverse effects for gatifloxacin in the overall study population were conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis. these events occurred in approximately 5-10% of patients. other reported reactions occurring in 1-4% of patients were chemosis, conjunctival hemorrhage, dry eye, eye discharge, eye irritation, eye pain, eyelid edema, headache, red eye, reduced visual acuity and taste disturbance. redness was the most commonly observed adverse event occurring in 6%. itching, discharge photophobia and blurred vision were seen in less than 2% cases. ",loteprednol etabonate + gatifloxacin
sign_symptom,infections,0.9806277," adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component or the anti-infective component, or the combination. reactions associated with ophthalmic steroids include elevated iop, which may be associated with infrequent optic nerve damage, visual acuity and field detects, posterior sub capsular cataract formation, delayed wound healing, and secondary ocular infections from pathogens including herpes simplex, and perforation of the globe where there is thinning of cornea or sclera. the most frequently reported adverse effects for gatifloxacin in the overall study population were conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis. these events occurred in approximately 5-10% of patients. other reported reactions occurring in 1-4% of patients were chemosis, conjunctival hemorrhage, dry eye, eye discharge, eye irritation, eye pain, eyelid edema, headache, red eye, reduced visual acuity and taste disturbance. redness was the most commonly observed adverse event occurring in 6%. itching, discharge photophobia and blurred vision were seen in less than 2% cases. ",loteprednol etabonate + gatifloxacin
disease_disorder,perforation,0.9118626," adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component or the anti-infective component, or the combination. reactions associated with ophthalmic steroids include elevated iop, which may be associated with infrequent optic nerve damage, visual acuity and field detects, posterior sub capsular cataract formation, delayed wound healing, and secondary ocular infections from pathogens including herpes simplex, and perforation of the globe where there is thinning of cornea or sclera. the most frequently reported adverse effects for gatifloxacin in the overall study population were conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis. these events occurred in approximately 5-10% of patients. other reported reactions occurring in 1-4% of patients were chemosis, conjunctival hemorrhage, dry eye, eye discharge, eye irritation, eye pain, eyelid edema, headache, red eye, reduced visual acuity and taste disturbance. redness was the most commonly observed adverse event occurring in 6%. itching, discharge photophobia and blurred vision were seen in less than 2% cases. ",loteprednol etabonate + gatifloxacin
medication,gati,0.96061194," adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component or the anti-infective component, or the combination. reactions associated with ophthalmic steroids include elevated iop, which may be associated with infrequent optic nerve damage, visual acuity and field detects, posterior sub capsular cataract formation, delayed wound healing, and secondary ocular infections from pathogens including herpes simplex, and perforation of the globe where there is thinning of cornea or sclera. the most frequently reported adverse effects for gatifloxacin in the overall study population were conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis. these events occurred in approximately 5-10% of patients. other reported reactions occurring in 1-4% of patients were chemosis, conjunctival hemorrhage, dry eye, eye discharge, eye irritation, eye pain, eyelid edema, headache, red eye, reduced visual acuity and taste disturbance. redness was the most commonly observed adverse event occurring in 6%. itching, discharge photophobia and blurred vision were seen in less than 2% cases. ",loteprednol etabonate + gatifloxacin
sign_symptom,redness,0.99930906," adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component or the anti-infective component, or the combination. reactions associated with ophthalmic steroids include elevated iop, which may be associated with infrequent optic nerve damage, visual acuity and field detects, posterior sub capsular cataract formation, delayed wound healing, and secondary ocular infections from pathogens including herpes simplex, and perforation of the globe where there is thinning of cornea or sclera. the most frequently reported adverse effects for gatifloxacin in the overall study population were conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis. these events occurred in approximately 5-10% of patients. other reported reactions occurring in 1-4% of patients were chemosis, conjunctival hemorrhage, dry eye, eye discharge, eye irritation, eye pain, eyelid edema, headache, red eye, reduced visual acuity and taste disturbance. redness was the most commonly observed adverse event occurring in 6%. itching, discharge photophobia and blurred vision were seen in less than 2% cases. ",loteprednol etabonate + gatifloxacin
sign_symptom,adverse,0.83842295," adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component or the anti-infective component, or the combination. reactions associated with ophthalmic steroids include elevated iop, which may be associated with infrequent optic nerve damage, visual acuity and field detects, posterior sub capsular cataract formation, delayed wound healing, and secondary ocular infections from pathogens including herpes simplex, and perforation of the globe where there is thinning of cornea or sclera. the most frequently reported adverse effects for gatifloxacin in the overall study population were conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis. these events occurred in approximately 5-10% of patients. other reported reactions occurring in 1-4% of patients were chemosis, conjunctival hemorrhage, dry eye, eye discharge, eye irritation, eye pain, eyelid edema, headache, red eye, reduced visual acuity and taste disturbance. redness was the most commonly observed adverse event occurring in 6%. itching, discharge photophobia and blurred vision were seen in less than 2% cases. ",loteprednol etabonate + gatifloxacin
sign_symptom,photophobia,0.9924444," adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component or the anti-infective component, or the combination. reactions associated with ophthalmic steroids include elevated iop, which may be associated with infrequent optic nerve damage, visual acuity and field detects, posterior sub capsular cataract formation, delayed wound healing, and secondary ocular infections from pathogens including herpes simplex, and perforation of the globe where there is thinning of cornea or sclera. the most frequently reported adverse effects for gatifloxacin in the overall study population were conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis. these events occurred in approximately 5-10% of patients. other reported reactions occurring in 1-4% of patients were chemosis, conjunctival hemorrhage, dry eye, eye discharge, eye irritation, eye pain, eyelid edema, headache, red eye, reduced visual acuity and taste disturbance. redness was the most commonly observed adverse event occurring in 6%. itching, discharge photophobia and blurred vision were seen in less than 2% cases. ",loteprednol etabonate + gatifloxacin
sign_symptom,blurred vision,0.9997752," adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component or the anti-infective component, or the combination. reactions associated with ophthalmic steroids include elevated iop, which may be associated with infrequent optic nerve damage, visual acuity and field detects, posterior sub capsular cataract formation, delayed wound healing, and secondary ocular infections from pathogens including herpes simplex, and perforation of the globe where there is thinning of cornea or sclera. the most frequently reported adverse effects for gatifloxacin in the overall study population were conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis. these events occurred in approximately 5-10% of patients. other reported reactions occurring in 1-4% of patients were chemosis, conjunctival hemorrhage, dry eye, eye discharge, eye irritation, eye pain, eyelid edema, headache, red eye, reduced visual acuity and taste disturbance. redness was the most commonly observed adverse event occurring in 6%. itching, discharge photophobia and blurred vision were seen in less than 2% cases. ",loteprednol etabonate + gatifloxacin
disease_disorder,glaucoma,0.9945862," glaucoma with optic nerve damage, visual acuity and field defects; cataract formation; secondary ocular infection following suppression of host response; and perforation of the globe may occur. ",loteprednol etabonate
disease_disorder,nerve,0.7958653," glaucoma with optic nerve damage, visual acuity and field defects; cataract formation; secondary ocular infection following suppression of host response; and perforation of the globe may occur. ",loteprednol etabonate
disease_disorder,infection,0.99511945," glaucoma with optic nerve damage, visual acuity and field defects; cataract formation; secondary ocular infection following suppression of host response; and perforation of the globe may occur. ",loteprednol etabonate
disease_disorder,volume depletion,0.92521846," side-effects are usually mild. symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion (e.g. those taking high-dose diuretics). hyperkalaemia occurs occasionally; angioedema has also been reported with some angiotensin-ii receptor antagonists. vertigo; less commonly gastro-intestinal disturbances, angina, palpitation, oedema, dyspnoea, headache, sleep disorders, malaise, urticaria, pruritus, rash; rarely hepatitis, atrial fibrillation, cerebrovascular accident, syncope, paraesthesia; also reported pancreatitis, anaphylaxis, cough, depression, erectile dysfunction, anaemia, thrombocytopenia, hyponatraemia, arthralgia, myalgia, renal impairment, rhabdomyolysis, tinnitus, photosensitivity, and vasculitis (including henoch-schonlein purpura) ",losartan potassium + hydrochlorothiazide
sign_symptom,hyper,0.9999622," side-effects are usually mild. symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion (e.g. those taking high-dose diuretics). hyperkalaemia occurs occasionally; angioedema has also been reported with some angiotensin-ii receptor antagonists. vertigo; less commonly gastro-intestinal disturbances, angina, palpitation, oedema, dyspnoea, headache, sleep disorders, malaise, urticaria, pruritus, rash; rarely hepatitis, atrial fibrillation, cerebrovascular accident, syncope, paraesthesia; also reported pancreatitis, anaphylaxis, cough, depression, erectile dysfunction, anaemia, thrombocytopenia, hyponatraemia, arthralgia, myalgia, renal impairment, rhabdomyolysis, tinnitus, photosensitivity, and vasculitis (including henoch-schonlein purpura) ",losartan potassium + hydrochlorothiazide
medication,losartan potassium,0.86848927," the side effects with the use of losartan potassium are mild and transient in nature. the most common side effects are dizziness, diarrhea, nasal congestion, cough, upper respiratory infection. other side effects are fatigue, oedema, abdominal pain, chest pain, nausea, headache &amp; pharyngitis. ",losartan potassium
sign_symptom,adverse reactions,0.9996445," the most frequently reported adverse reactions were hypercholesterolaemia (84.4%), hypertriglyceridaemia (67.1%), oedema (54.6%), peripheral neuropathy (47.8%), cognitive effects (28.8%), fatigue (28.1%), weight increased (26.4%) and mood effects (22.7%). dose reductions due to adverse reactions occurred in 23.4% of patients receiving lorlatinib. the most common adverse reactions that led to dose reductions were oedema and peripheral neuropathy. permanent treatment discontinuation associated with adverse reactions occurred in 3.1% of patients receiving lorlatinib. the most frequent adverse reaction that led to permanent discontinuations was cognitive effects. ",lorlatinib
sign_symptom,hypercholesterolaemia,0.9361102," the most frequently reported adverse reactions were hypercholesterolaemia (84.4%), hypertriglyceridaemia (67.1%), oedema (54.6%), peripheral neuropathy (47.8%), cognitive effects (28.8%), fatigue (28.1%), weight increased (26.4%) and mood effects (22.7%). dose reductions due to adverse reactions occurred in 23.4% of patients receiving lorlatinib. the most common adverse reactions that led to dose reductions were oedema and peripheral neuropathy. permanent treatment discontinuation associated with adverse reactions occurred in 3.1% of patients receiving lorlatinib. the most frequent adverse reaction that led to permanent discontinuations was cognitive effects. ",lorlatinib
sign_symptom,hypertrigly,0.85100514," the most frequently reported adverse reactions were hypercholesterolaemia (84.4%), hypertriglyceridaemia (67.1%), oedema (54.6%), peripheral neuropathy (47.8%), cognitive effects (28.8%), fatigue (28.1%), weight increased (26.4%) and mood effects (22.7%). dose reductions due to adverse reactions occurred in 23.4% of patients receiving lorlatinib. the most common adverse reactions that led to dose reductions were oedema and peripheral neuropathy. permanent treatment discontinuation associated with adverse reactions occurred in 3.1% of patients receiving lorlatinib. the most frequent adverse reaction that led to permanent discontinuations was cognitive effects. ",lorlatinib
disease_disorder,peripheral neuropathy,0.80596906," the most frequently reported adverse reactions were hypercholesterolaemia (84.4%), hypertriglyceridaemia (67.1%), oedema (54.6%), peripheral neuropathy (47.8%), cognitive effects (28.8%), fatigue (28.1%), weight increased (26.4%) and mood effects (22.7%). dose reductions due to adverse reactions occurred in 23.4% of patients receiving lorlatinib. the most common adverse reactions that led to dose reductions were oedema and peripheral neuropathy. permanent treatment discontinuation associated with adverse reactions occurred in 3.1% of patients receiving lorlatinib. the most frequent adverse reaction that led to permanent discontinuations was cognitive effects. ",lorlatinib
sign_symptom,cognitive effects,0.9999042," the most frequently reported adverse reactions were hypercholesterolaemia (84.4%), hypertriglyceridaemia (67.1%), oedema (54.6%), peripheral neuropathy (47.8%), cognitive effects (28.8%), fatigue (28.1%), weight increased (26.4%) and mood effects (22.7%). dose reductions due to adverse reactions occurred in 23.4% of patients receiving lorlatinib. the most common adverse reactions that led to dose reductions were oedema and peripheral neuropathy. permanent treatment discontinuation associated with adverse reactions occurred in 3.1% of patients receiving lorlatinib. the most frequent adverse reaction that led to permanent discontinuations was cognitive effects. ",lorlatinib
sign_symptom,fatigue,0.9999552," the most frequently reported adverse reactions were hypercholesterolaemia (84.4%), hypertriglyceridaemia (67.1%), oedema (54.6%), peripheral neuropathy (47.8%), cognitive effects (28.8%), fatigue (28.1%), weight increased (26.4%) and mood effects (22.7%). dose reductions due to adverse reactions occurred in 23.4% of patients receiving lorlatinib. the most common adverse reactions that led to dose reductions were oedema and peripheral neuropathy. permanent treatment discontinuation associated with adverse reactions occurred in 3.1% of patients receiving lorlatinib. the most frequent adverse reaction that led to permanent discontinuations was cognitive effects. ",lorlatinib
sign_symptom,weight,0.98946536," the most frequently reported adverse reactions were hypercholesterolaemia (84.4%), hypertriglyceridaemia (67.1%), oedema (54.6%), peripheral neuropathy (47.8%), cognitive effects (28.8%), fatigue (28.1%), weight increased (26.4%) and mood effects (22.7%). dose reductions due to adverse reactions occurred in 23.4% of patients receiving lorlatinib. the most common adverse reactions that led to dose reductions were oedema and peripheral neuropathy. permanent treatment discontinuation associated with adverse reactions occurred in 3.1% of patients receiving lorlatinib. the most frequent adverse reaction that led to permanent discontinuations was cognitive effects. ",lorlatinib
sign_symptom,mood,0.9950009," the most frequently reported adverse reactions were hypercholesterolaemia (84.4%), hypertriglyceridaemia (67.1%), oedema (54.6%), peripheral neuropathy (47.8%), cognitive effects (28.8%), fatigue (28.1%), weight increased (26.4%) and mood effects (22.7%). dose reductions due to adverse reactions occurred in 23.4% of patients receiving lorlatinib. the most common adverse reactions that led to dose reductions were oedema and peripheral neuropathy. permanent treatment discontinuation associated with adverse reactions occurred in 3.1% of patients receiving lorlatinib. the most frequent adverse reaction that led to permanent discontinuations was cognitive effects. ",lorlatinib
sign_symptom,peripheral,0.9217929," the most frequently reported adverse reactions were hypercholesterolaemia (84.4%), hypertriglyceridaemia (67.1%), oedema (54.6%), peripheral neuropathy (47.8%), cognitive effects (28.8%), fatigue (28.1%), weight increased (26.4%) and mood effects (22.7%). dose reductions due to adverse reactions occurred in 23.4% of patients receiving lorlatinib. the most common adverse reactions that led to dose reductions were oedema and peripheral neuropathy. permanent treatment discontinuation associated with adverse reactions occurred in 3.1% of patients receiving lorlatinib. the most frequent adverse reaction that led to permanent discontinuations was cognitive effects. ",lorlatinib
sign_symptom,adverse reaction,0.99942124," the most frequently reported adverse reactions were hypercholesterolaemia (84.4%), hypertriglyceridaemia (67.1%), oedema (54.6%), peripheral neuropathy (47.8%), cognitive effects (28.8%), fatigue (28.1%), weight increased (26.4%) and mood effects (22.7%). dose reductions due to adverse reactions occurred in 23.4% of patients receiving lorlatinib. the most common adverse reactions that led to dose reductions were oedema and peripheral neuropathy. permanent treatment discontinuation associated with adverse reactions occurred in 3.1% of patients receiving lorlatinib. the most frequent adverse reaction that led to permanent discontinuations was cognitive effects. ",lorlatinib
sign_symptom,cognitive,0.9827057," the most frequently reported adverse reactions were hypercholesterolaemia (84.4%), hypertriglyceridaemia (67.1%), oedema (54.6%), peripheral neuropathy (47.8%), cognitive effects (28.8%), fatigue (28.1%), weight increased (26.4%) and mood effects (22.7%). dose reductions due to adverse reactions occurred in 23.4% of patients receiving lorlatinib. the most common adverse reactions that led to dose reductions were oedema and peripheral neuropathy. permanent treatment discontinuation associated with adverse reactions occurred in 3.1% of patients receiving lorlatinib. the most frequent adverse reaction that led to permanent discontinuations was cognitive effects. ",lorlatinib
sign_symptom,adverse reactions,0.99985063," adverse reactions are usually observed at the beginning of therapy and generally disappeared on continued medication or upon decreasing the dose. the most frequent adverse reactions of lorazepamare sedation followed by dizziness, weakness and unsteadiness. less frequent adverse reactions are disorientation, depression, nausea, change in appetite, headache, sleep disturbance, agitation, dermatological symptoms, eye-function disturbance, together with various gastrointestinal symptoms and autonomic manifestations. ",lorazepam
medication,medication,0.99867296," adverse reactions are usually observed at the beginning of therapy and generally disappeared on continued medication or upon decreasing the dose. the most frequent adverse reactions of lorazepamare sedation followed by dizziness, weakness and unsteadiness. less frequent adverse reactions are disorientation, depression, nausea, change in appetite, headache, sleep disturbance, agitation, dermatological symptoms, eye-function disturbance, together with various gastrointestinal symptoms and autonomic manifestations. ",lorazepam
sign_symptom,weakness,0.99984884," adverse reactions are usually observed at the beginning of therapy and generally disappeared on continued medication or upon decreasing the dose. the most frequent adverse reactions of lorazepamare sedation followed by dizziness, weakness and unsteadiness. less frequent adverse reactions are disorientation, depression, nausea, change in appetite, headache, sleep disturbance, agitation, dermatological symptoms, eye-function disturbance, together with various gastrointestinal symptoms and autonomic manifestations. ",lorazepam
sign_symptom,adverse effects,0.97954," in general it is well tolerated. clinical trial suggests a very low of adverse effects commonly reported is dry mouth, somnolence, insomnia, pharyngitis, dizziness, coughing, fatigue, nausea, nervousness, anorexia, dysmenorrheal and headache. other less common side effects may include; increased sweating, thirst, back pain, chest pain, malaise, palpitations, hypertension, tachycardia, abdominal distension, altered taste, flatulence, myalgia, dry throat, agitation, micturation frequency etc. ",loratadine + pseudoephedrine
sign_symptom,dysmen,0.84534997," in general it is well tolerated. clinical trial suggests a very low of adverse effects commonly reported is dry mouth, somnolence, insomnia, pharyngitis, dizziness, coughing, fatigue, nausea, nervousness, anorexia, dysmenorrheal and headache. other less common side effects may include; increased sweating, thirst, back pain, chest pain, malaise, palpitations, hypertension, tachycardia, abdominal distension, altered taste, flatulence, myalgia, dry throat, agitation, micturation frequency etc. ",loratadine + pseudoephedrine
sign_symptom,mala,0.97877526," in general it is well tolerated. clinical trial suggests a very low of adverse effects commonly reported is dry mouth, somnolence, insomnia, pharyngitis, dizziness, coughing, fatigue, nausea, nervousness, anorexia, dysmenorrheal and headache. other less common side effects may include; increased sweating, thirst, back pain, chest pain, malaise, palpitations, hypertension, tachycardia, abdominal distension, altered taste, flatulence, myalgia, dry throat, agitation, micturation frequency etc. ",loratadine + pseudoephedrine
sign_symptom,palpit,0.9092902," in general it is well tolerated. clinical trial suggests a very low of adverse effects commonly reported is dry mouth, somnolence, insomnia, pharyngitis, dizziness, coughing, fatigue, nausea, nervousness, anorexia, dysmenorrheal and headache. other less common side effects may include; increased sweating, thirst, back pain, chest pain, malaise, palpitations, hypertension, tachycardia, abdominal distension, altered taste, flatulence, myalgia, dry throat, agitation, micturation frequency etc. ",loratadine + pseudoephedrine
sign_symptom,altered taste,0.73834866," in general it is well tolerated. clinical trial suggests a very low of adverse effects commonly reported is dry mouth, somnolence, insomnia, pharyngitis, dizziness, coughing, fatigue, nausea, nervousness, anorexia, dysmenorrheal and headache. other less common side effects may include; increased sweating, thirst, back pain, chest pain, malaise, palpitations, hypertension, tachycardia, abdominal distension, altered taste, flatulence, myalgia, dry throat, agitation, micturation frequency etc. ",loratadine + pseudoephedrine
sign_symptom,flatule,0.89678144," in general it is well tolerated. clinical trial suggests a very low of adverse effects commonly reported is dry mouth, somnolence, insomnia, pharyngitis, dizziness, coughing, fatigue, nausea, nervousness, anorexia, dysmenorrheal and headache. other less common side effects may include; increased sweating, thirst, back pain, chest pain, malaise, palpitations, hypertension, tachycardia, abdominal distension, altered taste, flatulence, myalgia, dry throat, agitation, micturation frequency etc. ",loratadine + pseudoephedrine
sign_symptom,myalgia,0.9425835," in general it is well tolerated. clinical trial suggests a very low of adverse effects commonly reported is dry mouth, somnolence, insomnia, pharyngitis, dizziness, coughing, fatigue, nausea, nervousness, anorexia, dysmenorrheal and headache. other less common side effects may include; increased sweating, thirst, back pain, chest pain, malaise, palpitations, hypertension, tachycardia, abdominal distension, altered taste, flatulence, myalgia, dry throat, agitation, micturation frequency etc. ",loratadine + pseudoephedrine
sign_symptom,mictura,0.7498852," in general it is well tolerated. clinical trial suggests a very low of adverse effects commonly reported is dry mouth, somnolence, insomnia, pharyngitis, dizziness, coughing, fatigue, nausea, nervousness, anorexia, dysmenorrheal and headache. other less common side effects may include; increased sweating, thirst, back pain, chest pain, malaise, palpitations, hypertension, tachycardia, abdominal distension, altered taste, flatulence, myalgia, dry throat, agitation, micturation frequency etc. ",loratadine + pseudoephedrine
sign_symptom,anticholinergic effects,0.9998406," during controlled clinical studies the incidence of adverse events, including sedation and anticholinergic effects observed with 10 mg loratadine was comparable to that observed with placebo. studies on the effect of loratadine on actual driving performance, and on tests of cognitive and psychomotor functioning have shown it to be comparable to placebo. ",loratadine
sign_symptom,hyper,0.99580485," commonly reported side effects included diarrhea, nausea, vomiting, hypertriglyceridemia and hypercholesterolemia. ",lopinavir + ritonavir
sign_symptom,pain,0.9999603," abdominal pain and other gastrointestinal disturbances including dry mouth, dizziness, fatigue and skin rashes etc. have been reported. ",loperamide hydrochloride
sign_symptom,gastrointestinal disturbances,0.9480761," abdominal pain and other gastrointestinal disturbances including dry mouth, dizziness, fatigue and skin rashes etc. have been reported. ",loperamide hydrochloride
sign_symptom,dry mouth,0.99981666," abdominal pain and other gastrointestinal disturbances including dry mouth, dizziness, fatigue and skin rashes etc. have been reported. ",loperamide hydrochloride
sign_symptom,fatigue,0.9998882," abdominal pain and other gastrointestinal disturbances including dry mouth, dizziness, fatigue and skin rashes etc. have been reported. ",loperamide hydrochloride
sign_symptom,rash,0.9999291," abdominal pain and other gastrointestinal disturbances including dry mouth, dizziness, fatigue and skin rashes etc. have been reported. ",loperamide hydrochloride
sign_symptom,restless,0.9952773," common side effects arenausea, headache, photosensitivity, dizziness, diarrhea, dry mouth, fatigue, convulsions, cns stimulation which may lead to tremors, restlessness, light headedness, confusion &amp; hallucinations and pseudomembranous colitis. ",lomefloxacin (oral)
sign_symptom,light headedness,0.9188903," common side effects arenausea, headache, photosensitivity, dizziness, diarrhea, dry mouth, fatigue, convulsions, cns stimulation which may lead to tremors, restlessness, light headedness, confusion &amp; hallucinations and pseudomembranous colitis. ",lomefloxacin (oral)
sign_symptom,confusion,0.99973315," common side effects arenausea, headache, photosensitivity, dizziness, diarrhea, dry mouth, fatigue, convulsions, cns stimulation which may lead to tremors, restlessness, light headedness, confusion &amp; hallucinations and pseudomembranous colitis. ",lomefloxacin (oral)
sign_symptom,hallucinations,0.91912764," common side effects arenausea, headache, photosensitivity, dizziness, diarrhea, dry mouth, fatigue, convulsions, cns stimulation which may lead to tremors, restlessness, light headedness, confusion &amp; hallucinations and pseudomembranous colitis. ",lomefloxacin (oral)
sign_symptom,burning,0.99960893," slight and transient burning immediately after instillation of the eye drops has been reported in 4.7% of users. although phototoxicity has not been reported after ophthalmic use, photosensitization is possible. since the following allergic reactions have been reported after systemic use of lomefloxacin, they can not be excluded after topical ophthalmic use: allergic reactions, asthma, dyspnoea, urticaria, erythema, pruritus, and hypersensitization. ",lomefloxacin (ophthalmic)
sign_symptom,phototoxicity,0.97544044," slight and transient burning immediately after instillation of the eye drops has been reported in 4.7% of users. although phototoxicity has not been reported after ophthalmic use, photosensitization is possible. since the following allergic reactions have been reported after systemic use of lomefloxacin, they can not be excluded after topical ophthalmic use: allergic reactions, asthma, dyspnoea, urticaria, erythema, pruritus, and hypersensitization. ",lomefloxacin (ophthalmic)
sign_symptom,allergic reactions,0.9997412," slight and transient burning immediately after instillation of the eye drops has been reported in 4.7% of users. although phototoxicity has not been reported after ophthalmic use, photosensitization is possible. since the following allergic reactions have been reported after systemic use of lomefloxacin, they can not be excluded after topical ophthalmic use: allergic reactions, asthma, dyspnoea, urticaria, erythema, pruritus, and hypersensitization. ",lomefloxacin (ophthalmic)
sign_symptom,tired,0.9744556," tiredness, loss of appetite, nausea, vomiting, diarrhoea, hands shaking, memory problems, increased thirst and consequently passing urine more often by day, and perhaps also by night. ",lithium carbonate
sign_symptom,loss of appetite,0.99957186," tiredness, loss of appetite, nausea, vomiting, diarrhoea, hands shaking, memory problems, increased thirst and consequently passing urine more often by day, and perhaps also by night. ",lithium carbonate
sign_symptom,thirst,0.9734482," tiredness, loss of appetite, nausea, vomiting, diarrhoea, hands shaking, memory problems, increased thirst and consequently passing urine more often by day, and perhaps also by night. ",lithium carbonate
sign_symptom,headache,0.9387772," headache, fatigue, persistent and non-productive cough, chest and abdominal pain, dizziness, nausea, vomiting, diarrhoea, upper resp tract infection, asthenia, rash, orthostatic effects, hypotension, renal dysfunction, hyperkalaemia, intestinal angioedema; increased bun and serum creatinine levels. ",lisinopril
sign_symptom,fatigue,0.9411068," headache, fatigue, persistent and non-productive cough, chest and abdominal pain, dizziness, nausea, vomiting, diarrhoea, upper resp tract infection, asthenia, rash, orthostatic effects, hypotension, renal dysfunction, hyperkalaemia, intestinal angioedema; increased bun and serum creatinine levels. ",lisinopril
sign_symptom,cough,0.967694," headache, fatigue, persistent and non-productive cough, chest and abdominal pain, dizziness, nausea, vomiting, diarrhoea, upper resp tract infection, asthenia, rash, orthostatic effects, hypotension, renal dysfunction, hyperkalaemia, intestinal angioedema; increased bun and serum creatinine levels. ",lisinopril
sign_symptom,pain,0.8999757," headache, fatigue, persistent and non-productive cough, chest and abdominal pain, dizziness, nausea, vomiting, diarrhoea, upper resp tract infection, asthenia, rash, orthostatic effects, hypotension, renal dysfunction, hyperkalaemia, intestinal angioedema; increased bun and serum creatinine levels. ",lisinopril
sign_symptom,diarr,0.9609672," headache, fatigue, persistent and non-productive cough, chest and abdominal pain, dizziness, nausea, vomiting, diarrhoea, upper resp tract infection, asthenia, rash, orthostatic effects, hypotension, renal dysfunction, hyperkalaemia, intestinal angioedema; increased bun and serum creatinine levels. ",lisinopril
sign_symptom,vomiting,0.76790094," most common adverse reactions, reported in greater than or equal to 5% are: nausea, diarrhea, constipation, vomiting, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis ",liraglutide
sign_symptom,dyspeps,0.87181646," most common adverse reactions, reported in greater than or equal to 5% are: nausea, diarrhea, constipation, vomiting, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis ",liraglutide
sign_symptom,adverse events,0.9971062," most of the adverse events reported with linezolid were mild to moderate in intensity. the most common adverse events in patients treated with linezolid were diarrhea, headache and nausea. other adverse events includes oral moniliasis, vaginal moniliasis, hypertension, dyspepsia, localized abdominal pain, pruritus, and tongue discoloration. ",linezolid
medication,line,0.7050137," most of the adverse events reported with linezolid were mild to moderate in intensity. the most common adverse events in patients treated with linezolid were diarrhea, headache and nausea. other adverse events includes oral moniliasis, vaginal moniliasis, hypertension, dyspepsia, localized abdominal pain, pruritus, and tongue discoloration. ",linezolid
sign_symptom,diarr,0.80636346," most of the adverse events reported with linezolid were mild to moderate in intensity. the most common adverse events in patients treated with linezolid were diarrhea, headache and nausea. other adverse events includes oral moniliasis, vaginal moniliasis, hypertension, dyspepsia, localized abdominal pain, pruritus, and tongue discoloration. ",linezolid
sign_symptom,headache,0.9998467," most of the adverse events reported with linezolid were mild to moderate in intensity. the most common adverse events in patients treated with linezolid were diarrhea, headache and nausea. other adverse events includes oral moniliasis, vaginal moniliasis, hypertension, dyspepsia, localized abdominal pain, pruritus, and tongue discoloration. ",linezolid
sign_symptom,nasopharyngitis,0.94492716, most common side effects are nasopharyngitis and diarrhea. hypoglycemia is more common in patients treated with this combination and sulfonylureas. ,linagliptin + metformin hydrochloride
sign_symptom,angio,0.7852324," generally mebeverine is well tolerated. however, few side-effects like skin rash, urticaria and angioedema may appear ",mebeverine hydrochloride
sign_symptom,pain,0.9999633,"  
 gastrointestinal: transient symptoms of abdominal pain and diarrhoea in case of massive infection and expulsion of worms. 
 hypersensitivity: rash, urticaria and angioedema have been observed on rare occasions. 
 central nervous system: very rare cases of convulsions have been reported. 
 haematologic: neutropenia and agranulocytosis. 
  ",mebendazole
sign_symptom,diarr,0.9996556,"  
 gastrointestinal: transient symptoms of abdominal pain and diarrhoea in case of massive infection and expulsion of worms. 
 hypersensitivity: rash, urticaria and angioedema have been observed on rare occasions. 
 central nervous system: very rare cases of convulsions have been reported. 
 haematologic: neutropenia and agranulocytosis. 
  ",mebendazole
disease_disorder,infection,0.9998197,"  
 gastrointestinal: transient symptoms of abdominal pain and diarrhoea in case of massive infection and expulsion of worms. 
 hypersensitivity: rash, urticaria and angioedema have been observed on rare occasions. 
 central nervous system: very rare cases of convulsions have been reported. 
 haematologic: neutropenia and agranulocytosis. 
  ",mebendazole
sign_symptom,hyper,0.9994412,"  
 gastrointestinal: transient symptoms of abdominal pain and diarrhoea in case of massive infection and expulsion of worms. 
 hypersensitivity: rash, urticaria and angioedema have been observed on rare occasions. 
 central nervous system: very rare cases of convulsions have been reported. 
 haematologic: neutropenia and agranulocytosis. 
  ",mebendazole
sign_symptom,rash,0.99987864,"  
 gastrointestinal: transient symptoms of abdominal pain and diarrhoea in case of massive infection and expulsion of worms. 
 hypersensitivity: rash, urticaria and angioedema have been observed on rare occasions. 
 central nervous system: very rare cases of convulsions have been reported. 
 haematologic: neutropenia and agranulocytosis. 
  ",mebendazole
sign_symptom,urticaria,0.9884741,"  
 gastrointestinal: transient symptoms of abdominal pain and diarrhoea in case of massive infection and expulsion of worms. 
 hypersensitivity: rash, urticaria and angioedema have been observed on rare occasions. 
 central nervous system: very rare cases of convulsions have been reported. 
 haematologic: neutropenia and agranulocytosis. 
  ",mebendazole
sign_symptom,angioedema,0.9997849,"  
 gastrointestinal: transient symptoms of abdominal pain and diarrhoea in case of massive infection and expulsion of worms. 
 hypersensitivity: rash, urticaria and angioedema have been observed on rare occasions. 
 central nervous system: very rare cases of convulsions have been reported. 
 haematologic: neutropenia and agranulocytosis. 
  ",mebendazole
sign_symptom,agranu,0.8251333,"  
 gastrointestinal: transient symptoms of abdominal pain and diarrhoea in case of massive infection and expulsion of worms. 
 hypersensitivity: rash, urticaria and angioedema have been observed on rare occasions. 
 central nervous system: very rare cases of convulsions have been reported. 
 haematologic: neutropenia and agranulocytosis. 
  ",mebendazole
sign_symptom,pain,0.999948," common side-effects: 
 
 generally pain and tenderness at the injection site may occur within 24 hours after vaccination, which usually disappear by itself within 2-3 days. 
 generally transient fever reaction may occur within 1-2 weeks after vaccination. 
 rash: generally mild rash may occur within 12 days after vaccination, which generally lasts for no more than 2 days. 
 
rare side-effects: 
 
 severe fever reaction: physical methods and drugs should be used for symptomatic treatment to prevent febrile seizures. 
 
very rare side-effects: 
 
 allergic rash: generally urticaria may occur within 72 hours after vaccination, and if this reaction occurs, anti-allergy treatment should be timely given. 
 anaphylactic shock: generally occurs within 1 hour after vaccination. injection of epinephrine and other emergency measures should be timely given for treatment. 
 anaphylactoid purpura: medical care should be timely given if anaphylactoid purpura occurs. cortical steroids can be given for anti-allergy treatment. improper or not timely treatment is likely to cause anaphylatic purpura nephritis. 
 thrombocytopenia purpura. 
 adults may develop arthritis, pain and swelling of large joints after vaccination. 
  ",measles and rubella
sign_symptom,tenderness,0.99993706," common side-effects: 
 
 generally pain and tenderness at the injection site may occur within 24 hours after vaccination, which usually disappear by itself within 2-3 days. 
 generally transient fever reaction may occur within 1-2 weeks after vaccination. 
 rash: generally mild rash may occur within 12 days after vaccination, which generally lasts for no more than 2 days. 
 
rare side-effects: 
 
 severe fever reaction: physical methods and drugs should be used for symptomatic treatment to prevent febrile seizures. 
 
very rare side-effects: 
 
 allergic rash: generally urticaria may occur within 72 hours after vaccination, and if this reaction occurs, anti-allergy treatment should be timely given. 
 anaphylactic shock: generally occurs within 1 hour after vaccination. injection of epinephrine and other emergency measures should be timely given for treatment. 
 anaphylactoid purpura: medical care should be timely given if anaphylactoid purpura occurs. cortical steroids can be given for anti-allergy treatment. improper or not timely treatment is likely to cause anaphylatic purpura nephritis. 
 thrombocytopenia purpura. 
 adults may develop arthritis, pain and swelling of large joints after vaccination. 
  ",measles and rubella
sign_symptom,fever,0.9999465," common side-effects: 
 
 generally pain and tenderness at the injection site may occur within 24 hours after vaccination, which usually disappear by itself within 2-3 days. 
 generally transient fever reaction may occur within 1-2 weeks after vaccination. 
 rash: generally mild rash may occur within 12 days after vaccination, which generally lasts for no more than 2 days. 
 
rare side-effects: 
 
 severe fever reaction: physical methods and drugs should be used for symptomatic treatment to prevent febrile seizures. 
 
very rare side-effects: 
 
 allergic rash: generally urticaria may occur within 72 hours after vaccination, and if this reaction occurs, anti-allergy treatment should be timely given. 
 anaphylactic shock: generally occurs within 1 hour after vaccination. injection of epinephrine and other emergency measures should be timely given for treatment. 
 anaphylactoid purpura: medical care should be timely given if anaphylactoid purpura occurs. cortical steroids can be given for anti-allergy treatment. improper or not timely treatment is likely to cause anaphylatic purpura nephritis. 
 thrombocytopenia purpura. 
 adults may develop arthritis, pain and swelling of large joints after vaccination. 
  ",measles and rubella
sign_symptom,rash,0.9966677," common side-effects: 
 
 generally pain and tenderness at the injection site may occur within 24 hours after vaccination, which usually disappear by itself within 2-3 days. 
 generally transient fever reaction may occur within 1-2 weeks after vaccination. 
 rash: generally mild rash may occur within 12 days after vaccination, which generally lasts for no more than 2 days. 
 
rare side-effects: 
 
 severe fever reaction: physical methods and drugs should be used for symptomatic treatment to prevent febrile seizures. 
 
very rare side-effects: 
 
 allergic rash: generally urticaria may occur within 72 hours after vaccination, and if this reaction occurs, anti-allergy treatment should be timely given. 
 anaphylactic shock: generally occurs within 1 hour after vaccination. injection of epinephrine and other emergency measures should be timely given for treatment. 
 anaphylactoid purpura: medical care should be timely given if anaphylactoid purpura occurs. cortical steroids can be given for anti-allergy treatment. improper or not timely treatment is likely to cause anaphylatic purpura nephritis. 
 thrombocytopenia purpura. 
 adults may develop arthritis, pain and swelling of large joints after vaccination. 
  ",measles and rubella
disease_disorder,allergy,0.98390186," common side-effects: 
 
 generally pain and tenderness at the injection site may occur within 24 hours after vaccination, which usually disappear by itself within 2-3 days. 
 generally transient fever reaction may occur within 1-2 weeks after vaccination. 
 rash: generally mild rash may occur within 12 days after vaccination, which generally lasts for no more than 2 days. 
 
rare side-effects: 
 
 severe fever reaction: physical methods and drugs should be used for symptomatic treatment to prevent febrile seizures. 
 
very rare side-effects: 
 
 allergic rash: generally urticaria may occur within 72 hours after vaccination, and if this reaction occurs, anti-allergy treatment should be timely given. 
 anaphylactic shock: generally occurs within 1 hour after vaccination. injection of epinephrine and other emergency measures should be timely given for treatment. 
 anaphylactoid purpura: medical care should be timely given if anaphylactoid purpura occurs. cortical steroids can be given for anti-allergy treatment. improper or not timely treatment is likely to cause anaphylatic purpura nephritis. 
 thrombocytopenia purpura. 
 adults may develop arthritis, pain and swelling of large joints after vaccination. 
  ",measles and rubella
disease_disorder,anaphylactic shock,0.991823," common side-effects: 
 
 generally pain and tenderness at the injection site may occur within 24 hours after vaccination, which usually disappear by itself within 2-3 days. 
 generally transient fever reaction may occur within 1-2 weeks after vaccination. 
 rash: generally mild rash may occur within 12 days after vaccination, which generally lasts for no more than 2 days. 
 
rare side-effects: 
 
 severe fever reaction: physical methods and drugs should be used for symptomatic treatment to prevent febrile seizures. 
 
very rare side-effects: 
 
 allergic rash: generally urticaria may occur within 72 hours after vaccination, and if this reaction occurs, anti-allergy treatment should be timely given. 
 anaphylactic shock: generally occurs within 1 hour after vaccination. injection of epinephrine and other emergency measures should be timely given for treatment. 
 anaphylactoid purpura: medical care should be timely given if anaphylactoid purpura occurs. cortical steroids can be given for anti-allergy treatment. improper or not timely treatment is likely to cause anaphylatic purpura nephritis. 
 thrombocytopenia purpura. 
 adults may develop arthritis, pain and swelling of large joints after vaccination. 
  ",measles and rubella
medication,epineph,0.9120938," common side-effects: 
 
 generally pain and tenderness at the injection site may occur within 24 hours after vaccination, which usually disappear by itself within 2-3 days. 
 generally transient fever reaction may occur within 1-2 weeks after vaccination. 
 rash: generally mild rash may occur within 12 days after vaccination, which generally lasts for no more than 2 days. 
 
rare side-effects: 
 
 severe fever reaction: physical methods and drugs should be used for symptomatic treatment to prevent febrile seizures. 
 
very rare side-effects: 
 
 allergic rash: generally urticaria may occur within 72 hours after vaccination, and if this reaction occurs, anti-allergy treatment should be timely given. 
 anaphylactic shock: generally occurs within 1 hour after vaccination. injection of epinephrine and other emergency measures should be timely given for treatment. 
 anaphylactoid purpura: medical care should be timely given if anaphylactoid purpura occurs. cortical steroids can be given for anti-allergy treatment. improper or not timely treatment is likely to cause anaphylatic purpura nephritis. 
 thrombocytopenia purpura. 
 adults may develop arthritis, pain and swelling of large joints after vaccination. 
  ",measles and rubella
medication,cortical steroids,0.9941741," common side-effects: 
 
 generally pain and tenderness at the injection site may occur within 24 hours after vaccination, which usually disappear by itself within 2-3 days. 
 generally transient fever reaction may occur within 1-2 weeks after vaccination. 
 rash: generally mild rash may occur within 12 days after vaccination, which generally lasts for no more than 2 days. 
 
rare side-effects: 
 
 severe fever reaction: physical methods and drugs should be used for symptomatic treatment to prevent febrile seizures. 
 
very rare side-effects: 
 
 allergic rash: generally urticaria may occur within 72 hours after vaccination, and if this reaction occurs, anti-allergy treatment should be timely given. 
 anaphylactic shock: generally occurs within 1 hour after vaccination. injection of epinephrine and other emergency measures should be timely given for treatment. 
 anaphylactoid purpura: medical care should be timely given if anaphylactoid purpura occurs. cortical steroids can be given for anti-allergy treatment. improper or not timely treatment is likely to cause anaphylatic purpura nephritis. 
 thrombocytopenia purpura. 
 adults may develop arthritis, pain and swelling of large joints after vaccination. 
  ",measles and rubella
sign_symptom,swelling,0.9999578," common side-effects: 
 
 generally pain and tenderness at the injection site may occur within 24 hours after vaccination, which usually disappear by itself within 2-3 days. 
 generally transient fever reaction may occur within 1-2 weeks after vaccination. 
 rash: generally mild rash may occur within 12 days after vaccination, which generally lasts for no more than 2 days. 
 
rare side-effects: 
 
 severe fever reaction: physical methods and drugs should be used for symptomatic treatment to prevent febrile seizures. 
 
very rare side-effects: 
 
 allergic rash: generally urticaria may occur within 72 hours after vaccination, and if this reaction occurs, anti-allergy treatment should be timely given. 
 anaphylactic shock: generally occurs within 1 hour after vaccination. injection of epinephrine and other emergency measures should be timely given for treatment. 
 anaphylactoid purpura: medical care should be timely given if anaphylactoid purpura occurs. cortical steroids can be given for anti-allergy treatment. improper or not timely treatment is likely to cause anaphylatic purpura nephritis. 
 thrombocytopenia purpura. 
 adults may develop arthritis, pain and swelling of large joints after vaccination. 
  ",measles and rubella
sign_symptom,hyper,0.9957163,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,tachycardia,0.88533473,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,palpitation,0.9688153,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,arrhythmia,0.98437643,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,heart,0.7233011,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,syncope,0.95788634,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,nervousness,0.9988251,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,anxiety,0.9998987,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,agitation,0.9999232,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,confusional states,0.99982363,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,halluc,0.7570714,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,unreality,0.81116724,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,tremor,0.99985313,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,dry mouth,0.9960258,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,constipation,0.9982203,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,blurred vision,0.9997928,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,rash,0.8530159,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,pete,0.99871755,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,nausea,0.9999374,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,bitter taste,0.8139932,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,elevation,0.99819165,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
sign_symptom,depression,0.99873024,"  cardiovascular : rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been reported with maprotiline.   psychiatric : nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, decrease in memory, and feelings of unreality    neurological : drowsiness (16%), dizziness (8%), tremor (3%), and, rarely, numbness, tingling, motor hyperactivity, akathisia, seizures, eeg alterations, tinnitus, extrapyramidal symptoms, ataxia, and dysarthria.   anticholinergic : dry mouth (22%), constipation (6%), and blurred vision (4%); rarely, accommodation disturbances, mydriasis, urinary retention, and delayed micturition.   allergic : rare instances of skin rash, petechiae, itching, photosensitization, edema, and drug fever.   gastrointestinal : nausea (2%) and, rarely, vomiting, epigastric distress, diarrhea, bitter taste, abdominal cramps and dysphagia.   endocrine : rare instances of increased or decreased libido, impotence, and elevation or depression of blood sugar levels. ",maprotiline hydrochloride
medication,mannitol,0.99278194," the most common side effects associated with mannitol intravenous infusion is fluid and electrolytes imbalance including circulatory overload and acidosis at high doses. other side effects include nausea, vomiting, thirst, headache, dizziness, fever, tachycardia, chest pain, hyponatraemia, dehydration, blurred vision, urticaria, and hypertension or hypotension. ",mannitol
sign_symptom,electrolytes,0.81221014," the most common side effects associated with mannitol intravenous infusion is fluid and electrolytes imbalance including circulatory overload and acidosis at high doses. other side effects include nausea, vomiting, thirst, headache, dizziness, fever, tachycardia, chest pain, hyponatraemia, dehydration, blurred vision, urticaria, and hypertension or hypotension. ",mannitol
sign_symptom,imbalance,0.99431425," the most common side effects associated with mannitol intravenous infusion is fluid and electrolytes imbalance including circulatory overload and acidosis at high doses. other side effects include nausea, vomiting, thirst, headache, dizziness, fever, tachycardia, chest pain, hyponatraemia, dehydration, blurred vision, urticaria, and hypertension or hypotension. ",mannitol
sign_symptom,acid,0.99994063," the most common side effects associated with mannitol intravenous infusion is fluid and electrolytes imbalance including circulatory overload and acidosis at high doses. other side effects include nausea, vomiting, thirst, headache, dizziness, fever, tachycardia, chest pain, hyponatraemia, dehydration, blurred vision, urticaria, and hypertension or hypotension. ",mannitol
sign_symptom,blurred vision,0.96896327," the most common side effects associated with mannitol intravenous infusion is fluid and electrolytes imbalance including circulatory overload and acidosis at high doses. other side effects include nausea, vomiting, thirst, headache, dizziness, fever, tachycardia, chest pain, hyponatraemia, dehydration, blurred vision, urticaria, and hypertension or hypotension. ",mannitol
medication,magnesium,0.99399513," excessive administration of magnesium results in hypermagnesaemia manifested by nausea, vomiting, flushing of the skin, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, respiratory depression, cardiac arrest etc ",magnesium sulfate heptahydrate
sign_symptom,hyper,0.9999579," excessive administration of magnesium results in hypermagnesaemia manifested by nausea, vomiting, flushing of the skin, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, respiratory depression, cardiac arrest etc ",magnesium sulfate heptahydrate
sign_symptom,vomiting,0.99390244," excessive administration of magnesium results in hypermagnesaemia manifested by nausea, vomiting, flushing of the skin, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, respiratory depression, cardiac arrest etc ",magnesium sulfate heptahydrate
sign_symptom,flushing of,0.9361545," excessive administration of magnesium results in hypermagnesaemia manifested by nausea, vomiting, flushing of the skin, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, respiratory depression, cardiac arrest etc ",magnesium sulfate heptahydrate
sign_symptom,skin,0.99914813," excessive administration of magnesium results in hypermagnesaemia manifested by nausea, vomiting, flushing of the skin, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, respiratory depression, cardiac arrest etc ",magnesium sulfate heptahydrate
sign_symptom,thirst,0.7192781," excessive administration of magnesium results in hypermagnesaemia manifested by nausea, vomiting, flushing of the skin, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, respiratory depression, cardiac arrest etc ",magnesium sulfate heptahydrate
sign_symptom,hypotension,0.99942034," excessive administration of magnesium results in hypermagnesaemia manifested by nausea, vomiting, flushing of the skin, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, respiratory depression, cardiac arrest etc ",magnesium sulfate heptahydrate
sign_symptom,drowsiness,0.97098845," excessive administration of magnesium results in hypermagnesaemia manifested by nausea, vomiting, flushing of the skin, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, respiratory depression, cardiac arrest etc ",magnesium sulfate heptahydrate
sign_symptom,loss of tendon reflex,0.998275," excessive administration of magnesium results in hypermagnesaemia manifested by nausea, vomiting, flushing of the skin, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, respiratory depression, cardiac arrest etc ",magnesium sulfate heptahydrate
sign_symptom,respiratory,0.9664325," excessive administration of magnesium results in hypermagnesaemia manifested by nausea, vomiting, flushing of the skin, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, respiratory depression, cardiac arrest etc ",magnesium sulfate heptahydrate
disease_disorder,cardiac arrest,0.98785627," excessive administration of magnesium results in hypermagnesaemia manifested by nausea, vomiting, flushing of the skin, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, respiratory depression, cardiac arrest etc ",magnesium sulfate heptahydrate
sign_symptom,hyper,0.99994826," the most common side effect is hypermagnesaemia developing from excessive administration of magnesium. symptoms of hypermagnesaemia may include nausea, vomiting, flushing of skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, muscle weakness etc. rarely diarrhea or skin irritation after soaking may occur. ",magnesium sulfate
medication,magnesium,0.9939207," the most common side effect is hypermagnesaemia developing from excessive administration of magnesium. symptoms of hypermagnesaemia may include nausea, vomiting, flushing of skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, muscle weakness etc. rarely diarrhea or skin irritation after soaking may occur. ",magnesium sulfate
sign_symptom,vomiting,0.974667," the most common side effect is hypermagnesaemia developing from excessive administration of magnesium. symptoms of hypermagnesaemia may include nausea, vomiting, flushing of skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, muscle weakness etc. rarely diarrhea or skin irritation after soaking may occur. ",magnesium sulfate
sign_symptom,flushing of,0.97529507," the most common side effect is hypermagnesaemia developing from excessive administration of magnesium. symptoms of hypermagnesaemia may include nausea, vomiting, flushing of skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, muscle weakness etc. rarely diarrhea or skin irritation after soaking may occur. ",magnesium sulfate
sign_symptom,hypotension,0.9796988," the most common side effect is hypermagnesaemia developing from excessive administration of magnesium. symptoms of hypermagnesaemia may include nausea, vomiting, flushing of skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, muscle weakness etc. rarely diarrhea or skin irritation after soaking may occur. ",magnesium sulfate
sign_symptom,confusion,0.9926823," the most common side effect is hypermagnesaemia developing from excessive administration of magnesium. symptoms of hypermagnesaemia may include nausea, vomiting, flushing of skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, muscle weakness etc. rarely diarrhea or skin irritation after soaking may occur. ",magnesium sulfate
sign_symptom,muscle weakness,0.99720836," the most common side effect is hypermagnesaemia developing from excessive administration of magnesium. symptoms of hypermagnesaemia may include nausea, vomiting, flushing of skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, muscle weakness etc. rarely diarrhea or skin irritation after soaking may occur. ",magnesium sulfate
sign_symptom,irritation,0.9977602," the most common side effect is hypermagnesaemia developing from excessive administration of magnesium. symptoms of hypermagnesaemia may include nausea, vomiting, flushing of skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, muscle weakness etc. rarely diarrhea or skin irritation after soaking may occur. ",magnesium sulfate
sign_symptom,effects,0.7038213," mild side effects include-nausea, vomiting, diarrhea, cramp, tiredness, weakness, confusion. these side effects disappear when the dose is reduced or treatment is discontinued. serious side effects include low blood pressure, changes in the recording of the heart's electrical activity (ecg), depression, severe allergic reaction (e.g. swelling in mouth and throat, itching, rash, redness), respiratory depression, coma. these may require emergency medical treatment. these serious side efects occur very rarely. ",magnesium oxide
sign_symptom,changes,0.9712026," mild side effects include-nausea, vomiting, diarrhea, cramp, tiredness, weakness, confusion. these side effects disappear when the dose is reduced or treatment is discontinued. serious side effects include low blood pressure, changes in the recording of the heart's electrical activity (ecg), depression, severe allergic reaction (e.g. swelling in mouth and throat, itching, rash, redness), respiratory depression, coma. these may require emergency medical treatment. these serious side efects occur very rarely. ",magnesium oxide
sign_symptom,allergic reaction,0.99956," mild side effects include-nausea, vomiting, diarrhea, cramp, tiredness, weakness, confusion. these side effects disappear when the dose is reduced or treatment is discontinued. serious side effects include low blood pressure, changes in the recording of the heart's electrical activity (ecg), depression, severe allergic reaction (e.g. swelling in mouth and throat, itching, rash, redness), respiratory depression, coma. these may require emergency medical treatment. these serious side efects occur very rarely. ",magnesium oxide
sign_symptom,swelling,0.99994326," mild side effects include-nausea, vomiting, diarrhea, cramp, tiredness, weakness, confusion. these side effects disappear when the dose is reduced or treatment is discontinued. serious side effects include low blood pressure, changes in the recording of the heart's electrical activity (ecg), depression, severe allergic reaction (e.g. swelling in mouth and throat, itching, rash, redness), respiratory depression, coma. these may require emergency medical treatment. these serious side efects occur very rarely. ",magnesium oxide
sign_symptom,side efect,0.9797168," mild side effects include-nausea, vomiting, diarrhea, cramp, tiredness, weakness, confusion. these side effects disappear when the dose is reduced or treatment is discontinued. serious side effects include low blood pressure, changes in the recording of the heart's electrical activity (ecg), depression, severe allergic reaction (e.g. swelling in mouth and throat, itching, rash, redness), respiratory depression, coma. these may require emergency medical treatment. these serious side efects occur very rarely. ",magnesium oxide
sign_symptom,irritation,0.9996401," rectal irritation, potassium loss (thirst, weakness, nausea and diarrhea). ",magnesium hydroxide + liquid paraffin
sign_symptom,potassium loss,0.9967663," rectal irritation, potassium loss (thirst, weakness, nausea and diarrhea). ",magnesium hydroxide + liquid paraffin
sign_symptom,nausea,0.9993344," rectal irritation, potassium loss (thirst, weakness, nausea and diarrhea). ",magnesium hydroxide + liquid paraffin
medication,magnesium hydroxide,0.98516124, magnesium hydroxide in common with other magnesium salts may cause diarrhoea. ,magnesium hydroxide
medication,magnesium salts,0.97489774, magnesium hydroxide in common with other magnesium salts may cause diarrhoea. ,magnesium hydroxide
sign_symptom,side - effects,0.99121886," gastrointestinal side-effects are uncommon. occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur. ",magaldrate + simethicone
sign_symptom,constipation,0.99396396," gastrointestinal side-effects are uncommon. occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur. ",magaldrate + simethicone
sign_symptom,consti,0.8994745, constipation and diarrhea may occur. ,magaldrate
sign_symptom,diarr,0.9974882," in the treatment of chronic constipation, diarrhoea or loose stools normally respond to a reduction in dose. diarrhoea, abdominal distension, anorectal discomfort and mild vomiting are more often observed during the treatment for fecal impaction. vomiting may be resolved if the dose is reduced or delayed. ",macrogol [polypropylene glycol] + electrolytes
sign_symptom,loose stool,0.99214625," in the treatment of chronic constipation, diarrhoea or loose stools normally respond to a reduction in dose. diarrhoea, abdominal distension, anorectal discomfort and mild vomiting are more often observed during the treatment for fecal impaction. vomiting may be resolved if the dose is reduced or delayed. ",macrogol [polypropylene glycol] + electrolytes
sign_symptom,discomfort,0.99964225," in the treatment of chronic constipation, diarrhoea or loose stools normally respond to a reduction in dose. diarrhoea, abdominal distension, anorectal discomfort and mild vomiting are more often observed during the treatment for fecal impaction. vomiting may be resolved if the dose is reduced or delayed. ",macrogol [polypropylene glycol] + electrolytes
sign_symptom,vomiting,0.9999546," in the treatment of chronic constipation, diarrhoea or loose stools normally respond to a reduction in dose. diarrhoea, abdominal distension, anorectal discomfort and mild vomiting are more often observed during the treatment for fecal impaction. vomiting may be resolved if the dose is reduced or delayed. ",macrogol [polypropylene glycol] + electrolytes
medication,placebo,0.9181012," the most common adverse reactions (more frequent than placebo by 3%) are anemia, nasopharyngitis/pharyngitis, bronchitis, headache, influenza, and urinary tract infection. ",macitentan
sign_symptom,nasopharyngitis,0.9989547," the most common adverse reactions (more frequent than placebo by 3%) are anemia, nasopharyngitis/pharyngitis, bronchitis, headache, influenza, and urinary tract infection. ",macitentan
sign_symptom,pharyngitis,0.962996," the most common adverse reactions (more frequent than placebo by 3%) are anemia, nasopharyngitis/pharyngitis, bronchitis, headache, influenza, and urinary tract infection. ",macitentan
disease_disorder,digest,0.8965851," in rare cases, respiratory, thoracic and mediastinal violations; skin and subcutaneous violations; general disorders, digestive disorders and local sublingual disturbances caused by the drug. in any case of violation, the treatment should be discontinued. ",lyophilized bacterial lysate
disease_disorder,disorders,0.7145466," in rare cases, respiratory, thoracic and mediastinal violations; skin and subcutaneous violations; general disorders, digestive disorders and local sublingual disturbances caused by the drug. in any case of violation, the treatment should be discontinued. ",lyophilized bacterial lysate
sign_symptom,sublingual disturbances,0.84998816," in rare cases, respiratory, thoracic and mediastinal violations; skin and subcutaneous violations; general disorders, digestive disorders and local sublingual disturbances caused by the drug. in any case of violation, the treatment should be discontinued. ",lyophilized bacterial lysate
sign_symptom,bleeding,0.99982303," during continuous treatment regimens with lynestrenol, breakthrough bleeding or spotting will occur frequently (over 10 per cent) during the first two months. later on the frequency gradually decreases. during cyclic treatment regimens breakthrough bleeding and spotting will be seen occasionally (1-10 per cent). temporarily increasing the dose will control the bleeding in most cases. other adverse events which occur frequently (over 10 per cent) are : change in libido (both increase and decrease), nausea or other gastrointestinal disturbances, and weight increase. adverse events which may be observed occasionally (1-10 per cent) or rare (less than 1 per cent) are : headache or migraine, dizziness, nervousness, depression, increased sweating, acne, hirsutism, chloasma, rash, pruritus, jaundice, change in lipoprotein profile, alterations in liver function tests, amenorrhoea, menstrual irregularity, reduced glucose tolerance, breast pain, oedema. most of these adverse events are transient and of minor importance in many cases. ",lynestrenol
sign_symptom,spotting,0.8668891," during continuous treatment regimens with lynestrenol, breakthrough bleeding or spotting will occur frequently (over 10 per cent) during the first two months. later on the frequency gradually decreases. during cyclic treatment regimens breakthrough bleeding and spotting will be seen occasionally (1-10 per cent). temporarily increasing the dose will control the bleeding in most cases. other adverse events which occur frequently (over 10 per cent) are : change in libido (both increase and decrease), nausea or other gastrointestinal disturbances, and weight increase. adverse events which may be observed occasionally (1-10 per cent) or rare (less than 1 per cent) are : headache or migraine, dizziness, nervousness, depression, increased sweating, acne, hirsutism, chloasma, rash, pruritus, jaundice, change in lipoprotein profile, alterations in liver function tests, amenorrhoea, menstrual irregularity, reduced glucose tolerance, breast pain, oedema. most of these adverse events are transient and of minor importance in many cases. ",lynestrenol
sign_symptom,adverse events,0.9963337," during continuous treatment regimens with lynestrenol, breakthrough bleeding or spotting will occur frequently (over 10 per cent) during the first two months. later on the frequency gradually decreases. during cyclic treatment regimens breakthrough bleeding and spotting will be seen occasionally (1-10 per cent). temporarily increasing the dose will control the bleeding in most cases. other adverse events which occur frequently (over 10 per cent) are : change in libido (both increase and decrease), nausea or other gastrointestinal disturbances, and weight increase. adverse events which may be observed occasionally (1-10 per cent) or rare (less than 1 per cent) are : headache or migraine, dizziness, nervousness, depression, increased sweating, acne, hirsutism, chloasma, rash, pruritus, jaundice, change in lipoprotein profile, alterations in liver function tests, amenorrhoea, menstrual irregularity, reduced glucose tolerance, breast pain, oedema. most of these adverse events are transient and of minor importance in many cases. ",lynestrenol
sign_symptom,nausea,0.99991286," during continuous treatment regimens with lynestrenol, breakthrough bleeding or spotting will occur frequently (over 10 per cent) during the first two months. later on the frequency gradually decreases. during cyclic treatment regimens breakthrough bleeding and spotting will be seen occasionally (1-10 per cent). temporarily increasing the dose will control the bleeding in most cases. other adverse events which occur frequently (over 10 per cent) are : change in libido (both increase and decrease), nausea or other gastrointestinal disturbances, and weight increase. adverse events which may be observed occasionally (1-10 per cent) or rare (less than 1 per cent) are : headache or migraine, dizziness, nervousness, depression, increased sweating, acne, hirsutism, chloasma, rash, pruritus, jaundice, change in lipoprotein profile, alterations in liver function tests, amenorrhoea, menstrual irregularity, reduced glucose tolerance, breast pain, oedema. most of these adverse events are transient and of minor importance in many cases. ",lynestrenol
sign_symptom,headache,0.99983895," during continuous treatment regimens with lynestrenol, breakthrough bleeding or spotting will occur frequently (over 10 per cent) during the first two months. later on the frequency gradually decreases. during cyclic treatment regimens breakthrough bleeding and spotting will be seen occasionally (1-10 per cent). temporarily increasing the dose will control the bleeding in most cases. other adverse events which occur frequently (over 10 per cent) are : change in libido (both increase and decrease), nausea or other gastrointestinal disturbances, and weight increase. adverse events which may be observed occasionally (1-10 per cent) or rare (less than 1 per cent) are : headache or migraine, dizziness, nervousness, depression, increased sweating, acne, hirsutism, chloasma, rash, pruritus, jaundice, change in lipoprotein profile, alterations in liver function tests, amenorrhoea, menstrual irregularity, reduced glucose tolerance, breast pain, oedema. most of these adverse events are transient and of minor importance in many cases. ",lynestrenol
medication,lymecycline capsule,0.90626806," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,feeling,0.9999037," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,sick,0.9997867," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,nausea,0.9999012," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,pain,0.99995124," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,diarrhoea,0.9975462," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,headache,0.99992025," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,eyesight disturbances,0.9980261," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,vomiting,0.9993327," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,yellowing of eyes,0.7519699," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,fever,0.9999677," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,hives,0.99916905," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
sign_symptom,inflammation,0.9997495," lymecycline capsules may also cause the following side effects.  common (occur in less than 1 in 10 patients): 
 
 feeling sick (nausea) 
 abdominal pain 
 diarrhoea 
 headache 
 
unknown (frequency cannot be estimated from available information): 
 
 eyesight disturbances 
 dizziness 
 being sick (vomiting) 
 yellowing of eyes or skin (jaundice) 
 increased sensitivity of the skin to sunlight (real or artificial) 
 increased pressure in the brain 
 changes in type or number of certain blood cells 
 pain in the upper part of the abdomen 
 changes in some blood tests (liver function tests) 
 fever 
 itchiness, skin rash, or hives 
 inflammation of the intestine 
  ",lymecycline
disease_disorder,contact dermatitis,0.9997592, contact dermatitis and cellulitis may occur. application site reactions were observed in iess than 1% of subjects in clinical trial. ,luliconazole
disease_disorder,cell,0.9998579, contact dermatitis and cellulitis may occur. application site reactions were observed in iess than 1% of subjects in clinical trial. ,luliconazole
sign_symptom,diarr,0.8186506," diarrhea, full or bloated feeling or pressure in the stomach, nausea, stomach pain, swelling of abdominal or stomach area, dyspnea ",lubiprostone
sign_symptom,feeling,0.9204577," diarrhea, full or bloated feeling or pressure in the stomach, nausea, stomach pain, swelling of abdominal or stomach area, dyspnea ",lubiprostone
sign_symptom,pressure,0.9752704," diarrhea, full or bloated feeling or pressure in the stomach, nausea, stomach pain, swelling of abdominal or stomach area, dyspnea ",lubiprostone
sign_symptom,swelling,0.9997845," diarrhea, full or bloated feeling or pressure in the stomach, nausea, stomach pain, swelling of abdominal or stomach area, dyspnea ",lubiprostone
sign_symptom,diarrhoea,0.70406216," hyperuricaemia, bone marrow toxicity, hypoplasia, anorexia, diarrhoea, leukopenia, thrombocytopenia, intestinal ulceration, crystalluria with haematuria, immunosuppression, interstitial pneumonitis. cutaneous hyperpigmentation, alopecia. ",mercaptopurine
sign_symptom,crystalluria,0.8822935," hyperuricaemia, bone marrow toxicity, hypoplasia, anorexia, diarrhoea, leukopenia, thrombocytopenia, intestinal ulceration, crystalluria with haematuria, immunosuppression, interstitial pneumonitis. cutaneous hyperpigmentation, alopecia. ",mercaptopurine
sign_symptom,swelling,0.98823893," redness, irritation, swelling or pain. ",menthol + pramoxine hydrochloride
disease_disorder,meningococcal,0.9718692," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
medication,polysaccharide vaccine,0.86056477," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,adverse reactions,0.9999257," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
disease_disorder,metabolism,0.9535179," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,appetite,0.99385864," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,lost,0.92518824," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
disease_disorder,psychiatric,0.9539448," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,irritability nervous system disorders,0.9070511," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,drowsiness,0.9403793," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,headache,0.99969447," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,dizziness,0.7538498," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,gastrointestinal symptoms,0.993103," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,nausea,0.9998796," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,vomiting,0.9999418," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,diarrhea,0.9968243," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,musculoskeletal,0.9418564," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
disease_disorder,connect,0.8562128," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
disease_disorder,tissue disorders,0.9594495," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,myal,0.9967284," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
disease_disorder,general disorders,0.98363465," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,pain,0.9999634," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,redness,0.99940133," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,fatigue,0.99990714," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,swelling,0.99996793," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,fever,0.9999615," meningococcal polysaccharide vaccine is generally well tolerated. adverse reactions usually occur within 48 hours following vaccination.   metabolism and nutrition disorders- 
 
 common: appetite lost psychiatric disorders: 
 very common: irritability 
 
nervous system disorders- 
 
 very common: drowsiness, headache. 
 uncommon: dizziness 
 
gastrointestinal disorders- 
 
 common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhea 
 
musculoskeletal and connective tissue disorders- 
 
 common: myalgia 
 
general disorders and administration site conditions- 
 
 very common: pain and redness at the injection site, fatigue 
 common: swelling at the injection site, fever 
  ",meningococcal polysaccharide vaccine
sign_symptom,adverse reactions,0.99933845," adverse reactions are appetite lost, irritability, insomnia, crying, drowsiness, headache, hypoaesthesia, dizziness, diarrhoea, vomiting, nausea, pruritus, rash, myalgia, pain in extremity, fever, swelling at injection site, pain at injection site, redness at injection site, fatigue, injection site haematoma, malaise, injection site induration, injection site pruritus, injection site warmth, injection site anaesthesia ",meningococcal conjugate vaccine
sign_symptom,appetite,0.996405," adverse reactions are appetite lost, irritability, insomnia, crying, drowsiness, headache, hypoaesthesia, dizziness, diarrhoea, vomiting, nausea, pruritus, rash, myalgia, pain in extremity, fever, swelling at injection site, pain at injection site, redness at injection site, fatigue, injection site haematoma, malaise, injection site induration, injection site pruritus, injection site warmth, injection site anaesthesia ",meningococcal conjugate vaccine
sign_symptom,pain,0.99990666," adverse reactions are appetite lost, irritability, insomnia, crying, drowsiness, headache, hypoaesthesia, dizziness, diarrhoea, vomiting, nausea, pruritus, rash, myalgia, pain in extremity, fever, swelling at injection site, pain at injection site, redness at injection site, fatigue, injection site haematoma, malaise, injection site induration, injection site pruritus, injection site warmth, injection site anaesthesia ",meningococcal conjugate vaccine
sign_symptom,swelling,0.9999298," adverse reactions are appetite lost, irritability, insomnia, crying, drowsiness, headache, hypoaesthesia, dizziness, diarrhoea, vomiting, nausea, pruritus, rash, myalgia, pain in extremity, fever, swelling at injection site, pain at injection site, redness at injection site, fatigue, injection site haematoma, malaise, injection site induration, injection site pruritus, injection site warmth, injection site anaesthesia ",meningococcal conjugate vaccine
sign_symptom,redness,0.9683019," adverse reactions are appetite lost, irritability, insomnia, crying, drowsiness, headache, hypoaesthesia, dizziness, diarrhoea, vomiting, nausea, pruritus, rash, myalgia, pain in extremity, fever, swelling at injection site, pain at injection site, redness at injection site, fatigue, injection site haematoma, malaise, injection site induration, injection site pruritus, injection site warmth, injection site anaesthesia ",meningococcal conjugate vaccine
sign_symptom,mala,0.999905," adverse reactions are appetite lost, irritability, insomnia, crying, drowsiness, headache, hypoaesthesia, dizziness, diarrhoea, vomiting, nausea, pruritus, rash, myalgia, pain in extremity, fever, swelling at injection site, pain at injection site, redness at injection site, fatigue, injection site haematoma, malaise, injection site induration, injection site pruritus, injection site warmth, injection site anaesthesia ",meningococcal conjugate vaccine
medication,anaesthesia,0.9467164," adverse reactions are appetite lost, irritability, insomnia, crying, drowsiness, headache, hypoaesthesia, dizziness, diarrhoea, vomiting, nausea, pruritus, rash, myalgia, pain in extremity, fever, swelling at injection site, pain at injection site, redness at injection site, fatigue, injection site haematoma, malaise, injection site induration, injection site pruritus, injection site warmth, injection site anaesthesia ",meningococcal conjugate vaccine
sign_symptom,hall,0.9922456," most frequent side effects (frequency of 2% or less) include hallucination, confusion, dizziness, headache and fatigue. occasional side effects include anxiety, hypertonus (heightened muscle tension), vomiting, bladder infections and increased sexual drive. if there is a history of epileptic seizures, there is a slight chance that memantine may increase the probability of an attack. ",memantine hydrochloride
sign_symptom,confusion,0.87874264," most frequent side effects (frequency of 2% or less) include hallucination, confusion, dizziness, headache and fatigue. occasional side effects include anxiety, hypertonus (heightened muscle tension), vomiting, bladder infections and increased sexual drive. if there is a history of epileptic seizures, there is a slight chance that memantine may increase the probability of an attack. ",memantine hydrochloride
sign_symptom,headache,0.99387413," most frequent side effects (frequency of 2% or less) include hallucination, confusion, dizziness, headache and fatigue. occasional side effects include anxiety, hypertonus (heightened muscle tension), vomiting, bladder infections and increased sexual drive. if there is a history of epileptic seizures, there is a slight chance that memantine may increase the probability of an attack. ",memantine hydrochloride
sign_symptom,hyper,0.99908745," most frequent side effects (frequency of 2% or less) include hallucination, confusion, dizziness, headache and fatigue. occasional side effects include anxiety, hypertonus (heightened muscle tension), vomiting, bladder infections and increased sexual drive. if there is a history of epileptic seizures, there is a slight chance that memantine may increase the probability of an attack. ",memantine hydrochloride
medication,placebo,0.99835014," the most common adverse reactions, occurring at a frequency of at least 5% and greater than placebo with memantine hydrochloride extended-release 28 mg/day, were headache, diarrhea, and dizziness. the most common adverse reactions occurring at a frequency of at least 5% in patients receiving donepezil and at twice or more the placebo rate, include diarrhea, anorexia, vomiting, nausea, and ecchymosis. ",memantine + donepezil
sign_symptom,adverse reactions,0.99502933," the most common adverse reactions, occurring at a frequency of at least 5% and greater than placebo with memantine hydrochloride extended-release 28 mg/day, were headache, diarrhea, and dizziness. the most common adverse reactions occurring at a frequency of at least 5% in patients receiving donepezil and at twice or more the placebo rate, include diarrhea, anorexia, vomiting, nausea, and ecchymosis. ",memantine + donepezil
medication,donepezil,0.9486816," the most common adverse reactions, occurring at a frequency of at least 5% and greater than placebo with memantine hydrochloride extended-release 28 mg/day, were headache, diarrhea, and dizziness. the most common adverse reactions occurring at a frequency of at least 5% in patients receiving donepezil and at twice or more the placebo rate, include diarrhea, anorexia, vomiting, nausea, and ecchymosis. ",memantine + donepezil
sign_symptom,vomiting,0.9989636," nausea, vomiting, abdominal pain, dyspepsia, constipation or diarrhoea may occur. ulcers or gastrointestinal bleeding may rarely occur. skin rash, or urticaria may occur in some individuals. oedema of the lower limbs may occur during treatment. onset of an asthma attack has been reported in certain individuals allergic to aspirin or to other nsaids. headache, vertigo or drowsiness may occur. ",meloxicam
sign_symptom,dyspepsia,0.9822048," nausea, vomiting, abdominal pain, dyspepsia, constipation or diarrhoea may occur. ulcers or gastrointestinal bleeding may rarely occur. skin rash, or urticaria may occur in some individuals. oedema of the lower limbs may occur during treatment. onset of an asthma attack has been reported in certain individuals allergic to aspirin or to other nsaids. headache, vertigo or drowsiness may occur. ",meloxicam
sign_symptom,constipation,0.9412757," nausea, vomiting, abdominal pain, dyspepsia, constipation or diarrhoea may occur. ulcers or gastrointestinal bleeding may rarely occur. skin rash, or urticaria may occur in some individuals. oedema of the lower limbs may occur during treatment. onset of an asthma attack has been reported in certain individuals allergic to aspirin or to other nsaids. headache, vertigo or drowsiness may occur. ",meloxicam
sign_symptom,diarr,0.9781804," nausea, vomiting, abdominal pain, dyspepsia, constipation or diarrhoea may occur. ulcers or gastrointestinal bleeding may rarely occur. skin rash, or urticaria may occur in some individuals. oedema of the lower limbs may occur during treatment. onset of an asthma attack has been reported in certain individuals allergic to aspirin or to other nsaids. headache, vertigo or drowsiness may occur. ",meloxicam
sign_symptom,ulcers,0.99807805," nausea, vomiting, abdominal pain, dyspepsia, constipation or diarrhoea may occur. ulcers or gastrointestinal bleeding may rarely occur. skin rash, or urticaria may occur in some individuals. oedema of the lower limbs may occur during treatment. onset of an asthma attack has been reported in certain individuals allergic to aspirin or to other nsaids. headache, vertigo or drowsiness may occur. ",meloxicam
sign_symptom,bleeding,0.99986374," nausea, vomiting, abdominal pain, dyspepsia, constipation or diarrhoea may occur. ulcers or gastrointestinal bleeding may rarely occur. skin rash, or urticaria may occur in some individuals. oedema of the lower limbs may occur during treatment. onset of an asthma attack has been reported in certain individuals allergic to aspirin or to other nsaids. headache, vertigo or drowsiness may occur. ",meloxicam
sign_symptom,asthma attack,0.98180073," nausea, vomiting, abdominal pain, dyspepsia, constipation or diarrhoea may occur. ulcers or gastrointestinal bleeding may rarely occur. skin rash, or urticaria may occur in some individuals. oedema of the lower limbs may occur during treatment. onset of an asthma attack has been reported in certain individuals allergic to aspirin or to other nsaids. headache, vertigo or drowsiness may occur. ",meloxicam
sign_symptom,vertigo,0.999869," nausea, vomiting, abdominal pain, dyspepsia, constipation or diarrhoea may occur. ulcers or gastrointestinal bleeding may rarely occur. skin rash, or urticaria may occur in some individuals. oedema of the lower limbs may occur during treatment. onset of an asthma attack has been reported in certain individuals allergic to aspirin or to other nsaids. headache, vertigo or drowsiness may occur. ",meloxicam
sign_symptom,headache,0.9998654, possible adverse effects include headache and depression. drowsiness may be experienced within 30 minutes after taking melatonin and may persist for 1 hour and thus may affect driving skills. ,melatonin
medication,melatonin,0.9952963, possible adverse effects include headache and depression. drowsiness may be experienced within 30 minutes after taking melatonin and may persist for 1 hour and thus may affect driving skills. ,melatonin
sign_symptom,weight gain,0.9980781,"  weight gain : weight gain is a frequent side effect of megestrol acetate. this gain has been associated with increased appetite and is not necessarily associated with fluid retention.   thromboembolic phenomena : thromboembolic phenomena including thrombophlebitis and pulmonary embolism (in some cases fatal) have been reported.   glucocorticoid effects : the glucocorticoid activity of megestrol acetate has not been fully evaluated. clinical cases of new onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, and overt cushings syndrome have been reported in association with the chronic use of megestrol acetate. in addition, clinical cases of adrenal insufficiency have been observed in patients receiving or being withdrawn from chronic megestrol acetate therapy in the stressed and non-stressed state.   other : nausea, dyspnea, tumor flare, hyperglycemia, glucose intolerance, alopecia, hypertension, carpal tunnel syndrome, mood changes, hot flashes, malaise, asthenia, lethargy, sweating and rash. ",megestrol acetate
disease_disorder,diabetes mel,0.9364368,"  weight gain : weight gain is a frequent side effect of megestrol acetate. this gain has been associated with increased appetite and is not necessarily associated with fluid retention.   thromboembolic phenomena : thromboembolic phenomena including thrombophlebitis and pulmonary embolism (in some cases fatal) have been reported.   glucocorticoid effects : the glucocorticoid activity of megestrol acetate has not been fully evaluated. clinical cases of new onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, and overt cushings syndrome have been reported in association with the chronic use of megestrol acetate. in addition, clinical cases of adrenal insufficiency have been observed in patients receiving or being withdrawn from chronic megestrol acetate therapy in the stressed and non-stressed state.   other : nausea, dyspnea, tumor flare, hyperglycemia, glucose intolerance, alopecia, hypertension, carpal tunnel syndrome, mood changes, hot flashes, malaise, asthenia, lethargy, sweating and rash. ",megestrol acetate
disease_disorder,diabetes,0.9707737,"  weight gain : weight gain is a frequent side effect of megestrol acetate. this gain has been associated with increased appetite and is not necessarily associated with fluid retention.   thromboembolic phenomena : thromboembolic phenomena including thrombophlebitis and pulmonary embolism (in some cases fatal) have been reported.   glucocorticoid effects : the glucocorticoid activity of megestrol acetate has not been fully evaluated. clinical cases of new onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, and overt cushings syndrome have been reported in association with the chronic use of megestrol acetate. in addition, clinical cases of adrenal insufficiency have been observed in patients receiving or being withdrawn from chronic megestrol acetate therapy in the stressed and non-stressed state.   other : nausea, dyspnea, tumor flare, hyperglycemia, glucose intolerance, alopecia, hypertension, carpal tunnel syndrome, mood changes, hot flashes, malaise, asthenia, lethargy, sweating and rash. ",megestrol acetate
medication,mefloquine,0.94291955," among subjects who received mefloquine for prophylaxis of malaria, following side effects was observed: 
 
 the most frequently observed sied-effects were vomiting, dizziness, syncope, extrasystoles and other complaints affecting less than 1%. among subjects who received mefloquine for treatment, following side-effects was observed: 
 the most frequently observed side-effects included : dizziness, myalgia, nausea, fever, headache, vomiting, chills, diarrhoea, skin rash, abdominal pain fatigue, loss of appetite, and tinnitus 
  ",mefloquine
sign_symptom,effects,0.7590442," among subjects who received mefloquine for prophylaxis of malaria, following side effects was observed: 
 
 the most frequently observed sied-effects were vomiting, dizziness, syncope, extrasystoles and other complaints affecting less than 1%. among subjects who received mefloquine for treatment, following side-effects was observed: 
 the most frequently observed side-effects included : dizziness, myalgia, nausea, fever, headache, vomiting, chills, diarrhoea, skin rash, abdominal pain fatigue, loss of appetite, and tinnitus 
  ",mefloquine
sign_symptom,sied,0.7662083," among subjects who received mefloquine for prophylaxis of malaria, following side effects was observed: 
 
 the most frequently observed sied-effects were vomiting, dizziness, syncope, extrasystoles and other complaints affecting less than 1%. among subjects who received mefloquine for treatment, following side-effects was observed: 
 the most frequently observed side-effects included : dizziness, myalgia, nausea, fever, headache, vomiting, chills, diarrhoea, skin rash, abdominal pain fatigue, loss of appetite, and tinnitus 
  ",mefloquine
sign_symptom,vomiting,0.9957975," among subjects who received mefloquine for prophylaxis of malaria, following side effects was observed: 
 
 the most frequently observed sied-effects were vomiting, dizziness, syncope, extrasystoles and other complaints affecting less than 1%. among subjects who received mefloquine for treatment, following side-effects was observed: 
 the most frequently observed side-effects included : dizziness, myalgia, nausea, fever, headache, vomiting, chills, diarrhoea, skin rash, abdominal pain fatigue, loss of appetite, and tinnitus 
  ",mefloquine
sign_symptom,syncope,0.99893904," among subjects who received mefloquine for prophylaxis of malaria, following side effects was observed: 
 
 the most frequently observed sied-effects were vomiting, dizziness, syncope, extrasystoles and other complaints affecting less than 1%. among subjects who received mefloquine for treatment, following side-effects was observed: 
 the most frequently observed side-effects included : dizziness, myalgia, nausea, fever, headache, vomiting, chills, diarrhoea, skin rash, abdominal pain fatigue, loss of appetite, and tinnitus 
  ",mefloquine
sign_symptom,extrasystoles,0.99986297," among subjects who received mefloquine for prophylaxis of malaria, following side effects was observed: 
 
 the most frequently observed sied-effects were vomiting, dizziness, syncope, extrasystoles and other complaints affecting less than 1%. among subjects who received mefloquine for treatment, following side-effects was observed: 
 the most frequently observed side-effects included : dizziness, myalgia, nausea, fever, headache, vomiting, chills, diarrhoea, skin rash, abdominal pain fatigue, loss of appetite, and tinnitus 
  ",mefloquine
sign_symptom,complaints,0.94637954," among subjects who received mefloquine for prophylaxis of malaria, following side effects was observed: 
 
 the most frequently observed sied-effects were vomiting, dizziness, syncope, extrasystoles and other complaints affecting less than 1%. among subjects who received mefloquine for treatment, following side-effects was observed: 
 the most frequently observed side-effects included : dizziness, myalgia, nausea, fever, headache, vomiting, chills, diarrhoea, skin rash, abdominal pain fatigue, loss of appetite, and tinnitus 
  ",mefloquine
sign_symptom,side,0.98416823," among subjects who received mefloquine for prophylaxis of malaria, following side effects was observed: 
 
 the most frequently observed sied-effects were vomiting, dizziness, syncope, extrasystoles and other complaints affecting less than 1%. among subjects who received mefloquine for treatment, following side-effects was observed: 
 the most frequently observed side-effects included : dizziness, myalgia, nausea, fever, headache, vomiting, chills, diarrhoea, skin rash, abdominal pain fatigue, loss of appetite, and tinnitus 
  ",mefloquine
sign_symptom,chill,0.7673121," among subjects who received mefloquine for prophylaxis of malaria, following side effects was observed: 
 
 the most frequently observed sied-effects were vomiting, dizziness, syncope, extrasystoles and other complaints affecting less than 1%. among subjects who received mefloquine for treatment, following side-effects was observed: 
 the most frequently observed side-effects included : dizziness, myalgia, nausea, fever, headache, vomiting, chills, diarrhoea, skin rash, abdominal pain fatigue, loss of appetite, and tinnitus 
  ",mefloquine
sign_symptom,pain,0.99994254," among subjects who received mefloquine for prophylaxis of malaria, following side effects was observed: 
 
 the most frequently observed sied-effects were vomiting, dizziness, syncope, extrasystoles and other complaints affecting less than 1%. among subjects who received mefloquine for treatment, following side-effects was observed: 
 the most frequently observed side-effects included : dizziness, myalgia, nausea, fever, headache, vomiting, chills, diarrhoea, skin rash, abdominal pain fatigue, loss of appetite, and tinnitus 
  ",mefloquine
sign_symptom,loss of appetite,0.9999051," among subjects who received mefloquine for prophylaxis of malaria, following side effects was observed: 
 
 the most frequently observed sied-effects were vomiting, dizziness, syncope, extrasystoles and other complaints affecting less than 1%. among subjects who received mefloquine for treatment, following side-effects was observed: 
 the most frequently observed side-effects included : dizziness, myalgia, nausea, fever, headache, vomiting, chills, diarrhoea, skin rash, abdominal pain fatigue, loss of appetite, and tinnitus 
  ",mefloquine
sign_symptom,adverse experiences,0.8649311," the most frequently reported adverse experiences occurring in approximately 1-10% of patients are gastrointestinal: abdominal pain, constipation, diarrhoea, dyspepsia, flatulence, nausea, gl ulcers, vomiting, dizziness, abnormal renal function, pruritus, rashes. ",mefenamic acid
sign_symptom,constipation,0.97873497," the most frequently reported adverse experiences occurring in approximately 1-10% of patients are gastrointestinal: abdominal pain, constipation, diarrhoea, dyspepsia, flatulence, nausea, gl ulcers, vomiting, dizziness, abnormal renal function, pruritus, rashes. ",mefenamic acid
sign_symptom,diarrhoea,0.99580324," the most frequently reported adverse experiences occurring in approximately 1-10% of patients are gastrointestinal: abdominal pain, constipation, diarrhoea, dyspepsia, flatulence, nausea, gl ulcers, vomiting, dizziness, abnormal renal function, pruritus, rashes. ",mefenamic acid
sign_symptom,dyspepsia,0.992198," the most frequently reported adverse experiences occurring in approximately 1-10% of patients are gastrointestinal: abdominal pain, constipation, diarrhoea, dyspepsia, flatulence, nausea, gl ulcers, vomiting, dizziness, abnormal renal function, pruritus, rashes. ",mefenamic acid
sign_symptom,flat,0.99841714," the most frequently reported adverse experiences occurring in approximately 1-10% of patients are gastrointestinal: abdominal pain, constipation, diarrhoea, dyspepsia, flatulence, nausea, gl ulcers, vomiting, dizziness, abnormal renal function, pruritus, rashes. ",mefenamic acid
sign_symptom,rash,0.7720004," the most frequently reported adverse experiences occurring in approximately 1-10% of patients are gastrointestinal: abdominal pain, constipation, diarrhoea, dyspepsia, flatulence, nausea, gl ulcers, vomiting, dizziness, abnormal renal function, pruritus, rashes. ",mefenamic acid
sign_symptom,adverse reactions,0.9997723," the following adverse reactions have been reported in women taking medroxyprogesterone acetate tablets, without concomitant estrogens treatment: 
 
  genitourinary system : abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 
  breasts : breast tenderness, mastodynia or galactorrhea has been reported. 
  cardiovascular : thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 
  gastrointestinal : nausea, cholestatic jaundice. 
  skin : sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. acne, alopecia and hirsutism have been reported. 
  eyes : neuro-ocular lesions, for example, retinal thrombosis, and optic neuritis. 
  central nervous system : mental depression, insomnia, somnolence, dizziness, headache, nervousness. 
  ",medroxyprogesterone acetate (tablet)
medication,medroxyprogesterone,0.9182242," the following adverse reactions have been reported in women taking medroxyprogesterone acetate tablets, without concomitant estrogens treatment: 
 
  genitourinary system : abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 
  breasts : breast tenderness, mastodynia or galactorrhea has been reported. 
  cardiovascular : thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 
  gastrointestinal : nausea, cholestatic jaundice. 
  skin : sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. acne, alopecia and hirsutism have been reported. 
  eyes : neuro-ocular lesions, for example, retinal thrombosis, and optic neuritis. 
  central nervous system : mental depression, insomnia, somnolence, dizziness, headache, nervousness. 
  ",medroxyprogesterone acetate (tablet)
sign_symptom,bleeding,0.9994696," the following adverse reactions have been reported in women taking medroxyprogesterone acetate tablets, without concomitant estrogens treatment: 
 
  genitourinary system : abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 
  breasts : breast tenderness, mastodynia or galactorrhea has been reported. 
  cardiovascular : thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 
  gastrointestinal : nausea, cholestatic jaundice. 
  skin : sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. acne, alopecia and hirsutism have been reported. 
  eyes : neuro-ocular lesions, for example, retinal thrombosis, and optic neuritis. 
  central nervous system : mental depression, insomnia, somnolence, dizziness, headache, nervousness. 
  ",medroxyprogesterone acetate (tablet)
sign_symptom,tenderness,0.9889311," the following adverse reactions have been reported in women taking medroxyprogesterone acetate tablets, without concomitant estrogens treatment: 
 
  genitourinary system : abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 
  breasts : breast tenderness, mastodynia or galactorrhea has been reported. 
  cardiovascular : thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 
  gastrointestinal : nausea, cholestatic jaundice. 
  skin : sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. acne, alopecia and hirsutism have been reported. 
  eyes : neuro-ocular lesions, for example, retinal thrombosis, and optic neuritis. 
  central nervous system : mental depression, insomnia, somnolence, dizziness, headache, nervousness. 
  ",medroxyprogesterone acetate (tablet)
disease_disorder,mastodynia,0.9463657," the following adverse reactions have been reported in women taking medroxyprogesterone acetate tablets, without concomitant estrogens treatment: 
 
  genitourinary system : abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 
  breasts : breast tenderness, mastodynia or galactorrhea has been reported. 
  cardiovascular : thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 
  gastrointestinal : nausea, cholestatic jaundice. 
  skin : sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. acne, alopecia and hirsutism have been reported. 
  eyes : neuro-ocular lesions, for example, retinal thrombosis, and optic neuritis. 
  central nervous system : mental depression, insomnia, somnolence, dizziness, headache, nervousness. 
  ",medroxyprogesterone acetate (tablet)
sign_symptom,gala,0.8343456," the following adverse reactions have been reported in women taking medroxyprogesterone acetate tablets, without concomitant estrogens treatment: 
 
  genitourinary system : abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 
  breasts : breast tenderness, mastodynia or galactorrhea has been reported. 
  cardiovascular : thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 
  gastrointestinal : nausea, cholestatic jaundice. 
  skin : sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. acne, alopecia and hirsutism have been reported. 
  eyes : neuro-ocular lesions, for example, retinal thrombosis, and optic neuritis. 
  central nervous system : mental depression, insomnia, somnolence, dizziness, headache, nervousness. 
  ",medroxyprogesterone acetate (tablet)
disease_disorder,pulmonary embolism,0.98370856," the following adverse reactions have been reported in women taking medroxyprogesterone acetate tablets, without concomitant estrogens treatment: 
 
  genitourinary system : abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 
  breasts : breast tenderness, mastodynia or galactorrhea has been reported. 
  cardiovascular : thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 
  gastrointestinal : nausea, cholestatic jaundice. 
  skin : sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. acne, alopecia and hirsutism have been reported. 
  eyes : neuro-ocular lesions, for example, retinal thrombosis, and optic neuritis. 
  central nervous system : mental depression, insomnia, somnolence, dizziness, headache, nervousness. 
  ",medroxyprogesterone acetate (tablet)
sign_symptom,pruri,0.82818127," the following adverse reactions have been reported in women taking medroxyprogesterone acetate tablets, without concomitant estrogens treatment: 
 
  genitourinary system : abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 
  breasts : breast tenderness, mastodynia or galactorrhea has been reported. 
  cardiovascular : thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 
  gastrointestinal : nausea, cholestatic jaundice. 
  skin : sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. acne, alopecia and hirsutism have been reported. 
  eyes : neuro-ocular lesions, for example, retinal thrombosis, and optic neuritis. 
  central nervous system : mental depression, insomnia, somnolence, dizziness, headache, nervousness. 
  ",medroxyprogesterone acetate (tablet)
sign_symptom,edema,0.8691374," the following adverse reactions have been reported in women taking medroxyprogesterone acetate tablets, without concomitant estrogens treatment: 
 
  genitourinary system : abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 
  breasts : breast tenderness, mastodynia or galactorrhea has been reported. 
  cardiovascular : thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 
  gastrointestinal : nausea, cholestatic jaundice. 
  skin : sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. acne, alopecia and hirsutism have been reported. 
  eyes : neuro-ocular lesions, for example, retinal thrombosis, and optic neuritis. 
  central nervous system : mental depression, insomnia, somnolence, dizziness, headache, nervousness. 
  ",medroxyprogesterone acetate (tablet)
sign_symptom,rash,0.99995375," the following adverse reactions have been reported in women taking medroxyprogesterone acetate tablets, without concomitant estrogens treatment: 
 
  genitourinary system : abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 
  breasts : breast tenderness, mastodynia or galactorrhea has been reported. 
  cardiovascular : thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 
  gastrointestinal : nausea, cholestatic jaundice. 
  skin : sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. acne, alopecia and hirsutism have been reported. 
  eyes : neuro-ocular lesions, for example, retinal thrombosis, and optic neuritis. 
  central nervous system : mental depression, insomnia, somnolence, dizziness, headache, nervousness. 
  ",medroxyprogesterone acetate (tablet)
sign_symptom,hirsutism,0.92373693," the following adverse reactions have been reported in women taking medroxyprogesterone acetate tablets, without concomitant estrogens treatment: 
 
  genitourinary system : abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 
  breasts : breast tenderness, mastodynia or galactorrhea has been reported. 
  cardiovascular : thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 
  gastrointestinal : nausea, cholestatic jaundice. 
  skin : sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. acne, alopecia and hirsutism have been reported. 
  eyes : neuro-ocular lesions, for example, retinal thrombosis, and optic neuritis. 
  central nervous system : mental depression, insomnia, somnolence, dizziness, headache, nervousness. 
  ",medroxyprogesterone acetate (tablet)
sign_symptom,heaviness,0.9284993,"  
 weight gain, feeling heaviness and pain in the abdomen, feeling pain, anxiety 
 amenorrhea 
 spotting 
 excessive bleeding 
 infection in the injected site 
 headache, blurring of vision 
 pain in the back of the leg 
 delay in pregnancy after withdrawing injectable contraceptive. 
  ",medroxyprogesterone acetate (injection)
sign_symptom,pain,0.9999496,"  
 weight gain, feeling heaviness and pain in the abdomen, feeling pain, anxiety 
 amenorrhea 
 spotting 
 excessive bleeding 
 infection in the injected site 
 headache, blurring of vision 
 pain in the back of the leg 
 delay in pregnancy after withdrawing injectable contraceptive. 
  ",medroxyprogesterone acetate (injection)
sign_symptom,anxiety,0.99987614,"  
 weight gain, feeling heaviness and pain in the abdomen, feeling pain, anxiety 
 amenorrhea 
 spotting 
 excessive bleeding 
 infection in the injected site 
 headache, blurring of vision 
 pain in the back of the leg 
 delay in pregnancy after withdrawing injectable contraceptive. 
  ",medroxyprogesterone acetate (injection)
sign_symptom,amenorrhea,0.99448895,"  
 weight gain, feeling heaviness and pain in the abdomen, feeling pain, anxiety 
 amenorrhea 
 spotting 
 excessive bleeding 
 infection in the injected site 
 headache, blurring of vision 
 pain in the back of the leg 
 delay in pregnancy after withdrawing injectable contraceptive. 
  ",medroxyprogesterone acetate (injection)
disease_disorder,infection,0.99933594,"  
 weight gain, feeling heaviness and pain in the abdomen, feeling pain, anxiety 
 amenorrhea 
 spotting 
 excessive bleeding 
 infection in the injected site 
 headache, blurring of vision 
 pain in the back of the leg 
 delay in pregnancy after withdrawing injectable contraceptive. 
  ",medroxyprogesterone acetate (injection)
sign_symptom,blur,0.9994266,"  
 weight gain, feeling heaviness and pain in the abdomen, feeling pain, anxiety 
 amenorrhea 
 spotting 
 excessive bleeding 
 infection in the injected site 
 headache, blurring of vision 
 pain in the back of the leg 
 delay in pregnancy after withdrawing injectable contraceptive. 
  ",medroxyprogesterone acetate (injection)
sign_symptom,discomfort,0.9999082," generally mecobalamin is well tolerated. however, a few side effects like gi discomfort (including anorexia, nausea or diarrhea) &amp; rash may be seen after administration of mecobalamin. ",mecobalamin
sign_symptom,nausea,0.9998393," generally mecobalamin is well tolerated. however, a few side effects like gi discomfort (including anorexia, nausea or diarrhea) &amp; rash may be seen after administration of mecobalamin. ",mecobalamin
sign_symptom,rash,0.99995446," generally mecobalamin is well tolerated. however, a few side effects like gi discomfort (including anorexia, nausea or diarrhea) &amp; rash may be seen after administration of mecobalamin. ",mecobalamin
sign_symptom,blurred vision,0.99988335," common side effects are drowsiness, dry mouth, and on rare occasions, blurred vision have been reported. ",meclizine hydrochloride
sign_symptom,dry mouth,0.99952114," drowsiness, dry mouth and, on rare occasions, blurred vision have been reported. ",meclizine + pyridoxine
sign_symptom,blurred vision,0.9998992," drowsiness, dry mouth and, on rare occasions, blurred vision have been reported. ",meclizine + pyridoxine
sign_symptom,constipation,0.84124047," lassitude, dizziness, hypotension, muscular weakness, nausea, vomiting, diarrhoea or constipation, epigastric pain, headache, blurred vision, tinnitus, depression, nightmares, anorexia, dryness of the mouth, tightness of the chest, tingling, sedation, drowsiness etc. may occur. ",mebhydrolin napadisylate
sign_symptom,dryness,0.9876437," lassitude, dizziness, hypotension, muscular weakness, nausea, vomiting, diarrhoea or constipation, epigastric pain, headache, blurred vision, tinnitus, depression, nightmares, anorexia, dryness of the mouth, tightness of the chest, tingling, sedation, drowsiness etc. may occur. ",mebhydrolin napadisylate
sign_symptom,tightness,0.9959186," lassitude, dizziness, hypotension, muscular weakness, nausea, vomiting, diarrhoea or constipation, epigastric pain, headache, blurred vision, tinnitus, depression, nightmares, anorexia, dryness of the mouth, tightness of the chest, tingling, sedation, drowsiness etc. may occur. ",mebhydrolin napadisylate
sign_symptom,gout,0.92723477," chest pain, palpitation, necrotising angiitis, orthostatic hypotension, syncope, venous thrombosis, vertigo, volume depletion; depression, dizziness, chills, drowsiness, fatigue, restlessness, headache, lightheadedness; petechiae, photosensitivity, hypersensitivity reactions; gout attacks, electrolyte disturbances; abdominal bloating, diarrhoea, abdominal pain, anorexia, constipation, epigastric distress, nausea, xerostomia, pancreatitis, vomiting; impotence; aplastic anaemia, thrombocytopenia, haemoconcentration, leukopenia; cholestatic jaundice, hepatitis; joint pain, muscle cramps, weakness, neuropathy, paraesthesia; blurred vision; increased bun, glucosuria. ",metolazone
sign_symptom,electrolyte,0.8463087," chest pain, palpitation, necrotising angiitis, orthostatic hypotension, syncope, venous thrombosis, vertigo, volume depletion; depression, dizziness, chills, drowsiness, fatigue, restlessness, headache, lightheadedness; petechiae, photosensitivity, hypersensitivity reactions; gout attacks, electrolyte disturbances; abdominal bloating, diarrhoea, abdominal pain, anorexia, constipation, epigastric distress, nausea, xerostomia, pancreatitis, vomiting; impotence; aplastic anaemia, thrombocytopenia, haemoconcentration, leukopenia; cholestatic jaundice, hepatitis; joint pain, muscle cramps, weakness, neuropathy, paraesthesia; blurred vision; increased bun, glucosuria. ",metolazone
sign_symptom,adverse reactions,0.9835013," most common adverse reactions (5%) are: dysgeusia, headache, and fatigue. ",metoclopramide hydrochloride
disease_disorder,failure,0.8757145," fluid and electrolyte disturbances: sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, hypokalemic alkalosis, hypertension.   musculoskeletal : muscle weakness, steroid myopathy, loss of muscle mass, severe arthralgia, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, osteoporosis.   gastrointestinal : peptic ulcer with possible perforation and hemorrhage, pancreatitis, abdominal distention, and ulcerative esophagitis.   dermatologic : impaired wound healing, thin fragile skin, petechiae and ecchymoses, facial erythema, increased sweating, may suppress reactions to skin tests.   neurological : increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment, convulsions, vertigo, headache.   endocrine : development of cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, menstrual irregularities, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic agents in diabetics.   ophthalmic : posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos.   others : negative nitrogen balance due to protein catabolism.  the following additional adverse reactions are related to parenteral corticosteroid therapy: hyperpigmentation or hypopigmentation, subcutaneous and cutaneous atrophy, sterile abscess, anaphylactic reaction with or without circulatory collapse, cardiac arrest, bronchospasm, urticaria, nausea and vomiting, cardiac arrhythmias; hypotension or hypertension. ",methylprednisolone sodium succcinate
sign_symptom,path,0.92944455," fluid and electrolyte disturbances: sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, hypokalemic alkalosis, hypertension.   musculoskeletal : muscle weakness, steroid myopathy, loss of muscle mass, severe arthralgia, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, osteoporosis.   gastrointestinal : peptic ulcer with possible perforation and hemorrhage, pancreatitis, abdominal distention, and ulcerative esophagitis.   dermatologic : impaired wound healing, thin fragile skin, petechiae and ecchymoses, facial erythema, increased sweating, may suppress reactions to skin tests.   neurological : increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment, convulsions, vertigo, headache.   endocrine : development of cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, menstrual irregularities, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic agents in diabetics.   ophthalmic : posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos.   others : negative nitrogen balance due to protein catabolism.  the following additional adverse reactions are related to parenteral corticosteroid therapy: hyperpigmentation or hypopigmentation, subcutaneous and cutaneous atrophy, sterile abscess, anaphylactic reaction with or without circulatory collapse, cardiac arrest, bronchospasm, urticaria, nausea and vomiting, cardiac arrhythmias; hypotension or hypertension. ",methylprednisolone sodium succcinate
sign_symptom,ulcer,0.79615575," fluid and electrolyte disturbances: sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, hypokalemic alkalosis, hypertension.   musculoskeletal : muscle weakness, steroid myopathy, loss of muscle mass, severe arthralgia, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, osteoporosis.   gastrointestinal : peptic ulcer with possible perforation and hemorrhage, pancreatitis, abdominal distention, and ulcerative esophagitis.   dermatologic : impaired wound healing, thin fragile skin, petechiae and ecchymoses, facial erythema, increased sweating, may suppress reactions to skin tests.   neurological : increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment, convulsions, vertigo, headache.   endocrine : development of cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, menstrual irregularities, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic agents in diabetics.   ophthalmic : posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos.   others : negative nitrogen balance due to protein catabolism.  the following additional adverse reactions are related to parenteral corticosteroid therapy: hyperpigmentation or hypopigmentation, subcutaneous and cutaneous atrophy, sterile abscess, anaphylactic reaction with or without circulatory collapse, cardiac arrest, bronchospasm, urticaria, nausea and vomiting, cardiac arrhythmias; hypotension or hypertension. ",methylprednisolone sodium succcinate
medication,insulin,0.98803586," fluid and electrolyte disturbances: sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, hypokalemic alkalosis, hypertension.   musculoskeletal : muscle weakness, steroid myopathy, loss of muscle mass, severe arthralgia, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, osteoporosis.   gastrointestinal : peptic ulcer with possible perforation and hemorrhage, pancreatitis, abdominal distention, and ulcerative esophagitis.   dermatologic : impaired wound healing, thin fragile skin, petechiae and ecchymoses, facial erythema, increased sweating, may suppress reactions to skin tests.   neurological : increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment, convulsions, vertigo, headache.   endocrine : development of cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, menstrual irregularities, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic agents in diabetics.   ophthalmic : posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos.   others : negative nitrogen balance due to protein catabolism.  the following additional adverse reactions are related to parenteral corticosteroid therapy: hyperpigmentation or hypopigmentation, subcutaneous and cutaneous atrophy, sterile abscess, anaphylactic reaction with or without circulatory collapse, cardiac arrest, bronchospasm, urticaria, nausea and vomiting, cardiac arrhythmias; hypotension or hypertension. ",methylprednisolone sodium succcinate
sign_symptom,adverse,0.9990313," fluid and electrolyte disturbances: sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, hypokalemic alkalosis, hypertension.   musculoskeletal : muscle weakness, steroid myopathy, loss of muscle mass, severe arthralgia, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, osteoporosis.   gastrointestinal : peptic ulcer with possible perforation and hemorrhage, pancreatitis, abdominal distention, and ulcerative esophagitis.   dermatologic : impaired wound healing, thin fragile skin, petechiae and ecchymoses, facial erythema, increased sweating, may suppress reactions to skin tests.   neurological : increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment, convulsions, vertigo, headache.   endocrine : development of cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, menstrual irregularities, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic agents in diabetics.   ophthalmic : posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos.   others : negative nitrogen balance due to protein catabolism.  the following additional adverse reactions are related to parenteral corticosteroid therapy: hyperpigmentation or hypopigmentation, subcutaneous and cutaneous atrophy, sterile abscess, anaphylactic reaction with or without circulatory collapse, cardiac arrest, bronchospasm, urticaria, nausea and vomiting, cardiac arrhythmias; hypotension or hypertension. ",methylprednisolone sodium succcinate
sign_symptom,hyper,0.99935013," fluid and electrolyte disturbances: sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, hypokalemic alkalosis, hypertension.   musculoskeletal : muscle weakness, steroid myopathy, loss of muscle mass, severe arthralgia, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, osteoporosis.   gastrointestinal : peptic ulcer with possible perforation and hemorrhage, pancreatitis, abdominal distention, and ulcerative esophagitis.   dermatologic : impaired wound healing, thin fragile skin, petechiae and ecchymoses, facial erythema, increased sweating, may suppress reactions to skin tests.   neurological : increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment, convulsions, vertigo, headache.   endocrine : development of cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, menstrual irregularities, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic agents in diabetics.   ophthalmic : posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos.   others : negative nitrogen balance due to protein catabolism.  the following additional adverse reactions are related to parenteral corticosteroid therapy: hyperpigmentation or hypopigmentation, subcutaneous and cutaneous atrophy, sterile abscess, anaphylactic reaction with or without circulatory collapse, cardiac arrest, bronchospasm, urticaria, nausea and vomiting, cardiac arrhythmias; hypotension or hypertension. ",methylprednisolone sodium succcinate
sign_symptom,nausea,0.9579283," fluid and electrolyte disturbances: sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, hypokalemic alkalosis, hypertension.   musculoskeletal : muscle weakness, steroid myopathy, loss of muscle mass, severe arthralgia, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, osteoporosis.   gastrointestinal : peptic ulcer with possible perforation and hemorrhage, pancreatitis, abdominal distention, and ulcerative esophagitis.   dermatologic : impaired wound healing, thin fragile skin, petechiae and ecchymoses, facial erythema, increased sweating, may suppress reactions to skin tests.   neurological : increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment, convulsions, vertigo, headache.   endocrine : development of cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, menstrual irregularities, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic agents in diabetics.   ophthalmic : posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos.   others : negative nitrogen balance due to protein catabolism.  the following additional adverse reactions are related to parenteral corticosteroid therapy: hyperpigmentation or hypopigmentation, subcutaneous and cutaneous atrophy, sterile abscess, anaphylactic reaction with or without circulatory collapse, cardiac arrest, bronchospasm, urticaria, nausea and vomiting, cardiac arrhythmias; hypotension or hypertension. ",methylprednisolone sodium succcinate
disease_disorder,heart failure,0.9995347," congestive heart failure in susceptible patients, hypertension, sodium retention, muscle weakness, osteoporosis, peptic ulcer with possible subsequent and hemorrhage, abdominal distention, increased sweating, convulsion, vertigo, headache, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness, increased intraocular pressure, glaucoma, allergic or hypersensitivity reactions, urticaria, hyperpigmentation or hypopigmentation. ",methylprednisolone acetate
disease_disorder,peptic ulcer,0.91459966," congestive heart failure in susceptible patients, hypertension, sodium retention, muscle weakness, osteoporosis, peptic ulcer with possible subsequent and hemorrhage, abdominal distention, increased sweating, convulsion, vertigo, headache, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness, increased intraocular pressure, glaucoma, allergic or hypersensitivity reactions, urticaria, hyperpigmentation or hypopigmentation. ",methylprednisolone acetate
sign_symptom,hyper,0.99975234," congestive heart failure in susceptible patients, hypertension, sodium retention, muscle weakness, osteoporosis, peptic ulcer with possible subsequent and hemorrhage, abdominal distention, increased sweating, convulsion, vertigo, headache, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness, increased intraocular pressure, glaucoma, allergic or hypersensitivity reactions, urticaria, hyperpigmentation or hypopigmentation. ",methylprednisolone acetate
medication,methylprednisolone,0.90541214," short courses of methylprednisolone are usually well-tolerated with few, mild side effects. long term, high doses of methyiprednisoione may produce predictable and potentially serious side effects. whenever possible, the lowest effective doses of methylprednisolone should be used for the shortest length of time to minimize side effects. alternate day dosing also can help reduce side effects. side effects of methylprednisolone and other corticosteroids range from mild annoyances to serious irreversible bodily damage. side effects include fluid retention, weight gain, high blood pressure, potassium loss, headache, muscle weakness, hair growth on the face, glaucoma, cataracts, peptic ulceration, growth retardation in children, convulsions, and psychic disturbances including depression, euphoria, insomnia etc. prolonged use of methylprednisolone can depress the ability of the body's adrenal glands to produce corticosteroids. abruptly stopping methylprednisolone in these individuals can cause symptoms of corticosteroid insufficiency, with accompanying nausea, vomiting, and even shock. therefore, withdrawal of methylprednisolone usually is accomplished by gradually lowering the dose. gradually tapering methylprednisolone not only minimizes the symptoms of corticosteroid insufficiency, it also reduces the risk of an abrupt flare of the disease being treated. ",methylprednisolone
medication,methylprednisolo,0.8208027," short courses of methylprednisolone are usually well-tolerated with few, mild side effects. long term, high doses of methyiprednisoione may produce predictable and potentially serious side effects. whenever possible, the lowest effective doses of methylprednisolone should be used for the shortest length of time to minimize side effects. alternate day dosing also can help reduce side effects. side effects of methylprednisolone and other corticosteroids range from mild annoyances to serious irreversible bodily damage. side effects include fluid retention, weight gain, high blood pressure, potassium loss, headache, muscle weakness, hair growth on the face, glaucoma, cataracts, peptic ulceration, growth retardation in children, convulsions, and psychic disturbances including depression, euphoria, insomnia etc. prolonged use of methylprednisolone can depress the ability of the body's adrenal glands to produce corticosteroids. abruptly stopping methylprednisolone in these individuals can cause symptoms of corticosteroid insufficiency, with accompanying nausea, vomiting, and even shock. therefore, withdrawal of methylprednisolone usually is accomplished by gradually lowering the dose. gradually tapering methylprednisolone not only minimizes the symptoms of corticosteroid insufficiency, it also reduces the risk of an abrupt flare of the disease being treated. ",methylprednisolone
medication,corticosteroids,0.8646971," short courses of methylprednisolone are usually well-tolerated with few, mild side effects. long term, high doses of methyiprednisoione may produce predictable and potentially serious side effects. whenever possible, the lowest effective doses of methylprednisolone should be used for the shortest length of time to minimize side effects. alternate day dosing also can help reduce side effects. side effects of methylprednisolone and other corticosteroids range from mild annoyances to serious irreversible bodily damage. side effects include fluid retention, weight gain, high blood pressure, potassium loss, headache, muscle weakness, hair growth on the face, glaucoma, cataracts, peptic ulceration, growth retardation in children, convulsions, and psychic disturbances including depression, euphoria, insomnia etc. prolonged use of methylprednisolone can depress the ability of the body's adrenal glands to produce corticosteroids. abruptly stopping methylprednisolone in these individuals can cause symptoms of corticosteroid insufficiency, with accompanying nausea, vomiting, and even shock. therefore, withdrawal of methylprednisolone usually is accomplished by gradually lowering the dose. gradually tapering methylprednisolone not only minimizes the symptoms of corticosteroid insufficiency, it also reduces the risk of an abrupt flare of the disease being treated. ",methylprednisolone
sign_symptom,growth,0.8174178," short courses of methylprednisolone are usually well-tolerated with few, mild side effects. long term, high doses of methyiprednisoione may produce predictable and potentially serious side effects. whenever possible, the lowest effective doses of methylprednisolone should be used for the shortest length of time to minimize side effects. alternate day dosing also can help reduce side effects. side effects of methylprednisolone and other corticosteroids range from mild annoyances to serious irreversible bodily damage. side effects include fluid retention, weight gain, high blood pressure, potassium loss, headache, muscle weakness, hair growth on the face, glaucoma, cataracts, peptic ulceration, growth retardation in children, convulsions, and psychic disturbances including depression, euphoria, insomnia etc. prolonged use of methylprednisolone can depress the ability of the body's adrenal glands to produce corticosteroids. abruptly stopping methylprednisolone in these individuals can cause symptoms of corticosteroid insufficiency, with accompanying nausea, vomiting, and even shock. therefore, withdrawal of methylprednisolone usually is accomplished by gradually lowering the dose. gradually tapering methylprednisolone not only minimizes the symptoms of corticosteroid insufficiency, it also reduces the risk of an abrupt flare of the disease being treated. ",methylprednisolone
sign_symptom,growth re,0.95387435," short courses of methylprednisolone are usually well-tolerated with few, mild side effects. long term, high doses of methyiprednisoione may produce predictable and potentially serious side effects. whenever possible, the lowest effective doses of methylprednisolone should be used for the shortest length of time to minimize side effects. alternate day dosing also can help reduce side effects. side effects of methylprednisolone and other corticosteroids range from mild annoyances to serious irreversible bodily damage. side effects include fluid retention, weight gain, high blood pressure, potassium loss, headache, muscle weakness, hair growth on the face, glaucoma, cataracts, peptic ulceration, growth retardation in children, convulsions, and psychic disturbances including depression, euphoria, insomnia etc. prolonged use of methylprednisolone can depress the ability of the body's adrenal glands to produce corticosteroids. abruptly stopping methylprednisolone in these individuals can cause symptoms of corticosteroid insufficiency, with accompanying nausea, vomiting, and even shock. therefore, withdrawal of methylprednisolone usually is accomplished by gradually lowering the dose. gradually tapering methylprednisolone not only minimizes the symptoms of corticosteroid insufficiency, it also reduces the risk of an abrupt flare of the disease being treated. ",methylprednisolone
sign_symptom,disturbances,0.9317403," short courses of methylprednisolone are usually well-tolerated with few, mild side effects. long term, high doses of methyiprednisoione may produce predictable and potentially serious side effects. whenever possible, the lowest effective doses of methylprednisolone should be used for the shortest length of time to minimize side effects. alternate day dosing also can help reduce side effects. side effects of methylprednisolone and other corticosteroids range from mild annoyances to serious irreversible bodily damage. side effects include fluid retention, weight gain, high blood pressure, potassium loss, headache, muscle weakness, hair growth on the face, glaucoma, cataracts, peptic ulceration, growth retardation in children, convulsions, and psychic disturbances including depression, euphoria, insomnia etc. prolonged use of methylprednisolone can depress the ability of the body's adrenal glands to produce corticosteroids. abruptly stopping methylprednisolone in these individuals can cause symptoms of corticosteroid insufficiency, with accompanying nausea, vomiting, and even shock. therefore, withdrawal of methylprednisolone usually is accomplished by gradually lowering the dose. gradually tapering methylprednisolone not only minimizes the symptoms of corticosteroid insufficiency, it also reduces the risk of an abrupt flare of the disease being treated. ",methylprednisolone
medication,methylpred,0.91969496," short courses of methylprednisolone are usually well-tolerated with few, mild side effects. long term, high doses of methyiprednisoione may produce predictable and potentially serious side effects. whenever possible, the lowest effective doses of methylprednisolone should be used for the shortest length of time to minimize side effects. alternate day dosing also can help reduce side effects. side effects of methylprednisolone and other corticosteroids range from mild annoyances to serious irreversible bodily damage. side effects include fluid retention, weight gain, high blood pressure, potassium loss, headache, muscle weakness, hair growth on the face, glaucoma, cataracts, peptic ulceration, growth retardation in children, convulsions, and psychic disturbances including depression, euphoria, insomnia etc. prolonged use of methylprednisolone can depress the ability of the body's adrenal glands to produce corticosteroids. abruptly stopping methylprednisolone in these individuals can cause symptoms of corticosteroid insufficiency, with accompanying nausea, vomiting, and even shock. therefore, withdrawal of methylprednisolone usually is accomplished by gradually lowering the dose. gradually tapering methylprednisolone not only minimizes the symptoms of corticosteroid insufficiency, it also reduces the risk of an abrupt flare of the disease being treated. ",methylprednisolone
disease_disorder,urinary disorder,0.9151781," sleep disturbances, restlessness, dizziness, headache, tremor, convulsion, rash, pruritis; urticaria, fever, arthralgia, alopecia, exfoliative, dermatitis, erythema multiforme, thrombocytopenic purpuria, thrombocytopenia, leucopenia, urinary disorder and very rarely liver damage. ",methylphenidate hydrochloride
sign_symptom,hypertension,0.9832523," the most common adverse reaction is hypertension associated in several cases with seizure and/or headache. hypotension has also been reported. abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally. rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. there have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product. ",methylergonovine maleate
sign_symptom,seizure,0.99986327," the most common adverse reaction is hypertension associated in several cases with seizure and/or headache. hypotension has also been reported. abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally. rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. there have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product. ",methylergonovine maleate
sign_symptom,headache,0.9856915," the most common adverse reaction is hypertension associated in several cases with seizure and/or headache. hypotension has also been reported. abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally. rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. there have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product. ",methylergonovine maleate
sign_symptom,pain,0.9999546," the most common adverse reaction is hypertension associated in several cases with seizure and/or headache. hypotension has also been reported. abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally. rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. there have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product. ",methylergonovine maleate
sign_symptom,nausea,0.99993825," the most common adverse reaction is hypertension associated in several cases with seizure and/or headache. hypotension has also been reported. abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally. rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. there have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product. ",methylergonovine maleate
sign_symptom,vomiting,0.9999368," the most common adverse reaction is hypertension associated in several cases with seizure and/or headache. hypotension has also been reported. abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally. rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. there have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product. ",methylergonovine maleate
sign_symptom,hall,0.8460965," the most common adverse reaction is hypertension associated in several cases with seizure and/or headache. hypotension has also been reported. abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally. rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. there have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product. ",methylergonovine maleate
sign_symptom,weakness,0.9994491," sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. headache, asthenia, or weakness may be noted as early and transient symptoms. the following systemic side effects may rarely occur with the use of methyldopa- angina pectoris, congestive heart failure, orthostatic hypotension, edema or weight gain, bradycardia, pancreatitis, colitis, vomiting, diarrhea, nausea, constipation, dryness of mouth, hyperprolactinemia, bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; rheumatoid factor, hepatitis, jaundice, myocarditis, pericarditis, vasculitis, eosinophilia, parkinsonism, bell's palsy, nightmares and reversible mild psychoses or depression, dizziness, lightheadedness, paresthesias, arthralgia, myalgia, nasal stuffiness, rash, amenorrhea, gynecomastia, lactation, impotence. however, significant adverse effects due to methyldopa have been infrequent and this agent usually is well tolerated. ",methyldopa
medication,methyldopa,0.8223848," sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. headache, asthenia, or weakness may be noted as early and transient symptoms. the following systemic side effects may rarely occur with the use of methyldopa- angina pectoris, congestive heart failure, orthostatic hypotension, edema or weight gain, bradycardia, pancreatitis, colitis, vomiting, diarrhea, nausea, constipation, dryness of mouth, hyperprolactinemia, bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; rheumatoid factor, hepatitis, jaundice, myocarditis, pericarditis, vasculitis, eosinophilia, parkinsonism, bell's palsy, nightmares and reversible mild psychoses or depression, dizziness, lightheadedness, paresthesias, arthralgia, myalgia, nasal stuffiness, rash, amenorrhea, gynecomastia, lactation, impotence. however, significant adverse effects due to methyldopa have been infrequent and this agent usually is well tolerated. ",methyldopa
sign_symptom,psycho,0.9800678," sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. headache, asthenia, or weakness may be noted as early and transient symptoms. the following systemic side effects may rarely occur with the use of methyldopa- angina pectoris, congestive heart failure, orthostatic hypotension, edema or weight gain, bradycardia, pancreatitis, colitis, vomiting, diarrhea, nausea, constipation, dryness of mouth, hyperprolactinemia, bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; rheumatoid factor, hepatitis, jaundice, myocarditis, pericarditis, vasculitis, eosinophilia, parkinsonism, bell's palsy, nightmares and reversible mild psychoses or depression, dizziness, lightheadedness, paresthesias, arthralgia, myalgia, nasal stuffiness, rash, amenorrhea, gynecomastia, lactation, impotence. however, significant adverse effects due to methyldopa have been infrequent and this agent usually is well tolerated. ",methyldopa
sign_symptom,adverse,0.99734145," sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. headache, asthenia, or weakness may be noted as early and transient symptoms. the following systemic side effects may rarely occur with the use of methyldopa- angina pectoris, congestive heart failure, orthostatic hypotension, edema or weight gain, bradycardia, pancreatitis, colitis, vomiting, diarrhea, nausea, constipation, dryness of mouth, hyperprolactinemia, bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; rheumatoid factor, hepatitis, jaundice, myocarditis, pericarditis, vasculitis, eosinophilia, parkinsonism, bell's palsy, nightmares and reversible mild psychoses or depression, dizziness, lightheadedness, paresthesias, arthralgia, myalgia, nasal stuffiness, rash, amenorrhea, gynecomastia, lactation, impotence. however, significant adverse effects due to methyldopa have been infrequent and this agent usually is well tolerated. ",methyldopa
sign_symptom,redness,0.99922264," redness or irritation may occur, especially in persons with sensitive skin. ",methyl salicylate + menthol + camphor
sign_symptom,irritation,0.9999064," redness or irritation may occur, especially in persons with sensitive skin. ",methyl salicylate + menthol + camphor
sign_symptom,redness,0.9992999," redness or irritation may occur, especially in persons with sensitive skin. adverse reactions possibly involved are mild to moderate local irritation, erythema, rash, desquamation, pruritis and relative local reaction at the application site. ",methyl salicylate + menthol
sign_symptom,irritation,0.99993515," redness or irritation may occur, especially in persons with sensitive skin. adverse reactions possibly involved are mild to moderate local irritation, erythema, rash, desquamation, pruritis and relative local reaction at the application site. ",methyl salicylate + menthol
sign_symptom,adverse reactions,0.9993948," redness or irritation may occur, especially in persons with sensitive skin. adverse reactions possibly involved are mild to moderate local irritation, erythema, rash, desquamation, pruritis and relative local reaction at the application site. ",methyl salicylate + menthol
disease_disorder,vascular access thrombosis,0.7694564," adverse reactions are hypertension, vascular access thrombosis, headache, hypersensitivity, hypertensive encephalopathy, rash (maculo-papular, serious). ",methoxy polyethylene glycol-epoetin beta
sign_symptom,hyper,0.7072013," adverse reactions are hypertension, vascular access thrombosis, headache, hypersensitivity, hypertensive encephalopathy, rash (maculo-papular, serious). ",methoxy polyethylene glycol-epoetin beta
sign_symptom,hypertensive,0.88172656," adverse reactions are hypertension, vascular access thrombosis, headache, hypersensitivity, hypertensive encephalopathy, rash (maculo-papular, serious). ",methoxy polyethylene glycol-epoetin beta
sign_symptom,rash,0.9998392," adverse reactions are hypertension, vascular access thrombosis, headache, hypersensitivity, hypertensive encephalopathy, rash (maculo-papular, serious). ",methoxy polyethylene glycol-epoetin beta
sign_symptom,disturbances,0.9317273," ulceration of the mouth and gi disturbances (e.g. stomatitis and diarrhoea), bone marrow depression, hepatotoxicity, renal failure, skin reactions, alopecia, ocular irritation, arachnoiditis in intrathecal use, megaloblastic anaemia, osteoporosis, precipitation of diabetes, arthralgias, necrosis of soft tissue and bone, anaphylaxis, impaired fertility. ",methotrexate
sign_symptom,arthralgia,0.86833215," ulceration of the mouth and gi disturbances (e.g. stomatitis and diarrhoea), bone marrow depression, hepatotoxicity, renal failure, skin reactions, alopecia, ocular irritation, arachnoiditis in intrathecal use, megaloblastic anaemia, osteoporosis, precipitation of diabetes, arthralgias, necrosis of soft tissue and bone, anaphylaxis, impaired fertility. ",methotrexate
sign_symptom,headache,0.99875426,"  body as a whole : anaphylactic reaction, angioneurotic edema, fever, headache   cardiovascular system : bradycardia, flushing, hypotension, syncope, thrombophlebitis   digestive system : dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting   hemic and lymphatic system : leukopenia   immune system : hypersensitivity reactions   nervous system : amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo   skin and special senses : blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria ",methocarbamol
sign_symptom,sync,0.99395835,"  body as a whole : anaphylactic reaction, angioneurotic edema, fever, headache   cardiovascular system : bradycardia, flushing, hypotension, syncope, thrombophlebitis   digestive system : dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting   hemic and lymphatic system : leukopenia   immune system : hypersensitivity reactions   nervous system : amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo   skin and special senses : blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria ",methocarbamol
sign_symptom,dyspeps,0.91121376,"  body as a whole : anaphylactic reaction, angioneurotic edema, fever, headache   cardiovascular system : bradycardia, flushing, hypotension, syncope, thrombophlebitis   digestive system : dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting   hemic and lymphatic system : leukopenia   immune system : hypersensitivity reactions   nervous system : amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo   skin and special senses : blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria ",methocarbamol
sign_symptom,nausea,0.999905,"  body as a whole : anaphylactic reaction, angioneurotic edema, fever, headache   cardiovascular system : bradycardia, flushing, hypotension, syncope, thrombophlebitis   digestive system : dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting   hemic and lymphatic system : leukopenia   immune system : hypersensitivity reactions   nervous system : amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo   skin and special senses : blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria ",methocarbamol
sign_symptom,vomiting,0.99988544,"  body as a whole : anaphylactic reaction, angioneurotic edema, fever, headache   cardiovascular system : bradycardia, flushing, hypotension, syncope, thrombophlebitis   digestive system : dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting   hemic and lymphatic system : leukopenia   immune system : hypersensitivity reactions   nervous system : amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo   skin and special senses : blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria ",methocarbamol
sign_symptom,hypersensitivity reactions,0.99859506,"  body as a whole : anaphylactic reaction, angioneurotic edema, fever, headache   cardiovascular system : bradycardia, flushing, hypotension, syncope, thrombophlebitis   digestive system : dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting   hemic and lymphatic system : leukopenia   immune system : hypersensitivity reactions   nervous system : amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo   skin and special senses : blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria ",methocarbamol
sign_symptom,lightheaded,0.9984669,"  body as a whole : anaphylactic reaction, angioneurotic edema, fever, headache   cardiovascular system : bradycardia, flushing, hypotension, syncope, thrombophlebitis   digestive system : dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting   hemic and lymphatic system : leukopenia   immune system : hypersensitivity reactions   nervous system : amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo   skin and special senses : blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria ",methocarbamol
sign_symptom,seizures,0.97812927,"  body as a whole : anaphylactic reaction, angioneurotic edema, fever, headache   cardiovascular system : bradycardia, flushing, hypotension, syncope, thrombophlebitis   digestive system : dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting   hemic and lymphatic system : leukopenia   immune system : hypersensitivity reactions   nervous system : amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo   skin and special senses : blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria ",methocarbamol
sign_symptom,vertigo,0.9990742,"  body as a whole : anaphylactic reaction, angioneurotic edema, fever, headache   cardiovascular system : bradycardia, flushing, hypotension, syncope, thrombophlebitis   digestive system : dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting   hemic and lymphatic system : leukopenia   immune system : hypersensitivity reactions   nervous system : amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo   skin and special senses : blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria ",methocarbamol
sign_symptom,blurred,0.83720434,"  body as a whole : anaphylactic reaction, angioneurotic edema, fever, headache   cardiovascular system : bradycardia, flushing, hypotension, syncope, thrombophlebitis   digestive system : dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting   hemic and lymphatic system : leukopenia   immune system : hypersensitivity reactions   nervous system : amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo   skin and special senses : blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria ",methocarbamol
sign_symptom,epigastric,0.9885291,"  common : skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.   rare : agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. nephritis occurs very rarely. ",methimazole
sign_symptom,arthral,0.99657184,"  common : skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.   rare : agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. nephritis occurs very rarely. ",methimazole
sign_symptom,loss of taste,0.99833804,"  common : skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.   rare : agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. nephritis occurs very rarely. ",methimazole
sign_symptom,loss of hair,0.9980354,"  common : skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.   rare : agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. nephritis occurs very rarely. ",methimazole
sign_symptom,myal,0.92447895,"  common : skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.   rare : agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. nephritis occurs very rarely. ",methimazole
sign_symptom,jaund,0.7795719,"  common : skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.   rare : agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. nephritis occurs very rarely. ",methimazole
sign_symptom,gran,0.94686794,"  common : skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.   rare : agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. nephritis occurs very rarely. ",methimazole
disease_disorder,lupus - like,0.800172,"  common : skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.   rare : agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. nephritis occurs very rarely. ",methimazole
disease_disorder,insulin,0.9549801,"  common : skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.   rare : agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. nephritis occurs very rarely. ",methimazole
disease_disorder,hepatitis,0.962055,"  common : skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.   rare : agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. nephritis occurs very rarely. ",methimazole
disease_disorder,blood and lymphatic system disorders,0.9039476,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
disease_disorder,metabolism,0.92971504,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
disease_disorder,nutrition disorders,0.9770355,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
disease_disorder,lactic acidosis,0.95659006,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
medication,vitamin b1,0.8286149,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
disease_disorder,nervous system disorder,0.9910113,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
disease_disorder,encephalopathy,0.9837079,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
medication,metformin,0.9544127,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
disease_disorder,hepatobiliary disorders,0.9401851,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
sign_symptom,abnormalities,0.92300487,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
disease_disorder,hepatitis,0.9998764,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
medication,metform,0.99734354,"  blood and lymphatic system disorders : not known: hemolytic anemia   metabolism and nutrition disorders : very rare: lactic acidosis. decrease of vitamin b12 absorption with a decrease of serum levels during long-term use of metformin. consideration of such etiology is recommended if a patient presents with megaloblastic anemia. cases of peripheral neuropathy in patients with vitamin b12 deficiency have been reported in post-marketing experience (frequency not known)   nervous system disorder s: common: taste disturbance. not known: encephalopathy   gastrointestinal disorders : very common: gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. these undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. to prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. a slow increase of the dose may also improve gastrointestinal tolerability.   hepatobiliary disorders : very rare: isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.   skin and subcutaneous tissue disorders : very rare: skin reactions, such as erythema, pruritus, urticaria. ",metformin hydrochloride
sign_symptom,adverse events,0.9839405,"  the commonly reported adverse events are headache, nausea, dizziness, asthenia, dyspepsia, vomiting, pruritus etc.  ",mesalazine [5-aminosalicylic acid]
sign_symptom,dyspepsia,0.9945496,"  the commonly reported adverse events are headache, nausea, dizziness, asthenia, dyspepsia, vomiting, pruritus etc.  ",mesalazine [5-aminosalicylic acid]
sign_symptom,vomiting,0.99806803,"  the commonly reported adverse events are headache, nausea, dizziness, asthenia, dyspepsia, vomiting, pruritus etc.  ",mesalazine [5-aminosalicylic acid]
sign_symptom,pain,0.9997216," meropenem is generally well tolerated. side effects like inflammation, thrombophlebitis, pain at the site of injection, skin reactions like rash, pruritus, urticaria, abdominal pain, nausea, vomiting, diarrhea, headache may occur. ",meropenem trihydrate
sign_symptom,headache,0.99907047," meropenem is generally well tolerated. side effects like inflammation, thrombophlebitis, pain at the site of injection, skin reactions like rash, pruritus, urticaria, abdominal pain, nausea, vomiting, diarrhea, headache may occur. ",meropenem trihydrate
disease_disorder,hemolytic uremic syndrome,0.9445639," hemolytic uremic syndrome (&lt;15%), myelosuppression (64%), nausea/ vomiting (14%), fever (14%), stomatitis (4%), increased serum creatinine (2%), mucous membrane toxicity (4%) , fatigue, pulmonary toxicity, dyspnea, cystitis, interstitial fibrosis, nephrotoxicity, amenorrhea, alopecia,myelosuppression, haemolytic-uraemic syndrome. ",mitomycin c
sign_symptom,myelosuppression,0.9607322," hemolytic uremic syndrome (&lt;15%), myelosuppression (64%), nausea/ vomiting (14%), fever (14%), stomatitis (4%), increased serum creatinine (2%), mucous membrane toxicity (4%) , fatigue, pulmonary toxicity, dyspnea, cystitis, interstitial fibrosis, nephrotoxicity, amenorrhea, alopecia,myelosuppression, haemolytic-uraemic syndrome. ",mitomycin c
sign_symptom,nausea / vomiting,0.9896609," hemolytic uremic syndrome (&lt;15%), myelosuppression (64%), nausea/ vomiting (14%), fever (14%), stomatitis (4%), increased serum creatinine (2%), mucous membrane toxicity (4%) , fatigue, pulmonary toxicity, dyspnea, cystitis, interstitial fibrosis, nephrotoxicity, amenorrhea, alopecia,myelosuppression, haemolytic-uraemic syndrome. ",mitomycin c
sign_symptom,fever,0.99995077," hemolytic uremic syndrome (&lt;15%), myelosuppression (64%), nausea/ vomiting (14%), fever (14%), stomatitis (4%), increased serum creatinine (2%), mucous membrane toxicity (4%) , fatigue, pulmonary toxicity, dyspnea, cystitis, interstitial fibrosis, nephrotoxicity, amenorrhea, alopecia,myelosuppression, haemolytic-uraemic syndrome. ",mitomycin c
disease_disorder,alope,0.79360896," hemolytic uremic syndrome (&lt;15%), myelosuppression (64%), nausea/ vomiting (14%), fever (14%), stomatitis (4%), increased serum creatinine (2%), mucous membrane toxicity (4%) , fatigue, pulmonary toxicity, dyspnea, cystitis, interstitial fibrosis, nephrotoxicity, amenorrhea, alopecia,myelosuppression, haemolytic-uraemic syndrome. ",mitomycin c
sign_symptom,dyspeps,0.9312242," generally, misoprostol is well tolerated. the most frequent adverse effects associated with misoprostol therapy involve the gi tract such as diarrhea, abdominal pain, dyspepsia, flatulence, nausea, vomiting, rashes and dizziness. the incidence of diarrhea may be minimized by administering the drug after meal and at bedtime and by avoiding concomitant administration with a magnesium-containing or other laxative antacid. ",misoprostol
sign_symptom,flat,0.96374786," generally, misoprostol is well tolerated. the most frequent adverse effects associated with misoprostol therapy involve the gi tract such as diarrhea, abdominal pain, dyspepsia, flatulence, nausea, vomiting, rashes and dizziness. the incidence of diarrhea may be minimized by administering the drug after meal and at bedtime and by avoiding concomitant administration with a magnesium-containing or other laxative antacid. ",misoprostol
sign_symptom,rash,0.93917304," generally, misoprostol is well tolerated. the most frequent adverse effects associated with misoprostol therapy involve the gi tract such as diarrhea, abdominal pain, dyspepsia, flatulence, nausea, vomiting, rashes and dizziness. the incidence of diarrhea may be minimized by administering the drug after meal and at bedtime and by avoiding concomitant administration with a magnesium-containing or other laxative antacid. ",misoprostol
medication,magnesium - containing,0.9348032," generally, misoprostol is well tolerated. the most frequent adverse effects associated with misoprostol therapy involve the gi tract such as diarrhea, abdominal pain, dyspepsia, flatulence, nausea, vomiting, rashes and dizziness. the incidence of diarrhea may be minimized by administering the drug after meal and at bedtime and by avoiding concomitant administration with a magnesium-containing or other laxative antacid. ",misoprostol
medication,mirtazapine,0.96813065," the most common side effects of mirtazapine are dizziness, drowsiness, dry mouth, increased appetite, weight gain etc. ",mirtazapine
sign_symptom,dry mouth,0.9914863," the most common side effects of mirtazapine are dizziness, drowsiness, dry mouth, increased appetite, weight gain etc. ",mirtazapine
sign_symptom,increased appetite,0.992529," the most common side effects of mirtazapine are dizziness, drowsiness, dry mouth, increased appetite, weight gain etc. ",mirtazapine
sign_symptom,weight gain,0.9998863," the most common side effects of mirtazapine are dizziness, drowsiness, dry mouth, increased appetite, weight gain etc. ",mirtazapine
medication,mirabegron,0.99242425," the most common side effects reported for patients treated with mirabegron 50 mg during the three 12-week phase 3 double blind, placebo controlled studies are tachycardia and urinary tract infections. the frequency of tachycardia was 1.2% in patients receiving mirabegron 50 mg. tachycardia led to discontinuation in 0.1% patients receiving mirabegron 50 mg. the frequency of urinary tract infections was 2.9% in patients receiving mirabegron 50 mg. urinary tract infections led to discontinuation in none of the patients receiving mirabegron 50 mg. serious adverse reactions included atrial fibrillation (0.2%). ",mirabegron
disease_disorder,infections,0.8751922," the most common side effects reported for patients treated with mirabegron 50 mg during the three 12-week phase 3 double blind, placebo controlled studies are tachycardia and urinary tract infections. the frequency of tachycardia was 1.2% in patients receiving mirabegron 50 mg. tachycardia led to discontinuation in 0.1% patients receiving mirabegron 50 mg. the frequency of urinary tract infections was 2.9% in patients receiving mirabegron 50 mg. urinary tract infections led to discontinuation in none of the patients receiving mirabegron 50 mg. serious adverse reactions included atrial fibrillation (0.2%). ",mirabegron
sign_symptom,reactions,0.9240773," the most common side effects reported for patients treated with mirabegron 50 mg during the three 12-week phase 3 double blind, placebo controlled studies are tachycardia and urinary tract infections. the frequency of tachycardia was 1.2% in patients receiving mirabegron 50 mg. tachycardia led to discontinuation in 0.1% patients receiving mirabegron 50 mg. the frequency of urinary tract infections was 2.9% in patients receiving mirabegron 50 mg. urinary tract infections led to discontinuation in none of the patients receiving mirabegron 50 mg. serious adverse reactions included atrial fibrillation (0.2%). ",mirabegron
sign_symptom,atrial fibrillation,0.95066196," the most common side effects reported for patients treated with mirabegron 50 mg during the three 12-week phase 3 double blind, placebo controlled studies are tachycardia and urinary tract infections. the frequency of tachycardia was 1.2% in patients receiving mirabegron 50 mg. tachycardia led to discontinuation in 0.1% patients receiving mirabegron 50 mg. the frequency of urinary tract infections was 2.9% in patients receiving mirabegron 50 mg. urinary tract infections led to discontinuation in none of the patients receiving mirabegron 50 mg. serious adverse reactions included atrial fibrillation (0.2%). ",mirabegron
disease_disorder,hypertrichosis,0.99355674, commonly encountered side effects in clinical trials with minoxidil topical solution were minor dermatological reactions. dermatitis or hypertrichosis may occur. these incidences may occur in 0.15% of patients. ,minoxidil
sign_symptom,hyper,0.9135338," reported side effects are oral and anogenital candidiasis, vulvovaginitis, eosinophilia, leucopenia, neutropenia, thrombocytopenia, haemolytic anaemia, pancytopenia, agranulocytosis, anaphylaxis, anaphylactoid reaction, hypersensitivity, pulmonary infiltrates, anaphylactoid purpura, polyarthritisnodosa, abnormal thyroid function, brown-black discolouration of the thyroid, anorexia, dizziness, headache, hypaesthesia, paraesthesia, intracranial hypertension, vertigo, bulging fontanelle, convulsions, sedation, impaired hearing, tinnitus, myocarditis, pericarditis, cough, dyspnoea, bronchospasm, exacerbation of asthma, pulmonary eosinophilia, pneumonitis, diarrhoea, nausea, stomatitis, discolouration of teeth, vomiting, dyspepsia, dysphagia, enamel hypoplasia, enterocolitis, oesophagitis, oesophageal ulceration, glossitis, pancreatitis, pseudomembranous colitis, increased liver enzymes, hepatitis, autoimmune hepatotoxicity, hepatic cholestatis, hepatic failure, hyperbilirubinemia, jaundice, autoimmune hepatitis, alopecia, erythema multiforme, erythema nodosum, fixed drug eruption, hyperpigmentation of the skin, photosensitivity, pruritis, rash, urticaria, vasculitis, angioedema, exfoliative dermatitis, hyperpigmentation of nails, stevens-johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (dress), arthralgia, lupus-like syndrome, myalgia, arthritis, bone discolouration, cases of systemic lupus erythematous (sle), joint stiffness, joint swelling, increased serum urea, acute renal failure, interstitial nephritis, balanitis, fever, etc. in some cases involving these syndromes, death has been reported.  hyperpigmentation of various body sites including the skin, nails, teeth, oral mucosa, bones, thyroid, eyes (including sclera and conjunctiva), breast milk, lacrimal secretions and perspiration has been reported. this blue/black/grey or muddy-brown discolouration may be localised or diffuse. the most frequently reported site is in the skin. pigmentation is often reversible on discontinuation of the drug, although it may take several months or may persist in some cases. the generalised muddy-brown skin pigmentation may persist, particularly in areas exposed to the sun. ",minocycline hydrochloride
sign_symptom,adverse reactions,0.9993733," adverse reactions occurring in 2% of patients include nausea, vomiting, diarrhea, headache, decreased appetite, dizziness, abdominal pain, pruritus, somnolence, elevated transaminases, and elevated creatinine. ",miltefosine
sign_symptom,mydr,0.7061765," increased heart rate, htn, increased liver enzymes, severe liver injury, hyponatraemia, abnormal bleeding, dysuria, mydriasis, nausea, vomiting, constipation, headache, insomnia, dizziness, hot flushes, hyperhidrosis, palpitations, dry mouth, migraine. ",milnacipran hydrochloride
sign_symptom,pain,0.9999491," abdominal pain or discomfort, diarrhoea, flatulence, skin rash. ",miglitol
sign_symptom,flat,0.98820657," abdominal pain or discomfort, diarrhoea, flatulence, skin rash. ",miglitol
sign_symptom,bleeding,0.98837155," mifepristone: the treatment procedure is designed to induce vaginal bleeding and uterine cramping necessary for menstrual regulation (mr). commonly reported side effects were nausea, vomiting and diarrhoea. pelvic pain, fainting, headache, dizziness, and asthenia occurred rarely.  misoprostol: gastro-intestinal side-effects like diarrhoea, abdominal pain, nausea, flatulence, dyspepsia, headache, vomiting and constipation, shivering, hyperthermia, dizziness, pain due to uterine contractions, severe vaginal bleeding, shock, pelvic pain, uterine rupture (requiring surgical repair, hysterectomy and/or salpingo-oophorectomy). ",mifepristone + misoprostol
sign_symptom,vomiting,0.999772," mifepristone: the treatment procedure is designed to induce vaginal bleeding and uterine cramping necessary for menstrual regulation (mr). commonly reported side effects were nausea, vomiting and diarrhoea. pelvic pain, fainting, headache, dizziness, and asthenia occurred rarely.  misoprostol: gastro-intestinal side-effects like diarrhoea, abdominal pain, nausea, flatulence, dyspepsia, headache, vomiting and constipation, shivering, hyperthermia, dizziness, pain due to uterine contractions, severe vaginal bleeding, shock, pelvic pain, uterine rupture (requiring surgical repair, hysterectomy and/or salpingo-oophorectomy). ",mifepristone + misoprostol
sign_symptom,faint,0.95296544," mifepristone: the treatment procedure is designed to induce vaginal bleeding and uterine cramping necessary for menstrual regulation (mr). commonly reported side effects were nausea, vomiting and diarrhoea. pelvic pain, fainting, headache, dizziness, and asthenia occurred rarely.  misoprostol: gastro-intestinal side-effects like diarrhoea, abdominal pain, nausea, flatulence, dyspepsia, headache, vomiting and constipation, shivering, hyperthermia, dizziness, pain due to uterine contractions, severe vaginal bleeding, shock, pelvic pain, uterine rupture (requiring surgical repair, hysterectomy and/or salpingo-oophorectomy). ",mifepristone + misoprostol
sign_symptom,asthenia,0.7523904," mifepristone: the treatment procedure is designed to induce vaginal bleeding and uterine cramping necessary for menstrual regulation (mr). commonly reported side effects were nausea, vomiting and diarrhoea. pelvic pain, fainting, headache, dizziness, and asthenia occurred rarely.  misoprostol: gastro-intestinal side-effects like diarrhoea, abdominal pain, nausea, flatulence, dyspepsia, headache, vomiting and constipation, shivering, hyperthermia, dizziness, pain due to uterine contractions, severe vaginal bleeding, shock, pelvic pain, uterine rupture (requiring surgical repair, hysterectomy and/or salpingo-oophorectomy). ",mifepristone + misoprostol
sign_symptom,flat,0.94469446," mifepristone: the treatment procedure is designed to induce vaginal bleeding and uterine cramping necessary for menstrual regulation (mr). commonly reported side effects were nausea, vomiting and diarrhoea. pelvic pain, fainting, headache, dizziness, and asthenia occurred rarely.  misoprostol: gastro-intestinal side-effects like diarrhoea, abdominal pain, nausea, flatulence, dyspepsia, headache, vomiting and constipation, shivering, hyperthermia, dizziness, pain due to uterine contractions, severe vaginal bleeding, shock, pelvic pain, uterine rupture (requiring surgical repair, hysterectomy and/or salpingo-oophorectomy). ",mifepristone + misoprostol
sign_symptom,hyperthermia,0.89339274," mifepristone: the treatment procedure is designed to induce vaginal bleeding and uterine cramping necessary for menstrual regulation (mr). commonly reported side effects were nausea, vomiting and diarrhoea. pelvic pain, fainting, headache, dizziness, and asthenia occurred rarely.  misoprostol: gastro-intestinal side-effects like diarrhoea, abdominal pain, nausea, flatulence, dyspepsia, headache, vomiting and constipation, shivering, hyperthermia, dizziness, pain due to uterine contractions, severe vaginal bleeding, shock, pelvic pain, uterine rupture (requiring surgical repair, hysterectomy and/or salpingo-oophorectomy). ",mifepristone + misoprostol
sign_symptom,pain,0.99991524," mifepristone: the treatment procedure is designed to induce vaginal bleeding and uterine cramping necessary for menstrual regulation (mr). commonly reported side effects were nausea, vomiting and diarrhoea. pelvic pain, fainting, headache, dizziness, and asthenia occurred rarely.  misoprostol: gastro-intestinal side-effects like diarrhoea, abdominal pain, nausea, flatulence, dyspepsia, headache, vomiting and constipation, shivering, hyperthermia, dizziness, pain due to uterine contractions, severe vaginal bleeding, shock, pelvic pain, uterine rupture (requiring surgical repair, hysterectomy and/or salpingo-oophorectomy). ",mifepristone + misoprostol
medication,prosta,0.9722533," it is very common for women to experience uterine contractions or cramping (10-45%) in the hours following prostaglandin intake. bleeding increases with gestational age. heavy bleeding occurs in about 5% of cases and from 0-1.4% may require haemostatic curettage. uterine rupture, hypotension, skin rashes, urticaria, hot flashes and dizziness have been uncommonly reported. ",mifepristone
sign_symptom,bleeding,0.9999404," it is very common for women to experience uterine contractions or cramping (10-45%) in the hours following prostaglandin intake. bleeding increases with gestational age. heavy bleeding occurs in about 5% of cases and from 0-1.4% may require haemostatic curettage. uterine rupture, hypotension, skin rashes, urticaria, hot flashes and dizziness have been uncommonly reported. ",mifepristone
sign_symptom,rash,0.9981627," it is very common for women to experience uterine contractions or cramping (10-45%) in the hours following prostaglandin intake. bleeding increases with gestational age. heavy bleeding occurs in about 5% of cases and from 0-1.4% may require haemostatic curettage. uterine rupture, hypotension, skin rashes, urticaria, hot flashes and dizziness have been uncommonly reported. ",mifepristone
sign_symptom,urticaria,0.84726286," it is very common for women to experience uterine contractions or cramping (10-45%) in the hours following prostaglandin intake. bleeding increases with gestational age. heavy bleeding occurs in about 5% of cases and from 0-1.4% may require haemostatic curettage. uterine rupture, hypotension, skin rashes, urticaria, hot flashes and dizziness have been uncommonly reported. ",mifepristone
sign_symptom,hot flashes,0.9997826," it is very common for women to experience uterine contractions or cramping (10-45%) in the hours following prostaglandin intake. bleeding increases with gestational age. heavy bleeding occurs in about 5% of cases and from 0-1.4% may require haemostatic curettage. uterine rupture, hypotension, skin rashes, urticaria, hot flashes and dizziness have been uncommonly reported. ",mifepristone
sign_symptom,confusion,0.9940195," at the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. following parenteral (iv or im) administration of midazolam, fluctuations in vital signs have been noted including respiratory depression, apnea, variations in blood pressure and pulse rate. ",midazolam
sign_symptom,fatigue,0.9984224," at the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. following parenteral (iv or im) administration of midazolam, fluctuations in vital signs have been noted including respiratory depression, apnea, variations in blood pressure and pulse rate. ",midazolam
sign_symptom,headache,0.99976236," at the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. following parenteral (iv or im) administration of midazolam, fluctuations in vital signs have been noted including respiratory depression, apnea, variations in blood pressure and pulse rate. ",midazolam
sign_symptom,muscle weakness,0.9910618," at the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. following parenteral (iv or im) administration of midazolam, fluctuations in vital signs have been noted including respiratory depression, apnea, variations in blood pressure and pulse rate. ",midazolam
sign_symptom,fluctuations in,0.99214745," at the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. following parenteral (iv or im) administration of midazolam, fluctuations in vital signs have been noted including respiratory depression, apnea, variations in blood pressure and pulse rate. ",midazolam
disease_disorder,gastric disorders,0.99961925, some cases of routine gastric disorders and neurovegetative disorders (feeling of discomfort) have been reported. in this cases discontinuation of treatment is not required. ,micronised diosmin + hesperidin
sign_symptom,discomfort,0.99981314, some cases of routine gastric disorders and neurovegetative disorders (feeling of discomfort) have been reported. in this cases discontinuation of treatment is not required. ,micronised diosmin + hesperidin
sign_symptom,nausea,0.99941134," occasionally nausea and vomiting, diarrhea with long term use and rarely allergic reactions. ",miconazole nitrate (oral gel)
sign_symptom,febril,0.7041725," nausea, vomiting, febrile reactions, rash, drowsiness, diarrhoea, anorexia and flushing, hepatitis. local irritation and sensitisation, contact dermatitis. ",metronidazole + miconazole nitrate
sign_symptom,drows,0.81367266," nausea, vomiting, febrile reactions, rash, drowsiness, diarrhoea, anorexia and flushing, hepatitis. local irritation and sensitisation, contact dermatitis. ",metronidazole + miconazole nitrate
sign_symptom,irritation,0.9999443," nausea, vomiting, febrile reactions, rash, drowsiness, diarrhoea, anorexia and flushing, hepatitis. local irritation and sensitisation, contact dermatitis. ",metronidazole + miconazole nitrate
sign_symptom,vomiting,0.70722336," metallic taste, nausea, vomiting, diarrhoea, drowsiness, rashes may be observed during treatment. ",metronidazole
sign_symptom,diarr,0.78337425," metallic taste, nausea, vomiting, diarrhoea, drowsiness, rashes may be observed during treatment. ",metronidazole
sign_symptom,drows,0.85658264," metallic taste, nausea, vomiting, diarrhoea, drowsiness, rashes may be observed during treatment. ",metronidazole
sign_symptom,rash,0.9999238," metallic taste, nausea, vomiting, diarrhoea, drowsiness, rashes may be observed during treatment. ",metronidazole
sign_symptom,tired,0.7495206," tiredness, dizziness, depression, diarrhea, itching or rash, shortness of breath, slow heart rate, mental confusion, headache, somnolence, nightmares, insomnia, dyspnea, nausea, dry mouth, gastric pain, constipation, flatulence, digestive tract disorders, heartburn, pruritus, musculoskeletal pain, blurred vision, decreased libido, and tinnitus have alsobeenreported,intensificationofavblock. ",metoprolol tartrate
sign_symptom,shortness of breath,0.9994789," tiredness, dizziness, depression, diarrhea, itching or rash, shortness of breath, slow heart rate, mental confusion, headache, somnolence, nightmares, insomnia, dyspnea, nausea, dry mouth, gastric pain, constipation, flatulence, digestive tract disorders, heartburn, pruritus, musculoskeletal pain, blurred vision, decreased libido, and tinnitus have alsobeenreported,intensificationofavblock. ",metoprolol tartrate
sign_symptom,blurred,0.9171105," tiredness, dizziness, depression, diarrhea, itching or rash, shortness of breath, slow heart rate, mental confusion, headache, somnolence, nightmares, insomnia, dyspnea, nausea, dry mouth, gastric pain, constipation, flatulence, digestive tract disorders, heartburn, pruritus, musculoskeletal pain, blurred vision, decreased libido, and tinnitus have alsobeenreported,intensificationofavblock. ",metoprolol tartrate
sign_symptom,allergic reactions,0.99683416," allergic reactions may occur in patients hypersensitive to any component of the preparation, e.g. thiamine. ",multivitamin [injection]
sign_symptom,allergic reactions,0.99683416," allergic reactions may occur in patients hypersensitive to any component of the preparation, e.g. thiamine. ",multivitamin & normal saline
sign_symptom,allergic reactions,0.99683416," allergic reactions may occur in patients hypersensitive to any component of the preparation, e.g. thiamine. ",multivitamin & 5% dextrose
sign_symptom,side - effect,0.9711821, no side-effect has been reported with such low dose of the vitamin. ,multivitamin [adult preparation]
sign_symptom,burning sensation,0.95174724," like all medicines, this gel preparation can cause side effects, although not everybody gets them. rarely, this medicine can cause the following in sensitive individuals: redness, burning sensation and rash. if any of these occur, stop using the gel and consult with a doctor. ",mucopolysaccharide polysulphate + salicylic acid
sign_symptom,effects,0.9946267," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,dry mouth,0.9377614," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,headache,0.99990785," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,flushing,0.9999249," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,weakness,0.999936," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,loss of strength,0.9997737," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,confusion,0.9996669," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,sleep,0.99650806," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,nausea,0.9999517," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,sick,0.8503132," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,upset,0.982447," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,rash,0.9999691," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,pain,0.9999685," the following side effects have been reported at the approximate frequencies shown: 
 
  very common : dry mouth, drowsiness 
  common : headache, dizziness (vertigo), flushing (vasodilation), weakness or loss of strength, confusion, sleep disturbances, nausea (feeling sick), being sick (vomiting), stomach upsets (dyspepsia), diarrhoea, rash or itching (pruritus), back pain 
  ",moxonidine
sign_symptom,adverse,0.99518687," in 1-6% patients the most frequently reported ocular adverse events are eye irritation, pyrexia, conjunctivitis, decreased visual acuity, dry eye, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage and tearing. ",moxifloxacin hydrochloride + xanthan gum
disease_disorder,conjunct,0.7479957," in 1-6% patients the most frequently reported ocular adverse events are eye irritation, pyrexia, conjunctivitis, decreased visual acuity, dry eye, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage and tearing. ",moxifloxacin hydrochloride + xanthan gum
disease_disorder,conjunctivitis,0.9693016," moxifloxacin: conjunctivitis decreased visual acuity, dry eye, keratitis, ocular discomfort, hyperemia, pain, subconjunctival hemorrhage and tearing.  dexamethasone: visual acuity &amp; field defects, cataract formation, secondary ocular infection following suppression of host response &amp; perforation of the globe. ",moxifloxacin hydrochloride + dexamethasone
sign_symptom,headache,0.96238667," common side effects of moxifloxacin include nausea, vomiting, diarrhea, headache and dizziness. ",moxifloxacin hydrochloride (tablet)
sign_symptom,adverse,0.98919827," the most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. these events occurred in approximately 1-6% of patients. nonocular adverse events reported at a rate of 1-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis. ",moxifloxacin hydrochloride (ophthalmic)
sign_symptom,adverse events,0.9527628," the most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. these events occurred in approximately 1-6% of patients. nonocular adverse events reported at a rate of 1-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis. ",moxifloxacin hydrochloride (ophthalmic)
sign_symptom,dyspepsia,0.9354458," treatment with moxifloxacin (oral, iv or sequential therapy) may cause some side effects. common (&gt;1%) side effects include headache, nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dizziness, pyrexia and insomnia etc. less common (0.1 to &lt;1%) side effects include neutropenia, palpitations, tachycardia, bradycardia, vertigo, tinnitus, dry mouth, gastritis, edema, fatigue, malaise, hyperglycemia, anorexia, hyperlipidemia, hypoglycemia, dehydration, back pain and arthralgia etc. ",moxifloxacin hydrochloride (injection)
sign_symptom,pyrexia,0.95060676," treatment with moxifloxacin (oral, iv or sequential therapy) may cause some side effects. common (&gt;1%) side effects include headache, nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dizziness, pyrexia and insomnia etc. less common (0.1 to &lt;1%) side effects include neutropenia, palpitations, tachycardia, bradycardia, vertigo, tinnitus, dry mouth, gastritis, edema, fatigue, malaise, hyperglycemia, anorexia, hyperlipidemia, hypoglycemia, dehydration, back pain and arthralgia etc. ",moxifloxacin hydrochloride (injection)
sign_symptom,insomnia,0.9964561," treatment with moxifloxacin (oral, iv or sequential therapy) may cause some side effects. common (&gt;1%) side effects include headache, nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dizziness, pyrexia and insomnia etc. less common (0.1 to &lt;1%) side effects include neutropenia, palpitations, tachycardia, bradycardia, vertigo, tinnitus, dry mouth, gastritis, edema, fatigue, malaise, hyperglycemia, anorexia, hyperlipidemia, hypoglycemia, dehydration, back pain and arthralgia etc. ",moxifloxacin hydrochloride (injection)
sign_symptom,dry mouth,0.9199215," treatment with moxifloxacin (oral, iv or sequential therapy) may cause some side effects. common (&gt;1%) side effects include headache, nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dizziness, pyrexia and insomnia etc. less common (0.1 to &lt;1%) side effects include neutropenia, palpitations, tachycardia, bradycardia, vertigo, tinnitus, dry mouth, gastritis, edema, fatigue, malaise, hyperglycemia, anorexia, hyperlipidemia, hypoglycemia, dehydration, back pain and arthralgia etc. ",moxifloxacin hydrochloride (injection)
sign_symptom,mala,0.9977118," treatment with moxifloxacin (oral, iv or sequential therapy) may cause some side effects. common (&gt;1%) side effects include headache, nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dizziness, pyrexia and insomnia etc. less common (0.1 to &lt;1%) side effects include neutropenia, palpitations, tachycardia, bradycardia, vertigo, tinnitus, dry mouth, gastritis, edema, fatigue, malaise, hyperglycemia, anorexia, hyperlipidemia, hypoglycemia, dehydration, back pain and arthralgia etc. ",moxifloxacin hydrochloride (injection)
sign_symptom,pain,0.99992883," treatment with moxifloxacin (oral, iv or sequential therapy) may cause some side effects. common (&gt;1%) side effects include headache, nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dizziness, pyrexia and insomnia etc. less common (0.1 to &lt;1%) side effects include neutropenia, palpitations, tachycardia, bradycardia, vertigo, tinnitus, dry mouth, gastritis, edema, fatigue, malaise, hyperglycemia, anorexia, hyperlipidemia, hypoglycemia, dehydration, back pain and arthralgia etc. ",moxifloxacin hydrochloride (injection)
sign_symptom,arthralgia,0.99771655," treatment with moxifloxacin (oral, iv or sequential therapy) may cause some side effects. common (&gt;1%) side effects include headache, nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dizziness, pyrexia and insomnia etc. less common (0.1 to &lt;1%) side effects include neutropenia, palpitations, tachycardia, bradycardia, vertigo, tinnitus, dry mouth, gastritis, edema, fatigue, malaise, hyperglycemia, anorexia, hyperlipidemia, hypoglycemia, dehydration, back pain and arthralgia etc. ",moxifloxacin hydrochloride (injection)
sign_symptom,dyspeps,0.895904," nausea, vomiting, constipation, abdominal pain, dry mouth, anorexia, taste disturbance, dyspepsia, resp depression, sedation, dizziness, confusion, insomnia, headache, somnolence, involuntary muscle contractions, hyperhidrosis, rash, pruritus, asthenic conditions, htn, bronchospasm, seizures, amenorrhoea, rhabdomyolysis, nystagmus. ",morphine sulfate
sign_symptom,mala,0.7478809,"  common : diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection.   uncommon : akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders.   rare : angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor. ",montelukast sodium
sign_symptom,concentration,0.9417538,"  common : diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection.   uncommon : akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders.   rare : angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor. ",montelukast sodium
sign_symptom,side - effects,0.86205834, very few side-effects occur with monosulfiram solution even in cases of undiluted application. a few cases of erythematous rash considered as idiosyncratic response have been reported. ,monosulfiram
medication,mono,0.9997149, very few side-effects occur with monosulfiram solution even in cases of undiluted application. a few cases of erythematous rash considered as idiosyncratic response have been reported. ,monosulfiram
sign_symptom,rash,0.9999552, very few side-effects occur with monosulfiram solution even in cases of undiluted application. a few cases of erythematous rash considered as idiosyncratic response have been reported. ,monosulfiram
sign_symptom,adverse reactions,0.99992603, no adverse reactions have been reported at the recommended dosages. ,monosemicarbazone adrenochrome
sign_symptom,inflammation,0.9988875," the most common side effects of this combination include inflammation of the nose and throat, inflammation of the sinuses, headache, flu, and upper respiratory infection. other less common side-effects include: serious allergic reactions, thrush in the mouth &amp; throat, reduces adrenal function, increase in wheezing, lower bone mineral density in osteoporosis patient, slowed growth in children, glaucoma, blurred vision &amp; hypokalemia. ",mometasone furoate + formoterol fumarate
sign_symptom,thrush,0.9883677," the most common side effects of this combination include inflammation of the nose and throat, inflammation of the sinuses, headache, flu, and upper respiratory infection. other less common side-effects include: serious allergic reactions, thrush in the mouth &amp; throat, reduces adrenal function, increase in wheezing, lower bone mineral density in osteoporosis patient, slowed growth in children, glaucoma, blurred vision &amp; hypokalemia. ",mometasone furoate + formoterol fumarate
sign_symptom,blurred vision,0.9960788," the most common side effects of this combination include inflammation of the nose and throat, inflammation of the sinuses, headache, flu, and upper respiratory infection. other less common side-effects include: serious allergic reactions, thrush in the mouth &amp; throat, reduces adrenal function, increase in wheezing, lower bone mineral density in osteoporosis patient, slowed growth in children, glaucoma, blurred vision &amp; hypokalemia. ",mometasone furoate + formoterol fumarate
medication,mometasone,0.99717," mometasone furoate cream is generally well tolerated. burning, pruritus and skin atrophy may occur. ",mometasone furoate (topical)
medication,furoate cream,0.98054206," mometasone furoate cream is generally well tolerated. burning, pruritus and skin atrophy may occur. ",mometasone furoate (topical)
medication,mizo,0.9834473," mizolastine is well tolerated in the recommended doses. the usual side effects are dry mouth, diarrhoea, abdominal pain, nausea, drowsiness, headache, dizziness, raised liver enzymes, hypotension, tachycardia and palpitations. bronchospasm and aggravation of asthma were reported, but in view of the high frequency of asthma in the treated patient population, a causality relationship remains uncertain. ",mizolastine
sign_symptom,aggra,0.76712126," mizolastine is well tolerated in the recommended doses. the usual side effects are dry mouth, diarrhoea, abdominal pain, nausea, drowsiness, headache, dizziness, raised liver enzymes, hypotension, tachycardia and palpitations. bronchospasm and aggravation of asthma were reported, but in view of the high frequency of asthma in the treated patient population, a causality relationship remains uncertain. ",mizolastine
disease_disorder,asthma,0.88140815," mizolastine is well tolerated in the recommended doses. the usual side effects are dry mouth, diarrhoea, abdominal pain, nausea, drowsiness, headache, dizziness, raised liver enzymes, hypotension, tachycardia and palpitations. bronchospasm and aggravation of asthma were reported, but in view of the high frequency of asthma in the treated patient population, a causality relationship remains uncertain. ",mizolastine
sign_symptom,adverse reactions,0.997959," the most common adverse reactions (20%) associated with the administration of mycophenolic acid are anemia, leukopenia, constipation, diarrhea, vomiting, dyspepsia, urinary tract infection, cmv infection, insomnia, and postoperative pain. ",mycophenolic acid
sign_symptom,vomiting,0.99886346," the principal adverse reactions associated with the administration of mycophenolate mofetil includes diarrhea, leukopenia, sepsis, gastrointestinal candidiasis, urinary tract infection, herpes simplex, vomiting and there is evidence of a higher frequency of certain types of infections eg. opportunistic infections. ",mycophenolate mofetil
disease_disorder,infections,0.9996675," the principal adverse reactions associated with the administration of mycophenolate mofetil includes diarrhea, leukopenia, sepsis, gastrointestinal candidiasis, urinary tract infection, herpes simplex, vomiting and there is evidence of a higher frequency of certain types of infections eg. opportunistic infections. ",mycophenolate mofetil
sign_symptom,allergic sensitization,0.99990195, allergic sensitization has been reported following oral administration of folic acid. ,multivitamins & multiminerals [a-z prenatal preparation]
sign_symptom,allergic sensitization,0.99990195, allergic sensitization has been reported following oral administration of folic acid. ,multivitamin & multimineral [a-z teen girls preparation]
sign_symptom,allergic sensitization,0.99990195, allergic sensitization has been reported following oral administration of folic acid. ,multivitamin & multimineral [a-z teen boys preparation]
sign_symptom,side effects,0.9992094, no clinically significant side effects or toxicity are reported with such kind of preparation. ,multivitamin & multimineral essentials [for nursing mother]
sign_symptom,toxicity,0.99849176, no clinically significant side effects or toxicity are reported with such kind of preparation. ,multivitamin & multimineral essentials [for nursing mother]
sign_symptom,allergic sensitization,0.97395086," generally, this preparation is well tolerated. allergic sensitization has been reported following oral administration of folic acid. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",multivitamin & multimineral [a-z silver preparation]
medication,folic,0.8215293," generally, this preparation is well tolerated. allergic sensitization has been reported following oral administration of folic acid. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",multivitamin & multimineral [a-z silver preparation]
medication,vitamin c,0.99924695," generally, this preparation is well tolerated. allergic sensitization has been reported following oral administration of folic acid. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",multivitamin & multimineral [a-z silver preparation]
medication,vitamin e,0.99909747," generally, this preparation is well tolerated. allergic sensitization has been reported following oral administration of folic acid. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",multivitamin & multimineral [a-z silver preparation]
sign_symptom,diarrhea,0.99377805," generally, this preparation is well tolerated. allergic sensitization has been reported following oral administration of folic acid. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",multivitamin & multimineral [a-z silver preparation]
sign_symptom,anaphyla,0.9986742," there have been rare reports of anaphylactic reactions following parenteral multivitamin administration. rare reports of anaphylactic reactions have also been reported after large intravenous doses of thiamine. the risk is negligible if thiamine is co-administered with other vitamins in the b group. there have been rare reports of the following types of reactions:- rash, erythema, pruritus, headache, dizziness, agitation, anxiety, diplopia, urticaria, shortness of breath, wheezing, and angioedema. ",multivitamin & multimineral [a-z junior infusion preparation]
medication,multi,0.9995295," there have been rare reports of anaphylactic reactions following parenteral multivitamin administration. rare reports of anaphylactic reactions have also been reported after large intravenous doses of thiamine. the risk is negligible if thiamine is co-administered with other vitamins in the b group. there have been rare reports of the following types of reactions:- rash, erythema, pruritus, headache, dizziness, agitation, anxiety, diplopia, urticaria, shortness of breath, wheezing, and angioedema. ",multivitamin & multimineral [a-z junior infusion preparation]
medication,other vitamins,0.98876244," there have been rare reports of anaphylactic reactions following parenteral multivitamin administration. rare reports of anaphylactic reactions have also been reported after large intravenous doses of thiamine. the risk is negligible if thiamine is co-administered with other vitamins in the b group. there have been rare reports of the following types of reactions:- rash, erythema, pruritus, headache, dizziness, agitation, anxiety, diplopia, urticaria, shortness of breath, wheezing, and angioedema. ",multivitamin & multimineral [a-z junior infusion preparation]
sign_symptom,shortness of breath,0.9967432," there have been rare reports of anaphylactic reactions following parenteral multivitamin administration. rare reports of anaphylactic reactions have also been reported after large intravenous doses of thiamine. the risk is negligible if thiamine is co-administered with other vitamins in the b group. there have been rare reports of the following types of reactions:- rash, erythema, pruritus, headache, dizziness, agitation, anxiety, diplopia, urticaria, shortness of breath, wheezing, and angioedema. ",multivitamin & multimineral [a-z junior infusion preparation]
sign_symptom,diarrhoea,0.9941843," generally, this preparation is well tolerated. diarrhoea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. vitamin c and vitamin e may cause diarrhoea and other gastrointestinal disturbances. ",multivitamin & multimineral [a-z gold preparation]
medication,beta carotene,0.9942974," generally, this preparation is well tolerated. diarrhoea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. vitamin c and vitamin e may cause diarrhoea and other gastrointestinal disturbances. ",multivitamin & multimineral [a-z gold preparation]
medication,vitamin c,0.9991956," generally, this preparation is well tolerated. diarrhoea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. vitamin c and vitamin e may cause diarrhoea and other gastrointestinal disturbances. ",multivitamin & multimineral [a-z gold preparation]
medication,vitamin e,0.99919105," generally, this preparation is well tolerated. diarrhoea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. vitamin c and vitamin e may cause diarrhoea and other gastrointestinal disturbances. ",multivitamin & multimineral [a-z gold preparation]
medication,specific vitamin,0.8907397," side effects have been reported with specific vitamins &amp; minerals, but at level substantially higher than those in this tablet. iron has been associated with gastrointestinal intolerance in some patients. ",multivitamin & multimineral
sign_symptom,gastro,0.83306783," side effects have been reported with specific vitamins &amp; minerals, but at level substantially higher than those in this tablet. iron has been associated with gastrointestinal intolerance in some patients. ",multivitamin & multimineral
medication,drug,0.9996252," the safety of nelfinavir was studied in over 1500 patients who received drug either alone or in combination with nucleoside analogues. the majority of adverse events were of mild intensity. the most frequently reported adverse event among patients receiving nelfinavir was diarrhoea, which was generally of mild to moderate intensity. adverse events occurring in less than 2% of patients receiving nelfinavir in all phase ii/iii clinical trials and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below.   general : abdominal pain, accidental injury, allergic reaction, asthenia, back pain, fever, headache, malaise, pain and redistribution/accumulation of body fat.   digestive system : anorexia, dyspepsia, epigastric pain, gastrointestinal bleeding, hepatitis, mouth ulceration, pancreatitis and vomiting.   haemic/lymphatic system : anaemia, leukopenia and thrombocytopenia.   metabolic/nutritional : increase in alkaline phosphate, amylase, creatinine phosphokinase, lactic dehydrogenase, sgot, sgpt and g glutamyl transpeptidase, hyperlipaemia, hyperuricaemia, hyperglycaemia, hypoglycaemia, dehydration and liver function tests abnormal.   musculoskeletal system : arthralgia, arthritis, cramps, myalgia, myasthenia and myopathy.   nervous system : anxiety, depression, dizziness, emotional lability, hyperkinesia, insomnia, migraine, paraesthesia, seizures, sleep disorder, somnolence and suicide ideation.   respiratory system : dyspnoea, pharyngitis, rhinitis and sinusitis.   skin/appendages : dermatitis, folliculitis, fungal dermatitis, maculopapular rash, pruitus, sweating, and urticaria.   ophthalmic : acute iritis and eye disorder.   urogenital system : kidney calculas, sexual dysfunction. ",nelfinavir
medication,nucleoside analogue,0.9515289," the safety of nelfinavir was studied in over 1500 patients who received drug either alone or in combination with nucleoside analogues. the majority of adverse events were of mild intensity. the most frequently reported adverse event among patients receiving nelfinavir was diarrhoea, which was generally of mild to moderate intensity. adverse events occurring in less than 2% of patients receiving nelfinavir in all phase ii/iii clinical trials and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below.   general : abdominal pain, accidental injury, allergic reaction, asthenia, back pain, fever, headache, malaise, pain and redistribution/accumulation of body fat.   digestive system : anorexia, dyspepsia, epigastric pain, gastrointestinal bleeding, hepatitis, mouth ulceration, pancreatitis and vomiting.   haemic/lymphatic system : anaemia, leukopenia and thrombocytopenia.   metabolic/nutritional : increase in alkaline phosphate, amylase, creatinine phosphokinase, lactic dehydrogenase, sgot, sgpt and g glutamyl transpeptidase, hyperlipaemia, hyperuricaemia, hyperglycaemia, hypoglycaemia, dehydration and liver function tests abnormal.   musculoskeletal system : arthralgia, arthritis, cramps, myalgia, myasthenia and myopathy.   nervous system : anxiety, depression, dizziness, emotional lability, hyperkinesia, insomnia, migraine, paraesthesia, seizures, sleep disorder, somnolence and suicide ideation.   respiratory system : dyspnoea, pharyngitis, rhinitis and sinusitis.   skin/appendages : dermatitis, folliculitis, fungal dermatitis, maculopapular rash, pruitus, sweating, and urticaria.   ophthalmic : acute iritis and eye disorder.   urogenital system : kidney calculas, sexual dysfunction. ",nelfinavir
sign_symptom,adverse events,0.9650537," the safety of nelfinavir was studied in over 1500 patients who received drug either alone or in combination with nucleoside analogues. the majority of adverse events were of mild intensity. the most frequently reported adverse event among patients receiving nelfinavir was diarrhoea, which was generally of mild to moderate intensity. adverse events occurring in less than 2% of patients receiving nelfinavir in all phase ii/iii clinical trials and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below.   general : abdominal pain, accidental injury, allergic reaction, asthenia, back pain, fever, headache, malaise, pain and redistribution/accumulation of body fat.   digestive system : anorexia, dyspepsia, epigastric pain, gastrointestinal bleeding, hepatitis, mouth ulceration, pancreatitis and vomiting.   haemic/lymphatic system : anaemia, leukopenia and thrombocytopenia.   metabolic/nutritional : increase in alkaline phosphate, amylase, creatinine phosphokinase, lactic dehydrogenase, sgot, sgpt and g glutamyl transpeptidase, hyperlipaemia, hyperuricaemia, hyperglycaemia, hypoglycaemia, dehydration and liver function tests abnormal.   musculoskeletal system : arthralgia, arthritis, cramps, myalgia, myasthenia and myopathy.   nervous system : anxiety, depression, dizziness, emotional lability, hyperkinesia, insomnia, migraine, paraesthesia, seizures, sleep disorder, somnolence and suicide ideation.   respiratory system : dyspnoea, pharyngitis, rhinitis and sinusitis.   skin/appendages : dermatitis, folliculitis, fungal dermatitis, maculopapular rash, pruitus, sweating, and urticaria.   ophthalmic : acute iritis and eye disorder.   urogenital system : kidney calculas, sexual dysfunction. ",nelfinavir
sign_symptom,adverse event,0.97442436," the safety of nelfinavir was studied in over 1500 patients who received drug either alone or in combination with nucleoside analogues. the majority of adverse events were of mild intensity. the most frequently reported adverse event among patients receiving nelfinavir was diarrhoea, which was generally of mild to moderate intensity. adverse events occurring in less than 2% of patients receiving nelfinavir in all phase ii/iii clinical trials and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below.   general : abdominal pain, accidental injury, allergic reaction, asthenia, back pain, fever, headache, malaise, pain and redistribution/accumulation of body fat.   digestive system : anorexia, dyspepsia, epigastric pain, gastrointestinal bleeding, hepatitis, mouth ulceration, pancreatitis and vomiting.   haemic/lymphatic system : anaemia, leukopenia and thrombocytopenia.   metabolic/nutritional : increase in alkaline phosphate, amylase, creatinine phosphokinase, lactic dehydrogenase, sgot, sgpt and g glutamyl transpeptidase, hyperlipaemia, hyperuricaemia, hyperglycaemia, hypoglycaemia, dehydration and liver function tests abnormal.   musculoskeletal system : arthralgia, arthritis, cramps, myalgia, myasthenia and myopathy.   nervous system : anxiety, depression, dizziness, emotional lability, hyperkinesia, insomnia, migraine, paraesthesia, seizures, sleep disorder, somnolence and suicide ideation.   respiratory system : dyspnoea, pharyngitis, rhinitis and sinusitis.   skin/appendages : dermatitis, folliculitis, fungal dermatitis, maculopapular rash, pruitus, sweating, and urticaria.   ophthalmic : acute iritis and eye disorder.   urogenital system : kidney calculas, sexual dysfunction. ",nelfinavir
sign_symptom,diarrhoea,0.95564187," the safety of nelfinavir was studied in over 1500 patients who received drug either alone or in combination with nucleoside analogues. the majority of adverse events were of mild intensity. the most frequently reported adverse event among patients receiving nelfinavir was diarrhoea, which was generally of mild to moderate intensity. adverse events occurring in less than 2% of patients receiving nelfinavir in all phase ii/iii clinical trials and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below.   general : abdominal pain, accidental injury, allergic reaction, asthenia, back pain, fever, headache, malaise, pain and redistribution/accumulation of body fat.   digestive system : anorexia, dyspepsia, epigastric pain, gastrointestinal bleeding, hepatitis, mouth ulceration, pancreatitis and vomiting.   haemic/lymphatic system : anaemia, leukopenia and thrombocytopenia.   metabolic/nutritional : increase in alkaline phosphate, amylase, creatinine phosphokinase, lactic dehydrogenase, sgot, sgpt and g glutamyl transpeptidase, hyperlipaemia, hyperuricaemia, hyperglycaemia, hypoglycaemia, dehydration and liver function tests abnormal.   musculoskeletal system : arthralgia, arthritis, cramps, myalgia, myasthenia and myopathy.   nervous system : anxiety, depression, dizziness, emotional lability, hyperkinesia, insomnia, migraine, paraesthesia, seizures, sleep disorder, somnolence and suicide ideation.   respiratory system : dyspnoea, pharyngitis, rhinitis and sinusitis.   skin/appendages : dermatitis, folliculitis, fungal dermatitis, maculopapular rash, pruitus, sweating, and urticaria.   ophthalmic : acute iritis and eye disorder.   urogenital system : kidney calculas, sexual dysfunction. ",nelfinavir
sign_symptom,mala,0.87528497," the safety of nelfinavir was studied in over 1500 patients who received drug either alone or in combination with nucleoside analogues. the majority of adverse events were of mild intensity. the most frequently reported adverse event among patients receiving nelfinavir was diarrhoea, which was generally of mild to moderate intensity. adverse events occurring in less than 2% of patients receiving nelfinavir in all phase ii/iii clinical trials and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below.   general : abdominal pain, accidental injury, allergic reaction, asthenia, back pain, fever, headache, malaise, pain and redistribution/accumulation of body fat.   digestive system : anorexia, dyspepsia, epigastric pain, gastrointestinal bleeding, hepatitis, mouth ulceration, pancreatitis and vomiting.   haemic/lymphatic system : anaemia, leukopenia and thrombocytopenia.   metabolic/nutritional : increase in alkaline phosphate, amylase, creatinine phosphokinase, lactic dehydrogenase, sgot, sgpt and g glutamyl transpeptidase, hyperlipaemia, hyperuricaemia, hyperglycaemia, hypoglycaemia, dehydration and liver function tests abnormal.   musculoskeletal system : arthralgia, arthritis, cramps, myalgia, myasthenia and myopathy.   nervous system : anxiety, depression, dizziness, emotional lability, hyperkinesia, insomnia, migraine, paraesthesia, seizures, sleep disorder, somnolence and suicide ideation.   respiratory system : dyspnoea, pharyngitis, rhinitis and sinusitis.   skin/appendages : dermatitis, folliculitis, fungal dermatitis, maculopapular rash, pruitus, sweating, and urticaria.   ophthalmic : acute iritis and eye disorder.   urogenital system : kidney calculas, sexual dysfunction. ",nelfinavir
sign_symptom,pain,0.9939843," the safety of nelfinavir was studied in over 1500 patients who received drug either alone or in combination with nucleoside analogues. the majority of adverse events were of mild intensity. the most frequently reported adverse event among patients receiving nelfinavir was diarrhoea, which was generally of mild to moderate intensity. adverse events occurring in less than 2% of patients receiving nelfinavir in all phase ii/iii clinical trials and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below.   general : abdominal pain, accidental injury, allergic reaction, asthenia, back pain, fever, headache, malaise, pain and redistribution/accumulation of body fat.   digestive system : anorexia, dyspepsia, epigastric pain, gastrointestinal bleeding, hepatitis, mouth ulceration, pancreatitis and vomiting.   haemic/lymphatic system : anaemia, leukopenia and thrombocytopenia.   metabolic/nutritional : increase in alkaline phosphate, amylase, creatinine phosphokinase, lactic dehydrogenase, sgot, sgpt and g glutamyl transpeptidase, hyperlipaemia, hyperuricaemia, hyperglycaemia, hypoglycaemia, dehydration and liver function tests abnormal.   musculoskeletal system : arthralgia, arthritis, cramps, myalgia, myasthenia and myopathy.   nervous system : anxiety, depression, dizziness, emotional lability, hyperkinesia, insomnia, migraine, paraesthesia, seizures, sleep disorder, somnolence and suicide ideation.   respiratory system : dyspnoea, pharyngitis, rhinitis and sinusitis.   skin/appendages : dermatitis, folliculitis, fungal dermatitis, maculopapular rash, pruitus, sweating, and urticaria.   ophthalmic : acute iritis and eye disorder.   urogenital system : kidney calculas, sexual dysfunction. ",nelfinavir
sign_symptom,leukopenia,0.9918253," the safety of nelfinavir was studied in over 1500 patients who received drug either alone or in combination with nucleoside analogues. the majority of adverse events were of mild intensity. the most frequently reported adverse event among patients receiving nelfinavir was diarrhoea, which was generally of mild to moderate intensity. adverse events occurring in less than 2% of patients receiving nelfinavir in all phase ii/iii clinical trials and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below.   general : abdominal pain, accidental injury, allergic reaction, asthenia, back pain, fever, headache, malaise, pain and redistribution/accumulation of body fat.   digestive system : anorexia, dyspepsia, epigastric pain, gastrointestinal bleeding, hepatitis, mouth ulceration, pancreatitis and vomiting.   haemic/lymphatic system : anaemia, leukopenia and thrombocytopenia.   metabolic/nutritional : increase in alkaline phosphate, amylase, creatinine phosphokinase, lactic dehydrogenase, sgot, sgpt and g glutamyl transpeptidase, hyperlipaemia, hyperuricaemia, hyperglycaemia, hypoglycaemia, dehydration and liver function tests abnormal.   musculoskeletal system : arthralgia, arthritis, cramps, myalgia, myasthenia and myopathy.   nervous system : anxiety, depression, dizziness, emotional lability, hyperkinesia, insomnia, migraine, paraesthesia, seizures, sleep disorder, somnolence and suicide ideation.   respiratory system : dyspnoea, pharyngitis, rhinitis and sinusitis.   skin/appendages : dermatitis, folliculitis, fungal dermatitis, maculopapular rash, pruitus, sweating, and urticaria.   ophthalmic : acute iritis and eye disorder.   urogenital system : kidney calculas, sexual dysfunction. ",nelfinavir
medication,nefopam hydrochloride,0.97657675," nefopam hydrochloride is generally well tolerated. however the most common side-effects are nausea, nervousness, dry mouth, lightheadedness and urinary retention.the less common side-effects are vomiting, blurred vision, drowsiness, sweating, insomnia, headache, confusion, hallucinations, tachycardia and aggravation of angina. ",nefopam hydrochloride
sign_symptom,lightheadedness,0.9929052," nefopam hydrochloride is generally well tolerated. however the most common side-effects are nausea, nervousness, dry mouth, lightheadedness and urinary retention.the less common side-effects are vomiting, blurred vision, drowsiness, sweating, insomnia, headache, confusion, hallucinations, tachycardia and aggravation of angina. ",nefopam hydrochloride
sign_symptom,nausea,0.99989915," headache, nausea and bradycardia. ",nebivolol hydrochloride
sign_symptom,brady,0.99907887," headache, nausea and bradycardia. ",nebivolol hydrochloride
sign_symptom,tired,0.9952781,"  nebivolol : headache, dizziness, tiredness, diarrhoea, constipation, nausea etc.   hydrochlorothiazide : vertigo, itchiness, rash, increased sensitivity of skin to sunlight etc. ",nebivolol + hydrochlorothiazide
sign_symptom,diarr,0.9480083,"  nebivolol : headache, dizziness, tiredness, diarrhoea, constipation, nausea etc.   hydrochlorothiazide : vertigo, itchiness, rash, increased sensitivity of skin to sunlight etc. ",nebivolol + hydrochlorothiazide
sign_symptom,consti,0.9942613,"  nebivolol : headache, dizziness, tiredness, diarrhoea, constipation, nausea etc.   hydrochlorothiazide : vertigo, itchiness, rash, increased sensitivity of skin to sunlight etc. ",nebivolol + hydrochlorothiazide
sign_symptom,nausea,0.99992967,"  nebivolol : headache, dizziness, tiredness, diarrhoea, constipation, nausea etc.   hydrochlorothiazide : vertigo, itchiness, rash, increased sensitivity of skin to sunlight etc. ",nebivolol + hydrochlorothiazide
medication,hydroch,0.97836834,"  nebivolol : headache, dizziness, tiredness, diarrhoea, constipation, nausea etc.   hydrochlorothiazide : vertigo, itchiness, rash, increased sensitivity of skin to sunlight etc. ",nebivolol + hydrochlorothiazide
sign_symptom,sensitivity,0.8582247,"  nebivolol : headache, dizziness, tiredness, diarrhoea, constipation, nausea etc.   hydrochlorothiazide : vertigo, itchiness, rash, increased sensitivity of skin to sunlight etc. ",nebivolol + hydrochlorothiazide
sign_symptom,chemosis,0.9803409," eye irritation, eye discomfort, eye edema, conjunctival chemosis and hyperemia has been reported. ",natamycin
sign_symptom,hyper,0.99996316," eye irritation, eye discomfort, eye edema, conjunctival chemosis and hyperemia has been reported. ",natamycin
sign_symptom,adverse reactions,0.9735693," in general, this preparation is well tolerated. the most common adverse reactions in clinical trials (&gt;5%): erosive gastritis, dyspepsia, gastritis, diarrhea, gastric ulcer, upper abdominal pain, nausea etc. ",naproxen sodium + esomeprazole magnesium
sign_symptom,dyspeps,0.8637387," in general, this preparation is well tolerated. the most common adverse reactions in clinical trials (&gt;5%): erosive gastritis, dyspepsia, gastritis, diarrhea, gastric ulcer, upper abdominal pain, nausea etc. ",naproxen sodium + esomeprazole magnesium
sign_symptom,pain,0.98798233," in general, this preparation is well tolerated. the most common adverse reactions in clinical trials (&gt;5%): erosive gastritis, dyspepsia, gastritis, diarrhea, gastric ulcer, upper abdominal pain, nausea etc. ",naproxen sodium + esomeprazole magnesium
sign_symptom,nausea,0.99992776," in general, this preparation is well tolerated. the most common adverse reactions in clinical trials (&gt;5%): erosive gastritis, dyspepsia, gastritis, diarrhea, gastric ulcer, upper abdominal pain, nausea etc. ",naproxen sodium + esomeprazole magnesium
sign_symptom,dyspeps,0.99903566," most frequently reported side effects include following: 
 
  gastrointestinal : heartburn, abdominal pain, nausea, diarrhea, dyspepsia. 
  central nervous system : headache, vertigo, drowsiness. 
  dermatological : pruritus (itching), purpura. 
  cardiovascular : edema, palpitation. 
  others : visual disturbances, hearing disturbances. 
  ",naproxen sodium
sign_symptom,mydriasis,0.9979274," mydriasis and a slight increase of intraocular pressure in isolated cases. a slight and transient burning sensation may occur after instillation, which does not affect the success of the treatment. long term use may result in reactive redness of the eye (rebound effect).  in very rare cases systemic cardiovascular effects, such as hypertension and arrhythmia, may occur. nonspecific fatigue has been observed in some patients. ",naphazoline + zinc sulfate
sign_symptom,burning sensation,0.9963219," mydriasis and a slight increase of intraocular pressure in isolated cases. a slight and transient burning sensation may occur after instillation, which does not affect the success of the treatment. long term use may result in reactive redness of the eye (rebound effect).  in very rare cases systemic cardiovascular effects, such as hypertension and arrhythmia, may occur. nonspecific fatigue has been observed in some patients. ",naphazoline + zinc sulfate
sign_symptom,redness,0.9928901," mydriasis and a slight increase of intraocular pressure in isolated cases. a slight and transient burning sensation may occur after instillation, which does not affect the success of the treatment. long term use may result in reactive redness of the eye (rebound effect).  in very rare cases systemic cardiovascular effects, such as hypertension and arrhythmia, may occur. nonspecific fatigue has been observed in some patients. ",naphazoline + zinc sulfate
sign_symptom,cardiovascular,0.7318453," mydriasis and a slight increase of intraocular pressure in isolated cases. a slight and transient burning sensation may occur after instillation, which does not affect the success of the treatment. long term use may result in reactive redness of the eye (rebound effect).  in very rare cases systemic cardiovascular effects, such as hypertension and arrhythmia, may occur. nonspecific fatigue has been observed in some patients. ",naphazoline + zinc sulfate
sign_symptom,hyper,0.98963565," mydriasis and a slight increase of intraocular pressure in isolated cases. a slight and transient burning sensation may occur after instillation, which does not affect the success of the treatment. long term use may result in reactive redness of the eye (rebound effect).  in very rare cases systemic cardiovascular effects, such as hypertension and arrhythmia, may occur. nonspecific fatigue has been observed in some patients. ",naphazoline + zinc sulfate
sign_symptom,fatigue,0.9999349," mydriasis and a slight increase of intraocular pressure in isolated cases. a slight and transient burning sensation may occur after instillation, which does not affect the success of the treatment. long term use may result in reactive redness of the eye (rebound effect).  in very rare cases systemic cardiovascular effects, such as hypertension and arrhythmia, may occur. nonspecific fatigue has been observed in some patients. ",naphazoline + zinc sulfate
sign_symptom,blur,0.99729985," blurring of vision, mild stinging and/or irritation, mydriasis and increased or decreased intraocular pressure. when used in high doses in elderly, naphazoline may liberate pigment granules from the iris. ",naphazoline + pheniramine
sign_symptom,stinging,0.9957705," blurring of vision, mild stinging and/or irritation, mydriasis and increased or decreased intraocular pressure. when used in high doses in elderly, naphazoline may liberate pigment granules from the iris. ",naphazoline + pheniramine
sign_symptom,mydr,0.9324913," blurring of vision, mild stinging and/or irritation, mydriasis and increased or decreased intraocular pressure. when used in high doses in elderly, naphazoline may liberate pigment granules from the iris. ",naphazoline + pheniramine
medication,naphazoline,0.98062766," blurring of vision, mild stinging and/or irritation, mydriasis and increased or decreased intraocular pressure. when used in high doses in elderly, naphazoline may liberate pigment granules from the iris. ",naphazoline + pheniramine
sign_symptom,gran,0.848505," blurring of vision, mild stinging and/or irritation, mydriasis and increased or decreased intraocular pressure. when used in high doses in elderly, naphazoline may liberate pigment granules from the iris. ",naphazoline + pheniramine
sign_symptom,hoarse,0.9999144," high dosages, prolonged treatment and/or too frequent administration may cause: 
 
 virilisation which appears in sensitive women as hoarseness, acne hirsutism and increase of libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice. 
 amenorrhoea. 
 inhibition of spermatogenesis. 
 premature epiphyseal closure. 
 fluid retention. 
  ",nandrolone phenylpropionate
sign_symptom,acne hirsutism,0.8943319," high dosages, prolonged treatment and/or too frequent administration may cause: 
 
 virilisation which appears in sensitive women as hoarseness, acne hirsutism and increase of libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice. 
 amenorrhoea. 
 inhibition of spermatogenesis. 
 premature epiphyseal closure. 
 fluid retention. 
  ",nandrolone phenylpropionate
sign_symptom,erections,0.83552235," high dosages, prolonged treatment and/or too frequent administration may cause: 
 
 virilisation which appears in sensitive women as hoarseness, acne hirsutism and increase of libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice. 
 amenorrhoea. 
 inhibition of spermatogenesis. 
 premature epiphyseal closure. 
 fluid retention. 
  ",nandrolone phenylpropionate
sign_symptom,hoarseness,0.96404594," high dosages, prolonged treatment and/or too frequent administration may cause: 
 
 virilisation which appears in sensitive women as hoarseness, acne hirsutism and increase of libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice. 
 amenorrhoea. 
 inhibition of spermatogenesis. 
 premature epiphyseal closure. 
 fluid retention. 
  ",nandrolone phenylpropionate
sign_symptom,vocal change,0.998925," high dosages, prolonged treatment and/or too frequent administration may cause: 
 
 virilisation which appears in sensitive women as hoarseness, acne hirsutism and increase of libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice. 
 amenorrhoea. 
 inhibition of spermatogenesis. 
 premature epiphyseal closure. 
 fluid retention. 
  ",nandrolone phenylpropionate
sign_symptom,chill,0.9508236," abdominal pain, nausea, vomiting; anxiety, insomnia, lethargy, headache, musculoskeletal pain; anorexia, diarrhoea, constipation; increased thirst; chest pain; chills, dizziness; sexual dysfunction; rash, liver function abnormalities and reversible idiopathic thrombocytopenia. inj-site reactions. ",naltrexone
medication,analgesia,0.9067182," occur secondarily to reversal (withdrawal) of narcotic analgesia and sedation. mental depression, apathy, inability to concentrate, sleepiness, irritability, anorexia, nausea, and vomiting in high oral doses during initial treatment of opiate addiction. ",naloxone hydrochloride
sign_symptom,inability to concentrate,0.9945453," occur secondarily to reversal (withdrawal) of narcotic analgesia and sedation. mental depression, apathy, inability to concentrate, sleepiness, irritability, anorexia, nausea, and vomiting in high oral doses during initial treatment of opiate addiction. ",naloxone hydrochloride
sign_symptom,sleepiness,0.87642," occur secondarily to reversal (withdrawal) of narcotic analgesia and sedation. mental depression, apathy, inability to concentrate, sleepiness, irritability, anorexia, nausea, and vomiting in high oral doses during initial treatment of opiate addiction. ",naloxone hydrochloride
sign_symptom,irritability,0.7869355," occur secondarily to reversal (withdrawal) of narcotic analgesia and sedation. mental depression, apathy, inability to concentrate, sleepiness, irritability, anorexia, nausea, and vomiting in high oral doses during initial treatment of opiate addiction. ",naloxone hydrochloride
sign_symptom,vomiting,0.99986327," occur secondarily to reversal (withdrawal) of narcotic analgesia and sedation. mental depression, apathy, inability to concentrate, sleepiness, irritability, anorexia, nausea, and vomiting in high oral doses during initial treatment of opiate addiction. ",naloxone hydrochloride
sign_symptom,intestinal disturbances,0.94355845," gastro-intestinal disturbances including nausea, vomiting, diarrhoea, haemolysis in g6pd deficiency, allergic reaction including urticaria, rashes, fever, arthralgia, eosinophilia, also myalgia, muscle weakness, phototoxicity, jaundice, visual disturbances and convulsions. ",nalidixic acid
sign_symptom,allergic reaction,0.9994071," gastro-intestinal disturbances including nausea, vomiting, diarrhoea, haemolysis in g6pd deficiency, allergic reaction including urticaria, rashes, fever, arthralgia, eosinophilia, also myalgia, muscle weakness, phototoxicity, jaundice, visual disturbances and convulsions. ",nalidixic acid
sign_symptom,rash,0.9997255," gastro-intestinal disturbances including nausea, vomiting, diarrhoea, haemolysis in g6pd deficiency, allergic reaction including urticaria, rashes, fever, arthralgia, eosinophilia, also myalgia, muscle weakness, phototoxicity, jaundice, visual disturbances and convulsions. ",nalidixic acid
sign_symptom,arthra,0.7455938," gastro-intestinal disturbances including nausea, vomiting, diarrhoea, haemolysis in g6pd deficiency, allergic reaction including urticaria, rashes, fever, arthralgia, eosinophilia, also myalgia, muscle weakness, phototoxicity, jaundice, visual disturbances and convulsions. ",nalidixic acid
sign_symptom,visual disturbances,0.9880542," gastro-intestinal disturbances including nausea, vomiting, diarrhoea, haemolysis in g6pd deficiency, allergic reaction including urticaria, rashes, fever, arthralgia, eosinophilia, also myalgia, muscle weakness, phototoxicity, jaundice, visual disturbances and convulsions. ",nalidixic acid
medication,nalbuphine,0.9519807," generally nalbuphine is well tolerated. however few side-effects like sedation, sweating, nausea, vomiting, dizziness, vertigo, dry mouth, headache, respiratory depression, dyspnea and asthma may be seen. ",nalbuphine
sign_symptom,dyspnea,0.99951005," generally nalbuphine is well tolerated. however few side-effects like sedation, sweating, nausea, vomiting, dizziness, vertigo, dry mouth, headache, respiratory depression, dyspnea and asthma may be seen. ",nalbuphine
sign_symptom,adverse reaction,0.9856409, the most common adverse reaction (1%) is pruritus. ,naftifine hydrochloride
disease_disorder,gastrointestinal disorders,0.9990261,"  
 gastrointestinal disorders (uncommon): diarrhoea, nausea, vomiting and epigastric pain. 
 renal and urinary disorders (very rare): calcium oxalate kidney stones. 
 skin and subcutaneous tissue disorders (uncommon): skin rash. 
 hepatobiliary disorders (rare): liver damage. 
  ",naftidrofuryl oxalate
sign_symptom,diarr,0.9397733,"  
 gastrointestinal disorders (uncommon): diarrhoea, nausea, vomiting and epigastric pain. 
 renal and urinary disorders (very rare): calcium oxalate kidney stones. 
 skin and subcutaneous tissue disorders (uncommon): skin rash. 
 hepatobiliary disorders (rare): liver damage. 
  ",naftidrofuryl oxalate
sign_symptom,nausea,0.9998367,"  
 gastrointestinal disorders (uncommon): diarrhoea, nausea, vomiting and epigastric pain. 
 renal and urinary disorders (very rare): calcium oxalate kidney stones. 
 skin and subcutaneous tissue disorders (uncommon): skin rash. 
 hepatobiliary disorders (rare): liver damage. 
  ",naftidrofuryl oxalate
sign_symptom,vomiting,0.9999069,"  
 gastrointestinal disorders (uncommon): diarrhoea, nausea, vomiting and epigastric pain. 
 renal and urinary disorders (very rare): calcium oxalate kidney stones. 
 skin and subcutaneous tissue disorders (uncommon): skin rash. 
 hepatobiliary disorders (rare): liver damage. 
  ",naftidrofuryl oxalate
disease_disorder,renal,0.9980326,"  
 gastrointestinal disorders (uncommon): diarrhoea, nausea, vomiting and epigastric pain. 
 renal and urinary disorders (very rare): calcium oxalate kidney stones. 
 skin and subcutaneous tissue disorders (uncommon): skin rash. 
 hepatobiliary disorders (rare): liver damage. 
  ",naftidrofuryl oxalate
disease_disorder,urinary disorders,0.9926328,"  
 gastrointestinal disorders (uncommon): diarrhoea, nausea, vomiting and epigastric pain. 
 renal and urinary disorders (very rare): calcium oxalate kidney stones. 
 skin and subcutaneous tissue disorders (uncommon): skin rash. 
 hepatobiliary disorders (rare): liver damage. 
  ",naftidrofuryl oxalate
disease_disorder,skin,0.99352705,"  
 gastrointestinal disorders (uncommon): diarrhoea, nausea, vomiting and epigastric pain. 
 renal and urinary disorders (very rare): calcium oxalate kidney stones. 
 skin and subcutaneous tissue disorders (uncommon): skin rash. 
 hepatobiliary disorders (rare): liver damage. 
  ",naftidrofuryl oxalate
sign_symptom,rash,0.9998436,"  
 gastrointestinal disorders (uncommon): diarrhoea, nausea, vomiting and epigastric pain. 
 renal and urinary disorders (very rare): calcium oxalate kidney stones. 
 skin and subcutaneous tissue disorders (uncommon): skin rash. 
 hepatobiliary disorders (rare): liver damage. 
  ",naftidrofuryl oxalate
disease_disorder,hepatobiliary disorders,0.99910235,"  
 gastrointestinal disorders (uncommon): diarrhoea, nausea, vomiting and epigastric pain. 
 renal and urinary disorders (very rare): calcium oxalate kidney stones. 
 skin and subcutaneous tissue disorders (uncommon): skin rash. 
 hepatobiliary disorders (rare): liver damage. 
  ",naftidrofuryl oxalate
sign_symptom,dyspepsia,0.999777,"  gastrointestinal : diarrhea (14%), dyspepsia (13%), abdominal pain (12%), constipation, flatulence, nausea, positive stool guaiac, dry mouth, gastritis, stomatitis, vomiting.   central nervous system : dizziness, headache, fatigue, increased sweating, insomnia, nervousness, somnolence.   dermatologic : pruritus, rash   special senses : tinnitus   miscellaneous : edema ",nabumetone
sign_symptom,pain,0.99996233,"  gastrointestinal : diarrhea (14%), dyspepsia (13%), abdominal pain (12%), constipation, flatulence, nausea, positive stool guaiac, dry mouth, gastritis, stomatitis, vomiting.   central nervous system : dizziness, headache, fatigue, increased sweating, insomnia, nervousness, somnolence.   dermatologic : pruritus, rash   special senses : tinnitus   miscellaneous : edema ",nabumetone
sign_symptom,flat,0.9998159,"  gastrointestinal : diarrhea (14%), dyspepsia (13%), abdominal pain (12%), constipation, flatulence, nausea, positive stool guaiac, dry mouth, gastritis, stomatitis, vomiting.   central nervous system : dizziness, headache, fatigue, increased sweating, insomnia, nervousness, somnolence.   dermatologic : pruritus, rash   special senses : tinnitus   miscellaneous : edema ",nabumetone
sign_symptom,rash,0.99994445,"  gastrointestinal : diarrhea (14%), dyspepsia (13%), abdominal pain (12%), constipation, flatulence, nausea, positive stool guaiac, dry mouth, gastritis, stomatitis, vomiting.   central nervous system : dizziness, headache, fatigue, increased sweating, insomnia, nervousness, somnolence.   dermatologic : pruritus, rash   special senses : tinnitus   miscellaneous : edema ",nabumetone
sign_symptom,adverse reactions,0.995734," the most common adverse reactions ( 20%) with single-agent use of nab-paclitaxel in metastaticbreast cancerarealopecia,neutropenia, sensoryneuropathy, abnormalecg, fatigue/asthenia, myalgia/arthralgia, ast elevation, alkaline phosphatase elevation,anemia, nausea, infections, and diarrhea.  the most common adverse reactions ( 20%) of nab-paclitaxel in combination with carboplatin fornon-small cell lung cancerare anemia, neutropenia,thrombocytopenia, alopecia,peripheral neuropathy, nausea, and fatigue.   the most common serious adverse reactions of nab-paclitaxel in combination with carboplatin for non-small cell lung cancer are anemia (4%) andpneumonia(3%).   the most common adverse reactions resulting in permanent discontinuation of nab-paclitaxel are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%).   the most common adverse reactions resulting in dose reduction of nab-paclitaxel are neutropenia (24%), thrombocytopenia (13%), and anemia (6%).   the most common adverse reactions leading to withholding or delay in nab-paclitaxel dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%). ",nab-paclitaxel [nanoparticle albumin-bound paclitaxel]
medication,nab - paclitaxel,0.94169325," the most common adverse reactions ( 20%) with single-agent use of nab-paclitaxel in metastaticbreast cancerarealopecia,neutropenia, sensoryneuropathy, abnormalecg, fatigue/asthenia, myalgia/arthralgia, ast elevation, alkaline phosphatase elevation,anemia, nausea, infections, and diarrhea.  the most common adverse reactions ( 20%) of nab-paclitaxel in combination with carboplatin fornon-small cell lung cancerare anemia, neutropenia,thrombocytopenia, alopecia,peripheral neuropathy, nausea, and fatigue.   the most common serious adverse reactions of nab-paclitaxel in combination with carboplatin for non-small cell lung cancer are anemia (4%) andpneumonia(3%).   the most common adverse reactions resulting in permanent discontinuation of nab-paclitaxel are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%).   the most common adverse reactions resulting in dose reduction of nab-paclitaxel are neutropenia (24%), thrombocytopenia (13%), and anemia (6%).   the most common adverse reactions leading to withholding or delay in nab-paclitaxel dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%). ",nab-paclitaxel [nanoparticle albumin-bound paclitaxel]
sign_symptom,abnormal,0.9947424," the most common adverse reactions ( 20%) with single-agent use of nab-paclitaxel in metastaticbreast cancerarealopecia,neutropenia, sensoryneuropathy, abnormalecg, fatigue/asthenia, myalgia/arthralgia, ast elevation, alkaline phosphatase elevation,anemia, nausea, infections, and diarrhea.  the most common adverse reactions ( 20%) of nab-paclitaxel in combination with carboplatin fornon-small cell lung cancerare anemia, neutropenia,thrombocytopenia, alopecia,peripheral neuropathy, nausea, and fatigue.   the most common serious adverse reactions of nab-paclitaxel in combination with carboplatin for non-small cell lung cancer are anemia (4%) andpneumonia(3%).   the most common adverse reactions resulting in permanent discontinuation of nab-paclitaxel are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%).   the most common adverse reactions resulting in dose reduction of nab-paclitaxel are neutropenia (24%), thrombocytopenia (13%), and anemia (6%).   the most common adverse reactions leading to withholding or delay in nab-paclitaxel dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%). ",nab-paclitaxel [nanoparticle albumin-bound paclitaxel]
sign_symptom,fatigue,0.9995628," the most common adverse reactions ( 20%) with single-agent use of nab-paclitaxel in metastaticbreast cancerarealopecia,neutropenia, sensoryneuropathy, abnormalecg, fatigue/asthenia, myalgia/arthralgia, ast elevation, alkaline phosphatase elevation,anemia, nausea, infections, and diarrhea.  the most common adverse reactions ( 20%) of nab-paclitaxel in combination with carboplatin fornon-small cell lung cancerare anemia, neutropenia,thrombocytopenia, alopecia,peripheral neuropathy, nausea, and fatigue.   the most common serious adverse reactions of nab-paclitaxel in combination with carboplatin for non-small cell lung cancer are anemia (4%) andpneumonia(3%).   the most common adverse reactions resulting in permanent discontinuation of nab-paclitaxel are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%).   the most common adverse reactions resulting in dose reduction of nab-paclitaxel are neutropenia (24%), thrombocytopenia (13%), and anemia (6%).   the most common adverse reactions leading to withholding or delay in nab-paclitaxel dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%). ",nab-paclitaxel [nanoparticle albumin-bound paclitaxel]
sign_symptom,myalgia,0.86237955," the most common adverse reactions ( 20%) with single-agent use of nab-paclitaxel in metastaticbreast cancerarealopecia,neutropenia, sensoryneuropathy, abnormalecg, fatigue/asthenia, myalgia/arthralgia, ast elevation, alkaline phosphatase elevation,anemia, nausea, infections, and diarrhea.  the most common adverse reactions ( 20%) of nab-paclitaxel in combination with carboplatin fornon-small cell lung cancerare anemia, neutropenia,thrombocytopenia, alopecia,peripheral neuropathy, nausea, and fatigue.   the most common serious adverse reactions of nab-paclitaxel in combination with carboplatin for non-small cell lung cancer are anemia (4%) andpneumonia(3%).   the most common adverse reactions resulting in permanent discontinuation of nab-paclitaxel are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%).   the most common adverse reactions resulting in dose reduction of nab-paclitaxel are neutropenia (24%), thrombocytopenia (13%), and anemia (6%).   the most common adverse reactions leading to withholding or delay in nab-paclitaxel dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%). ",nab-paclitaxel [nanoparticle albumin-bound paclitaxel]
medication,paclitaxel,0.97539145," the most common adverse reactions ( 20%) with single-agent use of nab-paclitaxel in metastaticbreast cancerarealopecia,neutropenia, sensoryneuropathy, abnormalecg, fatigue/asthenia, myalgia/arthralgia, ast elevation, alkaline phosphatase elevation,anemia, nausea, infections, and diarrhea.  the most common adverse reactions ( 20%) of nab-paclitaxel in combination with carboplatin fornon-small cell lung cancerare anemia, neutropenia,thrombocytopenia, alopecia,peripheral neuropathy, nausea, and fatigue.   the most common serious adverse reactions of nab-paclitaxel in combination with carboplatin for non-small cell lung cancer are anemia (4%) andpneumonia(3%).   the most common adverse reactions resulting in permanent discontinuation of nab-paclitaxel are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%).   the most common adverse reactions resulting in dose reduction of nab-paclitaxel are neutropenia (24%), thrombocytopenia (13%), and anemia (6%).   the most common adverse reactions leading to withholding or delay in nab-paclitaxel dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%). ",nab-paclitaxel [nanoparticle albumin-bound paclitaxel]
medication,carboplatin,0.9806705," the most common adverse reactions ( 20%) with single-agent use of nab-paclitaxel in metastaticbreast cancerarealopecia,neutropenia, sensoryneuropathy, abnormalecg, fatigue/asthenia, myalgia/arthralgia, ast elevation, alkaline phosphatase elevation,anemia, nausea, infections, and diarrhea.  the most common adverse reactions ( 20%) of nab-paclitaxel in combination with carboplatin fornon-small cell lung cancerare anemia, neutropenia,thrombocytopenia, alopecia,peripheral neuropathy, nausea, and fatigue.   the most common serious adverse reactions of nab-paclitaxel in combination with carboplatin for non-small cell lung cancer are anemia (4%) andpneumonia(3%).   the most common adverse reactions resulting in permanent discontinuation of nab-paclitaxel are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%).   the most common adverse reactions resulting in dose reduction of nab-paclitaxel are neutropenia (24%), thrombocytopenia (13%), and anemia (6%).   the most common adverse reactions leading to withholding or delay in nab-paclitaxel dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%). ",nab-paclitaxel [nanoparticle albumin-bound paclitaxel]
disease_disorder,lung,0.71816003," the most common adverse reactions ( 20%) with single-agent use of nab-paclitaxel in metastaticbreast cancerarealopecia,neutropenia, sensoryneuropathy, abnormalecg, fatigue/asthenia, myalgia/arthralgia, ast elevation, alkaline phosphatase elevation,anemia, nausea, infections, and diarrhea.  the most common adverse reactions ( 20%) of nab-paclitaxel in combination with carboplatin fornon-small cell lung cancerare anemia, neutropenia,thrombocytopenia, alopecia,peripheral neuropathy, nausea, and fatigue.   the most common serious adverse reactions of nab-paclitaxel in combination with carboplatin for non-small cell lung cancer are anemia (4%) andpneumonia(3%).   the most common adverse reactions resulting in permanent discontinuation of nab-paclitaxel are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%).   the most common adverse reactions resulting in dose reduction of nab-paclitaxel are neutropenia (24%), thrombocytopenia (13%), and anemia (6%).   the most common adverse reactions leading to withholding or delay in nab-paclitaxel dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%). ",nab-paclitaxel [nanoparticle albumin-bound paclitaxel]
sign_symptom,peripheral neuropathy,0.9710954," the most common adverse reactions ( 20%) with single-agent use of nab-paclitaxel in metastaticbreast cancerarealopecia,neutropenia, sensoryneuropathy, abnormalecg, fatigue/asthenia, myalgia/arthralgia, ast elevation, alkaline phosphatase elevation,anemia, nausea, infections, and diarrhea.  the most common adverse reactions ( 20%) of nab-paclitaxel in combination with carboplatin fornon-small cell lung cancerare anemia, neutropenia,thrombocytopenia, alopecia,peripheral neuropathy, nausea, and fatigue.   the most common serious adverse reactions of nab-paclitaxel in combination with carboplatin for non-small cell lung cancer are anemia (4%) andpneumonia(3%).   the most common adverse reactions resulting in permanent discontinuation of nab-paclitaxel are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%).   the most common adverse reactions resulting in dose reduction of nab-paclitaxel are neutropenia (24%), thrombocytopenia (13%), and anemia (6%).   the most common adverse reactions leading to withholding or delay in nab-paclitaxel dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%). ",nab-paclitaxel [nanoparticle albumin-bound paclitaxel]
sign_symptom,adverse events,0.99097574," adverse events (incidence &gt;1% and subject difference) were dysgeusia, diarrhea, hypertension, and myalgia. ",nirmatrelvir + ritonavir
sign_symptom,adverse reactions,0.9988295," in the pivotal engot-ov16 study, adverse reactions (adrs) occurring &gt; 10% of patients receiving niraparib monotherapy were nausea, thrombocytopenia, fatigue/asthenia, anaemia, constipation, vomiting, abdominal pain, neutropenia, insomnia, headache, decreased appetite, nasopharyngitis, diarrhoea, dyspnea, hypertension, dyspepsia, back pain, dizziness, cough, urinary tract infection, arthralgia, palpitations, and dysgeusia. the most common serious adverse reactions &gt;1% (treatment-emergent frequencies) were thrombocytopenia and anaemia. ",niraparib
sign_symptom,fatigue,0.9998274," in the pivotal engot-ov16 study, adverse reactions (adrs) occurring &gt; 10% of patients receiving niraparib monotherapy were nausea, thrombocytopenia, fatigue/asthenia, anaemia, constipation, vomiting, abdominal pain, neutropenia, insomnia, headache, decreased appetite, nasopharyngitis, diarrhoea, dyspnea, hypertension, dyspepsia, back pain, dizziness, cough, urinary tract infection, arthralgia, palpitations, and dysgeusia. the most common serious adverse reactions &gt;1% (treatment-emergent frequencies) were thrombocytopenia and anaemia. ",niraparib
sign_symptom,decreased appetite,0.81187916," in the pivotal engot-ov16 study, adverse reactions (adrs) occurring &gt; 10% of patients receiving niraparib monotherapy were nausea, thrombocytopenia, fatigue/asthenia, anaemia, constipation, vomiting, abdominal pain, neutropenia, insomnia, headache, decreased appetite, nasopharyngitis, diarrhoea, dyspnea, hypertension, dyspepsia, back pain, dizziness, cough, urinary tract infection, arthralgia, palpitations, and dysgeusia. the most common serious adverse reactions &gt;1% (treatment-emergent frequencies) were thrombocytopenia and anaemia. ",niraparib
sign_symptom,nasophar,0.8032668," in the pivotal engot-ov16 study, adverse reactions (adrs) occurring &gt; 10% of patients receiving niraparib monotherapy were nausea, thrombocytopenia, fatigue/asthenia, anaemia, constipation, vomiting, abdominal pain, neutropenia, insomnia, headache, decreased appetite, nasopharyngitis, diarrhoea, dyspnea, hypertension, dyspepsia, back pain, dizziness, cough, urinary tract infection, arthralgia, palpitations, and dysgeusia. the most common serious adverse reactions &gt;1% (treatment-emergent frequencies) were thrombocytopenia and anaemia. ",niraparib
medication,placebo,0.7239456," summary of the safety profile: nintedanib has been studied in clinical trials of 1,529 patients suffering from ipf. the safety data provided in the following are based on the two phase iii, randomized, double-blind, placebo-controlled studies in 1,061 patients comparing treatment with nintedanib 150 mg twice daily to placebo for 52 weeks (inpulsis-1 and inpulsis-2) and based on data observed during the post-marketing period.  the most frequently reported adverse reactions associated with the use of nintedanib included diarrhea, nausea and vomiting, abdominal pain, decreased appetite, weight decreased and hepatic enzyme increased.  tabulated list of adverse reactions: the below table provides a summary of the adverse reactions by meddra system organ class (soc) and frequency category.  below table summarizes the frequencies of adverse drug reactions (adrs) that were reported in the nintedanib group (638 patients) pooled from the two placebo-controlled phase iii clinical trials of 52 weeks duration or from the post-marketing period.  frequency categories are defined using the following convention: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). ",nintedanib
sign_symptom,adverse reactions,0.99790287," summary of the safety profile: nintedanib has been studied in clinical trials of 1,529 patients suffering from ipf. the safety data provided in the following are based on the two phase iii, randomized, double-blind, placebo-controlled studies in 1,061 patients comparing treatment with nintedanib 150 mg twice daily to placebo for 52 weeks (inpulsis-1 and inpulsis-2) and based on data observed during the post-marketing period.  the most frequently reported adverse reactions associated with the use of nintedanib included diarrhea, nausea and vomiting, abdominal pain, decreased appetite, weight decreased and hepatic enzyme increased.  tabulated list of adverse reactions: the below table provides a summary of the adverse reactions by meddra system organ class (soc) and frequency category.  below table summarizes the frequencies of adverse drug reactions (adrs) that were reported in the nintedanib group (638 patients) pooled from the two placebo-controlled phase iii clinical trials of 52 weeks duration or from the post-marketing period.  frequency categories are defined using the following convention: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). ",nintedanib
sign_symptom,nausea,0.99984074," summary of the safety profile: nintedanib has been studied in clinical trials of 1,529 patients suffering from ipf. the safety data provided in the following are based on the two phase iii, randomized, double-blind, placebo-controlled studies in 1,061 patients comparing treatment with nintedanib 150 mg twice daily to placebo for 52 weeks (inpulsis-1 and inpulsis-2) and based on data observed during the post-marketing period.  the most frequently reported adverse reactions associated with the use of nintedanib included diarrhea, nausea and vomiting, abdominal pain, decreased appetite, weight decreased and hepatic enzyme increased.  tabulated list of adverse reactions: the below table provides a summary of the adverse reactions by meddra system organ class (soc) and frequency category.  below table summarizes the frequencies of adverse drug reactions (adrs) that were reported in the nintedanib group (638 patients) pooled from the two placebo-controlled phase iii clinical trials of 52 weeks duration or from the post-marketing period.  frequency categories are defined using the following convention: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). ",nintedanib
sign_symptom,decreased appetite,0.9719738," summary of the safety profile: nintedanib has been studied in clinical trials of 1,529 patients suffering from ipf. the safety data provided in the following are based on the two phase iii, randomized, double-blind, placebo-controlled studies in 1,061 patients comparing treatment with nintedanib 150 mg twice daily to placebo for 52 weeks (inpulsis-1 and inpulsis-2) and based on data observed during the post-marketing period.  the most frequently reported adverse reactions associated with the use of nintedanib included diarrhea, nausea and vomiting, abdominal pain, decreased appetite, weight decreased and hepatic enzyme increased.  tabulated list of adverse reactions: the below table provides a summary of the adverse reactions by meddra system organ class (soc) and frequency category.  below table summarizes the frequencies of adverse drug reactions (adrs) that were reported in the nintedanib group (638 patients) pooled from the two placebo-controlled phase iii clinical trials of 52 weeks duration or from the post-marketing period.  frequency categories are defined using the following convention: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). ",nintedanib
sign_symptom,weight,0.99622536," summary of the safety profile: nintedanib has been studied in clinical trials of 1,529 patients suffering from ipf. the safety data provided in the following are based on the two phase iii, randomized, double-blind, placebo-controlled studies in 1,061 patients comparing treatment with nintedanib 150 mg twice daily to placebo for 52 weeks (inpulsis-1 and inpulsis-2) and based on data observed during the post-marketing period.  the most frequently reported adverse reactions associated with the use of nintedanib included diarrhea, nausea and vomiting, abdominal pain, decreased appetite, weight decreased and hepatic enzyme increased.  tabulated list of adverse reactions: the below table provides a summary of the adverse reactions by meddra system organ class (soc) and frequency category.  below table summarizes the frequencies of adverse drug reactions (adrs) that were reported in the nintedanib group (638 patients) pooled from the two placebo-controlled phase iii clinical trials of 52 weeks duration or from the post-marketing period.  frequency categories are defined using the following convention: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). ",nintedanib
sign_symptom,adverse drug reactions,0.9677272," summary of the safety profile: nintedanib has been studied in clinical trials of 1,529 patients suffering from ipf. the safety data provided in the following are based on the two phase iii, randomized, double-blind, placebo-controlled studies in 1,061 patients comparing treatment with nintedanib 150 mg twice daily to placebo for 52 weeks (inpulsis-1 and inpulsis-2) and based on data observed during the post-marketing period.  the most frequently reported adverse reactions associated with the use of nintedanib included diarrhea, nausea and vomiting, abdominal pain, decreased appetite, weight decreased and hepatic enzyme increased.  tabulated list of adverse reactions: the below table provides a summary of the adverse reactions by meddra system organ class (soc) and frequency category.  below table summarizes the frequencies of adverse drug reactions (adrs) that were reported in the nintedanib group (638 patients) pooled from the two placebo-controlled phase iii clinical trials of 52 weeks duration or from the post-marketing period.  frequency categories are defined using the following convention: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). ",nintedanib
sign_symptom,flushing,0.9996309," although side effects from nimodipine are not common, the following can occur: headache, dizziness, flushing (feeling of warmth), heartburn, fast heartbeat, slow heartbeat, upset stomach, stomach pain, constipation, depression etc. ",nimodipine
sign_symptom,depression,0.98248184," although side effects from nimodipine are not common, the following can occur: headache, dizziness, flushing (feeling of warmth), heartburn, fast heartbeat, slow heartbeat, upset stomach, stomach pain, constipation, depression etc. ",nimodipine
sign_symptom,vomiting,0.9998369," epigastric discomfort, heartburn or abdominal cramps, nausea, vomiting and diarrhoea; skin rash, pruritus, oedema, headache, dizziness, drowsiness; hypersensitivity reactions (e.g. bronchospasm, rhinitis, angioedema urticaria); gi haemorrhage/perforation; bullous/erosive stomatitis, purpura, thrombocytopenia, toxic epidermal necrolysis, haematuria, oliguria, and renal failure; increases in liver enzymes. ",nimesulide
sign_symptom,hypersensitivity reactions,0.9996772," epigastric discomfort, heartburn or abdominal cramps, nausea, vomiting and diarrhoea; skin rash, pruritus, oedema, headache, dizziness, drowsiness; hypersensitivity reactions (e.g. bronchospasm, rhinitis, angioedema urticaria); gi haemorrhage/perforation; bullous/erosive stomatitis, purpura, thrombocytopenia, toxic epidermal necrolysis, haematuria, oliguria, and renal failure; increases in liver enzymes. ",nimesulide
sign_symptom,fatigue,0.98896295," rash, pruritus, hepatotoxicity, headache, fever, fatigue, gi disturbances (nausea, constipation, diarrhoea), alopecia, asthenia, muscle spasms, arthralgia, myalgia, pain (e.g. musculoskeletal or chest pain), oedema, folliculitis, papilloma, insomnia, dizziness, vertigo, anxiety, paraesthesia, hyperhidrosis, dry skin, urticaria, acne, conjunctivitis, dry eye, flushing, dyspnoea, cough, myelosuppression (e.g. thrombocytopenia, neutropenia, and anaemia), thrombotic disorders or haemorrhage, arrhythmias, heart failure, pericarditis, palpitations, htn, angina, mi; elevated ast/alt, serum lipase; electrolyte imbalances. ",nilotinib
sign_symptom,gi disturbances,0.99181867," rash, pruritus, hepatotoxicity, headache, fever, fatigue, gi disturbances (nausea, constipation, diarrhoea), alopecia, asthenia, muscle spasms, arthralgia, myalgia, pain (e.g. musculoskeletal or chest pain), oedema, folliculitis, papilloma, insomnia, dizziness, vertigo, anxiety, paraesthesia, hyperhidrosis, dry skin, urticaria, acne, conjunctivitis, dry eye, flushing, dyspnoea, cough, myelosuppression (e.g. thrombocytopenia, neutropenia, and anaemia), thrombotic disorders or haemorrhage, arrhythmias, heart failure, pericarditis, palpitations, htn, angina, mi; elevated ast/alt, serum lipase; electrolyte imbalances. ",nilotinib
sign_symptom,myal,0.931998," rash, pruritus, hepatotoxicity, headache, fever, fatigue, gi disturbances (nausea, constipation, diarrhoea), alopecia, asthenia, muscle spasms, arthralgia, myalgia, pain (e.g. musculoskeletal or chest pain), oedema, folliculitis, papilloma, insomnia, dizziness, vertigo, anxiety, paraesthesia, hyperhidrosis, dry skin, urticaria, acne, conjunctivitis, dry eye, flushing, dyspnoea, cough, myelosuppression (e.g. thrombocytopenia, neutropenia, and anaemia), thrombotic disorders or haemorrhage, arrhythmias, heart failure, pericarditis, palpitations, htn, angina, mi; elevated ast/alt, serum lipase; electrolyte imbalances. ",nilotinib
sign_symptom,pain,0.9999124," rash, pruritus, hepatotoxicity, headache, fever, fatigue, gi disturbances (nausea, constipation, diarrhoea), alopecia, asthenia, muscle spasms, arthralgia, myalgia, pain (e.g. musculoskeletal or chest pain), oedema, folliculitis, papilloma, insomnia, dizziness, vertigo, anxiety, paraesthesia, hyperhidrosis, dry skin, urticaria, acne, conjunctivitis, dry eye, flushing, dyspnoea, cough, myelosuppression (e.g. thrombocytopenia, neutropenia, and anaemia), thrombotic disorders or haemorrhage, arrhythmias, heart failure, pericarditis, palpitations, htn, angina, mi; elevated ast/alt, serum lipase; electrolyte imbalances. ",nilotinib
sign_symptom,myelosuppression,0.953654," rash, pruritus, hepatotoxicity, headache, fever, fatigue, gi disturbances (nausea, constipation, diarrhoea), alopecia, asthenia, muscle spasms, arthralgia, myalgia, pain (e.g. musculoskeletal or chest pain), oedema, folliculitis, papilloma, insomnia, dizziness, vertigo, anxiety, paraesthesia, hyperhidrosis, dry skin, urticaria, acne, conjunctivitis, dry eye, flushing, dyspnoea, cough, myelosuppression (e.g. thrombocytopenia, neutropenia, and anaemia), thrombotic disorders or haemorrhage, arrhythmias, heart failure, pericarditis, palpitations, htn, angina, mi; elevated ast/alt, serum lipase; electrolyte imbalances. ",nilotinib
sign_symptom,- effects,0.76575935," the following is a list of possible side-effects that may occur from all constituting ingredients of nikethamide injection: skin irritation, eye irritation, respiratory irritation. ",nikethamide
medication,nikethamide,0.99063545," the following is a list of possible side-effects that may occur from all constituting ingredients of nikethamide injection: skin irritation, eye irritation, respiratory irritation. ",nikethamide
sign_symptom,photosensitivity,0.999372," headache, flushing, lethargy, gravitational oedema rash, nausea, increased frequency of micturation, eye pain, gum hyperplasia, depression, tremor, photosensitivity and few cases of jaundice have been reported. these reactions may regress on discontinuation of therapy. its introduction may induce attacks of ischaemic pain in some patients with angina pectoris. ",nifedipine
sign_symptom,pain,0.9998908," headache, flushing, lethargy, gravitational oedema rash, nausea, increased frequency of micturation, eye pain, gum hyperplasia, depression, tremor, photosensitivity and few cases of jaundice have been reported. these reactions may regress on discontinuation of therapy. its introduction may induce attacks of ischaemic pain in some patients with angina pectoris. ",nifedipine
sign_symptom,adverse reactions,0.99932444," niacin is generally well tolerated; adverse reactions have been mild and transient. the most frequent advers effects were flushing, itching, pruritis, nausea and gi upset, jaundice, hypotension, tachycardia, increased serum blood glucose and uric acid levels, myalgia. ",nicotinic acid [niacin]
sign_symptom,nausea,0.9999075," niacin is generally well tolerated; adverse reactions have been mild and transient. the most frequent advers effects were flushing, itching, pruritis, nausea and gi upset, jaundice, hypotension, tachycardia, increased serum blood glucose and uric acid levels, myalgia. ",nicotinic acid [niacin]
sign_symptom,hypotens,0.92153215," niacin is generally well tolerated; adverse reactions have been mild and transient. the most frequent advers effects were flushing, itching, pruritis, nausea and gi upset, jaundice, hypotension, tachycardia, increased serum blood glucose and uric acid levels, myalgia. ",nicotinic acid [niacin]
sign_symptom,headache,0.9999348," headache (usually transitory), flushing, dizziness, nausea, vomiting and weakness. hypotension and reflex tachycardia at high doses. ",nicorandil
sign_symptom,vomiting,0.9999362," headache (usually transitory), flushing, dizziness, nausea, vomiting and weakness. hypotension and reflex tachycardia at high doses. ",nicorandil
sign_symptom,adverse reaction,0.9996929," the most common ocular adverse reaction observed in controlled clinical studies with netarsudil was conjunctival hyperemia, corneal verticillata, instillation site pain, corneal staining and blurred vision. ",netarsudil dimesylate
sign_symptom,adverse reaction,0.99990046," the most common ocular adverse reaction observed in controlled clinical studies with netarsudil &amp; latanoprost was conjunctival hyperemia, instillation site pain, corneal verticillata, instillation site discomfort, foreign body sensation and blurred visions were reported in few patients. ",netarsudil + latanoprost
sign_symptom,foreign body sensation,0.9997365," the most common ocular adverse reaction observed in controlled clinical studies with netarsudil &amp; latanoprost was conjunctival hyperemia, instillation site pain, corneal verticillata, instillation site discomfort, foreign body sensation and blurred visions were reported in few patients. ",netarsudil + latanoprost
sign_symptom,blurred visions,0.9993902," the most common ocular adverse reaction observed in controlled clinical studies with netarsudil &amp; latanoprost was conjunctival hyperemia, instillation site pain, corneal verticillata, instillation site discomfort, foreign body sensation and blurred visions were reported in few patients. ",netarsudil + latanoprost
sign_symptom,hyper,0.99985445," reported side effects are foreign body sensation, lid margin crusting, ocular discomfort, ocular hyperemia etc. ",nepafenac
sign_symptom,salivation,0.8483012," nausea, vomiting, increased salivation, diarrhoea and abdominal cramps (more marked with high doses). signs of overdose are increased gastrointestinal discomfort, bronchial secretions and sweating, involuntary defecation and micturition, miosis, nystagmus, bradycardia, hypotension, agitation, excessive dreaming and weakness eventually leading to fasciculation and paralysis. ",neostigmine methyl sulphate
sign_symptom,diarr,0.9987266," nausea, vomiting, increased salivation, diarrhoea and abdominal cramps (more marked with high doses). signs of overdose are increased gastrointestinal discomfort, bronchial secretions and sweating, involuntary defecation and micturition, miosis, nystagmus, bradycardia, hypotension, agitation, excessive dreaming and weakness eventually leading to fasciculation and paralysis. ",neostigmine methyl sulphate
sign_symptom,bronchial secretions,0.9986808," nausea, vomiting, increased salivation, diarrhoea and abdominal cramps (more marked with high doses). signs of overdose are increased gastrointestinal discomfort, bronchial secretions and sweating, involuntary defecation and micturition, miosis, nystagmus, bradycardia, hypotension, agitation, excessive dreaming and weakness eventually leading to fasciculation and paralysis. ",neostigmine methyl sulphate
sign_symptom,dreaming,0.9920415," nausea, vomiting, increased salivation, diarrhoea and abdominal cramps (more marked with high doses). signs of overdose are increased gastrointestinal discomfort, bronchial secretions and sweating, involuntary defecation and micturition, miosis, nystagmus, bradycardia, hypotension, agitation, excessive dreaming and weakness eventually leading to fasciculation and paralysis. ",neostigmine methyl sulphate
sign_symptom,weakness,0.99968493," nausea, vomiting, increased salivation, diarrhoea and abdominal cramps (more marked with high doses). signs of overdose are increased gastrointestinal discomfort, bronchial secretions and sweating, involuntary defecation and micturition, miosis, nystagmus, bradycardia, hypotension, agitation, excessive dreaming and weakness eventually leading to fasciculation and paralysis. ",neostigmine methyl sulphate
medication,antibiotics,0.9873568," topical antibiotics, particularly neomycin sulphate, may cause cutaneous sensitization. the manifestations of sensitization to topical antibiotics are usually itching and reddening. when used in small doses, no common side effects have been reported with this product. ",neomycin sulphate + polymyxin b sulphate + pramoxine
sign_symptom,rash,0.99971706," common side effectsare nausea; vomiting; pain, burning, or swelling; skin rashes; possible kidney problems; hearing loss; dizziness; unusual numbness of the skin; muscle twitching; seizures; pain; redness; swelling at the injection site. ",neomycin sulfate + bacitracin zinc + polymyxin b sulfate
sign_symptom,numb,0.99991846," common side effectsare nausea; vomiting; pain, burning, or swelling; skin rashes; possible kidney problems; hearing loss; dizziness; unusual numbness of the skin; muscle twitching; seizures; pain; redness; swelling at the injection site. ",neomycin sulfate + bacitracin zinc + polymyxin b sulfate
sign_symptom,swelling,0.99992335," common side effectsare nausea; vomiting; pain, burning, or swelling; skin rashes; possible kidney problems; hearing loss; dizziness; unusual numbness of the skin; muscle twitching; seizures; pain; redness; swelling at the injection site. ",neomycin sulfate + bacitracin zinc + polymyxin b sulfate
sign_symptom,allergic reactions,0.9998768," this preparationis usually well tolerated. in rare cases, allergic reactions may be occurred. ",neomycin sulfate + bacitracin zinc
medication,acid,0.83757746," the most common side effects of obeticholic acid include: pruritus, fatigue &amp; stomach pain and discomfort. other common side effects include rash, arthralgia (joint pain), oropharyngeal pain (pain in the middle part of the throat), dizziness, constipation, abnormal thyroid function, and eczema (inflammation of the skin). ",obeticholic acid
sign_symptom,fatigue,0.99993217," the most common side effects of obeticholic acid include: pruritus, fatigue &amp; stomach pain and discomfort. other common side effects include rash, arthralgia (joint pain), oropharyngeal pain (pain in the middle part of the throat), dizziness, constipation, abnormal thyroid function, and eczema (inflammation of the skin). ",obeticholic acid
sign_symptom,pain,0.9999304," the most common side effects of obeticholic acid include: pruritus, fatigue &amp; stomach pain and discomfort. other common side effects include rash, arthralgia (joint pain), oropharyngeal pain (pain in the middle part of the throat), dizziness, constipation, abnormal thyroid function, and eczema (inflammation of the skin). ",obeticholic acid
sign_symptom,arthralgia,0.9996842," the most common side effects of obeticholic acid include: pruritus, fatigue &amp; stomach pain and discomfort. other common side effects include rash, arthralgia (joint pain), oropharyngeal pain (pain in the middle part of the throat), dizziness, constipation, abnormal thyroid function, and eczema (inflammation of the skin). ",obeticholic acid
sign_symptom,inflammation,0.95675325," the most common side effects of obeticholic acid include: pruritus, fatigue &amp; stomach pain and discomfort. other common side effects include rash, arthralgia (joint pain), oropharyngeal pain (pain in the middle part of the throat), dizziness, constipation, abnormal thyroid function, and eczema (inflammation of the skin). ",obeticholic acid
sign_symptom,adverse events,0.9998785," the frequency of adverse events reported in patients using nystatin cream is less than 0.1%. the more common events that were reported include allergic reactions, burning, itching, rash,eczema, and pain on application. ",nystatin (topical)
sign_symptom,allergic,0.9524812," the frequency of adverse events reported in patients using nystatin cream is less than 0.1%. the more common events that were reported include allergic reactions, burning, itching, rash,eczema, and pain on application. ",nystatin (topical)
sign_symptom,pain,0.9998745," the frequency of adverse events reported in patients using nystatin cream is less than 0.1%. the more common events that were reported include allergic reactions, burning, itching, rash,eczema, and pain on application. ",nystatin (topical)
sign_symptom,nausea,0.99986494," nausea, vomiting and diarrhoea have occasionally been reported with high doses of nystatin. no systemic effects or allergic reactions have been associated with its oral dose. ",nystatin (oral)
sign_symptom,vomiting,0.9999349," nausea, vomiting and diarrhoea have occasionally been reported with high doses of nystatin. no systemic effects or allergic reactions have been associated with its oral dose. ",nystatin (oral)
sign_symptom,diarr,0.88363016," nausea, vomiting and diarrhoea have occasionally been reported with high doses of nystatin. no systemic effects or allergic reactions have been associated with its oral dose. ",nystatin (oral)
sign_symptom,effects,0.9792579," nausea, vomiting and diarrhoea have occasionally been reported with high doses of nystatin. no systemic effects or allergic reactions have been associated with its oral dose. ",nystatin (oral)
sign_symptom,allergic reactions,0.9999149," nausea, vomiting and diarrhoea have occasionally been reported with high doses of nystatin. no systemic effects or allergic reactions have been associated with its oral dose. ",nystatin (oral)
sign_symptom,consti,0.8444344," the most common side effects include dry mouth, sedation, constipation and increased appetite, mild blurred vision, tinnitus, often euphoria and mania. an occasional side effect is a rapid or irregular heartbeat. alcohol may exacerbate some of its side effects and should be avoided. ",nortriptyline
sign_symptom,in weight,0.8550737," edema, weakness, amenorrhea, breakthrough bleeding, change in menstrual flow, spotting, anorexia, dvt, thrombophlebitis, depression, dizziness, headache, nervousness, somnolence, b reast tenderness, galactorrhea, abdominal pain, nausea, vomiting, change in weight, cholestatic jaundice ",norgestrel + ethinyl estradiol + ferrous fumarate
sign_symptom,adverse reactions,0.9997216," an increased risk of the following adverse reactions has been reported with the use of progestin-only oral contraceptives: delayed follicular atresia/ovarian cysts, menstrual irregularity, changes in menstrual flow; breakthrough bleeding/spotting; amenorrhea, prolonged bleeding. the following adverse reactions were reported in 5% of subjects in the norgestreltablet clinical studies: 
 
 headache 
 dizziness 
 nausea 
 increased appetite 
 abdominal pain, cramps and bloating 
 fatigue 
 vaginal discharge 
 dysmenorrhea 
 nervousness 
 backache 
 breast discomfort 
 acne 
  ",norgestrel
sign_symptom,headache,0.99995387," an increased risk of the following adverse reactions has been reported with the use of progestin-only oral contraceptives: delayed follicular atresia/ovarian cysts, menstrual irregularity, changes in menstrual flow; breakthrough bleeding/spotting; amenorrhea, prolonged bleeding. the following adverse reactions were reported in 5% of subjects in the norgestreltablet clinical studies: 
 
 headache 
 dizziness 
 nausea 
 increased appetite 
 abdominal pain, cramps and bloating 
 fatigue 
 vaginal discharge 
 dysmenorrhea 
 nervousness 
 backache 
 breast discomfort 
 acne 
  ",norgestrel
sign_symptom,nausea,0.9999527," an increased risk of the following adverse reactions has been reported with the use of progestin-only oral contraceptives: delayed follicular atresia/ovarian cysts, menstrual irregularity, changes in menstrual flow; breakthrough bleeding/spotting; amenorrhea, prolonged bleeding. the following adverse reactions were reported in 5% of subjects in the norgestreltablet clinical studies: 
 
 headache 
 dizziness 
 nausea 
 increased appetite 
 abdominal pain, cramps and bloating 
 fatigue 
 vaginal discharge 
 dysmenorrhea 
 nervousness 
 backache 
 breast discomfort 
 acne 
  ",norgestrel
sign_symptom,fatigue,0.9999466," an increased risk of the following adverse reactions has been reported with the use of progestin-only oral contraceptives: delayed follicular atresia/ovarian cysts, menstrual irregularity, changes in menstrual flow; breakthrough bleeding/spotting; amenorrhea, prolonged bleeding. the following adverse reactions were reported in 5% of subjects in the norgestreltablet clinical studies: 
 
 headache 
 dizziness 
 nausea 
 increased appetite 
 abdominal pain, cramps and bloating 
 fatigue 
 vaginal discharge 
 dysmenorrhea 
 nervousness 
 backache 
 breast discomfort 
 acne 
  ",norgestrel
sign_symptom,dysmenorrhea,0.96895504," an increased risk of the following adverse reactions has been reported with the use of progestin-only oral contraceptives: delayed follicular atresia/ovarian cysts, menstrual irregularity, changes in menstrual flow; breakthrough bleeding/spotting; amenorrhea, prolonged bleeding. the following adverse reactions were reported in 5% of subjects in the norgestreltablet clinical studies: 
 
 headache 
 dizziness 
 nausea 
 increased appetite 
 abdominal pain, cramps and bloating 
 fatigue 
 vaginal discharge 
 dysmenorrhea 
 nervousness 
 backache 
 breast discomfort 
 acne 
  ",norgestrel
sign_symptom,nervousness,0.9999258," an increased risk of the following adverse reactions has been reported with the use of progestin-only oral contraceptives: delayed follicular atresia/ovarian cysts, menstrual irregularity, changes in menstrual flow; breakthrough bleeding/spotting; amenorrhea, prolonged bleeding. the following adverse reactions were reported in 5% of subjects in the norgestreltablet clinical studies: 
 
 headache 
 dizziness 
 nausea 
 increased appetite 
 abdominal pain, cramps and bloating 
 fatigue 
 vaginal discharge 
 dysmenorrhea 
 nervousness 
 backache 
 breast discomfort 
 acne 
  ",norgestrel
sign_symptom,discomfort,0.9999596," an increased risk of the following adverse reactions has been reported with the use of progestin-only oral contraceptives: delayed follicular atresia/ovarian cysts, menstrual irregularity, changes in menstrual flow; breakthrough bleeding/spotting; amenorrhea, prolonged bleeding. the following adverse reactions were reported in 5% of subjects in the norgestreltablet clinical studies: 
 
 headache 
 dizziness 
 nausea 
 increased appetite 
 abdominal pain, cramps and bloating 
 fatigue 
 vaginal discharge 
 dysmenorrhea 
 nervousness 
 backache 
 breast discomfort 
 acne 
  ",norgestrel
sign_symptom,acne,0.98103166," an increased risk of the following adverse reactions has been reported with the use of progestin-only oral contraceptives: delayed follicular atresia/ovarian cysts, menstrual irregularity, changes in menstrual flow; breakthrough bleeding/spotting; amenorrhea, prolonged bleeding. the following adverse reactions were reported in 5% of subjects in the norgestreltablet clinical studies: 
 
 headache 
 dizziness 
 nausea 
 increased appetite 
 abdominal pain, cramps and bloating 
 fatigue 
 vaginal discharge 
 dysmenorrhea 
 nervousness 
 backache 
 breast discomfort 
 acne 
  ",norgestrel
sign_symptom,side - effects,0.99701005," side-effects are more common during the first months after start of intake of norethisterone, and subside with a duration of treatment. the side-effects are mentioned below: 
 
 eye disorders- visual disturbance 
 gi disorders- nausea 
 general disorders and administration site- conditions headache, edema 
 nervous system disorders- migraine, respiratory, thoracic and mediastinal disorders- dyspnoea, 
 skin and subcutaneous tissue disorders- hypersensitivity (eg. rash, urticaria). 
  ",norethisterone acetate
sign_symptom,side,0.81936353," side-effects are more common during the first months after start of intake of norethisterone, and subside with a duration of treatment. the side-effects are mentioned below: 
 
 eye disorders- visual disturbance 
 gi disorders- nausea 
 general disorders and administration site- conditions headache, edema 
 nervous system disorders- migraine, respiratory, thoracic and mediastinal disorders- dyspnoea, 
 skin and subcutaneous tissue disorders- hypersensitivity (eg. rash, urticaria). 
  ",norethisterone acetate
sign_symptom,effects,0.99682295," side-effects are more common during the first months after start of intake of norethisterone, and subside with a duration of treatment. the side-effects are mentioned below: 
 
 eye disorders- visual disturbance 
 gi disorders- nausea 
 general disorders and administration site- conditions headache, edema 
 nervous system disorders- migraine, respiratory, thoracic and mediastinal disorders- dyspnoea, 
 skin and subcutaneous tissue disorders- hypersensitivity (eg. rash, urticaria). 
  ",norethisterone acetate
disease_disorder,eye disorders,0.9190031," side-effects are more common during the first months after start of intake of norethisterone, and subside with a duration of treatment. the side-effects are mentioned below: 
 
 eye disorders- visual disturbance 
 gi disorders- nausea 
 general disorders and administration site- conditions headache, edema 
 nervous system disorders- migraine, respiratory, thoracic and mediastinal disorders- dyspnoea, 
 skin and subcutaneous tissue disorders- hypersensitivity (eg. rash, urticaria). 
  ",norethisterone acetate
disease_disorder,visual,0.9145067," side-effects are more common during the first months after start of intake of norethisterone, and subside with a duration of treatment. the side-effects are mentioned below: 
 
 eye disorders- visual disturbance 
 gi disorders- nausea 
 general disorders and administration site- conditions headache, edema 
 nervous system disorders- migraine, respiratory, thoracic and mediastinal disorders- dyspnoea, 
 skin and subcutaneous tissue disorders- hypersensitivity (eg. rash, urticaria). 
  ",norethisterone acetate
disease_disorder,gi disorders,0.7595465," side-effects are more common during the first months after start of intake of norethisterone, and subside with a duration of treatment. the side-effects are mentioned below: 
 
 eye disorders- visual disturbance 
 gi disorders- nausea 
 general disorders and administration site- conditions headache, edema 
 nervous system disorders- migraine, respiratory, thoracic and mediastinal disorders- dyspnoea, 
 skin and subcutaneous tissue disorders- hypersensitivity (eg. rash, urticaria). 
  ",norethisterone acetate
sign_symptom,nausea,0.8123025," side-effects are more common during the first months after start of intake of norethisterone, and subside with a duration of treatment. the side-effects are mentioned below: 
 
 eye disorders- visual disturbance 
 gi disorders- nausea 
 general disorders and administration site- conditions headache, edema 
 nervous system disorders- migraine, respiratory, thoracic and mediastinal disorders- dyspnoea, 
 skin and subcutaneous tissue disorders- hypersensitivity (eg. rash, urticaria). 
  ",norethisterone acetate
disease_disorder,general disorders,0.79441553," side-effects are more common during the first months after start of intake of norethisterone, and subside with a duration of treatment. the side-effects are mentioned below: 
 
 eye disorders- visual disturbance 
 gi disorders- nausea 
 general disorders and administration site- conditions headache, edema 
 nervous system disorders- migraine, respiratory, thoracic and mediastinal disorders- dyspnoea, 
 skin and subcutaneous tissue disorders- hypersensitivity (eg. rash, urticaria). 
  ",norethisterone acetate
sign_symptom,edema nervous system,0.957707," side-effects are more common during the first months after start of intake of norethisterone, and subside with a duration of treatment. the side-effects are mentioned below: 
 
 eye disorders- visual disturbance 
 gi disorders- nausea 
 general disorders and administration site- conditions headache, edema 
 nervous system disorders- migraine, respiratory, thoracic and mediastinal disorders- dyspnoea, 
 skin and subcutaneous tissue disorders- hypersensitivity (eg. rash, urticaria). 
  ",norethisterone acetate
disease_disorder,mediasti,0.75193137," side-effects are more common during the first months after start of intake of norethisterone, and subside with a duration of treatment. the side-effects are mentioned below: 
 
 eye disorders- visual disturbance 
 gi disorders- nausea 
 general disorders and administration site- conditions headache, edema 
 nervous system disorders- migraine, respiratory, thoracic and mediastinal disorders- dyspnoea, 
 skin and subcutaneous tissue disorders- hypersensitivity (eg. rash, urticaria). 
  ",norethisterone acetate
sign_symptom,hypersen,0.9850873," side-effects are more common during the first months after start of intake of norethisterone, and subside with a duration of treatment. the side-effects are mentioned below: 
 
 eye disorders- visual disturbance 
 gi disorders- nausea 
 general disorders and administration site- conditions headache, edema 
 nervous system disorders- migraine, respiratory, thoracic and mediastinal disorders- dyspnoea, 
 skin and subcutaneous tissue disorders- hypersensitivity (eg. rash, urticaria). 
  ",norethisterone acetate
sign_symptom,tissue hypox,0.8338395,"  body as a whole : ischemic injury due to potent vasoconstrictor action and tissue hypoxia.    cardiovascular system : bradycardia, probably as a reflex result of a rise in blood pressure, arrhythmias.   nervous system : anxiety, transient headache.    respiratory system : respiratory difficulty.   skin and appendages : extravasation necrosis at injection site. prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy. if plasma volumes are not corrected, hypotension may recur when norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. gangrene of extremities has been rarely reported. overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting. ",norepinephrine
sign_symptom,extra,0.9998858,"  body as a whole : ischemic injury due to potent vasoconstrictor action and tissue hypoxia.    cardiovascular system : bradycardia, probably as a reflex result of a rise in blood pressure, arrhythmias.   nervous system : anxiety, transient headache.    respiratory system : respiratory difficulty.   skin and appendages : extravasation necrosis at injection site. prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy. if plasma volumes are not corrected, hypotension may recur when norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. gangrene of extremities has been rarely reported. overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting. ",norepinephrine
medication,norepineph,0.9199465,"  body as a whole : ischemic injury due to potent vasoconstrictor action and tissue hypoxia.    cardiovascular system : bradycardia, probably as a reflex result of a rise in blood pressure, arrhythmias.   nervous system : anxiety, transient headache.    respiratory system : respiratory difficulty.   skin and appendages : extravasation necrosis at injection site. prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy. if plasma volumes are not corrected, hypotension may recur when norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. gangrene of extremities has been rarely reported. overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting. ",norepinephrine
sign_symptom,tissue hypoxia,0.95523655,"  body as a whole : ischemic injury due to potent vasoconstrictor action and tissue hypoxia.    cardiovascular system : bradycardia, probably as a reflex result of a rise in blood pressure, arrhythmias.   nervous system : anxiety, transient headache.    respiratory system : respiratory difficulty.   skin and appendages : extravasation necrosis at injection site. prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy. if plasma volumes are not corrected, hypotension may recur when norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. gangrene of extremities has been rarely reported. overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting. ",norepinephrine
sign_symptom,gangrene of extremities,0.99754566,"  body as a whole : ischemic injury due to potent vasoconstrictor action and tissue hypoxia.    cardiovascular system : bradycardia, probably as a reflex result of a rise in blood pressure, arrhythmias.   nervous system : anxiety, transient headache.    respiratory system : respiratory difficulty.   skin and appendages : extravasation necrosis at injection site. prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy. if plasma volumes are not corrected, hypotension may recur when norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. gangrene of extremities has been rarely reported. overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting. ",norepinephrine
sign_symptom,overdose,0.99563295,"  body as a whole : ischemic injury due to potent vasoconstrictor action and tissue hypoxia.    cardiovascular system : bradycardia, probably as a reflex result of a rise in blood pressure, arrhythmias.   nervous system : anxiety, transient headache.    respiratory system : respiratory difficulty.   skin and appendages : extravasation necrosis at injection site. prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy. if plasma volumes are not corrected, hypotension may recur when norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. gangrene of extremities has been rarely reported. overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting. ",norepinephrine
sign_symptom,hyper,0.71546155,"  body as a whole : ischemic injury due to potent vasoconstrictor action and tissue hypoxia.    cardiovascular system : bradycardia, probably as a reflex result of a rise in blood pressure, arrhythmias.   nervous system : anxiety, transient headache.    respiratory system : respiratory difficulty.   skin and appendages : extravasation necrosis at injection site. prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy. if plasma volumes are not corrected, hypotension may recur when norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. gangrene of extremities has been rarely reported. overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting. ",norepinephrine
sign_symptom,nausea,0.9994586," headache, dizziness, insomnia, abnormal dreams, somnolence, asthenia, anxiety, excessive sweating, diarrhoea, nausea and/or vomiting, abdominal pain/discomfort, constipation, flatulence, dyspepsia, dry mouth, anorexia, tooth disorder, urticaria, rash, pruritus, exfoliative dermatitis, anaemia, rhinitis, pharyngitis, sinusitis, reversible hepatocellular injury, diaphoresis, myalgia, fever. rarely, asymptomatic ventricular tachycardia, thrombocytopenic purpura, decreased libido, gynaecomastia, reversible cholestatic or mixed cholestatic-hepatocellular injury with jaundice. ",nizatidine
sign_symptom,pain,0.9965044," headache, dizziness, insomnia, abnormal dreams, somnolence, asthenia, anxiety, excessive sweating, diarrhoea, nausea and/or vomiting, abdominal pain/discomfort, constipation, flatulence, dyspepsia, dry mouth, anorexia, tooth disorder, urticaria, rash, pruritus, exfoliative dermatitis, anaemia, rhinitis, pharyngitis, sinusitis, reversible hepatocellular injury, diaphoresis, myalgia, fever. rarely, asymptomatic ventricular tachycardia, thrombocytopenic purpura, decreased libido, gynaecomastia, reversible cholestatic or mixed cholestatic-hepatocellular injury with jaundice. ",nizatidine
sign_symptom,flat,0.97639954," headache, dizziness, insomnia, abnormal dreams, somnolence, asthenia, anxiety, excessive sweating, diarrhoea, nausea and/or vomiting, abdominal pain/discomfort, constipation, flatulence, dyspepsia, dry mouth, anorexia, tooth disorder, urticaria, rash, pruritus, exfoliative dermatitis, anaemia, rhinitis, pharyngitis, sinusitis, reversible hepatocellular injury, diaphoresis, myalgia, fever. rarely, asymptomatic ventricular tachycardia, thrombocytopenic purpura, decreased libido, gynaecomastia, reversible cholestatic or mixed cholestatic-hepatocellular injury with jaundice. ",nizatidine
sign_symptom,dyspeps,0.8938385," headache, dizziness, insomnia, abnormal dreams, somnolence, asthenia, anxiety, excessive sweating, diarrhoea, nausea and/or vomiting, abdominal pain/discomfort, constipation, flatulence, dyspepsia, dry mouth, anorexia, tooth disorder, urticaria, rash, pruritus, exfoliative dermatitis, anaemia, rhinitis, pharyngitis, sinusitis, reversible hepatocellular injury, diaphoresis, myalgia, fever. rarely, asymptomatic ventricular tachycardia, thrombocytopenic purpura, decreased libido, gynaecomastia, reversible cholestatic or mixed cholestatic-hepatocellular injury with jaundice. ",nizatidine
sign_symptom,adverse reactions,0.998049," most common adverse reactions (incidence 20%) in patients were: 
 
  as a single agent : fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, abdominal pain, and vomiting. 
  in combination with ipilimumab : fatigue, diarrhea, rash, pruritus, nausea, musculoskeletal pain, pyrexia, cough, decreased appetite, vomiting, abdominal pain, dyspnea, upper respiratory tract infection, arthralgia, headache, hypothyroidism, decreased weight, and dizziness. 
  in combination with ipilimumab and platinum-doublet chemotherapy : fatigue, musculoskeletal pain, nausea, diarrhea, rash, decreased appetite, constipation, and pruritus. 
  in combination with cabozantinib : diarrhea, fatigue, hepatotoxicity, palmar-plantar erythrodysaesthesia syndrome, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection. 
  in combination with fluoropyrimidine- and platinum-containing chemotherapy : peripheral neuropathy, nausea, fatigue, diarrhea, vomiting, decreased appetite, abdominal pain, constipation, and musculoskeletal pain. 
  ",nivolumab
medication,chemotherapy,0.98988265," most common adverse reactions (incidence 20%) in patients were: 
 
  as a single agent : fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, abdominal pain, and vomiting. 
  in combination with ipilimumab : fatigue, diarrhea, rash, pruritus, nausea, musculoskeletal pain, pyrexia, cough, decreased appetite, vomiting, abdominal pain, dyspnea, upper respiratory tract infection, arthralgia, headache, hypothyroidism, decreased weight, and dizziness. 
  in combination with ipilimumab and platinum-doublet chemotherapy : fatigue, musculoskeletal pain, nausea, diarrhea, rash, decreased appetite, constipation, and pruritus. 
  in combination with cabozantinib : diarrhea, fatigue, hepatotoxicity, palmar-plantar erythrodysaesthesia syndrome, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection. 
  in combination with fluoropyrimidine- and platinum-containing chemotherapy : peripheral neuropathy, nausea, fatigue, diarrhea, vomiting, decreased appetite, abdominal pain, constipation, and musculoskeletal pain. 
  ",nivolumab
sign_symptom,headache,0.99986374," headache which may be severe and persistent may occur immediately after use. vertigo, dizziness, weakness, palpitation and other manifestations of postural hypotension may develop occasionally. ",nitroglycerin (sublingual tablet)
sign_symptom,vertigo,0.9885007," headache which may be severe and persistent may occur immediately after use. vertigo, dizziness, weakness, palpitation and other manifestations of postural hypotension may develop occasionally. ",nitroglycerin (sublingual tablet)
sign_symptom,weakness,0.9978999," headache which may be severe and persistent may occur immediately after use. vertigo, dizziness, weakness, palpitation and other manifestations of postural hypotension may develop occasionally. ",nitroglycerin (sublingual tablet)
sign_symptom,palpitation,0.9548604," headache which may be severe and persistent may occur immediately after use. vertigo, dizziness, weakness, palpitation and other manifestations of postural hypotension may develop occasionally. ",nitroglycerin (sublingual tablet)
sign_symptom,hypotension,0.91102093," headache which may be severe and persistent may occur immediately after use. vertigo, dizziness, weakness, palpitation and other manifestations of postural hypotension may develop occasionally. ",nitroglycerin (sublingual tablet)
sign_symptom,hypotension,0.9542144," a number of nitrate related adverse effects may occur including headache, facial flushing, dizziness, nausea, vomiting, feelings of weakness, postural hypotension and reflex tachycardia . ",nitroglycerin (sublingual spray)
sign_symptom,headache,0.99987066," headache may occur at the onset of treatment but will usually subside after a few days. if the headache persists dosage should be decreased. other side effects include tachycardia, postural hypotension and syncope, cyanosis and methaemoglobinaemia. ",nitroglycerin (oral preparation)
sign_symptom,subside,0.7221332," headache may occur at the onset of treatment but will usually subside after a few days. if the headache persists dosage should be decreased. other side effects include tachycardia, postural hypotension and syncope, cyanosis and methaemoglobinaemia. ",nitroglycerin (oral preparation)
sign_symptom,hypotension,0.97855246," headache may occur at the onset of treatment but will usually subside after a few days. if the headache persists dosage should be decreased. other side effects include tachycardia, postural hypotension and syncope, cyanosis and methaemoglobinaemia. ",nitroglycerin (oral preparation)
sign_symptom,sync,0.78131986," headache may occur at the onset of treatment but will usually subside after a few days. if the headache persists dosage should be decreased. other side effects include tachycardia, postural hypotension and syncope, cyanosis and methaemoglobinaemia. ",nitroglycerin (oral preparation)
sign_symptom,headache,0.9999454, headache and dizziness is a common side effect experienced with nitroglycerin 0.4% ointment. a possible side effect is reduced control over bowel movements and leaking of bowel motions although this is expected to be a rare event. ,nitroglycerin (ointment)
sign_symptom,leaking of bowel motions,0.9976357, headache and dizziness is a common side effect experienced with nitroglycerin 0.4% ointment. a possible side effect is reduced control over bowel movements and leaking of bowel motions although this is expected to be a rare event. ,nitroglycerin (ointment)
sign_symptom,adverse reactions,0.90269125," adverse reactions to nitroglycerin are generally dose-related and almost all of these reactions are the result of nitroglycerin's activity as a vasodilator. headache, which may be severe, is the most commonly reported side effect. headache may be recurrent with each daily dose, especially at higher doses. transient episodes of lightheadedness, occasionally related to blood pressure changes, may also occur. hypotension occurs infrequently, but in some patients it may be severe enough to warrant discontinuation of therapy. syncope, crescendo angina, and rebound hypertension have been reported but are uncommon. extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients. methemoglobinemia is so infrequent at these doses that further discussion of its diagnosis and treatment is deferred. ",nitroglycerin (iv infusion)
medication,nitroglycerin,0.94000816," adverse reactions to nitroglycerin are generally dose-related and almost all of these reactions are the result of nitroglycerin's activity as a vasodilator. headache, which may be severe, is the most commonly reported side effect. headache may be recurrent with each daily dose, especially at higher doses. transient episodes of lightheadedness, occasionally related to blood pressure changes, may also occur. hypotension occurs infrequently, but in some patients it may be severe enough to warrant discontinuation of therapy. syncope, crescendo angina, and rebound hypertension have been reported but are uncommon. extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients. methemoglobinemia is so infrequent at these doses that further discussion of its diagnosis and treatment is deferred. ",nitroglycerin (iv infusion)
sign_symptom,headache,0.9995278," adverse reactions to nitroglycerin are generally dose-related and almost all of these reactions are the result of nitroglycerin's activity as a vasodilator. headache, which may be severe, is the most commonly reported side effect. headache may be recurrent with each daily dose, especially at higher doses. transient episodes of lightheadedness, occasionally related to blood pressure changes, may also occur. hypotension occurs infrequently, but in some patients it may be severe enough to warrant discontinuation of therapy. syncope, crescendo angina, and rebound hypertension have been reported but are uncommon. extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients. methemoglobinemia is so infrequent at these doses that further discussion of its diagnosis and treatment is deferred. ",nitroglycerin (iv infusion)
sign_symptom,lightheadedness,0.9995814," adverse reactions to nitroglycerin are generally dose-related and almost all of these reactions are the result of nitroglycerin's activity as a vasodilator. headache, which may be severe, is the most commonly reported side effect. headache may be recurrent with each daily dose, especially at higher doses. transient episodes of lightheadedness, occasionally related to blood pressure changes, may also occur. hypotension occurs infrequently, but in some patients it may be severe enough to warrant discontinuation of therapy. syncope, crescendo angina, and rebound hypertension have been reported but are uncommon. extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients. methemoglobinemia is so infrequent at these doses that further discussion of its diagnosis and treatment is deferred. ",nitroglycerin (iv infusion)
sign_symptom,sync,0.9658274," adverse reactions to nitroglycerin are generally dose-related and almost all of these reactions are the result of nitroglycerin's activity as a vasodilator. headache, which may be severe, is the most commonly reported side effect. headache may be recurrent with each daily dose, especially at higher doses. transient episodes of lightheadedness, occasionally related to blood pressure changes, may also occur. hypotension occurs infrequently, but in some patients it may be severe enough to warrant discontinuation of therapy. syncope, crescendo angina, and rebound hypertension have been reported but are uncommon. extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients. methemoglobinemia is so infrequent at these doses that further discussion of its diagnosis and treatment is deferred. ",nitroglycerin (iv infusion)
sign_symptom,rebound,0.99899787," adverse reactions to nitroglycerin are generally dose-related and almost all of these reactions are the result of nitroglycerin's activity as a vasodilator. headache, which may be severe, is the most commonly reported side effect. headache may be recurrent with each daily dose, especially at higher doses. transient episodes of lightheadedness, occasionally related to blood pressure changes, may also occur. hypotension occurs infrequently, but in some patients it may be severe enough to warrant discontinuation of therapy. syncope, crescendo angina, and rebound hypertension have been reported but are uncommon. extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients. methemoglobinemia is so infrequent at these doses that further discussion of its diagnosis and treatment is deferred. ",nitroglycerin (iv infusion)
sign_symptom,hypertension,0.99913806," adverse reactions to nitroglycerin are generally dose-related and almost all of these reactions are the result of nitroglycerin's activity as a vasodilator. headache, which may be severe, is the most commonly reported side effect. headache may be recurrent with each daily dose, especially at higher doses. transient episodes of lightheadedness, occasionally related to blood pressure changes, may also occur. hypotension occurs infrequently, but in some patients it may be severe enough to warrant discontinuation of therapy. syncope, crescendo angina, and rebound hypertension have been reported but are uncommon. extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients. methemoglobinemia is so infrequent at these doses that further discussion of its diagnosis and treatment is deferred. ",nitroglycerin (iv infusion)
medication,organic nitrates,0.9936779," adverse reactions to nitroglycerin are generally dose-related and almost all of these reactions are the result of nitroglycerin's activity as a vasodilator. headache, which may be severe, is the most commonly reported side effect. headache may be recurrent with each daily dose, especially at higher doses. transient episodes of lightheadedness, occasionally related to blood pressure changes, may also occur. hypotension occurs infrequently, but in some patients it may be severe enough to warrant discontinuation of therapy. syncope, crescendo angina, and rebound hypertension have been reported but are uncommon. extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients. methemoglobinemia is so infrequent at these doses that further discussion of its diagnosis and treatment is deferred. ",nitroglycerin (iv infusion)
disease_disorder,methemoglobinemia,0.99653745," adverse reactions to nitroglycerin are generally dose-related and almost all of these reactions are the result of nitroglycerin's activity as a vasodilator. headache, which may be severe, is the most commonly reported side effect. headache may be recurrent with each daily dose, especially at higher doses. transient episodes of lightheadedness, occasionally related to blood pressure changes, may also occur. hypotension occurs infrequently, but in some patients it may be severe enough to warrant discontinuation of therapy. syncope, crescendo angina, and rebound hypertension have been reported but are uncommon. extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients. methemoglobinemia is so infrequent at these doses that further discussion of its diagnosis and treatment is deferred. ",nitroglycerin (iv infusion)
sign_symptom,allergic skin reactions,0.7728656, sensitization and generalized allergic skin reactions may be produced after few days of initial application. cross sensitization to other nitrofurazone derivatives may occur. intolerance to nitrofurazone necessitating withdrawal has been encountered. ,nitrofurazone
medication,nitrofurazone,0.96592987, sensitization and generalized allergic skin reactions may be produced after few days of initial application. cross sensitization to other nitrofurazone derivatives may occur. intolerance to nitrofurazone necessitating withdrawal has been encountered. ,nitrofurazone
sign_symptom,into,0.99858546, sensitization and generalized allergic skin reactions may be produced after few days of initial application. cross sensitization to other nitrofurazone derivatives may occur. intolerance to nitrofurazone necessitating withdrawal has been encountered. ,nitrofurazone
sign_symptom,adverse events,0.98125017," in clinical trials of macrobid, the most frequent clinical adverse events that were reported as possibly or probably drug related were nausea (8%), headache (6%), and flatulence (1.5%) ",nitrofurantoin + nitrofurantoin microcrystals
sign_symptom,nausea,0.99994516," in clinical trials of macrobid, the most frequent clinical adverse events that were reported as possibly or probably drug related were nausea (8%), headache (6%), and flatulence (1.5%) ",nitrofurantoin + nitrofurantoin microcrystals
sign_symptom,headache,0.99994016," in clinical trials of macrobid, the most frequent clinical adverse events that were reported as possibly or probably drug related were nausea (8%), headache (6%), and flatulence (1.5%) ",nitrofurantoin + nitrofurantoin microcrystals
sign_symptom,flatulence,0.97659016," in clinical trials of macrobid, the most frequent clinical adverse events that were reported as possibly or probably drug related were nausea (8%), headache (6%), and flatulence (1.5%) ",nitrofurantoin + nitrofurantoin microcrystals
sign_symptom,adverse,0.9349834," the most frequent clinical adverse events are nausea, headache, and flatulence. other less occurred adverse events are diarrhea, dyspepsia, abdominal pain, constipation, emesis, dizziness and drowsiness. ",nitrofurantoin
sign_symptom,flat,0.9560882," the most frequent clinical adverse events are nausea, headache, and flatulence. other less occurred adverse events are diarrhea, dyspepsia, abdominal pain, constipation, emesis, dizziness and drowsiness. ",nitrofurantoin
sign_symptom,dyspepsia,0.9671315," the most frequent clinical adverse events are nausea, headache, and flatulence. other less occurred adverse events are diarrhea, dyspepsia, abdominal pain, constipation, emesis, dizziness and drowsiness. ",nitrofurantoin
sign_symptom,pain,0.9854211," the most frequent side effects, reported by nitazoxanide are abdominal pain, vomiting and headache. these side effects are typically mild and transient in nature. very rare side effects include- nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, increased creatinine &amp; sgpt level, pruritus, rhinitis, sweating, dizziness, discolored urine etc. ",nitazoxanide
sign_symptom,vomiting,0.99990535," the most frequent side effects, reported by nitazoxanide are abdominal pain, vomiting and headache. these side effects are typically mild and transient in nature. very rare side effects include- nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, increased creatinine &amp; sgpt level, pruritus, rhinitis, sweating, dizziness, discolored urine etc. ",nitazoxanide
sign_symptom,headache,0.99930584," the most frequent side effects, reported by nitazoxanide are abdominal pain, vomiting and headache. these side effects are typically mild and transient in nature. very rare side effects include- nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, increased creatinine &amp; sgpt level, pruritus, rhinitis, sweating, dizziness, discolored urine etc. ",nitazoxanide
sign_symptom,nausea,0.9969758," the most frequent side effects, reported by nitazoxanide are abdominal pain, vomiting and headache. these side effects are typically mild and transient in nature. very rare side effects include- nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, increased creatinine &amp; sgpt level, pruritus, rhinitis, sweating, dizziness, discolored urine etc. ",nitazoxanide
sign_symptom,flat,0.99940467," the most frequent side effects, reported by nitazoxanide are abdominal pain, vomiting and headache. these side effects are typically mild and transient in nature. very rare side effects include- nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, increased creatinine &amp; sgpt level, pruritus, rhinitis, sweating, dizziness, discolored urine etc. ",nitazoxanide
sign_symptom,enlarged,0.9534659," the most frequent side effects, reported by nitazoxanide are abdominal pain, vomiting and headache. these side effects are typically mild and transient in nature. very rare side effects include- nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, increased creatinine &amp; sgpt level, pruritus, rhinitis, sweating, dizziness, discolored urine etc. ",nitazoxanide
sign_symptom,sweating,0.92521256," the most frequent side effects, reported by nitazoxanide are abdominal pain, vomiting and headache. these side effects are typically mild and transient in nature. very rare side effects include- nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, increased creatinine &amp; sgpt level, pruritus, rhinitis, sweating, dizziness, discolored urine etc. ",nitazoxanide
sign_symptom,disco,0.9997824," the most frequent side effects, reported by nitazoxanide are abdominal pain, vomiting and headache. these side effects are typically mild and transient in nature. very rare side effects include- nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, increased creatinine &amp; sgpt level, pruritus, rhinitis, sweating, dizziness, discolored urine etc. ",nitazoxanide
sign_symptom,paralysis,0.9991698, paralysis (very rarely reported) ,oral polio vaccine
sign_symptom,adverse events,0.9994309," the following adverse events are known to occur with cholera vaccine use. acute gastroenteritis, diarrhea, fever, vomiting, abdominal pain, itching, rash, nausea, weakness, cough, vertigo, dryness of mouth, oral ulcer (rare), sore throat (rare) and yellowing of urine (rare). it has been observed that the incidence of adverse events is less after the second dose as compared to the first. ",oral cholera vaccine
sign_symptom,dryness of mouth,0.9836829," the following adverse events are known to occur with cholera vaccine use. acute gastroenteritis, diarrhea, fever, vomiting, abdominal pain, itching, rash, nausea, weakness, cough, vertigo, dryness of mouth, oral ulcer (rare), sore throat (rare) and yellowing of urine (rare). it has been observed that the incidence of adverse events is less after the second dose as compared to the first. ",oral cholera vaccine
sign_symptom,ulcer,0.92312247," the following adverse events are known to occur with cholera vaccine use. acute gastroenteritis, diarrhea, fever, vomiting, abdominal pain, itching, rash, nausea, weakness, cough, vertigo, dryness of mouth, oral ulcer (rare), sore throat (rare) and yellowing of urine (rare). it has been observed that the incidence of adverse events is less after the second dose as compared to the first. ",oral cholera vaccine
sign_symptom,sore throat,0.9879154," the following adverse events are known to occur with cholera vaccine use. acute gastroenteritis, diarrhea, fever, vomiting, abdominal pain, itching, rash, nausea, weakness, cough, vertigo, dryness of mouth, oral ulcer (rare), sore throat (rare) and yellowing of urine (rare). it has been observed that the incidence of adverse events is less after the second dose as compared to the first. ",oral cholera vaccine
sign_symptom,yellowing of urine,0.9971371," the following adverse events are known to occur with cholera vaccine use. acute gastroenteritis, diarrhea, fever, vomiting, abdominal pain, itching, rash, nausea, weakness, cough, vertigo, dryness of mouth, oral ulcer (rare), sore throat (rare) and yellowing of urine (rare). it has been observed that the incidence of adverse events is less after the second dose as compared to the first. ",oral cholera vaccine
sign_symptom,adverse events,0.998996," frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. in chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving ondansetron. there also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to ondansetron is unclear. there have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. in case of ponv, with the exception of headache, rates of these events were not significantly different in the ondansetron and placebo groups. ",ondansetron
medication,chemotherapy,0.97886217," frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. in chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving ondansetron. there also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to ondansetron is unclear. there have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. in case of ponv, with the exception of headache, rates of these events were not significantly different in the ondansetron and placebo groups. ",ondansetron
sign_symptom,nausea,0.9999378," frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. in chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving ondansetron. there also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to ondansetron is unclear. there have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. in case of ponv, with the exception of headache, rates of these events were not significantly different in the ondansetron and placebo groups. ",ondansetron
sign_symptom,rash,0.99995637," frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. in chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving ondansetron. there also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to ondansetron is unclear. there have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. in case of ponv, with the exception of headache, rates of these events were not significantly different in the ondansetron and placebo groups. ",ondansetron
sign_symptom,flushing,0.99989724," frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. in chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving ondansetron. there also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to ondansetron is unclear. there have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. in case of ponv, with the exception of headache, rates of these events were not significantly different in the ondansetron and placebo groups. ",ondansetron
sign_symptom,hiccups,0.97834235," frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. in chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving ondansetron. there also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to ondansetron is unclear. there have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. in case of ponv, with the exception of headache, rates of these events were not significantly different in the ondansetron and placebo groups. ",ondansetron
sign_symptom,angina,0.99836814," frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. in chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving ondansetron. there also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to ondansetron is unclear. there have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. in case of ponv, with the exception of headache, rates of these events were not significantly different in the ondansetron and placebo groups. ",ondansetron
sign_symptom,shortness of breath,0.9999189," frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. in chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving ondansetron. there also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to ondansetron is unclear. there have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. in case of ponv, with the exception of headache, rates of these events were not significantly different in the ondansetron and placebo groups. ",ondansetron
sign_symptom,headache,0.999933," omeprazole is generally well tolerated. nausea, abdominal colic, paresthesia, dizziness and headache have been stated to be generally mild and transient and not requiring a reduction in dosage. ",omeprazole
sign_symptom,adverse events,0.9998809," adverse events are rarely reported such as dyspepsia, nausea, constipation, gastritis, dizziness etc. ",omega-3 acid ethyl esters [salmon fish oil]
sign_symptom,consti,0.9788552," adverse events are rarely reported such as dyspepsia, nausea, constipation, gastritis, dizziness etc. ",omega-3 acid ethyl esters [salmon fish oil]
sign_symptom,asthma,0.9728598,"  asthma : the most common adverse reactions (1% of patients) in clinical studies with adult and adolescent patients 12 years of age were arthralgia, pain (general), leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache. in clinical studies with pediatric patients 6 to &lt;12 years of age, the most common adverse reactions were nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bites, and epistaxis.   nasal polyps : the most common adverse reactions (3% of patients) in clinical studies with adult patients included the following: headache, injection site reaction, arthralgia, upper abdominal pain, and dizziness.   chronic spontaneous urticaria : the most common adverse reactions (2% of patients) included the following: nausea, nasopharyngitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection, arthralgia, headache, and cough. ",omalizumab
sign_symptom,adverse reactions,0.99980175,"  asthma : the most common adverse reactions (1% of patients) in clinical studies with adult and adolescent patients 12 years of age were arthralgia, pain (general), leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache. in clinical studies with pediatric patients 6 to &lt;12 years of age, the most common adverse reactions were nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bites, and epistaxis.   nasal polyps : the most common adverse reactions (3% of patients) in clinical studies with adult patients included the following: headache, injection site reaction, arthralgia, upper abdominal pain, and dizziness.   chronic spontaneous urticaria : the most common adverse reactions (2% of patients) included the following: nausea, nasopharyngitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection, arthralgia, headache, and cough. ",omalizumab
sign_symptom,pain,0.99992967,"  asthma : the most common adverse reactions (1% of patients) in clinical studies with adult and adolescent patients 12 years of age were arthralgia, pain (general), leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache. in clinical studies with pediatric patients 6 to &lt;12 years of age, the most common adverse reactions were nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bites, and epistaxis.   nasal polyps : the most common adverse reactions (3% of patients) in clinical studies with adult patients included the following: headache, injection site reaction, arthralgia, upper abdominal pain, and dizziness.   chronic spontaneous urticaria : the most common adverse reactions (2% of patients) included the following: nausea, nasopharyngitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection, arthralgia, headache, and cough. ",omalizumab
sign_symptom,headache,0.9812127,"  asthma : the most common adverse reactions (1% of patients) in clinical studies with adult and adolescent patients 12 years of age were arthralgia, pain (general), leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache. in clinical studies with pediatric patients 6 to &lt;12 years of age, the most common adverse reactions were nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bites, and epistaxis.   nasal polyps : the most common adverse reactions (3% of patients) in clinical studies with adult patients included the following: headache, injection site reaction, arthralgia, upper abdominal pain, and dizziness.   chronic spontaneous urticaria : the most common adverse reactions (2% of patients) included the following: nausea, nasopharyngitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection, arthralgia, headache, and cough. ",omalizumab
sign_symptom,nausea,0.9998828,"  asthma : the most common adverse reactions (1% of patients) in clinical studies with adult and adolescent patients 12 years of age were arthralgia, pain (general), leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache. in clinical studies with pediatric patients 6 to &lt;12 years of age, the most common adverse reactions were nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bites, and epistaxis.   nasal polyps : the most common adverse reactions (3% of patients) in clinical studies with adult patients included the following: headache, injection site reaction, arthralgia, upper abdominal pain, and dizziness.   chronic spontaneous urticaria : the most common adverse reactions (2% of patients) included the following: nausea, nasopharyngitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection, arthralgia, headache, and cough. ",omalizumab
sign_symptom,nasopharyn,0.87182844,"  asthma : the most common adverse reactions (1% of patients) in clinical studies with adult and adolescent patients 12 years of age were arthralgia, pain (general), leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache. in clinical studies with pediatric patients 6 to &lt;12 years of age, the most common adverse reactions were nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bites, and epistaxis.   nasal polyps : the most common adverse reactions (3% of patients) in clinical studies with adult patients included the following: headache, injection site reaction, arthralgia, upper abdominal pain, and dizziness.   chronic spontaneous urticaria : the most common adverse reactions (2% of patients) included the following: nausea, nasopharyngitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection, arthralgia, headache, and cough. ",omalizumab
sign_symptom,headache,0.9999176," headaches have been reported at an incidence of 7%. the following adverse experiences have been reported in less than 5% of patients: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion ",olopatadine hydrochloride (ophthalmic)
sign_symptom,adverse experiences,0.9898038," headaches have been reported at an incidence of 7%. the following adverse experiences have been reported in less than 5% of patients: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion ",olopatadine hydrochloride (ophthalmic)
sign_symptom,blurred,0.74989504," headaches have been reported at an incidence of 7%. the following adverse experiences have been reported in less than 5% of patients: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion ",olopatadine hydrochloride (ophthalmic)
sign_symptom,dry eye,0.83612573," headaches have been reported at an incidence of 7%. the following adverse experiences have been reported in less than 5% of patients: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion ",olopatadine hydrochloride (ophthalmic)
sign_symptom,foreign body,0.98031414," headaches have been reported at an incidence of 7%. the following adverse experiences have been reported in less than 5% of patients: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion ",olopatadine hydrochloride (ophthalmic)
sign_symptom,sinus,0.7636628," headaches have been reported at an incidence of 7%. the following adverse experiences have been reported in less than 5% of patients: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion ",olopatadine hydrochloride (ophthalmic)
sign_symptom,taste,0.99653316," headaches have been reported at an incidence of 7%. the following adverse experiences have been reported in less than 5% of patients: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion ",olopatadine hydrochloride (ophthalmic)
sign_symptom,perversion,0.99183285," headaches have been reported at an incidence of 7%. the following adverse experiences have been reported in less than 5% of patients: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion ",olopatadine hydrochloride (ophthalmic)
sign_symptom,bitter taste,0.9922764," a bitter taste in the mouth, nosebleeds, or irritation/soreness in the nose may occur. drowsiness may rarely occur. if any of these effects persist or worsen, tell your doctor or pharmacist promptly. ",olopatadine hydrochloride (nasal spray)
sign_symptom,irritation,0.9999207," a bitter taste in the mouth, nosebleeds, or irritation/soreness in the nose may occur. drowsiness may rarely occur. if any of these effects persist or worsen, tell your doctor or pharmacist promptly. ",olopatadine hydrochloride (nasal spray)
sign_symptom,soreness,0.9885161," a bitter taste in the mouth, nosebleeds, or irritation/soreness in the nose may occur. drowsiness may rarely occur. if any of these effects persist or worsen, tell your doctor or pharmacist promptly. ",olopatadine hydrochloride (nasal spray)
disease_disorder,hyper,0.7663537,"  common : the most common side effects include back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, and sinusitis.   rare : chest pain, peripheral edema, arthritis. ",olmesartan medoxomil
sign_symptom,influenza - like symptoms,0.93921363,"  common : the most common side effects include back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, and sinusitis.   rare : chest pain, peripheral edema, arthritis. ",olmesartan medoxomil
disease_disorder,pharyngitis,0.7916701,"  common : the most common side effects include back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, and sinusitis.   rare : chest pain, peripheral edema, arthritis. ",olmesartan medoxomil
sign_symptom,adverse reaction,0.9978622," the most common serious adverse reaction reported was anemia (2.4% olaparib vs 2.2% chemotherapy). the following serious adrs were reported in one patient each: dermatitis allergic, neutrophil count decreased and platelet count decreased. the proportion of patients who permanently discontinued olaparib due to adverse events was 4.9% in the olaparib arm compared with 7.7% in the chemotherapy arm. anemia and platelet count decrease were the only adverse reactions leading to discontinuation of olaparib in more than one patient. ",olaparib
medication,chemotherapy,0.99926287," the most common serious adverse reaction reported was anemia (2.4% olaparib vs 2.2% chemotherapy). the following serious adrs were reported in one patient each: dermatitis allergic, neutrophil count decreased and platelet count decreased. the proportion of patients who permanently discontinued olaparib due to adverse events was 4.9% in the olaparib arm compared with 7.7% in the chemotherapy arm. anemia and platelet count decrease were the only adverse reactions leading to discontinuation of olaparib in more than one patient. ",olaparib
disease_disorder,adrs,0.94094586," the most common serious adverse reaction reported was anemia (2.4% olaparib vs 2.2% chemotherapy). the following serious adrs were reported in one patient each: dermatitis allergic, neutrophil count decreased and platelet count decreased. the proportion of patients who permanently discontinued olaparib due to adverse events was 4.9% in the olaparib arm compared with 7.7% in the chemotherapy arm. anemia and platelet count decrease were the only adverse reactions leading to discontinuation of olaparib in more than one patient. ",olaparib
sign_symptom,adverse events,0.982988," the most common serious adverse reaction reported was anemia (2.4% olaparib vs 2.2% chemotherapy). the following serious adrs were reported in one patient each: dermatitis allergic, neutrophil count decreased and platelet count decreased. the proportion of patients who permanently discontinued olaparib due to adverse events was 4.9% in the olaparib arm compared with 7.7% in the chemotherapy arm. anemia and platelet count decrease were the only adverse reactions leading to discontinuation of olaparib in more than one patient. ",olaparib
medication,olapa,0.8364333," the most common serious adverse reaction reported was anemia (2.4% olaparib vs 2.2% chemotherapy). the following serious adrs were reported in one patient each: dermatitis allergic, neutrophil count decreased and platelet count decreased. the proportion of patients who permanently discontinued olaparib due to adverse events was 4.9% in the olaparib arm compared with 7.7% in the chemotherapy arm. anemia and platelet count decrease were the only adverse reactions leading to discontinuation of olaparib in more than one patient. ",olaparib
sign_symptom,consti,0.7645883," very common undesirable effects are somnolence and weight gain. besides increased appetite, elevated glucose levels, elevated triglyceride levels, dizziness, akathisia, parkinson's disease, dyskinesia, orthostatic hypotension, mild and transient anticholinergic effects including constipation and dry mouth, asthenia, edema and photosensitivity reaction etc. may be observed. ",olanzapine
sign_symptom,dry mouth,0.9992131," very common undesirable effects are somnolence and weight gain. besides increased appetite, elevated glucose levels, elevated triglyceride levels, dizziness, akathisia, parkinson's disease, dyskinesia, orthostatic hypotension, mild and transient anticholinergic effects including constipation and dry mouth, asthenia, edema and photosensitivity reaction etc. may be observed. ",olanzapine
sign_symptom,edema,0.9983759," very common undesirable effects are somnolence and weight gain. besides increased appetite, elevated glucose levels, elevated triglyceride levels, dizziness, akathisia, parkinson's disease, dyskinesia, orthostatic hypotension, mild and transient anticholinergic effects including constipation and dry mouth, asthenia, edema and photosensitivity reaction etc. may be observed. ",olanzapine
sign_symptom,photosensitivity reaction,0.9995537," very common undesirable effects are somnolence and weight gain. besides increased appetite, elevated glucose levels, elevated triglyceride levels, dizziness, akathisia, parkinson's disease, dyskinesia, orthostatic hypotension, mild and transient anticholinergic effects including constipation and dry mouth, asthenia, edema and photosensitivity reaction etc. may be observed. ",olanzapine
sign_symptom,adverse,0.8404071," the systemic side-effects are not common with this ear drops. the following adverse reactions may be observed when using this product: itching, burning, irritation, dryness, earache, headache, vertigo, dizziness, redness, folliculitis, hypertrichosis, acne form eruptions and hypopigmentation. ",ofloxacin + clotrimazole + beclomethasone + lidocaine
sign_symptom,acne form,0.9528207," the systemic side-effects are not common with this ear drops. the following adverse reactions may be observed when using this product: itching, burning, irritation, dryness, earache, headache, vertigo, dizziness, redness, folliculitis, hypertrichosis, acne form eruptions and hypopigmentation. ",ofloxacin + clotrimazole + beclomethasone + lidocaine
medication,ofloxacin,0.77121675," ofloxacin is generally well tolerated and clinical side-effects of ofloxacin has been quite low. among the adverse effects gastrointestinal and central nervous systems' reactions are common. nausea, rash, vomiting, abdominal pain, diarrhoea and gastrointestinal distress are the gastrointestinal adverse effects. common central nervous system reactions are headache, dizziness and insomnia. ",ofloxacin (oral & injection)
medication,ofloxa,0.71344256," ofloxacin is generally well tolerated and clinical side-effects of ofloxacin has been quite low. among the adverse effects gastrointestinal and central nervous systems' reactions are common. nausea, rash, vomiting, abdominal pain, diarrhoea and gastrointestinal distress are the gastrointestinal adverse effects. common central nervous system reactions are headache, dizziness and insomnia. ",ofloxacin (oral & injection)
sign_symptom,adverse effects,0.9998429," ofloxacin is generally well tolerated and clinical side-effects of ofloxacin has been quite low. among the adverse effects gastrointestinal and central nervous systems' reactions are common. nausea, rash, vomiting, abdominal pain, diarrhoea and gastrointestinal distress are the gastrointestinal adverse effects. common central nervous system reactions are headache, dizziness and insomnia. ",ofloxacin (oral & injection)
sign_symptom,nausea,0.9920483," ofloxacin is generally well tolerated and clinical side-effects of ofloxacin has been quite low. among the adverse effects gastrointestinal and central nervous systems' reactions are common. nausea, rash, vomiting, abdominal pain, diarrhoea and gastrointestinal distress are the gastrointestinal adverse effects. common central nervous system reactions are headache, dizziness and insomnia. ",ofloxacin (oral & injection)
sign_symptom,rash,0.99934524," ofloxacin is generally well tolerated and clinical side-effects of ofloxacin has been quite low. among the adverse effects gastrointestinal and central nervous systems' reactions are common. nausea, rash, vomiting, abdominal pain, diarrhoea and gastrointestinal distress are the gastrointestinal adverse effects. common central nervous system reactions are headache, dizziness and insomnia. ",ofloxacin (oral & injection)
sign_symptom,vomiting,0.9984785," ofloxacin is generally well tolerated and clinical side-effects of ofloxacin has been quite low. among the adverse effects gastrointestinal and central nervous systems' reactions are common. nausea, rash, vomiting, abdominal pain, diarrhoea and gastrointestinal distress are the gastrointestinal adverse effects. common central nervous system reactions are headache, dizziness and insomnia. ",ofloxacin (oral & injection)
sign_symptom,diarr,0.99972814," ofloxacin is generally well tolerated and clinical side-effects of ofloxacin has been quite low. among the adverse effects gastrointestinal and central nervous systems' reactions are common. nausea, rash, vomiting, abdominal pain, diarrhoea and gastrointestinal distress are the gastrointestinal adverse effects. common central nervous system reactions are headache, dizziness and insomnia. ",ofloxacin (oral & injection)
sign_symptom,gastrointestinal distress,0.96468085," ofloxacin is generally well tolerated and clinical side-effects of ofloxacin has been quite low. among the adverse effects gastrointestinal and central nervous systems' reactions are common. nausea, rash, vomiting, abdominal pain, diarrhoea and gastrointestinal distress are the gastrointestinal adverse effects. common central nervous system reactions are headache, dizziness and insomnia. ",ofloxacin (oral & injection)
sign_symptom,photophobia,0.9826839,"  eye : transient ocular irritation, burning, stinging, redness, itching or photophobia have been reported.   ear : mild irritation or mild discomfort in the ear may occur. symptoms of an allergic reaction include rash, itching, swelling or trouble breathing. ",ofloxacin (ophthalmic)
sign_symptom,irritation,0.9999219,"  eye : transient ocular irritation, burning, stinging, redness, itching or photophobia have been reported.   ear : mild irritation or mild discomfort in the ear may occur. symptoms of an allergic reaction include rash, itching, swelling or trouble breathing. ",ofloxacin (ophthalmic)
sign_symptom,discomfort,0.9999486,"  eye : transient ocular irritation, burning, stinging, redness, itching or photophobia have been reported.   ear : mild irritation or mild discomfort in the ear may occur. symptoms of an allergic reaction include rash, itching, swelling or trouble breathing. ",ofloxacin (ophthalmic)
sign_symptom,allergic reaction,0.9014484,"  eye : transient ocular irritation, burning, stinging, redness, itching or photophobia have been reported.   ear : mild irritation or mild discomfort in the ear may occur. symptoms of an allergic reaction include rash, itching, swelling or trouble breathing. ",ofloxacin (ophthalmic)
sign_symptom,swelling,0.99929595,"  eye : transient ocular irritation, burning, stinging, redness, itching or photophobia have been reported.   ear : mild irritation or mild discomfort in the ear may occur. symptoms of an allergic reaction include rash, itching, swelling or trouble breathing. ",ofloxacin (ophthalmic)
sign_symptom,tingling,0.99325633," local pain, stinging, tingling at site of inj; anorexia, nausea, vomiting, abdominal pain, bloating, flatulence, loose stools, steatorrhoea; biliary tract abnormalities. hypoglycaemia and hyperglycaemia, hypothyroidism, cardiac conduction abnormalitles, pancreatitis. ",octreotide acetate
sign_symptom,adverse reactions,0.9988916," the following adverse reactions are discussed in greater detail in other sections of the label: 
 
 hepatitis b reactivation 
 progressive multifocal leukoencephalopathy 
 infusion reactions 
 tumor lysis syndrome 
 infections 
 neutropenia 
 thrombocytopenia 
  ",obinutuzumab
disease_disorder,hepatitis b,0.998561," the following adverse reactions are discussed in greater detail in other sections of the label: 
 
 hepatitis b reactivation 
 progressive multifocal leukoencephalopathy 
 infusion reactions 
 tumor lysis syndrome 
 infections 
 neutropenia 
 thrombocytopenia 
  ",obinutuzumab
sign_symptom,reactions,0.96452326," the following adverse reactions are discussed in greater detail in other sections of the label: 
 
 hepatitis b reactivation 
 progressive multifocal leukoencephalopathy 
 infusion reactions 
 tumor lysis syndrome 
 infections 
 neutropenia 
 thrombocytopenia 
  ",obinutuzumab
disease_disorder,tumor,0.8433806," the following adverse reactions are discussed in greater detail in other sections of the label: 
 
 hepatitis b reactivation 
 progressive multifocal leukoencephalopathy 
 infusion reactions 
 tumor lysis syndrome 
 infections 
 neutropenia 
 thrombocytopenia 
  ",obinutuzumab
disease_disorder,lysis syndrome,0.992421," the following adverse reactions are discussed in greater detail in other sections of the label: 
 
 hepatitis b reactivation 
 progressive multifocal leukoencephalopathy 
 infusion reactions 
 tumor lysis syndrome 
 infections 
 neutropenia 
 thrombocytopenia 
  ",obinutuzumab
disease_disorder,infections,0.97393894," the following adverse reactions are discussed in greater detail in other sections of the label: 
 
 hepatitis b reactivation 
 progressive multifocal leukoencephalopathy 
 infusion reactions 
 tumor lysis syndrome 
 infections 
 neutropenia 
 thrombocytopenia 
  ",obinutuzumab
sign_symptom,neut,0.96615237," the following adverse reactions are discussed in greater detail in other sections of the label: 
 
 hepatitis b reactivation 
 progressive multifocal leukoencephalopathy 
 infusion reactions 
 tumor lysis syndrome 
 infections 
 neutropenia 
 thrombocytopenia 
  ",obinutuzumab
medication,medicines,0.7979276," all medicines may cause side effects, but many people have no, or minor, side effects. when used in small doses, no common side effects have been reported with this product. seek medical attention right away if any of these severe side effects occur: severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); eye swelling or redness. ",oxytetracycline + polymixin b sulphate
sign_symptom,allergic reactions,0.99990964," all medicines may cause side effects, but many people have no, or minor, side effects. when used in small doses, no common side effects have been reported with this product. seek medical attention right away if any of these severe side effects occur: severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); eye swelling or redness. ",oxytetracycline + polymixin b sulphate
sign_symptom,difficulty,0.969415," all medicines may cause side effects, but many people have no, or minor, side effects. when used in small doses, no common side effects have been reported with this product. seek medical attention right away if any of these severe side effects occur: severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); eye swelling or redness. ",oxytetracycline + polymixin b sulphate
sign_symptom,tightness,0.99794626," all medicines may cause side effects, but many people have no, or minor, side effects. when used in small doses, no common side effects have been reported with this product. seek medical attention right away if any of these severe side effects occur: severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); eye swelling or redness. ",oxytetracycline + polymixin b sulphate
sign_symptom,swelling,0.9999645," all medicines may cause side effects, but many people have no, or minor, side effects. when used in small doses, no common side effects have been reported with this product. seek medical attention right away if any of these severe side effects occur: severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); eye swelling or redness. ",oxytetracycline + polymixin b sulphate
sign_symptom,rash,0.9075123," side effects of oxytetracycline, which have been reported in some patients, are anorexia, nausea, vomiting, diarrhoea, glossitis, skin rashes and urticaria. ",oxytetracycline
sign_symptom,tension,0.96521133," xerostomia, decreased sweating, urinary hesitancy and retention, blurred vision, cycloplegia, increased ocular tension, loss of taste, headache, nervousness, mental confusion, impotence, suppression of lactation, urticaria, constipation. ",oxyphencyclimine hydrochloride
sign_symptom,loss of taste,0.99942166," xerostomia, decreased sweating, urinary hesitancy and retention, blurred vision, cycloplegia, increased ocular tension, loss of taste, headache, nervousness, mental confusion, impotence, suppression of lactation, urticaria, constipation. ",oxyphencyclimine hydrochloride
sign_symptom,irritation,0.9999455," occasionally it may cause local irritation and dryness of the mouth and throat. temporarily discomfort such as burning, stinging, sneezing or increase in nasal discharge may occur. ",oxymetazoline hydrochloride (nasal preparation)
sign_symptom,discomfort,0.9999434," occasionally it may cause local irritation and dryness of the mouth and throat. temporarily discomfort such as burning, stinging, sneezing or increase in nasal discharge may occur. ",oxymetazoline hydrochloride (nasal preparation)
sign_symptom,lesions,0.9985631," most common side effects are application site dermatitis, worsening inflammatory lesions of rosacea, application site pruritis, application site erythema and application site pain. ",oxymetazoline hydrochloride (cream)
sign_symptom,dry mouth,0.99803025," the incidence of dry mouth may occur which is dose-related. abdominal pain, dry nasal and sinus mucous membranes, back pain, hypertension, palpitation, vasodilatation, flatulence, gastro-esophageal reflux, insomnia, nervousness, confusion, cough, sinusitis, bronchitis, dry skin, rash, impaired urination (hesitancy), urinary retention, etc. may be reported. ",oxybutynin chloride
sign_symptom,impaired urination,0.99465543," the incidence of dry mouth may occur which is dose-related. abdominal pain, dry nasal and sinus mucous membranes, back pain, hypertension, palpitation, vasodilatation, flatulence, gastro-esophageal reflux, insomnia, nervousness, confusion, cough, sinusitis, bronchitis, dry skin, rash, impaired urination (hesitancy), urinary retention, etc. may be reported. ",oxybutynin chloride
sign_symptom,hypersensitivity,0.97861934, hypersensitivity reactions; transient stinging and blurring of vision; excitation of cns; muscle twitching and tremors; convulsions. ,oxybuprocaine hydrochloride
sign_symptom,stinging,0.9852899, hypersensitivity reactions; transient stinging and blurring of vision; excitation of cns; muscle twitching and tremors; convulsions. ,oxybuprocaine hydrochloride
sign_symptom,blur,0.9999038, hypersensitivity reactions; transient stinging and blurring of vision; excitation of cns; muscle twitching and tremors; convulsions. ,oxybuprocaine hydrochloride
sign_symptom,twitching,0.906227, hypersensitivity reactions; transient stinging and blurring of vision; excitation of cns; muscle twitching and tremors; convulsions. ,oxybuprocaine hydrochloride
sign_symptom,tremor,0.99910706, hypersensitivity reactions; transient stinging and blurring of vision; excitation of cns; muscle twitching and tremors; convulsions. ,oxybuprocaine hydrochloride
sign_symptom,irritation,0.9988931," pruritus, burning, irritation and allergic contact dermatitis, folliculitis, erythema, and papules, fissure, maceration, rash, stinging and nodules. ",oxiconazole nitrate
disease_disorder,folliculitis,0.9309982," pruritus, burning, irritation and allergic contact dermatitis, folliculitis, erythema, and papules, fissure, maceration, rash, stinging and nodules. ",oxiconazole nitrate
sign_symptom,adverse reactions,0.95317984," the most commonly reported adverse reactions are somnolence, headache, dizziness, diplopia, nausea; vomiting and fatigue. very rarely clinically significant hyponatraemia can develop during oxazep use. class i (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and reports of anaphylaxis have been received. ",oxcarbazepine
sign_symptom,vomiting,0.99950206," the most commonly reported adverse reactions are somnolence, headache, dizziness, diplopia, nausea; vomiting and fatigue. very rarely clinically significant hyponatraemia can develop during oxazep use. class i (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and reports of anaphylaxis have been received. ",oxcarbazepine
medication,oxazep,0.8956394," the most commonly reported adverse reactions are somnolence, headache, dizziness, diplopia, nausea; vomiting and fatigue. very rarely clinically significant hyponatraemia can develop during oxazep use. class i (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and reports of anaphylaxis have been received. ",oxcarbazepine
sign_symptom,hyper,0.8338603," the most commonly reported adverse reactions are somnolence, headache, dizziness, diplopia, nausea; vomiting and fatigue. very rarely clinically significant hyponatraemia can develop during oxazep use. class i (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and reports of anaphylaxis have been received. ",oxcarbazepine
sign_symptom,angio,0.7690866," the most commonly reported adverse reactions are somnolence, headache, dizziness, diplopia, nausea; vomiting and fatigue. very rarely clinically significant hyponatraemia can develop during oxazep use. class i (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and reports of anaphylaxis have been received. ",oxcarbazepine
sign_symptom,anaphyla,0.9694143," the most commonly reported adverse reactions are somnolence, headache, dizziness, diplopia, nausea; vomiting and fatigue. very rarely clinically significant hyponatraemia can develop during oxazep use. class i (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and reports of anaphylaxis have been received. ",oxcarbazepine
sign_symptom,rash,0.9992828," side effects cannot be anticipated. if any develop or change in intensity, doctor should be informed immediately. doctor will determine if it is safe for a patient to continue taking oxazepam. more common side effect includes drowsiness. less common or rare side effects include: blood disorders, change in libido, dizziness, excitement, fainting, headache, liver problems, loss or lack of muscle control, nausea, skin rashes or eruptions, sluggishness or unresponsiveness, slurred speech, swelling due to fluid retention, tremors, vertigo, yellowed eyes and skin. side effects due to rapid decrease or abrupt withdrawal from oxazepam: abdominal and muscle cramps, convulsions, depressed mood, inability to fall or stay asleep, sweating, tremors, vomiting. ",oxazepam
sign_symptom,swelling,0.9986576," side effects cannot be anticipated. if any develop or change in intensity, doctor should be informed immediately. doctor will determine if it is safe for a patient to continue taking oxazepam. more common side effect includes drowsiness. less common or rare side effects include: blood disorders, change in libido, dizziness, excitement, fainting, headache, liver problems, loss or lack of muscle control, nausea, skin rashes or eruptions, sluggishness or unresponsiveness, slurred speech, swelling due to fluid retention, tremors, vertigo, yellowed eyes and skin. side effects due to rapid decrease or abrupt withdrawal from oxazepam: abdominal and muscle cramps, convulsions, depressed mood, inability to fall or stay asleep, sweating, tremors, vomiting. ",oxazepam
sign_symptom,yellow,0.99120224," side effects cannot be anticipated. if any develop or change in intensity, doctor should be informed immediately. doctor will determine if it is safe for a patient to continue taking oxazepam. more common side effect includes drowsiness. less common or rare side effects include: blood disorders, change in libido, dizziness, excitement, fainting, headache, liver problems, loss or lack of muscle control, nausea, skin rashes or eruptions, sluggishness or unresponsiveness, slurred speech, swelling due to fluid retention, tremors, vertigo, yellowed eyes and skin. side effects due to rapid decrease or abrupt withdrawal from oxazepam: abdominal and muscle cramps, convulsions, depressed mood, inability to fall or stay asleep, sweating, tremors, vomiting. ",oxazepam
medication,oxaz,0.7708387," side effects cannot be anticipated. if any develop or change in intensity, doctor should be informed immediately. doctor will determine if it is safe for a patient to continue taking oxazepam. more common side effect includes drowsiness. less common or rare side effects include: blood disorders, change in libido, dizziness, excitement, fainting, headache, liver problems, loss or lack of muscle control, nausea, skin rashes or eruptions, sluggishness or unresponsiveness, slurred speech, swelling due to fluid retention, tremors, vertigo, yellowed eyes and skin. side effects due to rapid decrease or abrupt withdrawal from oxazepam: abdominal and muscle cramps, convulsions, depressed mood, inability to fall or stay asleep, sweating, tremors, vomiting. ",oxazepam
sign_symptom,depressed,0.99213046," side effects cannot be anticipated. if any develop or change in intensity, doctor should be informed immediately. doctor will determine if it is safe for a patient to continue taking oxazepam. more common side effect includes drowsiness. less common or rare side effects include: blood disorders, change in libido, dizziness, excitement, fainting, headache, liver problems, loss or lack of muscle control, nausea, skin rashes or eruptions, sluggishness or unresponsiveness, slurred speech, swelling due to fluid retention, tremors, vertigo, yellowed eyes and skin. side effects due to rapid decrease or abrupt withdrawal from oxazepam: abdominal and muscle cramps, convulsions, depressed mood, inability to fall or stay asleep, sweating, tremors, vomiting. ",oxazepam
sign_symptom,inability to fall,0.9991312," side effects cannot be anticipated. if any develop or change in intensity, doctor should be informed immediately. doctor will determine if it is safe for a patient to continue taking oxazepam. more common side effect includes drowsiness. less common or rare side effects include: blood disorders, change in libido, dizziness, excitement, fainting, headache, liver problems, loss or lack of muscle control, nausea, skin rashes or eruptions, sluggishness or unresponsiveness, slurred speech, swelling due to fluid retention, tremors, vertigo, yellowed eyes and skin. side effects due to rapid decrease or abrupt withdrawal from oxazepam: abdominal and muscle cramps, convulsions, depressed mood, inability to fall or stay asleep, sweating, tremors, vomiting. ",oxazepam
sign_symptom,pain,0.9726083," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,adverse reactions,0.993047," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,cardiovascularthrombotic events,0.9700697," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,ulceration,0.9841027," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,perforation,0.937385," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,hepatotoxicity,0.9762831," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,hypertension,0.99907345," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
disease_disorder,heart,0.9190398," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,failure,0.8300565," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,toxicity,0.99863106," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,anaphylactic reactions,0.988307," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,skin reactions,0.99135816," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,hemato,0.83194137," common side effects are depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or gi bleeding, abnormalities in lfts, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, bp changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.  the following adverse reactions may occur: 
 
 cardiovascularthrombotic events 
 gibleeding,ulcerationand perforation 
 hepatotoxicity 
 hypertension 
 heart failureand edema 
 renal toxicity andhyperkalemia 
 anaphylactic reactions 
 serious skin reactions 
 hematologic toxicity 
  ",oxaprozin
sign_symptom,flat,0.9715736," fatigue, fever, pain, headache, insomnia, nausea, diarrheoa, vomiting, abdominal pain, constipation, anorexia, stomatitis, anemia, thrombocytopenia, leukopenia, aspartate and alanine transaminases increased, total bilirubin increased, peripheral neuropathy, back pain, dyspnoea, cough, oedema, chest pain, peripheral oedema, flushing , thromboembolism, dizziness, rash, alopecia , hand-foot syndrome dehydration, hypokalaemia, dyspepsia, taste perversion, flatulence, mucositis, gastroesophageal reflux, dysphagia, dysuria, neutropenia, inj site reaction, rigors, arthralgia, abnormal lacrimation, serum creatinine increased, rhinitis, epistaxis, pharyngitis, pharyngolaryngeal dysesthesia, allergic reactions, hiccup. ",oxaliplatin
disease_disorder,cardiom,0.7878679," common side effects areinterstitial lung disease or pneumonitis,qtc interval prolongation, cardiomyopathy, keratitis ",osimertinib
sign_symptom,adverse events,0.9982993," the most frequently reported adverse events are nausea and vomiting. these events generally of mild to moderate degree and usually are occurred on the first 2 days of administration. additional adverse events occurring in &lt;1% of patients receiving oseltamivir for treatment include unstable angina, anemia, pseudomembranous colitis, humerus fracture, pneumonia, pyrexia, and peritonsillar abscess. ",oseltamivir
sign_symptom,nausea,0.99986005," the most frequently reported adverse events are nausea and vomiting. these events generally of mild to moderate degree and usually are occurred on the first 2 days of administration. additional adverse events occurring in &lt;1% of patients receiving oseltamivir for treatment include unstable angina, anemia, pseudomembranous colitis, humerus fracture, pneumonia, pyrexia, and peritonsillar abscess. ",oseltamivir
sign_symptom,adverse,0.99980146," the most frequently reported adverse events are nausea and vomiting. these events generally of mild to moderate degree and usually are occurred on the first 2 days of administration. additional adverse events occurring in &lt;1% of patients receiving oseltamivir for treatment include unstable angina, anemia, pseudomembranous colitis, humerus fracture, pneumonia, pyrexia, and peritonsillar abscess. ",oseltamivir
sign_symptom,leuk,0.961388," side effects of ornidazole have been mainly limited to the gastrointestinal tract (nausea, vomiting, epigastric pain) and central nervous system (dizziness, headache, lassitude). unlike other nitroimidazoles, ornidazole does not interact with alcohol, although this requires further study.  leukopenia has been described occasionally during therapy. adverse central nervous system (cns) effects of ornidazole have mainly included headache, dizziness, lassitude or somnolence, fatigue and weakness. adverse cns effects of ornidazole may be less than that happens with metronidazole. seizures have not been reported with ornidazole in studies available to date. ",ornidazole
sign_symptom,adverse,0.91919744," side effects of ornidazole have been mainly limited to the gastrointestinal tract (nausea, vomiting, epigastric pain) and central nervous system (dizziness, headache, lassitude). unlike other nitroimidazoles, ornidazole does not interact with alcohol, although this requires further study.  leukopenia has been described occasionally during therapy. adverse central nervous system (cns) effects of ornidazole have mainly included headache, dizziness, lassitude or somnolence, fatigue and weakness. adverse cns effects of ornidazole may be less than that happens with metronidazole. seizures have not been reported with ornidazole in studies available to date. ",ornidazole
sign_symptom,fatigue,0.95908487," side effects of ornidazole have been mainly limited to the gastrointestinal tract (nausea, vomiting, epigastric pain) and central nervous system (dizziness, headache, lassitude). unlike other nitroimidazoles, ornidazole does not interact with alcohol, although this requires further study.  leukopenia has been described occasionally during therapy. adverse central nervous system (cns) effects of ornidazole have mainly included headache, dizziness, lassitude or somnolence, fatigue and weakness. adverse cns effects of ornidazole may be less than that happens with metronidazole. seizures have not been reported with ornidazole in studies available to date. ",ornidazole
sign_symptom,seizures,0.9999243," side effects of ornidazole have been mainly limited to the gastrointestinal tract (nausea, vomiting, epigastric pain) and central nervous system (dizziness, headache, lassitude). unlike other nitroimidazoles, ornidazole does not interact with alcohol, although this requires further study.  leukopenia has been described occasionally during therapy. adverse central nervous system (cns) effects of ornidazole have mainly included headache, dizziness, lassitude or somnolence, fatigue and weakness. adverse cns effects of ornidazole may be less than that happens with metronidazole. seizures have not been reported with ornidazole in studies available to date. ",ornidazole
sign_symptom,flat,0.999468,"  common : undesirable effects of orlistat are largely gastrointestinal in nature. common gastrointestinal side effects are oily spotting from the rectum, flatulence, fecal urgency, oily or fatty stool, abdominal discomfort etc.   rare : influenza, anxiety. headache, fatigue etc may rarely occur in some patients. rare cases of hypersensitivity have been reported. main clinical symptoms are pruritus, exanthema, urticaria, angioedema and anaphylaxis. ",orlistat
sign_symptom,discomfort,0.9999541,"  common : undesirable effects of orlistat are largely gastrointestinal in nature. common gastrointestinal side effects are oily spotting from the rectum, flatulence, fecal urgency, oily or fatty stool, abdominal discomfort etc.   rare : influenza, anxiety. headache, fatigue etc may rarely occur in some patients. rare cases of hypersensitivity have been reported. main clinical symptoms are pruritus, exanthema, urticaria, angioedema and anaphylaxis. ",orlistat
sign_symptom,headache,0.999848,"  common : undesirable effects of orlistat are largely gastrointestinal in nature. common gastrointestinal side effects are oily spotting from the rectum, flatulence, fecal urgency, oily or fatty stool, abdominal discomfort etc.   rare : influenza, anxiety. headache, fatigue etc may rarely occur in some patients. rare cases of hypersensitivity have been reported. main clinical symptoms are pruritus, exanthema, urticaria, angioedema and anaphylaxis. ",orlistat
sign_symptom,fatigue,0.9999367,"  common : undesirable effects of orlistat are largely gastrointestinal in nature. common gastrointestinal side effects are oily spotting from the rectum, flatulence, fecal urgency, oily or fatty stool, abdominal discomfort etc.   rare : influenza, anxiety. headache, fatigue etc may rarely occur in some patients. rare cases of hypersensitivity have been reported. main clinical symptoms are pruritus, exanthema, urticaria, angioedema and anaphylaxis. ",orlistat
sign_symptom,hypersensitivity,0.9998828,"  common : undesirable effects of orlistat are largely gastrointestinal in nature. common gastrointestinal side effects are oily spotting from the rectum, flatulence, fecal urgency, oily or fatty stool, abdominal discomfort etc.   rare : influenza, anxiety. headache, fatigue etc may rarely occur in some patients. rare cases of hypersensitivity have been reported. main clinical symptoms are pruritus, exanthema, urticaria, angioedema and anaphylaxis. ",orlistat
sign_symptom,dyspeps,0.9819043," occasionally observed reactions are - gastrointestinal disturbance: epigastric pain, nausea, vomiting, diarrhoea, dyspepsia. central nervous system disturbance: headache, insomnia. hypersensitivity reaction: skin rash, pruritis, photosensitization. others: myalgia and/or arthralgia, tendonitis, rupture of achilles tendon. ",pefloxacin mesylate dihydrate
sign_symptom,hyper,0.9753709," occasionally observed reactions are - gastrointestinal disturbance: epigastric pain, nausea, vomiting, diarrhoea, dyspepsia. central nervous system disturbance: headache, insomnia. hypersensitivity reaction: skin rash, pruritis, photosensitization. others: myalgia and/or arthralgia, tendonitis, rupture of achilles tendon. ",pefloxacin mesylate dihydrate
sign_symptom,myal,0.9001864," occasionally observed reactions are - gastrointestinal disturbance: epigastric pain, nausea, vomiting, diarrhoea, dyspepsia. central nervous system disturbance: headache, insomnia. hypersensitivity reaction: skin rash, pruritis, photosensitization. others: myalgia and/or arthralgia, tendonitis, rupture of achilles tendon. ",pefloxacin mesylate dihydrate
sign_symptom,arthral,0.90658206," occasionally observed reactions are - gastrointestinal disturbance: epigastric pain, nausea, vomiting, diarrhoea, dyspepsia. central nervous system disturbance: headache, insomnia. hypersensitivity reaction: skin rash, pruritis, photosensitization. others: myalgia and/or arthralgia, tendonitis, rupture of achilles tendon. ",pefloxacin mesylate dihydrate
disease_disorder,impairment,0.80750924," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
sign_symptom,torsades de pointes cardiac,0.95612514," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
sign_symptom,hemorrhagic events,0.9991842," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
sign_symptom,thromboembolic events,0.9952412," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
disease_disorder,microangiopathy,0.9882072," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
disease_disorder,gastrointestinal perforation,0.9979477," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
disease_disorder,fistula,0.98431486," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
disease_disorder,inter,0.99842334," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
disease_disorder,pneumonitis,0.99356544," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
disease_disorder,posterior leukoencephalopathy syndrome,0.9996654," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
sign_symptom,hypertension,0.8096075," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
disease_disorder,proteinuria,0.8582055," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
disease_disorder,tumor,0.9982381," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
disease_disorder,lysis syndrome,0.9897397," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
disease_disorder,infection,0.99979347," common side effects of pazopanib include: 
 
 hepatic toxicity and hepatic impairment 
 qt prolongation and torsades de pointes 
 cardiac dysfunction 
 hemorrhagic events 
 arterial and venous thromboembolic events 
 thrombotic microangiopathy 
 gastrointestinal perforation and fistula 
 interstitial lung disease/pneumonitis 
 reversible posterior leukoencephalopathy syndrome 
 hypertension 
 hypothyroidism 
 proteinuria 
 tumor lysis syndrome 
 infection 
 increased toxicity with other cancer therapy 
  ",pazopanib hydrochloride
disease_disorder,major,0.7593062,"  major depressive disorder:  asthenia, sweating, nausea, decreased appetite, somnolence, dizziness, insomnia, tremor, nervousness, ejaculatory disturbance and other male genital disorders.   obsessive compulsive disorder:  nausea, dry mouth, decreased appetite, constipation, dizziness, somnolence, tremor, sweating, impotence and abnormal ejaculation.   panic disorder:  asthenia, sweating, decreased appetite, decreased libido , tremor, abnormal ejaculation, female genital disorders and impotence.   social anxiety disorder:  sweating, nausea, dry mouth, constipation, decreased appetite, somnolence, tremor, decreased libido, yawn, abnormal ejaculation, female genital disorders and impotence.   generalised anxiety disorder:  asthenia, infection, constipation, decreased appetite, dry mouth, nausea, decreased libido, somnolence, tremor, sweating and abnormal ejaculation.   post-traumatic stress disorder:  asthenia, sweating nausea, dry mouth, diarrhoea, decreased appetite, somnolence, decreased libido, abnormal ejaculation, female genital disorders and impotence. ",paroxetine hydrochloride
sign_symptom,adverse reactions,0.7014444," the most common adverse reactions (&gt;5% and more frequent than placebo) include diarrhea, nasopharyngitis, dizziness, vomiting, hypertension, hypersensitivity, nausea, and edema. ",paricalcitol
sign_symptom,nasopharyngitis,0.9996397," the most common adverse reactions (&gt;5% and more frequent than placebo) include diarrhea, nasopharyngitis, dizziness, vomiting, hypertension, hypersensitivity, nausea, and edema. ",paricalcitol
sign_symptom,pain,0.9999566," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,swell,0.7372061," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,numb,0.9998648," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,agitated,0.9999205," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,to sleep,0.99718404," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,anaemia,0.99945515," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,fatigue,0.99995494," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,breathlessness,0.9998368," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,sore throat,0.9979825," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,difficulty breathing,0.99922615," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,short,0.7075827," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,inflammation,0.99759114," commonside effects are- 
 
 change in your blood pressure (up or down) 
 you may get back pain 
 ankles, legs and feet may swell (fluid retention) 
 you may feel numb- your skin may lose sensitivity to pain and touch 
 you may get vomiting, stomach ache, indigestion, constipation, bloating and wind 
 tests may show abnormal kidney function 
 you may feel agitated or find it hard to sleep 
 dizziness 
 there is a risk of anaemia- changes in red blood cells after an operation that may cause fatigue and breathlessness 
 you may get a sore throat or difficulty breathing (shortness of breath) 
 your skin may be itchy 
 you may pass less urine than usual. 
 dry socket (inflammation and pain after a tooth extraction) 
 increased sweating 
 low levels of potassium in blood test results. 
  ",parecoxib
sign_symptom,adverse reactions,0.99945456," the following adverse reactions may happen to this therapy: asthenia, fatigue, hot flushes, dizziness, headache, tremor, abdominal pain, constipation, diarrhea, dyspepsia, dry mouth, nausea, vomiting, anorexia, anxiety, confusion, euphoria, insomnia, nervousness, somnolence pruritus, rash, increased sweating etc. ",paracetamol+tramadolhydrochloride
sign_symptom,dyspe,0.9578703," the following adverse reactions may happen to this therapy: asthenia, fatigue, hot flushes, dizziness, headache, tremor, abdominal pain, constipation, diarrhea, dyspepsia, dry mouth, nausea, vomiting, anorexia, anxiety, confusion, euphoria, insomnia, nervousness, somnolence pruritus, rash, increased sweating etc. ",paracetamol+tramadolhydrochloride
sign_symptom,sweating,0.99859995," the following adverse reactions may happen to this therapy: asthenia, fatigue, hot flushes, dizziness, headache, tremor, abdominal pain, constipation, diarrhea, dyspepsia, dry mouth, nausea, vomiting, anorexia, anxiety, confusion, euphoria, insomnia, nervousness, somnolence pruritus, rash, increased sweating etc. ",paracetamol+tramadolhydrochloride
medication,paracetamol,0.8332535," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leukopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol + caffeine
sign_symptom,reactions,0.9992944," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leukopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol + caffeine
sign_symptom,leuk,0.7635095," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leukopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol + caffeine
sign_symptom,neut,0.89153695," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leukopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol + caffeine
disease_disorder,agranulocytosis,0.84894097," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leukopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol + caffeine
sign_symptom,rash,0.9996644," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leukopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol + caffeine
sign_symptom,allergic reactions,0.9995372," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leukopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol + caffeine
medication,para,0.9993968," as all paracetamol products, adverse drug reactions are rare (&gt;1/10000, &lt;1/1000) or very rare (&lt;1/10000). frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation). very rare cases of hypersensitivity reactions ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment. cases of erythema, flushing, pruritus and tachycardia have been reported. ",paracetamol (iv infusion)
sign_symptom,adverse,0.99995863," as all paracetamol products, adverse drug reactions are rare (&gt;1/10000, &lt;1/1000) or very rare (&lt;1/10000). frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation). very rare cases of hypersensitivity reactions ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment. cases of erythema, flushing, pruritus and tachycardia have been reported. ",paracetamol (iv infusion)
sign_symptom,reactions,0.99926156," as all paracetamol products, adverse drug reactions are rare (&gt;1/10000, &lt;1/1000) or very rare (&lt;1/10000). frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation). very rare cases of hypersensitivity reactions ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment. cases of erythema, flushing, pruritus and tachycardia have been reported. ",paracetamol (iv infusion)
sign_symptom,adverse reactions,0.9999206," as all paracetamol products, adverse drug reactions are rare (&gt;1/10000, &lt;1/1000) or very rare (&lt;1/10000). frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation). very rare cases of hypersensitivity reactions ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment. cases of erythema, flushing, pruritus and tachycardia have been reported. ",paracetamol (iv infusion)
sign_symptom,pain,0.9999609," as all paracetamol products, adverse drug reactions are rare (&gt;1/10000, &lt;1/1000) or very rare (&lt;1/10000). frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation). very rare cases of hypersensitivity reactions ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment. cases of erythema, flushing, pruritus and tachycardia have been reported. ",paracetamol (iv infusion)
sign_symptom,burning,0.9955258," as all paracetamol products, adverse drug reactions are rare (&gt;1/10000, &lt;1/1000) or very rare (&lt;1/10000). frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation). very rare cases of hypersensitivity reactions ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment. cases of erythema, flushing, pruritus and tachycardia have been reported. ",paracetamol (iv infusion)
sign_symptom,hypersensitivity reactions,0.9999092," as all paracetamol products, adverse drug reactions are rare (&gt;1/10000, &lt;1/1000) or very rare (&lt;1/10000). frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation). very rare cases of hypersensitivity reactions ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment. cases of erythema, flushing, pruritus and tachycardia have been reported. ",paracetamol (iv infusion)
sign_symptom,rash,0.9998123," as all paracetamol products, adverse drug reactions are rare (&gt;1/10000, &lt;1/1000) or very rare (&lt;1/10000). frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation). very rare cases of hypersensitivity reactions ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment. cases of erythema, flushing, pruritus and tachycardia have been reported. ",paracetamol (iv infusion)
sign_symptom,"flushing,",0.9545654," as all paracetamol products, adverse drug reactions are rare (&gt;1/10000, &lt;1/1000) or very rare (&lt;1/10000). frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation). very rare cases of hypersensitivity reactions ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment. cases of erythema, flushing, pruritus and tachycardia have been reported. ",paracetamol (iv infusion)
sign_symptom,pruritus,0.9992618," as all paracetamol products, adverse drug reactions are rare (&gt;1/10000, &lt;1/1000) or very rare (&lt;1/10000). frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation). very rare cases of hypersensitivity reactions ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment. cases of erythema, flushing, pruritus and tachycardia have been reported. ",paracetamol (iv infusion)
medication,pantoprazole,0.8189165," pantoprazole is well tolerated in both short-term and long-term treatment. headache and diarrhea are the common side effects and rarely included side effects are abdominal pain, flatulence, rash, insomnia and hyperglycemia. ",pantoprazole sodium sesquihydrate
sign_symptom,headache,0.999731," pantoprazole is well tolerated in both short-term and long-term treatment. headache and diarrhea are the common side effects and rarely included side effects are abdominal pain, flatulence, rash, insomnia and hyperglycemia. ",pantoprazole sodium sesquihydrate
medication,paracetamol,0.85349035," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol
sign_symptom,reactions,0.99921227," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol
disease_disorder,agranulocytosis,0.95035094," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol
sign_symptom,rash,0.99966," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol
sign_symptom,allergic reactions,0.99957013," side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. pancreatitis, skin rashes, and other allergic reactions occur occasionally. ",paracetamol
sign_symptom,pain,0.99995947," tachycardia, htn, bradycardia, bronchospasm, hypotension, cv collapse, excessive salivation; pain or local skin reactions at inj site. rarely, hypersensitivity reactions. ",pancuronium bromide
sign_symptom,skin reactions,0.9683555," tachycardia, htn, bradycardia, bronchospasm, hypotension, cv collapse, excessive salivation; pain or local skin reactions at inj site. rarely, hypersensitivity reactions. ",pancuronium bromide
sign_symptom,hypersensitivity,0.986634," tachycardia, htn, bradycardia, bronchospasm, hypotension, cv collapse, excessive salivation; pain or local skin reactions at inj site. rarely, hypersensitivity reactions. ",pancuronium bromide
sign_symptom,vomiting,0.99982506," the most frequent side effects are gastrointestinal including nausea, vomiting and abdominal discomfort. buccal and perianal soreness may occur, particularly in infants. hypersensitivity reactions manifested by sneezing, lacrimation or skin rashes have been reported. ",pancreatin
sign_symptom,sore,0.99981767," the most frequent side effects are gastrointestinal including nausea, vomiting and abdominal discomfort. buccal and perianal soreness may occur, particularly in infants. hypersensitivity reactions manifested by sneezing, lacrimation or skin rashes have been reported. ",pancreatin
sign_symptom,hypersensitivity reactions,0.99979466," the most frequent side effects are gastrointestinal including nausea, vomiting and abdominal discomfort. buccal and perianal soreness may occur, particularly in infants. hypersensitivity reactions manifested by sneezing, lacrimation or skin rashes have been reported. ",pancreatin
sign_symptom,lacrimation,0.996675," the most frequent side effects are gastrointestinal including nausea, vomiting and abdominal discomfort. buccal and perianal soreness may occur, particularly in infants. hypersensitivity reactions manifested by sneezing, lacrimation or skin rashes have been reported. ",pancreatin
sign_symptom,rash,0.9998832," the most frequent side effects are gastrointestinal including nausea, vomiting and abdominal discomfort. buccal and perianal soreness may occur, particularly in infants. hypersensitivity reactions manifested by sneezing, lacrimation or skin rashes have been reported. ",pancreatin
sign_symptom,headache,0.9999249, the most common adverse reactions are headaches and constipation. ,palonosetron
sign_symptom,adverse reactions,0.9987147," the most common adverse reactions (incidence  5% and occurring at least twice as often as placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder. ",paliperidone palmitate
sign_symptom,adverse reactions,0.9982425," the most common adverse reactions of paliperidone are tachycardia, akathisia, somnolence, tremor, dystonia, cogwheel rigidity, anxiety, weight increased, dyspepsia, constipation, nasopharyngitis etc. ",paliperidone
medication,pali,0.9994276," the most common adverse reactions of paliperidone are tachycardia, akathisia, somnolence, tremor, dystonia, cogwheel rigidity, anxiety, weight increased, dyspepsia, constipation, nasopharyngitis etc. ",paliperidone
sign_symptom,cogwheel rigid,0.97593015," the most common adverse reactions of paliperidone are tachycardia, akathisia, somnolence, tremor, dystonia, cogwheel rigidity, anxiety, weight increased, dyspepsia, constipation, nasopharyngitis etc. ",paliperidone
sign_symptom,weight,0.94331956," the most common adverse reactions of paliperidone are tachycardia, akathisia, somnolence, tremor, dystonia, cogwheel rigidity, anxiety, weight increased, dyspepsia, constipation, nasopharyngitis etc. ",paliperidone
sign_symptom,consti,0.988477," the most common adverse reactions of paliperidone are tachycardia, akathisia, somnolence, tremor, dystonia, cogwheel rigidity, anxiety, weight increased, dyspepsia, constipation, nasopharyngitis etc. ",paliperidone
sign_symptom,nasopharyngitis,0.9988794," the most common adverse reactions of paliperidone are tachycardia, akathisia, somnolence, tremor, dystonia, cogwheel rigidity, anxiety, weight increased, dyspepsia, constipation, nasopharyngitis etc. ",paliperidone
sign_symptom,inflammation,0.9995586," common side effects of palbociclib include: wbc decreased, neutrophils decreased, neutropenia, platelets decreased, infections, ast increased, alt increased, leukopenia, fatigue, nausea, hair loss, inflammation of the mouth and lips, diarrhea, anemia, rash, weakness/lethargy, vomiting, thrombocytopenia, dry skin, fever. ",palbociclib
sign_symptom,weakness,0.99970347," common side effects of palbociclib include: wbc decreased, neutrophils decreased, neutropenia, platelets decreased, infections, ast increased, alt increased, leukopenia, fatigue, nausea, hair loss, inflammation of the mouth and lips, diarrhea, anemia, rash, weakness/lethargy, vomiting, thrombocytopenia, dry skin, fever. ",palbociclib
sign_symptom,irritation,0.9991726," signs of irritations (including erythema, burning or rash) may appear when applied to sensitive or broken skin. ",padimate o + avobenzone + oxybenzone + titanium dioxide
sign_symptom,arthralgias,0.986345,"  common : low blood counts leading to increased risk for infection, anemia and/or bleeding, hair loss, arthralgias and myalgias, pain in the joints and muscles, peripheral neuropathy, nausea, vomiting (usually mild), diarrhea, mouth sores, hypersensitivity reaction, fever, facial flushing, chills, shortness of breath, or hives after paclitaxel is given.   rare : swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given. ",paclitaxel
sign_symptom,myalgia,0.984998,"  common : low blood counts leading to increased risk for infection, anemia and/or bleeding, hair loss, arthralgias and myalgias, pain in the joints and muscles, peripheral neuropathy, nausea, vomiting (usually mild), diarrhea, mouth sores, hypersensitivity reaction, fever, facial flushing, chills, shortness of breath, or hives after paclitaxel is given.   rare : swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given. ",paclitaxel
sign_symptom,pain,0.9998518,"  common : low blood counts leading to increased risk for infection, anemia and/or bleeding, hair loss, arthralgias and myalgias, pain in the joints and muscles, peripheral neuropathy, nausea, vomiting (usually mild), diarrhea, mouth sores, hypersensitivity reaction, fever, facial flushing, chills, shortness of breath, or hives after paclitaxel is given.   rare : swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given. ",paclitaxel
sign_symptom,vomiting,0.9997943,"  common : low blood counts leading to increased risk for infection, anemia and/or bleeding, hair loss, arthralgias and myalgias, pain in the joints and muscles, peripheral neuropathy, nausea, vomiting (usually mild), diarrhea, mouth sores, hypersensitivity reaction, fever, facial flushing, chills, shortness of breath, or hives after paclitaxel is given.   rare : swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given. ",paclitaxel
sign_symptom,hypersensitivity reaction,0.9143729,"  common : low blood counts leading to increased risk for infection, anemia and/or bleeding, hair loss, arthralgias and myalgias, pain in the joints and muscles, peripheral neuropathy, nausea, vomiting (usually mild), diarrhea, mouth sores, hypersensitivity reaction, fever, facial flushing, chills, shortness of breath, or hives after paclitaxel is given.   rare : swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given. ",paclitaxel
sign_symptom,shortness of breath,0.9995811,"  common : low blood counts leading to increased risk for infection, anemia and/or bleeding, hair loss, arthralgias and myalgias, pain in the joints and muscles, peripheral neuropathy, nausea, vomiting (usually mild), diarrhea, mouth sores, hypersensitivity reaction, fever, facial flushing, chills, shortness of breath, or hives after paclitaxel is given.   rare : swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given. ",paclitaxel
sign_symptom,hives,0.99954325,"  common : low blood counts leading to increased risk for infection, anemia and/or bleeding, hair loss, arthralgias and myalgias, pain in the joints and muscles, peripheral neuropathy, nausea, vomiting (usually mild), diarrhea, mouth sores, hypersensitivity reaction, fever, facial flushing, chills, shortness of breath, or hives after paclitaxel is given.   rare : swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given. ",paclitaxel
medication,paclitaxel,0.9967452,"  common : low blood counts leading to increased risk for infection, anemia and/or bleeding, hair loss, arthralgias and myalgias, pain in the joints and muscles, peripheral neuropathy, nausea, vomiting (usually mild), diarrhea, mouth sores, hypersensitivity reaction, fever, facial flushing, chills, shortness of breath, or hives after paclitaxel is given.   rare : swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given. ",paclitaxel
sign_symptom,swelling,0.9999652,"  common : low blood counts leading to increased risk for infection, anemia and/or bleeding, hair loss, arthralgias and myalgias, pain in the joints and muscles, peripheral neuropathy, nausea, vomiting (usually mild), diarrhea, mouth sores, hypersensitivity reaction, fever, facial flushing, chills, shortness of breath, or hives after paclitaxel is given.   rare : swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given. ",paclitaxel
sign_symptom,darkening,0.99994457,"  common : low blood counts leading to increased risk for infection, anemia and/or bleeding, hair loss, arthralgias and myalgias, pain in the joints and muscles, peripheral neuropathy, nausea, vomiting (usually mild), diarrhea, mouth sores, hypersensitivity reaction, fever, facial flushing, chills, shortness of breath, or hives after paclitaxel is given.   rare : swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given. ",paclitaxel
sign_symptom,skin,0.9836623,"  common : low blood counts leading to increased risk for infection, anemia and/or bleeding, hair loss, arthralgias and myalgias, pain in the joints and muscles, peripheral neuropathy, nausea, vomiting (usually mild), diarrhea, mouth sores, hypersensitivity reaction, fever, facial flushing, chills, shortness of breath, or hives after paclitaxel is given.   rare : swelling of the feet or ankles (edema), liver problems, low blood pressure, darkening of the skin where previous radiation treatment has been given. ",paclitaxel
sign_symptom,adverse reaction,0.99798644," because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. the safety profile of ozenoxacin was assessed in two clinical trials (trial 1 and trial 2) in 362 adult and pediatric patients two months of age and older with impetigo. the patients used at least one dose from a 5-day, twice a day regimen of ozenoxacin. control groups included 361 patients who used placebo and 152 patients who used retapamulin ointment. the median age of the patients enrolled in the clinical trials was 10 years; 3 % of patients were 2 months to less than 2 years of age, 55 % of patients were 2 to less than 12 years of age, 11 % of patients were 12 to less than 18 years of age, and 31 % of patients were 18 years of age or older. adverse reactions (rosacea and seborrheic dermatitis) were reported in 1 adult patient treated with ozenoxacin. ",ozenoxacin
medication,placebo,0.99935806," because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. the safety profile of ozenoxacin was assessed in two clinical trials (trial 1 and trial 2) in 362 adult and pediatric patients two months of age and older with impetigo. the patients used at least one dose from a 5-day, twice a day regimen of ozenoxacin. control groups included 361 patients who used placebo and 152 patients who used retapamulin ointment. the median age of the patients enrolled in the clinical trials was 10 years; 3 % of patients were 2 months to less than 2 years of age, 55 % of patients were 2 to less than 12 years of age, 11 % of patients were 12 to less than 18 years of age, and 31 % of patients were 18 years of age or older. adverse reactions (rosacea and seborrheic dermatitis) were reported in 1 adult patient treated with ozenoxacin. ",ozenoxacin
sign_symptom,adverse reactions,0.99977577," because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. the safety profile of ozenoxacin was assessed in two clinical trials (trial 1 and trial 2) in 362 adult and pediatric patients two months of age and older with impetigo. the patients used at least one dose from a 5-day, twice a day regimen of ozenoxacin. control groups included 361 patients who used placebo and 152 patients who used retapamulin ointment. the median age of the patients enrolled in the clinical trials was 10 years; 3 % of patients were 2 months to less than 2 years of age, 55 % of patients were 2 to less than 12 years of age, 11 % of patients were 12 to less than 18 years of age, and 31 % of patients were 18 years of age or older. adverse reactions (rosacea and seborrheic dermatitis) were reported in 1 adult patient treated with ozenoxacin. ",ozenoxacin
disease_disorder,seborrheic dermatitis,0.7632109," because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. the safety profile of ozenoxacin was assessed in two clinical trials (trial 1 and trial 2) in 362 adult and pediatric patients two months of age and older with impetigo. the patients used at least one dose from a 5-day, twice a day regimen of ozenoxacin. control groups included 361 patients who used placebo and 152 patients who used retapamulin ointment. the median age of the patients enrolled in the clinical trials was 10 years; 3 % of patients were 2 months to less than 2 years of age, 55 % of patients were 2 to less than 12 years of age, 11 % of patients were 12 to less than 18 years of age, and 31 % of patients were 18 years of age or older. adverse reactions (rosacea and seborrheic dermatitis) were reported in 1 adult patient treated with ozenoxacin. ",ozenoxacin
sign_symptom,hyper,0.9993424,"  
 hypersensitivity to the drug may result in uterine hypertonicity, spasm, titanic contraction or rupture of the uterus. 
 the possibility of increased blood loss and afbrinigenemia should be kept in mind when administering the drug. 
 severe water intoxication with convulsions and coma has occurred. 
 oxytocin may occasionally cause nausea, vomiting, haemorrhage or cardiac arrhythmias, anaphylactic reaction. 
  ",oxytocin
disease_disorder,blood,0.9467527,"  
 hypersensitivity to the drug may result in uterine hypertonicity, spasm, titanic contraction or rupture of the uterus. 
 the possibility of increased blood loss and afbrinigenemia should be kept in mind when administering the drug. 
 severe water intoxication with convulsions and coma has occurred. 
 oxytocin may occasionally cause nausea, vomiting, haemorrhage or cardiac arrhythmias, anaphylactic reaction. 
  ",oxytocin
disease_disorder,afbrinigen,0.7694437,"  
 hypersensitivity to the drug may result in uterine hypertonicity, spasm, titanic contraction or rupture of the uterus. 
 the possibility of increased blood loss and afbrinigenemia should be kept in mind when administering the drug. 
 severe water intoxication with convulsions and coma has occurred. 
 oxytocin may occasionally cause nausea, vomiting, haemorrhage or cardiac arrhythmias, anaphylactic reaction. 
  ",oxytocin
sign_symptom,water intoxication,0.8794987,"  
 hypersensitivity to the drug may result in uterine hypertonicity, spasm, titanic contraction or rupture of the uterus. 
 the possibility of increased blood loss and afbrinigenemia should be kept in mind when administering the drug. 
 severe water intoxication with convulsions and coma has occurred. 
 oxytocin may occasionally cause nausea, vomiting, haemorrhage or cardiac arrhythmias, anaphylactic reaction. 
  ",oxytocin
sign_symptom,convulsions,0.8801963,"  
 hypersensitivity to the drug may result in uterine hypertonicity, spasm, titanic contraction or rupture of the uterus. 
 the possibility of increased blood loss and afbrinigenemia should be kept in mind when administering the drug. 
 severe water intoxication with convulsions and coma has occurred. 
 oxytocin may occasionally cause nausea, vomiting, haemorrhage or cardiac arrhythmias, anaphylactic reaction. 
  ",oxytocin
sign_symptom,coma,0.99965596,"  
 hypersensitivity to the drug may result in uterine hypertonicity, spasm, titanic contraction or rupture of the uterus. 
 the possibility of increased blood loss and afbrinigenemia should be kept in mind when administering the drug. 
 severe water intoxication with convulsions and coma has occurred. 
 oxytocin may occasionally cause nausea, vomiting, haemorrhage or cardiac arrhythmias, anaphylactic reaction. 
  ",oxytocin
medication,oxyt,0.99153364,"  
 hypersensitivity to the drug may result in uterine hypertonicity, spasm, titanic contraction or rupture of the uterus. 
 the possibility of increased blood loss and afbrinigenemia should be kept in mind when administering the drug. 
 severe water intoxication with convulsions and coma has occurred. 
 oxytocin may occasionally cause nausea, vomiting, haemorrhage or cardiac arrhythmias, anaphylactic reaction. 
  ",oxytocin
sign_symptom,nausea,0.8962846,"  
 hypersensitivity to the drug may result in uterine hypertonicity, spasm, titanic contraction or rupture of the uterus. 
 the possibility of increased blood loss and afbrinigenemia should be kept in mind when administering the drug. 
 severe water intoxication with convulsions and coma has occurred. 
 oxytocin may occasionally cause nausea, vomiting, haemorrhage or cardiac arrhythmias, anaphylactic reaction. 
  ",oxytocin
sign_symptom,hypersensitivity reactions,0.90995324," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,allergic,0.91231424," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,sickness,0.9232301," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,reactions,0.88312894," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,oedema,0.89700836," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,bronch,0.7544918," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,spasm,0.9265063," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,shock,0.99929583," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,rash,0.9996136," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,inflammation,0.9999243," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,dryness,0.998833," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,disorders of taste,0.99990433," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,skin reactions,0.9983239," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,gastrointestinal disturbances,0.96142787," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,loose stool,0.99842286," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,diarr,0.8418572," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
disease_disorder,enter,0.9501287," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
medication,antibiotics,0.9736299," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
disease_disorder,pseudo,0.9986582," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
medication,penicillin,0.9868042," occasionally, hypersensitivity reactions involving the skin (e.g. urticaria, morbilliform or scarlatiniform rashes, pruritus), eosinophilia or more serious allergic reactions, e.g. drug fever, vasculitis, serum sickness or interstitial nephritis, may develop. anaphylactic or anaphylactoid reactions accompanied by, e.g- angioneurotic oedema, oedema of the larynx, bronchial spasm and shock may occur.  in the event of signs pointing to anaphylactic/anaphylactoid reactions, the treatment must be terminated immediately. in occasional instances, there may be skin rashes or inflammation of mucous membranes, especially in the region of the mouth (stomatitis); dryness of the mouth and disorders of taste may rarely occur.  the occurrence of severe bullous skin reactions- usually involving the mucosae- has been reported in isolated cases (stevens-johnson syndrome, lyell's syndrome). gastrointestinal disturbances with, e.g., nausea, vomiting, abdominal pain, loose stools, or diarrhoea may develop.   diarrhoea may sometimes be a symptom of enterocolitis which may, in some cases, be haemorrhagic. a particular form of enterocolitis that can occur with antibiotics is pseudomembranous colitis (in most cases due to clostridium diffcile). this must be considered in patients in whom severe, persistent diarrhoea occurs during treatment or in the initial weeks thereafter. even if pseudomembranous colitis is only suspected, administration of phenoxymethyl penicillin must be halted immediately. this type of colitis requires immediate and appropriate treatment by a physician. drugs that inhibit intestinal peristalsis must not be taken in such cases. in isolated cases, particularly after high doses and prolonged administration, changes in blood picture such as reduction in the number of white blood cells (e.g.,leucopenia, granulocytopenia, agranulocytosis), erythrocytes (e.g., due to haemolytic anaemia), thrombocytes, or pancytopenia and myelosuppression may occur. during treatment for spirochaetal infections, herxheimer's reaction characterized by the occurrence or worsening of general symptoms such as fever, chills, headache, and joint pains may develop. in isolated cases, drug-induced aseptic meningitis may occur.   in extremely rare cases, transient discolouration of the teeth may be seen during treatment with phenoxymethyl penicillin. administration of antibiotics, especially if prolonged, may lead to the proliferation of resistant micro organisms.  beta-lactams predispose the patient to encephalopathy risk (which may include convulsions, confusion, impairment of consciousness, movement disorders), particularly in case of overdose or renal impairment. ",phenoxymethyl penicillin [penicillin v]
sign_symptom,adverse,0.7684821," the most common adverse reaction is somnolence. other less frequent adverse reactions are agitation, confusion, hyperkinesia, ataxia, cns depression, nightmares, nervousness, psychiatric disturbance, hallucinations, insomnia, anxiety, dizziness, thinking abnormality, apnea, bradycardia, hypotension, nausea, vomiting and constipation. ",phenobarbital
sign_symptom,vomiting,0.98912746," the most common adverse reaction is somnolence. other less frequent adverse reactions are agitation, confusion, hyperkinesia, ataxia, cns depression, nightmares, nervousness, psychiatric disturbance, hallucinations, insomnia, anxiety, dizziness, thinking abnormality, apnea, bradycardia, hypotension, nausea, vomiting and constipation. ",phenobarbital
sign_symptom,tolerance,0.9880117," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
sign_symptom,hypersensitivity reactions,0.9972922," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
sign_symptom,inability to concentrate,0.98378277," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
sign_symptom,insomnia,0.98443335," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
sign_symptom,agitation,0.9995097," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
sign_symptom,hallucinations,0.9770792," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
sign_symptom,vomiting,0.988771," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
sign_symptom,dryness of mouth,0.9994673," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
sign_symptom,consti,0.7556125," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
disease_disorder,blood,0.7641992," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
sign_symptom,dyscrasias,0.85073364," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
disease_disorder,agranu,0.97571087," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
sign_symptom,anaemia,0.9988067," the most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. hypersensitivity reactions have been reported. 
 
  central nervous system : lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose. 
  gastrointestinal : nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. 
  genitourinary : urinary retention. 
  cardiovascular : palpitations, headache. 
  ocular : blurred vision, increased intraocular pressure. 
  musculoskeletal : muscular weakness. 
  haematological : rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported. 
  ",pheniramine maleate
sign_symptom,nausea,0.9998642,"  central nervous system : lightheadedness, dizziness, sedation, sweating, bizarre feelings, disorientation, hallucinations, psychosis. some of these effects seem to be more prominent in ambulatory patients and those not experiencing severe pain, and may be relieved by reducing the dose slightly and lying down.   gastrointestinal : nausea and vomiting, constipation. ",pethidine hydrochloride
sign_symptom,adverse reactions,0.97934747," metastatic breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy. 
 
neoadjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of fec were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (tch) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddac were nausea, diarrhea, alopecia, fatigue, constipation and headache. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of fec were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia. 
 
adjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting. 
  ",pertuzumab
medication,docetaxel,0.86812556," metastatic breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy. 
 
neoadjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of fec were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (tch) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddac were nausea, diarrhea, alopecia, fatigue, constipation and headache. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of fec were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia. 
 
adjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting. 
  ",pertuzumab
sign_symptom,adverse,0.98134667," metastatic breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy. 
 
neoadjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of fec were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (tch) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddac were nausea, diarrhea, alopecia, fatigue, constipation and headache. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of fec were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia. 
 
adjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting. 
  ",pertuzumab
sign_symptom,vomiting,0.9614384," metastatic breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy. 
 
neoadjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of fec were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (tch) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddac were nausea, diarrhea, alopecia, fatigue, constipation and headache. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of fec were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia. 
 
adjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting. 
  ",pertuzumab
medication,docetax,0.9102721," metastatic breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy. 
 
neoadjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of fec were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (tch) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddac were nausea, diarrhea, alopecia, fatigue, constipation and headache. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of fec were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia. 
 
adjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting. 
  ",pertuzumab
medication,trastuzumab,0.8676341," metastatic breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy. 
 
neoadjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of fec were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (tch) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddac were nausea, diarrhea, alopecia, fatigue, constipation and headache. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of fec were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia. 
 
adjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting. 
  ",pertuzumab
medication,trast,0.8422415," metastatic breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy. 
 
neoadjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of fec were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (tch) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddac were nausea, diarrhea, alopecia, fatigue, constipation and headache. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of fec were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia. 
 
adjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting. 
  ",pertuzumab
medication,paclitaxel,0.9637028," metastatic breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy. 
 
neoadjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of fec were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (tch) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddac were nausea, diarrhea, alopecia, fatigue, constipation and headache. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of fec were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia. 
 
adjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting. 
  ",pertuzumab
sign_symptom,consti,0.78273004," metastatic breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy. 
 
neoadjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of fec were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (tch) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddac were nausea, diarrhea, alopecia, fatigue, constipation and headache. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of fec were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia. 
 
adjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting. 
  ",pertuzumab
medication,pertu,0.83309495," metastatic breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy. 
 
neoadjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of fec were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (tch) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddac were nausea, diarrhea, alopecia, fatigue, constipation and headache. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of fec were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia. 
 
adjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting. 
  ",pertuzumab
medication,chemotherapy,0.99978274," metastatic breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia,neutropenia, nausea, fatigue, rash, and peripheral neuropathy. 
 
neoadjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt; 30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of fec were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (tch) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddac were nausea, diarrhea, alopecia, fatigue, constipation and headache. 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of fec were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia. 
 
adjuvant treatment of breast cancer: 
 
 the most common adverse reactions (&gt;30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting. 
  ",pertuzumab
sign_symptom,stinging sensation,0.9044621," occasional reports of burning or stinging sensation which passes quickly. this isusually mild and occurs more frequently in patients with severe scabies. transient signs andsymptoms of skin irritation including rash or itching, erythema, edema and eczema. these aregenerally considered to be part of the natural history of scabies. ",permethrin + crotamiton
sign_symptom,irritation,0.99988663," occasional reports of burning or stinging sensation which passes quickly. this isusually mild and occurs more frequently in patients with severe scabies. transient signs andsymptoms of skin irritation including rash or itching, erythema, edema and eczema. these aregenerally considered to be part of the natural history of scabies. ",permethrin + crotamiton
sign_symptom,rash,0.99994504," occasional reports of burning or stinging sensation which passes quickly. this isusually mild and occurs more frequently in patients with severe scabies. transient signs andsymptoms of skin irritation including rash or itching, erythema, edema and eczema. these aregenerally considered to be part of the natural history of scabies. ",permethrin + crotamiton
sign_symptom,tingling,0.99965024," in scabies patients, skin discomfort, usually described as burning, stinging or tingling occurs in a few individuals soon after the cream is applied. others transient signs and symptoms of irritation including enythema, edema, eczema, rash and puritis. ",permethrin
sign_symptom,irritation,0.9998503," in scabies patients, skin discomfort, usually described as burning, stinging or tingling occurs in a few individuals soon after the cream is applied. others transient signs and symptoms of irritation including enythema, edema, eczema, rash and puritis. ",permethrin
sign_symptom,rash,0.9986217," in scabies patients, skin discomfort, usually described as burning, stinging or tingling occurs in a few individuals soon after the cream is applied. others transient signs and symptoms of irritation including enythema, edema, eczema, rash and puritis. ",permethrin
sign_symptom,hypotension,0.98685247," during dialysis amino acids and water soluble vitamins may be lost. fluid and electrolyte imbalance, hypovolemia, hypotension or muscle cramping may occur. ",peritoneal dialysis solutions
sign_symptom,adverse reactions,0.9916402," the most commonly reported adverse reactions with perindopril and amlodipine given separately are: oedema, somnolence, dizziness, headache (especially at the beginning of the treatment), dysgeusia, paraesthesia, visual impairment (including diplopia), tinnitus, vertigo, palpitations, flushing, hypotension (and effects related to hypotension), dyspnoea, cough, abdominal pain, nausea, vomiting, dyspepsia, change of bowel habit, diarrhoea, constipation, pruritus, rash, exanthema, joint swelling (ankle swelling), muscle spasms, fatigue, asthenia. ",perindopril arginine + amlodipine
sign_symptom,headache,0.9997687," the most commonly reported adverse reactions with perindopril and amlodipine given separately are: oedema, somnolence, dizziness, headache (especially at the beginning of the treatment), dysgeusia, paraesthesia, visual impairment (including diplopia), tinnitus, vertigo, palpitations, flushing, hypotension (and effects related to hypotension), dyspnoea, cough, abdominal pain, nausea, vomiting, dyspepsia, change of bowel habit, diarrhoea, constipation, pruritus, rash, exanthema, joint swelling (ankle swelling), muscle spasms, fatigue, asthenia. ",perindopril arginine + amlodipine
sign_symptom,impairment,0.74642867," the most commonly reported adverse reactions with perindopril and amlodipine given separately are: oedema, somnolence, dizziness, headache (especially at the beginning of the treatment), dysgeusia, paraesthesia, visual impairment (including diplopia), tinnitus, vertigo, palpitations, flushing, hypotension (and effects related to hypotension), dyspnoea, cough, abdominal pain, nausea, vomiting, dyspepsia, change of bowel habit, diarrhoea, constipation, pruritus, rash, exanthema, joint swelling (ankle swelling), muscle spasms, fatigue, asthenia. ",perindopril arginine + amlodipine
sign_symptom,change of bowel,0.862261," the most commonly reported adverse reactions with perindopril and amlodipine given separately are: oedema, somnolence, dizziness, headache (especially at the beginning of the treatment), dysgeusia, paraesthesia, visual impairment (including diplopia), tinnitus, vertigo, palpitations, flushing, hypotension (and effects related to hypotension), dyspnoea, cough, abdominal pain, nausea, vomiting, dyspepsia, change of bowel habit, diarrhoea, constipation, pruritus, rash, exanthema, joint swelling (ankle swelling), muscle spasms, fatigue, asthenia. ",perindopril arginine + amlodipine
sign_symptom,swelling,0.998738," the most commonly reported adverse reactions with perindopril and amlodipine given separately are: oedema, somnolence, dizziness, headache (especially at the beginning of the treatment), dysgeusia, paraesthesia, visual impairment (including diplopia), tinnitus, vertigo, palpitations, flushing, hypotension (and effects related to hypotension), dyspnoea, cough, abdominal pain, nausea, vomiting, dyspepsia, change of bowel habit, diarrhoea, constipation, pruritus, rash, exanthema, joint swelling (ankle swelling), muscle spasms, fatigue, asthenia. ",perindopril arginine + amlodipine
sign_symptom,headache,0.99697626,"  rare and mild : usually at the start oftreatment cough, fatigue, asthenia, headache, disturbances of mood and/or sleep have been reported.   less often : taste impairment, epigastric discomfort, nausea, abdominal pain andrash.reversible increase in blood urea and creatinine may be observed. proteinuria has occurred in some patients.   rarely : angioneurotic edema and decrease in hemoglobin, red cells and platelets have been reported. ",perindopril arginine
sign_symptom,disturbances of mood,0.99993306,"  rare and mild : usually at the start oftreatment cough, fatigue, asthenia, headache, disturbances of mood and/or sleep have been reported.   less often : taste impairment, epigastric discomfort, nausea, abdominal pain andrash.reversible increase in blood urea and creatinine may be observed. proteinuria has occurred in some patients.   rarely : angioneurotic edema and decrease in hemoglobin, red cells and platelets have been reported. ",perindopril arginine
sign_symptom,sleep,0.9990245,"  rare and mild : usually at the start oftreatment cough, fatigue, asthenia, headache, disturbances of mood and/or sleep have been reported.   less often : taste impairment, epigastric discomfort, nausea, abdominal pain andrash.reversible increase in blood urea and creatinine may be observed. proteinuria has occurred in some patients.   rarely : angioneurotic edema and decrease in hemoglobin, red cells and platelets have been reported. ",perindopril arginine
sign_symptom,taste,0.99986196,"  rare and mild : usually at the start oftreatment cough, fatigue, asthenia, headache, disturbances of mood and/or sleep have been reported.   less often : taste impairment, epigastric discomfort, nausea, abdominal pain andrash.reversible increase in blood urea and creatinine may be observed. proteinuria has occurred in some patients.   rarely : angioneurotic edema and decrease in hemoglobin, red cells and platelets have been reported. ",perindopril arginine
sign_symptom,epigastric,0.98932105,"  rare and mild : usually at the start oftreatment cough, fatigue, asthenia, headache, disturbances of mood and/or sleep have been reported.   less often : taste impairment, epigastric discomfort, nausea, abdominal pain andrash.reversible increase in blood urea and creatinine may be observed. proteinuria has occurred in some patients.   rarely : angioneurotic edema and decrease in hemoglobin, red cells and platelets have been reported. ",perindopril arginine
sign_symptom,discomfort,0.98579586,"  rare and mild : usually at the start oftreatment cough, fatigue, asthenia, headache, disturbances of mood and/or sleep have been reported.   less often : taste impairment, epigastric discomfort, nausea, abdominal pain andrash.reversible increase in blood urea and creatinine may be observed. proteinuria has occurred in some patients.   rarely : angioneurotic edema and decrease in hemoglobin, red cells and platelets have been reported. ",perindopril arginine
sign_symptom,nausea,0.9972894,"  rare and mild : usually at the start oftreatment cough, fatigue, asthenia, headache, disturbances of mood and/or sleep have been reported.   less often : taste impairment, epigastric discomfort, nausea, abdominal pain andrash.reversible increase in blood urea and creatinine may be observed. proteinuria has occurred in some patients.   rarely : angioneurotic edema and decrease in hemoglobin, red cells and platelets have been reported. ",perindopril arginine
sign_symptom,pain,0.99996173,"  rare and mild : usually at the start oftreatment cough, fatigue, asthenia, headache, disturbances of mood and/or sleep have been reported.   less often : taste impairment, epigastric discomfort, nausea, abdominal pain andrash.reversible increase in blood urea and creatinine may be observed. proteinuria has occurred in some patients.   rarely : angioneurotic edema and decrease in hemoglobin, red cells and platelets have been reported. ",perindopril arginine
sign_symptom,proteinuria,0.9998223,"  rare and mild : usually at the start oftreatment cough, fatigue, asthenia, headache, disturbances of mood and/or sleep have been reported.   less often : taste impairment, epigastric discomfort, nausea, abdominal pain andrash.reversible increase in blood urea and creatinine may be observed. proteinuria has occurred in some patients.   rarely : angioneurotic edema and decrease in hemoglobin, red cells and platelets have been reported. ",perindopril arginine
sign_symptom,suicidal behavior,0.85836345," perampanel may cause serious psychiatric and behavioral reactions, suicidal behavior and ideation, dizziness, somnolence, fatigue, irritability, falls, nausea, ataxia, balance disorder etc. ",perampanel
disease_disorder,balance disorder,0.9702594," perampanel may cause serious psychiatric and behavioral reactions, suicidal behavior and ideation, dizziness, somnolence, fatigue, irritability, falls, nausea, ataxia, balance disorder etc. ",perampanel
sign_symptom,tachycardia,0.81628627," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
disease_disorder,system,0.78598744," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
sign_symptom,leuc,0.8063108," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
disease_disorder,meningitis,0.9826579," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
sign_symptom,epigast,0.9856897," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
sign_symptom,discomfort,0.9507145," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
sign_symptom,nausea,0.99217814," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
sign_symptom,vomiting,0.98754627," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
sign_symptom,hypersalivation,0.98992056," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
disease_disorder,rash,0.75251555," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
disease_disorder,shock,0.97397184," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
sign_symptom,sleep disorder,0.99076104," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
sign_symptom,sleep,0.99843496," these adverse reactions have been reported in clinical trials or post-marketing- 
 
 investigations: transaminases increased (transaminase elevation), blood pressure decreased (fall in blood pressure) 
 cardiac disorders: arrhythmia (cardiac arrhythmia), tachycardia, angina pectoris 
 blood and lymphatic system disorders: thrombocytopenia (thrombopenia), leucopenia/neutropenia 
 nervous system disorders: dizziness, headache, meningitis aseptic (aseptic meningitis) 
 gastrointestinal disorders: gastrointestinal disorder (gastrointestinal complaints), epigastric discomfort (gastric pressure), abdominal distension (fullness), nausea, vomiting, diarrhoea, constipation, hypersalivation 
 skin and subcutaneous tissue disorders: pruritus, erythema (reddening of the skin), urticaria, rash 
 vascular disorders: hot fush (flushes), haemorrhage (bleedings) 
 immune system disorders: anaphylactic reaction, anaphylactoid reaction, angioedema (angioneurotic edema), bronchospasm, anaphylactic shock (shock) 
 hepatobiliary disorders: cholestasis (intrahepatic cholestasis) 
 psychiatric disorders: agitation, sleep disorder (sleep disturbances) 
  ",pentoxifylline
disease_disorder,alopecia,0.98664504," alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%). ",pentosan polysulfate sodium
sign_symptom,diarrhea,0.9990733," alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%). ",pentosan polysulfate sodium
sign_symptom,nausea,0.9999356," alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%). ",pentosan polysulfate sodium
sign_symptom,headache,0.9999268," alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%). ",pentosan polysulfate sodium
sign_symptom,rash,0.99992824," alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%). ",pentosan polysulfate sodium
sign_symptom,dyspepsia,0.99977523," alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%). ",pentosan polysulfate sodium
sign_symptom,pain,0.99995255," alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%). ",pentosan polysulfate sodium
sign_symptom,constipati,0.7392456," physical dependence; sedation, dizziness, euphoria, lightheadedness, alterations of mood; respiratory depression; visual hallucinations, disorientation, confusion; hypertension, tachycardia, circulatory depression; shock; hypotension; nausea, vomiting, constipation; seizures, diaphoresis; rash; blood dyscrasias; local tissue damages (sc), muscle fibrosis (im). ",pentazocine hydrochloride
sign_symptom,diaph,0.9400672," physical dependence; sedation, dizziness, euphoria, lightheadedness, alterations of mood; respiratory depression; visual hallucinations, disorientation, confusion; hypertension, tachycardia, circulatory depression; shock; hypotension; nausea, vomiting, constipation; seizures, diaphoresis; rash; blood dyscrasias; local tissue damages (sc), muscle fibrosis (im). ",pentazocine hydrochloride
disease_disorder,damages,0.9338345," physical dependence; sedation, dizziness, euphoria, lightheadedness, alterations of mood; respiratory depression; visual hallucinations, disorientation, confusion; hypertension, tachycardia, circulatory depression; shock; hypotension; nausea, vomiting, constipation; seizures, diaphoresis; rash; blood dyscrasias; local tissue damages (sc), muscle fibrosis (im). ",pentazocine hydrochloride
disease_disorder,fibrosis,0.8306239," physical dependence; sedation, dizziness, euphoria, lightheadedness, alterations of mood; respiratory depression; visual hallucinations, disorientation, confusion; hypertension, tachycardia, circulatory depression; shock; hypotension; nausea, vomiting, constipation; seizures, diaphoresis; rash; blood dyscrasias; local tissue damages (sc), muscle fibrosis (im). ",pentazocine hydrochloride
sign_symptom,headache,0.99967206," burning of eye, dry eye, ocular discomfort, non ocular allergy, sinusitis, headache and sneezing or nasal congestion. ",pemirolast potassium
sign_symptom,adverse reactions,0.9998219," the following adverse reactions are discussed in greater detail in other sections of the labeling: 
 
 myelosuppression 
 renal failure 
 bullousand exfoliative skin toxicity 
 interstitialpneumonitis 
 radiationrecall 
  ",pemetrexed
disease_disorder,renal failure,0.9996679," the following adverse reactions are discussed in greater detail in other sections of the labeling: 
 
 myelosuppression 
 renal failure 
 bullousand exfoliative skin toxicity 
 interstitialpneumonitis 
 radiationrecall 
  ",pemetrexed
sign_symptom,bullous,0.7160423," the following adverse reactions are discussed in greater detail in other sections of the labeling: 
 
 myelosuppression 
 renal failure 
 bullousand exfoliative skin toxicity 
 interstitialpneumonitis 
 radiationrecall 
  ",pemetrexed
disease_disorder,skin,0.731873," the following adverse reactions are discussed in greater detail in other sections of the labeling: 
 
 myelosuppression 
 renal failure 
 bullousand exfoliative skin toxicity 
 interstitialpneumonitis 
 radiationrecall 
  ",pemetrexed
sign_symptom,toxicity,0.9825264," the following adverse reactions are discussed in greater detail in other sections of the labeling: 
 
 myelosuppression 
 renal failure 
 bullousand exfoliative skin toxicity 
 interstitialpneumonitis 
 radiationrecall 
  ",pemetrexed
sign_symptom,inter,0.7505943," the following adverse reactions are discussed in greater detail in other sections of the labeling: 
 
 myelosuppression 
 renal failure 
 bullousand exfoliative skin toxicity 
 interstitialpneumonitis 
 radiationrecall 
  ",pemetrexed
sign_symptom,adverse reactions,0.99112946," most common adverse reactions (reported in 20% of patients) were:   pembrolizumab as a single agent : fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain, and abdominal pain.   pembrolizumab in combination with chemotherapy : fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, and stomatitis.   pembrolizumab in combination with axitinib : diarrhea, fatigue/asthenia, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.   pembrolizumab in combination with lenvatinib : fatigue, hypertension, musculoskeletal pain, diarrhea, decreased appetite, hypothyroidism, nausea, stomatitis, vomiting, decreased weight, abdominal pain, headache, constipation, urinary tract infection, dysphonia, hemorrhagic events, hypomagnesemia, palmar-plantar erythrodysesthesia, dyspnea, cough, and rash. ",pembrolizumab
sign_symptom,decreased,0.7137336," most common adverse reactions (reported in 20% of patients) were:   pembrolizumab as a single agent : fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain, and abdominal pain.   pembrolizumab in combination with chemotherapy : fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, and stomatitis.   pembrolizumab in combination with axitinib : diarrhea, fatigue/asthenia, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.   pembrolizumab in combination with lenvatinib : fatigue, hypertension, musculoskeletal pain, diarrhea, decreased appetite, hypothyroidism, nausea, stomatitis, vomiting, decreased weight, abdominal pain, headache, constipation, urinary tract infection, dysphonia, hemorrhagic events, hypomagnesemia, palmar-plantar erythrodysesthesia, dyspnea, cough, and rash. ",pembrolizumab
sign_symptom,fatigue,0.9810705," most common adverse reactions (reported in 20% of patients) were:   pembrolizumab as a single agent : fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain, and abdominal pain.   pembrolizumab in combination with chemotherapy : fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, and stomatitis.   pembrolizumab in combination with axitinib : diarrhea, fatigue/asthenia, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.   pembrolizumab in combination with lenvatinib : fatigue, hypertension, musculoskeletal pain, diarrhea, decreased appetite, hypothyroidism, nausea, stomatitis, vomiting, decreased weight, abdominal pain, headache, constipation, urinary tract infection, dysphonia, hemorrhagic events, hypomagnesemia, palmar-plantar erythrodysesthesia, dyspnea, cough, and rash. ",pembrolizumab
sign_symptom,tumor,0.9996265,"  
 increased mortality, myocardial infarction, stroke, and thromboembolism 
 increased mortality and/or tumor progression in patients with cancer 
 hypertension 
 seizures 
 pure red cell aplasia 
 serious allergic reactions 
  ",pegylated erythropoietin
sign_symptom,seizures,0.998558,"  
 increased mortality, myocardial infarction, stroke, and thromboembolism 
 increased mortality and/or tumor progression in patients with cancer 
 hypertension 
 seizures 
 pure red cell aplasia 
 serious allergic reactions 
  ",pegylated erythropoietin
sign_symptom,cell,0.8464693,"  
 increased mortality, myocardial infarction, stroke, and thromboembolism 
 increased mortality and/or tumor progression in patients with cancer 
 hypertension 
 seizures 
 pure red cell aplasia 
 serious allergic reactions 
  ",pegylated erythropoietin
disease_disorder,aplasia,0.99553037,"  
 increased mortality, myocardial infarction, stroke, and thromboembolism 
 increased mortality and/or tumor progression in patients with cancer 
 hypertension 
 seizures 
 pure red cell aplasia 
 serious allergic reactions 
  ",pegylated erythropoietin
sign_symptom,allergic reactions,0.999722,"  
 increased mortality, myocardial infarction, stroke, and thromboembolism 
 increased mortality and/or tumor progression in patients with cancer 
 hypertension 
 seizures 
 pure red cell aplasia 
 serious allergic reactions 
  ",pegylated erythropoietin
sign_symptom,nausea,0.9992536,"  
 depression, suicide, relapse of drug abuse and bacterial infection 
 flu like symptoms: fatigue, pyrexia, 
 gastrointestinal: nausea/vomiting, diarrhea, abdominal pain 
 metabolic and nutritional: anorexia 
 musculoskeletal: myalgia, arthralgia 
 neurological: headache, dizziness, insomnia 
 psychiatric reactions: irritability, anxiety 
 injection site reaction, skin problems, hair loss 
 endocrine: hypothyroidism 
  ",peginterferon alfa-2a [pegylated interferon alfa-2a]
sign_symptom,pain,0.9999144,"  
 depression, suicide, relapse of drug abuse and bacterial infection 
 flu like symptoms: fatigue, pyrexia, 
 gastrointestinal: nausea/vomiting, diarrhea, abdominal pain 
 metabolic and nutritional: anorexia 
 musculoskeletal: myalgia, arthralgia 
 neurological: headache, dizziness, insomnia 
 psychiatric reactions: irritability, anxiety 
 injection site reaction, skin problems, hair loss 
 endocrine: hypothyroidism 
  ",peginterferon alfa-2a [pegylated interferon alfa-2a]
sign_symptom,arthralgia,0.95455885,"  
 depression, suicide, relapse of drug abuse and bacterial infection 
 flu like symptoms: fatigue, pyrexia, 
 gastrointestinal: nausea/vomiting, diarrhea, abdominal pain 
 metabolic and nutritional: anorexia 
 musculoskeletal: myalgia, arthralgia 
 neurological: headache, dizziness, insomnia 
 psychiatric reactions: irritability, anxiety 
 injection site reaction, skin problems, hair loss 
 endocrine: hypothyroidism 
  ",peginterferon alfa-2a [pegylated interferon alfa-2a]
sign_symptom,anxiety,0.93814737,"  
 depression, suicide, relapse of drug abuse and bacterial infection 
 flu like symptoms: fatigue, pyrexia, 
 gastrointestinal: nausea/vomiting, diarrhea, abdominal pain 
 metabolic and nutritional: anorexia 
 musculoskeletal: myalgia, arthralgia 
 neurological: headache, dizziness, insomnia 
 psychiatric reactions: irritability, anxiety 
 injection site reaction, skin problems, hair loss 
 endocrine: hypothyroidism 
  ",peginterferon alfa-2a [pegylated interferon alfa-2a]
sign_symptom,hair loss,0.9634607,"  
 depression, suicide, relapse of drug abuse and bacterial infection 
 flu like symptoms: fatigue, pyrexia, 
 gastrointestinal: nausea/vomiting, diarrhea, abdominal pain 
 metabolic and nutritional: anorexia 
 musculoskeletal: myalgia, arthralgia 
 neurological: headache, dizziness, insomnia 
 psychiatric reactions: irritability, anxiety 
 injection site reaction, skin problems, hair loss 
 endocrine: hypothyroidism 
  ",peginterferon alfa-2a [pegylated interferon alfa-2a]
disease_disorder,rupt,0.90539026,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
sign_symptom,enlarged,0.9994685,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
sign_symptom,pain,0.99994695,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
disease_disorder,respiratory distress,0.99452734,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
disease_disorder,acute respiratory distress syndrome,0.98415166,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
sign_symptom,fever,0.9999229,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
sign_symptom,infiltrates,0.9723619,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
sign_symptom,respiratory distress,0.9992514,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
medication,pegfilgrastim,0.864722,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
sign_symptom,allergic reactions,0.9049318,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
sign_symptom,allergic,0.9998622,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
sign_symptom,anaphyla,0.97644264,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
disease_disorder,sickle cell disorders,0.9994565,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
disease_disorder,sickle cell crises,0.9942696,"  splenic rupture : splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim. evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving pegfilgrastim.   acute respiratory distress syndrome : acute respiratory distress syndrome (ards) can occur in patients receiving pegfilgrastim. evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving pegfilgrastim for ards. discontinue pegfilgrastim in patients with ards.   serious allergic reactions : serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim. the majority of reported events occurred upon initial exposure. allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. permanently discontinue pegfilgrastim in patients: with serious allergic reactions. do not administer pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.    patients with sickle cell disorders : severe sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim. severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim, the parent compound of pegfilgrastim. ",pegfilgrastim [pegylated filgrastim]
sign_symptom,irritating,0.965063," irritating to the eyes and mucous membranes; gi disturbances; thrombocytopenia, leucopenia; renal failure; hepatotoxicity; cns effects; eeg changes; peripheral and autonomic neuropathies; local reactions ",podophyllotoxin
disease_disorder,renal,0.73819953," irritating to the eyes and mucous membranes; gi disturbances; thrombocytopenia, leucopenia; renal failure; hepatotoxicity; cns effects; eeg changes; peripheral and autonomic neuropathies; local reactions ",podophyllotoxin
sign_symptom,nausea,0.99992," pivmecillinam is generally well tolerated, even by patients with reduced kidney function. upper gastrointestinal disturbances such as nausea, vomiting and diarrhoea or indigestion may occur when a dose has been given on an empty stomach. skin rashes have been reported in some cases, but the characteristic ampicillin-rash has never been observed, nor has there been any evidence of hepato-, nephro-, or ototoxicity. the occurrence of anaphylaxis, though not yet reported, cannot be entirely excluded. ",pivmecillinam
sign_symptom,vomiting,0.99989784," pivmecillinam is generally well tolerated, even by patients with reduced kidney function. upper gastrointestinal disturbances such as nausea, vomiting and diarrhoea or indigestion may occur when a dose has been given on an empty stomach. skin rashes have been reported in some cases, but the characteristic ampicillin-rash has never been observed, nor has there been any evidence of hepato-, nephro-, or ototoxicity. the occurrence of anaphylaxis, though not yet reported, cannot be entirely excluded. ",pivmecillinam
sign_symptom,diarrhoea,0.90743273," pivmecillinam is generally well tolerated, even by patients with reduced kidney function. upper gastrointestinal disturbances such as nausea, vomiting and diarrhoea or indigestion may occur when a dose has been given on an empty stomach. skin rashes have been reported in some cases, but the characteristic ampicillin-rash has never been observed, nor has there been any evidence of hepato-, nephro-, or ototoxicity. the occurrence of anaphylaxis, though not yet reported, cannot be entirely excluded. ",pivmecillinam
sign_symptom,rash,0.99992204," pivmecillinam is generally well tolerated, even by patients with reduced kidney function. upper gastrointestinal disturbances such as nausea, vomiting and diarrhoea or indigestion may occur when a dose has been given on an empty stomach. skin rashes have been reported in some cases, but the characteristic ampicillin-rash has never been observed, nor has there been any evidence of hepato-, nephro-, or ototoxicity. the occurrence of anaphylaxis, though not yet reported, cannot be entirely excluded. ",pivmecillinam
sign_symptom,anaphyla,0.8790503," pivmecillinam is generally well tolerated, even by patients with reduced kidney function. upper gastrointestinal disturbances such as nausea, vomiting and diarrhoea or indigestion may occur when a dose has been given on an empty stomach. skin rashes have been reported in some cases, but the characteristic ampicillin-rash has never been observed, nor has there been any evidence of hepato-, nephro-, or ototoxicity. the occurrence of anaphylaxis, though not yet reported, cannot be entirely excluded. ",pivmecillinam
sign_symptom,adverse reactions,0.99988854," the safety of pirfenidone has been evaluated in clinical studies including 1345 healthy volunteers and patients. the most commonly reported (10%) adverse reactions during clinical study experience with pirfenidone at a dose of 2403 mg/day compared to placebo, respectively, were nausea (32.8% versus 13.3%), rash (28.7% versus 8.6%), fatigue (22.3% versus 13.3%), diarrhoea (21.7% versus 13.5%), dyspepsia (16.8% versus 5.5%), and photosensitivity reaction (12.2% versus 1.7%). serious adverse reactions were recorded at similar frequencies among patients treated with 2403 mg/day of pirfenidone and placebo in clinical studies. the adverse reactions reported at a frequency of 2% in 345 patients receiving pirfenidone at the recommended dose of 2403 mg/day in two pivotal phase 3 studies. adverse reactions from post-marketing experience are also listed. adverse reactions are listed by system organ class (soc) and within each frequency grouping the adverse reactions are presented in order of decreasing seriousness. ",pirfenidone
sign_symptom,nausea,0.99995816," the safety of pirfenidone has been evaluated in clinical studies including 1345 healthy volunteers and patients. the most commonly reported (10%) adverse reactions during clinical study experience with pirfenidone at a dose of 2403 mg/day compared to placebo, respectively, were nausea (32.8% versus 13.3%), rash (28.7% versus 8.6%), fatigue (22.3% versus 13.3%), diarrhoea (21.7% versus 13.5%), dyspepsia (16.8% versus 5.5%), and photosensitivity reaction (12.2% versus 1.7%). serious adverse reactions were recorded at similar frequencies among patients treated with 2403 mg/day of pirfenidone and placebo in clinical studies. the adverse reactions reported at a frequency of 2% in 345 patients receiving pirfenidone at the recommended dose of 2403 mg/day in two pivotal phase 3 studies. adverse reactions from post-marketing experience are also listed. adverse reactions are listed by system organ class (soc) and within each frequency grouping the adverse reactions are presented in order of decreasing seriousness. ",pirfenidone
sign_symptom,rash,0.99995816," the safety of pirfenidone has been evaluated in clinical studies including 1345 healthy volunteers and patients. the most commonly reported (10%) adverse reactions during clinical study experience with pirfenidone at a dose of 2403 mg/day compared to placebo, respectively, were nausea (32.8% versus 13.3%), rash (28.7% versus 8.6%), fatigue (22.3% versus 13.3%), diarrhoea (21.7% versus 13.5%), dyspepsia (16.8% versus 5.5%), and photosensitivity reaction (12.2% versus 1.7%). serious adverse reactions were recorded at similar frequencies among patients treated with 2403 mg/day of pirfenidone and placebo in clinical studies. the adverse reactions reported at a frequency of 2% in 345 patients receiving pirfenidone at the recommended dose of 2403 mg/day in two pivotal phase 3 studies. adverse reactions from post-marketing experience are also listed. adverse reactions are listed by system organ class (soc) and within each frequency grouping the adverse reactions are presented in order of decreasing seriousness. ",pirfenidone
sign_symptom,fatigue,0.9999548," the safety of pirfenidone has been evaluated in clinical studies including 1345 healthy volunteers and patients. the most commonly reported (10%) adverse reactions during clinical study experience with pirfenidone at a dose of 2403 mg/day compared to placebo, respectively, were nausea (32.8% versus 13.3%), rash (28.7% versus 8.6%), fatigue (22.3% versus 13.3%), diarrhoea (21.7% versus 13.5%), dyspepsia (16.8% versus 5.5%), and photosensitivity reaction (12.2% versus 1.7%). serious adverse reactions were recorded at similar frequencies among patients treated with 2403 mg/day of pirfenidone and placebo in clinical studies. the adverse reactions reported at a frequency of 2% in 345 patients receiving pirfenidone at the recommended dose of 2403 mg/day in two pivotal phase 3 studies. adverse reactions from post-marketing experience are also listed. adverse reactions are listed by system organ class (soc) and within each frequency grouping the adverse reactions are presented in order of decreasing seriousness. ",pirfenidone
sign_symptom,diarr,0.9873791," the safety of pirfenidone has been evaluated in clinical studies including 1345 healthy volunteers and patients. the most commonly reported (10%) adverse reactions during clinical study experience with pirfenidone at a dose of 2403 mg/day compared to placebo, respectively, were nausea (32.8% versus 13.3%), rash (28.7% versus 8.6%), fatigue (22.3% versus 13.3%), diarrhoea (21.7% versus 13.5%), dyspepsia (16.8% versus 5.5%), and photosensitivity reaction (12.2% versus 1.7%). serious adverse reactions were recorded at similar frequencies among patients treated with 2403 mg/day of pirfenidone and placebo in clinical studies. the adverse reactions reported at a frequency of 2% in 345 patients receiving pirfenidone at the recommended dose of 2403 mg/day in two pivotal phase 3 studies. adverse reactions from post-marketing experience are also listed. adverse reactions are listed by system organ class (soc) and within each frequency grouping the adverse reactions are presented in order of decreasing seriousness. ",pirfenidone
sign_symptom,photosensitivity reaction,0.99988824," the safety of pirfenidone has been evaluated in clinical studies including 1345 healthy volunteers and patients. the most commonly reported (10%) adverse reactions during clinical study experience with pirfenidone at a dose of 2403 mg/day compared to placebo, respectively, were nausea (32.8% versus 13.3%), rash (28.7% versus 8.6%), fatigue (22.3% versus 13.3%), diarrhoea (21.7% versus 13.5%), dyspepsia (16.8% versus 5.5%), and photosensitivity reaction (12.2% versus 1.7%). serious adverse reactions were recorded at similar frequencies among patients treated with 2403 mg/day of pirfenidone and placebo in clinical studies. the adverse reactions reported at a frequency of 2% in 345 patients receiving pirfenidone at the recommended dose of 2403 mg/day in two pivotal phase 3 studies. adverse reactions from post-marketing experience are also listed. adverse reactions are listed by system organ class (soc) and within each frequency grouping the adverse reactions are presented in order of decreasing seriousness. ",pirfenidone
medication,placebo,0.9953855," the safety of pirfenidone has been evaluated in clinical studies including 1345 healthy volunteers and patients. the most commonly reported (10%) adverse reactions during clinical study experience with pirfenidone at a dose of 2403 mg/day compared to placebo, respectively, were nausea (32.8% versus 13.3%), rash (28.7% versus 8.6%), fatigue (22.3% versus 13.3%), diarrhoea (21.7% versus 13.5%), dyspepsia (16.8% versus 5.5%), and photosensitivity reaction (12.2% versus 1.7%). serious adverse reactions were recorded at similar frequencies among patients treated with 2403 mg/day of pirfenidone and placebo in clinical studies. the adverse reactions reported at a frequency of 2% in 345 patients receiving pirfenidone at the recommended dose of 2403 mg/day in two pivotal phase 3 studies. adverse reactions from post-marketing experience are also listed. adverse reactions are listed by system organ class (soc) and within each frequency grouping the adverse reactions are presented in order of decreasing seriousness. ",pirfenidone
sign_symptom,anxiety,0.9981128," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,sleep,0.9925921," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,fatigue,0.99908876," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,nausea,0.9969415," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,vomiting,0.9968773," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,diarrhoea,0.9733707," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,stomachache,0.8727997," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,symptoms,0.959972," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,vertigo,0.9851364," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,headache,0.9970693," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,trembling,0.9992804," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,sexual stimulation,0.9961766," the side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. the incidence of these during clinical trials was ( 5%) and they were more often noted in the older patients taking &gt; 2.4 gm daily. in the majority of cases, a dose reduction sufficed to make these symptoms disappear. some patients may complain of fatigue or drowsiness, gastrointestinal problems, e.g. nausea, vomiting, diarrhoea and stomachache have also been reported but their incidence during clinical trials was  2%. other symptoms e.g. vertigo, headache, trembling and sexual stimulation have occasionally been reported. ",piracetam
sign_symptom,adverse events,0.98507535," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,rash,0.88387084," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,pruritus,0.9951098," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,purpura,0.9610405," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,constipation,0.95925033," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,nausea,0.9925895," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,vomiting,0.99794036," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,dyspepsia,0.9997156," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,fever,0.9990722," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,immune,0.8401608," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,anaphylactic /,0.90751666," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,anaphylactoid reactions,0.9251158," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,shock,0.9999286," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
disease_disorder,infections,0.8132788," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
disease_disorder,candidiasis,0.96042734," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
disease_disorder,pseudomembranous colitis,0.9069857," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
disease_disorder,hypoglycemia,0.9603741," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
disease_disorder,connective tissue disorders,0.8450192," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
disease_disorder,psychiatric disorders,0.72611874," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
disease_disorder,vascular disorders,0.916529," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
disease_disorder,- phlebitis thrombophlebitis,0.93517756," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,flushing,0.904358," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
disease_disorder,media,0.9752491," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,epista,0.95093906," adverse events primarily involving the skin, including rash, pruritus and purpura; the gastrointestinal system including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions including fever, injection site reaction (1%) and rigors. (1%), immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (1%), infections-candidiasis and pseudomembranous colitis (1%), metabolism and nutrition disorders- hypoglycemia (1%), musculoskeletal and connective tissue disorders- myalgia and arthralgia (1%), psychiatric disorders insomnia, vascular disorders- phlebitis thrombophlebitis(1%), hypotension(1%), flushing(1%), respiratory, thoracic and mediastinal disorders- epistaxis (1%). ",piperacillin + tazobactam
sign_symptom,edema,0.70759475," generally this combined preparation is well tolerated. however, the most common side effects are upper respiratory tract infection, diarrhea, peripheral edema and headache, respectively. these are mild in severity. ",pioglitazone + metformin hydrochloride
medication,pioglitazone,0.91692084,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
sign_symptom,adverse,0.9886077,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
medication,sulfonylurea,0.993687,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
sign_symptom,adverse events,0.7792871,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
medication,placebo,0.9898258,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
sign_symptom,myalgia,0.94442636,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
disease_disorder,tooth disorder,0.97822297,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
disease_disorder,diabetes mellitus,0.9993572,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
disease_disorder,pharyngitis,0.9969466,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
sign_symptom,glim,0.8249581,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
sign_symptom,headache,0.9999255,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
sign_symptom,nausea,0.9999279,"  pioglitazone : the most common adverse experiences with pioglitazone monotherapy (5%) were upper respiratory tract infection, injury, and headache. overall, the types of adverse experiences reported when pioglitazone was used in combination with a sulfonylurea were similar to those during monotherapy with pioglitazone. other adverse events reported in at least 5% of patients in controlled clinical studies between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively. in monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo treated patients.   glimepiride : hypoglycemia: the incidence of hypoglycemia with glimepiride is documented. in patients treated with glimepiride, adverse events, other than hypoglycemia, considered to be possibly or probably related to study drug that occurred in more than 1% of patients included dizziness (1.7%), asthenia (1.6%), headache (1.5%), and nausea (1.1%). dermatologic reactions: allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. these may be transient and may disappear despite continued use of glimepiride. ",pioglitazone + glimepiride
sign_symptom,adverse events,0.9178528," the overall incidence and types of adverse events reported in placebo controlled clinical trials of pioglitazone monotherapy at doses of 7.5 mg, 15 mg, 30 mg or 45 mg once daily are upper respiratory tract infection (13.2%), headache (9.1%), sinusitis (6.3%), myalgia (5.4%), tooth disorder (5.3%), and pharyngitis (5.1%). ",pioglitazone
medication,placebo,0.99360394," the overall incidence and types of adverse events reported in placebo controlled clinical trials of pioglitazone monotherapy at doses of 7.5 mg, 15 mg, 30 mg or 45 mg once daily are upper respiratory tract infection (13.2%), headache (9.1%), sinusitis (6.3%), myalgia (5.4%), tooth disorder (5.3%), and pharyngitis (5.1%). ",pioglitazone
disease_disorder,infection,0.9987822," the overall incidence and types of adverse events reported in placebo controlled clinical trials of pioglitazone monotherapy at doses of 7.5 mg, 15 mg, 30 mg or 45 mg once daily are upper respiratory tract infection (13.2%), headache (9.1%), sinusitis (6.3%), myalgia (5.4%), tooth disorder (5.3%), and pharyngitis (5.1%). ",pioglitazone
sign_symptom,headache,0.99983215," the overall incidence and types of adverse events reported in placebo controlled clinical trials of pioglitazone monotherapy at doses of 7.5 mg, 15 mg, 30 mg or 45 mg once daily are upper respiratory tract infection (13.2%), headache (9.1%), sinusitis (6.3%), myalgia (5.4%), tooth disorder (5.3%), and pharyngitis (5.1%). ",pioglitazone
sign_symptom,sinusitis,0.9929108," the overall incidence and types of adverse events reported in placebo controlled clinical trials of pioglitazone monotherapy at doses of 7.5 mg, 15 mg, 30 mg or 45 mg once daily are upper respiratory tract infection (13.2%), headache (9.1%), sinusitis (6.3%), myalgia (5.4%), tooth disorder (5.3%), and pharyngitis (5.1%). ",pioglitazone
sign_symptom,myalgia,0.93249464," the overall incidence and types of adverse events reported in placebo controlled clinical trials of pioglitazone monotherapy at doses of 7.5 mg, 15 mg, 30 mg or 45 mg once daily are upper respiratory tract infection (13.2%), headache (9.1%), sinusitis (6.3%), myalgia (5.4%), tooth disorder (5.3%), and pharyngitis (5.1%). ",pioglitazone
disease_disorder,tooth disorder,0.9998591," the overall incidence and types of adverse events reported in placebo controlled clinical trials of pioglitazone monotherapy at doses of 7.5 mg, 15 mg, 30 mg or 45 mg once daily are upper respiratory tract infection (13.2%), headache (9.1%), sinusitis (6.3%), myalgia (5.4%), tooth disorder (5.3%), and pharyngitis (5.1%). ",pioglitazone
disease_disorder,pharyngitis,0.9967802," the overall incidence and types of adverse events reported in placebo controlled clinical trials of pioglitazone monotherapy at doses of 7.5 mg, 15 mg, 30 mg or 45 mg once daily are upper respiratory tract infection (13.2%), headache (9.1%), sinusitis (6.3%), myalgia (5.4%), tooth disorder (5.3%), and pharyngitis (5.1%). ",pioglitazone
sign_symptom,sore,0.98347384," common side effects include headache, common coldorstuffy nose,sore throat, cough flu (influenza), fever, viral infection. some people may get viral skin infections (like cold sores, chicken pox,shingles, or warts) or swollen lymph nodes (glands). ",pimecrolimus
disease_disorder,infections,0.83608586," common side effects include headache, common coldorstuffy nose,sore throat, cough flu (influenza), fever, viral infection. some people may get viral skin infections (like cold sores, chicken pox,shingles, or warts) or swollen lymph nodes (glands). ",pimecrolimus
sign_symptom,swollen,0.9989054," common side effects include headache, common coldorstuffy nose,sore throat, cough flu (influenza), fever, viral infection. some people may get viral skin infections (like cold sores, chicken pox,shingles, or warts) or swollen lymph nodes (glands). ",pimecrolimus
sign_symptom,confusion,0.99981576," nausea, constipation, peripheral edema, gait disturbance, hallucination, confusional state. ",pimavanserin
sign_symptom,tremor,0.9998399," headache, visual disturbance, lacrimation, sweating, respiratory distress, gastrointestinal spasm, nausea, vomiting, diarrhea, atrioventricular block, tachycardia, bradycardia, hypotension, hypertension, shock, mental confusion, cardiac arrhythmia, and tremors etc may occur. most of the adverse experiences observed during pilocarpine treatment were consequences of exaggerated parasympathetic stimulation. these adverse experiences were dose-dependent and usually mild and self-limited. ",pilocarpine hydrochloride (oral)
sign_symptom,adverse,0.9968094," headache, visual disturbance, lacrimation, sweating, respiratory distress, gastrointestinal spasm, nausea, vomiting, diarrhea, atrioventricular block, tachycardia, bradycardia, hypotension, hypertension, shock, mental confusion, cardiac arrhythmia, and tremors etc may occur. most of the adverse experiences observed during pilocarpine treatment were consequences of exaggerated parasympathetic stimulation. these adverse experiences were dose-dependent and usually mild and self-limited. ",pilocarpine hydrochloride (oral)
sign_symptom,blurred,0.91704553,"  common : temporary blurred vision, burning, stinging, redness, watering of the eyes, decrease in night vision, eye irritation, headache.    rare : eye pain, increased sweating, muscle tremors, nausea, vomiting, diarrhea, watering of the mouth, troubled breathing or wheezing. ",pilocarpine hydrochloride (ophthalmic)
sign_symptom,troubled,0.9978066,"  common : temporary blurred vision, burning, stinging, redness, watering of the eyes, decrease in night vision, eye irritation, headache.    rare : eye pain, increased sweating, muscle tremors, nausea, vomiting, diarrhea, watering of the mouth, troubled breathing or wheezing. ",pilocarpine hydrochloride (ophthalmic)
sign_symptom,adverse effects,0.99973404, no adverse effects have been associated with oral administration. ,phytomenadione (oral)
sign_symptom,irritation,0.9999447, there are isolated unconfirmed reports on the possible occurrence of anaphylactoid reactions and venous irritation or phlebitis after parenteral use of phytomenadione injections. ,phytomenadione (injection)
sign_symptom,phle,0.7258513, there are isolated unconfirmed reports on the possible occurrence of anaphylactoid reactions and venous irritation or phlebitis after parenteral use of phytomenadione injections. ,phytomenadione (injection)
medication,phytomenadione,0.95228773, there are isolated unconfirmed reports on the possible occurrence of anaphylactoid reactions and venous irritation or phlebitis after parenteral use of phytomenadione injections. ,phytomenadione (injection)
sign_symptom,hyper,0.8916199," hypersensitivity, lack of appetite, headache, dizziness, tremor, transient nervousness, insomnia, gi disturbances (e.g. nausea, vomiting, constipation), tenderness and hyperplasia of the gums, acne, hirsutism, coarsening of the facial features, rashes, osteomalacia. phenytoin toxicity as manifested as a syndrome of cerebellar, vestibular, ocular effects, notably nystagmus, diplopia, slurred speech, and ataxia; also with mental confusion, dyskinesias, exacerbations of seizure frequency, hyperglycaemia. solutions for inj may cause local irritation or phlebitis. prolonged use may produce subtle effects on mental function and cognition, especially in children. ",phenytoin sodium
sign_symptom,of appetite,0.7710194," hypersensitivity, lack of appetite, headache, dizziness, tremor, transient nervousness, insomnia, gi disturbances (e.g. nausea, vomiting, constipation), tenderness and hyperplasia of the gums, acne, hirsutism, coarsening of the facial features, rashes, osteomalacia. phenytoin toxicity as manifested as a syndrome of cerebellar, vestibular, ocular effects, notably nystagmus, diplopia, slurred speech, and ataxia; also with mental confusion, dyskinesias, exacerbations of seizure frequency, hyperglycaemia. solutions for inj may cause local irritation or phlebitis. prolonged use may produce subtle effects on mental function and cognition, especially in children. ",phenytoin sodium
sign_symptom,disturbances,0.72348255," hypersensitivity, lack of appetite, headache, dizziness, tremor, transient nervousness, insomnia, gi disturbances (e.g. nausea, vomiting, constipation), tenderness and hyperplasia of the gums, acne, hirsutism, coarsening of the facial features, rashes, osteomalacia. phenytoin toxicity as manifested as a syndrome of cerebellar, vestibular, ocular effects, notably nystagmus, diplopia, slurred speech, and ataxia; also with mental confusion, dyskinesias, exacerbations of seizure frequency, hyperglycaemia. solutions for inj may cause local irritation or phlebitis. prolonged use may produce subtle effects on mental function and cognition, especially in children. ",phenytoin sodium
sign_symptom,tenderness,0.9998535," hypersensitivity, lack of appetite, headache, dizziness, tremor, transient nervousness, insomnia, gi disturbances (e.g. nausea, vomiting, constipation), tenderness and hyperplasia of the gums, acne, hirsutism, coarsening of the facial features, rashes, osteomalacia. phenytoin toxicity as manifested as a syndrome of cerebellar, vestibular, ocular effects, notably nystagmus, diplopia, slurred speech, and ataxia; also with mental confusion, dyskinesias, exacerbations of seizure frequency, hyperglycaemia. solutions for inj may cause local irritation or phlebitis. prolonged use may produce subtle effects on mental function and cognition, especially in children. ",phenytoin sodium
sign_symptom,coarse,0.9986657," hypersensitivity, lack of appetite, headache, dizziness, tremor, transient nervousness, insomnia, gi disturbances (e.g. nausea, vomiting, constipation), tenderness and hyperplasia of the gums, acne, hirsutism, coarsening of the facial features, rashes, osteomalacia. phenytoin toxicity as manifested as a syndrome of cerebellar, vestibular, ocular effects, notably nystagmus, diplopia, slurred speech, and ataxia; also with mental confusion, dyskinesias, exacerbations of seizure frequency, hyperglycaemia. solutions for inj may cause local irritation or phlebitis. prolonged use may produce subtle effects on mental function and cognition, especially in children. ",phenytoin sodium
sign_symptom,toxicity,0.8093695," hypersensitivity, lack of appetite, headache, dizziness, tremor, transient nervousness, insomnia, gi disturbances (e.g. nausea, vomiting, constipation), tenderness and hyperplasia of the gums, acne, hirsutism, coarsening of the facial features, rashes, osteomalacia. phenytoin toxicity as manifested as a syndrome of cerebellar, vestibular, ocular effects, notably nystagmus, diplopia, slurred speech, and ataxia; also with mental confusion, dyskinesias, exacerbations of seizure frequency, hyperglycaemia. solutions for inj may cause local irritation or phlebitis. prolonged use may produce subtle effects on mental function and cognition, especially in children. ",phenytoin sodium
sign_symptom,irritation,0.99976474," hypersensitivity, lack of appetite, headache, dizziness, tremor, transient nervousness, insomnia, gi disturbances (e.g. nausea, vomiting, constipation), tenderness and hyperplasia of the gums, acne, hirsutism, coarsening of the facial features, rashes, osteomalacia. phenytoin toxicity as manifested as a syndrome of cerebellar, vestibular, ocular effects, notably nystagmus, diplopia, slurred speech, and ataxia; also with mental confusion, dyskinesias, exacerbations of seizure frequency, hyperglycaemia. solutions for inj may cause local irritation or phlebitis. prolonged use may produce subtle effects on mental function and cognition, especially in children. ",phenytoin sodium
sign_symptom,nervousness,0.9904903," common side effects include increased appetite, indigestion, nervousness or restlessness. less frequent or rare side effects are darkening or lightening of skin color, dizziness or lightheadedness, flushing of face or cheeks, hiccups, increased sweating, the sensation of spinning. ",prednisolone
sign_symptom,restless,0.71486896," common side effects include increased appetite, indigestion, nervousness or restlessness. less frequent or rare side effects are darkening or lightening of skin color, dizziness or lightheadedness, flushing of face or cheeks, hiccups, increased sweating, the sensation of spinning. ",prednisolone
sign_symptom,darkening,0.9612645," common side effects include increased appetite, indigestion, nervousness or restlessness. less frequent or rare side effects are darkening or lightening of skin color, dizziness or lightheadedness, flushing of face or cheeks, hiccups, increased sweating, the sensation of spinning. ",prednisolone
sign_symptom,flushing,0.99809283," common side effects include increased appetite, indigestion, nervousness or restlessness. less frequent or rare side effects are darkening or lightening of skin color, dizziness or lightheadedness, flushing of face or cheeks, hiccups, increased sweating, the sensation of spinning. ",prednisolone
medication,medicine,0.7182001," along with its needed effects, a medicine may cause some unwanted effects. although not all of these side effects may occur, if they do occur they may need medical attention.  check with your doctor as soon as possible if any of the following side effects occur: skin irritation not present before use of salicylic acid and sulfur  some side effects may occur that usually do not need medical attention. these side effects may go away during treatment as your body adjusts to the medicine. also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them: 
 
 redness and peeling of skin (may occur after a few days) 
 unusual dryness of skin 
  ",precipitated sulpher + salicylic acid
sign_symptom,irritation,0.9998448," along with its needed effects, a medicine may cause some unwanted effects. although not all of these side effects may occur, if they do occur they may need medical attention.  check with your doctor as soon as possible if any of the following side effects occur: skin irritation not present before use of salicylic acid and sulfur  some side effects may occur that usually do not need medical attention. these side effects may go away during treatment as your body adjusts to the medicine. also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them: 
 
 redness and peeling of skin (may occur after a few days) 
 unusual dryness of skin 
  ",precipitated sulpher + salicylic acid
medication,salicylic acid,0.97594863," along with its needed effects, a medicine may cause some unwanted effects. although not all of these side effects may occur, if they do occur they may need medical attention.  check with your doctor as soon as possible if any of the following side effects occur: skin irritation not present before use of salicylic acid and sulfur  some side effects may occur that usually do not need medical attention. these side effects may go away during treatment as your body adjusts to the medicine. also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them: 
 
 redness and peeling of skin (may occur after a few days) 
 unusual dryness of skin 
  ",precipitated sulpher + salicylic acid
sign_symptom,redness,0.9956237," along with its needed effects, a medicine may cause some unwanted effects. although not all of these side effects may occur, if they do occur they may need medical attention.  check with your doctor as soon as possible if any of the following side effects occur: skin irritation not present before use of salicylic acid and sulfur  some side effects may occur that usually do not need medical attention. these side effects may go away during treatment as your body adjusts to the medicine. also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them: 
 
 redness and peeling of skin (may occur after a few days) 
 unusual dryness of skin 
  ",precipitated sulpher + salicylic acid
sign_symptom,peeling of skin,0.87307733," along with its needed effects, a medicine may cause some unwanted effects. although not all of these side effects may occur, if they do occur they may need medical attention.  check with your doctor as soon as possible if any of the following side effects occur: skin irritation not present before use of salicylic acid and sulfur  some side effects may occur that usually do not need medical attention. these side effects may go away during treatment as your body adjusts to the medicine. also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them: 
 
 redness and peeling of skin (may occur after a few days) 
 unusual dryness of skin 
  ",precipitated sulpher + salicylic acid
sign_symptom,dryness,0.92610264," along with its needed effects, a medicine may cause some unwanted effects. although not all of these side effects may occur, if they do occur they may need medical attention.  check with your doctor as soon as possible if any of the following side effects occur: skin irritation not present before use of salicylic acid and sulfur  some side effects may occur that usually do not need medical attention. these side effects may go away during treatment as your body adjusts to the medicine. also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them: 
 
 redness and peeling of skin (may occur after a few days) 
 unusual dryness of skin 
  ",precipitated sulpher + salicylic acid
sign_symptom,halluc,0.9613788," the most common side effects of prazosin areallergic reaction, depression, nervousness, insomnia, hallucinations, dizziness, drowsiness, headache, faintness, syncope, paraesthesia, worsening of pre-existing narcolepsy, blurred vision, eye pain, reddened sclera, vertigo, tinnitus, palpitations etc. ",prazosin hydrochloride
sign_symptom,purpura,0.90657216,"  
 bleeding 
 thrombotic thrombocytopenic purpura 
 other side effects (headache, back pain, dyspnea, nausea, hypertension, bradycardia, rash etc) 
  ",prasugrel hydrochloride
sign_symptom,dyspnea,0.9515772,"  
 bleeding 
 thrombotic thrombocytopenic purpura 
 other side effects (headache, back pain, dyspnea, nausea, hypertension, bradycardia, rash etc) 
  ",prasugrel hydrochloride
sign_symptom,rash,0.9153456,"  
 bleeding 
 thrombotic thrombocytopenic purpura 
 other side effects (headache, back pain, dyspnea, nausea, hypertension, bradycardia, rash etc) 
  ",prasugrel hydrochloride
sign_symptom,peeling,0.9603006," local skin reaction, e.g. anaphylactoid, burning, stinging, contact dermatitis, tenderness, urticaria, skin peeling and skin lesions ",pramoxine hydrochloride + calamine
sign_symptom,lesions,0.9999083," local skin reaction, e.g. anaphylactoid, burning, stinging, contact dermatitis, tenderness, urticaria, skin peeling and skin lesions ",pramoxine hydrochloride + calamine
sign_symptom,rash,0.9990246," the common side effects are dizziness, dyskinesia, nausea, hypotension, abnormal dreams, confusion, constipation, delusion, hallucinations, headache, hyperkinesia, increased eating (binge eating, hyperphagia), insomnia, libido disorders, nausea, peripheral oedema, paranoia, pathological gambling, hypersexuality and other abnormal behaviour, somnolence, weight increase, sudden onset of sleep, pruritus and rash and other hypersensitivity. ",pramipexole
sign_symptom,visual,0.81410545," drowsiness, dizziness, visual disturbances, nausea, htn, tachycardia, headache, hyperventilation, muscle weakness, impaired renal function, elevated liver enzymes, transient increase in creatine phosphokinase, transient neuromuscular blockade; mild to moderate pain at inj site. ",pralidoxime chloride
sign_symptom,pain,0.99996245," drowsiness, dizziness, visual disturbances, nausea, htn, tachycardia, headache, hyperventilation, muscle weakness, impaired renal function, elevated liver enzymes, transient increase in creatine phosphokinase, transient neuromuscular blockade; mild to moderate pain at inj site. ",pralidoxime chloride
medication,povidone io,0.9800036," povidone iodine may cause hypersensitivity reactions and irritation of the skin and mucous membranes. the application of povidone iodine to severe burns or to large areas otherwise denuded of skin may produce systemic adverse effects such as metabolic acidosis, hypernatraemia, and impairment of renal function. it may interfere with thyroid function tests. ",povidone iodine
sign_symptom,hypersensitivity reactions,0.9996196," povidone iodine may cause hypersensitivity reactions and irritation of the skin and mucous membranes. the application of povidone iodine to severe burns or to large areas otherwise denuded of skin may produce systemic adverse effects such as metabolic acidosis, hypernatraemia, and impairment of renal function. it may interfere with thyroid function tests. ",povidone iodine
sign_symptom,irritation,0.99995387," povidone iodine may cause hypersensitivity reactions and irritation of the skin and mucous membranes. the application of povidone iodine to severe burns or to large areas otherwise denuded of skin may produce systemic adverse effects such as metabolic acidosis, hypernatraemia, and impairment of renal function. it may interfere with thyroid function tests. ",povidone iodine
sign_symptom,burns,0.9793084," povidone iodine may cause hypersensitivity reactions and irritation of the skin and mucous membranes. the application of povidone iodine to severe burns or to large areas otherwise denuded of skin may produce systemic adverse effects such as metabolic acidosis, hypernatraemia, and impairment of renal function. it may interfere with thyroid function tests. ",povidone iodine
sign_symptom,hyper,0.9814409," povidone iodine may cause hypersensitivity reactions and irritation of the skin and mucous membranes. the application of povidone iodine to severe burns or to large areas otherwise denuded of skin may produce systemic adverse effects such as metabolic acidosis, hypernatraemia, and impairment of renal function. it may interfere with thyroid function tests. ",povidone iodine
medication,potassium,0.8919279," this solution is generally well tolerated without any unpleasant side effect when given in recommended doses to patients with normal renal function and urinary output. however, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis. potassium intoxication causes listlessness, weakness, mental confusion, tingling of extremities and other symptoms associated with a high concentration of potassium in the serum. ",potassium citrate + citric acid
sign_symptom,mental confusion,0.99607706," this solution is generally well tolerated without any unpleasant side effect when given in recommended doses to patients with normal renal function and urinary output. however, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis. potassium intoxication causes listlessness, weakness, mental confusion, tingling of extremities and other symptoms associated with a high concentration of potassium in the serum. ",potassium citrate + citric acid
sign_symptom,tingling of extremities,0.9991104," this solution is generally well tolerated without any unpleasant side effect when given in recommended doses to patients with normal renal function and urinary output. however, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis. potassium intoxication causes listlessness, weakness, mental confusion, tingling of extremities and other symptoms associated with a high concentration of potassium in the serum. ",potassium citrate + citric acid
sign_symptom,pain,0.9997297," nausea, vomiting, diarrhea, and stomach pain may occur. taking it after meals will help prevent these side effects. an empty tablet shell may appear in your stool. this is harmless because your body has already absorbed the medication.  this drug may cause serious stomach or intestinal problems (e.g., bleeding, blockage, puncture). this medication may cause high potassium levels in the blood (hyperkalemia). a very serious allergic reaction to this drug is rare. ",potassium citrate
sign_symptom,allergic reaction,0.99853504," nausea, vomiting, diarrhea, and stomach pain may occur. taking it after meals will help prevent these side effects. an empty tablet shell may appear in your stool. this is harmless because your body has already absorbed the medication.  this drug may cause serious stomach or intestinal problems (e.g., bleeding, blockage, puncture). this medication may cause high potassium levels in the blood (hyperkalemia). a very serious allergic reaction to this drug is rare. ",potassium citrate
medication,potassium,0.8477545," excessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. pain or phlebitis may occur during i.v. administration of solutions containing about 30 mmol or more potassium per litre. nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration. ",potassium chloride
sign_symptom,hyper,0.992188," excessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. pain or phlebitis may occur during i.v. administration of solutions containing about 30 mmol or more potassium per litre. nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration. ",potassium chloride
sign_symptom,para,0.9988708," excessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. pain or phlebitis may occur during i.v. administration of solutions containing about 30 mmol or more potassium per litre. nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration. ",potassium chloride
sign_symptom,muscle weakness,0.95515436," excessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. pain or phlebitis may occur during i.v. administration of solutions containing about 30 mmol or more potassium per litre. nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration. ",potassium chloride
sign_symptom,heart block,0.89252865," excessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. pain or phlebitis may occur during i.v. administration of solutions containing about 30 mmol or more potassium per litre. nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration. ",potassium chloride
sign_symptom,pain,0.9999652," excessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. pain or phlebitis may occur during i.v. administration of solutions containing about 30 mmol or more potassium per litre. nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration. ",potassium chloride
sign_symptom,phlebitis,0.9965337," excessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. pain or phlebitis may occur during i.v. administration of solutions containing about 30 mmol or more potassium per litre. nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration. ",potassium chloride
sign_symptom,nausea,0.999521," excessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. pain or phlebitis may occur during i.v. administration of solutions containing about 30 mmol or more potassium per litre. nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration. ",potassium chloride
sign_symptom,vomiting,0.99982965," excessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. pain or phlebitis may occur during i.v. administration of solutions containing about 30 mmol or more potassium per litre. nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration. ",potassium chloride
sign_symptom,diarrhoea,0.9010751," excessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. pain or phlebitis may occur during i.v. administration of solutions containing about 30 mmol or more potassium per litre. nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration. ",potassium chloride
sign_symptom,cramps,0.9121592," excessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. pain or phlebitis may occur during i.v. administration of solutions containing about 30 mmol or more potassium per litre. nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration. ",potassium chloride
sign_symptom,adverse reactions,0.7104309," common treatment-emergent adverse reactions in studies with posaconazole are diarrhea, nausea, fever, vomiting, headache, coughing and hypokalemia. ",posaconazole
sign_symptom,adverse reactions,0.9969442," the most common non-hematologic adverse reactions (20%) were, abdominal pain, rash, constipation, headache, dry skin, arterial occlusion, fatigue, hypertension, pyrexia, arthralgia, nausea, diarrhea, lipase increased, vomiting, myalgia and pain in extremity. ",ponatinib hydrochloride
sign_symptom,pain,0.9367165," the most common non-hematologic adverse reactions (20%) were, abdominal pain, rash, constipation, headache, dry skin, arterial occlusion, fatigue, hypertension, pyrexia, arthralgia, nausea, diarrhea, lipase increased, vomiting, myalgia and pain in extremity. ",ponatinib hydrochloride
sign_symptom,myal,0.99806195," the most common non-hematologic adverse reactions (20%) were, abdominal pain, rash, constipation, headache, dry skin, arterial occlusion, fatigue, hypertension, pyrexia, arthralgia, nausea, diarrhea, lipase increased, vomiting, myalgia and pain in extremity. ",ponatinib hydrochloride
medication,p neumococcal vaccine,0.9675702," the most common adverse reactions, reported in &gt;10% of subjects vaccinated with p neumococcal vaccine for the first time in a clinical trial, were: injection-site pain/soreness/tenderness (60.0%), injection-site swelling/ induration (20.3%), headache (17.6%), injection-site erythema (16.4%), asthenia and fatigue (13.2%), and myalgia (11.9%). ",polysaccharide pneumococcal vaccine
sign_symptom,pain,0.9999534," the most common adverse reactions, reported in &gt;10% of subjects vaccinated with p neumococcal vaccine for the first time in a clinical trial, were: injection-site pain/soreness/tenderness (60.0%), injection-site swelling/ induration (20.3%), headache (17.6%), injection-site erythema (16.4%), asthenia and fatigue (13.2%), and myalgia (11.9%). ",polysaccharide pneumococcal vaccine
sign_symptom,soreness,0.96626115," the most common adverse reactions, reported in &gt;10% of subjects vaccinated with p neumococcal vaccine for the first time in a clinical trial, were: injection-site pain/soreness/tenderness (60.0%), injection-site swelling/ induration (20.3%), headache (17.6%), injection-site erythema (16.4%), asthenia and fatigue (13.2%), and myalgia (11.9%). ",polysaccharide pneumococcal vaccine
sign_symptom,tenderness,0.9999056," the most common adverse reactions, reported in &gt;10% of subjects vaccinated with p neumococcal vaccine for the first time in a clinical trial, were: injection-site pain/soreness/tenderness (60.0%), injection-site swelling/ induration (20.3%), headache (17.6%), injection-site erythema (16.4%), asthenia and fatigue (13.2%), and myalgia (11.9%). ",polysaccharide pneumococcal vaccine
sign_symptom,swelling,0.99995494," the most common adverse reactions, reported in &gt;10% of subjects vaccinated with p neumococcal vaccine for the first time in a clinical trial, were: injection-site pain/soreness/tenderness (60.0%), injection-site swelling/ induration (20.3%), headache (17.6%), injection-site erythema (16.4%), asthenia and fatigue (13.2%), and myalgia (11.9%). ",polysaccharide pneumococcal vaccine
sign_symptom,induration,0.981161," the most common adverse reactions, reported in &gt;10% of subjects vaccinated with p neumococcal vaccine for the first time in a clinical trial, were: injection-site pain/soreness/tenderness (60.0%), injection-site swelling/ induration (20.3%), headache (17.6%), injection-site erythema (16.4%), asthenia and fatigue (13.2%), and myalgia (11.9%). ",polysaccharide pneumococcal vaccine
sign_symptom,headache,0.9999579," the most common adverse reactions, reported in &gt;10% of subjects vaccinated with p neumococcal vaccine for the first time in a clinical trial, were: injection-site pain/soreness/tenderness (60.0%), injection-site swelling/ induration (20.3%), headache (17.6%), injection-site erythema (16.4%), asthenia and fatigue (13.2%), and myalgia (11.9%). ",polysaccharide pneumococcal vaccine
sign_symptom,fatigue,0.9999212," the most common adverse reactions, reported in &gt;10% of subjects vaccinated with p neumococcal vaccine for the first time in a clinical trial, were: injection-site pain/soreness/tenderness (60.0%), injection-site swelling/ induration (20.3%), headache (17.6%), injection-site erythema (16.4%), asthenia and fatigue (13.2%), and myalgia (11.9%). ",polysaccharide pneumococcal vaccine
sign_symptom,adverse events,0.9987428,"  common (10%) : solicited adverse events in infants and toddlers 9 and 12 months of age were injection site tenderness, erythema, and swelling; irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever.   common (10%) : solicited adverse events in individuals 2 through 55 years of age who received a single dose were injection site pain, redness, induration, and swelling; anorexia and diarrhea. other common solicited adverse events were irritability and drowsiness (2-10 years of age), headache, fatigue, malaise, and arthralgia (11-55 years of age). ",polysaccharide diphtheria toxoid conjugate vaccine
sign_symptom,headache,0.9984389,"  common (10%) : solicited adverse events in infants and toddlers 9 and 12 months of age were injection site tenderness, erythema, and swelling; irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever.   common (10%) : solicited adverse events in individuals 2 through 55 years of age who received a single dose were injection site pain, redness, induration, and swelling; anorexia and diarrhea. other common solicited adverse events were irritability and drowsiness (2-10 years of age), headache, fatigue, malaise, and arthralgia (11-55 years of age). ",polysaccharide diphtheria toxoid conjugate vaccine
sign_symptom,fatigue,0.9844434,"  common (10%) : solicited adverse events in infants and toddlers 9 and 12 months of age were injection site tenderness, erythema, and swelling; irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever.   common (10%) : solicited adverse events in individuals 2 through 55 years of age who received a single dose were injection site pain, redness, induration, and swelling; anorexia and diarrhea. other common solicited adverse events were irritability and drowsiness (2-10 years of age), headache, fatigue, malaise, and arthralgia (11-55 years of age). ",polysaccharide diphtheria toxoid conjugate vaccine
sign_symptom,malaise,0.7575904,"  common (10%) : solicited adverse events in infants and toddlers 9 and 12 months of age were injection site tenderness, erythema, and swelling; irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever.   common (10%) : solicited adverse events in individuals 2 through 55 years of age who received a single dose were injection site pain, redness, induration, and swelling; anorexia and diarrhea. other common solicited adverse events were irritability and drowsiness (2-10 years of age), headache, fatigue, malaise, and arthralgia (11-55 years of age). ",polysaccharide diphtheria toxoid conjugate vaccine
sign_symptom,arthralgia,0.9997142,"  common (10%) : solicited adverse events in infants and toddlers 9 and 12 months of age were injection site tenderness, erythema, and swelling; irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever.   common (10%) : solicited adverse events in individuals 2 through 55 years of age who received a single dose were injection site pain, redness, induration, and swelling; anorexia and diarrhea. other common solicited adverse events were irritability and drowsiness (2-10 years of age), headache, fatigue, malaise, and arthralgia (11-55 years of age). ",polysaccharide diphtheria toxoid conjugate vaccine
medication,poly,0.9997472," clostridium difficile associated diarrhea has been reported with use of polymyxin b. nephrotixic reactions: albuminuria, cylinduria, azotemia, and rising blood levels, neurotoxic reactions: facial flushing, dizziness progressing to ataxia, drowsiness, peripheral aresthesias (circumoral and stocking glove), apnea due to concurrent use of curariform muscle relaxants, other neurotoxic drugs or inadvertent overdosage, and signs of meningeal irritation with intrathecal administration, e.g., fever, headache, stiff neck. other reactions occasionally reported: drug fever, urticaria rash, severe pain at im injections sites and thrombophelbitis at iv injections sites. ",polymyxin b sulfate
sign_symptom,album,0.97193223," clostridium difficile associated diarrhea has been reported with use of polymyxin b. nephrotixic reactions: albuminuria, cylinduria, azotemia, and rising blood levels, neurotoxic reactions: facial flushing, dizziness progressing to ataxia, drowsiness, peripheral aresthesias (circumoral and stocking glove), apnea due to concurrent use of curariform muscle relaxants, other neurotoxic drugs or inadvertent overdosage, and signs of meningeal irritation with intrathecal administration, e.g., fever, headache, stiff neck. other reactions occasionally reported: drug fever, urticaria rash, severe pain at im injections sites and thrombophelbitis at iv injections sites. ",polymyxin b sulfate
sign_symptom,ares,0.99884087," clostridium difficile associated diarrhea has been reported with use of polymyxin b. nephrotixic reactions: albuminuria, cylinduria, azotemia, and rising blood levels, neurotoxic reactions: facial flushing, dizziness progressing to ataxia, drowsiness, peripheral aresthesias (circumoral and stocking glove), apnea due to concurrent use of curariform muscle relaxants, other neurotoxic drugs or inadvertent overdosage, and signs of meningeal irritation with intrathecal administration, e.g., fever, headache, stiff neck. other reactions occasionally reported: drug fever, urticaria rash, severe pain at im injections sites and thrombophelbitis at iv injections sites. ",polymyxin b sulfate
sign_symptom,irritation,0.9993611," clostridium difficile associated diarrhea has been reported with use of polymyxin b. nephrotixic reactions: albuminuria, cylinduria, azotemia, and rising blood levels, neurotoxic reactions: facial flushing, dizziness progressing to ataxia, drowsiness, peripheral aresthesias (circumoral and stocking glove), apnea due to concurrent use of curariform muscle relaxants, other neurotoxic drugs or inadvertent overdosage, and signs of meningeal irritation with intrathecal administration, e.g., fever, headache, stiff neck. other reactions occasionally reported: drug fever, urticaria rash, severe pain at im injections sites and thrombophelbitis at iv injections sites. ",polymyxin b sulfate
sign_symptom,pain,0.9999609," clostridium difficile associated diarrhea has been reported with use of polymyxin b. nephrotixic reactions: albuminuria, cylinduria, azotemia, and rising blood levels, neurotoxic reactions: facial flushing, dizziness progressing to ataxia, drowsiness, peripheral aresthesias (circumoral and stocking glove), apnea due to concurrent use of curariform muscle relaxants, other neurotoxic drugs or inadvertent overdosage, and signs of meningeal irritation with intrathecal administration, e.g., fever, headache, stiff neck. other reactions occasionally reported: drug fever, urticaria rash, severe pain at im injections sites and thrombophelbitis at iv injections sites. ",polymyxin b sulfate
sign_symptom,pain,0.99961936," some common side effects of this medicine can be injection site reactions such as redness, pain or swelling. if these side effects persist for a longer duration, please consult your doctor. ",polygeline + electrolytes
sign_symptom,effects,0.86896425," some common side effects of this medicine can be injection site reactions such as redness, pain or swelling. if these side effects persist for a longer duration, please consult your doctor. ",polygeline + electrolytes
sign_symptom,electrolyte disturbances,0.9987209," generally well tolerated. however side effects like allergic reactions, electrolyte disturbances particularly hyperkalaemia and hypokalaemia, abdominal pain, diarrhea, headache, peripheral edema may appear. ",polyethylene glycol 3350 + electrolytes
sign_symptom,hyper,0.99994934," generally well tolerated. however side effects like allergic reactions, electrolyte disturbances particularly hyperkalaemia and hypokalaemia, abdominal pain, diarrhea, headache, peripheral edema may appear. ",polyethylene glycol 3350 + electrolytes
sign_symptom,edema,0.8734485," generally well tolerated. however side effects like allergic reactions, electrolyte disturbances particularly hyperkalaemia and hypokalaemia, abdominal pain, diarrhea, headache, peripheral edema may appear. ",polyethylene glycol 3350 + electrolytes
sign_symptom,allergic condition,0.99848974, generally well tolerated. this sterile eye drops should not be used if allergic condition occurs to any ingredients of the product. ,polyethylene glycol + propylene glycol
sign_symptom,flat,0.99994147," nausea, abdominal bloating, cramping and flatulence may occur. high doses may produce diarrhea and excessive stool frequency, particularly in elderly nursing home patients. patients taking other medications containing polyethylene glycol have occasionally developed urticaria suggestive of an allergic reaction. ",polyethylene glycol
sign_symptom,diarr,0.9244271," nausea, abdominal bloating, cramping and flatulence may occur. high doses may produce diarrhea and excessive stool frequency, particularly in elderly nursing home patients. patients taking other medications containing polyethylene glycol have occasionally developed urticaria suggestive of an allergic reaction. ",polyethylene glycol
medication,medications,0.91257596," nausea, abdominal bloating, cramping and flatulence may occur. high doses may produce diarrhea and excessive stool frequency, particularly in elderly nursing home patients. patients taking other medications containing polyethylene glycol have occasionally developed urticaria suggestive of an allergic reaction. ",polyethylene glycol
medication,prop,0.9995913," the adverse effects of propantheline bromide are usually dose-related and are usually reversible when the therapy is discontinued. variable degrees of dry mouth, dry skin, mydriasis might be noted. other reported adverse effects include urinary retention, nausea, vomiting, constipation, headache, nervousness, mental confusion etc. ",propantheline bromide
sign_symptom,vomiting,0.9781627," the adverse effects of propantheline bromide are usually dose-related and are usually reversible when the therapy is discontinued. variable degrees of dry mouth, dry skin, mydriasis might be noted. other reported adverse effects include urinary retention, nausea, vomiting, constipation, headache, nervousness, mental confusion etc. ",propantheline bromide
sign_symptom,consti,0.9393729," the adverse effects of propantheline bromide are usually dose-related and are usually reversible when the therapy is discontinued. variable degrees of dry mouth, dry skin, mydriasis might be noted. other reported adverse effects include urinary retention, nausea, vomiting, constipation, headache, nervousness, mental confusion etc. ",propantheline bromide
sign_symptom,headache,0.7562398," the adverse effects of propantheline bromide are usually dose-related and are usually reversible when the therapy is discontinued. variable degrees of dry mouth, dry skin, mydriasis might be noted. other reported adverse effects include urinary retention, nausea, vomiting, constipation, headache, nervousness, mental confusion etc. ",propantheline bromide
sign_symptom,nervousness,0.84938246," the adverse effects of propantheline bromide are usually dose-related and are usually reversible when the therapy is discontinued. variable degrees of dry mouth, dry skin, mydriasis might be noted. other reported adverse effects include urinary retention, nausea, vomiting, constipation, headache, nervousness, mental confusion etc. ",propantheline bromide
sign_symptom,mental confusion,0.99462," the adverse effects of propantheline bromide are usually dose-related and are usually reversible when the therapy is discontinued. variable degrees of dry mouth, dry skin, mydriasis might be noted. other reported adverse effects include urinary retention, nausea, vomiting, constipation, headache, nervousness, mental confusion etc. ",propantheline bromide
sign_symptom,adverse reactions,0.9995488," adverse reactions associated with propafenone occur most frequently in the gastrointestinal, cardiovascular and central nervous systems. change in taste, constipation, diarrhea, dizziness, drowsiness, dry mouth, gas, headache, light-headedness, nausea, tiredness etc. may happen. severe allergic reactions also reported with propafenone. ",propafenone hydrochloride
medication,prop,0.9390829," adverse reactions associated with propafenone occur most frequently in the gastrointestinal, cardiovascular and central nervous systems. change in taste, constipation, diarrhea, dizziness, drowsiness, dry mouth, gas, headache, light-headedness, nausea, tiredness etc. may happen. severe allergic reactions also reported with propafenone. ",propafenone hydrochloride
sign_symptom,drows,0.7331668," adverse reactions associated with propafenone occur most frequently in the gastrointestinal, cardiovascular and central nervous systems. change in taste, constipation, diarrhea, dizziness, drowsiness, dry mouth, gas, headache, light-headedness, nausea, tiredness etc. may happen. severe allergic reactions also reported with propafenone. ",propafenone hydrochloride
sign_symptom,light - headedness,0.98565435," adverse reactions associated with propafenone occur most frequently in the gastrointestinal, cardiovascular and central nervous systems. change in taste, constipation, diarrhea, dizziness, drowsiness, dry mouth, gas, headache, light-headedness, nausea, tiredness etc. may happen. severe allergic reactions also reported with propafenone. ",propafenone hydrochloride
sign_symptom,nausea,0.9972826," adverse reactions associated with propafenone occur most frequently in the gastrointestinal, cardiovascular and central nervous systems. change in taste, constipation, diarrhea, dizziness, drowsiness, dry mouth, gas, headache, light-headedness, nausea, tiredness etc. may happen. severe allergic reactions also reported with propafenone. ",propafenone hydrochloride
sign_symptom,tiredness,0.9946035," adverse reactions associated with propafenone occur most frequently in the gastrointestinal, cardiovascular and central nervous systems. change in taste, constipation, diarrhea, dizziness, drowsiness, dry mouth, gas, headache, light-headedness, nausea, tiredness etc. may happen. severe allergic reactions also reported with propafenone. ",propafenone hydrochloride
sign_symptom,allergic reactions,0.99989897," adverse reactions associated with propafenone occur most frequently in the gastrointestinal, cardiovascular and central nervous systems. change in taste, constipation, diarrhea, dizziness, drowsiness, dry mouth, gas, headache, light-headedness, nausea, tiredness etc. may happen. severe allergic reactions also reported with propafenone. ",propafenone hydrochloride
medication,medicines,0.99920315," medicines and their possible side effects can affect individual people in different ways. the following are some of the side effects that are known to be associated with promethazine. just because a side effect is stated here does not mean that all people using promethazine theoclate will experience that or any side effect. 
 
 drowsiness or feeling tired. 
 dizziness. 
 restlessness. 
 headache. 
 nightmares. 
 blurred vision. 
 difficulty passing urine. 
 dry mouth. 
 confusion. 
 feeling disorientated. 
 unexpected increase in excitability in children. 
 increased sensitivity of the skin to sunlight (photosensitivity). if affected you should avoid sun lamps and direct sunlight while you are taking this medicine. 
 loss of appetite. 
 awareness of your heartbeat (palpitations). 
 abnormal heartbeats (arrhythmias). 
 low blood pressure (hypotension). 
 abnormal movements of the hands, legs, face, neck and tongue, eg tremor, twitching, rigidity (extrapyramidal effects). 
 blood disorders. 
  ",promethazine theoclate
medication,prometh,0.93018866," medicines and their possible side effects can affect individual people in different ways. the following are some of the side effects that are known to be associated with promethazine. just because a side effect is stated here does not mean that all people using promethazine theoclate will experience that or any side effect. 
 
 drowsiness or feeling tired. 
 dizziness. 
 restlessness. 
 headache. 
 nightmares. 
 blurred vision. 
 difficulty passing urine. 
 dry mouth. 
 confusion. 
 feeling disorientated. 
 unexpected increase in excitability in children. 
 increased sensitivity of the skin to sunlight (photosensitivity). if affected you should avoid sun lamps and direct sunlight while you are taking this medicine. 
 loss of appetite. 
 awareness of your heartbeat (palpitations). 
 abnormal heartbeats (arrhythmias). 
 low blood pressure (hypotension). 
 abnormal movements of the hands, legs, face, neck and tongue, eg tremor, twitching, rigidity (extrapyramidal effects). 
 blood disorders. 
  ",promethazine theoclate
medication,theoclate,0.9939272," medicines and their possible side effects can affect individual people in different ways. the following are some of the side effects that are known to be associated with promethazine. just because a side effect is stated here does not mean that all people using promethazine theoclate will experience that or any side effect. 
 
 drowsiness or feeling tired. 
 dizziness. 
 restlessness. 
 headache. 
 nightmares. 
 blurred vision. 
 difficulty passing urine. 
 dry mouth. 
 confusion. 
 feeling disorientated. 
 unexpected increase in excitability in children. 
 increased sensitivity of the skin to sunlight (photosensitivity). if affected you should avoid sun lamps and direct sunlight while you are taking this medicine. 
 loss of appetite. 
 awareness of your heartbeat (palpitations). 
 abnormal heartbeats (arrhythmias). 
 low blood pressure (hypotension). 
 abnormal movements of the hands, legs, face, neck and tongue, eg tremor, twitching, rigidity (extrapyramidal effects). 
 blood disorders. 
  ",promethazine theoclate
sign_symptom,restless,0.9996563," medicines and their possible side effects can affect individual people in different ways. the following are some of the side effects that are known to be associated with promethazine. just because a side effect is stated here does not mean that all people using promethazine theoclate will experience that or any side effect. 
 
 drowsiness or feeling tired. 
 dizziness. 
 restlessness. 
 headache. 
 nightmares. 
 blurred vision. 
 difficulty passing urine. 
 dry mouth. 
 confusion. 
 feeling disorientated. 
 unexpected increase in excitability in children. 
 increased sensitivity of the skin to sunlight (photosensitivity). if affected you should avoid sun lamps and direct sunlight while you are taking this medicine. 
 loss of appetite. 
 awareness of your heartbeat (palpitations). 
 abnormal heartbeats (arrhythmias). 
 low blood pressure (hypotension). 
 abnormal movements of the hands, legs, face, neck and tongue, eg tremor, twitching, rigidity (extrapyramidal effects). 
 blood disorders. 
  ",promethazine theoclate
sign_symptom,affected,0.9755746," medicines and their possible side effects can affect individual people in different ways. the following are some of the side effects that are known to be associated with promethazine. just because a side effect is stated here does not mean that all people using promethazine theoclate will experience that or any side effect. 
 
 drowsiness or feeling tired. 
 dizziness. 
 restlessness. 
 headache. 
 nightmares. 
 blurred vision. 
 difficulty passing urine. 
 dry mouth. 
 confusion. 
 feeling disorientated. 
 unexpected increase in excitability in children. 
 increased sensitivity of the skin to sunlight (photosensitivity). if affected you should avoid sun lamps and direct sunlight while you are taking this medicine. 
 loss of appetite. 
 awareness of your heartbeat (palpitations). 
 abnormal heartbeats (arrhythmias). 
 low blood pressure (hypotension). 
 abnormal movements of the hands, legs, face, neck and tongue, eg tremor, twitching, rigidity (extrapyramidal effects). 
 blood disorders. 
  ",promethazine theoclate
sign_symptom,loss,0.7961776," medicines and their possible side effects can affect individual people in different ways. the following are some of the side effects that are known to be associated with promethazine. just because a side effect is stated here does not mean that all people using promethazine theoclate will experience that or any side effect. 
 
 drowsiness or feeling tired. 
 dizziness. 
 restlessness. 
 headache. 
 nightmares. 
 blurred vision. 
 difficulty passing urine. 
 dry mouth. 
 confusion. 
 feeling disorientated. 
 unexpected increase in excitability in children. 
 increased sensitivity of the skin to sunlight (photosensitivity). if affected you should avoid sun lamps and direct sunlight while you are taking this medicine. 
 loss of appetite. 
 awareness of your heartbeat (palpitations). 
 abnormal heartbeats (arrhythmias). 
 low blood pressure (hypotension). 
 abnormal movements of the hands, legs, face, neck and tongue, eg tremor, twitching, rigidity (extrapyramidal effects). 
 blood disorders. 
  ",promethazine theoclate
sign_symptom,appetite,0.97125614," medicines and their possible side effects can affect individual people in different ways. the following are some of the side effects that are known to be associated with promethazine. just because a side effect is stated here does not mean that all people using promethazine theoclate will experience that or any side effect. 
 
 drowsiness or feeling tired. 
 dizziness. 
 restlessness. 
 headache. 
 nightmares. 
 blurred vision. 
 difficulty passing urine. 
 dry mouth. 
 confusion. 
 feeling disorientated. 
 unexpected increase in excitability in children. 
 increased sensitivity of the skin to sunlight (photosensitivity). if affected you should avoid sun lamps and direct sunlight while you are taking this medicine. 
 loss of appetite. 
 awareness of your heartbeat (palpitations). 
 abnormal heartbeats (arrhythmias). 
 low blood pressure (hypotension). 
 abnormal movements of the hands, legs, face, neck and tongue, eg tremor, twitching, rigidity (extrapyramidal effects). 
 blood disorders. 
  ",promethazine theoclate
sign_symptom,abnormal,0.99598134," medicines and their possible side effects can affect individual people in different ways. the following are some of the side effects that are known to be associated with promethazine. just because a side effect is stated here does not mean that all people using promethazine theoclate will experience that or any side effect. 
 
 drowsiness or feeling tired. 
 dizziness. 
 restlessness. 
 headache. 
 nightmares. 
 blurred vision. 
 difficulty passing urine. 
 dry mouth. 
 confusion. 
 feeling disorientated. 
 unexpected increase in excitability in children. 
 increased sensitivity of the skin to sunlight (photosensitivity). if affected you should avoid sun lamps and direct sunlight while you are taking this medicine. 
 loss of appetite. 
 awareness of your heartbeat (palpitations). 
 abnormal heartbeats (arrhythmias). 
 low blood pressure (hypotension). 
 abnormal movements of the hands, legs, face, neck and tongue, eg tremor, twitching, rigidity (extrapyramidal effects). 
 blood disorders. 
  ",promethazine theoclate
sign_symptom,abnormal movements,0.9161966," medicines and their possible side effects can affect individual people in different ways. the following are some of the side effects that are known to be associated with promethazine. just because a side effect is stated here does not mean that all people using promethazine theoclate will experience that or any side effect. 
 
 drowsiness or feeling tired. 
 dizziness. 
 restlessness. 
 headache. 
 nightmares. 
 blurred vision. 
 difficulty passing urine. 
 dry mouth. 
 confusion. 
 feeling disorientated. 
 unexpected increase in excitability in children. 
 increased sensitivity of the skin to sunlight (photosensitivity). if affected you should avoid sun lamps and direct sunlight while you are taking this medicine. 
 loss of appetite. 
 awareness of your heartbeat (palpitations). 
 abnormal heartbeats (arrhythmias). 
 low blood pressure (hypotension). 
 abnormal movements of the hands, legs, face, neck and tongue, eg tremor, twitching, rigidity (extrapyramidal effects). 
 blood disorders. 
  ",promethazine theoclate
sign_symptom,", rigidity",0.82396966," medicines and their possible side effects can affect individual people in different ways. the following are some of the side effects that are known to be associated with promethazine. just because a side effect is stated here does not mean that all people using promethazine theoclate will experience that or any side effect. 
 
 drowsiness or feeling tired. 
 dizziness. 
 restlessness. 
 headache. 
 nightmares. 
 blurred vision. 
 difficulty passing urine. 
 dry mouth. 
 confusion. 
 feeling disorientated. 
 unexpected increase in excitability in children. 
 increased sensitivity of the skin to sunlight (photosensitivity). if affected you should avoid sun lamps and direct sunlight while you are taking this medicine. 
 loss of appetite. 
 awareness of your heartbeat (palpitations). 
 abnormal heartbeats (arrhythmias). 
 low blood pressure (hypotension). 
 abnormal movements of the hands, legs, face, neck and tongue, eg tremor, twitching, rigidity (extrapyramidal effects). 
 blood disorders. 
  ",promethazine theoclate
sign_symptom,extrapyramidal reactions,0.97775143,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
sign_symptom,tremor,0.91548514,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
sign_symptom,hall,0.8902976,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
medication,promethazine,0.98330265,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
medication,hydrochloride,0.9811274,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
sign_symptom,nausea,0.99995136,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
sign_symptom,vomiting,0.99992895,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
sign_symptom,allergic,0.7792984,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
sign_symptom,edema,0.7680549,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
medication,prom,0.9994031,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
sign_symptom,nasal stuffiness,0.997684,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
sign_symptom,dry mouth,0.9922708,"  cns effects : drowsiness is the most prominent cns effect of the drug. extrapyramidal reactions may occur with high doses; this is almost always responsive to a reduction in dosage. other reported reactions include dizziness, lassitude, tinnitus, incoordination, fatigue, blurred vision, euphoria, diplopia, nervousness, insomnia, tremors, convulsive seizures, oculogyric crises, excitation, catatonic-like states, hysteria, and hallucinations.   cardiovascular effects : tachycardia, bradycardia, faintness, dizziness, and increases and decreases in blood pressure have been reported following the use of promethazine hydrochloride injection. venous thrombosis at the injection site has been reported.   gastrointestinal effects : nausea and vomiting have been reported, usually in association with surgical procedures and combination drug therapy.   allergic reactions : these include urticaria, dermatitis, asthma, and photosensitivity. angioneurotic edema has been reported.   other reported reactions : leukopenia and agranulocytosis, usually when promethazine has been used in association with other known marrow-toxic agents, have been reported. thrombocytopenic purpura and jaundice of the obstructive type have been associated with the use of promethazine. the jaundice is usually reversible on discontinuation of the drug. subcutaneous injection has resulted in tissue necrosis. nasal stuffiness may occur. dry mouth has been reported. ",promethazine hydrochloride (injection)
disease_disorder,disorders,0.79442245,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,anticholinergic efects,0.99698925,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,confusion,0.9997514,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,headache,0.9931532,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,extrapyramidal efect,0.9954827,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,muscle spa,0.94685304,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,tic - like movements,0.9788763,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
disease_disorder,health problem,0.96838963,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,muscle cramps,0.9089339,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,system,0.7036009,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,allergic reactions,0.9699192,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,photosensitivity reaction,0.9910911,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,epigastric,0.9479722,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,dry mouth eye disorders,0.8748792,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,blurred vision blood,0.9992469,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,blood dyscrasias,0.9320002,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
disease_disorder,agra,0.88043207,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
disease_disorder,renal,0.7429069,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,paradoxical,0.9905971,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,hyperexcitability,0.9952874,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,restlessness,0.9523431,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,disorientation,0.93785316,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
disease_disorder,arrhythmias,0.8216957,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,disorders,0.80649745,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
sign_symptom,tired,0.99994516,"  
 nervous system disorders: frequency unknown: neuroleptic malignant syndrome the elderly are particularly susceptible to the anticholinergic efects and confusion due to promethazine, somnolence, dizziness, headaches, extrapyramidal efects including muscle spasm, tic-like movements of the head and face. a very serious and sometimes deadly health problem called neuroleptic malignant syndrome (nms) may happen. stop treatment and call your doctor right away if you have high fever, muscle cramps or stifness, dizziness, very bad headache, fast heartbeat, confusion, agitation, hallucinations, or are sweating a lot. 
 immune system disorders- frequency unknown: allergic reactions, including urticaria, rash, pruritus, and anaphylaxis, have been reported. 
 skin and subcutaneous tissue disorders- frequency unknown: photosensitivity reaction 
 metabolism and nutrition disorders- frequency unknown: anorexia 
 gastrointestinal disorders- frequency unknown: epigastric discomfort, dry mouth 
 eye disorders- frequency unknown: blurred vision 
 blood and lymphatic system disorders- frequency unknown: blood dyscrasias including hemolytic anemia, agranulocytosis 
 renal and urinary disorders- frequency unknown: urinary retention 
 psychiatric disorders- frequency unknown: infants, newborns and premature are susceptible to the anticholinergic efects of promethazine, while other children may display paradoxical hyperexcitability, restlessness, nightmares, disorientation 
 cardiac disorders- frequency unknown: palpitations, arrhythmias 
 vascular disorders- frequency unknown: hypotension 
 hepatobiliary disorders- frequency unknown: jaundice 
 general disorders and administration site conditions- frequency unknown: tiredness 
 
use this drug only as recommended. do not exceed the recommended dose. there have been case reports of promethazine abuse. do not take for longer than 10 days. ",promethazine hydrochloride
medication,progesterone,0.84242195," micronized progesterone is devoid of estrogenic, androgenic and mineralocorticoid effects. mild somnolence and other cns side effects like depression, breast tenderness and bloating are reported. side effects are less when vaginal route is used. ",progesterone (vaginal pessary)
sign_symptom,tenderness,0.99990857," micronized progesterone is devoid of estrogenic, androgenic and mineralocorticoid effects. mild somnolence and other cns side effects like depression, breast tenderness and bloating are reported. side effects are less when vaginal route is used. ",progesterone (vaginal pessary)
sign_symptom,headache,0.9999143," common (may affect up to 1 in 10 people): 
 
 headache 
 feeling very tired 
 stomach or gut (gastro-intestinal) cramps 
 breast tenderness 
  ",progesterone (vaginalgel)
sign_symptom,tired,0.99967945," common (may affect up to 1 in 10 people): 
 
 headache 
 feeling very tired 
 stomach or gut (gastro-intestinal) cramps 
 breast tenderness 
  ",progesterone (vaginalgel)
sign_symptom,tenderness,0.99995863," common (may affect up to 1 in 10 people): 
 
 headache 
 feeling very tired 
 stomach or gut (gastro-intestinal) cramps 
 breast tenderness 
  ",progesterone (vaginalgel)
medication,progesterone,0.99680257," progesterone is devoid of estrogenic, androgenic and mineralocorticoid effects. mild somnolence and other cns side effects like depression, breast tenderness and bloating are reported. side effects are less when vaginal route is used. ",progesterone (capsule)
sign_symptom,tenderness,0.99987113," progesterone is devoid of estrogenic, androgenic and mineralocorticoid effects. mild somnolence and other cns side effects like depression, breast tenderness and bloating are reported. side effects are less when vaginal route is used. ",progesterone (capsule)
sign_symptom,dryness,0.8932268," at usual dosage levels dryness of the mouth is generally the only adverse effect. mydriasis, blurred vision and adverse g.i. effects (nausea, vomiting, epigastric distress, constipation) occur occasionally. an allergic reaction (e.g. rash) or muscular weakness may occasionally occur. high doses may cause vertigo and possibly confusion and hallucination. adverse effect mayusually be minimized by adjustment of dosage and administration after meal. ",procyclidine hydrochloride
sign_symptom,blurred vision,0.99855316," at usual dosage levels dryness of the mouth is generally the only adverse effect. mydriasis, blurred vision and adverse g.i. effects (nausea, vomiting, epigastric distress, constipation) occur occasionally. an allergic reaction (e.g. rash) or muscular weakness may occasionally occur. high doses may cause vertigo and possibly confusion and hallucination. adverse effect mayusually be minimized by adjustment of dosage and administration after meal. ",procyclidine hydrochloride
sign_symptom,adverse,0.79245603," at usual dosage levels dryness of the mouth is generally the only adverse effect. mydriasis, blurred vision and adverse g.i. effects (nausea, vomiting, epigastric distress, constipation) occur occasionally. an allergic reaction (e.g. rash) or muscular weakness may occasionally occur. high doses may cause vertigo and possibly confusion and hallucination. adverse effect mayusually be minimized by adjustment of dosage and administration after meal. ",procyclidine hydrochloride
sign_symptom,allergic reaction,0.99967384," at usual dosage levels dryness of the mouth is generally the only adverse effect. mydriasis, blurred vision and adverse g.i. effects (nausea, vomiting, epigastric distress, constipation) occur occasionally. an allergic reaction (e.g. rash) or muscular weakness may occasionally occur. high doses may cause vertigo and possibly confusion and hallucination. adverse effect mayusually be minimized by adjustment of dosage and administration after meal. ",procyclidine hydrochloride
sign_symptom,rash,0.73666036," at usual dosage levels dryness of the mouth is generally the only adverse effect. mydriasis, blurred vision and adverse g.i. effects (nausea, vomiting, epigastric distress, constipation) occur occasionally. an allergic reaction (e.g. rash) or muscular weakness may occasionally occur. high doses may cause vertigo and possibly confusion and hallucination. adverse effect mayusually be minimized by adjustment of dosage and administration after meal. ",procyclidine hydrochloride
sign_symptom,vertigo,0.9996724," at usual dosage levels dryness of the mouth is generally the only adverse effect. mydriasis, blurred vision and adverse g.i. effects (nausea, vomiting, epigastric distress, constipation) occur occasionally. an allergic reaction (e.g. rash) or muscular weakness may occasionally occur. high doses may cause vertigo and possibly confusion and hallucination. adverse effect mayusually be minimized by adjustment of dosage and administration after meal. ",procyclidine hydrochloride
sign_symptom,confusion,0.993954," at usual dosage levels dryness of the mouth is generally the only adverse effect. mydriasis, blurred vision and adverse g.i. effects (nausea, vomiting, epigastric distress, constipation) occur occasionally. an allergic reaction (e.g. rash) or muscular weakness may occasionally occur. high doses may cause vertigo and possibly confusion and hallucination. adverse effect mayusually be minimized by adjustment of dosage and administration after meal. ",procyclidine hydrochloride
sign_symptom,hall,0.9943798," at usual dosage levels dryness of the mouth is generally the only adverse effect. mydriasis, blurred vision and adverse g.i. effects (nausea, vomiting, epigastric distress, constipation) occur occasionally. an allergic reaction (e.g. rash) or muscular weakness may occasionally occur. high doses may cause vertigo and possibly confusion and hallucination. adverse effect mayusually be minimized by adjustment of dosage and administration after meal. ",procyclidine hydrochloride
sign_symptom,restlessness,0.98697764," drowsiness; jaw, neck, and back muscle spasms; fine worm-like tongue movements; rhythmic face, mouth, or jaw movements; slow or difficult speech; difficulty swallowing; restlessness and pacing; tremors; shuffling walk; skin rash; yellowing of the skin or eyes. ",prochlorperazine maleate
sign_symptom,tremor,0.99971265," drowsiness; jaw, neck, and back muscle spasms; fine worm-like tongue movements; rhythmic face, mouth, or jaw movements; slow or difficult speech; difficulty swallowing; restlessness and pacing; tremors; shuffling walk; skin rash; yellowing of the skin or eyes. ",prochlorperazine maleate
sign_symptom,yellow,0.9995314," drowsiness; jaw, neck, and back muscle spasms; fine worm-like tongue movements; rhythmic face, mouth, or jaw movements; slow or difficult speech; difficulty swallowing; restlessness and pacing; tremors; shuffling walk; skin rash; yellowing of the skin or eyes. ",prochlorperazine maleate
sign_symptom,allergic reactions,0.99988806, allergic reactions may occur but usually resolve on cessation of therapy. ,procaine penicillin + benzyl penicillin
medication,probiotics,0.989901, probiotics are generally well tolerated. ,probiotic combination [9 billion]
sign_symptom,dry mouth,0.880391," most common side effects in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal (primarily difficulty with concentration/attention). most common side effects in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite. ",pregabalin
sign_symptom,blurred vision,0.99912965," most common side effects in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal (primarily difficulty with concentration/attention). most common side effects in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite. ",pregabalin
sign_symptom,weight gain,0.99978185," most common side effects in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal (primarily difficulty with concentration/attention). most common side effects in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite. ",pregabalin
sign_symptom,thinking abnormal,0.94144773," most common side effects in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal (primarily difficulty with concentration/attention). most common side effects in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite. ",pregabalin
sign_symptom,seizures,0.9999112," most common side effects in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal (primarily difficulty with concentration/attention). most common side effects in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite. ",pregabalin
sign_symptom,infections,0.9104846," elevation of intraocular pressure (iop) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation and delayed wound healing. fungal and viral infections of the cornea are particularly may develop coincidentally with long-term applications of steroid. ",prednisolone acetate
sign_symptom,infections,0.98492485," elevation of intraocular pressure (iop) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation and delayed wound healing.  fungal and viral infections of the cornea are particularly may develop coincidentally with long-term applications of steroid ",prednisolone + neomycin sulphate + polymixin b sulphate
medication,steroid,0.9962703," elevation of intraocular pressure (iop) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation and delayed wound healing.  fungal and viral infections of the cornea are particularly may develop coincidentally with long-term applications of steroid ",prednisolone + neomycin sulphate + polymixin b sulphate
sign_symptom,hyper,0.97377115," immediate or delayed hypersensitive type reactions may be developed on administration of rabies immune globulin. the observed immediate reactions are hypotension, dyspnoea, and urticaria. delayed reactions consist of inflammatory reaction, fever, pruritis, rash or urticaria, adenopathy and arthralgia. ",rabies immunoglobulin
sign_symptom,rash,0.9942264," immediate or delayed hypersensitive type reactions may be developed on administration of rabies immune globulin. the observed immediate reactions are hypotension, dyspnoea, and urticaria. delayed reactions consist of inflammatory reaction, fever, pruritis, rash or urticaria, adenopathy and arthralgia. ",rabies immunoglobulin
sign_symptom,adverse reactions,0.9999306," adverse reactions which were reported as possibly or probably related to treatment (&lt;3%) in clinical trials when all three components of this therapy were given concomitantly are listed below and divided by body systems.    digestive system : nausea, vomiting, diarrhoea, dark stools, dry mouth, glossitis, oral moniliasis, stomatitis, tongue discoloration; musculoskeletal system: myalgia;    nervous system : confusion, headache, dizziness; skin: skin reactions; urogenital system: vaginitis, vaginal moniliasis. ",rabeprazole + amoxicillin + clarithromycin
sign_symptom,headache,0.9981844," cinchonism which includes tinnitus, headache, nausea and visual disturbances. hematological disorders and skin reaction may occur. ",quinine sulfate
sign_symptom,nausea,0.9998555," cinchonism which includes tinnitus, headache, nausea and visual disturbances. hematological disorders and skin reaction may occur. ",quinine sulfate
sign_symptom,visual,0.9626691," cinchonism which includes tinnitus, headache, nausea and visual disturbances. hematological disorders and skin reaction may occur. ",quinine sulfate
sign_symptom,hematological disorders,0.95621014," cinchonism which includes tinnitus, headache, nausea and visual disturbances. hematological disorders and skin reaction may occur. ",quinine sulfate
sign_symptom,skin reaction,0.9995558," cinchonism which includes tinnitus, headache, nausea and visual disturbances. hematological disorders and skin reaction may occur. ",quinine sulfate
sign_symptom,adverse drug reactions,0.99940246," the most commonly reported adverse drug reactions (adrs) with quetiapine are somnolence, dizziness, dry mouth, withdrawal (discontinuation) symptoms, elevations in serum triglyceride levels, elevations in total cholesterol (predominantly ldl cholesterol), decreases in hdl cholesterol, weight gain, decreased haemoglobin and extrapyramidal symptoms. ",quetiapine fumarate
sign_symptom,hyper,0.99934834," hypersensitivity reactions, occasionally severe (such as stevens-johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and anaphylaxis), and hyperphenylalaninemia, can occur particularly when pyrimethamine is administered concomitantly with a sulfonamide. consult the complete prescribing information for the relevant sulfonamide for sulfonamideassociated adverse events. with doses of pyrimethamine used for the treatment of toxoplasmosis, anorexia and vomiting may occur. vomiting may be minimized by giving the medication with meals; it usually disappears promptly upon reduction of dosage. doses used in toxoplasmosis may produce megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia, atrophic glossitis, hematuria, and disorders of cardiac rhythm. ",pyrimethamine
medication,sulfo,0.7779676," hypersensitivity reactions, occasionally severe (such as stevens-johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and anaphylaxis), and hyperphenylalaninemia, can occur particularly when pyrimethamine is administered concomitantly with a sulfonamide. consult the complete prescribing information for the relevant sulfonamide for sulfonamideassociated adverse events. with doses of pyrimethamine used for the treatment of toxoplasmosis, anorexia and vomiting may occur. vomiting may be minimized by giving the medication with meals; it usually disappears promptly upon reduction of dosage. doses used in toxoplasmosis may produce megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia, atrophic glossitis, hematuria, and disorders of cardiac rhythm. ",pyrimethamine
medication,sulfonamide,0.7918468," hypersensitivity reactions, occasionally severe (such as stevens-johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and anaphylaxis), and hyperphenylalaninemia, can occur particularly when pyrimethamine is administered concomitantly with a sulfonamide. consult the complete prescribing information for the relevant sulfonamide for sulfonamideassociated adverse events. with doses of pyrimethamine used for the treatment of toxoplasmosis, anorexia and vomiting may occur. vomiting may be minimized by giving the medication with meals; it usually disappears promptly upon reduction of dosage. doses used in toxoplasmosis may produce megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia, atrophic glossitis, hematuria, and disorders of cardiac rhythm. ",pyrimethamine
sign_symptom,vomiting,0.99990964," hypersensitivity reactions, occasionally severe (such as stevens-johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and anaphylaxis), and hyperphenylalaninemia, can occur particularly when pyrimethamine is administered concomitantly with a sulfonamide. consult the complete prescribing information for the relevant sulfonamide for sulfonamideassociated adverse events. with doses of pyrimethamine used for the treatment of toxoplasmosis, anorexia and vomiting may occur. vomiting may be minimized by giving the medication with meals; it usually disappears promptly upon reduction of dosage. doses used in toxoplasmosis may produce megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia, atrophic glossitis, hematuria, and disorders of cardiac rhythm. ",pyrimethamine
medication,doxylamine succinate,0.9991687, somnolence or other accidents resulting from the effect of the combined use of doxylamine succinate &amp; pyridoxine hydrochloride with cns depressants. ,pyridoxine hydrochloride + doxylamine succinate
medication,pyridoxine hydrochloride,0.9991704, somnolence or other accidents resulting from the effect of the combined use of doxylamine succinate &amp; pyridoxine hydrochloride with cns depressants. ,pyridoxine hydrochloride + doxylamine succinate
medication,pyridoxin,0.852352," pyridoxineusually has no side effects when used in recommended doses.  if your doctor has prescribed this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. many people using this medication do not have serious side effects.  pyridoxine can cause side effects when taken in large doses for a long time. tell your doctor right away if any of these unlikely but serious side effects occur: headache, nausea, drowsiness, numbness/tingling of arms/legs.  a very seriousallergic reactionto this drug is rare. however, seek immediate medical attention if you notice any symptoms of a seriousallergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.  this is not a complete list of possible side effects. if you notice other effects not listed above, contact your doctor orpharmacist. ",pyridoxine hydrochloride
sign_symptom,effects,0.92016804," pyridoxineusually has no side effects when used in recommended doses.  if your doctor has prescribed this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. many people using this medication do not have serious side effects.  pyridoxine can cause side effects when taken in large doses for a long time. tell your doctor right away if any of these unlikely but serious side effects occur: headache, nausea, drowsiness, numbness/tingling of arms/legs.  a very seriousallergic reactionto this drug is rare. however, seek immediate medical attention if you notice any symptoms of a seriousallergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.  this is not a complete list of possible side effects. if you notice other effects not listed above, contact your doctor orpharmacist. ",pyridoxine hydrochloride
medication,pyridoxine,0.896578," pyridoxineusually has no side effects when used in recommended doses.  if your doctor has prescribed this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. many people using this medication do not have serious side effects.  pyridoxine can cause side effects when taken in large doses for a long time. tell your doctor right away if any of these unlikely but serious side effects occur: headache, nausea, drowsiness, numbness/tingling of arms/legs.  a very seriousallergic reactionto this drug is rare. however, seek immediate medical attention if you notice any symptoms of a seriousallergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.  this is not a complete list of possible side effects. if you notice other effects not listed above, contact your doctor orpharmacist. ",pyridoxine hydrochloride
sign_symptom,side effects,0.8351289," pyridoxineusually has no side effects when used in recommended doses.  if your doctor has prescribed this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. many people using this medication do not have serious side effects.  pyridoxine can cause side effects when taken in large doses for a long time. tell your doctor right away if any of these unlikely but serious side effects occur: headache, nausea, drowsiness, numbness/tingling of arms/legs.  a very seriousallergic reactionto this drug is rare. however, seek immediate medical attention if you notice any symptoms of a seriousallergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.  this is not a complete list of possible side effects. if you notice other effects not listed above, contact your doctor orpharmacist. ",pyridoxine hydrochloride
sign_symptom,numb,0.9885188," pyridoxineusually has no side effects when used in recommended doses.  if your doctor has prescribed this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. many people using this medication do not have serious side effects.  pyridoxine can cause side effects when taken in large doses for a long time. tell your doctor right away if any of these unlikely but serious side effects occur: headache, nausea, drowsiness, numbness/tingling of arms/legs.  a very seriousallergic reactionto this drug is rare. however, seek immediate medical attention if you notice any symptoms of a seriousallergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.  this is not a complete list of possible side effects. if you notice other effects not listed above, contact your doctor orpharmacist. ",pyridoxine hydrochloride
sign_symptom,tingling,0.9988269," pyridoxineusually has no side effects when used in recommended doses.  if your doctor has prescribed this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. many people using this medication do not have serious side effects.  pyridoxine can cause side effects when taken in large doses for a long time. tell your doctor right away if any of these unlikely but serious side effects occur: headache, nausea, drowsiness, numbness/tingling of arms/legs.  a very seriousallergic reactionto this drug is rare. however, seek immediate medical attention if you notice any symptoms of a seriousallergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.  this is not a complete list of possible side effects. if you notice other effects not listed above, contact your doctor orpharmacist. ",pyridoxine hydrochloride
sign_symptom,reaction,0.98250765," pyridoxineusually has no side effects when used in recommended doses.  if your doctor has prescribed this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. many people using this medication do not have serious side effects.  pyridoxine can cause side effects when taken in large doses for a long time. tell your doctor right away if any of these unlikely but serious side effects occur: headache, nausea, drowsiness, numbness/tingling of arms/legs.  a very seriousallergic reactionto this drug is rare. however, seek immediate medical attention if you notice any symptoms of a seriousallergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.  this is not a complete list of possible side effects. if you notice other effects not listed above, contact your doctor orpharmacist. ",pyridoxine hydrochloride
sign_symptom,swelling,0.9999248," pyridoxineusually has no side effects when used in recommended doses.  if your doctor has prescribed this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. many people using this medication do not have serious side effects.  pyridoxine can cause side effects when taken in large doses for a long time. tell your doctor right away if any of these unlikely but serious side effects occur: headache, nausea, drowsiness, numbness/tingling of arms/legs.  a very seriousallergic reactionto this drug is rare. however, seek immediate medical attention if you notice any symptoms of a seriousallergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.  this is not a complete list of possible side effects. if you notice other effects not listed above, contact your doctor orpharmacist. ",pyridoxine hydrochloride
sign_symptom,rash,0.9981343," the side effects of pyridostigmine are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. among those in the former group are nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis and diaphoresis. nicotinic side effects are comprised chiefly of muscle cramps, fasciculation and weakness. muscarinic side effects can usually be counteracted by atropine, but for reasons shown in the preceding section the expedient is not without danger. as with any compound containing the bromide radical, a skin rash may be seen in an occasional patient. such reactions usually subside promptly upon discontinuance of the medication. ",pyridostigmine bromide
sign_symptom,fever,0.99994457,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,porphyria,0.9989099,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,gi disturbances,0.99988186,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,nausea,0.99992275,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,vomiting,0.9999403,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,adverse effects,0.99982214,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,arthralgia,0.99986213,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,myalgia,0.9980323,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,hypersensitivity reactions,0.99866235,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,rash,0.999864,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,urticaria,0.9680257,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,pruritis,0.9486154,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,photosensitivity,0.9583043,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,dysuria,0.999809,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
sign_symptom,interstitial nephritis,0.9997516,"  general : fever, porphyria and dysuria have rarely been reported.gout.   gastrointestinal : the principal adverse effect is a hepatic reaction. hepatotoxicity appears to be dose related, and may appear at any time during therapy. gi disturbances including nausea, vomiting and anorexia have also been reported.   hematologic and lymphatic : thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. adverse effects on blood clotting mechanisms have also been rarely reported.   other : mild arthralgia and myalgia have been reported frequently. hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely. ",pyrazinamide
medication,pamoate,0.8745435," pyrantel pamoate is well tolerated in recommended dosage. when given in large dosage, pyrantel pamoate may cause gastrointestinal upset such as anorexia, nausea, vomiting and diarrhoea. other side effects that may occur in rare occasions are headache, dizziness and rash. ",pyrantel pamoate
sign_symptom,vomiting,0.99982244," pyrantel pamoate is well tolerated in recommended dosage. when given in large dosage, pyrantel pamoate may cause gastrointestinal upset such as anorexia, nausea, vomiting and diarrhoea. other side effects that may occur in rare occasions are headache, dizziness and rash. ",pyrantel pamoate
sign_symptom,adverse effects,0.9998145," serious adverse effects associated with the use of pseudoephedrine are rare. symptoms of central nervous system excitation may occur, including sleep disturbances and, rarely, hallucinations have been reported. skin rashes, with or without irritation, have occasionally been reported. ",pseudoephedrine hydrochloride
medication,pseudoephedrine,0.9758122," serious adverse effects associated with the use of pseudoephedrine are rare. symptoms of central nervous system excitation may occur, including sleep disturbances and, rarely, hallucinations have been reported. skin rashes, with or without irritation, have occasionally been reported. ",pseudoephedrine hydrochloride
sign_symptom,symptoms of central nervous system excitation,0.99884534," serious adverse effects associated with the use of pseudoephedrine are rare. symptoms of central nervous system excitation may occur, including sleep disturbances and, rarely, hallucinations have been reported. skin rashes, with or without irritation, have occasionally been reported. ",pseudoephedrine hydrochloride
sign_symptom,sleep disturbances,0.9998841," serious adverse effects associated with the use of pseudoephedrine are rare. symptoms of central nervous system excitation may occur, including sleep disturbances and, rarely, hallucinations have been reported. skin rashes, with or without irritation, have occasionally been reported. ",pseudoephedrine hydrochloride
sign_symptom,hallucinations,0.9597962," serious adverse effects associated with the use of pseudoephedrine are rare. symptoms of central nervous system excitation may occur, including sleep disturbances and, rarely, hallucinations have been reported. skin rashes, with or without irritation, have occasionally been reported. ",pseudoephedrine hydrochloride
sign_symptom,rash,0.99984956," serious adverse effects associated with the use of pseudoephedrine are rare. symptoms of central nervous system excitation may occur, including sleep disturbances and, rarely, hallucinations have been reported. skin rashes, with or without irritation, have occasionally been reported. ",pseudoephedrine hydrochloride
sign_symptom,depression,0.9999261," cns depression or excitation, drowsiness (reported most frequently), sleep disturbances, hallucinations (rarely reported), skin rashes with or without irritation, tachycardia, dryness of mouth, nose and throat have occasionally been reported. ",pseudoephedrine + guaiphenasine + triprolidine
sign_symptom,sleep,0.99940896," cns depression or excitation, drowsiness (reported most frequently), sleep disturbances, hallucinations (rarely reported), skin rashes with or without irritation, tachycardia, dryness of mouth, nose and throat have occasionally been reported. ",pseudoephedrine + guaiphenasine + triprolidine
sign_symptom,hallucinations,0.99349004," cns depression or excitation, drowsiness (reported most frequently), sleep disturbances, hallucinations (rarely reported), skin rashes with or without irritation, tachycardia, dryness of mouth, nose and throat have occasionally been reported. ",pseudoephedrine + guaiphenasine + triprolidine
sign_symptom,rash,0.9999219," cns depression or excitation, drowsiness (reported most frequently), sleep disturbances, hallucinations (rarely reported), skin rashes with or without irritation, tachycardia, dryness of mouth, nose and throat have occasionally been reported. ",pseudoephedrine + guaiphenasine + triprolidine
sign_symptom,dryness of mouth,0.9953889," cns depression or excitation, drowsiness (reported most frequently), sleep disturbances, hallucinations (rarely reported), skin rashes with or without irritation, tachycardia, dryness of mouth, nose and throat have occasionally been reported. ",pseudoephedrine + guaiphenasine + triprolidine
sign_symptom,adverse reactions,0.9998553," the most frequently reported adverse reactions associated with prucalopride therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain), nausea and diarrhoea. the adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment. other adverse reactions have been reported occasionally. the majority of adverse events were mild to moderate in intensity. ",prucalopride succinate
sign_symptom,headache,0.9999559," the most frequently reported adverse reactions associated with prucalopride therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain), nausea and diarrhoea. the adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment. other adverse reactions have been reported occasionally. the majority of adverse events were mild to moderate in intensity. ",prucalopride succinate
sign_symptom,gastrointestinal symptoms,0.9496282," the most frequently reported adverse reactions associated with prucalopride therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain), nausea and diarrhoea. the adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment. other adverse reactions have been reported occasionally. the majority of adverse events were mild to moderate in intensity. ",prucalopride succinate
sign_symptom,pain,0.9999473," the most frequently reported adverse reactions associated with prucalopride therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain), nausea and diarrhoea. the adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment. other adverse reactions have been reported occasionally. the majority of adverse events were mild to moderate in intensity. ",prucalopride succinate
sign_symptom,nausea,0.99995196," the most frequently reported adverse reactions associated with prucalopride therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain), nausea and diarrhoea. the adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment. other adverse reactions have been reported occasionally. the majority of adverse events were mild to moderate in intensity. ",prucalopride succinate
sign_symptom,diarr,0.98529375," the most frequently reported adverse reactions associated with prucalopride therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain), nausea and diarrhoea. the adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment. other adverse reactions have been reported occasionally. the majority of adverse events were mild to moderate in intensity. ",prucalopride succinate
sign_symptom,adverse events,0.9999034," the most frequently reported adverse reactions associated with prucalopride therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain), nausea and diarrhoea. the adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment. other adverse reactions have been reported occasionally. the majority of adverse events were mild to moderate in intensity. ",prucalopride succinate
sign_symptom,vomiting,0.82501525," intravenousinjections of protamine sulfate may cause a sudden fall inblood pressure, bradycardia, pulmonary hypertension,dyspnea, or transitory flushing and a feeling of warmth. there have been reports ofanaphylaxisthat resulted in respiratory embarrassment. other reported adverse reactions include systemic hypertension, nausea, vomiting and lassitude.back painhas been reported rarely in conscious patients undergoing such procedures ascardiaccatheterization. because fatal reactions often resembling anaphylaxis have been reported after administration of protamine sulfate, the drug should be given only whenresuscitationtechniques and treatment of anaphylactoid shockare readily available. ",protamine sulfate
sign_symptom,pain,0.9999132," intravenousinjections of protamine sulfate may cause a sudden fall inblood pressure, bradycardia, pulmonary hypertension,dyspnea, or transitory flushing and a feeling of warmth. there have been reports ofanaphylaxisthat resulted in respiratory embarrassment. other reported adverse reactions include systemic hypertension, nausea, vomiting and lassitude.back painhas been reported rarely in conscious patients undergoing such procedures ascardiaccatheterization. because fatal reactions often resembling anaphylaxis have been reported after administration of protamine sulfate, the drug should be given only whenresuscitationtechniques and treatment of anaphylactoid shockare readily available. ",protamine sulfate
sign_symptom,reactions,0.7097137," intravenousinjections of protamine sulfate may cause a sudden fall inblood pressure, bradycardia, pulmonary hypertension,dyspnea, or transitory flushing and a feeling of warmth. there have been reports ofanaphylaxisthat resulted in respiratory embarrassment. other reported adverse reactions include systemic hypertension, nausea, vomiting and lassitude.back painhas been reported rarely in conscious patients undergoing such procedures ascardiaccatheterization. because fatal reactions often resembling anaphylaxis have been reported after administration of protamine sulfate, the drug should be given only whenresuscitationtechniques and treatment of anaphylactoid shockare readily available. ",protamine sulfate
sign_symptom,anaphylaxis,0.9992269," intravenousinjections of protamine sulfate may cause a sudden fall inblood pressure, bradycardia, pulmonary hypertension,dyspnea, or transitory flushing and a feeling of warmth. there have been reports ofanaphylaxisthat resulted in respiratory embarrassment. other reported adverse reactions include systemic hypertension, nausea, vomiting and lassitude.back painhas been reported rarely in conscious patients undergoing such procedures ascardiaccatheterization. because fatal reactions often resembling anaphylaxis have been reported after administration of protamine sulfate, the drug should be given only whenresuscitationtechniques and treatment of anaphylactoid shockare readily available. ",protamine sulfate
medication,anaphylactoid shock,0.9087038," intravenousinjections of protamine sulfate may cause a sudden fall inblood pressure, bradycardia, pulmonary hypertension,dyspnea, or transitory flushing and a feeling of warmth. there have been reports ofanaphylaxisthat resulted in respiratory embarrassment. other reported adverse reactions include systemic hypertension, nausea, vomiting and lassitude.back painhas been reported rarely in conscious patients undergoing such procedures ascardiaccatheterization. because fatal reactions often resembling anaphylaxis have been reported after administration of protamine sulfate, the drug should be given only whenresuscitationtechniques and treatment of anaphylactoid shockare readily available. ",protamine sulfate
medication,prop,0.99915636," the most common side effects of propylthiouracil include: 
 
 nausea 
 muscle pain 
 vomiting 
 headache 
 upper stomach pain or tenderness 
 sleepiness 
 joint pain 
 nerve pain 
 itching or tingling 
 swelling (edema) 
 loss or change in taste 
 dizziness 
 loss of hair 
 enlarged salivary glands or enlarged lymph node 
  ",propylthiouracil
sign_symptom,nausea,0.9999527," the most common side effects of propylthiouracil include: 
 
 nausea 
 muscle pain 
 vomiting 
 headache 
 upper stomach pain or tenderness 
 sleepiness 
 joint pain 
 nerve pain 
 itching or tingling 
 swelling (edema) 
 loss or change in taste 
 dizziness 
 loss of hair 
 enlarged salivary glands or enlarged lymph node 
  ",propylthiouracil
sign_symptom,pain,0.9999354," the most common side effects of propylthiouracil include: 
 
 nausea 
 muscle pain 
 vomiting 
 headache 
 upper stomach pain or tenderness 
 sleepiness 
 joint pain 
 nerve pain 
 itching or tingling 
 swelling (edema) 
 loss or change in taste 
 dizziness 
 loss of hair 
 enlarged salivary glands or enlarged lymph node 
  ",propylthiouracil
sign_symptom,vomiting,0.99994683," the most common side effects of propylthiouracil include: 
 
 nausea 
 muscle pain 
 vomiting 
 headache 
 upper stomach pain or tenderness 
 sleepiness 
 joint pain 
 nerve pain 
 itching or tingling 
 swelling (edema) 
 loss or change in taste 
 dizziness 
 loss of hair 
 enlarged salivary glands or enlarged lymph node 
  ",propylthiouracil
sign_symptom,headache,0.9999229," the most common side effects of propylthiouracil include: 
 
 nausea 
 muscle pain 
 vomiting 
 headache 
 upper stomach pain or tenderness 
 sleepiness 
 joint pain 
 nerve pain 
 itching or tingling 
 swelling (edema) 
 loss or change in taste 
 dizziness 
 loss of hair 
 enlarged salivary glands or enlarged lymph node 
  ",propylthiouracil
sign_symptom,tenderness,0.99993765," the most common side effects of propylthiouracil include: 
 
 nausea 
 muscle pain 
 vomiting 
 headache 
 upper stomach pain or tenderness 
 sleepiness 
 joint pain 
 nerve pain 
 itching or tingling 
 swelling (edema) 
 loss or change in taste 
 dizziness 
 loss of hair 
 enlarged salivary glands or enlarged lymph node 
  ",propylthiouracil
sign_symptom,sleepiness,0.99969053," the most common side effects of propylthiouracil include: 
 
 nausea 
 muscle pain 
 vomiting 
 headache 
 upper stomach pain or tenderness 
 sleepiness 
 joint pain 
 nerve pain 
 itching or tingling 
 swelling (edema) 
 loss or change in taste 
 dizziness 
 loss of hair 
 enlarged salivary glands or enlarged lymph node 
  ",propylthiouracil
sign_symptom,swelling,0.994938," the most common side effects of propylthiouracil include: 
 
 nausea 
 muscle pain 
 vomiting 
 headache 
 upper stomach pain or tenderness 
 sleepiness 
 joint pain 
 nerve pain 
 itching or tingling 
 swelling (edema) 
 loss or change in taste 
 dizziness 
 loss of hair 
 enlarged salivary glands or enlarged lymph node 
  ",propylthiouracil
sign_symptom,change in taste,0.99934524," the most common side effects of propylthiouracil include: 
 
 nausea 
 muscle pain 
 vomiting 
 headache 
 upper stomach pain or tenderness 
 sleepiness 
 joint pain 
 nerve pain 
 itching or tingling 
 swelling (edema) 
 loss or change in taste 
 dizziness 
 loss of hair 
 enlarged salivary glands or enlarged lymph node 
  ",propylthiouracil
sign_symptom,loss of hair,0.99936086," the most common side effects of propylthiouracil include: 
 
 nausea 
 muscle pain 
 vomiting 
 headache 
 upper stomach pain or tenderness 
 sleepiness 
 joint pain 
 nerve pain 
 itching or tingling 
 swelling (edema) 
 loss or change in taste 
 dizziness 
 loss of hair 
 enlarged salivary glands or enlarged lymph node 
  ",propylthiouracil
sign_symptom,enlarged,0.9997863," the most common side effects of propylthiouracil include: 
 
 nausea 
 muscle pain 
 vomiting 
 headache 
 upper stomach pain or tenderness 
 sleepiness 
 joint pain 
 nerve pain 
 itching or tingling 
 swelling (edema) 
 loss or change in taste 
 dizziness 
 loss of hair 
 enlarged salivary glands or enlarged lymph node 
  ",propylthiouracil
sign_symptom,cold,0.9119419," cold extremities, lassitude, nausea, dizziness, insomnia, paresthesia etc. ",propranolol hydrochloride
sign_symptom,insomnia,0.795248," cold extremities, lassitude, nausea, dizziness, insomnia, paresthesia etc. ",propranolol hydrochloride
medication,propofol,0.88591117,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
sign_symptom,pain,0.9999286,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
medication,lidocaine,0.96984226,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
sign_symptom,oedema,0.796691,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
sign_symptom,headache,0.9998715,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
sign_symptom,nausea,0.9999076,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
sign_symptom,vomiting,0.99993074,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
sign_symptom,hypersensitivity,0.91843843,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
sign_symptom,symptoms,0.8739926,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
disease_disorder,cardiac arrest,0.8973576,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
medication,prop,0.99287945,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
sign_symptom,disco,0.9997776,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
sign_symptom,altered,0.93869954,"  local : propofol is normally well tolerated. its most common undesirable effect is pain at the site of injection that can be reduced by mixing the preparation with lidocaine or by injecting it into one of the larger veins of the forearm or the intercubital fossa. thrombosis and phlebitis are rare.    general : hypotension and transient apnea may occur at the induction of anaesthesia, and may be severe especially in patients who are in a poor general condition. epileptic movement, convulsions and dystonic reactions have been seen in rare cases. pulmonary oedema has also been reported. headache, nausea and, more rarely, vomiting may occur in some patients during recovery. recovery may also be associated with another short period of impaired consciousness. hypersensitivity has been reported in some cases, connected with anaphylactic symptoms such as marked hypotension, bronchospasm, oedema and facial erythema. some cases of cardiac arrest have occurred in connection with the administration of propofol. in connection with long-term administration of propofol, green or reddish brown discolouration of urine may occur. this is caused by the quinol metabolites of propofol, and is not dangerous. as with other anaesthetics, altered sexual behaviour may occur. ",propofol
sign_symptom,adverse reactions,0.9998978," the most common adverse reactions in adults receiving combination therapy are psychiatric and central nervous system effects, severe ocular disorder, dental and periodontal disorders &amp; growth inhibition in children and adolescents that may be irreversible in some patients. the most common adverse reactions in pediatric subjects were similar to those seen in adults. ",ribavirin
sign_symptom,growth inhibition,0.99993074," the most common adverse reactions in adults receiving combination therapy are psychiatric and central nervous system effects, severe ocular disorder, dental and periodontal disorders &amp; growth inhibition in children and adolescents that may be irreversible in some patients. the most common adverse reactions in pediatric subjects were similar to those seen in adults. ",ribavirin
sign_symptom,burning sensation,0.99918246, a transient local burning sensation at the site of application occurs very commonly. temporary discoloration of teeth or oral mucosa has been described commonly following administration of the oral solution. ,rhubarb extract + salicylic acid
sign_symptom,disco,0.9999645, a transient local burning sensation at the site of application occurs very commonly. temporary discoloration of teeth or oral mucosa has been described commonly following administration of the oral solution. ,rhubarb extract + salicylic acid
sign_symptom,irritation,0.9998958, adverse effects: application site irritation (&lt;2% of patients may experience). ,retapamulin
medication,repaglinide,0.8637855," the most common side effects of repaglinide are hypoglycemia and related symptoms. others include upper respiratory tract infections, diarrhea, constipation, nausea and vomiting. hypersensitivity reactions include rashes and urticaria. ",repaglinide
sign_symptom,nausea,0.84597176," the most common side effects of repaglinide are hypoglycemia and related symptoms. others include upper respiratory tract infections, diarrhea, constipation, nausea and vomiting. hypersensitivity reactions include rashes and urticaria. ",repaglinide
sign_symptom,hypersensitivity,0.9863123," the most common side effects of repaglinide are hypoglycemia and related symptoms. others include upper respiratory tract infections, diarrhea, constipation, nausea and vomiting. hypersensitivity reactions include rashes and urticaria. ",repaglinide
sign_symptom,rash,0.99631387," the most common side effects of repaglinide are hypoglycemia and related symptoms. others include upper respiratory tract infections, diarrhea, constipation, nausea and vomiting. hypersensitivity reactions include rashes and urticaria. ",repaglinide
sign_symptom,reaction,0.77488965, an adverse reaction associated with remdesivir in clinical trials in healthy adult subjects was increased liver transaminases. ,remdesivir
sign_symptom,adverse reactions,0.96676993,"  adverse reactions : the most common adverse reactions (10%) and laboratory abnormalities (15%) were hot flushes, glucose increased, triglycerides increased, musculoskeletal pain, haemoglobin decreased, alanine aminotransferase (alt) increased, fatigue, aspartate aminotransferase (ast) increased, constipation, and diarrhea.   common side effects : hot flushes, increased blood sugar levels, increased blood fat (triglyceride) levels, muscle and joint pain, decreased hemoglobin levels, increased liver enzymes, tiredness, constipation, diarrhoea   rare side effects : relugolix may cause rare side effects, including changes in the electrical activity of your heart (qt prolongation), dizziness, fainting, feeling that your heart is pounding or racing (palpitations), chest pain. other side effects include weight gain, decreased sex drive, and erectile function problems. ",relugolix
sign_symptom,abnormalities,0.7650069,"  adverse reactions : the most common adverse reactions (10%) and laboratory abnormalities (15%) were hot flushes, glucose increased, triglycerides increased, musculoskeletal pain, haemoglobin decreased, alanine aminotransferase (alt) increased, fatigue, aspartate aminotransferase (ast) increased, constipation, and diarrhea.   common side effects : hot flushes, increased blood sugar levels, increased blood fat (triglyceride) levels, muscle and joint pain, decreased hemoglobin levels, increased liver enzymes, tiredness, constipation, diarrhoea   rare side effects : relugolix may cause rare side effects, including changes in the electrical activity of your heart (qt prolongation), dizziness, fainting, feeling that your heart is pounding or racing (palpitations), chest pain. other side effects include weight gain, decreased sex drive, and erectile function problems. ",relugolix
sign_symptom,pounding,0.9629678,"  adverse reactions : the most common adverse reactions (10%) and laboratory abnormalities (15%) were hot flushes, glucose increased, triglycerides increased, musculoskeletal pain, haemoglobin decreased, alanine aminotransferase (alt) increased, fatigue, aspartate aminotransferase (ast) increased, constipation, and diarrhea.   common side effects : hot flushes, increased blood sugar levels, increased blood fat (triglyceride) levels, muscle and joint pain, decreased hemoglobin levels, increased liver enzymes, tiredness, constipation, diarrhoea   rare side effects : relugolix may cause rare side effects, including changes in the electrical activity of your heart (qt prolongation), dizziness, fainting, feeling that your heart is pounding or racing (palpitations), chest pain. other side effects include weight gain, decreased sex drive, and erectile function problems. ",relugolix
sign_symptom,weight,0.9461814,"  adverse reactions : the most common adverse reactions (10%) and laboratory abnormalities (15%) were hot flushes, glucose increased, triglycerides increased, musculoskeletal pain, haemoglobin decreased, alanine aminotransferase (alt) increased, fatigue, aspartate aminotransferase (ast) increased, constipation, and diarrhea.   common side effects : hot flushes, increased blood sugar levels, increased blood fat (triglyceride) levels, muscle and joint pain, decreased hemoglobin levels, increased liver enzymes, tiredness, constipation, diarrhoea   rare side effects : relugolix may cause rare side effects, including changes in the electrical activity of your heart (qt prolongation), dizziness, fainting, feeling that your heart is pounding or racing (palpitations), chest pain. other side effects include weight gain, decreased sex drive, and erectile function problems. ",relugolix
sign_symptom,decreased,0.7905447," the most common side effects (30%) are asthenia/fatigue, decreased appetite and food intake, hand-foot skin reaction (hfsr) [palmar-plantar erythrodysesthesia (ppe)], diarrhea, mucositis, weight loss, infection, hypertension, and dysphonia. ",regorafenib
sign_symptom,nausea,0.98058665," general side effects may include headache, nausea and rash. due to its coumarin derivatives, trifolium pratense should be used with caution in individuals with coagulation disorders or currently undergoing anticoagulation therapy. ",red clover [trifolium pratense]
disease_disorder,coagulation disorders,0.7769022," general side effects may include headache, nausea and rash. due to its coumarin derivatives, trifolium pratense should be used with caution in individuals with coagulation disorders or currently undergoing anticoagulation therapy. ",red clover [trifolium pratense]
sign_symptom,pain,0.99992144," recombinant fsh sometimes excites the ovaries too much. this may cause pelvic pain or breathing problems. it may also make you urinate less. in rare cases, patients with this problem have had serious lung problems, including fluid in the lungs, troublebreathing, and worsening of asthma blood clots, severe pelvic pain, chest pain, or abdominal pain, nausea, vomiting, sudden weight gain, bloating, trouble, breathing. recombinant fsh may cause twins or multiple births. ",recombinant follicle stimulating hormone (rfsh)
sign_symptom,spinning,0.85696787," common side effects of rasagiline include: dizziness, spinning sensation, joint pain, headache, heartburn, nausea, muscle pain etc. ",rasagiline
sign_symptom,pain,0.92157197," common side effects of rasagiline include: dizziness, spinning sensation, joint pain, headache, heartburn, nausea, muscle pain etc. ",rasagiline
sign_symptom,palpitations,0.9987678,"  cardiac disorders : bradycardia, palpitations  ear and labyrinth disorders : tinnitus, vertigo  gastrointestinal disorders : abdominal pain, dry mouth, vomiting  general disorders and administrative site adverse events : peripheral edema  respiratory, thoracic, and mediastinal disorders : dyspnea  vascular disorders: hypotension, orthostatic hypotension ",ranolazine
disease_disorder,labyrinth,0.8226148,"  cardiac disorders : bradycardia, palpitations  ear and labyrinth disorders : tinnitus, vertigo  gastrointestinal disorders : abdominal pain, dry mouth, vomiting  general disorders and administrative site adverse events : peripheral edema  respiratory, thoracic, and mediastinal disorders : dyspnea  vascular disorders: hypotension, orthostatic hypotension ",ranolazine
sign_symptom,dry mouth,0.9822564,"  cardiac disorders : bradycardia, palpitations  ear and labyrinth disorders : tinnitus, vertigo  gastrointestinal disorders : abdominal pain, dry mouth, vomiting  general disorders and administrative site adverse events : peripheral edema  respiratory, thoracic, and mediastinal disorders : dyspnea  vascular disorders: hypotension, orthostatic hypotension ",ranolazine
sign_symptom,vomiting,0.9113248,"  cardiac disorders : bradycardia, palpitations  ear and labyrinth disorders : tinnitus, vertigo  gastrointestinal disorders : abdominal pain, dry mouth, vomiting  general disorders and administrative site adverse events : peripheral edema  respiratory, thoracic, and mediastinal disorders : dyspnea  vascular disorders: hypotension, orthostatic hypotension ",ranolazine
disease_disorder,general,0.72631395,"  cardiac disorders : bradycardia, palpitations  ear and labyrinth disorders : tinnitus, vertigo  gastrointestinal disorders : abdominal pain, dry mouth, vomiting  general disorders and administrative site adverse events : peripheral edema  respiratory, thoracic, and mediastinal disorders : dyspnea  vascular disorders: hypotension, orthostatic hypotension ",ranolazine
sign_symptom,adverse,0.9997292,"  cardiac disorders : bradycardia, palpitations  ear and labyrinth disorders : tinnitus, vertigo  gastrointestinal disorders : abdominal pain, dry mouth, vomiting  general disorders and administrative site adverse events : peripheral edema  respiratory, thoracic, and mediastinal disorders : dyspnea  vascular disorders: hypotension, orthostatic hypotension ",ranolazine
sign_symptom,hypotension,0.9921708,"  cardiac disorders : bradycardia, palpitations  ear and labyrinth disorders : tinnitus, vertigo  gastrointestinal disorders : abdominal pain, dry mouth, vomiting  general disorders and administrative site adverse events : peripheral edema  respiratory, thoracic, and mediastinal disorders : dyspnea  vascular disorders: hypotension, orthostatic hypotension ",ranolazine
medication,ranitidine,0.99902505," ranitidine is well tolerated and side effects are usually uncommon. altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, muscle or joint pain have rarely been reported. ",ranitidine hydrochloride
sign_symptom,side effects,0.99338293," ranitidine is well tolerated and side effects are usually uncommon. altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, muscle or joint pain have rarely been reported. ",ranitidine hydrochloride
sign_symptom,altered,0.9953068," ranitidine is well tolerated and side effects are usually uncommon. altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, muscle or joint pain have rarely been reported. ",ranitidine hydrochloride
sign_symptom,tired,0.94588846," ranitidine is well tolerated and side effects are usually uncommon. altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, muscle or joint pain have rarely been reported. ",ranitidine hydrochloride
sign_symptom,confusional states,0.928652," ranitidine is well tolerated and side effects are usually uncommon. altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, muscle or joint pain have rarely been reported. ",ranitidine hydrochloride
sign_symptom,pain,0.99994385," ranitidine is well tolerated and side effects are usually uncommon. altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, muscle or joint pain have rarely been reported. ",ranitidine hydrochloride
sign_symptom,irritation,0.9999442," ocular pain, hyperaemia, irritation and pruritus; increased intraocular pressure, vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, vitreous floaters, conjunctival haemorrhage, foreign body sensation in eyes, increased lacrimation, blepharitis, dry eye, headache, nasopharyngitis, arthralgia, thromboembolic events. less frequently, endophthalmitis, blindness, retinal detachment, retinal tear and iatrogenic traumatic cataract. ",ranibizumab
sign_symptom,pruritus,0.8230057," ocular pain, hyperaemia, irritation and pruritus; increased intraocular pressure, vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, vitreous floaters, conjunctival haemorrhage, foreign body sensation in eyes, increased lacrimation, blepharitis, dry eye, headache, nasopharyngitis, arthralgia, thromboembolic events. less frequently, endophthalmitis, blindness, retinal detachment, retinal tear and iatrogenic traumatic cataract. ",ranibizumab
sign_symptom,foreign body sensation,0.91653377," ocular pain, hyperaemia, irritation and pruritus; increased intraocular pressure, vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, vitreous floaters, conjunctival haemorrhage, foreign body sensation in eyes, increased lacrimation, blepharitis, dry eye, headache, nasopharyngitis, arthralgia, thromboembolic events. less frequently, endophthalmitis, blindness, retinal detachment, retinal tear and iatrogenic traumatic cataract. ",ranibizumab
sign_symptom,adverse reactions,0.99862856," the most common adverse reactions observed in single agent ramucirumab-treated gastric cancer patients at a rate of 10% and 2% higher than placebo were hypertension and diarrhea.  the most common adverse reactions observed in patients treated with ramucirumab with paclitaxel at a rate of 30% and 2% higher than placebo with paclitaxel were fatigue/asthenia, neutropenia, diarrhea, and epistaxis.  the most common adverse reactions observed in patients treated with ramucirumab with erlotinib at a rate of 30% and 2% higher than placebo with erlotinib were, infections, hypertension, stomatitis, proteinuria, alopecia, and epistaxis. the most common laboratory abnormalities at a rate of 30% and 2% higher difference in incidence between arms were increased alanine aminotransferase, increased aspartate aminotransferase, anemia, thrombocytopenia, and neutropenia.  the most common adverse reactions observed in patients treated with ramucirumab with docetaxel at a rate of 30% and 2% higher than placebo with docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation.  the most common adverse reactions observed in patients treated with ramucirumab with folfiri at a rate of 30% and 2% higher than placebo with folfiri were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.  the most common adverse reactions observed in single agent ramucirumab-treated hcc patients at a rate of 15% and 2% higher than placebo were fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. the most common laboratory abnormalities at a rate of 30% and a 2% higher difference in incidence between arms were thrombocytopenia, hypoalbuminemia, and hyponatremia. ",ramucirumab
disease_disorder,gastric cancer,0.97555286," the most common adverse reactions observed in single agent ramucirumab-treated gastric cancer patients at a rate of 10% and 2% higher than placebo were hypertension and diarrhea.  the most common adverse reactions observed in patients treated with ramucirumab with paclitaxel at a rate of 30% and 2% higher than placebo with paclitaxel were fatigue/asthenia, neutropenia, diarrhea, and epistaxis.  the most common adverse reactions observed in patients treated with ramucirumab with erlotinib at a rate of 30% and 2% higher than placebo with erlotinib were, infections, hypertension, stomatitis, proteinuria, alopecia, and epistaxis. the most common laboratory abnormalities at a rate of 30% and 2% higher difference in incidence between arms were increased alanine aminotransferase, increased aspartate aminotransferase, anemia, thrombocytopenia, and neutropenia.  the most common adverse reactions observed in patients treated with ramucirumab with docetaxel at a rate of 30% and 2% higher than placebo with docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation.  the most common adverse reactions observed in patients treated with ramucirumab with folfiri at a rate of 30% and 2% higher than placebo with folfiri were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.  the most common adverse reactions observed in single agent ramucirumab-treated hcc patients at a rate of 15% and 2% higher than placebo were fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. the most common laboratory abnormalities at a rate of 30% and a 2% higher difference in incidence between arms were thrombocytopenia, hypoalbuminemia, and hyponatremia. ",ramucirumab
medication,placebo,0.9962139," the most common adverse reactions observed in single agent ramucirumab-treated gastric cancer patients at a rate of 10% and 2% higher than placebo were hypertension and diarrhea.  the most common adverse reactions observed in patients treated with ramucirumab with paclitaxel at a rate of 30% and 2% higher than placebo with paclitaxel were fatigue/asthenia, neutropenia, diarrhea, and epistaxis.  the most common adverse reactions observed in patients treated with ramucirumab with erlotinib at a rate of 30% and 2% higher than placebo with erlotinib were, infections, hypertension, stomatitis, proteinuria, alopecia, and epistaxis. the most common laboratory abnormalities at a rate of 30% and 2% higher difference in incidence between arms were increased alanine aminotransferase, increased aspartate aminotransferase, anemia, thrombocytopenia, and neutropenia.  the most common adverse reactions observed in patients treated with ramucirumab with docetaxel at a rate of 30% and 2% higher than placebo with docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation.  the most common adverse reactions observed in patients treated with ramucirumab with folfiri at a rate of 30% and 2% higher than placebo with folfiri were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.  the most common adverse reactions observed in single agent ramucirumab-treated hcc patients at a rate of 15% and 2% higher than placebo were fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. the most common laboratory abnormalities at a rate of 30% and a 2% higher difference in incidence between arms were thrombocytopenia, hypoalbuminemia, and hyponatremia. ",ramucirumab
sign_symptom,hypertension,0.98227495," the most common adverse reactions observed in single agent ramucirumab-treated gastric cancer patients at a rate of 10% and 2% higher than placebo were hypertension and diarrhea.  the most common adverse reactions observed in patients treated with ramucirumab with paclitaxel at a rate of 30% and 2% higher than placebo with paclitaxel were fatigue/asthenia, neutropenia, diarrhea, and epistaxis.  the most common adverse reactions observed in patients treated with ramucirumab with erlotinib at a rate of 30% and 2% higher than placebo with erlotinib were, infections, hypertension, stomatitis, proteinuria, alopecia, and epistaxis. the most common laboratory abnormalities at a rate of 30% and 2% higher difference in incidence between arms were increased alanine aminotransferase, increased aspartate aminotransferase, anemia, thrombocytopenia, and neutropenia.  the most common adverse reactions observed in patients treated with ramucirumab with docetaxel at a rate of 30% and 2% higher than placebo with docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation.  the most common adverse reactions observed in patients treated with ramucirumab with folfiri at a rate of 30% and 2% higher than placebo with folfiri were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.  the most common adverse reactions observed in single agent ramucirumab-treated hcc patients at a rate of 15% and 2% higher than placebo were fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. the most common laboratory abnormalities at a rate of 30% and a 2% higher difference in incidence between arms were thrombocytopenia, hypoalbuminemia, and hyponatremia. ",ramucirumab
medication,ramuc,0.9157939," the most common adverse reactions observed in single agent ramucirumab-treated gastric cancer patients at a rate of 10% and 2% higher than placebo were hypertension and diarrhea.  the most common adverse reactions observed in patients treated with ramucirumab with paclitaxel at a rate of 30% and 2% higher than placebo with paclitaxel were fatigue/asthenia, neutropenia, diarrhea, and epistaxis.  the most common adverse reactions observed in patients treated with ramucirumab with erlotinib at a rate of 30% and 2% higher than placebo with erlotinib were, infections, hypertension, stomatitis, proteinuria, alopecia, and epistaxis. the most common laboratory abnormalities at a rate of 30% and 2% higher difference in incidence between arms were increased alanine aminotransferase, increased aspartate aminotransferase, anemia, thrombocytopenia, and neutropenia.  the most common adverse reactions observed in patients treated with ramucirumab with docetaxel at a rate of 30% and 2% higher than placebo with docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation.  the most common adverse reactions observed in patients treated with ramucirumab with folfiri at a rate of 30% and 2% higher than placebo with folfiri were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.  the most common adverse reactions observed in single agent ramucirumab-treated hcc patients at a rate of 15% and 2% higher than placebo were fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. the most common laboratory abnormalities at a rate of 30% and a 2% higher difference in incidence between arms were thrombocytopenia, hypoalbuminemia, and hyponatremia. ",ramucirumab
medication,paclitaxel,0.98629415," the most common adverse reactions observed in single agent ramucirumab-treated gastric cancer patients at a rate of 10% and 2% higher than placebo were hypertension and diarrhea.  the most common adverse reactions observed in patients treated with ramucirumab with paclitaxel at a rate of 30% and 2% higher than placebo with paclitaxel were fatigue/asthenia, neutropenia, diarrhea, and epistaxis.  the most common adverse reactions observed in patients treated with ramucirumab with erlotinib at a rate of 30% and 2% higher than placebo with erlotinib were, infections, hypertension, stomatitis, proteinuria, alopecia, and epistaxis. the most common laboratory abnormalities at a rate of 30% and 2% higher difference in incidence between arms were increased alanine aminotransferase, increased aspartate aminotransferase, anemia, thrombocytopenia, and neutropenia.  the most common adverse reactions observed in patients treated with ramucirumab with docetaxel at a rate of 30% and 2% higher than placebo with docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation.  the most common adverse reactions observed in patients treated with ramucirumab with folfiri at a rate of 30% and 2% higher than placebo with folfiri were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.  the most common adverse reactions observed in single agent ramucirumab-treated hcc patients at a rate of 15% and 2% higher than placebo were fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. the most common laboratory abnormalities at a rate of 30% and a 2% higher difference in incidence between arms were thrombocytopenia, hypoalbuminemia, and hyponatremia. ",ramucirumab
sign_symptom,fatigue,0.99993205," the most common adverse reactions observed in single agent ramucirumab-treated gastric cancer patients at a rate of 10% and 2% higher than placebo were hypertension and diarrhea.  the most common adverse reactions observed in patients treated with ramucirumab with paclitaxel at a rate of 30% and 2% higher than placebo with paclitaxel were fatigue/asthenia, neutropenia, diarrhea, and epistaxis.  the most common adverse reactions observed in patients treated with ramucirumab with erlotinib at a rate of 30% and 2% higher than placebo with erlotinib were, infections, hypertension, stomatitis, proteinuria, alopecia, and epistaxis. the most common laboratory abnormalities at a rate of 30% and 2% higher difference in incidence between arms were increased alanine aminotransferase, increased aspartate aminotransferase, anemia, thrombocytopenia, and neutropenia.  the most common adverse reactions observed in patients treated with ramucirumab with docetaxel at a rate of 30% and 2% higher than placebo with docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation.  the most common adverse reactions observed in patients treated with ramucirumab with folfiri at a rate of 30% and 2% higher than placebo with folfiri were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.  the most common adverse reactions observed in single agent ramucirumab-treated hcc patients at a rate of 15% and 2% higher than placebo were fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. the most common laboratory abnormalities at a rate of 30% and a 2% higher difference in incidence between arms were thrombocytopenia, hypoalbuminemia, and hyponatremia. ",ramucirumab
medication,docetaxel,0.9352471," the most common adverse reactions observed in single agent ramucirumab-treated gastric cancer patients at a rate of 10% and 2% higher than placebo were hypertension and diarrhea.  the most common adverse reactions observed in patients treated with ramucirumab with paclitaxel at a rate of 30% and 2% higher than placebo with paclitaxel were fatigue/asthenia, neutropenia, diarrhea, and epistaxis.  the most common adverse reactions observed in patients treated with ramucirumab with erlotinib at a rate of 30% and 2% higher than placebo with erlotinib were, infections, hypertension, stomatitis, proteinuria, alopecia, and epistaxis. the most common laboratory abnormalities at a rate of 30% and 2% higher difference in incidence between arms were increased alanine aminotransferase, increased aspartate aminotransferase, anemia, thrombocytopenia, and neutropenia.  the most common adverse reactions observed in patients treated with ramucirumab with docetaxel at a rate of 30% and 2% higher than placebo with docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation.  the most common adverse reactions observed in patients treated with ramucirumab with folfiri at a rate of 30% and 2% higher than placebo with folfiri were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.  the most common adverse reactions observed in single agent ramucirumab-treated hcc patients at a rate of 15% and 2% higher than placebo were fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. the most common laboratory abnormalities at a rate of 30% and a 2% higher difference in incidence between arms were thrombocytopenia, hypoalbuminemia, and hyponatremia. ",ramucirumab
medication,hydroch,0.9607667," the combination of ramipril and hydrochlorothiazide is generally well tolerated. side effects commonly reported include headache, dizziness, asthenia, nausea, vomiting, hypotension, cough, weakness, diarrhoea, fever, gastric irritation, pulmonary oedema, photosensitivity, electrolyte imbalance, hyperglycaemia, hyperuricaemia and vertigo. ",ramipril + hydrochlorothiazide
sign_symptom,hyper,0.7313735," the combination of ramipril and hydrochlorothiazide is generally well tolerated. side effects commonly reported include headache, dizziness, asthenia, nausea, vomiting, hypotension, cough, weakness, diarrhoea, fever, gastric irritation, pulmonary oedema, photosensitivity, electrolyte imbalance, hyperglycaemia, hyperuricaemia and vertigo. ",ramipril + hydrochlorothiazide
sign_symptom,headache,0.9986682," ramipril is generally well tolerated. dizziness, headache, fatigue and asthenia are commonly reported side effects. other side effects occurring less frequently include symptomatic hypotension, cough, nausea, vomiting, diarrhoea, rash, urticaria, oliguria, anxiety, amnesia etc. angioneurotic oedema, anaphylactic reactions and hyperkalaemia have also been reported rarely. ",ramipril
sign_symptom,fatigue,0.9999019," ramipril is generally well tolerated. dizziness, headache, fatigue and asthenia are commonly reported side effects. other side effects occurring less frequently include symptomatic hypotension, cough, nausea, vomiting, diarrhoea, rash, urticaria, oliguria, anxiety, amnesia etc. angioneurotic oedema, anaphylactic reactions and hyperkalaemia have also been reported rarely. ",ramipril
sign_symptom,hypotens,0.90470165," ramipril is generally well tolerated. dizziness, headache, fatigue and asthenia are commonly reported side effects. other side effects occurring less frequently include symptomatic hypotension, cough, nausea, vomiting, diarrhoea, rash, urticaria, oliguria, anxiety, amnesia etc. angioneurotic oedema, anaphylactic reactions and hyperkalaemia have also been reported rarely. ",ramipril
sign_symptom,olig,0.809795," ramipril is generally well tolerated. dizziness, headache, fatigue and asthenia are commonly reported side effects. other side effects occurring less frequently include symptomatic hypotension, cough, nausea, vomiting, diarrhoea, rash, urticaria, oliguria, anxiety, amnesia etc. angioneurotic oedema, anaphylactic reactions and hyperkalaemia have also been reported rarely. ",ramipril
sign_symptom,amnesia,0.9858898," ramipril is generally well tolerated. dizziness, headache, fatigue and asthenia are commonly reported side effects. other side effects occurring less frequently include symptomatic hypotension, cough, nausea, vomiting, diarrhoea, rash, urticaria, oliguria, anxiety, amnesia etc. angioneurotic oedema, anaphylactic reactions and hyperkalaemia have also been reported rarely. ",ramipril
sign_symptom,anaphyla,0.99933916," ramipril is generally well tolerated. dizziness, headache, fatigue and asthenia are commonly reported side effects. other side effects occurring less frequently include symptomatic hypotension, cough, nausea, vomiting, diarrhoea, rash, urticaria, oliguria, anxiety, amnesia etc. angioneurotic oedema, anaphylactic reactions and hyperkalaemia have also been reported rarely. ",ramipril
sign_symptom,hyper,0.99997175," ramipril is generally well tolerated. dizziness, headache, fatigue and asthenia are commonly reported side effects. other side effects occurring less frequently include symptomatic hypotension, cough, nausea, vomiting, diarrhoea, rash, urticaria, oliguria, anxiety, amnesia etc. angioneurotic oedema, anaphylactic reactions and hyperkalaemia have also been reported rarely. ",ramipril
sign_symptom,adverse reactions,0.9836196,"  most common adverse reactions (3% and more common than with placebo) are : somnolence, dizziness, fatigue, nausea, and exacerbated insomnia ",ramelteon
sign_symptom,fatigue,0.8652,"  most common adverse reactions (3% and more common than with placebo) are : somnolence, dizziness, fatigue, nausea, and exacerbated insomnia ",ramelteon
sign_symptom,insomnia,0.98224235,"  most common adverse reactions (3% and more common than with placebo) are : somnolence, dizziness, fatigue, nausea, and exacerbated insomnia ",ramelteon
medication,race,0.99751675," side effects of racepinephrine includes headache, loss of appetite, nausea &amp; vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis. severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. besides, elevations of heart rate and blood pressure or arrhythmias may occur. cardiac patients with coronary artery disease or hypertension may worsen condition. ",racepinephrine
sign_symptom,loss of appetite,0.96282274," side effects of racepinephrine includes headache, loss of appetite, nausea &amp; vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis. severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. besides, elevations of heart rate and blood pressure or arrhythmias may occur. cardiac patients with coronary artery disease or hypertension may worsen condition. ",racepinephrine
sign_symptom,nausea,0.9992993," side effects of racepinephrine includes headache, loss of appetite, nausea &amp; vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis. severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. besides, elevations of heart rate and blood pressure or arrhythmias may occur. cardiac patients with coronary artery disease or hypertension may worsen condition. ",racepinephrine
sign_symptom,allergic reactions,0.99959207," side effects of racepinephrine includes headache, loss of appetite, nausea &amp; vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis. severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. besides, elevations of heart rate and blood pressure or arrhythmias may occur. cardiac patients with coronary artery disease or hypertension may worsen condition. ",racepinephrine
sign_symptom,rash,0.9963415," side effects of racepinephrine includes headache, loss of appetite, nausea &amp; vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis. severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. besides, elevations of heart rate and blood pressure or arrhythmias may occur. cardiac patients with coronary artery disease or hypertension may worsen condition. ",racepinephrine
sign_symptom,difficulty,0.9801705," side effects of racepinephrine includes headache, loss of appetite, nausea &amp; vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis. severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. besides, elevations of heart rate and blood pressure or arrhythmias may occur. cardiac patients with coronary artery disease or hypertension may worsen condition. ",racepinephrine
sign_symptom,swelling,0.9998429," side effects of racepinephrine includes headache, loss of appetite, nausea &amp; vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis. severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. besides, elevations of heart rate and blood pressure or arrhythmias may occur. cardiac patients with coronary artery disease or hypertension may worsen condition. ",racepinephrine
sign_symptom,pain,0.9998344," side effects of racepinephrine includes headache, loss of appetite, nausea &amp; vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis. severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. besides, elevations of heart rate and blood pressure or arrhythmias may occur. cardiac patients with coronary artery disease or hypertension may worsen condition. ",racepinephrine
sign_symptom,fast heartbeat,0.7094278," side effects of racepinephrine includes headache, loss of appetite, nausea &amp; vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis. severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. besides, elevations of heart rate and blood pressure or arrhythmias may occur. cardiac patients with coronary artery disease or hypertension may worsen condition. ",racepinephrine
disease_disorder,coronary artery disease,0.989137," side effects of racepinephrine includes headache, loss of appetite, nausea &amp; vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis. severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. besides, elevations of heart rate and blood pressure or arrhythmias may occur. cardiac patients with coronary artery disease or hypertension may worsen condition. ",racepinephrine
disease_disorder,hypertension,0.9848592," side effects of racepinephrine includes headache, loss of appetite, nausea &amp; vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis. severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. besides, elevations of heart rate and blood pressure or arrhythmias may occur. cardiac patients with coronary artery disease or hypertension may worsen condition. ",racepinephrine
sign_symptom,induration,0.9978236," minor local reactions like pain, erythema, oedema, pruritus and induration at the injection site and lasting to 24-48 hours. moderate fever, shivering, fainting, asthenia, dizziness, respiratory manifestations (dyspnoea, wheezing), fever, abdominal pain, vomiting and allergic skin reactions (urticaria, rash, itching). ",rabies vaccine
sign_symptom,manifestation,0.92689407," minor local reactions like pain, erythema, oedema, pruritus and induration at the injection site and lasting to 24-48 hours. moderate fever, shivering, fainting, asthenia, dizziness, respiratory manifestations (dyspnoea, wheezing), fever, abdominal pain, vomiting and allergic skin reactions (urticaria, rash, itching). ",rabies vaccine
sign_symptom,vomiting,0.9874111," minor local reactions like pain, erythema, oedema, pruritus and induration at the injection site and lasting to 24-48 hours. moderate fever, shivering, fainting, asthenia, dizziness, respiratory manifestations (dyspnoea, wheezing), fever, abdominal pain, vomiting and allergic skin reactions (urticaria, rash, itching). ",rabies vaccine
sign_symptom,skin reactions,0.8550981," minor local reactions like pain, erythema, oedema, pruritus and induration at the injection site and lasting to 24-48 hours. moderate fever, shivering, fainting, asthenia, dizziness, respiratory manifestations (dyspnoea, wheezing), fever, abdominal pain, vomiting and allergic skin reactions (urticaria, rash, itching). ",rabies vaccine
disease_disorder,general,0.7975442,"  general disorders : fatigue.  metabolism and nutrition disorders : decreased appetite, weight decreased.  musculoskeletal and connective tissue disorders : back pain, muscle spasms.  nervous system disorders : dizziness, headache, tremor.  psychiatric disorders : anxiety, depression, insomnia. ",roflumilast
sign_symptom,fatigue,0.78655016,"  general disorders : fatigue.  metabolism and nutrition disorders : decreased appetite, weight decreased.  musculoskeletal and connective tissue disorders : back pain, muscle spasms.  nervous system disorders : dizziness, headache, tremor.  psychiatric disorders : anxiety, depression, insomnia. ",roflumilast
sign_symptom,hyper,0.95022166," in clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. other are: 
 
 anaphylaxis 
 residual paralysis 
 myopathy 
 increased pulmonary vascular resistance 
 
although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). these reactions have, in some cases, been fatal. due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.  since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematosus reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these agents.in clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3 0.9mg/kg rocuronium bromide.   prolonged neuromuscular block : the most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of the agent's pharmacological action beyond the time period needed. this may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.   myopathy : myopathy has been reported after the use of various neuromuscular blocking agents in the icu in combination with corticosteroids.   local injection site reactions : during rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. in clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental. ",rocuronium bromide
sign_symptom,anaphyla,0.9925456," in clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. other are: 
 
 anaphylaxis 
 residual paralysis 
 myopathy 
 increased pulmonary vascular resistance 
 
although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). these reactions have, in some cases, been fatal. due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.  since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematosus reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these agents.in clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3 0.9mg/kg rocuronium bromide.   prolonged neuromuscular block : the most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of the agent's pharmacological action beyond the time period needed. this may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.   myopathy : myopathy has been reported after the use of various neuromuscular blocking agents in the icu in combination with corticosteroids.   local injection site reactions : during rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. in clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental. ",rocuronium bromide
sign_symptom,paralysis,0.999884," in clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. other are: 
 
 anaphylaxis 
 residual paralysis 
 myopathy 
 increased pulmonary vascular resistance 
 
although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). these reactions have, in some cases, been fatal. due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.  since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematosus reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these agents.in clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3 0.9mg/kg rocuronium bromide.   prolonged neuromuscular block : the most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of the agent's pharmacological action beyond the time period needed. this may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.   myopathy : myopathy has been reported after the use of various neuromuscular blocking agents in the icu in combination with corticosteroids.   local injection site reactions : during rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. in clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental. ",rocuronium bromide
sign_symptom,myopathy,0.9353133," in clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. other are: 
 
 anaphylaxis 
 residual paralysis 
 myopathy 
 increased pulmonary vascular resistance 
 
although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). these reactions have, in some cases, been fatal. due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.  since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematosus reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these agents.in clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3 0.9mg/kg rocuronium bromide.   prolonged neuromuscular block : the most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of the agent's pharmacological action beyond the time period needed. this may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.   myopathy : myopathy has been reported after the use of various neuromuscular blocking agents in the icu in combination with corticosteroids.   local injection site reactions : during rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. in clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental. ",rocuronium bromide
sign_symptom,cardiovascular changes,0.93474996," in clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. other are: 
 
 anaphylaxis 
 residual paralysis 
 myopathy 
 increased pulmonary vascular resistance 
 
although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). these reactions have, in some cases, been fatal. due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.  since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematosus reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these agents.in clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3 0.9mg/kg rocuronium bromide.   prolonged neuromuscular block : the most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of the agent's pharmacological action beyond the time period needed. this may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.   myopathy : myopathy has been reported after the use of various neuromuscular blocking agents in the icu in combination with corticosteroids.   local injection site reactions : during rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. in clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental. ",rocuronium bromide
sign_symptom,weakness,0.90706295," in clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. other are: 
 
 anaphylaxis 
 residual paralysis 
 myopathy 
 increased pulmonary vascular resistance 
 
although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). these reactions have, in some cases, been fatal. due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.  since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematosus reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these agents.in clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3 0.9mg/kg rocuronium bromide.   prolonged neuromuscular block : the most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of the agent's pharmacological action beyond the time period needed. this may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.   myopathy : myopathy has been reported after the use of various neuromuscular blocking agents in the icu in combination with corticosteroids.   local injection site reactions : during rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. in clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental. ",rocuronium bromide
sign_symptom,pain,0.9999409," in clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. other are: 
 
 anaphylaxis 
 residual paralysis 
 myopathy 
 increased pulmonary vascular resistance 
 
although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). these reactions have, in some cases, been fatal. due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.  since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematosus reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these agents.in clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3 0.9mg/kg rocuronium bromide.   prolonged neuromuscular block : the most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of the agent's pharmacological action beyond the time period needed. this may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.   myopathy : myopathy has been reported after the use of various neuromuscular blocking agents in the icu in combination with corticosteroids.   local injection site reactions : during rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. in clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental. ",rocuronium bromide
sign_symptom,lost consciousness,0.9963985," in clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. other are: 
 
 anaphylaxis 
 residual paralysis 
 myopathy 
 increased pulmonary vascular resistance 
 
although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). these reactions have, in some cases, been fatal. due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.  since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematosus reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these agents.in clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3 0.9mg/kg rocuronium bromide.   prolonged neuromuscular block : the most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of the agent's pharmacological action beyond the time period needed. this may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.   myopathy : myopathy has been reported after the use of various neuromuscular blocking agents in the icu in combination with corticosteroids.   local injection site reactions : during rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. in clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental. ",rocuronium bromide
medication,propof,0.7540138," in clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. other are: 
 
 anaphylaxis 
 residual paralysis 
 myopathy 
 increased pulmonary vascular resistance 
 
although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). these reactions have, in some cases, been fatal. due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.  since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematosus reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these agents.in clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3 0.9mg/kg rocuronium bromide.   prolonged neuromuscular block : the most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of the agent's pharmacological action beyond the time period needed. this may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.   myopathy : myopathy has been reported after the use of various neuromuscular blocking agents in the icu in combination with corticosteroids.   local injection site reactions : during rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. in clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental. ",rocuronium bromide
medication,propofol,0.83094525," in clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. other are: 
 
 anaphylaxis 
 residual paralysis 
 myopathy 
 increased pulmonary vascular resistance 
 
although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). these reactions have, in some cases, been fatal. due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.  since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematosus reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these agents.in clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3 0.9mg/kg rocuronium bromide.   prolonged neuromuscular block : the most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of the agent's pharmacological action beyond the time period needed. this may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.   myopathy : myopathy has been reported after the use of various neuromuscular blocking agents in the icu in combination with corticosteroids.   local injection site reactions : during rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. in clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental. ",rocuronium bromide
sign_symptom,adverse reactions,0.9995637," the following adverse reactions are discussed in more detail in other sections of the labeling: 
 
 myocardialischemia,myocardial infarction, and prinzmetal'sangina 
 arrhythmias 
 chest, throat, neck and/or jaw pain/tightness/pressure 
 cerebrovascularevents 
 other vasospasm reactions 
 medication overuse headache 
 serotoninsyndrome 
 increase in blood pressure 
  ",rizatriptan benzoate
sign_symptom,pain,0.9999633," the following adverse reactions are discussed in more detail in other sections of the labeling: 
 
 myocardialischemia,myocardial infarction, and prinzmetal'sangina 
 arrhythmias 
 chest, throat, neck and/or jaw pain/tightness/pressure 
 cerebrovascularevents 
 other vasospasm reactions 
 medication overuse headache 
 serotoninsyndrome 
 increase in blood pressure 
  ",rizatriptan benzoate
sign_symptom,tightness / pressure,0.9990521," the following adverse reactions are discussed in more detail in other sections of the labeling: 
 
 myocardialischemia,myocardial infarction, and prinzmetal'sangina 
 arrhythmias 
 chest, throat, neck and/or jaw pain/tightness/pressure 
 cerebrovascularevents 
 other vasospasm reactions 
 medication overuse headache 
 serotoninsyndrome 
 increase in blood pressure 
  ",rizatriptan benzoate
sign_symptom,cere,0.76567495," the following adverse reactions are discussed in more detail in other sections of the labeling: 
 
 myocardialischemia,myocardial infarction, and prinzmetal'sangina 
 arrhythmias 
 chest, throat, neck and/or jaw pain/tightness/pressure 
 cerebrovascularevents 
 other vasospasm reactions 
 medication overuse headache 
 serotoninsyndrome 
 increase in blood pressure 
  ",rizatriptan benzoate
medication,medication,0.99933004," the following adverse reactions are discussed in more detail in other sections of the labeling: 
 
 myocardialischemia,myocardial infarction, and prinzmetal'sangina 
 arrhythmias 
 chest, throat, neck and/or jaw pain/tightness/pressure 
 cerebrovascularevents 
 other vasospasm reactions 
 medication overuse headache 
 serotoninsyndrome 
 increase in blood pressure 
  ",rizatriptan benzoate
sign_symptom,headache,0.99993575," the following adverse reactions are discussed in more detail in other sections of the labeling: 
 
 myocardialischemia,myocardial infarction, and prinzmetal'sangina 
 arrhythmias 
 chest, throat, neck and/or jaw pain/tightness/pressure 
 cerebrovascularevents 
 other vasospasm reactions 
 medication overuse headache 
 serotoninsyndrome 
 increase in blood pressure 
  ",rizatriptan benzoate
medication,serotoninsyndrome,0.76692325," the following adverse reactions are discussed in more detail in other sections of the labeling: 
 
 myocardialischemia,myocardial infarction, and prinzmetal'sangina 
 arrhythmias 
 chest, throat, neck and/or jaw pain/tightness/pressure 
 cerebrovascularevents 
 other vasospasm reactions 
 medication overuse headache 
 serotoninsyndrome 
 increase in blood pressure 
  ",rizatriptan benzoate
sign_symptom,adverse reactions,0.9665254," the most commonly reported adverse reactions are gastrointestinal,including nausea (38%) and vomiting (23%), especially during titration. female patientsin clinical studies were found to be more susceptible than male patients togastrointestinal adverse reactions and weight loss. ",rivastigmine tartrate
sign_symptom,nausea,0.99993193," the most commonly reported adverse reactions are gastrointestinal,including nausea (38%) and vomiting (23%), especially during titration. female patientsin clinical studies were found to be more susceptible than male patients togastrointestinal adverse reactions and weight loss. ",rivastigmine tartrate
sign_symptom,vomiting,0.9999255," the most commonly reported adverse reactions are gastrointestinal,including nausea (38%) and vomiting (23%), especially during titration. female patientsin clinical studies were found to be more susceptible than male patients togastrointestinal adverse reactions and weight loss. ",rivastigmine tartrate
sign_symptom,adverse,0.99979585," the most commonly reported adverse reactions are gastrointestinal,including nausea (38%) and vomiting (23%), especially during titration. female patientsin clinical studies were found to be more susceptible than male patients togastrointestinal adverse reactions and weight loss. ",rivastigmine tartrate
disease_disorder,stroke,0.9912916," the most common side effects of rivaroxaban have increased chance of bleeding, spinal or epidural hematoma and increased risk of stroke after discontinuation in nonvalvular atrial fibrillation. ",rivaroxaban
disease_disorder,hepatitis b,0.8843883," reactivation of hepatitis b virus. fever and rigors. pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, asthenia, headache, rhinitis, thrombocytopenia, neutropenia, anaemia, abdominal pain, bowel obstruction, and perforation. exacerbation of heart failure and angina pectoris. reversible interstitial pneumonia and interstitial fibrosis. depletion of immunoglobulin concentrations. ",rituximab
sign_symptom,fever,0.98462105," reactivation of hepatitis b virus. fever and rigors. pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, asthenia, headache, rhinitis, thrombocytopenia, neutropenia, anaemia, abdominal pain, bowel obstruction, and perforation. exacerbation of heart failure and angina pectoris. reversible interstitial pneumonia and interstitial fibrosis. depletion of immunoglobulin concentrations. ",rituximab
sign_symptom,rash,0.99990666," reactivation of hepatitis b virus. fever and rigors. pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, asthenia, headache, rhinitis, thrombocytopenia, neutropenia, anaemia, abdominal pain, bowel obstruction, and perforation. exacerbation of heart failure and angina pectoris. reversible interstitial pneumonia and interstitial fibrosis. depletion of immunoglobulin concentrations. ",rituximab
disease_disorder,heart failure,0.9997817," reactivation of hepatitis b virus. fever and rigors. pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, asthenia, headache, rhinitis, thrombocytopenia, neutropenia, anaemia, abdominal pain, bowel obstruction, and perforation. exacerbation of heart failure and angina pectoris. reversible interstitial pneumonia and interstitial fibrosis. depletion of immunoglobulin concentrations. ",rituximab
disease_disorder,angina pector,0.9868901," reactivation of hepatitis b virus. fever and rigors. pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, asthenia, headache, rhinitis, thrombocytopenia, neutropenia, anaemia, abdominal pain, bowel obstruction, and perforation. exacerbation of heart failure and angina pectoris. reversible interstitial pneumonia and interstitial fibrosis. depletion of immunoglobulin concentrations. ",rituximab
disease_disorder,pneumonia,0.9996997," reactivation of hepatitis b virus. fever and rigors. pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, asthenia, headache, rhinitis, thrombocytopenia, neutropenia, anaemia, abdominal pain, bowel obstruction, and perforation. exacerbation of heart failure and angina pectoris. reversible interstitial pneumonia and interstitial fibrosis. depletion of immunoglobulin concentrations. ",rituximab
medication,ritodrine hydrochloride,0.98364234," the common side-effects of ritodrine hydrochloride are nausea, vomiting, flushing, sweating, tremor, hypokalaemia, tachycardia, palpitations, hypotension (left lateral position throughout infusion to minimize risk), uterine bleeding, pulmonary oedema; chest pain or tightness, arrhythmias and salivary gland enlargement. on prolonged administration for several weeks may cause leucopenia and agranulocytosis; liver function abnormalities including increased transaminases and hepatitis. ",ritodrine hydrochloride
sign_symptom,palpit,0.98008937," the common side-effects of ritodrine hydrochloride are nausea, vomiting, flushing, sweating, tremor, hypokalaemia, tachycardia, palpitations, hypotension (left lateral position throughout infusion to minimize risk), uterine bleeding, pulmonary oedema; chest pain or tightness, arrhythmias and salivary gland enlargement. on prolonged administration for several weeks may cause leucopenia and agranulocytosis; liver function abnormalities including increased transaminases and hepatitis. ",ritodrine hydrochloride
sign_symptom,pain,0.99978024," the common side-effects of ritodrine hydrochloride are nausea, vomiting, flushing, sweating, tremor, hypokalaemia, tachycardia, palpitations, hypotension (left lateral position throughout infusion to minimize risk), uterine bleeding, pulmonary oedema; chest pain or tightness, arrhythmias and salivary gland enlargement. on prolonged administration for several weeks may cause leucopenia and agranulocytosis; liver function abnormalities including increased transaminases and hepatitis. ",ritodrine hydrochloride
sign_symptom,leucopenia,0.70505714," the common side-effects of ritodrine hydrochloride are nausea, vomiting, flushing, sweating, tremor, hypokalaemia, tachycardia, palpitations, hypotension (left lateral position throughout infusion to minimize risk), uterine bleeding, pulmonary oedema; chest pain or tightness, arrhythmias and salivary gland enlargement. on prolonged administration for several weeks may cause leucopenia and agranulocytosis; liver function abnormalities including increased transaminases and hepatitis. ",ritodrine hydrochloride
disease_disorder,agra,0.74187523," the common side-effects of ritodrine hydrochloride are nausea, vomiting, flushing, sweating, tremor, hypokalaemia, tachycardia, palpitations, hypotension (left lateral position throughout infusion to minimize risk), uterine bleeding, pulmonary oedema; chest pain or tightness, arrhythmias and salivary gland enlargement. on prolonged administration for several weeks may cause leucopenia and agranulocytosis; liver function abnormalities including increased transaminases and hepatitis. ",ritodrine hydrochloride
sign_symptom,impaired concentration,0.9996505," insomnia, agitation, anxiety, headache, less commonly drowsiness, impaired concentration, fatigue, blurred vision, constipation, nausea and vomiting, dyspepsia, abdominal pain, hyperprolactinaemia, urine incontinence, tachycardia, hypertension, edema, rash, rhinitis, cerebrovascular accident, neurtropenia and thrombocytopenia have been reported. ",risperidone (oral)
sign_symptom,fatigue,0.82037824," insomnia, agitation, anxiety, headache, less commonly drowsiness, impaired concentration, fatigue, blurred vision, constipation, nausea and vomiting, dyspepsia, abdominal pain, hyperprolactinaemia, urine incontinence, tachycardia, hypertension, edema, rash, rhinitis, cerebrovascular accident, neurtropenia and thrombocytopenia have been reported. ",risperidone (oral)
sign_symptom,blurred vision,0.99833566," insomnia, agitation, anxiety, headache, less commonly drowsiness, impaired concentration, fatigue, blurred vision, constipation, nausea and vomiting, dyspepsia, abdominal pain, hyperprolactinaemia, urine incontinence, tachycardia, hypertension, edema, rash, rhinitis, cerebrovascular accident, neurtropenia and thrombocytopenia have been reported. ",risperidone (oral)
sign_symptom,consti,0.99737656," insomnia, agitation, anxiety, headache, less commonly drowsiness, impaired concentration, fatigue, blurred vision, constipation, nausea and vomiting, dyspepsia, abdominal pain, hyperprolactinaemia, urine incontinence, tachycardia, hypertension, edema, rash, rhinitis, cerebrovascular accident, neurtropenia and thrombocytopenia have been reported. ",risperidone (oral)
sign_symptom,nausea,0.9998704," insomnia, agitation, anxiety, headache, less commonly drowsiness, impaired concentration, fatigue, blurred vision, constipation, nausea and vomiting, dyspepsia, abdominal pain, hyperprolactinaemia, urine incontinence, tachycardia, hypertension, edema, rash, rhinitis, cerebrovascular accident, neurtropenia and thrombocytopenia have been reported. ",risperidone (oral)
sign_symptom,dyspeps,0.999652," insomnia, agitation, anxiety, headache, less commonly drowsiness, impaired concentration, fatigue, blurred vision, constipation, nausea and vomiting, dyspepsia, abdominal pain, hyperprolactinaemia, urine incontinence, tachycardia, hypertension, edema, rash, rhinitis, cerebrovascular accident, neurtropenia and thrombocytopenia have been reported. ",risperidone (oral)
sign_symptom,hyper,0.9190596," insomnia, agitation, anxiety, headache, less commonly drowsiness, impaired concentration, fatigue, blurred vision, constipation, nausea and vomiting, dyspepsia, abdominal pain, hyperprolactinaemia, urine incontinence, tachycardia, hypertension, edema, rash, rhinitis, cerebrovascular accident, neurtropenia and thrombocytopenia have been reported. ",risperidone (oral)
sign_symptom,tachycard,0.91031474," insomnia, agitation, anxiety, headache, less commonly drowsiness, impaired concentration, fatigue, blurred vision, constipation, nausea and vomiting, dyspepsia, abdominal pain, hyperprolactinaemia, urine incontinence, tachycardia, hypertension, edema, rash, rhinitis, cerebrovascular accident, neurtropenia and thrombocytopenia have been reported. ",risperidone (oral)
sign_symptom,neurtropenia,0.9995597," insomnia, agitation, anxiety, headache, less commonly drowsiness, impaired concentration, fatigue, blurred vision, constipation, nausea and vomiting, dyspepsia, abdominal pain, hyperprolactinaemia, urine incontinence, tachycardia, hypertension, edema, rash, rhinitis, cerebrovascular accident, neurtropenia and thrombocytopenia have been reported. ",risperidone (oral)
disease_disorder,psychosis,0.9554281,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
disease_disorder,cerebrovas,0.7550921,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
disease_disorder,adverse,0.9847001,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
disease_disorder,neuroleptic malignant syndrome,0.96339035,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
sign_symptom,metabolic changes,0.99963534,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
sign_symptom,hyper,0.9999366,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
sign_symptom,hypotension falls,0.99668646,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
sign_symptom,leukopenia,0.99931455,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
sign_symptom,agranu,0.99874604,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
sign_symptom,cognitive,0.8068215,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
sign_symptom,motor impairment,0.9989774,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
sign_symptom,seizures,0.999931,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
sign_symptom,priapism,0.9834638,"  
 increased mortality in elderly patients with dementia-related psychosis 
 cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis 
 neuroleptic malignant syndrome 
 tardive dyskinesia 
 metabolic changes 
 hyperprolactinemia 
 orthostatic hypotension 
 falls 
 leukopenia/neutropenia and agranulocytosis 
 potential for cognitive and motor impairment 
 seizures 
 dysphagia 
 priapism 
 thrombotic thrombocytopenic purpura (ttp) 
 disruption of body temperature regulation 
 avoidance of inadvertent injection into a blood vessel 
  ",risperidone (injection)
sign_symptom,difficulty,0.9992256," chest pain, difficulty or pain when swallowing, pain or burning under the ribs or in the back, new or worsening heartburn, severe joint, bone, or muscle pain, jaw pain, numbness, or swelling, mild heartburn or stomach upset, diarrhea, gas, or constipation, mild joint or back pain, headache. ",risedronate sodium + calcium
sign_symptom,pain,0.999895," chest pain, difficulty or pain when swallowing, pain or burning under the ribs or in the back, new or worsening heartburn, severe joint, bone, or muscle pain, jaw pain, numbness, or swelling, mild heartburn or stomach upset, diarrhea, gas, or constipation, mild joint or back pain, headache. ",risedronate sodium + calcium
sign_symptom,burning,0.9993191," chest pain, difficulty or pain when swallowing, pain or burning under the ribs or in the back, new or worsening heartburn, severe joint, bone, or muscle pain, jaw pain, numbness, or swelling, mild heartburn or stomach upset, diarrhea, gas, or constipation, mild joint or back pain, headache. ",risedronate sodium + calcium
sign_symptom,difficulty,0.99971515," serious side effects: 
 
 chest pain; 
 difficulty or pain when swallowing; 
 pain or burning under the ribs or in the back; 
 new or worsening heartburn; 
 severe joint, bone, or muscle pain; or 
 jaw pain, numbness, or swelling. 
 
less serious side effects: 
 
 mild heartburn or stomach upset; 
 diarrhea, gas,or constipation; 
 mild joint or back pain; 
 headache. 
  ",risedronate sodium
sign_symptom,pain,0.9989868," serious side effects: 
 
 chest pain; 
 difficulty or pain when swallowing; 
 pain or burning under the ribs or in the back; 
 new or worsening heartburn; 
 severe joint, bone, or muscle pain; or 
 jaw pain, numbness, or swelling. 
 
less serious side effects: 
 
 mild heartburn or stomach upset; 
 diarrhea, gas,or constipation; 
 mild joint or back pain; 
 headache. 
  ",risedronate sodium
sign_symptom,burning,0.99304056," serious side effects: 
 
 chest pain; 
 difficulty or pain when swallowing; 
 pain or burning under the ribs or in the back; 
 new or worsening heartburn; 
 severe joint, bone, or muscle pain; or 
 jaw pain, numbness, or swelling. 
 
less serious side effects: 
 
 mild heartburn or stomach upset; 
 diarrhea, gas,or constipation; 
 mild joint or back pain; 
 headache. 
  ",risedronate sodium
sign_symptom,reactions,0.9326067," reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. ",ringer's lactate solution
disease_disorder,infection,0.8110956," reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. ",ringer's lactate solution
disease_disorder,phlebitis,0.8410331," reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. ",ringer's lactate solution
sign_symptom,acuity,0.8243549," reactions associated with ophthalmic steroids include elevatedintraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of thecorneaorsclera.  ocular adverse reactions occurring in 1 - 5% of patients in clinical studies of rimexolone1% (rimexolone ophthalmic suspension) includedblurred vision, discharge, discomfort, ocular pain, increased intraocular pressure, foreign body sensation, hyperemia andpruritus.  other ocular adverse reactions occurring in less than 1% of patients included sticky sensation, increasedfibrin, dry eye, conjunctival edema, corneal staining,keratitis, tearing,photophobia, edema, irritation, corneal ulcer, browache, lid margin crusting, corneal edema,infiltrate, and corneal erosion.  non-ocular adverse reactions occurred in less than 2% of patients. these included headache, hypotension, rhinitis, pharyngitis, and taste perversion. ",rimexolone
disease_disorder,perforation,0.8964359," reactions associated with ophthalmic steroids include elevatedintraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of thecorneaorsclera.  ocular adverse reactions occurring in 1 - 5% of patients in clinical studies of rimexolone1% (rimexolone ophthalmic suspension) includedblurred vision, discharge, discomfort, ocular pain, increased intraocular pressure, foreign body sensation, hyperemia andpruritus.  other ocular adverse reactions occurring in less than 1% of patients included sticky sensation, increasedfibrin, dry eye, conjunctival edema, corneal staining,keratitis, tearing,photophobia, edema, irritation, corneal ulcer, browache, lid margin crusting, corneal edema,infiltrate, and corneal erosion.  non-ocular adverse reactions occurred in less than 2% of patients. these included headache, hypotension, rhinitis, pharyngitis, and taste perversion. ",rimexolone
sign_symptom,thin,0.9986823," reactions associated with ophthalmic steroids include elevatedintraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of thecorneaorsclera.  ocular adverse reactions occurring in 1 - 5% of patients in clinical studies of rimexolone1% (rimexolone ophthalmic suspension) includedblurred vision, discharge, discomfort, ocular pain, increased intraocular pressure, foreign body sensation, hyperemia andpruritus.  other ocular adverse reactions occurring in less than 1% of patients included sticky sensation, increasedfibrin, dry eye, conjunctival edema, corneal staining,keratitis, tearing,photophobia, edema, irritation, corneal ulcer, browache, lid margin crusting, corneal edema,infiltrate, and corneal erosion.  non-ocular adverse reactions occurred in less than 2% of patients. these included headache, hypotension, rhinitis, pharyngitis, and taste perversion. ",rimexolone
sign_symptom,adverse reactions,0.9758154," reactions associated with ophthalmic steroids include elevatedintraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of thecorneaorsclera.  ocular adverse reactions occurring in 1 - 5% of patients in clinical studies of rimexolone1% (rimexolone ophthalmic suspension) includedblurred vision, discharge, discomfort, ocular pain, increased intraocular pressure, foreign body sensation, hyperemia andpruritus.  other ocular adverse reactions occurring in less than 1% of patients included sticky sensation, increasedfibrin, dry eye, conjunctival edema, corneal staining,keratitis, tearing,photophobia, edema, irritation, corneal ulcer, browache, lid margin crusting, corneal edema,infiltrate, and corneal erosion.  non-ocular adverse reactions occurred in less than 2% of patients. these included headache, hypotension, rhinitis, pharyngitis, and taste perversion. ",rimexolone
medication,rimex,0.79965687," reactions associated with ophthalmic steroids include elevatedintraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of thecorneaorsclera.  ocular adverse reactions occurring in 1 - 5% of patients in clinical studies of rimexolone1% (rimexolone ophthalmic suspension) includedblurred vision, discharge, discomfort, ocular pain, increased intraocular pressure, foreign body sensation, hyperemia andpruritus.  other ocular adverse reactions occurring in less than 1% of patients included sticky sensation, increasedfibrin, dry eye, conjunctival edema, corneal staining,keratitis, tearing,photophobia, edema, irritation, corneal ulcer, browache, lid margin crusting, corneal edema,infiltrate, and corneal erosion.  non-ocular adverse reactions occurred in less than 2% of patients. these included headache, hypotension, rhinitis, pharyngitis, and taste perversion. ",rimexolone
sign_symptom,foreign,0.83486134," reactions associated with ophthalmic steroids include elevatedintraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of thecorneaorsclera.  ocular adverse reactions occurring in 1 - 5% of patients in clinical studies of rimexolone1% (rimexolone ophthalmic suspension) includedblurred vision, discharge, discomfort, ocular pain, increased intraocular pressure, foreign body sensation, hyperemia andpruritus.  other ocular adverse reactions occurring in less than 1% of patients included sticky sensation, increasedfibrin, dry eye, conjunctival edema, corneal staining,keratitis, tearing,photophobia, edema, irritation, corneal ulcer, browache, lid margin crusting, corneal edema,infiltrate, and corneal erosion.  non-ocular adverse reactions occurred in less than 2% of patients. these included headache, hypotension, rhinitis, pharyngitis, and taste perversion. ",rimexolone
sign_symptom,adverse,0.95023113," reactions associated with ophthalmic steroids include elevatedintraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of thecorneaorsclera.  ocular adverse reactions occurring in 1 - 5% of patients in clinical studies of rimexolone1% (rimexolone ophthalmic suspension) includedblurred vision, discharge, discomfort, ocular pain, increased intraocular pressure, foreign body sensation, hyperemia andpruritus.  other ocular adverse reactions occurring in less than 1% of patients included sticky sensation, increasedfibrin, dry eye, conjunctival edema, corneal staining,keratitis, tearing,photophobia, edema, irritation, corneal ulcer, browache, lid margin crusting, corneal edema,infiltrate, and corneal erosion.  non-ocular adverse reactions occurred in less than 2% of patients. these included headache, hypotension, rhinitis, pharyngitis, and taste perversion. ",rimexolone
sign_symptom,adverse reactions,0.99989176," the following adverse reactions are described below and elsewhere in the labeling: hepatic injury, neutropenia, interstitial lung disease ",riluzole
disease_disorder,interstitial lung disease,0.9916401," the following adverse reactions are described below and elsewhere in the labeling: hepatic injury, neutropenia, interstitial lung disease ",riluzole
sign_symptom,disco,0.8916623,"  rifampicin:  reddish discolouration of body fluids, asymptomatic increase in liver enzymes, elevations of bun &amp; uric acid, hemolysis, hematuria, intestinal nephritis, renal insufficiency, gl discomfort, cns effects, hematological changes, skin rash, endocrine effects.   isoniazid:  disturbances of liver function, hepatitis, gl disturbances, peripheral neuropathy, dizziness, lightheadedness, hematological changes, allergic reactions.    pyrazinamide:  transient rise in serum transaminases, hepatotoxicity, hepatomegaly, jaundice, hyperuricemia, intestinal nephritis, dysuria, gl disturbances, hematological changes, allergic reactions.   ethambutol:  confusion, disorientation, headache, visual disturbances, jaundice, transient liver dysfunction, gl disturbances, hematological changes, allergic effects, acute gout (rare). ",rifampicin + isoniazid + pyrazinamide + ethambutol
sign_symptom,light,0.92363477,"  rifampicin:  reddish discolouration of body fluids, asymptomatic increase in liver enzymes, elevations of bun &amp; uric acid, hemolysis, hematuria, intestinal nephritis, renal insufficiency, gl discomfort, cns effects, hematological changes, skin rash, endocrine effects.   isoniazid:  disturbances of liver function, hepatitis, gl disturbances, peripheral neuropathy, dizziness, lightheadedness, hematological changes, allergic reactions.    pyrazinamide:  transient rise in serum transaminases, hepatotoxicity, hepatomegaly, jaundice, hyperuricemia, intestinal nephritis, dysuria, gl disturbances, hematological changes, allergic reactions.   ethambutol:  confusion, disorientation, headache, visual disturbances, jaundice, transient liver dysfunction, gl disturbances, hematological changes, allergic effects, acute gout (rare). ",rifampicin + isoniazid + pyrazinamide + ethambutol
sign_symptom,hyperurice,0.9585931,"  rifampicin:  reddish discolouration of body fluids, asymptomatic increase in liver enzymes, elevations of bun &amp; uric acid, hemolysis, hematuria, intestinal nephritis, renal insufficiency, gl discomfort, cns effects, hematological changes, skin rash, endocrine effects.   isoniazid:  disturbances of liver function, hepatitis, gl disturbances, peripheral neuropathy, dizziness, lightheadedness, hematological changes, allergic reactions.    pyrazinamide:  transient rise in serum transaminases, hepatotoxicity, hepatomegaly, jaundice, hyperuricemia, intestinal nephritis, dysuria, gl disturbances, hematological changes, allergic reactions.   ethambutol:  confusion, disorientation, headache, visual disturbances, jaundice, transient liver dysfunction, gl disturbances, hematological changes, allergic effects, acute gout (rare). ",rifampicin + isoniazid + pyrazinamide + ethambutol
sign_symptom,discolouration,0.7028458,"  unwanted effects which may occur during continuous daily or intermittent therapy : rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects:  elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency.   gastrointestinal effects : nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects:  tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances.   haematological changes:  leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura.   effects on skin and appendages:  flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions.   endocrine effects:  disturbances in the menstrual cycle, induction of crisis in addison patients.  unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid + pyrazinamide
sign_symptom,vomiting,0.86403346,"  unwanted effects which may occur during continuous daily or intermittent therapy : rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects:  elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency.   gastrointestinal effects : nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects:  tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances.   haematological changes:  leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura.   effects on skin and appendages:  flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions.   endocrine effects:  disturbances in the menstrual cycle, induction of crisis in addison patients.  unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid + pyrazinamide
sign_symptom,redden,0.9934716,"  unwanted effects which may occur during continuous daily or intermittent therapy : rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects:  elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency.   gastrointestinal effects : nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects:  tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances.   haematological changes:  leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura.   effects on skin and appendages:  flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions.   endocrine effects:  disturbances in the menstrual cycle, induction of crisis in addison patients.  unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid + pyrazinamide
disease_disorder,conjunctivitis,0.9569027,"  unwanted effects which may occur during continuous daily or intermittent therapy : rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects:  elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency.   gastrointestinal effects : nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects:  tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances.   haematological changes:  leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura.   effects on skin and appendages:  flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions.   endocrine effects:  disturbances in the menstrual cycle, induction of crisis in addison patients.  unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid + pyrazinamide
sign_symptom,hyper,0.99995494,"  unwanted effects which may occur during continuous daily or intermittent therapy : rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects:  elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency.   gastrointestinal effects : nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects:  tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances.   haematological changes:  leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura.   effects on skin and appendages:  flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions.   endocrine effects:  disturbances in the menstrual cycle, induction of crisis in addison patients.  unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid + pyrazinamide
sign_symptom,disturbances,0.99686396,"  unwanted effects which may occur during continuous daily or intermittent therapy : rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects:  elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency.   gastrointestinal effects : nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects:  tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances.   haematological changes:  leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura.   effects on skin and appendages:  flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions.   endocrine effects:  disturbances in the menstrual cycle, induction of crisis in addison patients.  unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid + pyrazinamide
sign_symptom,menstru,0.7873604,"  unwanted effects which may occur during continuous daily or intermittent therapy : rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects:  elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency.   gastrointestinal effects : nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects:  tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances.   haematological changes:  leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura.   effects on skin and appendages:  flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions.   endocrine effects:  disturbances in the menstrual cycle, induction of crisis in addison patients.  unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid + pyrazinamide
sign_symptom,discolouration,0.7028458," unwanted effects which may occur during continuous daily or intermittent therapy: rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects : elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency. gastrointestinal effects: nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects : tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances. haematological changes: leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura. effects on skin and appendages: flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions. endocrine effects: disturbances in the menstrual cycle, induction of crisis in addison patients. unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid
sign_symptom,vomiting,0.86403346," unwanted effects which may occur during continuous daily or intermittent therapy: rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects : elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency. gastrointestinal effects: nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects : tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances. haematological changes: leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura. effects on skin and appendages: flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions. endocrine effects: disturbances in the menstrual cycle, induction of crisis in addison patients. unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid
sign_symptom,redden,0.9934716," unwanted effects which may occur during continuous daily or intermittent therapy: rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects : elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency. gastrointestinal effects: nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects : tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances. haematological changes: leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura. effects on skin and appendages: flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions. endocrine effects: disturbances in the menstrual cycle, induction of crisis in addison patients. unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid
disease_disorder,conjunctivitis,0.9569027," unwanted effects which may occur during continuous daily or intermittent therapy: rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects : elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency. gastrointestinal effects: nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects : tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances. haematological changes: leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura. effects on skin and appendages: flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions. endocrine effects: disturbances in the menstrual cycle, induction of crisis in addison patients. unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid
sign_symptom,hyper,0.99995494," unwanted effects which may occur during continuous daily or intermittent therapy: rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects : elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency. gastrointestinal effects: nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects : tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances. haematological changes: leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura. effects on skin and appendages: flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions. endocrine effects: disturbances in the menstrual cycle, induction of crisis in addison patients. unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid
sign_symptom,disturbances,0.99686396," unwanted effects which may occur during continuous daily or intermittent therapy: rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects : elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency. gastrointestinal effects: nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects : tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances. haematological changes: leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura. effects on skin and appendages: flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions. endocrine effects: disturbances in the menstrual cycle, induction of crisis in addison patients. unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid
sign_symptom,menstru,0.7873604," unwanted effects which may occur during continuous daily or intermittent therapy: rifampicin: rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. it may permanently discolour soft contact lenses.   hepatic effects : very common (&gt;10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (&gt;0.1% and &lt;1%). in isolated cases (&lt;0.01 %), a fatal outcome was observed.   renal effects : elevations of bun and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency. gastrointestinal effects: nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.   central and peripheral nervous system effects : tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances. haematological changes: leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura. effects on skin and appendages: flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, lyell's syndrome and pemphigoid reactions. endocrine effects: disturbances in the menstrual cycle, induction of crisis in addison patients. unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption ",rifampicin + isoniazid
sign_symptom,flushing,0.99991703," facial flushing and itching, with or without a rash, flu-like syndrome characterised by episodes of fever, chills, headache, dizziness, bone pain, shortness of breath, and malaise; gi adverse effects (e.g. nausea, vomiting, anorexia, diarrhoea, epigastric distress), pseudomembranous colitis, eosinophilia, leucopenia, haemolytic anaemia; alterations in kidney function and renal failure, menstrual disturbances, oedema, myopathy, muscular weakness; orange-red discolouration of the urine, faeces, sweat, saliva, sputum, tears, and other body fluids; thrombophlebitis, local irritation and inflammation after prolonged iv infusion. rarely, eye irritation and visual disturbances, anaphylaxis or shock. ",rifampicin
sign_symptom,shortness of breath,0.9928117," facial flushing and itching, with or without a rash, flu-like syndrome characterised by episodes of fever, chills, headache, dizziness, bone pain, shortness of breath, and malaise; gi adverse effects (e.g. nausea, vomiting, anorexia, diarrhoea, epigastric distress), pseudomembranous colitis, eosinophilia, leucopenia, haemolytic anaemia; alterations in kidney function and renal failure, menstrual disturbances, oedema, myopathy, muscular weakness; orange-red discolouration of the urine, faeces, sweat, saliva, sputum, tears, and other body fluids; thrombophlebitis, local irritation and inflammation after prolonged iv infusion. rarely, eye irritation and visual disturbances, anaphylaxis or shock. ",rifampicin
sign_symptom,mala,0.997341," facial flushing and itching, with or without a rash, flu-like syndrome characterised by episodes of fever, chills, headache, dizziness, bone pain, shortness of breath, and malaise; gi adverse effects (e.g. nausea, vomiting, anorexia, diarrhoea, epigastric distress), pseudomembranous colitis, eosinophilia, leucopenia, haemolytic anaemia; alterations in kidney function and renal failure, menstrual disturbances, oedema, myopathy, muscular weakness; orange-red discolouration of the urine, faeces, sweat, saliva, sputum, tears, and other body fluids; thrombophlebitis, local irritation and inflammation after prolonged iv infusion. rarely, eye irritation and visual disturbances, anaphylaxis or shock. ",rifampicin
sign_symptom,adverse,0.8993155," facial flushing and itching, with or without a rash, flu-like syndrome characterised by episodes of fever, chills, headache, dizziness, bone pain, shortness of breath, and malaise; gi adverse effects (e.g. nausea, vomiting, anorexia, diarrhoea, epigastric distress), pseudomembranous colitis, eosinophilia, leucopenia, haemolytic anaemia; alterations in kidney function and renal failure, menstrual disturbances, oedema, myopathy, muscular weakness; orange-red discolouration of the urine, faeces, sweat, saliva, sputum, tears, and other body fluids; thrombophlebitis, local irritation and inflammation after prolonged iv infusion. rarely, eye irritation and visual disturbances, anaphylaxis or shock. ",rifampicin
sign_symptom,discolou,0.9482911," facial flushing and itching, with or without a rash, flu-like syndrome characterised by episodes of fever, chills, headache, dizziness, bone pain, shortness of breath, and malaise; gi adverse effects (e.g. nausea, vomiting, anorexia, diarrhoea, epigastric distress), pseudomembranous colitis, eosinophilia, leucopenia, haemolytic anaemia; alterations in kidney function and renal failure, menstrual disturbances, oedema, myopathy, muscular weakness; orange-red discolouration of the urine, faeces, sweat, saliva, sputum, tears, and other body fluids; thrombophlebitis, local irritation and inflammation after prolonged iv infusion. rarely, eye irritation and visual disturbances, anaphylaxis or shock. ",rifampicin
sign_symptom,irritation,0.9983771," facial flushing and itching, with or without a rash, flu-like syndrome characterised by episodes of fever, chills, headache, dizziness, bone pain, shortness of breath, and malaise; gi adverse effects (e.g. nausea, vomiting, anorexia, diarrhoea, epigastric distress), pseudomembranous colitis, eosinophilia, leucopenia, haemolytic anaemia; alterations in kidney function and renal failure, menstrual disturbances, oedema, myopathy, muscular weakness; orange-red discolouration of the urine, faeces, sweat, saliva, sputum, tears, and other body fluids; thrombophlebitis, local irritation and inflammation after prolonged iv infusion. rarely, eye irritation and visual disturbances, anaphylaxis or shock. ",rifampicin
sign_symptom,inflammation,0.99849546," facial flushing and itching, with or without a rash, flu-like syndrome characterised by episodes of fever, chills, headache, dizziness, bone pain, shortness of breath, and malaise; gi adverse effects (e.g. nausea, vomiting, anorexia, diarrhoea, epigastric distress), pseudomembranous colitis, eosinophilia, leucopenia, haemolytic anaemia; alterations in kidney function and renal failure, menstrual disturbances, oedema, myopathy, muscular weakness; orange-red discolouration of the urine, faeces, sweat, saliva, sputum, tears, and other body fluids; thrombophlebitis, local irritation and inflammation after prolonged iv infusion. rarely, eye irritation and visual disturbances, anaphylaxis or shock. ",rifampicin
medication,salmeterol,0.99110323," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,adverse reactions,0.9859805," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,adverse events,0.9958186," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,adverse,0.99971277," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
medication,salmeter,0.767683," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
medication,beta,0.81194586," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,subjective,0.9292002," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,palpitations,0.90448266," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,extra systoles,0.911446," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,arthralgia,0.99821156," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,hyper,0.9999349," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,rash,0.99754447," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,irritation,0.99914694," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,hoarseness,0.9989777," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,candidiasis,0.99975324," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,thrush,0.9955951," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,hypersensitivity reactions,0.9795715," as this preparation contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. there is no incidence of additional adverse events following concurrent administration of the two compounds. adverse events, which have been associated with salmeterol or fluticasone propionate, are given below.  salmeterol: the pharmacological side effects of beta-2-agonist treatment, such as tremor, subjective palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy. cardiac arrhythmia (including atrial fibrillation, supraventricular tachycardia and extra systoles) may occur, usually in susceptible patients. there have been reports of arthralgia and hypersensitivity reactions, including rash, oedema and angioedema. there have been reports of oropharyngeal irritation. there have been rare reports of muscle cramps.  fluticasone propionate: hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. cutaneous hypersensitivity reactions have been reported. rare cases of facial and oropharyngeal oedema have been reported. both hoarseness and incidence of candidiasis may be relieved by gargling with water after use of salmeterol/ fluticasone propionate inhaler. ",salmeterol + fluticasone propionate
sign_symptom,irritation,0.99111545," stinging, burning, or irritation of the skin,itching, prolonged use over a large skin area may cause salicylate toxicity, ringing sound in the ears (tinnitus), diarrhoea, vomiting. ",salicylic acid + lactic acid
sign_symptom,allergic reaction,0.9997665," an allergic reaction (shortness of breath, closing of the throat, swelling of the lips, face or tongue or hives) or severe skin irritation. ",salicylic acid
sign_symptom,short,0.999899," an allergic reaction (shortness of breath, closing of the throat, swelling of the lips, face or tongue or hives) or severe skin irritation. ",salicylic acid
sign_symptom,closing,0.99915695," an allergic reaction (shortness of breath, closing of the throat, swelling of the lips, face or tongue or hives) or severe skin irritation. ",salicylic acid
sign_symptom,swelling,0.99994934," an allergic reaction (shortness of breath, closing of the throat, swelling of the lips, face or tongue or hives) or severe skin irritation. ",salicylic acid
medication,beta - agonist,0.8889619," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,tremor,0.9996176," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,muscles,0.967512," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,nervousness,0.9982394," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,palpit,0.75242925," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
medication,beta2,0.8046167," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,irritation,0.99971765," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
medication,- mi,0.891791," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,vomiting,0.985355," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,weakness,0.99984217," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,myalgia,0.8397905," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,muscle cramps,0.8377635," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,dryness of mouth,0.99650663," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,complications,0.9357323," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
medication,ipratropium bromide,0.9334888," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,motility disturbances,0.91586894," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,urinary retention,0.98651576," in common with other beta-agonists containing products, side effects of this solution can include fine tremor of skeletal muscles and nervousness and less frequently tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.  potentially serious hypokalaemia may result from prolonged and/or high dose beta2 agonist therapy.  as with use of other inhalation therapy, cough, local irritation and less commonly inhalation induced bronchospasm can occur. as with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. in rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.  in individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.  the most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia. there have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2 agonist, has escaped into the eyes. ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible. ",salbutamol + ipratropium (solution for inhalation)
sign_symptom,tremor,0.99994504," due to presence of salbutamol, mild tremor and headache have been reported. these usually disappear with continuous treatment. there have been very rare reports of treatments muscle cramp, hypersensitivity reactions including angioedema, urticaria, bronchospasm and hypotension.   for the presence of ipratropium bromide headache, influenza, chest pain, nausea, dyspnea, coughing, pharyngitis, sinusitis are rarely reported. ",salbutamol + ipratropium (inhaler)
sign_symptom,headache,0.9999497," due to presence of salbutamol, mild tremor and headache have been reported. these usually disappear with continuous treatment. there have been very rare reports of treatments muscle cramp, hypersensitivity reactions including angioedema, urticaria, bronchospasm and hypotension.   for the presence of ipratropium bromide headache, influenza, chest pain, nausea, dyspnea, coughing, pharyngitis, sinusitis are rarely reported. ",salbutamol + ipratropium (inhaler)
sign_symptom,hyper,0.9998247," due to presence of salbutamol, mild tremor and headache have been reported. these usually disappear with continuous treatment. there have been very rare reports of treatments muscle cramp, hypersensitivity reactions including angioedema, urticaria, bronchospasm and hypotension.   for the presence of ipratropium bromide headache, influenza, chest pain, nausea, dyspnea, coughing, pharyngitis, sinusitis are rarely reported. ",salbutamol + ipratropium (inhaler)
medication,salbutamol,0.99616736," salbutamol is generally well tolerated. few side effects have been observed during inhalation. there are tremors, anxiety, muscle cramps, headache, palpitation, a compensatory small increase in heart rate, cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles), tachycardia may occur in some patients. mouth and throat irritation may occur with inhaled salbutamol ",salbutamol (inhaler)
sign_symptom,side effects,0.86484265," salbutamol is generally well tolerated. few side effects have been observed during inhalation. there are tremors, anxiety, muscle cramps, headache, palpitation, a compensatory small increase in heart rate, cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles), tachycardia may occur in some patients. mouth and throat irritation may occur with inhaled salbutamol ",salbutamol (inhaler)
sign_symptom,irritation,0.9999392," salbutamol is generally well tolerated. few side effects have been observed during inhalation. there are tremors, anxiety, muscle cramps, headache, palpitation, a compensatory small increase in heart rate, cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles), tachycardia may occur in some patients. mouth and throat irritation may occur with inhaled salbutamol ",salbutamol (inhaler)
medication,salbutamol,0.97599244," salbutamol may cause fine tremor of skeletal muscles (particularly the hands), palpitations and muscle cramps. tachycardia, tenseness, headaches and peripheral vasodilatation have been reported after large doses. ",salbutamol
sign_symptom,tremor,0.99986374," salbutamol may cause fine tremor of skeletal muscles (particularly the hands), palpitations and muscle cramps. tachycardia, tenseness, headaches and peripheral vasodilatation have been reported after large doses. ",salbutamol
sign_symptom,tense,0.99985266," salbutamol may cause fine tremor of skeletal muscles (particularly the hands), palpitations and muscle cramps. tachycardia, tenseness, headaches and peripheral vasodilatation have been reported after large doses. ",salbutamol
sign_symptom,headaches,0.9972627," salbutamol may cause fine tremor of skeletal muscles (particularly the hands), palpitations and muscle cramps. tachycardia, tenseness, headaches and peripheral vasodilatation have been reported after large doses. ",salbutamol
sign_symptom,peripheral vasodilatation,0.9896507," salbutamol may cause fine tremor of skeletal muscles (particularly the hands), palpitations and muscle cramps. tachycardia, tenseness, headaches and peripheral vasodilatation have been reported after large doses. ",salbutamol
sign_symptom,allergic reactions,0.9524773," saccharin belongs to a class of compounds known as sulfonamides, which can cause allergic reactions in some individuals. reactions can include: headaches breathing difficulties diarrhoea and skin problems ",saccharin sodium
sign_symptom,headache,0.9999087," saccharin belongs to a class of compounds known as sulfonamides, which can cause allergic reactions in some individuals. reactions can include: headaches breathing difficulties diarrhoea and skin problems ",saccharin sodium
sign_symptom,breathing difficulties,0.9997479," saccharin belongs to a class of compounds known as sulfonamides, which can cause allergic reactions in some individuals. reactions can include: headaches breathing difficulties diarrhoea and skin problems ",saccharin sodium
sign_symptom,diarrhoea,0.92243004," saccharin belongs to a class of compounds known as sulfonamides, which can cause allergic reactions in some individuals. reactions can include: headaches breathing difficulties diarrhoea and skin problems ",saccharin sodium
sign_symptom,skin problems,0.98923224," saccharin belongs to a class of compounds known as sulfonamides, which can cause allergic reactions in some individuals. reactions can include: headaches breathing difficulties diarrhoea and skin problems ",saccharin sodium
sign_symptom,adverse reactions,0.99719596," most common adverse reactions to amlodipine is edema which occurred in a dose related manner. other adverse experiences not dose related but reported with an incidence &gt;1.0% are fatigue, nausea, abdominal pain and somnolence. ",s-amlodipine besilate (levamlodipine)
medication,amlo,0.9475759," most common adverse reactions to amlodipine is edema which occurred in a dose related manner. other adverse experiences not dose related but reported with an incidence &gt;1.0% are fatigue, nausea, abdominal pain and somnolence. ",s-amlodipine besilate (levamlodipine)
sign_symptom,edema,0.99854136," most common adverse reactions to amlodipine is edema which occurred in a dose related manner. other adverse experiences not dose related but reported with an incidence &gt;1.0% are fatigue, nausea, abdominal pain and somnolence. ",s-amlodipine besilate (levamlodipine)
sign_symptom,adverse experiences,0.8534657," most common adverse reactions to amlodipine is edema which occurred in a dose related manner. other adverse experiences not dose related but reported with an incidence &gt;1.0% are fatigue, nausea, abdominal pain and somnolence. ",s-amlodipine besilate (levamlodipine)
sign_symptom,pain,0.9997123," most common adverse reactions to amlodipine is edema which occurred in a dose related manner. other adverse experiences not dose related but reported with an incidence &gt;1.0% are fatigue, nausea, abdominal pain and somnolence. ",s-amlodipine besilate (levamlodipine)
sign_symptom,headache,0.9998565," the most common side effects are- 
 
 thrombocytopenia, anemia and neutropenia 
 risk of infection, bruising, dizziness, headache 
 symptom exacerbation following interruption or discontinuation of treatment with ruxolitinib 
 non-melanoma skin cancer 
  ",ruxolitinib
sign_symptom,symptom,0.99915427," the most common side effects are- 
 
 thrombocytopenia, anemia and neutropenia 
 risk of infection, bruising, dizziness, headache 
 symptom exacerbation following interruption or discontinuation of treatment with ruxolitinib 
 non-melanoma skin cancer 
  ",ruxolitinib
disease_disorder,non - melanoma,0.91029614," the most common side effects are- 
 
 thrombocytopenia, anemia and neutropenia 
 risk of infection, bruising, dizziness, headache 
 symptom exacerbation following interruption or discontinuation of treatment with ruxolitinib 
 non-melanoma skin cancer 
  ",ruxolitinib
disease_disorder,skin cancer,0.99980426," the most common side effects are- 
 
 thrombocytopenia, anemia and neutropenia 
 risk of infection, bruising, dizziness, headache 
 symptom exacerbation following interruption or discontinuation of treatment with ruxolitinib 
 non-melanoma skin cancer 
  ",ruxolitinib
sign_symptom,concentration,0.9033555," common: asthenia, dizziness, drowsiness. uncommon: appetite increased, arthralgia, back pain, concentration impaired, constipation, cough, diarrhea, dry throat, epistaxis, fever, gastrointestinal discomfort, increased risk of infection, irritability, malaise, myalgia, nasal dryness, nausea, oropharyngeal pain, rash, thirst, vomiting, weight increased. rare: palpitations, tachycardia. ",rupatadine fumarate
medication,roxithromycin,0.95428014," roxithromycin is well tolerated by patients of all age groups. less than 4% of treated patients complain of side effects mainly nausea, abdominal pain, diarrhoea and hypersensitivity rash. other side effects reported include vomiting, dizziness, headache, pruritus, dyspepsia, flatulence, tinnitus, vertigo and constipation. these are in general minor and do not necessitate withdrawal of therapy. ",roxithromycin
sign_symptom,effects,0.916454," roxithromycin is well tolerated by patients of all age groups. less than 4% of treated patients complain of side effects mainly nausea, abdominal pain, diarrhoea and hypersensitivity rash. other side effects reported include vomiting, dizziness, headache, pruritus, dyspepsia, flatulence, tinnitus, vertigo and constipation. these are in general minor and do not necessitate withdrawal of therapy. ",roxithromycin
sign_symptom,nausea,0.9915018," roxithromycin is well tolerated by patients of all age groups. less than 4% of treated patients complain of side effects mainly nausea, abdominal pain, diarrhoea and hypersensitivity rash. other side effects reported include vomiting, dizziness, headache, pruritus, dyspepsia, flatulence, tinnitus, vertigo and constipation. these are in general minor and do not necessitate withdrawal of therapy. ",roxithromycin
sign_symptom,diarrhoea,0.99670124," roxithromycin is well tolerated by patients of all age groups. less than 4% of treated patients complain of side effects mainly nausea, abdominal pain, diarrhoea and hypersensitivity rash. other side effects reported include vomiting, dizziness, headache, pruritus, dyspepsia, flatulence, tinnitus, vertigo and constipation. these are in general minor and do not necessitate withdrawal of therapy. ",roxithromycin
sign_symptom,hypersensitivity,0.9996383," roxithromycin is well tolerated by patients of all age groups. less than 4% of treated patients complain of side effects mainly nausea, abdominal pain, diarrhoea and hypersensitivity rash. other side effects reported include vomiting, dizziness, headache, pruritus, dyspepsia, flatulence, tinnitus, vertigo and constipation. these are in general minor and do not necessitate withdrawal of therapy. ",roxithromycin
sign_symptom,dyspeps,0.91605884," roxithromycin is well tolerated by patients of all age groups. less than 4% of treated patients complain of side effects mainly nausea, abdominal pain, diarrhoea and hypersensitivity rash. other side effects reported include vomiting, dizziness, headache, pruritus, dyspepsia, flatulence, tinnitus, vertigo and constipation. these are in general minor and do not necessitate withdrawal of therapy. ",roxithromycin
sign_symptom,flatule,0.8015155," roxithromycin is well tolerated by patients of all age groups. less than 4% of treated patients complain of side effects mainly nausea, abdominal pain, diarrhoea and hypersensitivity rash. other side effects reported include vomiting, dizziness, headache, pruritus, dyspepsia, flatulence, tinnitus, vertigo and constipation. these are in general minor and do not necessitate withdrawal of therapy. ",roxithromycin
sign_symptom,vertigo,0.99976," roxithromycin is well tolerated by patients of all age groups. less than 4% of treated patients complain of side effects mainly nausea, abdominal pain, diarrhoea and hypersensitivity rash. other side effects reported include vomiting, dizziness, headache, pruritus, dyspepsia, flatulence, tinnitus, vertigo and constipation. these are in general minor and do not necessitate withdrawal of therapy. ",roxithromycin
sign_symptom,headache,0.8966937," occasional headache, gi disturbances, gynaecomastia, alopecia, blood dyscrasias, pancreatitis, sleep disturbances, restlessness, rarely dizziness. hypersensitivity reactions e.g. rash and itching reported occasionally. changes in pulse rate and transient impairment of sexual drive. possible increase in liver enzyme activity. may reduce leucocytes and/or thrombocytes. ",roxatidine
sign_symptom,hypersensitivity reactions,0.9915892," occasional headache, gi disturbances, gynaecomastia, alopecia, blood dyscrasias, pancreatitis, sleep disturbances, restlessness, rarely dizziness. hypersensitivity reactions e.g. rash and itching reported occasionally. changes in pulse rate and transient impairment of sexual drive. possible increase in liver enzyme activity. may reduce leucocytes and/or thrombocytes. ",roxatidine
sign_symptom,rash,0.99995065," occasional headache, gi disturbances, gynaecomastia, alopecia, blood dyscrasias, pancreatitis, sleep disturbances, restlessness, rarely dizziness. hypersensitivity reactions e.g. rash and itching reported occasionally. changes in pulse rate and transient impairment of sexual drive. possible increase in liver enzyme activity. may reduce leucocytes and/or thrombocytes. ",roxatidine
sign_symptom,hyper,0.9994228," the common adverse reactions associated with roxadustat are hypertension, vascular access thrombosis, diarrhoea, peripheral oedema, hyperkalaemia and nausea. ",roxadustat
sign_symptom,adverse reaction,0.9992448," in controlled clinical studies, the adverse reaction profile observed in the subjects receiving rotavirus vaccine was similar to the adverse reaction profile observed in subjects receiving placebo. no increase in the incidence or severity of these reactions was seen with the second dose.  however, some adverse reactions considered as being at least possibly related to rotavirus vaccine vaccination were reported. very common areirritability, loss of appetite; common arediarrhoea, vomiting, flatulence, abdominal pain, regurgitation of food, fever, fatigue; uncommon are- crying, sleep disorder, somnolence, constipation rare; upper respiratory tract infection hoarseness, rhinorrhoea, dermatitis, rash, muscle cramp; very rare- gastro-enteritis. in a large safety trial, subjects vaccinated with rotavirus vaccine gave evidence of no increased risk of intussusception when compared with subjects receiving a placebo. ",rotavirus vaccine
sign_symptom,adverse reactions,0.999897," in controlled clinical studies, the adverse reaction profile observed in the subjects receiving rotavirus vaccine was similar to the adverse reaction profile observed in subjects receiving placebo. no increase in the incidence or severity of these reactions was seen with the second dose.  however, some adverse reactions considered as being at least possibly related to rotavirus vaccine vaccination were reported. very common areirritability, loss of appetite; common arediarrhoea, vomiting, flatulence, abdominal pain, regurgitation of food, fever, fatigue; uncommon are- crying, sleep disorder, somnolence, constipation rare; upper respiratory tract infection hoarseness, rhinorrhoea, dermatitis, rash, muscle cramp; very rare- gastro-enteritis. in a large safety trial, subjects vaccinated with rotavirus vaccine gave evidence of no increased risk of intussusception when compared with subjects receiving a placebo. ",rotavirus vaccine
sign_symptom,infection,0.96194834," in controlled clinical studies, the adverse reaction profile observed in the subjects receiving rotavirus vaccine was similar to the adverse reaction profile observed in subjects receiving placebo. no increase in the incidence or severity of these reactions was seen with the second dose.  however, some adverse reactions considered as being at least possibly related to rotavirus vaccine vaccination were reported. very common areirritability, loss of appetite; common arediarrhoea, vomiting, flatulence, abdominal pain, regurgitation of food, fever, fatigue; uncommon are- crying, sleep disorder, somnolence, constipation rare; upper respiratory tract infection hoarseness, rhinorrhoea, dermatitis, rash, muscle cramp; very rare- gastro-enteritis. in a large safety trial, subjects vaccinated with rotavirus vaccine gave evidence of no increased risk of intussusception when compared with subjects receiving a placebo. ",rotavirus vaccine
sign_symptom,hoarse,0.9228924," in controlled clinical studies, the adverse reaction profile observed in the subjects receiving rotavirus vaccine was similar to the adverse reaction profile observed in subjects receiving placebo. no increase in the incidence or severity of these reactions was seen with the second dose.  however, some adverse reactions considered as being at least possibly related to rotavirus vaccine vaccination were reported. very common areirritability, loss of appetite; common arediarrhoea, vomiting, flatulence, abdominal pain, regurgitation of food, fever, fatigue; uncommon are- crying, sleep disorder, somnolence, constipation rare; upper respiratory tract infection hoarseness, rhinorrhoea, dermatitis, rash, muscle cramp; very rare- gastro-enteritis. in a large safety trial, subjects vaccinated with rotavirus vaccine gave evidence of no increased risk of intussusception when compared with subjects receiving a placebo. ",rotavirus vaccine
medication,vaccine,0.7965228," in controlled clinical studies, the adverse reaction profile observed in the subjects receiving rotavirus vaccine was similar to the adverse reaction profile observed in subjects receiving placebo. no increase in the incidence or severity of these reactions was seen with the second dose.  however, some adverse reactions considered as being at least possibly related to rotavirus vaccine vaccination were reported. very common areirritability, loss of appetite; common arediarrhoea, vomiting, flatulence, abdominal pain, regurgitation of food, fever, fatigue; uncommon are- crying, sleep disorder, somnolence, constipation rare; upper respiratory tract infection hoarseness, rhinorrhoea, dermatitis, rash, muscle cramp; very rare- gastro-enteritis. in a large safety trial, subjects vaccinated with rotavirus vaccine gave evidence of no increased risk of intussusception when compared with subjects receiving a placebo. ",rotavirus vaccine
sign_symptom,intussusception,0.99348116," in controlled clinical studies, the adverse reaction profile observed in the subjects receiving rotavirus vaccine was similar to the adverse reaction profile observed in subjects receiving placebo. no increase in the incidence or severity of these reactions was seen with the second dose.  however, some adverse reactions considered as being at least possibly related to rotavirus vaccine vaccination were reported. very common areirritability, loss of appetite; common arediarrhoea, vomiting, flatulence, abdominal pain, regurgitation of food, fever, fatigue; uncommon are- crying, sleep disorder, somnolence, constipation rare; upper respiratory tract infection hoarseness, rhinorrhoea, dermatitis, rash, muscle cramp; very rare- gastro-enteritis. in a large safety trial, subjects vaccinated with rotavirus vaccine gave evidence of no increased risk of intussusception when compared with subjects receiving a placebo. ",rotavirus vaccine
medication,rosuvastatin,0.81934816," rosuvastatin is generally well tolerated. the most frequent adverse events thought to be related to rosuvastatin were headache, myalgia, constipation, asthenia, abdominal pain and nausea. ",rosuvastatin
sign_symptom,adverse events,0.87936586," rosuvastatin is generally well tolerated. the most frequent adverse events thought to be related to rosuvastatin were headache, myalgia, constipation, asthenia, abdominal pain and nausea. ",rosuvastatin
medication,rosuvas,0.8640559," rosuvastatin is generally well tolerated. the most frequent adverse events thought to be related to rosuvastatin were headache, myalgia, constipation, asthenia, abdominal pain and nausea. ",rosuvastatin
sign_symptom,pain,0.8592431," rosuvastatin is generally well tolerated. the most frequent adverse events thought to be related to rosuvastatin were headache, myalgia, constipation, asthenia, abdominal pain and nausea. ",rosuvastatin
sign_symptom,adverse events,0.9861522," the incidence and types of adverse events reported in clinical trials of rosiglitazone as monotherapy are upper respiratory tract infection, headache, back pain, hyperglycemia, fatigue, sinusitis, diarrhea, and hypoglycemia. adverse reactions reported in greater than 5% of the metformin patients, and that were more common in metformin- than placebo-treated patients are diarrhea, nausea, vomiting, flatulence, asthenia, indigestion, abdominal discomfort, headache. ",rosiglitazone + metformin hydrochloride
sign_symptom,adverse reactions,0.9999059," the incidence and types of adverse events reported in clinical trials of rosiglitazone as monotherapy are upper respiratory tract infection, headache, back pain, hyperglycemia, fatigue, sinusitis, diarrhea, and hypoglycemia. adverse reactions reported in greater than 5% of the metformin patients, and that were more common in metformin- than placebo-treated patients are diarrhea, nausea, vomiting, flatulence, asthenia, indigestion, abdominal discomfort, headache. ",rosiglitazone + metformin hydrochloride
medication,metform,0.9769401," the incidence and types of adverse events reported in clinical trials of rosiglitazone as monotherapy are upper respiratory tract infection, headache, back pain, hyperglycemia, fatigue, sinusitis, diarrhea, and hypoglycemia. adverse reactions reported in greater than 5% of the metformin patients, and that were more common in metformin- than placebo-treated patients are diarrhea, nausea, vomiting, flatulence, asthenia, indigestion, abdominal discomfort, headache. ",rosiglitazone + metformin hydrochloride
sign_symptom,nausea,0.98977494," the most common side effects of ropinirole include fainting, drowsiness, hallucinations, dizziness, nausea or vomiting, uncontrolled sudden movements, leg swelling, fatigue, confusion, headache, upset stomach, abdominal pain or discomfort, increased sweating etc. ",ropinirole
sign_symptom,pain,0.9993475," the most common side effects of ropinirole include fainting, drowsiness, hallucinations, dizziness, nausea or vomiting, uncontrolled sudden movements, leg swelling, fatigue, confusion, headache, upset stomach, abdominal pain or discomfort, increased sweating etc. ",ropinirole
sign_symptom,abnormal,0.761293," the adverse effects treated with sildenafil are headache, flushing, dyspepsia, nasal congestion, urinary tract infection, abnormal vision, diarrhea, dizziness and rash. ",sildenafil citrate
sign_symptom,brady,0.9543634," cardiorespiratory depression, hypotension, bradycardia; laryngospasm, increased cough and salivation; urinary retention, acute renal failure, changes in liver enzyme values, liver damage; nausea, vomiting, delirium, seizure; rash, urticaria, pruritus, dyspnoea, wheezing, chest discomfort, bronchospasm, anaphylactic/anaphylactoid reaction; agitation, dystonic movements (childn). ",sevoflurane
sign_symptom,cough,0.9998956," cardiorespiratory depression, hypotension, bradycardia; laryngospasm, increased cough and salivation; urinary retention, acute renal failure, changes in liver enzyme values, liver damage; nausea, vomiting, delirium, seizure; rash, urticaria, pruritus, dyspnoea, wheezing, chest discomfort, bronchospasm, anaphylactic/anaphylactoid reaction; agitation, dystonic movements (childn). ",sevoflurane
sign_symptom,saliva,0.9989945," cardiorespiratory depression, hypotension, bradycardia; laryngospasm, increased cough and salivation; urinary retention, acute renal failure, changes in liver enzyme values, liver damage; nausea, vomiting, delirium, seizure; rash, urticaria, pruritus, dyspnoea, wheezing, chest discomfort, bronchospasm, anaphylactic/anaphylactoid reaction; agitation, dystonic movements (childn). ",sevoflurane
sign_symptom,dystonic movements,0.9985999," cardiorespiratory depression, hypotension, bradycardia; laryngospasm, increased cough and salivation; urinary retention, acute renal failure, changes in liver enzyme values, liver damage; nausea, vomiting, delirium, seizure; rash, urticaria, pruritus, dyspnoea, wheezing, chest discomfort, bronchospasm, anaphylactic/anaphylactoid reaction; agitation, dystonic movements (childn). ",sevoflurane
sign_symptom,arthralgia,0.98103213," sevelamer may cause dyspepsia, peritonitis, diarrhea, nausea, constipation, pruritus, abdominal distension, vomiting, fatigue, anorexia, arthralgia and less commonly ileus, bowel obstruction and bowel perforation. ",sevelamer hydrochloride
sign_symptom,obstruction,0.98727965," sevelamer may cause dyspepsia, peritonitis, diarrhea, nausea, constipation, pruritus, abdominal distension, vomiting, fatigue, anorexia, arthralgia and less commonly ileus, bowel obstruction and bowel perforation. ",sevelamer hydrochloride
sign_symptom,consti,0.8600546," sertraline may cause side effects like upset stomach, diarrhoea, constipation, vomiting, dry mouth, loss of appetite, weight changes, drowsiness, dizziness, headache, pain, burning or tingling in the hands or feet, excitement, sore throat etc. ",sertraline hydrochloride
sign_symptom,dry mouth,0.81473756," sertraline may cause side effects like upset stomach, diarrhoea, constipation, vomiting, dry mouth, loss of appetite, weight changes, drowsiness, dizziness, headache, pain, burning or tingling in the hands or feet, excitement, sore throat etc. ",sertraline hydrochloride
sign_symptom,loss of appetite,0.99892205," sertraline may cause side effects like upset stomach, diarrhoea, constipation, vomiting, dry mouth, loss of appetite, weight changes, drowsiness, dizziness, headache, pain, burning or tingling in the hands or feet, excitement, sore throat etc. ",sertraline hydrochloride
sign_symptom,weight,0.9646532," sertraline may cause side effects like upset stomach, diarrhoea, constipation, vomiting, dry mouth, loss of appetite, weight changes, drowsiness, dizziness, headache, pain, burning or tingling in the hands or feet, excitement, sore throat etc. ",sertraline hydrochloride
sign_symptom,tingling,0.9987727," sertraline may cause side effects like upset stomach, diarrhoea, constipation, vomiting, dry mouth, loss of appetite, weight changes, drowsiness, dizziness, headache, pain, burning or tingling in the hands or feet, excitement, sore throat etc. ",sertraline hydrochloride
sign_symptom,sore,0.9974293," sertraline may cause side effects like upset stomach, diarrhoea, constipation, vomiting, dry mouth, loss of appetite, weight changes, drowsiness, dizziness, headache, pain, burning or tingling in the hands or feet, excitement, sore throat etc. ",sertraline hydrochloride
sign_symptom,adverse reactions,0.9876586," most common adverse reactions observed in clinical trials are contact dermatitis, dry skin, burning skin, application site skin tenderness. ",sertaconazole nitrate
sign_symptom,discomfort,0.99995697," mild abdominal discomfort e.g. colic and cramps; diarrhoea, hypokalaemia and atonic non-functioning colon (prolonged use); reversible melanosis coli (chronic use). may colour the urine yellowish-brown at acidic ph or red at alkaline ph. ",sennosides
disease_disorder,coli,0.99397075," mild abdominal discomfort e.g. colic and cramps; diarrhoea, hypokalaemia and atonic non-functioning colon (prolonged use); reversible melanosis coli (chronic use). may colour the urine yellowish-brown at acidic ph or red at alkaline ph. ",sennosides
sign_symptom,diarr,0.87100756," mild abdominal discomfort e.g. colic and cramps; diarrhoea, hypokalaemia and atonic non-functioning colon (prolonged use); reversible melanosis coli (chronic use). may colour the urine yellowish-brown at acidic ph or red at alkaline ph. ",sennosides
disease_disorder,melanosis coli,0.9945915," mild abdominal discomfort e.g. colic and cramps; diarrhoea, hypokalaemia and atonic non-functioning colon (prolonged use); reversible melanosis coli (chronic use). may colour the urine yellowish-brown at acidic ph or red at alkaline ph. ",sennosides
sign_symptom,adverse,0.9321153," the most common adverse reactions, reported in 5% of patients treated with semaglutide are: nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation. ",semaglutide (tablet)
sign_symptom,decreased,0.99916196," the most common adverse reactions, reported in 5% of patients treated with semaglutide are: nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation. ",semaglutide (tablet)
sign_symptom,vomiting,0.9998697," the most common adverse reactions, reported in 5% of patients treated with semaglutide are: nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation. ",semaglutide (tablet)
sign_symptom,adverse reactions,0.99984825," the following serious adverse reactions are described below or elsewhere in the prescribing information: 
 
 risk of thyroid c-cell tumors 
 pancreatitis 
 diabetic retinopathy complications 
 hypoglycemia with concomitant use of insulin secretagogues or insulin 
 acute kidney injury 
 hypersensitivity 
  ",semaglutide (injection)
disease_disorder,thyroid,0.9996613," the following serious adverse reactions are described below or elsewhere in the prescribing information: 
 
 risk of thyroid c-cell tumors 
 pancreatitis 
 diabetic retinopathy complications 
 hypoglycemia with concomitant use of insulin secretagogues or insulin 
 acute kidney injury 
 hypersensitivity 
  ",semaglutide (injection)
disease_disorder,c - cell tumors,0.9845426," the following serious adverse reactions are described below or elsewhere in the prescribing information: 
 
 risk of thyroid c-cell tumors 
 pancreatitis 
 diabetic retinopathy complications 
 hypoglycemia with concomitant use of insulin secretagogues or insulin 
 acute kidney injury 
 hypersensitivity 
  ",semaglutide (injection)
disease_disorder,pancreatitis,0.9997529," the following serious adverse reactions are described below or elsewhere in the prescribing information: 
 
 risk of thyroid c-cell tumors 
 pancreatitis 
 diabetic retinopathy complications 
 hypoglycemia with concomitant use of insulin secretagogues or insulin 
 acute kidney injury 
 hypersensitivity 
  ",semaglutide (injection)
disease_disorder,diabetic retinopathy,0.9969733," the following serious adverse reactions are described below or elsewhere in the prescribing information: 
 
 risk of thyroid c-cell tumors 
 pancreatitis 
 diabetic retinopathy complications 
 hypoglycemia with concomitant use of insulin secretagogues or insulin 
 acute kidney injury 
 hypersensitivity 
  ",semaglutide (injection)
disease_disorder,complications,0.9996675," the following serious adverse reactions are described below or elsewhere in the prescribing information: 
 
 risk of thyroid c-cell tumors 
 pancreatitis 
 diabetic retinopathy complications 
 hypoglycemia with concomitant use of insulin secretagogues or insulin 
 acute kidney injury 
 hypersensitivity 
  ",semaglutide (injection)
medication,insulin,0.99980706," the following serious adverse reactions are described below or elsewhere in the prescribing information: 
 
 risk of thyroid c-cell tumors 
 pancreatitis 
 diabetic retinopathy complications 
 hypoglycemia with concomitant use of insulin secretagogues or insulin 
 acute kidney injury 
 hypersensitivity 
  ",semaglutide (injection)
medication,secretagogues,0.99929976," the following serious adverse reactions are described below or elsewhere in the prescribing information: 
 
 risk of thyroid c-cell tumors 
 pancreatitis 
 diabetic retinopathy complications 
 hypoglycemia with concomitant use of insulin secretagogues or insulin 
 acute kidney injury 
 hypersensitivity 
  ",semaglutide (injection)
disease_disorder,kidney injury,0.9333259," the following serious adverse reactions are described below or elsewhere in the prescribing information: 
 
 risk of thyroid c-cell tumors 
 pancreatitis 
 diabetic retinopathy complications 
 hypoglycemia with concomitant use of insulin secretagogues or insulin 
 acute kidney injury 
 hypersensitivity 
  ",semaglutide (injection)
sign_symptom,hypersensitivity,0.99986684," the following serious adverse reactions are described below or elsewhere in the prescribing information: 
 
 risk of thyroid c-cell tumors 
 pancreatitis 
 diabetic retinopathy complications 
 hypoglycemia with concomitant use of insulin secretagogues or insulin 
 acute kidney injury 
 hypersensitivity 
  ",semaglutide (injection)
sign_symptom,low appetite,0.9974375," the most common side-effects of selexipag are nausea, diarrhoea, vomiting, headache, jaw pain, muscle pain, low appetite and low rbc count. ",selexipag
sign_symptom,adverse reactions,0.9998867," the clinical studies have shown that secnidazole is characterized by very good tolerance and no serious adverse reactions have been reported to date. the following side-effects may be observed with secnidazole as with all nitroimidazole derivatives &amp; are rarely serious: 
 
  most frequent side-effects : gastrointestinal disturbances, nausea, epigastric pain, metallic taste, glossitis, stomatitis. 
  occasional side effects : urticaria, moderate leukopenia which is reversible on treatment discontinuation. 
  rare side-effects : vertigo, ataxia and motor incoordination, paresthesia, peripheral neuropathy. with secnidazole, gastrointestinal disorders e.g. nausea, vomiting, eoigastric pain, etc., have been reported in very rare cases. 
  ",secnidazole
medication,secni,0.80628204," the clinical studies have shown that secnidazole is characterized by very good tolerance and no serious adverse reactions have been reported to date. the following side-effects may be observed with secnidazole as with all nitroimidazole derivatives &amp; are rarely serious: 
 
  most frequent side-effects : gastrointestinal disturbances, nausea, epigastric pain, metallic taste, glossitis, stomatitis. 
  occasional side effects : urticaria, moderate leukopenia which is reversible on treatment discontinuation. 
  rare side-effects : vertigo, ataxia and motor incoordination, paresthesia, peripheral neuropathy. with secnidazole, gastrointestinal disorders e.g. nausea, vomiting, eoigastric pain, etc., have been reported in very rare cases. 
  ",secnidazole
sign_symptom,epigast,0.79897493," the clinical studies have shown that secnidazole is characterized by very good tolerance and no serious adverse reactions have been reported to date. the following side-effects may be observed with secnidazole as with all nitroimidazole derivatives &amp; are rarely serious: 
 
  most frequent side-effects : gastrointestinal disturbances, nausea, epigastric pain, metallic taste, glossitis, stomatitis. 
  occasional side effects : urticaria, moderate leukopenia which is reversible on treatment discontinuation. 
  rare side-effects : vertigo, ataxia and motor incoordination, paresthesia, peripheral neuropathy. with secnidazole, gastrointestinal disorders e.g. nausea, vomiting, eoigastric pain, etc., have been reported in very rare cases. 
  ",secnidazole
sign_symptom,adverse reactions,0.99984634," the following serious adverse reactions are described below or elsewhere in the prescribing information: pancreatitis, heart failure, hypoglycemiawith concomitant use ofsulfonylureaorinsulin, hypersensitivity reactions, severe and disablingarthralgia, bullous pemphigoid ",saxagliptin
disease_disorder,heart,0.8938918," the following serious adverse reactions are described below or elsewhere in the prescribing information: pancreatitis, heart failure, hypoglycemiawith concomitant use ofsulfonylureaorinsulin, hypersensitivity reactions, severe and disablingarthralgia, bullous pemphigoid ",saxagliptin
sign_symptom,hypersensitivity,0.78185743," the following serious adverse reactions are described below or elsewhere in the prescribing information: pancreatitis, heart failure, hypoglycemiawith concomitant use ofsulfonylureaorinsulin, hypersensitivity reactions, severe and disablingarthralgia, bullous pemphigoid ",saxagliptin
disease_disorder,pemphigo,0.7250503," the following serious adverse reactions are described below or elsewhere in the prescribing information: pancreatitis, heart failure, hypoglycemiawith concomitant use ofsulfonylureaorinsulin, hypersensitivity reactions, severe and disablingarthralgia, bullous pemphigoid ",saxagliptin
sign_symptom,adverse reactions,0.9958322," the most common adverse reactions are nausea, vomiting, diarrhea, fatigue, pneumonia, lipodystrophy and abdominal pain ",saquinavir mesylate
sign_symptom,lipodystrophy,0.9757608," the most common adverse reactions are nausea, vomiting, diarrhea, fatigue, pneumonia, lipodystrophy and abdominal pain ",saquinavir mesylate
sign_symptom,pain,0.9999683," the most common adverse reactions are nausea, vomiting, diarrhea, fatigue, pneumonia, lipodystrophy and abdominal pain ",saquinavir mesylate
sign_symptom,hypersensitivity,0.9903511," gi symptoms, hypersensitivity reactions, skin eruptions, angioedema, weakness, rhinitis and dyspnoea, hypoprothrombinaemia. hepatotoxicity, renal impairment, iron-deficiency anaemia, occult bleeding. local irritation (rectally); reye's syndrome. ",salsalate
sign_symptom,angio,0.76313627," gi symptoms, hypersensitivity reactions, skin eruptions, angioedema, weakness, rhinitis and dyspnoea, hypoprothrombinaemia. hepatotoxicity, renal impairment, iron-deficiency anaemia, occult bleeding. local irritation (rectally); reye's syndrome. ",salsalate
sign_symptom,dyspnoea,0.9910008," gi symptoms, hypersensitivity reactions, skin eruptions, angioedema, weakness, rhinitis and dyspnoea, hypoprothrombinaemia. hepatotoxicity, renal impairment, iron-deficiency anaemia, occult bleeding. local irritation (rectally); reye's syndrome. ",salsalate
disease_disorder,deficiency,0.8990305," gi symptoms, hypersensitivity reactions, skin eruptions, angioedema, weakness, rhinitis and dyspnoea, hypoprothrombinaemia. hepatotoxicity, renal impairment, iron-deficiency anaemia, occult bleeding. local irritation (rectally); reye's syndrome. ",salsalate
sign_symptom,irritation,0.99993455," gi symptoms, hypersensitivity reactions, skin eruptions, angioedema, weakness, rhinitis and dyspnoea, hypoprothrombinaemia. hepatotoxicity, renal impairment, iron-deficiency anaemia, occult bleeding. local irritation (rectally); reye's syndrome. ",salsalate
sign_symptom,tingling,0.99931943," gi disturbances, dizziness, flushing, tingling of the hands, unpleasant taste, skin rash, abdominal pain, urinary frequency, tremor, inj site inflammation. rarely, diabetogenic effect. ",salmon calcitonin
sign_symptom,headache,0.99992657," dose related tremor, subjective palpitations and headaches are usually mild and transient. skin reactions, muscle cramps, non-specific chest pain, local irritation and arthralgia have been reported. ",salmeterol xinafoate
sign_symptom,irritation,0.9999504," dose related tremor, subjective palpitations and headaches are usually mild and transient. skin reactions, muscle cramps, non-specific chest pain, local irritation and arthralgia have been reported. ",salmeterol xinafoate
sign_symptom,irritation,0.99994075,"  skin contact : there may be irritation and redness at the site of contact. repeated or prolonged contact may cause dermatitis.   eye contact:  there may be severe pain, redness and irritation.   ingestion : there may be nausea and vomiting, occasionally with abdominal pain.   inhalation : mild poisoning causes cough, irritation of the throat and shortness of breath. very toxic to aquatic organisms, may cause long term adverse effects in the aquatic environment. ",sodium dichloroisocyanurate
sign_symptom,redness,0.99957395,"  skin contact : there may be irritation and redness at the site of contact. repeated or prolonged contact may cause dermatitis.   eye contact:  there may be severe pain, redness and irritation.   ingestion : there may be nausea and vomiting, occasionally with abdominal pain.   inhalation : mild poisoning causes cough, irritation of the throat and shortness of breath. very toxic to aquatic organisms, may cause long term adverse effects in the aquatic environment. ",sodium dichloroisocyanurate
sign_symptom,nausea,0.99991703,"  skin contact : there may be irritation and redness at the site of contact. repeated or prolonged contact may cause dermatitis.   eye contact:  there may be severe pain, redness and irritation.   ingestion : there may be nausea and vomiting, occasionally with abdominal pain.   inhalation : mild poisoning causes cough, irritation of the throat and shortness of breath. very toxic to aquatic organisms, may cause long term adverse effects in the aquatic environment. ",sodium dichloroisocyanurate
sign_symptom,shortness of breath,0.999838,"  skin contact : there may be irritation and redness at the site of contact. repeated or prolonged contact may cause dermatitis.   eye contact:  there may be severe pain, redness and irritation.   ingestion : there may be nausea and vomiting, occasionally with abdominal pain.   inhalation : mild poisoning causes cough, irritation of the throat and shortness of breath. very toxic to aquatic organisms, may cause long term adverse effects in the aquatic environment. ",sodium dichloroisocyanurate
sign_symptom,adverse effects,0.78368676,"  skin contact : there may be irritation and redness at the site of contact. repeated or prolonged contact may cause dermatitis.   eye contact:  there may be severe pain, redness and irritation.   ingestion : there may be nausea and vomiting, occasionally with abdominal pain.   inhalation : mild poisoning causes cough, irritation of the throat and shortness of breath. very toxic to aquatic organisms, may cause long term adverse effects in the aquatic environment. ",sodium dichloroisocyanurate
sign_symptom,effects,0.86305076," no serious side effects have been reported. occasional irritation of the nasal mucosa may occur during the first day of use. in rare cases with sodium cromoglicate solutions alone wheezing and tightness of the chest has been reported. because a lower dose of xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations. ",sodium cromoglicate + xylometazoline hydrochloride
sign_symptom,irritation,0.9999602," no serious side effects have been reported. occasional irritation of the nasal mucosa may occur during the first day of use. in rare cases with sodium cromoglicate solutions alone wheezing and tightness of the chest has been reported. because a lower dose of xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations. ",sodium cromoglicate + xylometazoline hydrochloride
medication,sodium cromoglicate solutions,0.9990371," no serious side effects have been reported. occasional irritation of the nasal mucosa may occur during the first day of use. in rare cases with sodium cromoglicate solutions alone wheezing and tightness of the chest has been reported. because a lower dose of xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations. ",sodium cromoglicate + xylometazoline hydrochloride
sign_symptom,tightness,0.97006226," no serious side effects have been reported. occasional irritation of the nasal mucosa may occur during the first day of use. in rare cases with sodium cromoglicate solutions alone wheezing and tightness of the chest has been reported. because a lower dose of xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations. ",sodium cromoglicate + xylometazoline hydrochloride
medication,xylometazoline,0.9901996," no serious side effects have been reported. occasional irritation of the nasal mucosa may occur during the first day of use. in rare cases with sodium cromoglicate solutions alone wheezing and tightness of the chest has been reported. because a lower dose of xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations. ",sodium cromoglicate + xylometazoline hydrochloride
sign_symptom,stinging,0.99981874, transient stinging and burning may occur after instillation of this drops. other symptoms of local irritation have been reported rarely. ,sodium cromoglicate [4%]
sign_symptom,irritation,0.9999093, transient stinging and burning may occur after instillation of this drops. other symptoms of local irritation have been reported rarely. ,sodium cromoglicate [4%]
medication,sodium cromoglycate,0.99893636, the most frequent adverse effect reported with use of sodium cromoglycate 2% eye drops is transient ocular stinging or burning upon instillation of the drug. ,sodium cromoglicate [2%]
medication,eye drops,0.972811, the most frequent adverse effect reported with use of sodium cromoglycate 2% eye drops is transient ocular stinging or burning upon instillation of the drug. ,sodium cromoglicate [2%]
sign_symptom,stinging,0.9996402, the most frequent adverse effect reported with use of sodium cromoglycate 2% eye drops is transient ocular stinging or burning upon instillation of the drug. ,sodium cromoglicate [2%]
sign_symptom,reactions,0.96506727," reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. ",sodium chloride + dextrose
disease_disorder,thrombosis,0.9496984," reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. ",sodium chloride + dextrose
disease_disorder,phlebitis,0.8586664," reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. ",sodium chloride + dextrose
sign_symptom,extra,0.9973411," reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. ",sodium chloride + dextrose
sign_symptom,side effects,0.9996516, no side effects have been reported with sodium chloride 300 mg tablet at the recommended dosage. ,sodium chloride (tablet)
medication,sodium chloride,0.9986347, no side effects have been reported with sodium chloride 300 mg tablet at the recommended dosage. ,sodium chloride (tablet)
sign_symptom,burning,0.9989969," vision may be temporarily blurred or unstable for a period after applying the drops. use caution if driving or performing duties requiring clear vision. burning or irritation of the eye may occur when first applied. if these symptoms continue or become worse, inform your doctor. notify your doctor immediately if you develop: redness, pain, swelling in or around the eyes, vision problems, sensitivity to light, headache. if you notice other effects not listed above, contact your doctor or pharmacist. ",sodium chloride (ophthalmic solution)
sign_symptom,irritation,0.9998276," vision may be temporarily blurred or unstable for a period after applying the drops. use caution if driving or performing duties requiring clear vision. burning or irritation of the eye may occur when first applied. if these symptoms continue or become worse, inform your doctor. notify your doctor immediately if you develop: redness, pain, swelling in or around the eyes, vision problems, sensitivity to light, headache. if you notice other effects not listed above, contact your doctor or pharmacist. ",sodium chloride (ophthalmic solution)
sign_symptom,swelling,0.99992716," vision may be temporarily blurred or unstable for a period after applying the drops. use caution if driving or performing duties requiring clear vision. burning or irritation of the eye may occur when first applied. if these symptoms continue or become worse, inform your doctor. notify your doctor immediately if you develop: redness, pain, swelling in or around the eyes, vision problems, sensitivity to light, headache. if you notice other effects not listed above, contact your doctor or pharmacist. ",sodium chloride (ophthalmic solution)
sign_symptom,side effects,0.9561639," no side effects are expected to occur. however stinging, sneezing, increased nasal discharge, or salty taste may occur in some cases. ",sodium chloride (nasal preparation)
sign_symptom,salty,0.9466268," no side effects are expected to occur. however stinging, sneezing, increased nasal discharge, or salty taste may occur in some cases. ",sodium chloride (nasal preparation)
sign_symptom,reactions,0.95798665," reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. ",sodium chloride (intravenous solution)
disease_disorder,thrombosis,0.9412095," reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. ",sodium chloride (intravenous solution)
disease_disorder,phlebitis,0.77132106," reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. ",sodium chloride (intravenous solution)
sign_symptom,nausea,0.8711721," this medication is generally well tolerated. however, high doses may cause headache, nausea or irritability. if any of these effects continue or become bothersome, inform your doctor. notify your doctor if you develop: muscle weakness, slow reflexes, confusion, swelling of the feet or ankles, black tar-like stools, coffee-ground vomit. if you notice other effects not listed above, contact your doctor or pharmacist. ",sodium bicarbonate
sign_symptom,swelling,0.9999324," this medication is generally well tolerated. however, high doses may cause headache, nausea or irritability. if any of these effects continue or become bothersome, inform your doctor. notify your doctor if you develop: muscle weakness, slow reflexes, confusion, swelling of the feet or ankles, black tar-like stools, coffee-ground vomit. if you notice other effects not listed above, contact your doctor or pharmacist. ",sodium bicarbonate
sign_symptom,consti,0.8865546," in addition to the desired effect of the drug, some side effects may appear such as: constipation, flatulence, stomach cramp or belching. in these cases consult a physician. if too big dose has been taken, there might appear a sensation of swelling. in this case, it is advisable to consult a physician. ",sodium alginate + sodium bicarbonate + calcium carbonate
sign_symptom,flatule,0.8762242," in addition to the desired effect of the drug, some side effects may appear such as: constipation, flatulence, stomach cramp or belching. in these cases consult a physician. if too big dose has been taken, there might appear a sensation of swelling. in this case, it is advisable to consult a physician. ",sodium alginate + sodium bicarbonate + calcium carbonate
sign_symptom,adverse reactions,0.9997431," snake venom antiserum being derived from equines is heterologous to human can give either early or late reaction. adrenaline should be always kept handy, before starting the dose of snake venom antiserum.reduction in adverse reactions has been reported by use of adequate dilution of snake venom antiserum with saline and controlling rate of infusion. ",snake venom antiserum
sign_symptom,adverse reactions,0.99948126," the most common adverse reactions reported in 5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.  adverse reactions reported in 5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.  hypoglycemia was the only adverse reaction reported in 5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.  nasopharyngitis was the only adverse reaction reported in 5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.  the most common (&gt;5%) adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache. ",sitagliptin + metformin hydrochloride
medication,sitagliptin,0.8701887," the most common adverse reactions reported in 5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.  adverse reactions reported in 5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.  hypoglycemia was the only adverse reaction reported in 5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.  nasopharyngitis was the only adverse reaction reported in 5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.  the most common (&gt;5%) adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache. ",sitagliptin + metformin hydrochloride
medication,metformin,0.98529154," the most common adverse reactions reported in 5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.  adverse reactions reported in 5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.  hypoglycemia was the only adverse reaction reported in 5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.  nasopharyngitis was the only adverse reaction reported in 5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.  the most common (&gt;5%) adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache. ",sitagliptin + metformin hydrochloride
medication,placebo,0.990525," the most common adverse reactions reported in 5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.  adverse reactions reported in 5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.  hypoglycemia was the only adverse reaction reported in 5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.  nasopharyngitis was the only adverse reaction reported in 5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.  the most common (&gt;5%) adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache. ",sitagliptin + metformin hydrochloride
medication,sitaglip,0.915982," the most common adverse reactions reported in 5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.  adverse reactions reported in 5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.  hypoglycemia was the only adverse reaction reported in 5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.  nasopharyngitis was the only adverse reaction reported in 5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.  the most common (&gt;5%) adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache. ",sitagliptin + metformin hydrochloride
medication,sulfo,0.79141426," the most common adverse reactions reported in 5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.  adverse reactions reported in 5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.  hypoglycemia was the only adverse reaction reported in 5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.  nasopharyngitis was the only adverse reaction reported in 5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.  the most common (&gt;5%) adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache. ",sitagliptin + metformin hydrochloride
sign_symptom,adverse reaction,0.9996965," the most common adverse reactions reported in 5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.  adverse reactions reported in 5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.  hypoglycemia was the only adverse reaction reported in 5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.  nasopharyngitis was the only adverse reaction reported in 5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.  the most common (&gt;5%) adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache. ",sitagliptin + metformin hydrochloride
medication,insulin,0.99888736," the most common adverse reactions reported in 5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.  adverse reactions reported in 5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.  hypoglycemia was the only adverse reaction reported in 5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.  nasopharyngitis was the only adverse reaction reported in 5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.  the most common (&gt;5%) adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache. ",sitagliptin + metformin hydrochloride
sign_symptom,adverse,0.9982843," the most common adverse reactions reported in 5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.  adverse reactions reported in 5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.  hypoglycemia was the only adverse reaction reported in 5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.  nasopharyngitis was the only adverse reaction reported in 5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.  the most common (&gt;5%) adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache. ",sitagliptin + metformin hydrochloride
medication,metform,0.9893534," the most common adverse reactions reported in 5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.  adverse reactions reported in 5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.  hypoglycemia was the only adverse reaction reported in 5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.  nasopharyngitis was the only adverse reaction reported in 5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.  the most common (&gt;5%) adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache. ",sitagliptin + metformin hydrochloride
sign_symptom,nausea,0.992272," the most common adverse reactions reported in 5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.  adverse reactions reported in 5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.  hypoglycemia was the only adverse reaction reported in 5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.  nasopharyngitis was the only adverse reaction reported in 5% of patients treated with sitagliptin monotherapy and more commonly than in patients given placebo.  the most common (&gt;5%) adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, fatulence, abdominal discomfort, indigestion, asthenia, and headache. ",sitagliptin + metformin hydrochloride
disease_disorder,infection,0.84807146," the most common adverse reactions include headache, upper respiratory tract infection and nasopharyngitis. hypoglycemia may occur in patients treated with the combination to sitagliptin and sulfonylurea and add on to insulin. ",sitagliptin
medication,simvas,0.94529396," simvastatin is generally well tolerated. headache, fatigue, insomnia, gastrointestinal effects like nausea, constipation or diarrhoea, flatulence, dyspepsia, abdominal cramps and muscular effects like myalgia, myositis and myopathy have been reported. rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been associated with simvastatin therapy. hepatitis, pancreatitis, rash, angio-oedema have also been reported. no potentially life threatening effects have been reported. ",simvastatin
sign_symptom,nausea,0.80481386," simvastatin is generally well tolerated. headache, fatigue, insomnia, gastrointestinal effects like nausea, constipation or diarrhoea, flatulence, dyspepsia, abdominal cramps and muscular effects like myalgia, myositis and myopathy have been reported. rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been associated with simvastatin therapy. hepatitis, pancreatitis, rash, angio-oedema have also been reported. no potentially life threatening effects have been reported. ",simvastatin
sign_symptom,consti,0.76800495," simvastatin is generally well tolerated. headache, fatigue, insomnia, gastrointestinal effects like nausea, constipation or diarrhoea, flatulence, dyspepsia, abdominal cramps and muscular effects like myalgia, myositis and myopathy have been reported. rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been associated with simvastatin therapy. hepatitis, pancreatitis, rash, angio-oedema have also been reported. no potentially life threatening effects have been reported. ",simvastatin
sign_symptom,diarrhoe,0.8045171," simvastatin is generally well tolerated. headache, fatigue, insomnia, gastrointestinal effects like nausea, constipation or diarrhoea, flatulence, dyspepsia, abdominal cramps and muscular effects like myalgia, myositis and myopathy have been reported. rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been associated with simvastatin therapy. hepatitis, pancreatitis, rash, angio-oedema have also been reported. no potentially life threatening effects have been reported. ",simvastatin
sign_symptom,flatulence,0.8997793," simvastatin is generally well tolerated. headache, fatigue, insomnia, gastrointestinal effects like nausea, constipation or diarrhoea, flatulence, dyspepsia, abdominal cramps and muscular effects like myalgia, myositis and myopathy have been reported. rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been associated with simvastatin therapy. hepatitis, pancreatitis, rash, angio-oedema have also been reported. no potentially life threatening effects have been reported. ",simvastatin
sign_symptom,dyspepsia,0.98907965," simvastatin is generally well tolerated. headache, fatigue, insomnia, gastrointestinal effects like nausea, constipation or diarrhoea, flatulence, dyspepsia, abdominal cramps and muscular effects like myalgia, myositis and myopathy have been reported. rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been associated with simvastatin therapy. hepatitis, pancreatitis, rash, angio-oedema have also been reported. no potentially life threatening effects have been reported. ",simvastatin
sign_symptom,myal,0.98882115," simvastatin is generally well tolerated. headache, fatigue, insomnia, gastrointestinal effects like nausea, constipation or diarrhoea, flatulence, dyspepsia, abdominal cramps and muscular effects like myalgia, myositis and myopathy have been reported. rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been associated with simvastatin therapy. hepatitis, pancreatitis, rash, angio-oedema have also been reported. no potentially life threatening effects have been reported. ",simvastatin
disease_disorder,rhabdomyolysis,0.9970194," simvastatin is generally well tolerated. headache, fatigue, insomnia, gastrointestinal effects like nausea, constipation or diarrhoea, flatulence, dyspepsia, abdominal cramps and muscular effects like myalgia, myositis and myopathy have been reported. rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been associated with simvastatin therapy. hepatitis, pancreatitis, rash, angio-oedema have also been reported. no potentially life threatening effects have been reported. ",simvastatin
disease_disorder,renal failure,0.9996803," simvastatin is generally well tolerated. headache, fatigue, insomnia, gastrointestinal effects like nausea, constipation or diarrhoea, flatulence, dyspepsia, abdominal cramps and muscular effects like myalgia, myositis and myopathy have been reported. rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been associated with simvastatin therapy. hepatitis, pancreatitis, rash, angio-oedema have also been reported. no potentially life threatening effects have been reported. ",simvastatin
sign_symptom,angio - o,0.9984827," simvastatin is generally well tolerated. headache, fatigue, insomnia, gastrointestinal effects like nausea, constipation or diarrhoea, flatulence, dyspepsia, abdominal cramps and muscular effects like myalgia, myositis and myopathy have been reported. rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been associated with simvastatin therapy. hepatitis, pancreatitis, rash, angio-oedema have also been reported. no potentially life threatening effects have been reported. ",simvastatin
medication,simethicone,0.97266924, simethicone is physiologically inert and no adverse effect has been noted after oral ingestion. ,simethicone
sign_symptom,adverse effect,0.9996438, simethicone is physiologically inert and no adverse effect has been noted after oral ingestion. ,simethicone
medication,silver sulfa,0.8245011," several cases of transient leukopenia have been reported in-patients receiving silver sulfadiazine therapy. other infrequently occurring events include skin necrosis, erythema multiform, skin discoloration, burning sensation, rashes, and interstitial nephritis. ",silver sulfadiazine
sign_symptom,hypotension,0.7700578," most common adverse reactions are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis and nasal congestion. ",silodosin
sign_symptom,nasopharyngitis,0.9988997," most common adverse reactions are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis and nasal congestion. ",silodosin
sign_symptom,nausea,0.9997193," nausea, vertigo, and flushing have been reported rarely. nausea and vomiting have been reported when the infusion rate is greater than 50g/min. ",somatostatin
sign_symptom,vertigo,0.9997415," nausea, vertigo, and flushing have been reported rarely. nausea and vomiting have been reported when the infusion rate is greater than 50g/min. ",somatostatin
sign_symptom,flushing,0.999941," nausea, vertigo, and flushing have been reported rarely. nausea and vomiting have been reported when the infusion rate is greater than 50g/min. ",somatostatin
sign_symptom,vomiting,0.9999541," nausea, vertigo, and flushing have been reported rarely. nausea and vomiting have been reported when the infusion rate is greater than 50g/min. ",somatostatin
sign_symptom,adverse reaction,0.9968145," due to the pharmacological effect of solifenacin, it may cause anticholinergic undesirable effects of (in general) mild or moderate severity. the frequency of anticholinergic undesirable effects is dose related. the most commonly reported adverse reactionwith solifenacin is dry mouth. it occurred in 11% of patients treated with 5 mg once daily, in 22% of patients treated with 10 mg once daily and in 4% of placebo-treated patients. the severity of dry mouth was generally mild and only occasionally led to discontinuation of treatment. in general,medicinal product compliance was very high (approximately 99%) and approximately 90% of the patients treated with solifenacin completed the full study period of 12 weeks treatment. 
 
 gastrointestinal disorders: very common- dry mouth, common-constipation, nausea, dyspepsia, abdominal pain, uncommon- gastroesophageal reflux diseases, dry throat, rare- colonic obstruction, faecal impaction, very rare- vomiting. 
 infections and infestations: uncommonurinary tract infection, cystitis. 
 nervous system disorders: uncommon- somnolence, dysgeusia, very rare-dizziness, headache. 
 psychiatric disorders: very rare- hallucinations. 
 eye disorders: common- blurred vision, uncommon- dry eyes. 
 general disorders and administration site conditions: uncommon- fatigue, peripheral oedema. 
 respiratory, thoracic and mediastinal disorders: uncommon nasal dryness. 
 skin and subcutaneous tissue disorders: uncommon- dry skin, very rare- pruritus, rash, urticaria. 
 renal and urinary disorders: uncommon- difficulty in micturition, rare- urinary retention. 
  ",solifenacin succinate
medication,solifenac,0.9813716," due to the pharmacological effect of solifenacin, it may cause anticholinergic undesirable effects of (in general) mild or moderate severity. the frequency of anticholinergic undesirable effects is dose related. the most commonly reported adverse reactionwith solifenacin is dry mouth. it occurred in 11% of patients treated with 5 mg once daily, in 22% of patients treated with 10 mg once daily and in 4% of placebo-treated patients. the severity of dry mouth was generally mild and only occasionally led to discontinuation of treatment. in general,medicinal product compliance was very high (approximately 99%) and approximately 90% of the patients treated with solifenacin completed the full study period of 12 weeks treatment. 
 
 gastrointestinal disorders: very common- dry mouth, common-constipation, nausea, dyspepsia, abdominal pain, uncommon- gastroesophageal reflux diseases, dry throat, rare- colonic obstruction, faecal impaction, very rare- vomiting. 
 infections and infestations: uncommonurinary tract infection, cystitis. 
 nervous system disorders: uncommon- somnolence, dysgeusia, very rare-dizziness, headache. 
 psychiatric disorders: very rare- hallucinations. 
 eye disorders: common- blurred vision, uncommon- dry eyes. 
 general disorders and administration site conditions: uncommon- fatigue, peripheral oedema. 
 respiratory, thoracic and mediastinal disorders: uncommon nasal dryness. 
 skin and subcutaneous tissue disorders: uncommon- dry skin, very rare- pruritus, rash, urticaria. 
 renal and urinary disorders: uncommon- difficulty in micturition, rare- urinary retention. 
  ",solifenacin succinate
sign_symptom,dry mouth,0.999145," due to the pharmacological effect of solifenacin, it may cause anticholinergic undesirable effects of (in general) mild or moderate severity. the frequency of anticholinergic undesirable effects is dose related. the most commonly reported adverse reactionwith solifenacin is dry mouth. it occurred in 11% of patients treated with 5 mg once daily, in 22% of patients treated with 10 mg once daily and in 4% of placebo-treated patients. the severity of dry mouth was generally mild and only occasionally led to discontinuation of treatment. in general,medicinal product compliance was very high (approximately 99%) and approximately 90% of the patients treated with solifenacin completed the full study period of 12 weeks treatment. 
 
 gastrointestinal disorders: very common- dry mouth, common-constipation, nausea, dyspepsia, abdominal pain, uncommon- gastroesophageal reflux diseases, dry throat, rare- colonic obstruction, faecal impaction, very rare- vomiting. 
 infections and infestations: uncommonurinary tract infection, cystitis. 
 nervous system disorders: uncommon- somnolence, dysgeusia, very rare-dizziness, headache. 
 psychiatric disorders: very rare- hallucinations. 
 eye disorders: common- blurred vision, uncommon- dry eyes. 
 general disorders and administration site conditions: uncommon- fatigue, peripheral oedema. 
 respiratory, thoracic and mediastinal disorders: uncommon nasal dryness. 
 skin and subcutaneous tissue disorders: uncommon- dry skin, very rare- pruritus, rash, urticaria. 
 renal and urinary disorders: uncommon- difficulty in micturition, rare- urinary retention. 
  ",solifenacin succinate
sign_symptom,infections,0.9243464," due to the pharmacological effect of solifenacin, it may cause anticholinergic undesirable effects of (in general) mild or moderate severity. the frequency of anticholinergic undesirable effects is dose related. the most commonly reported adverse reactionwith solifenacin is dry mouth. it occurred in 11% of patients treated with 5 mg once daily, in 22% of patients treated with 10 mg once daily and in 4% of placebo-treated patients. the severity of dry mouth was generally mild and only occasionally led to discontinuation of treatment. in general,medicinal product compliance was very high (approximately 99%) and approximately 90% of the patients treated with solifenacin completed the full study period of 12 weeks treatment. 
 
 gastrointestinal disorders: very common- dry mouth, common-constipation, nausea, dyspepsia, abdominal pain, uncommon- gastroesophageal reflux diseases, dry throat, rare- colonic obstruction, faecal impaction, very rare- vomiting. 
 infections and infestations: uncommonurinary tract infection, cystitis. 
 nervous system disorders: uncommon- somnolence, dysgeusia, very rare-dizziness, headache. 
 psychiatric disorders: very rare- hallucinations. 
 eye disorders: common- blurred vision, uncommon- dry eyes. 
 general disorders and administration site conditions: uncommon- fatigue, peripheral oedema. 
 respiratory, thoracic and mediastinal disorders: uncommon nasal dryness. 
 skin and subcutaneous tissue disorders: uncommon- dry skin, very rare- pruritus, rash, urticaria. 
 renal and urinary disorders: uncommon- difficulty in micturition, rare- urinary retention. 
  ",solifenacin succinate
sign_symptom,headache,0.9999219, the most common side effects of sofosbuvir and velpatasvir combination include headache and tiredness. treatment may result in slowing of the heart rate along with other symptoms when taken with amiodarone (a medicine used to treat certain heart problems). ,sofosbuvir + velpatasvir
sign_symptom,tired,0.9999026, the most common side effects of sofosbuvir and velpatasvir combination include headache and tiredness. treatment may result in slowing of the heart rate along with other symptoms when taken with amiodarone (a medicine used to treat certain heart problems). ,sofosbuvir + velpatasvir
sign_symptom,symptoms,0.9895001, the most common side effects of sofosbuvir and velpatasvir combination include headache and tiredness. treatment may result in slowing of the heart rate along with other symptoms when taken with amiodarone (a medicine used to treat certain heart problems). ,sofosbuvir + velpatasvir
medication,amiodarone,0.93378085, the most common side effects of sofosbuvir and velpatasvir combination include headache and tiredness. treatment may result in slowing of the heart rate along with other symptoms when taken with amiodarone (a medicine used to treat certain heart problems). ,sofosbuvir + velpatasvir
sign_symptom,adverse events,0.82072264," the most common adverse events (incidence greater than or equal to 20%, all grades) observed with sofosbuvir in combination with ribavirin were fatigue and headache. the most common adverse events observed with sofosbuvir in combination with peginterferon alfa and ribavirin were fatigue, headache, nausea, insomnia, anemia, pruritus, asthenia, rash, decreased appetite, chills, influenza like illness, pyrexia, diarrhea, neutropenia, myalgia, irritability. ",sofosbuvir
medication,sofosbuvir,0.8054266," the most common adverse events (incidence greater than or equal to 20%, all grades) observed with sofosbuvir in combination with ribavirin were fatigue and headache. the most common adverse events observed with sofosbuvir in combination with peginterferon alfa and ribavirin were fatigue, headache, nausea, insomnia, anemia, pruritus, asthenia, rash, decreased appetite, chills, influenza like illness, pyrexia, diarrhea, neutropenia, myalgia, irritability. ",sofosbuvir
medication,ribavirin,0.9973852," the most common adverse events (incidence greater than or equal to 20%, all grades) observed with sofosbuvir in combination with ribavirin were fatigue and headache. the most common adverse events observed with sofosbuvir in combination with peginterferon alfa and ribavirin were fatigue, headache, nausea, insomnia, anemia, pruritus, asthenia, rash, decreased appetite, chills, influenza like illness, pyrexia, diarrhea, neutropenia, myalgia, irritability. ",sofosbuvir
sign_symptom,fatigue,0.99992967," the most common adverse events (incidence greater than or equal to 20%, all grades) observed with sofosbuvir in combination with ribavirin were fatigue and headache. the most common adverse events observed with sofosbuvir in combination with peginterferon alfa and ribavirin were fatigue, headache, nausea, insomnia, anemia, pruritus, asthenia, rash, decreased appetite, chills, influenza like illness, pyrexia, diarrhea, neutropenia, myalgia, irritability. ",sofosbuvir
sign_symptom,headache,0.9969098," the most common adverse events (incidence greater than or equal to 20%, all grades) observed with sofosbuvir in combination with ribavirin were fatigue and headache. the most common adverse events observed with sofosbuvir in combination with peginterferon alfa and ribavirin were fatigue, headache, nausea, insomnia, anemia, pruritus, asthenia, rash, decreased appetite, chills, influenza like illness, pyrexia, diarrhea, neutropenia, myalgia, irritability. ",sofosbuvir
medication,peginterferon alfa,0.99301416," the most common adverse events (incidence greater than or equal to 20%, all grades) observed with sofosbuvir in combination with ribavirin were fatigue and headache. the most common adverse events observed with sofosbuvir in combination with peginterferon alfa and ribavirin were fatigue, headache, nausea, insomnia, anemia, pruritus, asthenia, rash, decreased appetite, chills, influenza like illness, pyrexia, diarrhea, neutropenia, myalgia, irritability. ",sofosbuvir
sign_symptom,nausea,0.99886787," the most common side effects are anorexia, nausea and vomiting. however, these side effects are minimized with the use of enteric coated tablets. effects on the cns include sedation, ataxia and tremor. these symptoms occur infrequently and usually respond to a decrease in doses. rash, alopecia and stimulation of appetite have been observed occasionally. sodium vaiproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. rarely a fulminate hepatitis that may be fatal may develop. children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of sodium valproate. ",sodium valproate
sign_symptom,vomiting,0.96842873," the most common side effects are anorexia, nausea and vomiting. however, these side effects are minimized with the use of enteric coated tablets. effects on the cns include sedation, ataxia and tremor. these symptoms occur infrequently and usually respond to a decrease in doses. rash, alopecia and stimulation of appetite have been observed occasionally. sodium vaiproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. rarely a fulminate hepatitis that may be fatal may develop. children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of sodium valproate. ",sodium valproate
sign_symptom,ataxia,0.7622154," the most common side effects are anorexia, nausea and vomiting. however, these side effects are minimized with the use of enteric coated tablets. effects on the cns include sedation, ataxia and tremor. these symptoms occur infrequently and usually respond to a decrease in doses. rash, alopecia and stimulation of appetite have been observed occasionally. sodium vaiproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. rarely a fulminate hepatitis that may be fatal may develop. children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of sodium valproate. ",sodium valproate
sign_symptom,tremor,0.9848475," the most common side effects are anorexia, nausea and vomiting. however, these side effects are minimized with the use of enteric coated tablets. effects on the cns include sedation, ataxia and tremor. these symptoms occur infrequently and usually respond to a decrease in doses. rash, alopecia and stimulation of appetite have been observed occasionally. sodium vaiproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. rarely a fulminate hepatitis that may be fatal may develop. children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of sodium valproate. ",sodium valproate
sign_symptom,symptoms,0.8084277," the most common side effects are anorexia, nausea and vomiting. however, these side effects are minimized with the use of enteric coated tablets. effects on the cns include sedation, ataxia and tremor. these symptoms occur infrequently and usually respond to a decrease in doses. rash, alopecia and stimulation of appetite have been observed occasionally. sodium vaiproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. rarely a fulminate hepatitis that may be fatal may develop. children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of sodium valproate. ",sodium valproate
sign_symptom,alopecia,0.9936207," the most common side effects are anorexia, nausea and vomiting. however, these side effects are minimized with the use of enteric coated tablets. effects on the cns include sedation, ataxia and tremor. these symptoms occur infrequently and usually respond to a decrease in doses. rash, alopecia and stimulation of appetite have been observed occasionally. sodium vaiproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. rarely a fulminate hepatitis that may be fatal may develop. children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of sodium valproate. ",sodium valproate
sign_symptom,stimulation of appetite,0.99945873," the most common side effects are anorexia, nausea and vomiting. however, these side effects are minimized with the use of enteric coated tablets. effects on the cns include sedation, ataxia and tremor. these symptoms occur infrequently and usually respond to a decrease in doses. rash, alopecia and stimulation of appetite have been observed occasionally. sodium vaiproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. rarely a fulminate hepatitis that may be fatal may develop. children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of sodium valproate. ",sodium valproate
medication,sodium vaiproate,0.9986628," the most common side effects are anorexia, nausea and vomiting. however, these side effects are minimized with the use of enteric coated tablets. effects on the cns include sedation, ataxia and tremor. these symptoms occur infrequently and usually respond to a decrease in doses. rash, alopecia and stimulation of appetite have been observed occasionally. sodium vaiproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. rarely a fulminate hepatitis that may be fatal may develop. children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of sodium valproate. ",sodium valproate
medication,antiep,0.7618431," the most common side effects are anorexia, nausea and vomiting. however, these side effects are minimized with the use of enteric coated tablets. effects on the cns include sedation, ataxia and tremor. these symptoms occur infrequently and usually respond to a decrease in doses. rash, alopecia and stimulation of appetite have been observed occasionally. sodium vaiproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. rarely a fulminate hepatitis that may be fatal may develop. children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of sodium valproate. ",sodium valproate
sign_symptom,hyper,0.9964497," the most common side effects are anorexia, nausea and vomiting. however, these side effects are minimized with the use of enteric coated tablets. effects on the cns include sedation, ataxia and tremor. these symptoms occur infrequently and usually respond to a decrease in doses. rash, alopecia and stimulation of appetite have been observed occasionally. sodium vaiproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. rarely a fulminate hepatitis that may be fatal may develop. children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of sodium valproate. ",sodium valproate
medication,sodium val,0.9861847," the most common side effects are anorexia, nausea and vomiting. however, these side effects are minimized with the use of enteric coated tablets. effects on the cns include sedation, ataxia and tremor. these symptoms occur infrequently and usually respond to a decrease in doses. rash, alopecia and stimulation of appetite have been observed occasionally. sodium vaiproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. rarely a fulminate hepatitis that may be fatal may develop. children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of sodium valproate. ",sodium valproate
sign_symptom,osmotic disturbances,0.99982107, osmotic disturbances. oral: catharsis (at high doses). ,sodium thiosulfate
sign_symptom,discomfort,0.9991215," like any active ingredient, this drug may cause more or less discomfort in some patients. ",sodium succinate + cytochrome c + adenosine + nicotinamide
medication,sodium stibogluconate,0.98917854," sodium stibogluconate is exceedingly toxic toveins. one of the practical problems is that after a few doses it can become exceedingly difficult to find a vein in which to inject the drug. the insertion of apiccdoes not prevent the problem and can instead exacerbate it: the entire vein along the course of the picc line can become inflamed andthrombose. large doses of sodium stibogluconate are often administered as dilute solutions.  pancreatitisis a common deleterious effect of the drug, and theserumamylaseorlipaseshould be monitored twice weekly; there is no need to stop treatment if the amylase remains less than four times the upper limit of normal; if the amylase rises above the cut-off, then treatment should be interrupted until the amylase falls to less than twice the upper limit of normal, whereupon treatment can be resumed. cardiac conduction disturbances are less common, butecgmonitoring while the medicine is injected is advisable and changes quickly reverse after the drug is stopped or the infusion rate is decreased.  the drug can be given intramuscularly but is exceedingly painful when given by this route. it can also be given intralesionally when treatingcutaneous leishmaniasis(i.e., injected directly into the area of infected skin) and again, this is exceedingly painful and does not give results superior to intravenous administration.  sodium stibogluconate can also cause a reduced appetite, metallic taste in mouth,nausea,vomiting,diarrhoea, headache, tiredness, joint pains, muscle aches, dizziness, andanaphylaxis. ",sodium stibogluconate
sign_symptom,cardiac,0.9123796," sodium stibogluconate is exceedingly toxic toveins. one of the practical problems is that after a few doses it can become exceedingly difficult to find a vein in which to inject the drug. the insertion of apiccdoes not prevent the problem and can instead exacerbate it: the entire vein along the course of the picc line can become inflamed andthrombose. large doses of sodium stibogluconate are often administered as dilute solutions.  pancreatitisis a common deleterious effect of the drug, and theserumamylaseorlipaseshould be monitored twice weekly; there is no need to stop treatment if the amylase remains less than four times the upper limit of normal; if the amylase rises above the cut-off, then treatment should be interrupted until the amylase falls to less than twice the upper limit of normal, whereupon treatment can be resumed. cardiac conduction disturbances are less common, butecgmonitoring while the medicine is injected is advisable and changes quickly reverse after the drug is stopped or the infusion rate is decreased.  the drug can be given intramuscularly but is exceedingly painful when given by this route. it can also be given intralesionally when treatingcutaneous leishmaniasis(i.e., injected directly into the area of infected skin) and again, this is exceedingly painful and does not give results superior to intravenous administration.  sodium stibogluconate can also cause a reduced appetite, metallic taste in mouth,nausea,vomiting,diarrhoea, headache, tiredness, joint pains, muscle aches, dizziness, andanaphylaxis. ",sodium stibogluconate
sign_symptom,nausea,0.9967181," the drug may cause some degree of gastric irritation. anorexia, nausea, vomiting, and constipation may occur especially if high doses are given. also, hypokalemia, hypocalcemia, and significant sodium retention, and their related clinical manifestations, may occur. occasionally diarrhea develops. large doses in elderly individuals may cause fecal impaction. rare instances of colonic necrosis have been reported. intestinal obstruction due to concretions of aluminum hydroxide, when used in combination with such resin has been reported. ",sodium polystyrene sulfonate
sign_symptom,vomiting,0.99952996," the drug may cause some degree of gastric irritation. anorexia, nausea, vomiting, and constipation may occur especially if high doses are given. also, hypokalemia, hypocalcemia, and significant sodium retention, and their related clinical manifestations, may occur. occasionally diarrhea develops. large doses in elderly individuals may cause fecal impaction. rare instances of colonic necrosis have been reported. intestinal obstruction due to concretions of aluminum hydroxide, when used in combination with such resin has been reported. ",sodium polystyrene sulfonate
sign_symptom,diarrhea,0.84746003," the drug may cause some degree of gastric irritation. anorexia, nausea, vomiting, and constipation may occur especially if high doses are given. also, hypokalemia, hypocalcemia, and significant sodium retention, and their related clinical manifestations, may occur. occasionally diarrhea develops. large doses in elderly individuals may cause fecal impaction. rare instances of colonic necrosis have been reported. intestinal obstruction due to concretions of aluminum hydroxide, when used in combination with such resin has been reported. ",sodium polystyrene sulfonate
sign_symptom,obstruction,0.74727905," the drug may cause some degree of gastric irritation. anorexia, nausea, vomiting, and constipation may occur especially if high doses are given. also, hypokalemia, hypocalcemia, and significant sodium retention, and their related clinical manifestations, may occur. occasionally diarrhea develops. large doses in elderly individuals may cause fecal impaction. rare instances of colonic necrosis have been reported. intestinal obstruction due to concretions of aluminum hydroxide, when used in combination with such resin has been reported. ",sodium polystyrene sulfonate
medication,aluminum,0.92487615," the drug may cause some degree of gastric irritation. anorexia, nausea, vomiting, and constipation may occur especially if high doses are given. also, hypokalemia, hypocalcemia, and significant sodium retention, and their related clinical manifestations, may occur. occasionally diarrhea develops. large doses in elderly individuals may cause fecal impaction. rare instances of colonic necrosis have been reported. intestinal obstruction due to concretions of aluminum hydroxide, when used in combination with such resin has been reported. ",sodium polystyrene sulfonate
sign_symptom,adverse reactions,0.99738383," most common adverse reactions (&gt;1%) are nausea, headache and vomiting (abdominal bloating, distension, pain/cramping and watery diarrhea not requiring an intervention were not collected). ",sodium picosulfate + magnesium oxide + citric acid
sign_symptom,nausea,0.99280095," most common adverse reactions (&gt;1%) are nausea, headache and vomiting (abdominal bloating, distension, pain/cramping and watery diarrhea not requiring an intervention were not collected). ",sodium picosulfate + magnesium oxide + citric acid
sign_symptom,headache,0.99996364," most common adverse reactions (&gt;1%) are nausea, headache and vomiting (abdominal bloating, distension, pain/cramping and watery diarrhea not requiring an intervention were not collected). ",sodium picosulfate + magnesium oxide + citric acid
sign_symptom,vomiting,0.99995995," most common adverse reactions (&gt;1%) are nausea, headache and vomiting (abdominal bloating, distension, pain/cramping and watery diarrhea not requiring an intervention were not collected). ",sodium picosulfate + magnesium oxide + citric acid
sign_symptom,pain,0.99995124," most common adverse reactions (&gt;1%) are nausea, headache and vomiting (abdominal bloating, distension, pain/cramping and watery diarrhea not requiring an intervention were not collected). ",sodium picosulfate + magnesium oxide + citric acid
sign_symptom,pain,0.99992657," hypersensitivity, dizziness, syncope, vasovagal response, gastrointestinal disorders, diarrhea, abdominal pain and abdominal cramps, nausea, vomiting. ",sodium picosulfate
sign_symptom,restlessness,0.9726725," bradyarrhythmia, hypotension, palpitations, tachyarrhythmia apprehension, restlessness, confusion, dizziness, headache, somnolence rash, sweating, thyroid suppression, injection site irritation, muscle twitch, oliguria, renal azotemia, cardiac dysrhythmia, hemorrhage, decreased platelet aggregation, excessive hypotensive response, raised intracranial pressure, metabolic acidosis, bowel obstruction, methemoglobinemia, cyanide poisoning, thiocyanate toxicity ",sodium nitroprusside dihydrate
sign_symptom,confusion,0.9921795," bradyarrhythmia, hypotension, palpitations, tachyarrhythmia apprehension, restlessness, confusion, dizziness, headache, somnolence rash, sweating, thyroid suppression, injection site irritation, muscle twitch, oliguria, renal azotemia, cardiac dysrhythmia, hemorrhage, decreased platelet aggregation, excessive hypotensive response, raised intracranial pressure, metabolic acidosis, bowel obstruction, methemoglobinemia, cyanide poisoning, thiocyanate toxicity ",sodium nitroprusside dihydrate
disease_disorder,cyanide,0.76885074," bradyarrhythmia, hypotension, palpitations, tachyarrhythmia apprehension, restlessness, confusion, dizziness, headache, somnolence rash, sweating, thyroid suppression, injection site irritation, muscle twitch, oliguria, renal azotemia, cardiac dysrhythmia, hemorrhage, decreased platelet aggregation, excessive hypotensive response, raised intracranial pressure, metabolic acidosis, bowel obstruction, methemoglobinemia, cyanide poisoning, thiocyanate toxicity ",sodium nitroprusside dihydrate
disease_disorder,thiocyanate toxicity,0.86003214," bradyarrhythmia, hypotension, palpitations, tachyarrhythmia apprehension, restlessness, confusion, dizziness, headache, somnolence rash, sweating, thyroid suppression, injection site irritation, muscle twitch, oliguria, renal azotemia, cardiac dysrhythmia, hemorrhage, decreased platelet aggregation, excessive hypotensive response, raised intracranial pressure, metabolic acidosis, bowel obstruction, methemoglobinemia, cyanide poisoning, thiocyanate toxicity ",sodium nitroprusside dihydrate
sign_symptom,blur,0.9999287," the chance of side effect is highly unlikely. however, transient blurring of vision may occur. ",sodium hyaluronate + carboxymethylcellulose sodium
sign_symptom,vision,0.9995419," the chance of side effect is highly unlikely. however, transient blurring of vision may occur. ",sodium hyaluronate + carboxymethylcellulose sodium
sign_symptom,blurred vision,0.92495614," transient burning sensation, temporarily blurred vision and transient rise in intraocular pressure. precautions: to avoid contamination, the tip of the container should not touch any surface and should be fully closed between applications. ",sodium hyaluronate (ophthalmic)
sign_symptom,swelling,0.99481505," the common side-effects include gastrointestinal complaints, injection site pain, knee swelling/effusion, local skin reactions (rash, ecchymosis), pruritus, and headache. ",sodium hyaluronate (injection)
medication,sodium fusidate,0.99918866," sodium fusidate ointment is remarkably well tolerated, and there is an extremely low frequency of hypersensitivity reactions. ",sodium fusidate (topical)
sign_symptom,hyper,0.95329475," sodium fusidate ointment is remarkably well tolerated, and there is an extremely low frequency of hypersensitivity reactions. ",sodium fusidate (topical)
sign_symptom,disturbances,0.84684795," gi disturbances eg, dyspepsia, nausea, vomiting, epigastric pain, anorexia; jaundice &amp; change of liver function. ",sodium fusidate (oral)
sign_symptom,hypersensitivity,0.9920472," hypersensitivity reactions, rash, nausea, vomiting. products containing stannous fluoride may cause teeth staining. ",sodium fluoride (mouthwash)
medication,biphosphate,0.79506487," gastrointestinal side effects of sodium biphosphate and sodium phosphate have included bloating (31% to 41%), nausea (26% to 30%), abdominal pain (23% to 25%), and vomiting (4% to 9%). nervous system side effects have included dizziness, headache, and seizures. renal side effects have included renal impairment, increased blood urea nitrogen (bun), increased creatinine, acute renal failure, acute phosphate nephropathy, nephrocalcinosis, and renal tubular necrosis. hypersensitivity reactions reported have included anaphylaxis, rash, pruritus, urticaria, throat tightness, bronchospasm, dyspnea . ",sodium dihydrogen phosphate + disodium hydrogen phosphate
sign_symptom,nausea,0.99990463," gastrointestinal side effects of sodium biphosphate and sodium phosphate have included bloating (31% to 41%), nausea (26% to 30%), abdominal pain (23% to 25%), and vomiting (4% to 9%). nervous system side effects have included dizziness, headache, and seizures. renal side effects have included renal impairment, increased blood urea nitrogen (bun), increased creatinine, acute renal failure, acute phosphate nephropathy, nephrocalcinosis, and renal tubular necrosis. hypersensitivity reactions reported have included anaphylaxis, rash, pruritus, urticaria, throat tightness, bronchospasm, dyspnea . ",sodium dihydrogen phosphate + disodium hydrogen phosphate
sign_symptom,pain,0.9998995," gastrointestinal side effects of sodium biphosphate and sodium phosphate have included bloating (31% to 41%), nausea (26% to 30%), abdominal pain (23% to 25%), and vomiting (4% to 9%). nervous system side effects have included dizziness, headache, and seizures. renal side effects have included renal impairment, increased blood urea nitrogen (bun), increased creatinine, acute renal failure, acute phosphate nephropathy, nephrocalcinosis, and renal tubular necrosis. hypersensitivity reactions reported have included anaphylaxis, rash, pruritus, urticaria, throat tightness, bronchospasm, dyspnea . ",sodium dihydrogen phosphate + disodium hydrogen phosphate
sign_symptom,vomiting,0.99988556," gastrointestinal side effects of sodium biphosphate and sodium phosphate have included bloating (31% to 41%), nausea (26% to 30%), abdominal pain (23% to 25%), and vomiting (4% to 9%). nervous system side effects have included dizziness, headache, and seizures. renal side effects have included renal impairment, increased blood urea nitrogen (bun), increased creatinine, acute renal failure, acute phosphate nephropathy, nephrocalcinosis, and renal tubular necrosis. hypersensitivity reactions reported have included anaphylaxis, rash, pruritus, urticaria, throat tightness, bronchospasm, dyspnea . ",sodium dihydrogen phosphate + disodium hydrogen phosphate
sign_symptom,hyper,0.9751517," gastrointestinal side effects of sodium biphosphate and sodium phosphate have included bloating (31% to 41%), nausea (26% to 30%), abdominal pain (23% to 25%), and vomiting (4% to 9%). nervous system side effects have included dizziness, headache, and seizures. renal side effects have included renal impairment, increased blood urea nitrogen (bun), increased creatinine, acute renal failure, acute phosphate nephropathy, nephrocalcinosis, and renal tubular necrosis. hypersensitivity reactions reported have included anaphylaxis, rash, pruritus, urticaria, throat tightness, bronchospasm, dyspnea . ",sodium dihydrogen phosphate + disodium hydrogen phosphate
sign_symptom,neut,0.77741444," the side effects like crystalluria, allergic reactions, haemolysis, thrombocytopenia, neutropenia, agranulocytosis etc. have been reported rarely with sulphamethoxazole-trimethoprim combination. other side effects are less serious in nature such as malaise, headache, nausea and vomiting. these are normally transient and do not require withdrawal of treatment. ",sulphamethoxazole + trimethoprim
disease_disorder,agranulocytosis,0.7494682," the side effects like crystalluria, allergic reactions, haemolysis, thrombocytopenia, neutropenia, agranulocytosis etc. have been reported rarely with sulphamethoxazole-trimethoprim combination. other side effects are less serious in nature such as malaise, headache, nausea and vomiting. these are normally transient and do not require withdrawal of treatment. ",sulphamethoxazole + trimethoprim
medication,trimethoprim,0.9507108," the side effects like crystalluria, allergic reactions, haemolysis, thrombocytopenia, neutropenia, agranulocytosis etc. have been reported rarely with sulphamethoxazole-trimethoprim combination. other side effects are less serious in nature such as malaise, headache, nausea and vomiting. these are normally transient and do not require withdrawal of treatment. ",sulphamethoxazole + trimethoprim
sign_symptom,mala,0.99789715," the side effects like crystalluria, allergic reactions, haemolysis, thrombocytopenia, neutropenia, agranulocytosis etc. have been reported rarely with sulphamethoxazole-trimethoprim combination. other side effects are less serious in nature such as malaise, headache, nausea and vomiting. these are normally transient and do not require withdrawal of treatment. ",sulphamethoxazole + trimethoprim
sign_symptom,nausea,0.758087," the side effects like crystalluria, allergic reactions, haemolysis, thrombocytopenia, neutropenia, agranulocytosis etc. have been reported rarely with sulphamethoxazole-trimethoprim combination. other side effects are less serious in nature such as malaise, headache, nausea and vomiting. these are normally transient and do not require withdrawal of treatment. ",sulphamethoxazole + trimethoprim
medication,amp ;,0.79548436," sulphadoxine &amp; pyrimethamine at the recommended dose is well tolerated. main side effects are given below  
 
  skin reactions : drug rash, pruritus and slight hair loss have been observed. 
  gastro-intestinal reactions:  feeling of fullness, nausea, rarely vomiting, stomatitis. 
  haematological reactions : in rare cases, leukopenia, thrombocytopenia, and megaloblastic anemia have been observed. 
  other reactions : fatigue, headache, fever, polyneuritis may occasionally occur. 
  ",sulphadoxine + pyrimethamine
medication,pyrimethamine,0.90092564," sulphadoxine &amp; pyrimethamine at the recommended dose is well tolerated. main side effects are given below  
 
  skin reactions : drug rash, pruritus and slight hair loss have been observed. 
  gastro-intestinal reactions:  feeling of fullness, nausea, rarely vomiting, stomatitis. 
  haematological reactions : in rare cases, leukopenia, thrombocytopenia, and megaloblastic anemia have been observed. 
  other reactions : fatigue, headache, fever, polyneuritis may occasionally occur. 
  ",sulphadoxine + pyrimethamine
sign_symptom,hair loss,0.99989," sulphadoxine &amp; pyrimethamine at the recommended dose is well tolerated. main side effects are given below  
 
  skin reactions : drug rash, pruritus and slight hair loss have been observed. 
  gastro-intestinal reactions:  feeling of fullness, nausea, rarely vomiting, stomatitis. 
  haematological reactions : in rare cases, leukopenia, thrombocytopenia, and megaloblastic anemia have been observed. 
  other reactions : fatigue, headache, fever, polyneuritis may occasionally occur. 
  ",sulphadoxine + pyrimethamine
sign_symptom,full,0.93563306," sulphadoxine &amp; pyrimethamine at the recommended dose is well tolerated. main side effects are given below  
 
  skin reactions : drug rash, pruritus and slight hair loss have been observed. 
  gastro-intestinal reactions:  feeling of fullness, nausea, rarely vomiting, stomatitis. 
  haematological reactions : in rare cases, leukopenia, thrombocytopenia, and megaloblastic anemia have been observed. 
  other reactions : fatigue, headache, fever, polyneuritis may occasionally occur. 
  ",sulphadoxine + pyrimethamine
sign_symptom,fatigue,0.9839676," sulphadoxine &amp; pyrimethamine at the recommended dose is well tolerated. main side effects are given below  
 
  skin reactions : drug rash, pruritus and slight hair loss have been observed. 
  gastro-intestinal reactions:  feeling of fullness, nausea, rarely vomiting, stomatitis. 
  haematological reactions : in rare cases, leukopenia, thrombocytopenia, and megaloblastic anemia have been observed. 
  other reactions : fatigue, headache, fever, polyneuritis may occasionally occur. 
  ",sulphadoxine + pyrimethamine
sign_symptom,headache,0.97098225," sulphadoxine &amp; pyrimethamine at the recommended dose is well tolerated. main side effects are given below  
 
  skin reactions : drug rash, pruritus and slight hair loss have been observed. 
  gastro-intestinal reactions:  feeling of fullness, nausea, rarely vomiting, stomatitis. 
  haematological reactions : in rare cases, leukopenia, thrombocytopenia, and megaloblastic anemia have been observed. 
  other reactions : fatigue, headache, fever, polyneuritis may occasionally occur. 
  ",sulphadoxine + pyrimethamine
sign_symptom,fever,0.7665161," sulphadoxine &amp; pyrimethamine at the recommended dose is well tolerated. main side effects are given below  
 
  skin reactions : drug rash, pruritus and slight hair loss have been observed. 
  gastro-intestinal reactions:  feeling of fullness, nausea, rarely vomiting, stomatitis. 
  haematological reactions : in rare cases, leukopenia, thrombocytopenia, and megaloblastic anemia have been observed. 
  other reactions : fatigue, headache, fever, polyneuritis may occasionally occur. 
  ",sulphadoxine + pyrimethamine
disease_disorder,polyneuritis,0.9658015," sulphadoxine &amp; pyrimethamine at the recommended dose is well tolerated. main side effects are given below  
 
  skin reactions : drug rash, pruritus and slight hair loss have been observed. 
  gastro-intestinal reactions:  feeling of fullness, nausea, rarely vomiting, stomatitis. 
  haematological reactions : in rare cases, leukopenia, thrombocytopenia, and megaloblastic anemia have been observed. 
  other reactions : fatigue, headache, fever, polyneuritis may occasionally occur. 
  ",sulphadoxine + pyrimethamine
sign_symptom,effects,0.8252276," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,nausea,0.9998578," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,bleeding,0.99975663," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,headache,0.99298865," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,light - headed,0.82099205," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,blurred vision,0.99933064," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,rash,0.93304694," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,hyper,0.9871503," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,fever,0.999803," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,chill,0.98587877," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
disease_disorder,renal toxicity,0.8735249," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,arthralgia,0.98457646," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,epita,0.7666185," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,hyperkalaemia,0.9853975," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,hepatitis,0.73461264," gastrointestinal side effects are the most common and consist of abdominal pain, nausea and constipation. gastrointestinal ulceration and bleeding may also occur. the most frequently reported central nervous system side effects are drowsiness, dizziness, headache and nervousness. other adverse effects include depression, tinnitus, confusion, light-headedness, insomnia, psychiatric disturbances, syncope, convulsions, coma, peripheral neuropathy, blurred vision and other ocular effects, oedema and mass gain, hypertension, hematuria, skin rashes, pruritus, urticaria, stomatitis, alopecia and hypersensitivity reactions. a hypersensitivity syndrome consisting of fever and chills, skin rashes or other cutaneous manifestations, hepatotoxicity, renal toxicity (including renal failure), leukopenia, thrombocytopenia, eosinophilia, inflammed glands or lymph nodes, and arthralgia have been reported. leucopenia, purpura, thrombocytopenia, aplastic anaemia, haemolytic anaemia, agranulocytosis, epitaxis, hyperglycaemia, hyperkalaemia and vaginal bleeding have been reported. there have also been reports of hepatitis and jaundice or renal failure. ",sulindac
sign_symptom,upset,0.99974316," the symptoms are upset stomach, vomiting, loss of appetite and joint pain. if you experience any of the following symptoms like difficulty in breathing, tightness in the chest, skin rash, unusual bleeding, fever, sore throat and mouth sores, call your doctor immediately. ",sulfinpyrazone
sign_symptom,loss of appetite,0.9998932," the symptoms are upset stomach, vomiting, loss of appetite and joint pain. if you experience any of the following symptoms like difficulty in breathing, tightness in the chest, skin rash, unusual bleeding, fever, sore throat and mouth sores, call your doctor immediately. ",sulfinpyrazone
sign_symptom,difficulty,0.9921428," the symptoms are upset stomach, vomiting, loss of appetite and joint pain. if you experience any of the following symptoms like difficulty in breathing, tightness in the chest, skin rash, unusual bleeding, fever, sore throat and mouth sores, call your doctor immediately. ",sulfinpyrazone
sign_symptom,tightness,0.99824715," the symptoms are upset stomach, vomiting, loss of appetite and joint pain. if you experience any of the following symptoms like difficulty in breathing, tightness in the chest, skin rash, unusual bleeding, fever, sore throat and mouth sores, call your doctor immediately. ",sulfinpyrazone
sign_symptom,dyspepsia,0.9551096," the common adverse reactions are anorexia, headache, nausea, vomiting, gastric distress, dyspepsia, abdominal pain, dizziness, apparently reversible oligospermia etc. ",sulfasalazine
disease_disorder,oligo,0.9946803," the common adverse reactions are anorexia, headache, nausea, vomiting, gastric distress, dyspepsia, abdominal pain, dizziness, apparently reversible oligospermia etc. ",sulfasalazine
sign_symptom,ulcers,0.9666613," bacterial and fungal corneal ulcers have developed during treatment with sulfonamide ophthalmic preparations. the most frequently reported reactions are local irritation, stinging and burning. less commonly reported reactions include non-specific conjunctivitis, conjunctival hyperemia, secondary infections and allergic reactions.  fatalities have occurred, although rarely, due to severe reactions to sulfonamides including stevens-johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias ",sulfacetamide sodium
sign_symptom,dyscrasias,0.99570835," bacterial and fungal corneal ulcers have developed during treatment with sulfonamide ophthalmic preparations. the most frequently reported reactions are local irritation, stinging and burning. less commonly reported reactions include non-specific conjunctivitis, conjunctival hyperemia, secondary infections and allergic reactions.  fatalities have occurred, although rarely, due to severe reactions to sulfonamides including stevens-johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias ",sulfacetamide sodium
sign_symptom,adverse reactions,0.99993616, there were no systemic effects and only infrequent cutaneous adverse reactions in 370 patients treated with sulconazole nitrate solution in controlled clinical trials. approximately 1% of these patients reported itching and 1% burning or stinging. these complaints did not usually interfere with treatment. ,sulconazole nitrate
medication,sulconazole nitrate solution,0.94022924, there were no systemic effects and only infrequent cutaneous adverse reactions in 370 patients treated with sulconazole nitrate solution in controlled clinical trials. approximately 1% of these patients reported itching and 1% burning or stinging. these complaints did not usually interfere with treatment. ,sulconazole nitrate
sign_symptom,side effects,0.99725777, no known side effects ,sucralose
sign_symptom,adverse,0.79696876," the most common adverse event was headache (3.4%) followed by nausea (2.3%), abdominal pain (2.3%), constipation (1.1%), diarrhea (1.1%), and urticaria (1.1%). the majority of patients who reported bezoars, had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. episodes of hyperglycemia have been reported in diabetic patient. ",sucralfate
sign_symptom,headache,0.99995077," the most common adverse event was headache (3.4%) followed by nausea (2.3%), abdominal pain (2.3%), constipation (1.1%), diarrhea (1.1%), and urticaria (1.1%). the majority of patients who reported bezoars, had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. episodes of hyperglycemia have been reported in diabetic patient. ",sucralfate
sign_symptom,nausea,0.99995184," the most common adverse event was headache (3.4%) followed by nausea (2.3%), abdominal pain (2.3%), constipation (1.1%), diarrhea (1.1%), and urticaria (1.1%). the majority of patients who reported bezoars, had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. episodes of hyperglycemia have been reported in diabetic patient. ",sucralfate
sign_symptom,pain,0.9999467," the most common adverse event was headache (3.4%) followed by nausea (2.3%), abdominal pain (2.3%), constipation (1.1%), diarrhea (1.1%), and urticaria (1.1%). the majority of patients who reported bezoars, had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. episodes of hyperglycemia have been reported in diabetic patient. ",sucralfate
sign_symptom,consti,0.9907613," the most common adverse event was headache (3.4%) followed by nausea (2.3%), abdominal pain (2.3%), constipation (1.1%), diarrhea (1.1%), and urticaria (1.1%). the majority of patients who reported bezoars, had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. episodes of hyperglycemia have been reported in diabetic patient. ",sucralfate
sign_symptom,diarrhea,0.99889547," the most common adverse event was headache (3.4%) followed by nausea (2.3%), abdominal pain (2.3%), constipation (1.1%), diarrhea (1.1%), and urticaria (1.1%). the majority of patients who reported bezoars, had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. episodes of hyperglycemia have been reported in diabetic patient. ",sucralfate
sign_symptom,hyperglycemia,0.9163095," the most common adverse event was headache (3.4%) followed by nausea (2.3%), abdominal pain (2.3%), constipation (1.1%), diarrhea (1.1%), and urticaria (1.1%). the majority of patients who reported bezoars, had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. episodes of hyperglycemia have been reported in diabetic patient. ",sucralfate
medication,stron,0.76250446," like all medicines, strontiumcan cause side effects, although not everybody gets them. the most common side effects are nausea, diarrhoea, headache and skin irritation. however,these effects were mild and short-lived and usually did not cause the patients to stop taking their treatment. other events less commonly reported included blood clots, fainting fit, memory troubles and, in rare cases, seizures. if any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. ",strontium ranelate
sign_symptom,headache,0.99974865," like all medicines, strontiumcan cause side effects, although not everybody gets them. the most common side effects are nausea, diarrhoea, headache and skin irritation. however,these effects were mild and short-lived and usually did not cause the patients to stop taking their treatment. other events less commonly reported included blood clots, fainting fit, memory troubles and, in rare cases, seizures. if any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. ",strontium ranelate
sign_symptom,troubles,0.93413," like all medicines, strontiumcan cause side effects, although not everybody gets them. the most common side effects are nausea, diarrhoea, headache and skin irritation. however,these effects were mild and short-lived and usually did not cause the patients to stop taking their treatment. other events less commonly reported included blood clots, fainting fit, memory troubles and, in rare cases, seizures. if any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. ",strontium ranelate
sign_symptom,side effects,0.97721297," like all medicines, strontiumcan cause side effects, although not everybody gets them. the most common side effects are nausea, diarrhoea, headache and skin irritation. however,these effects were mild and short-lived and usually did not cause the patients to stop taking their treatment. other events less commonly reported included blood clots, fainting fit, memory troubles and, in rare cases, seizures. if any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. ",strontium ranelate
sign_symptom,para,0.98994595," neurotoxic reactions (e.g. vestibular and cochlear function disturbance, optic nerve dysfunction, peripheral neuritis, arachnoiditis, encephalopathy); paraesthesia of face, rash, fever, angioneurotic oedema, eosinophilia; exfoliative dermatitis, azotemia, leucopenia, thrombocytopenia, pancytopenia, haemolytic anaemia, muscular weakness, amblyopia. ",streptomycin
sign_symptom,headache,0.9999161," the following adverse reactions are based on experience from clinical trials and on post marketing experience of streptokinase.  general disorders: 
 
  common : headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. 
 
haemorrhage and bleeding: 
 
  common : haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. 
  uncommon : intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. blood transfusions are rarely required. 
 
immune system disorders: 
 
  very common : development of antistreptokinase antibodies 
  common : allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension. 
 
nervous system disorders: 
 
  rare : neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain. 
 
cardiac complication and vascular disorders: 
 
  very common : hypotension, heart rate and rhythm disorders, angina pectoris. 
  common : recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. 
  uncommon : cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism. 
 
respiratory disorders: 
 
  very rare : non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction. 
 
gastrointestinal disorders: 
 
  common : nausea, diarrhoea, epigastric pain and vomiting. 
  ",streptokinase
sign_symptom,pain,0.9999176," the following adverse reactions are based on experience from clinical trials and on post marketing experience of streptokinase.  general disorders: 
 
  common : headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. 
 
haemorrhage and bleeding: 
 
  common : haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. 
  uncommon : intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. blood transfusions are rarely required. 
 
immune system disorders: 
 
  very common : development of antistreptokinase antibodies 
  common : allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension. 
 
nervous system disorders: 
 
  rare : neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain. 
 
cardiac complication and vascular disorders: 
 
  very common : hypotension, heart rate and rhythm disorders, angina pectoris. 
  common : recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. 
  uncommon : cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism. 
 
respiratory disorders: 
 
  very rare : non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction. 
 
gastrointestinal disorders: 
 
  common : nausea, diarrhoea, epigastric pain and vomiting. 
  ",streptokinase
sign_symptom,chills,0.954967," the following adverse reactions are based on experience from clinical trials and on post marketing experience of streptokinase.  general disorders: 
 
  common : headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. 
 
haemorrhage and bleeding: 
 
  common : haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. 
  uncommon : intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. blood transfusions are rarely required. 
 
immune system disorders: 
 
  very common : development of antistreptokinase antibodies 
  common : allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension. 
 
nervous system disorders: 
 
  rare : neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain. 
 
cardiac complication and vascular disorders: 
 
  very common : hypotension, heart rate and rhythm disorders, angina pectoris. 
  common : recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. 
  uncommon : cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism. 
 
respiratory disorders: 
 
  very rare : non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction. 
 
gastrointestinal disorders: 
 
  common : nausea, diarrhoea, epigastric pain and vomiting. 
  ",streptokinase
sign_symptom,fever,0.9993661," the following adverse reactions are based on experience from clinical trials and on post marketing experience of streptokinase.  general disorders: 
 
  common : headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. 
 
haemorrhage and bleeding: 
 
  common : haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. 
  uncommon : intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. blood transfusions are rarely required. 
 
immune system disorders: 
 
  very common : development of antistreptokinase antibodies 
  common : allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension. 
 
nervous system disorders: 
 
  rare : neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain. 
 
cardiac complication and vascular disorders: 
 
  very common : hypotension, heart rate and rhythm disorders, angina pectoris. 
  common : recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. 
  uncommon : cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism. 
 
respiratory disorders: 
 
  very rare : non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction. 
 
gastrointestinal disorders: 
 
  common : nausea, diarrhoea, epigastric pain and vomiting. 
  ",streptokinase
sign_symptom,mala,0.9036285," the following adverse reactions are based on experience from clinical trials and on post marketing experience of streptokinase.  general disorders: 
 
  common : headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. 
 
haemorrhage and bleeding: 
 
  common : haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. 
  uncommon : intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. blood transfusions are rarely required. 
 
immune system disorders: 
 
  very common : development of antistreptokinase antibodies 
  common : allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension. 
 
nervous system disorders: 
 
  rare : neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain. 
 
cardiac complication and vascular disorders: 
 
  very common : hypotension, heart rate and rhythm disorders, angina pectoris. 
  common : recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. 
  uncommon : cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism. 
 
respiratory disorders: 
 
  very rare : non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction. 
 
gastrointestinal disorders: 
 
  common : nausea, diarrhoea, epigastric pain and vomiting. 
  ",streptokinase
sign_symptom,bleeding,0.9995931," the following adverse reactions are based on experience from clinical trials and on post marketing experience of streptokinase.  general disorders: 
 
  common : headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. 
 
haemorrhage and bleeding: 
 
  common : haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. 
  uncommon : intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. blood transfusions are rarely required. 
 
immune system disorders: 
 
  very common : development of antistreptokinase antibodies 
  common : allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension. 
 
nervous system disorders: 
 
  rare : neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain. 
 
cardiac complication and vascular disorders: 
 
  very common : hypotension, heart rate and rhythm disorders, angina pectoris. 
  common : recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. 
  uncommon : cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism. 
 
respiratory disorders: 
 
  very rare : non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction. 
 
gastrointestinal disorders: 
 
  common : nausea, diarrhoea, epigastric pain and vomiting. 
  ",streptokinase
sign_symptom,antist,0.9535654," the following adverse reactions are based on experience from clinical trials and on post marketing experience of streptokinase.  general disorders: 
 
  common : headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. 
 
haemorrhage and bleeding: 
 
  common : haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. 
  uncommon : intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. blood transfusions are rarely required. 
 
immune system disorders: 
 
  very common : development of antistreptokinase antibodies 
  common : allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension. 
 
nervous system disorders: 
 
  rare : neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain. 
 
cardiac complication and vascular disorders: 
 
  very common : hypotension, heart rate and rhythm disorders, angina pectoris. 
  common : recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. 
  uncommon : cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism. 
 
respiratory disorders: 
 
  very rare : non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction. 
 
gastrointestinal disorders: 
 
  common : nausea, diarrhoea, epigastric pain and vomiting. 
  ",streptokinase
sign_symptom,allergic - anaphylactic reactions,0.8764649," the following adverse reactions are based on experience from clinical trials and on post marketing experience of streptokinase.  general disorders: 
 
  common : headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. 
 
haemorrhage and bleeding: 
 
  common : haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. 
  uncommon : intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. blood transfusions are rarely required. 
 
immune system disorders: 
 
  very common : development of antistreptokinase antibodies 
  common : allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension. 
 
nervous system disorders: 
 
  rare : neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain. 
 
cardiac complication and vascular disorders: 
 
  very common : hypotension, heart rate and rhythm disorders, angina pectoris. 
  common : recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. 
  uncommon : cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism. 
 
respiratory disorders: 
 
  very rare : non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction. 
 
gastrointestinal disorders: 
 
  common : nausea, diarrhoea, epigastric pain and vomiting. 
  ",streptokinase
sign_symptom,symptoms,0.86258465," the following adverse reactions are based on experience from clinical trials and on post marketing experience of streptokinase.  general disorders: 
 
  common : headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. 
 
haemorrhage and bleeding: 
 
  common : haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. 
  uncommon : intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. blood transfusions are rarely required. 
 
immune system disorders: 
 
  very common : development of antistreptokinase antibodies 
  common : allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension. 
 
nervous system disorders: 
 
  rare : neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain. 
 
cardiac complication and vascular disorders: 
 
  very common : hypotension, heart rate and rhythm disorders, angina pectoris. 
  common : recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. 
  uncommon : cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism. 
 
respiratory disorders: 
 
  very rare : non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction. 
 
gastrointestinal disorders: 
 
  common : nausea, diarrhoea, epigastric pain and vomiting. 
  ",streptokinase
sign_symptom,agitation,0.9996383," the following adverse reactions are based on experience from clinical trials and on post marketing experience of streptokinase.  general disorders: 
 
  common : headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. 
 
haemorrhage and bleeding: 
 
  common : haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. 
  uncommon : intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. blood transfusions are rarely required. 
 
immune system disorders: 
 
  very common : development of antistreptokinase antibodies 
  common : allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension. 
 
nervous system disorders: 
 
  rare : neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain. 
 
cardiac complication and vascular disorders: 
 
  very common : hypotension, heart rate and rhythm disorders, angina pectoris. 
  common : recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. 
  uncommon : cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism. 
 
respiratory disorders: 
 
  very rare : non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction. 
 
gastrointestinal disorders: 
 
  common : nausea, diarrhoea, epigastric pain and vomiting. 
  ",streptokinase
disease_disorder,cardiovascular,0.8955486," the following adverse reactions are based on experience from clinical trials and on post marketing experience of streptokinase.  general disorders: 
 
  common : headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. 
 
haemorrhage and bleeding: 
 
  common : haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. 
  uncommon : intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. blood transfusions are rarely required. 
 
immune system disorders: 
 
  very common : development of antistreptokinase antibodies 
  common : allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension. 
 
nervous system disorders: 
 
  rare : neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain. 
 
cardiac complication and vascular disorders: 
 
  very common : hypotension, heart rate and rhythm disorders, angina pectoris. 
  common : recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. 
  uncommon : cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism. 
 
respiratory disorders: 
 
  very rare : non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction. 
 
gastrointestinal disorders: 
 
  common : nausea, diarrhoea, epigastric pain and vomiting. 
  ",streptokinase
sign_symptom,gynaecomastia,0.9730645," gynaecomastia may develop in association with the use of spironolactone. other adverse reactions are: gi symptoms including cramping and diarrhoea, drowsiness, lethargy, headache, urticaria, mental confusion, impotence, irregular menses or amenorrhoea and post-menopausal bleeding. ",spironolactone
sign_symptom,symptoms,0.8075006," gynaecomastia may develop in association with the use of spironolactone. other adverse reactions are: gi symptoms including cramping and diarrhoea, drowsiness, lethargy, headache, urticaria, mental confusion, impotence, irregular menses or amenorrhoea and post-menopausal bleeding. ",spironolactone
sign_symptom,diarrhoea,0.9923036," gynaecomastia may develop in association with the use of spironolactone. other adverse reactions are: gi symptoms including cramping and diarrhoea, drowsiness, lethargy, headache, urticaria, mental confusion, impotence, irregular menses or amenorrhoea and post-menopausal bleeding. ",spironolactone
sign_symptom,drowsiness,0.7650521," gynaecomastia may develop in association with the use of spironolactone. other adverse reactions are: gi symptoms including cramping and diarrhoea, drowsiness, lethargy, headache, urticaria, mental confusion, impotence, irregular menses or amenorrhoea and post-menopausal bleeding. ",spironolactone
sign_symptom,impotence,0.8473651," gynaecomastia may develop in association with the use of spironolactone. other adverse reactions are: gi symptoms including cramping and diarrhoea, drowsiness, lethargy, headache, urticaria, mental confusion, impotence, irregular menses or amenorrhoea and post-menopausal bleeding. ",spironolactone
sign_symptom,menses,0.9695209," gynaecomastia may develop in association with the use of spironolactone. other adverse reactions are: gi symptoms including cramping and diarrhoea, drowsiness, lethargy, headache, urticaria, mental confusion, impotence, irregular menses or amenorrhoea and post-menopausal bleeding. ",spironolactone
sign_symptom,amenorrhoea,0.99836934," gynaecomastia may develop in association with the use of spironolactone. other adverse reactions are: gi symptoms including cramping and diarrhoea, drowsiness, lethargy, headache, urticaria, mental confusion, impotence, irregular menses or amenorrhoea and post-menopausal bleeding. ",spironolactone
sign_symptom,tingling,0.9990916," side effects of include: nausea, vomiting, diarrhea, inflamed bowels, pruritus (itchy skin), tingling or numbness in the skin. ",spiramycin
sign_symptom,numbness,0.99202895," side effects of include: nausea, vomiting, diarrhea, inflamed bowels, pruritus (itchy skin), tingling or numbness in the skin. ",spiramycin
sign_symptom,sore,0.99994445," the following reactions were observed during the single dose clinical trials: soreness at the injection site, urticaria, dizziness, nausea, chills, fever and insomnia ",spectinomycin
sign_symptom,nausea,0.92662823," the following reactions were observed during the single dose clinical trials: soreness at the injection site, urticaria, dizziness, nausea, chills, fever and insomnia ",spectinomycin
sign_symptom,chill,0.99884903," the following reactions were observed during the single dose clinical trials: soreness at the injection site, urticaria, dizziness, nausea, chills, fever and insomnia ",spectinomycin
sign_symptom,fever,0.9998412," the following reactions were observed during the single dose clinical trials: soreness at the injection site, urticaria, dizziness, nausea, chills, fever and insomnia ",spectinomycin
sign_symptom,adverse events,0.9989455," most of the adverse events were mild to moderate in severity and transient in nature. the most frequently reported events among the sparfloxacin treated patients with the recommended dosage are: diarrhea, nausea, headache, dyspepsia, dizziness, insomnia, abdominal pain and qtc interval prolongation. ",sparfloxacin
medication,sparfloxacin,0.99870205," most of the adverse events were mild to moderate in severity and transient in nature. the most frequently reported events among the sparfloxacin treated patients with the recommended dosage are: diarrhea, nausea, headache, dyspepsia, dizziness, insomnia, abdominal pain and qtc interval prolongation. ",sparfloxacin
sign_symptom,pain,0.92408085," most of the adverse events were mild to moderate in severity and transient in nature. the most frequently reported events among the sparfloxacin treated patients with the recommended dosage are: diarrhea, nausea, headache, dyspepsia, dizziness, insomnia, abdominal pain and qtc interval prolongation. ",sparfloxacin
sign_symptom,adverse effects,0.85046214, the most significant adverse effects are those which are typical of its class i and class ii (cardiac action potential duration prolongation) effects. ,sotalol hydrochloride
sign_symptom,rash,0.99972135," rash and hand-foot skin reactions. hypophosphataemia, hypertension, bleeding, tinnitus, depression and erectile dysfunction. alopecia, pruritus, dry skin, erythema, acne, flushing, exfoliative dermatitis, hoarseness, gi disturbances, arthralgia, myalgia, asthenia, pain and peripheral neuropathy. ",sorafenib tosylate
disease_disorder,erect,0.9467241," rash and hand-foot skin reactions. hypophosphataemia, hypertension, bleeding, tinnitus, depression and erectile dysfunction. alopecia, pruritus, dry skin, erythema, acne, flushing, exfoliative dermatitis, hoarseness, gi disturbances, arthralgia, myalgia, asthenia, pain and peripheral neuropathy. ",sorafenib tosylate
sign_symptom,headache,0.97424906," the most common side effects of somatropin include headaches, muscle pain, joint stiffness, high blood sugar (hyperglycemia), sugar in your urine (glucosuria). ",somatropin
sign_symptom,stiff,0.96732205," the most common side effects of somatropin include headaches, muscle pain, joint stiffness, high blood sugar (hyperglycemia), sugar in your urine (glucosuria). ",somatropin
sign_symptom,adverse reactions,0.99392223," the most common adverse reactions (&gt;2%) are nausea, headache, diarrhea, vomiting, and dizziness ",tedizolid phosphate
sign_symptom,vomiting,0.99970144," the most common adverse reactions (&gt;2%) are nausea, headache, diarrhea, vomiting, and dizziness ",tedizolid phosphate
sign_symptom,irritation,0.9978126," topical treatment with tea tree oil (tto) enriched with geothermal water is generally well tolerated. as with other shampoos, a local burning sensation, itching or contact dermatitis (due to irritation or allergy) may occur on exposed areas. oily and dry hair have been reported rarely with the use of tea tree oil (tto) enriched with geothermal water. ",tea tree oil + geothermal water (hair & body)
sign_symptom,oily,0.9982017," topical treatment with tea tree oil (tto) enriched with geothermal water is generally well tolerated. as with other shampoos, a local burning sensation, itching or contact dermatitis (due to irritation or allergy) may occur on exposed areas. oily and dry hair have been reported rarely with the use of tea tree oil (tto) enriched with geothermal water. ",tea tree oil + geothermal water (hair & body)
sign_symptom,dry hair,0.9992304," topical treatment with tea tree oil (tto) enriched with geothermal water is generally well tolerated. as with other shampoos, a local burning sensation, itching or contact dermatitis (due to irritation or allergy) may occur on exposed areas. oily and dry hair have been reported rarely with the use of tea tree oil (tto) enriched with geothermal water. ",tea tree oil + geothermal water (hair & body)
sign_symptom,adverse events,0.9998723," the most frequent adverse events reported with tazarotene cream were limited to the skin. those occurring in 10 to 23% of patients, in descending order, included pruritus, erythema and burning. for acne treatment, in 10 to 30% patients, it is reported desquamation, dry skin, face pain, irritation and stinging sensation. ",tazarotene
sign_symptom,irritation,0.71061254," the most frequent adverse events reported with tazarotene cream were limited to the skin. those occurring in 10 to 23% of patients, in descending order, included pruritus, erythema and burning. for acne treatment, in 10 to 30% patients, it is reported desquamation, dry skin, face pain, irritation and stinging sensation. ",tazarotene
sign_symptom,adverse,0.8902416," the following treatment-emergent adverse events may happen: heart rate increased, heart rate decreased, visual disturbance, abdominal discomfort, impaired gastric emptying, irritability, edema, drug withdrawal syndrome, hypersensitivity, involuntary muscle contractions, sensation of heaviness, hypoesthesia, paresthesia, disturbance in attention, sedation, dysarthria, memory impairment, ataxia, presyncope, syncope, coordination abnormal, seizure, urticaria, blood pressure decreased etc. ",tapentadol hydrochloride
sign_symptom,disturbance,0.9886283," the following treatment-emergent adverse events may happen: heart rate increased, heart rate decreased, visual disturbance, abdominal discomfort, impaired gastric emptying, irritability, edema, drug withdrawal syndrome, hypersensitivity, involuntary muscle contractions, sensation of heaviness, hypoesthesia, paresthesia, disturbance in attention, sedation, dysarthria, memory impairment, ataxia, presyncope, syncope, coordination abnormal, seizure, urticaria, blood pressure decreased etc. ",tapentadol hydrochloride
sign_symptom,syncope,0.84645," the following treatment-emergent adverse events may happen: heart rate increased, heart rate decreased, visual disturbance, abdominal discomfort, impaired gastric emptying, irritability, edema, drug withdrawal syndrome, hypersensitivity, involuntary muscle contractions, sensation of heaviness, hypoesthesia, paresthesia, disturbance in attention, sedation, dysarthria, memory impairment, ataxia, presyncope, syncope, coordination abnormal, seizure, urticaria, blood pressure decreased etc. ",tapentadol hydrochloride
sign_symptom,adverse reactions,0.9997324," the most common adverse reactions reported in subjects receiving combination therapy were impotence, decreased libido, breast disorders (including breast enlargement and tenderness), ejaculation disorders and dizziness. the percentages of subjects with ejaculation disorders, decreased libido and impotence were higher in the combination therapy group compared with either monotherapy groups. ",tamsulosin hydrochloride + dutasteride
sign_symptom,ejaculation disorders,0.9294645," the most common adverse reactions reported in subjects receiving combination therapy were impotence, decreased libido, breast disorders (including breast enlargement and tenderness), ejaculation disorders and dizziness. the percentages of subjects with ejaculation disorders, decreased libido and impotence were higher in the combination therapy group compared with either monotherapy groups. ",tamsulosin hydrochloride + dutasteride
sign_symptom,adverse reactions,0.9962619," the following adverse reactions have been reported during the use of tamsulosin: dizziness, abnormal ejaculation and; less frequently headache, asthenia, postural hypotension and palpitations. ",tamsulosin  hydrochloride
sign_symptom,ejaculation,0.9911399," the following adverse reactions have been reported during the use of tamsulosin: dizziness, abnormal ejaculation and; less frequently headache, asthenia, postural hypotension and palpitations. ",tamsulosin  hydrochloride
sign_symptom,light - headedness,0.9814708," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
sign_symptom,fluid retention,0.99726176," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
sign_symptom,rash,0.99520004," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
disease_disorder,stevens johnson syndrome,0.9928797," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
sign_symptom,metasta,0.7791213," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
sign_symptom,hyper,0.99994683," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
medication,tamoxife,0.93419963," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
sign_symptom,visual disturbances,0.9998541," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
sign_symptom,corneal changes,0.9998047," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
sign_symptom,retinopathy,0.9827917," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
sign_symptom,catara,0.9622576," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
sign_symptom,endome,0.96976084," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
sign_symptom,polyps,0.99077934," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
disease_disorder,deep,0.9149754," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
disease_disorder,thrombosis,0.99165666," side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare or as more general side effects, e.g., gastrointestinal intolerance, headache, light-headedness and occasionally fluid retention and alopecia. when such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease.  skin rashes including isolated reports of erythema multiforme, stevens johnson syndrome and bullous pemphigoid and rare hypersensitivity reactions, including angio-oedema have been reported. a small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy.  falls in platelet count, usually only to 80,000-90,000 per/mm3 but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.  a number of cases of visual disturbances including infrequent reports of corneal changes and retinopathy have been described in patients receiving tamoxifen therapy. an increased incidence of cataracts has been reported in association with the administration of the drug. uterine fibroids and endometrial changes including hyperplasia and polyps have been reported. cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen.  leucopenia has been observed following the administration of tamoxifen, sometimes in association with anaemia and/or thrombocytopenia. neutropenia has been reported on rare occasions; this can sometimes be severe. there is evidence of an increased incidence of thromboembolic events including deep vein thrombosis and pulmonary embolism during tamoxifen therapy.  tamoxifen has been associated with changes in liver enzyme levels and on rare occasions with a spectrum of more severe liver abnormalities, including fatty liver, cholestasis and hepatitis. rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen. ",tamoxifen citrate
sign_symptom,irritation,0.9995415, the most frequently reported treatment-related side effect is ocular hyperemia. rare side effects observed include eye irritation and blurred vision. ,tafluprost
sign_symptom,dyspe,0.92267245," headache, dyspepsia, back pain, myalgia, nasal pharyngitis, nasal congestion are common side effects. change in color vision, sudden vision loss, hearing loss, stevens-johnson syndrome, exfoliative dermatitis, angina, stroke, myocardial infarction, severe hypotension, tachycardia may also occur rarely. ",tadalafil
sign_symptom,myal,0.78134084," headache, dyspepsia, back pain, myalgia, nasal pharyngitis, nasal congestion are common side effects. change in color vision, sudden vision loss, hearing loss, stevens-johnson syndrome, exfoliative dermatitis, angina, stroke, myocardial infarction, severe hypotension, tachycardia may also occur rarely. ",tadalafil
medication,tacrolimus,0.98142636," topically applied tacrolimus ointment have very few and rare type of side-effects including skin burning, pruritus, flu-like symptoms, allergic reactions, skin erythema, skin infections, headache, etc. ",tacrolimus (topical)
sign_symptom,flu - like symptoms,0.9096941," topically applied tacrolimus ointment have very few and rare type of side-effects including skin burning, pruritus, flu-like symptoms, allergic reactions, skin erythema, skin infections, headache, etc. ",tacrolimus (topical)
sign_symptom,respiratory,0.9852297,"  cardiovascular : bradycardia, tachycardia, hypertension, hypotension, arrhythmias.    respiratory : bronchospasm, prolonged respiratory depression and apnea.    musculoskeletal : muscle fasciculation, post-operative muscle pains, myoglobinemia.    others : hyperthermia, increased intra-ocular pressure increased intra-gastric pressure, rash, excessive salivation. ",suxamethonium chloride
sign_symptom,hyper,0.99585956,"  cardiovascular : bradycardia, tachycardia, hypertension, hypotension, arrhythmias.    respiratory : bronchospasm, prolonged respiratory depression and apnea.    musculoskeletal : muscle fasciculation, post-operative muscle pains, myoglobinemia.    others : hyperthermia, increased intra-ocular pressure increased intra-gastric pressure, rash, excessive salivation. ",suxamethonium chloride
sign_symptom,sleepiness,0.99869716," common side effects are sleepiness during the day, not thinking clearly, act strangely, confused, or upset, sleep-walking ",suvorexant
sign_symptom,thinking clearly,0.8050113," common side effects are sleepiness during the day, not thinking clearly, act strangely, confused, or upset, sleep-walking ",suvorexant
sign_symptom,sleep,0.9211595," common side effects are sleepiness during the day, not thinking clearly, act strangely, confused, or upset, sleep-walking ",suvorexant
sign_symptom,diarr,0.9606141," generally, this preparation is well-tolerated. diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. the side-effects of vitamin a are reversible. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",super antioxidant [vitamins & minerals]
sign_symptom,diarr,0.9606141," generally, this preparation is well-tolerated. diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. the side-effects of vitamin a are reversible. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",vitamin c + vitamin e
medication,beta carotene,0.99841225," generally, this preparation is well-tolerated. diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. the side-effects of vitamin a are reversible. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",super antioxidant [vitamins & minerals]
medication,beta carotene,0.99841225," generally, this preparation is well-tolerated. diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. the side-effects of vitamin a are reversible. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",vitamin c + vitamin e
medication,vitamin a,0.99949634," generally, this preparation is well-tolerated. diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. the side-effects of vitamin a are reversible. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",super antioxidant [vitamins & minerals]
medication,vitamin a,0.99949634," generally, this preparation is well-tolerated. diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. the side-effects of vitamin a are reversible. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",vitamin c + vitamin e
medication,vitamin c,0.9994416," generally, this preparation is well-tolerated. diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. the side-effects of vitamin a are reversible. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",super antioxidant [vitamins & minerals]
medication,vitamin c,0.9994416," generally, this preparation is well-tolerated. diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. the side-effects of vitamin a are reversible. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",vitamin c + vitamin e
medication,vitamin e,0.9994452," generally, this preparation is well-tolerated. diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. the side-effects of vitamin a are reversible. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",super antioxidant [vitamins & minerals]
medication,vitamin e,0.9994452," generally, this preparation is well-tolerated. diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. the side-effects of vitamin a are reversible. vitamin c and vitamin e may cause diarrhea and other gastrointestinal disturbances. ",vitamin c + vitamin e
sign_symptom,stuffy,0.9717984,"  common side effects : unusual or unpleasant taste in the mouth; pain, burning, numbness, or tingling in the nose or throat; runny or stuffy nose after using the nasal medicine.   rare side effects : anxiety, burning sensation, discomfort of the nasal cavity and throat, general feeling of illness or tiredness &amp; vision changes. ",sumatriptan
sign_symptom,discomfort,0.99995065,"  common side effects : unusual or unpleasant taste in the mouth; pain, burning, numbness, or tingling in the nose or throat; runny or stuffy nose after using the nasal medicine.   rare side effects : anxiety, burning sensation, discomfort of the nasal cavity and throat, general feeling of illness or tiredness &amp; vision changes. ",sumatriptan
sign_symptom,tired,0.9999193,"  common side effects : unusual or unpleasant taste in the mouth; pain, burning, numbness, or tingling in the nose or throat; runny or stuffy nose after using the nasal medicine.   rare side effects : anxiety, burning sensation, discomfort of the nasal cavity and throat, general feeling of illness or tiredness &amp; vision changes. ",sumatriptan
sign_symptom,skin sensitization,0.70870215," mild irritation, skin sensitization ",sulphonated surfactant
sign_symptom,sexual desire,0.94026846," in general: 
 
 increased sexual desire 
 fluid retention in the tissues, usually marked by swelling of ankles or feet 
 
in men: 
 
 prolonged abnormal, painful erection of the penis 
 disturbed formation of sperm 
 decreased amount of sperm with seminal discharge 
 
in elderly men: 
 
 problems with passing urine 
 
in young boys: 
 
 early sexual development 
 erections occurring more often than normal 
 enlarged penis 
 disturbed growth 
 
tell your doctor as soon as possible if any side-effect becomes troublesome or continues. ",testosterone undecanoate
sign_symptom,fluid retention,0.9261583," in general: 
 
 increased sexual desire 
 fluid retention in the tissues, usually marked by swelling of ankles or feet 
 
in men: 
 
 prolonged abnormal, painful erection of the penis 
 disturbed formation of sperm 
 decreased amount of sperm with seminal discharge 
 
in elderly men: 
 
 problems with passing urine 
 
in young boys: 
 
 early sexual development 
 erections occurring more often than normal 
 enlarged penis 
 disturbed growth 
 
tell your doctor as soon as possible if any side-effect becomes troublesome or continues. ",testosterone undecanoate
sign_symptom,swelling,0.9999641," in general: 
 
 increased sexual desire 
 fluid retention in the tissues, usually marked by swelling of ankles or feet 
 
in men: 
 
 prolonged abnormal, painful erection of the penis 
 disturbed formation of sperm 
 decreased amount of sperm with seminal discharge 
 
in elderly men: 
 
 problems with passing urine 
 
in young boys: 
 
 early sexual development 
 erections occurring more often than normal 
 enlarged penis 
 disturbed growth 
 
tell your doctor as soon as possible if any side-effect becomes troublesome or continues. ",testosterone undecanoate
sign_symptom,erection,0.998563," in general: 
 
 increased sexual desire 
 fluid retention in the tissues, usually marked by swelling of ankles or feet 
 
in men: 
 
 prolonged abnormal, painful erection of the penis 
 disturbed formation of sperm 
 decreased amount of sperm with seminal discharge 
 
in elderly men: 
 
 problems with passing urine 
 
in young boys: 
 
 early sexual development 
 erections occurring more often than normal 
 enlarged penis 
 disturbed growth 
 
tell your doctor as soon as possible if any side-effect becomes troublesome or continues. ",testosterone undecanoate
sign_symptom,passing urine,0.9190227," in general: 
 
 increased sexual desire 
 fluid retention in the tissues, usually marked by swelling of ankles or feet 
 
in men: 
 
 prolonged abnormal, painful erection of the penis 
 disturbed formation of sperm 
 decreased amount of sperm with seminal discharge 
 
in elderly men: 
 
 problems with passing urine 
 
in young boys: 
 
 early sexual development 
 erections occurring more often than normal 
 enlarged penis 
 disturbed growth 
 
tell your doctor as soon as possible if any side-effect becomes troublesome or continues. ",testosterone undecanoate
sign_symptom,disturbed,0.8395778," in general: 
 
 increased sexual desire 
 fluid retention in the tissues, usually marked by swelling of ankles or feet 
 
in men: 
 
 prolonged abnormal, painful erection of the penis 
 disturbed formation of sperm 
 decreased amount of sperm with seminal discharge 
 
in elderly men: 
 
 problems with passing urine 
 
in young boys: 
 
 early sexual development 
 erections occurring more often than normal 
 enlarged penis 
 disturbed growth 
 
tell your doctor as soon as possible if any side-effect becomes troublesome or continues. ",testosterone undecanoate
sign_symptom,growth,0.9903893," in general: 
 
 increased sexual desire 
 fluid retention in the tissues, usually marked by swelling of ankles or feet 
 
in men: 
 
 prolonged abnormal, painful erection of the penis 
 disturbed formation of sperm 
 decreased amount of sperm with seminal discharge 
 
in elderly men: 
 
 problems with passing urine 
 
in young boys: 
 
 early sexual development 
 erections occurring more often than normal 
 enlarged penis 
 disturbed growth 
 
tell your doctor as soon as possible if any side-effect becomes troublesome or continues. ",testosterone undecanoate
medication,testosterone,0.9538785," the most common side effects of testosterone therapy are precocious sexual development, increased frequency of erections, phallic enlargement and premature epiphyseal closure, priapism, oligospermia, decreased ejaculatory volume and fluid &amp; sodium retention. ",testosterone decanoate
sign_symptom,erection,0.7434872," the most common side effects of testosterone therapy are precocious sexual development, increased frequency of erections, phallic enlargement and premature epiphyseal closure, priapism, oligospermia, decreased ejaculatory volume and fluid &amp; sodium retention. ",testosterone decanoate
sign_symptom,enlargement,0.82232785," the most common side effects of testosterone therapy are precocious sexual development, increased frequency of erections, phallic enlargement and premature epiphyseal closure, priapism, oligospermia, decreased ejaculatory volume and fluid &amp; sodium retention. ",testosterone decanoate
sign_symptom,anxiety,0.7718632," anxiety, palpitations, insomnia, mild gi distubances, erythema multiforme and galactorrhoea. ",terfenadine
sign_symptom,pain,0.99990857," vulvovaginal burning, vulvar itching, dysmenorrhoea, genital, body and abdominal pain. flu-like syndrome with headache, fever, chills and hypotension with doses &gt;80 mg. ",terconazole
disease_disorder,like syndrome,0.9558383," vulvovaginal burning, vulvar itching, dysmenorrhoea, genital, body and abdominal pain. flu-like syndrome with headache, fever, chills and hypotension with doses &gt;80 mg. ",terconazole
sign_symptom,fever,0.9716096," vulvovaginal burning, vulvar itching, dysmenorrhoea, genital, body and abdominal pain. flu-like syndrome with headache, fever, chills and hypotension with doses &gt;80 mg. ",terconazole
sign_symptom,chills,0.99927807," vulvovaginal burning, vulvar itching, dysmenorrhoea, genital, body and abdominal pain. flu-like syndrome with headache, fever, chills and hypotension with doses &gt;80 mg. ",terconazole
sign_symptom,side - effects,0.8436788," the frequency of side-effects is low at the recommended doses. side-effects which have been recorded such as tremor, headache, tonic cramp and palpitations are all characteristic of sympathomimetic amines. a few patients feel tense; this is also due to the effects on skeletal muscle and not to direct cns stimulation. whenever these side-effects have occurred the majority have usually been spontaneously reversible within the first week of treatment. urticaria and exanthema may occur. in children sleep disturbances and disturbances of behavioural effects have been observed. potentially serious hypokalaemia may result from 2-agonist therapy. ",terbutaline sulfate
sign_symptom,side,0.99694866," the frequency of side-effects is low at the recommended doses. side-effects which have been recorded such as tremor, headache, tonic cramp and palpitations are all characteristic of sympathomimetic amines. a few patients feel tense; this is also due to the effects on skeletal muscle and not to direct cns stimulation. whenever these side-effects have occurred the majority have usually been spontaneously reversible within the first week of treatment. urticaria and exanthema may occur. in children sleep disturbances and disturbances of behavioural effects have been observed. potentially serious hypokalaemia may result from 2-agonist therapy. ",terbutaline sulfate
sign_symptom,effects,0.99967873," the frequency of side-effects is low at the recommended doses. side-effects which have been recorded such as tremor, headache, tonic cramp and palpitations are all characteristic of sympathomimetic amines. a few patients feel tense; this is also due to the effects on skeletal muscle and not to direct cns stimulation. whenever these side-effects have occurred the majority have usually been spontaneously reversible within the first week of treatment. urticaria and exanthema may occur. in children sleep disturbances and disturbances of behavioural effects have been observed. potentially serious hypokalaemia may result from 2-agonist therapy. ",terbutaline sulfate
sign_symptom,tremor,0.9998982," the frequency of side-effects is low at the recommended doses. side-effects which have been recorded such as tremor, headache, tonic cramp and palpitations are all characteristic of sympathomimetic amines. a few patients feel tense; this is also due to the effects on skeletal muscle and not to direct cns stimulation. whenever these side-effects have occurred the majority have usually been spontaneously reversible within the first week of treatment. urticaria and exanthema may occur. in children sleep disturbances and disturbances of behavioural effects have been observed. potentially serious hypokalaemia may result from 2-agonist therapy. ",terbutaline sulfate
sign_symptom,headache,0.99992585," the frequency of side-effects is low at the recommended doses. side-effects which have been recorded such as tremor, headache, tonic cramp and palpitations are all characteristic of sympathomimetic amines. a few patients feel tense; this is also due to the effects on skeletal muscle and not to direct cns stimulation. whenever these side-effects have occurred the majority have usually been spontaneously reversible within the first week of treatment. urticaria and exanthema may occur. in children sleep disturbances and disturbances of behavioural effects have been observed. potentially serious hypokalaemia may result from 2-agonist therapy. ",terbutaline sulfate
sign_symptom,tonic cramp,0.99831957," the frequency of side-effects is low at the recommended doses. side-effects which have been recorded such as tremor, headache, tonic cramp and palpitations are all characteristic of sympathomimetic amines. a few patients feel tense; this is also due to the effects on skeletal muscle and not to direct cns stimulation. whenever these side-effects have occurred the majority have usually been spontaneously reversible within the first week of treatment. urticaria and exanthema may occur. in children sleep disturbances and disturbances of behavioural effects have been observed. potentially serious hypokalaemia may result from 2-agonist therapy. ",terbutaline sulfate
sign_symptom,exanthema,0.9997079," the frequency of side-effects is low at the recommended doses. side-effects which have been recorded such as tremor, headache, tonic cramp and palpitations are all characteristic of sympathomimetic amines. a few patients feel tense; this is also due to the effects on skeletal muscle and not to direct cns stimulation. whenever these side-effects have occurred the majority have usually been spontaneously reversible within the first week of treatment. urticaria and exanthema may occur. in children sleep disturbances and disturbances of behavioural effects have been observed. potentially serious hypokalaemia may result from 2-agonist therapy. ",terbutaline sulfate
sign_symptom,sleep disturbances,0.9999008," the frequency of side-effects is low at the recommended doses. side-effects which have been recorded such as tremor, headache, tonic cramp and palpitations are all characteristic of sympathomimetic amines. a few patients feel tense; this is also due to the effects on skeletal muscle and not to direct cns stimulation. whenever these side-effects have occurred the majority have usually been spontaneously reversible within the first week of treatment. urticaria and exanthema may occur. in children sleep disturbances and disturbances of behavioural effects have been observed. potentially serious hypokalaemia may result from 2-agonist therapy. ",terbutaline sulfate
sign_symptom,disturbances of behavioural effects,0.9996659," the frequency of side-effects is low at the recommended doses. side-effects which have been recorded such as tremor, headache, tonic cramp and palpitations are all characteristic of sympathomimetic amines. a few patients feel tense; this is also due to the effects on skeletal muscle and not to direct cns stimulation. whenever these side-effects have occurred the majority have usually been spontaneously reversible within the first week of treatment. urticaria and exanthema may occur. in children sleep disturbances and disturbances of behavioural effects have been observed. potentially serious hypokalaemia may result from 2-agonist therapy. ",terbutaline sulfate
sign_symptom,symptoms,0.8216308," the adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia and abdominal pain), liver test abnormalities, rashes, urticaria, pruritus, and taste disturbances. in general, the adverse events were mild, transient, and did not lead to discontinuation. adverse events, based on worldwide experience with terbinafine use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of liver failure, some leading to death or liver transplant, serious skin reactions, severe neutropenia, thrombocytopenia, angioedema and allergic reactions (including anaphylaxis). other adverse reactions that have been reported include malaise, fatigue, vomiting, arthralgia, myalgia, and hair loss. ",terbinafine hydrochloride
sign_symptom,dyspepsia,0.9957223," the adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia and abdominal pain), liver test abnormalities, rashes, urticaria, pruritus, and taste disturbances. in general, the adverse events were mild, transient, and did not lead to discontinuation. adverse events, based on worldwide experience with terbinafine use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of liver failure, some leading to death or liver transplant, serious skin reactions, severe neutropenia, thrombocytopenia, angioedema and allergic reactions (including anaphylaxis). other adverse reactions that have been reported include malaise, fatigue, vomiting, arthralgia, myalgia, and hair loss. ",terbinafine hydrochloride
sign_symptom,pain,0.99881697," the adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia and abdominal pain), liver test abnormalities, rashes, urticaria, pruritus, and taste disturbances. in general, the adverse events were mild, transient, and did not lead to discontinuation. adverse events, based on worldwide experience with terbinafine use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of liver failure, some leading to death or liver transplant, serious skin reactions, severe neutropenia, thrombocytopenia, angioedema and allergic reactions (including anaphylaxis). other adverse reactions that have been reported include malaise, fatigue, vomiting, arthralgia, myalgia, and hair loss. ",terbinafine hydrochloride
sign_symptom,rash,0.995237," the adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia and abdominal pain), liver test abnormalities, rashes, urticaria, pruritus, and taste disturbances. in general, the adverse events were mild, transient, and did not lead to discontinuation. adverse events, based on worldwide experience with terbinafine use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of liver failure, some leading to death or liver transplant, serious skin reactions, severe neutropenia, thrombocytopenia, angioedema and allergic reactions (including anaphylaxis). other adverse reactions that have been reported include malaise, fatigue, vomiting, arthralgia, myalgia, and hair loss. ",terbinafine hydrochloride
sign_symptom,adverse events,0.84948075," the adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia and abdominal pain), liver test abnormalities, rashes, urticaria, pruritus, and taste disturbances. in general, the adverse events were mild, transient, and did not lead to discontinuation. adverse events, based on worldwide experience with terbinafine use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of liver failure, some leading to death or liver transplant, serious skin reactions, severe neutropenia, thrombocytopenia, angioedema and allergic reactions (including anaphylaxis). other adverse reactions that have been reported include malaise, fatigue, vomiting, arthralgia, myalgia, and hair loss. ",terbinafine hydrochloride
sign_symptom,angioedema,0.84840035," the adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia and abdominal pain), liver test abnormalities, rashes, urticaria, pruritus, and taste disturbances. in general, the adverse events were mild, transient, and did not lead to discontinuation. adverse events, based on worldwide experience with terbinafine use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of liver failure, some leading to death or liver transplant, serious skin reactions, severe neutropenia, thrombocytopenia, angioedema and allergic reactions (including anaphylaxis). other adverse reactions that have been reported include malaise, fatigue, vomiting, arthralgia, myalgia, and hair loss. ",terbinafine hydrochloride
sign_symptom,allergic reactions,0.9866406," the adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia and abdominal pain), liver test abnormalities, rashes, urticaria, pruritus, and taste disturbances. in general, the adverse events were mild, transient, and did not lead to discontinuation. adverse events, based on worldwide experience with terbinafine use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of liver failure, some leading to death or liver transplant, serious skin reactions, severe neutropenia, thrombocytopenia, angioedema and allergic reactions (including anaphylaxis). other adverse reactions that have been reported include malaise, fatigue, vomiting, arthralgia, myalgia, and hair loss. ",terbinafine hydrochloride
sign_symptom,adverse reactions,0.996071," the adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia and abdominal pain), liver test abnormalities, rashes, urticaria, pruritus, and taste disturbances. in general, the adverse events were mild, transient, and did not lead to discontinuation. adverse events, based on worldwide experience with terbinafine use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of liver failure, some leading to death or liver transplant, serious skin reactions, severe neutropenia, thrombocytopenia, angioedema and allergic reactions (including anaphylaxis). other adverse reactions that have been reported include malaise, fatigue, vomiting, arthralgia, myalgia, and hair loss. ",terbinafine hydrochloride
sign_symptom,mala,0.98862326," the adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia and abdominal pain), liver test abnormalities, rashes, urticaria, pruritus, and taste disturbances. in general, the adverse events were mild, transient, and did not lead to discontinuation. adverse events, based on worldwide experience with terbinafine use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of liver failure, some leading to death or liver transplant, serious skin reactions, severe neutropenia, thrombocytopenia, angioedema and allergic reactions (including anaphylaxis). other adverse reactions that have been reported include malaise, fatigue, vomiting, arthralgia, myalgia, and hair loss. ",terbinafine hydrochloride
sign_symptom,bleeding,0.9849668," based on clinical trials including large numbers of patients, tenoxicam proved to be well tolerated in the recommended dose. usually, the undesirable effects reported were mild and transient. in a small proportion of patients, the interruption of treatment due to undesirable effects was necessary. local tolerance of tenoxicam given parenterally was good. the following undesirable effects have been reported:   frequency is greater than 1%- 
 
 gastrointestinal tract: gastric, epigastric and abdominal discomfort, dyspepsia, heartburn, nausea. 
 central nervous system: dizziness, headache. 
 
frequency less than 1%- 
 
 gastrointestinal tract: constipation, diarrhea, stomatitis, gastritis, vomiting, ulcers, gl-bleeding including hematemesis and melena. 
 central nervous system: fatigue, sleep disturbances, appetite loss, dry mouth, vertigo. 
 skin: itching (also in the anal region after rectal administration), erythema, exanthema, rash, urticaria. 
 urinary tract and kidneys: increase in bun or creatinine, edema. 
 liver and biliary tract: increased liver enzyme activity. 
 cardiovascular system: palpitations. 
 
isolated cases (frequency less than 0.01%)- 
 
 gastrointestinal tract: gl-perforation. 
 central nervous system: visual disturbances. 
 skin: stevens-johnson and lyell's syndrome, photosensitivity reaction, vasculitis. 
 blood: anemia, agranulocytosis, leukopenia, thrombocytopenia. 
 hypersensitivity reactions: dyspnea, asthma, anaphylaxis, angioedema. 
 cardiovascular system: elevated blood pressure, mainly in patients treated with cardiovascular drugs. 
 liver/biliary tract: hepatitis. 
  ",tenoxicam
sign_symptom,hyper,0.9138342," based on clinical trials including large numbers of patients, tenoxicam proved to be well tolerated in the recommended dose. usually, the undesirable effects reported were mild and transient. in a small proportion of patients, the interruption of treatment due to undesirable effects was necessary. local tolerance of tenoxicam given parenterally was good. the following undesirable effects have been reported:   frequency is greater than 1%- 
 
 gastrointestinal tract: gastric, epigastric and abdominal discomfort, dyspepsia, heartburn, nausea. 
 central nervous system: dizziness, headache. 
 
frequency less than 1%- 
 
 gastrointestinal tract: constipation, diarrhea, stomatitis, gastritis, vomiting, ulcers, gl-bleeding including hematemesis and melena. 
 central nervous system: fatigue, sleep disturbances, appetite loss, dry mouth, vertigo. 
 skin: itching (also in the anal region after rectal administration), erythema, exanthema, rash, urticaria. 
 urinary tract and kidneys: increase in bun or creatinine, edema. 
 liver and biliary tract: increased liver enzyme activity. 
 cardiovascular system: palpitations. 
 
isolated cases (frequency less than 0.01%)- 
 
 gastrointestinal tract: gl-perforation. 
 central nervous system: visual disturbances. 
 skin: stevens-johnson and lyell's syndrome, photosensitivity reaction, vasculitis. 
 blood: anemia, agranulocytosis, leukopenia, thrombocytopenia. 
 hypersensitivity reactions: dyspnea, asthma, anaphylaxis, angioedema. 
 cardiovascular system: elevated blood pressure, mainly in patients treated with cardiovascular drugs. 
 liver/biliary tract: hepatitis. 
  ",tenoxicam
sign_symptom,adverse reactions,0.999866," the following adverse reactions are discussed in other sections of the labeling: 
 
 lactic acidosis/severehepatomegalywith steatosis 
 severe acute exacerbation ofhepatitis b 
 new onset or worsening of renal impairment 
 
the most common side effects are headache, stomach pain, tiredness, cough, nausea, back pain ",tenofovir alafenamide
sign_symptom,lactic acidosis,0.96365166," the following adverse reactions are discussed in other sections of the labeling: 
 
 lactic acidosis/severehepatomegalywith steatosis 
 severe acute exacerbation ofhepatitis b 
 new onset or worsening of renal impairment 
 
the most common side effects are headache, stomach pain, tiredness, cough, nausea, back pain ",tenofovir alafenamide
sign_symptom,steatosis,0.9646805," the following adverse reactions are discussed in other sections of the labeling: 
 
 lactic acidosis/severehepatomegalywith steatosis 
 severe acute exacerbation ofhepatitis b 
 new onset or worsening of renal impairment 
 
the most common side effects are headache, stomach pain, tiredness, cough, nausea, back pain ",tenofovir alafenamide
disease_disorder,renal impairment,0.8554783," the following adverse reactions are discussed in other sections of the labeling: 
 
 lactic acidosis/severehepatomegalywith steatosis 
 severe acute exacerbation ofhepatitis b 
 new onset or worsening of renal impairment 
 
the most common side effects are headache, stomach pain, tiredness, cough, nausea, back pain ",tenofovir alafenamide
sign_symptom,tired,0.9996823," the following adverse reactions are discussed in other sections of the labeling: 
 
 lactic acidosis/severehepatomegalywith steatosis 
 severe acute exacerbation ofhepatitis b 
 new onset or worsening of renal impairment 
 
the most common side effects are headache, stomach pain, tiredness, cough, nausea, back pain ",tenofovir alafenamide
sign_symptom,pain,0.9999665," the following adverse reactions are discussed in other sections of the labeling: 
 
 lactic acidosis/severehepatomegalywith steatosis 
 severe acute exacerbation ofhepatitis b 
 new onset or worsening of renal impairment 
 
the most common side effects are headache, stomach pain, tiredness, cough, nausea, back pain ",tenofovir alafenamide
sign_symptom,adverse reaction,0.9994752," the most frequent adverse reaction associated with tenecteplase is bleeding. should serious bleeding occur, concomitant heparin and antiplatelet therapy should be discontinued. death or permanent disability can occur in patients who experience stroke or serious bleeding episodes. for tenecteplase-treated patients in assent-2, the incidence of intracranial hemorrhage was 0.9% and any stroke was 1.8%. the incidence of all strokes, including intracranial bleeding, increases with increasing age ",tenecteplase
medication,tenecteplase,0.8445298," the most frequent adverse reaction associated with tenecteplase is bleeding. should serious bleeding occur, concomitant heparin and antiplatelet therapy should be discontinued. death or permanent disability can occur in patients who experience stroke or serious bleeding episodes. for tenecteplase-treated patients in assent-2, the incidence of intracranial hemorrhage was 0.9% and any stroke was 1.8%. the incidence of all strokes, including intracranial bleeding, increases with increasing age ",tenecteplase
sign_symptom,bleeding,0.999721," the most frequent adverse reaction associated with tenecteplase is bleeding. should serious bleeding occur, concomitant heparin and antiplatelet therapy should be discontinued. death or permanent disability can occur in patients who experience stroke or serious bleeding episodes. for tenecteplase-treated patients in assent-2, the incidence of intracranial hemorrhage was 0.9% and any stroke was 1.8%. the incidence of all strokes, including intracranial bleeding, increases with increasing age ",tenecteplase
disease_disorder,disability,0.9891762," the most frequent adverse reaction associated with tenecteplase is bleeding. should serious bleeding occur, concomitant heparin and antiplatelet therapy should be discontinued. death or permanent disability can occur in patients who experience stroke or serious bleeding episodes. for tenecteplase-treated patients in assent-2, the incidence of intracranial hemorrhage was 0.9% and any stroke was 1.8%. the incidence of all strokes, including intracranial bleeding, increases with increasing age ",tenecteplase
disease_disorder,stroke,0.8468989," the most frequent adverse reaction associated with tenecteplase is bleeding. should serious bleeding occur, concomitant heparin and antiplatelet therapy should be discontinued. death or permanent disability can occur in patients who experience stroke or serious bleeding episodes. for tenecteplase-treated patients in assent-2, the incidence of intracranial hemorrhage was 0.9% and any stroke was 1.8%. the incidence of all strokes, including intracranial bleeding, increases with increasing age ",tenecteplase
sign_symptom,stroke,0.9569268," the most frequent adverse reaction associated with tenecteplase is bleeding. should serious bleeding occur, concomitant heparin and antiplatelet therapy should be discontinued. death or permanent disability can occur in patients who experience stroke or serious bleeding episodes. for tenecteplase-treated patients in assent-2, the incidence of intracranial hemorrhage was 0.9% and any stroke was 1.8%. the incidence of all strokes, including intracranial bleeding, increases with increasing age ",tenecteplase
sign_symptom,concentration,0.91852987," nausea, vomiting, taste perversion, constipation, diarrhoea, abdominal pain, stomatitis, anorexia, headache, fatigue, convulsions, dizziness, memory impairment, impaired concentration, tremors, blurred vision, hearing impairment, speech disorder, rash, infection, oral candidiasis, dyspnoea, coughing, neutropenia, thrombocytopenia, leucopenia, anaemia, hyperglycemia, decreased wt, insomnia, anxiety, alopecia, muscle weakness, urinary incontinence, increased alanine aminotransferase. rarely, myelodysplastic syndrome and secondary malignancies. ",temozolomide
sign_symptom,vision,0.7627932," nausea, vomiting, taste perversion, constipation, diarrhoea, abdominal pain, stomatitis, anorexia, headache, fatigue, convulsions, dizziness, memory impairment, impaired concentration, tremors, blurred vision, hearing impairment, speech disorder, rash, infection, oral candidiasis, dyspnoea, coughing, neutropenia, thrombocytopenia, leucopenia, anaemia, hyperglycemia, decreased wt, insomnia, anxiety, alopecia, muscle weakness, urinary incontinence, increased alanine aminotransferase. rarely, myelodysplastic syndrome and secondary malignancies. ",temozolomide
disease_disorder,myelodysplastic syndrome,0.9230334," nausea, vomiting, taste perversion, constipation, diarrhoea, abdominal pain, stomatitis, anorexia, headache, fatigue, convulsions, dizziness, memory impairment, impaired concentration, tremors, blurred vision, hearing impairment, speech disorder, rash, infection, oral candidiasis, dyspnoea, coughing, neutropenia, thrombocytopenia, leucopenia, anaemia, hyperglycemia, decreased wt, insomnia, anxiety, alopecia, muscle weakness, urinary incontinence, increased alanine aminotransferase. rarely, myelodysplastic syndrome and secondary malignancies. ",temozolomide
sign_symptom,drowsiness,0.9895336," the most common side effects of temazepam are: 
 
 drowsiness 
 headache 
 tiredness 
 nervousness 
 dizziness 
 nausea 
  ",temazepam
sign_symptom,headache,0.9998814," the most common side effects of temazepam are: 
 
 drowsiness 
 headache 
 tiredness 
 nervousness 
 dizziness 
 nausea 
  ",temazepam
sign_symptom,tiredness,0.9998837," the most common side effects of temazepam are: 
 
 drowsiness 
 headache 
 tiredness 
 nervousness 
 dizziness 
 nausea 
  ",temazepam
sign_symptom,nervousness,0.99990416," the most common side effects of temazepam are: 
 
 drowsiness 
 headache 
 tiredness 
 nervousness 
 dizziness 
 nausea 
  ",temazepam
sign_symptom,nausea,0.9999306," the most common side effects of temazepam are: 
 
 drowsiness 
 headache 
 tiredness 
 nervousness 
 dizziness 
 nausea 
  ",temazepam
sign_symptom,tired,0.9881121," common side effects include dizziness, drowsiness, tired feeling, flushing (warmth, redness, or tingly feeling), back pain, nausea, diarrhea, stomach pain. other adverse events include allergy, fever, leg pain, chest pain, insomnia, somnolence, and dry mouth, elevations of liver enzymes or serum bilirubin, leg cramps, myalgia, dermatitis. other adverse events that have been reported includes weakness, gastric irritation, photosensitivity, urticaria, muscle spasm, restlessness. ",telmisartan + hydrochlorothiazide
sign_symptom,flushing,0.990569," common side effects include dizziness, drowsiness, tired feeling, flushing (warmth, redness, or tingly feeling), back pain, nausea, diarrhea, stomach pain. other adverse events include allergy, fever, leg pain, chest pain, insomnia, somnolence, and dry mouth, elevations of liver enzymes or serum bilirubin, leg cramps, myalgia, dermatitis. other adverse events that have been reported includes weakness, gastric irritation, photosensitivity, urticaria, muscle spasm, restlessness. ",telmisartan + hydrochlorothiazide
sign_symptom,hyper,0.9871524,"  in hypertensive patients : the most common side effects of telmisartan tablets include sinus pain and congestion (sinusitis), back pain, diarrhea etc.    for patients of cardiovascular risk reduction : the most common side effects of telmisartan tablets in cv risk reduction include intermittent claudication and skin ulcer. ",telmisartan
sign_symptom,pain,0.99995375,"  in hypertensive patients : the most common side effects of telmisartan tablets include sinus pain and congestion (sinusitis), back pain, diarrhea etc.    for patients of cardiovascular risk reduction : the most common side effects of telmisartan tablets in cv risk reduction include intermittent claudication and skin ulcer. ",telmisartan
sign_symptom,congestion,0.9999167,"  in hypertensive patients : the most common side effects of telmisartan tablets include sinus pain and congestion (sinusitis), back pain, diarrhea etc.    for patients of cardiovascular risk reduction : the most common side effects of telmisartan tablets in cv risk reduction include intermittent claudication and skin ulcer. ",telmisartan
sign_symptom,fatigue,0.7859506," cough, dizziness, fatigue, gi effects (e.g. abdominal pain, diarrhoea, nausea, vomiting, dyspepsia), rash, arthralgia, myalgia, myopathy, malaise, back pain, nasopharyngitis, headache, flu or flu-like symptoms, insomnia; increased serum amylase, lipase, creatine phosphokinase, alanine aminotransferase levels; peripheral neuropathy, rhabdomyolysis. ",telbivudine
sign_symptom,gi effects,0.78766215," cough, dizziness, fatigue, gi effects (e.g. abdominal pain, diarrhoea, nausea, vomiting, dyspepsia), rash, arthralgia, myalgia, myopathy, malaise, back pain, nasopharyngitis, headache, flu or flu-like symptoms, insomnia; increased serum amylase, lipase, creatine phosphokinase, alanine aminotransferase levels; peripheral neuropathy, rhabdomyolysis. ",telbivudine
sign_symptom,arthral,0.87933975," cough, dizziness, fatigue, gi effects (e.g. abdominal pain, diarrhoea, nausea, vomiting, dyspepsia), rash, arthralgia, myalgia, myopathy, malaise, back pain, nasopharyngitis, headache, flu or flu-like symptoms, insomnia; increased serum amylase, lipase, creatine phosphokinase, alanine aminotransferase levels; peripheral neuropathy, rhabdomyolysis. ",telbivudine
sign_symptom,mala,0.8980263," cough, dizziness, fatigue, gi effects (e.g. abdominal pain, diarrhoea, nausea, vomiting, dyspepsia), rash, arthralgia, myalgia, myopathy, malaise, back pain, nasopharyngitis, headache, flu or flu-like symptoms, insomnia; increased serum amylase, lipase, creatine phosphokinase, alanine aminotransferase levels; peripheral neuropathy, rhabdomyolysis. ",telbivudine
sign_symptom,side,0.99756205," teicoplanin is generally well tolerated. serious side-effects are rare. side-effects are gastrointestinal like nausea, vomiting, diarrhea, cns associated with urticaria, rash, anaphylactic shock as well as hearing problems like vertigo, tinnitus and vestibular disorder may occur. ",teicoplanin
sign_symptom,effects,0.98621595," teicoplanin is generally well tolerated. serious side-effects are rare. side-effects are gastrointestinal like nausea, vomiting, diarrhea, cns associated with urticaria, rash, anaphylactic shock as well as hearing problems like vertigo, tinnitus and vestibular disorder may occur. ",teicoplanin
disease_disorder,shock,0.9863067," teicoplanin is generally well tolerated. serious side-effects are rare. side-effects are gastrointestinal like nausea, vomiting, diarrhea, cns associated with urticaria, rash, anaphylactic shock as well as hearing problems like vertigo, tinnitus and vestibular disorder may occur. ",teicoplanin
sign_symptom,problems,0.992997," teicoplanin is generally well tolerated. serious side-effects are rare. side-effects are gastrointestinal like nausea, vomiting, diarrhea, cns associated with urticaria, rash, anaphylactic shock as well as hearing problems like vertigo, tinnitus and vestibular disorder may occur. ",teicoplanin
disease_disorder,tinnitus,0.99485964," teicoplanin is generally well tolerated. serious side-effects are rare. side-effects are gastrointestinal like nausea, vomiting, diarrhea, cns associated with urticaria, rash, anaphylactic shock as well as hearing problems like vertigo, tinnitus and vestibular disorder may occur. ",teicoplanin
disease_disorder,vestib,0.97869086," teicoplanin is generally well tolerated. serious side-effects are rare. side-effects are gastrointestinal like nausea, vomiting, diarrhea, cns associated with urticaria, rash, anaphylactic shock as well as hearing problems like vertigo, tinnitus and vestibular disorder may occur. ",teicoplanin
sign_symptom,flat,0.84100235," abdominal pain, diarrhea, nausea, flatulence, headache, fatigue, back pain etc. ",tegaserod
sign_symptom,pain,0.999663," abdominal pain, diarrhea, nausea, flatulence, headache, fatigue, back pain etc. ",tegaserod
sign_symptom,hyper,0.99990916," occasional local transient &amp; mild irritation; if hypersensitivity reaction develop, treatment should be discontinued &amp; appropriate therapy should be instituted. ",tioconazole
sign_symptom,diarrhoea,0.99586093," reported side effects have generally been infrequent, mild and self-limiting. side effects from the gastrointestinal tract include nausea, vomiting, anorexia, diarrhoea and metallic taste. hypersensitivity reactions, occasionally severe, may occur in rare cases in the form of skin rash, pruritis, urticaria and angioneurotic oedema. as with related compounds, tinidazole may produce transient leukopenia. other rarely reported side-effects are headache, tiredness, furry tongue and dark urine. ",tinidazole
sign_symptom,hypersensitivity,0.99230444," reported side effects have generally been infrequent, mild and self-limiting. side effects from the gastrointestinal tract include nausea, vomiting, anorexia, diarrhoea and metallic taste. hypersensitivity reactions, occasionally severe, may occur in rare cases in the form of skin rash, pruritis, urticaria and angioneurotic oedema. as with related compounds, tinidazole may produce transient leukopenia. other rarely reported side-effects are headache, tiredness, furry tongue and dark urine. ",tinidazole
medication,tinida,0.8104819," reported side effects have generally been infrequent, mild and self-limiting. side effects from the gastrointestinal tract include nausea, vomiting, anorexia, diarrhoea and metallic taste. hypersensitivity reactions, occasionally severe, may occur in rare cases in the form of skin rash, pruritis, urticaria and angioneurotic oedema. as with related compounds, tinidazole may produce transient leukopenia. other rarely reported side-effects are headache, tiredness, furry tongue and dark urine. ",tinidazole
sign_symptom,tired,0.99706453," reported side effects have generally been infrequent, mild and self-limiting. side effects from the gastrointestinal tract include nausea, vomiting, anorexia, diarrhoea and metallic taste. hypersensitivity reactions, occasionally severe, may occur in rare cases in the form of skin rash, pruritis, urticaria and angioneurotic oedema. as with related compounds, tinidazole may produce transient leukopenia. other rarely reported side-effects are headache, tiredness, furry tongue and dark urine. ",tinidazole
sign_symptom,arrhythmia,0.7879359," burning and stinging sensation of the eyes, bradycardia, hypotension, arrhythmia and av or sa nodal block, chf, pulmonary oedema, raynaud's phenomenon, headache, dizziness, fatigue, asthenia, abdominal discomfort, nausea, constipation, hypoglycaemia. ",timolol maleate
sign_symptom,adverse,0.99860483," the most common treatment-emergent adverse events are nausea and vomiting which generally occurre during the first 1-2 days of therapy.   the following drug-related adverse events are reported infrequently in patients receiving tigecycline: injection site inflammation &amp; pain, septic shock, allergic reaction, chills, thrombophlebitis, bradycardia, tachycardia, vasodilatation, anorexia, dry mouth, hypoglycemia, hyponatremia, prolonged prothrombin time, eosinophilia, thrombocytopenia, vaginal moniliasis, vaginitis, leukorrhea. ",tigecycline
sign_symptom,nausea,0.99995255," the most common treatment-emergent adverse events are nausea and vomiting which generally occurre during the first 1-2 days of therapy.   the following drug-related adverse events are reported infrequently in patients receiving tigecycline: injection site inflammation &amp; pain, septic shock, allergic reaction, chills, thrombophlebitis, bradycardia, tachycardia, vasodilatation, anorexia, dry mouth, hypoglycemia, hyponatremia, prolonged prothrombin time, eosinophilia, thrombocytopenia, vaginal moniliasis, vaginitis, leukorrhea. ",tigecycline
sign_symptom,vomiting,0.99994993," the most common treatment-emergent adverse events are nausea and vomiting which generally occurre during the first 1-2 days of therapy.   the following drug-related adverse events are reported infrequently in patients receiving tigecycline: injection site inflammation &amp; pain, septic shock, allergic reaction, chills, thrombophlebitis, bradycardia, tachycardia, vasodilatation, anorexia, dry mouth, hypoglycemia, hyponatremia, prolonged prothrombin time, eosinophilia, thrombocytopenia, vaginal moniliasis, vaginitis, leukorrhea. ",tigecycline
sign_symptom,adverse events,0.79055786," the most common treatment-emergent adverse events are nausea and vomiting which generally occurre during the first 1-2 days of therapy.   the following drug-related adverse events are reported infrequently in patients receiving tigecycline: injection site inflammation &amp; pain, septic shock, allergic reaction, chills, thrombophlebitis, bradycardia, tachycardia, vasodilatation, anorexia, dry mouth, hypoglycemia, hyponatremia, prolonged prothrombin time, eosinophilia, thrombocytopenia, vaginal moniliasis, vaginitis, leukorrhea. ",tigecycline
sign_symptom,inflammation,0.985421," the most common treatment-emergent adverse events are nausea and vomiting which generally occurre during the first 1-2 days of therapy.   the following drug-related adverse events are reported infrequently in patients receiving tigecycline: injection site inflammation &amp; pain, septic shock, allergic reaction, chills, thrombophlebitis, bradycardia, tachycardia, vasodilatation, anorexia, dry mouth, hypoglycemia, hyponatremia, prolonged prothrombin time, eosinophilia, thrombocytopenia, vaginal moniliasis, vaginitis, leukorrhea. ",tigecycline
medication,tiemonium methylsulphate,0.90502805, tiemonium methylsulphate may have the risk of hypotension &amp; tachycardia in certain individuals. ,tiemonium methylsulphate
sign_symptom,dyspe,0.9613592," diarrhoea, nausea, dyspepsia, bleeding, pupura, skin rash, increase in serum cholesterol concentration, elevation of lfts, hepatitis, cholestatic jaundice. ",ticlopidine hydrochloride
sign_symptom,bleeding,0.96993166," occasionally, vaginal bleeding or spotting may occur, mainly during the first months of treatment. other adverse effects are headache and migraine, oedema, dizziness, pruritus, increase in body weight, nausea, abdominal pain, rash, and depression. ",tibolone
sign_symptom,headache,0.9974585," occasionally, vaginal bleeding or spotting may occur, mainly during the first months of treatment. other adverse effects are headache and migraine, oedema, dizziness, pruritus, increase in body weight, nausea, abdominal pain, rash, and depression. ",tibolone
sign_symptom,pseudo,0.99978966," tardive dyskinesia; leucopenia, neutropenia, agranulocytosis; drowsiness, pseudoparkinsonism and other extrapyramidal symptoms; dry mouth, blurred vision, constipation, nausea, vomiting, diarrhoea, nasal stuffiness, pallor; galactorrhoea, breast engorgement, amenorrhoea, inhibition of ejaculation, peripheral oedema; dermatitis, skin eruptions. rarely, nocturnal confusion, hyperactivity, lethargy, psychotic reactions, restlessness, headache, photosensitivity, parotid swelling. ",thioridazine
sign_symptom,dry mouth,0.9359976," tardive dyskinesia; leucopenia, neutropenia, agranulocytosis; drowsiness, pseudoparkinsonism and other extrapyramidal symptoms; dry mouth, blurred vision, constipation, nausea, vomiting, diarrhoea, nasal stuffiness, pallor; galactorrhoea, breast engorgement, amenorrhoea, inhibition of ejaculation, peripheral oedema; dermatitis, skin eruptions. rarely, nocturnal confusion, hyperactivity, lethargy, psychotic reactions, restlessness, headache, photosensitivity, parotid swelling. ",thioridazine
sign_symptom,blurred vision,0.99275905," tardive dyskinesia; leucopenia, neutropenia, agranulocytosis; drowsiness, pseudoparkinsonism and other extrapyramidal symptoms; dry mouth, blurred vision, constipation, nausea, vomiting, diarrhoea, nasal stuffiness, pallor; galactorrhoea, breast engorgement, amenorrhoea, inhibition of ejaculation, peripheral oedema; dermatitis, skin eruptions. rarely, nocturnal confusion, hyperactivity, lethargy, psychotic reactions, restlessness, headache, photosensitivity, parotid swelling. ",thioridazine
sign_symptom,inhibition of ejacula,0.96808517," tardive dyskinesia; leucopenia, neutropenia, agranulocytosis; drowsiness, pseudoparkinsonism and other extrapyramidal symptoms; dry mouth, blurred vision, constipation, nausea, vomiting, diarrhoea, nasal stuffiness, pallor; galactorrhoea, breast engorgement, amenorrhoea, inhibition of ejaculation, peripheral oedema; dermatitis, skin eruptions. rarely, nocturnal confusion, hyperactivity, lethargy, psychotic reactions, restlessness, headache, photosensitivity, parotid swelling. ",thioridazine
sign_symptom,hypersensitivity reactions,0.9977411," hypersensitivity reactions have been reported. other adverse reactions to thiopental sodium include the followings: respiratory depression, myocardial depression, cardiac arrhythmias, prolonged somnolence and recovery, hypotension, tachycardia, sneezing, coughing, bronchospasm, laryngospasm and shivering. anaphylactic reactions have been reported. symptoms, e.g., urticaria, bronchospasm, vasodilation and edema. ",thiopental sodium
medication,sodium,0.87534183," hypersensitivity reactions have been reported. other adverse reactions to thiopental sodium include the followings: respiratory depression, myocardial depression, cardiac arrhythmias, prolonged somnolence and recovery, hypotension, tachycardia, sneezing, coughing, bronchospasm, laryngospasm and shivering. anaphylactic reactions have been reported. symptoms, e.g., urticaria, bronchospasm, vasodilation and edema. ",thiopental sodium
medication,vitamin b1,0.99949557," vitamin b1 does not have adverse effects when given orally, but in a few fatal cases anaphylactic reactions have occurred after intravenous administration of large doses (400 mg) in sensitive patients, especially children, and in one case following an intramuscular dose of 125 mg. the risk of such reactions increases with repeated administration of the drug by parenteral route. transient mild soreness may occur at the site of intramuscular administration ",thiamine hydrochloride
sign_symptom,anaphylactic reactions,0.9982084," vitamin b1 does not have adverse effects when given orally, but in a few fatal cases anaphylactic reactions have occurred after intravenous administration of large doses (400 mg) in sensitive patients, especially children, and in one case following an intramuscular dose of 125 mg. the risk of such reactions increases with repeated administration of the drug by parenteral route. transient mild soreness may occur at the site of intramuscular administration ",thiamine hydrochloride
sign_symptom,soreness,0.99655354," vitamin b1 does not have adverse effects when given orally, but in a few fatal cases anaphylactic reactions have occurred after intravenous administration of large doses (400 mg) in sensitive patients, especially children, and in one case following an intramuscular dose of 125 mg. the risk of such reactions increases with repeated administration of the drug by parenteral route. transient mild soreness may occur at the site of intramuscular administration ",thiamine hydrochloride
sign_symptom,side effects,0.87945," generally side effects are rare at normal dosage. it may include gastrointestinal discomfort, headache, nausea, insomnia and hypotension. cns stimulation and diuresis may also occur, especially in children. ",theophylline
sign_symptom,stimulation,0.9923539," generally side effects are rare at normal dosage. it may include gastrointestinal discomfort, headache, nausea, insomnia and hypotension. cns stimulation and diuresis may also occur, especially in children. ",theophylline
sign_symptom,consti,0.77417886," severe and irreversible peripheral neuropathy, constipation, dizziness, orthostatic hypotension, drowsiness, somnolence, bradycardia, increase of viral load in hiv-infected patients, hypersensitivity reaction. ",thalidomide
sign_symptom,hypotens,0.87537354," severe and irreversible peripheral neuropathy, constipation, dizziness, orthostatic hypotension, drowsiness, somnolence, bradycardia, increase of viral load in hiv-infected patients, hypersensitivity reaction. ",thalidomide
sign_symptom,depression,0.9393614,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
sign_symptom,graybrown,0.7621924,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
sign_symptom,discoloration,0.98692065,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
sign_symptom,hypersensitivity reactions,0.999718,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
sign_symptom,anaphylaxi,0.84322923,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
sign_symptom,urticaria,0.99941164,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
sign_symptom,rash,0.9999285,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
sign_symptom,photosensitivity reactions,0.955317,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
sign_symptom,epigastric distress,0.99485874,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
sign_symptom,nausea,0.99994564,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
sign_symptom,vomiting,0.99995637,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
disease_disorder,renal failure,0.9598286,"  teeth and bone : tetracycline can cause depression of bone growth, permanent graybrown discoloration of the teeth and enamel hypoplasia when given during tooth development (i.e. during the later half of pregnancy, during infancy and in childhood).  hypersensitivity reactions such as anaphylaxis, urticaria and rashes are uncommon. photosensitivity reactions consisting of a red rash on areas exposed to intense sunlight can occur with tetracycline.   gastrointestinal effects : epigastric distress and nausea are commonly seen after oral administration, and these symptoms are somewhat dose related. vomiting can occur.   accentuated prerenal azotemia : tetracycline appears to aggravate pre-existing renal failure by inhibiting protein synthesis, which increases the azotemia from amino acid metabolism.  superinfections with oral and anogenital candidiasis are relatively common in patients taking tetracycline.   esophageal ulcerations : in most cases, the patients were taking the capsules with little or no fluid before going to bed. to help minimize this, oral doses should be given with adequate amounts of fluid. ",tetracycline hydrochloride (oral)
sign_symptom,super,0.80288696," burning, irritation, visual disturbances, superinfections, photosensitivity, hypersensitivity ",tetracycline hydrochloride (ophthalmic)
sign_symptom,photos,0.99984," burning, irritation, visual disturbances, superinfections, photosensitivity, hypersensitivity ",tetracycline hydrochloride (ophthalmic)
sign_symptom,hypersensitivity,0.9998504," burning, irritation, visual disturbances, superinfections, photosensitivity, hypersensitivity ",tetracycline hydrochloride (ophthalmic)
sign_symptom,adverse reactions,0.9885188," the following serious adverse reactions are depression, suicidality akathisia, restlessness, and agitation, parkinsonism, dysphagia, sedation andsomnolence ",tetrabenazine
sign_symptom,suicidal,0.90442705," the following serious adverse reactions are depression, suicidality akathisia, restlessness, and agitation, parkinsonism, dysphagia, sedation andsomnolence ",tetrabenazine
sign_symptom,hypersensitive reactions,0.9989875," hypersensitive reactions may occur after the injection of any serum of animal origin. in rare cases hypotension, dyspnoea, urticaria may occur. it should be treated with adrenalin, possibly in association with antihistamine and corticosteroid therapy. serum sickness may occur 7 to 10 days after injection of serum of animal origin; symptoms include fever, vomiting, diarrhoea, bronchospasm and urticaria. ",tetanus antitoxin [equine]
sign_symptom,dyspnoea,0.97392625," hypersensitive reactions may occur after the injection of any serum of animal origin. in rare cases hypotension, dyspnoea, urticaria may occur. it should be treated with adrenalin, possibly in association with antihistamine and corticosteroid therapy. serum sickness may occur 7 to 10 days after injection of serum of animal origin; symptoms include fever, vomiting, diarrhoea, bronchospasm and urticaria. ",tetanus antitoxin [equine]
sign_symptom,urticaria,0.9861297," hypersensitive reactions may occur after the injection of any serum of animal origin. in rare cases hypotension, dyspnoea, urticaria may occur. it should be treated with adrenalin, possibly in association with antihistamine and corticosteroid therapy. serum sickness may occur 7 to 10 days after injection of serum of animal origin; symptoms include fever, vomiting, diarrhoea, bronchospasm and urticaria. ",tetanus antitoxin [equine]
sign_symptom,sickness,0.992626," hypersensitive reactions may occur after the injection of any serum of animal origin. in rare cases hypotension, dyspnoea, urticaria may occur. it should be treated with adrenalin, possibly in association with antihistamine and corticosteroid therapy. serum sickness may occur 7 to 10 days after injection of serum of animal origin; symptoms include fever, vomiting, diarrhoea, bronchospasm and urticaria. ",tetanus antitoxin [equine]
sign_symptom,adverse reactions,0.9913543," the most serious adverse reactions caused by trastuzumab includes cardiomyopathy, infusion reactions, embryo-fetal toxicity, pulmonary toxicity, exacerbation of chemotherapy-induced neutropenia. the most common adverse reactions in patients receiving trastuzumab in the adjuvant and metastatic breast cancer setting are fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia. ",trastuzumab
medication,tranexamic acid,0.9246089,"  
 tranexamic acid is generally well tolerated; there may be infrequent cases of sense of fatigue, conjunctival irritation, nasal blockage, itching, skin reddening, exanthems. 
 after oral administration there may be sign of nausea, diarrhea, gastric pyrosis. 
 there are rare cases of postural hypotension. 
 in the case of hypersensitivity to tranexamic acid, avoid or suspend treatment and start a suitable therapy. 
  ",tranexamic acid
medication,tranexami,0.7785247,"  
 tranexamic acid is generally well tolerated; there may be infrequent cases of sense of fatigue, conjunctival irritation, nasal blockage, itching, skin reddening, exanthems. 
 after oral administration there may be sign of nausea, diarrhea, gastric pyrosis. 
 there are rare cases of postural hypotension. 
 in the case of hypersensitivity to tranexamic acid, avoid or suspend treatment and start a suitable therapy. 
  ",tranexamic acid
sign_symptom,tired,0.9993363," usually torasemide is well tolerated. however, a few side effects like dry mouth, dizziness, tiredness, skin rash, diarrhea, constipation, nausea, vomiting, orthostatic hypotention and muscle cramp may occur. all side effects usually are mild and transient. ",torasemide
sign_symptom,diarr,0.82414263," usually torasemide is well tolerated. however, a few side effects like dry mouth, dizziness, tiredness, skin rash, diarrhea, constipation, nausea, vomiting, orthostatic hypotention and muscle cramp may occur. all side effects usually are mild and transient. ",torasemide
sign_symptom,consti,0.98376286," usually torasemide is well tolerated. however, a few side effects like dry mouth, dizziness, tiredness, skin rash, diarrhea, constipation, nausea, vomiting, orthostatic hypotention and muscle cramp may occur. all side effects usually are mild and transient. ",torasemide
sign_symptom,mala,0.9998417," neutropenia (nadir of white cell count occurs about 9-12 days after admin), thrombocytopenia and anaemia. gi upset, total alopecia, headache, dyspnoea. fatigue, weakness, malaise, pruritus and hyperbilirubinaemia. ",topotecan
sign_symptom,hyper,0.9984144," neutropenia (nadir of white cell count occurs about 9-12 days after admin), thrombocytopenia and anaemia. gi upset, total alopecia, headache, dyspnoea. fatigue, weakness, malaise, pruritus and hyperbilirubinaemia. ",topotecan
sign_symptom,dyspeps,0.90010494," nausea, abdominal pain, dyspepsia, diarrhoea, dry mouth, taste disturbance, weight loss, anorexia, paraesthesia, hypoaesthesia, headache, fatigue, dizziness, speech disorder, drowsiness, insomnia, impaired memory &amp; concentration, anxiety, depression, visual disturbance, lesscommonly: sucidal ideation, rarely: reduced sweetening mainly children, metabolic acidosis and alopecia, very rarely: leucopenia, thrombocytopenia and serious skin reaction. ",topiramate
sign_symptom,dry mouth,0.97027934," nausea, abdominal pain, dyspepsia, diarrhoea, dry mouth, taste disturbance, weight loss, anorexia, paraesthesia, hypoaesthesia, headache, fatigue, dizziness, speech disorder, drowsiness, insomnia, impaired memory &amp; concentration, anxiety, depression, visual disturbance, lesscommonly: sucidal ideation, rarely: reduced sweetening mainly children, metabolic acidosis and alopecia, very rarely: leucopenia, thrombocytopenia and serious skin reaction. ",topiramate
sign_symptom,taste,0.78281486," nausea, abdominal pain, dyspepsia, diarrhoea, dry mouth, taste disturbance, weight loss, anorexia, paraesthesia, hypoaesthesia, headache, fatigue, dizziness, speech disorder, drowsiness, insomnia, impaired memory &amp; concentration, anxiety, depression, visual disturbance, lesscommonly: sucidal ideation, rarely: reduced sweetening mainly children, metabolic acidosis and alopecia, very rarely: leucopenia, thrombocytopenia and serious skin reaction. ",topiramate
sign_symptom,sweetening,0.97293365," nausea, abdominal pain, dyspepsia, diarrhoea, dry mouth, taste disturbance, weight loss, anorexia, paraesthesia, hypoaesthesia, headache, fatigue, dizziness, speech disorder, drowsiness, insomnia, impaired memory &amp; concentration, anxiety, depression, visual disturbance, lesscommonly: sucidal ideation, rarely: reduced sweetening mainly children, metabolic acidosis and alopecia, very rarely: leucopenia, thrombocytopenia and serious skin reaction. ",topiramate
disease_disorder,metabolic acidosis,0.99002033," nausea, abdominal pain, dyspepsia, diarrhoea, dry mouth, taste disturbance, weight loss, anorexia, paraesthesia, hypoaesthesia, headache, fatigue, dizziness, speech disorder, drowsiness, insomnia, impaired memory &amp; concentration, anxiety, depression, visual disturbance, lesscommonly: sucidal ideation, rarely: reduced sweetening mainly children, metabolic acidosis and alopecia, very rarely: leucopenia, thrombocytopenia and serious skin reaction. ",topiramate
sign_symptom,dryness,0.7305042," tolterodine may cause mild to moderate antimuscarinic effects, like dryness of mouth, dyspepsia and/or reduced lacrimation. ",tolterodine tartrate
sign_symptom,dyspepsia,0.8961997," tolterodine may cause mild to moderate antimuscarinic effects, like dryness of mouth, dyspepsia and/or reduced lacrimation. ",tolterodine tartrate
sign_symptom,weakness,0.8905218," possible side-effects include sometimes muscular weakness, headache, nausea, vomiting and rarely hypersensitivity reactions (itching, redness of the skin, skin rash) may occur. ",tolperisone hydrochloride
sign_symptom,vomiting,0.99341583," possible side-effects include sometimes muscular weakness, headache, nausea, vomiting and rarely hypersensitivity reactions (itching, redness of the skin, skin rash) may occur. ",tolperisone hydrochloride
sign_symptom,hypersensitivity reactions,0.9983406," possible side-effects include sometimes muscular weakness, headache, nausea, vomiting and rarely hypersensitivity reactions (itching, redness of the skin, skin rash) may occur. ",tolperisone hydrochloride
sign_symptom,vomiting,0.9997054," sometimes, muscular weakness, headache, nausea, vomiting and rarely hypersensitivity reactions may occur as side effects. ",tolperisone + lidocaine
sign_symptom,hypersensitivity reactions,0.9998062," sometimes, muscular weakness, headache, nausea, vomiting and rarely hypersensitivity reactions may occur as side effects. ",tolperisone + lidocaine
sign_symptom,irritation,0.99872273," irritation of the treatedskinmay occur. if this effect persists or worsens, notify your doctor orpharmacistpromptly.  if your doctor has directed you to use thismedication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. many people using this medication do not have serious side effects.  a very seriousallergic reactionto this drug is unlikely, but seek immediate medical attention if it occurs. symptoms of a seriousallergic reactionmay include:rash,itching/swelling (especially of the face/tongue/throat), severedizziness,trouble breathing.  this is not a complete list of possible side effects. if you notice other effects not listed above, contact your doctor or pharmacist. ",tolnaftate
sign_symptom,swelling,0.99957126," irritation of the treatedskinmay occur. if this effect persists or worsens, notify your doctor orpharmacistpromptly.  if your doctor has directed you to use thismedication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. many people using this medication do not have serious side effects.  a very seriousallergic reactionto this drug is unlikely, but seek immediate medical attention if it occurs. symptoms of a seriousallergic reactionmay include:rash,itching/swelling (especially of the face/tongue/throat), severedizziness,trouble breathing.  this is not a complete list of possible side effects. if you notice other effects not listed above, contact your doctor or pharmacist. ",tolnaftate
sign_symptom,severediz,0.87028766," irritation of the treatedskinmay occur. if this effect persists or worsens, notify your doctor orpharmacistpromptly.  if your doctor has directed you to use thismedication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. many people using this medication do not have serious side effects.  a very seriousallergic reactionto this drug is unlikely, but seek immediate medical attention if it occurs. symptoms of a seriousallergic reactionmay include:rash,itching/swelling (especially of the face/tongue/throat), severedizziness,trouble breathing.  this is not a complete list of possible side effects. if you notice other effects not listed above, contact your doctor or pharmacist. ",tolnaftate
sign_symptom,dysuria,0.9920731," dysuria especially in males, diarrhoea, nausea epigastric pain, vomiting, dyspepsia, erythema, headache, tremor, euphoria, fatigue, pulmonary infiltration &amp; haematuria. potentially fatal: blood dyscrasias and hepatitis. ",tolfenamic acid
sign_symptom,nausea,0.9999101," dysuria especially in males, diarrhoea, nausea epigastric pain, vomiting, dyspepsia, erythema, headache, tremor, euphoria, fatigue, pulmonary infiltration &amp; haematuria. potentially fatal: blood dyscrasias and hepatitis. ",tolfenamic acid
sign_symptom,vomiting,0.8927575," dysuria especially in males, diarrhoea, nausea epigastric pain, vomiting, dyspepsia, erythema, headache, tremor, euphoria, fatigue, pulmonary infiltration &amp; haematuria. potentially fatal: blood dyscrasias and hepatitis. ",tolfenamic acid
sign_symptom,dyspepsia,0.9432995," dysuria especially in males, diarrhoea, nausea epigastric pain, vomiting, dyspepsia, erythema, headache, tremor, euphoria, fatigue, pulmonary infiltration &amp; haematuria. potentially fatal: blood dyscrasias and hepatitis. ",tolfenamic acid
sign_symptom,adverse reactions,0.99967885," the most commonly reported adverse reactions during the first 3 months in controlled clinical trials (occurring in greater than or equal to 2% of patients treated with tofacitinib monotherapy or in combination with dmards) were upper respiratory tract infections, headache, diarrhea and nasopharyngitis. ",tofacitinib
sign_symptom,adverse reactions,0.9987779," most common adverse reactions (incidence of at least 5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased alt, injection site reactions. ",tocilizumab
sign_symptom,nasopharyngitis,0.8732889," most common adverse reactions (incidence of at least 5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased alt, injection site reactions. ",tocilizumab
sign_symptom,hyper,0.99967027," the most frequent side effect of tobramycin ophthalmic solution is localized ocular toxicity, conjunctival erythema, hypersensitivity including lid itching and swelling. ",tobramycin (ophthalmic)
sign_symptom,lid itching,0.9314534," the most frequent side effect of tobramycin ophthalmic solution is localized ocular toxicity, conjunctival erythema, hypersensitivity including lid itching and swelling. ",tobramycin (ophthalmic)
sign_symptom,voice alterations,0.9996333, inhaled tobramycin is generally well-tolerated. voice alterations and tinnitus are more common in the on-drug periods. however all the episodes are transient and resolved without discontinuation of the regimen. others like dizziness and increase in serum creatinine were similar to those occurring with placebo. ,tobramycin (nebuliser solution)
sign_symptom,tinnitus,0.9997483, inhaled tobramycin is generally well-tolerated. voice alterations and tinnitus are more common in the on-drug periods. however all the episodes are transient and resolved without discontinuation of the regimen. others like dizziness and increase in serum creatinine were similar to those occurring with placebo. ,tobramycin (nebuliser solution)
disease_disorder,gastro,0.9861293," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
sign_symptom,adverse,0.9994931," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
sign_symptom,adverse reactions,0.9998212," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
disease_disorder,nervous system,0.771311," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
disease_disorder,vascular disorders,0.84388155," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
disease_disorder,common,0.8581522," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
disease_disorder,gastrointestinal,0.9711372," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
disease_disorder,connective tissue disorders,0.9180953," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
sign_symptom,muscular,0.77518636," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
disease_disorder,general disorders,0.70080245," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
sign_symptom,fatigue,0.9896834," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
sign_symptom,transaminases,0.8420642," with low doses, such as those recommended for the relief of painful muscle spasms, somnolence, fatigue, dizziness, dry mouth, blood pressure decrease, nausea, gastrointestinal disorder and transaminase increase have been reported, usually as mild and transient adverse reactions.  with the higher doses recommended for the treatment of spasticity, the adverse reactions reported with low doses are more frequent and more pronounced, but seldom severe enough to require discontinuation of treatment. in addition, the following adverse reactions may occur: hypotension, bradycardia, muscular weakness, insomnia, sleep disorder, hallucination &amp; hepatitis. 
 
 psychiatric disorders: common- insomnia, sleep disorder. 
 nervous system disorders: very common- somnolence, dizziness 
 cardiac disorders: uncommon- bradycardia 
 vascular disorders: common- hypotension 
 gastrointestinal disorders: very common- gastrointestinal disorder, dry mouth; common- nausea. 
 musculoskeletal and connective tissue disorders: very common- muscular weakness 
 general disorders and administration site conditions: very common- fatigue 
 investigations: common- blood pressure decreased, transaminases increased. 
  ",tizanidine hydrochloride
sign_symptom,effects,0.9381022," the following is a list of possibleside-effectsthat may occur from all constituting ingredients of thislotion. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 rash 
 itching 
 severe dizziness 
 trouble breathing 
 skin irritation 
 skin redness 
 acne 
 burning or itching of the skin 
 dark red spots on the skin 
 painful, red and pus-filled blisters in hair follicles 
  ",titanium dioxide + butyl methoxydibenzoyl methane + padimate + oxybenzone
sign_symptom,rash,0.9997147," the following is a list of possibleside-effectsthat may occur from all constituting ingredients of thislotion. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 rash 
 itching 
 severe dizziness 
 trouble breathing 
 skin irritation 
 skin redness 
 acne 
 burning or itching of the skin 
 dark red spots on the skin 
 painful, red and pus-filled blisters in hair follicles 
  ",titanium dioxide + butyl methoxydibenzoyl methane + padimate + oxybenzone
sign_symptom,itching,0.8037784," the following is a list of possibleside-effectsthat may occur from all constituting ingredients of thislotion. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 rash 
 itching 
 severe dizziness 
 trouble breathing 
 skin irritation 
 skin redness 
 acne 
 burning or itching of the skin 
 dark red spots on the skin 
 painful, red and pus-filled blisters in hair follicles 
  ",titanium dioxide + butyl methoxydibenzoyl methane + padimate + oxybenzone
sign_symptom,trouble,0.9815476," the following is a list of possibleside-effectsthat may occur from all constituting ingredients of thislotion. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 rash 
 itching 
 severe dizziness 
 trouble breathing 
 skin irritation 
 skin redness 
 acne 
 burning or itching of the skin 
 dark red spots on the skin 
 painful, red and pus-filled blisters in hair follicles 
  ",titanium dioxide + butyl methoxydibenzoyl methane + padimate + oxybenzone
sign_symptom,irritation,0.9999182," the following is a list of possibleside-effectsthat may occur from all constituting ingredients of thislotion. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 rash 
 itching 
 severe dizziness 
 trouble breathing 
 skin irritation 
 skin redness 
 acne 
 burning or itching of the skin 
 dark red spots on the skin 
 painful, red and pus-filled blisters in hair follicles 
  ",titanium dioxide + butyl methoxydibenzoyl methane + padimate + oxybenzone
sign_symptom,redness,0.86463416," the following is a list of possibleside-effectsthat may occur from all constituting ingredients of thislotion. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 rash 
 itching 
 severe dizziness 
 trouble breathing 
 skin irritation 
 skin redness 
 acne 
 burning or itching of the skin 
 dark red spots on the skin 
 painful, red and pus-filled blisters in hair follicles 
  ",titanium dioxide + butyl methoxydibenzoyl methane + padimate + oxybenzone
sign_symptom,acne,0.9144708," the following is a list of possibleside-effectsthat may occur from all constituting ingredients of thislotion. this is not a comprehensive list. these side-effects are possible, but do not always occur. some of the side-effects may be rare but serious. consult your doctor if you observe any of the following side-effects, especially if they do not go away. 
 
 rash 
 itching 
 severe dizziness 
 trouble breathing 
 skin irritation 
 skin redness 
 acne 
 burning or itching of the skin 
 dark red spots on the skin 
 painful, red and pus-filled blisters in hair follicles 
  ",titanium dioxide + butyl methoxydibenzoyl methane + padimate + oxybenzone
sign_symptom,adverse drug reaction,0.9893972," the most commonly reported adverse drug reaction was dry mouth. dry mouth was usually mild and often resolved during continued treatment. other reactions reported in individual patients and consistent with possible anticholinergic effects included constipation, increased heart rate, blurredvision, glaucoma, urinary difficulty, and urinary retention. ",tiotropium (dry powder inhaler)
sign_symptom,dry mouth,0.97144246," the most commonly reported adverse drug reaction was dry mouth. dry mouth was usually mild and often resolved during continued treatment. other reactions reported in individual patients and consistent with possible anticholinergic effects included constipation, increased heart rate, blurredvision, glaucoma, urinary difficulty, and urinary retention. ",tiotropium (dry powder inhaler)
sign_symptom,consti,0.84392357," the most commonly reported adverse drug reaction was dry mouth. dry mouth was usually mild and often resolved during continued treatment. other reactions reported in individual patients and consistent with possible anticholinergic effects included constipation, increased heart rate, blurredvision, glaucoma, urinary difficulty, and urinary retention. ",tiotropium (dry powder inhaler)
sign_symptom,blurred,0.71367633," elevated iop (occasionally), stinging, blurred vision, tachycardia, photophobia, headache, parasympathetic stimulation and allergic reactions. systemic effects include arrhythmias, hypertension and coronary artery spasm. ",tropicamide + phenylephrine hydrochloride
sign_symptom,photo,0.97590953," elevated iop (occasionally), stinging, blurred vision, tachycardia, photophobia, headache, parasympathetic stimulation and allergic reactions. systemic effects include arrhythmias, hypertension and coronary artery spasm. ",tropicamide + phenylephrine hydrochloride
sign_symptom,allergic,0.88975215," elevated iop (occasionally), stinging, blurred vision, tachycardia, photophobia, headache, parasympathetic stimulation and allergic reactions. systemic effects include arrhythmias, hypertension and coronary artery spasm. ",tropicamide + phenylephrine hydrochloride
sign_symptom,hyper,0.99883646," elevated iop (occasionally), stinging, blurred vision, tachycardia, photophobia, headache, parasympathetic stimulation and allergic reactions. systemic effects include arrhythmias, hypertension and coronary artery spasm. ",tropicamide + phenylephrine hydrochloride
disease_disorder,complications,0.93651736," most serious well-known complications occurring during or after cataract surgery: uncommon: may affect up to 1 in 100 people 
 
 injury to the lens (posterior capsule rupture) 
 swelling of the retina (cystoid macular edema) 
 
please seek urgent medical advice in this case. other side effects: uncommon: may affect up to 1 in 100 people 
 
 nervous system disorder: headache 
 eye disorder: swelling of the cornea (keratitis), increased pressure in the eye, redness of the eye (ocular hyperaemia) 
 vascular disorder: high blood pressure (hypertension) 
  ",tropicamide + phenylephrine + lidocaine
disease_disorder,injury,0.9690439," most serious well-known complications occurring during or after cataract surgery: uncommon: may affect up to 1 in 100 people 
 
 injury to the lens (posterior capsule rupture) 
 swelling of the retina (cystoid macular edema) 
 
please seek urgent medical advice in this case. other side effects: uncommon: may affect up to 1 in 100 people 
 
 nervous system disorder: headache 
 eye disorder: swelling of the cornea (keratitis), increased pressure in the eye, redness of the eye (ocular hyperaemia) 
 vascular disorder: high blood pressure (hypertension) 
  ",tropicamide + phenylephrine + lidocaine
sign_symptom,swelling,0.9999385," most serious well-known complications occurring during or after cataract surgery: uncommon: may affect up to 1 in 100 people 
 
 injury to the lens (posterior capsule rupture) 
 swelling of the retina (cystoid macular edema) 
 
please seek urgent medical advice in this case. other side effects: uncommon: may affect up to 1 in 100 people 
 
 nervous system disorder: headache 
 eye disorder: swelling of the cornea (keratitis), increased pressure in the eye, redness of the eye (ocular hyperaemia) 
 vascular disorder: high blood pressure (hypertension) 
  ",tropicamide + phenylephrine + lidocaine
disease_disorder,system,0.71208936," most serious well-known complications occurring during or after cataract surgery: uncommon: may affect up to 1 in 100 people 
 
 injury to the lens (posterior capsule rupture) 
 swelling of the retina (cystoid macular edema) 
 
please seek urgent medical advice in this case. other side effects: uncommon: may affect up to 1 in 100 people 
 
 nervous system disorder: headache 
 eye disorder: swelling of the cornea (keratitis), increased pressure in the eye, redness of the eye (ocular hyperaemia) 
 vascular disorder: high blood pressure (hypertension) 
  ",tropicamide + phenylephrine + lidocaine
disease_disorder,headache,0.89058584," most serious well-known complications occurring during or after cataract surgery: uncommon: may affect up to 1 in 100 people 
 
 injury to the lens (posterior capsule rupture) 
 swelling of the retina (cystoid macular edema) 
 
please seek urgent medical advice in this case. other side effects: uncommon: may affect up to 1 in 100 people 
 
 nervous system disorder: headache 
 eye disorder: swelling of the cornea (keratitis), increased pressure in the eye, redness of the eye (ocular hyperaemia) 
 vascular disorder: high blood pressure (hypertension) 
  ",tropicamide + phenylephrine + lidocaine
sign_symptom,pressure,0.9000782," most serious well-known complications occurring during or after cataract surgery: uncommon: may affect up to 1 in 100 people 
 
 injury to the lens (posterior capsule rupture) 
 swelling of the retina (cystoid macular edema) 
 
please seek urgent medical advice in this case. other side effects: uncommon: may affect up to 1 in 100 people 
 
 nervous system disorder: headache 
 eye disorder: swelling of the cornea (keratitis), increased pressure in the eye, redness of the eye (ocular hyperaemia) 
 vascular disorder: high blood pressure (hypertension) 
  ",tropicamide + phenylephrine + lidocaine
sign_symptom,redness of the eye,0.999376," most serious well-known complications occurring during or after cataract surgery: uncommon: may affect up to 1 in 100 people 
 
 injury to the lens (posterior capsule rupture) 
 swelling of the retina (cystoid macular edema) 
 
please seek urgent medical advice in this case. other side effects: uncommon: may affect up to 1 in 100 people 
 
 nervous system disorder: headache 
 eye disorder: swelling of the cornea (keratitis), increased pressure in the eye, redness of the eye (ocular hyperaemia) 
 vascular disorder: high blood pressure (hypertension) 
  ",tropicamide + phenylephrine + lidocaine
sign_symptom,blurred vision,0.90208745," transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide. increased intraocular pressure has been reported following the use of mydriatics. dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide. ",tropicamide
sign_symptom,photophobia,0.9997855," transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide. increased intraocular pressure has been reported following the use of mydriatics. dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide. ",tropicamide
disease_disorder,keratitis,0.750299," transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide. increased intraocular pressure has been reported following the use of mydriatics. dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide. ",tropicamide
sign_symptom,allergic,0.99054927," transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide. increased intraocular pressure has been reported following the use of mydriatics. dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide. ",tropicamide
sign_symptom,central nervous system,0.98432034," transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide. increased intraocular pressure has been reported following the use of mydriatics. dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide. ",tropicamide
sign_symptom,disturbances,0.9997824," transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide. increased intraocular pressure has been reported following the use of mydriatics. dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide. ",tropicamide
sign_symptom,rigidity,0.9797132," transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide. increased intraocular pressure has been reported following the use of mydriatics. dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide. ",tropicamide
sign_symptom,accommodation,0.9977718," dry mouth, accommodation disturbances, tachycardia, constipation, hesitancy of micturation, drowsiness, sweating, postural hypotension, skin rashes, cholestatic jaundice, hypomania, convulsions, cardiac arrhythmias and peripheral neuropathy. agitation, confusion (elderly). ",trimipramine
sign_symptom,hypotension,0.9887627," dry mouth, accommodation disturbances, tachycardia, constipation, hesitancy of micturation, drowsiness, sweating, postural hypotension, skin rashes, cholestatic jaundice, hypomania, convulsions, cardiac arrhythmias and peripheral neuropathy. agitation, confusion (elderly). ",trimipramine
sign_symptom,rash,0.9998209," dry mouth, accommodation disturbances, tachycardia, constipation, hesitancy of micturation, drowsiness, sweating, postural hypotension, skin rashes, cholestatic jaundice, hypomania, convulsions, cardiac arrhythmias and peripheral neuropathy. agitation, confusion (elderly). ",trimipramine
sign_symptom,cholestatic,0.91960406," dry mouth, accommodation disturbances, tachycardia, constipation, hesitancy of micturation, drowsiness, sweating, postural hypotension, skin rashes, cholestatic jaundice, hypomania, convulsions, cardiac arrhythmias and peripheral neuropathy. agitation, confusion (elderly). ",trimipramine
sign_symptom,jaund,0.9971076," dry mouth, accommodation disturbances, tachycardia, constipation, hesitancy of micturation, drowsiness, sweating, postural hypotension, skin rashes, cholestatic jaundice, hypomania, convulsions, cardiac arrhythmias and peripheral neuropathy. agitation, confusion (elderly). ",trimipramine
sign_symptom,confusion,0.99990284," dry mouth, accommodation disturbances, tachycardia, constipation, hesitancy of micturation, drowsiness, sweating, postural hypotension, skin rashes, cholestatic jaundice, hypomania, convulsions, cardiac arrhythmias and peripheral neuropathy. agitation, confusion (elderly). ",trimipramine
medication,trimetazidine,0.9892639," trimetazidine is safe and well tolerated. the common side effects associated with trimetazidine are dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria and asthenia ",trimetazidine dihydrochloride
sign_symptom,diarrhoea,0.8938744," trimetazidine is safe and well tolerated. the common side effects associated with trimetazidine are dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria and asthenia ",trimetazidine dihydrochloride
sign_symptom,dyspepsia,0.9429232," trimetazidine is safe and well tolerated. the common side effects associated with trimetazidine are dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria and asthenia ",trimetazidine dihydrochloride
disease_disorder,asthenia,0.82070655," trimetazidine is safe and well tolerated. the common side effects associated with trimetazidine are dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria and asthenia ",trimetazidine dihydrochloride
medication,trimebutine maleate,0.97233826," trimebutine maleate is generally well tolerated. the infrequently reported adverse effects are as follows: dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea, constipation, drowsiness, fatigue, dizziness, hot/cold sensations, headache etc. ",trimebutine maleate
sign_symptom,dyspepsia,0.97000235," trimebutine maleate is generally well tolerated. the infrequently reported adverse effects are as follows: dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea, constipation, drowsiness, fatigue, dizziness, hot/cold sensations, headache etc. ",trimebutine maleate
sign_symptom,drows,0.9811769," trimebutine maleate is generally well tolerated. the infrequently reported adverse effects are as follows: dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea, constipation, drowsiness, fatigue, dizziness, hot/cold sensations, headache etc. ",trimebutine maleate
sign_symptom,fatigue,0.9609069," trimebutine maleate is generally well tolerated. the infrequently reported adverse effects are as follows: dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea, constipation, drowsiness, fatigue, dizziness, hot/cold sensations, headache etc. ",trimebutine maleate
sign_symptom,headache,0.99986684," trimebutine maleate is generally well tolerated. the infrequently reported adverse effects are as follows: dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea, constipation, drowsiness, fatigue, dizziness, hot/cold sensations, headache etc. ",trimebutine maleate
sign_symptom,blur,0.99987555," minor side effects such as dryness of the mouth, blurring of vision, dizziness, mild nausea or nervousness. patients with arteriosclerosis or with a history of idiosyncrasy to other drugs may exhibit reactions of mental confusion, agitation, disturbed behavior, or nausea and vomiting. potential side effects are constipation, drowsiness, urinary hesitancy or retention, pupil dilation, increased intraocular tension, vomiting and headache. ",trihexyphenidyl hydrochloride
sign_symptom,nausea,0.9997141," minor side effects such as dryness of the mouth, blurring of vision, dizziness, mild nausea or nervousness. patients with arteriosclerosis or with a history of idiosyncrasy to other drugs may exhibit reactions of mental confusion, agitation, disturbed behavior, or nausea and vomiting. potential side effects are constipation, drowsiness, urinary hesitancy or retention, pupil dilation, increased intraocular tension, vomiting and headache. ",trihexyphenidyl hydrochloride
disease_disorder,arteriosclerosis,0.9995494," minor side effects such as dryness of the mouth, blurring of vision, dizziness, mild nausea or nervousness. patients with arteriosclerosis or with a history of idiosyncrasy to other drugs may exhibit reactions of mental confusion, agitation, disturbed behavior, or nausea and vomiting. potential side effects are constipation, drowsiness, urinary hesitancy or retention, pupil dilation, increased intraocular tension, vomiting and headache. ",trihexyphenidyl hydrochloride
sign_symptom,vomiting,0.81569576," minor side effects such as dryness of the mouth, blurring of vision, dizziness, mild nausea or nervousness. patients with arteriosclerosis or with a history of idiosyncrasy to other drugs may exhibit reactions of mental confusion, agitation, disturbed behavior, or nausea and vomiting. potential side effects are constipation, drowsiness, urinary hesitancy or retention, pupil dilation, increased intraocular tension, vomiting and headache. ",trihexyphenidyl hydrochloride
sign_symptom,stinging sensation,0.9496431," reported side effects are mild, transient burning or stinging sensation upon instillation. other side effects are superficial punctate keratopathy, epithelial keratopathy, hypersensitivity reaction, stromal edema, irritation, keratitis sicca, hyperemia and increased intraocular pressure. ",trifluridine
sign_symptom,hyper,0.8067802," reported side effects are mild, transient burning or stinging sensation upon instillation. other side effects are superficial punctate keratopathy, epithelial keratopathy, hypersensitivity reaction, stromal edema, irritation, keratitis sicca, hyperemia and increased intraocular pressure. ",trifluridine
sign_symptom,restless,0.9955173," common side effects are transient restlessness, dystonias or may resemble parkinsonism. other cns reactions are drowsiness, dizziness, fatigue, blurred vision, seizures. without these peripheral oedema, blood dyscrasias, jaundice may occasionally occur. tachycardia, constipation, urinary hesitancy and retention and hyperpyrexia have been reported very rarely. ",trifluoperazine
sign_symptom,dystonias,0.99749565," common side effects are transient restlessness, dystonias or may resemble parkinsonism. other cns reactions are drowsiness, dizziness, fatigue, blurred vision, seizures. without these peripheral oedema, blood dyscrasias, jaundice may occasionally occur. tachycardia, constipation, urinary hesitancy and retention and hyperpyrexia have been reported very rarely. ",trifluoperazine
sign_symptom,urinary,0.8859622," common side effects are transient restlessness, dystonias or may resemble parkinsonism. other cns reactions are drowsiness, dizziness, fatigue, blurred vision, seizures. without these peripheral oedema, blood dyscrasias, jaundice may occasionally occur. tachycardia, constipation, urinary hesitancy and retention and hyperpyrexia have been reported very rarely. ",trifluoperazine
sign_symptom,hesitancy,0.85926276," common side effects are transient restlessness, dystonias or may resemble parkinsonism. other cns reactions are drowsiness, dizziness, fatigue, blurred vision, seizures. without these peripheral oedema, blood dyscrasias, jaundice may occasionally occur. tachycardia, constipation, urinary hesitancy and retention and hyperpyrexia have been reported very rarely. ",trifluoperazine
sign_symptom,retention,0.99961746," common side effects are transient restlessness, dystonias or may resemble parkinsonism. other cns reactions are drowsiness, dizziness, fatigue, blurred vision, seizures. without these peripheral oedema, blood dyscrasias, jaundice may occasionally occur. tachycardia, constipation, urinary hesitancy and retention and hyperpyrexia have been reported very rarely. ",trifluoperazine
sign_symptom,hyper,0.9999697," common side effects are transient restlessness, dystonias or may resemble parkinsonism. other cns reactions are drowsiness, dizziness, fatigue, blurred vision, seizures. without these peripheral oedema, blood dyscrasias, jaundice may occasionally occur. tachycardia, constipation, urinary hesitancy and retention and hyperpyrexia have been reported very rarely. ",trifluoperazine
sign_symptom,adverse reactions,0.9996476," most common adverse reactions (incidence &gt;1%) in patients treated with trifarotene cream were application site irritation, application site pruritus, and sunburn. ",trifarotene
disease_disorder,dermatitis,0.8458484," the following local side effects have been reported with topical corticosteroids, either with or without occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis and allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. ",triamcinolone acetonide (topical)
sign_symptom,mace,0.9996891," the following local side effects have been reported with topical corticosteroids, either with or without occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis and allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. ",triamcinolone acetonide (topical)
sign_symptom,adverse reactions,0.9986124," the most commonly reported adverse reactions in clinical trials with triamcinolone included those involving mucous membranes of the nose &amp; throat. the most prevalent adverse reactions considered are rhinitis, headache, &amp; pharyngitis. the nasopharyngeal adverse effects included epistaxis, nasal irritation, dry mucous membrane,naso-sinus congestion and sneezing although these are seen as frequently with placebo. as with other nasally inhaled corticosteroids, nasal septal perforation has been reported. ",triamcinolone acetonide (nasal spray)
sign_symptom,effects,0.73624885," the most commonly reported adverse reactions in clinical trials with triamcinolone included those involving mucous membranes of the nose &amp; throat. the most prevalent adverse reactions considered are rhinitis, headache, &amp; pharyngitis. the nasopharyngeal adverse effects included epistaxis, nasal irritation, dry mucous membrane,naso-sinus congestion and sneezing although these are seen as frequently with placebo. as with other nasally inhaled corticosteroids, nasal septal perforation has been reported. ",triamcinolone acetonide (nasal spray)
sign_symptom,congestion,0.99980086," the most commonly reported adverse reactions in clinical trials with triamcinolone included those involving mucous membranes of the nose &amp; throat. the most prevalent adverse reactions considered are rhinitis, headache, &amp; pharyngitis. the nasopharyngeal adverse effects included epistaxis, nasal irritation, dry mucous membrane,naso-sinus congestion and sneezing although these are seen as frequently with placebo. as with other nasally inhaled corticosteroids, nasal septal perforation has been reported. ",triamcinolone acetonide (nasal spray)
medication,corticoster,0.7628787," the most commonly reported adverse reactions in clinical trials with triamcinolone included those involving mucous membranes of the nose &amp; throat. the most prevalent adverse reactions considered are rhinitis, headache, &amp; pharyngitis. the nasopharyngeal adverse effects included epistaxis, nasal irritation, dry mucous membrane,naso-sinus congestion and sneezing although these are seen as frequently with placebo. as with other nasally inhaled corticosteroids, nasal septal perforation has been reported. ",triamcinolone acetonide (nasal spray)
disease_disorder,septal perforation,0.89227057," the most commonly reported adverse reactions in clinical trials with triamcinolone included those involving mucous membranes of the nose &amp; throat. the most prevalent adverse reactions considered are rhinitis, headache, &amp; pharyngitis. the nasopharyngeal adverse effects included epistaxis, nasal irritation, dry mucous membrane,naso-sinus congestion and sneezing although these are seen as frequently with placebo. as with other nasally inhaled corticosteroids, nasal septal perforation has been reported. ",triamcinolone acetonide (nasal spray)
sign_symptom,thin,0.9916515," prolonged use may cause sensitivity reactions, impaired wound healing, thinning of skin, striae, telangiectasia, hirsutism, hypothalamic-pituitary-adrenal axis suppression, cushing's syndrome. ",triamcinolone + neomycin + nystatin + gramicidin
sign_symptom,burning,0.97575366," initial external application of tretinoin generally may cause burning or slight irritation, erythema and peeling at the site of application may also occur. if irritation becomes severe and persists, discontinue application and consult your physicians, if necessary. ",tretinoin (topical)
sign_symptom,peeling,0.9996056," initial external application of tretinoin generally may cause burning or slight irritation, erythema and peeling at the site of application may also occur. if irritation becomes severe and persists, discontinue application and consult your physicians, if necessary. ",tretinoin (topical)
sign_symptom,irritation,0.9999335," initial external application of tretinoin generally may cause burning or slight irritation, erythema and peeling at the site of application may also occur. if irritation becomes severe and persists, discontinue application and consult your physicians, if necessary. ",tretinoin (topical)
sign_symptom,fatigue,0.7846471," virtually all patients experience some drug-related toxicity, especially headache, fever, weakness, and fatigue. these adverse effects are seldom permanent or irreversible nor do they usually require interruption of therapy. some of the adverse events are common in patients with apl, including hemorrhage, infections, gastrointestinal hemorrhage, disseminated intravascular coagulation, pneumonia, septicemia, and cerebral hemorrhage. the following describes the adverse events, regardless of drug relationship, that were observed in patients treated with tretinoin. ",tretinoin (oral)
sign_symptom,adverse events,0.8375901," virtually all patients experience some drug-related toxicity, especially headache, fever, weakness, and fatigue. these adverse effects are seldom permanent or irreversible nor do they usually require interruption of therapy. some of the adverse events are common in patients with apl, including hemorrhage, infections, gastrointestinal hemorrhage, disseminated intravascular coagulation, pneumonia, septicemia, and cerebral hemorrhage. the following describes the adverse events, regardless of drug relationship, that were observed in patients treated with tretinoin. ",tretinoin (oral)
medication,medication,0.87658244," among 901 domestic clinical trial cases up to the time of approval, 103 cases ( 11.4%) showed clinical results that included abnormalities and side effects. these mainly included hypoglycemia, nasopharyngitis, and elevated lipase.  given the appearance of serious side effects such as hypoglycemia (0.1~5%) , administer medication in conjunction with close observation of patient status. other dpp-4 inhibitors have been reported to present serious hypoglycemia in combination with sulfonylurea medications as well as some cases of loss of consciousness. moreover, decreased blood sugar from the use of this medication, once confirmed, can be remedied by giving sucrose. however, hypoglycemia resulting from a combination with glucosidase inhibitors should be treated with fructose. ",trelagliptin succinate
medication,dpp - 4 inhibitors,0.99476445," among 901 domestic clinical trial cases up to the time of approval, 103 cases ( 11.4%) showed clinical results that included abnormalities and side effects. these mainly included hypoglycemia, nasopharyngitis, and elevated lipase.  given the appearance of serious side effects such as hypoglycemia (0.1~5%) , administer medication in conjunction with close observation of patient status. other dpp-4 inhibitors have been reported to present serious hypoglycemia in combination with sulfonylurea medications as well as some cases of loss of consciousness. moreover, decreased blood sugar from the use of this medication, once confirmed, can be remedied by giving sucrose. however, hypoglycemia resulting from a combination with glucosidase inhibitors should be treated with fructose. ",trelagliptin succinate
sign_symptom,loss of consciousness,0.99872404," among 901 domestic clinical trial cases up to the time of approval, 103 cases ( 11.4%) showed clinical results that included abnormalities and side effects. these mainly included hypoglycemia, nasopharyngitis, and elevated lipase.  given the appearance of serious side effects such as hypoglycemia (0.1~5%) , administer medication in conjunction with close observation of patient status. other dpp-4 inhibitors have been reported to present serious hypoglycemia in combination with sulfonylurea medications as well as some cases of loss of consciousness. moreover, decreased blood sugar from the use of this medication, once confirmed, can be remedied by giving sucrose. however, hypoglycemia resulting from a combination with glucosidase inhibitors should be treated with fructose. ",trelagliptin succinate
medication,inhibitors,0.9684212," among 901 domestic clinical trial cases up to the time of approval, 103 cases ( 11.4%) showed clinical results that included abnormalities and side effects. these mainly included hypoglycemia, nasopharyngitis, and elevated lipase.  given the appearance of serious side effects such as hypoglycemia (0.1~5%) , administer medication in conjunction with close observation of patient status. other dpp-4 inhibitors have been reported to present serious hypoglycemia in combination with sulfonylurea medications as well as some cases of loss of consciousness. moreover, decreased blood sugar from the use of this medication, once confirmed, can be remedied by giving sucrose. however, hypoglycemia resulting from a combination with glucosidase inhibitors should be treated with fructose. ",trelagliptin succinate
sign_symptom,adverse reactions,0.9999326, no serious adverse reactions are reported. most frequently reported side effects are ocular hyperemia. ,travoprost + timolol maleate
medication,vancom,0.8104743," vancomycin is well tolerated. however during or soon after rapid infusion of vancomycin, patients may develop anaphylactic reactions including hypotension, wheezing, dyspnoea, urticaria or pruritus. rapid infusion may also cause flushing of the upper body (""red neck"") or pain and muscle spasm of the chest and back. these reactions usually resolve within 20 minutes but may persist for several hours. such events are infrequent if vancomycin is given by a slow infusion over 60 minutes. ",vancomycin hydrochloride
sign_symptom,anaphylactic reactions,0.9920165," vancomycin is well tolerated. however during or soon after rapid infusion of vancomycin, patients may develop anaphylactic reactions including hypotension, wheezing, dyspnoea, urticaria or pruritus. rapid infusion may also cause flushing of the upper body (""red neck"") or pain and muscle spasm of the chest and back. these reactions usually resolve within 20 minutes but may persist for several hours. such events are infrequent if vancomycin is given by a slow infusion over 60 minutes. ",vancomycin hydrochloride
sign_symptom,wheezing,0.74106866," vancomycin is well tolerated. however during or soon after rapid infusion of vancomycin, patients may develop anaphylactic reactions including hypotension, wheezing, dyspnoea, urticaria or pruritus. rapid infusion may also cause flushing of the upper body (""red neck"") or pain and muscle spasm of the chest and back. these reactions usually resolve within 20 minutes but may persist for several hours. such events are infrequent if vancomycin is given by a slow infusion over 60 minutes. ",vancomycin hydrochloride
sign_symptom,dyspnoea,0.8834733," vancomycin is well tolerated. however during or soon after rapid infusion of vancomycin, patients may develop anaphylactic reactions including hypotension, wheezing, dyspnoea, urticaria or pruritus. rapid infusion may also cause flushing of the upper body (""red neck"") or pain and muscle spasm of the chest and back. these reactions usually resolve within 20 minutes but may persist for several hours. such events are infrequent if vancomycin is given by a slow infusion over 60 minutes. ",vancomycin hydrochloride
sign_symptom,flushing,0.9998896," vancomycin is well tolerated. however during or soon after rapid infusion of vancomycin, patients may develop anaphylactic reactions including hypotension, wheezing, dyspnoea, urticaria or pruritus. rapid infusion may also cause flushing of the upper body (""red neck"") or pain and muscle spasm of the chest and back. these reactions usually resolve within 20 minutes but may persist for several hours. such events are infrequent if vancomycin is given by a slow infusion over 60 minutes. ",vancomycin hydrochloride
sign_symptom,pain,0.9999523," vancomycin is well tolerated. however during or soon after rapid infusion of vancomycin, patients may develop anaphylactic reactions including hypotension, wheezing, dyspnoea, urticaria or pruritus. rapid infusion may also cause flushing of the upper body (""red neck"") or pain and muscle spasm of the chest and back. these reactions usually resolve within 20 minutes but may persist for several hours. such events are infrequent if vancomycin is given by a slow infusion over 60 minutes. ",vancomycin hydrochloride
sign_symptom,reactions,0.989861," vancomycin is well tolerated. however during or soon after rapid infusion of vancomycin, patients may develop anaphylactic reactions including hypotension, wheezing, dyspnoea, urticaria or pruritus. rapid infusion may also cause flushing of the upper body (""red neck"") or pain and muscle spasm of the chest and back. these reactions usually resolve within 20 minutes but may persist for several hours. such events are infrequent if vancomycin is given by a slow infusion over 60 minutes. ",vancomycin hydrochloride
medication,vancomy,0.8904226," vancomycin is well tolerated. however during or soon after rapid infusion of vancomycin, patients may develop anaphylactic reactions including hypotension, wheezing, dyspnoea, urticaria or pruritus. rapid infusion may also cause flushing of the upper body (""red neck"") or pain and muscle spasm of the chest and back. these reactions usually resolve within 20 minutes but may persist for several hours. such events are infrequent if vancomycin is given by a slow infusion over 60 minutes. ",vancomycin hydrochloride
medication,hydroch,0.9020436," the combination of valsartan and hydrochlorothiazide is generally well tolerated and side effects are rare. the most common side effects include headache, dizziness, fatigue, abdominal pain, cough, diarrhea and nausea. patient may also experience hyperkalemia, impotency, reduced renal function, allergic reactions, dyspnea, constipation, back pain, muscle cramps, rash, anxiety, insomnia and vertigo. hypotension may also occur. ",valsartan + hydrochlorothiazide
medication,valsartan,0.8651653," valsartan is generally well tolerated and side effects are rare. the most common side effects include headache, dizziness, fatigue, abdominal pain, cough, diarrhea and nausea. patient may also experience hyperkalemia, impotency, reduced renal function, allergic reactions, dyspnea, constipation, back pain, muscle cramps, rash, anxiety, insomnia and vertigo. hypotension may also occur if patient have been taking diuretics along with valsartan. ",valsartan
sign_symptom,effects,0.81438845," valsartan is generally well tolerated and side effects are rare. the most common side effects include headache, dizziness, fatigue, abdominal pain, cough, diarrhea and nausea. patient may also experience hyperkalemia, impotency, reduced renal function, allergic reactions, dyspnea, constipation, back pain, muscle cramps, rash, anxiety, insomnia and vertigo. hypotension may also occur if patient have been taking diuretics along with valsartan. ",valsartan
sign_symptom,hyper,0.9791378," valsartan is generally well tolerated and side effects are rare. the most common side effects include headache, dizziness, fatigue, abdominal pain, cough, diarrhea and nausea. patient may also experience hyperkalemia, impotency, reduced renal function, allergic reactions, dyspnea, constipation, back pain, muscle cramps, rash, anxiety, insomnia and vertigo. hypotension may also occur if patient have been taking diuretics along with valsartan. ",valsartan
sign_symptom,impotency,0.93455726," valsartan is generally well tolerated and side effects are rare. the most common side effects include headache, dizziness, fatigue, abdominal pain, cough, diarrhea and nausea. patient may also experience hyperkalemia, impotency, reduced renal function, allergic reactions, dyspnea, constipation, back pain, muscle cramps, rash, anxiety, insomnia and vertigo. hypotension may also occur if patient have been taking diuretics along with valsartan. ",valsartan
sign_symptom,allergic reactions,0.8504615," valsartan is generally well tolerated and side effects are rare. the most common side effects include headache, dizziness, fatigue, abdominal pain, cough, diarrhea and nausea. patient may also experience hyperkalemia, impotency, reduced renal function, allergic reactions, dyspnea, constipation, back pain, muscle cramps, rash, anxiety, insomnia and vertigo. hypotension may also occur if patient have been taking diuretics along with valsartan. ",valsartan
sign_symptom,dyspnea,0.803082," valsartan is generally well tolerated and side effects are rare. the most common side effects include headache, dizziness, fatigue, abdominal pain, cough, diarrhea and nausea. patient may also experience hyperkalemia, impotency, reduced renal function, allergic reactions, dyspnea, constipation, back pain, muscle cramps, rash, anxiety, insomnia and vertigo. hypotension may also occur if patient have been taking diuretics along with valsartan. ",valsartan
sign_symptom,adverse reactions,0.9998721," the following serious adverse reactions are discussed in greater detail in other sections of the labeling: 
 
 hematologic toxicity 
 acute renal failure 
 impairment of fertility 
 fetal toxicity 
 mutagenesis and carcinogenesis 
  ",valganciclovir
sign_symptom,hematologic toxicity,0.9996233," the following serious adverse reactions are discussed in greater detail in other sections of the labeling: 
 
 hematologic toxicity 
 acute renal failure 
 impairment of fertility 
 fetal toxicity 
 mutagenesis and carcinogenesis 
  ",valganciclovir
disease_disorder,renal failure,0.910705," the following serious adverse reactions are discussed in greater detail in other sections of the labeling: 
 
 hematologic toxicity 
 acute renal failure 
 impairment of fertility 
 fetal toxicity 
 mutagenesis and carcinogenesis 
  ",valganciclovir
sign_symptom,impairment,0.96790576," the following serious adverse reactions are discussed in greater detail in other sections of the labeling: 
 
 hematologic toxicity 
 acute renal failure 
 impairment of fertility 
 fetal toxicity 
 mutagenesis and carcinogenesis 
  ",valganciclovir
sign_symptom,fetal toxicity,0.9733013," the following serious adverse reactions are discussed in greater detail in other sections of the labeling: 
 
 hematologic toxicity 
 acute renal failure 
 impairment of fertility 
 fetal toxicity 
 mutagenesis and carcinogenesis 
  ",valganciclovir
sign_symptom,adverse reactions,0.999712," the most frequently reported adverse reactions were nausea (15%), headache (14%), vomiting (6%), dizziness (3%) and abdominal pain (3%). ",valacyclovir
sign_symptom,nausea,0.99995387," the most frequently reported adverse reactions were nausea (15%), headache (14%), vomiting (6%), dizziness (3%) and abdominal pain (3%). ",valacyclovir
sign_symptom,headache,0.9999511," the most frequently reported adverse reactions were nausea (15%), headache (14%), vomiting (6%), dizziness (3%) and abdominal pain (3%). ",valacyclovir
sign_symptom,vomiting,0.9999522," the most frequently reported adverse reactions were nausea (15%), headache (14%), vomiting (6%), dizziness (3%) and abdominal pain (3%). ",valacyclovir
sign_symptom,pain,0.99995613," the most frequently reported adverse reactions were nausea (15%), headache (14%), vomiting (6%), dizziness (3%) and abdominal pain (3%). ",valacyclovir
sign_symptom,gall,0.95060176," commonly reported side effects are nausea, vomiting, diarrhoea, gallstone opacilication, pruritus. ",ursodeoxycholic acid
sign_symptom,pain,0.9999604," overt bleeding, haemorrhagic complications, fever, haematuria, initial severe pain &amp; dull ache in shunt limb. ",urokinase
sign_symptom,ache,0.99992216," overt bleeding, haemorrhagic complications, fever, haematuria, initial severe pain &amp; dull ache in shunt limb. ",urokinase
sign_symptom,toxicity,0.9996381," no serious toxicity has been reported with topical urea. historically it is considered a safe drug. but on some occasions, topical urea has been shown to cause burning and irritation, if applied to inflamed, broken or exudative skin eruptions. ",urea (25%)
sign_symptom,toxicity,0.9996381," no serious toxicity has been reported with topical urea. historically it is considered a safe drug. but on some occasions, topical urea has been shown to cause burning and irritation, if applied to inflamed, broken or exudative skin eruptions. ",urea (10%)
sign_symptom,adverse reactions,0.9375452," adverse reactions (greater than or equal to 1%) are: upper respiratory tract infections, nausea, cough, and pyrexia. ",upadacitinib
medication,boron,0.9349741," the combination of undenatured type ii collagen, glucosamine, boswellia &amp; boron is generally well-tolerated in the recommended dose. overdose may cause headache &amp; constipation. ",undenatured type ii collagen + glucosamine sulfate + boswellia serrata + boron
sign_symptom,headache,0.99973077," the combination of undenatured type ii collagen, glucosamine, boswellia &amp; boron is generally well-tolerated in the recommended dose. overdose may cause headache &amp; constipation. ",undenatured type ii collagen + glucosamine sulfate + boswellia serrata + boron
sign_symptom,dysmenorrhea,0.9222719," most common side-effects are headache, nausea, abdominal pain, dysmenorrhea, fatigue, dizziness, breast tenderness etc. ",ulipristal acetate [for emergency contraception]
sign_symptom,fatigue,0.88623524," most common side-effects are headache, nausea, abdominal pain, dysmenorrhea, fatigue, dizziness, breast tenderness etc. ",ulipristal acetate [for emergency contraception]
sign_symptom,tenderness,0.9993647," most common side-effects are headache, nausea, abdominal pain, dysmenorrhea, fatigue, dizziness, breast tenderness etc. ",ulipristal acetate [for emergency contraception]
medication,typh,0.73298526," most recepients of typhoid vaccine experience some reactions upon vaccination. these are generally moderate and short in duration. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. in very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed. ",typhoid polysaccharide vaccine
sign_symptom,reactions,0.94695514," most recepients of typhoid vaccine experience some reactions upon vaccination. these are generally moderate and short in duration. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. in very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed. ",typhoid polysaccharide vaccine
sign_symptom,mala,0.9999205," most recepients of typhoid vaccine experience some reactions upon vaccination. these are generally moderate and short in duration. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. in very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed. ",typhoid polysaccharide vaccine
sign_symptom,myalgia,0.983763," most recepients of typhoid vaccine experience some reactions upon vaccination. these are generally moderate and short in duration. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. in very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed. ",typhoid polysaccharide vaccine
sign_symptom,allergic type reactions,0.79089946," most recepients of typhoid vaccine experience some reactions upon vaccination. these are generally moderate and short in duration. they mainly consist of local reactions at the injection site (erythema, induration and tenderness). systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. in very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed. ",typhoid polysaccharide vaccine
sign_symptom,adverse reactions,0.924641," the adverse reactions of tulobuterol are similar in nature to those of other sympathomimetic agents, however the incidence of certain cardiovascular effects is less with tulobuterol. dose-related finger tremor is common with these agents, but the effects tend to lessen with continued administration of the drug. oral formulations of tulobuterol, like other sympathomimetic agents, can also cause less frequent adverse reactions such as hypertension, palpitations, angina, tachycardia, vomiting, vertigo, central nervous system stimulation, insomnia and headache. ",tulobuterol hydrochloride
sign_symptom,cardiovascular effects,0.7792342," the adverse reactions of tulobuterol are similar in nature to those of other sympathomimetic agents, however the incidence of certain cardiovascular effects is less with tulobuterol. dose-related finger tremor is common with these agents, but the effects tend to lessen with continued administration of the drug. oral formulations of tulobuterol, like other sympathomimetic agents, can also cause less frequent adverse reactions such as hypertension, palpitations, angina, tachycardia, vomiting, vertigo, central nervous system stimulation, insomnia and headache. ",tulobuterol hydrochloride
sign_symptom,finger tremor,0.99945503," the adverse reactions of tulobuterol are similar in nature to those of other sympathomimetic agents, however the incidence of certain cardiovascular effects is less with tulobuterol. dose-related finger tremor is common with these agents, but the effects tend to lessen with continued administration of the drug. oral formulations of tulobuterol, like other sympathomimetic agents, can also cause less frequent adverse reactions such as hypertension, palpitations, angina, tachycardia, vomiting, vertigo, central nervous system stimulation, insomnia and headache. ",tulobuterol hydrochloride
medication,tulobu,0.9560396," the adverse reactions of tulobuterol are similar in nature to those of other sympathomimetic agents, however the incidence of certain cardiovascular effects is less with tulobuterol. dose-related finger tremor is common with these agents, but the effects tend to lessen with continued administration of the drug. oral formulations of tulobuterol, like other sympathomimetic agents, can also cause less frequent adverse reactions such as hypertension, palpitations, angina, tachycardia, vomiting, vertigo, central nervous system stimulation, insomnia and headache. ",tulobuterol hydrochloride
sign_symptom,discolor,0.7760185,"  
 discoloration of high water content hydrogen intraocular lenses. 
 inadvertent staining of the posterior lens capsule and vitreous face. 
 it is generally self limited, lasting up to one week. 
  ",trypan blue
sign_symptom,adverse reactions,0.9995854," the following adverse reactions have been identified during post-approval use of trospium chloride. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  
 
 gastrointestinal: gastritis 
 cardiovascular: palpitations, supraventricular tachycardia, chest pain, syncope, 
 hypertensive crisis 
 immunological: stevens-johnson syndrome, anaphylactic reaction, angioedema 
 nervous system: dizziness, confusion, vision abnormal, hallucinations, somnolence and delirium 
 musculoskeletal: rhabdomyolysis 
 general: rash 
  ",trospium chloride
sign_symptom,hypertensive crisis,0.9991665," the following adverse reactions have been identified during post-approval use of trospium chloride. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  
 
 gastrointestinal: gastritis 
 cardiovascular: palpitations, supraventricular tachycardia, chest pain, syncope, 
 hypertensive crisis 
 immunological: stevens-johnson syndrome, anaphylactic reaction, angioedema 
 nervous system: dizziness, confusion, vision abnormal, hallucinations, somnolence and delirium 
 musculoskeletal: rhabdomyolysis 
 general: rash 
  ",trospium chloride
disease_disorder,stevens,0.70265085," the following adverse reactions have been identified during post-approval use of trospium chloride. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  
 
 gastrointestinal: gastritis 
 cardiovascular: palpitations, supraventricular tachycardia, chest pain, syncope, 
 hypertensive crisis 
 immunological: stevens-johnson syndrome, anaphylactic reaction, angioedema 
 nervous system: dizziness, confusion, vision abnormal, hallucinations, somnolence and delirium 
 musculoskeletal: rhabdomyolysis 
 general: rash 
  ",trospium chloride
sign_symptom,vision,0.93300825," the following adverse reactions have been identified during post-approval use of trospium chloride. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  
 
 gastrointestinal: gastritis 
 cardiovascular: palpitations, supraventricular tachycardia, chest pain, syncope, 
 hypertensive crisis 
 immunological: stevens-johnson syndrome, anaphylactic reaction, angioedema 
 nervous system: dizziness, confusion, vision abnormal, hallucinations, somnolence and delirium 
 musculoskeletal: rhabdomyolysis 
 general: rash 
  ",trospium chloride
sign_symptom,hall,0.9932066," the following adverse reactions have been identified during post-approval use of trospium chloride. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  
 
 gastrointestinal: gastritis 
 cardiovascular: palpitations, supraventricular tachycardia, chest pain, syncope, 
 hypertensive crisis 
 immunological: stevens-johnson syndrome, anaphylactic reaction, angioedema 
 nervous system: dizziness, confusion, vision abnormal, hallucinations, somnolence and delirium 
 musculoskeletal: rhabdomyolysis 
 general: rash 
  ",trospium chloride
sign_symptom,delirium,0.99948764," the following adverse reactions have been identified during post-approval use of trospium chloride. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  
 
 gastrointestinal: gastritis 
 cardiovascular: palpitations, supraventricular tachycardia, chest pain, syncope, 
 hypertensive crisis 
 immunological: stevens-johnson syndrome, anaphylactic reaction, angioedema 
 nervous system: dizziness, confusion, vision abnormal, hallucinations, somnolence and delirium 
 musculoskeletal: rhabdomyolysis 
 general: rash 
  ",trospium chloride
sign_symptom,rash,0.9999603," the following adverse reactions have been identified during post-approval use of trospium chloride. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  
 
 gastrointestinal: gastritis 
 cardiovascular: palpitations, supraventricular tachycardia, chest pain, syncope, 
 hypertensive crisis 
 immunological: stevens-johnson syndrome, anaphylactic reaction, angioedema 
 nervous system: dizziness, confusion, vision abnormal, hallucinations, somnolence and delirium 
 musculoskeletal: rhabdomyolysis 
 general: rash 
  ",trospium chloride
sign_symptom,anaphyla,0.9866449, anaphylactic reactions have been reported following large intravenous doses of thiamine. urticaria and rash have also been associated with this preparation. there have been very rare reports of anaphylactic reactions following iv injection/infusion with this preparation over 1-4 minutes. ,"vitamin a, vitamin b complex, vitamin c , vitamin d and vitamin e"
sign_symptom,rash,0.99992526, anaphylactic reactions have been reported following large intravenous doses of thiamine. urticaria and rash have also been associated with this preparation. there have been very rare reports of anaphylactic reactions following iv injection/infusion with this preparation over 1-4 minutes. ,"vitamin a, vitamin b complex, vitamin c , vitamin d and vitamin e"
medication,vitamin a,0.9681979," vitamin a intoxication includes irritability, vomiting, loss of appetite, headache, dry and pruritic skin, skin desquamation, fatique, pain in ankles and feet, myalgia, loss of body hair, papilledema, nystagmus, liver sclerosis and cirrhosis. ",vitamin a
sign_symptom,loss of appetite,0.9913419," vitamin a intoxication includes irritability, vomiting, loss of appetite, headache, dry and pruritic skin, skin desquamation, fatique, pain in ankles and feet, myalgia, loss of body hair, papilledema, nystagmus, liver sclerosis and cirrhosis. ",vitamin a
sign_symptom,pain,0.99976546," vitamin a intoxication includes irritability, vomiting, loss of appetite, headache, dry and pruritic skin, skin desquamation, fatique, pain in ankles and feet, myalgia, loss of body hair, papilledema, nystagmus, liver sclerosis and cirrhosis. ",vitamin a
sign_symptom,loss of body,0.9867694," vitamin a intoxication includes irritability, vomiting, loss of appetite, headache, dry and pruritic skin, skin desquamation, fatique, pain in ankles and feet, myalgia, loss of body hair, papilledema, nystagmus, liver sclerosis and cirrhosis. ",vitamin a
sign_symptom,loss,0.99910045," neurotoxicity, peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, severe constipation, diarrhoea, alopecia, severe local irritation. dose limiting granulocytopenia, leukopenia and anaemia. intestinal obstruction, paralytic ileus, nausea, vomitinh, increased in lft, chest pain, fatigue. local pain and thrombophlebitis with repeated inj. ",vinorelbine tartrate
sign_symptom,deep,0.7426015," neurotoxicity, peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, severe constipation, diarrhoea, alopecia, severe local irritation. dose limiting granulocytopenia, leukopenia and anaemia. intestinal obstruction, paralytic ileus, nausea, vomitinh, increased in lft, chest pain, fatigue. local pain and thrombophlebitis with repeated inj. ",vinorelbine tartrate
sign_symptom,diarr,0.931973," neurotoxicity, peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, severe constipation, diarrhoea, alopecia, severe local irritation. dose limiting granulocytopenia, leukopenia and anaemia. intestinal obstruction, paralytic ileus, nausea, vomitinh, increased in lft, chest pain, fatigue. local pain and thrombophlebitis with repeated inj. ",vinorelbine tartrate
sign_symptom,vomit,0.97833043," neurotoxicity, peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, severe constipation, diarrhoea, alopecia, severe local irritation. dose limiting granulocytopenia, leukopenia and anaemia. intestinal obstruction, paralytic ileus, nausea, vomitinh, increased in lft, chest pain, fatigue. local pain and thrombophlebitis with repeated inj. ",vinorelbine tartrate
sign_symptom,pain,0.9999229," neurotoxicity, peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, severe constipation, diarrhoea, alopecia, severe local irritation. dose limiting granulocytopenia, leukopenia and anaemia. intestinal obstruction, paralytic ileus, nausea, vomitinh, increased in lft, chest pain, fatigue. local pain and thrombophlebitis with repeated inj. ",vinorelbine tartrate
sign_symptom,hyper,0.7542145," dose limiting neurotoxicity (e.g. motor function impairment, gait abnormalities), hyperuricaemia, bronchospasm, azospermia, amenorrhoea, alopoecia, leucopenia, urinary dysfunction, abdominal cramps, vomiting, diarrhoea, severe constipation, paralytic ileus, convulsions, hypertension, orthostatic hypotension, ptosis, hoarseness, optic neuropathies, hallucinations, blindness, neurological deafness, difficulty in walking, syndrome of inappropriate adh secretion. ",vincristine sulfate
sign_symptom,hoarse,0.9987643," dose limiting neurotoxicity (e.g. motor function impairment, gait abnormalities), hyperuricaemia, bronchospasm, azospermia, amenorrhoea, alopoecia, leucopenia, urinary dysfunction, abdominal cramps, vomiting, diarrhoea, severe constipation, paralytic ileus, convulsions, hypertension, orthostatic hypotension, ptosis, hoarseness, optic neuropathies, hallucinations, blindness, neurological deafness, difficulty in walking, syndrome of inappropriate adh secretion. ",vincristine sulfate
sign_symptom,consti,0.80829304," alopecia, constipation, malaise, stomatitis, dose-limiting bone marrow suppression (e.g. granulocytopenia, thrombocytopenia, anaemia), hypertension, central and peripheral neurotoxicity, 8th cranial nerve damage resulting in vestibular and auditory toxicity, ischaemic cardiac toxicity, breathlessness, bone, tumour or jaw pain. nausea, vomiting, gi bleed, syndrome of inappropriate antidiuretic hormone. necrosis, cellulitis if extravasation occurs. ",vinblastine sulfate
sign_symptom,mala,0.9997415," alopecia, constipation, malaise, stomatitis, dose-limiting bone marrow suppression (e.g. granulocytopenia, thrombocytopenia, anaemia), hypertension, central and peripheral neurotoxicity, 8th cranial nerve damage resulting in vestibular and auditory toxicity, ischaemic cardiac toxicity, breathlessness, bone, tumour or jaw pain. nausea, vomiting, gi bleed, syndrome of inappropriate antidiuretic hormone. necrosis, cellulitis if extravasation occurs. ",vinblastine sulfate
disease_disorder,cellulitis,0.9998397," alopecia, constipation, malaise, stomatitis, dose-limiting bone marrow suppression (e.g. granulocytopenia, thrombocytopenia, anaemia), hypertension, central and peripheral neurotoxicity, 8th cranial nerve damage resulting in vestibular and auditory toxicity, ischaemic cardiac toxicity, breathlessness, bone, tumour or jaw pain. nausea, vomiting, gi bleed, syndrome of inappropriate antidiuretic hormone. necrosis, cellulitis if extravasation occurs. ",vinblastine sulfate
sign_symptom,extra,0.99935895," alopecia, constipation, malaise, stomatitis, dose-limiting bone marrow suppression (e.g. granulocytopenia, thrombocytopenia, anaemia), hypertension, central and peripheral neurotoxicity, 8th cranial nerve damage resulting in vestibular and auditory toxicity, ischaemic cardiac toxicity, breathlessness, bone, tumour or jaw pain. nausea, vomiting, gi bleed, syndrome of inappropriate antidiuretic hormone. necrosis, cellulitis if extravasation occurs. ",vinblastine sulfate
sign_symptom,nausea,0.8263076," the most common side effects are headache, tremor, dizziness, nausea, hypoglycaemia etc. ",vildagliptin + metformin hydrochloride
sign_symptom,adverse reactions,0.99976623," the majority of adverse reactions were mild and transient, not requiring treatment discontinuations. a rare case of hepatic dysfunction is seen. clinical trials of up to and more than 2 years duration did not show any additional safety signals or unforeseen risks when using this combination. ",vildagliptin
sign_symptom,suicidal thoughts,0.9998312,"  
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 increased risk of bleeding 
 activation of mania or hypomania 
 discontinuation syndrome 
 seizures 
 angle-closure glaucoma 
 hyponatremia 
 sexual dysfunction 
  ",vilazodone hydrochloride
sign_symptom,behaviors,0.9997147,"  
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 increased risk of bleeding 
 activation of mania or hypomania 
 discontinuation syndrome 
 seizures 
 angle-closure glaucoma 
 hyponatremia 
 sexual dysfunction 
  ",vilazodone hydrochloride
disease_disorder,serotonin syndrome,0.9269788,"  
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 increased risk of bleeding 
 activation of mania or hypomania 
 discontinuation syndrome 
 seizures 
 angle-closure glaucoma 
 hyponatremia 
 sexual dysfunction 
  ",vilazodone hydrochloride
sign_symptom,bleeding,0.99739933,"  
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 increased risk of bleeding 
 activation of mania or hypomania 
 discontinuation syndrome 
 seizures 
 angle-closure glaucoma 
 hyponatremia 
 sexual dysfunction 
  ",vilazodone hydrochloride
sign_symptom,mania,0.9997149,"  
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 increased risk of bleeding 
 activation of mania or hypomania 
 discontinuation syndrome 
 seizures 
 angle-closure glaucoma 
 hyponatremia 
 sexual dysfunction 
  ",vilazodone hydrochloride
sign_symptom,seizures,0.7251264,"  
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 increased risk of bleeding 
 activation of mania or hypomania 
 discontinuation syndrome 
 seizures 
 angle-closure glaucoma 
 hyponatremia 
 sexual dysfunction 
  ",vilazodone hydrochloride
sign_symptom,angle - closure,0.8921043,"  
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 increased risk of bleeding 
 activation of mania or hypomania 
 discontinuation syndrome 
 seizures 
 angle-closure glaucoma 
 hyponatremia 
 sexual dysfunction 
  ",vilazodone hydrochloride
disease_disorder,glaucoma,0.98523384,"  
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 increased risk of bleeding 
 activation of mania or hypomania 
 discontinuation syndrome 
 seizures 
 angle-closure glaucoma 
 hyponatremia 
 sexual dysfunction 
  ",vilazodone hydrochloride
disease_disorder,hyponatremia,0.9234312,"  
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 increased risk of bleeding 
 activation of mania or hypomania 
 discontinuation syndrome 
 seizures 
 angle-closure glaucoma 
 hyponatremia 
 sexual dysfunction 
  ",vilazodone hydrochloride
disease_disorder,sexual dysfunction,0.8072417,"  
 suicidal thoughts and behaviors in adolescents and young adults 
 serotonin syndrome 
 increased risk of bleeding 
 activation of mania or hypomania 
 discontinuation syndrome 
 seizures 
 angle-closure glaucoma 
 hyponatremia 
 sexual dysfunction 
  ",vilazodone hydrochloride
sign_symptom,adverse reactions,0.8327587,"  common side efects in copd : most common adverse reactions (incidence 3%) are nasopharyngitis, upper respiratory tract infection, headache, oral candidiasis, back pain, pneumonia, bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, hypertension, infuenza, pharyngitis, and pyrexia.   common side efects in asthma : most common adverse reactions (incidence 2%) are nasopharyngitis, oral candidiasis, headache, infuenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough. ",vilanterol trifenatate + fluticasone furoate
sign_symptom,adverse reactions,0.9951073,"  copd : most common adverse reactions (incidence 1%) are upper respiratory tract infection, pneumonia, bronchitis, oral candidiasis, headache, back pain, arthralgia, infuenza, sinusitis, pharyngitis, rhinitis, dysgeusia, constipation, urinary tract infection, diarrhea, gastroenteritis, oropharyngeal pain, cough, and dysphonia.   asthma : most common adverse reactions (incidence 2%) are pharyngitis/nasopharyngitis, upper respiratory tract infection/viral upper respiratory tract infection, bronchitis, respiratory tract infection/viral respiratory tract infection, sinusitis/acute sinusitis, urinary tract infection, rhinitis, infuenza, headache, and back pain. ",vilanterol + umeclidinium + fluticasone furoate
sign_symptom,vision loss,0.9998013, visual disturbances; severe vision loss with or without subretinal or vitreous bleeding; inj site reactions; nausea; photosensitivity; asthenia; cataracts; blepharitis; conjunctivitis; dry eyes; ocular itching; flu-like syndrome; atrial fibrillation; hypertension; peripheral vascular disorder; varicose veins; eczema; constipation; gl cancers; fever; lachrymation disorder; hypersensitivity reactions; increased lft. ,verteporfin
sign_symptom,hypersensitivity,0.7353097, visual disturbances; severe vision loss with or without subretinal or vitreous bleeding; inj site reactions; nausea; photosensitivity; asthenia; cataracts; blepharitis; conjunctivitis; dry eyes; ocular itching; flu-like syndrome; atrial fibrillation; hypertension; peripheral vascular disorder; varicose veins; eczema; constipation; gl cancers; fever; lachrymation disorder; hypersensitivity reactions; increased lft. ,verteporfin
medication,verapamil,0.98913443," verapamil is generally well tolerated. the following reaction to orally administered verapamil appeared clearly drug-related or occurred at rates greater than 1% in clinical trials with approximately 5000 patients. 
 
  digestive system : constipation, nausea; 
  cardiovascular system : hypotension, edema, chf, pulmonary edema, bradycardia, av block; 
  respiratory system : upper respiratory tract infections; 
  nervous system : dizziness, headache, fatigue; 
  skin : rash, flashing; 
  hepatic : elevated liver enzyme. 
  ",verapamil hydrochloride
sign_symptom,drug - related,0.92520446," verapamil is generally well tolerated. the following reaction to orally administered verapamil appeared clearly drug-related or occurred at rates greater than 1% in clinical trials with approximately 5000 patients. 
 
  digestive system : constipation, nausea; 
  cardiovascular system : hypotension, edema, chf, pulmonary edema, bradycardia, av block; 
  respiratory system : upper respiratory tract infections; 
  nervous system : dizziness, headache, fatigue; 
  skin : rash, flashing; 
  hepatic : elevated liver enzyme. 
  ",verapamil hydrochloride
sign_symptom,chill,0.9594699," changes in behaviour, suicidal ideation, agitation, tremor, nervousness, anxiety, insomnia, confusions, abnormal dreams, htn, nausea, headache, asthenia, somnolence, dizziness, dry mouth, vomiting, constipation, diarrhoea, dyspepsia, abdominal pain, anorexia, sexual dysfunction, urinary frequency, visual disturbances, mydriasis, vasodilatation, paraesthesia, hypertonia, chills or fever, palpitations, wt gain or loss, arthralgia, myalgia, tinnitus, pruritus, dyspnoea, yawning, rashes, sweating, increased serum cholesterol, may impair platelet aggregation. ",venlafaxine hydrochloride
medication,venetoclax,0.90112865," the most commonly occurring side effects (&gt;20%) of any grade in patients receiving venetoclax in the combination study with rituximab were neutropenia, diarrhoea, and upper respiratory tract infection. in the monotherapy studies, the most common side effects were neutropenia/neutrophil count decreased, diarrhoea, nausea, anaemia, fatigue, and upper respiratory tract infection. the most frequently reported serious side effects (&gt;2%) in patients receiving venetoclax in combination with rituximab were pneumonia, febrile neutropenia, and tls. in the monotherapy studies, the most frequently reported serious side effects (&gt;2%) were pneumonia and febrile neutropenia. ",venetoclax
disease_disorder,pneumonia,0.76280737," the most commonly occurring side effects (&gt;20%) of any grade in patients receiving venetoclax in the combination study with rituximab were neutropenia, diarrhoea, and upper respiratory tract infection. in the monotherapy studies, the most common side effects were neutropenia/neutrophil count decreased, diarrhoea, nausea, anaemia, fatigue, and upper respiratory tract infection. the most frequently reported serious side effects (&gt;2%) in patients receiving venetoclax in combination with rituximab were pneumonia, febrile neutropenia, and tls. in the monotherapy studies, the most frequently reported serious side effects (&gt;2%) were pneumonia and febrile neutropenia. ",venetoclax
sign_symptom,side effects,0.9982487," side effects are rare (&lt;1/1000). the most commonly occurring side effects include changes in vital signs and prolonged neuromuscular block. the most frequently reported side effects during post-marketing surveillance is 'anaphylactic and anaphylactoid reactions' and associated symptoms (reporting frequency &lt;1/100,000). ",vecuronium bromide
sign_symptom,changes,0.99752337," side effects are rare (&lt;1/1000). the most commonly occurring side effects include changes in vital signs and prolonged neuromuscular block. the most frequently reported side effects during post-marketing surveillance is 'anaphylactic and anaphylactoid reactions' and associated symptoms (reporting frequency &lt;1/100,000). ",vecuronium bromide
sign_symptom,symptoms,0.9993876," side effects are rare (&lt;1/1000). the most commonly occurring side effects include changes in vital signs and prolonged neuromuscular block. the most frequently reported side effects during post-marketing surveillance is 'anaphylactic and anaphylactoid reactions' and associated symptoms (reporting frequency &lt;1/100,000). ",vecuronium bromide
sign_symptom,adverse reactions,0.9998609," frequently reported (10%) adverse reactions in children ages 1 to 12 years include: 
 
 fever 102.0f (38.9c) oral: 14.7% 
 injection-site complaints: 19.3% 
 
frequently reported (10%) adverse reactions in adolescents and adults ages 13 years and older include: 
 
 fever 100.0f (37.8c) oral: 10.2% 
 injection-site complaints: 24.4% 
 
other reported adverse reactions in all age groups include: 
 
 varicella-like rash (injection site) 
 varicella-like rash (generalized) 
  ",varicella virus vaccine
sign_symptom,fever,0.9999597," frequently reported (10%) adverse reactions in children ages 1 to 12 years include: 
 
 fever 102.0f (38.9c) oral: 14.7% 
 injection-site complaints: 19.3% 
 
frequently reported (10%) adverse reactions in adolescents and adults ages 13 years and older include: 
 
 fever 100.0f (37.8c) oral: 10.2% 
 injection-site complaints: 24.4% 
 
other reported adverse reactions in all age groups include: 
 
 varicella-like rash (injection site) 
 varicella-like rash (generalized) 
  ",varicella virus vaccine
sign_symptom,complaints,0.9856058," frequently reported (10%) adverse reactions in children ages 1 to 12 years include: 
 
 fever 102.0f (38.9c) oral: 14.7% 
 injection-site complaints: 19.3% 
 
frequently reported (10%) adverse reactions in adolescents and adults ages 13 years and older include: 
 
 fever 100.0f (37.8c) oral: 10.2% 
 injection-site complaints: 24.4% 
 
other reported adverse reactions in all age groups include: 
 
 varicella-like rash (injection site) 
 varicella-like rash (generalized) 
  ",varicella virus vaccine
sign_symptom,rash,0.9998567," frequently reported (10%) adverse reactions in children ages 1 to 12 years include: 
 
 fever 102.0f (38.9c) oral: 14.7% 
 injection-site complaints: 19.3% 
 
frequently reported (10%) adverse reactions in adolescents and adults ages 13 years and older include: 
 
 fever 100.0f (37.8c) oral: 10.2% 
 injection-site complaints: 24.4% 
 
other reported adverse reactions in all age groups include: 
 
 varicella-like rash (injection site) 
 varicella-like rash (generalized) 
  ",varicella virus vaccine
sign_symptom,flat,0.99949133," nasopharyngitis, bronchitis, sinusitis, increased wt, decreased &amp;/or increased appetite, abnormal dreams, insomnia, headache, somnolence, dizziness, dysgeusia, dyspnea, cough, nausea, gerd, vomiting, constipation, diarrhea, abdominal distension &amp; pain, toothache, dyspepsia, flatulence, dry mouth, rash, pruritus, arthralgia, myalgia, back pain, chest pain, fatigue, abnormal liver function test. ",varenicline tartrate
sign_symptom,upset,0.98907185," the most common side effects with vardenafil are headache, flushing, stuffy or runny nose, indigestion, upset stomach, dizziness or back pain. ",vardenafil
sign_symptom,effects,0.81246257," the following serious side effects have sometimes been reported: allergic reactions: 
 
 rash, itching or hives on the skin 
 swelling of the face, lips, tongue or other parts of the body 
 difficulty swallowing or breathing 
 loss of consciousness 
  ",yellow fever vaccine
sign_symptom,allergic reactions,0.92032266," the following serious side effects have sometimes been reported: allergic reactions: 
 
 rash, itching or hives on the skin 
 swelling of the face, lips, tongue or other parts of the body 
 difficulty swallowing or breathing 
 loss of consciousness 
  ",yellow fever vaccine
sign_symptom,hives,0.9998504," the following serious side effects have sometimes been reported: allergic reactions: 
 
 rash, itching or hives on the skin 
 swelling of the face, lips, tongue or other parts of the body 
 difficulty swallowing or breathing 
 loss of consciousness 
  ",yellow fever vaccine
sign_symptom,swelling,0.9999577," the following serious side effects have sometimes been reported: allergic reactions: 
 
 rash, itching or hives on the skin 
 swelling of the face, lips, tongue or other parts of the body 
 difficulty swallowing or breathing 
 loss of consciousness 
  ",yellow fever vaccine
sign_symptom,swallowing,0.9094906," the following serious side effects have sometimes been reported: allergic reactions: 
 
 rash, itching or hives on the skin 
 swelling of the face, lips, tongue or other parts of the body 
 difficulty swallowing or breathing 
 loss of consciousness 
  ",yellow fever vaccine
sign_symptom,breathing loss of consciousness,0.98627603," the following serious side effects have sometimes been reported: allergic reactions: 
 
 rash, itching or hives on the skin 
 swelling of the face, lips, tongue or other parts of the body 
 difficulty swallowing or breathing 
 loss of consciousness 
  ",yellow fever vaccine
sign_symptom,irritation,0.9999485," the following side-effects have occasionally been encountered:  
 
 a burning sensation in the nose and throat 
 local irritation 
 nausea and dryness of the nasal mucosa. 
  ",xylometazoline hydrochloride
sign_symptom,nausea,0.9999418," the following side-effects have occasionally been encountered:  
 
 a burning sensation in the nose and throat 
 local irritation 
 nausea and dryness of the nasal mucosa. 
  ",xylometazoline hydrochloride
sign_symptom,stinging /,0.98422885," stinging/redness in the eye, widened pupils or blurred vision may occur. ",white soft paraffin + liquid paraffin + wool alcohol
sign_symptom,redness,0.87103015," stinging/redness in the eye, widened pupils or blurred vision may occur. ",white soft paraffin + liquid paraffin + wool alcohol
sign_symptom,widened pupils,0.999756," stinging/redness in the eye, widened pupils or blurred vision may occur. ",white soft paraffin + liquid paraffin + wool alcohol
sign_symptom,blurred vision,0.99989605," stinging/redness in the eye, widened pupils or blurred vision may occur. ",white soft paraffin + liquid paraffin + wool alcohol
sign_symptom,hemorrhage,0.84898996," hemorrhage is the principal adverse effect of oral anticoagulants. other adverse reactions include nausea, vomiting, diarrhea, hypersensitivity, rash, alopecia, and unexplained drop in haematocrit, ""purple toes"", skin necrosis, jaundice, and hepatic dysfunction. ",warfarin sodium
sign_symptom,loose,0.9856124," diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. ohas plus voglibose may cause hypoglycaemia (0.1% to &lt;5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase). ",voglibose
sign_symptom,consti,0.8225775," diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. ohas plus voglibose may cause hypoglycaemia (0.1% to &lt;5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase). ",voglibose
sign_symptom,loss of appetite,0.99971837," diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. ohas plus voglibose may cause hypoglycaemia (0.1% to &lt;5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase). ",voglibose
sign_symptom,urge to vomit,0.99311566," diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. ohas plus voglibose may cause hypoglycaemia (0.1% to &lt;5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase). ",voglibose
sign_symptom,intestinal obstruction,0.98631525," diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. ohas plus voglibose may cause hypoglycaemia (0.1% to &lt;5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase). ",voglibose
sign_symptom,symptoms,0.9995962," diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. ohas plus voglibose may cause hypoglycaemia (0.1% to &lt;5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase). ",voglibose
medication,ohas,0.81503266," diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. ohas plus voglibose may cause hypoglycaemia (0.1% to &lt;5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase). ",voglibose
medication,voglibose,0.8975135," diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. ohas plus voglibose may cause hypoglycaemia (0.1% to &lt;5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase). ",voglibose
sign_symptom,delay,0.9997222," diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. ohas plus voglibose may cause hypoglycaemia (0.1% to &lt;5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase). ",voglibose
sign_symptom,blurred vision,0.97931087," diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. ohas plus voglibose may cause hypoglycaemia (0.1% to &lt;5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase). ",voglibose
sign_symptom,mala,0.99978036," diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. ohas plus voglibose may cause hypoglycaemia (0.1% to &lt;5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase). ",voglibose
medication,vitamin c,0.99969083," large doses of vitamin c are reported to cause diarrhoea and other gastrointestinal disturbances. large doses of vitamin e may cause diarrhoea, abdominal pain, and other gastrointestinal disturbances; fatigue and weakness have also been reported. side effects of zinc salt are abdominal pain and dyspepsia. ","vitamin c, vitamin e, lutein, copper & zinc"
sign_symptom,diarrhoea,0.9968366," large doses of vitamin c are reported to cause diarrhoea and other gastrointestinal disturbances. large doses of vitamin e may cause diarrhoea, abdominal pain, and other gastrointestinal disturbances; fatigue and weakness have also been reported. side effects of zinc salt are abdominal pain and dyspepsia. ","vitamin c, vitamin e, lutein, copper & zinc"
medication,vitamin e,0.9996271," large doses of vitamin c are reported to cause diarrhoea and other gastrointestinal disturbances. large doses of vitamin e may cause diarrhoea, abdominal pain, and other gastrointestinal disturbances; fatigue and weakness have also been reported. side effects of zinc salt are abdominal pain and dyspepsia. ","vitamin c, vitamin e, lutein, copper & zinc"
sign_symptom,fatigue,0.9999349," large doses of vitamin c are reported to cause diarrhoea and other gastrointestinal disturbances. large doses of vitamin e may cause diarrhoea, abdominal pain, and other gastrointestinal disturbances; fatigue and weakness have also been reported. side effects of zinc salt are abdominal pain and dyspepsia. ","vitamin c, vitamin e, lutein, copper & zinc"
sign_symptom,weakness,0.9999099," large doses of vitamin c are reported to cause diarrhoea and other gastrointestinal disturbances. large doses of vitamin e may cause diarrhoea, abdominal pain, and other gastrointestinal disturbances; fatigue and weakness have also been reported. side effects of zinc salt are abdominal pain and dyspepsia. ","vitamin c, vitamin e, lutein, copper & zinc"
medication,zinc salt,0.96058184," large doses of vitamin c are reported to cause diarrhoea and other gastrointestinal disturbances. large doses of vitamin e may cause diarrhoea, abdominal pain, and other gastrointestinal disturbances; fatigue and weakness have also been reported. side effects of zinc salt are abdominal pain and dyspepsia. ","vitamin c, vitamin e, lutein, copper & zinc"
sign_symptom,pain,0.9998983," large doses of vitamin c are reported to cause diarrhoea and other gastrointestinal disturbances. large doses of vitamin e may cause diarrhoea, abdominal pain, and other gastrointestinal disturbances; fatigue and weakness have also been reported. side effects of zinc salt are abdominal pain and dyspepsia. ","vitamin c, vitamin e, lutein, copper & zinc"
medication,vitamin c,0.7640113," vitamin c, vitamin d3 &amp; folic acid combinationis well tolerated. mild gastrointestinal disturbances may occur. ",vitamin c + vitamin d3 + folic acid
medication,folic acid combination,0.9423112," vitamin c, vitamin d3 &amp; folic acid combinationis well tolerated. mild gastrointestinal disturbances may occur. ",vitamin c + vitamin d3 + folic acid
medication,vitamin c,0.9978657," vitamin c has little toxicity and only mega-doses of vitamin c may cause diarrhoea, abdominal bloating, iron over-absorption that is harmful in patients with thalassaemia, sideroblastic anemia, and haemochromatosis; hyperoxaluria, hyperuricosuria, and hemolysis in patients with glucose-6 phosphate dehydrogenase deficiency. a pregnant woman taking more than 5 gm/day may suffer fetal abortion. ",vitamin c [ascorbic acid]
sign_symptom,iron over - absorption,0.7724831," vitamin c has little toxicity and only mega-doses of vitamin c may cause diarrhoea, abdominal bloating, iron over-absorption that is harmful in patients with thalassaemia, sideroblastic anemia, and haemochromatosis; hyperoxaluria, hyperuricosuria, and hemolysis in patients with glucose-6 phosphate dehydrogenase deficiency. a pregnant woman taking more than 5 gm/day may suffer fetal abortion. ",vitamin c [ascorbic acid]
sign_symptom,hyper,0.999858," vitamin c has little toxicity and only mega-doses of vitamin c may cause diarrhoea, abdominal bloating, iron over-absorption that is harmful in patients with thalassaemia, sideroblastic anemia, and haemochromatosis; hyperoxaluria, hyperuricosuria, and hemolysis in patients with glucose-6 phosphate dehydrogenase deficiency. a pregnant woman taking more than 5 gm/day may suffer fetal abortion. ",vitamin c [ascorbic acid]
sign_symptom,hyperuri,0.9858117," vitamin c has little toxicity and only mega-doses of vitamin c may cause diarrhoea, abdominal bloating, iron over-absorption that is harmful in patients with thalassaemia, sideroblastic anemia, and haemochromatosis; hyperoxaluria, hyperuricosuria, and hemolysis in patients with glucose-6 phosphate dehydrogenase deficiency. a pregnant woman taking more than 5 gm/day may suffer fetal abortion. ",vitamin c [ascorbic acid]
sign_symptom,hemol,0.9994376," vitamin c has little toxicity and only mega-doses of vitamin c may cause diarrhoea, abdominal bloating, iron over-absorption that is harmful in patients with thalassaemia, sideroblastic anemia, and haemochromatosis; hyperoxaluria, hyperuricosuria, and hemolysis in patients with glucose-6 phosphate dehydrogenase deficiency. a pregnant woman taking more than 5 gm/day may suffer fetal abortion. ",vitamin c [ascorbic acid]
sign_symptom,allergic sensitization,0.9998604," allergic sensitization has been reported following both oral and parenteral administration of folic acid. paresthesia, somnolence, nausea and headache have been reported with pyridoxine hydrochlloride. mild transient diarrhea, polycythemia vera, itching, transitory exanthema, and the feeling of swelling of the entire body has been associated with cyanocobalamin.  elevate your arsenal by taking things to the next level withlouboutin herrenschuhe, two new additions to the collection that mirror streetwall's attention to detail with matching perforated ecussons. men just like herrenschuhe very much. ","vitamin b6, b9 & b12"
sign_symptom,nausea,0.9999416," allergic sensitization has been reported following both oral and parenteral administration of folic acid. paresthesia, somnolence, nausea and headache have been reported with pyridoxine hydrochlloride. mild transient diarrhea, polycythemia vera, itching, transitory exanthema, and the feeling of swelling of the entire body has been associated with cyanocobalamin.  elevate your arsenal by taking things to the next level withlouboutin herrenschuhe, two new additions to the collection that mirror streetwall's attention to detail with matching perforated ecussons. men just like herrenschuhe very much. ","vitamin b6, b9 & b12"
sign_symptom,headache,0.9999269," allergic sensitization has been reported following both oral and parenteral administration of folic acid. paresthesia, somnolence, nausea and headache have been reported with pyridoxine hydrochlloride. mild transient diarrhea, polycythemia vera, itching, transitory exanthema, and the feeling of swelling of the entire body has been associated with cyanocobalamin.  elevate your arsenal by taking things to the next level withlouboutin herrenschuhe, two new additions to the collection that mirror streetwall's attention to detail with matching perforated ecussons. men just like herrenschuhe very much. ","vitamin b6, b9 & b12"
medication,hydro,0.99964964," allergic sensitization has been reported following both oral and parenteral administration of folic acid. paresthesia, somnolence, nausea and headache have been reported with pyridoxine hydrochlloride. mild transient diarrhea, polycythemia vera, itching, transitory exanthema, and the feeling of swelling of the entire body has been associated with cyanocobalamin.  elevate your arsenal by taking things to the next level withlouboutin herrenschuhe, two new additions to the collection that mirror streetwall's attention to detail with matching perforated ecussons. men just like herrenschuhe very much. ","vitamin b6, b9 & b12"
sign_symptom,swelling,0.99995804," allergic sensitization has been reported following both oral and parenteral administration of folic acid. paresthesia, somnolence, nausea and headache have been reported with pyridoxine hydrochlloride. mild transient diarrhea, polycythemia vera, itching, transitory exanthema, and the feeling of swelling of the entire body has been associated with cyanocobalamin.  elevate your arsenal by taking things to the next level withlouboutin herrenschuhe, two new additions to the collection that mirror streetwall's attention to detail with matching perforated ecussons. men just like herrenschuhe very much. ","vitamin b6, b9 & b12"
sign_symptom,adverse reactions,0.99963045," adverse reactions have been reported with specific vitamins, and generally at levels substantially higher than those in vitamin b1, b2 &amp; b6. however, allergic and idiosyncratic reactions are possible at lower levels. ","vitamin b1, b2 & b6"
medication,specific,0.99583614," adverse reactions have been reported with specific vitamins, and generally at levels substantially higher than those in vitamin b1, b2 &amp; b6. however, allergic and idiosyncratic reactions are possible at lower levels. ","vitamin b1, b2 & b6"
sign_symptom,allergic,0.9984738," adverse reactions have been reported with specific vitamins, and generally at levels substantially higher than those in vitamin b1, b2 &amp; b6. however, allergic and idiosyncratic reactions are possible at lower levels. ","vitamin b1, b2 & b6"
sign_symptom,idiosyncratic reactions,0.9985874," adverse reactions have been reported with specific vitamins, and generally at levels substantially higher than those in vitamin b1, b2 &amp; b6. however, allergic and idiosyncratic reactions are possible at lower levels. ","vitamin b1, b2 & b6"
sign_symptom,allergic reactions,0.99993336, generally well tolerated but allergic reactions may be observed in few cases. ,"vitamin b1, b6 & b12"
sign_symptom,side effects,0.99583375," this is generally well tolerated. however, a few side effects like nausea, vomiting, diarrhoea &amp; stomach upset may occur. side effects have been reported with specific vitamins but generally at levels substantially higher than recommended doses. ",vitamin b complex + zinc
sign_symptom,upset,0.99564326," this is generally well tolerated. however, a few side effects like nausea, vomiting, diarrhoea &amp; stomach upset may occur. side effects have been reported with specific vitamins but generally at levels substantially higher than recommended doses. ",vitamin b complex + zinc
medication,specific vitamins,0.9992185," this is generally well tolerated. however, a few side effects like nausea, vomiting, diarrhoea &amp; stomach upset may occur. side effects have been reported with specific vitamins but generally at levels substantially higher than recommended doses. ",vitamin b complex + zinc
sign_symptom,hypersensitivity reactions,0.99981725," hypersensitivity reactions have been reported with thiamine and folic acid, although these are rare. ",vitamin b complex + vitamin c
sign_symptom,adverse reactions,0.9966748," adverse reactions have been reported with specific vitamins and minerals, but generally at levels substantially higher than those in vitamin-b complex. however, allergic and idiosyncratic reactions are possible at lower levels. iron, even at the usual recommended level has been associated with gastrointestinal intolerance in some patients. ",vitamin b complex
medication,specific vitamin,0.9279282," adverse reactions have been reported with specific vitamins and minerals, but generally at levels substantially higher than those in vitamin-b complex. however, allergic and idiosyncratic reactions are possible at lower levels. iron, even at the usual recommended level has been associated with gastrointestinal intolerance in some patients. ",vitamin b complex
medication,vitamin,0.93214566," adverse reactions have been reported with specific vitamins and minerals, but generally at levels substantially higher than those in vitamin-b complex. however, allergic and idiosyncratic reactions are possible at lower levels. iron, even at the usual recommended level has been associated with gastrointestinal intolerance in some patients. ",vitamin b complex
sign_symptom,allergic and,0.9276445," adverse reactions have been reported with specific vitamins and minerals, but generally at levels substantially higher than those in vitamin-b complex. however, allergic and idiosyncratic reactions are possible at lower levels. iron, even at the usual recommended level has been associated with gastrointestinal intolerance in some patients. ",vitamin b complex
sign_symptom,idiosyncratic reactions,0.98283654," adverse reactions have been reported with specific vitamins and minerals, but generally at levels substantially higher than those in vitamin-b complex. however, allergic and idiosyncratic reactions are possible at lower levels. iron, even at the usual recommended level has been associated with gastrointestinal intolerance in some patients. ",vitamin b complex
sign_symptom,racing heart,0.99829006," common side effects are racing heart (tachycardia), a sensation of a rapid, forceful, or irregular beating of the heart (palpitations) tremor, twisting or repetitive movements or abnormal postures due to sustained muscle contractions (dystonia), increased muscle stiffness (hypertonia). ",zuclopenthixol
sign_symptom,repetitive movements,0.94626737," common side effects are racing heart (tachycardia), a sensation of a rapid, forceful, or irregular beating of the heart (palpitations) tremor, twisting or repetitive movements or abnormal postures due to sustained muscle contractions (dystonia), increased muscle stiffness (hypertonia). ",zuclopenthixol
sign_symptom,abnormal postures,0.99958664," common side effects are racing heart (tachycardia), a sensation of a rapid, forceful, or irregular beating of the heart (palpitations) tremor, twisting or repetitive movements or abnormal postures due to sustained muscle contractions (dystonia), increased muscle stiffness (hypertonia). ",zuclopenthixol
sign_symptom,muscle contractions,0.99703246," common side effects are racing heart (tachycardia), a sensation of a rapid, forceful, or irregular beating of the heart (palpitations) tremor, twisting or repetitive movements or abnormal postures due to sustained muscle contractions (dystonia), increased muscle stiffness (hypertonia). ",zuclopenthixol
sign_symptom,muscle stiffness,0.99863744," common side effects are racing heart (tachycardia), a sensation of a rapid, forceful, or irregular beating of the heart (palpitations) tremor, twisting or repetitive movements or abnormal postures due to sustained muscle contractions (dystonia), increased muscle stiffness (hypertonia). ",zuclopenthixol
sign_symptom,hyper,0.93545836," common side effects are racing heart (tachycardia), a sensation of a rapid, forceful, or irregular beating of the heart (palpitations) tremor, twisting or repetitive movements or abnormal postures due to sustained muscle contractions (dystonia), increased muscle stiffness (hypertonia). ",zuclopenthixol
sign_symptom,dysgeusia,0.8367667," common side effects are somnolence, dizziness, confusion, anterograde amnesia or memory impairment, feeling of drunkenness, euphoria, nightmares, agitation, anxiety or nervousness, hostility, depression, decreased libido, libido disorder, coordination abnormality, headache, hypotonia, tremor, muscle spasms, paresthesia, and speech disorder, palpitations, dysgeusia (bitter taste), dry mouth, coated tongue, bad breath, nausea, vomiting, diarrhea, constipation, anorexia or increased appetite. ",zopiclone
sign_symptom,adverse reactions,0.99919665," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,dizziness,0.7621588," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,ataxia,0.9140953," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,agitation,0.9994405," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,adverse reaction,0.99909556," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,fatigue,0.99991107," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,difficulty concentrating,0.94299424," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,difficulty,0.94985485," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,mental slowing,0.9701127," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,nausea /,0.9941262," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,vomiting,0.9014289," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,weight loss,0.9993243," the most common adverse reactions with zonisamide (an incidence at least 4% greater than placebo) in controlled clinical trials and shown in descending order of frequency weresomnolence,anorexia, dizziness,ataxia, agitation/irritability, and difficulty with memory and/or concentration.  in controlled clinical trials, 12% of patients receiving zonisamide as adjunctive therapy discontinued due to an adverse reaction compared to 6% receiving placebo. approximately 21% of the 1,336 patients withepilepsywho received zonisamide in clinical studies discontinued treatment because of an adverse reaction. the most common adverse reactions leading to discontinuation were somnolence, fatigue and/or ataxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). many of these adverse reactions were doserelated ",zonisamide
sign_symptom,reactions,0.74436766," most common adverse reactions were neck/throat/jaw pain or pressure, dizziness, paresthesia, asthenia, somnolence, warm/cold sensation, nausea, heaviness sensation, and dry mouth. ",zolmitriptan
sign_symptom,pain,0.9998093," most common adverse reactions were neck/throat/jaw pain or pressure, dizziness, paresthesia, asthenia, somnolence, warm/cold sensation, nausea, heaviness sensation, and dry mouth. ",zolmitriptan
sign_symptom,arthralgia,0.9396008," the post-dose side-effects are fever, myalgia, flu-like symptoms, arthralgia and headache, the majority of which occur within the first 3 days following zoledronic acid administration. the majority of these symptoms were mild to moderate in nature and resolved within 3 days of the event onset. the incidence of these symptoms occurring within the first 3 days after administration of zoledronic acid, can be reduced with the administration of paracetamol or ibuprofen shortly following zoledronic acid administration. severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking zoledronic acid. ",zoledronic acid [for osteoporosis]
medication,zoledronic acid,0.85515565," the post-dose side-effects are fever, myalgia, flu-like symptoms, arthralgia and headache, the majority of which occur within the first 3 days following zoledronic acid administration. the majority of these symptoms were mild to moderate in nature and resolved within 3 days of the event onset. the incidence of these symptoms occurring within the first 3 days after administration of zoledronic acid, can be reduced with the administration of paracetamol or ibuprofen shortly following zoledronic acid administration. severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking zoledronic acid. ",zoledronic acid [for osteoporosis]
sign_symptom,symptoms,0.9329224," the post-dose side-effects are fever, myalgia, flu-like symptoms, arthralgia and headache, the majority of which occur within the first 3 days following zoledronic acid administration. the majority of these symptoms were mild to moderate in nature and resolved within 3 days of the event onset. the incidence of these symptoms occurring within the first 3 days after administration of zoledronic acid, can be reduced with the administration of paracetamol or ibuprofen shortly following zoledronic acid administration. severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking zoledronic acid. ",zoledronic acid [for osteoporosis]
medication,zoledron,0.94529265," the post-dose side-effects are fever, myalgia, flu-like symptoms, arthralgia and headache, the majority of which occur within the first 3 days following zoledronic acid administration. the majority of these symptoms were mild to moderate in nature and resolved within 3 days of the event onset. the incidence of these symptoms occurring within the first 3 days after administration of zoledronic acid, can be reduced with the administration of paracetamol or ibuprofen shortly following zoledronic acid administration. severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking zoledronic acid. ",zoledronic acid [for osteoporosis]
medication,para,0.99984217," the post-dose side-effects are fever, myalgia, flu-like symptoms, arthralgia and headache, the majority of which occur within the first 3 days following zoledronic acid administration. the majority of these symptoms were mild to moderate in nature and resolved within 3 days of the event onset. the incidence of these symptoms occurring within the first 3 days after administration of zoledronic acid, can be reduced with the administration of paracetamol or ibuprofen shortly following zoledronic acid administration. severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking zoledronic acid. ",zoledronic acid [for osteoporosis]
medication,ibuprofen,0.99661124," the post-dose side-effects are fever, myalgia, flu-like symptoms, arthralgia and headache, the majority of which occur within the first 3 days following zoledronic acid administration. the majority of these symptoms were mild to moderate in nature and resolved within 3 days of the event onset. the incidence of these symptoms occurring within the first 3 days after administration of zoledronic acid, can be reduced with the administration of paracetamol or ibuprofen shortly following zoledronic acid administration. severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking zoledronic acid. ",zoledronic acid [for osteoporosis]
sign_symptom,pain,0.9998815," the post-dose side-effects are fever, myalgia, flu-like symptoms, arthralgia and headache, the majority of which occur within the first 3 days following zoledronic acid administration. the majority of these symptoms were mild to moderate in nature and resolved within 3 days of the event onset. the incidence of these symptoms occurring within the first 3 days after administration of zoledronic acid, can be reduced with the administration of paracetamol or ibuprofen shortly following zoledronic acid administration. severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking zoledronic acid. ",zoledronic acid [for osteoporosis]
sign_symptom,arthral,0.74866134," the post-dose side-effects are headache, nausea, anorexia, fatigue, osteonecrosis of jaw, anemia, bone pain, constipation, fever, vomiting, flu-like syndrome, hypocalcemia, myalgia, arthralgia and hypophosphataemia. ",zoledronic acid [for hypercalcemia]
sign_symptom,adverse reactions,0.999879," commonly observed adverse reactions (incidence 5% and at least twice the incidence for placebo) were: 
 
 schizophrenia: somnolence, respiratory tract infection. 
 manic and mixed episodes associated with bipolar disorder: somnolence, extrapyramidal symptoms, dizziness, akathisia, abnormal vision, asthenia, vomiting. 
 intramuscular administration (5% and at least twice the lowest intramuscular ziprasidone group): headache, nausea, somnolence. 
  ",ziprasidone
medication,zipras,0.86117023," commonly observed adverse reactions (incidence 5% and at least twice the incidence for placebo) were: 
 
 schizophrenia: somnolence, respiratory tract infection. 
 manic and mixed episodes associated with bipolar disorder: somnolence, extrapyramidal symptoms, dizziness, akathisia, abnormal vision, asthenia, vomiting. 
 intramuscular administration (5% and at least twice the lowest intramuscular ziprasidone group): headache, nausea, somnolence. 
  ",ziprasidone
sign_symptom,irritation,0.9996309," signs of irritations (erythema, burning or rash) may appear when applied to sensitive or broken skin. ","zinc oxide, octinoxate, enzacamene and avobenzone"
sign_symptom,allergic reactions,0.99984753," severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue). ",zinc oxide + ethylhexyl methoxycinnamate + 4-methylbenzylidene camphor + butyl methoxydibenzoylmethane
sign_symptom,allergic reactions,0.99984753," severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue). ",zinc oxide [microfine]
sign_symptom,difficulty,0.99804664," severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue). ",zinc oxide + ethylhexyl methoxycinnamate + 4-methylbenzylidene camphor + butyl methoxydibenzoylmethane
sign_symptom,difficulty,0.99804664," severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue). ",zinc oxide [microfine]
sign_symptom,tightness,0.96701413," severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue). ",zinc oxide + ethylhexyl methoxycinnamate + 4-methylbenzylidene camphor + butyl methoxydibenzoylmethane
sign_symptom,tightness,0.96701413," severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue). ",zinc oxide [microfine]
sign_symptom,swelling,0.99991715," severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue). ",zinc oxide + ethylhexyl methoxycinnamate + 4-methylbenzylidene camphor + butyl methoxydibenzoylmethane
sign_symptom,swelling,0.99991715," severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue). ",zinc oxide [microfine]
sign_symptom,hyper,0.99990034, side effects include local hypersensitivity occasionally. ,zinc oxide + benzyl alcohol + benzyl benzoate + benzyl cinnamate + lanolin
sign_symptom,hypersensit,0.9774513, usually well tolerated. extremely low frequency of hypersensitivity reaction. ,zinc oxide
sign_symptom,vomiting,0.9992151," zinc might cause nausea, vomiting, metallic taste and stomach upset etc. ",zinc orotate
sign_symptom,metallic taste,0.9997134," zinc might cause nausea, vomiting, metallic taste and stomach upset etc. ",zinc orotate
sign_symptom,upset,0.9999124," zinc might cause nausea, vomiting, metallic taste and stomach upset etc. ",zinc orotate
sign_symptom,mala,0.9824076," dizziness, headache, malaise, myalgia, gi symptoms (e.g. abdominal pain, diarrhoea, nausea, vomiting), anorexia, immune reconstitution syndrome, lipodystrophy, metabolic abnormalities, mitochondrial dysfunction, osteonecrosis; raised liver enzymes, creatine phosphokinase; hyperbilirubinaemia, myalgia, myositis. rarely, aplastic anaemia, pure red cell aplasia, pancytopenia, thrombocytopenia, rhabdomyolysis, cardiomyopathy, convulsions, pancreatitis. ",zidovudine
medication,placebo,0.9425764,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
sign_symptom,headache,0.99993944,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
sign_symptom,nausea,0.9999466,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
sign_symptom,vomiting,0.99994934,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
sign_symptom,diarr,0.76725674,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
sign_symptom,pain,0.99994373,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
disease_disorder,menorrhagia,0.7362089,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
disease_disorder,agranulo,0.883303,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
sign_symptom,hyper,0.8536274,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
sign_symptom,angio - oedema,0.9725296,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
sign_symptom,rash,0.9998877,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
disease_disorder,infection,0.99931407,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
disease_disorder,infections,0.99749315,"  effect on ability to drive or operate machinery : there is no evidence that zafirlukast affects the ability to drive and use machinery. administration of zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). these symptoms are usually mild and do not necessitate withdrawal from therapy. during post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.  hypersensitivity reactions, including urticaria and angio-oedema have been reported. rashes, including blistering, have also been reported. the above events have usually resolved during continued treatment or following cessation of therapy.   infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with zafirlukast (increased ast 1.0% vs. 0.9%, increased ast 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of zafirlukast therapy. during post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. these cases were usually reversible.  in placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given zafirlukast (7.8% vs. 1.4%). infections were usually mild, predominantly affecting the respiratory tract. ",zafirlukast
